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Prepared by and for policy-makers, leaders of public sector research establishments, 
technology transfer professionals, licensing executives, and scientists, this Handbook
offers up-to-date information and strategies for utilizing the power of both intellectual 
property and the public domain.
Eschewing ideological debates and general proclamations, the authors always keep 
their eye on the practical side of IP management. The Handbook provides substantive 
discussions and analyses of the opportunities awaiting anyone in the field who wants 
to put intellectual property to work.
“This Handbook is timely. [It] is a valuable guide in helping to navigate the complex—
but rewarding—world of an increasingly global innovation system.”
—From the Foreword of Norman Borlaug, Nobel Peace Prize Laureate
“[This] Handbook is an important step towards transnational networks … involving multiple 
partners in both North and South—donors and doers alike—who believe in the power of 
innovation to address the needs of the poor.”
—From the Foreword of Sir Gordon Conway, KCMG DL FRS, Chief Scientific Adviser, DFID UK
“At the dawn of the 21st 
century the world created 
an unprecedented wave of 
public–private partnerships. 
For such investments to 
bear fruit as public goods 
it is paramount to manage 
intellectual property with the 
public interest in mind. This 
Handbook provides expert 
guidance to do just that 
and will assist in developing 





“This Handbook—which really transcends the category of handbooks altogether—
is a must read for anyone who deals with intellectual property.”
—Pramilla Senanayake, FRCOG, Chair, Global Forum for Health Research, MIHR, and the Concept Foundation
The companion Executive Guide distills the key points 
of each chapter into simple language and places them 
in the context of evolving best practices.
“For all who believe, as I believe, that developing countries can—and should—participate in
and benefit from an interconnected world of innovation, this book is an indispensable guide.”
—Mahmoud F. Fathalla, Professor and former Dean, Medical School at Assiut University, Egypt,
and Chairperson of the WHO Advisory Committee on Health Research
“Intellectual property (IP) has become a much richer field of endeavor as it has moved from 
isolationism in the world of policy to a position of engagement …  [This Handbook] will serve
as an invaluable resource in this challenging new environment.”
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March 21, 2007 
Dear Reader, 
Over the last decade, the world has been paying increasing attention to the 
agricultural, health, and economic disparities between industrialized and 
developing countries. The Rockefeller Foundation is proud to have helped develop 
and launch some of the numerous initiatives to address these issues—initiatives 
such as the African Agricultural Technology Foundation, the Alliance for a Green 
Revolution in Africa, the International AIDS Vaccine Initiative, the Global Alliance 
for TB Drug Development, and others. 
We believe, however, that launching the success of these and other similar 
initiatives requires that we both engage directly with research universities in the 
industrialized world and encourage the growing innovation capacity of developing 
countries. The Public Intellectual Property Resource for Agriculture (PIPRA) and 
the Centre for the Management of Intellectual Property in Health Research and 
Development (MIHR) were created for precisely these reasons. Their mission 
is to enhance the power of publicly funded research institutions to harness new 
technologies and to ensure that the benefits of globalization are shared more 
equitably. This Handbook and the companion Executive Guide and online version 
are a natural outcome of their efforts to contribute new solutions to this two-fold 
challenge. A follow-on interactive electronic version will reach an even wider 
audience and, we hope, provide even greater benefits. 
The Rockefeller Foundation is delighted to have supported the creation of this 
unique resource. It holds lessons that are valuable (in many senses of the word) 
for policy-makers, leaders of research institutions, researchers, and technology 
managers alike—in both industrialized and developing countries. Indeed, this 
Handbook and Executive Guide, a testament to the committed, excellent work of 
MIHR and PIPRA, might be the most thorough primer on intellectual property 
management for the public interest ever assembled. As such, it will be an 
indispensable tool for both planners and practitioners for years to come. 




Message from the Board of Patrons 
Dear Reader, 
Intellectual property can be a powerful tool. When effectively and ethically managed, it can 
both accelerate the development of lifesaving, poverty-alleviating innovations and secure 
access to them. Both development and access are urgently needed in health and agriculture 
to improve the lives of people in need—particularly those living in the developing world. 
This Handbook and its companion Executive Guide constitute an authoritative, comprehen­
sive, and practical reference on intellectual property management and best practices. These 
works will be invaluable for anyone seeking to use intellectual property strategically to en­
hance economic growth and equitably distribute innovative technologies. This Handbook
uniquely contributes to efforts in global health and food security. We are pleased to endorse 
its use. ■ 
Charles J. Arntzen, USA Alex F. McCalla, USA 
Roger N. Beachy, USA Carlos Morel, Brazil 
Norman E. Borlaug, Mexico Ingo Potrykus, Switzerland 
Zhang Liang Chen, China Judith Rodin, USA 
Mahmoud F. Fathalla, Egypt Emil Salim, Indonesia 
Maria Freire, USA Albert Sasson, Morocco/France 
William Hennessey, USA Akinori Seki, Japan 
Kamil Idris, Sudan/Switzerland Ismail Serageldin, Egypt 
Molly Jahn, USA Victor S. Shevelukha, Russia 
Gurdev Khush, India/USA M. S. Swaminathan, India 
Mosibudi Mangena, South Africa Baron Marc Van Montagu, Belgium 
R. A. Mashelkar, India Vo-Tong Xuan, Vietnam 













Law Offices of and Gerow D. Brill, Esq. ’91
DODDS AND ASSOCIATES 
Thomson-Shore 
Book Manufacturing 
A number of organizations, after seeing sample chapters of the Handbook, came forward to purchase copies for wide 
distribution in developing countries. We are grateful for their generosity and extend our thanks in advance to others
who will join their ranks. For an updated list of Distribution Supporters, please visit www.ipHandbook.org. 
In-kind support provided by AUTM, PIIPA, and Venable LLP.
 
Individuals are also encouraged to purchase Handbooks on behalf of developing countries; we will distribute such orders at cost.
 














        
   
   
 
   
 
   
   
  Table of Contents
 
Foreword by Norman E. Borlaug ................................................................................................... xxvii
 
Foreword by R. A. Mashelkar ......................................................................................................... xxix
 
Foreword by Francis Gurry ............................................................................................................. xxxi
 
Foreword by Howard A. Zucker.................................................................................................... xxxiii
 
Foreword by Sir Gordon Conway....................................................................................................xxxv
 








About PIPRA ................................................................................................................................. xlix
 





Section 1: innovation and iP Management: A Contextual Overview 
1.1	 The Role of IP Management in Health and Agricultural Innovation...................................... 3
 
Richard T. Mahoney and Anatole Krattiger 
1.2	 Building Product Innovation Capability in Health .............................................................. 13
 
Richard T. Mahoney 
1.3	 IP Management and Deal Making for Global Health Outcomes: 
The New “Return on Imagination” (ROI) ........................................................................... 19
John Fraser 
1.4	 Ensuring Developing-Country Access to New Inventions: 
The Role of Patents and the Power of Public Sector Research Institutions............................ 23
Lita Nelsen and Anatole Krattiger 
1.5	 Genomics, Ethics, and Intellectual Property ........................................................................ 29
 
Gary E. Marchant 
HANDBOOK OF BEST PRACTICES | xv 
     
          
   
   
 
   
   
   
   
 
   
 
   
        
   
   
 
   
 
   
 
   
 
   
   
   
Section 2: Specific Strategies and Mechanisms for Facilitating Access to innovation 
2.1	 Reservation of Rights for Humanitarian Uses ...................................................................... 41
 
Alan B. Bennett 
2.2	 Facilitating Humanitarian Access to Pharmaceutical and Agricultural Innovation................ 47
 
Amanda L. Brewster, Stephen A. Hansen, and Audrey R. Chapman 
2.3	 Ensuring Global Access through Effective IP Management:
 
Strategies of Product-Development Partnerships.................................................................. 63
 
Robert Eiss, Kathi E. Hanna, and Richard T. Mahoney 
2.4	 Patenting and Licensing Research Tools............................................................................... 79
 
Charles Clift 
2.5	 Valuation and Licensing in Global Health ........................................................................... 89
 
Ashley J. Stevens 
2.6	 Open Source Licensing...................................................................................................... 107
 
Janet Hope 
2.7	 Using Milestones in Healthcare Product Licensing Deals
 
to Ensure Access in Developing Countries......................................................................... 119
 
Joachim Oehler 
2.8	 Facilitating Assembly of and Access to Intellectual Property: 

Focus on Patent Pools and a Review of Other Mechanisms................................................ 131
 
Anatole Krattiger and Stanley P. Kowalski 
Section 3: the Policy and Legal environment for innovation 
3.1	 The Courts and Innovation ............................................................................................... 147
 
Pauline Newman 
3.2	 Global Health: Lessons from Bayh-Dole............................................................................ 153
 
Rachel A. Nugent and Gerald T. Keusch 
3.3	 Echoes of Bayh-Dole? A Survey of IP and Technology Transfer Policies
 
in Emerging and Developing Economies ........................................................................... 169
 
Gregory D. Graff 
3.4	 Technology Transfer Snapshots from Middle-Income Countries:
 
Creating Socio-Economic Benefits through Innovation ..................................................... 197
 
Susan K. Finston 
3.5	 Benchmarking of Technology Transfer Offices and
 
What It Means for Developing Countries.......................................................................... 207
 
Anthony D. Heher 
3.6	 Public Sector IP Management in the Life Sciences: 

Reconciling Practice and Policy—Perspectives from WIPO ............................................... 229
 
Antony Taubman and Roya Ghafele 
3.7	 Developing Countries and TRIPS: What Next?................................................................. 247
 
Robert Eiss, Richard T. Mahoney, and Kanikaram Satyanarayana 
3.8	 The TRIPS Agreement and Intellectual Property in Health and Agriculture ...................... 253
 
Jayashree Watal and Roger Kampf 
xvi | HANDBOOK OF BEST PRACTICES 
       
   
   
   
 
   
 
   
 
   
    
   
   
   
   
   
 
   
 
   
 
   
   
   
3.9	 U.S. Laws Affecting the Transfer of Intellectual Property ................................................... 265
 
Howard Bremer 
3.10	 Compulsory Licensing: How to Gain Access to Patented Technology ................................ 273
 
Carlos María Correa 
3.11	 The Role of Clusters in Driving Innovation ....................................................................... 281
 
Peter W. B. Phillips and Camile D. Ryan 
3.12	 What Does It Take to Build a Local Biotechnology Cluster in a Small Country?
 
The Case of Turku, Finland ............................................................................................... 295
 
Kimmo Viljamaa 
3.13	 The Activities and Roles of M.I.T. in Forming Clusters 

and Strengthening Entrepreneurship ................................................................................. 309
 
Lita Nelsen 
3.14	 Building Research Clusters: Exploring Public Policy Options
 
for Supporting Regional Innovation .................................................................................. 317
 
Peter W. B. Phillips and Camille D. Ryan 
Section 4: the iP toolbox 
4.1	 The Statutory Toolbox: An Introduction............................................................................ 337
 
John Dodds and Anatole Krattiger 
4.2	 How to Read a Biotech Patent........................................................................................... 351
 
Carol Nottenburg 
4.3	 Trademark Primer.............................................................................................................. 361
 
William Needle 
4.4	 The Statutory Toolbox: Plants............................................................................................ 371
 
Jay P. Kesan 
4.5	 Plant Breeders’ Rights: An Introduction ............................................................................ 381
 
William H. Lesser 
4.6	 Plants, Germplasm, Genebanks, and Intellectual Property:
 
Principles, Options, and Management............................................................................... 389
 
John Dodds, Anatole Krattiger, and Stanley P. Kowalski 
4.7	 Plant Variety Protection, International Agricultural Research, and Exchange 

of Germplasm: Legal Aspects of Sui Generis and Patent Regimes ...................................... 401
 
Michael Blakeney 
4.8	 IP and Information Management: Libraries, Databases,
 
Geographic Information Systems, and Software................................................................. 419
 
John Dodds, Susanne Somersalo, Stanley P. Kowalski, and Anatole Krattiger 
4.9	 Data Protection and Data Exclusivity in Pharmaceuticals and Agrochemicals .................... 431
 
Charles Clift 
4.10	 Regulatory Data Protection in Pharmaceuticals and Other Sectors .................................... 437
 
Trevor Cook 
HANDBOOK OF BEST PRACTICES | xvii 
     
     
   
   
   
   
   
   
 
  
       
 
   
   
   
   
   
   
   
   
   
   
   
Section 5: institutional Policies and Strategies
 
5.1	 IP Strategy......................................................................................................................... 459
 
Robert Pitkethly 
5.2	 IP Management Policy: A Donor’s Perspective................................................................... 475
 
Zoë Ballantyne and Daniel Nelki 
5.3	 Making the Most of Intellectual Property: Developing an Institutional IP Policy............... 485
 
Stanley P. Kowalski 
5.4	 Ownership of University Inventions: Practical Considerations........................................... 495
 
B. Jean Weidemier 
5.5	 The Role of the Inventor in the Technology Transfer Process ............................................. 507
 
Anne C. Di Sante 
5.6	 Conducting IP Audits ....................................................................................................... 515
 
Michael Blakeney 
5.7	 Conflict of Interest and Conflict of Commitment Management
 
in Technology Transfer....................................................................................................... 527
 
Alan B. Bennett 
Section 6: establishing and Operating technology transfer Offices 
6.1	 Ten Things Heads of Institutions Should Know 

about Setting Up a Technology Transfer Office.................................................................. 537
 
Lita Nelsen 
6.2	 Establishing a Technology Transfer Office.......................................................................... 545
 
Terry A. Young 
6.3	 How to Set Up a Technology Transfer Office: Experiences from Europe ............................ 559
 
Alison F. Campbell 
6.4	 How to Set Up a Technology Transfer System in a Developing Country............................ 567
 
Carlos Fernandez 
6.5	 Practical Considerations for the Establishment of a Technology Transfer Office................. 575
 
John Dodds and Susanne Somersalo 
6.6	 Administration of a Large Technology Transfer Office ....................................................... 581
 
Sally Hines 
6.7	 Training Staff in IP Management....................................................................................... 597
 
Sibongile Pefile and Anatole Krattiger 
6.8	 Building Networks: The National and International Experiences of AUTM ...................... 617
 
Karen Hersey 
6.9	 How to Select and Work with Patent Counsel ................................................................... 625
 
Michael L. Goldman 
6.10	 How to Hire an IP Attorney and Not Go Bankrupt .......................................................... 635
 
John Dodds 
6.11	 Technology Transfer Data Management............................................................................. 641
 
Robert G. Sloman 
xviii | HANDBOOK OF BEST PRACTICES 
       
 
   
   
   
       
   
   
   
   
   
 
   
    
   
   
   
   
      
   
  
6.12	 WIIPS™: Whitehead Institute Intellectual Property System (A Relational Database
 
for IP Management and Technology Transfer) ................................................................... 649
 
Amina Hamzaoui 
6.13	 Organizing and Managing Agreements and Contracts ....................................................... 651
 
Robert Potter and Hild Rygnestad 
6.14	 Monitoring, Evaluating, and Assessing Impact................................................................... 659
 
Sibongile Pefile 
Section 7: Contracts and Agreements to Support Partnerships 
7.1	 Agreements: A Review of Essential Tools of IP Management ............................................. 675
 
Richard T. Mahoney and Anatole Krattiger 
7.2	 Confidentiality Agreements: A Basis for Partnerships......................................................... 689
 
Stanley P. Kowalski and Anatole Krattiger 
7.3	 Specific Issues with Material Transfer Agreements.............................................................. 697
 
Alan B. Bennett, Wendy D. Streitz, and Rafael A. Gacel 
7.4	 How to Draft a Collaborative Research Agreement............................................................ 717
 
Martha Bair Steinbock 
7.5	 Drafting Effective Collaborative Research Agreements and Related Contracts ................... 725
 
E. Richard Gold and Tania Bubela 
7.6	 The Use of Nonassertion Covenants: A Tool to Facilitate
 
Humanitarian Licensing, Manage Liability, and Foster Global Access................................ 739
 
Anatole Krattiger 
Section 8: inventors and inventions 
8.1	 Introduction to IP Issues in the University Setting: A Primer for Scientists ........................ 747
 
Martha Mutschler and Gregory D. Graff 
8.2	 How to Start–and Keep–a Laboratory Notebook: Policy and Practical Guidelines ............. 763
 
Jennifer A. Thomson 
8.3	 Documentation of Inventions............................................................................................ 773
 
W. Mark Crowell 
8.4	 Invention Disclosures and the Role of Inventors................................................................ 779
 
David R. McGee 
Section 9: evaluation and Valuation of technologies 
9.1	 Evaluating Inventions from Research Institutions .............................................................. 795
 
Lita Nelsen 
9.2	 Technology Valuation: An Introduction............................................................................. 805
 
Robert H. Potter 
HANDBOOK OF BEST PRACTICES | xix 




   
          
   
   
  
   
   
   
 
 
   
   
  
 
   
 
   
     
   
   
9.3	 Pricing the Intellectual Property of Early-Stage Technologies:
 
A Primer of Basic Valuation Tools and Considerations .................................................... 813
 
Richard Razgaitis 
9.4	 Valuation of Bioprospecting Samples: Approaches, Calculations,
 
and Implications for Policy-Makers ................................................................................... 861
 
William H. Lesser and Anatole Krattiger 
Section 10: Patents and Patenting: Balancing Protection with the Public domain 
10.1	 Defensive Publishing and the Public Domain.................................................................... 879
 
Sara Boettiger and Cecilia Chi-Ham 
10.2	 Provisional Patent Applications: Advantages and Limitations............................................. 897
 
Richard L. Cruz 
10.3	 Designing Patent Applications for Possible Field-of-Use Licensing..................................... 903
 
Arne M. Olson 
10.4	 Patenting Strategies: Building an IP Fortress...................................................................... 911
 
John Dodds 
10.5	 Cost-Conscious Strategies for Patent Application Filings ................................................... 921
 
Oren Livne 
10.6	 A Guide to International Patent Protection ....................................................................... 927
 
Ann S. Viksnins and Ann M. McCrackin 
10.7	 Filing International Patent Applications under the Patent Cooperation Treaty (PCT):
 
Strategies for Delaying Costs and Maximizing the Value 

of Your Intellectual Property Worldwide............................................................................ 941
 
Anne M. Schneiderman 
10.8	 Filing and Defending Patents in Different Jurisdictions ..................................................... 953
 
Ronald Yin and Sean Cunningham 
10.9	 The Interface of Patents with the Regulatory Drug Approval Process 

and How Resulting Interplay Can Affect Market Entry................................................... 965
 
Dennis S. Fernandez, James Huie, and Justin Hsu 
10.10 Deposit of Biological Materials in Support of a U.S. Patent Application............................ 973
 
Dennis J. Harney and Timothy B. McBride 
10.11 Protecting New Plant Varieties through PVP: Practical Suggestions
 
from a Plant Breeder for Plant Breeders ............................................................................. 981
 
William D. Pardee 
VOLUME TWO 
Section 11: technology and Product Licensing 
11.1	 Licensing Biotechnology Inventions .................................................................................. 991
 
John W. Freeman 
11.2	 Licensing Agreements in Agricultural Biotechnology ....................................................... 1009
 
Richard S. Cahoon 
xx | HANDBOOK OF BEST PRACTICES 
       
   
 
   
   
   
   
   
   
   
  
      
  
   
   
   
   
   
   
 
   
 
   
 
   
11.3	 The In- and Out-Licensing of Plant Varieties................................................................... 1017
 
Malin Nilsson 
11.4	 Potential Use of a Computer-Generated Contract Template System (CoGenCo)
 
to Facilitate Licensing of Traits and Varieties.................................................................... 1029
 
Anatole Krattiger, John Dodds, and Donna Bobrowicz 
11.5	 Trade Secrets and Trade-Secret Licensing ......................................................................... 1043
 
Karl F. Jorda 
11.6	 Use of Trademarks in a Plant-Licensing Program ............................................................. 1059
 
William T. Tucker and Gavin S. Ross 
11.7	 Commercialization Agreements: Practical Guidelines in Dealing with Options ............... 1069
 
Mark Anderson and Simon Keevey-Kothari 
11.8	 Field-of-Use Licensing ..................................................................................................... 1113
 
Sandra L. Shotwell 
11.9	 Problems with Royalty Rates, Royalty Stacking, and Royalty Packing Issues .................... 1121
 
Keith J. Jones, Michael E. Whitham, and Philana S. Handler 
11.10 In-Licensing Strategies by Public-Sector Institutions in Developing Countries ................ 1127
 
Kanikaram Satyanarayana 
11.11 A Checklist for Negotiating License Agreements.............................................................. 1133
 
Donna Bobrowicz 
Section 12: dealmaking and Marketing technology
to Product-development Partners 
12.1	 Negotiating an Agreement: Skills, Tactics, and Best Practices........................................... 1155
 
Richard T. Mahoney 
12.2	 An Introduction to Marketing Early-Stage Technologies.................................................. 1165
 
Marcel D. Mongeon 
12.3	 Technology Marketing..................................................................................................... 1173
 
Robert S. MacWright and John F. Ritter 
12.4	 IP Portfolio Management: Negotiating the Information Labyrinth.................................. 1195
 
Jeremy Burdon 
12.5	 The IP Sales Process......................................................................................................... 1203
 
Todd S. Keiller 
12.6	 Patent Licensing for Small Agricultural Biotechnology Companies.................................. 1213
 
Clinton H. Neagley 
12.7	 Business Partnerships in Agriculture and Biotechnology
 
that Advance Early-State Technology ............................................................................... 1221
 
Martha Dunn, Brett Lund, and Eric Barbour 
12.8	 Biotechnology and Pharmaceutical Commercialization Alliances: 

Their Structure and Implications for University Technology Transfer Offices ................... 1227
 
Mark G. Edwards 
12.9	 Product Development and IP Strategies for Global Health
 
Product Development Partnerships.................................................................................. 1247
 
Sandra L. Shotwell 
HANDBOOK OF BEST PRACTICES | xxi 
     
      
   
   
   
 
   
 
   
  
       
 
   
   
 
   
   
   
      
   
   
   
   
Section 13: the Public Sector and entrepreneurship
 
13.1	 Creating and Developing Spinouts: Experiences from Yale University and Beyond.......... 1253
 
Alfred (Buz) Brown and Jon Soderstrom 
13.2	 Dealing with Spinout Companies.................................................................................... 1271
 
Jon C. Sandelin 
13.3	 What the Public Sector Should Know about Venture Capital .......................................... 1281
 
Roger Wyse 
13.4	 The Role of Technology Transfer Intermediaries in Commercializing
 
Intellectual Property through Spinouts and Start-ups....................................................... 1289
 
Tim Cook 
13.5	 New Companies to Commercialize Intellectual Property: 

Should You Spinout or Start-up? ..................................................................................... 1295
 
Cathy Garner and Philip Ternouth 
13.6	 Formation of a Business Incubator................................................................................... 1305
 
Edward M. Zablocki 
Section 14: Freedom to Operate and Risk Management 
14.1	 Freedom to Operate, Public Sector Research, and Product-Development Partnerships:
 
Strategies and Risk-Management Options ....................................................................... 1317
 
Anatole Krattiger 
14.2	 Freedom to Operate: The Preparations ............................................................................ 1329
 
Stanley P. Kowalski 
14.3	 How and Where to Search for IP Information on the World Wide Web:
 
The “Tricks of the Trade” and an Annotated Listing of Web Resources ............................ 1345
 
Harry Thangaraj, Robert H. Potter, and Anatole Krattiger 
14.4	 Freedom to Operate: The Law Firm’s Approach and Role ................................................ 1363
 
Gillian M. Fenton, Cecilia Chi-Ham, and Sara Boettiger 
14.5	 Managing Liability Associated with Genetically Modified Crops ..................................... 1385
 
Richard Y. Boadi 
Section 15: Monitoring, enforcement, and Resolving disputes 
15.1	 Administration of Technology Licenses............................................................................ 1395
 
Hans H. Feindt 
15.2	 Policing Intellectual Property........................................................................................... 1405
 
H. Walter Haeussler and Richard S. Cahoon 
15.3	 Alternative Dispute-Resolution Procedures: International View....................................... 1415
 
Eun-Joo Min 
15.4	 Parallel Trade: A User’s Guide .......................................................................................... 1429
 
Duncan Matthews and Viviana Munoz-Tellez 
xxii | HANDBOOK OF BEST PRACTICES 
       
       
   
 
   
 
   
   




   
 
   
       





   
 
   
  
   
  
   
   
   
Section 16: Bioprospecting, traditional Knowledge, and Benefit Sharing
 
16.1	 Biotechnology Patents and Indigenous Peoples ................................................................ 1437
 
Dennis S. Karjala 
16.2	 Access and Benefit Sharing: Understanding the Rules for Collection 
and Use of Biological Materials........................................................................................ 1461
Carl-Gustaf Thornström 
16.3	 Access and Benefit Sharing: Illustrated Procedures 
for the Collection and Importation of Biological Materials ............................................. 1469
Carl-Gustaf Thornström and Lars Björk 
16.4	 Deal Making in Bioprospecting ....................................................................................... 1495
 
Charles Costanza, Leif Christoffersen, Carolyn Anderson, and Jay M. Short 
16.5	 Bioprospecting Arrangements: Cooperation between the North and the South ............... 1511
Djaja Djendoel Soejarto, C. Gyllenhaal, Jill A. Tarzian Sorensen, H.H.S. Fong, L.T. Xuan,
L.T. Binh, N.T. Hiep,  N.V. Hung, B.M. Vu, T.Q. Bich, B.H. Southavong, K. Sydara, 
J.M. Pezzuto, and M.C. Riley 
16.6	 Issues and Options for Traditional Knowledge Holders 
in Protecting Their Intellectual Property .......................................................................... 1523
Stephen A. Hansen and Justin W. Van Fleet 
16.7	 Reconciling Traditional Knowledge with Modern Agriculture: 
A Guide for Building Bridges .......................................................................................... 1539
Klaus Ammann 
Section 17: Putting intellectual Property to Work:
experiences from around the World 
A 	 Country Studies 
17.1	 Current Issues of IP Management in Health and Agriculture in Brazil............................. 1563
 
Claudia Inês Chamas, Sergio M. Paulino De Carvalho, and Sergio Salles-Filho 
17.2	 A Model for the Collaborative Development of Agricultural 
Biotechnology Products in Chile ..................................................................................... 1577
Carlos Fernandez and Michael R. Moynihan 
17.3	 IP Rights in China: Spurring Invention and Driving Innovation 
in Health and Agriculture................................................................................................ 1585
Zhang Liang Chen, Wangsheng Gao, and Ji Xu 
17.4	 Experiences from the European Union: 
Managing Intellectual Property Under the Sixth Framework Programme ........................ 1593
Alicia Blaya 
17.5	 Current IP Management Issues for Health and Agriculture in India ................................ 1605
 
Kanikaram Satyanarayana 
17.6	 Current Issues of IP Management for Health and Agriculture in Japan............................ 1621
 
Junko Chapman and Kazuo N. Watanabe 
17.7	 Technology Transfer in South African Public Research Institutions.................................. 1651
 
Rosemary Wolson 
HANDBOOK OF BEST PRACTICES | xxiii 
     
 
 
   
  
 
   
   
 
   
 
   
   
 
   
   
 
   
   
   
 
   
 
   
 
   
   
B	 Public Sector Institutions and Universities 
17.8	 The New American University and the Role of “Technology Translation”:
 
The Approach of Arizona State University ....................................................................... 1661
 
Peter J. Slate and Michael Crow 
17.9	 IP Management at Chinese Universities........................................................................... 1673
 
Hua Guo 
17.10 Application and Examples of Best Practices in IP Management:
 
The Donald Danforth Plant Science Center .................................................................... 1683
 
Karel R. Schubert 
17.11 IP Management in the National Health Service in England............................................. 1697
 
Tony Bates 
17.12 Partnerships for Innovation and Global Health: 

NIH International Technology Transfer Activities............................................................ 1709
 
Luis A. Salicrup and Mark L. Rohrbaugh 
17.13 The Making of a Licensing Legend: Stanford University’s 

Office of Technology Licensing........................................................................................ 1719
 
Nigel Page 
17.14 Technology Transfer at the University of California ......................................................... 1729
 
Alan B. Bennett and Michael Carriere 
17.15 Intellectual Property and Technology Transfer by
 
the University of California Agricultural Experiment Station........................................... 1739
 
Gregory D. Graff and Alan B. Bennett 
17.16 From University to Industry: Technology Transfer at Unicamp in Brazil .......................... 1747
 
Rosana Ceron Di Giorgio 
C	 Product-Development Partnerships 
17.17 How Public–Private Partnerships Handle Intellectual Property: The PATH Experience... 1755
 
Steve Brooke, Claudia M. Harner-Jay, Heidi Lasher, and Erica Jacoby 
17.18 The African Agricultural Technology Foundation Approach to IP Management .............. 1765
 
Richard Y. Boadi and Mpoko Bokanga 
17.19 Pragmatic and Principled: DNDi’s Approach to IP Management .................................... 1775
 
Jaya Banerji and Bernard Pecoul
 
17.20 From Science to Market: Transferring Standards Certification Know-How from 

ICIPE to Africert Ltd. ..................................................................................................... 1783
 
Peter Munyi and Ruth Nyagah 
D	 Focus on Solutions: Accelerating Product Development and Delivery 
17.21 Patent Consolidation and Equitable Access: PATH’s Malaria Vaccines............................. 1789
 
Sandra L. Shotwell 
17.22 Lessons from the Commercialization of the Cohen-Boyer Patents: 

The Stanford University Licensing Program..................................................................... 1797
 
Maryann P. Feldman, Alessandra Colaianni, and Connie Kang Liu 
17.23 Specific IP Issues with Molecular Pharming: Case Study of Plant-Derived Vaccines......... 1809
 
Anatole Krattiger and Richard T. Mahoney 
xxiv | HANDBOOK OF BEST PRACTICES 
       
 
   
 
   
   
 
   










           
  
 
17.24 How Intellectual Property and Plant Breeding Come Together:
 
Corn as a Case Study for Breeders and Research Managers .............................................. 1819
 
Vernon Gracen 
17.25 Successful Commercialization of Insect-Resistant Eggplant by 

a Public–Private Partnership: Reaching and Benefiting Resource-Poor Farmers................ 1829
 
Akshat Medakker and Vijay Vijayaraghavan 
17.26 The University of California’s Strawberry Licensing Program........................................... 1833
 
Alan B. Bennett and Michael Carriere 
17.27 The IP Management of the PRSV-Resistant Papayas Developed by Cornell University 

and the University of Hawaii and Commercialized in Hawaii.......................................... 1837
 
Michael Goldman 
17.28 Fundación Chile: Technology Transfer for Somatic Embryogenesis of Grapes.................. 1845
 
Carlos Fernandez 
Appendix: Sample Agreements 
1. Editor’s Note ................................................................................................................... 1853
 
2. Co-Development Agreement ........................................................................................... 1855
 
3. Public Sector Technology License .................................................................................... 1865
 
4. Public Sector Patent License (Medical Research Council of South Africa) ....................... 1877
 
5. Plant Variety and Trademark License ............................................................................... 1893
 
6. Intellectual Property and Trademark License (Stanford  University) ................................ 1903
 
7. Distributorship Agreement .............................................................................................. 1921
 






HANDBOOK OF BEST PRACTICES | xxv 





     
            
 
     
Foreword by Norman E. Borlaug 
This Handbook is timely for several reasons. Whether we like it or not, when it comes to 
technology transfer, global integration has created a complex system of intellectual property 
management. This system includes public sector research institutions in developing coun­
tries that need guidance on how to negotiate the new and changing terrain. The Handbook
aims to provide these institutions with such guidance in the form of a reference resource. 
But the Handbook is more than that. It not only explains the intellectual property system, 
but shows how both public sector research institutions and developed countries can use 
intellectual property to achieve their humanitarian and socio-economic objectives. 
The past 50 years make up the most productive period in history, in terms of ag­
riculture. Innovations in agricultural science and technology made possible the Green 
Revolution, which is reputed to have spared one billion people the pain of hunger and 
starvation. New health innovations have helped control the scourges of polio, leprosy, and 
smallpox. Although we have seen the greatest reductions in hunger in history, it has not 
been enough. And despite the enormous potential of modern medicine, its reach is still too 
short for the hundreds of millions most in need of its preventative and curative powers. 
Several billion people around the globe require access to new agricultural technologies 
that could feed families while protecting the environment, as well as new health innova­
tions to combat HIV/AIDS, malaria, tuberculosis, dengue, and a host of other diseases that 
typically afflict the poor in developing countries. New science and technology—including 
biotechnology—have the potential to satisfy these needs. 
Today, the world food supply is nearly six billion gross metric tons and three billion 
net metric tons of edible dry matter. It includes cereals, roots and tubers, legumes, fruits 
and vegetables, livestock and fish. Within the next 50 years, the world’s population is likely 
to increase 60%–80%, requiring global food production to nearly double. We will have to 
achieve this increase on a shrinking agricultural land base, with most of the increased pro­
duction to occur in the countries that will consume it. Compounding the problem is the 
fact that more than half of the world’s 800 million hungry people are small-scale farmers 
who cultivate environmentally sensitive marginal lands in developing countries. Bringing 
the power of science and technology to bear on the protection of these fragile environments 
is one of the greatest challenges of the 21st century. 
Borlaug NE. 2007. Foreword. In Intellectual Property Management in Health and Agricultural Innovation: A 
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Despite these serious and daunting challenges, there is reason for hope. With the new 
biotechnology tools, we are poised for another period of rapid agricultural innovation. New 
science has the power to increase yields, address agroclimatic extremes, and mitigate a range 
of environmental and biological problems. Private industry has invested billions of dollars in 
research to make astonishing new discoveries and products, such as genetically modified crops. 
Unfortunately, with the notable exception of insect resistant Bt cotton in China and India, 
relatively few of the new crops developed by private industry are reaching smallholder farmers 
in the developing world. This situation must be corrected as soon as possible. 
The world of scientific innovation works differently today than it did 50, or even 20, years 
ago. Developing countries can no longer rely primarily on innovations from the public sector, 
because the private sector has taken the lead in inventing new technologies. Even those innova­
tions developed by public sector research institutions are inextricably part of a global IP regime 
since they normally build on inventions made by both public and private entities. 
As part of a global system, scientific institutions in developing countries need to un­
derstand how the IP system works to be able to capitalize on new opportunities. Moreover, 
global public sector research no longer marches to its own beat; to move forward, it must 
now work in tandem with the private sector. The promise offered by the new system is 
enormous; developing countries need to know how to negotiate access and how to build 
partnerships based on mutual value exchange. 
This Handbook is a valuable guide to navigating the complex—but bountiful—world 
of an increasingly global innovation system. The reader will find relevant case studies, con­
crete observations, and practical suggestions. The Handbook should be most useful to gov­
ernment policy-makers, senior managers of public research institutions, technology trans­
fer officers, and scientists in developing and developed countries. It is a resource that can 
help governments and other institutions move forward to meet the agricultural and health 
challenges of tomorrow. ■ 
December 2006 
El Batán, Mexico 
NORMAN E. BORLAUG, CIMMYT, Apdo. Postal 6-641, 06600 Mexico, D.F., Mexico. N.Borlaug@cgiar.org 
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Foreword by R. A. Mashelkar 
Intellectual property (IP) is no longer seen as a self-contained domain in which specialists 
alone work and dwell. It is viewed as an integral part of innovation-driven socio-economic 
development across the globe and is increasingly becoming an effective policy instrument 
with respect to a range of technological, socio-economic, and political concerns. This 
Handbook of best practices in intellectual property management, with its novel and useful 
Executive Guide is, therefore, an extraordinary contribution that has arrived at precisely the 
right time. 
The issues of generation, valuation, protection, and valorization of intellectual 
property are growing in complexity. There is increasing demand for new forms of IP 
protection. Economies are changing, with a new knowledge-based economy replacing 
“bricks-and-mortar” based economies. Scientific knowledge is growing exponentially. 
A new “geography of science” exists with innovative developing countries, such as 
India, China, and Brazil, having emerged as major contributors to science and technol­
ogy. Policy-makers, researchers, and entrepreneurs have begun to appreciate the vast 
resource of traditional knowledge in the developing world and to recognize the com­
plex issues connected with intellectual property therein. Not long ago, IP experts had 
only to deal with inanimate objects. Today, IP involving plants and animals, including 
humans, raises new complex issues and perplexing questions. Therefore, a book dealing 
with guidance on these issues with authority and clarity was sorely needed. The timely 
issuance of the Handbook and Executive Guide fulfills that need. The book is authorita­
tive, comprising contributions by many of the leading practitioners and thought lead­
ers in the field of IP management. The book has clarity. Its best practices and strategies 
have been explained in a way that is very easy to assimilate. 
Books on intellectual property that were published in the past, while in many ways 
valuable, dealt only with enterprises and institutions in developed countries. This Handbook
represents the first major effort to deal with issues of concern within the developing world. 
Furthermore, the role of public sector research institutions in fulfilling the socio-econom­
ic goals and objectives of developing nations, by contributing immensely to the public 
good as well as to the private good, had never before been written about extensively. This 
Handbook fills this void admirably. 
Mashelkar RA. 2007. Foreword. In Intellectual Property Management in Health and Agricultural Innovation:
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In the past, issues of emerging global innovation networks related only to North–North 
partnerships. But today North–South partnerships as well as South–South partnerships 
are emerging. As “technonationalism” finds a new equilibrium with “technoglobalism,” 
IP management issues are becoming ever more complex. New forms of knowledge in the 
private domain as well as the public domain are being created. It is no longer Linux versus 
Windows—it is Linux with Windows! In general, how do we create a new nexus between 
the public and the private? The Handbook has taken up this new challenge head-on. 
Drafting, interpreting, and analyzing the techno-legal and business information con­
tained in IP documents requires specialized skills. Monitoring, through online databases, 
the wealth of information in patents and other forms of intellectual property in order to 
ward off threats to national IP portfolios is becoming critical. Analyzing such information, 
for market intelligence, to identify strategic alliances, and to exploit potential niche areas 
for the innovative use of intellectual property will, itself, give rise to new knowledge-based 
businesses. This Handbook is invaluable from this perspective, as well. 
Today, start-up companies and spinouts reach beyond Stanford, M.I.T., Cambridge, 
and Oxford. Leadership in China reports that Chinese universities have set up several hun­
dred high-tech start-ups. India is introducing a Bayh-Dole-type law for Indian universities 
and research institutions. In short, the phenomenon of wealth creation through the knowl­
edge generated at universities is spreading across the world. The Handbook offers valuable 
guidance to university inventors and administrators with regard to licensing, negotiating 
agreements, technology transfer, dispute resolution, and so on. 
One of the most fascinating sections presents institutional case studies, providing in­
sights from Stanford, M.I.T., Cambridge, and other leading public sector research institu­
tions. The case studies will be most revealing for institutions in emerging economies setting 
up their own technology transfer systems and wishing to emulate those universities. 
When a patenting culture starts in an institution, issues of how to read and write 
patent applications, how to document inventions, as well as how to prepare laboratory 
notebooks and invention disclosures become crucial. In India, there was nothing to guide 
us when our own “patent literacy movement” began. We learned the hard way. How much 
easier and productive our work would have been had the Handbook and Executive Guide 
been available to us then! 
The issues of IP management in low- and middle-income countries are vastly complex. 
In particular, lifesaving innovations in health and livelihood-generating innovations in ag­
riculture directly affect those countries’ socio-economic development. Special attention has 
been given in the Handbook to address these issues. 
I do hope this Handbook will not only help in providing guiding principles and best 
practices in IP management, but will become a lighthouse that will show the way toward 
a more equitable and inclusive world. After all, making intellectual property work for the 
poor, whether it is owned by the public or by private entities, can be the only way to create 
an innovation-led inclusive growth movement. 
March 2007 
Pune, India 
R. A. MAshELkAR, Bhatnagar Fellow, National Chemical Laboratory, Pune 411 008, India. ram@ncl.res.in. 
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Foreword by Francis Gurry 
Intellectual property (IP) has become a much richer field of endeavor as it has moved from 
isolationism in the world of policy to a position of engagement. From a one-dimensional 
technical specialization, intellectual property has become a multidimensional complex of 
policies. The transition has not, however, been without cost, in this case in the form of 
greater complexity. The range of policy fora in which intellectual property is discussed has 
expanded, seemingly without limit, to encompass most international organizations, as each 
of the policy domains for which these organizations are responsible confronts the implica­
tions of IP rights in the new environment of the knowledge economy. These policy inter­
sections recur at each of the regional, bilateral, and national levels. And the cast of actors 
involved in the drama contains a much wider and more diverse range of characters, per­
forming a more demanding repertoire than would have been imaginable two decades ago. 
Nowhere is this development more striking than in the life sciences, especially related to in­
novation for public health and agriculture, where the promises of new technology that may 
serve the most fundamental of human needs vie with complex concerns over the impact of 
technologies, ethical issues, and claims over fundamental justice and human rights. 
Intellectual Property Management in Health and Agricultural Innovation: A Handbook 
of Best Practices will serve as an invaluable resource in this challenging new environment. 
The Handbook is based on a number of orientations that contribute in highly positive ways 
to an understanding of the utility, value, and limitations of IP rights as a system of law, a 
mechanism for policy development, and a policy instrument. 
The Handbook’s first positive orientation is the practical approach embraced by it and by 
the companion Executive Guide. The increased attention that intellectual property has, quite un­
derstandably, attracted has brought with it a certain tendency to conflate IP issues with some of 
the grandes idées that permeate the reflections of contemporary society, such as globalization, the 
ethical limits of scientific endeavor, and distributional equity. This tendency has had an adverse 
effect on IP management because it has redirected the focus of intellectual property away from 
practical issues; intellectual property is not necessarily neutral with respect to any of these grand 
movements of thought. But we would do well to remember that policies involving intellectual 
property are operational policies, the effects of which depend heavily on how the intellectual 
property is deployed and used. Solid practical guidance and experience are precious resources 
and they are to be found in abundance in the Handbook. 
Gurry F. 2007. Foreword. In Intellectual Property Management in Health and Agricultural Innovation: A Hand-
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Practical approaches and solutions offer a welcome contrast to the notion that every­
thing has a legislative solution. Legislation, whether national or international, is of limited 
value and is always without meaning unless given life through practical action or imple­
mentation. We have experienced an explosion of IP legislation at the international level in 
the past 15 years, with ten new multilateral treaties being concluded between 1989 and 
2000. Experience of the practical management of IP rights provides a rich knowledge base 
for evaluating and harnessing the benefits of this legislative landscape and for assessing the 
full range of options open to public- and private-sector actors to deliver, in practice, the 
ostensible benefits of this intense phase of legislative activity. 
A second very positive orientation of the Handbook is through the espousal of a meth­
odology of best practices. In the complex world of international negotiations, solutions 
are often based on the identification of the lowest common denominator of the varied 
positions and underlying interests of the countries involved. Such an approach is often 
necessary for finding agreement in a world with, as yet, a still underdeveloped sense of the 
common sphere. Few examples are to be found of agreements based on the identification 
of best practices, as a positive expression of the common interest, and agreement on the 
aspiration of striving toward such best practices. While the world awaits more widespread 
acceptance of the methodology of best practices with regard to the international legislative 
process, the Handbook makes a major contribution, by providing a description of the use 
of that methodology, with respect to practical choices for the management of intellectual 
property within the current legislative environment. 
An understanding of best practices is essential for the Handbook’s strategic orienta­
tion—a strategic approach to the management of intellectual property. The complexity of 
the environment of intellectual property demands the use of effective strategies for navi­
gating the sophisticated institutional architecture and for utilizing the potential that intel­
lectual property offers for the generation, deployment, and diffusion of new knowledge in 
the commercial, scientific, and public sectors. The patent system has developed the most 
comprehensive, systematic, and accessible record of humanity’s technology. Fifteen years 
ago, this treasure of knowledge was known only to a small group of experts who had access 
to the paper collections in which the record was stored. Digital technology has combined 
with the accessibility of the Internet to make this record available, free of charge, to the 
whole world. When mined intelligently, this wealth of raw data can provide the techno­
logical and policy information that enables the public and private sectors to have a more 
strategic approach to the identification of research opportunities, freedom to operate, and 
business strategies. 
The Centre for the Management of Intellectual Property in Health Research and 
Development (MIHR) and the Public Intellectual Property Resource for Agriculture 
(PIPRA) are to be commended for the development and publication of the Handbook, 
which will advance the understanding and practice of intellectual property in a construc­
tive, pragmatic, and highly effective manner. 
March 2007 
Geneva, Switzerland 
FRANcis GURRy, Deputy Director-General, World Intellectual Property Organization (WIPO), 34, chemin des 
Colombettes, 1211 Geneva 20, Switzerland. francis.gurry@wipo.int 
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Foreword by Howard A. Zucker 
The past 25 years have witnessed major challenges and successes in the field of public health. 
Carefully planned and implemented measures for prevention and control have shown their 
worth in battling formidable infectious scourges: smallpox was eradicated in 1979, and 
the public health menace measles has been contained. New drugs have been developed for 
HIV infection, dramatically improving the prognosis of those who receive antiretroviral 
therapy. Even with new menaces, such as avian influenza, and setbacks to such programs as 
polio eradication, the control of communicable diseases is technically feasible. 
What is technically possible, however, has not always been accessible by developing 
countries. Indeed, access to appropriate treatments for diseases and conditions that dispro­
portionately affect developing countries is still a big stumbling block. Part of the problem 
stems from inadequate health-services coverage: one-third of the world’s population lacks 
regular access to essential modern medicine (up to one-half, in certain parts of Africa and 
Asia). Direct financial constraints contribute to the problem. Drug discovery and develop­
ment is a complex, lengthy, and costly process. As recently reviewed in the World Health 
Organization Report of the Commission on Intellectual Property Rights, Innovation and 
Public Health (see pages 17 and 76 of that report*), even moderate estimates of the cost of 
R&D for some drugs put the total between US$115 million and US$240 million. 
Socio-cultural inequalities also have a profound affect on distribution. The majority of 
potential patients live in the poorer parts of the world, whereas the majority of drug and 
vaccine producers—and purchasers—are found in affluent countries. Although developing 
countries have more than 80 percent of the world’s population, they account for only about 
10% of drug sales. Major pharmaceutical producers—however great their desire to benefit 
all—are answerable to market forces and to the wishes of shareholders. 
For health products, both demand and supply are out of balance. Many public-health­
policy experts have pointed to the concept of IP (intellectual property) rights—the protec­
tion of intellectual and financial investments in new drugs and vaccines—as contributing 
to this imbalance and inequity. As part of the ongoing international debate about the wider 
aspects of the relationship between IP rights, innovation, and public health, the World 
Health Assembly under the auspices of the World Health Organization decided to establish 
an independent Commission to analyze the issue. The Commission’s report, released in 
Zucker HA. 2007. Foreword. In Intellectual Property Management in Health and Agricultural Innovation: A 
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2006, states that governments around the world have recognized moral and legal issues 
with respect to ensuring general access to existing drugs (see pages 8 and 9 of that report). 
This access is essential for sustaining government efforts in developing countries and else­
where to control disease. 
As a follow-up to the Commission’s report, a working group comprising government 
officials and other key stakeholders in public health, innovation, and intellectual prop­
erty is developing a global strategy and plan of action. The goal is to secure an enhanced 
and sustainable basis for need-driven health research and development aimed at curing or 
treating diseases that disproportionately affect developing countries. The strategy being 
discussed includes “making intellectual property work for health” as one of three major chal­
lenges. Among eight elements of the proposed plan of action for implementing the strategy 
is the management of intellectual property, including such aspects as legislation, incentives, 
documentation, training, and regulation. 
In deliberations of the intergovernmental working group, Member States have identi­
fied IP management as a key element of progress in the fight against diseases, an element 
that poses complex and sensitive problems in the realms of ethics, economics, and health 
policies. This Handbook of Best Practices is both timely and highly relevant. It is hoped that 
the Handbook will help build capacity in decision making at the national level by assisting 
academics, researchers, and policy-makers—especially in the developing world—to clarify 
many of the issues that currently influence the relationship between generalized access to 
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Foreword by Sir Gordon Conway 
From 1998 to 2004, I served as president of the Rockefeller Foundation. During that time, 
it’s fair to say there was no universally accepted understanding of the exact relationship be­
tween intellectual property (IP) and affordable essential goods for the poor. The foundation 
chose to approach this issue in a variety of ways, including support for the creation of the 
Centre for the Management of Intellectual Property in Health Research and Development 
(MIHR) and the Public Intellectual Property Resource for Agriculture (PIPRA). Until now, 
these organizations have worked independently. But although they differ in many respects, 
they share a common goal: to develop and disseminate best practices for the management 
of IP for the public good. Now, for the first time, the organizations have joined forces to 
weave together the common threads of their respective fields in order to create this unique 
and comprehensive book titled IP Management in Health and Agricultural Innovation: A 
Handbook of Best Practices. 
I would like to reflect a bit on the founding principles of these complementary orga­
nizations. Both PIPRA and MIHR were developed to promote the ethical stewardship of 
new technologies in their respective fields, based on the idea that publicly owned IP can be 
a currency to improve access to health and agricultural products and know-how. Yet the idea 
for each organization arose independently within The Rockefeller Foundation, following 
separate consultations with the agricultural and health communities. During the time that 
the foundation’s rice biotechnology program was operational, food security officers were 
keenly aware that many proprietary technologies developed in public institutions were 
then locked up in large corporations, a problem that was becoming evident to experts at 
U.S. universities as well. The “health equity” theme encountered similar problems as the 
foundation was working to establish global public–private partnerships for the develop­
ment of affordable drugs and vaccines. 
How had this situation developed? In many cases, research institutions in developed 
countries simply hadn’t considered the impact of their technology-licensing practices on 
developing countries. Public institutions in both developed and developing countries 
lacked sound policies that were specifically designed to maximize the benefits of global 
public goods resulting from their own public–private partnerships in R&D. To address 
these problems, local technology managers would need to become better informed and 
empowered to think globally, while public research institutions would need sound insti-
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tutional policies to ensure that public investment would lead to affordable essential goods 
for the poor. 
So far, MIHR’s efforts have focused on capacity building, working to build a cadre 
of technology management professionals in developing countries and to raise the stature 
of these professionals. MIHR has also worked to develop and promote a “tool kit” of best 
practices for technology managers in both developed and developing countries to encour­
age licensing practices that would benefit global health. 
PIPRA, in contrast to MIHR, is a consortium made up of more than 40 major 
American research universities and not-for-profit research institutions in the United States 
and abroad. The consortium was established to enhance global access to agricultural tech­
nologies that are developed by its member institutions. PIPRA promotes research collabo­
ration and collective management of IP among its members for public benefit. 
The PIPRA consortium is creating a broad patent/license database that will make it 
possible to determine readily both the range of technologies available from its member 
institutions and the manners in which these technologies will be made available to allow 
for specific applications. Where freedom to operate is clear, PIPRA is developing strategies 
that will promote the use of technologies by scientists to address the agricultural needs of 
poor farmers in developing countries. PIPRA is also creating public sector tools for use of 
improved subsistence crops for developing countries and of specialty crops to be grown in 
the United States. 
The PIPRA business plan envisioned future work in the building of agricultural tech­
nology–management capacity in developing countries—an effort that has been central to 
the mission of MIHR. At the same time, MIHR’s business plan envisioned the creation 
of a patent-and-licensing database for health technologies, and MIHR is currently explor­
ing the creation of a PIPRA-like consortium of university technology-management offices 
based in developed countries. In biotechnology, the similarities between agriculture and 
health range from the reagents used in the laboratory to their national regulatory and 
industrial policies. The potential for collaboration between PIPRA and MIHR on a wide 
range of issues is obvious. This publication is an exciting first step in that direction. 
I believe the global community must do more to promote the ethical stewardship of 
new technologies arising from public funding in developed countries to benefit agricul­
ture and health in the developing world. At the same time, we must begin to recognize 
that developing countries themselves are increasingly capable of contributing solutions 
to their own food shortages and public health challenges. This Handbook advances these 
goals. It is an important step toward both building upon and transcending the work of 
MIHR and PIPRA, by creating new transnational networks that involve multiple part­
ners—donors and doers alike—who believe that the power of innovation can address the 
needs of the poor. ■ 
December 2006 
London, U.K. 
siR GORdON cONwAy kcMG dL FRs, Chief Scientific Adviser, Department for International Development 
(DFID), 1 Palace Street, London, SW1E 5HE, U.K. g-conway@dfid.gov.uk 
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 Message from the Editorial Board:

From Best Principles to Best Practice
 
As members of the Editorial Board, we represent not only a diversity of professional back­
grounds, institutions, and geographic regions, but also a diversity of viewpoints about in­
tellectual property (IP). We agree on many things and we share a common goal: to broaden 
and accelerate access—especially in developing countries—to life-saving and poverty-al­
leviating innovations in health and agriculture. A fundamental vision of a more equitable 
world—represented in the points that follow—binds us together in this endeavor. 
•	 Intellectual property is a tool to foster innovation. Intellectual property is 
here. And here to stay. Whether viewed as a legal concept, a social construct, a 
business asset, or an instrument to achieve humanitarian objectives, the value 
of intellectual property cannot be disputed. The notion that inventions can 
become property and can therefore be owned and sold, has encouraged scien­
tists and researchers to invent, and entrepreneurs and companies to invest in 
innovation, by allowing them to profit from the resulting technologies. But 
by permitting entrepreneurs to exclude competitors and set higher prices, IP 
protection may also prevent some individuals, or populations, from being able 
to access products. There are many ways, however, that intellectual property 
can be utilized and distributed. Through the publishing of this Handbook, the 
companion Executive Guide, and the online version, we intend to help put 
intellectual property to work for the public sector and the public interest. We 
agree that intellectual property should be neither feared, nor blindly embraced; 
rather, it should be managed to maximize the benefits of innovation for all of 
society, especially the poor. 
•	 IP rights are a compromise and an imperfect solution. They represent the 
search for balance between making all knowledge freely available within the 
public domain and granting ownership of valuable discoveries to the inven­
tors. Historically, we have seen that this balance encourages investment—and 
reinvestment—in innovation, although this innovation too infrequently is di­
rected toward the needs of the poor. Reaching an appropriate balance requires 
Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB Bennett, K Satyanarayana, GD Graff, C Fernandez and SP 
Kowalski. 2007. From Best Principles to Best Practice: Message from the Editorial Board. In Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. A Krattiger, et al. Sharing the Art of IP Management: Photocopying and distribution through the 
Internet for noncommercial purposes is permitted and encouraged. 
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continuous, sound IP management, and our desire to encourage this was a ma­
jor impetus for compiling this Handbook and for writing the Executive Guide. 
Fortunately, as numerous case studies have shown, the public sector can craft 
effective solutions that can achieve, or at least approach, a suitable balance. This 
can be accomplished by using the existing IP system, especially as it addresses 
situations in which companies agree to donate or otherwise share their intel­
lectual property. 
•	 Genius can flourish anywhere, and the emerging global systems of innovation 
in health and agriculture open up new prospects for innovation everywhere. 
This notion has profound implications for the management of innovation, 
technology transfer, market competition, and economic development in every 
country, regardless of its economic status. Provided with opportunities and re­
sources, scientists and scholars from any locale can create promising inventions 
with the potential to become valuable technology. And whether inventions are 
home grown or come from outside, authoritative IP management will play a 
crucial role in enabling and preserving access to the resulting innovations. 
•	 Policies to promote the creation and management of intellectual property by 
public sector institutions should give first priority to advancing the mission 
of those institutions. In most countries, the mission of universities is edu­
cation, research, and public service. Universities are not revenue generators. 
Technology transfer should support the larger mission, and not merely the 
budgets, of those institutions. 
•	 The historical trend has been for intellectual property to benefit mostly the 
affluent. This is due, in part, to the fact that insufficient attention has been 
paid by the public sector to managing intellectual property. This lack of fo­
cused attention must be corrected. Public sector IP management is a rather 
young discipline, and there have been enormous changes in the public sector’s 
involvement in health research since the 1970s and in agri-biotechnology since 
the 1990s. The public sector is only now beginning to appreciate how it can 
use its own intellectual property—and leverage that of others—to help meet its 
social mission, including its responsibilities to the poor. We believe that there 
is growing interest, within both the public and private sectors, in using intel­
lectual property for public benefit but, also, a lack of knowledge and capacity. 
This Handbook is designed to help address these needs. 
We hope this Handbook and Executive Guide will encourage all parties to take greater 
advantage of the unprecedented opportunity to benefit from the strategic management of 
intellectual property aimed at promoting the public welfare—especially those people who 
have, until now, been unable to partake in technology’s benefits—and that this will con­
tribute to building a healthier and more equitable world. ■ 
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Prelude 
The many voices in this Handbook make up an expert chorus in the field of intellectual 
property (IP) management. Motivated by their passion for a better world, these virtuosos 
volunteered to share their experiences as part of a broader effort to bring innovation to the 
poor and improve the lives of millions of people. These selfless, ground-breaking experts 
bring to mind another revolutionary, Ludwig van Beethoven, who declared, “I have never 
thought of writing for reputation and honor. What I have in my heart must come out; 
that is the reason why I compose.” The compositions here are obviously less sublime than 
Beethoven’s, but their potential to inspire is nonetheless comparable: they are always writ­
ten from the heart. 
The creativity in these chapters reflects the fact that IP management is an emerging 
discipline, one best described not as science but as art. This is why the title pages of ev­
ery chapter announce that this Handbook is “Sharing the Art of IP Management.” These 
chapters offer lucid, cogent analyses of the role of intellectual property in many practical 
contexts and give free play to the imagination, inspiring readers to try new strategies, risk 
improvisation, and embrace new motifs. Such creativity is a necessary response to the in­
creasing complexity and importance of the nexus of intellectual property and the public 
good. 
Given that intellectual property is a critical institutional management and global pol­
icy issue, it can no longer be ignored by public sector-research institutions or left to the 
legal establishment. Policy-makers, leaders of scientific institutions, licensing experts, and 
scientists everywhere all need to act in concert to make the most of their work. But protect­
ing intellectual property is just the beginning. The real challenge is to use one’s intellectual 
property and to leverage that of others. This approach is at least as important for the public 
sector as it is for the private sector, given its humanitarian and socio-economic mandate. 
This concerto grosso gathers the experiences of IP professionals from North, South, 
East, and West, and offers innovative knowledge and strategies that can be applied to many 
institutional settings. Because increasing numbers of developing countries are seeking to 
optimize the economic, social, and cultural value of their IP assets and resources, I believe 
this Handbook will find a ready audience. The suite of chapters, composed by nearly 200 
authors, offers pragmatic suggestions and reference resources that will pave the way to 
greater access to health solutions and agricultural innovations. The authors write about 
Krattiger A. 2007. Prelude. In Intellectual Property Management in Health and Agricultural Innovation: A Hand-
book of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A.
Available online at www.ipHandbook.org. 
© 2007. A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
HANDBOOK OF BEST PRACTICES | xli 





the topics from various perspectives, an approach that inevitably led to some overlap. This 
overlap allows the reader to see a topic from several perspectives. The authors have distinc­
tive voices, and, as with Beethoven’s famous counterpoint, the distinctive parts are precisely 
what make the whole so compelling. 
Driven by rapid advances in science and technology and by the dawn of a worldwide, 
networked society, the increasing economic and humanitarian centrality of intellectual 
property will lead to more sophisticated and complex institutional infrastructures. The 
process is happening even as you read this Prelude. This is no time, therefore, to remain in 
complacent isolation. It is time to join your voices—and aggregate your values and your ac­
tions—to form a network of effective partnerships. A solo performance will lack the power 
of a full orchestra, and solo efforts at innovation will be stymied without collaboration. 
The strength of this Handbook is the depth and breadth of its information. But just 
as notes only become music when the bow meets the viola string and the timpani sounds, 
so these chapters will matter only when the reader translates them into action. My high­
est hope is that this Handbook will incite a passionate, rousing performance, one that will 
touch the lives of others and reverberate far beyond these pages. 
Anatole Krattiger 
Editor-in-Chief 
ANAtOLE kRAttiGER, Research Professor, the Biodesign Institute at Arizona State University; Chair, bioDe­
velopments-International Institute; and Adjunct Professor, Cornell University. PO Box 26, Interlaken, NY, 
14847, U.S.A. afk3@cornell.edu 
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Like the progress of any invention from bench to bedside (to use a health-related meta­
phor), or from sowing to harvesting (to borrow from agriculture), the road leading to the 
creation of this Handbook, and its companion Executive Guide and online version, has 
required a great deal of effort and more than a little good fortune. As editor-in-chief, I have 
discovered that compiling a book composed of 158 chapters and prefatory comments, 
written by nearly 200 authors, presents many unique challenges but offers many more 
unique rewards. 
The authors, first and foremost, deserve special thanks for their willingness to share 
their experiences and insights, their cooperation in meeting sometimes rather tight dead­
lines, and for their readiness to volunteer their valuable time (thanks are also due to their 
employers for allowing the authors to take the time to write). The hard work of these au­
thors is the good fortune of any reader of this Handbook. 
Special thanks go to the Rockefeller Foundation, particularly Ariel Pablos-Méndez 
and Charles Gardner, in health; Gary Toenniessen and Deborah Delmer, in agriculture; 
and Jacob Werksman (now at the World Resources Institute). Under their leadership, the 
Centre for the Management of Intellectual Property in Health Research and Development 
(MIHR) and the Public Intellectual Property Resource for Agriculture (PIPRA) were estab­
lished several years ago. Their inspired vision and determination, along with the foresight 
of Judith Rodin, president of the Rockefeller Foundation, has enabled us to bring you this 
Handbook. On behalf of all the users of the Handbook, the Editorial Board, and MIHR 
and PIPRA, I would like to offer my sincere appreciation to the Rockefeller Foundation 
for its commitment to and primary funding of this venture. Funding from the Ewing 
Marion Kauffman Foundation is also gratefully acknowledged. Lesa Mitchell’s interest in 
the Executive Guide was particularly welcome. Their combined sponsorship of these two 
foundations made the preparation of this Handbook possible. We would like to emphasize, 
however, that all of the policy, content, and editorial decisions were the sole purview of 
the Editorial Board. Naturally, as editor-in-chief, I take full responsibility for any errors or 
omissions. 
We are grateful for the generosity of our Distribution Supporters. After the Handbook
content had been prepared, a number of organizations were provided copies of sample 
chapters which prompted some to come forward to purchase copies for wide distribution 
in low- and middle-income countries. It is particularly noteworthy that the Distribution 
Supporters include several institutions from developing economies, in addition to aca­
demic and public-sector research institutions, philanthropic foundations, and companies. 
The impact of this Handbook will be greatly enhanced by the support of the Distribution 
Supporters–including those that we hope will come forward in the future. 
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The Editorial Board would like to express its gratitude to all the members of the Board 
of Patrons for their generous endorsement of the Handbook. Their wise counsel is much 
valued. 
The Editorial Board also wishes to thank the Association of University Technology 
Managers (AUTM) for allowing us to choose, update, and edit selected papers from the 
AUTM Technology Transfer Practice Manual, which appear as chapters in this Handbook, as 
well as for giving us permission to reproduce case studies from the association’s Better World 
Project and Reports from the Field (which appear in the Executive Guide). These contribu­
tions add much breadth and depth to the Handbook’s content. Mark Crowell, John Fraser, 
Stu Gordon, Vicki Loise, and Lisa Richter were all especially helpful. The Editorial Board 
would also like to thank the Public Interest Intellectual Property Advisors, Inc. (PIIPA), 
especially Michael Gollin and Steven Price, for assistance in enlisting the help of the law 
firms within its network; members of those law firms contributed many important chap­
ters. The individuals proved their commitment to PIIPA’s ideals by responding so promptly 
to our request and willingly contributing their ideas and experiences to the Handbook. 
The University Companies Association of the United Kingdom (UNICO) deserves ap­
preciation for sharing a valuable UNICO Practical Guide. My sincere gratitude also goes 
to the Guide’s main author, Mark Anderson, of Anderson & Company, for his coopera­
tion during the editing phase. I extend my gratitude to Intellectual Asset Magazine (IAM, 
published by Globe White Page, Ltd.) and particularly its editor, Joff Wild, for allowing 
the Handbook’s editors to edit and update an important chapter that previously appeared 
as an article in IAM. Thanks go also to Les Nouvelles, published by the Licensing Executives 
Society, for allowing us to revise two of its articles for inclusion in the Handbook. 
Particular thanks go to the Whitehead Institute for Biomedical Research, which, 
through the good offices of Amina Hamzaoui, granted us a license to its valuable, pro­
prietary patent- and agreements-management system, WIIPS™ (the Whitehead Institute 
Intellectual Property System), and granted us the right to sublicense the system to technol­
ogy transfer offices through the online version of the Handbook. 
The members of the Editorial Board are most grateful to the colleagues at MIHR in 
Oxford, U.K. First, the Editorial Board would like to thank Robert Eiss, CEO, for his 
resourcefulness in facilitating progress on the Handbook. Thanks are due also to Junko 
Chapman for coordinating, most diligently and always with characteristic Japanese cour­
teousness, all of the authors’ biographies, deeds, and photographs (the latter appear in the 
online version of the Handbook). Rachelle Harris deserves special appreciation for her in­
dustrious help—and always enthusiastic support—on many different crucial fronts. Thanks 
to the administrative staff at MIHR who always went the extra mile to get things done. 
Sincere thanks go to the entire Board of Trustees of MIHR, particularly the chair, Pramilla 
Senanayake, for their foresight in establishing a Board subcommittee for the Handbook. 
That committee, composed of Lita Nelsen, Richard T. Mahoney, and Jerry Keusch, was 
astonishingly effective. I thank them for their pragmatism and encouragement. 
This endeavor has truly been a collaborative effort between MIHR and PIPRA—an 
essential partnership that made this Handbook possible. Members of PIPRA’s staff, led by 
Alan Bennett and Greg Graff (both members of the Editorial Board), Sara Boettiger, and 
Cecilia Chi-Ham, were always a pleasure to work with. Their efforts, always indispensable, 
were executed with PIPRA’s characteristic professionalism and efficiency. 
Without its skillful and effective editorial and production team, this Handbook could 
not have taken shape nor reached its high level of readability and quality. My personal and 
most sincere thanks go to David Alvarez, for his unstinting help and commitment. He 
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worked with me throughout this project and his good humor made crunch times more 
bearable. Thanks also to his most able and enthusiastic manuscript editors, Jacqueline 
Stuhmiller and Katy Dixon. I am most grateful also to Paula Douglass for her diligent, 
sharp, and sensitive editing of the manuscripts and her exacting standards. I wish to espe­
cially acknowledge the efforts of the contributing editors, Stan Kowalski and Greg Graff, 
for their perseverance. Their ability to organize and process complex and diverse material 
proved indispensable. 
The elegant design work by Linette Lao will be evident to anyone holding this 
Handbook. She is truly a pleasure to work with, and I am grateful to her staff—Mary Penn, 
Julie Morelli, and Kristin Schrader—who sometimes worked around the clock on the lay­
out and design of this book. On behalf of all of the Handbook’s readers, I thank eagle-eyed 
Barry Hall who performed the final copyediting of each and every chapter. 
Stan, David, Jacqueline, Paula, Greg, Linette, Mary, and Barry deserve special mention 
for extraordinary dedication, which allowed us to go to press in a timely manner. 
It is a particular pleasure to acknowledge the creativity and superb work of the staff of 
Dynamic Diagrams, Inc.—Lisa Agustin and her team of Timothy Roy, Fred Toth, Matt 
DeMeis, and Henry Woodbury—for their excellent work in developing the online version 
of this Handbook. Their enthusiasm and focus have taken the online version further than 
we could ever have imagined. Jacob Werksman’s foresight proved particularly valuable. 
A special word of appreciation goes to Charles Arntzen at the Biodesign Institute at 
Arizona State University for having recognized the importance of this Handbook and for 
his thoughtful support. Michael Crow, president of Arizona State University, with his vi­
sion and enthusiasm, encouraged me both directly and indirectly. I am indebted to John 
Dodds of Dodds & Associates for having taught me a great deal about the ins and outs of 
intellectual property management. His advice on legal matters during the chapter review 
process was extremely helpful. 
I have been most fortunate, as editor-in-chief, to have had the assistance and support 
of an outstanding Editorial Board. The hard work, deep commitment, expert guidance, 
and collective experience of these dedicated and talented Board members have inspired 
and motivated me, personally and professionally, and have kept this project on course. I am 
grateful for having had the opportunity to lead this worthwhile and far-reaching endeavor 
with these fine individuals. 
Finally, on behalf of the Editorial Board, I would specifically like to thank Richard 
T. Mahoney, co-editor-in-chief of this Handbook and sole editor of an earlier and more 
concise version. Richard’s book—and life work—inspired me throughout the work on this 
Handbook. His enthusiastic support and creativity and generous investment of time and 
energy over the last two years were always delivered allegro maestoso. His good humor and 
pragmatism—which helped keep everything in perspective—have contributed in immea­
surable ways to creating this Handbook and making it available to you. ■ 
Anatole Krattiger 
Editor-in-Chief 
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Centre for the Management of Intellectual Property

in Health Research and Development
 
To contribute to a world in which the thoughtful stewardship and creative
management of intellectual property leads to better health for the poorest. 
Over successive generations, innovations result­
ing from research have dramatically improved 
life expectancy and quality of life. However, the 
benefits of these innovations are not reaching the 
populations with the greatest need. Stark dis­
parities persist with regard to health status both 
among and within populations. Today there is 
an urgent need to identify practical mechanisms 
that translate R&D investments more effectively 
into affordable interventions for diseases of the 
poor. Central to resolving the issue is the need to 
develop and promote forms of IP management 
and technology transfer practices that enable and 
empower local public–private technology part­
nerships, that direct them toward public health 
priorities, and that follow licensing practices that 
ensure access for the poor. 
MIHR was established in 2002 with funds 
from The Rockefeller Foundation, to advance 
the goal of improving availability of health 
products needed by the poorest in develop­
ing countries. MIHR is a not-for-profit global 
organization headquartered in Oxford, U.K. 
Its foundational tenet is that improved man­
agement of innovation and intellectual prop­
erty (IP) by the public sector is a key means to 
achieve that goal. 
The organization works to improve the 
processes of innovation management in the 
biomedical arena by building skills, know-how, 
and awareness in developing countries and by 
contributing to the understanding of sustain­
able innovation and IP policies that affect global 
health research. 
MIHR also works to ensure that holders and 
managers of technology worldwide are aware of 
the need for and potential applicability of their in­
ventions for improving health in developing coun­
tries. The Centre accomplishes this by facilitating 
local development of appropriate, affordable, and 
innovative biomedical technologies for poor pop­
ulations. MIHR contributes to economic devel­
opment by enhancing essential linkages between 
sectors, institutions, and disciplines involved in 
biomedical innovation and by enhancing the ca­
pabilities relevant to technology transfer that con­
tribute to economic and social welfare. 
MIHR’s core objectives are: 
•	 to create a broad and sustained program 
of capacity building in IP and technology 
management to promote global health equi­
ty through North–South and South–South 
institutional partnerships and networks 
•	 to help ensure that access considerations for 
global health are pursued in parallel with 
product development, so that successfully 
developed products become available and 
affordable to populations in need 
•	 to develop technology and IP management 
approaches that create incentives for re­
search cooperation in global health by sup­
porting analysis and new models 
MIHR achieves its goals by working through 
and with other institutions. It functions with 
a small core operational staff, a Committee of 
Interested Parties, and a Board of Trustees. ■ 
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Public Intellectual Property Resource for Agriculture
 
A public sector collaboration for agricultural IP management:
 
Enabling access to intellectual property for the development of improved crops
 
Patenting of agricultural biotechnologies has ex­
panded dramatically over the last 25 years, and 
today a lack of access to patented technologies 
represents a significant barrier to new crop devel­
opment. Companies are addressing the develop­
ment of major crops and large market opportuni­
ties, yet most crops in developing countries and 
specialty crops in developed countries are being 
neglected. Developing countries are not receiving 
research investment or opportunties to benefit 
from the many promising technologies developed 
and patented by both public and private sector 
researchers. 
The public sector and publicly supported 
research continues to play a major role, as it has 
historically, in agricultural innovation. This is par­
ticularly true in developing countries where the 
public sector and publicly supported research in­
stitutions are virtually the only innovative forces. 
In spite of this and the now well-established im­
portance of intellectual property (IP) in agricul­
tural innovation, public sector institutions have 
not developed the skill base and infrastructure 
needed to actively manage intellectual property. 
Consequently, these institutions find that their 
research programs may be blocked at the point of 
application or that they are unable to effectively 
transfer their own technology for private sector 
development. 
The primary objective of the Public 
Intellectual Property Resource for Agriculture 
(PIPRA) is to promote access to agricultural tech­
nologies developed in public and/or private non­
profit research institutions for both humanitar­
ian and neglected commercial purposes. PIPRA 
was created as a result of lengthy consultations 
involving two philanthropic foundations, the 
Rockefeller and McKnight foundations, and ap­
proximately 12 public and/or private nonprofit 
agricultural research institutions. The consulta­
tions identified many of the IP issues and barriers 
that were affecting the ability of public institu­
tions to address their historic mission of deploy­
ing new agricultural technologies. 
In response, PIPRA has established a strategy 
and a series of programs that promote broad ac­
cess to agricultural technologies. The strategy is 
based on bringing together a strong membership 
base of the major public or nonprofit agricultural 
technology developers of the world. PIPRA is 
seeking, through its membership base, to build a 
framework of open and collaborative communi­
cation and principles for IP management and to 
begin to coordinate the highly fragmented port­
folio of agricultural intellectual property owned 
by its member institutions. 
PIPRA does not subscribe to a single phi­
losophy or approach to addressing IP issues. 
Instead, PIPRA believes in employing a wide 
range of available IP management tactics. These 
include defensive publishing, trademarks, bail­
ment, open source, patenting, and careful licens­
ing. In each case PIPRA chooses the best tools 
available to achieve the goals of a specific project. 
This approach is practical in that it recognizes 
that technologies may need to be sourced from a 
wide range of public and private technology de­
velopers who have their own objectives and their 
own IP strategies. PIPRA has developed sufficient 
internal capability to work flexibly in navigating 
HANDBOOK OF BEST PRACTICES | xlix 

















a path to enable agricultural projects that meet 
the complementary objectives of a community of 
public/nonprofit technology developers. 
PIPRA’s services, its broad membership base, 
its extensive knowledge of public sector agricul­
ture, its legal network, and its capacity for legal 
research, work to reduce the IP hurdles that exist 
along the path from research, through develop­
ment, to distribution. This work enables the 
strategic use of IP rights to further the goals of 
public sector research and reduces the diversion 
of individual institutional resources into the legal 
issues of technology access and IP rights. 
PIPRA’s primary strategies to improve access 
to technologies are to: 
•	 provide an IP clearinghouse for access to 
public-sector patented technologies 
•	 provide a resource for the analysis of pat­
ented technologies for implementation of 
specific projects 
•	 develop gene transfer and gene-based-trait 
technologies that have maximum legal free­
dom to operate 
•	 manage pools of public sector technologies 
to promote availability and reduce transac­
tion costs associated with the transfer of 
rights to patented technologies 
•	 support the development of IP manage­
ment best practices and capacity enhance­
ment in developing countries. ■ 
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CHAPTER 1.1 
The Role of IP Management

in Health and Agricultural Innovation
 
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric Dengue Vaccine Initiative, 
International Vaccine Institute, Republic of Korea
 
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University;
 
Chair, bioDevelopments-International Institute; and Adjunct Professor, Cornell University, U.S.A.
 
ABSTRACT 
Recent national and international changes in intellectual 
property (IP) legislative frameworks are likely to have 
profound effects on the ways in which health and agri­
cultural innovations reach the poor and on how public 
and private research and development institutions pursue 
their work. Whereas IP rights are sometimes viewed as 
creating barriers to access to innovations in health and ag­
riculture, we argue that it is not intellectual property, per 
se, that raises barriers, but rather how intellectual prop­
erty is used and managed, particularly by public sector 
institutions. Above all, we argue that intellectual property 
is only one of six components of innovation. It is rarely 
the most important component. 
The chapter reviews recent dramatic developments 
in institutional aspects of intellectual property, as well 
as global policy shifts and international studies that, 
among other outcomes, affected the environment for the 
creation of MIHR and PIPRA. In the field of health, 
changes have been particularly pronounced with the 
founding of a new form of institution for innovation: 
product-development partnerships (PDPs). As a result, 
we make the case for a fundamental shift in the way in 
which IP management in health and agricultural innova­
tion is viewed and conducted. In addition, we argue that 
IP management should be seen as an important element 
in developing countries’ strategies to become more in­
novative in addressing diseases of poverty, the alleviation 
of poverty, and malnutrition. The public sector can em­
ploy new ways to achieve its goals within the evolving IP 
framework. These new ways can help it better mobilize 
the resources to take a product through the process of 
innovation. These new ways should include, a) creative 
licensing practices that ensure global access and afford-
ability, b) improved institutional IP management capa­
bilities, c) the formulation of comprehensive national IP 
policies, and d) the strengthening of IP court systems 
and patent offices. 
These are what best practices in IP management are all 
about, and what this Handbook seeks to help bring about 
and promote. 
1. InTRoduCTIon 
Changes in both national and international legis­
lative frameworks have profoundly affected how 
innovation reaches the poor and how public and 
private research and development institutions 
pursue their work. In this regard, the experience 
of the United States with the Bayh-Dole Act of 
1980, which harmonized the numerous IP own­
ership policies of U.S. government agencies, is 
quite instructive.1 The act significantly changed 
how academic institutions manage intellectual 
property. Universities had to adapt to an increas­
ingly knowledge-based economy, a trend that is 
continuing and even intensifying. And because of 
the increasing interaction between developed and 
developing economies and the increased number 
and complexity of relationships between the pub­
lic and private sectors, the need for understand­
ing these partnerships and how they can best op­
erate is becoming compelling. Some of the major 
changes in this environment of the last decade in 
health, agriculture, and intellectual property itself 
are shown in Box 1. 
Mahoney RT and A Krattiger. The Role of IP Management in Health and Agricultural Innovation. In Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et
al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. RT Mahoney and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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MAHONEY & KRATTIGER 
In addition, the last several years have been 
marked both by big changes in institutional IP 
infrastructures and by dramatic developments 
in the world of non-governmental organizations 
(NGOs), public sector research institutions, and 
public–private partnerships (see Box 2 for a dis­
cussion on agricultural biotechnology-related as­
pects). These developments promise to reshape 
the global IP environment, especially for devel­
oping countries. Some of the more significant of 
these events include:2 
•	 2003: The founding of the African 
Agricultural Technology Foundation 
(AATF) 
•	 2003: The founding of the Centre for 
the Management of Intellectual Property 
in Health Research and Development 
(MIHR) 
•	 2003: The creation, within AUTM, of the 
Technology Managers for Global Health 
(TMGH) group 
•	 2004: The founding of the Public Intellectual 
Property Resource for Agriculture (PIPRA) 
In the field of health, the changes have been 
no less dramatic. A number of product-develop­
ment partnerships (PDPs), concerned with most 
of the high priority diseases in developing coun­
tries, emerged during the 1990s and 2000s. PDPs 
must deal daily with IP management issues, and 
the lessons they are learning about the role of in­
tellectual property are of great interest. MIHR 
has convened two meetings to analyze IP man­
agement in PDPs, both of which took place at the 
Aeras Global TB Vaccine Foundation, the first in 
December 2004 and the second in July 2006.3 
In fact, MIHR’s founding and development in 
Box 1: Major Recent Events in the Global IP system
 
Concerning IP in General 
•	 2002: Report of the Commission on Intellectual Property Rights of the United Kingdom4 
•	 2005: Entry of many low- and middle-income countries into TRIPS on January 1 
Primarily Health-Related 
• 	 2001: Meeting of the 4th Ministerial Conference of the World Trade Organization (WTO),
which adopted the Doha Declaration concerning the TRIPS Agreement and Public Health5 
• 	 2005:Approval of the amendment to the TRIPS Agreement providing for the supply of drugs 
manufactured under compulsory licenses for developing countries without manufacturing 
capability 
• 	 2006: Report of the WHO Commission on Intellectual Property Rights, Innovation and 
Public Health6 
Primarily Agriculture-Related 
• 	 2001: Creation of the World Intellectual Property Organization (WIPO) Intergovernmental 
Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and 
Folklore7 
• 	 2001: Creation of the International Treaty on Plant Genetic Resources for Food and 
Agriculture, under the Food and Agriculture Organization of the United Nations (FAO) 
• 	 2002: Establishment of the Global Crop Diversity Trust, by FAO and the World Bank 
• 	 2002: Adoption of the Bonn Guidelines on Access to Genetic Resources and Fair and 
Equitable Sharing of Benefits Arising out of Their Utilization, under the Convention on 
Biological Diversity 
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CHAPTER 1.1 
Box 2: Putting Public-Sector Agricultural Intellectual Property to Work 
During the 1990s, the field of agricultural biotechnology was consolidated. A few large companies 
owned important elements of the enabling technology platforms. That ownership, coupled 
with strong R&D capability, existing marketing and distribution networks, and substantial cash 
flows from agro-chemicals and seeds, gave the companies incentives to invest heavily in the 
development of agricultural biotechnology products. With these increased R&D investments,
the companies became the dominant providers of new crop genetics and genetically modified 
crops.8 During the same period, biosafety regulatory requirements led to greatly increased R&D 
costs that slowed public sector developments of agri-biotechnology crops, especially public 
sector crop breeding programs.9 Research on minor crops and on traits of low economic value 
in developing country agriculture also decreased, even though these crops and traits have high 
social, humanitarian, and environmental value.10 
A significant turning point in the relationship between the public sector and intellectual property 
in agriculture occurred when a freedom-to-operate (FTO) review,commissioned by the Rockefeller 
Foundation, led by one of us (AK), of pro-Vitamin A-containing Golden Rice showed that around 
70 patents and patent applications were applicable to the improved rice.11 Fortunately, all of these 
constraints were resolved in a few months by a straightforward IP management strategy (grant
back of rights to a single entity that could use the rights for the benefit of developing countries).
The rapid resolution of these obstacles demonstrated, first of all, how effective IP management,
coupled with strong collaborations between the public and private sectors, can help achieve 
humanitarian goals. The IP constraints did not delay the development of the product, and their 
resolution did not cost much, especially when compared to the overall R&D costs.The FTO review,
moreover, served as a wake-up call to the public sector to pay more attention to IP management
as a powerful tool. 
Concern about potential constraints on public sector research and innovation in agriculture 
spurred the public sector’s interest in intellectual property. One important response was work 
that led to the formation of the Public Intellectual Property Resource for Agriculture (PIPRA).12 
Supported by the Rockefeller and McKnight foundations, among others, PIPRA is a public sector 
initiative that recognizes that continuing and enhancing relationships with the private sector are 
critical components of successfully utilizing intellectual property to meet public sector goals.
As part of its initial work, PIPRA began a study of the structure of IP ownership in agricultural 
biotechnology. In the words of the study’s authors, Richard C. Atkinson and colleagues: 
This study found that roughly one-fourth of the patented inventions were made by public-sector 
researchers, which is substantially larger than the IP portfolio held by any single agricultural 
biotechnology company. It is, however, highly fragmented across institutions and across technology 
categories. And much of this IP has been licensed, often under terms that are confidential but which 
have likely resulted in greatly restricted access to the underlying technologies. This study suggested 
that, apart from a few important exceptions, public-sector scientists have invented many of the 
types of technologies that are necessary to conduct basic biological research and develop new 
transgenic plant varieties. For instance, they have developed technologies to transfer genes into 
plant cells; have characterized specific DNA elements that drive unique patterns of gene expression;
and have identified many genes that confer important plant traits. Such discoveries underscore 
the fact that public-sector research institutions have been significant sources of technological 
innovation … .13 
We believe that these innovations can be put to work more directly to help the poor with more 
focused public sector IP management. 
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MAHONEY & KRATTIGER 
many ways reflect, and perhaps have helped to in­
fluence, the changing environment of IP manage­
ment. We summarize here the story of MIHR’s 
founding to help understand the major changes 
that have occurred and are underway. 
We believe that the events of the last decade 
have led the international development commu­
nity in health and agriculture to fundamentally 
reconceptualize the role of intellectual property 
in health and agricultural innovation, especially 
in relation to the needs of the poor. In the 1980s 
and 1990s, many individuals argued that intel­
lectual property and patents were bad for people’s 
health and innovative biotechnology products 
bad for their food. According to this argument, 
intellectual property was controlled by large 
pharmaceutical and agricultural companies that 
used the power of IP rights to capture markets, 
limit consumer choice in both health and agri­
culture, and, above all, raise prices. This not only 
priced the poor out of the market, but also dis­
couraged further innovation of products needed 
by the poor.14 
The claims of these arguments hold, howev­
er, only when the public sector responds passively 
to the global IP system. Like everyone else, the 
public sector needs to adapt to the changes in this 
system so that it can seize new opportunities and 
take advantage of previously unavailable options. 
Indeed, by neglecting to utilize the IP system ef­
fectively, the public sector not only neglects its 
own interests but the interests of those it serves. 
Without effective IP management, the public sec­
tor risks squandering the new powers that the re­
vised IP system provides. Intellectual property is 
a tool, and the impact of a tool depends on who
uses it, how it is used, and for what purpose. 
This perspective has led to new efforts, in­
cluding the founding of MIHR (see below) and 
of PIPRA (see Box 3), to make IP management a 
powerful tool for the benefit of the public sector. 
2. THE RoAd	 LEAdInG To	 MIHR 
Toward the end of the 1990s, staff of the Health 
Equity program at the Rockefeller Foundation 
became concerned about the possible impact of 
patents and other intellectual property on the 
development and availability of new health tech­
nologies that addressed diseases affecting people 
in developing countries. In the 1990s, the staff 
had observed a significant amount of agricultural 
intellectual property captured by multinational 
companies, a situation that made it difficult to 
conduct certain kinds of agricultural research for 
the benefit of poor countries. The Rockefeller 
Foundation staff sought to ensure that a similar 
situation did not occur vis-à-vis health technol­
ogy development. The Foundation therefore 
commissioned a group of individuals, led by one 
of us (RTM), to assess in detail the needs and op­
portunities in intellectual property and health. 
The results of this assessment eventually led to the 
founding of MIHR. 
The study was launched in April 2001. At 
the time there was a lot of confusion about the 
role and impact of patents and other intellectual 
property. It was feared that crucial intellectual 
property would be controlled by private entities, 
and that this control would make it impossible 
to conduct product research and development. 
With respect to existing products, there was con­
cern that patents provided virtual monopolies 
for companies—monopolies that the companies 
would use to extract high rents on the market­
place, making it difficult, if not impossible, for 
the poor to access the technologies that could 
benefit them. 
The Rockefeller Foundation study immedi­
ately faced a practical difficulty: little research had 
been done on needs and opportunities in intel­
lectual property and health. Only a small body 
of published literature addressed issues of interest 
to the foundation. Moreover, few scholars were 
studying these issues. The study team therefore 
decided to carry out its work by interviewing a 
wide array of individuals in the public and private 
sectors and in developed and developing coun­
tries. Nearly 200 individuals were interviewed, 
sometimes in groups but most often one-on-one. 
The following highlights some of the study’s sig­
nificant findings. 
The study began by contextualizing the prob­
lem. In market economies, the private sector is 
driven by the desire to maximize returns on in­
vestment. Modern economic theory holds that 
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maximizing such returns spurs economic growth. 
Because selling highly profitable health products 
to the well-to-do leads to the highest maximiza­
tion of return on investment, the private sector 
accords priority to products for these individuals. 
Conversely, the private sector does not and can­
not be expected to accord priority to the needs of 
the very poor. 
The public sector, on the other hand, is driv­
en, in democracies, by its search to maximize hu­
man well-being. Modern social theory holds that 
all humans, regardless of citizenship, economic 
status, or other demographic variables, should 
be given the chance to maximize their well-be­
ing. Because the poor suffer the lowest quality 
of health, and because they often cannot afford 
to buy needed pharmaceuticals, the public sec­
tor has the responsibility of according priority to 
these individuals. 
Within this political and economic frame­
work, which is certain to be with us for the fore­
seeable future, intellectual property has grown 
increasingly important. Capitalist companies 
energetically seek and avidly protect intellectual 
property to obtain adequate returns on invest­
ment. Indeed, it is widely accepted that intel­
lectual property is essential for the private sector. 
But what about the public sector? Does or can 
intellectual property help achieve important pub­
lic sector goals? 
. THE	SoCIAL	And 	EConoMIC	 
IMpERATIvES	 of pRoduCT	
dEvELopMEnT	And 	ACCESS 
On the most pragmatic level, intellectual prop­
erty is important to the public sector because it 
is important to the private sector. If public sector 
Box 3: The Public Intellectual Property Resource for Agriculture (PIPRA)
 
PIPRA is an international initiative undertaken by universities, foundations, and non-
profit research institutions to make agricultural technologies more easily available for the 
development and distribution of subsistence crops in the developing world and specialty 
crops in the developed world.
With the introduction of biotechnology in agriculture, researchers have a unique opportunity 
to contribute to the development of improved staple and specialty crop varieties. However,
developing new crop varieties with biotechnology depends on access to multiple technologies,
which are often patented or otherwise protected by IP rights. Ownership of these rights is 
fragmented across many institutions in the public and private sector, a situation that makes it
difficult to identify who holds what rights to what technologies, and in which countries. Such 
information is necessary, however, to establish whether or not a new crop variety is at risk of 
infringing those rights. The current situation thus creates barriers to commercializing new 
staple and specialty crop varieties. PIPRA members believe that if public-sector institutions 
collaborated in gathering information about and in the use of agricultural IP rights, it would 
be easier for them to speed up the creation and commercialization of improved staple and 
specialty crops and thereby fulfill part of their public missions. Specifically, PIPRA focuses on 
the following principal activities: 
• Reviewing public sector licensing practices 
• Implementing a collective public IP asset database 
• Developing shared technology packages 
• Providing information, engaging other organizations, and stimulating discussions 
• Engaging private sector organizations 
Source: Adapted from PIPRA.15 
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MAHONEY & KRATTIGER 
organizations, such as PDPs, want to collaborate 
with the private sector to develop new, valuable 
health technologies, they must address IP issues. 
Many, if not all, of the PDPs have recognized 
this. In fact, their experiences have led many of 
them to reassess the role that intellectual property 
plays in making health and agricultural products 
available to the poor. Before PDPs, critics con­
tended that intellectual property allowed private 
pharmaceutical companies to dominate markets, 
perpetuating high prices and excluding the poor. 
The experience of PDPs, however, shows not only 
that intellectual property can be utilized to serve 
the needs of the poor, but also that its misuse or 
waste slows the development of new technologies 
for developing countries. 
But how can the public sector best use the 
IP system? Should it seek to minimize the prob­
lems that emerge from patents and other forms 
of intellectual property? Or should it take a more 
active role and seek to take advantage of some of 
the powers provided by intellectual property? To 
answer these questions, one must be able to see 
what capabilities and what benefits might accrue 
from the exercise of these powers. 
The study ultimately concluded that there is 
a very important reason for public sector support 
of intellectual property: it is an essential tool for 
achieving safe and effective health technologies. 
Why? The answer is found in a combination of 
government actions and economic imperatives. 
During the latter half of the 20th century, de­
veloped countries created whole new systems 
of drug regulation. Of these, the Center for 
Biologics Evaluation and Research of the Food 
and Drug Administration (FDA) in the United 
States is one of the more influential. One of the 
motivations for its founding was the death of 
several children from polio vaccinations; the 
vaccine turned out to contain live poliovirus.16 
Rules and regulations, therefore, were estab­
lished to produce and distribute vaccines and 
drugs that are safe and effective. Over the years, 
these rules and regulations have become steadily 
more rigorous, making it increasingly expensive 
to develop new, safe, and effective pharmaceuti­
cals. As the costs of developing drugs rose, the 
pharmaceutical industry had to raise greater 
amounts of capital in order to pay for them. The 
investors who put up such huge sums naturally 
sought high returns on their risky investments, 
and such high returns could not be achieved 
without IP protection. In fact, the existence of 
intellectual property allowed the private sector 
to mobilize the funds necessary to develop safe 
and effective pharmaceuticals. The public sec­
tor could not (or at least did not) provide these 
funds, nor was it capable of developing the new 
products that were needed. 
The study therefore concluded that the IP 
regime plays an essential role in achieving an im­
portant public sector goal: the development of 
safe and effective pharmaceuticals. Accordingly, 
its next question was whether or not intellectual 
property had some additional practical benefits 
for the public sector. The study consequently 
identified a number of licensing practices that 
public sector organizations have used for the 
public’s benefit. If the public sector owned valu­
able intellectual property, it could license that 
intellectual property to private sector companies 
with conditions that benefited the public sector. 
For example, the licensing terms could require fa­
vorable pricing to the public sector. Moreover, by 
licensing to more than one company, the public 
sector could foster competition that could lead 
to lower prices for consumers. And finally, the 
public sector could require that the product be 
made available to both the lucrative private sector 
market and to the public sector. 
In addition, the emergence of Innovative 
Developing Countries (IDCs),17 such as Brazil, 
China, and India, is changing the face of global 
health and agricultural innovation. These coun­
tries and others like them will certainly contrib­
ute significantly to biomedical R&D in the near 
future. A major unresolved question, however, is 
whether their innovations will benefit the poor 
within their own borders and in other less well-off 
countries. It is important to identify innovation 
strategies and IP management policies and prac­
tices that will help ensure that the investments of 
IDCs in R&D benefit the poor. 
The study also concluded that the public sec­
tor, especially in developing countries, had very 
little capability—in terms of staff, policies, and 
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practices—to extract the benefits that could be 
obtained were they to implement enlightened li­
censing practices. The study therefore proposed 
programs to document best licensing practices 
and capacity-building initiatives. These are two of 
MIHR’s major programs, and this Handbook ad­
dresses both of these goals: it seeks to document 
best practices and to be a teaching and capacity-
building resource. 
As noted above, one of the concerns the study 
addressed was the extent to which the existence 
of patents and other intellectual property might 
inhibit or prevent the development of products 
needed by the poor in developing countries. The 
study, like that of Golden Rice (see Box 2 above), 
concluded that intellectual property rarely, if ever, 
blocks product development. This conclusion 
was supported by interviews with individuals in 
both the public and private sectors. They noted 
that there were several ways that companies or 
product developers could address “blocking pat­
ents.” First, one could seek a license from the pat­
ent owner. If this attempt was unsuccessful, other 
courses of action could be taken. For example, if 
an expert opinion determined that the blocking 
patents might not withstand legal challenge, then 
one could proceed without a license. In addition, 
Europe has a general research exemption that al­
lows one to undertake research using a patented 
technology without having to obtain a license for 
that technology. In the United States, however, 
“safe harbor” provisions18 greatly facilitated the 
development of a vigorous generic drug industry 
through a research exemption of the patent laws 
allowing them to make and use (but not to sell) a 
drug during its period of patent protection. This 
exclusion was critical to developing data neces­
sary for regulatory approval once the patents had 
expired. A third option is to “invent around” 
intellectual property: in other words, to create 
a similar technology that does not infringe on 
any existing patents. For vaccines, this is a com­
mon practice because it is often difficult to secure 
one or more dominating patents (that is, patents 
that would make it nearly impossible to invent 
around). Yet another strategy is to develop and 
market the products in countries where patents 
have not yet been filed.19 This was the strategy 
used by several Korean manufacturers that jointly 
developed a hepatitis B vaccine.20 
The study’s analysis concluded that intellec­
tual property is almost never the most important 
factor affecting the development and availabil­
ity of pharmaceuticals and vaccines. Instead, the 
most important factor seems to be the existence 
or absence of a market for those pharmaceuticals. 
Hepatitis B again presents a cogent case study. 
From a price of greater than $18 a dose, hepatitis 
B vaccine cost fell to less than $0.30 a dose once 
the public sector “made a market,” i.e. started 
buying tens of millions of doses per year.21 This 
finding about the relative lack of importance of 
IP led Rockefeller Foundation staff to study all 
of the major issues affecting the development 
and availability of pharmaceuticals. Briefly, the 
analysis revealed that the other factors were: sup­
port for research and development, the existence 
of domestic markets (including national health 
systems), the existence of international trade in 
the products (including procurement by inter­
national public-sector procurement agencies), 
the operation of capable regulatory systems, and 
the ability to manufacture products to high stan­
dards. Intellectual property was only one of six 
factors—and rarely the most important. These 
six factors are referred to as the “components of 
innovation.” 
We believe that placing intellectual prop­
erty in a broader product-development context 
is necessary to improve the development and 
availability of health technologies for the poor. 
Conversely, any strategy that focuses only on IP 
issues is bound to fail and may be counterpro­
ductive. Thus, efforts to promote compulsory 
licensing to get low prices for pharmaceuticals 
in developing countries must overcome not only 
IP difficulties but also the obstacles presented by 
other components of innovation: the existence 
of capable manufacturing facilities that meet 
international standards, the availability of funds 
to procure the products for both domestic and 
international distribution, and the cost of ob­
taining regulatory approval for products manu­
factured under compulsory licenses. These are all 
significant, costly hurdles; any one of them could 
prevent a compulsory license from being useful 
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or cost effective, i.e. the cost of production un­
der a compulsory license may be greater than the 
cost that could have been obtained through direct 
procurement of bulk quantities either individu­
ally by nations or through mechanisms such as 
the GAVI Alliance. (The Global Fund to Fight 
AIDS, TB and Malaria is [as of mid-2007] recon­
sidering it procurement policies. Rather than al­
lowing each country to do its own procurement, 
the Fund is considering doing bulk procurement 
to ensure getting the best prices.) 
.  InnovATIon	 And	 Ip	 MAnAGEMEnT
In	 A 	poST-TRIpS WoRLd 
Shortly after the MIHR study began, the Doha 
Declaration was approved. It called for accord­
ing higher priority to public health than to trade 
concerns, and it emphasized that countries were 
free to use the “flexibilities” of TRIPS to protect 
public health. A few years after MIHR was estab­
lished, the Doha Declaration was approved as an 
amendment to the TRIPS agreement. In the in­
terval between the Doha meeting and the approv­
al of the amendment, there were vigorous debates 
about the potential impact of TRIPS on access 
to medicines in developing countries. Some felt 
that TRIPS would be disastrous for developing 
countries. There were fears that it would suppress 
R&D, cause generics to disappear, and rapidly 
raise drug prices. Others felt that TRIPS would 
create a surge of support in developing coun­
tries for R&D, encourage joint ventures between 
pharmaceutical companies in developed and de­
veloping countries, and have little if any impact 
on the availability and prices of generics. 
In January 2005, India and many other devel­
oping countries came under the rules of TRIPS. In 
December 2005, MIHR and the Indian Council 
of Medical Research convened an international 
symposium to examine the impact of TRIPS. The 
full report of the symposium has since been pub­
lished.22 In short, the meeting’s conclusions tend 
to support the positive predictions mentioned 
above. Of perhaps greater importance, however, 
the meeting emphasized the need for developing 
countries to increase their capacities to manage 
intellectual property in ways that meet their own 
needs. The meeting also concluded that innova­
tion is such a complex process—of which intel­
lectual property is only one component—that it 
would be very difficult to document the impact 
of TRIPS on innovation; conversely, any impacts 
will be the result of a combination of factors, and 
will never be due to intellectual property alone. 
Toward the end of the MIHR study that 
began in 2001, but before the establishment of 
MIHR, the UK Commission on Intellectual 
Property Rights (CIPR) issued its report,23 which 
was read with great interest by the MIHR study 
team. A core conclusion of the CIPR report was 
that a one-size-fits-all approach to intellectual 
property was undesirable. Each country should 
have some freedom to adopt and implement laws 
and regulations that fit its own needs. Most re­
cently, the WHO Commission on Intellectual 
Property Rights, Innovation, and Public Health 
(CIPIH) report has emerged. It takes an even 
broader view of intellectual property and innova­
tion than the CIPR report. Both reports come to 
the following conclusions: 
•	 Innovation takes place in a complex en­
vironment in which intellectual property 
is only one factor, and rarely is the most 
important. 
•	 Developing countries need to determine 
what kinds of rules and regulations best ad­
dress their particular needs. 
•	 IP management capabilities in developing 
countries need to be rapidly improved in 
order to ensure that intellectual property is 
used to improve health. 
An analysis of IP management and innova­
tion by Morel and colleagues24 found that donors 
have already marshaled significant resources and 
created organizational structures that accelerate 
the development of new health products and that 
procure and distribute drugs and vaccines for the 
poor. Their analysis concluded with a proposal 
for complementary strategies to improve health 
equity: national governments should support 
product-development efforts, and the public and 
private sectors need a coherent strategy to address 
each of the six interrelated components of inno­
vation, also called determinants.25 
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CHAPTER 1.1 
.  ConCLuSIonS 
The Rockefeller Foundation launched in-depth 
evaluations of the role of intellectual property in 
innovation of health and agricultural technologies 
that benefit the poor, especially those in develop­
ing countries. Its efforts and those of the many 
individuals and organizations that have worked 
in this space to date have helped to reconceptual­
ize the relationship between the global intellectu­
al property system and developing countries. This 
reconceptualization has the following elements: 
•	 The dominant political/social framework 
of capitalism, markets, and democracy ac­
cords high priority to the protection of in­
tellectual property. This framework is going 
to be with us for the foreseeable future, and 
so the public sector needs to find ways to 
achieve its goals within this framework. 
•	 Intellectual property is important to the 
private sector because it helps investors 
achieve high returns on their investments. 
•	 Intellectual property is also of importance 
to the public sector because: 
− It mobilizes the resources that are needed 
to take a product through the process of 
research and development (especially 
those steps that are designed to ensure 
the product’s safety and efficacy). 
−	 It can help the poor. Creative licensing 
practices, for example, can help ensure 
global access and affordability. 
•	 IP management capabilities need to be im­
proved, particularly in developing coun­
tries, so that intellectual property can be 
managed for the benefit of the poor. 
•	 Intellectual property is only one of six 
components of innovation and is rarely the 
most important. Efforts to meet the needs 
of the poor must also: 
- Support R&D 
- Develop national health programs and 
agricultural extension systems that are 
sustaining domestic markets, including 
distribution systems in both the public 
and private sectors 
-	 Be conducive to facilitating trade in 
health and agricultural technologies and 
products (both input and output) 
- Encourage high-quality manufacturing 
of drugs and vaccines and investments 
in high-quality seed production and that 
of other agricultural inputs 
- Adopt policies and develop safe and ef­
fective regulatory systems (for drug and 
vaccine registration; biosafety and food 
safety for applications of biotechnology 
in food, feed, and fiber; and seed quality 
certifications) 
•	 Each country needs to take advantage of the 
freedoms granted by TRIPS and formulate 
and implement policies and practices that 
best meet its own needs. Short-cut solu­
tions to technology needs in medicine and 
health, such as compulsory licenses, are un­
likely to be as effective or sustainable as are 
collaborative efforts between the public and 
private sectors. Countries would benefit 
substantially from developing their internal 
IP management capabilities, strengthening 
their IP court systems and patent offices, 
and according priority to meeting the needs 
of the poor. 
When it comes to increasing developing 
countries’ access to fundamental innovations in 
health and agriculture, success requires knowl­
edge, capacity, and active engagement. These 
are what best practices in IP management are all 
about and what this Handbook seeks to help cre­
ate and promote. n 
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric 
Dengue Vaccine Initiative, International Vaccine Institute, 
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818, 
Republic of Korea. rmahoney@pdvi.org 
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute; and Adjunct Professor, 
Cornell University, PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu 
1	 The Patent and Trademark Amendment Act of 1980 (35 
U.S.C. §§ 200–211). See, also in this Handbook, chapters
3.2 By RA Nugent and GT Keusch and 3.4 by SK Finston. 
2 While these developments trace their origins to many 
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3 See, also in this Handbook, chapter 2.3 by R Eiss, KE 
Hanna and RT Mahoney. 
4	 Commission on Intellectual Property Rights.
2002. Integrating Intellectual Property Rights and 
Development Policy. Final Report of the Commission 
on Intellectual Property Rights. DFID: London. www.
iprcommission.org. 
5 WT/MIN(01)/DEC/W/2, 14 November 2001. www.wto. 
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Review of Economics & Statistics 85(2):349–363. 
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a Crossroads: Biotechnology and Intellectual Property.
California Agriculture 52(6):8–13; Kowalski S. 2007.
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Developing Countries: Towards Optimizing the Benefits 
for the Poor. Kluwer Academic Publishers.The Hague. p.
433;Wambugu FM. 1999.Why Africa Needs Agricultural 
Biotech. Nature 400(6739):15–16. 
11	 Kryder D, SP Kowalski and AF Krattiger. 2000. The 
Intellectual and Technical Property Components of pro-
Vitamin A Rice (GoldenRice™): A Preliminary Freedom-
to-Operate Review. ISAAA Briefs No 20. ISAAA: Ithaca,
NY. www.isaaa.org/kc/bin/isaaa_briefs/index.htm.
Vitamin A deficiency (VAD) is one such problem.In many 
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thousands of impoverished people lose their eyesight
because of VAD. In fact,severe VAD (xerophthalmia,also 
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every year. VAD also leads to a depressed immune 
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12	 Graff G, A Bennett, B Wright and D Zilberman. 2001.
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21	 Advances in molecular pharming, the so-called third 
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22 See, also in this Handbook, chapter 3.7 by R Eiss, RT 
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23 See supra note 2. 
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Tool for the Introduction of Vaccines in Developing 
Countries. Journal of Health, Population and Nutrition 
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CHAPTER 1.2 
Building Product Innovation Capability in Health
 
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric Dengue Vaccine Initiative, 

International Vaccine Institute, Republic of Korea
 
ABSTRACT 
This chapter presents a theoretical framework to explain 
the role of intellectual property (IP) in innovation and ap­
plies the framework to the growth of the pharmaceutical 
industry. Developing countries progress through stages of 
capability to reach the status of Innovative Developing 
Country (IDC). To reach the status of an IDC, coun­
tries need to give concerted attention to six components 
of product innovation: R&D in the public and private 
sectors, regulatory mechanisms for drugs and vaccines to 
achieve safety and efficacy, the ability to manufacture to 
high standards new health technology products, national 
distribution systems in both the public and private sec­
tors, international distribution systems (including supply 
of drugs and vaccines through international organizations 
such as UNICEF, the operation of global funds, and trade 
among countries), and systems for managing IP. 
An analysis of pharmaceutical innovation in Korea’s 
vaccine industry concludes that its success in develop­
ing its impressive capabilities was achieved by paying 
close attention to all six components of innovation. 
Yet unknown is the extent to which the Agreement on 
Trade-Related Aspects of Intellectual Property will stimu­
late or thwart progress in the other innovation compo­
nents when IP is quickly moved to an advanced stage. 
1. InTRoduCTIon 
Several developing countries, including Brazil, 
China, India, and South Africa, are rapidly in­
creasing funding for biotechnology. These 
countries and others are improving their drug 
regulatory agencies and are adopting modern 
laws and regulations for IP management, as well. 
Some of the pharmaceutical companies in those 
countries have entered the international market 
with both generics and self-developed products. 
Rapid economic development is leading to ex­
panded domestic markets. This expansion is in­
creasing demand for products that address domes­
tic diseases. Countries that are developing in the 
ways mentioned here are referred to as Innovative 
Developing Countries (IDCs).1 Because diseases 
of the poor disproportionately affect these and 
other developing countries, IDCs may become 
a major source of health product innovation for 
diseases of the poor. 
The changes in IP management taking place 
in IDCs need to be assessed so that the interna­
tional development community can understand 
how IDCs can best participate in and, in some 
instances, actually lead efforts to develop new 
health technologies for the poor in developing 
countries. Such an assessment should consider 
changes in biotechnology manufacture, local de­
mand for these products, potential for export, 
the nature and extent of public and private sec­
tor support for biotechnology research, and the 
changing environment of IP, drug, and vaccine 
regulations. This chapter describes a framework 
for analyzing these factors. 
Mahoney RT. 2007. Building Product Innovation Capability in Health. In Intellectual Property Management in Health and 
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. RT Mahoney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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2. A fRAMEWoRk foR	AnALyzInG	 THE	
pHARMACEuTICAL	InduSTRy 
2.1  The six components 
The framework allows us to analyze the develop­
ment of the pharmaceutical industry in develop­
ing countries through six components: 
1. R&D in the public and private sectors 
2. Ability to manufacture to high standards 
new health technology products 
3. National distribution systems in both the 
public and private sectors 
4. International distribution systems, includ­
ing supply through international organiza­
tions such as UNICEF, the operation of 
global funds, and trade between countries 
5. Systems to manage IP 
6. Systems for drug and vaccine regulation to 
achieve safety and efficacy 
The components of the framework are linked 
dynamically. Progress in one requires progress in 
most—if not all—of the other components. It is 
difficult to improve R&D capability without first 
increasing manufacturing capability or having a 
national or international export market (requiring 
a distribution system) to generate resources for 
investment in production facilities. It is likewise 
difficult to enter markets in developed countries 
without good IP or regulatory systems. And while 
developing countries can access new technologies 
by entering into joint ventures with sophisticated 
firms in developed countries, these foreign firms 
will decide to form joint ventures based on the 
value of the domestic market in the developing 
country, the capability of local R&D centers, and 
IP protection levels. The interconnectedness of 
the six components is clearly very strong. And IP 
is an important aspect in all of them. 
2.2  From knowledge access to the role of IP 
IP policy-making in developing countries seems 
to be driven by conflicting goals. One goal is to 
encourage the influx of foreign technology. This 
can be achieved by providing enough protection 
for IP rights to enable foreign IP owners to pursue 
profits through licensing, marketing, and invest­
ment in the recipient country. This protection is 
needed especially when domestic R&D is focused 
on imitating or modifying foreign technology. 
On the other hand, developing countries have 
been able to access foreign technology cheaply 
and build manufacturing capability more quickly 
when unfettered by IP rights. This has worked to 
keep IP protection levels low, especially since few 
domestic innovators are harmed by such a regime. 
Instead of viewing the goals of foreign IP owners 
and domestic innovators as simply opposed, how­
ever, a closer analysis leads to a dynamic perspec­
tive. In the early stage of development, conflicts 
with foreign IP holders are minimal, typically, 
because domestic capability is poor and few for­
eign firms are interested in bringing technologies 
to the country. As the country’s technological ca­
pability improves, poor protection of foreign IP 
rights is likely to conflict with the further growth 
of domestic capability. In the last stage, when lo­
cal firms are able to generate their own IP, local 
demand for greater IP protection increases, re­
ducing conflicts with foreign IP holders.2 
2.  The special role of drug and 
vaccine regulation 
One key difference between the pharmaceutical 
industry and most other industries is the role of 
the stringency of the regulatory system for drugs 
and vaccines. As a country develops, the IP sys­
tem and the regulatory system often progress in 
tandem.3 In the early stage, there is little need 
for a well-developed national regulatory system. 
Most drugs and vaccines are imported from other 
countries, and it is assumed that the regulatory 
agencies of the producing countries have ensured 
their safety and efficacy. Any local production is 
contracted by foreign companies, which ensure 
quality control in order to meet regulatory stan­
dards in their home country or other countries 
where the products will be sold. 
However, as the local production of copied 
products intended for the domestic market be­
comes important, the need for local regulation 
emerges. The government now has an interest 
in ensuring quality products. Initially, its main 
activities are to check composition and review 
the production facilities. Later, domestic compa­
nies demand a much more developed regulatory 
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CHAPTER 1.2 
capability. They want greater regulation and a 
capable regulatory agency for two reasons: to es­
tablish an approval process for newly developed 
products and to support the development and 
sustenance of export markets. 
.  Ip	And THE	GRoWTH	 of
BIoTECHnoLoGy 	In 	koREA 
.1 A dynamic version of the framework 
The growth of biotechnology in developing coun­
tries is illustrated in Figure 1, which shows the 
patenting trends in Korea and the United States 
by Korean vaccine inventors. Korea is a good 
example for purposes of this chapter because of 
its rapid development in biotechnology. Korean 
vaccine biotechnology evolved rapidly, especially 
beginning in the mid-1990s. 
The growth of the biotechnology industry 
in Korea can be interpreted in terms of the six 
framework components illustrated in Table 1. 
Showing the varying levels of capability with re­
spect to each of the components of innovation 
at each stage, the table illustrates how developing 
countries can progress through four stages of capa­
bility in pharmaceuticals. The table distinguishes 
between national and international distribution 
and breaks out support for R&D into public and 
private sectors. The table illustrates that there are 
different systems of IP management at different 
stages of development. The table assists our think­
ing about one of the challenges brought about 
by the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS Agreement), 
namely that all developing countries that are sig­
natories of the Agreement will have to move im­
mediately to Stage 3. Several countries, such as 
Figure 1: Vaccine-Related Patents Obtained by Koreans 
50 
Korean patents related to vaccines
obtained by Korean inventors
U.S. patents related to vaccines






















1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 
Source: Based on data from the U.S. Patent and Trademark Office (PTO)4 
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Brazil, China, and India, have achieved this goal. 
Others are in the process. The major unresolved 
issue is whether the immediate move to Stage 3 
IP systems will provide a pull effect on the other 
components of innovation or whether it will lead 
to imbalances that will adversely affect access to 
pharmaceutical products. 
.2 Development of IP systems in Korea 
Korea provides a useful case study of a coun­
try that developed economically and, for the 
most part, independently enhanced IP protec­
tion without the requirements of TRIPS. Now 
in Stage 3, Korea was able to develop a vaccine 
industry very rapidly because it addressed each 
of the framework components stage-by-stage. It 
passed through the first two stages of the frame­
work in roughly ten-year steps during the 1980s 
and 1990s. Having joined the World Intellectual 
Property Organization (WIPO) in 1979, Korea 
acceded to the Paris Convention in 1980 and the 
Patent Cooperation Treaty (PCT) in 1984. The 
country revised its laws in 1987 to allow product 
patents. By the end of the 1980s, Korean laws and 
policies largely conformed to the requirements 
that TRIPS would eventually impose. 
As with the development of biotechnology 
R&D capability, Korea completed Stage 1 of its 
IP system in about 1990. It acceded to the TRIPS 
Agreement in 1995 and further revised its IP 
laws in 1997–98 to reach full compliance with 
TRIPS. The World Trade Organization (WTO) 
conducted a trade policy review of Korea in 2000 
and concluded that “protection of [intellectual 
property] rights has been strengthened by the signing 
of the new treaties, increased international coopera­
tion, and stricter enforcement.”5 
Unlike the United States, universities and 
research institutes in Korea were not major 
sources of technology for the country’s industry 
during the 1980s and most of the 1990s. Most 
companies wishing to obtain new technology 
had to look outside the country. In the United 
States, on the other hand, the Bayh-Dole legisla­
tion had gone into effect in 1980, and universi­
ties invested heavily in efforts to manage new IP 
that they developed. This included not only the 
out-licensing of patents for inventions made by 
research scientists, but also the creation of spin-
outs, in which a professor set up a company for 
the specific purpose of developing an invention 
into a commercial product. Beginning in the 
late 1990s, Korea followed suit, revolutionizing 
its laws and regulations concerning IP manage­
ment by public institutions. Public universities 
were allowed to retain ownership of new IP and 
were encouraged to set up technology transfer of­
fices. The Technology Transfer Facilitation Law 
was passed, mandating the establishment of tech­
nology transfer offices and setting guidelines for 
sharing licensing income with a specific allotment 
for the inventors. 
Based in part on the patent data in Table 1, 
Korea seems to have completed Stage 2 of its IP 
system in about 2000, again in tandem with its 
progress in biotechnology R&D capability. Thus, 
the country was able to develop its IP system in 
tandem with the growth of capability in the five 
other components of innovation. It will be in­
teresting to see what happens in other develop­
ing countries that, under the TRIPS Agreement, 
must move immediately to Stage 3 in IP systems. 
A broader survey of the development of IP sys­
tems in Korea is available in Lee, et al.6 While we 
lack sufficient data to make any unequivocal con­
clusions, it is worth noting that Korea was able 
to move forward by addressing all six innovation 
components. 
. ConCLuSIon 
The framework shows that IP is an important 
component of innovation in pharmaceutical de­
velopment, but it is only one of six. As the analy­
sis of biotechnology shows, the regulatory system 
is also a very important component. Above all, 
however, the above analysis demonstrates that 
developing countries will pass through the four 
stages of development as they increase their capa­
bilities in biotechnology innovation. Such prog­
ress is possible only by attending to each of the six 
components of innovation. A key question that 
the framework highlights is what impact the im­
mediate movement of IP systems to Stage 3 will 
have on countries that are still in Stage 1 or 2 of 
pharmaceutical innovative capability. Will it hin-
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der or help their progress? We lack the data need­
ed to assess the impact of this TRIPS requirement 
for moving from Stage 1 to Stage 3. But the case 
study of Korea shows that it was able to under­
take a wide range of initiatives that helped it to 
advance in biotechnology. The country addressed 
all six components of innovation. In particular, 
it made its IP systems compatible with those of 
more developed countries and thus compatible 
with TRIPS. At least with respect to vaccines, 
Korea has experienced considerable success in 
biotechnology. We conclude that TRIPS should 
not inhibit efforts to enhance biotechnological 
capabilities. It may actually promote such efforts. 
Conversely, arguments that TRIPS is inimical to 
the interests of developing countries seem prema­
ture at best. At worst, they are counterproductive 
because they may lead countries to seek higher 
levels of biotechnology capability ineffectively: 
They will not be able to participate in interna­
tional trade (other than as importers) because 
their products will not be accepted in markets 
that observe IP rights. n 
acKnowledgMenTs 
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per: Mahoney R, K Lee and M Yun.. 2005. Intellectual 
Property, Drug Regulation, and Building Product 
Innovation Capability in Biotechnology: The Case of 
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IP Management and Deal Making for Global Health 

Outcomes: The New “Return on Imagination” (ROI)
 
JOHN FRASER, 2006 President of AUTM and Executive Director, 

Office of IP Development & Commercialization, Florida State University, U.S.A.
 
ABSTRACT 
The benefits of technology transfer are everywhere ap­
parent, and perhaps the best news—as this Handbook’s 
compilation of case studies demonstrates—is that these 
benefits are already reaching developing countries. Build­
ing on the success of the U.S. Bayh-Dole Act, countries 
everywhere are seeking to better utilize the research ca­
pacities of their universities and public research institu­
tions. The growth of such technology transfer initiatives 
is inspiring, as are the innovative varieties of partnerships 
that have developed to ensure that the world’s poor ben­
efit from the global intellectual property system. 
1. INTRODuCTION 
Technology transfer works. Evidence of its suc­
cess is everywhere and even unavoidable. We ben­
efit from it when we get into a car and buckle up, 
when we sweeten our coffee with saccharin, and 
when we search the Internet using Google™. And 
we all enjoy better health because of the success 
of technology transfer: Allegra®; Taxol®, Trusopt®, 
pap smears, hepatitus B vaccine, the carcinoem­
bryonic antigen immunoassay for colon cancer, 
insulin, the Rheo-Knee (the high-tech replace­
ment knee), a nontoxic drug therapy for Chagas 
disease, and the nicotine patch are just a few of 
the health care innovations based on early inven­
tions in university laboratories. 
In addition to educating the next generation 
and creating new knowledge, universities are con­
tributing to saving lives, enhancing the quality of 
life, and increasing productivity in the economy. 
This innovation explosion began in the United 
States with the passage of the Bayh-Dole Act, 
which allowed universities and public research in­
stitutions to patent inventions based on publicly 
funded research and then license the inventions to 
the private sector. The goal was to move inventions 
from the laboratory onto store shelves by attracting 
the private investments needed for commercializa­
tion. In the words of one of its authors in the U.S. 
Senate, “The Bayh-Dole Act more than fulfilled our 
hopes and dreams. Many, many lives are the better for 
the success our universities, small businesses and non­
profit organizations have had as a result of this law. It 
simply works.” Indeed, it is no accident that the rest 
of the world is copying the Bayh-Dole model. The 
European Union, Japan, China, India, and many 
other countries hope to tap their own cutting-edge 
university research to develop new products. And, 
as the following case studies demonstrate, the ris­
ing tide of innovation has the capacity to improve 
the quality of life for people in both developed and 
developing countries. 
2. TECHNOlOGy TRANSFER
By THE NuMBERS 
One way to look at how technology transfer is 
changing the world is to consider the statistics 
(culled from the AUTM Licensing Survey™ which 
Fraser J. 2007. IP Management and Deal Making for Global Health Outcomes: The New “Return on Imagination” (ROI). In 
Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT 
Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. J Fraser. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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FRASER 
regularly surveys U.S. and Canadian members). 
In fiscal year 2004, U.S. institutions:1 
•	 spent US$40 billion in research and develop­
ment 
•	 issued 4,783 licenses 
•	 managed 27,322 active licenses 
•	 facilitated 462 new spinout companies, 
bringing the total since 1980 to 4,543 
Each of the 27,322 licenses reflects a one­
to-one relationship between a U.S. academic 
center and a company focused on a product 
development project. While reflecting the fact 
that such innovations are increasingly an en­
gine of the “knowledge economy,” what is re­
ally impressive about these numbers is the myr­
iad ways academic technology transfer impacts 
people—through new products that save lives, 
enhance quality of life, and increase economic 
productivity. 
Those of us who are involved in technology 
transfer have some idea of how far-reaching and 
valuable this work is, but even we cannot fully 
realize the scope of the impact of technology 
transfer. As technology transfer expands inside 
developing countries, creative mechanisms are 
emerging to further its impact and bring it to 
bear on global health outcomes. The Association 
of University Technology Managers (AUTM) 
has increased its efforts to spotlight some of 
the products that have originated at universi­
ties around the world. The Better World Proj­
ect (BWR) is an ongoing series of publications 
and an online database.2 With two publications 
showcasing 125 products, BWR includes an 
electronic database of stories that document 
the outcomes of academic technology transfer 
in human terms (new editions are due out in 
March each year). 
3. THE ASSOCIATION OF uNIVERSITy 
TECHNOlOGy MANAGERS 
Another conspicuous sign of the growth of tech­
nology transfer is the continued growth of AUTM. 
Currently, the organization brings together more 
than 3,500 technology transfer professionals, in 
more than 30 countries, to define, develop, and 
promote leadership excellence in academic tech­
nology transfer. 
More specifically, among AUTM members: 
•	 65% are based in academic technology 
transfer offices (TTOs) 
•	 35% work outside of academia, in corpo­
rate and service sectors 
•	 80% reside and work in the United States 
•	 9% live in Canada 
•	 11% live in other parts of the world 
It is evident that, though relatively small in 
number, this varied global network of profession­
als is effecting change throughout the world. 
4. THE TECHNOlOGy TRANSFER SPINOuT
Rather than asking existing companies to de­
velop university-based products, universities and 
their faculties are increasingly turning to a new 
mechanism—the spinout company. This is a new 
company typically created to produce and market 
intellectual property developed at a university by 
one of its employees. In fiscal year 2004, AUTM 
reported 462 new U.S. companies had been 
formed in this way. More than 4,443 spinout 
companies have been reported since 1980. These 
companies seek public and private funding (from 
venture capital companies) to grow and put prod­
ucts in the marketplace. 
.1  Social responsibility: public–private 
partnerships for product development 
Product development partnerships (PDPs) are a 
relatively recent phenomenon. They are similar to 
spinout companies in that they are tightly focused 
organizations created to develop products for ne­
glected diseases in developing countries with the 
aim of reducing the disease burden and improv­
ing health. Several PDPs have licensed university 
innovations to include the technologies in their 
product development efforts. PDPs were set up as 
virtual product-development companies for such 
infectious diseases as tuberculosis, HIV, and malar­
ia. The companies are supported by philanthropic 
funds, employ corporate expertise, are structured 
to reduce costs, and are driven by the urgent 
need to make an impact. As the following cases 
20 | HANDBOOK OF BEST PRACTICES 
        
       
        
     
      
    
	 	 	 	 	 	 	
	 	
      
        
        
       
     
       
   
     
     
       
      
      
     
        
    
      
    
      
        
       
         
      
      
       
     
      
        
        
       
      
       
      
     
      
      
       
 
       
      
       
       
       
    
        
     
       
      
       
       
      
     
        
      
      
       
        
       
      
       
        
       
          
       
         
        
      
       
 
  
   
  
 






studies involving PDPs reveal, they are marked by 
creativity, a trait that will be invaluable as these 
organizations move through clinical trials, address 
manufacturing products, and face the critical issue 
of distribution and patient compliance. 
.2  Creativity for diseases in the developing 
world: Venture Philanthropy 
Venture Philanthropy was developed over the same 
period as were PDPs. The mission of Venture Phi­
lanthropy is to align good science with good busi­
ness for developing new and improved drugs. In 
several cases, individual serial entrepreneurs whose 
families have been stricken by disease have created 
disease-specific foundations, raised foundation 
philanthropic and individual donations, and ap­
plied the entrepreneurial business model approach 
to disease research. For example, the Milken Insti­
tute3 has been instrumental in educating people 
and in highlighting best practices. Its recently 
published report4 offers innovative financial solu­
tions offered to help solve the serious decline in 
funding for early-stage biomedical research. 
5.	 CAuSE FOR ENTHuSIASM: THE BIG
NEWS ABOuT THE BIG PICTuRE 
While some voices continue to raise objections 
about the fairness of the global IP system, oth­
ers are seizing new opportunities provided by the 
system to improve the lives of the poor in the 
developing world. The evidence is clear: creative 
work is raising our expectations and allowing 
us to pursue hopes that seemed like unattain­
able utopian dreams before technology transfer 
released the power of human imagination. The 
University has always been the site of such vi­
sionary imaginations, and it is fitting that a new 
age of potentially greater global equity has been 
envisioned in its classrooms and laboratories. In­
deed, the age of technology transfer is changing 
the perception and importance of these univer­
sity-connected activities. Measures of the success 
of academic technology transfer have broadened 
beyond economics to include numbers of lives 
saved, reductions in the disease burden, im­
provements in the quality of life, and increases 
in productivity. 
Our understanding of what we do as technol­
ogy transfer officers is changing. Traditionally, the 
mission of the TTO was to bring university-gener­
ated intellectual property into public use as rapidly 
as possible. The TTO did this through corporate 
partnerships that protected academic freedoms 
and, in many cases, generated a financial return to 
the university, inventors, and their departments. 
TTOs still serve these functions. But over the 
years, academic technology transfer has evolved to 
serve a broader purpose: to enhance the reputation 
of academic institutions and to help them achieve 
their missions of education, research and commu­
nity outreach by facilitating research relationships 
with the private sector for the benefit of all. 
Anyone who reads subsequent pages of this 
Handbook, case studies that document the success 
of technology transfer, will feel the same enthusi­
asm and hope for the future that technology trans­
fer officers feel. Today, problems can be tackled 
that yesterday appeared intractable. And let me 
say to my fellow technology transfer officers: we 
should hold our heads high when we talk about 
our work and our mission. When someone asks 
you “What do you do?” be ready to tell them, “As 
a technology transfer professional, I help make the 
world a better place.” If they ask what financial re­
turn on investment (ROI) you hope to make, tell 
them, “Oh, ROI—you mean ‘Return on Imagi­
nation.’ Let me show you what is possible.” 
Then give them a copy of this Handbook, and 
point to the successes in these case studies! ■ 
JOHN FRASER, 2006 President of AUTM and Executive 
Director, Office of IP Development & Commercialization, 
Florida State University, Suite 109, Westcott Building, Co­
peland Avenue, Tallahassee, FL, 32306, U.S.A. jfraser@ 
research.fsu.edu 
1	 AUTM 2005. AUTM Licensing Survey.™ FY 2004. Associ-
ation of University Technology Managers: Northbrook,
Illinois. www.autm.net. 
2	 Visit the Web site at www.betterworldproject.net. 
3	 www.milkeninstitute.org. 
4	 Financial Innovations for Accelerating Medical 
Solutions [Financial Innovations Lab Report, Vol. 2] 
Milken Institute, October 2006. www.milkeninstitute. 
org/publications/publications.taf?function=detail&ID 
=580&cat=finlab. 
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ABSTRACT 
If universities adopt sound licensing practices, the univer­
sities will not only help stimulate investment in research 
on diseases that primarily afflict the poor in developing 
countries, but also ensure that the products of the re­
search are affordable and widely available in those coun­
tries. Ensuring global access is one of the central goals of 
intellectual property management. But universities con­
front two main obstacles in their efforts to achieve the 
goal. First, university administrators, technology transfer 
officers, and business people are too often unaware of 
both the need to ensure access to new health technologies 
in developing countries and the manner in which patent­
ing and licensing practices can be an integral component 
of global access strategies. Second, there is only a short 
history of experience in incorporating such concerns in 
negotiating licenses, so no best practices have yet evolved. 
This chapter offers a few possible approaches to ensuring 
broad access to university inventions while preserving in­
centives to development, including patenting inventions 
in a select list of developing countries. The chapter con­
cludes by urging all of the players in this field to build 
upon their own experience and to take creative risks in 
the pursuit of new solutions. 
1. InTRoduCTIon 
From a humanitarian point of view, a patent sys­
tem presents a paradox. How can a system de­
signed to restrict access to technologies, including 
medical technologies, also be used to maximize 
availability of needed medicines and vaccines at 
affordable prices? One way of looking at that 
paradox is to consider an extreme case: if all the 
medicines and vaccines needed for diseases in 
developing countries existed today, the patent 
system might be unnecessary. The absence of 
patents, some experts suggest, would presumably 
allow for maximum competition, driving prices 
down and thereby maximizing affordability and 
availability. 
But for many of the diseases of developing 
countries, few drugs or preventatives exist; in 
some cases none exists. Patent protection can 
provide the necessary incentive to encourage in­
dustry to use its skills and resources to discover, 
develop, test, ensure quality control of, manufac­
ture, and distribute new drugs and vaccines. Few 
companies—if any—would embark on the long 
trail of new-drug discovery and development, 
if they could not be protected by patents from 
competitors. 
Thus, patents are neither inherently bad 
nor inherently good with regard to this purpose, 
but—like all tools—must be used wisely. 
Research institutions, such as universities, 
medical schools, and other nonprofit institutions 
engaged in biological and medical research (col­
lectively referred to as “universities” in this chap­
ter), have a special role to play regarding the use 
of patents for developing and distributing drugs 
and vaccines for developing countries. These 
Nelsen L and A Krattiger. 2007. Ensuring Developing-Country Access to New Inventions:The Role of Patents and the Power 
of Public Sector Research Institutions. In Intellectual Property Management in Health and Agricultural Innovation: A Hand-
book of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available 
online at www.ipHandbook.org. 
© 2007. L Nelsen and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
HANDBOOK OF BEST PRACTICES | 2
  
     
      
    
      
         
      
      
      
   
      
     
     
    
       
   
        
      
       
      
    
      
      
      
        
     
       
      
        
      
      
      
       
       
     
     
        
        
     
        
         
       
      
      
 
	
NElSEN & KRATTIGER 
institutions are often the source of the core tech­
nology and, occasionally, lead compounds that 
could be developed into drugs and vaccines. 
Despite the avowed public purpose of their 
technology transfer activities, universities have 
recently come under criticism for using patents 
in a way that could inhibit (and in very few 
cases, has inhibited), the distribution of medi­
cines at accessible costs to developing countries. 
Critics argue that by granting exclusive licenses 
to developed-country pharmaceutical compa­
nies, the universities are allowing the pharma­
ceutical companies, sometimes, to prevent local 
companies from producing and selling drugs, 
potentially at affordable prices—thus effectively 
denying life-saving drugs to poor people in these 
countries. 
Although nonprofit research institutions 
are not often involved in these issues, (in part 
because the fraction of medically related patents 
owned by these institutions is small), their vis­
ibility, coupled with the universities’ public re­
sponsibility, is causing university technology 
transfer offices to modify their licensing practices 
for patents relevant to healthcare in developing 
countries. 
Some thinkers have suggested that the best 
thing universities can do to ensure access is to 
cease patenting medically related inventions and 
place everything in the public domain. But doing 
so would be both unrealistic and counterproduc­
tive. Patents have been shown to be a powerful 
tool for directing investment into the develop­
ment of technologies that would otherwise lie 
fallow. University inventions are usually at such 
an early stage (embryonic is a term commonly 
used to describe them) that investment in de­
velopment involves substantial risk. Neither the 
technical practicality nor the market acceptabil­
ity of the invention is proven. And many more 
inventions fail to reach than do reach the mar­
ket—particularly in the medical field. Patents 
are an essential way for companies to manage the 
risk, and the use of patents is even more impor­
tant for medicines and vaccines, where the costs 
of development and particularly of clinical tri­
als require much larger investments and much 
greater risk. 
Universities and research institutions hope 
for some financial return from their patents, but 
contrary to widely held beliefs, this return is sel­
dom large. On average, U.S. universities receive 
licensing royalties equivalent to only 2%–4% of 
their research budgets. Most universities believe 
that the primary purpose of their technology 
transfer activities is either (1) to induce invest­
ment in developing technologies to bring prod­
ucts to public use, (2) to aid local economic de­
velopment through spinout companies based on 
licenses to their technology, or (3) both. 
Given their commitment to encouraging the 
development of new technologies via patenting, 
universities need sophisticated policies and pro­
cedures in licensing to ensure that the poor will 
have access to medicines based on the universi­
ties’ technologies. Potentially, the access policies 
developed by universities may—if the policies 
are practical, properly implemented, and publi­
cized—become “norms” that will be more widely 
adopted by the private sector. 
Awareness about these issues is new; tech­
niques for addressing the problem are only just 
emerging, and there is no consensus yet on best 
practices. The remainder of this chapter addresses 
some potential solutions. 
2. RAISInG	AWAREnESS 
The first task in encouraging effective licens­
ing policies and practices is to raise awareness of 
the issues (discussed in section 1 above) in the 
research institution community. Technology 
transfer officers need to become aware of devel­
oping country health-care needs and the univer­
sities’ responsibilities with respect to those needs. 
Given the general commitment of universities to 
transfer technology to promote public welfare, 
this awareness alone will go a long way toward 
preventing the inadvertent granting of licenses 
that lack consideration for the health needs of 
developing countries. Senior administrators and 
researchers also need to become more aware of 
the issues involved so that these professionals 
will acknowledge the broader value of licensing 
terms that may be somewhat less profitable from 
an economic standpoint, but that may address 
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urgent medical problems in poor parts of the 
world. Finally, consistent university policies on 
these issues will raise awareness inside the com­
panies universities work with, making such com­
panies more readily accepting of licensing terms 
that address these issues. 
Awareness is already growing. In the United 
States, the Association of University Technology 
Managers (AUTM) began to publicize this issue 
to its members in 2003. This organization is hav­
ing a substantial impact on the understanding of 
technology transfer professionals with respect to 
these concerns: more than 90% of technology 
transfer professionals from nonprofit research 
institutions in the United States and Canada 
belong to AUTM, along with several hundred 
professionals from other countries. An AUTM 
Special Interest Group, formed in 2003, has 
evolved into theTechnology Managers for Global 
Health (TMGH),1 which is partially supported 
by MIHR (the Centre for the Management of IP 
in Health Research and Development). TMGH’s 
purpose is to raise awareness about global health 
issues and, with AUTM, to compile a collection 
of best-practice policies and licensing terms that 
can be distributed to AUTM members and oth­
ers. The interest shown on the part of the greater 
AUTM membership is especially encourag­
ing. At its 2006 annual meeting, the opening 
plenary session of AUTM was on “Innovative 
Policies and Practices in Technology Transfer: A 
Global Health Perspective.” The meeting agenda 
included a program of education with several 
workshops on global-health technology transfer 
issues. 
Through its guidelines on the patenting and 
licensing of research tools, the National Institutes 
of Health (NIH) have helped alert universities 
to the need for thoughtful policies in exclusive 
licensing.2 The NIH wants to make certain that 
researchers in the health arena have access to re­
search materials without undue hindrance by 
patents, and so NIH has issued guidelines for 
patenting and licensing research tools. The two 
objectives—fostering access to medicines and 
making research materials widely available—of­
ten merge in the minds of technology transfer 
professionals, making them more aware of the 
need to exercise care when licensing university 
technology. 
.  SuGGESTEd 	AppRoACHES	 
.1 Considering where to file patents 
When a research institution patents and licenses 
out a technology, usually the institution can—if 
it insists—continue to own the patent after li­
censing. (This is the practice in most U.S. univer­
sities.) The institution can then control, by con­
tract with the licensee, which countries the patent 
will be filed in. Determining a strategy of where 
to file, however, is not easy. 
.1.1 Prohibition-of-filing strategy 
Where a drug or vaccine in question has a large 
developed-country market, one possible strategy 
is to prohibit the patent from being filed in de­
veloping countries. Most of the licensee’s profits 
would presumably come from markets in de­
veloped countries—with or without developing 
country patents. The loss of potential revenue 
from developing countries (which in any case 
could not afford to purchase large quantities of 
the medicines at developed country prices) would 
be negligible, and the licensee mostly likely 
would not be substantially disadvantaged by this 
approach. The absence of patents in the develop­
ing world, however, could allow “generic” com­
petitors to produce the drugs in those countries 
at low prices. 
This strategy will be effective only if: 
•	 The developed country market for the 
medicine is large. If the developed country 
market is only a specialty “travelers’ market” 
and the primary demand for the medicine 
is in developing countries (malaria vaccines 
are a good example), this strategy may not 
be acceptable to the licensee company. 
•	 The drug or vaccine is relatively easy to 
manufacture and does not rely on special 
know-how possessed only by the licensee 
company (including valuable regulator 
dossiers). This is more likely with simple 
chemical drugs than with biological drugs 
(including vaccines), whose techniques for 
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production and purification may be beyond 
the capabilities of most developing country 
manufactures. Also, if the drug is easy to 
manufacture, then safeguards must be in 
place to avoid parallel imports.3 
•	 The research institution owns the core pat­
ent for the drug or vaccine, while other “sec­
ondary” patents, owned by the licensee, are 
not critical to developing and manufactur­
ing the medicine. If secondary patents are 
critical and the licensee chooses to file them 
in developing countries, then attempts by 
the university to provide its own technol­
ogy free of charge may be moot. The only 
benefit would be to shelter the university 
from criticism. Theoretically, it is also pos­
sible for the university to demand in its 
licensing agreement that the licensee not 
file such secondary patents in developing 
countries, but it is doubtful that the uni­
versity would have the negotiating power 
to make that demand—particularly if the 
university’s invention, at the time it is li­
censed, is still far from a product. 
.1.2  When patent filing in developing 
countries may be beneficial for access 
When the demand for a drug or vaccine is pri­
marily (or exclusively) in developing countries 
and there are no alternative products, the prima­
ry problem is to develop a sufficiently profitable 
market to provide an incentive for the private sec­
tor to invest in R&D. The only other alternative 
is for governments or nongovernmental organiza­
tions (NGOs) to fund all of the research, devel­
opment, clinical testing costs, and manufacture. 
But having a public sector entity develop a com­
mercially viable product is usually impossible. 
Patents may provide an incentive to the pri­
vate sector to invest by aggregating the develop­
ing world market into a single, larger market. To 
be successful, this strategy relies on: 
•	 sufficient available resources for buying the 
product once it is developed (Governments 
and NGOs may have to step in to supply 
money to the public sector of low-income 
developing countries so that the product 
can be purchased—particularly if there is 
no private travelers’ market that can sup­
port higher prices.) 
•	 adequate systems for quality control and 
regulatory approval to ensure consistent, 
high-quality products in the absence of de­
veloped country regulatory controls 
•	 a belief that the legal systems in the non-
manufacturing countries will be strong and 
consistent enough to allow the supplier to 
enforce its patent rights and to maintain its 
monopoly for a reasonable period of time 
•	 a willingness of governments and NGOs to 
accept prices that are high enough for sup­
pliers to recoup research and development 
costs 
.1.  Licensing strategies 
Research institutions have the most control over 
optimizing the use of their inventions at the time 
of licensing. It is before the invention is licensed 
that the university can best ensure that the in­
vention will be used to advance—or at least not 
hinder—solutions to developing country health 
needs. 
The first decision is whether to grant (1) a 
fully exclusive license, (2) an exclusive license 
limited by product type, (3) an exclusive license 
limited by geographical territory, or (4) a nonex­
clusive license.4 Considering two extreme cases is 
illuminating: 
•	 Where the invention is a tool for discovery 
that is useful to many without significant 
development, then nonexclusive licensing 
is probably most appropriate for developed 
country use. Patents in developing coun­
tries will essentially be unnecessary. (Many 
universities will also require that the patents 
not be asserted against nonprofit research 
institutions in any country, thus allowing 
free access by such institutions.) 
•	 Where the patent covers the core invention 
of a potential new drug or a vaccine that re­
quire many years and tens, if not hundreds, 
of million dollars of investment, an exclu­
sive license may be the best strategy. In such 
a case, patenting in selected developing 
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countries may be an important element in 
a strategy to ensure global access. 
Exclusive licensing places a large responsibil­
ity on the university to negotiate license clauses 
that ensure both development of the product 
and rapid distribution to developing countries 
at affordable prices. Not every member of the 
university technology transfer community is yet 
conscious of this requirement. Best practices have 
not yet been established for such negotiations, 
and so strategies need to be based on evolving ex­
perience. A few situations, we know in retrospect, 
were clearly mistakes—experiences we can now 
learn from. Some better, but still experimental 
strategies include: 
•	 development of milestones. As a condi­
tion for a company maintaining a license, 
the university requires that the company 
devote at least a certain reasonable mini­
mum of resources (money or staff time) to 
developing the technology. The university 
may also require certain success milestones 
(for example, first clinical trials by a certain 
date, product on the market by a certain 
later date, and so forth).5 However, success 
milestones are particularly difficult to nego­
tiate for very early-stage technology. 
•	 requirement of delivery of product for 
developing countries. The university may 
require the company to begin testing and 
distributing the product for developing 
countries simultaneously, or nearly simulta­
neously, with its introduction to developed 
countries. This is particularly important 
for vaccines, for which the trickle-down 
theory6 has sometimes deprived developing 
countries of suitable product for decades. 
•	 control over pricing in developing coun­
tries. This is usually set at a small percentage 
over cost (so-called cost-plus pricing). This 
may be particularly relevant where there is a 
large—and presumably profitable—market 
as in the developed world. 
•	 sublicensing. If the company cannot deliver 
the product or deliver it at acceptable prices, 
then the university may require the compa­
ny to sublicense the patent to others. When 
manufacturing the product is simple, this 
strategy may work, but when the product 
requires substantial company know-how 
and background technology, the “victory” 
in forcing a sublicense of the patent alone 
may be a hollow one. This is particularly 
true for complex biological drugs and many 
vaccines. The university should therefore 
negotiate clauses that make sublicensing as 
attractive as possible, so that the company 
will cooperate fully in the venture. A paper 
by Friedman and colleagues7 describes such 
a strategy by the Pharmacia Company. The 
company enthusiastically sublicenses the 
patent along with its know-how and exerts 
some control over the quality of the prod­
uct. The benefits to the company are pri­
marily to its reputation, with a justifiable 
pride in the good that is done, but allow­
ing sublicensing also protects the company 
from the criticism of not meeting the needs 
of the poor in developing countries. 
.  ConCLuSIon 
University technology transfer professionals are 
becoming more aware of their obligations to en­
sure that the poor have access to medicines based 
on university technologies. To a large extent, 
universities are embracing this obligation in the 
hope that well-crafted patent and licensing poli­
cies can be powerful tools to provide such access. 
But there are no clear-cut mechanisms, nor many 
precedents to guide professionals in this endeavor. 
This chapter presented just a few of the strategies 
that research institutions can pursue in their quest 
to provide developing countries with access to 
new medicines. Each of these strategies has been 
tried, but they are all relatively new and will need 
further refinements. This can only be achieved, 
however, in actual negotiations between research 
institutions and companies. New approaches will 
also certainly develop in the future. None of these 
efforts will be effective unless both research insti­
tutions and companies first become more aware 
of their obligations to the poor in developing 
countries. Awareness is only the first step, how­
ever, for none of these strategies will thrive unless 
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they meet the needs of both the research institu­ 1 See www.tmgh.org. 
tions and the companies that are developing new 
technologies to improve human health. Building 
upon the knowledge and successes we already 
possess, we must not only strive for novel, cre­
ative solutions but also take reasonable risks in 
2
3
NIH. 2005. Best Practices for the Licensing of Genomic 
Inventions: Final Notice. Federal Register 70(68): 18413– 
415. www.ott.nih.gov/pdfs/70FR18413.pdf. 
See, also in this Handbook, chapter 15.4 by D Matthews 
and V Munoz-Tellez. 
the pursuit of these much-needed solutions. n 4
5
See, also in this Handbook, chapter 11.8 by SL Shotwell. 
See, also in this Handbook, chapter 2.7 by J Oehler.
liTa nelsen, Director, M.I.T. Technology Licensing Office, 
Massachusetts Institute of Technology, Five Cambridge 
Center, Kendall Square, Room NE25-230, Cambridge, 
MA, 02142-1493, U.S.A. lita@mit.edu 
6
7
Trickle-down theory relates to a product that may at
first be so expensive that only wealthy people can 
afford it. The theory states that over time, however, the 
price will fall until it is available to the general public.
In other words, the benefits trickle down. 
Friedman MA, H den Besten and A Attaran. 2003. Out-
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute, and Adjunct Professor, 
Licensing: A Practical Approach for Improvement of 
Access to Medicines in Poor Countries.Lancet 361:341–44.
www.fightingmalaria.org/pdfs/Lancet%20Article.pdf. 
Cornell University. PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu 
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CHAPTER 1.5 
Genomics, Ethics, and Intellectual Property
 
gaRy e. MaRchanT, Professor, Sandra Day O’Connor College of Law, Arizona State University, U.S.A. 
ABSTRACT 
Ethical concerns and controversies about patenting are 
playing an increasingly prominent role in the develop­
ment and applications of the biosciences. Despite the 
growing importance of ethical issues, there is currently no 
consensus or clarity on the ethical principles that should 
guide patenting of human, animal, and plant genes and 
cells. The three major areas of contention are: (1) whether 
some or all patents on genes and cells are unethical per 
se, based on concerns such as commodification, dignity, 
and similar concepts; (2) how tissue samples are col­
lected, particularly in reference to the principles of prior 
informed consent and benefit sharing; and (3) how pat­
ents are used to restrict access to medical and agricultural 
use of biotechnology innovations. Given the lack of any 
agreed guiding principles for navigating these issues, pol­
icy-makers, decision-makers, scientists, and users of bio­
technology have no choice but to address these contested 
ethical concerns using a case-by-case approach. 
1. InTRoduCTIon 
Over the past three decades, much ink has been 
spilt about the ethics of patenting in the life sci­
ences. Unfortunately, these dialogues and debates 
have produced very little clarity and consensus 
on the ethical principles and practices that should 
apply to patenting of biological materials. Policy­
makers, decision-makers, companies, scientists, 
and product end users therefore must navigate 
through a complex web of unsettled legal prin­
ciples, moral arguments, social norms, and po­
litical influences that collectively represent the 
ethical landscape for patents in this field. Failure 
to adequately consider and conform to these in­
fluences can result in an eruption of controversy, 
disruption, and opposition. At the same time, ex­
cessive caution and hewing to the most extreme 
views and positions has the potential to impede 
the scientific, economic, and developmental ben­
efits of life-science research and innovation. 
This chapter does not attempt to fully expli­
cate or resolve the many ethical issues relating to 
life-science patents. Rather, its more modest goal 
is to briefly describe the various ethical contro­
versies and landmines related to the patenting of 
genes and other biological materials, and to dis­
cuss how such issues are being resolved or man­
aged in practice. The major controversies can be 
grouped into the following three categories: (1) 
whether some or all biotechnology patents are 
unethical per se; (2) the manner in which the 
patented invention was obtained or discovered; 
and (3) how the patent is used. 
2. ETHICS 	of	pATEnTS 
A threshold question is whether biological patents 
are per se unethical. Some individuals, groups, 
cultures, and nations adhere to a position that 
any patenting of human, animal, or plant genes 
and tissues is unethical. Various ethical argu­
ments have been advanced against any patenting 
of genetic or related biomedical innovations. One 
Marchant GE. 2007. Genomics, Ethics, and Intellectual Property. In Intellectual Property Management in Health and Agricul-
tural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. GE Marchant. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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MARCHANT 
of the most common arguments is that patent­
ing commodifies life-forms. A related critique 
is that living materials are naturally occurring, 
and thus isolation and description of “nature’s 
handiwork” should not qualify as patentable 
subject matter.1 Other ethical concerns include 
fears that patenting will facilitate and accelerate 
applications and commercialization of biotech­
nology that are themselves viewed to be unethi­
cal by some, that patenting will lead to greater 
animal suffering, and that patenting undermines 
the dignity of humans and other species by mak­
ing their genes and cells subject to ownership by 
others.2 
A prominent expression of this deontologi­
cal opposition to biotechnology patents was a 
statement, issued by almost 200 religious lead­
ers in 1995 opposing any patents of human or 
genetically engineered animal tissues, that as­
serted that “[w]e believe that humans and ani­
mals are creations of God, not humans, and as such 
should not be patented as human interventions.”3 
Another much-publicized denunciation of gene 
patenting was the 2000 statement of the French 
Justice Minister, Elisabeth Guigou, that human 
gene patents are contrary to the ethical norms of 
France. The Council for Responsible Genetics 
issued a Genetic Bill of Rights, which contends 
that “all people have the right to a world in which 
living organisms cannot be patented, including 
human beings, animals, plants, and all of their 
parts.”4 
While some organizations and individuals 
denounce patenting of living materials on some 
or all of the grounds identified above, others de­
fend the patentability of genes and other living 
materials on ethical grounds.5, 6, 7 For example, 
the United Nations Educational, Scientific, and 
Cultural Organization (UNESCO) International 
Bioethics Committee concluded that the “law 
on intellectual property serves useful purposes, has a 
foundation in ethical principles and universal hu­
man rights, and often contributes to the benefit of 
humanity.”8 Moreover, religious leaders are not 
unified in their opposition to patents for genes 
and other living tissues, with many prominent 
religious organizations and individuals expressly 
or implicitly supporting such patents.9 
Others argue that while there may indeed be 
important ethical and policy concerns with some 
biotechnological inventions, the patent office is 
not the appropriate forum to address those con­
cerns, if only because patent examiners have no 
specialized training in ethics and policy. Yet an­
other argument is that eliminating patent protec­
tions from biotechnology inventions would make 
those innovations less rather than more ethical, 
in part by making new technologies less trans­
parent as companies rely more on trade secrets in 
place of patents and their requirement for public 
disclosure.10 
A blanket prohibition on any patents of 
genes or other biological materials is inconsistent 
with the Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS), which 
requires countries to provide IP protection for 
most biotechnology products. Thus, any exist­
ing and prospective nation-state member of the 
World Trade Organization (WTO) is unlikely to 
try to adopt or enforce a generic prohibition on 
biological patents. While advocates against any 
patenting may advance the political and ethical 
arguments summarized above against all patent­
ing, such arguments will have little or no legal 
force and relevance. 
More relevant will often be arguments that 
specific patents or types of patents are unethical. 
For example, the TRIPS agreement allows WTO 
countries to exclude bioengineered animals from 
patentability. Thus, each nation must individu­
ally decide whether it will extend its patent laws 
to animals, and these debates generally focus on 
ethical arguments about animal rights and com-
modification of life. 
More generally, the TRIPS agreement specif­
ically provides that nations may elect to include 
a provision in their patent laws that deny patents 
for specific innovations and inventions that are 
not ethical. For example, the European Union has 
an ordre public, or public morality clause that de­
nies patent protections to inventions that are con­
trary to public morality. Other nations, includ­
ing the United States, have declined to include 
such a morality clause, and the U.S. Patent and 
Trademark Office claims that it does not have the 
authority to deny otherwise valid patents based 
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CHAPTER 1. 
on the morality or ethical characteristics of the 
underlying invention. 
The U.S. courts have also disavowed any 
role in reviewing the ethical or policy aspects of 
patents. In approving the first patent of a living 
organism in the United States, the U.S. Supreme 
Court stated: 
[W]e are without competence to entertain these 
arguments… The choice we are urged to make is a 
matter of high policy for resolution within the leg­
islative process after the kind of investigation, ex­
amination, and study that legislative bodies can 
provide and courts cannot. That process involves the 
balancing of competing values and interests, which 
in our democratic system is the business of elected 
representatives. Whatever their validity, the conten­
tions now pressed on us should be addressed to the 
political branches of the Government, the Congress 
and the Executive, and not to the courts.11 
In jurisdictions that recognize a morality ex­
ception to patents, controversial patents are sub­
ject to challenge under such clauses, both during 
initial application, and in subsequent post-is­
suance challenges. For example, challenges to 
European patents for the BRCA1/2 breast cancer 
genes and the oncogene mouse have been chal­
lenged under the ordre public clause several years 
after the original patents issued, which resulted 
in the patents being narrowed but not rescind­
ed.12 The European Union’s ordre public clause 
also prohibits patents related to human cloning, 
modifying human germ lines, using human em­
bryos for commercial purposes, and genetically 
engineering animals in ways that cause suffering 
without a substantial medical benefit to humans. 
In other cases, challenges under the ordre pub­
lic clause to biotechnology patents have failed.13 
One criticism of the ordre public provision is that 
the European Patent Office has failed to articulate 
a clear definition and criteria for the provision’s 
application, resulting in case-by-case analyses that 
do not always use consistent approaches.14 
No issue has generated more outrage and 
concern than attempts to patent products and 
processes based on traditional knowledge. The 
1992 Convention on Biological Diversity encour­
ages nations to respect and protect traditional 
knowledge. Any attempts to patent products 
based on traditional knowledge is likely to gen­
erate considerable controversy, as demonstrated 
by the disputes that erupted over patents issued 
for basmati rice, neem, and tumeric, all of which 
were subsequently abandoned or revoked in re­
sponse to a chorus of objections.15 The bottom 
line is that any attempt to patent products that 
are derived from traditional knowledge are likely 
to generate considerable opposition and contro­
versy, which may only be avoided if the biological 
material is collected consistent with the principles 
of prior informed consent and benefit-sharing 
discussed in the next section. 
. oBTAInInG BIoLoGICAL SAMpLES 
Another area of ethical controversy over some bio­
technology patents relates to the manner in which 
the biological samples used for the patentable dis­
covery were collected. In most human genetic re­
search, the prevailing scientific norm is that donors 
of tissue for research retain no property or other 
rights in their cells or genes.16 This means tissue 
donors receive no financial compensation for their 
samples (other than reimbursement of their out-of­
pocket expenses), are given no share of any profits 
or revenues that may result from any commercial 
products developed using the donated tissues, and 
have no patent rights to any patentable discoveries 
that may result from research using their tissues. 
The legal and property rights of local populations 
and national governments with regard to animal 
and plant specimens collected within their terri­
tory and used for a patented discovery are uncer­
tain and often disputed. At the international level, 
some of the most inflamed controversies have in­
volved claims of biopiracy in which scientists from 
an industrialized nation seek patents based on 
human, animal, or plant materials collected from 
other, less-developed nations. Two specific issues 
that have been at the forefront of these ethical de­
bates about the collection of biological samples are 
prior consent and benefit sharing. 
.1 Prior consent 
Prior consent refers to the procurement of ad­
vance approval from the relevant entities before 
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taking biological samples. One issue relating to 
prior consent is who must provide such consent. 
The consent may need to be given by the specific 
individuals from whom the tissue is taken (in the 
case of human samples), from the local commu­
nity, tribe, or local government in the region from 
which the samples would be taken, and from the 
national governmental authorities. Controversies 
have arisen when only some but not all of these 
three levels (individual, local, and national) of de­
cision-makers have provided prior consent. For 
example, the U.S. National Institutes of Health 
(NIH) sought a patent in 1991 for a cell line de­
rived from a member of the Hagahai, an isolated 
tribe in Papua New Guinea, that had a high fre­
quency of a gene related to leukemia. The focus 
of the ensuing international controversy over this 
patent application, which was subsequently aban­
doned in response to the pressure, was whether 
the NIH was required to obtain informed con­
sent separately from the individual donor, the 
Hagahai tribe, and the Papua New Guinea gov­
ernment.17, 18 
Another example of an international contro­
versy over the alleged lack of appropriate prior 
informed consent relates to the Guaymi Indians, 
the largest indigenous tribe in Panama.19, 20
Thousands of Guaymi tribal members are in­
fected with an HIV-like virus known as the 
Human T-Lymphotropic Virus Type 2 (HTVL­
II). The U.S. Centers for Disease Control and 
Prevention (CDC) undertook a research project 
to investigate infection in the early 1990s, and 
subsequently the U.S. Department of Commerce 
applied for a patent claiming a cell line isolated 
from blood taken from a 26-year old Guaymi 
woman being treated for leukemia in Panama. 
The United States claimed that the woman gave 
oral consent in the hospital (although the woman 
was reportedly illiterate, unschooled, and quite 
sick, which raises questions about the effective­
ness of the informed consent). However, the fo­
cus of the ensuing controversy was that the tribe 
was never informed of, nor asked to consent to, 
the removal of the blood sample to the United 
States, the establishment of cell lines using those 
samples, or the patent application. The presi­
dent of the Guaymi General Congress strongly 
criticized the patent application as “immoral, con­
trary to the Guaymi view of nature, and our place 
in it.” The United States subsequently dropped 
the patent application in response to the contro­
versy. The lesson from these examples is that any 
patent application based on tissues from identifi­
able populations, such as indigenous tribes, may 
be subject to significant controversy if prior in­
formed consent is not obtained from the person 
or persons providing the tissue samples as well as 
the tribal authorities and, perhaps also, the na­
tional government. 
The content and form of the information 
provided in the prior consent has also been con­
troversial. In particular, must the consent process 
include disclosure that the collected material may 
be used to secure a patent? According to one critic 
of current consent procedures, “over the past thirty 
years, blood, tissue, and other bodily fluid samples 
have been collected from individuals and used in ge­
netic research without the person’s consent or knowl­
edge. If a lucrative gene was found, it was patented. 
Once a gene is identified and patented, its availabil­
ity is often severely restricted, even to the people who 
provided tissue samples and funding for the genetic 
research.”21 
The European Union’s Group of Advisers on 
the Ethical Implications of Biotechnology has en­
dorsed the need for prior consent before using a 
donor’s tissue to develop a patentable invention: 
The ethical principle of informed and free con­
sent of the person from whom retrievals are per­
formed must be respected. This principle includes 
that the information of this person is complete and 
specific, in particular on the potential patent appli­
cation on the invention which could be made from 
the use of this element. An invention based on the 
use of elements of human origin, having been re­
trieved without respecting the principle of consent, 
will not fulfil the ethical requirements.22 
In its directive on patenting of biotechnology 
inventions, the European Union carried forward 
this recommendation in Recital 26, which pro­
vides “Whereas if an invention is based on biologi­
cal material of human origin or if it uses such mate­
rial, where a patent application is filed, the person 
from whose body the material is taken must have 
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had an opportunity of expressing free and informed 
consent thereto, in accordance with national law”23 
However, because this statement is in the recitals 
of the directive, it is not legally binding but only 
hortatory. There are also practical problems with 
a requirement for prior consent in this context— 
the original researchers, or subsequent research­
ers who may have access to the tissue, may not 
have the intent or knowledge at the time of tissue 
collection that they will be pursuing a patent ap­
plication based on that tissue. In addition, except 
for rare cases (including in Moore v. The Regents 
of the University of California discussed below), 
most patentable inventions resulting from hu­
man tissue are based on findings using large num­
bers of samples, complicating and attenuating the 
requirement for prior consent on future patents 
from each individual tissue donor. 
The most famous—some would say infa­
mous—court case on this issue is Moore v. The 
Regents of the University of California decided by 
the California Supreme Court in 1991.24 Moore 
had his spleen removed by doctors at the UCLA 
Medical Center as part of his treatment for can­
cer, but unbeknownst to him, his doctors used 
the removed tissue to create a potentially lucrative 
patented cell line. The doctors did not disclose 
their intentions to Moore that they would pat­
ent his cells without sharing any of the proceeds, 
nor did they request his permission to do so. 
Even more egregiously, they affirmatively misled 
Moore into returning to the hospital on several 
subsequent occasions to collect additional tissue. 
The California Supreme Court rejected Moore’s 
argument that he continued to own his cells after 
they were removed from his body, but the court 
refused to dismiss Moore’s claim that his doctors 
failed to provide adequate informed consent by 
not disclosing their potential financial interest in 
Moore’s cells. 
A more recent U.S. case raised similar issues, 
but this time in the research context rather than 
the clinical setting. Parents of children with the 
inherited Canavan disease convinced a medi­
cal researcher to attempt to isolate the gene re­
sponsible for the disease, and provided tissue 
samples from affected children and their families 
and helped to raise funds for the research.25 The 
researcher successfully identified the gene, but, 
without informing the parents who had donated 
tissue samples to the research, the researcher’s em­
ployer (Miami Children’s Hospital) patented the 
gene, and the genetic test based on the gene, and 
began charging a modest licensing fee to clinics 
that had starting using the newly discovered ge­
netic test. The families and various support orga­
nizations were outraged by these actions and sued 
the hospital alleging various legal claims includ­
ing conversion, failure to provide informed con­
sent, unjust enrichment, and breach of fiduciary 
duty. The federal district court dismissed most of 
the families’ claims, but concluded that the un­
just-enrichment claim was sufficiently viable to 
go forward, and the case subsequently settled.26 
This case, like the Moore case before it, demon­
strates that a physician or researcher may have a 
legal duty to inform tissue donors of their intent 
to pursue patents using the donor’s tissue, but 
even if such disclosure is not legally mandated, 
the failure to obtain prior informed consent from 
tissue donors runs the risk of provoking ethical 
controversies that can result in bad publicity and 
expensive, time-consuming litigation. 
The ethical duty of informed consent is less 
established in the context of plant and animal 
samples compared to human tissue collection, 
but there has been considerable momentum to­
ward recognizing such a duty in recent years. 
The 1992 Convention on Biological Diversity re­
quires informed consent from the appropriate na­
tional authorities as a condition of access to plant 
or animal genetic resources. Several nations have 
adopted their own laws requiring prior informed 
consent to the collection of plant and animal re­
sources.27 Several recent international studies and 
proposals have been published on this subject in 
recent years, but the legal and ethical status of 
informed consent requirements for nonhuman 
biological materials continues to be hotly debated 
and uncertain. 
.2 Benefit Sharing 
A second major issue is whether entities that col­
lect tissue samples that are used to patent a prod­
uct are ethically obliged to share the economic 
benefits of their discoveries with the individuals 
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or population from whom the samples were tak­
en. The Human Genome Organization (HUGO) 
adopted a Statement on Benefit Sharing with re­
gard to human genetic research in 2000, which 
states: “in the interest of justice, the last decade 
has witnessed an emerging international consensus 
that groups participating in research should, at a 
minimum, receive some benefit.”28 The statement 
suggests that profit-making research institutions 
“should dedicate 1-3% of their after-tax net prof­
its to healthcare infrastructure and/or humanitar­
ian efforts to benefit communities donating genetic 
samples.” For nonprofit institutions, “immediate 
health benefits as determined by community needs 
could be provided.” Similarly, Article 19 of the 
International Declaration on Human Genetic 
Data provides that: “Benefits resulting from the use 
of human genetic data, human proteomic data or 
biological samples collected for medical and scientific 
research should be shared with society as a whole and 
the international community.”29 
An important precedent for benefit sharing 
in human genetic research is the ill-fated Human 
Genome Diversity Project (HGDP), which sought 
to collect genetic samples from as many human 
populations as possible on the planet. Although 
the project was never implemented, largely be­
cause of ethical critiques and controversies about 
the project,30 it did adopt precedent-setting ethi­
cal guidelines that recognized an ethical duty for 
benefit sharing. 31 The guidelines specify that “a 
fair share of the financial rewards shall return to the 
sampled populations” when the research results in 
commercial products. The suggested mechanisms 
for returning such payments to the donors in­
clude (1) paying “a set percentage royalty … for the 
benefit of the sampled populations” or (2) negotiat­
ing “a reasonable financial payment with a trustee 
for the sampled populations, with the proceeds for 
the population’s benefit.” 
With regard to food and agricultural prod­
ucts, the 1992 Convention on Biological Diversity 
clearly recognized that sovereign states have the 
authority to regulate the collection and use of ge­
netic resources within their territory by provid­
ing in Article 15 that “the authority to determine 
access to genetic resources rests with the national 
government and is subject to national legislation.”32 
The Convention also recognizes in Article 1 the 
principle of “fair and equitable sharing of the ben­
efits” of biodiversity. The Treaty on Plant Genetic 
Resources for Food and Agriculture, negotiated 
under the Food and Agriculture Organization 
(FAO) of the United Nations and concluded in 
2001, goes further and establishes the principles 
of “facilitated access” and “sharing of benefits” for 
the commercial or scientific uses of the nation’s 
resources by out-of-country entities.33 Of course, 
these treaty obligations are only mandatory for 
nations that have ratified the treaty, and many 
prominent nations including the United States 
and some European nations have yet to ratify the 
2001 treaty. In addition, many individual nations 
have adopted their own laws restricting access 
to biological materials within their borders that 
usually require some form of benefit sharing and 
prior consent. By one recent count, more than 40 
nations have enacted such laws since 1993.34 
Despite the endorsement of benefit sharing 
in the various statements and international agree­
ments described above, benefit sharing remains a 
controversial and uncertain principle. One prac­
tical problem is that many scientific researchers 
are not provided funds in their research grants for 
providing economic compensation to individu­
als or populations providing the tissue samples. 
Another problem is that there is uncertainty in 
many cases in identifying who should decide how 
the benefits are allocated within populations. 
When the samples are taken from a discrete com­
munity or tribe with a recognized governance 
structure, the allocation of the benefits is usually 
not problematic in that the existing local govern­
ment can take responsibility for using and dis­
tributing the benefits, but when the population 
is more dispersed or more difficult to clearly de­
fine, the distribution of benefits becomes more 
difficult. Finally, there is an ethical objection that 
paying significant financial benefits to individual 
tissue donors may unduly induce some individu­
als to participate in research. 
In sum, while some legal rules and precedents 
address the issues of prior consent and benefit 
sharing in certain limited contexts, these issues 
are primarily ethical issues at the present time, 
in the absence of applicable laws. At their core, 
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the largely unresolved ethical debates on these 
issues represent a concern with the fairness and 
distributional aspects of biotechnology research 
and commercialization, and are important factors 
that should be considered in the context of any 
research project or program involving the collec­
tion of biological samples from plants, animals, 
or human populations. 
. uSE 	of	pATEnTS 
The final major area of controversy associated with 
patents of biological materials is the use (or mis­
use) of such patents after they have issued. Perhaps 
the most common concern is that the availability 
of the patented invention is unduly restricted or 
costly due to high licensing fees, exclusive licens­
ing, or similar access-limiting strategies by the 
patent owner.35 Such practices may inhibit access 
to the benefits associated with the patented tech­
nology by entities with limited funding, includ­
ing public research institutes, patients, farmers, 
some healthcare providers, university researchers, 
and similar entities. This restricted availability 
could adversely affect, in particular, subsistence 
agriculture, medical research, and health care. 
For example, critics allege that Myriad 
Genetic’s patents on the BRCA1 and BRCA2 
breast-cancer genes, and the nearly US$3000 
licensing fee per use it charges, adversely affects 
scientific research and health care.36 This high 
licensing fee and monopoly prevent some non­
profit and other clinical-care units from offering 
a genetic test for these mutations, particularly for 
patients without health insurance or the means to 
pay for such tests, and may also burden or restrict 
scientific research related to hereditary breast can­
cer, although the company provides a substantial 
discount in the license fee to university and non­
profit researchers.37 
A 2003 survey of 132 directors of diagnostic 
laboratories found that 25 percent had stopped 
performing a medical test because of a patent or 
license and 53% stopped research efforts because 
of a patent or license.38 The practice of exclusive 
licensing also limits access to important scien­
tific tools, materials, and procedures. A survey 
in the late 1990s found that out of 27 disease 
gene patents studied, 14 had been licensed, and 
all the licenses were exclusive.39 The American 
College of Medical Genetics has adopted a po­
sition statement advocating broad licensing of 
patents on genes with clinical implications and 
that “[l]icensing agreements should not limit access 
through excessive royalties and other unreasonable 
terms.”40 
Other commentators are concerned that the 
“upstream” patenting of research tools and genes 
will create a “tragedy of the anticommons” that 
will result in excessive and overlapping proprie­
tary hurdles that will impede scientific research.41 
A recent survey of 1,240 university geneticists 
found that patenting and commercialization of 
research may be impeding the scientific ideals of 
openness and sharing, with 73% of respondents 
claiming that withholding of data by colleagues is 
slowing progress in their field.42 
Yet another argument is that some biotech­
nology patent holders are exploiting their patent 
rights to provide greater market power and profits, 
to the detriment of patients, farmers, and other 
potential end users of the patented technologies. 
For example, some farmers and public interest 
groups have alleged that Monsanto’s patents on 
genetically modified crops such as the herbicide 
tolerant Roundup Ready® technology are being 
used to promote sales of Monsanto’s Roundup 
herbicide through license agreements that re­
quires farmers who buy Roundup Ready® seeds 
to also use Monsanto’s Roundup® rather than 
competing brands of the herbicide glyphosate. 
In several cases, lawsuits have been filed against 
Monsanto for “patent misuse,” but to date these 
legal claims have been unsuccessful,43 leaving the 
issue to be debated in the ethical realm. 
As with all other ethical issues relating to bio­
technology patenting, the alleged harmful effects 
of patenting on scientific research and healthcare 
are not uncontroverted. Many biotechnology and 
pharmaceutical companies consider their patents 
to be the lifeblood of their business, without which 
they could not raise and invest the substantial 
amounts of money needed to develop innovative 
products that can enhance human health. Some 
independent analyses have concluded, contrary 
to some of the arguments summarized above, that 
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MARCHANT 
the benefits of patenting outweigh the costs in 
the context of both scientific research and health 
care,44 or that the problems feared from biological 
patents have largely not manifested.45 
Some commentators have suggested that 
companies and other patent holders can take 
steps to minimize these consequentialist argu­
ments against patenting, including not enforcing 
patents against university researchers and charg­
ing reduced licensing fees for clinical testing by 
nonprofit clinics and hospitals.46 Other policy ap­
proaches that have been suggested for addressing 
these concerns include requirements for compul­
sory licensing, prohibition of exclusive licensing, 
liability exemptions for clinical uses of patented 
materials and tests, an expanded experimental-use 
exemption, the development of patent pools, and 
open-source approaches to biomedical research. 
A related and relatively new issue is the use of 
patent rights to promote certain ethical or political 
objectives. For example, Myriad Genetics, which 
has the exclusive patent rights to the BRCA1/2 
breast-cancer genes in the United States and some 
other jurisdictions, refuses to allow the patent to 
be licensed for prenatal testing for these genetic 
markers.47 This is an example of the patent right 
being used to achieve a policy outcome—that is, 
preventing prenatal testing (and presumably fol­
low-up abortion in some cases) for cancer-suscep­
tibility traits. 
One group of researchers has suggested that 
patent licensing could be used as a “moral toll­
booth” to ensure the ethical use of biotechnol­
ogy technologies.48 Under this proposal, patent 
holders could be held liable for the unethical use 
of genetic inventions. The authors suggest “that 
a patent holder could be expected to ensure that a 
licensee of that invention be required to meet emerg­
ing legal and ethical norms associated with the use 
of the technology, such as the requirement to provide 
fully informed consent or genetic counseling where 
appropriate.”49 
.  ConCLuSIon 
Ethical issues and controversies about biotechnol­
ogy patents are a significant, and growing, factor 
in the development and implementation of 
biomedical and agricultural technologies. In a 
few limited contexts, ethical concerns have been 
translated into legal rules that specify a clear 
course of conduct, but those situations are the 
exception. In most cases, ethical concerns about 
gene patents have not been incorporated into 
laws, and the ethical issues remain largely unre­
solved and hotly debated. The lack of clear ethical 
principles and guidelines creates a problem for ac­
tors in this field. As the U.S. Office of Technology 
Assessment recognized many years ago: 
Uncertainty about how courts will resolve dis­
putes between specimen sources and specimen users 
could be detrimental to both academic researchers 
and the infant biotechnology industry… [R]egardless 
of the merit of claims by the different interested par­
ties, resolving the current uncertainty may be more 
important to the future of biotechnology than resolv­
ing it in any particular way.50 
In the absence of greater ethical consensus 
and clarity, decision-makers must navigate the 
ethical minefields of biotechnology patents on a 
case-by-case basis, seeking to avoid the ethical hot 
spots that will likely trigger controversy, disrup­
tion, and opposition, while avoiding being para­
lyzed into inaction by the matrix of conflicting 
ethical viewpoints and positions that exist. n 
gaRy e. MaRchanT, Professor, Sandra Day O’Connor 
College of Law, Arizona State University, P.O. Box 877906, 
Tempe, AZ, 85287-7906, U.S.A. gary.marchant@asu.edu 
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CHAPTER 2.1 
Reservation of Rights for Humanitarian Uses
 
ALAN B. BENNETT, Associate Vice Chancellor, Office of Research, University of California, Davis; 
and Executive Director, PIPRA, U.S.A. 
ABSTRACT 
An explicit reservation of rights in a commercial tech­
nology license can ensure that the licensor’s institutional 
objectives to support humanitarian applications of its 
technology are not inadvertently blocked or sidetracked 
by overly broad terms in the commercial license. Many 
universities routinely use a reservation of rights to guaran­
tee continued use of licensed technologies within the on­
going research or educational programs of the university. 
Clauses included in license agreements to reserve rights for 
humanitarian use of technology are still rare, but aware­
ness is increasing of the utility and importance of such 
clauses, particularly as philanthropic-research sponsors be­
gin to require grantees to ensure that results and discover­
ies will be made available for humanitarian purposes. The 
structure of a clause to reserve rights for humanitarian use 
ideally both expresses the philosophical intent of the li­
censee and clearly defines the boundaries of humanitarian 
use, particularly in relation to commercial use. 
1. INTRODuCTION 
The reservation of certain rights in commercial 
license agreements is a means for the technol­
ogy provider (the licensor) to declare its explicit 
intent to reserve or retain certain rights over the 
technology—to not grant those rights under the 
license—in order to help ensure that the terms 
of the license will not block other specific goals 
that the licensor may have. Such goals are typi­
cally noncommercial and therefore do not di­
rectly impair the licensee’s ability to commercial­
ize the technology, but they may be important 
to ensure that the licensor can continue to meet 
other institutional objectives such as education, 
research, and public service. In the case of uni­
versity research, this typically includes the goal 
of ensuring that future noncommercial research 
is not blocked and, increasingly, that humanitar­
ian uses and applications of the technology are 
not blocked.1 This chapter will briefly address a 
single issue—that of creating an explicit reserva­
tion of rights in a commercial technology license 
to ensure that institutional objectives to support 
humanitarian applications of its technology are 
not inadvertently sidetracked by an overly broad 
commercial license. Furthermore, the regular use 
of this type of reservation-of-rights clause provides 
a means to regularly articulate an institution’s 
commitment to manage technologies for the 
broadest public benefit. 
2. RESERVATION-OF-RIGHTS ClAuSE 
License agreements broadly define the terms un­
der which a technology provider (licensor) will 
transfer intellectual property and/or tangible 
property to a technology user or developer (li­
censee), usually for commercial development. In 
many cases, the license agreement is nonexclu­
sive or it carefully defines the use of the technol­
ogy for a specific field or a specific geography. 
In such cases, the licensee does not grant—but 
Bennett AB. 2007. Reservation of Rights for Humanitarian Uses. In Intellectual Property Management in Health and Agricul-
tural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. AB Bennett. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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BENNETT 
instead retains—rights to the technology in all 
areas other than those defined within the scope 
of the license, and therefore a specific reserva­
tion of rights may not be necessary. However, 
for some technologies and in some technol­
ogy sectors—including biotechnology—broad 
exclusive licenses are often required to induce 
follow-on investment in research and develop­
ment. In these cases it can be important for the 
licensee to explicitly reserve rights to ensure that 
its noncommercial institutional objectives are 
not blocked by the exclusive terms of the com­
mercial license. 
For example, universities frequently incorpo­
rate a clause that reserves rights to carry on re­
search using licensed patents and/or technology. 
This has become increasingly important since the 
Madey v. Duke University2 ruling effectively nar­
rowed, beyond any practical use, the research ex­
emption codified in U.S. patent law for university 
research.3 This lack of a research exemption in the 
United States has created the unusual situation 
where a university invention, if licensed exclusive­
ly, may be unavailable for ongoing research even 
in the very laboratory where the invention itself 
was made. To address this situation, many univer­
sities in their exclusive license agreements now re­
serve rights for the use of inventions within their 
own institution or, even more broadly, within all 
academic or nonprofit research institutions. 
The University of California and Stanford 
University routinely incorporate clauses into their 
exclusive license agreements (Box 1). This type of 
reservation-of-rights clause is perhaps the most 
common type used in university license agree­
ments, although even this straightforward and 
reasonable term still is not used by many univer­
sities in their exclusive license agreements. 
Clauses in university license agreements that 
reserve rights for humanitarian use of the tech­
nology are an exception, rather than a rule, but 
awareness of the utility and potential importance 
of such clauses is increasing. Today there are 
examples of research sponsors and programs— 
such as philanthropic foundations—that require 
grantees to ensure that research results and dis­
coveries will be made available for humanitar­
ian purposes. Based on this type of sponsor re­
quirement, grantees who execute a commercial 
license to any technology developed under the 
research agreement would thus be required to 
include a clause that acknowledged this existing 
obligation and reserved rights for humanitarian 
purposes. 
3. THE STRuCTuRE OF A
RESERVATION OF RIGHTS 
A reservation of rights for humanitarian uses can 
be a very simple statement expressing the philo­
sophical intent of the licensee. For example, at 
the Donald Danforth Plant Science Center all re­
search and license agreements include a statement 
that the “Company and Danforth Center shall dil­
igently and in good faith negotiate the terms of a 
worldwide license, making provision for preserving 
Box 1: Sample Reservation of Rights in Exclusive licensing Agreements 
The university of California 
Nothing in this Agreement will be deemed to limit the right of The Regents (the University)… to 
make and use the Invention … and associated technology and allow other educational and nonprofit
institutions to do so for educational and research purposes. 
Stanford university
Stanford retains the right, on behalf of itself and all other nonprofit academic research institutions,
to practice the Licensed Patent and Technology for any purpose, including sponsored research and 
collaborations. Licensee agrees that, notwithstanding any other provision of this Agreement, it has 
no right to enforce the Licensed Patent against any such institution. 
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the availability of the intellectual property (IP) for 
meeting the needs of developing countries.”4 While 
this has the advantages of being simple and en­
suring that the licensee is on notice with regard 
to the intention of the licensor, the statement 
may not provide sufficient definition of “meeting 
the needs of developing countries” for the licensor 
to assess the extent to which this statement may 
affect its commercial markets. As a consequence, 
more elaborate clauses have been crafted in ef­
forts to clearly define the boundaries of humani­
tarian uses, particularly in relation to commercial 
uses. 
.1 Definitions 
The definitions are the most critical component 
of a reservation of humanitarian use rights. The 
key definitions are: 
Humanitarian purposes. There are several 
approaches used to define humanitarian purpos­
es: by income level, by uses (subsistence or com­
mercial), and by geography. Each approach has 
its own set of limitations. Using a definition that 
equates humanitarian uses with subsistence uses has 
been adopted for some agricultural applications 
but will probably not be applicable in the health 
sector, since few technology applications can be 
achieved without significant investment by a 
commercial partner (this is becoming increas­
ingly true in agricultural innovations as well). 
Where subsistence uses are part of the definition, 
it may be important to define income levels of 
the subsistence “users.” This criterion has been 
applied in the case of the humanitarian license for 
Golden Rice5 but could raise difficult practical is­
sues for compliance or monitoring. Alternatively, 
humanitarian uses can be defined geographically 
by specifying all uses of the technology within de­
veloping countries. 
Developing countries. If humanitarian uses
is defined geographically then an explicit defini­
tion of developing countries is needed. For exam­
ple, developing countries can be defined as those 
listed by the World Bank or other international 
agencies. While this definition can effectively 
segment the commercial and humanitarian uses 
of a technology, the current lists of develop­
ing countries may not capture the entire set of 
desired geographies. Such a definition should 
have flexibility to allow the expansion of the geo­
graphical list. In addition, if such a geographical 
definition of humanitarian uses is used, then the 
issue of use and sales outside of this defined ter­
ritory should be explicitly addressed. 
Commercial purposes. Because the reserva­
tion of rights for humanitarian uses is designed 
to be used in the context of a commercial license 
and, specifically, to segment the markets for a 
technology between commercial and humanitar­
ian uses, it may be important to define the scope 
of commercial uses as well. 
.2 Reservation of rights 
The reservation of rights is the operative paragraph 
of the clause, and its structure will rely upon and 
follow the above definitions. The reservation of 
rights needs to clearly articulate what rights are 
being reserved and should leave no doubt that the 
reserved rights may be granted to other appropri­
ate companies or organizations that can fulfill the 
humanitarian objectives. This may be a topic of 
discussion in license negotiations, largely because 
it is likely to be an unfamiliar term to a commer­
cial licensee. 
4. STANDARD ClAuSES 
There are relatively few examples of standard­
ized reservation-of-rights clauses, because they 
are likely to be crafted individually to meet spe­
cific situations. However, as an object lesson, here 
are two examples, one developed for agricultural 
technology licenses and one developed for health 
technology licenses. 
The Public Intellectual Property Resource of 
Agriculture (PIPRA) has crafted a standard res­
ervation of humanitarian-use-rights clause that 
encourages its members to include in commercial 
licenses for agricultural technologies, particularly 
in exclusive licenses. The clause (Box 2) may serve 
as a model or starting point for similar license 
clauses that seek similar objectives. 
The Office of Technology Licensing at the 
University of California, Davis crafted a reserva­
tion-of-rights clause intended for a commercial 
license of a health technology (Box 3). Likewise, 
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Box 2: PIPRA’s Reservation of Rights for Humanitarian uses 
Definitions.
“Humanitarian Purposes” means (a) the use of Invention/Germplasm for research and 
development purposes by any not-for-profit organization anywhere in the World that has the 
express purpose of developing plant materials and varieties for use in a Developing Country, and 
(b) the use of Invention/Germplasm for Commercial Purposes, including the use and production 
of Germplasm, seed, propagation materials and crops for human or animal consumption, in a 
Developing Country.
“Commercial Purposes” means to make, have made, propagate, have propagated, use, have used,
import, or export a product, good or service for the purpose of selling or offering to sell such 
product, good or service.
“Developing Country”means any one of those countries identified as low-income or lower-middle-
income economies by the World Bank Group at the time of the effective date of this agreement
and all other countries mutually agreed to by Licensor and Licensee (the current list of countries 
is typically given in an appendix to the agreement).6 
Reservation of rights.
Notwithstanding other provision of rights granted under this agreement, University hereby 
reserves an irrevocable, nonexclusive right in the Invention/Germplasm for Humanitarian 
Purposes. Such Humanitarian Purposes shall expressly exclude the right for the not-for-profit
organization and/or the Developing Country, or any individual or organization therein, to export
or sell the Germplasm, seed, propagation materials or crops from the Developing Country into a 
market outside of the Developing Country where a commercial licensee has introduced or will 
introduce a product embodying the Invention/Germplasm. For avoidance of doubt, not-for-profit
organization and/or the Developing Country, or any individual or organization therein, may export
the Germplasm, seed, propagation materials or crops from the Developing Country of origin to 
other Developing Countries and all other countries mutually agreed to by Licensor and Licensee.
Box 3: Reservation of Rights for Humanitarian use:
university of California, Davis 
1.40 “Humanitarian Purposes” means (a) the use of Licensed Products covered under Compound 
Patent Rights (“Compound Products”) for research and development purposes by any 
organization or other third party, anywhere in the world that has the express purpose of 
developing the Compound Products for use in an Economically Disadvantaged Country,
and (b) the use of the Compound Products by any organization or other third party for 
Commercial Purposes in an Economically Disadvantaged Country. 
1.41 “Commercial Purposes” means to make, have made, use, have used, import, or export a 
product, good, method, or service for the purpose of selling or offering to sell such product,
good, method, or service.
1.42 “Economically Disadvantaged Country” (“EDC”) means all countries listed on the United 
Nations Conference on Trade and Development list of “Least Developed Countries” in effect
as of the Effective Date of this Agreement which are set forth on Appendix I hereto. 
2.14 In any license to the Licensee, Licensee’s commercial use of the Compound Patent Rights to 
make, use, sell, offer for sale and import Compound Products in EDCs will be royalty free and 
the Licensee will be required to give away the Compound Products for free or at cost. 
(Continued on Next Page) 
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CHAPTER 2.1 
it may serve as a model or starting point for simi­
lar license clauses that seek such an objective. 
5.	 CONCluSIONS 
It has recently been suggested that national pub­
lic policy guidance is needed to support measures 
that require that publicly funded research results 
be managed in a way that preserves the oppor­
tunity to mobilize new technologies to meet hu­
manitarian needs of the world’s poorest people in 
addition to meeting the commercial needs of the 
developed world.7 In the absence of such national 
policies, voluntary measures can still be taken to 
ensure that research results, new discoveries, and 
patented inventions are not unnecessarily blocked 
from serving humanitarian purposes and meet­
ing the needs of the world’s poor. For public re­
search institutions, a reservation of humanitarian 
rights in commercial technology licenses is one 
mechanism to help it meet its mission to serve 
the public benefit through both commercial and 
humanitarian channels. n 
ALAN B. BENNETT, Associate Vice Chancellor, Executive 
Director, PIPRA, Office of Research, University of California, 
Davis, 1850 Research Park Drive, Davis, CA, 95616, 
U.S.A. abbennett@ucdavis.edu
1	 The broader topic of humanitarian access to health and 
agricultural innovations and a discussion of strategies 
to ensure broader access are also addressed in this 
Handbook in various chapters, most notably chapter 
2.2 by AL Brewster, SA Hansen and AR Chapman. For 
specific aspects of the topic, see in this Handbook,
chapter 12.1 by RT Mahoney. 
2	 (307 F.3d 1351 [Fed. Cir. 2002]) . 
3	 Ludwig SP and JC Chumney. 2003. No Room for 
Experiment: The Federal Circuit’s Narrow Construction 
of the Experimental Use Defense.Nature Biotechnology
21:453. 
4	 Beachy R. 2003. IP Policies and Serving the Public.
Science 299:473. See also in this Handbook, chapter 
17.10 by K Schubert. 
5	 Brewster AL, AR Chapman and SA Hansen. 2005.
Facilitating Humanitarian Access to Pharmaceutical 






00.html. Last updated by the World Bank July 2006. 
7	 Boettiger S and AB Bennett. 2006. Bayh-Dole: If We 
Knew Then What We Know Now. Nature Biotechnology.
24:320–24. 
Box 3 (continued) 
2.15	 Notwithstanding other provision of rights granted under this Agreement, The Regents 
[the university] hereby reserves the right to license the Compound Patent Rights to any 
third parties for solely Humanitarian Purposes. Such licenses for Humanitarian Purposes 
will expressly exclude the right of the third party licensee to export or sell the Compound 
Products from an EDC into a market outside of the EDC where Licensee has introduced or 
will introduce a Compound Product and where Patent Rights exist. In any such license, the 
third party licensee’s commercial use of the Compound Patent Rights to make, use, sell,
offer for sale and import Compound Products in EDCs will be royalty free and the third 
party licensee will be required to give away the Compound Products for free or at cost.
For avoidance of doubt, the third party licensee may be permitted to export Compound 
Products from the EDC of origin to other EDCs and all other countries mutually agreed to 
by The Regents and Licensee.
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ABSTRACT 
Because certain patenting and licensing strategies can in­
hibit the development and dissemination of products for 
developing countries, intellectual property management 
strategies need to be developed that can help remove some 
of these obstacles. It is equally important to apply creative 
patent management strategies that actively promote access 
to needed products in developing countries. Care must be 
taken, however, to ensure that patents on research inputs do 
not discourage or unreasonably increase the cost for prod­
uct development that targets needs in small or unprofitable 
markets. The American Association for the Advancement of 
Science project on Science and Intellectual Property in the 
Public Interest convened a working group to explore these 
issues in 2004. This chapter draws upon the expertise of 
that group to identify licensing strategies that are effective 
in promoting humanitarian access to health and agricul­
tural product innovations and expanding their use among 
poor and disadvantaged groups, particularly in low-income 
countries. The chapter encourages more public sector IP 
managers to understand and employ strategies that will 
achieve these goals and seeks to help private sector licensees 
to understand the rationale behind and potential benefits 
of such strategies. Indeed, humanitarian licensing strategies 
should more and more become the norm by contributing to 
the development and dissemination of essential medicines 
and agricultural technologies for developing countries. 
1. INTRODuCTION 
1.1 Patents and neglected markets 
Intellectual property (IP) rights play an increasingly 
important role in the development, manufacture, 
and distribution of products in agriculture and 
health. During the past 25 years, there has been 
an unprecedented increase in the scope, level, role, 
and geographic and subject-matter coverage of IP 
protection.1 Strong patent protection is intended 
to contribute to increased research investments and 
a favorable climate for technology transfer. But it 
may not always produce these effects. In fact, IP li­
censing practices may inhibit access to IP-protected 
knowledge, research tools, and products. 
The unmet medical and agricultural needs 
of developing countries are vast. Reflecting the 
technological and financial disparity between de­
veloped and developing countries, low- and mid­
dle-income countries account for less than 10% 
of worldwide research and development expendi­
tures.2 And despite increasing levels of investment 
in pharmaceutical R&D during the past 30 years, 
only 1% of new compounds marketed have been 
for developing-world diseases.3 Recent research 
has identified some increase in innovative activ­
ity related to diseases specific to poor countries, 
though this activity “remains extremely low rela­
tive to pharmaceutical research overall,”4 and has 
resulted, in large part, from increased public R&D 
funding for global health.4, 5 Similarly, private sec­
tor agricultural research is more likely to focus on 
specialty crops of interest to developed countries 
than on staple crops that are important to re-
source-poor farmers in developing countries.6 
Brewster AL, SA Hansen and AR Chapman. 2007. Facilitating Humanitarian Access to Pharmaceutical and Agricultural Inno-
vation. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krat-
tiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. AL Brewster, SA Hansen and AR Chapman. Sharing the Art of IP Management: Photocopying and distribution 
through the Internet for noncommercial purposes is permitted and encouraged. 
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1.2 Background and related initiatives 
Our discussion of strategies builds on the initia­
tives, experience, and proposals of other organi­
zations for the management of IP. The United 
Nations Millennium Project Task Force on 
Science, Technology, and Innovation recom­
mended expanding mechanisms for inventors 
to make their ideas available royalty free for uses 
that meet the needs of poor countries, noting in 
its final report that “only a handful of mecha­
nisms are designed to promote such activities.”7 
However, beginning in the 1980s, and expand­
ing through the 1990s and the early years of the 
21st century, an increasing number of organi­
zations have been using IP management prac­
tices to promote the health and food security 
of underserved populations. These include the 
Program for Appropriate Technologies in Health 
(PATH) and the Population Council, as well as 
various other public and public/private partner­
ships, such as the International AIDS Vaccine 
Initiative, the Global Alliance for TB Drug 
Development, the Global Vaccine Initiative, the 
Diseases of the Most Impoverished Program 
of the International Vaccine Institute, and the 
Centre for the Management of Intellectual 
Property in Health Research and Development 
(MIHR). International entities (for example, 
the World Health Organization [WHO]) have 
undertaken humanitarian licensing, as have na­
tional entities such as the U.S. National Institutes 
of Health (NIH), which now includes humani­
tarian clauses in its licensing agreements as ap­
propriate. Several governmental organizations 
in developing countries, such as the Council for 
Scientific and Industrial Research of India, are 
beginning to undertake humanitarian licensing. 
Agricultural organizations with relevant experi­
ence include the African Agricultural Technology 
Foundation8 (AATF), the International Service 
for the Acquisition of Agri-biotech Applications 
(ISAAA), and the institutes of the Consultative 
Group on International Agricultural Research 
(CGIAR). 
One of the most noted examples of hu­
manitarian IP management involves vitamin-
A-enriched Golden Rice. Although developed 
mainly with public sector funding and research, 
around 45 patents associated with Golden Rice 
are owned by approximately 30 companies and 
public institutions in the United States, and only 
a few patents are held in developing countries.9 
The inventors of Golden Rice licensed their in­
ventions related to golden gice to Greenovation, a 
biotech spinout company from the University of 
Freiburg, which is owned by the inventors them­
selves. Greenovation then exclusively licensed its 
Golden-Rice-related patents to AstraZeneca, PLC 
(now Syngenta). Subsequently, Syngenta entered 
into a license agreement with the inventors that 
allowed them, and Syngenta, to license Golden 
Rice technologies to developing countries. Other 
companies holding Golden-Rice-related pat­
ents also agreed to the same arrangement. That 
arrangement allows both Syngenta and the in­
ventors to grant licenses—with the right to sub­
license—to any bona fide research organization 
for the development of Golden Rice. The rice can 
be used royalty free and allows farmers to earn 
as much as US$10,000 per year from its sale. 
Higher sales would require farmers to acquire a 
commercial license from Syngenta.10 The example 
of Golden Rice illustrates that it is possible to 
make IP available for research and commercial­
ization in developing countries. 
Yale University offers another example of hu­
manitarian IP management. It holds a key patent 
on stavudine (d4T), a widely used HIV/AIDS 
antiretroviral drug. Yale renegotiated its exclusive 
license with Bristol-Myers Squibb Co. to incor­
porate renegotiated humanitarian terms, allowing 
the drug to be subsequently licensed for generic 
production in South Africa. The university also 
negotiated a price cut, immediately reducing the 
price of d4T in Africa to 1/30th of the price in the 
United States. When the generic product came 
on the market, it further reduced the price by as 
much as 40%. 
Other examples of humanitarian IP manage­
ment include Cornell University’s transfer of ring­
spot-virus-resistant papaya to Thailand, as well 
as several projects brokered by the International 
Service for the Acquisition of Agri-biotech 
Applications (ISAAA). The latter include local 
varieties of potato transferred from Monsanto 
Co. to Mexico, as well as ring-spot-virus-resistant 
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CHAPTER 2.2 
and delayed-ripening papayas transferred from 
Monsanto and Syngenta, respectively, to Southeast 
Asia.11 Finally, a recent agreement between Gilead 
Sciences and the South African drugmaker Aspen 
Pharmacare is another example of humanitarian 
IP management for health products. Gilead will 
allow Aspen to produce generic versions of the 
HIV/AIDS antiretrovirals Truvada® and Viread®, 
and university inventors who own foundation­
al patents for both drugs have agreed to waive 
royalties in the developing countries served by 
Aspen.12 
1.3 Intended audience 
This paper is written primarily for licensors, par­
ticularly university-based technology transfer 
managers and public sector intellectual property 
managers and, secondarily, for the staff of intel­
lectual property departments in corporations with 
which these entities may enter into agreements or 
who may themselves decide to adopt some of the 
following strategies. Foundations or agencies that 
fund research and that may wish to encourage or 
require their grantees to engage in humanitarian 
IP management are another important audience. 
1.3.1 Public sector 
Universities and public sector institutions play 
key roles in the development of medicines and 
agricultural products. Their roles are generally 
early in the process, and because university-based 
research is most often upstream, final products 
based on their research often involve significant 
development by others. The manner in which 
public sector researchers make their “upstream” 
technologies and research tools available can 
influence whether populations in developing 
countries have access to the end products of this 
research.13
In recent years a number of nonprofit pub-
lic/private partnerships (PPPs) have formed with 
the mission of developing health and agricultural 
products for markets that are neglected by tradi­
tional for-profit R&D companies. These PPPs are 
typically funded by foundations or public sources 
and may receive in-kind support, or in some cases 
direct funding, from private companies. 
Like typical drug companies, health-focused 
PPPs often develop a portfolio of candidate 
products, hoping that a few will be safe and ef­
fective enough to treat their focal condition. 
Examples of PPPs that develop pharmaceuticals 
are listed in Box 1. 
If a university has already licensed IP to a 
company, renegotiating to provide access for a 
PPP can be costly and difficult—even if the PPP 
seeks to develop the invention into a noncom­
peting product. However, the university can take 
steps at the beginning of the technology transfer 
process to facilitate the use of its invention for 
developing products that serve the poor. If a tech­
nology does not interest commercial licensees, 
university IP managers can seek PPPs or other 
nontraditional license partners to develop it for 
neglected markets. To be able to take advantage 
of these opportunities, it is very important for 
universities to establish policies and guidelines to 
manage university-generated IP for humanitarian 
use and applications. 
Why should universities and public sector in­
stitutions take advantage of these opportunities to 
promote humanitarian use? Most universities and 
public sector research institutions seek to contrib­
ute to the wellbeing of humankind through their 
patenting and licensing activities. For example, 
each of the top four university recipients of U.S 
patents in 200416 states public benefit as an ex­
plicit goal in its patent policy: 
•	 University of California (424 patents). 
“It is the intent of the President of the 
University of California, in administering 
intellectual property rights for the public 
benefit, to encourage and assist members of 
the faculty, staff, and others associated with 
the University in the use of the patent system 
with respect to their discoveries and inven­
tions in a manner that is equitable to all 
parties involved.”17 
•	 California Institute of Technology (135 
patents). “It is the policy of the Institute that 
such patents be used for the public benefit. If 
there are innovations or discoveries that result 
in the filing of patent applications and the 
acquisition of patents, the Institute intends to 
serve the public interest by prudent and ap-
HANDBOOK OF BEST PRACTICES | 49 
   
     




















BREWSTER, HANSEN & CHAPMAN 
Box 1: PPPs That Develop Pharmaceuticals 
Aeras (Aeras Global TB Vaccine Foundation)
www.aeras.org 




DNDi (Drugs for Neglected Diseases Initiative)
www.dndi.org 
FIND (Foundation for Innovative New Diagnostics)
www.finddiagnostics.org 







Human Hookworm Vaccine Initiative at Sabin Vaccine Institute
www.sabin.org/hookworm_slides.htm 
IAVI: International AIDS Vaccine Initiative
www.iavi.org 
Infectious Disease Research Institute
www.idri.org 
iOWH (Institute for OneWorld Health)
www.oneworldhealth.org 
IPM (International Partnership for Microbicides)
www.ipm-microbicides.org 
MMV (Medicines for Malaria Venture)
www.mmv.org 
MVI (Malaria Vaccine Initiative)
www.malariavaccine.org 
PATH (Program for Appropriate Technology in Health)
www.path.org 
PDVI (Pediatric Dengue Vaccine Initiative)
www.pdvi.org 
PneumoADIP (Pneumococcal Vaccines Accelerated Development and Introduction Plan)
www.pneumoADIP.org 
TB Alliance (Global Alliance for TB Drug Development)
www.tballiance.org 
Source: Compiled from Gardner and Garner14 and Merz.15 
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CHAPTER 2.2 
propriate efforts to transfer the technology to Public funding agencies also seek to promote 
those who will facilitate public use.”18 public benefit. The mission of NIH, for exam­
• Massachusetts Institute of Technology (132 ple, is to support biomedical research to extend 
patents): “It has long been acknowledged that healthy life by reducing illness worldwide. NIH 
the primary functions of a university are edu­ therefore seeks to understand and overcome the 
cation, research, and public service. It is in the obstacles hindering the public availability of in-
context of public service that M.I.T. supports ventions made by NIH scientists. To this end, 
efforts directed toward bringing the fruits of NIH engages in a variety of forms of humanitar-
M.I.T. research to public use and benefit.”19 ian licensing and humanitarian-use agreements.21
• University of Texas (101 patents): “It is the Many other public sector actors and universities 
objective of this policy to encourage the devel­ are also interested in “doing the right thing” in 
opment of inventions and other intellectual terms of promoting access, but they often do not 
creations for the best interest of the public, the know how to proceed.22 
creator, and the research sponsor, if any, and We anticipate that at least some types of 
to permit the timely protection and disclosure humanitarian IP strategies will have little or no 
of such intellectual property by development, impact on licensing revenues for the technol­
commercialization after securing available ogy creators. Whether that will be the case may 
protection for the creation, by publication, or depend on whether humanitarian licensing be­
both.”20 comes commonly practiced and accepted. It may 
be important for a university or research insti­
tute’s administration to commit to humanitarian 
Box 2: Developing a low-Cost Malaria Treatment 
Strategy employed: Agreeing on IP management conditions in advance 
A research group sponsored by the Medicines for Malaria Venture (MMV) has developed a 
promising, low-cost malaria treatment known as OZ277 /RBx11160. MMV supported collaboration 
between scientists at the University of Nebraska, Swiss Tropical Research Institute, Monash 
University, and the F. Hoffman-La Roche, Ltd. to develop OZ. The drug incorporates some chemical 
features of the plant-derived antimalarial artemesin, but can be produced through synthetic 
chemical processes, making it significantly cheaper. Patents covering OZ have been assigned to 
MMV, and MMV has engaged the Indian drug manufacturer Ranbaxy to further develop it. Upon 
regulatory approval, Ranbaxy Laboratories, Ltd. will distribute OZ at low cost in malaria endemic 
countries. MMV facilitated arrangements for patent, royalty, and pricing structures to benefit
those in need by establishing an IP management plan with its collaborators in advance. Below 
are excerpts from the Statement of MMV Collaborative Principles:
MMV’s central objective is to ensure the sustainable and continuous generation of appropriate 
new malaria medicines that are accessible to all of those in need in developing countries at the 
lowest prices practicable. 
MMV requires intellectual property rights on a royalty-free basis to the relevant intellectual 
property, in the field of malaria, and developed through the collaboration. 
MMV will seek the right to the relevant background intellectual property necessary to achieve 
the objectives identified herein. 
MMV would not normally have a desire to retain any interest in relevant intellectual property 
rights for use outside the field of malaria or to constrain such use by its collaborators. 
Source: MMV and JC CraftMedicines for Malaria Ventures. Statement of MMV
Collaboration Principles. Personal communication, J. Carl Craft, Chief Scientific Officer, MMV.23 
HANDBOOK OF BEST PRACTICES | 51 
   
     
       
       
     
       
     
      
    
     
     
   
  	
   
 	 	 	
BREWSTER, HANSEN & CHAPMAN 
IP management as an extension of the institu­
tion’s public mission (Box 2). This might enable 
technology licensing officers to risk sacrificing 
small amounts of licensing revenue when there is 
an opportunity to enhance product development 
initiatives for the poor. In addition, institutional 
administrations can foster approaches among 
technology licensing officers that would enhance 
such product development initiatives when fi­
nancial promise is low. 
1.3.2 Private Sector 
Why address intellectual property managers in 
the commercial sector? Most technologies devel­
oped by universities and public sector institutions 
are at early stages of development and require pri­
vate companies to invest more in research and 
development to create practical applications. 
Universities generally license these early-stage 
technologies to the private sector. The success 
of humanitarian licensing therefore depends on 
the willingness of private sector actors to accept 
certain conditions and requirements that would 
increase access later in the product development 
and marketing stages. 
We think there are two reasons that commer­
cial licensees may support humanitarian licensing. 
First, commercial entities usually expect major fi­
nancial returns in developed world markets, but 
developing country markets are often considered 
unprofitable. Hence, many types of humanitarian 
licensing may not harm the financial interest of 
the commercial licensee. Moreover, a corporation 
may advance its reputation for social responsibil­
ity and win greater esteem from the public by ac­
cepting humanitarian licensing. 
Multinational companies have already 
shown a willingness to segment their markets 
and offer concessionary terms to facilitate ac­
cess to their products in poor countries. A num­
ber of examples have been highlighted already, 
including AstraZeneca, Bristol-Myers, Gilead, 
Monsanto, and Syngenta. Activities by Chiron 
Corp., GlaxoSmithKline, Pioneer International, 
Inc. (affiliate of E. I. du Pont de Nemours and 
Company), and Roche are mentioned later. 
2. HuMANITARIAN lICENSING STRATEGIES 
In this section we discuss some successful strat­
egies and some new proposals for managing IP 
to facilitate humanitarian use and applications. 
These include case studies in which IP owners 
have used nontraditional IP management tech­
niques to promote the development of products 
for neglected markets. In this section, we describe 
general approaches to licensing and some specific 
license features that a patent owner can use when 
transferring technology to a commercial entity. 
2.1 Identifying the intended beneficiaries 
Rights reserved or obligations set out to facilitate 
access in developing countries will need to specify 
the intended beneficiaries. In the end, all human­
itarian licensing efforts should strive to benefit 
underserved people in developing countries by 
providing greater access to needed technologies. 
However, defining this population or identifying 
the institutions that could serve this population 
with the licensed technology may require dif­
ferent approaches, depending on the particular 
technology and requirements of the primary li­
censee. Below are some options for defining the 
beneficiaries of humanitarian license terms. 
A developing country can be defined in a 
number of ways, for example, by reference to 
the United Nations list of least developed coun­
tries, by locale, or by reference to lists provided 
by the Organisation for Economic Co-operation 
and Development (OECD) countries, the World 
Bank, or the Food and Agriculture Organization 
(FAO). Beneficiary countries may also be mu­
tually agreed to by the contracting parties, who 
may also need to decide whether the agreement 
will cover middle-income as well as low-income 
countries. 
In addition to or in place of defining a list 
of countries covered by the reservations and/or 
exemptions in a humanitarian license, negotia­
tors may wish to further define the population 
in those countries that would be covered. The 
intended population might be “the poor,” “those 
in need,” subsistence farmers, populations in geo­
graphically underserved regions, or a particular 
market segment. 
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CHAPTER 2.2 
A market segmentation, or dual market, ap­
proach is often used to target intended benefi­
ciaries and is involved in many of the strategies 
discussed in this paper. With this approach, an 
exclusive license might give a private sector en­
tity the sole right to use a technology in profitable 
markets, while allowing others to use the technol­
ogy at no cost or reduced royalties to serve market 
segments that do not interest the private sector. 
In the licensing arrangements for Golden 
Rice, a humanitarian-use clause was used to seg­
ment access to an agricultural technology, com­
mitting the owners of key proprietary compo­
nents to donating their technology to the poor. 
Negotiations over how exactly to define and make 
operational such “donations” are ongoing. These 
negotiations focus on defining the humanitarian-
use market and ultimately on the precise wording 
of the humanitarian-use clause. This humanitar­
ian-use clause will determine who qualifies as a 
beneficiary of royalty-free access to Golden Rice 
and exactly how they would benefit.24 
Although market segmentation strategies 
have been employed successfully,25 certain chal­
lenges remain, namely the containment of the IP 
within the targeted markets. In addition to the 
humanitarian transfer of products to the intend­
ed populations, many developing countries may 
also have emerging private markets for the same 
goods. Markets that would not be attractive to 
large companies may nevertheless present niche 
opportunities for smaller companies. Market seg­
mentation might be most successful where non­
commercial markets can be sharply delineated by 
region, which makes it easier to exclude spillovers 
to nontargeted markets.26 In addition, market 
segmentation often requires intense negotiation, 
the development of trust between partners, and 
the capacity to enforce agreements. 
2.2	 Nonexclusive licensing 
In nonexclusive licensing, in addition to the pri­
mary license agreement, the licensor retains the 
freedom to license the technology to other par­
ties. Some institutions (for example, NIH) seek 
to use nonexclusive licensing or to license to mul­
tiple companies whenever possible. If a university 
can accomplish technology transfer to a company 
using nonexclusive licensing, it is free to subse­
quently license the technology for humanitarian 
applications. Sometimes a commercial licensee 
insists upon an exclusive license, in which case 
public sector licensors may limit the exclusive 
license to developed-country markets (as dis­
cussed later) or for specific product applications. 
2.3	 Transferring technology to 
public-private partnerships (PPPs) 
When it is clear that a technology could benefit 
neglected markets (for example, a low-cost HIV 
diagnostic or an agricultural trait important for 
subsistence agriculture), university technology 
managers may be able to transfer the technology 
to a nonprofit corporation for product devel­
opment either on an exclusive or nonexclusive 
basis. The business models of PPPs vary. Some 
conduct in-house product development; others 
manage collaborative development by public 
and private sector labs (Box 3). The transfer of 
technology could take forms ranging from di­
rect licensing or donation of a patented inven­
tion to contributions of know-how or scientific 
expertise. 
Another possible model is an arrangement in 
which a commercial licensee focused on markets 
in affluent countries makes the technology avail­
able to a PPP on concessionary terms for market­
ing or development for poor countries. In order 
to minimize transaction costs for the PPP, it is 
highly preferable for the university to engage with 
the nonprofit developer before completing nego­
tiations with the commercial licensee. 
University technology managers can also fa­
cilitate nonprofit product-development efforts 
by offering PPPs ownership of patents that the 
university no longer wishes to maintain. Even 
when a technology does not appear to have a 
clear application for developing regions, it may 
prove useful for some aspect of the PPP’s work to 
develop products for these regions. 
2.4	 Transferring technology to 
companies in developing countries 
Technology managers may seek commercial part­
ners in low- or middle-income countries to devel­
op technologies that address conditions specific to 
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those regions. These companies are likely to have 
greater interest in developing products that meet 
the needs of these countries than commercial 
entities in wealthier countries. They may also be 
able to develop, produce, and distribute products 
at much lower cost than typical partners in the 
United States or other industrialized countries. 
2.5 Out-licensing 
Out-licensing is primarily executed by drug com­
panies that are already producing name-brand 
versions of a patented drug, but universities could 
negotiate with corporate licensees to ensure that 
out-licensing to generic companies takes place. 
Under the out-licensing approach, drug patent 
holders award nonexclusive licenses to generics 
manufacturers, allowing them to produce cheap 
copies of drugs for sale exclusively in designated 
poor countries. The generic makers are prohibited 
from selling products in the patent holder’s devel­
oped country markets, and they may be required 
to modify their packaging so as to discourage re-
importation by making the generic versions easier 
for customs officials to identify. Generic produc­
ers pay a royalty to the patent holder, and are 
encouraged to compete on price. An advantage 
of this semicooperative approach is that generic 
makers in developing countries can get more in­
formation from the patent holder than just the 
patented technology itself, such as manufactur­
ing expertise and regulatory data. In the rare case 
that a university holds IP that needs little addi­
tional development, it could essentially make the 
out-licensing arrangement itself by licensing the 
patent to a name-brand pharmaceutical company 
(as opposed to a company specializing in the pro­
duction and marketing of generics) for wealthy 
markets and to generic manufacturers for pro­
duction in developing countries. It may be more 
difficult, though not impossible, to encourage the 
sharing of manufacturing expertise and regula­
tory information. 
2.6 Conditions in funding agreements 
Foundations, government agencies, and other 
organizations can require that funded work be 
licensed under humanitarian terms by inserting 
conditions into funding agreements. Establishing 
humanitarian IP management conditions in 
advance can simplify later negotiations, help 
researchers and IP managers plan ahead, and 
increase the prospects of success (Box 4). The 
Rockefeller Foundation has crafted language to 
include in research agreements for this purpose, 
offering a model for ways that funders can increase 
humanitarian access to the research supported by 
their grants. The Rockefeller Foundation requires 
grantees, whether or not they claim or obtain 
Box 3: CDA Malaria Treatment
 
Strategy employed:
PPP-sponsored product development and preferential pricing requirement 
The WHO Tropical Disease Research program, the Medicines for Malaria Venture (MMV), and 
GlaxoSmithKline have formed a partnership to build upon the two-drug antimalarial LapDap™ 
by adding artesunate to the combination. The new therapy will be called CDA, for its ingredients 
chloroproguanil, dapsone, and artesunate. The original LapDap was conceived by scientists 
from the Wellcome Trust Laboratory in Nairobi and the University of Liverpool, then brought to 
market by a public/private partnership involving MMV, British universities, the Wellcome Trust,
GlaxoSmithKline, and the U.K. Department for International Development. It was approved by 
the U.K. Medicines and Healthcare Products Regulatory Agency in 2003. Under the agreement for 
developing the new triple-drug combination, it will be made available at preferential prices to the 
public sector in malaria endemic countries. 
Source: TDR News.27 
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patents or other proprietary rights in their dis­
coveries, “to license or otherwise make available 
the Discoveries to third parties in the commercial 
and public sectors (to the extent permitted under the 
MTAs) for the purpose of furthering the creation, 
reproduction, modification, and/or sale of the im­
proved end product.” 
2.7	 Humanitarian conditionality 
in licensing agreements 
Licensing conditions may require the licensee to 
do specific good things to benefit disadvantaged 
populations. These conditions are sometimes re­
ferred to as white knight clauses. These may in­
clude marketing a product in developing nations 
at a reduced royalty or price, donating materials 
for clinical trials, or cooperating with a humani­
tarian licensee in a specified way (for example, by 
providing clinical or field trial results). A licensor 
could also insert language requiring the licensee 
to make products developed from improvements 
to the technology available in low- and middle-
income countries at a reduced cost. 
NIH often uses these clauses in its agree­
ments to ensure that the licensee undertakes 
specific actions to benefit the public sector (for 
example, mandating the supply-back of licensed 
products or services, health education programs, 
indigent access programs, reduced royalties for 
developing countries, biodiversity compliance for 
natural products, and other means of ensuring 
developing country access for licensed products). 
NIH also requires licensees to create a worldwide 
development and marketing plan to facilitate de­
veloping country access to licensed products, the 
implementation of which it monitors through 
agreed-upon benchmarks.29 
2.8	 Performance milestones 
A milestone is a performance requirement on the 
part of the licensee. Milestones are often used in 
public/private partnerships and sponsored re­
search agreements to measure a project’s progress 
and success. An example of a humanitarian licens­
ing milestone might be a requirement that on or 
before the date of the first phase of a clinical trial 
for a new drug, the licensee will have identified a 
generic manufacturer in a middle-income country 
to produce the licensed technology at a reason­
able price for developing countries. Subsequently, 
if this milestone is not met, other provisions and 
reservations in the agreement would be activated, 
for example, loss of exclusivity, sublicensing, ex­
ercise of march-in rights, and even termination of 
the agreement. 
2.9	 Ensuring accessibility through pricing 
To help ensure access to products, the licensor 
may require that any product developed and 
brought to the market be distributed at a rea­
sonable price. Despite the inherent difficulties 
in defining what is reasonable, price is a readily 
measurable condition that is easier to monitor 
than more broadly defined requirements con­
cerning access.30 This model could be expanded, 
whereby licenses to companies include an appro-
Box 4: Developing a Portable HIV Diagnostic
Strategy employed: Condition in funding agreement 
When technology transfer officers at Massachusetts General Hospital and the University of Texas 
were licensing a prototype HIV diagnostic device to a start-up company, the requirements of the 
foundation funders allowed the foundations to grant additional licenses to entities capable of 
meeting charitable objectives in LDCs. Since it is a portable device, the technology could provide 
an inexpensive, practical means of diagnosing HIV in resource-poor settings.
Source: Foskett, Menapace and Basu.28 
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BREWSTER, HANSEN & CHAPMAN 
priate balance of incentives to the licensee and 
market access for the poor. Licensees might be 
required to meet certain milestones, such as gov­
ernment procurement targets in defined coun­
tries, and at prices that are deemed appropriate 
for that market. Here, an appropriate price may 
be defined as the cost of production plus a small 
profit, usually in the 5%–10% range prior to 
being allowed to commercialize the product in 
more lucrative markets.31 To ensure that an ap­
propriate price is reached and maintained, the 
licensor may include contractual language that 
mandates the submission of manufacturing cost 
reports and product cost calculation details on a 
regular basis.32 
2.10 Reserving rights in license agreements 
It is important to think through how the hu­
manitarian-purpose licensee will actually use the 
technology and to reserve an appropriate set of 
rights and exemptions. For example, the negotia­
tors will certainly want to consider the scope of 
research rights and, depending on the particular 
technology and application, the scope of inter­
national trade rights. The humanitarian licensee 
might need the right to carry out research or 
manufacture within the commercial licensee’s 
territory, so long as the research is done only for 
developing nation needs or the manufacture for 
export to developing nations. The commercial 
licensee may then wish to be protected against 
re-export into its primary commercial market. 
As noted earlier, the humanitarian licensee may 
also need rights for commercial use in low- and 
middle-income regions. Although the reserva­
tion may be defined as humanitarian use, licen­
sors may wish to consider additional, more spe­
cific reservations as described below. 
2.11 Research exemption 
One of the several goals of humanitarian IP 
management is to encourage research to de­
velop products appropriate to the needs of the 
developing world. To this end, licensors could 
opt to insert into licensing agreements a re­
search exemption clause that exempts specified 
categories and types of research from patent 
infringement in using its proprietary technolo­
gies, (for example, to develop products that 
broadly benefit the public or the population of 
poor countries). The University of California 
technology transfer office has begun to insert 
such research exemption clauses into licensing 
agreements.33 Other universities already re­
serve research rights for academic institutions 
in their standard exclusive licensing agreements 
(for example, Stanford, whose standard license 
language is reproduced in Box 5). Such a clause 
could facilitate humanitarian use of the tech­
nology if it also reserved rights for nonprofit re­
search institutions developing products for use 
in developing countries. 
2.12 Sublicenses for developing countries 
Unless provided for in the agreement, a licens­
ee generally does not have sublicensing rights. 
Box 5: Stanford Reservation of Academic 

Research Rights in Standard license Agreement
 
Strategy employed: Reservation of research rights 
3.4 Retained Rights. Stanford retains the right, on behalf of itself and all other nonprofit academic 
research institutions, to practice the Licensed Patent and use Technology for any purpose,
including sponsored research and collaborations. Licensee agrees that, notwithstanding any 
other provision of this Agreement, it has no right to enforce the Licensed Patent against any such 
institution. Stanford and any such other institution have the right to publish any information 
included in the Technology or a Licensed Patent. 
Source: Stanford Office of Technology Licensing.34 
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Should the parties agree to allow sublicensing, 
the main agreement should specify the rights 
and obligations of the licensee with respect to 
the sublicensee(s). In allowing for sublicenses, 
consideration should be given to the possibility 
of the original licensee entering into sublicenses 
inconsistent with the humanitarian goals of the 
agreement. This should be restricted. It is gen­
eral practice for the licensor to hold the licensee 
responsible for assuring that the sublicensee ful­
fills all the requirements of the principal license. 
The best way to ensure that the sublicensee has 
obligations comparable to the licensee’s is for 
the licensor to draft the sublicense terms. The 
licensor can thus be certain that all the humani­
tarian requirements within the primary agree­
ment are included. 
2.13 March-in rights 
A licensor may wish to reserve march-in rights if 
the humanitarian purposes or milestones embod­
ied in the agreement are not met (for example, 
revoking a license or sublicensing to third parties 
in order to ensure access). 
2.14 Treatment of future rights 
in license agreements 
2.14.1 Reach-through clauses 
Reach-through clauses attempt to reach beyond 
the licensed technology and to ensure that the 
licensee treats new technologies, developed 
through use of the licensed technology or un­
der a cooperative agreement, honoring the same 
kinds of development obligations covered by the 
original license. This type of clause is often used 
by public–private partnerships to encourage the 
development of specific technologies that benefit 
developing nations while allowing the private 
sector partner to benefit in the developed world. 
Licensors can also help make inventions more 
available to populations in need by insisting on cer­
tain terms when licensing inventions to commercial 
partners. Opportunities to transfer technologies to 
be developed by public–private partnerships or by 
other organizations can also be pursued. 
2.14.2 Grant-back clauses 
If it is likely that the commercial licensee will 
develop improvements to the technology, it 
would be wise to require that the licensee grant 
back nonexclusive rights to those improvements. 
This would ensure that they would be available 
later for a humanitarian purpose licensee. The 
same might go for access to test results or regu­
latory data. If either party is concerned about 
liability issues, there might be, for example, re­
quirements for any humanitarian licensee to be 
adequately insured or to be operating in com­
pliance with relevant regulations. 
2.14.3 Amending existing agreements 
While the goal of this document is to promote 
humanitarian licensing from the outset, when 
agreements already exist they can be amended 
or revised to meet humanitarian needs. There 
are several examples of successful renegotia­
tions. For example, the humanitarian license 
mentioned earlier between Yale University and 
Bristol-Myers Squibb was actually the result of 
a renegotiation of their license for the AIDS 
drug d4T, which permitted generic d4T to be 
made and used in South Africa. There are also 
examples from the agricultural sector in which 
parties successfully addressed barriers posed by 
a worldwide exclusive license between a uni­
versity and a company. In one case, a compa­
ny insisted that no license was required to use 
the licensed technology in a certain country. It 
stated this in a letter that permitted the univer­
sity to transfer a gene construct directly to the 
country. In general, renegotiating license terms 
is not desirable because it increases transaction 
costs, delays projects, and may not always suc­
ceed. However, while there are clear benefits to 
addressing these issues up front wherever possi­
ble, the fact that an agreement has already been 
concluded should not discourage participants 
from revisiting the agreement when an unfore­
seen need arises. 
3. PROPOSAlS FOR NEW APPROACHES
FOR HuMANITARIAN lICENSING OF IP 
Two new proposals conclude our discussion of 
specific strategies for humanitarian licensing: (1) 
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BREWSTER, HANSEN & CHAPMAN 
considering a shorter length for an exclusive li­
cense and (2) equitable access licensing. 
3.1 Shorter lengths of license exclusivity 
Instead of granting exclusive licenses that match the 
term of the patent, the licensor can grant licenses 
for shorter periods, allowing access by multiple 
licensors over the life of the patent. There may 
be practical complications to this approach, since 
universities often receive patent-cost reimburse­
ments from licensees, which in turn require ex­
clusivity until expiration of the patent term. 
Granting short-term exclusive licenses would 
likely require the university to bear all the costs 
related to maintaining and enforcing the patent, 
which it could only afford to do if the patent itself 
was bringing in significant licensing revenues. In 
that case, the university may be reluctant to end 
its licensing relationship with the high-revenue 
licensor.35 
3.2 Equitable access licensing 
Universities can also make use of an equitable 
access license to create enabling conditions for 
competition in low- and middle-income coun­
tries. An equitable access license (1) ensures free­
dom to operate for any party that manufactures 
and distributes the licensed technology and any 
derivative products in low- and middle-income 
countries and (2) minimizes administrative 
overhead and political contingency by initiat­
ing a self-enforcing open licensing regime. In 
such a license, a university and licensee agree 
that any licensed technology, as well as licensee 
improvements (including improvement patents 
and registration data), to be sold in low- or mid­
dle-income countries will be openly licensed to 
any company that meets Good Manufacturing 
Practice standards.36 This arrangement allows 
multiple producers (including producers in 
high-income countries) to compete to produce 
low-price products for sale only in low- and 
middle-income countries simply after notifying 
the parties to the license. 
The Equitable Access License developed 
by Universities Allied for Essential Medicines 
(UAEM) includes a humanitarian research clause 
to encourage research on neglected diseases. It 
provides that any party may pursue research 
anywhere in the world using the university tech­
nology and licensee improvements without pay­
ing a royalty, if the research targets a neglected 
disease.37 
4. NExT STEPS FOR AAAS HuMANITARIAN
IP MANAGEMENT INITIATIVE 
This document emphasizes the importance of 
managing public sector IP to facilitate humani­
tarian use and applications. It seeks to raise 
awareness about some of the techniques that have 
been pursued so far, and we are optimistic that 
additional approaches will emerge as more insti­
tutions undertake IP management with humani­
tarian use and applications in mind. We certainly 
do not mean to preclude other options. 
Even if technology managers adopt humani­
tarian IP management strategies in the construc­
tion, negotiation, and formalization of legal 
agreements, they will also need to connect with 
development partners who can utilize the pro­
tected technologies to serve unmet needs in de­
veloping countries. In some cases, these partners 
may not yet exist. But when they do, it will be 
important to establish simple, efficient ways for 
them to identify technologies that public sector 
institutions are willing to share. 
We believe that the number and variety of 
technologies being managed with humanitar­
ian goals in mind will continue to increase, and 
so the Science and Intellectual Property in the 
Public Interest (SIPPI) project plans to explore 
ways to increase the transparency of license terms 
covering these technologies, thus making this 
information more widely available to potential 
beneficiaries. 
In continuing its work on humanitarian li­
censing, the SIPPI project will identify ways to 
encourage the use of humanitarian licensing 
practices and increase the transparency of license 
terms covering technologies in health and agricul­
tural innovation, thus making that information 
more widely available to potential beneficiaries. 
It is pursuing the following interrelated activities 
as a means to advance the use of humanitarian 
licensing strategies. 
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Promoting the use of humanitarian licens­
ing practices. In collaboration with the Centre 
for the Management of Intellectual Property in 
Health Research and Development (MIHR), 
SIPPI plans to identify and develop approaches 
for encouraging technology managers to adopt 
humanitarian licensing models. That will be 
accomplished through a wide range of outreach 
activities that will include holding workshops 
to coincide with meetings of the Association 
of University Technology Managers and the 
Association of American Universities, and host­
ing a series of meetings on this topic at the AAAS 
headquarters in Washington, D.C., as well as at 
SIPPI’s annual meeting. 
Developing a Web-based clearinghouse. We 
will develop and implement a Web-based clear­
inghouse of technologies that are available for 
humanitarian licensing for product development. 
The clearinghouse will be designed as an openly 
accessible database listing technologies available 
for humanitarian use. It will identify the owner of 
the technology and provide information as to the 
specific licensing terms for each listed technology, 
including type of license, field of use, and the in­
tended beneficiaries for the use of the technology. 
In addition to facilitating access to technologies, 
the clearinghouse will allow technology transfer 
managers to submit detailed information about 
new technologies and, similar to the creative com­
mons model, will supply online tools to build spe­
cific humanitarian licenses for those technologies. 
This model will allow the clearinghouse to con­
tinue serving its intended purpose over the long 
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ABSTRACT 
In the last decade, product development partnerships 
(PDPs) have become significant components of efforts to 
develop and disseminate therapies for diseases in the de­
veloping world. PDPs seek to fill a gap left by the private 
sector—a gap that leaves 90% of the world’s disease burden 
with only 10% of the world’s research money—through 
innovative, comprehensive partnership strategies that tap 
into the strengths of both the private and public sectors. 
This chapter, based on the proceedings of a conference titled 
Ensuring Global Access through Effective Management 
of Intellectual Property in 2006, provides an overview of 
the history and approaches of numerous PDPs. The chap­
ter is anchored by reports from eight different PDPs and 
aims toward explaining what potential problems to guard 
against, what does not work, and—above all what does 
work—when the public sector plugs into the dynamism of 
the private sector to try to meet the health and agricultural 
needs of developing countries. Recognizing that there is no 
single business model, PDPs employ a common toolbox to 
manage intellectual property for global health outcomes. It 
includes defining a discrete territorial market; establishing 
distinct structures for public sector and private sector mar­
kets; determining field of use in a strategic manner; estab­
lishing royalty rates to optimize incentives; and providing 
for access to the developed technology in the event that 
the research/industry partner abandons the project. Other 
key areas of discussion, where parallels between PDPs exist, 
include global-access strategies, pricing issues, the impor­
tance of market segmentation, production capacity, stra­
tegic early-stage licensing, the IP landscape, and systemic 
challenges. Collectively, PDPs have broadened the creative 
understanding of practical ways to resolve the public-policy 
dilemma of balancing private incentives to generate needed 
R&D investment with the goal of access to those in need. 
1. InTRoduCTIon 
Infectious diseases such as HIV/AIDS, tuberculo­
sis (TB), and malaria are among the world’s lead­
ing killers, affecting the poorest people in the most 
impoverished countries. Yet affordable and acces­
sible interventions are frequently unavailable to 
them. Moreover, neglected diseases such as leish­
maniasis and Chagas’ disease kill or disable mil­
lions of people in the developing world every year. 
Treatment options for these diseases are either in­
adequate or nonexistent because of a lack of public 
funds and private sector incentive to research and 
develop new drugs and vaccines. This lack of R&D 
has created what some call the 10/90 gap; less than 
10% of global health R&D spending worldwide is 
focused on diseases or conditions that account for 
90% of the world’s disease burden.1 
Focusing science and technology innova­
tion on tackling these diseases is a necessary, but 
not sufficient, condition for progress. Improving 
global health will also require concerted efforts 
by academic and industrial scientists, technology 
developers, IP (intellectual property) experts, in­
vestors, government officials, policy-makers, and 
public-health officials. Partnerships are needed, 
not only to develop the products and strate­
gies for delivering interventions to populations 
most in need, but also to forge IP and technol­
ogy transfer agreements that will protect private 
Eiss R, KE Hanna and RT Mahoney. Ensuring Global Access through Effective IP Management: Strategies of Product-De-
velopment Partnerships. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best
Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.
ipHandbook.org. 
© 2007. R Eiss, KE Hanna and RT Mahoney. Sharing the Art of IP Management: Photocopying and distribution through the 
Internet for noncommercial purposes is permitted and encouraged. 
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interests while simultaneously promoting public 
health. Mahoney and Morel have named this new 
era, “the Era of Partnerships.”2 They argue for an 
innovation framework having six components: 
1. Development and expansion of national 
health delivery systems, including an at­
tractive, domestic, private-sector market 
for health products 
2. Development of manufacturing capability 
for health products 
3. Development of a drug and vaccine regula­
tory system 
4. Development of an IP regulatory system 
5. Development of R&D capability by the 
public and private sectors 
6. Development of international trade sys­
tems for health products, including global 
procurement funds 
The authors note that the components are 
comprehensive in that they cover all the areas nec­
essary to innovate successfully.3 All of the compo­
nents are dynamically linked and attention to all 
is required, since the failure of one component 
will almost certainly guarantee failure for the 
whole effort. Thus, though the IP system is only 
one component of innovation, it is a necessary 
component. Product development partnerships 
(PDPs) must therefore attend to all the compo­
nents of innovation, including intellectual prop­
erty, in the quest to ensure global access.4 
The emergence of PDPs over the past decade 
has provided a unique mechanism, a hybrid pub-
lic/private approach, by which to generate new 
products for the neglected diseases of poverty. 
PDPs employ a variety of strategies to achieve 
goals (for example, creating new technologies 
and ensuring that the developed technology is 
available and affordable to as many beneficiaries 
as possible in the developing world). The most 
basic challenge is to provide access to needed 
technologies and pay close attention to how the 
technology is to be distributed or marketed, while 
simultaneously offering appropriate incentives to 
private sector partners to encourage the commit­
ment of research, development, and manufactur­
ing resources. To do this, PDPs are both chart­
ing new territory and employing management 
models that borrow frequently from the private 
sector. Moreover, in some cases PDPs have re­
invented R&D approaches for preventing and 
treating human diseases. Unlike traditional R&D 
agreements, PDPs must make deals that extend 
well beyond the scope of traditional commercial 
agreements, stipulating access conditions to en­
sure that the product reaches the target popula­
tion. These terms and conditions frequently focus 
on the strategic use of intellectual property and 
often have to address such issues as market seg­
mentation, pricing, and distribution. 
The experiences of PDPs have shown that 
several factors are driving some companies to 
work collaboratively and to share disease-related 
intellectual property. These factors include cor­
porate social responsibility and strategic consid­
erations, such as positioning in emerging mar­
kets. An additional incentive is the potential that 
R&D projects with PDPs may have relevance for 
commercial compounds. For example, MMV 
carries out joint studies on malaria tetracycline 
resistance with industrial partners, which benefits 
their commercial anti-bacterial research. 
PDPs are an increasing and innovative group 
of organizations. The diverse experiences of PDPs 
can help inform the makeup and negotiation of 
R&D partnerships and lead to better agreements 
dealing with the various forms of IP. Several PDPs 
are reaching a new mature phase, with products in 
clinical development for poverty-related diseases. 
These PDPs have designed workable solutions to 
ensure access and affordability, from planning 
production that will meet the size of demand, to 
addressing issues of end-user acceptability. PDPs 
are pioneering a new form of social contract to 
promote the development of health products 
where commercial incentive is lacking. 
To promote and facilitate discussion among 
those who have embarked on or are developing 
plans for PDPs, the Centre for the Management 
of Intellectual Property in Health Research and 
Development (MIHR) and the Aeras Global 
TB Vaccine Foundation, in partnership with the 
Bill and Melinda Gates Foundation, convened a 
meeting titled Ensuring Global Access through 
Effective Management of Intellectual Property 
in 2006.5 It built on a similar joint meeting held 
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in 2004, also involving around 50 participants 
including senior management, legal counsel, 
program officers, and business development pro­
fessionals from institutions and organizations in­
volved with PDPs.6 
This chapter summarizes presentations made 
at the meeting by representative PDPs. Their sto­
ries illustrate the diversity of approaches used in 
making R&D agreements and managing intellec­
tual property in the context of global health. The 
structure of these agreements defines and is influ­
enced by the relationships among the partners. As 
Oehler noted: 
By the nature of their business model, the 
commercial interests of private sector companies 
are, on the whole, oriented toward maximizing 
profitability. It is not justified to expect that pri­
vate sector business will automatically ensure best 
services to the public sector and focus the genera­
tion and use of intellectual property toward maxi­
mized public-sector benefits. 
To prepare for a situation where the original 
targets of a license agreement are delayed or are 
not achieved, and to avoid the situation where pro­
jected public-sector benefits are delayed or are not 
realized, it is good practice to establish contractual 
milestones that regulate target achievement under 
the license and to set incentives to keep to timelines 
and performance accordingly. This allows licensor 
and licensee(s) to focus resources on their efforts to 
perform as was agreed upon in the first place.7 
2. pdpS	In 	ACTIon 
2.1	 Collaborative research with 
centralized IP management: DNDi 
Nicoletta Dentico noted that several PDPs fo­
cus on creating R&D partnerships to achieve 
outcomes that would otherwise be impossible. 
For example, in 2003, seven organizations from 
around the world joined forces to establish the 
Drugs for Neglected Diseases initiative (DNDi).8 
Among the seven were five public-sector institu­
tions, one humanitarian organization, and one 
international research organization. 
DNDi was created in response to the fact 
that of all the new drugs developed over the past 
30 years, drugs for tropical diseases and TB ac­
count for only 1.3%. The organization itself does 
not conduct research and scientific work to devel­
op drugs. Instead, it capitalizes on existing, frag­
mented R&D capacity, especially in the develop­
ing world, and complements it with additional 
expertise as needed. According to Dentico, the 
DNDi policy advisor, this integrative approach 
helps cut costs. 
The group builds its portfolio by identifying 
medical needs and R&D opportunities and then 
seeking letters of interest to conduct R&D proj­
ects. Current projects by academic and industrial 
laboratories are focused on identifying new drug 
candidates for tropical diseases, such as trypano­
somiasis, which afflicts over 66 million people 
in 36 countries of Sub-Saharan Africa. Other 
projects involve developing products that sim­
plify and reduce the length of malaria treatments. 
Participating partners provide funding, phar­
maceutical development, in vitro and molecular 
studies, development of analytical models, ani­
mal toxicity testing, and clinical trials, all under 
DNDi coordination and management. This col­
laborative mode of operation blends centralized 
management, which gives a clear project-specific 
focus, and decentralized operations, which mimic 
modern drug companies. 
DNDi has also built regional networks of 
scientists actively involved in the research of new 
drugs for neglected diseases in Asia, Africa, and 
Latin America. These regional networks, coordi­
nated by DNDi regional liaison officers, are vital 
to the success of DNDi. They are able to collect 
data on available regional expertise, capacity, and 
patients’ needs, and they actively advocate for 
DNDi by encouraging scientists to submit pro­
posals to DNDi. 
DNDi negotiates intellectual property and 
knowledge dissemination agreements to obtain 
the best possible conditions for patients and to 
ensure that the fruits of DNDi-sponsored re­
search will be readily available and affordable in 
developing countries. Exclusive rights, titles, and 
interest in the results of a given research project 
are retained by DNDi, including but not limited 
to any resulting patents on any inventions. DNDi 
decides on the best way to make the results of a 
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EISS, HANNA & MAHONEY 
research project available to the public, including 
by putting the results in the public domain with 
no limitations. 
In addition, DNDi may choose a number 
of IP management options: (1) apply for pat­
ent protection to protect some or all of the out­
puts of a research project, (2) keep such outputs 
confidential, or (3) take any other measures that 
would promote DNDi’s mission (such as publicly 
disclosing the results). To ensure that DNDi can 
make full use of the results of a research project, 
DNDi asks partners to grant a nonexclusive, 
worldwide, royalty-free, irrevocable license to use 
any background IP rights that may be needed to 
develop and commercialize a compound devel­
oped during the course of a research project. 
According to the experience of DNDi, forg­
ing agreements with North American universities 
is often a lengthy process: the average negotiating 
time with academic entities in the United States 
and Canada is eight months, whereas the aver­
age negotiating time in Europe is four months. 
Dentico added that PDPs could provide useful 
collaborative R&D models to borrow from and to 
create precedents for improving the current R&D 
environment. This is especially the case for filling 
needs not adequately addressed by government in­
vestment, which often focuses on the earliest stages 
of research. Unlike some other PDPs, DNDi fo­
cuses much of its efforts at the public sector level. 
In addition, DNDi wages public information cam­
paigns that urge citizens to advocate governments 
to fund research on diseases of the poor. 
2.2  Bridging academe and industry through 
social entrepreneurship: iOWH 
Often characterized as the first nonprofit phar­
maceutical company in the United States, the 
Institute for OneWorld Health (iOWH) is an­
other example of a PDP focused on finding 
new drug candidates for the developing world.
Katherine Woo, director of scientific affairs at 
iOWH, pointed out that the focus of the com­
pany is to remove the profit element from the 
business plan and to build a global organization 
with core competencies in R&D and regulatory 
approval for new drugs. A defining feature of 
iOWH is its social entrepreneurial component, 
which aims to deliver medicines to the world’s 
neediest populations. 
According to Katherine Woo, the strategy is 
to assemble an experienced team of pharmaceuti­
cal scientists to identify the most promising drug 
and vaccine candidates—often, the most prom­
ising drug candidates are those that have been 
discarded for lack of a viable market. Once such 
candidates are identified, iOWH focuses on de­
veloping them into safe, effective, and affordable 
medicines. The group then partners with compa­
nies, nonprofit hospitals, and organizations in the 
developing world to complete the requisite ani­
mal studies, conduct clinical trials, secure qual­
ity manufacturing in disease endemic countries, 
obtain regulatory approval, and distribute newly 
approved therapies. 
The group’s strategy, according to Woo, is 
based on the assumption that pharmaceutical 
R&D to create the new medicines for the develop­
ing world need not involve huge costs. By partner­
ing and collaborating with industry and research­
ers, securing donated intellectual property, and 
relying on and using the scientific and manufac­
turing capacity of the developing world, needed 
vaccines and drugs can be delivered affordably and 
effectively. The PDP’s goal is to provide the bridge 
between novel bench science and its conversion 
into applications for the developing world. For ex­
ample, industrial scientists are brought together to 
assist university scientists on late-stage processes, 
such as high-throughput screening and lead opti­
mization of potential new drugs. 
Carrying basic scientific research forward 
through product development requires the par­
ticipation of many groups; however, one partner 
ultimately must take responsibility and be held 
accountable if new drug development is to be 
successful. In many cases iOWH serves as that 
global development partner. It takes responsibil­
ity for markets in the least developed countries 
(dual market opportunities) and obtains resourc­
es from private foundations and governments to 
fund the development costs of taking a new drug 
through to market in the developing world. In 
addition, iOWH provides international regula­
tory expertise to increase the number of countries 
in which important new drugs are marketed. 
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The company interprets global access as af­
fordable prices, a sustainable supply, and en­
gaged distributors. It directly controls pricing as 
much as possible and attempts to maintain maxi­
mum flexibility to engage downstream partners 
(for example, by offering royalty-free licenses). 
Negotiations on geographic coverage for market­
ing, public sector price and exclusivity consider­
ations can be complex and protracted. 
As a nonprofit corporation, OneWorld 
Health provides a tax deduction for the project­
ed future value of donated intellectual property. 
However, iOWH seeks exclusive licensing to pro­
tect investment by philanthropy. Woo emphasized 
that iOWH tries to avoid being surprised in its 
IP management strategy and that they are always 
on the lookout for intellectual property that has 
the potential to discourage important research in 
developing countries. When the IP requirements 
of a partner become too burdensome or onerous, 
the group sometimes walks away from the deal 
and searches for another partner. 
2.  Managing intellectual property 
in a research consortium: IAVI 
Some PDPs serve as enabling bodies to create 
incentive systems, modes of operation, and ne­
gotiators for IP management. The International 
AIDS Vaccine Initiative (IAVI) focuses on spur­
ring R&D for the development of safe, effective, 
and accessible preventive AIDS vaccines for use 
throughout the world. Labeeb Abboud observed 
that, in addition, IAVI is involved in advocacy 
work, seeking to secure and sustain global, na­
tional, and local community involvement and 
commitment for the development of an AIDS 
vaccine. Efforts focus on the developing world, 
where the epidemic is most severe. 
IAVI is supporting research into several key, 
unresolved questions of vaccine development. 
Among other projects and lines of investigation, 
their effort involves a consortium of academic and 
industrial research laboratories focusing on HIV-
neutralizing antibodies, mechanisms of protec­
tion, and vector design. The consortium currently 
has 16 members located in the United States and 
Europe. IAVI negotiates the joint work plan and 
provides a governance structure. The members of 
the research consortium have agreed to common 
provisions relating to IP management and owner­
ship, including access provisions. IAVI is provided 
with license rights to program intellectual proper­
ty, and certain background intellectual property, 
and is responsible for diligently pursuing further 
development. Future licensing revenues are to be 
shared among all members, with the expectation 
that no royalties will be received from develop­
ing country sales. Key to the effective functioning 
of the consortium are the close working relation­
ships among its members. 
IAVI also has had several vaccine development 
programs; it is currently conducting human clini­
cal trials of three vaccine candidates in the United 
States, Europe, Africa, and India. Although con­
sistency in IP management is sought, flexibility 
in the approach to IP ownership, management, 
and licensing is also important. Ownership may 
be determined by inventorship, by ownership of 
background intellectual property, or by funding. 
License rights to program intellectual property 
may be exclusive or nonexclusive, and they may be 
worldwide or restricted to certain geographic sec­
tors. With respect to partnerships in which IAVI’s 
partners control the intellectual property or license 
rights, and thus are responsible for manufacturing 
and distributing a future vaccine, IAVI’s contracts 
require that the partners make access commit­
ments for the developing world (relating to price, 
quantity, and availability) and provide IAVI with 
remedies, such as march-in rights, to ensure that 
products developed through the consortium are 
made available to people in need. 
There are a number of challenges that arise in 
the contracting process, as well as in the manage­
ment of the ongoing relationships with partners. 
Some of the greatest challenges are in the IP area, 
with regard to due diligence, management (when 
to file and where), meeting the requirements of 
donors (including audits), and establishing termi­
nation rights. 
2. 	 Tailoring IP provisions for each 
agreement: Aeras Foundation 
The Aeras Global TB Vaccine Foundation, found­
ed in 1997, is an international nonprofit PDP 
working toward developing a vaccine against TB, 
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both at Aeras facilities and in collaboration with 
academic/industrial partners. Rita Khanna, the 
foundation’s legal counsel, explained that Aeras 
actively pursues and helps fund joint-develop­
ment activities with leading TB vaccine develop­
ers around the world. It also develops candidate 
vaccines in its own laboratory. Aeras’s partners 
with other groups in order to develop vaccine 
candidates and field sites for clinical development 
and to ensure vaccine supply. Aeras’ partners in­
clude companies in nine countries, academic lab­
oratories in eight countries, and five foundation 
or government partners. It is the goal of Aeras to 
develop, test, characterize, license, manufacture, 
and distribute at least one new TB vaccine within 
10 years. 
Aeras takes promising research and early-de­
velopment candidates through preclinical regula­
tory requirements; clinical phase one, two, and 
three studies; process development; manufactur­
ing; and release. The overarching scientific strat­
egy is to improve the current, widely used bacille 
Calmette-Guérin (BCG) vaccine—which has 
limited efficacy—and boost the current BCG vac­
cine with either a recombinant TB protein plus 
adjuvant or a recombinant viral vector making 
TB antigens. Prime-boost regimens of this sort 
have proven to be the most powerful inducers of 
immune responses and protection against TB in 
animal models. 
The focus of Aeras’s IP management strategy, 
according to Khanna, is to ensure global access 
to any resulting vaccine. Aeras has executed nu­
merous research collaborations, licensing, and 
other agreements with commercial and academic 
partners. In one joint development collaboration, 
the partner owns the background intellectual 
property, while the ownership of new intellectual 
property is determined by inventorship. Aeras 
has a royalty-free, sublicensable exclusive license 
to distribute and sell in developing countries and 
public markets in emerging economy countries 
(EECs), and the partner has a royalty-free, sub-
licensable exclusive license to commercialize in 
developed countries and private markets in EECs. 
The partner has the first right to negotiate—and 
right of first refusal—to an exclusive manufac­
turing contract to supply Aeras with vaccine for 
sale in developing countries and public markets 
in EECs. If the partner is not able to meet the 
demand of vaccine for distribution by Aeras, then 
the partner must transfer the rights to Aeras or 
to a mutually acceptable third party. Should the 
partner breach the contract, Aeras would nego­
tiate a license to continue commercialization for 
developing countries and EECs. 
A second type of agreement has many of the 
same provisions, except Aeras and the partner 
have a royalty-free, coexclusive license to distrib­
ute and sell in developing countries with a right to 
grant one sublicense. In this scenario, the collabo­
rator has the exclusive right to commercialize in 
developed countries and EECs. In addition, Aeras 
has a royalty-free license for EECs if the partner 
has not pursued regulatory approval within three 
years of regulatory approval in an industrialized 
country. The partner has manufacturing rights for 
the first five years only. Should the partner breach 
this contract, Aeras has a nonexclusive license to 
continue development in the licensed territories 
or the right to select an alternative manufacturer. 
In similar agreements, Aeras has negotiated 
terms in which the collaborator may use a “rea­
sonable commercial effort” to manufacture and 
supply the product. In addition, the collaborator 
may provide the vaccine at two-tier differential 
pricing in public and private markets. In this sce­
nario, no IP rights are granted to Aeras. 
Other agreements focus on license rights: 
Aeras has a nonexclusive license in EECs in one 
case and an exclusive, worldwide license in anoth­
er case. In these types of agreements, Aeras owns 
improvements and pays license fees, patent pros­
ecution costs (past and future), minimum annual 
royalties, milestone payments, and royalty on net 
sales. These agreements typically include royalty-
stacking terms. 
In a clinical trial agreement, Aeras retains 
rights in intellectual property relating to clinical 
trials, although there is joint ownership of intel­
lectual property resulting from epidemiologi­
cal studies. In a sponsored-research agreement, 
Aeras provides funding for the research and has 
an exclusive, first right to negotiate an exclusive 
or nonexclusive, royalty-bearing license to make, 
use, and sell any patentable inventions conceived 
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and reduced to practice during the term of and 
in the performance of the research supported by 
Aeras. In another sponsored-research agreement, 
Aeras owns all rights, title, and interest in and to 
any intellectual property, material, data, and re­
cords derived from performance of research sup­
ported by Aeras. 
Many of these agreements contain other key 
provisions related to confidentiality, publishing 
rights, patent enforcement and infringement, 
indemnification, liability and insurance, law and 
jurisdiction, dispute resolution and arbitration, 
and termination. 
2.  Ensuring access to new drugs: from 
aspiration to operation at MMV 
Richard Wilder noted that while many PDPs 
focus on early-stage efforts to discover and de­
liver new drugs for neglected diseases, few have 
reached the point of delivery. Indeed, planning 
for the access and delivery of new drugs in dis­
ease-endemic countries cannot be accomplished 
by one PDP working alone. 
The efforts of Medicines for Malaria Venture 
(MMV) are focused on both delivery and R&D. 
Formed in 1999, MMV is a nonprofit organiza­
tion created to discover, develop, and deliver new 
antimalarial drugs through effective public–pri­
vate partnerships. MMV brings together global 
public health organizations, the pharmaceutical 
industry, government ministries, research institu­
tions, and foundations to combine their expertise 
and resources to ensure the needed research, de­
velopment, and release of antimalarial drugs. 
Currently, MMV is managing more than 20 
projects that are in various stages of drug R&D, 
and several in Phase Three clinical trials, with 
reports that good progress is being made. The 
group’s goal is to register at least one new antima­
larial drug before 2010 and to maintain a sustain­
able pipeline of antimalarials that can meet the 
needs of the more than 2.4 billion people at risk. 
These goals are bolstered by MMV’s ground­
breaking collaboration with nearly 40 public 
and private institutions around the world. In 
particular, MMV entered into discussions with 
pharmaceutical companies conducting antican­
cer therapy research that led to the development 
of compounds that are highly active against the 
malaria parasite. 
Because much of MMV’s focus is on later-
stage issues, it already is discussing with collabo­
rators provisions for pricing agreements, negotiat­
ing third-party rights, and ensuring that sufficient 
quantities of the drug are available once devel­
oped. Provisions for handoff are discussed and 
negotiated well in advance. All parties must un­
derstand the goals, the need for speed, and a clear 
view of the regulatory pathway in each country 
where drugs are being tested. MMV negotiates 
time limits for late-stage clinical trials and filings. 
Products are registered and launched immedi­
ately following regulatory approval. In addition, 
deals with collaborators include requirements for 
quality assurance. 
MMV manages the ownership and licensing 
of intellectual property so that the partners’ in­
terests are reflected in the terms of agreements. 
Depending on the situation, MMV might own 
the intellectual property outright, retain licenses 
to the intellectual property, or place conditions 
in its agreements that, if not met, will transfer IP 
rights back to MMV. Sometimes MMV’s owner­
ship of IP rights is unnecessary because the group 
is working with a company to both discover and 
develop a promising compound as an antima­
larial. In those cases, the company might retain 
ownership of the IP rights for use in meeting 
their obligations to MMV to develop and bring 
an antimalarial to market. 
MMV’s agreements specify the conditions 
that have to be met, including price specifica­
tions and access requirements (for example, ac­
cess milestones). The experience of MMV sug­
gests that setting access milestones should not be 
done too late in the process, when time pressures 
are heightened. Pricing agreements, moreover, are 
particularly challenging because of the division of 
markets in many countries where MMV is work­
ing. And difficulties can arise if the price issues 
are driven too far in advance. An advance com­
mitment to a set price ceiling can, for example, 
deter investment. If a partner company cannot or 
will not meet the conditions of the agreement, 
MMV requires that IP rights be returned so it can 
seek another partner. However, the focus of deals 
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is not on IP rights per se, but rather on the ability 
of MMV to ensure that new antimalarial drugs 
under development are brought to market and 
made affordable and accessible to those who need 
them in the developing world. From MMV’s per­
spective, IP rights are merely a tool to help bring 
partners together toward a common goal. 
2.  Securing candidate products 
through creative licensing: IPM 
The International Partnership for Microbicides 
(IPM) is a nonprofit PDP established in 2002 
to prevent HIV transmission by accelerating the 
development and availability of safe and effec­
tive microbicides for use by women in develop­
ing countries. Paul Model explained that IPM’s 
basic strategy involves the licensing of active 
compounds from commercial pharmaceutical 
companies for development as microbicides. IPM 
already has announced compound licenses with 
Johnson & Johnson/Tibotec, Merck, and Bristol 
Myers-Squibb. IPM has found that larger phar­
maceutical companies are more likely to grant 
licenses on a no profit/no loss basis. 
IPM promotes the rapid development and 
delivery of safe and effective microbicide prod­
ucts by pioneering best-practices approaches to: 
•	 screen compounds and design optimal 
formulations 
•	 develop clinical trial sites and conduct clin­
ical trials 
•	 identify appropriate regulatory pathways 
for microbicide products 
•	 establish manufacturing and distribution 
capacity to ensure rapid access to a micro­
bicide as soon as it becomes available 
IPM also funds, co-funds, or leverages re­
sources to support the drug development projects 
of other entities. In some cases, however, the most 
efficient approach is for IPM to take the lead in 
developing, testing, and conducting clinical tri­
als of promising microbicide compounds. In this 
role, IPM is the technology developer and receives 
a nonexclusive license from the owner of the com­
pound that is royalty free and permits distribution 
on an affordable basis in resource-poor countries. 
Rules and procedures are, however, imposed on 
access to the compound for research purposes. 
Importantly, the compounds in development re­
main proprietary. Thus, a grant-back license to 
the owner of a compound typically is required 
for modifications to the compound. Grant-back 
licenses of products or formulations are subject to 
negotiation. 
According to Model, one of the more impor­
tant aspects of negotiations involves defining what 
constitutes a resource-poor country. In his experi­
ence, each partner has its own list of countries; 
there is often disagreement over whether certain 
countries, such as China, India, and Brazil, qual­
ify as resource-poor. However, so far IPM and its 
partners have succeeded in reaching agreement 
on this issue. In some cases, IPM has obtained 
worldwide rights, recognizing that compounds 
are still proprietary and ensuring that products 
will be made available on an “affordable basis.” 
Other important issues involve territory and 
access. Some granting organizations are particu­
larly concerned about access to results of funded 
research. IPM has encountered complex “public 
sector pricing regimes” in grant agreements that 
are similar to those proposed to several other or­
ganizations. These may present inconsistencies 
with the structure of the licenses that IPM has 
been able to negotiate with commercial pharma­
ceutical companies. IPM strives in all cases to 
reach agreement on affordable-basis criteria in all 
agreements. These criteria include no compen­
sation for intellectual property or development 
costs, manufacture at lowest reasonable cost con­
sistent with quality, and recognition that IPM’s 
rights under its licenses are limited. Although 
some collaborators are initially resistant to these 
or other terms, peer pressure and the desire to do 
the right thing are frequently the motivating fac­
tors in closing a deal. 
2.  Deal making with a marketed 
product: TB Alliance 
Two billion people—one-third of the global pop­
ulation—are infected with Mycobacterium tuber­
culosis. More than eight million people develop 
active diseases every year and two million people 
die from the disease. Existing drugs are 40 years 
old and impose a daily regimen that is long and 
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cumbersome, which slows the control of the dis­
ease and promotes the rise of drug-resistance. In 
addition, TB/HIV co-infections are fueling each 
other, and multidrug-resistant TB (MDR-TB) 
and extremely drug resistant TB (XDR-TB) cases 
are on the rise. 
Gerald Siuta explained that the Global 
Alliance for TB Drug Development (TB Alliance) 
is a not-for-profit, product-development partner­
ship that aims to accelerate the discovery and/or 
development of affordable, new TB drugs. It is 
hoped that such drugs will shorten treatment and 
be easier to take, be more effective against drug-
resistant strains, be appropriate for patients with 
HIV-TB co-infection, and be capable of improv­
ing the treatment of latent infection. 
In its first five years, the TB Alliance has 
built the most robust TB drug pipeline in his­
tory, helping to fill a gap left by the private sector. 
Any new drug regimen must be more than just 
highly effective and easy to use; it must also be 
universally affordable, adopted, and accessible. 
According to Siuta, this “AAA” goal guides all de­
cisions on project selection and development, as 
well as concurrent work to influence the policy 
and regulatory environments to foster appropri­
ate pricing in developing countries, ensure that 
new drugs are incorporated into existing treat­
ment programs, and facilitate procurement and 
distribution to those patients who most need the 
drugs. 
One of two TB Alliance’s projects now in the 
clinical phase is the testing of moxifloxacin for the 
treatment of TB. Moxifloxacin is a fluroquino­
lone antibiotic already approved in 104 countries 
to treat respiratory and skin infections. It is novel 
in that it kills mycobacterium TB through DNA 
inhibition. Moxifloxacin has been shown to re­
duce treatment time by two months when substi­
tuted for isoniazid. Moreover, it is safe when used 
in combination with antiretrovirals. 
In October 2005, the TB Alliance and Bayer 
Healthcare announced a partnership to coordinate 
a global clinical trial program to study the poten­
tial of moxifloxacin to shorten the standard six-
month treatment of TB. Clinical trials will assess 
the efficacy and safety of moxifloxacin as a front-
line agent for the treatment of TB. If successful, 
the partnership will register moxifloxacin for a 
TB indication. Both parties are committed to 
making the product affordable and accessible to 
patients in the developing world. Nearly 2,500 
TB patients are being enrolled in trials in Brazil, 
Canada, South Africa, Spain, Tanzania, Uganda, 
the United States, and Zambia. 
Bayer has committed to donating moxi­
floxacin to each clinical trial site, covering the 
costs of regulatory filing, and providing moxi­
floxacin at an affordable price for patients with 
TB in the developing world. The TB Alliance 
has committed to coordinate and help cover the 
costs of the clinical trials, ensure coordination 
of information and results for registration goals, 
and leverage substantial support from the U.S. 
Centers for Disease Control and Prevention, the 
Orphan Products Development Center of the 
U.S. Food and Drug Administration, and the 
European and Developing Countries Clinical 
Trials Partnership. 
A crucial aspect of the deal was ensuring that 
Bayer’s market for moxifloxacin was protected. 
At the same time, if a TB indication is approved, 
there is a potential for dual markets in which 
there would be separate pricing and distribution 
plans. 
2. A focus on diagnostics: FIND 
Herbert Clemens discussed The Foundation for 
Innovative New Diagnostics (FIND), launched 
in 2003 at the World Health Assembly in Geneva. 
FIND is a nonprofit organization based in 
Switzerland and dedicated to the development of 
rapid, accurate, and affordable diagnostic tests for 
poverty-related diseases in the developing world. 
FIND aims to provide a bridge that can ef­
fectively link academic research and the diagnos­
tic industry to the specific needs of developing 
countries. The agency provides this bridge by le­
veraging the strengths of its diverse partners to 
develop technological platforms for diagnosing 
poverty-related diseases in the public, as well as 
the private, health sector. Working in close collab­
oration with the Special Programme for Research 
and Training in Tropical Diseases (TDR) of the 
United Nations Children’s Fund, the United 
Nations Development Program (UNDP), the 
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World Bank and the World Health Organization 
(WHO), the diagnostics industry, and other orga­
nizations, the Foundation develops and validates 
affordable, novel diagnostic tests for diseases in 
high-burden countries. It is leveraging new tech­
nologies that have revolutionized the simplicity, 
speed, and accuracy of diagnostic tools for identi­
fying diseases in the developed world. 
FIND conducts its business essentially as 
a spinout venture and has project portfolios in 
the areas of malaria, TB, and sleeping sickness. 
Although it is involved in project management 
at all levels—financial, administration, strategic 
planning, business development, communica­
tions, information technology, and legal servic-
es—FIND focuses on the middle spectrum of 
product development. FIND leverages its invest­
ments to secure affordable pricing in developing 
countries, thus helping to ensure equitable access 
to diagnostic products for those most in need of 
them. 
Clemens noted that although FIND has IP 
expectations for each project, there is a high de­
gree of good faith among collaborators. IP own­
ership generally rests with the partner. At the 
end of a project, FIND negotiates with the col­
laborator on how to dispose of the intellectual 
property. 
One of the most challenging issues is dealing 
with market segmentation. Of the 193 countries 
in the world, only 25% are developed, and many 
have dual markets, so FIND must arrive at pric­
ing agreements that satisfy both the market re­
quirements of a sponsor (unit product cost plus 
mark up) and FIND’s own access requirements 
2.  Biotechnology investment 
in global health: BVGH 
Christopher Earl observed that biotechnology 
companies lead the world in developing new 
health care products, often for “orphan dis­
eases,” conditions for which the development 
of drugs in not commercially viable or that are 
rare. However, few companies have focused on 
developing treatments for neglected diseases. 
While many biotechnology industry leaders are 
dedicated to contributing to advances in global 
health, their companies often perceive market, 
financial, and information barriers that limit 
their involvement. 
BIO Ventures for Global Health (BVGH) 
combines expertise in industry, in investing, and 
in policy to bridge biotechnology and global 
health. It operates on the assumption that be­
cause technology platforms are already built and 
“money is already sunk,” there is good reason to 
take advantage of the existing infrastructure for 
creating medicine for diseases of the developing 
world. 
BVGH was spun out of the Biotechnology 
Industry Organization (BIO) and is supported 
by the Bill and Melinda Gates Foundation and 
The Rockefeller Foundation, as well as by leading 
biotechnology companies. Earl noted that with 
more than 4,000 companies and 270 approved 
products on the market, the biotechnology in­
dustry has created an extraordinarily diverse set 
of high-technology platforms for drug discovery, 
and thus is well situated to take on the challenges 
of global health. 
BVGH’s approach is market based: it seeks to 
create or facilitate economic incentives and mar­
ket mechanisms. Its approaches include: (1) iden­
tifying targets for the development of new drugs, 
vaccines, and diagnostics; (2) identifying market 
opportunities for neglected diseases through a se­
ries of disease-specific business cases; (3) working 
with companies to build global health strategies 
that optimally employ their core capabilities; and 
(4) expanding access to information and resourc­
es, providing opportunities to exchange informa­
tion, facilitating new partnerships, and securing 
financing for the most persuasive projects. 
According to Earl, the biotechnology indus­
try is made up of three tiers. Top-tier companies 
are the largest and “act like pharmaceutical com­
panies.” These companies are in the process of 
building social responsibility models within their 
organizations. Second-tier companies are insti­
tutionally backed. They are “preprofitable,” their 
investors are “tough,” and company strategies 
are still focused very much on opportunity costs 
and avoiding potential loss of focus. The third 
tier consist of very small companies, essentially 
“mom and pop” operations. The second tier com­
panies are often the best targets for BVGH efforts 
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because they have the infrastructure in place, have 
financial backing, and yet are not committed to 
a binding, long-term R&D plan. Moreover, if 
a PDP already has pathways for production or 
manufacturing, it reduces the opportunity costs 
for such companies in that they can transfer their 
technology directly to the effort without high 
costs. 
In brokering deals between PDPs and bio­
technology companies, the innovation should be 
in the product, not in the deal. Anytime one can 
use existing agreements as models for moving for­
ward, time and costs will be minimized, both of 
which are at a premium for PDPs and midsize 
biotechnology companies. 
2.10 An agricultural model for cooperative 
IP management: PIPRA 
The Public Intellectual Property Resource for 
Agriculture (PIPRA) is not a PDP, but rather an 
initiative by universities, foundations, and non­
profit research institutions to make agricultural 
technologies more easily available for the devel­
opment and distribution of subsistence crops for 
humanitarian purposes in the developing world 
and for specialty crops in the developed world. 
Alan Bennett explained that although the IP 
stakes are low in agriculture, the social and hu­
man health stakes are quite high. Traditionally, 
discoveries in public research institutions and ag­
ricultural universities were seen as “public goods” 
that flowed directly down the chain of public in­
stitutions to farmers and businesses. This system 
formed the basis for crop improvements and a 
robust seed industry in developed countries while 
significantly increasing food production in several 
developing countries. 
In the past few decades, however, changes in 
U.S. patent law and university technology trans­
fer programs have resulted in an increasing use of 
the patent system to protect agricultural innova­
tions. In many cases, dominant patents held by 
the public sector were licensed for private use. 
Companies then adopted and often improved 
discoveries from public sector institutions and 
turned them into crop varieties for commercial 
markets. However, because of the many public 
institutions conducting agricultural research, the 
overall portfolio of public sector technologies is 
highly fragmented across multiple institutions 
and technology categories. Information about 
existing technologies and where rights are held 
is difficult to find. In addition, more intellectual 
property has been licensed to the private sector, 
sometimes under terms that are confidential and 
often that provide exclusive rights to the licensee. 
Since applied research and crop genetic improve­
ment is a derivative process based on preexisting 
plant material, each incremental improvement 
that involves biotechnology can bring with it a 
number of intellectual property and germplasm 
constraints, which accumulate in the plant mate­
rial. As a result, it has become more difficult for 
public sector researchers to access technologies to 
fulfill their missions, especially with regard to de­
veloping sustainable agriculture for the develop­
ing world. 
The development of vitamin A-enhanced 
rice, or “Golden Rice,” illustrates the conse­
quences of the complex IP ownership of agri­
cultural biotechnology. Golden Rice provides 
dietary vitamin A when consumed. Thus, it offers 
direct health benefits to millions of poor children 
in developing countries, where vitamin-A de­
ficiency causes 500,000 cases of blindness each 
year, and is a contributing factor in over two mil­
lion premature deaths each year. However, when 
the time came to prepare this product, many of 
the techniques used by the researchers were pat­
ented in some countries, and some of the ma­
terials had been used informally, or under legal 
agreements that restricted further dissemination. 
There were 70 proprietary technologies involved, 
including 40 issued patents in the United States 
and more than a dozen material transfer agree­
ments (MTAs). Although these issues have now 
been largely resolved through the cooperation of 
the private and public sector, much effort was ex­
pended to overcome these barriers. 
As a result of this and other cases, PIPRA was 
formed to help public sector agricultural-research 
institutions achieve their public missions by en­
suring access to the intellectual property they 
need to develop and distribute improved crops. 
Two PIPRA programs of relevance are focused on 
IP best practices and management. One program 
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is exploring and clarifying the implications of 
public sector IP licensing practices and is seek­
ing a series of best practices that will encourage 
the commercial development of publicly funded 
research innovations. At the same time, PIPRA 
will also retain rights that public research institu­
tions need to fulfill their mission of research for 
the broader public benefit. 
Another PIPRA program involves building 
an IP database. Currently, the database contains 
over 6,600 patents and patent applications from 
39 different countries. Using the database, these 
patents are searchable with respect to various 
parameters, including licensing status. The data 
represents the agricultural portfolios of 27 par­
ticipating universities and nonprofit research in­
stitutions. The goal of the database is to inform 
public sector researchers about their freedom 
to operate (that is, clear all IP barriers to bring­
ing a new product to market). The software also 
finds ways to invalidate patents and minimize the 
chances of patent blocking. Use of the database 
and PIPRA’s analytical services are free for aca­
demic research and humanitarian purposes. 
.  kEy LESSonS 
Many different models exist for identifying can­
didate drugs, vaccines, and technologies, from 
owning inventions to finding new uses or mar­
kets for already-marketed products or abandoned 
product lines. After patents have been issued, the 
IP issues and liability concerns become simpler to 
manage, since there will be an increasing amount 
of safety data available. Partners owning the in­
tellectual property are able to provide the back­
ground technology and expertise, setting condi­
tions for licensing and access. 
There is no single business model that PDPs 
ought to pursue. PDPs vary from virtual organi­
zations that contract all aspects of product devel­
opment, to universities and firms, to PDPs that 
have developed considerable international capac­
ities and expertise in product management and 
regulatory affairs. Regardless of the type, all PDPs 
negotiate diverse ranges of agreements, including, 
sponsored-research contracts, know-how and pat­
ent licenses, and distributorship agreements. 
Although their business models vary, PDPs 
employ a common set of strategies to manage 
intellectual property for global health outcomes, 
usefully summarized by Antony Taubman of the 
World Intellectual Property Organization. These 
include: 
•	 defining a discrete territorial market (sepa­
rating industrialized markets from develop­
ing countries, or focusing on target mar­
kets), allowing investments and earnings 
from Organisation for Economic Co-op­
eration and Development markets to sub­
sidize product availability in developing 
countries 
•	 establishing distinct structures for public 
sector marketing, social marketing, and 
private markets (for example, more open 
licensing for the public sector balanced by 
exclusivity over lucrative markets) 
•	 determining field of use in a manner that 
enables the covered technology or prod­
uct to extend to indications for conditions 
of prevalence in industrialized countries, 
where feasible, as an investment incentive 
•	 establishing royalty rates in a manner that 
benefits the party requiring the greatest 
incentive 
•	 providing for access to the developed tech­
nology in the event that the research/indus­
try partner abandons the project or does 
not service a particular sector, including 
background and foreground intellectual 
property, product development know-how, 
and regulatory approval data 
If the industrial partner bears some of the 
risk, because of early-stage involvement either 
through investment or conduct of R&D, then 
IP issues, such as agreements about royalties, 
licenses, and access, must be resolved early on. 
These issues can be quite complex. The differ­
ent levels and forms of contribution by the part­
ner will influence the extent of and flexibility 
of the terms. If multiple partners are involved, 
each with background intellectual property and 
expectations for foreground intellectual prop­
erty, then royalty-stacking provisions may be 
required. 
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CHAPTER 2. 
.1 Preparing for access 
As PDPs plan for access, they face a series of prac­
tical and conceptual challenges to ensure supply, 
an affordable price, and effective delivery once 
the product is successfully developed. An analysis 
prepared for WHO’s Commission on Intellectual 
Property Rights, Innovation and Public Health 
by Jon Merz, indicates that many PDP R&D 
contracts defer downstream issues related to man­
ufacturing and distribution to future resolution.
Operational challenges face PDPs with regard to 
pricing to the public sector, market segmenta­
tion, market sizing, ensuring the lowest sustain­
able cost of production, and quality control, as 
well post-launch issues, such as pharmacovigi­
lance and product liability. 
Specifying requirements and strategies for ac­
cess early on is critical so that unsurmountable 
hurdles or costly delays are not encountered once 
the product is developed. Indeed, experience 
demonstrates that even where certain products 
have been developed for distribution in develop­
ing countries, uptake has been sluggish or stalled 
due to a variety of downstream constraints. This 
has been the case, for example, with the combina­
tion antimalarial Coartem; praziquantel, for the 
treatment of schistosomiasis; and the slow uptake 
of hepatitis B vaccines. Some PDPs, especially 
those that face inadequate delivery systems in tar­
get countries (regarding deployment of microbi­
cides or HIV vaccines, for example), have identi­
fied preparation for access as a core aspect of their 
mission and have begun to document their needs. 
Moreover, the GAVI Accelerated Development 
and Introduction Plans are forging approaches for 
the phased introduction of selected vaccines.9 In 
some cases, PDPs also may be able to work with 
access public–private partnerships in fields where 
they exist (e.g., Roll Back Malaria Partnership), 
especially with regard to pricing and financ­
ing mechanisms and delivery networks in target 
countries. 
An important tool in intellectual property 
management is the detailed development of 
contractual milestones in licensing intellectual 
property from public to private sector, including 
provisions for performance review and modifi­
cations, when required. Key milestones include 
pricing to the public sector, territory and exclu­
sivity; regulatory work and time to market; royal­
ties and terms; and termination of the licensing 
agreement. 
.2 Pricing issues 
A key consideration in access negotiations is tar­
get pricing. PDPs typically require the product 
to be made available at affordable or reasonable 
pricing, which may lead to complex negotiations 
about how to calculate price, or consideration 
of available price discriminate models. Price set­
ting requires both parties to know in advance 
the technical details of production, marketing,
and distributions costs. A clear framework to 
compute manufacturing cost is required. Since
many PDPs enter negotiations based on early-
stage discoveries, stipulating price in a contrac­
tual arrangement could be a risky or impractical 
proposition. In most instances, the cost of the 
final product is the cost of production plus a 
reasonably negotiated mark-up. Assessments on 
what constitutes an affordable price are complex, 
since they take into account the epidemiology of 
the disease, purchasing power of those affected, 
and government financing schemes, among oth­
er factors. In comparison to drugs, where one 
can project costs once a compound is identified, 
pricing is more difficult with vaccines because 
one does not know in advance what the accept­
able price will be or what a government might 
support. There was general agreement that pric­
ing done too far in advance can deter industry 
partners and discourage extended R&D com­
mitments. Approaches to calculating price are a 
priority topic for focused exchange among PDPs 
and relevant experts.
. Market segmentation 
Market segmentation has emerged as a common 
issue in negotiation. Although there are com­
mon sources for differentiating countries (for 
example, World Bank income data), challenges 
emerge with the division of rights in so-called 
mixed-payer markets, such as Brazil and India. As 
more agreements are pursued, it would be useful 
to generate descriptive case studies on price tier­
ing and its effectiveness at segmenting domestic 
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markets. A correlative need is to prevent arbitrage 
or leakage between public and private markets. 
. Production and capacity issues 
Production also must be addressed. PDPs pose a 
new business model with new challenges, (for ex­
ample, convincing a party to build a factory with 
uptake, rights, and options for manufacturing and 
operations that are uncertain). Identifying exist­
ing facilities is a strength for some PDPs. Those 
working in vaccines, however, have a greater chal­
lenge in that for regulatory reasons, they must 
find a purpose-built factory for every vaccine. 
While excess capacity can typically be absorbed 
for drug manufacturing plants, the same is there­
fore not the case for vaccines. Thus, the price of 
a vaccine is linked to the cost of production and 
investment in the manufacturing plant. 
Another critical issue is projecting and assur­
ing capacity commitments as products approach 
the large-scale processing stage. Some therefore 
suggest that in some cases there should be public­
ly dedicated capacity for manufacturing and that 
PDPs should enter into deals with that expecta­
tion in mind. 
. Early-stage licensing 
In negotiations with universities, several PDPs 
note challenges with in-licensing the needed tech­
nologies from academic institutions. Universities 
may overvalue inventions or lack flexibility. 
However, through the efforts of organizations 
such as MIHR and PIPRA, many universities 
are becoming increasingly able to use IP tools 
to promote access in developing countries, such 
as through the use of humanitarian licensing 
provisions. 
There are several constructive actions that 
could assist the PDPs, including the establish­
ment of inventories of IP rights held and a sur­
vey of the licensing status in key global health 
fields. A prototype database is being developed 
at the U.S. National Institutes of Health (NIH), 
based on the U.S. Federal Interagency Edison da­
tabase of invention reports. At the institutional 
level, there is growing interest among technology 
transfer offices to operate against performance 
expectations aligned with both economic and 
social goals. AUTM is considering new initiatives 
in performance metrics, which potentially could 
facilitate academic licensing to PDPs, if measure­
ments incorporate global health or global access 
considerations. 
In some instances, negotiations with small 
biotechnology firms are comparably difficult. 
Such firms are sometimes concerned that sharing 
platform technologies for use in the development 
of noncommercial products may weaken com­
mercial positions. The types of outreach initiatives 
undertaken with universities may equally benefit 
small biotechnology companies (for example, 
through dissemination of case studies). A key 
challenge is to demonstrate creditable demand to 
encourage risk taking by corporate partners. In 
several areas (HIV, pneumococcal, and rotavirus 
vaccines), useful modeling work is being pursued 
to assess demand and its implications for financ­
ing mechanisms. 
. Negotiating the IP landscape 
PDPs practice due diligence and, where needed, 
engage in IP mapping exercises to ensure freedom 
to operate. IP assembly issues are becoming more 
challenging, due to the increasing need for pro­
prietary tools. This is especially the case for broad 
umbrella or vaccine component patents, where a 
variety of technologies may be required to express 
or purify an antigen, bolster immunity, or devise 
a delivery system. Related problems include roy­
alty stacking and lack of ownership of intellectual 
property to cross license.
Responses to patent thickets include li­
cense mapping and exploring creative licensing 
schemes. There is an emerging range of IP man­
agement tools that can be applied, depending on 
the particular needs of the scientific challenge. 
However, more systematic efforts are needed to 
identify where and when current or emerging IP 
management strategies might best be considered 
and to facilitate their application. The challenge 
may be to identify the specific technology plat­
forms around where public and private sector 
product development interests strongly coincide.
It is also important to identify the key institutions 
to bring together to discuss such a consortium-
based approach. Negotiating the patent landscape 
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and access to research tools is a general challenge 
for the scientific community. However, creative 
models in the health sciences may find the most 
fertile ground in the context of global health 
products, since they represent noncommercial, or 
“low margin,” R&D. 
. Systemic challenges 
The workshop emphasized the broader systemic 
needs of the PDPs, including distribution chal­
lenges within countries with poor infrastructures. 
Reducing the time gap between development and 
implementation also will require the continued 
development of an international clinical trials 
system that engages local investigators, commu­
nities, ethical review committees, and regulatory 
bodies in low- and middle-income countries. It
will require adequate systems for quality con­
trol and regulatory approval to assure consistent, 
high-quality products in the absence of first-world 
regulatory control, and legal systems within man­
ufacturing countries that enable the supplier to 
effectively support its patent rights. To reach their 
goal, PDPs will need greater engagement of the 
scientific community and funding agencies in op­
erational and health-services research, including 
mode and cost of delivery, patient acceptability 
and compliance, dosage and toxicity, and meth­
ods to adapt interventions to local conditions and 
integrate them into existing services. 
.  ConCLuSIonS 
Workshop presenters broadly endorsed the use­
fulness of bringing together diverse groups of 
practitioners to address the challenges of IP man­
agement for global health outcomes. The value 
of such a platform increases as the numbers of 
practitioners and institutions associated with 
PDPs expand. There is value in continuing broad 
discussion, as well as in more focused discussion 
with respect to specific issues, such as calculat­
ing price. From discussions at the workshop ideas 
emerged in regard to a number of actions that 
could both contribute to a wider understanding 
of issues surrounding intellectual property: 
•	 developing best practice standards and dis­
seminating these widely 
•	 developing and disseminating case studies 
of various IP approaches related to market 
segmentation, tiered pricing, and royalties 
•	 pursuing focused workshops on common 
issues such as pricing, product liability, ear­
ly-stage licensing, and sponsored-research 
agreements with academe, or IP assembly 
and freedom to operate 
•	 organizing inventories of IP rights held and 
the licensing status of these IP rights in key 
global health fields 
•	 encouraging academic licensing practices 
that make products more accessible to 
impoverished populations and provisions 
within research sponsorship agreements 
that are responsive to the special require­
ments of PDPs 
•	 supporting IP mapping and/or IP-land­
scape analysis for products of particular 
priority, or disseminating such landscapes 
where available 
•	 instituting training programs and personnel 
exchanges to build research and technology 
management competencies and partner­
ships in low- and middle-income countries 
•	 encouraging needed market analysis, such 
as estimates of need, to engage corporate 
interest 
It is clear that many PDPs have matured 
over the past few years, progressing along the 
continuum from R&D to dissemination. Many 
have secured funding and negotiated successful 
deals, sometimes with numerous partners. Most, 
however, are still in the early stage of product de­
velopment, and few have reached the threshold 
of product completion and distribution. Thus, 
there are no real outcomes to measure at this 
time. Moreover, deals are highly contextual. Still, 
although best practices will continue to emerge 
and be refined, a set of best principles or working 
tenets for ensuring product access and availability 
has clearly been established. In all cases, the role 
of intellectual property in PDP agreements is to 
provide incentives for private investment in pub­
lic health and to structure and define the nature of 
the relationship among the partners with regard 
to how rights will be shared or exercised. There 
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EISS, HANNA & MAHONEY 
is nothing particularly novel about the terms of 
agreements reached by PDPs; rather, it is their 
totality as a public/private hybrid that sets them 
apart. Collectively, the PDPs are broadening our 
creative understanding of practical ways to resolve 
the public-policy dilemma of balancing private 
incentives to generate needed R&D investment 
with the goal of access to those in need. n 
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into Developing Countries IV: Global Access Strategies.
Vaccine (in press). 
5	 25 and 26 July 2006 at the Aeras facility in Rockville,
Maryland, U.S.A. The meeting included representatives 
of PDPs, industry, and academe, who shared their 
perspectives on IP issues, partnership strategies, and 
value propositions or incentives in deal making. The 
involvement of corporate and academic partners 
helped facilitate discussions about the dynamics 
that shape and direct successful public-private 
partnerships. For example, there is a strong interest
on the part of the PDPs in building knowledge 
among university technology managers of the special 
needs and requirements of the PDPs as nonprofit
enterprises. Correspondingly, PDPs can learn from 
university technology offices how to more effectively 
negotiate sponsored research or early-stage licensing 
agreements with universities, given the requirements 
and needs of academic environments.
6	 To view the 2004 MIHR report, see: www. 
globalforumhealth.org/filesupld/ippph/dealmaking.
pdf. The 2006 meeting, like its predecessor, provided 
a platform for exchanging emerging best practices 
in structuring and negotiating product development
agreements for technologies needed in developing 
countries. Presentations centered on case studies 
of several PDPs to illustrate terms, conditions, and 
strategies that may be employed to help ensure 
product availability and access. Topics included:
segmentation of markets, pricing, negotiating with 
universities, liability issues, ownership and use of 
clinical trial and regulatory data, partnerships with 
emerging suppliers, and technical assistance needs to 
ensure technology transfer. Discussions were focused 
on best practices for deal making in various contexts,
from understanding complementarities of missions to 
negotiating contract language.
7	 See, also in this Handbook, chapter 2.7 by J 
Oehler. See also Kaplan W. 2005. www.who.int/ 
intellectualproperty/studies/W.Kaplan2.pdf. 
8	 See, also in this Handbook, chapter 17.9 by J Banerji and 
B Pecoul. 
9	 www.gavialliance.org. 
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CHAPTER 2.4 
Patenting and Licensing Research Tools
 
CHARLES CLIFT, London, U.K. 
ABSTRACT 
Research tools encompass a wide range of resources, in­
cluding genes/gene fragments, cell lines, monoclonal an­
tibodies, reagents, animal models, growth factors, combi­
natorial chemistry and DNA libraries, clones and cloning 
tools such as polymerase chain reaction, methods, labo­
ratory equipment and machines, databases and computer 
software. Access to research tools is integral to advancing 
progress in biotechnological R&D, in both the biomedical 
and agricultural sciences. However, a complex web of re­
search tool patents has arisen as a result of the revolution in 
molecular biology and coincident changes in public policy 
and patent law. These patents can pose a potential block 
to accessing research tools. For developing countries, sev­
eral approaches can be formulated and then implemented 
in order to overcome potential problems associated with 
research tools. These include changes in patenting poli­
cies, research exemptions in patent law to reduce the risk 
of infringement in R&D, compulsory licensing to allow 
access to upstream technologies, and institutional adapta­
tions to facilitate access to needed technologies, such as 
guidelines intended to promote more appropriate behav­
ior by participants in the system. With carefully formu­
lated, multitiered approaches, research tool patenting and 
licensing (and its possible impact on innovation in health 
and agricultural research) may be effectively managed. 
1. INTRODuCTION 
Research tools are difficult to define precisely. 
They may be described, broadly, as any tangible 
or informational input required in the pro­
cess of discovering a drug, a medical therapy, 
a diagnostic method, or a new crop variety. In 
short, anything that a researcher needs to use or 
access in the course of research—such as an as­
say, a genomic database, an animal model, crop 
germplasm and so on—may be classified as a 
research tool.1 Research tools are defined by 
the U.S. National Institutes of Health (NIH) 
as the full range of resources that scientists use 
in the laboratory, including “cell lines, monoclo­
nal antibodies, reagents, animal models, growth 
factors, combinatorial chemistry libraries, drugs 
and drug targets, clones and cloning tools (such 
as PCR), methods, laboratory equipment and ma­
chines, databases and computer software.” 2 To 
this definition, one should add genes and gene 
fragments. 
The classic statement on the possible con­
sequences of protection by intellectual property 
(IP) rights of research tools in biomedical re­
search was made by Heller and Eisenberg: 
… the recent proliferation of intellectual prop­
erty rights in biomedical research suggests a dif­
ferent tragedy, an “anticommons” in which people 
underuse scarce resources because too many owners 
can block each other. Privatization of biomedical 
research must be more carefully deployed to sustain 
both upstream research and downstream product 
development. Otherwise, more intellectual prop­
erty rights may lead paradoxically to fewer useful 
products for improving human health.3 
Clift C. 2007. Patenting and Licensing Research Tools. In Intellectual Property Management in Health and Agricultural In-
novation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. 
© 2007. C Clift. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial 
purposes is permitted and encouraged. 
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Similar concerns have been expressed about 
agricultural research, for example by Boettiger 
and Bennett.4 
2. RESEARCH TOOlS: KEy EVENTS 
There are three key events of relevance to the global 
debate on the pros and cons of patenting research 
tools, all of which date from 1980, or thereabouts. 
2.1  Event one: the revolution in 
molecular biology 
The revolution in molecular biology has fostered 
the development of wholly new branches of sci­
entific investigation, such as proteomics (the sci­
ence of proteins expressed by genes), which has 
transformed the way research is conducted, as 
well as widened, enormously, the potential for 
scientific advances to address fundamental hu­
man problems in health and agriculture. Many 
of the immediate products of such research are 
intermediate or platform technologies of use to 
other researchers, but not (with certain exceptions 
such as diagnostic tests) final products capable of 
application by medical practitioners or farmers. 
2.2  Event two: the Chakrabarty case 
The landmark 1980 U.S. Supreme Court deci­
5sion, Diamond v. Chakrabarty, established that 
genetic inventions (in this case a genetically en­
gineered bacterium capable of breaking down 
crude oil) were patentable subject matter under 
U.S. law. The application of the patent system in 
this way facilitated the development of a viable 
business model for the biotechnology industry. 
With the development of potentially revenue-
earning products, often a long way off for many 
companies, they could nevertheless raise money, 
or realize value (for example, via licensing, assign­
ment, or other forms of acquisition) through the 
patents taken out on research tools or other up­
stream genetic technologies.6 
2.  Event three: the Bayh-Dole Act 
The 1980 Bayh-Dole Act amended the patent 
code in the United States, granting universities 
permission to patent inventions resulting from 
government-funded (federal) research, subject 
to government march-in rights. This was based 
on the premise that implementation of the Bayh-
Dole Act would hasten innovation, facilitate the 
commercialization of research, and thereby move 
new and innovative products into the marketplace 
more quickly. As a result universities themselves 
have become key players in the development 
and patenting of new biotechnology inventions, 
most of which are in the nature of research tools 
rather than final products. Increasingly universi­
ties have developed extensive patent portfolios in 
both agricultural and biomedical technologies. 
Subsequently, most of the developed world has 
pursued similar policies to the United States in 
promoting the commercialization of the products 
of university research. 
3. RESEARCH TOOlS: IMPlICATIONS
AND CHAllENGES 
The more technologically advanced developing 
countries, including Brazil, India and China, have 
in recent years pursued essentially similar policies 
to the United States in promoting the commer­
cialization of the products of university research. 
But developing countries, even those with a rela­
tively well-developed scientific and medical infra­
structure, face very different circumstances from 
those in the United States and other developed 
countries. Although most developed countries 
have tried to emulate Bayh-Dole policies in differ­
ent ways, the success of such policies in the United 
States owes much to institutional arrangements 
specific to the United States and is based on its 
unique higher education system and history of in­
teractions between universities and businesses.7 
An emphasis on patenting and licensing by 
universities as the chief means by which technol­
ogy transfer occurs, as compared to publication 
and open knowledge sharing, may have negative 
implications for research in the area of public 
health or agriculture, as well as other areas. Since 
revenue prospects will be greater for products 
that would have a market in a developed coun­
try, this promise may further distort the alloca­
tion of research funding away from the specific 
public health problems of developing countries. 
Therefore, care must be taken to ensure that 
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CHAPTER 2. 
research priorities, particularly those that could 
directly benefit poor people, are not distorted by 
the quest for larger licensing income. 
Concerns about access to research tools ap­
ply both to the public and private sectors. In the 
public sector, for example, one university may wish 
to access the patented technology of another for 
research. Universities may wish to access private 
sector technologies, and vice versa. Private sector 
companies may experience difficulties in access­
ing each others’ technologies. 
Some see one university paying another to 
license a technology as perverse when most re­
search in universities is publicly funded, even 
if the university is privately funded. But this is 
a logical consequence of introducing patenting 
into the university arena. In the United States, 
in the Supreme Court case Madey v. Duke,8 the 
Court found that, since the “business” of Duke 
University was research and teaching, there was 
no exemption from patent infringement in its 
research, as the use of the patented invention 
was in furtherance of that business. The profit or 
nonprofit status of the user was not a critical fac­
tor for the court. Although not part of the court’s 
judgment, the implication was that as universities 
were now enthusiastic users of patents and licens­
es, and litigated to enforce their patent rights, it 
would therefore be inconsistent for universities to 
seek exemptions for the use of third-party patent­
ed inventions for R&D in their own programs. 
4. THE REAlITy OF RESEARCH TOOlS 
.1 Biomedical research 
In developed countries the evidence to date, which 
mainly comes from the United States, suggests 
that researchers in both the public and private sec­
tor have found various ways of coping with the 
new environment of patented research tools. 
In biomedical research, working solutions 
include licensing, inventing around patents, in­
fringement (often informally invoking a research 
exemption), developing and using public tools, 
and challenging patents in court. Changes in the 
institutional environment, such as the tightening 
of gene patenting rules introduced by the U.S. 
Patent and Trademark Office, and guidelines pro­
duced by NIH to encourage good patenting and 
licensing practices, appear to have further reduced 
the threat of breakdown and access restrictions, 
although the environment remains uncertain. It 
is clear, however, that these various working so­
lutions involve costs in terms of either time or 
money or both.9 
Furthermore, a recent study in the U.S. of re­
searchers in academia, government and nonprofit 
organizations, and industry suggests that difficul­
ties in gaining access to materials (for example, data 
or cell lines) through Material Transfer Agreements 
(MTAs) may have more significant implications 
for the conduct of research than patenting itself.10 
A critical finding is that industry researchers 
experience significantly greater delays and diffi­
culties in accessing proprietary technologies than 
academic researchers. In large part this is because 
industry researchers work, self-evidently, in a 
more commercial environment, are more patent 
aware than academics, and more liable to respect 
the patent rights of others and to assert their own 
rights with respect to their own proprietary tech­
nologies (including research tools). By contrast, 
while commercial activity and pressures have be­
come much more widespread in academic circles, 
and patenting is common, researchers are less 
aware of patent issues, more likely not to check 
whether the technologies they use are protected, 
and less likely to assert their own rights against 
other academic researchers. 
Another recent report from the Committee on 
IP Rights in Genomic and Protein Research and 
Innovation reached the following conclusion: 
…the number of projects abandoned or delayed 
as a result of difficulties in technology access is re­
ported to be small, as is the number of occasions in 
which investigators revise their protocols to avoid in­
tellectual property issues or in which they pay high 
costs to obtain intellectual property. Thus, for the 
time being, it appears that access to patented inven­
tions or information inputs into biomedical research 
rarely imposes a significant burden for biomedical 
researchers. For a number of reasons, however, the 
committee concluded that the patent landscape, 
which already is becoming complicated in areas such 
as gene expression and protein-protein interactions, 
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could become considerably more complex and bur­
densome over time.11 
Accordingly the committee made recommen­
dations that addressed “an increasingly problematic 
environment for research in genomics and proteomics 
as more knowledge is created, more patent applica­
tions are filed, and more restrictions are placed on 
the availability of and access to information and 
resources.” 
A special case is that of genetic diagnostic 
tests, which may be used either clinically or in 
the course of follow-on research. They, therefore, 
have a dual nature, both as a final product, and 
as a discovery tool. A survey of over 100 labora­
tories in the United States concluded that patent­
ing and licensing practices in this field had had a 
negative impact on clinical use and the develop­
ment of further genetic tests.12 
These survey results relate to mainstream re­
search of potential commercial value. Furthermore, 
it is likely that transaction costs could weigh more 
heavily on those working with limited resources on 
projects focusing on specific diseases particularly 
affecting developing countries. On the other hand, 
some public–private partnerships (for example, the 
Global Alliance for TB Drug Development) say 
that their philanthropic mandates can be useful 
in encouraging companies to license their IP more 
easily, and more cheaply, than would be likely in a 
wholly commercial exchange. It is, therefore, dif­
ficult to draw valid, general conclusions from the 
evidence currently available. 
There is also very little empirical evidence of 
the impact of research tool patents in the biomedi­
cal field in developing countries themselves. More 
experience and empirical research are needed. The 
impact of such patents may be more significant in 
developing countries than in developed countries, 
as research institutions or companies in developing 
countries generally lack the legal and negotiating 
capacity to engage in complex negotiations and 
lack the organizational flexibility and funds to pay 
license fees, if required by patent holders. 
.2 Agricultural research 
The institutional context for agricultural re­
search, by which in this context we mainly mean 
crop research, differs from biomedical research. 
The size of the sector, and of the potential com­
mercial market, is much smaller than in medi­
cine. There is also a tradition of public sector 
institutes taking research right through to the 
point of commercialization (at least in tradi­
tional breeding programs), whereas in medicine 
commercialization is overwhelmingly a private 
sector activity. 
The advent of biotechnology and the spread 
of gene patenting is one reason why the private 
sector in agricultural research has come to be 
dominated by a few large companies. In particu­
lar, the existence of a large number of overlapping 
patents for relatively important technologies has 
been a powerful incentive for merger and acquisi­
tions, as well as strategic alliances. For example, 
patents on the Bt gene which can confer insect 
resistance on a wide range of different crops are 
strategically important for the whole industry. 
Controlling or denying access to strategic tech­
nologies is both commercially important to their 
owners and, correspondingly, liable to adversely 
affect research on crops where the commercial 
market is small (for example, subsistence crops in 
developing countries). 
With respect to IP, research tools and agri­
cultural research, a recent survey concluded that 
evidence: 
…suggests that the effects on research of lack of 
access to needed technology have been more serious 
on average for biotechnologists working on agricul­
ture than for those focused on human health. This 
might reflect the smaller set of promising technologies 
in agriculture and the lower level of resources avail­
able to help scientists surmount or invent around 
roadblocks. 13 
It also seems to be the case that patented ge­
netic crop material (such as the Bt gene) is viewed 
as having more commercial value than many of 
the research tools used in biomedical research. 
Thus, whereas patent holders may disregard in­
fringements in upstream biomedical research, or 
think it not cost effective to sue for infringement, 
in the case of more downstream agricultural re­
search this may not be so. 
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5.	 ADDRESSING THE RESEARCH
TOOlS CHAllENGE 
Developing countries have a number of possible 
options, at the level of policy and practice, to 
address the possibility that proprietary restric­
tions will unduly limit the use of research tools. 
Possible approaches used or considered to address 
this issue include the following: 
• changes in patenting policies 
• research exemptions in patent law to reduce 
the risk of infringement in R&D 
• compulsory licensing to allow access to up­
stream technologies 
• institutional adaptations to facilitate access 
to needed technologies, such as guidelines 
intended to promote more appropriate be­
havior by participants in the system 
.1 Patenting policies 
Countries may adopt different approaches to 
patenting. On the one hand, the Agreement on 
Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) in Article 27 (1) obliges coun­
tries to grant patents across all fields of technology 
provided that the technology is new, involves an 
inventive step (or is nonobvious,) and is capable of 
industrial application (or is useful). On the other 
hand, the agreement allows various exclusions 
from patentability, such as discoveries of natural 
phenomena (which could include genes) that do 
not meet the patentability criteria. 
Governments may choose whether or not to 
allow the patenting of genetic material. Plants and 
animals may be excluded from patentability, ex­
cept for microorganisms, and nonbiological and 
microbiological processes. The TRIPS agreement 
does not specify how countries should define what 
an “invention” is, or how the criteria of patent-
ability should be interpreted. Nor does it actually 
refer to genes, or genetic material, at any point. 
The desirability of restricting patentability 
of genetic discoveries in this way will need to be 
assessed according to the circumstances of each 
country. For instance, countries that are mainly 
users of research tools patented abroad might 
promote the use of such tools by limiting their 
patentability. Other countries, with more ad­
vanced capacities in genomics, might favor a 
less-stringent interpretation of patentability but 
would need to be mindful of the possibility of 
restrictions on their widespread use. 
If patents are granted, they can limit the 
scope of the claims to what has actually been in­
vented. Patenting policy in biotechnology should 
aim to facilitate R&D of healthcare products and 
new agricultural crops. Unlike some other coun­
tries, France and Germany have introduced rules 
that limit the scope of patent protection for hu­
man gene sequences to the specific use disclosed 
in the patent application, thus excluding protec­
tion for future, as yet undiscovered, uses.14 These 
rules were introduced because broad protection 
may disadvantage those wishing to build on the 
invention, while narrower claims may facilitate 
their downstream use. 
.2 Research exemptions 
The TRIPS agreement allows the use of limited ex­
emptions under Article 30, which has a possible ap­
plication to the research tool issue as well as others: 
Members may provide limited exceptions to the 
exclusive rights conferred by a patent, provided that 
such exceptions do not unreasonably conflict with a 
normal exploitation of the patent and do not unrea­
sonably prejudice the legitimate interests of the pat­
ent owner, taking account of the legitimate interests 
of third parties. 
In most of Europe, exemptions exist for acts 
performed privately, for purposes that are noncom­
mercial, and for experimentation on the subject mat­
ter of the invention, even for commercial purposes. 
In the United States, by contrast, there are no 
equivalent statutory exemptions, even for non­
commercial or research uses. In the past, however, 
the courts have generally recognized some scope 
for “making or using of a patented invention merely 
for experimental purposes, without any intent to de­
rive profits or practical advantage… .” In 2002, as 
noted above, the case of Madey v. Duke essentially 
ended this informal research exemption.15 
There is an active debate in several coun­
tries about the appropriate scope of any re­
search exemption. In 2004, the U.S. National 
Academies of Science (NAS) published a report 
on the U.S. patent system recommending that 
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the introduction of a formal research exemption 
for noncommercial purposes.16 This recommen­
dation was repeated in the subsequent report on 
genomic and proteomic research.17 
Thus, there is a broad spectrum of ways in 
which the research exemptions allowed under 
the TRIPS agreement are implemented in dif­
ferent countries, and how these are interpreted 
by courts. The essential point, in this context, is 
how to ensure that follow-on research that may 
be important to innovation in the fields of health 
and agriculture is not inhibited. The appropriate 
scope of the research exemption must be consid­
ered in this light. 
. Compulsory licensing 
In most countries, the law allows governments 
to issue compulsory licenses on a number of 
grounds, including in circumstances where the 
development of a research field of importance to 
public health or agriculture could be inhibited by 
the actions of particular patentees. For example, 
in the United Kingdom there are extensive pow­
ers in the Patent Act that, although rarely used, 
can remedy such situations. Section 48A (1) of 
the act, for instance, covers: 
refusal of the proprietor of the patent to grant 
a licence or licences on reasonable terms … the ex­
ploitation … of any other patented invention which 
involves an important technical advance of consider­
able economic significance in relation to the inven­
tion for which the patent concerned was granted is 
prevented or hindered. 
Similar provisions exist in many other coun­
tries. In the United States, the Patent Act does 
not provide for compulsory licensing as such, but 
there are similar march-in rights, as part of the 
Bayh-Dole amendments, only where federal fund­
ing of an invention is involved (Section 203). 
In the European Union, the 1998 
Biotechnology Directive, which has been imple­
mented in national law by many member states, 
contains provisions that allow for compulsory li­
censing of patents or plant variety rights if prior 
negotiations with the owner are unsuccessful, 
provided that the resultant invention constitutes 
significant technical progress of considerable 
economic interest compared to the original inven­
tion claimed in the patent or plant variety right. 
. Institutional adaptations 
Various initiatives have been considered or imple­
mented to adapt or modify institutional practices 
around patenting and licensing. 
One example of adaptation to the changing 
technical environment was the announcement in 
2001 by the U.S. Patent Office of new guide­
lines on expressed sequence tags (short pieces 
of DNA that help to identify when particular 
genes are being expressed in cells). These guide­
lines tighten the specifications regarding what 
constitutes “utility,” and provide guidance to 
patent examiners about how to apply the util­
ity criterion to biotechnological inventions. In 
such cases, patentability can be established only 
if the patent application discloses a specific, sub­
stantial and credible utility.18 It was intended that 
this new standard would prevent patents being 
granted on inventions for which only a specula­
tive application is disclosed. The introduction of 
these tighter criteria may be one reason, among 
others, why patent applications in this area have 
declined recently. 
Countries may also consider guidelines or oth­
er means to encourage or mandate patenting and 
licensing policies that promote innovation. In the 
United States, NIH, as the principal funder of aca­
demic biomedical research, took the lead in pub­
lishing in 1999 principles and guidelines on sharing 
biomedical research resources. These sought to pro­
mote the widest possible dissemination of research 
tools developed with NIH funds, in the interests 
of accelerating scientific discovery and facilitating 
product development. At the same time NIH con­
sidered that “reasonable restrictions on the dissemina­
tion of research tools are sometimes necessary to protect 
legitimate proprietary interests and to preserve incen­
tives for commercial development.”19 
In 2005, NIH introduced voluntary guide­
lines (“best practices”) on the patenting and li­
censing of genetic inventions funded by NIH 
grants. On patenting, the guidelines said it should 
be considered whether: 
…significant further research and develop­
ment by the private sector is required to bring the 
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invention to practical and commercial application. 
Intellectual property protection should be sought 
when it is clear that private sector investment will be 
necessary to develop and make the invention widely 
available. By contrast, when significant further re­
search and development investment is not required, 
such as with many research material and research 
tool technologies, best practices dictate that patent 
protection rarely should be sought. 
On licensing, the guidelines provided a 
more extensive set of principles that support 
nonexclusive licensing as a general rule. Where 
exclusive licensing might be necessary to promote 
further development, the guidelines suggest that 
care should be taken to license only in the spe­
cific area where the licensee is working, to avoid 
blocking off other areas of research that may use 
the same technology. In addition, they said con­
sideration should be given to including specific 
provisions to protect further research and public 
health. For instance, a license could reserve the 
right for the invention to be used in nonprofit 
research organizations for either research or edu­
cational uses.20 Boettiger and Bennett argue that 
since the NIH guidelines appear to be working 
well, they should be applied across the board 
where federal funding is involved, keeping in 
mind, specifically, the situation in agricultural 
biotechnology.21 
Guidelines on the licensing of genetic inven­
tions have also been produced by the Organisation 
for Economic Co-operation and Development 
(OECD).22 Apart from the text of the guidelines, 
an appendix contains a useful list of Web links to 
model agreements on various aspects of licensing 
and material transfers. 
The international network of agricultural re­
search centers, that is, the Consultative Group on 
International Agricultural Research (CGIAR), 
has a policy on IP, with the underlying principle 
to “take every possible measure to facilitate access 
to research products for the public benefit, in par­
ticular in developing countries,” while recognizing 
also that there will be exceptional circumstanc­
es when taking out patents may be necessary 
for the various centers to pursue their specific 
objectives.23 
Some U.S. universities are indeed experi­
menting with new licensing arrangements. For 
instance, Stanford University proposes wording, 
along the following lines, as a standard means of 
establishing freedom for universities, public sec­
tor research organizations or, indeed, organiza­
tions such as public–private partnerships to be 
able to use particular technologies that it licenses 
exclusively to a third party: 
Stanford retains the right, on behalf of itself and 
all other nonprofit academic research institutions, to 
practice the Licensed Patent and use Technology for 
any purpose, including sponsored research and col­
laborations. Licensee agrees that, notwithstanding 
any other provision of this Agreement, it has no right 
to enforce the Licensed Patent against any such insti­
tution. Stanford and any such other institution has 
the right to publish any information included in the 
Technology or a Licensed Patent.24 
The organization Universities Allied for 
Essential Medicines has been set up in the United 
States to explore how universities can help ensure 
that biomedical end products, such as drugs, are 
made more accessible in poor countries, and to 
increase the amount of research conducted on ne­
glected diseases, or those diseases predominantly 
affecting people who are too poor to constitute a 
market attractive to private sector R&D invest­
ment. The organization recognizes that university 
scientists are major contributors in the drug-de­
velopment pipeline and that universities have an 
avowed commitment to advancing the public 
good.25 The organization has developed a model 
equitable access license to further these aims.26 
A body of technology managers called the 
Technology Managers for Global Health has 
been formed, as a subgroup within the influential 
Association of University Technology Managers 
in the United States, to press for similar sorts 
of arrangements to those promulgated by the 
Universities Allied for Essential Medicines and 
others. In conjunction with the Centre for the 
Management of Intellectual Property in Health 
Research and Development (MIHR), a co-spon­
sor of this Handbook, the Technology Managers 
for Global Health has published a booklet provid­
ing case studies of academic licensing to product 
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development partnerships for treatments for dis­
eases affecting developing countries particularly.27 
Another initiative seeks to draw on the suc­
cess of the Open Source Initiative (OSI) which 
has developed a more or less proven research 
model, based on a general public license that 
makes modifications of a software program freely 
available to others to use or develop further. The 
important aspect of this approach is that it mobi­
lizes innovative effort from a range of developers 
at little cost. 
CAMBIA, a nonprofit organization based in 
Australia, both undertakes research in molecu­
lar biology in agriculture directed at the needs 
of developing countries and also seeks to over­
come the problems of fragmented technologies 
by developing patent and technology databases 
and innovative licensing techniques that draw on 
the experience of OSI. CAMBIA has prepared a 
model license28 that has the objective of creating 
a common pool within which improvements can 
be freely shared. On the other hand, the terms of 
this license may conflict with the existing licens­
ing terms of other technologies, which should 
form part of the common pool. 
The Public Intellectual Property Resource 
for Agriculture (PIPRA), the other co-sponsor 
of this Handbook, is an organization comprising 
universities, foundations, and nonprofit research 
institutions, which aims to make agricultural tech­
nologies more easily available for the development 
and distribution of subsistence crops for humani­
tarian purposes in the developing world. PIPRA 
seeks, through a variety of activities, including the 
compilation of patent and licensing databases, to 
mitigate problems arising from the fragmentation 
of proprietary technologies and materials among 
different institutions. It has also proposed a draft 
license to facilitate research relevant to developing 
countries.29 
Another institutional approach is the poten­
tial use of patent pools. In 2000, a report by the 
U.S. Patent Office on patent pools and biotech­
nology patents concluded that the “use of pat­
ent pools in the biotechnology field could serve the 
interests of both the public and private industry, a 
win-win situation.”30 Among the benefits cited 
for this approach to licensing were: efficiency in 
obtaining rights to patented technology through 
one-stop licensing mechanisms; the distribution 
of risks associated with research and develop­
ment; and the elimination of blocking patents or 
stacking licenses, and the consequent encourage­
ment of cooperative efforts. Patent pools, there­
fore, could be most useful for technologies par­
ticularly relevant to developing countries, because 
the lack of strong market incentives may enable 
agreements that would otherwise be more dif­
ficult to engineer. Low-margin research directed 
toward problems of poor people might be pro­
moted. Patent pools have also been proposed for 
the development of vaccines, which is appropri­
ate given the large number of products owned by
different entities and, consequently, the 
complexity of identifying, tracking, and obtain­
ing licenses for patented technologies. 
Patent pools have been established in the con­
sumer electronics industry, specifically in relation 
to the broad adoption of industry standards. The 
biotechnology industry, however, is very different 
from the electronics industry. An OECD report 
noted: 
…the pharmaceutical biotechnology industry 
may be fundamentally different from the electron­
ics sector. It is not an industry in which defining 
standards is important, and assuring interoperabil­
ity of technologies is not very important, especially 
not in the development of therapeutics. A company’s 
worth is tightly tied to its intellectual property and 
fosters a “bunker mentality.” There are likely to be 
disagreements among partners over the value of the 
different patents in a pool, and dominant players 
may not have a strong incentive to join the pool. If 
a limited field of application and essential patents 
can be defined, the patent pool model is worthy of 
consideration in biotechnology…31 
The suitability of the patent pool for biotech­
nology patents certainly requires further study, as 
does the role of government in promoting them. 
For these reasons, and others, patent pools in 
biotechnology have not developed as a response 
to fragmented patent ownership. In agricultural 
biotechnology in particular, cross-licensing and, 
ultimately, mergers and acquisitions are the
common response. 
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CHAPTER 2. 
6. CONCluSIONS 
While no specific guidance or conclusions can 
cover the specific circumstances of policy-mak­
ers, researchers, universities, research institu­
tions, foundations or other organizations in given
developed or developing countries, the sev­
eral guidelines, enumerated below, might
help to conceptualize a starting point within a 
broader framework: 
•	 Developing countries need to consider im­
plementing patent legislation, consistent 
with TRIPS, that meets their objectives, in 
particular with respect to genetic discoveries. 
•	 Countries need to consider in their own 
legislation what form of research exemption 
might be appropriate, in their own circum­
stances, to foster research and innovation in 
health and agriculture. 
•	 Countries should consider providing in 
their legislation powers to use compulsory 
licensing, in accordance with the TRIPS 
agreement, where this power might be use­
ful as one of the means available to promote, 
inter alia, research that is directly relevant 
to the health and agriculture problems of 
developing countries. 
•	 Countries should seek through patent­
ing and licensing policies to maximize the 
availability of innovations, including re­
search tools and platform technologies, for 
the development of products for human 
health and agriculture. 
•Public fundingbodies should introducepolicies 
for sensible patenting and licensing practices, 
for technologies arising from their funding, 
to promote downstream innovation. 
•	 Public research institutions and universi­
ties in developed countries should seriously 
consider initiatives designed to ensure that 
access to R&D outputs relevant to the 
health concerns of developing countries, 
and to products derived therefrom, are 
facilitated through appropriate licensing 
policies and practices. n 
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CHAPTER 2.5 
Valuation and Licensing in Global Health
 
ashley J. sTevens, Associate Director, Institute for Technology Entrepreneurship and Commercialization, 
School of Management, and Director, Office of Technology Transfer, Boston University, U.S.A. 
ABSTRACT 
Since 1999, two trends have transformed the landscape of 
treating endemic diseases in the developing world: (1) the 
establishment of highly effective drug development pub­
lic private partnerships, which have secured substantial 
amounts of philanthropic funding to develop new drugs 
for developing countries and (2) the emergence of tiered 
pricing for drugs that are under patent protection and 
that treat diseases in both the developed and the develop­
ing world. As a result, the options have increased for both 
academic institutions and companies for developing new 
therapies for low- and middle-income countries. This 
also means that traditional bilateral licensing arrange­
ments will be replaced by multimember networks that 
bring together the necessary skills for R&D, regulatory 
work, intellectual property (IP) management, produc­
tion, and distribution and marketing. New licensing ap­
proaches will be needed to ensure that IP issues facilitate, 
rather than hinder, such collaborations and transactions. 
This chapter presents evidence that suggests that all par­
ties to such transactions should strive for a no profit–no 
loss financial model in order to maximize humanitarian 
benefits. 
1.  TWo 	pHARMACEuTICAL	 InduSTRIES: 
TWo 	pRICInG	pHILoSopHIES 
In developed countries, the pharmaceutical in­
dustry consists of two quite separate and largely 
nonoverlapping sectors:1 
•	 In the research-driven sector, new drugs are 
developed and tested through clinical trials. 
Typically, a new drug application (NDA) 
is filed with the FDA; when the NDA is 
approved, the drugs are sold at legal, patent-
protected, monopoly prices based on the 
benefits the drugs provide to patients. 
•	 In the generic sector, drugs that are nearing 
the end of their patent protection term are 
prepared for market and, when patents ex­
pire, sold competitively at commodity prices 
based on the cost of production. 
According to the Generic Pharmaceutical 
Association, using IMS health data, generics ac­
counted for 56% of all prescriptions dispensed in the 
United States in 2005, but less than 13.1% of every 
dollar spent on prescription drugs. Generics cost, on 
average, 30% to 80% less than their branded coun­
terparts.2 Prices for generic drugs are typically 10% 
to 20% of their prepatent expiration price and are 
cost based (that is, the price is based on a mark up 
over the cost of production).3 Analysis of the finan­
cial results of publicly traded generic-drug companies 
shows that these companies typically operate with a 
gross margin—the amount by which sales exceed the 
cost of goods sold—of around 50%.4 This margin 
covers the companies’ general and administrative 
costs, marketing and selling costs, and profits. 
2.	 dRuG pRICES In dEvELopEd CounTRIES 
The United States has had a love–hate rela­
tionship with the research-driven sector of the 
Stevens AJ 2007. Valuation and Licensing in Global Health. In Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. 
© 2007. AJ Stevens. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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STEVENS 
pharmaceutical industry almost from its incep­
tion. Consumers love the new life-saving medica­
tions that the industry has been able to discover, 
but they hate the prices resulting from the patent-
protected monopoly. 
The issue first emerged in the late 1940s, 
with the launch of the tetracycline family of anti­
biotics.5 This was the first family of antibiotics to 
be discovered by the U.S. pharmaceutical indus­
try itself. The first antibiotics—penicillin, strep­
tomycin, and neomycin—had been discovered 
in academic laboratories (penicillin at St. Mary’s 
Hospital in London, U.K. and Oxford University 
with the critical process scale-up under war­
time conditions led by the U.S. Department of 
Agriculture6 and streptomycin, and neomycin at 
Rutgers University7). All were licensed non-exclu­
sively and the resulting competition caused prices 
to fall rapidly. 
By contrast, thanks to the patent protection 
they enjoyed, prices for tetracyclines remained 
high. However, eventually competition came 
from overseas. At that time, Italy was the “rogue 
state” of pharmaceutical patents, and through 
bids by an Italian company for a U.S. military 
procurement of tetracyclines, the government 
became aware of the high profit margins on the 
patented drugs. This discovery led to hearings fo­
cused on the pharmaceutical industry led by U.S. 
Senator Estes Kefauver, Chairman of the Senate 
Antitrust and Monopoly Subcommittee, from 
1959 to 1963. Kefauver correctly identified that 
the pharmaceutical industry was making enor­
mous profits on the new generation of antibiot­
ics. Disclosures of price markups of thousands of 
percents led to sensational headlines across the 
country and to widespread public outrage. He 
identified a number of other problems in the in­
dustry, notably the lack of any requirement for 
systematic testing for the safety and efficacy of 
new drugs and the industry’s freedom to advertise 
new drugs with the flimsiest of scientific support 
for their claims. 
Kefauver drafted a law to increase regula­
tion of the industry. The report included re­
quirements for demonstration of safety and ef­
ficacy and for compulsory licensing of patents 
three years after product launch. His colleague, 
U.S. Representative Oren Harris, introduced 
companion legislation in the U.S. House of 
Representatives, and the combined bill became 
known as the Kefauver-Harris Amendments to 
the Antitrust Act. Hearings went on for seven 
months, in the face of strong opposition from 
the Pharmaceutical Manufacturers Association 
and the American Medical Association, and the 
legislation may well have died were it not for the 
thalidomide catastrophe, which demonstrated 
the critical need for a much more rigorous review 
of new drugs. The Kefauver-Harris Amendment 
passed, though without the compulsory licens­
ing provision. And while it started the process of 
FDA reform, no action was taken at that time to 
control pricing. 
The only substantive action the United 
States has taken to control drug prices has 
been the Drug Price Competition and Patent 
Term Restoration Act of 1984, more common­
ly known as the Hatch-Waxman Act. This leg­
islation greatly facilitated the development of 
a vigorous generic drug industry. Companies 
received an exemption—the Section 271(e) re­
search exemption of the patent laws—allowing 
them to make and use (but not to sell) a drug 
during its period of patent protection, for pur­
poses of developing data to prove that a new 
version of the drug was equivalent to the pat­
ented version. The company could then file an 
Abbreviated New Drug Application (ANDA) 
with the FDA and be ready to put its gener­
ic version of the drug on sale as soon as pat­
ents expired. Absent this research exemption, 
a drug company would enjoy a de facto year 
or two of additional exclusivity, since generic 
producers would not be able to make and use 
the drug for testing until the patent had actu­
ally expired. 
Despite these legislative changes, drug pric­
es remain a major issue in the United States. The 
problem was exacerbated when the products of 
the biotechnology industry were introduced in 
the mid-1980s. These had substantially high­
er production costs than those of traditional 
(small-molecule or simple chemical) drugs, 
resulting in prices of thousands of dollars per 
year per patient, an order of magnitude higher 
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CHAPTER 2. 
than traditional drugs, already perceived to be 
high priced. More recently, orphan drugs such as 
Genzyme’s Ceredase® for Gaucher’s disease and 
some cancer treatments are even more costly, 
costing as much as US$300,000 per patient per 
year. 
A combination of third-party payers for the 
insured and compassionate-access programs for 
the uninsured has allowed the generally high-
priced drug market to persist in the United 
States. In Canada, Europe, and Japan, however, 
a combination of single purchaser systems and 
legislative activities have led to lower prices 
than those in the United States, although prices 
for drugs in these countries are still well above 
the costs of production. The opportunity for 
American citizens to purchase the same patent­
ed drugs in Canada or online at low cost has ag­
gravated the concern of patients over high drug 
prices in the United States. This has made an 
impression on the Congress and local govern­
ment officials. 
.  THE	dEvELopInG	 WoRLd 	And 
TWo-TIER	pRICInG 
In the developing world, situations have var­
ied widely. Countries such as India, Argentina, 
and Brazil encouraged the development of the 
generic-drug industry by recognizing only phar­
maceutical process patents. Thus, drugs whose 
composition of matter was patent-protected 
in the United States and Europe could legally 
be produced in these countries by a company 
that could develop a novel production process. 
However, countries without their own generic-
drug industries could afford only to import 
drugs whose patents had expired and were sub­
ject to generic competition. 
The second issue for developing countries is 
that the diseases that afflict them tend to be very 
different from those that afflict the developed 
world, although more recently it has become ap­
parent that the “diseases of the poor are not the only 
diseases of the poor.”8 While Western drug compa­
nies have set out to discover and develop drugs to 
treat the diseases of the developed world, through 
which they are able to earn an attractive return, 
these companies have, for the most part, ignored 
tropical diseases. One study showed that of the 
1,339 new drugs introduced between 1975 and 
1999, only 13 addressed tropical diseases, and 
only three addressed tuberculosis, which still 
takes an enormous human toll in the developing 
world. A later study identified that even these 13 
drugs were poorly suited to the needs of the de­
veloping world.9 
Fortunately, serendipity has sometimes 
worked to help the developing world. For in­
stance in the early 1980s, the animal health 
division of Merck (now Merial, Inc.) devel­
oped an antiparasitic called ivermectin (Ivomec 
Plus Cattle Injection®), to treat gastrointestinal 
roundworms, lungworms, sucking lice, mange 
mites, cattle grubs, and adult liver flukes in 
cattle. Ivermectin also had a large market for 
use in treating lungworm infection in dogs and 
cats. In addition, the drug was found to effec­
tively treat two human parasitic diseases in sub-
Saharan Africa: 
•	 Onchocerciasis, commonly known as river 
blindness, is a nematode infection trans­
mitted through the bite of black flies. The 
disease causes intense itching, disfiguring 
dermatitis, eye lesions, and, over time, 
blindness. 
•	 Lymphatic filariasis, commonly referred to 
as elephantiasis, coexists with river blind­
ness in a number of African countries and 
also occurs in a small number of Latin 
American countries. 
Merck developed ivermectin under the trade-
name Mectizan® for registration to treat humans 
for these conditions, but it was the UNICEF­
UNDP-World Bank-WHO10 Special Programme 
for Research and Training in Tropical Diseases 
that subsequently conducted the extensive trials 
needed to establish the safety of mass adminis­
tered Mectizan® for eradication or control pur­
poses. Merck then created a donation program 
that has donated enough Mectizan® to treat over 
40 million patients a year since 1987. 
GlaxoSmithKline (GSK) donates a treat­
ment for parasitic worms, albendazole, which 
is co-administered with Mectizan®.11 These 
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STEVENS 
programs have had a major impact on rates of 
infection for these diseases. 
.  AIdS 
.1. AIDS in the developed world 
The uneasy status quo in the pharmaceutical indus­
try fell apart with the AIDS crisis and the political 
activism that emerged from it. The crisis created a 
demand for access to effective, new drugs. 
The response to the emergence of HIV/AIDS 
represents a triumph for basic scientific research 
in the U.S. and Europe, largely funded by gov­
ernment, and its integration with the pharma­
ceutical and biotechnology industries. While it 
now appears that the first person to die of AIDS 
was an inhabitant of the Democratic Republic of 
the Congo who died in 195912 and that the HIV 
virus was slowly spreading and infecting people 
during the 1970s, (a U.S. teen who died in 1969 
and a Norwegian sailor who died around 1976 
have also subsequently been shown to have been 
infected with HIV13) it was not until 1981 that 
physicians in San Francisco and New York started 
noticing an unusual incidence of a rare cancer, 
Karposi’s sarcoma, and of a rare form of pneu­
monia, pneumocystis carinii pneumonia, or PCP, 
in the gay community. It was only then that it 
became clear that a new disease was emerging.14 
Although a new Republican administration 
took office in early 1981 that was unsympathetic 
to the gay community, investigators at the U.S. 
National Institutes of Health (NIH) quickly re­
alized the risk posed by HIV. Scientists at NIH 
recognized the virus’ unique ability to infect and 
destroy the human immune system. As a result, 
NIH quickly devoted substantial resources to 
fighting HIV and, together with the Centers for 
Disease Control and Prevention (CDC), included 
funds for investigating its epidemiology in Africa. 
Progress in fighting the disease was rapid: 
•	 In 1983, Luc Montagnier of the Pasteur 
Institute in Paris identified a putative in­
fectious agent, which he called lymphade­
nopathy-associated virus or LAV. 
•	 In 1984, Robert Gallo of the National 
Cancer Institute in Washington, D.C., 
confirmed that LAV and a virus he had 
identified and called human T-cell lympho­
tropic virus III or HTLV-III were identi­
cal and that it was the etiologic agent of 
AIDS.15 
•	 In 1985, a diagnostic test was developed, li­
censed, and put into routine use for screen­
ing blood donations. 
•	 In 1987, Retrovir (AZT), the first drug that 
was effective against HIV, received FDA 
approval. 
•	 In 1992, a second antiretroviral drug, 
Hivid (ddC, discovered by NIH scientists 
and marketed by Roche), was approved and 
combination therapy was started. 
•	 In 1996, Invirase (saquinavir; marketed 
by Roche) the first drug of a second class 
of drugs, the protease inhibitors, was ap­
proved and “triple therapy” was launched. 
With triple therapy, HIV infection was trans­
formed from a delayed death sentence, to the ex­
tent that opportunistic infections or Kaposi’s sar­
coma could be treated, into a chronic condition 
whose victims could enjoy a reasonable quality of 
life for longer and longer periods as the drug regi­
men improved. HIV was only the second viral 
disease for which an effective treatment (as op­
posed to a prophylactic vaccine) had been discov­
ered, the first having been the use of Acyclovir to 
treat herpes simplex in 1982. 
.2. The impact of AIDS on the developing world 
The incidence and impact of AIDS in the de­
veloping world, particularly sub-Saharan Africa, 
dwarfs anything seen in the developed world. In 
some countries today, a third or more of the adult 
population is infected with HIV. While preva­
lence in some Asian countries remains low, the 
sheer size of the population of India or China 
means that there are an enormous number of in­
fected people in these countries, official denials 
notwithstanding. 
As AIDS began to be well-controlled in de­
veloped countries thanks to highly active antiret­
roviral therapy (the “triple cocktail” or HAART) 
in the mid- to late-1990s, the developing world 
started to demand the same access to these life- 
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saving medications. But there was a critical dif­
ference between AIDS and other diseases. There 
simply were no older, patent-expired drugs avail­
able from generic manufacturers to provide to the 
developing world. The disease was new, and the 
drugs to treat it even newer, so the drugs were 
all still under patent protection and would be for 
years to come. AZT’s patent would be the first to 
expire, in 2005. 
Brazil invoked public-health-crisis measures 
included in the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS), 
which allowed it to override international patents 
and make AIDS drugs in its state-owned phar­
maceutical factories and make them available to 
HIV-infected Brazilians under a free-drug pro­
gram. Between 1997 and 2002, the cost of treat­
ing an AIDS patient in Brazil fell from US$6,500 
to US$1,500 per year,16 and the number of deaths 
from AIDS was reduced to half. 
Conditions in Africa were desperate. There 
was no capacity to do what Brazil had done, and 
the cost of importing AIDS drugs at developed-
world prices, at an annual per patient cost that was 
many multiples of average per capita GDP, meant 
very few people were able to receive treatment. In 
2001, 25 million people in Africa were infected 
with HIV, but only 25,000—just 0.1% of the in­
fected population—were receiving HAART.17 
In December 1997, the Mandela govern­
ment passed amendments to the South African 
Medicines Act to break patents and to allow the 
manufacture or importation of generic versions. 
In 1999, the World Health Organization (WHO) 
raised the issue of patents in the pricing of AIDS 
medications in developing countries. 
In response, six major pharmaceutical com­
panies—Merck, Bristol-Myers, GSK, Pfizer,18 and 
Boehringer-Ingelheim—approached WHO in 
2000 with an offer to lower prices on AIDS drugs 
in Africa. The initiative was called Accelerating 
Access. In return, the companies asked that 
WHO help distribute the drugs. Discussions be­
gan and progressed slowly. Individual companies 
started various philanthropic initiatives, primarily 
focused on education, research, and community 
outreach, but critics were not assuaged and con­
tinued to demand lower prices for drugs. 
A year after the launch of the initiative, 
only three countries—Senegal, Uganda, and 
Rwanda—had reached specific agreements with 
WHO. Antiretroviral therapy cost US$1,000 
to US$1,500 per patient per year through this 
initiative, which is around 10% of U.S. prices. 
Then Medecins Sans Frontiéres (MSF) entered 
the debate. Everything changed in February 2001, 
when the Indian generics manufacturer Cipla 
offered to supply MSF with triple cocktail pills 
for US$350 per patient. Cipla offered to supply 
African governments with the pills for US$600 per 
patient per year, US$400 below the Accelerating 
Access price. Cipla’s initiative demonstrated that 
most pharmaceutical companies only applied for 
patents in South Africa. Only GSK, Boehringer-
Ingelheim, and Agouron tended to apply for 
patents throughout Africa. 
In 2001, 39 pharmaceutical companies filed 
suit against the South African government to en­
force their IP rights and prevent Medecins Sans 
Frontiéres from buying Cipla’s products. 
. Yale University and Zerit 
A pivotal catalyst for change was Amy Kapczynski, a 
first-year student at Yale Law School in early 2001. 
A seemingly innocuous decision made at 
Yale in 1987—one that most academic institu­
tions would make without hesitation even today 
without thinking twice about it—backfired and 
became a major issue in the debate about global 
health and fair access to medicines. Yale’s fateful 
decision was to allow the licensee of one of their 
drugs to decide in which countries to apply for 
patent protection. 
The story began in the early 1960s at the 
Detroit Institute of Cancer Research (now the 
Barbara Ann Karmanos Cancer Institute), where 
Jerome Horowitz, working on the then-prevalent 
theory that cancer was caused by viruses, synthe­
sized a number of compounds that would inhibit 
DNA replication in the expectation that they 
would be effective against cancer. Some of the 
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The theory was incorrect for the overwhelm­
ing majority of types of cancer, so the compounds 
were not effective and were shelved. 
When the HIV epidemic emerged, Horowitz’ 
work resurfaced. Several of his compounds were 
evaluated against HIV and found to be effective. 
AZT (Burroughs Wellcome), ddC and ddI ( both 
discovered by the NIH) were all discovered by 
evaluating the efficacy of Horowitz compounds 
against HIV 
Tai-Shun Lin and William Prusoff of Yale 
University worked with another Horowitz com­
pound, d4T (stavudine), with funding from 
NIH and Bristol-Myers Squibb (BMS), to eval­
uate d4T’s effectiveness against HIV. BMS re­
ceived an exclusive option to exclusive license to 
any patents that emerged from the work. Prusoff 
and Lin found d4T to be effective, and Yale filed 
for a method-of-treating patent on December 
17, 1986 (U.S. patent No. 4,978,655 was even­
tually issued on December 18, 1990). Bristol-
Myers Squibb exercised its option and signed a 
license January 12, 1988. As is normal in aca­
demic licenses, Yale gave BMS the right to file 
in foreign countries, with Yale identified as the 
assignee, and the company filed corresponding 
applications in major western countries, such as 
Europe, Japan, and Canada. Critically, the com­
pany decided to include South Africa, Mexico, 
and Egypt in its filings. 
BMS commenced clinical development of 
stavudine and received FDA approval on June 
24, 1994. The product was trademarked Zerit®. 
In 2001, 13 years after the license had been 
signed, the South African patent made Zerit 
too expensive for most South African AIDS 
patients, particularly those living in the poor­
est areas (typically the townships). Because 
South Africa is the commercial gateway to Sub-
Saharan Africa, Zerit was similarly unavailable 
everywhere else on the continent. 
Zerit was on the list of essential medicines 
compiled by Toby Kasper, the head of the Access 
to Essential Medicines Program for MSF. He had 
met Amy Kapczynski at an AIDS conference in 
Durban in July 2000 and immediately realized 
that Amy could help put pressure on Yale for a 
better license deal from within.19 Kapczynski’s 
first recruit to this cause was possibly one of the 
most embarrassing to Yale—William Prusoff, 
the inventor of Zerit. Then Kaczynski turned to 
Michael Merson, Dean of Yale’s School of Public 
Health, who formerly headed the AIDS program 
of WHO. 
On February 14, 2001, MSF wrote to Yale 
and asked if it “would consider the importation 
of generic versions of stavudine for use in provid­
ing treatment free of charge to people with HIV/ 
AIDS unable to afford treatment an infringement 
of your intellectual property rights,” and if not, if 
Yale would “issue a voluntary license to allow the 
importation and use of generic stavudine in South 
Africa.” 
On February 28, 2001: Yale replied, deny­
ing the request on legal grounds, because it had 
granted an exclusive license to BMS. Kapczynski 
then put reporters at the Yale Daily News on the 
trail of the story. The student paper published 
its first story on the subject on March 2, 2001, 
which served to mobilize opinion on campus. 
A group of students in the graduate student 
union—which had already been campaigning 
against Yale’s relationship with corporate spon­
sors—circulated a petition calling on the school 
to ease its patent. The group collected 600 sig­
natures from students, professors, and researchers 
on campus. The students also assailed Yale for its 
close ties with BMS—the company had donated 
US$250,000 to the school in 1999. Kapczynski 
carried out legal research on campus and tried, 
unsuccessfully, to get a copy of the license agree­
ment. She provided the information she discov­
ered to MSF. 
On March 9, 2001, MSF responded to Yale 
suggesting that Yale’s own policy stated that a key 
objective of their technology transfer program 
was intended to be “the benefit of society in general” 
and pointing out that d4T was not reaching those 
who needed it in South Africa. Finally, MSF also 
suggested that Yale had the ultimate power over 
their patent and could breach their contract with 
BMS if need be. 
Two days later, The New York Times ran a 
story “Yale Pressed to Help Cut Drug Costs in 
Africa.” The impact was almost immediate. On 
March 14, 2001, BMS issued a statement that 
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“The Company will ensure that its patents do not 
prevent inexpensive HIV/AIDS therapy in Africa. 
The patent for Zerit, rights to which are owned by 
Yale University and Bristol-Myers Squibb, will be 
made available at no cost to treat AIDS in South 
Africa under an agreement the Company has re­
cently concluded with Yale.” In June 2001 Bristol-
Myers signed an “agreement not to sue” with 
Aspen Pharmacare, South Africa’s leading generic 
manufacturer. 
So, in less than two years, the world pharma­
ceutical paradigm had been turned upside down. 
“Two tier” pricing, whereby drugs could in the 
future be sold at generic prices in developing 
countries during the period of patent protected 
exclusivity had been established. There is some 
evidence that the pharmaceutical industry, or at 
least its vaccine sector, has started to accept the 
concept of tiered or segmented pricing according 
to ability to pay.20 
.  THE	 AppRopRIATE	 LICEnSInG	
AppRoACH? 
The Yale lesson discussed above shows that every 
license to a drug or vaccine candidate with the 
remotest potential for treating developing world 
needs must include fair-access licensing provi­
sions from the outset. This is because after the 
license is executed, the university cedes to the li­
censee control of both the development strategy 
and the patenting strategy.21 
The objectives of a licensing program for 
drugs with the potential to treat developing coun­
try diseases should be: 
•	 to maximize the possibilities that the drug 
will be developed 
•	 to structure the arrangements so that tiered 
pricing will result, with the poorest coun­
tries having access to drugs at the lowest 
prices 
An excellent review of potential licens­
ing approaches and structures was published 
by the open-access online journal Innovation 
Strategy Today in a special issue jointly pub­
lished with the American Association for the 
Advancement of Science.22 However, the article 
does not propose any model languages or stan­
dard approaches. 
Others, however, have put forward such 
suggestions. With its considerable experience in 
both developing and licensing neglected disease 
treatments,23 the NIH has developed a set of white­
knight-model licensing provisions (see Box 1). 
A set of provisions has also been developed 
at Boston University (BU) (see Box 2). They are 
meant for use as a starting point to discuss prod­
ucts that have markets in both the developed 
and the developing world. The provisions utilize 
a nonassert approach to manufacture for sale in 
developing countries. 
If the products envisioned by a partner­
ship would only have relevance in the develop­
ing world, then the role of IP protection may 
only be to provide an incentive for a develop­
ing country manufacturer to obtain a license to 
develop the product, and a second source ap­
proach may provide sufficient safeguards. BU’s 
model provisions for these approaches are given 
in Boxes 2 and 3. 
These licensing principles remain valid, even 
though traditional one-to-one licensing models 
are not adequate for the complex networks that 
have evolved over the past five to seven years 
and have transformed the prospects for effec­
tive and affordable therapies for the develop­
ing world. The emergence of drug development 
public-private-partnerships (PPPs), which have 
secured large amounts of philanthropic funding 
from the Bill and Melinda Gates Foundation, 
The Rockefeller Foundation, and so forth, have 
transformed drug development for neglected 
diseases:24 
•	 Large companies have been motivated 
to contribute their drug-discovery skills 
and resources because they are secure in 
the knowledge that others would be re­
sponsible for funding late-stage clinical 
development. 
•	 Small companies have secured funding to 
develop technologies with dual-market 
uses, with the PPPs securing license rights 
for developing countries at zero or low roy­
alty rates, and the small company retaining 
rights for use in developed countries. 
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STEVENS 
•	 Academic institutions have had a new 
channel to advance their neglected disease 
discoveries. 
•	 Developing country pharmaceutical com­
panies have found their production and 
distribution skills in demand. 
In addition, the PPPs have had the financial 
clout to insist on affordability conditions as part 
of the transactions they have negotiated. 
.	 LICEnSE	 TERMS	 foR	dEvELopInG	
CounTRy MARkETS 
As has been discussed in many forums, it is pos­
sible to obtain copies of a substantial number of 
license agreements from public filings with the 
Securities and Exchange Commission (SEC).25 
However, only development-stage companies 
that are publicly traded, or that have filed reg­
istration statements to become publicly traded, 
need to make such filings, and only for material 
agreements—those affecting 10% of company 
sales or 5% of company assets. 
These restrictions mean that the transactions 
discussed here are unavailable from SEC sources; 
the examples that follow are all based on volun­
tary disclosures. Because the underlying agree­
ments are unavailable and because the examples 
are based on third-party accounts, these third-
party accounts are reported here generally verba­
tim from the cited sources (sections 6.2 through 
6.12 of this chapter). 
In the course of researching this article, the 
author was surprised at the lack of transparency in 
what was expected to be the most transparent sec­
tor of licensing. PPPs, companies, and academic 
institutions that were approached to discuss trans­
actions they had publicly announced having en­
tered into all expressed an unwillingness to reveal 
details, even when it was made clear that the infor­
mation would be used to create a guide for others. 
Box 1: National Institutes of Health: Excerpts of White Knight Provisions
 
Within six (6) months of New Drug Application/Biologic License Application approval in the United 
States or its equivalent in Europe, Licensee shall send a written report to the Public Health Service 
detailing the potential Public Sector market to fulfill the public health need for the approved drug or 
vaccine in Developing Countries, including the impact of any approved competing drug or vaccine.
The report shall also include Licensee’s proposed amendment to the Commercial Development
Plan, Appendix E [not included here], and the Benchmarks and Performance, Appendix D [not
included here] to address the needs for Licensed Products in Developing Countries. Licensee will 
diligently consider if it is possible from a commercial and technical point of view, to satisfy said 
potential Public Sector market, either directly with Licensee’s own resources and/or through 
joint ventures with third parties. Acceptance of this report and amendment is required by PHS in 
writing; such acceptance will not be unreasonably denied. 
“Public Sector” means the government of a Developing Country, or any entity empowered by the 
government of a Developing Country to act for said government in matters applicable to this 
Agreement, organizations within the United Nations system including the World Health Global 
Organization and UNICEF, and other nonprofit agencies which may purchase drugs or vaccines for 
delivery, manufacture and/or sale in Developing Countries. 
“Developing Country” means countries eligible for support from the Global Fund for Children’s 
Vaccines (GAVI) or successor organization, which at the effective date of this Agreement are those 
countries with a Gross National Product of less than US$1,000 per capita per year, and at the 
effective date of this Agreement include the countries listed in Appendix G [not included here]. 
Source: Stephen Ferguson, NIH, personal communication. 
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CHAPTER 2. 
Box 2: Boston university’s Nonassert Approach 
1. Include in the “WHEREAS” clauses: 
WHEREAS, University and Licensee acknowledge that it may serve the public good to make 
certain drugs available at affordable prices to Non-Market Countries in certain circumstances,
with appropriate safeguards to Licensee’s economic interests in other markets. 
2. Include in the “definitions”: 
Market Countries shall mean: 
(a) All current and future member countries of the Organisation for Economic Cooperation 
and Development (OECD), presently consisting of Australia, Austria, Belgium, Canada,
Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy,
Japan, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal,
Spain, Sweden, Switzerland, Turkey, the United Kingdom, and the United States; and 
(b) All current and future members of the European Union; and 
(c) Russian Federation, Republic of China (Chinese Taipei), Korea, Malaysia and Singapore.
Amend the definition of Net Sales to exclude sales of products made pursuant to the Non-Suit
provision of Section [XX; not given here] from the calculation of Net Sales 
Non-Market Countries shall mean all countries other than Market Countries.
Public Sector shall include:
(a) The sovereign government of a country; 
(b) Agencies of the United Nations, the World Health Organization, and the World Bank;
(c) Organizations which are members of the International Committee of the Red Cross
and Red Crescent; 
(d) International charitable agencies (also known as Non-Governmental Organizations or 
NGOs), including but not limited to Oxfam, Medecins Sans Frontiéres, and so forth; 
(e) Organizations substantially supported by philanthropic 	 organizations including but
not limited to the Bill and Melinda Gates Foundation, the Rockefeller Foundation, and so 
forth, specifically including global product development and distribution public-private 
partnerships. 
Trade Dress shall mean the physical appearance of Product as sold in any Market Country by 
Licensee, including but not limited to such characteristics as shape, color, flavor, tradename,
trademark, service mark, etc. 
3. Include in the “Grant” clauses: 
Non-suit: University and Licensee on behalf of themselves and any successors-in-interest to the 
Intellectual Property covenant that they will not, before or after the date of this Agreement,
assert any claim of infringement (including direct infringement, contributory infringement,
and inducing infringement) of the Intellectual Property against any person or entity that sells 
or offers to sell the Licensed Product to Public Sector entities for use in Non-Market countries, or 
any entity that manufactures or otherwise makes the Licensed Product for sale to Public Sector 
entities for use in Non-Market countries, or any person or entity that uses the Licensed Product
in a Non-Market country, to the extent such claims relate to or arise out of such manufacture,
sale or offer to sell. 
Notwithstanding any other provision herein, this non-suit provision shall not apply to Products 
that bear any element of the Trade Dress used by Licensee in any of the Market Countries, or 
to Products that have not gained regulatory approval from either the U.S. Food and Drug 
Administration (FDA), the European Agency for the Evaluation of Medicinal Products (EMEA) or 
been pre-qualified by the World Health Organization pre-qualification scheme. 
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STEVENS 
.1 Compulsory licensing models 
Several approaches to establishing fair license 
terms (and, as will be discussed in Section 6.2 
below licensing structures themselves) for devel­
oping country markets have looked to compulsory 
licensing principles for guidance. Such approach­
es, authorized under the TRIPS Agreement, talk 
about “adequate remuneration” to the patent 
holder but without offering specific guidelines.26 
A comprehensive review of the issues of compen­
sation in compulsory licensing has been under­
taken by Scherer.27 
For much of the 1970s and 1980s, Canada 
had an extensive compulsory pharmaceutical li­
censing policy. In general, Canada required the 
recipient of a compulsory license to pay the pat­
ent holder a 4% royalty on the licensee’s sales price. 
After the Doha Round of WTO, Canada was 
the first country to implement the TRIPS com­
pulsory licensing principles to supply countries 
that could not produce drugs for their own use. 
Canada has continued to use a 4% royalty rate, 
adjusted for the gross domestic product (GDP) 
of the country, so that in the poorest countries, a 
royalty rate of 0.2% would apply.28, 29 
.2 Equitable access license 
Universities Allied for Essential Medicines, which 
grew out of Amy Kapczynski ‘s student col­
leagues (see section 4.3 above), has endorsed an 
Equitable Access and Neglected Disease License30 
(EAL) created by a working group at Yale. The 
EAL proposes a US$50,000 fee plus a 5% roy­
alty for licenses to sell in countries defined by the 
World Bank as “middle-income countries” and 
a US$5,000 fee and a 2% royalty on sales in the 
World Bank’s “low-income countries. These fees 
would be split 50:50 with the primary licensee. 
However, the license terms require the licensee to 
share with the university all of the know-how nec­
essary to make, use, and sell the licensed products 
in developing countries, so that the university 
can, in turn, transfer that know-how to the devel­
oping country licensees. The developing country 
licensees will, likewise, share any know-how they 
develop with the university. Universities Allied 
for Essential Medicines formalized this approach 
as the Philadelphia Consensus Statement at their 
annual meeting in Philadelphia in October 2006 
and provided a mechanism for individuals and 
organizations to sign on. 
The structure the EAL would establish pro­
vides the ideal mechanism for providing low-cost 
drugs to developing countries, but it is a utopian 
standard that will likely create a strong disincen­
tive to large companies to take out licenses to 
develop academic technologies. A 1% or 2.5% 
royalty on sales in developing countries in which 
the target per patient cost is in cents rather than 
dollars is unlikely to provide a sufficient incen­
tive for them to provide all of their production 
know-how to the licensing university. Spinouts 
are probably equally likely to resist these terms 
because of their potential to scare away poten­
tial downstream partners. In addition, the EAL 
would put a considerable administrative bur­
den on the university’s technology transfer of­
fice managing these various flows of confidential 
know-how. The EAL would therefore likely vio­
late the first of Hippocrates’ maxims as applied 
to academic licensing: First Do No Harm. 
As of this writing (February 2007), a signifi­
cant number of individuals and not-for-profits 
operating in the global health arena have signed 
on to the Philadelphia Consensus Statement. 
Noticeably, no universities have signed on as 
Box 3: Boston university Second Source Approach 
1. Include in the “Grant” clauses: 
Second Source: University may, at any time after the first anniversary of Licensee’s receipt of the 
first regulatory approval to sell Licensed Products, start to qualify a supplier for up to one third of 
annual requirements of Licensed Products. 
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CHAPTER 2. 
corporate entities, and only one person with cur­
rent, and one person with prior executive author­
ity for academic licensing were listed as initial 
signatories. 
. 	 Global Alliance for TB Drug 
Development—Chiron 
In one of the first drug development deals 
between a drugmaker and a nonprofit orga­
nization, the Global Alliance for TB Drug 
Development announced that it had licensed 
PA-824, a compound effective against M. tuber­
culosis, from Chiron Corp.31 PA-824 was discov­
ered and protected by PathoGenesis Inc., which 
was subsequently acquired by Chiron. Chiron 
has provided a worldwide exclusive license to 
the TB Alliance for PA-824 and all its analogs, 
in return for a modest, one-time licensing fee 
(modest, that is, compared to the industry av­
erage of US$1 million to US$3 million)32 and 
yearly threshold R&D investments by the al­
liance to ensure rapid progress. All preclinical 
R&D on PA-824 is subcontracted to commer­
cial clinical research organizations (CROs; paid 
by the TB Alliance), and project management 
(paid by the NIH) is conducted by the Research 
Triangle Institute, a not-for-profit that conducts 
contract research for the NIH and others. If and 
when development is successful, Chiron has the 
option of buying back the OECD rights by re­
imbursing the TB alliance for all development 
costs. The TB alliance would retain rights in all 
developing country markets. The deal includes 
“an expansive commitment” to affordable pric­
ing. The agreement has a grant-back clause that 
allows Chiron to reenter the TB drug develop­
ment process, within a specific time period, in 
wealthy countries. The deal also includes manu­
facturing options for the company. 
Though it has not proceeded beyond the 
laboratory, the compound, called PA-824, has 
been shown to be effective against drug-resis­
tant strains of M. tuberculosis in tests carried 
out in vitro. Researchers believe PA-824 may 
be powerful enough to considerably shorten 
the current short-course-treatment time of six 
months, which would enable more people to 
complete treatment. 
. 	 Institute for OneWorld Health— 
Celera Genomics 
The Institute for OneWorld Health (iOWH) 
is a not-for-profit drug company founded by 
Victoria Hale, a former employee of Genentech 
and winner of a McArthur Foundation Genius 
Award in 2006. The company sources drug 
candidates for the treatment of diseases in 
developing countries from universities and 
drug companies and then seeks philanthropic 
donations to fund clinical development. 
In 2002, iOWH licensed Celera Genomics’ 
CRA-3316 as a potential new treatment for 
Chagas’ disease. CRA-3316, formerly known 
as APC-3116, is a cysteine protease inhibitor. 
Development has been started in collabora­
tion with NIH.33 Celera licensed CRA 3316 
to iOWH royalty free because, according to 
Wayne Montgomery, who heads intellectual 
property at Celera, “the drug would have gath­
ered dust otherwise.”34 
.  Institute for OneWorld Health—University 
of California Berkeley—Amyris 
Biotechnologies35 
In December 2004, the Bill and Melinda Gates 
Foundation awarded a five-year product de­
velopment grant to iOWH to create a three-
way partnership between iOWH, a university 
(University of California, Berkeley), and a for-
profit company (Amyris Biotechnologies, Inc.). 
Using synthetic biology, industrial fermentation, 
and chemical synthesis, the goal of this project 
is to significantly reduce the cost of artemisinin, 
a key precursor in the production of artemis­
inin combination therapies (ACT) for malaria. 
Artemisinin is chemically converted to one of 
several derivatives that are then combined with 
other drugs to make an ACT. 
Artemisinin is currently extracted from 
wormwood plant, which is supplied by farmers 
in Vietnam and China (and more recently from 
Africa). Seasonality and availability of the plant 
contribute to the drug’s high price. The project, 
funded by the Gates foundation, hopes to elimi­
nate the need for plant extraction by utilizing 
a platform technology of “synthetic biology” 
developed by Jay Keasling at UC Berkeley. The 
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goal is to lower the cost of artemisinin-contain­
ing drugs ten-fold by producing a consistent, 
reliable, high-quality supply of artemisinin in 
microbes. 
The US$42.6 million grant was divided 
among the three parties: US$8 million to UC 
Berkeley for continued basic research; US$12 mil­
lion to Amyris for applied research on the fermen­
tation and chemical processes; and US$22.6 mil­
lion to iOWH to perform the required regulatory 
work and lead the implementation of the product 
development strategy for the developing world. 
UC Berkeley’s role focuses on the engineering of 
drug-precursor-producing microbe. Amyris’s ef­
forts span the engineering of the production mi­
crobe to optimizing the semi-synthesis of the drug 
through fermentation and novel downstream 
synthetic chemistry. The role of iOWHs includes 
developing a commercialization strategy based on 
a thorough understanding of worldwide regula­
tory requirements and an analysis of the current 
ACT manufacturing supply-chain and distribu­
tion models. This one grant enables activities in all 
three areas of development. It creates an integrat­
ed team of partners, each applying its expertise to 
streamline translation from bench to bedside. The 
financial terms of the partnership are as follows: 
License Grant(s) 
•	 The arrangement is governed by a three-
party collaboration agreement and two 
license agreements (from UC Berkeley to 
each of Amyris and iOWH). 
•	 UC Berkeley granted iOWH a royalty-free 
license for the manufacture of artemisinin­
based malaria treatments used in the de­
veloping world. UC Berkeley further shall 
grant royalty-free licenses to iOWH for 
intellectual property developed under the 
three-party collaboration agreement for use 
in manufacturing artemisinin-based malar­
ia treatments used in the developing world, 
and iOWH is to establish partnerships for 
ACT manufacture and distribution. 
•	 UC Berkeley granted Amyris licenses to 
develop the manufacturing process for the 
developing world malaria market. Amyris 
also has licenses for the developed world 
malaria market, nonmalaria indications 
of artemisinin, and alternative uses of the 
platform worldwide. UC Berkeley further 
shall grant similar licenses to Amyris for 
intellectual property developed under the 
three-part collaboration agreement. 
•	 Amyris shall grant iOWH a royalty-free 
license for intellectual property developed 
under the three-part collaboration agree­
ment for the manufacture of artemisinin­
based malaria treatments used in the devel­
oping world. 
Royalties 
•	 The license from UC Berkeley to iOWH is 
royalty free. 
•	 The license from UC Berkeley to Amyris is 
royalty free for the developing world ma­
laria market (development for iOWH), and 
royalty bearing for the developed world and 
nonmalaria indications in the developing 
world. 
Patents 
•	 Patent costs for UC Berkeley’s preexisting 
patents are shared between iOWH and 
Amyris. 
•	 UC Berkeley patents on intellectual prop­
erty arising from the collaborative research 
may be filed by UC Berkeley and licensed 
to iOWH and/or Amyris under the prear­
ranged terms mentioned above. Costs are 
shared by the licensee on a pro rata basis. 
UC Berkeley has no obligation to file an 
application if it does not have a commit­
ment by a licensee to pay patent costs. 
•	 Patents that are the sole property of Amyris 
and/or iOWH may be filed by Amyris 
and/or iOWH as the case may be, at their 
own expense. 
•	 Logistics of filing and payment of costs on 
jointly owned intellectual property will be 
negotiated in good faith by the joint own­
ers when such joint intellectual property 
arises. If the joint owners cannot agree, 
and if iOWH has an ownership interest 
in a joint property, then iOWH may file 
and prosecute on behalf of the owners at its 
own expense. 
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CHAPTER 2. 
. 	Aeras Global TB Vaccine Foundation— 
Vanderbilt University36 
On May 4, 2006, Aeras and Vanderbilt University 
announced an exclusive license agreement for a 
TB vaccine based on technology developed at 
Vanderbilt. The technology enhances the abil­
ity of the Bacille Calmette-Guérin (BCG) vac­
cine to trigger immune-system responses. Under 
the agreement, Aeras will use the technology to 
modify the BCG vaccine and will guide the new 
vaccine through clinical trials. The license agree­
ment grants Aeras exclusive rights for developing 
a TB vaccine. If a successful vaccine results from 
the use of this technology, then Aeras will manu­
facture the new vaccine at its facility in Rockville, 
Maryland. Vanderbilt retains rights to the tech­
nology as a delivery system for other uses. This 
could potentially include new vaccines or immu­
notherapies against other diseases from HIV and 
malaria to cancer. 
The Vanderbilt technology, called proapop­
totic BCG, is designed to weaken the BCG 
bacterium. It is a version of BCG with genetic 
modifications designed to inhibit the bacterium’s 
ability to stop the programmed cell death of a 
patient’s immune cells. These modifications are 
likely to result in a vaccine that provides better, 
longer-lasting protection against TB and may 
prevent progression to active TB among people 
with compromised immune systems. The finan­
cial terms are as follows: 
•	 Grant: Aeras obtained an exclusive license 
in its field of use. 
•	 Field of Use: Aeras has an exclusive license 
to the TB field; Vanderbilt retains rights in 
other fields. 
•	 Payments/Royalties: The license is royalty 
bearing (including stacking terms) along 
with milestone payments. 
•	 Patents: Patent costs paid by Aeras. 
. 	 Global Alliance for TB Drug Development— 
Bayer Healthcare AG37 
Moxifloxacin is an antibiotic first approved in 
1999 and currently used in 104 countries to treat 
certain bacterial respiratory, skin, and intraab­
dominal infections. It has been used by more than 
47 million patients worldwide. Moxifloxacin is 
generally well tolerated, but treatment may result 
in certain usually mild side effects, including nau­
sea, diarrhea, and dizziness. In vitro and in vivo 
studies have demonstrated moxifloxacin activity 
against Mycobacterium tuberculosis. Investigators 
at Johns Hopkins discovered that substitution of 
moxifloxacin for isoniazid in the reduced treat­
ment time (two months shorter in mice) of the 
TB treatment regimen. The treatment regimen 
included rifampin, pyrazinamide, and either 
moxifloxacin or isoniazid. 
In October 2005, the TB Alliance and Bayer 
Healthcare AG announced a partnership to co­
ordinate a global clinical development program 
to study the potential of moxifloxacin to shorten 
the standard six-month treatment of TB by two 
to three months. The trials will evaluate whether 
the substitution of moxifloxacin for one of the 
standard TB drugs (ethambutol or isoniazid) 
eliminates TB infection faster than the current 
standard therapy. If successful and approved by 
the respective regulatory agencies, a new, shorter 
regimen could be available in the next five years. 
The Phase II/III clinical trial program spans 
four continents and will enroll close to 2,500 
patients with TB. The trials will take place in 
Brazil, Canada, South Africa, Spain, Tanzania, 
Uganda, the United States, and Zambia. If the 
trials are successful, the partnership aims to reg­
ister moxifloxacin for a TB indication. Upon 
regulatory approval, the partnership is com­
mitted to making it affordable and accessible in 
developing countries where TB patients need it 
most. 
For this project, Bayer will donate moxifloxa­
cin for each trial site and will cover the costs of reg­
ulatory filings; the TB Alliance will coordinate and 
help cover the costs of the trials, seeking to leverage 
support from the U.S. Centers for Disease Control 
and Prevention (CDC), the Orphan Products 
Development Center of the U.S. Food and Drug 
Administration, and the European and Developing 
Countries Clinical Trials Partnership. In May 2006, 
the TB Alliance received a US$104 million grant 
from the Bill and Melinda Gates Foundation. The 
grant will be used, in part, to fund Phase II and III 
trials of moxifloxacin with the goal of showing the 
efficacy of moxifloxacin in reducing TB treatment 
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STEVENS 
times by two months by 2010. The financial terms 
for this development project are: 
•	 Field of Use: Tuberculosis drugs. 
•	 Payments/Royalties: Products will be made 
available in developing countries at cost, 
for use against tuberculosis. 
•	 Patent strategy: Patents previously issued. 
6.8	 International AIDS Vaccine Initiative— 
Neutralizing Antibody Consortium 
The mission of the International AIDS Vaccine 
Initiative (IAVI) is to ensure the development 
of safe, effective, accessible, preventive HIV/ 
AIDS vaccines for use throughout the world.
Central to IAVI’s mission is to improve access 
to a vaccine for the developing world,38 which 
requires speed of development, as well as avail­
ability and affordable pricing. IAVI uses a large 
portion of its resources to conduct R&D to 
design, manufacture, and test promising HIV/ 
AIDS vaccine candidates. 
In July 2002, IAVI announced the forma­
tion of the Neutralizing Antibody Consortium 
(NAC), a five-year, multimillion dollar research 
program to develop a preventative HIV/AIDS 
vaccine that fills a critical gap not addressed by 
most HIV/AIDS vaccines undergoing clinical tri­
als. The original NAC consisted of four founding 
institutions. Today, the NAC includes an interna­
tional group of 15 laboratories, funded by IAVI, 
representing academia, government, and not-for­
profit research organizations. The financial terms 
for the NAC are: 
•	 IAVI funds individual research work plans 
for NAC principal scientists; in some cases 
restricted grant monies are used for select­
ed research projects. These carry special 
compliance terms that apply specifically 
to that project. 
•	 IAVI manages intellectual property
on behalf of the NAC. IAVI rights include: 
- option for exclusive license to program 
intellectual property in the field 
- option for nonexclusive license to back­
ground intellectual property 
•	 IAVI pays for certain patent costs related 
to program inventions and background 
inventions. 
•	 Predetermined sharing of revenues among 
all collaborators. 
•	 Other provisions include diligence, gover­
nance, publications, patent management, 
and process for adding new members. 
.  Medicines for Malaria Venture (MMV)— 
GlaxoSmithKline (GSK) 
At the 2003, World Economic Forum’s Africa 
Economic Summit in Durban, South Africa, 
Medicines for Malaria Venture (MMV) and GSK 
announced a joint portfolio of projects: 
•	 Fab I—Fatty acid biosynthesis I 
•	 Falcipains—Cysteine protease inhibition 
•	 4(1H)-pyridones—backups 
•	 PDF—Peptide deformylase inhibitor [ter­
minated in March 2005] 
The main objective is to subsidize the so­
cio-economic and public health benefit for the 
developing world. Any successful medicines dis­
covered as a result of this initiative will be made 
available in endemic areas on a not-for-profit 
basis. Research work will take place at the GSK 
drug discovery unit in Tres Cantos, Spain, which 
GSK has dedicated to research on diseases of the 
developing world. The center has a team of 50 
permanent staff with particular expertise in drug 
discovery. The Tres Cantos Center is fully inte­
grated into the GSK R&D organization, which 
provides expertise and infrastructure for all as­
pects of drug discovery and development. GSK 
will contribute funding, staff with drug discovery 
expertise in malaria, and state-of-the-art facilities. 
MMV contributes funding for malaria drug dis­
covery projects by subsidizing the employment of 
additional scientists to join the existing staff at 
Tres Cantos and expertise from its expert scien­
tific advisory committee (ESAC). 
.10 Harvard University—Medicine in Need 
In November 2006, Harvard announced that 
it would license a new aerosolized tuberculosis 
vaccine invented by Professor David Edwards 
to Medicine in Need (MEND), a Cambridge 
nonprofit founded by the inventor.39 Sales to de­
veloping countries will be royalty free, while sales 
to developed countries will be royalty bearing, 
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CHAPTER 2. 
but Harvard will return a large proportion of 
the royalties back to MEND. Edward’s work 
was funded by a US$7.6 million grant from 
the Bill and Melinda Gates Foundation, which 
stipulated as part of the grant that Harvard 
would have to license the technology to MEND 
and that Harvard could not take royalties from 
MEND’s sales to the developing world. The 
Gates Foundation has also used this strategy in 
its Grand Challenge Grants. 
.11	 Coley Pharmaceutical Group, Inc.— 
Gates Foundation 
Coley Pharmaceuticals Group, a publicly trad­
ed biotechnology company based in Wellesley, 
Massachusetts, has agreed to license VaxImmune 
to the Bill and Melinda Gates Foundation for use 
in conjunction with a vaccine for postinfection 
malaria. VaxImmune is a TLR9-agonist designed 
to enhance both antibody levels and potent killer 
T-cell immune response to infection or tumors. 
The agreement is a no-profit/no-loss arrangement, 
in which all clinical development is performed by 
the Institute forTropical Diseases Research, funded 
by the Gates foundation, while Coley receives no 
royalties or other payments. Coley has partnered 
VaxImmune with GSK for cancer and infectious 
disease vaccines and with Novartis Vaccines and 
Diagnostics for infectious-disease applications. It 
will receive royalties on any commercial applica­
tions of the technology that emerge from the Gates 
foundation collaborations.40 
.12 Unattributed transactions 
Various sources41 quote royalty rates of no more 
than 3%–5% of sales for those companies that 
do insist on obtaining a financial return on sales 
of drugs to the poorest of the poor. Procurement 
costs for finished products are described as typi­
cally being at cost of production or cost of pro­
duction plus 3%–5%, with agreements having 
not been reached when a margin of 15% over 
cost was demanded. However, what was not clear 
was how overhead, corporate costs, and cost of 
capital were allocated. At some point, there will 
need to be some incentive provided if private cap­
ital is to be utilized and for-profit entities are to 
become dependable suppliers, or alternatively the 
PPPs will need to provide the necessary invest­
ments for the construction of dedicated produc­
tion facilities. 
.	 CONCluSIONS: ToWARd AppRopRIATE	
vALuATIon STRuCTuRES 
Thecomparisons aboveclearly showthat the right 
valuation formula is to ask for the licensee(s) in 
developing countries to take over responsibility 
for future patent costs and to ask for no upfront 
fees, no milestone payments, and no running 
royalties. Any financial return to the university 
will be derived from opportunities in developed 
countries. Indeed, if a university’s objective tru­
ly is to get drugs that have been discovered at 
rich universities in developed countries, using 
“other people’s money,” whether governmental 
or philanthropic, to the worlds’ neediest people 
as cheaply as possible, then true leadership re­
quires that those same universities not start off 
the process by putting their hands out and say­
ing, “We have to charge a royalty.” 
Universities are under no obligation, under 
Bayh-Dole or any other law or regulation, to 
charge a royalty. The message communicated by 
asking for a royalty—even the modest rates sug­
gested by the analysis above—would be inappro­
priate and inconsistent with the public mission 
of the university. Doing so would cost the moral 
high ground and weaken universities’ ability to 
lead in this humanitarian endeavor. 
Clearly, internal consensus between the 
research community, academic leadership, and 
technology transfer offices within the university 
is needed. The researchers who put their time 
and effort into developing a drug or vaccine to 
treat developing country diseases will certainly 
be happy with this approach, as Yale’s experi­
ence with William Prusoff shows. The dean of 
the school of public health is a suitable avenue 
to the administration, if one is needed, as Amy 
Kapczynski also found at Yale. The develop­
ment and public relations offices should be in­
volved to ensure that the institution’s objectives 
are properly portrayed and that the institution 
receives the appropriate recognition for its hu­
manitarian efforts. 
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The technology transfer professional’s nego­
tiating skills will be called into play when nego­
tiating for the rights and financial terms for any 
potential uses of the technology in developed 
countries and for spinout technologies. If there 
are none, it should be a simple negotiation, with 
indemnification provisions likely to be the most 
contentious issue. n 
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ABSTRACT 
This chapter provides an introduction to open source 
software licensing. The chapter seeks to demystify the 
concept of open source so that intellectual property (IP) 
owners and managers can decide whether an open source 
approach is worth pursuing. The chapter explains the 
principles of free and open source software licensing and 
outlines the decisions that an innovator must make when 
deciding which strategy to use for developing a new in­
novation. Also explained are the differences between open 
source and public domain, and between the uses of the 
terms copyleft and academic to describe open source li­
censes, as well as the incentives (financial and otherwise) 
for open source licensing. Finally, the author identifies 
important considerations regarding the possibilities for 
open source licensing in fields other than software de­
velopment, particularly biomedicine and agricultural 
biotechnology. 
1. InTRoduCTIon 
Open source software has had remarkable tech­
nological and commercial success. Since the late 
1990s, many people have been interested in ap­
plying the principles of open source to other 
fields, including biomedicine and agriculture. 
The term open source is sometimes used very 
broadly to mean any approach to intellectual asset 
management that entails a higher level of trans­
parency, or greater access to information, than is 
usual in a proprietary setting. This broad use of 
the term is of little value to IP managers because 
it is too imprecise. 
In fact, the only context in which the term 
open source has a generally accepted definition is 
in software development.1 This chapter uses the 
term in as far as possible the same sense as it is 
used in the software context but suggests that the 
underlying IP management approach could be 
applied in other contexts. 
Conventional software development is some­
times termed cathedral building because it pro­
ceeds according to the hierarchical directions of 
one or more software architects (the word archi­
tect is derived from words meaning “chief build­
er”). Conventional software is usually protected 
through IP rights, as a strategy to exclude some or 
all prospective users of the technology. 
By contrast, open source software develop­
ment projects, such as those that produced Linux, 
Apache, and BIND, are decentralized and self-or­
ganized. Open source software development is an 
evolutionary process: the contributions of self-se­
lected project participants are subjected to trial­
and-error testing in diverse use environments, 
and the resulting information influences further 
development. This mode of production has been 
termed “the bazaar” and is also known as collective
or commons-based peer production.2 
In order for open source software develop­
ment to work, would-be users and developers 
must be authorized to access the source code. In 
Hope J. 2007. Open Source Licensing. In Intellectual Property Management in Health and Agricultural Innovation: A Hand-
book of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available 
online at www.ipHandbook.org. 
© 2007. J Hope. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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the conventional “proprietary” approach to soft­
ware development, source code is not freely avail­
able for two reasons: (1) source code is treated 
as a trade secret and (2) the original expression 
contained in a program’s source code is subject 
to copyright protection. To enable open source 
development, therefore, the software owner must 
(1) refrain from keeping the source code secret 
and (2) grant an IP license to others so that they 
have the legal right to access and manipulate 
copyright-protected aspects of the code. 
Open source licensing should not, in theory, 
pose any antitrust problem (at least in jurisdic­
tions where the relevant test takes into account 
substantive effects on competition), because its 
effects are fundamentally pro-competitive.3 
2.	 WHAT IS OPEN	SOURCE? 
2.1 The open source definition (OSD) 
An open source software license is one that con­
forms to the latest version of the open source defi­
nition (OSD), published on the Web site of the 
Open Source Initiative (OSI), a nonprofit cor­
poration established in 1998 by a small group of 
programmers who wanted to promote the wider 
adoption of open source licenses.4 Licenses that 
conform to the OSD are permitted to carry a reg­
istered certification mark. 
A summary of the requirements of the OSD 
is that in order for a software license to be open 
source, licensees must be free 1) to use the soft­
ware for any purpose whatsoever; 2) to make cop­
ies and distribute them without paying royalties 
to the licensor; 3) to prepare derivative works and 
distribute them, also without payment of royal­
ties; 4) to access and use the source code; and 5) 
to use the open source software in combination 
with other software, including proprietary (that 
is, non-open source) software.5 An open source 
license may not restrict the number of products 
a licensee is allowed to distribute, the identity or 
geographic location of the recipients, or the price 
the licensee asks them to pay. Optionally, these 
same guidelines may be stipulated to apply to cer­
tain improvements or other downstream uses of 
the original software.  
The OSD’s definition could be summed up even 
more concisely: in open source software licens­
ing, anyone, anywhere, and for any purpose must 
be allowed to copy, modify, and distribute the 
software (either for free or for a fee) and, there­
fore, must be allowed full access to the software’s 
source code.6 
2.2 The free software definition (FSD) 
The OSI is not the only de facto standard-setting 
body in the field of free and open source soft­
ware licensing. Others include the Free Software 
Foundation (FSF)7 and the Debian Linux 
community8. 
According to the FSF’s Free Software 
Definition (FSD), software “freedom” is the
freedom to use, copy, study, modify and redis­
tribute both modified and unmodified copies 
of software programs, all without having to pay
for or otherwise obtain specific permission. To 
give practical effect to this freedom the licensor 
must allow users access to the software’s source 
code.9 
Clearly, the FSD is very similar to the OSD. 
There are ongoing debates about the differences 
between what constitutes free software and open 
source software, but in fact the two are virtually 
identical: with very few exceptions, free software 
conforms to the OSD, and open source software 
conforms to the FSD.10 
.	 THE	 pRoCESS	 of dEvELopInG	
A	LICEnSInG	STRATEGy 
Open source licensing is just one kind of IP 
strategy. Figure 1 depicts the process of choosing 
which licensing strategies (if any) to use. 
The first thing to do when formulating an 
appropriate strategy for exploiting new technol­
ogy is to make a careful cost-benefit analysis of all 
the possible avenues for development. 
This analysis will require certain 
considerations: 
•	 The first decision. If the technology is to 
be disseminated rather than kept in-house, 
resources must be committed to market­
ing the technology, demonstrating and 
improving its usefulness, and establishing it 
10 | HANDBOOK OF BEST PRACTICES 








within extended research and development 
networks.11 
The second decision. If an innovator de­ •
born out of altruism or ideology: it can in­
stead be born out of healthy self-interest. 
The third decision. If an innovator decides 
cides to disseminate the technology, it is 
not always advantageous for him or her to 
restrict public access to it. Sometimes, an in­
novation can be freely offered to the public 
and still generate at least as much economic 
advantage for the innovator as would a pro­
prietary strategy. Nonproprietary strategies 
can be more advantageous to the research 
community, society as a whole, and the in­
novator. Open source licensing generally 
creates fewer transaction costs and is inher­
ently more transparent than a proprietary 
licensing strategy. The decision to follow a 
nonproprietary strategy does not have to be 
•
on a nonproprietary strategy, the innova­
tion can be licensed on an open source basis 
or placed in the public domain: that is, the 
innovator can refrain from obtaining any 
IP or other property rights at all. Licensing 
an innovation is costly and time-consum­
ing and should be considered only if there 
is good reason to obtain or retain owner­
ship of the technology. 
The fourth decision. After choosing an 
open source approach, an innovator must 
choose between an academic open source 
license and a copyleft-style license (both 
terms are defined in a later section). If the 
Disseminate 












HANDBOOK OF BEST PRACTICES | 10
     
       
      
      
       
      
       
      
       
     
      
      
     
     
 
 










main objective is to encourage widespread 
adoption of the technology in its current 
state, the more permissive academic license 
is likely to be preferable. If the main objec­
tive is to guarantee access for the innova­
tor or others to improved versions of the 
technology, or to other innovations built 
upon it, a copyleft-style license is worth 
considering. 
•	 The fifth decision. If the innovator de­
cides on a copyleft-style license, the final 
decision must be how broad or narrow 
the copyright obligation is to be. The nar­
rowness or broadness of a copyright ob­
ligation may be thought of as the reach 
of the copyleft “hook.” Although the dia­
gram depicts this decision as a binary one, 
in fact, possible formulations of copyleft 
obligations form a spectrum. The reach of 
the copyright hook should be dictated by 
the licensor’s assessment of prospective li­
censees’ incentives to contribute to ongo­
ing development. 
This remainder of this chapter will explore 
the nonproprietary options that are available to 
the innovator, with a special emphasis on the var­
ious types of open source licensing. 
.	 opEn 	SouRCE	 vERSuS	 puBLIC	 doMAIn 
Once an innovator has decided to disseminate his 
or her technology in a nonproprietary fashion, he 
or she must decide between open source licensing 
and placing the innovation in the public domain 
(also known as straightforward publication): that 
is, foregoing IP protection altogether. 
.1	 The advantages of public 
domain over open source 
The primary advantage of straightforward pub­
lication or dissemination of a new technology 
over an open source approach is that it does not 
require the innovator to obtain or maintain IP 
protection. Depending on the type of IP right, 
protecting IP can be costly in terms of time and 
resources. It also has the disadvantage of contrib­
uting to the proliferation of IP rights. 
In some contexts, claiming ownership over an 
innovation may also create a negative effect with 
respect to ongoing collaborations. It may create 
ill will among prospective users and decrease the 
chances that a technology will be widely adopted 
or improved. Such negative effects are especially 
likely when the ownership claim is particularly 
broad (as in the case of the non-coding DNA se­
quence patents or junk DNA)12 or when user-de­
velopers have a strong belief that the technology 
ought to be in the public domain (as in the case 
of human genome project sequence data).13 
.2 	 The advantages of open 
source over public domain 
There are several circumstances in which an open 
source strategy might have advantages over a pub­
lic domain approach as a way of encouraging the 
widespread adoption and ongoing development 
of an innovation. 
One situation in which an open source ap­
proach may be useful is where inventors have au­
tomatic ownership rights over some part of the 
relevant technology. Some biological innovations 
incorporate tangible material components (such 
as cell lines or germplasm) that are owned by the 
inventor regardless of whether active efforts are 
made to protect the innovation. Similarly, soft­
ware programs, data, or written protocols that are 
incorporated into biological innovations are au­
tomatically subject to copyright protection pro­
vided they meet statutory criteria. In such cases, 
a license may help to reduce the transaction costs 
of transferring the technology to other prospec­
tive users because the license clarifies the owner’s 
intention to make the technology available on 
open source terms. (This is analogous to Creative 
Commons’ objective of facilitating the dissemi­
nation of cultural material by helping copyright 
owners to specify which rights are reserved.)14 
A second situation in which an open source 
license may be preferable to straightforward pub­
lication from the perspective of the innovator is 
a situation in which there is a proliferation of 
overlapping IP rights or the field of innovation is 
especially competitive or litigious. While even an 
open source license has the drawback of adding 
to the complexity of the IP landscape, failure to 
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assert ownership over a technology before making 
it available for public use sometimes means that 
someone else can patent the technology and pur­
sue a proprietary exploitation strategy to the det­
riment of the innovator and other potential users. 
In this case, patenting followed by open source 
licensing of an innovation is a form of defensive 
disclosure that may be more reliable than other 
defensive disclosure mechanisms as a means of 
protecting against subsequent patent claims. 
Third, IP ownership gives an innovator the 
right to set terms of use and exclude anyone who 
will not abide by those terms. For example, in a 
copyleft-style arrangement, follow-on innova­
tors must make some improvements available 
to others on the same liberal terms as the initial 
innovation was made available to them. Another 
example is the litigation deterrent clause found 
in many licenses (both open source and propri­
etary), which terminates the licensee’s rights if he 
or she sues the licensor (for example, for infringe­
ment of one of the licensee’s patents). 
Finally, IP rights may facilitate certain path­
ways to development even if they are licensed on 
open source terms. The existence of IP protection 
signals to potential investors that the innovator is 
disciplined and has financial backing and that the 
innovation is worth supporting. 
. 	 Combining proprietary licensing, open 
source, and public domain 
There is nothing to stop an open source licensor 
from offering a technology under both propri­
etary and open source licenses. This approach, 
known as dual licensing, generates a surprising 
amount of income for many open source software 
programmers, some of whose customers prefer, 
and are willing to pay for, a more conventional 
licensing arrangement. Thus, the commercial 
application of an open source license does leave 
some room for recovery of the costs of protecting 
the relevant IP. 
It is possible to adopt a nonproprietary strat­
egy at a relatively late stage in an innovation’s 
life cycle, perhaps when the amount of propri­
etary licensing revenue the innovation generates 
begins to decline. In this case, granting an open 
source license to the innovation may be a sensible 
alternative to abandoning the patent altogether.
In such circumstances the full cost of obtaining 
and maintaining IP protection has little bear­
ing on the decision to go open source, because 
the majority of these costs have already been 
incurred. 
.	 InCEnTIvES	 foR	 opEn
SouRCE	 dEvELopMEnT 
Why would any rational, self-interested IP owner 
decide to adopt an open source license? Many 
people think of open source licensing as an al­
truistic exercise, or alternatively, as a strategy pur­
sued for the sake of purely personal rewards, such 
as fun or a sense of belonging to a community. 
This is an unnecessarily limited view. 
.1	 Direct financial incentives 
An open source license must permit the shar­
ing and distribution of the technology without 
charging any royalty. In this context, a royalty is 
any ongoing payment that is linked to the use 
of the technology (for example, a percentage of 
profits on products generated using a technology, 
or a regular payment whose amount depends on 
the number of people who are given access to the 
technology), not a one-time payment. Therefore, 
although open source licensors cannot charge 
royalties, they can charge a one-time fee that is as 
high as the market will bear.15 
Of course, the fact that an open source soft­
ware license must guarantee its licensees’ freedom 
to make copies of the licensed software and dis­
tribute them to others without having to make 
additional payments to the licensor means that 
the price of the technology tends to be driven 
down to the marginal cost of reproduction and 
distribution—for software, close to zero. Keep 
in mind that while the inexpensiveness of open 
source software production relative to convention­
al proprietary production is an inherent feature 
of the open source model, the low price of open 
source software to consumers (and hence the low 
rate of return to licensors in the form of license 
fees) is a consequence of market forces that may 
not exist with respect to other types of technol­
ogy. For example, because the marginal cost of 
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reproduction and distribution may be quite high 
for technologies that are less highly codified than 
software or are embedded in tangible objects the 
production costs of which are sensitive to econo­
mies of scale, fewer distributors may come for­
ward to compete with the original licensor, and 
licensees may be more willing to pay the licensor 
for extra “copies” of the technology than is the 
case in the software context.16 This means that 
there may be more opportunities for a licensor to 
profit directly from the sale of non-software open 
source technologies. 
.2	 Indirect financial incentives 
Most of the incentives for open source licens­
ing are indirect rather than direct. Sections 4.3 
and 4.4 describe incentives relating to cost sav­
ings, productivity gains, and reputational capital.
However, one of the most important effects of 
open source licensing is to expand the user base 
for a technology, thereby expanding the market 
for complementary goods and services. 
There are several reasons why an open source 
license tends to increase user numbers. In the first 
place, a technology that is distributed according 
to open source terms is often more attractive to 
users because it is more affordable and available 
than its proprietary counterparts and because its 
availability is not dependent on any particular 
supply chain. 
Next, open source technology is malleable. 
Licensees can make modifications to the tech­
nology and access the means for doing so. The 
malleable nature of the technology creates mar­
kets not just for the technology itself, but also for 
associated maintenance services, upgrades, and 
adjustments. 
These market-expanding effects are especially 
pronounced for technologies with strong network 
effects (that is, technologies that become more 
valuable as more people adopt them, which in 
turn increases their popularity): this includes not 
only information and communication technolo­
gies but also many biomedical and agricultural 
technologies. For example, a microarray reader 
that displays data in a particular format becomes 
more useful if a number of scientists use the same 
reader: the uniformity of data output makes it 
easier to compare and verify data that originated 
in many different laboratories. 
As the market expands, revenues from sales, 
one-off licenses, and dual licensing may be 
enough to offset the opportunity cost of adopting 
a nonproprietary licensing strategy. At the same 
time, the demand will increase for complemen­
tary products and services, including technology 
training, technical support, customization ser­
vices, hardware or wetware supplies, proprietary 
data-analysis software, and so on. Many successful 
commercial open source software ventures turn a 
profit by providing complementary products and 
services. Perhaps the most striking example is that 
of IBM: a substantial investment in open source 
software production provides IBM with access to 
a better operating system that makes its primary 
commercial offering, server hardware, more valu­
able to consumers. 
. 	 Non-financial incentives for 
individual researchers 
Computer programmers are often motivated 
to contribute to open source software develop­
ment by incentives that are not strictly monetary 
(though they can be translated into monetary re­
wards in the employment market): the possibility 
of enhanced personal reputation and the oppor­
tunity to learn new skills.17 
At first glance, such nonmonetary benefits 
may seem irrelevant to the biomedical or agri­
culture fields, where decisions about research 
investments are commonly made at an institu­
tional rather than an individual level. However, 
individual researchers in both of these fields can 
decide, to some extent, how and where they will 
direct their own or their laboratory’s resources. 
Such self-determination is common for academic 
researchers, but is also evident in biotechnology 
and pharmaceutical companies, many of which 
allow staff to spend some designated fraction of 
their time on personal research projects in order 
to encourage creativity, increase job satisfaction, 
and, it is hoped, generate new commercial op­
portunities for the company.18 Researchers with 
some creative freedom might decide to partici­
pate in open source development under appro­
priate funding and employment conditions. The 
112 | HANDBOOK OF BEST PRACTICES 










same is true for the many open source software 
developers who are not hobbyists but, instead, 
professionals whose contributions form part of 
their employment.19 
. Institutional incentives 
..1 Intrainstitutional incentives 
It is to an organization’s advantage to build a 
reputation for cutting-edge technological innova­
tion, and to keep its researchers sharp by allow­
ing them to participate in a range of projects, 
regardless of their projected commercial value. 
Furthermore, open source development encour­
ages the development of a productive, collabora­
tive environment. 
..2 Interinstitutional incentives 
In both biomedicine and agriculture, the locus of 
innovation is often not the individual company 
or university but the network of diverse collabora­
tions among organizations.20 Open source licens­
ing offers a way of sharing the costs and risk of 
technology development among many prospec­
tive users: in other words, open source develop­
ment can be a form of precompetitive collabo­
ration. As users and developers collaborate on a 
project, technological applications multiply and 
diversify, and robust and reliable tools are created. 
Bruce Perens, author of the OSD, points out that 
the same groups of companies often have a low 
rate of success of proprietary consortium software 
development but a high rate of success with large 
open source projects; he suggests that the inher­
ent fairness of open source licensing encourages 
effective collaboration between parties with dif­
ferent interests.21 
Open source licensing is not primarily a 
means of dealing with existing “anticommons 
tragedies,” that is, bargaining failures among own­
ers of multiple complementary IP assets.22 Unless 
the technology in question is a killer app—a 
software term for any tool that renders obsolete 
all others in its class—the terms on which it is 
licensed, whether open source or otherwise, can 
have little impact on existing reach throughs, 
royalty-stacking provisions, and other restrictive 
licensing terms. Rather, open source is a means 
of pre-empting such tragedies by establishing a 
robust commons for basic or fundamental tech­
nologies whose value is likely to be enhanced by 
cumulative innovation. In situations where an 
anticommons problem already exists, nonpro­
prietary strategies can have a beneficial tipping 
effect, because the greater the number of nonpro­
prietary tools in any given tool kit, the greater the 
incentive of everyone in the field to invest in de­
veloping substitutes for the remaining proprietary 
technologies for the sake of achieving freedom to 
operate with the tool kit as a whole. 
.	 dIffEREnT	 TypES	 of
opEn 	SouRCE	LICEnSES 
.1 Copyleft licenses 
A copyleft, or reciprocal, license allows the user to 
modify and redistribute a software program at 
will. The licensee’s obligation under a copyleft 
license is to make relevant downstream technolo­
gies available to all comers (including the original 
licensor) under the same terms as provided by the 
original license. No one (including the original li­
censor and his or her licensees) obtains any special 
privilege regarding any next-generation technol­
ogy, such as a right to preview any improvements 
or exclusive sublicensing rights to any improve­
ments. The point of a copyleft license is to create 
an ever-growing pool of downstream innovations 
that remain freely accessible to all comers.23 
However, a copyleft license is not always the 
best way for innovators to guarantee themselves 
access to future improvements in the technology. 
Instead, prospective licensors should carefully 
consider how they can best encourage licensees to 
contribute to a technology commons. 
When deciding whether or not to use a 
copyleft license, the innovator should take into 
account the attitudes, needs, and constraints of 
prospective users, as well as the other tools that 
they are likely to use in conjunction with the 
technology. For example, if licensees use tools 
that are subject to proprietary intellectual prop­
erty licenses, the conditions imposed by owners 
of that intellectual property may conflict with 
the copyleft obligation to make downstream 
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innovations freely available. Furthermore, it is 
possible to trigger a cycle of cumulative innova­
tion even if users do not perfectly comply with 
the copyleft ideal, provided there is a critical mass 
of user-developers who do. 
A copyleft-style obligation is probably neces­
sary only if potential contributors are likely to be 
seriously put off by the existence of free riders, 
those who let others put in the time and mon­
ey for research and development and then help 
themselves to the results. Even then, an innovator 
should take care to explain to his or her licens­
ees why such an obligation is necessary. Under 
no circumstances should an open source license 
restrict licensees’ freedom to take development in 
new directions, with or without the licensor’s ap­
proval. The strength of open source is, after all, 
its ability to harness the creativity of diverse user-
contributors who are allowed to work in relative 
freedom. 
If it is decided to adopt a copyleft license, 
the licensor has two main ways of tailoring the 
license terms to maximize the incentives of pro­
spective contributors. Not every modification, 
improvement, or new application of a technology 
that has been licensed on copyleft terms must be 
made available on those same terms. In the first 
place, only derivative works that are externally 
deployed—that is, sold or otherwise distributed 
outside the boundaries of the licensee’s organiza­
tion—are subject to the reciprocal obligation un­
der a copyleft license. 
Second, even if a downstream innovation is 
externally deployed, it still may not fall within 
the definition of improvements in a particular 
copyleft license, because different licenses have 
broader or narrower definitions. The only real 
check on the licensor’s discretion with respect 
to the breadth of this definition, apart from the 
willingness of other contributors to accept the 
license terms, is the scope of the licensed intel­
lectual property. A licensor who seeks to control 
that which he or she does not own may run afoul 
of competition laws. 
In this connection, a trap for would-be 
copyleft-style licensors tobeawareof is that anopen 
source license must grant the licensee the freedom 
to create a new collaborative-development project 
based on previous contributions (a phenomenon 
known in the software industry as a code fork), 
for any reason at all.24 The possibility of forking 
means that technologies can still be improved even 
if their initial innovators have lost interest in the 
technologies or have lost the capability to develop 
them. In practice, forking is rare, largely because 
it is difficult to persuade others to abandon the 
old project in order to start on a new one. It is 
often easier for dissenters to continue working on 
the original project and then invest some of their 
own resources adapting its output to their specific 
needs rather than abandon the original project al­
together. However, in formulating the definition 
of improvements in a copyleft license, the licen­
sor (or his or her agent) must avoid restricting the 
freedom to fork development. 
Thus, the two most important aspects of a 
copyleft-style license are: (1) the definition of 
“improvements” (or an equivalent term) which 
determines which follow-on innovations must be 
licensed on the same terms as the initial licensed 
innovation; and (2) the definition of “external 
deployment” (or equivalent), which determines 
under which circumstances the aforementioned 
obligation must be fulfilled. These may be ad­
justed by the licensor to create a copyleft license 
that strikes the appropriate balance of incentives 
to contribute to any given project. 
.2 Academic licenses 
Another type of open source license is the aca­
demic or BSD-style license (named after the 
Berkeley software distribution license, the old­
est license in the OSI’s list of approved licenses). 
These licenses do not require users to make ex­
ternally deployed improvements available to the 
licensor on the same terms as the original tech­
nology; in some cases, the downstream user’s 
only obligation is that he or she must give the 
innovator credit for the innovation. According to 
Larry Rosen, the difference between copyleft and 
academic open source licenses is that the former 
are employed by generous sharers of IP freedoms, 
whereas the latter are employed by generous do­
nors of IP freedoms.25 
An academic license can achieve some of the 
goals of open source as effectively as can a copyleft 
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CHAPTER 2. 
license. Indeed, where the licensor’s primary goal 
is to encourage widespread adoption of the ini­
tial innovation, an academic-style license may be 
more effective because a copyleft license could 
deter potential licensees who want to be able to 
commercialize their own improvements on a pro­
prietary basis. 
.	 opEn 	SouRCE	In fIELdS 
oTHER	 THAn 	SofTWARE 
Although most of the examples given here come 
from the software industry, the principles of open 
source can be applied to other fields as well. Open 
source technology could be especially useful in 
niche markets that are too small to be profitable 
for companies that make off-the-shelf, proprietary 
technologies. Importantly, open source technolo­
gies can be tailored to serve small agricultural and 
pharmaceutical markets in developing countries 
(where small may refer either to the numbers of 
potential users or the amount that potential users 
can afford to pay). 
.1	 Biological innovations 
Open source can have a place even in fields domi­
nated by proprietary strategies, such as the life 
sciences. Open source tools are important—and 
growing ever more important—to life sciences re­
search and development. Many of the most valu­
able and widely used enabling technologies in the 
field are bioinformatics software programs, li­
censed on terms that are open source in the strict­
est sense. A good starting point for readers inter­
ested in exploring the possibilities of open source 
software for biomedical and agricultural applica­
tions is the Web site of the Open Bioinformatics 
Foundation.26 
What about open source licensing for non-
software biotechnologies? Starting as early as 1999, 
a variety of life-sciences initiatives have conscious­
ly adopted one or more open source principles 
in attempts to overcome some of the challenges 
posed by an increasingly complex IP landscape. 
These initiatives include a Canadian proposal for 
a General Public License for plant germplasm,27 a 
draft license (never adopted) for human genome 
project sequence data,28 the data access policy of 
the international haplotype mapping (HapMap) 
project,29 the Biobricks Foundation,30 Tropical 
Diseases Initiative (TDI),31 Science Commons,32 
and Biological Innovation for Open Society 
(BIOS).33 
Many open source software licenses are 
drafted as generically as possible so that as many 
people as possible can use them, as templates, for 
as little cost as possible. It would be helpful, of 
course, if the life sciences had open source prec­
edents or template licenses—or, for that matter, 
a voluntary licensing standard, equivalent to the 
OSD, or a set of best-practice guidelines. Such 
tools would not only help prospective licensees 
decide whether a biomedical or agricultural tech­
nology license is genuinely “open source”(thereby 
helping them judge whether it is likely to achieve 
the positive collaborative outcomes for which 
open source licensing is valued) but would also 
help prospective licensors set universally benefi­
cial terms for technology transfer. 
These tools, however, do not yet exist. In 
developing such tools, the biomedical and agri­
cultural research and development communities 
could learn a lot from the experiences of software 
developers. However, it may turn out that bio­
technology—which is a far more technologically 
diverse field than computer programming, and 
which relies on expensive, time-consuming, and 
complicated patents rather than automatic no-
cost copyrights—simply does not lend itself to 
the use of template licenses. 
Therefore, for the present, at least, IP manag­
ers should be wary of uncritically imitating ex­
isting attempts to formulate open source licenses 
for non-software technologies, both because these 
licenses are not generic enough to be appropriate 
in all contexts and because some may not truly 
embody the principles that make open source 
work. Instead, prospective licensors and their ad­
visors should develop tailored strategies. 
.2 	 Examples of open source in 
molecular diagnostics 
The following examples reveal how open source 
licensing could be advantageous in both the pub­
lic and the private sector even outside the soft­
ware context. 
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.2.1 Case #1: A nonprofit setting 
Suppose that a clinical scientist working in a not-
for-profit setting (a university or hospital labora­
tory) discovers a genetic mutation that seems to 
correspond with the occurrence of an inherited 
disease in one of his or her patients’ families. 
Using standard molecular biology tools, the sci­
entist creates a diagnostic test and confirms the 
discovery. Imagine that the diagnostic test is pat­
entable, but, because there are probably tens or 
hundreds of mutations associated with the dis­
ease, the new test will detect only a fraction of 
these mutations. As a result, the test has limited 
value. 
Clearly, the utility of this diagnostic test— 
and hence the utility of the service the scientist’s 
lab provides to patients, their families, and the 
community as a whole—would be enhanced if 
the new test could be combined with previously 
existing tests for other mutations associated with 
the same disease. The utility of the new test would 
also be enhanced by increased use: the more peo­
ple who use the test, the more likely that systemic 
errors would be detected and corrected, and the 
greater would be the cost-effectiveness, for regula­
tors, of enforcing best-practice standards for the 
test. 
In this case, a copyleft-style open source li­
cense might be the most sensible way to protect 
the new genetic test. Such an approach would 
ensure that users do not have to pay license fees 
to subsequent developers in order to gain ac­
cess to the most comprehensive version of the 
test. 
.2.2 Case #2: A for-profit setting 
Suppose now that our hypothetical scientist works 
for a small company that operates on a mixed-rev­
enue business model. Some of the company’s rev­
enue comes from the development and marketing 
of diagnostic tests for use in hospitals, physicians’ 
offices, and in the home. More revenue comes 
from data analysis and contract research services. 
The rest of the revenue comes from licensing its 
collection of gene patents. 
The inventor’s company also conducts broad-
ranging R&D activities that are economically 
important to the company in two ways. First, by 
developing and patenting new technologies, the 
company generates more revenue through patent 
licensing. Second, the company’s research agenda 
enhances the company’s reputation as a high-tech 
organization, which in turn attracts new cus­
tomers. Because of its small size, the company’s 
stand-alone research capacity is limited, so it 
makes a point of pooling resources with other 
research organizations. However, competition is 
fierce among small companies that want to forge 
alliances with the most desirable partners from 
industry and the nonprofit sector, so our imagi­
nary company is always looking for ways to en­
hance its capacity for cutting-edge research and 
to advertise its excellent track record of scientific 
collaborations. 
If the genetic test mentioned above were to 
be licensed under a copyleft-style license, the 
company would gain access to any new versions 
of the test—which are likely to be more reliable, 
easier to perform, and more comprehensive than 
the old ones—without having to pay exorbitant 
fees to other developers or having to deal with 
restrictive licensing terms. The better the test be­
comes and the cheaper it is for people to use, the 
larger the market will be for associated products 
and services (for example, test kits and genetic 
counseling). If the company is known as the pro­
ducer of a cheap, effective test, the company’s 
reputation will improve; the enhanced reputa­
tion, in turn, will lead to greater demand for 
its contract research services and, perhaps also, 
greater demand for access to the company’s gene 
patents. Further, a better standing in the indus­
try will make it easier for the company to attract 
and keep excellent employees and research part­
ners. Meanwhile, the experience of leading an 
open source project would give the company a 
chance to acquire, and demonstrate, experience 
in collaborative research. 
Note that although open source develop­
ment makes sense for the two hypothetical cases 
outlined here, open source may not always be 
appropriate. There are no hard-and-fast rules 
about whether or not the benefits of an open 
source approach will outweigh the costs, so each 
situation must be evaluated on a case-by-case 
basis. 
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CHAPTER 2. 
. ConCLuSIonS	 
Much work remains to be done before open 
source licensing is fully integrated into the bio­
medical and agricultural spheres, and this chapter 
has done no more than scratch the surface of the 
topic. Ideally, those who are interested in explor­
ing nonproprietary exploitation strategies in the 
life sciences will continue discussions that will 
eventually lead to the creation of open source 
standards and open source license templates. 
Until then, prospective licensors in the life scienc­
es must be prepared to independently interpret 
the lessons of open source software licensing. n 
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CHAPTER 2.7 
Using Milestones in Healthcare Product Licensing 

Deals to Ensure Access in Developing Countries
 
JoachiM oehleR, Chief Executive Officer, Concept Foundation, Thailand 
ABSTRACT 
When public–sector organizations and public–private 
product development partnerships (PDPs) manage intel­
lectual property (IP), they need to balance the commercial 
interests of private–sector manufacturers with the public 
sector’s mission to obtain access to products at the lowest 
possible cost. An important tool for achieving this bal­
ance is the detailed definition of contractual milestones, 
which should clearly specify the terms for pricing to the 
public sector, territory and exclusivity, regulatory work, 
and time to market. Milestones should not, however, be 
cast in stone. Based on detailed analyses of market condi­
tions, milestones need to remain adjustable throughout 
the life of the contract. When well defined, milestones 
can be used to ensure the availability of the most modern 
healthcare products to the developing world. After all, for 
the public sector, successful IP management is defined by 
how many poor people a product will reach, how easily 
it will be available to them, and who and how many will 
be able to afford the product. Accordingly, out-licensing 
intellectual property from public–sector-based organiza­
tions to private–sector partners requires the licensor to 
actively guard public–sector interests. 
1. InTRoduCTIon 
When public–sector organizations and pub-
lic–private product development partnerships 
(PDPs) manage intellectual property, they need 
to balance the commercial interests of pri­
vate–sector manufacturers with the mission of 
the public–sector to provide access to products 
at the lowest possible cost. Many of the impor­
tant inventions oriented toward public needs in 
healthcare and biotechnology result from R&D 
in public–sector research centers and interna­
tional organizations. By adequately managing 
the resulting IP, the public–sector can benefit 
from its R&D investments by making the most 
modern healthcare products available to the de­
veloping world, eliminating significant barriers 
to access. 
1.1  The importance of contracts 
and milestones 
For parties entering into agreements of any 
kind, the primary assumption of contractual re­
lationships is that the principal subject of their 
deal will be realized successfully. Obviously, this 
is not always a safe assumption, and when un­
foreseen events prevent the partners from reach­
ing their goals, contracts differ considerably in 
the quality and substance of the remedies they 
provide. Too many contractual relations go sour 
because partners rush into agreements without 
carefully thinking about contingencies. 
Without an early elaboration of contin­
gency plans and crisis management, this honey­
moon trap is why many contractual agreements 
contain unclear, foggy language and omit defini­
tive, detailed, and enforceable conditions. Such 
conditions should address not only the con­
tractual rights but also the obligations of each 
partner and the specific countermeasures to be 
Oehler J. 2007. Using Milestones in Healthcare Product Licensing Deals to Ensure Access in Developing Countries. In In-
tellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT 
Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. J Oehler. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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taken should one party run into difficulties in 
fulfilling its part of the deal. Instead, “best ef­
forts clauses” or provisions for consultations to 
solve problems case by case are used, so as not to 
spoil the initial enthusiasm of making the deal. 
When unforseen events occur, that can be a sure 
recipe for disaster, especially if the mechanisms 
to settle disputes over differing opinions about 
contractual performance are unclear. 
A typical contract specifies the subject mat­
ter, the duration and terms, and the rights and 
obligations of each party under the agreement. 
Licensing agreements between two organiza­
tions identify, among many issues, the nature 
and scope of the intellectual property or prod­
uct that is being licensed, the territorial grant to 
the licensee where the licensed product would 
be made available, and the financial obligations 
of the licensee. 
A practical example is the use of technical 
know-how, or the results of scientific research, 
that represents the particular intellectual prop­
erty of a licensor and is to be licensed out to a 
commercial company able to create a product 
from the intellectual property and distribute it 
to consumers and users. The interests of both 
parties in the arrangement are straightforward 
and mutually advantageous—it is a win-win 
situation. This ordinary, idealistic assump­
tion prevails at the beginning of any licensing 
deal. All too often, however, reality thwarts the 
goals of the initial agreement. Planned goals are 
missed, or forecasts wrong, and the contractual 
partners are left with only a subset of the origi­
nal targets. 
Too often, the public sector forgets that the 
commercial interests of private-sector companies 
are oriented toward maximizing profitability. 
Accordingly, it should not be expected that pri­
vate-sector businesses will automatically provide 
the best services to the public sector or that they 
will focus on the generation and use of intellec­
tual property to maximize public–sector benefits. 
To prepare for situations when the original tar­
gets of a license agreement are delayed or not 
achieved, and to avoid situations when projected 
public–sector benefits are delayed or unrealized, it 
is good practice to establish contractual milestones. 
These govern the goals of the license contract and 
set incentives for keeping to timelines and perfor­
mance targets. They encourage both the licensor 
and licensee(s) to focus resources on their efforts 
to perform as initially agreed. 
But milestones should not be fixed or inflex­
ible. They need to remain adjustable through­
out the lifetime of a license contract because of 
potential changes in project development, the 
market environment, and other factors that 
cannot be completely anticipated. When it 
comes to the detailed specifications of individu­
al milestones, it does not really matter if one is 
choosing an absolute or a relative goal, or which 
definition is finally settled upon. What matters 
is to get the commitment of the private–sector 
company to recognize public–sector targets. To 
do this, a working set of adequate milestones 
should be put in place, and periods for perfor­
mance assessment of the private–sector contract 
partner should be defined. And when new, solid 
evidence requires a change of rules to keep both 
the product and the public sector’s goals alive, 
both parties should be open to revisions. Such 
results-oriented milestones require intensive 
preparations, detailed knowledge of the pro­
cesses related to developing and marketing the 
product, realistic forecasting of product poten­
tial, persistence in quantitative forecasting and 
establishing a master plan for the entire product 
roll-out, and a mission-driven mindset to estab­
lish optimum goals for the public sector. 
Additionally, it is useful to spell out the level 
and conditions of fines (monetary or otherwise) 
to be paid when a partner does not fulfill its ob­
ligations. This should include a mechanism to 
prevent prolonged periods of quarreling over 
differing opinions and disagreements over per­
formance. Otherwise, product development or 
marketing efforts could cease, which would ulti­
mately hurt the public sector. 
Most milestones cover: 
•	 pricing to the public sector 
•	 territory and exclusivity 
•	 regulatory work and time-to-market 
•	 royalties 
•	 terms and termination of the license 
agreement 
120 | HANDBOOK OF BEST PRACTICES 
        
	 	 	 	
	 	 	 	 	 	
     
        
   
     
     
      
     
      
       
    
      
       
     
        
        
     
        
        
        
       
     
      
    
     
    
     
    
         
    
        
     
     
    
        
       
    
    
        
      
     
       
       
      
      
     
       
      
      
       
        
     
       
      
     
     
       
      
      
     
      
   
      
      
        
     
      
    
      
         
        
       
      
    
       
      
    
      
      
    
  
  
      
  
   
   
   
CHAPTER 2. 
1.2  Public–private partnerships: closing 
the medicines access gap in developing 
countries 
The role of public–private partnerships (PPPs), 
or, in the context of health, more and more 
frequently public-private product development 
partnerships (PDPs), as an innovative approach 
to the discovery, development, and distribu­
tion of health products, drugs, and vaccines 
for developing countries has been emphasized 
repeatedly in various publications. In fact, more 
than 90 PPPs have been established worldwide.1 
However, the accomplishments of PPPs/PDPs 
are rarely publicized, partly because most of 
these entities are relatively young. Half of these 
partnerships have been established since 1999. 
Since normal times to market range from no less 
than ten to around 12–15 years, on average, in 
a pharmaceutical R&D or healthcare environ­
ment, the time in existense of these partner­
ships has been relatively short. It is still possible 
to begin to gauge, however, the success of these 
ventures. 
One example of a PDP is the Concept 
Foundation,2 established in 1989 through the 
initiative and funding of the World Health 
Organization’s Special Programme of Research, 
Development, and Research Training in Human 
Reproduction (WHO/HRP), the World Bank, 
and United Nations Population Fund (UNFPA), 
PATH/PIACT,3 andTheRockefellerFoundation. 
The mission is “to provide access to top quality re­
productive-health products for developing countries 
at lowest possible prices in order to realize maximum 
public-sector benefits through the management of 
intellectual property and technology transfer for 
contraceptives and pharmaceuticals that otherwise 
would not be available to the public sector with 
the intended quality and prices.” The Concept
Foundation has accumulated extensive experi­
ence managing health technologies develop­
ment and technology transfer in the pursuit of
rolling out new technologies in the developing 
world. 
Successful PPPs/PDPs are built on value 
propositions, from the public sector to the pri­
vate sector, that take advantage of the inherent 
capabilities of the former. The public-sector IP 
manager should identify the capabilities that are 
relevant to a particular public–private partner­
ship and turn these capabilities into specific val­
ue propositions that will help the private–sector 
partner realize its commercial goals. No poten­
tial benefit to the public sector, however, should 
be sacrificed. In this context, it is especially im­
portant to overcome the common phenomenon 
of further marginalizing the poor in the small 
and smallest countries of the developing world. 
Market attractiveness governs priorities in a 
commercial environment, but in a public–sec­
tor context, the poor in the smallest countries 
have the highest needs for accessing affordable 
products. As the experiences of the Concept 
Foundation reveal, the public sector successfully 
manages its intellectual property when it bridges 
these ostensibly opposing interests. 
The R&D process for developing new drugs, 
vaccines, and diagnostics for diseases that afflict 
the poor is a crucial step toward ultimately erad­
icating these diseases. Many PPPs/PDPs con­
centrate their efforts on product development,
and the largest product-development PPPs/ 
PDPs have successfully raised (in combined fig­
ures) more than half a billion U.S. dollars in re­
cent years to fund their R&D efforts. However,
product delivery is an equally important, if not 
more decisive, factor for access to medicines, 
and most product-development PPPs/PDPs are 
not working to ensure that their products can 
be delivered to the local healthcare infrastruc­
ture. Indeed, product-development PPPs/PDPs
have little experience with the downstream
issues involved in bringing products to such 
markets. 
But PPPs/PDPs face numerous downstream 
concerns associated with handling and financ­
ing the introduction and launch of new products 
including: 
•	 adequacy of healthcare infrastructure 
•	 disease surveillance 
•	 compliance monitoring 
•	 education and training of health workers 
and medical staff 
•	 improving healthcare facilities 
•	 physical distribution networks 
•	 satisfactory supply volumes 
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OEHlER 
•	 adequate volume forecasting 
•	 minimizing product waste at the point of 
treatment 
As is well known from experiences in the 
pharmaceutical industry, successful marketing 
and distribution of a new medicine is a significant, 
decisive part of its cost structure. While nobody 
would expect the need to create market demand 
(in other words, investing marketing dollars) for 
products to fight diseases of poverty (these mar­
kets exist!), huge investments are needed to com­
pensate for the inability of the poorest regions to 
pay for both modern, effective products and for 
all downstream tasks related to effectively sup­
plying and distributing these medicines. In ad­
dition, costs for surveillance programs to guaran­
tee successful outreach to all who need treatment 
must be included. Product development pub-
lic–private partnerships lack the experiences to 
address these downstream issues. 
These efforts must include achieving the 
lowest possible manufacturing costs so that pref­
erential pricing can be provided to public health 
services, establishing sustainable manufacturing 
with a continuous system for monitoring qual­
ity, and creating a business model that is finan­
cially attractive to private pharmaceutical com­
panies thereby overcoming the expected poor 
returns of operating in public sector markets. 
The PPP/PDP business model of the Concept 
Foundation has helped to realize these goals. It 
takes into account the downstream issues sur­
rounding product delivery and successfully uti­
lizes contractual milestones to achieve the prin­
cipal goal of closing the medical-product access 
gap in developing countries. 
2. THE GREAT DIVIDE IN BuSINESS
MODElS: INDuSTRy AND
THE PuBlIC SECTOR 
No matter how well public sector players think 
they understand industry, the discussion between 
the public sector and industry is a cross-cultural 
event. In such a cross-cultural environment, 
there is nothing more dangerous and conducive 
to misunderstandings than to assume the obvious, 
since what is obvious for a person with a public 
sector background may be different for a poten­
tial partner. Do not leave obligations and con­
tractual performance to best efforts and com­
mon sense! It is much better for both partners to 
specify in writing exactly what the public sector 
wants to achieve with a commercial partner. The 
document should detail exactly when and how 
the objective will be achieved and specify penal­
ties for failure to meet objectives. If the agree­
ment specifies only best efforts and unspecified 
performance, disaster threatens! 
To manage intellectual property for maxi­
mized benefits to the public sector, the expec­
tations of the public sector to obtain products 
at the lowest possible prices, with excellent 
quality, and in sufficient quantities must be 
balanced with the expectations of private sec­
tor companies to generate a satisfactory rate of 
return. 
Important value propositions for pharma­
ceutical companies are: 
•	 Save time to market. An earlier market 
entry means higher market share oppor­
tunities for the company and, ultimately, 
more sales. Example: Pharmaceutical or 
clinical research, using an existing net­
work of public sector institutions in paral­
lel speeds the generation of results needed 
for drug regulatory approval by saving the 
lead time required to approach new, unfa­
miliar trial sites and train in GCP (good 
clinical practices). 
•	 Save resources. Reduced need for inter­
nal company resources means a lower cost 
burden for the licensee and improves the 
bottom line. On the other hand, when 
investment levels are maintained, more 
parallel activities are possible with the 
same amount of resources, helping to in­
crease the company’s commercial output. 
Example: Existing public sector distribu­
tion networks, formal or informal, allow a 
product to reach a large public sector mar­
ket very quickly without the costly build­
up of a supply chain. 
•	 Save investments. A reduced need for 
investments means better cash flow 
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CHAPTER 2. 
utilization within the company, which is 
very important for investors. 
Any plan for a value proposition must deal 
specifically with the nature of the partnership, 
and a successful proposal must present an au­
thentic and actual value to a potential partner. 
These authentic, actual values must be based on 
the set of capabilities that the public sector orga­
nization can offer—this is precisely the platform 
for the creation of value—and based on what 
private sector partner needs could be met by the 
public sector. Such genuine values include the 
examples above: save time to market, save re­
sources, and save investments. As these demon­
strate, one must look behind the immediate and 
apparent face value of individual capabilities 
in the public sector to be able to identify and 
compose the true value of such contributions. 
Indeed, an authentic value proposition is more 
often composed of several contributions from 
various capabilities than a single value factor. 
Understanding all the specific values when 
just beginning to approach potential licensing 
partners is essential—especially those values that 
drive an industry and are particularly important 
for the potential licensee. A detailed analysis of 
these values and their alignment with existing 
public sector capabilities helps to identify the 
value propositions that public sector organiza­
tions can offer their private sector partners. 
.  THE	MoST	IMpoRTAnT	MILESTonES 
Maximizing public sector benefits through IP 
management has three key aspects: 
1	 definition of the geographic coverage for 
marketing the product (that is, territory) 
2	 the claim for product exclusivity by the 
private sector licensee 
3	 the definition of the preferred public sec­
tor price or other public sector benefit 
These may seem very straightforward. It is 
easy to imagine that the partners in a license 
arrangement would agree on a set price for the 
product for public sector distribution, agree on 
the countries in which the product could be 
sold and that, as a result, the private sector com­
pany, as licensee, obtains the exclusive rights to 
marketing and sales of the product in this ter­
ritory. However, in real life, this does not nec­
essarily mean that public sector benefits have 
been maximized. Some key questions need to be 
answered: 
•	 How well will we reach smaller countries 
with our product? 
•	 How well will we reach rural populations 
in developing countries that normally re­
main underserved? 
•	 Who will benefit from obtaining the prod­
uct at a special public sector price? 
•	 How can we ensure that we will obtain the 
product at prices affordable to public sec­
tor agencies? 
The principal way to address these issues is 
to set contractual milestones that prevent the 
marginalization of the poor in smaller coun­
tries, regulate public sector access, and set the 
geographic coverage for all countries in a terri­
tory (even in countries and regions that are not 
interesting enough to generate sizeable returns 
on investments and would therefore normally 
not be served). Finally, there must be a clear 
framework for computing manufacturing costs, 
and this cost calculation must be available to the 
public sector partner. 
Due to commercial pressures, putting the 
private sector and its commercial interests be­
fore those of the public sector is an inherent 
danger. Such prioritizing usually reflects at­
tempts to simplify the private sector partner’s 
participation because of fears about failing to 
make a deal. While simplifying agreements is 
good practice, establishing specific contractual 
milestones and clarifying them under the terms 
of an agreement are not necessarily complica­
tions. Success requires focusing on which areas 
to target and which issues to exclude. A tight 
focus will guarantee the simplicity of the provi­
sions and regulations without overburdening an 
agreement. 
When it comes to public sector benefits, 
simply making a product available at market 
prices or quickly placing it on the market does 
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OEHlER 
not indicate progress. Success is instead defined 
by how many poor people the product will 
reach, how easily it will be available to them, 
and who and how many will be able to afford 
the product. The goal is to reduce morbidity 
and mortality. For the public sector, this is the 
ultimate aim of product development. The nec­
essary achievements for obtaining this outcome 
need to be clearly specified as milestones in an 
agreement. We will next take a closer look at ter­
ritory, exclusivity, and pricing. 
.1 Territory and field-of-use 
A typical license agreement will specify the grant 
of the license. Language such as: “LICENSOR 
grants COMPANY the rights to manufacture 
and sell the PRODUCT into the PRIVATE 
SECTOR and PUBLIC SECTOR markets of 
the TERRITORY” is commonly used. The 
terms LICENSOR, COMPANY, PRODUCT, 
PRIVATE SECTOR, PUBLIC SECTOR, and 
TERRITORY are used according to the defini­
tions in the introductory “Whereas” chapter to 
the agreement.4 
Under this wording, the license grant is es­
tablished as a right of the licensee to the prod­
uct. However, the license grant does not specify 
the obligation to sell into the territory. This is 
a very important issue of practical IP manage­
ment for public sector benefits. While it is rea­
sonable to assume in the case of a one-product, 
home market manufacturer that the licensee will 
introduce the product into this (single) market, 
it is not necessarily true that a licensee will in­
troduce the product into all markets of a mul­
ticountry territory, especially the public sector. 
This failure to reach all the desired markets may 
result from various factors that were not known 
or were underestimated when the license agree­
ment was established. 
Between the signing of a license agreement 
and the commercial roll-out of the product, a 
considerable period of time may be needed for 
product development, manufacturing scale-
up, and regulatory approval. Depending on 
the capabilities of the licensee, this time peri­
od may well extend over several years. During 
this time, the company’s business and the 
business environment may change significantly, 
and resources that originally were available for 
dealing with the product may have been partial­
ly redirected to other, possibly more profitable, 
products and projects. Markets that initially 
seemed attractive may have lost their appeal 
compared to other opportunities since recog­
nized by the company. 
Changes in the business environment and the 
focus of the business may affect the licensee’s com­
mitment to serve the public sector as originally 
envisioned for the entire area. To ensure availabil­
ity and access to the product in the public sector’s 
territory, it is only prudent to use the license grant 
to obligate the licensee to sell the product in that 
area—not just as a right of the licensee. This can 
be accomplished in various ways: 
•	 By separating the grant of the rights to 
manufacture the product from the obliga­
tion to sell the product into all countries of 
the territory (Emphasis here should be on
all countries in the territory.) 
•	 By attaching milestones to the execution 
of the sales rights for the product (Only 
after showing defined success according 
to the milestones would the licensee be 
granted additional sales rights for other 
countries.) 
•	 The rights of the public and private sec­
tor to sell the product could be dealt with 
in separate regulations that prioritize the 
public sector organization’s goal of intro­
ducing the product into the public sector 
at a satisfactory level (to be defined by an 
adequate milestone) in one country, be­
fore additional rights to markets—public 
and private—in other countries would be 
granted. The license grant could specify, 
for example, the rights of a Brazilian man­
ufacturer to produce and sell the product 
in Brazil, the home market, and the rights 
to sell it in other Latin American coun­
tries, once certain conditions are met. A 
wide range of options for these conditions 
are available and could be specified in the 
license agreement, such as: 
- Market share. licensee will gain the 
rights to sell into other countries after 
12 | HANDBOOK OF BEST PRACTICES 
         
      
     
 
      
      
     
      




      
        
      
        
       
       
      
        
      
       
       
      
       
     
       
      
       
       
   
     
      
      
         
        
        
       
     
       
       
       
      
     
   
      
       
     
       
        
      
     
     
      
       
       
      
      
        
      
        
       
        
     
        
        
        
        
       
      
      
      
      
      
    
      
     
       
      
     
     
      
       
      
       
CHAPTER 2. 
establishing a market share of 20% in 
the specific market segment, as reported 
by IMS.5 
- Market position. licensee will gain the 
rights to sell into other countries after 
positioning the product among the top- 
three products within its category in the 
Brazilian market, as measured by ana­
lyst reports. 
- Sales volume. licensee will gain the 
rights to sell into other countries after 
an annual sales volume of five million 
units is realized in the Brazilian market, 
as measured by cumulative sales reports 
from distribution agents. 
- Public sector penetration. licensee will 
gain the rights to sell into other coun­
tries after the total output/annual out­
put into the public sector in Brazil has 
reached ten million units, as measured 
by procurement orders from public sec­
tor agencies. 
In addition to the milestones for gaining 
the rights to sell in additional countries, the re­
maining countries in the licensed territory could 
be prioritized in order of importance for the li­
censee, and eventually the licensor as well. Each 
country on the list would then be characterized 
by individual milestones that the company must 
reach before it could sell in an additional coun­
try. These country priorities and milestone defi­
nitions should be set when signing the license 
agreement, with the option to revise the priori­
ties and milestones after a certain period. 
It is unwise to leave country priorities or 
milestone definitions open and uncovered for 
the sake of higher flexibility (for example, set­
ting the next country priority shortly before 
reaching the last defined milestone in the actual 
country of activity or a similarly flexible model 
that postpones decision-making). Reaching 
consensus about country priorities and mile­
stone definitions might become more and more 
difficult for the licensor and licensee, especially 
the closer the country of choice is to the bottom 
of the priority list. The licensee might then no 
longer desire to sell in a particular country, and 
especially to the public sector, due to various, 
possibly hidden, reasons. The company could 
walk away from its responsibilities to serve a 
particular country. In this case, the private sec­
tor company would not be violating the license 
agreement, since the milestones had not already 
been mutually defined and negotiations about 
new milestones had failed. 
On the other hand, priorities and milestone 
definitions may change over time in a fast-mov­
ing business environment. Indeed, they might 
not be considered valid after several years into 
the lifetime of a license agreement. This is a 
common concern when it comes to defining 
priorities and milestones, especially among ad­
vocates of real-time implementation. Given the 
need to eventually define priorities and mile­
stones, to protect public sector access to the 
product everywhere as far as possible, and to 
avoid the inherent dangers of leaving important 
parts of an agreement initially undefined pend­
ing a later mutual understanding, it is close to 
irresponsible to skip over these definitions and 
omit them from the initial version of the signed 
license agreement. One can provide for a regular 
update of the details of these conditions, when a 
changed environment requires them, for exam­
ple, by calls for revisions. At that time, however, 
it would be up to the licensee to demonstrate 
the need for changes and to prepare a detailed 
proposal of what to change and how to change 
it. Unless the proposed changes bring up com­
pelling reasons for the licensor, original priori­
ties and milestones would prevail. The originally 
defined public sector goals would remain in 
force without alteration and the licensee would 
still be required to honor these goals. 
Initially defining contractual priorities and 
detailed milestones is, of course, a painstaking 
process that requires intensive preparations to 
ensure that essential aspects of the public sec­
tor’s objectives are not overlooked. This desk 
research and information collection is essential 
for adequately preparing license agreements that 
serve public sector interests. For initial negotia­
tions between parties, the terms of a licensing 
agreement should be rolled-out in all related 
details, even though it may be difficult and 
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OEHlER 
resource-intensive to formulate all of them. The 
tendency to postpone detailing specifications, 
or calls from the contract partner to omit the 
necessary detail in order to simplify and quickly 
reach an agreement is a trap. It does not allow 
the parties to establish the necessary framework 
for an efficient and effective public sector-ori­
ented licensing arrangement. If it is impossible 
to reach an agreement on staggered priorities 
with detailed milestones in the beginning of the 
contract relationship, how can these differences 
be ironed out later? 
.2 Exclusivity 
One of the first things that companies ask for is 
exclusivity. It is important to link such requests 
with specific milestones, such as: 
•	 volume of sales reached in certain markets 
after a certain time period from launch or 
from the signing of the agreement 
•	 level of market share reached against 
competition 
•	 level of market share established in a new 
market segment, measured against the to­
tal product potential 
•	 level of coverage of different regions in a 
large market or across different countries 
of a region 
•	 latest product launch date into a market 
that will secure product/technology ex­
clusivity for the company, in general, for
a selected territory 
Specifying penalties and fines for the licens­
ee if these milestones are not reached is just as 
important as setting the specific milestones. The 
penalties could be: 
•	 temporary increase of royalties on private
sector sales until the milestone condition 
has been reached 
•	 loss of exclusivity for the product or tech­
nology and conversion to a nonexclusive 
license, in general, or for a specific region 
•	 loss of exclusivity and territory to a 
competitor 
•	 payment of a fine, in a predefined amount, 
for failure to introduce a product into a 
country under exclusivity for the licensee. 
It is good practice to evaluate the request 
for exclusivity with respect to the public sector 
benefits that a potential licensee could deliver. 
Again, it is unreasonable to expect that a private 
sector company would concentrate major re­
sources on serving the public sector when there 
are no specific obligations in the license agree­
ment or milestones are inadequate or undefined. 
Since the request for exclusivity is made to pro­
tect the commercial potential of a market place, 
the public-sector partner has the right in a quid 
pro quo to ensure the protection of public-sec­
tor needs. It is especially important for the pub­
lic sector partner to understand what kind of re­
sources—in terms of quality and quantity—the 
private sector company will make available and 
mobilize for the public sector segment of the ex­
clusive territory. This understanding should be 
clearly stated in the license agreement. 
. Pricing for the public sector 
A key issue for the public sector in develop­
ing countries is product affordability. Prices 
must ensure the widest possible availability. 
Prices, however, are calculated differently in
the pharmaceutical industry than in the public 
sector. 
Pharmaceutical companies commonly use a 
retrograde calculation scheme. They base prod­
uct prices on the perceived purchasing power of 
the target segment in a market. Manufacturing 
costs are not a major factor for the price calcu­
lation. Overhead and marketing costs are usu­
ally higher than production costs and need to be 
well offset by product pricing. To a large extent, 
adequate product positioning into affluent mar­
kets determines achievable margins and operat­
ing profitability. 
In contrast, the public sector mostly uses 
the cost-plus model for price determination. 
Manufacturing and organizational infrastruc­
ture contribute significantly to costs. Sales and 
marketing costs are kept at the lowest possible 
levels so as not to increase the product’s price. 
A reasonable, but small, rate of operating profit 
is added on top of these costs to determine the 
product price. With the purchasing power of the 
public sector under severe limitations, a price 
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CHAPTER 2. 
determination along the lines of a cost-plus 
model is the method of choice. 
An effective license agreement needs to em­
ploy a detailed cost-calculation model. Its aim 
should be to understand all directly and indi­
rectly attributed product costs that contribute to 
final cost. By applying the model and marking 
up the ex-factory product price with a mutually 
accepted profit margin for sales into the pub­
lic sector, a reasonable platform for determin­
ing the lowest possible public sector price can 
be achieved. For indirect costs, it is necessary 
to find out if the cost burden on the product 
is fairly allocated. In the end, of course, private 
sector pricing of the product is entirely up to the 
discretion of the manufacturer and not a public 
sector concern. 
It is good practice to mandate the an­
nual submission of manufacturing cost reports
andproductcost-calculationdetails.Furthermore, 
the licensor should reserve the right to have these 
cost reports independently audited. 
Should a manufacturer be unable to match 
expected price levels for the public sector when 
the company begins manufacturing, a definite 
timeline should be set to reach those levels. 
Adequate penalties should be in place to cover 
such cases. While a license agreement cannot be 
a tool to force a manufacturer to sell a product 
below cost, a detailed agreement based on the 
manufacturing cost-calculation model and the 
overall pricing structure for the product will 
eliminate related concerns. 
The licensor should define which public sec­
tor organizations could obtain the product at the 
preferred price. For pharmaceutical products, it 
should be clearly defined whether these pub­
lic sector organizations can be only ministries 
of health, government purchase organizations, 
public sector hospitals, and similar institutions 
or if nongovernmental agencies with charitable 
functions, social marketing organizations in a 
country, international organizations with a hu­
manitarian mission, and other institutions are 
also potential beneficiaries. The license should 
define how these agencies and organizations 
would be informed about the availability of a 
preferred public sector price for the product. 
.  Regulatory work and time-to-market 
Pharmaceuticals are subject to drug regulatory 
approval by health authorities, and the time 
required for the regulatory approval process in­
creases the time it takes for a product to reach 
a market. It is good practice to stipulate in the 
license agreement when the licensee must bring 
the product forward to registration. It is also 
best to specify within what time period after 
signing the license agreement the licensee has to 
forward a complete registration filing to the rel­
evant authorities. For a multicountry territory, 
specifying the sequence of registration filings in 
the various countries and the maximum time al­
lowed between individual filings is vital. 
It is also advantageous to specify how much 
time may pass between registration approval and 
the product launch in the public sector. This 
prevents the unusual, but realistic, scenario in 
which a licensee sits on its rights and doesn’t uti­
lize them for the benefit of the public sector. 
.  Avoiding the marginalization 
of the poor in small countries 
For commercial companies, large markets domi­
nate priorities and occupy the top spots of ter­
ritorial ranking, while small countries regularly 
occupy the bottom. This is because market at­
tractiveness rules priorities in a commercial 
environment. The needs of the poor and of 
public sector agencies in small countries are not 
normally attractive markets for companies that 
are expecting to generate sizeable commercial 
returns from their manufacturing and market­
ing efforts. A licensor must ensure that product 
access is not limited just to larger markets and 
that small countries will be covered in order to 
avoid further marginalizing the poor. 
When it comes to the territorial grant of a 
license agreement aimed at maximizing public 
sector benefits, the licensor must thoroughly 
consider this particular issue. The prospect of 
substantial profits from product sales in the 
private markets of any territory is an important 
issue for deciding to award the licensee com­
mercial advantages under the license agreement. 
However, the territorial grant must cover not 
only large countries and their sizeable private 
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OEHlER 
markets—as main incentive that the public sec­
tor would be reached as well—but also small 
countries and their public sector markets that 
the private sector partner would not normally 
cover. An effective territorial grant must contain 
a mix of large and small markets to balance the 
commercial potentials for the licensee against 
the humanitarian needs of the public sector. 
Only the licensor can guard these public sector 
interests. 
It is good practice, therefore, not to grant 
sales rights in large countries to a single licensee 
without including an obligation to serve the 
public sector and markets in the smallest coun­
tries. If a single licensee cannot cover all of a 
region’s markets, the entire region should be 
appropriately segmented to ensure that two or 
more licensees each get a profitable share and 
that the public sector in the smallest countries 
will be served. As outlined above, this goal 
needs to be adequately supported by specific 
milestones. 
The up-front definition of territorial mile­
stones is often skipped, or neglected, to the 
public sector’s disadvantage. One very common 
reason for this is that the primary needs of the 
public sector are spread over a wide territorial 
area and/or over a variety of minority groups in 
dire need of services. Satisfactory coverage re­
quires detailing a multitude of distinctive pri­
orities and characteristic milestone definitions, 
a burden squarely placed on the initial license 
partners—especially the licensor. 
One strategy for expanding territories is for 
the licensor to generate sales to public sector 
agencies in countries that are not covered by the 
initial territory grant but that need the product 
very much. This approach has the following ad­
vantage: the licensee can focus on the obligations 
and related milestones under the license agree­
ment without facing multiple targets, while the 
licensor serves public sector agencies outside the 
territory and potentially establishes other useful 
partnerships. If desired, this additional market 
may be assumed by the licensee. 
Setting a quantitative goal for public sector 
sales needs special consideration. The licensor 
could use absolute or relative target figures. The 
market share percentage reached after a certain 
time from product launch is one good target 
figure. Other possibilities would be to 1) define 
the sales growth reached in the first years on the 
market or 2) to use the sales volume after one, 
three, or five years on the market to characterize 
the expected—and initially agreed upon—suc­
cess rate. The licensor could specify, for example, 
that the product should be among the top-three 
products within the specific market segment in 
its third year of introduction. 
In the private sector, competitiveness is an 
important factor for measuring the success of 
any product. Licensees need to achieve the high­
est levels of competitiveness in private sector 
markets in order to be able to reach their com­
mercial objectives. This in turn would support a 
very competitive manufacturing cost structure, 
which ultimately would provide the public sec­
tor with the lowest possible cost. Measuring pri­
vate market targets is therefore, also an adequate 
way to express public sector goals. 
Another way to set milestones for perfor­
mance in the public sector is to set sales volumes 
in the private and public sectors in relation to 
each other. A powerful milestone definition, for 
example, specifies that public sector sales reach 
40% (or any other agreed upon ratio) of the 
sales volume for the private market within three 
years after product launch. 
With respect to the availability of the prod­
uct in the public sectors, it is essential to spec­
ify expected launch dates for the product. For 
example, the license agreement could stipulate 
that the product be made available in the public 
sector not later than two years after the signing 
of the agreement. Should a product require ini­
tial sales in the private market for any reason, 
an adequate requirement for public sector intro­
duction could be “not later than X years after pri­
vate-sector launch.” For multicountry territories, 
specific requirements for each country would 
need to be established and defined. 
Remedies for unmet milestones need to 
be part of the license agreement. One effective 
remedy is to significantly increase royalties on 
private market sales when a milestone has not 
been reached. 
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CHAPTER 2. 
.  ConCLuSIonS: TouGH	MILESTonES	 
foR	A	 TouGH	InduSTRy 
Finally, some thoughts about milestones for the 
cautious few who feel uncomfortable with the 
idea of setting tough milestones in a tough in­
dustry. In a process-oriented sense, milestones 
represent and define the outcome of standard 
operating procedures (SOPs) for organizations 
that have voluntarily subjected themselves to cer­
tification procedures, such as ISO. Why should 
the public sector not also define such SOPs and 
specific outcomes for the important targets of a 
license agreement? 
However, one of the underlying assump­
tions for everything outlined above is that mile­
stones are not cast in stone. Milestones should 
be and need to remain adjustable throughout 
the lifetime of a license agreement to respond 
to changes in the project, changes in the mar­
ket environment, and other factors that cannot 
be anticipated. When it comes to the detailed 
specifications of individual milestones, it does 
not really matter if one is choosing an absolute 
or a relative goal, or which definitions are finally 
selected. What matters is getting a private sec­
tor company to commit to accepting public sec­
tor targets. To accomplish this, it is important 
to have a working set of adequate milestones in 
place, to define review periods for performance 
assessment by the contract partner, and to be 
ready to be open to, and to accept, milestone 
revisions when new, solid evidence requires a 
change of rules to keep the product and public
sector goals alive. 
Such result-oriented milestones require: 
•	 intensive preparation 
•	 detailed knowledge of processes related to 
product development and marketing 
•	 detailed knowledge of markets 
•	 realistic anticipation and forecasting of 
product potential 
•	 persistence in quantitative forecasting and 
in establishing a master plan for the entire 
product roll-out 
•	 a mission-driven mindset to establish the 
optimum public sector goals and to pre­
vent the public sector from losing out to 
commercial thinking 
Finally, it is crucial to recognize that pub-
lic–private partnerships are not a magic solution 
per se for tasks that have not been well specified! 
In this sense, public–private partnerships are a 
poor substitute for specific, well-defined targets. 
In fact, successful public–private partnerships 
are built upon specific, well-defined targets. n 
JoachiM oehleR, Chief Executive Officer, Concept 
Foundation, Thailand Science Park, Klong 1, Klong 
Luang, Pathumthani 12120, Thailand. joehler@concept­
foundation.org 
1	 See www.ippph.org for a complete list. 
2	 www.ConceptFoundation.org. 
3	 PIACT, the Program for the Introduction and 
Adaptation of Contraceptive Technology, is a 
predecessor of PATH. 
4	 For a broader discussion on field-of-use licensing, see 
the chapter 10.3, also in this Handbook, by SL Shotwell.
Also, the chapter by M Olson, also in this Handbook. 
5	 IMS is an international company that publishes 
reports on pharmaceutical sales by conducting 
pharmacy audits and other means. 
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ABSTRACT 
This chapter reviews different forms of IP (intellectual 
property) “assembly” mechanisms (royalty-collection 
agencies, information clearinghouses, technology clear­
inghouses, open-source innovation clearinghouses, honest 
brokers, and other forms of facilitators, IP management 
services, IP commercialization agents, the services of mer­
chant banks and venture capital enterprises, and patent 
pools). Emphasis is placed on patent pools, which are vol­
untary agreements between two or more patent owners to 
license one or more of their patents to one another or to 
third parties. Although there are many forms of patent 
pools, such arrangements fundamentally consist of the 
interchange (cross-licensing) of rights to essential patents 
by a number of entities, as well as an agreed framework 
for out-licensing the pooled intellectual property to each 
other and/or to third parties, including an agreed-pricing 
and royalty-sharing scheme. 
There are both benefits and risks associated with pat­
ent pools. Benefits include greater ease with respect to 
resolving patent conflicts, making assembled patents in 
the pool available to others, and resolving disputes over 
blocking patents. Risks include antitrust liability. Under 
certain circumstances, patent pools have application in 
the area of humanitarian licensing as instruments of as­
sembly of intellectual property. 
1. InTRoduCTIon 
The importance of IP (intellectual property) 
“assembly” is becoming increasingly evident as 
the biotechnological components, both meth­
ods and materials, that are used in the R&D of 
agricultural and health innovations become more 
and more complex. The use of patent pools can 
be one way to achieve IP assembly. However, pat­
ent-pool formation is complex and often costly; 
it requires special economic, business, and legal 
considerations, and it is but one option to facili­
tate assembly and access. 
One aspect of IP management is obtaining 
freedom to operate (FTO) for a given product in 
a given market.1 Assembling intellectual property 
is therefore an essential step in innovation man­
agement. But having FTO alone does not bring a 
product to market, much less provide the product 
to the poor in developing countries. In this con­
text, the value of patent pools must be carefully 
considered on a case-by-case basis, and, hence, 
the appropriateness of a patent pool for any giv­
en technological innovation will require careful 
analysis and consideration. This analysis will nec­
essarily include legal, business, operational, and 
strategic considerations. Furthermore, it is im­
portant to remember that a patent pool simplifies 
the assembly of intellectual property, but does not 
in itself do much or necessarily lead to technology 
transfer or market access and distribution. 
Before discussing patent pools in detail, the 
chapter will provide a brief overview of IP assem­
bly options and mechanisms. This broader per­
spective will therefore place patent pools within 
Krattiger A and SP Kowalski. 2007. Facilitating Assembly of and Access to Intellectual Property: Focus on Patent Pools and 
a Review of Other Mechanisms. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of 
Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org. 
© 2007. A Krattiger and SP Kowalski. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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KRATTIGER & KOWAlSKI 
a context of available IP assembly tactics and ex­
plain the advantages and disadvantages of each. 
2.	 Ip	ASSEMBLy: 	MECHAnISMS	And 
opTIonS	In pERSpECTIvE 
A complex mix of factors drives technologi­
cal innovation, but they essentially boil down 
to national policies, international agreements, 
and market dynamics. Innovation is the starting 
point for making inventions commercially and 
socially useful, but innovation alone will not lead 
to technological products that can produce goods 
or services. An invention must be assembled by 
putting together the patents and other forms of 
intellectual property from third parties. In-licens­
ing is the best-known mechanism for intellectual 
property assembly, and patent pools are a com­
plex form of licensing. But other mechanisms are 
also standard corporate approaches, including: 
•	 mergers and acquisitions (M&As) 
•	 strategic alliances (collaborations, joint 
ventures, corporate partnerships) 
•	 licensing (principally IP bundles compris­
ing an entire range of inventions required 
to practice, also called freedom to operate) 
By itself, however, the assembly of IP will not 
make an invention commercially useful; many 
other steps are required, ranging from regula­
tory to the access of know-how. From a broader 
perspective, assembly and licensing can be fa­
cilitated through a range of mechanisms. These 
are summarized in Table 1. In the context of 
this Handbook, the range of mechanisms listed 
also include capacity-building services that more 
broadly deal with technology transfer. 
2.1 Royalty collection agencies 
In its simplest form, a license collection agency 
is a mechanism whereby one entity collects roy­
alties on behalf of its members for a small fee. 
In this situation, the members make deals and 
set royalty rates, either bilaterally or multilater­
ally. The multilateral system is best known in the 
music business. Many restaurants and bars, for 
example, have jukeboxes with hundreds of CDs 
where customers insert money and select songs 
from individual CDs. Each time a song is played, 
a percentage of the revenue goes to the publisher 
of the CD and to the artist. In the United States, 
the American Society of Composers, Authors, and 
Publishers (ASCAP), composed of over 170,000 
artists and publishers of every kind of music, pro­
tects the rights of its members by licensing and 
distributing royalties for the nondramatic pub­
lic performances of their copyrighted works.3 
ASCAP makes giving and obtaining permission 
to perform music simple for both creators and us­
ers of music, and its licensees encompass all who 
want to perform copyrighted music publicly. 
2.2 Information clearinghouses 
The term clearinghouse derives from banking in­
stitutions and refers to the mechanism by which 
checks and bills are exchanged among member 
banks so that only the net balances need to be 
transferred in cash. Today, the term has much 
broader meaning and includes any mechanism 
whereby providers of goods, services, or infor­
mation are matched. The CBD (Convention on 
Biological Diversity) clearinghouse4 for biodiver­
sity aims to promote and facilitate technical and 
scientific cooperation, develop a global mecha­
nism for exchanging and integrating information 
on biodiversity, and develop the necessary human 
and technological network. Information clearing­
houses also provide entry to a country’s biotech­
nology (for example, Finland5), as do training 
clearinghouses that offer training for biotechnol­
ogy technicians (for example, BioLink6), and in­
dustry links, updates, news, and job markets (for 
example, BioPortfolio7). 
2. Technology clearinghouses 
A comprehensive Web-based clearinghouse can 
lower the transaction costs and increase partici­
pation. In practice, however, such gains have not 
been realized with IP exchanges. This is because 
the applications specified in patents are highly 
heterogeneous, often difficult to define, and 
can only be valued after considerable experi­
mentation and refinement has taken place and 
then only within the technological application.8 
However, IP exchanges are not very common. 
Few of them are complete enough to allow a 
12 | HANDBOOK OF BEST PRACTICES 
         




















Table 1: Summary of IP Assembly Mechanisms and Options
 
Type of Mechanism or Service Characteristics Examples 
Royalty collection agencies: Useful if licensing industries American Society of 
Collection of royalties for a small are already established; can be Composers, Authors,
fee by one entity on behalf of its created by industry itself and Publishers;
members British Society of 
Plant Breeders 
Information clearinghouses: Useful for the exchange of BioBin,BINAS; portals 
Broad term denoting a specific information related to to countries or 
mechanism matching providers an activity or industry; does not industries biotech,
of goods, services, or info. facilitate tech transfer per se training programs 
Technology clearinghouses: Appropriate for general Virtual trading floors,
purpose technologies, platform patent auctions 1. Web-based IP auctions and 
technologies, bundles; limited licensing, including business-
ability to spread tech transfer to-business 
further 
2. Public-sector initiatives Appropriate for development; Public Intellectual 
dealing with training, good furthers tech transfer Property Resource for 
practices, and the bundling of Agriculture (PIPRA) 
technologies 
open-source innovation Potentially appropriate for open- Barry Nalebuff and 
clearinghouses: source licensing and diffusion of Ian Ayres “Why Not?”
Web sites on which anyone can tangible research materials or HalfBakery 
post ideas or inventions, and 
anyone is allowed to turn the 
ideas into products 
Brokers and other forms Appropriate for charting new African Agricultural 
of facilitators: territory and bringing public and Technology 
Typically focused on creating private actors closer Foundation (AATF);
public–private partnerships, Global Alliance 
providing “managed” tech for Vaccines and 
transfer Immunization (GAVI) 
(Continued on Next Page) 
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Type of Mechanism or Service Characteristics Examples 
Ip	 management services:
Comprises a wide range of 
entities, both public and 
private, assisting institutions in 
managing their IP assets 
Good for addressing systemic 









Ip	 commercialization agents: 
1. Commercial entities dedicated 
to commercialization of third-
party intellectual property 
Highly effective business model;
useful to learn from their 
experiences and adapt to serve 
nascent private sectors. 
BTG Ltd.; certain 
specialized law firms 
2. Mixed commercial and public- 
good objectives 
Useful to learn from their 
experiences and adapt the model 




A range of services for M&As,
spinouts, including IP audits,
business valuation, due diligence 
There could be a need for a 
nonprofit merchant-bank-type 
institution to provide services to 





A voluntary agreement between 
two or more patent owners to 
license one or more of their 
patents to one another or third 
parties 
Pooling unlikely to change the 
underlying structural barriers to 
technology transfer; difficult to 
establish because industry players 
have divergent strategic interests;
in partial/modified form, effective 








other public technology transfer
and financing mechanisms 
Range from education and training institutions, to 
consortia in health, and to certain specialized UN 




strategic partnerships, and 
corporate partnering 
Some of the most ubiquitous and efficient systems 
of technology transfer, rarely requiring public sector 
assistance; different government policies either 
encourage or thwart them 
Table 1 (continued) 
Source: Krattiger.2 
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prospective licensee to assemble all the needed 
licenses to obtain freedom to operate (FTO). In 
addition, actually negotiating with a company 
often not only allows for cross-licensing but also 
for the transfer of know-how or trade secrets. 
And finally, IP owners typically use their patent 
portfolios as a strategic tool, a practice not con­
ducive to wide licensing. Merely clicking on a 
Web link, downloading a standard license, and 
wiring money is rarely sufficient for technology 
transfer to occur. 
The Public Intellectual Property Resource 
for Agriculture (PIPRA),9 on the other hand, as a 
managed IP exchange initiative involving univer­
sities, foundations, and nonprofit research insti­
tutions, seeks to make agricultural technologies 
more easily available so that subsistence crops for 
humanitarian purposes in the developing world 
and specialty crops in the developed world can 
be more rapidly developed and distributed. The 
rationale for PIPRA is that intellectual property 
is often unwillingly encumbered. Universities, 
for example, typically grant worldwide exclusive 
licenses. Changing these licensing policies and 
retaining the rights for humanitarian uses in the 
developing world would make it much easier to 
transfer intellectual property and tangible prop­
erty (TP) from universities to the developing 
world. 
PIPRA brings together public sector institu­
tions to collaborate and bundle their licensed and 
unlicensed technologies, as “shared technology 
packages,” making the technologies more readily 
available to member institutions for commercial 
licensing or for designated humanitarian or spe­
cial use. As part of this effort, a database of pat­
ented agricultural technologies is being developed 
to inform researchers about FTO, allowing them 
to modify their research plan to include more li­
censable technologies (IP and TP) or public ones. 
PIPRA is also currently exploring the creation of 
a patent pool. 
2.	 Open-source innovation clearinghouses 
One special category of clearing houses is worth 
mentioning, the open-source innovation clear­
inghouse. Consider a Web site initiated by two 
Harvard Business School professors, economist 
Barry Nalebuff and law professor Ian Ayres, 
to prove that innovation is a skill that can be 
taught. One hotly debated idea at the site in re­
cent months is the so-called “reverse 900 num­
ber”—where telemarketers pay people to accept 
calls. Their system of innovation is growing on 
the Web10 and deploys economics, game theory, 
psychology, and contract law to argue that inno­
vation can be routinized and institutionalized. 
Another Web initiative, called HalfBakery,11 
allows anyone to post ideas for innovative prod­
ucts and services. Anyone can turn the ideas into 
marketable products if they wish, without the 
need for licenses. The service quickly gained in­
ternational fame when what may have appeared 
as “half baked ideas” were turned into commer­
cially successful products, though none, as yet, in 
the area of health and agriculture. 
This mechanism should not be confused with 
open-source licensing.12 With software, open-
source licensing is essentially the licensing of in­
ventions without patent protection—the only 
requirement is that any licensee must agree to 
make available to others any improvements in the 
invention or technology. Applying this established 
mechanism of open source from software to bio­
technology, where source code has no real equiva­
lent, has not worked as yet. New terminology 
might be appropriate, such as distributed, inter­
net-based collaboration or “non-proprietary peer-
production of information-embedding goods.”13 
One attempt to implement open source is the 
Biological Innovation for Open Society (BiOS).14 
Essentially, BiOS is a specific form of a patent li­
cense. It is really another way to describe a pat­
ent license with some novel terms. To what extent 
BiOS will foster innovation remains to be seen. 
2.	 Honest brokers and other 
forms of facilitators 
Honest broker is a term often used in peace negoti­
ations but it has also been used by nonprofit orga­
nizations engaged in public–private partnership 
building. One institution that had its foundation 
as an honest broker is the International Service 
for the Acquisition of Agri-biotech Applications 
(ISAAA).15 During the 1990s, it operated primar­
ily as a facilitator, matching available technologies 
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to meet identified needs, brokering technologies, 
and building capacity by transferring knowledge 
and know-how between companies in developed 
countries and the public sector in developing 
countries. ISAAA addressed other constraints in 
biotechnology transfer, such as regulatory issues. 
In the last few years, the organization has shifted 
its strategy toward knowledge sharing. 
A similar, more-recent institutional mecha­
nism is the African Agricultural Technology 
Foundation (AATF).16 Like PIPRA, AATF is 
emerging from a Rockefeller Foundation initia­
tive. AATF recognizes that new and unique pub-
lic–private partnerships are needed to remove 
many of the barriers that have prevented small-
holder farmers in Africa from gaining access to 
existing agricultural technologies. Focusing on 
the creation of these public–private partnerships, 
it seeks to dramatically improve access to agricul­
tural technologies, materials, and know-how, at 
the same time promoting efforts to create sustain­
able markets. 
A similar organization in human health bio­
technology is the Global Alliance for Vaccines 
and Immunization (GAVI).17 Created in 1999, it 
functions as a broker for private and public sec­
tor entities committed to expanding the use of 
vaccines in the developing world. International 
organizations, governments, vaccine industry, 
research institutions, and major philanthropists 
collectively form a dedicated partnership serving 
the shared GAVI objectives. It includes as a sub­
sidiary, or financial arm, the Vaccine Fund, which 
sponsors GAVI’s objectives in poorer countries. 
The alliance also has programs to stimulate the 
vaccine industry to develop and supply vaccines 
that are vital to low-income countries. GAVI acts 
more at the product transfer level, whereas ISAAA 
and AATF function somewhat further upstream. 
ISAAA initially also aimed at charting new terri­
tory and creating models (which are more time 
consuming) rather than transferring large quanti­
ties of technologies. 
2. IP management services 
The best-known IP management services are law 
firms that specialize in patenting and licensing 
and management consultants, such as KPMG, 
the Boston Consulting Group, and Ernst & 
Young. These commercially oriented entities are 
discussed in the next section, but let us first focus 
on the nonprofit players in this field. A new orga­
nization headquartered in the United Kingdom, 
the Centre for the Management of IP in Health 
R&D (MIHR),18 essentially acts as a service to 
public sector organizations in developing coun­
tries (and some private ones) to manage their 
intellectual property (in-house–generated, in-li­
censed, and to-be in-licensed) more authorita­
tively. It assumes that health programs that man­
age intellectual property well are more effective at 
mobilizing resources, technologies, and partners 
to deliver improved health care to the poor. 
2. IP commercialization agents 
Many types of “consulting” services fall broadly 
within this category, but only one institution is 
solely dedicated to the profitable commercializa­
tion of third-party intellectual property in the 
fields of health, medicine, and other biotechnolo­
gies: BTG Ltd.,19 formerly known as the British 
Technology Group. Perhaps the world leader in 
commercializing novel technologies, BTG op­
erates globally with a focus on Europe, North 
America, and Japan. The firm combines a strong 
commercial focus with a deep understanding of 
how to develop innovation, enhance intellectual 
property, and achieve critical development mile­
stones. Clients include public research centers 
and global technology companies, from start­
ups to multinational companies. It functions as 
a retainer for technology innovators, charging 
fees and sharing in revenues generated from its 
services. 
In addition to services in several areas, the 
company seeks licenses for the technologies they 
manage. This includes assistance in seeking ven­
ture capital, the management of startups around 
platform technologies, and R&D funding to 
ensure that the technologies in BTG’s portfo­
lio become commercially viable. To accomplish 
this, BTG acquires or in-licenses promising 
technologies, assists in patent protection of in­
ventions, forms alliances to advance inventions 
through an R&D phase, and develops technol­
ogy marketing strategies. In effect, BTG pools 
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CHAPTER 2. 
necessary technologies centered on the core in­
novations it manages, in order to increase the 
value of its portfolio. On the development side, 
the most prominent enterprise is the Concept 
Foundation,20 headquartered in Thailand, which 
provides a mechanism to turn intellectual prop­
erty, developed or owned by international or­
ganizations, into competitive and cost-effective 
products to be distributed at the lowest possible 
cost, especially into the public sector healthcare 
channels of developing countries. This intellec­
tual property is typically owned in the form of 
data from medical research and clinical trials, 
data from pharmacological studies, manufactur­
ing instructions, and so on. In some cases, the in­
tellectual property owned by international orga­
nizations such as the World Health Organization 
(WHO) is enhanced through IP donations from 
pharmaceutical manufacturers earmarked for 
public sector healthcare services in the develop­
ing world. The licenses are negotiated by highly 
experienced foundation staff led by a former se­
nior executive in pharmaceuticals. 
2. Merchant banks 
The term merchant bank was developed hundreds 
of years ago to describe well-financed organiza­
tions that sought high returns on their invest­
ments in return for predictable risk (which was 
also the original idea of a limited-liability com­
pany). Today’s investment bank services include 
IP audits, business valuation, due diligence, and 
fairness opinions,21 acting as a confidential advi­
sor in preparing divestiture, managing the entire 
process of initial public offerings (IPOs), market­
ing divestitures, finding acquisition targets, struc­
turing transactions, providing financing, facilitat­
ing financing, and refinancing existing debt. 
Merchant Banks are essentially full-service 
centers for M&As, financial management, agree­
ments, required government filings, antitrust is­
sues, valuations, due diligence, and so on. Their 
services are crucial for any type of business, large 
or small. 
2. Other technology transfer mechanisms 
It would be negligent to fail to mention other 
types of technology transfer facilitators, ranging 
from education and training institutions (for ex­
ample, universities across the world), to interna­
tional agricultural research centers (for example, 
the CGIAR), to health consortia (for example, the 
Program for Appropriate Technology in Health 
[PATH]), or the many specialized UN programs. 
Company-to-company arrangements (including 
collaborations, joint ventures, strategic partner­
ships, and corporate partnering) are some of the 
most ubiquitous and efficient systems of technol­
ogy transfer. 
. foCuS	 on pATEnT	pooLS 
A patent pool is “an interchange of patent rights by 
several companies. Either one or more of the patent 
owners, or some separate entity, has the right to li­
cense others under the pooled patents.”22 In essence, 
a patent pool is a voluntary agreement between 
two or more patent owners to license one or more 
of their patents to one another or to third par­
ties. In other words, they are “the aggregation of 
intellectual property rights which are the subject of 
cross-licensing, whether they are transferred directly 
by patentee to licensee or through some medium, such 
as a joint venture, set up specifically to administer 
the patent pool.”23 And further, “The rationale for 
patent pools is simple: by reducing the number of nec­
essary transactions and by simplifying patent land­
scapes, they can reduce transaction costs and facilitate 
technology transfers. Patent pools have the obvious 
but important advantage of considerably reducing 
the number of licences that need to be negotiated.”24 
Although there are many forms of patent 
pools, such an arrangement fundamentally con­
sists of the interchange (cross-licensing) of rights 
to essential patents by a number of companies, 
as well as an agreed framework for out-licensing 
the pooled intellectual property to third parties, 
including an agreed-pricing and royalty-sharing 
scheme. Patentees can provide licenses directly to 
licensees, or licenses can be provided indirectly 
via a licensing entity that is specifically authorized 
to administer the patent pool.25 “A key difference 
between a patent pool and a cross-licensing agree­
ment is that, in the former, the patent owners agree 
to license to third parties that do not themselves con­
tribute patents to the pool.”26 
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.1 The main pros and cons 
Patent pools are “competitively beneficial in that 
they may help resolve patent conflicts, make assem­
bled patents in the pool available to others, or resolve 
disputes over blocking patents. On the other hand, 
a patent pool is a horizontal agreement among com­
petitors and carries the potential for abuse and as 
a cover for an anticompetitive cartel.”27 Hence, a 
patent pool, depending on how it is organized 
and implemented, represents a potential double-
edged legal sword: able to cut through patent-
thicket blockages to facilitate access to critical 
technological innovations, yet also potentially 
honed in such a way that antitrust issues arise. In 
other words, patent pools can facilitate access by 
overcoming IP obstacles via assembly of patents 
or can inhibit access via monopolization of in­
tellectual property (complete with inequitable re­
munerations) and shielding of invalid patents.28 
In addition, from a practical perspective, it 
is important to know what patent pools can, and 
cannot, facilitate. For example, patent pools serve 
the assembly of intellectual property, not the 
transfer of technologies per se. Although the U.S. 
Department of Justice (DOJ) along with the U.S. 
Federal Trade Commission (FTC) have observed 
that “by promoting the dissemination of technol­
ogy, cross-licensing and pooling arrangement are 
often procompetitive,” it is critical to understand 
that, in the context of technology transfer and 
collaboration with developing country partners, 
patent pools would mainly assist with licensing in­
tellectual property. That is, such developing coun­
tries would not necessarily benefit equally from 
sharing know-how, show-how, and trade secrets. 
Hence, patent pools can serve certain purposes 
and confer benefits, but they are not an IP man­
agement panacea. 
Still, a patent pool can have advantages: in­
tellectual property can be licensed through an 
efficient one-stop shop, stacking licenses can 
be eliminated, patent litigation can be averted, 
and institutionalized exchanges of otherwise 
proprietary know-how (trade secrets) can be fa­
cilitated.29 Significant research and administra­
tive costs would decrease dramatically. Speed and 
efficiency would be greatly increased. A patent 
pool is an IP management tactic that can have a 
significant positive affect on facilitating access to 
innovations, yet, it is important to recognize that 
a pool may not be the only way to achieve these 
objectives, and that, in the overall context of best 
practices in IP management, there may be other 
equally effective approaches. 
Patent pooling has been more focused in 
the realm of DVD technologies, where it makes 
sense to generate revenue through sales and not 
licensing. Such patent pools help to clear block­
ing positions. But with regard to patent pools for 
public-health initiatives, it appears that there is 
less likelihood that companies will give up their 
exclusive IP rights, depending, of course, on the 
technologies under consideration. This is because 
pools tend to arise organically because the own­
ers of intellectual property are mutually stymied; 
this, for example, has not yet happened for vac­
cines. The technology is not at the same level of 
maturity as in the DVD industry. Patent pools 
are especially useful for developing industry stan­
dards. Hence, although patent pools have been 
successfully implemented in various industries 
(notably electronics), their application to health 
and agriculture may still be, relatively speaking, 
premature. The pros and cons are summarized 
in Table 2. 
.2 Organization and establishment 
Organizing and establishing a patent pool is not 
a simple matter.30 It is a long, complex, multistep 
process, with many technical, legal, and business 
challenges. It therefore requires the interdisciplin­
ary coordination of efforts by attorneys, scientists, 
business professionals, and other experts. Setting 
up a successful patent pool therefore requires or­
ganization and planning, based on sound infor­
mation and solid analysis. These conditions hav­
ing been met, the operational, business and legal 
aspects of the pool can be effectively managed 
and successfully executed. 
A ten-step checklist for setting up a patent 
pool would include the following considerations: 
1.	 Determining the validity of the patents to 
be pooled 
2.	 Determining the essentiality of the patents 
being considered for inclusion in the pool 
3.	 Patent analysis by an independent expert 
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4.	 Nonexclusive licenses to the pool 
5.	 Licensees must be free to develop and use 
alternative technologies 
6.	 Grant-back licensing provisions, from li­
censees to licensors, on improvements to 
essential patents and with reasonable terms, 
should be available on a nonexclusive basis 
7.	 Royalties should be distributed among the 
licensors according to a formula set forth 
in the patent pool agreement 
8.	 Royalties paid to the pool by licens­
ees should be fair, reasonable, and 
nondiscriminatory 
9.	 Sensitive business information must be 
safeguarded 
10. Appropriate dispute 	 resolutions, prefer­
ably, independent and neutral, should be 
part of the patent-pool agreement 
A ten-step procedure for setting up a patent 
pool would include the following activities: 
1.	 Observation of a potential patent thicket 
that could be overcome by an appropri­
ately structured patent pool 
2.	 Patent and scientific experts identify essen­
tial technologies 
3.	 Patent experts identify patents and 
patentees 
4.	 Working group set up by counsel 
5.	 Initial agreement among patentees to move 
forward with pool development 
6.	 Further evaluation of patents by both sci­
entists and patent experts 
7.	 Agreement on patent-pool conditions 
8.	 Signing of patent-pool consortium 
agreement 
9.	 Antitrust analysis and evaluation as per 
the jurisdictions under consideration (for 
example, the United States, Europe, and 
Japan) 
10. Execution of patent-pool agreement 
Patent pools are set up by the patent holders, 
who function both as shareholders of the pool 
and also as financiers of the designated licensing 
authority (if the patentees themselves do not func­
tion as the actual licensors). The patent holders, 
Table 2: Summary and the Pros and Cons of Patent Pools
 
Pros Cons 
Integrates complementary Difficult to agree on the value of 
technologies individual patents contributed to a pool 
Reduces transaction costs Complex to set up and avoid antitrust
problems (collusion and price fixing) 
Clears blocking positions 
May inflate licensing costs through 
Avoids costly infringement nonblocking or unnecessary patents 
litigation 
Complex when many patents are 
Promotes the dissemination of under litigation, as is the case with 
technology biotechnology 
Levels the playing field May shield invalid patents and thus 
prevent much technology from entering 
the public domain 
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KRATTIGER & KOWAlSKI 
therefore, establish and retain authority over the 
licensing provisions.31 
. Examples of pools 
One of the first such patent pools was created for 
the manufacturing of sewing machines in the mid­
19th century.32 Other examples of early patent pools 
include aircraft manufacturing, glass manufactur­
ing, and radio technology. In each case, the pool 
contributed significantly to industry standards (for 
example, radio waves). More recently, patent pools 
were created to enable standard settings in DVDs, 
video games, and MPEG2 video-compression 
technology. Interestingly, private and public sector 
participants formed the latter in 1997: Columbia 
University, Fujitsu, General Instrument, Lucent, 
Matshushita, Mitsubishi, Philips, and Sony. 
Typically, however, patent pools are consti­
tuted by members who each contribute patents 
in their respective fields. Whether or not devel­
oping country institutions will qualify to become 
members of patent pools will, naturally, depend 
on their respective potential contributions. 
The following types of patent pools exist 
today: 
•	 internal, company specific. For example, 
DuPont combining technologies through 
internal development or Syngenta comple­
menting its internal portfolio with outside 
technology through licensing and M&As; 
critical challenge is to keep internal innova­
tion ongoing and tightly managed 
•	 portfolio pooling. Internal technology sup­
plemented with third-party technologies, 
for example, Microsoft; critical challenge is 
to have a dynamic team handling in-licens­
ing and aligning strategies closely with the 
overall corporate strategy 
•	 cooperative pooling. Companies agree to 
combine their technologies and allow them 
to be managed by a separate entity, typi­
cally for standard-setting purposes; critical 
challenge is to avoid antitrust issues 
•	 third-party aggregations. For example, 
strategy practiced by BTG Ltd.; critical 
challenge is to work around antistacking 
provisions that are very common in bio­
technology licenses 
•	 forced pooling. For example, rarely en­
forced compulsory licensing and the pool­
ing forced by the U.S. government shortly 
after the radio was invented 
. Patent pools in biotechnology 
In biotechnology, unlike in much of the electron­
ics industry, standard setting is not really an issue, 
which may explain why patent pools have not 
been necessary for the biotechnology industry to 
commercialize products (for example, in the de­
velopment of drugs and vaccines). Nonetheless, 
as the biotechnology industry continues to grow 
and mature, and with specific sectors becoming 
commercially focused, there may be fundamen­
tal challenges that can be effectively addressed via 
patent pooling. 
For example, the issue of “research tools” in 
the life sciences has led to a call for patent pooling 
in the U.S. companies, and institutions involved 
in biotechnology research are encountering wide­
spread delays due to the near-universal patent­
ing of research techniques that were traditionally 
available in the public domain. Uncertainty over 
the prospective costs of licenses, royalty stacking 
that creates uncompetitive costs, delays in obtain­
ing licenses, and the differing definitions of pure 
research versus product development across differ­
ent territories are all inhibiting biotechnology 
R&D in many areas. 
Similarly, one of the biggest public concerns 
voiced against the PTO for its practice of granting 
of patents for inventions in biotechnology, par­
ticularly in genomics, is the difficulty of accessing 
patented inventions for basic biological research 
and R&D. One solution to this constraint is to 
form patent pools, a mechanism successfully im­
plemented by other industries. 
In a rapidly changing field such as biotech­
nology, patent pools can have significant pro-
competitive effects and may improve an indus­
try’s ability to survive. For developing countries, 
patent pools may eventually become even more 
important because companies can easily obtain 
the licenses required to practice a particular tech­
nology, which reduces transaction costs and facili­
tates the rapid deployment of new applications in 
health and agriculture. Hence, there is no reason 
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that a novel type of patent pool, centered on pref­
erential licensing terms to developing countries, 
could not be established. 
Still, when considered from the perspective 
of the overall biotechnology industry, while pat­
ent pools may be very useful for assembling IP re­
lated to platform technologies that need to estab­
lish industry-wide standards (for example, DVD, 
MP3), the value of patent pooling is much less 
when industry interests are not aligned (still ma­
turing industries), which, indeed, is the general 
case with biotechnology. Hence, in the context of 
R&D in many biotechnological applications, for 
example, with respect to vaccines—an evolving 
field with no platform and with no technology 
clearly in the lead—industry interests can hardly 
be considered aligned. Indeed, if a technology has 
not matured to the stage where industry standards 
can even be contemplated, then a patent pool 
would likely not be the favored option. At these 
earlier stages in the R&D of innovative technolo­
gies, few companies will have an interest in giving 
their rivals preferential access to their technolo­
gies. Companies also typically become cautious 
about antitrust issues when a patent pool is sug­
gested, which might also hinder participation. 
As an illustrative example of the current situ­
ation with (at least most of ) the biotechnology 
industry and the potential for using patent pools, 
Gaulé draws our attention to the recent SARS 
outbreak: 
Shortly after the severe acute respiratory syn­
drome (SARS) outbreak in February 2003, patent 
applications covering sequences of the genome of 
the SARS coronavirus were filed by several research 
teams around the globe. Some have argued that this 
may result in a complex, uncertain IP situation that 
could delay the development of SARS vaccines and 
diagnostic tools. As a result, the four parties known 
to own key patent applications (CDC) have ex­
pressed their willingness to form a patent pool and 
enable wide access to the SARS genome. But con­
sider the differences between the SARS patent pool 
and the consumer electronics pools. The SARS patent 
pool will not be in an industry characterized by all-
important network effects or be closely linked to a 
standard. For the moment, the licensors are not ver­
tically integrated firms but universities and public 
institutions, and so there will be far fewer licensees. 
Most importantly, however, the commercial products 
in which the licensed technology will be embedded 
do not yet exist and will be developed by the licensees 
after extensive R&D efforts. Therefore, the licensing 
policy of the SARS patent pool might be quite differ­
ent from other modern patent pools.33 
However, the use of patent pools in biotech­
nology will likely increase as sectors of the indus­
try mature into focused, identifiable technologies 
and products/services (as has been the case in the 
electronics industry). One area where this ap­
pears to be the case is diagnostic genetics, that 
is, disease-specific (for example, breast cancer and 
cystic fibrosis) diagnostics. This indeed appears to 
be an example of a rapidly emerging area of the 
biotechnology industry where patent pools might 
be applicable and advantageous. Unlike the gen­
eral area of genomics, which is broadly diverse, 
diagnostic genetics is commercially focused on 
identified diseases with clear industry standards 
(mutations for analysis), and the players in the 
field share common goals. Hence, patent pools, 
narrowly constructed to address the diagnosis of 
specific polymutational diseases (for example, 
cystic fibrosis), could have great utility in over­
coming IP thickets that inhibit access to advances 
in genetic diagnostics.34 
Those who advocate patent pools as a solution 
to a general problem with assembling intellectual 
property related to biotechnological advances in 
health and agriculture should keep in mind that 
they embody many challenges; for example, in ad­
dition to the presence, or lack thereof, of industry 
standards, patent pools are expensive to establish 
and maintain. Hence, unless a given technology 
reaches a certain economic threshold, there is no 
financial incentive to establish a patent pool. The 
economic feasibility of a pool is determined by: 
•	 number of pool participants 
•	 number of patents held by each pool 
participant 
•	 likelihood of a patent being useful for a 
given platform 
•	 number of patents required to assemble a 
viable platform 
•	 market value of the assembled platform 
HANDBOOK OF BEST PRACTICES | 11 
  
     
 
	
       
      
      
      
     
       
         
       
     
      












      
     
      
       
       




      
    
 
     
     
      
     
     
      
       
 
KRATTIGER & KOWAlSKI 
•	 cost to assemble and maintain the pool 
As the biotechnology industry continues 
to grow and mature, the applicability of patent 
pools will also likely increase. 
. Legal concerns 
One reason why patent pools are often ap­
proached with caution is because U.S. antitrust 
law has the reputation for precariously situating 
patent pools on the borderline between allowed 
monopolies and antitrust violations. Although the 
legalities of forming patent pools exceed the scope 
of this chapter, it is worth noting that the U.S. 
Department of Justice (DOJ) along with the U.S. 
Federal Trade Commission (FTC) have published 
guidelines for patent pool applications and require 
an opportunity to review applications for them.35 
The PTO has summarized the DOJ/FTC 
patent pooling antitrust guidelines, and this 
serves as a concise template for understanding the 
potential antitrust implications of patent pools.36 
When making antitrust determinations, courts 
consider these guidelines as part of a multifactor 
weighing “rule of reason” analysis.37 What follows 
is a brief excerpt from the PTO paper. 
Since 1979, the FTC has had a similar proce­
dure, in which businesses may seek FTC advisory 
opinions concerning proposed business practices. 
These procedures led to Justice Department and 
FTC policies in the IP licensing area, and in 1995, 
these agencies issued Antitrust Guidelines for the 
Licensing of Intellectual Property, “IP Guidelines,”
which sets forth their enforcement policies in this 
area. The IP Guidelines specifically address pooling 
arrangements involving IP owners and their rights. 
In particular, the IP Guidelines state that IP 
pooling is procompetitive when it: 
•	 integrates complementary technologies 
•	 reduces transaction costs 
•	 clears blocking positions 
•	 avoids costly infringement litigation 
•	 promotes the dissemination of technology 
The IP Guidelines also discuss that excluding 
firms from an IP pool may be anticompetitive in 
these circumstances: 
•	 The excluded firms cannot effectively com­
pete in the relevant market for the good in­
corporating the licensed technologies. 
•	 The pool participants collectively possess 
market power in the relevant market. 
•	 The limitations on participation are not 
reasonably related to the efficient devel­
opment and exploitation of the pooled 
technologies. 
Anticompetitive effects may also occur if the 
pooling arrangement deters or discourages par­
ticipants from engaging in research and develop­
ment that is more likely when the arrangement 
includes a large fraction of the potential research 
and development in an innovation market. 
The DOJ has applied these guidelines in 
considering and approving three proposed patent 
pools. Its first review set forth the following ad­
ditional guidelines: 
•	 The patents in the pool must be valid and 
not expired. 
•	 These can be no aggregation of competitive 
technologies and setting a single price for 
them. 
•	 An independent expert should be used to 
determine whether a patent is essential to 
complement technologies in the pool. 
•	 The pool agreement must not disadvan­
tage competitors in downstream product 
markets. 
•	 The pool participants must not collude on 
prices outside the scope of the pool, for ex­
ample, on downstream products. 
Currently, the guidelines have been “collapsed” 
into the following two overarching questions: 
1. Whether the proposed licensing program is 
likely to integrate complementary patent rights 
And if so: 
2. Whether the resulting competitive benefits 
are likely to be outweighed by competitive 
harm posed by other aspects of the program 
.	 ConCLuSIonS 
Patent pools have received much attention in 
recent years as a possible solution to the patent 
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CHAPTER 2. 
thicket. This review shows that patent pools are 
indeed one possible option, but others should 
also be considered. Organizing and establishing 
a patent pool is not a simple matter. It is a long, 
complex, multistep process, with many techni­
cal, legal, and business challenges involving the 
interdisciplinary coordination of efforts by attor­
neys, scientists, business professionals, and other 
experts. Setting up a successful patent pool there­
fore requires organization and planning, based on 
sound information and solid analysis. 
As procompetitive arrangements, patent pools 
are aimed at IP assembly. They seek to resolve pat­
ent conflicts (reducing litigation), to settle dis­
putes over blocking patents (accelerating product 
development and FTO), and to facilitate arrange­
ments for licensing patents in the pool to outside 
members (accelerating the setting of standards and 
reducing licensing transaction costs). They exploit 
economies of scale by integrating the technical 
complementarities of the pool members. 
From a legal perspective, pools require care­
ful antitrust considerations to avoid potential, 
perceived, or real anticompetitive behavior by 
pool members or, more importantly, by the pool 
itself. From an operational perspective, only es­
sential patents can be included in a pool. And fi­
nally, from a business perspective, the interests of 
the various IP holders need to be aligned in order 
to bring them to the table (pools are invariably 
voluntary arrangements). n 
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CHAPTER 3.1 
The Courts and Innovation
 
pauline newMan, Judge, U.S. Court of Appeals for the Federal Circuit, U.S.A. 
ABSTRACT 
Established and enforceable rules of law can provide just 
and expeditious resolution of the disputes that are inevi­
table in vigorous commerce. But in the rapidly evolving 
subject matter of biotechnology, this science can bring to 
court issues for which there is no precedent and about 
which there is no consensus. The rule of law, however, is 
vibrant, adapting to the evolving contexts of science and 
technology. In today’s era of rapid technological change, 
jurisprudence provides the stability of the law, while re­
flecting the social implications of the science. But the 
scientific and technologic issues of today, such as arise in 
IP disputes, must also be correctly decided to promote a 
uniform and predictable application of the law that pro­
motes commercial stability adequate to support industrial 
innovation and the national interest. 
1. InTRoduCTIon 
The role of courts in technology development, 
protection, transfer, and commercialization, in 
biotechnology as in all fields, is a combination of 
the traditional role of courts in dispute resolution 
and the common-law role of courts in the evolu­
tion of law. In a national and world economy that 
is increasingly technology based and yet governed 
by jurisprudence reflecting cultural norms, new 
fields of science and technology propel the courts 
into proceedings and decisions of economic and 
societal impact. 
With respect to commerce and trade, legal 
systems have been described as having three mis­
sions. The first is to establish the rights and rules 
of property ownership, including intellectual 
property (IP). The second is to protect property 
rights from illegal disposition by guarding against 
civil wrongs and crimes. The third is to provide 
and enforce the rules of exchanges and transfers 
of property: the laws of contracts and sales and 
competition. In addition, legal systems establish 
rules for entering and leaving commercial activity, 
such as corporate law and bankruptcy law, and 
rules that promote competition and innovation, 
such as antitrust and IP law. In the development, 
management, and transfer of technology, effective 
legal systems provide stability and predictability 
of national and international force. This concept 
is globally applicable: strengthening the rule of 
law has broad-ranging implications for every 
country and organization. In regard to IP laws, 
which partake of so many interrelated policies, 
understanding how the courts balance conflicting 
policies can provide useful guidance to business, 
technology managers, and scientists. 
Litigation in the fields of today’s biological 
advances takes us to the edge, not only of science, 
but also of conflicting policies—often at the limit 
of judicial experience. Justice Holmes said, “The 
life of the law has not been logic: it has been ex­
perience.” Human experience absorbed science 
and technology into the common law and its 
basic concepts of property, human responsibility, 
and fairness. But litigation of disputes concerning 
Newman P. 2007. The Courts and Innovation. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org. 
© 2007. P Newman. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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NEWMAN 
science and technology is bringing new challenges 
to the search for justice through truth—the foun­
dation of judicial systems. 
Judges do not create national policy or in­
dustrial policy; such policy finds its origins in the 
cultures of nations, and its sustenance in the laws 
of nations. Yet policy comprehension is essential 
to judicial decisions. When technology and biol­
ogy are involved, then the jurisprudential over­
view (as well as the decision of individual cases) 
can affect the nation’s economy and the public 
interest. It will additionally have an even broader 
global impact. This Handbook arises from the 
premise that developing the products of science 
and technology is of profound public benefit, a 
benefit that requires both scientific and industrial 
participation. This is a many-faceted concept, yet 
today we exist in an era of such pervasive scien­
tific and technological advance that the develop­
ment of these benefits, and their movement into 
commerce and among nations, warrant our most 
concerned efforts. 
2. THE CouRTS And 
TECHnoLoGIC AdvAnCE 
The courts implement the rules by which society 
chooses to be governed. A reliable mechanism of 
dispute resolution eases the path to sustainable 
technologic advance, economic growth, and en­
suing public benefit. Established and enforceable 
rules of law can provide just and expeditious reso­
lution of the disputes that are inevitable in vig­
orous commerce. In the rapidly evolving subject 
matter of biotechnology, this science can bring to 
court issues for which there is no precedent and 
about which there is no consensus. In such areas, 
legal issues arising from developments in science 
and technology often reach the courts for primary 
resolution, and the decision can affect both eco­
nomic and technologic advance. 
Anexample is seenintheU.S.SupremeCourt’s 
decision in the Chakrabarty case in 1980,1 when 
despite predictions of the dire consequences of au­
thorizing patents on life forms, the Court opened 
the nation’s economy to industrial biotechnology, 
enabling commercialization of this nascent field, 
to the human benefit that is today bearing fruit. 
The growth of the biotech industry is a testament 
to judicial vision, for the U.S. Patent Office had 
refused to patent Dr. Chakrabarty’s modified bac­
terium that was designed to digest oil spills. It was 
the Court of Customs and Patent Appeals and the 
Supreme Court that held otherwise. 
Another example is seen in the U.S. Court 
of Appeals for the Federal Circuit, created for the 
purpose of revitalizing technologic innovation in 
a faltering economy. The industrial and scientific 
communities had recognized that national policy, 
as implemented in the courts, was inadequately 
supporting industrial innovation, a failure attrib­
uted to an inadequate understanding of the re­
lationships among scientific research, technologic 
advance, and commercial investment. The ad­
verse effects included a negative balance of trade, 
retrenchments in industrial R&D, mass layoffs of 
scientists and engineers, sparse capital formation, 
stagnation in productivity, and loss of interna­
tional competitiveness. 
Judicial misunderstanding of the system of 
patents and its purposes and processes was a pri­
mary problem. As a result, patents were not viewed 
as reliable support for commercial investment, for 
they could be litigated in circuit after circuit until 
they fell. And the Justice Department’s “nine no­
no’s” of patent licensing were a further disincen­
tive to technology transfer. During the economic 
recession of the late 1970s, the retrenchment of 
investment in new technologies was so severe that 
dramatic remedies were accepted—including the 
first major change in the federal judicial structure 
in a hundred years.2 
Thus the federal judicial system was restruc­
tured to provide a national appellate court that 
would receive all patent appeals throughout the 
nation, whether from the district courts, the 
International Trade Commission, or the Patent 
Office.3 The hope was that a single appellate court 
would better understand, and correct, the policy 
misperceptions that had led to a judge-made re­
duction of the patent incentive for investment in 
technologic advance. The goal was a uniform and 
predictable application of the law that would pro­
mote commercial stability adequate to support in­
dustrial innovation. The change was not without 
vigorous controversy, but it was implemented 
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CHAPTER .1 
with the congressional leadership of Wisconsin 
Representative Robert W. Kastenmeier and sena­
tors Robert Dole and Patrick Leahy. It was an ex­
traordinary and creative action to change the na­
tion’s court system as an incentive to technologic 
advance. And the effect of this juridical change 
was dramatic, as entrepreneurial business as well 
as established industry returned to developing 
new and improved technological products. 
The change in industrial activity based on a 
strengthened patent incentive surpassed the most 
optimistic expectations. One rarely sees so direct a 
relationship between judicial structure and com­
mercial vigor. 
.  THE EvoLvInG pATEnT JuRISpRudEnCE	 
The legal framework of technology movement 
into public availability through market forces 
partakes primarily of the law governing all com­
merce. As for all laws, the overarching consid­
eration is the national interest. Patent law is 
designed to serve as an incentive to promote 
technologic research and industrial commercial­
ization, not only to bring to the public the ben­
efits and conveniences of new technologies, but 
also to achieve a vigorous combination of indus­
trial products and employment and trade. These 
societal and economic policies undergird the laws 
of intellectual property. 
Starting about two decades ago, the U.S. 
Court of Appeals for the Federal Circuit methodi­
cally undertook to restore the patent law to the 
legal mainstream. In decisions applying across all 
areas of technology, the court implemented the 
patent statute and revived dormant legal princi­
ples. Some examples are the rulings that 
•	 summary judgment is as available in patent 
cases as in any other 
•	 consent judgments and settlement agree­
ments in patent cases are not contrary to 
public policy 
•	 an assignor can be estopped from challeng­
ing the validity of an assigned patent, as 
others are estopped who transfer property 
for value 
•	 infringement is a wrong and subject to rem­
edy like other torts 
•	 the measure of damages is to make the in­
jured party whole, as for other torts 
•	 patents are presumed valid, as the statute 
requires 
•	 proof of inequitable conduct in patent 
prosecution requires both materiality and 
deceptive intent 
•	 preliminary injunctions in patent cases are 
decided on the same criteria as in other 
fields (as recently clarified by the Supreme 
Court4) 
The court, in its first years, developed ob­
jective standards for determination of obvious­
ness (this topic is at present under review by the 
Supreme Court), applied the same law to the 
Patent Office and to the courts, eliminated appel­
late forum shopping, and generally restored the 
effectiveness of the patent system as support for 
industrial innovation. Much media attention was 
given to the “new strength” of patents. 
Subsequent decisions of the Federal Circuit 
and the Supreme Court were geared toward refin­
ing the law and adding precision, for many deci­
sions depend more on the science and technology 
than on the letter of the law. To this end, the court 
adjusted the roles of judge and jury in interpret­
ing patents. The Markman5 case, assigning the in­
terpretation of patent claims to the judge instead 
of the jury, has affected trial procedures as well 
as the content and interpretation of patents. This 
decision and its implementation are still not free 
of controversy. Another controversial decision, 
Festo,6 reduced the patentee’s access to unclaimed 
technological equivalents, generally limiting pat­
entees to what they actually described. The main 
emphasis of these decisions is the enhancement of 
predictability of patent scope, an emphasis that 
has led to requiring more technical description by 
the inventor and often more development of the 
inventive subject matter. The balance between a 
rigorous-notice function of patent claims and the 
cost of protecting the innovator against imitators 
who use the inventive concept but manage to skirt 
the claims warrants an objective evaluation of the 
benefits and obstacles presented by this direction 
of the law, as the interested communities seek the 
optimum policy and its legal implementation. 
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NEWMAN 
New issues of law are constantly arising, for 
developments in biological science and their ap­
plication present factual situations that do not 
easily fit into precedent, such as questions of pat­
entable subject matter, or the nature and conduct 
of scientific research. Such questions reach the 
courts when disputes arise; as, depending on the 
facts of the case, the courts try to implement the 
law in line with statute, precedent, and a judicial 
balance of practical economics, research incen­
tive, and fairness. With each judicial decision, 
precedent adds its weight to one or another com­
peting policy, for there are many facets to the legal 
and economic theory of intellectual property. For 
example, some theorists see patents primarily as 
an economic tool; some as founded on principles 
of natural right and fairness. Some are concerned 
lest the patent law impede the flow of ideas and 
knowledge; others suggest that without patents, 
fewer ideas and less knowledge would be gener­
ated, and even less used for public benefit. Much 
of the controversy concerning the role of patents 
arises, I believe, from vested interests that em­
phasize one or another of the purposes and uses 
of patent systems, as the courts apply a one-law­
fits-all structure to service the public and national 
interests. 
.  AdJudICATInG ISSuES of 
SCIEnCE And TECHnoLoGy 
Judicial interpretation and application of every 
aspect of IP law is challenged by the complexity 
of science and technology. In Thomas Jefferson’s 
day, an educated person could understand every 
known technological aspect of life. Today we liti­
gate questions whose scientific framework strains 
even persons within the corresponding discipline. 
These include the classical areas of technological 
applications of law, such as medical causation and 
product liability, as well as environmental issues 
and patent infringement; these questions also in­
clude new issues of constitutional and personal 
and commercial rights that flow from new scien­
tific knowledge and its applications. 
The scientific issues in litigation are rarely 
straightforward, and they tend to fall in incom­
pletely explored areas and are often intermingled 
with policy concerns. The ongoing scientific ad­
vances in biology and genetics come to court in 
many guises: there are issues of criminal behavior, 
employment, insurance, and medical and product 
liability, as well as intellectual property. No matter 
how finely tuned a judge’s judicial intuition, no 
matter how wise and benevolent, cases that turn 
on findings of science or technology cannot al­
ways be decided using the judge’s traditional tools 
of reasoned analysis, an instinct for credibility, 
and worldly experience. 
How then can the truths of science and tech­
nology be found in the courtroom? The just reso­
lution of issues that turn on such findings presents 
a profound challenge to the administration of jus­
tice. Despite this concern, most judges prefer not 
to depart from the procedures of the adversary 
system—not as a matter of principle but of expe­
rience. Judges learn that not all scientific questions 
have clear answers; we have learned that scientific 
truth is often a matter of the honest but divergent 
viewpoints of scientist witnesses and that many 
of the questions of science and technology that 
come to court do not have a firm answer. Scientific 
facts are not like the traditional facts of lawsuits, 
based on the human components of recollection 
and credibility. In traditional judicial fact finding 
there are gradations of truth or falsity, questions 
of weight and value of evidence. What judges call 
“facts” are matters on which there is a difference 
of opinion, while scientific facts are supposed to 
be objective and absolute. The problem is that for 
issues in litigation the scientific answer is often 
unknown at the time of the lawsuit. By requiring 
the judge to decide questions that the scientists 
have not decided—and perhaps cannot decide— 
on the present state of knowledge, the side with 
the burden of proof simply is penalized. 
Yet there is a natural partnership between 
jurisprudence and science, for both enhance our 
understanding of natural law. Both the law, and 
the science it deals with, progress along irregular 
pathways, via incremental steps in diverse direc­
tions, sometimes with false starts and often en­
countering dead ends, building on the past until 
the present presents a coherent and stable body 
of knowledge. Justice Felix Frankfurter called 
the decision-making process the “correlation of 
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CHAPTER .1 
imponderables,” a term never more apt than in 
the evolving fields of biotechnology. 
The rule of law is vibrant, adapting to the evolv­
ing contexts of science and technology. In today’s 
era of rapid technological change, jurisprudence 
provides the stability of the law, while reflecting the 
social implications of the science. But the scientific 
and technologic issues of today, such as arise in IP 
disputes, must also be correctly decided. 
For determining the reliability of scientific 
and technologic evidence, the Supreme Court 
has exhorted judges to apply the same standards 
as the scientific community. That is not easy, for 
although judges can readily understand the meth­
odology of science, it is the science itself that is 
daunting. Habits of logical thinking, precision of 
reasoning, are common to science and law, each 
an elegant intellectual blend of theory and testing 
that leads the mind through complexity. Although 
as judges we do not test our theories in the labo­
ratory, we do test them against the accumulated 
knowledge and wisdom of the past. This is the 
tradition and strength of the common law, as it 
continually adapts and is usefully and effectively 
applied to the new biology. 
.  WHAT ABouT THE fuTuRE? 
A major problem in judicial decision-making is 
how to achieve practical justice for the high-tech, 
science-based issues of today’s disputes. The prob­
lem goes beyond the laws of intellectual property, 
for many issues that reach the courts (for example, 
in environmental law, communications technol­
ogy, product liability, forensics and other criminal 
issues) turn on questions of science and technol­
ogy of a complexity that did not exist even a few 
years ago. These issues require full access to the 
rule of law, with its protection of the public inter­
est and private rights, its safeguards to litigants, 
its concern for legislative intent, its openness, its 
checks and balances. Its justice. 
The rule of law contemplates a living law, 
adapting to changing contexts while benefiting 
from the experience of the past. Judges must un­
derstand the social and economic fabric of the 
statutes and precedent that we apply. It is essential 
to preserve a stable jurisprudence, lest we build 
uncertainty into areas whose strengths lie in their 
reliability. Yet new questions are constantly aris­
ing, or old questions in new contexts, such as the 
question of whether there is, or should be, a re­
search exception to the use of another’s patented 
invention. No one really worried about that ques­
tion until science, particularly biological science, 
reached the stage where the boundary between 
basic and applied research was blurred or lost. 
For the new biology, in general the law has 
lagged the science. Law usually lags social change. 
The evolution may be too slow for the enlarging 
issues of biology and genetics, as well as the devel­
oping issues of biodiversity and agri-biotechnol­
ogy. As we ponder the legal and policy aspects of 
these new sciences (for example, with respect to 
advances in genetic science), constitutional prin­
ciples arise. Is the preservation of human diver-
sity—including the sick, or the ugly, or the mo­
ronic—a constitutional question? Justice Holmes 
is still criticized for ruling that “three generations 
of imbeciles is enough.”7 Would he be criticized 
for ordering remedy in the womb—or for deny­
ing such remedy? The cases in court often inspire 
thinking about the foundations of the law, as well 
as the historical and social and economic policies 
of the law. 
Disputes arising in the biological sciences are 
likely to encounter the uncertainties of this juris­
prudence, for the new biology raises new issues in 
the context of commerce and the interaction of 
public and private interests. I encourage you who 
are engaged in the creation and dissemination of 
these sciences to think about what the law should 
be, so that together we may seek the optimum 
legal framework for today’s and tomorrow’s scien­
tific and technologic advances. n 
pauline newMan, Judge, U.S. Court of Appeals for the 
Federal Circuit, National Courts Building, 717 Madison 
Place NW, Washington, DC, 20439, U.S.A. NewmanP@ 
cafc.uscourts.gov. 
1	 Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
2	 The Bayh-Dole Act, discussed elsewhere in this 
Handbook, was also implemented at this time, as 
part of the larger purpose of revitalizing commercial 
development of the products of academic science.
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See also, in this Handbook, chapter 3.3 by GD Graff and 
chapter 3.2 by R Nugent and J Keusch. 
3	 This patent-related jurisdiction was initially about
12% of the Federal Circuit’s assignment, for the plan 
was to assure diversity and breadth of experience and 
responsibility. The number of patent-related cases has 
since increased, but they are still a minority of the 
court’s assignment, which includes claims against
the government, childhood vaccine injury cases, tax 
cases, Native American claims, veterans appeals, Fifth 
Amendment property takings, international trade and 
customs cases, and several other areas of national 
appellate jurisdiction. 
4	 eBay v. MercExchange, L.L.C., 126 S. Ct. 1837 (2006). 
5	 Markman v. Westview Instruments, Inc., 517 U.S. 370 
(1996). 
6	 Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 
U.S. 722 (2002). 
7 Buck v. Bell, 274 US 200 (1927). 
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CHAPTER 3.2 
Global Health: Lessons from Bayh-Dole
 
RACHEL A. NUgENT, Senior Health Program Associate, Center for Global Development, U.S.A. 
gERALd T. kEUSCH, Provost and Dean for Global Health, Boston University Medical Center 
and School of Public Health, U.S.A. 
ABSTRACT 
Public sector institutions help deliver public health goods. 
By extension, universities that receive public research 
funds must deliver a benefit to the public that goes be­
yond licensing a discovery to the private sector for devel­
opment. In the United States, 25 years of experience with 
the Bayh-Dole Act, which governs the use of intellectual 
property (IP) derived from public research, offers both 
lessons and warnings for developing countries currently 
establishing their own IP systems. Bayh-Dole successfully 
created a large body of IP from publicly funded research. 
Absent a strong profit motive for the private sector, how­
ever, the Act has been much less successful at producing 
public goods for health. Current practice undervalues 
the “public benefit” aspect of the mandate, especially for 
the poor. Possible ways to address this mandate would be 
for public sector entities (and their academic partners in 
the biomedical sciences) to invest some of their earnings 
from licensing publicly funded discoveries into programs 
for neglected diseases of the poor. IP rights from public 
funded research could also be leveraged in negotiating 
licensing agreements with the private sector to address 
these neglected diseases. IP laws and institutions should 
be designed to encourage such sharing. The public and 
academic research sectors should also seek a new compact 
with the private sector aimed at reducing the burden of 
disease affecting the poor. 
1. INTRODuCTION 
In the past 50 years, the intensity of research 
and the pace of discovery in the biomedical and 
health fields have accelerated dramatically in the 
United States, in both the public and private sec­
tors. As a result, the number of safe and effective 
drugs, vaccines, and medical devices for a broad 
range of illnesses and conditions has skyrocketed. 
But current laws and practices may mismeasure 
the benefits of publicly funded health research by 
relying too closely on a private sector yardstick. 
Furthermore, in an increasingly global world— 
where the risk of disease and the benefits of re­
search can come from any corner—the society 
that benefits from public sector health investment 
should be the global society. The “public benefit” 
aspect of U.S. federal research investments should 
thus include the poor in societies inside as well 
as outside of the United States, and IP laws and 
practices should be changed to enhance the ben­
efit of our investments. 
Out of an estimated US$106 billion in 
health R&D expenditures globally, about 50% 
is estimated to come from public sources.1 In the 
United States, most public funding of biomedical 
and behavioral research is through the National 
Institutes of Health (NIH), whose spending 
on research is approximately US$28 billion in 
2006. Those numbers dwarf the amount of pub­
lic research funding in developing countries, 
but developing country R&D investment will 
continue to grow, along with IP derived from 
it. As IP systems evolve in developing countries, 
they should avoid or reduce barriers to the de­
velopment of health and medical products for 
the poor. 
Nugent RA and GT Keusch. 2007. Global Health: Lessons from Bayh-Dole. In Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K.,
and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. RA Nugent and GT Keusch. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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NuGENT & KEuSCH 
Only in the past decade has global atten­
tion focused on the health needs of poor and
marginalized populations in developing coun­
tries.2 This new attention has opened to public 
view the system of protections for IP and trade 
embodied in national rules and in the global 
Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) Agreement. Moreover, recent de­
bates over access to drugs for low-income popu­
lations in developing countries have highlighted 
the controversies found in the often arcane details 
of the patent system and IP laws.3 The media of­
ten portray these debates as a struggle between 
rich and poor countries, big drug companies and 
sick people, or insensitive bureaucracies and car­
ing relief organizations. While such portrayals 
may gain the attention of the public and of poli­
cy-makers, they at best oversimplify and at worst 
obscure the true nature of the problems, and thus 
create further barriers to finding solutions. 
The economic, legal, and policy arrange­
ments that move innovation from research labs 
to consumers are the same ones that erect barriers 
between those same labs and the poor. The main 
economic barrier is the high cost of developing 
a product from a basic discovery. The main legal 
barrier is a complex ownership system, one that 
goes too far in protecting the interests of those 
who invest in research and development. Finally, 
there is a policy barrier: the inability to balance 
the competing interests of the scientific com­
munity, consumers, and industrial development, 
all of which vie for advantage in the increasingly 
lucrative world of health care products. As IP sys­
tems evolve in developing countries, they should 
avoid repeating mistakes and act to reduce barri­
ers to development of health and medical prod­
ucts for the poor. 
This chapter outlines several ways that public 
and university decision makers can reorient their 
IP strategies to remove these barriers. It first con­
siders the rationale for government investment 
in biomedical research, and then explains what 
kind of public benefits should be expected from 
that investment. The chapter then examines the 
key U.S. laws governing technology transfer from 
federally funded research and provides a synopsis 
of the legislative context of their passage. Some 
creative options for extending the benefits of 
biomedical research to poor countries or global 
beneficiaries are then proposed for the public sec­
tor and universities. A few of these options could 
also be adopted by developing-country research 
funders and universities. 
Indeed, there are several ways for public in­
stitutions to increase the resources and tools de­
voted to public health needs in the developing 
world. At the upstream end, public institutions 
could direct funds toward research in developing 
countries and their diseases; they could also part­
ner with private and nonprofit entities wishing 
to do the same. At the downstream end public 
institutions could directly render assistance to de­
veloping country institutions in building research 
capacity, provide products to users in poor coun­
tries, reduce barriers to the transfer of technology, 
or partner with industry and academia to expe­
dite the development of products from research. 
Most of these steps also apply to fields outside of 
health and medicine. 
2. PuBlIC SECTOR INVESTMENT
IN HEAlTH RESEARCH 
It is generally acknowledged that publicly sup­
ported basic research invaluably contributes to 
the development of new medical technologies. 
Creating such benefits is part of the mission of 
the U.S. National Institutes of Health (NIH). 
Moreover, the U.S. Congress and the NIH lead­
ership recognize the direct connection between 
global health improvement and the health and 
well being of U.S. citizens. Public research agen­
cies, such as the NIH, have a clear commitment 
from Congress to provide global benefits from 
their research. NIH has therefore allocated some 
of its resources for research and research train­
ing related to specific developing country health 
needs (for example, HIV/AIDS, tuberculosis, 
malaria, tobacco-related illness, cognitive devel­
opment, and others). It has also advanced such 
efforts through technology transfer negotiations 
with private companies developing the discover­
ies of NIH laboratories. 
It is worth emphasizing that about 90% of 
NIH research funds support extramural research, 
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CHAPTER .2 
the vast majority in universities. Control of tech­
nology from that research was placed in the hands 
of universities by the Bayh-Dole Act of 1980. 
Therefore, by far the greatest impact of any in­
novation in intellectual property (IP) manage­
ment comes from decisions made by university 
presidents and their technology transfer officials. 
They determine how IP derived from publicly 
supported research is used. Most of the following 
suggestions are meant for their special consider­
ation. Similar arrangements, of course, could be 
adapted in developing countries. 
2.1	 Rationale for public sector investment 
in biomedical research 
Several arguments have been put forth to jus­
tify the government’s role in funding research. 
Although this discussion mostly focuses on bio­
medical research, the same arguments apply to 
other sectors. First, funding basic research is a 
classic example of the role of the government to 
provide public goods, as applications for health 
are built on the foundation of fundamental 
knowledge. Because the market typically under-
invests in fundamental knowledge creation and 
utilization, government support of basic bio­
medical and health research is an efficient use of 
society’s resources. Furthermore, it is important 
that the public sector continues to invest lest 
the increasing expenditures of the private sector 
unduly control access to basic knowledge. The 
fruits of publicly funded research—whether in 
genomics, developmental biology, aging, emerg­
ing infectious diseases, molecular virology, can­
cer, or other fields of science—benefit the public 
in many ways. These benefits are delivered, not 
only in the form of new medical technologies, 
but also in ways unspecified and unforeseen. An 
example of the latter is the NIH’s investment in 
basic retrovirology, which paved the way for an 
early understanding of the nature of HIV. 
Second, public funding of research ensures 
that data is available to scientists at the earliest 
possible time. Academic research careers depend 
on research productivity, often expressed as the 
“publish or perish” dictum. Publicly funded re­
search discoveries are often placed immediately 
in the public domain through presentations, 
publication, and professional networks. Privately
funded researchers, however, are under no obli­
gation to make their findings available to other 
researchers or to the public and indeed may in 
some instances be prevented from doing so by 
company policies.4 This difference is illustrated 
in the approaches of the publicly funded hu­
man genome project and the privately funded 
sequencing research. The former placed the data 
in the public realm in real time via the Internet, 
whereas the latter did not—though the private 
sector could still benefit from the publicly funded 
program’s findings. 
Third, publicly supported research can fill 
knowledge gaps not addressed by private industry. 
Because the public sector is based on incentives 
other than the profit motive, government research 
can set priorities based on society’s needs, scientific 
promise, and other factors that—when no market 
for a product exists—are not of paramount con­
cern to the private sector. Therefore, the choice 
of whether to develop new ideas into products is 
largely left up to the private sector. The implication 
of this is that technology development from pub­
lic research by and large gets rationed according to 
the priorities of the private sector, typically from 
a “return on investment” perspective. Admittedly, 
there are tensions across these public and private 
sector interests. However, in the United States 
these divergent paradigms are sorted out through 
a multi-agent lobbying and vetting process that 
occasionally produces disagreement but is gener­
ally accessible and transparent. 
One important consequence of this third 
point is that publicly funded research can address 
fundamental questions without undo concern 
for the immediacy of its application. When pat­
ents are derived from federally supported science 
they are in fact generally for early-stage technol­
ogy—often processes and materials to be used by 
other researchers.5 Rarely does a discovery occur 
in federal labs that does not require years of ad­
ditional funding to enter into the market. This is 
why public and private investments in biomedical 
research are mutually dependent: a public sector 
invention is usually brought to market by private 
sector product development. Still, inherent in 
this relationship is the reservation of the choice of 
HANDBOOK OF BEST PRACTICES | 1
  
     






     
 
NuGENT & KEuSCH 
whether to develop new ideas into products being 
largely left up to the private sector. The implica­
tion of this is that technology development from 
public research gets rationed according to the pri­
orities of the private sector. 
2.2	 Balancing public and private 
research investment 
The synergistic relationship between the public 
and private sectors is generally highly efficient 
and productive; however, the potential of this ar­
rangement to create public goods from the invest­
ment of the public sector is by no means certain. 
In principle, the case can be made that beyond 
the support for the research itself, public agencies 
have a role to ensure that the benefits of basic re­
search get delivered to the public. How it can best 
carry out this role, however, is not obvious. Under 
current arrangements, the public sector has lim­
ited capacity and experience in the downstream 
steps of developing and delivering products to 
consumer markets. These steps are not only costly 
but are also not aligned with the public sector’s 
comparative advantage. 
The public sector, therefore, requires two 
kinds of investment: one enhances private sector 
investment by supporting basic research that will 
eventually lead to private sector product develop­
ment; the other augments the private sector by 
investing in those areas that are unattractive for 
private sector investment. Both avenues are essen­
tial for the public sector to pursue, and shifting 
public health needs require the frequent rebalanc­
ing of priorities. 
The conundrum for public research agencies 
is that however large their public funding may 
appear, their resources are still limited relative to 
scientific opportunity. They must prioritize re­
search investments and are often unable to take 
a technology far enough to determine how much 
public benefit might be derived from the full, 
vigorous exploration of its potential. The cost of 
fully developing a new technology is great, and 
the rate of attrition—explorations that end with­
out a product or a profit—is very high.6 
This underlies the crucial concern that 
some explorations end prematurely because the 
estimated market is too small to justify the needed 
up-front investments. In the health sciences, this 
may be particularly true of research for products 
that target diseases of the poor or of developing 
nations (for example, tropical and parasitic dis­
eases) or that are more appropriate for delivery 
and application in developing country health sys­
tems. One hopeful note in the past five years has 
been the substantial expansion in R&D invest­
ment in neglected diseases of the poor via public/ 
private partnerships (PPPs): between 2000 and 
2004, R&D expenditures from public/industry 
nonprofit partnerships grew from US$23 million 
to US$44 million per year.7 
To help balance the above interests, the NIH 
has created guidelines for sharing research tools.8 
It is also tracking inventions produced from NIH 
investments that result in therapeutic drugs or 
vaccines. FDA-approved therapeutic drugs and 
vaccines developed with technologies from the 
intramural research programs at NIH are report­
ed on the NIH Web site.9 Eventually this system 
will document the public health outcomes of any 
commercial technology developed with NIH 
support. These steps may be worth emulating as 
developing countries establish their own systems 
for tracking the results of their research invest­
ments. But while this system will produce valu­
able information about the benefits of research 
investments, it is still an a posteriori exercise. 
3. IP lAWS AND PuBlIC
RESEARCH INVESTMENT 
A successful research endeavor creates IP, but when 
does this ownership enhance the public good? 
The status and ownership of IP derived from gov­
ernment-funded research in the United States is 
framed by a series of public laws that establish 
the current principles and procedures used by 
the U.S. government and its private partners. For 
purposes of this discussion, the most important 
laws date from a quarter-century ago, although 
the laws have been amended and enhanced in 
minor ways since then. These are the Stevenson-
Wydler Technology Innovation Act (P.L. 96-480) 
pertaining to intramural research in government 
laboratories, and the Bayh-Dole Act (officially 
Amendments to the Patent and Trademark Act, 
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P.L. 96-517), pertaining to extramural research 
outside of government laboratories.10 Both Acts 
were passed in 1980 to stimulate greater use of 
technologies developed through government 
support. Their legislative history is instructive for 
understanding the public benefit the laws were 
designed to create. 
.1	 History of Bayh-Dole and 
Stevenson-Wydler acts 
In the mid-1970s, Congress became concerned 
about the failure to use federally owned patents to 
encourage product development stemming from 
federally funded R&D. At the time, only 5% of 
the 28,000 patents retained by the U.S. govern­
ment had been licensed for use, whereas 25%– 
30% of industry patents were being applied.11 
These circumstances prompted Congress to in­
quire into how federal research was transformed 
into usable technology. Congress concluded that 
the barriers were too great and the incentives too 
small for academia or the private sector to develop 
technology from the patents produced with gov­
ernment research support. At the time, there was 
no discussion about public sector involvement in 
downstream activities. 
The main barrier to the use of federally pat­
ented technology was believed to rest with the 
unwillingness of the responsible agencies to grant 
exclusive licenses for companies to use the pat­
ented technology and invest in product devel­
opment. An exclusive license would allow one 
company to have a monopoly in the invention 
produced with government funds as an incen­
tive to develop and test the product. Companies 
complained also that even the attempt to obtain 
nonexclusive licensing was an excruciatingly slow 
process. Federal agencies imposed many paper­
work requirements and other burdens on their 
licensees in an apparent effort to protect the pub­
lic’s interest in the invention. It became clear to 
Congress that private companies would not ac­
cept the risk and expense of developing technol­
ogy for the marketplace without some exclusive 
rights and without a more streamlined way to 
obtain patent rights across agencies.12 
The Bayh-Dole and Stevenson-Wydler acts 
were intended to rectify this situation. They did 
this by creating a uniform licensing system for 
all federal agencies, reducing the steps needed 
to grant licenses, and providing incentives for 
industry to invest risk capital in product com­
mercialization from federal patents. Most impor­
tantly, Bayh-Dole allowed universities and small-
business government contractors to receive title 
to inventions derived from government support, 
rather than the prior arrangement in which gov­
ernment was the sole holder of the patent. It also 
allowed the grantees and contractors to license 
the technology developed under these patents for 
use by small business and private industry.13 The 
Stevenson-Wydler Act effectively allowed federal 
labs conducting intramural research to exercise 
the same privileges. 
The effect of these new statutes was to trans­
fer the ownership of IP and the benefits derived 
from it. They allowed companies to license and 
develop products based on the discoveries of fed­
erally funded university research with full legal 
protection from competition. According to the 
Congressional Research Service, “Proponents of 
this approach contend that these benefits are more 
important than the initial cost of the technology to 
the government or any potential unfair advantage 
one company may have over another in their deal­
ings with the federal departments and agencies.”14 
Interestingly, the Bayh-Dole legislation ini­
tially proposed a formula for repayment to the 
taxpayers of the government investment when a 
patent yielded commercialized technology. This 
provision was dropped in the final stages of pas­
sage because of disagreements over technical as­
pects of the repayment mechanisms.15 While the 
legislative history demonstrates that there was 
widespread acceptance of the principle of a right­
ful return to the public from private sector use 
of publicly funded technology, it was the details 
of implementation that ultimately defeated its in­
clusion in the bill.16 
Nonetheless, the legislation was passed with 
several clauses intended to ensure that the mo­
nopoly powers granted to patent holders and li­
censees would not be abused. These clauses have 
been the subject of much debate among IP spe­
cialists and are a cause of anxiety for the private 
sector, which is concerned about when and with 
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NuGENT & KEuSCH 
what justification they would be invoked by the 
government. The legislation expressed Congress’s 
view that the use of discoveries from federal re­
search to improve health was clearly in the public 
interest, even if it must be carried out by govern­
ment action. 
The Bayh-Dole law states the intention “to 
ensure that the Government obtains sufficient rights 
in federally-supported inventions to meet the needs 
of the Government and protect the public against 
nonuse or unreasonable use of inventions…”17 The 
means to achieve that goal were codified in the 
following provisions that reserve certain rights for 
the government: 
•	 The right to a nonexclusive, nontransfer­
able, irrevocable, paid-up license to prac­
tice for or on behalf of the United States 
throughout the world.18 
•	 “March-in” rights that enable the gov­
ernment to require the licensee or pat­
ent holder to grant use rights to another 
user with due compensation under special 
circumstances. The special circumstances 
envisioned in this clause refer to lack of 
use within an agreed-upon time frame 
or special health or safety needs that are 
not being met by the licensee or patent 
holder.19 
The first clause, allowing government use 
of the technology, has been narrowly interpret­
ed to refer only to a true government purpose. 
This interpretation has not been fully litigated 
and therefore it is likely that private pharmaceu­
tical companies remain concerned that changes 
in its interpretation could expand to threaten 
their economic interests. This provision could 
theoretically allow the government to practice 
the technology—or contract with a third party 
to have the technology practiced—for authorized 
government purposes. Because the mission of the 
NIH is “to secure, develop and maintain, distribute 
and support the development and maintenance of 
resources needed for research,” some have suggested 
that there appears to be a limited scope for NIH 
action in this regard.20 However, the Department 
of Health and Human Services might, due to its 
public health mission, have a clearer justification 
to invoke the government-use clause in pursuit of 
its mission. 
The second clause, the so-called march-in 
right of government, has attracted greater at­
tention and has been more extensively explored. 
It has been formally tested just once, in a case 
in which the NIH declined to initiate march-in 
proceedings, thereby disallowing the petitioner 
use of the technology.21 This test case provided 
the opportunity for both the government and 
affected parties (who were primarily third-party 
recipients of government research funds or pro­
spective licensees) to indicate their views on how 
restrictive the march-in rights should be.22 The 
debate centered on questions of what constitut­
ed timely delivery and how critical the public 
health or safety need had to be to in order to 
warrant government action. The voluminous 
record produced for this petition demonstrated 
that universities and industry were extremely 
concerned that the march-in provision would 
undermine licensing rights under Bayh-Dole. 
It also demonstrated that petitions for march 
in would prompt a full-blown legal procedure, 
imposing both time and financial costs on any 
potential petitioner. 
.2	 Twenty-five years after Bayh-Dole 
and Stevenson-Wydler 
The laws that govern the disposition and use of 
technology derived from U.S. government invest­
ment in health R&D must be judged first and 
foremost by how well they have met their original 
legislative intent. Assessments of the impacts of 
the Bayh-Dole Act and related legislation suggest 
that the laws performed as Congress intended.23 
Most independent analyses have concluded that 
the acts greatly increased technology transfer from 
researchers to private industry in the biomedical 
sciences, improved the governmental patenting 
and licensing process, and made available to the 
public products that improve their health and 
well being.24 Thus, the goal of greater private sec­
tor utilization of the research output by federally 
funded scientists seems to have been achieved.25 
Simultaneously, research universities expe­
rienced significant upheavals as agendas and re­
searcher time focused more and more on revenue 
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opportunities. In the two and a half decades since 
passage of the Bayh-Dole Act, the major U.S. 
research universities have developed highly pro­
ficient offices of technology transfer, staffed by 
professionals who deal with patents and licens­
ing. Through this infrastructure, these universi­
ties have come to expect financial rewards from 
their research efforts in the form of royalties and 
fees from patents and licenses. In the eyes of some 
university officials, this income flow is justified as 
partial compensation for the costs incurred dur­
ing the conduct of federally supported research— 
an enterprise most universities believe costs them 
more than the infrastructure support provided 
with federal grants. 
Yet there is no guarantee of financial returns 
from research, and most universities have long 
operated without this extra income. They still do, 
albeit there are consequences on investments in 
expansions of faculty and facilities. The intent 
of Bayh-Dole was not to produce supplemental 
revenue streams to universities. Rather, it was to 
engender innovation and increase the use of tech­
nology for economic development. Universities 
do accept their responsibilities to contribute to 
the public good, but these have generally focused 
first on university, state, and national health is­
sues, in that order. Most universities have either 
not addressed or achieved a balance between en­
trepreneurship and the generation, use, and dis­
semination of knowledge for the public good. 
Recent analysis concludes that, although more 
university technology transfer operations have be­
come profitable over time, many universities do 
not earn profits from licensing the results of re­
search.26 The occasional blockbuster technology 
has produced large royalties for a few universities 
holding patent rights, and some others generate 
a few million dollars annually. Most universities, 
however, are still barely in the technology devel­
opment business. Out of almost 1,500 licenses 
executed during 2004, only 1.5% (67) generated 
more than US$1 million in revenues. In 2004, 
US$1.4 billion in earnings from licenses and 
US$1.2 billion in royalties was reported by the 
196 U.S. institutions that responded to an annual 
survey of university research technology offices. 
The survey respondents reported about US$41 
billion in research expenditures for the same year, 
and over 10,000 new patent applications filed.27 
Much has changed in the 25 years since 
the Bayh-Dole and Stevenson-Wydler acts were 
passed. Not the least of these changes is an in­
creasing concern for global health, a concern 
arising from a recognition that the health issues 
of poor country populations and the U.S. popu­
lation are connected, as are the health of poor 
country populations and their economic and 
social prospects. For example, the devastating 
impact of HIV/AIDS and the limited use in im­
poverished developing countries of technologi­
cal advances for diagnosis and management of 
this infection and its complications is very much 
in the news today. As a consequence, many 
countries are trying to figure out how to deliver 
health technology to poor and technologically 
marginalized populations. In the process, ques­
tions are being raised about the balance of in­
terests between the use of new technology to re­
duce threats to health and the ownership rights 
to that technology. 
. Current debates 
The obligations to a larger, more global pub-
lic—and the rights of this public—are raising 
critical questions: just who is the public and 
what return on the investment is due the public? 
Debate continues about how to ensure the avail­
ability of effective treatments to all in need while 
ensuring that research partnerships with industry 
remain viable and productive. Public research 
and research funding agencies such as NIH, the 
academic community, and industry will be chal­
lenged to consider how to interpret and apply IP 
laws and regulations in the context of how a pat­
ent or a license, granted or denied, will affect the 
public good. Not only are economic, legal, and 
policy issues involved, but there are also complex 
ethical and social considerations created by deci­
sions to apply IP laws. 
The controversial nature of IP for biomedi­
cal research is illustrated in public debate and in
proposals in recent sessions of the U.S. 
Congress:28 
•	 disputes over competing claims to IP devel­
oped under government/industry ventures 
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•	 delays in negotiating Cooperative Re­
search and Development Agreements 
[CRADAs] because of issues related to 
dispensation of IP 
•	 controversies over the rights of drug com­
panies to set prices on drugs developed in 
part with federal funding 
•	 uncertainties due to the increasing mix of 
funding sources among government, founda­
tions and the private sector, and the portion 
of IP that represents the public good return 
•	 problems obtaining technologies for re­
search developed in the private sector for 
use in federal laboratories (A more general 
problem of access to research tools has not 
been considered by Congress.) 
This list of issues is not exhaustive and raises 
more questions than answers. Moreover, each 
could be—and indeed most have been—the sub­
ject of a rousing debate and the occasion for a 
flurry of letters, testimony, articles, op-ed pieces, 
and books. One place to start searching for ways 
to increase the return to the public—both global 
and U.S.—of the public investment in research 
is to review the arrangements currently or poten­
tially in use to deliver these benefits. 
4. THE PuBlIC SECTOR AND GlOBAl 
HEAlTH RESEARCH
There are several ways that government research 
funders can increase the resources and tools de­
voted to the public health needs of the developing 
world. At the upstream end they can direct funds 
toward research on specific diseases; they can also 
partner with private and nonprofit entities wish­
ing to do the same. At the downstream end they 
can directly provide products to users in poor 
countries, reduce barriers to the transfer of tech­
nology, or partner with industry and academia 
to expedite the development of products from 
research. Some of these steps could be adopted 
by academic recipients of public funds, especially 
those that actively develop IP ownership derived 
from public research funds. 
The following specific actions could be taken 
by public funders and their academic and private 
sector partners to increase global public goods for 
health. Many of these actions could also be adapt­
ed, by implementing IP rules and procedures, for 
use in developing countries. 
.1 Action within the research enterprise 
Strengthen capacity for research in developing 
world. Increasing funding for research in devel­
oping countries is, if sustained, one of the most 
direct ways to create a global benefit and ulti­
mately increase access to the results of scientific 
research for the world’s poor. Such funding can 
also lead to collaborations between developed 
and developing country scientists, creating more 
sustainable research environments and the oppor­
tunity for human capacity building and research 
infrastructure development. 
Government research awards can contain 
provisions requiring researchers to train develop­
ing country scientists in these highly successful 
laboratories. In the health sciences, for example, a 
portion of the royalties from the NIH intramural 
program is returned to the lab that discovers and 
invents new technology—this also applies to uni­
versity labs that produce patentable inventions. 
These funds could be devoted to training new sci­
entists. In addition, the same opportunities could 
be provided in developing countries. 
Academic/industry partnerships. Both 
within and apart from the university research en­
vironment, the relative importance of private sec­
tor funding has increased. Private companies are 
now estimated to spend three times as much on 
biomedical research as the NIH, most of it within 
their own research laboratories.29 However, in-
dustry-funded university research is also growing. 
It is unclear how involved industry is in academ­
ic biomedical research at present, although one 
source indicates that a small portion of private 
R&D (about 12%) is conducted within U.S. 
academic institutions.30 Whatever the magnitude 
of industry’s involvement, it is large enough to 
possibly blur the distinction between the objec­
tives of universities and private industry, and it 
has caused some to question university motives 
for carrying out research.31 
The nature of science and its conduct has 
also changed since Bayh-Dole was instituted. 
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Few academic or public research organizations 
have the particular combination of scientific 
know-how, application tools, and commercial­
ization potential that it takes to turn ideas into 
real deliverable products. Public/private part­
nerships are increasingly looked to as the mode 
of operation for future biomedical research 
that rapidly develops products. Nowadays, the 
complementary human capital and financial re­
sources of the public sector, academia, and in­
dustry are all needed to bring scientific inquiry 
to fruition. The power of the Gates Foundation 
to influence this process is a major new force 
shaping this landscape. 
In recent years, new approaches have been 
devised to sweeten the pot and bring new players 
into the development of health technologies for 
the poor. These include public/private partner­
ships such as MIHR (Centre for the Management 
of Intellectual Property in Health R & D,) estab­
lished in 2002 precisely to address public sector 
needs in IP management. It provides a forum for 
multiple public and private entities to improve the 
management of health IP for the benefit of devel­
oping countries through information exchange, 
training, defining best practices in licensing, and 
help in developing norms for IP management.32 
MIHR is working with developing countries to 
help them bridge the gaps between what the pub­
lic and private sectors can provide in addressing 
global health needs.33 
Many universities prominent in health re­
search are also seeking to balance their financial 
objectives, their charge to advance scientific dis­
covery, and their dissemination of the benefits 
of those discoveries to the public. Universities in 
both developed and developing countries could 
explore how to create research partnerships with 
one another and with the private sector that 
achieve a public benefit goal, while still meeting 
the profit motive of private companies. 
.2 Technology transfer options 
The evolution of technology transfer practices 
since Bayh-Dole has placed public sector insti­
tutions and research universities in a difficult 
position. The delicate balancing of their scien­
tific interests, their responsibilities to the public, 
and their need to maintain a competitive posi­
tion vis-a-vis the private sector to retain expertise 
has been jarred repeatedly in the past few years. 
Developing country institutions are particularly 
challenged by the lure of greater research oppor­
tunities and higher salaries and benefits for their 
top and young scientists in the U.S. 
The following list suggests how public invest­
ment can use technology transfer more effectively 
to create global public-health goods. The list also 
makes the important point that all possibilities 
should be open to discussion among committed 
and interested parties—including policy-mak­
ers and research leaders in the developing world. 
Many of the suggestions are derived from NIH 
experiences, but they could be applied far more 
widely. Most importantly, the engagement and 
involvement of all stakeholders is essential, with­
out this it will be impossible to change current 
operating principles. Change will not be accom­
plished by fiat. 
1. A 	 straightforward way to deliver social 
dividends from research is to write provi­
sions into licensing agreements. On an ad 
hoc basis, NIH has incorporated voluntary 
provisions for public benefits into license 
agreements with private industry. As a re­
sult, many licenses granted by NIH include 
a public benefit of some sort.34 The types 
of public benefits called for in these purely 
voluntary arrangements include education­
al Web sites, product donations, and drug 
delivery to needy communities. The initia­
tive has been palatable because no specific 
level of benefit or outcomes is requested in 
the license provisions. It appears, however, 
that the public benefit delivered through 
this approach has been, at best, modest. 
Public-benefit provisions in licens­
ing agreements could state a specific aim 
to benefit poor countries. Both publicly 
funded research agencies and university 
technology transfer offices could increase 
the use of such provisions. If employed 
in developing country licensing agree­
ments, the provisions could ensure the 
delivery of drugs or technologies to the 
poor by whatever direct mechanism the 
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NuGENT & KEuSCH 
commercial partner prefers (for example, 
drug donations or reduced prices), or 
even indirectly through a nonprofit or­
ganization. For instance, a reasonable 
proportion (however difficult it is to de­
termine the meaning of reasonable) of the 
royalties to a university from the license 
would be placed within a foundation es­
tablished to support global public-health 
goods. It is necessary to recognize that the 
funds available for diversion are meager, 
if they exist at all, at most universities. 
2. The private sector lacks interest in many 
available technologies because of its per­
ceived lack of profitability. Therefore, ways 
to increase profitability need to be explored. 
One method open to the public sector and 
academic institutions is to bundle technol­
ogies developed in their laboratories. This 
would require companies to license anoth­
er, less profitable technology for develop­
ment in order to obtain a license for more 
lucrative technologies. This is consistent 
with the paramount aim of the Bayh-Dole 
Act to get technologies used. 
So far in the United States, there have 
been few takers for this type of arrange­
ment, and its impact will likely be small. 
The argument is that bundling may help li­
cense less-attractive technologies, although 
it will not make them more profitable for 
companies to develop. However, in a de­
veloping country setting, the economics of 
bundling may be different. For instance, 
if the public institution can help identify 
a large buyer to take the initial output, a 
profitability threshold might be reached 
if the price from the bulk purchaser met 
minimum average cost of production at 
the appropriate scale. A private company 
wishing to expand its capacity in a devel­
oping country could anticipate potential 
profits.35 Merck reached such a level when 
it chose to produce recombinant hepatitis 
B antigens in China for that market. It 
even built a state-of-the-art plant to pro­
duce vaccine. This led to widespread use 
of the vaccine in China and a foothold for 
the company in the country—a win-win 
situation. 
The economics of bringing products to 
market in developing countries differs from 
those in developed countries.36 Human 
clinical trials are the most costly phase of 
product development; this phase is also 
when most experimental technologies fail. 
Developing countries have the opportunity 
to streamline procedures for carrying out 
clinical trials, including establishing more 
rational and less time-consuming institu­
tional review board (IRB) processes. Other 
components of the R&D process that 
generally cost less in developing countries 
are legal, marketing, and regulatory fees. 
Also, the medical research companies in 
developing countries may be more willing 
to take risks than are those companies in 
the United States. Moreover, both compa­
nies and their government regulators may 
be more strongly motivated by the clear, 
urgent need for improved diagnostics and 
therapeutics. 
Developing country markets can also be 
segmented: the technology could be pro­
vided at low or no cost to the poorest coun­
tries through a subsidy mechanism (market 
pull), at a sustained rather than reduced 
price in middle-income developing coun­
tries, and at a higher price as the market 
develops. Such an arrangement would be 
consistent with economic theory, in which 
price discrimination can increase market ef­
ficiency and equity.37 It actually resembles 
the pricing methods that pharmaceuti­
cal companies currently use in developed 
country markets and could make some 
technologies suddenly more financially at­
tractive. For this approach to work, mea­
sures must be taken to ensure that there is 
no parallel importation or smuggling from 
the low price to the higher price nations. 
This is a difficult goal, but one that might 
be expedited through TRIPS to allow trade 
in generics among developing countries. 
A variant of this approach would be 
for technology transfer offices (TTOs) to 
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CHAPTER .2 
work more with nonprofit organizations 
to deliver technology, instead of seeking 
commercial avenues. NIH currently uses 
CRADAs to work with the World Health 
Organization (WHO) and nongovern­
mental organizations (NGOs) (for ex­
ample, PATH) to move malaria drugs and 
other less-profitable technologies into use. 
The overriding concern for a CRADA is 
whether the organization can carry out the 
necessary R&D to develop a product. The 
current fully capitalized cost (including 
post-approval R&D costs) to the private 
sector to develop one drug is estimated 
to be nearly US$900 million. And with 
more than eight years required for the 
clinical and approval phases of develop­
ment alone, nonprofit organizations just 
do not have the capacity to sustain such an 
investment.38 However, as already noted, 
it is extremely difficult to make such esti­
mates because the necessary information is 
not in the public domain; it is likely that 
goals can be achieved at much lower cost 
in developing countries , and this can be 
put to the test. 
3. In 	 an effort to increase the licensing of 
vaccine technology in selected developing 
countries, the NIH is now requiring com­
panies seeking to license NIH technology 
to produce a plan to market the technology 
in developing countries within two years of 
regulatory agency approval. They can either 
opt to deliver the product themselves or ini­
tiate a joint venture with another company. 
The goal is to use the potential profits from 
sales in developed countries to encourage 
companies to manufacture for the devel­
oping world at or near cost, although the 
expense of adding manufacturing capacity 
or the opportunity cost of shifting exist­
ing production to this product should be 
factored in. Another way to achieve access 
and affordability for the poor is by manu­
facturing in developing countries at lower 
cost than in the United States.39 This sort 
of a tie-in is difficult to accomplish from 
the United States, but a developing country 
government could arrange it much more 
easily. 
4. Delivering	 technologies for developing 
country use through multiple-use licensing 
is too rarely used. This approach identifies 
and licenses basic technology for specific 
fields of use (for example, a cancer vaccine) 
and requires the same (or another) company 
to do parallel development of the same tech­
nology for another field of use (for instance, 
an HIV vaccine). In the existing regulatory 
framework, an expansion of this approach 
would require renegotiating existing li­
censing agreements and would certainly 
be strongly resisted by licensees. However, 
in an open playing field such as exists in 
some developing countries, it could become 
common. 
5. A radical approach open to the U.S. gov­
ernment but not to universities is to exert 
march-in rights on already-licensed NIH-
derived technology to meet special health 
or safety needs that are not being satisfied. 
This option, referred to as compulsory li­
censing, should be retained by develop­
ing country governments in case of public 
health emergency—and it should be used 
when necessary, and never frivolously. 
6. Finally, all activities—from early-stage de­
velopment to manufacture and distribu­
tion—could theoretically be performed by 
a government agency, university, or con­
tractor. For instance, government research 
institutions could move their own involve­
ment further down the development pipe­
line to include whatever steps would be 
needed to get the product ready for uptake 
by a private or nonprofit entity. Although 
this is clearly not a priority for a research 
agency such as NIH, there are already some 
programs to develop medications at NIH 
instead of relying on the private sector. It 
is worth emphasizing that, within the con­
text of the Bayh-Dole Act in the United 
States, by far the greatest impact from IP 
innovations will come from decisions made 
by university presidents and their technol­
ogy transfer officials. They control how IP 
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NuGENT & KEuSCH 
derived from publicly supported research 
is used. 
If universities decide to adopt any of these 
options, the decision, in our view, should 
come from a consultative process among 
all interested parties, including public re­
search agencies, developing country repre­
sentatives, potential funding partners, and 
industry. Universities and their faculties 
would have to embrace the moral and so­
cial imperative of enhanced delivery mech­
anisms and become full partners in the 
means selected to achieve them. Because 
most of the relevant technology is devel­
oped by a small subset of research-intensive 
universities, it would not be necessary to 
bring all universities on board; instead, a 
focus on the leaders would establish stan­
dards that others could follow. The process 
would be strengthened if developing coun­
tries joined and were led, for example, by 
a multinational organization such as the 
Inter-Academy Medical Panel. 
5. CONCluSION 
.1 Considerations for senior policy-makers 
Economic development, drugs for the poor, break­
through technologies for the world’s most com­
mon diseases, and scientific advances for treating 
tropical diseases are legitimate social goals for all 
nations. But these goals vie for limited financial 
and expert resources and are not always compat­
ible with each other. Policy-makers must ensure 
that the public’s investment in research is reward­
ed. A system should spur economic development 
and creative innovation, as was the intent of the 
Bayh-Dole Act. Just as importantly, the IP system 
should clearly articulate and codify an overarch­
ing social goal. 
It is understood that subsidies to research 
universities in the form of indirect costs in 
grants funded by the government may not cover 
the actual cost of supporting research infrastruc­
ture, and that industry risks capital in R&D for 
products that fail somewhere along the path, 
and that this has implications in terms of fi­
duciary responsibility to stockholders due a 
return on investment for success in product
development. None-the-less, policy-makers 
should insist that, as a condition of receiving the 
protections of patents and licensing, companies 
and universities must pay some “dividend” back 
to the public. This dividend could be indirect 
and used to support further research to address 
needs the market alone does not satisfy. Further, 
policy-makers should retain the government’s 
right to exercise a technology license on behalf 
of the public, as well as full march-in rights. 
The government should be prepared to exercise 
these rights in the event of a real public-health 
emergency or in the event that the private sec­
tor licensee fails to develop or bring to market 
a product that has potential public benefit. The 
government must accept its responsibility to en­
sure that the public’s investment pays returns to 
the public. As it turns out, the option for gov­
ernment action itself will likely provide compa­
nies with a strong incentive to make products 
available in the market. Government should also 
embrace principles of segmented markets and 
tiered pricing for vulnerable populations in the 
U.S. and abroad—the poor, the elderly and the 
vulnerable in particular. In this way, the govern­
ment accepts its responsibility to ensure that the 
public investment pays returns. 
.2 For presidents of universities 
In their approach to IP laws, the academic com­
munity is faced with complex ethical and social 
issues. If partnerships are to promote research 
that leads to global benefits, there should be 
agreements that explicitly commit all of the part­
ners to this goal at the outset. Creative financ­
ing and IP sharing arrangements will have to be 
developed. And scientists will need to prioritize 
the delivery of global benefits. Similarly, univer­
sity officials will have to fully embrace the larger 
role of universities in society and in the global 
community. Leadership must come from the 
very top of the institution, for example valuing 
applied research and including the creation of 
global public goods among the criteria for aca­
demic advancement. 
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Many universities prominent in health re­
search are seeking to balance their financial ob­
jectives, their commitment to scientific discovery, 
and the dissemination of benefits to the public. 
PIIPA (Public Interest Intellectual Property 
Advisors) is one example of how U.S. universi­
ties can use their stock-in-trade to serve the global 
public need by offering expertise and training.40 
PIIPA is a newly formed consortium of universi­
ties and companies that provides pro bono legal 
and professional assistance about IP issues to en­
tities in developing countries, including govern­
ments and universities. 
There are many ways that universities can 
help meet global public health needs. They can 
include including public benefit clauses in their 
licenses to the private sector, investing part of 
their royalty stream in a foundation, ensuring 
that returns to the university itself are used 
in part to support capacity building and ap­
plied research of global relevance, establishing 
an “ethical” investment fund,41 licensing tech­
nologies to nonprofits or others who would 
develop and manufacture for poor countries, 
or bundling technologies to encourage the de­
velopment of medicines aimed at diseases of 
the poor. Research universities or public fund­
ing agencies could unilaterally adopt any or all 
of these options, but a multilateral approach 
would have far greater public awareness and 
public health impacts. Ideally, this approach 
would be an international, multi-institutional 
effort. 
. For the technology transfer officer 
The job of the TTO is to create the incentives 
needed to move discovery into the product devel­
opment arena, motivating academic researchers 
not by the sole promise of high profits—which 
rarely appear—but by applying royalty toward 
the support of research in the inventor’s laborato­
ry, and by balancing some financial reward to the 
inventor with the satisfaction of seeing his or her 
work used for public benefit. Although not the 
responsibility of the technology transfer officer, 
the latter can become so. This will require creat­
ing opportunities for various forms of licensing 
(including exclusive licensing where appropriate, 
but a nonexclusive license should be insisted upon 
if that is likely to move a promising technology 
to market sooner), maintaining a very low paper­
work and expense burden for private (including 
nonprofit) companies wishing to license govern­
ment-funded technology and insisting on explicit 
public-benefit clauses. Technology transfer offi­
cers should report such efforts and their potential 
impact to the President him/herself. 
. For a university scientist 
Individual researchers in the United States have 
established product development companies in 
large numbers, and developing country research 
scientists and their institutions will feel pressure 
to do the same. When considering a research col­
laboration with a scientist from the United States, 
developing country scientists should be certain 
that they receive equitable treatment in whatever 
IP ownership arrangements are made. While IP 
protection is often necessary to convince indus­
try to move discovery into product development, 
something neither academia nor government, for 
that matter, do with distinction, not every dis­
covery should or need be protected. Scientists 
should be capable of participating in these dis­
cussions. Developing country scientists should 
also resist the excessive protections that are some­
times placed on research output in the United 
States—protections that delay and sometimes 
prevent discoveries from being published and 
shared in the scientific community. It is very im­
portant for developing country researchers to get 
the professional exposure and opportunities that 
scientific publication can offer. Narrow-minded 
efforts to establish property rights can inhibit 
those benefits. 
. A global vision 
Creating and delivering global public health 
goods is much more difficult than creating and 
delivering national public health goods. Yet we are 
committed, in the words of Tennyson, “to strive, 
to seek, to find, and not to yield.” To change the 
current reality will require a coalition of univer­
sity officials, government, industry, foundations, 
and NGOs to identify priorities and opportuni­
ties and then collectively carry them out. 
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Although IP has clearly spurred the devel­
opment of technologies that promote the public 
health of wealthier nations, the impact of IP in 
promoting global public health goods is mixed 
at best. Although the fundamental premise of IP 
protection—that it acts as a spur to innovation 
and a reward for risk-taking—applies equally to 
all industries, some characteristics of the health 
care industry set it apart from other fields where 
IP is important. Quite simply, in health care, the 
outcomes of technology development and its 
availability are matters of life and death. 
In 2002, The Economist observed “Rich coun­
tries should accept that considerations of how IP 
rights affect poor countries are not just a concern 
of overseas aid agencies but play a part in broader 
trade and economic relations too.”42 This chapter 
builds upon the truth of that insight. Indeed, if 
Bayh-Dole were being debated today, then surely 
the economic development objectives at the core 
of the legislation would take on a much broader 
meaning. n 
RACHEL A. NUgENT, Senior Health Program Associate, Center 
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1	 Global Forum for Health Research. 2006; Monitoring 
Financial Flows for Health Research 2005. Global Fo-
rum for Health Research: Geneva. www.GlobalForum-
Health.org.
2	 This attention has been prompted significantly by the 
World Bank’s publication of Investing in Health, which 
was the World Development Report of 1993 (World 
Bank. 1993. Investing in Health. World Development
Report 1993. The World Bank: Washington, DC). The 
concern has been reinforced by the expanded activities 
of the Bill and Melinda Gates Foundation for global 
public health, as well as the development of many 
other partnerships for public health. 
3 See extensive media coverage in 2001 of the South 
Africa AIDS drug controversy, Brazil’s decision to issue 
compulsory licenses for AIDS drugs, and the stalemate 
subsequent totheNovember2001WTOmeetinginDoha,
Qatar, over drug access in public health emergencies.
4	 Thursby and Thursby report that 27% of university 
research licensed by industry allows for prepublication 
deletion of information from research papers; 44% of 
them allow for publication delays of about 4 months,
on average (see Thursby J and M Thursby. 2003.
Intellectual Property, University Licensing and the 
Bayh-Dole Act. Science 301: 1052). 
5	 Seventy-five percent of licensed inventions from 
universities are “proof of concept” (see Jensen R and M 
Thursby. 1998. Proofs and Prototypes for Sale: The Tale 
of University Licensing. National Bureau of Economic 
Research: Cambridge, MA). This means that most
universityinventionsareat anearlystageofdevelopment
at time of license and require further involvement from 
the inventor to reach the commercial stage. 
6	 One rule of thumb is that one of 5,000 drug candidates 
discovered in labs will be commercialized, Business 
Week, July 9, 2001. p. 96. 
7	 Moran M and J Guzman. 2005. Drug R&D for Neglected 
Diseases: Are Public Funds Appropriately Distributed?
chap. 2. Global Forum For Health Research: Geneva. 
8	 Nass S and B Stillman (eds). 2003. Large-Scale 
Biomedical Science: Exploring Strategies for Future 
Research. National Academies of Science, Washington,
DC. p. 168. 
9	 ott.od.nih.gov/about_nih/fda_approved_products.html.
10 Stevenson-Wydler established technology transfer as a 
federal agency mission, creating rules by which federal 
agencies could license discoveries for commercial use 
and receive royalties and fees. Bayh-Dole extended 
these powers to other organizations performing 
federally sponsored research, including universities.
See Congressional Research Service (various) and supra
note 11 for further details about federal patent law.
11	 U.S.General Accounting Office.1998.TechnologyTransfer,
Administration of the Bayh-Dole Act by Research 
Universities. RCED 98-126,Washington, DC. p. 3. 
12	 Ibid. 
13	 A 1983 presidential directive extended licensing rights 
to large businesses.
14	 CRS.2000a.Patent Ownership and Federal Research and 
Development (R&D): A Discussion on the Bayh-Dole Act
and the Stevenson-Wydler Act. RL30320, December 11.
Congressional Research Service:Washington, DC. p. 11. 
15	 National Institutes of Health. 2001. NIH Response to 
the Conference Report Request for a Plan to Ensure 
Taxpayers’ Interests Are Protected. NIH, Washington,
DC. p. 10. www.nih.gov/news/070101wyden.htm. 
16 Prompted by persistent Congressional concerns about
returns to taxpayers from federal research, NIH later 
attempted to impose a policy of “reasonable pricing”
on the technology developed from certain types of 
federal research. The private sector refused to comply 
with this arrangement and it was eventually dropped.
Reference is made to NIH Cooperative Research and 
Development Agreements (CRADAs); see supra note 15 
for discussion. 
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17	 35 U.S.C. § 202. 
18	 35 U.S.C. § 202(c)(4). Exclusivity grants the licensee the 
sole right to use the IP, which serves essentially as a 
monopoly. Nonexclusive rights allow the grantee to 
use the IP, but they do not provide the right to be the 
only user.
19 35 U.S.C. §.203(1). 
20 McGarey B and A Levey. 1999. Patents, Products and 
Public Health: An Analysis of the CellPro March-In 
Petition. Berkeley Technology Law Journal 14(3): 1114. 
21	 CellPro Petition to DHHS, March 3, 1997, cited and 
discussed in McGarey and Levey (see supra note 20).
CellPro petitioned for a license to practice a stem-cell 
separation technique developed by a researcher at
Johns Hopkins University. CellPro had not been able 
to negotiate a license agreement with Johns Hopkins 
or the existing licensee but had used the technology.
It was found guilty of willful infringement on the 
Johns Hopkins patent. CellPro argued in its petition 
for government march in that Johns Hopkins and the 
licensee had failed to commercialize the technology 
in a timely fashion and that public health and safety 
needs were not being met. The NIH rejected both 
grounds of the petition. More recently, NIH was 
petitioned in 2004 to march in due to steep price 
increases imposed by Abbott Labs on ritonavir, an 
HIV/AIDS drug developed in part from public funds.
NIH declined the petitioner’s request. www.aamc.org/
advocacy/library/washhigh/2004/060404/_4.htm. 
22 Both the timeliness clause and the public health and 
safety clause were tested in the CellPro case. 
23 National Academy of Science. 2001. Board on Science,
Technology, and Economic Policy; Committee on 
Intellectual Property Rights in the Knowledge-Based 
Economy, Workshop and Related Papers. April. NAS:
Washington, DC www7.nationalacademies.org/step/ 
STEP_Projects_Intellectual_Property_Rights.html. 
24 CRS. 2000b. R&D Partnerships and Intellectual 
Property: Implications for U.S. Policy. 98-862 STM,
Updated December 6. Congressional Research Service:
Washington DC. p. 11. 
25 See supra note 4.
26 See supra note 4. 
27 AUTM 2005. AUTM Licensing SurveyTM: FY 2004.
Association of University Technology Managers:
Northbrook, IL. www.autm.net. Note that figures 
include royalties and fees from all patents and licenses.
In comparison, NIH royalties from intramural licensing 
were US$52 million in fiscal year 2000.
28 See supra note 24. 
29 Goldberg R. 2001. In Changing Times, NIH, NSF Look 
Outdated. Trendspotter (May). www.genomeweb.com.
This includes product development expenditures.
30 Blumenthal MD and M David. 1995. Capitalizing 
on Public Sector Research Investments: The Case of 
Academic-Industry Relationships in the Biomedical 
Sciences. Presented at NIH Economics Roundtable on 
Biomedical Research: Bethesda, October 19. 
31	 See for example: Bok D. 2002. The Commercialization of 
Higher Education. Princeton University Press: Princeton,
NJ; Kennedy D. 2005. Bayh-Dole: Almost 25. Science 307:
1375; Krimsky S. 2003. Science in the Private Interest.
Rowman & Littlefield: Lanham, MD. 
32 Mission statement and partners in MIHR can be 
viewed at www.mihr.org.
33 See also Widdus R and K White. 2004. Combating 
Diseases Associated with Poverty: Financing Strategies 
Associated with Public Health and the Potential Role 
of Public/Private Partnerships. The Initiative on Public/ 
Private Partnerships for Health, Global Forum for 
Health Research: Geneva. 
34 Ted Roumel, former deputy director of OTT/NIH.
Personal communication, June 2001.
35 It is important to note that many existing purchase 
arrangements through WHO and nonprofits are on 
off-patent medicine and technology. Thus, the bulk 
purchase through a competitive bidding process 
by WHO for TB drugs allowed a 30% lower unit
price through the purchase of generic drugs from 
manufacturers based in The Netherlands and India 
(The New York Times, June 22, 2001).
36 Light D. 2005. Basic Research Funds to Discover 
Important New Drugs: Who Contributes How Much? 
chap. 3 in Global Forum for Health Research: Geneva. 
37 Efficiency is maximized with an arrangement of 
perfect price discrimination (in which each buyer 
pays his maximum price), but can also be improved by 
using block pricing according to the willingness to pay 
of different market segments. This pricing scheme is 
referred to as Ramsey pricing.
38 Tufts Center for the Study of Drug Development.
Outlook 2004. csdd.tufts.edu/InfoServices.
39 The domestic manufacturing requirement in the law 
can be waived and applies only to U.S. sales.
40 For information about PIIPA, see www.piipa.org and 
Gollin M. 2003. Answering the Call: Public Interest
Intellectual Property Advisers. Paper presented at
the Biodiversity and Biotechnology Conference,
Washington University School of Law, St. Louis, MO,
April 4–6, 2003. 
41	 Ethical investment funds or other financial tools are 
recommended among the “Top 10 Biotechnology”
approaches for improving global health by a 
commission of the Joint Center for Bioethics at the 
University of Toronto (see Daar AS, H Thorsteinsdottir,
DK Martin, AC Smith and PA Singer. 2002. Top Ten 
Biotechnologies for Improving Health in Developing 
Countries. Nature Genetics 32: 229–32). 
42	 The Economist. 2002. September 14. p. 14. 
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ABSTRACT 
Seeking to drive economic growth within the knowl­
edge economy, governments have increasingly sought to 
commercialize the results of publicly funded research. 
The ability to use intellectual property (IP) as a tool to 
encourage and facilitate commercialization hinges on 
three fundamental policy concerns: protection, owner­
ship, and management capacity. This chapter surveys 
the policies and practices across an array of emerging 
and developing economies, including Argentina, Brazil, 
Chile, China, Ethiopia, India, Indonesia, Jordan, Kenya, 
Malaysia, Mexico, the Philippines, Poland, Russia, South 
Africa, Tanzania, Uganda, and Vietnam. In regard to the 
availability of intellectual property protections, the sur­
vey finds that countries can logically be sorted into three 
tiers. The first tier contains the most innovative countries, 
those with an active intellectual property system used vig­
orously by domestic patentees. The second tier consists 
of countries actively seeking to become more innovative, 
with intellectual property systems that are only beginning 
to be used by domestic patentees. The third-tier countries 
are those with limited or nascent intellectual property 
systems and virtually no domestic patentees. Almost all 
first tier innovative countries, about half of second-tier 
countries, and no third-tier countries have formally ad­
dressed the question of intellectual property ownership 
through national policy. Among those that have, how­
ever, the survey finds a wide range of policy approaches 
used to address the question of intellectual property own­
ership, including patent law, labor law, government pro­
curement or contract law, and laws governing national 
R&D or innovation systems, as well as rulings by min­
istries of science and technology or ministries of higher 
education. With regard to institutional intellectual prop­
erty management capacity, the survey finds a very broad 
range of sophistication and expertise, both across and 
within countries of all three tiers. Higher capacities for 
institutional intellectual property management appear to 
be more closely associated with levels of R&D expendi­
ture than with the existence or absence of national poli­
cies that allow or encourage institutional ownership. The 
implication is that intellectual property management at 
the institutional level grows in tandem with strong R&D 
and the capacity for the local economy to commercialize 
the technology. 
1. InTRoduCTIon 
As governments in countries with emerging and 
developing economies confront the issues of 
globalization and technological advance, many 
have focused on how domestic universities and 
research institutes can promote economic growth 
by supporting and seeding innovation in the pri­
vate sector. Such institutions have traditionally 
served two core missions: to educate the elites of 
the workforce and to conduct applied or adap­
tive research to address domestic economic and 
social needs. Institutions in developing coun­
tries are also often concerned with carving out a 
place for the country within the global scientific 
community. 
Increasingly, government officials in devel­
oping countries are under pressure to democra­
tize higher education and fund a broader range 
of research and development priorities. At the 
Graff GD. 2007. Echoes of Bayh-Dole? A Survey of IP and Technology Transfer Policies in Emerging and Developing Econo-
mies. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krat-
tiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. GD Graff. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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GRAFF 
same time, commercializing innovation is being 
emphasized as a core mission of publicly funded 
research. To advance this mission, the tools of pat­
enting, technology transfer, and venture creation 
are increasingly deployed. Indeed, in countries 
like China and India, student numbers are swell­
ing, rates of publication in prestigious interna­
tional journals are climbing, academic patents are 
growing, and the number of start-up companies 
is increasing. Like other areas of development 
policy, academic innovation may be an area in 
which developing countries can leapfrog directly 
to the standards and practices of the knowledge 
economy. 
National systems of innovation are not made 
overnight; they evolve over generations. Those 
economies that are today actively seeking to ex­
pand the private economic impact of their pub­
licly funded R&D are building upon the legacies 
of past investment in their institutions and in 
the human capital that is the very source of in­
novation. Today’s challenge is to adapt the policy 
environment to improve the social rate of return 
on those investments. This can be achieved by in­
creasing the flow of technologies into the private 
sector. It is therefore important to understand 
how technology transfer from universities and 
public research institutions is affected by national 
policies. The three fundamental policy questions 
that any country must answer are: 
1. To 	 what extent are intellectual property 
(IP) protections available? 
2. To 	 whom can/should the ownership of 
those property rights be assigned? (To 
the government or third-party sponsor of 
the research? To the institution where the 
work was conducted, or to the individual 
inventor?) 
3. What capacity, in the form of dedicated in­
frastructure, programs, or other resources, 
will be provided to identify, protect, and 
commercialize new technologies and to 
support industrial development and tech­
nology-based entrepreneurship activities?
IP is just one part of an economy’s system of 
innovation. The research base, the legal IP regime, 
and the institutional infrastructure all co-evolve 
in a synergistic process with each part supporting, 
and supported by, the others, just as the differ­
ent parts of an ecosystem co-evolve. This chapter 
provides brief sketches of the national policies 
governing university and public sector technology 
transfer by means of intellectual property, looking 
at how the three basic policy questions have been 
addressed around the world. From these observa­
tions, we can distill general trends in legislative, 
regulatory, and institutional reforms from around 
the world. 
2.  pRIMARy 	AREAS	 of poLICy 	AffECTInG	 
TECHnoLoGy TRAnSfER 
2.1 Availability of IP protection 
The first policy question is whether private-
property rights can be claimed over the intangi­
ble results of research. This issue is governed by a 
country’s intellectual or industrial property laws. 
Some degree of global standardization has been 
achieved through multilateral agreements. The 
Paris Convention of 1883 ensures that foreign 
inventors from signatory countries are treated as 
nationals. The Patent Cooperation Treaty (PCT) 
of 1970 provides a common patent application 
clearinghouse for inventors wishing to file for 
patents in multiple countries. The Agreement on 
Trade-Related Aspects of Intellectual Property 
(TRIPS) of the WTO, adopted in 1994 and 
entered into force in 1995, stipulates minimum 
IP standards for members of the WTO. In ad­
dition, provisions or conditions for IP protec­
tion are often the subject of bilateral trade agree­
ments. Influential centers of trade such as the 
United States and the European Union exert a 
harmonizing influence on the national policies 
of trade partners with whom they have con­
cluded bilateral trade agreements. These trade 
leaders often set standards for IP protection that 
are even higher than the conditions set forth in 
TRIPS. In the specific area of newly bred plant 
varieties, the Union for the Protection of New 
Plant Varieties (UPOV) Convention, adopted 
in 1961 and revised in 1972, 1978, and 1991, 
has established international standards for plant 
variety protection (PVP). Each revision of the 
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CHAPTER . 
treaty outlined increasing levels of protection 
that countries can decide to adopt. 
Even if domestic IP rights are not available 
for a newly invented technology, the inventor 
does have the option of filing in other countries 
where IP rights may be granted. It is common 
for inventors around the world to minimally file 
in the major triad of the United States, Europe, 
and Japan. 
2.2 Ownership of intellectual property 
The second policy question concerns the locus 
of ownership of intellectual property that results 
from work done at publicly funded organizations. 
Legislative reforms have been introduced in many 
countries seeking to systematize and promote 
the commercialization of technologies. Many 
of these efforts have taken inspiration from the 
experience of the United States under the Bayh-
Dole Act of 1980, which harmonized the variety 
of U.S. government agency IP ownership poli­
cies. The Bayh-Dole Act specifically focused on 
the rules concerning the disposition of IP rights 
over inventions that result from federally funded 
research. It effectively limited the government’s 
role in ownership, vesting ownership rights to the 
organization where the invention is made, along 
with responsibilities and conditions for how the 
intellectual property is to be managed. It is pos­
sible, however, for other areas of law, including 
patent law and labor law, to shape how universi­
ties manage intellectual property.1 
2.2.1	 IP, industrial property, or 
patent laws and regulations 
IP or patent law often provides conditions for the 
disposition of patent rights between the individ­
ual inventor, the institution that employs him or 
her, and a designated assignee of the rights, which 
can be either the employing institution or a third 
party. 
2.2.2  Labor or employment 
laws and regulations 
Employment laws and regulations can stipulate 
the privileges, rights, and responsibilities of em­
ployees, including the disposition of rights to in­
ventions made during the course of employment. 
These commonly specify that inventions made in 
the natural course of employment are to become 
the property of the employer, although conditions 
may be put in place, such as requiring additional 
compensation for the employee-inventor. In some 
countries, particularly in continental Europe and 
Scandinavia, an exemption to labor law has been 
historically granted to university faculty, dubbed 
the “professor’s exemption.” This exemption gives 
faculty the right to take ownership over any intel­
lectual property resulting from the research they 
conduct at the university. 
2.2.  Laws of funded or contracted research 
Government funds or contracts, including those 
granted for the conduct of research, often carry re­
quirements for the recipients of those funds or for 
the parties to that contract. In some (increasingly 
rare) cases, a government may explicitly require 
that the results of research funded by the govern­
ment be made freely available to the public, thus 
prohibiting any private IP claims. In other cases, 
a government may itself take ownership of IP 
rights over the results of research. Alternatively, a 
government may choose to devolve the rights of 
ownership, either to the institution that hosted 
the research or to the individual inventor. The pri­
mary justification of the latter two policies is that 
putting the IP rights into the hands of the host 
institution or the inventor properly aligns private 
economic incentives to encourage inventions and 
entrepreneurial activity. The premise is that eco­
nomic activity governed by the market will better 
serve the economy and consumers—while at the 
same time generating rewards and incentives for 
institutions and researchers based on the actual 
market impact of their contribution. 
2.2.  Laws and regulations of 
the national R&D system 
Governments in many countries are taking specif­
ic steps to develop national innovation or R&D 
systems supported by an integrated set of policies 
covering the creation of new research institutions, 
increased research funding, management of hu­
man resources, and the provision of grants and 
subsidies. These policies might include tax incen­
tives for industry R&D and institutions along 
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with funds to support venture investment and 
entrepreneurship. As part of the integrated policy, 
there may be rules for the provenance of intellectual 
property created within the national system. 
2.2.  Ownership questions in the absence of 
domestic policies 
In cases when IP rights are not available in an 
inventor’s home country, the question of owner­
ship may still arise, in particular the ownership 
of available foreign IP rights, whether it be by 
the individual inventor, their government, their 
employing institution, or a third-party assignee. 
Importantly, in the absence of laws specifi­
cally enabling or restricting ownership of intel­
lectual property, universities and public research 
institutions are free to establish their own policies 
and practices. This is the situation in many coun­
tries, including developed countries such as the 
U.K. Such openness can allow a research insti­
tution greater IP management flexibility. On the 
other hand, the lack of a specific national policy 
on IP ownership often indicates a lack of coordi­
nation or transparency. 
2. IP management capacities 
The third fundamental policy question concerns 
the provision for IP management and technol­
ogy commercialization. Merely providing for the 
existence of private-property rights over intellec­
tual assets is not enough. Public institutions need 
more than rights to own intellectual assets; they 
need to develop the infrastructure and expertise 
required to manage these intellectual assets and 
engage in productive commercial relationships 
with private companies and investors. Even in 
high-income countries such as the United States, 
institutional developments took a decade or more 
to spread through universities. While universities 
were left to create infrastructure and expertise on 
their own in the United States, many other coun­
tries have pursued policies that range from pro­
viding subsidies to universities to set up technol­
ogy transfer offices (TTOs)—Denmark is a good 
example—to establishing national networks or 
central offices to coordinate and assist universi­
ties in developing their technology transfer opera­
tions (such as Chile).2 
While national laws and regulations provide 
a legal framework within which universities and 
public research institutes operate, these are ulti­
mately implemented by the staff dedicated to the 
management of technology commercialization. 
Institutional policies can be slow to take shape, 
and dedicating resources, establishing offices, 
and deploying staff takes time and commitment. 
However, while universities develop or adapt for­
mal policies, rules, and regulations, the informal 
norms and practices within the academic culture 
are equally crucial. Once policies and capacity are 
established at the institutional level, an effective 
IP management program can take up to ten years 
to develop and mature into a self-sustaining en­
terprise that is supported by the academic com­
munity. These capacity developments are often 
most visible in the creation of offices or units for 
IP management, technology transfer, or commer­
cialization, and in the volume of patents, licensing 
deals, or spinouts coming from the public sector. 
.  CuRREnT	 poLICIES	In
EMERGInG	EConoMIES 
.1 Argentina 
IP protection. Argentina’s current patent law, the 
Law on Patents and Utility Models No. 24.481 
was adopted in 1995, amended by Law No. 
24.572 in 1995, and harmonized in 1996 by 
Executive Decree No. 260.96. Argentina joined 
the WTO and became signatory to TRIPS in 
1995, which entered into force in Argentina on 
1 January 2000.3, 4 Under Article 100 of the new 
Law on Patents, pharmaceutical products became 
patentable as of 2000 (with patent applications 
accepted as of 1995). Article 6 of the new Law 
on Patents, however, clearly stipulates that plants, 
animals, and indeed “all classes of living materials 
and substances existing in nature” cannot be pat­
ented. Article 7 reinforces this, excluding from 
patentability “the totality of biological and genetic 
material existing in nature…”5 Patents are admin­
istered by the Instituto Nacional de la Propiedad 
Industrial (INPI).6 
Plant varieties are protected in Argentina 
under the 1973 Law No. 20.247 on Seed and 
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Phytogenetical Creation (the Plant Varieties 
Law). Argentina joined UPOV in 1994, as en­
acted by Law No. 24.376 on the Protection New 
Varieties of Plants.7, 8 
In 2004, the National Agency of Scientific 
and Technologic Promotion announced an ini­
tiative to help researchers, both in industry and 
government laboratories, to pay for foreign pat­
ent filings, in an effort to boost the rate of do­
mestic patenting (in many jurisdictions, domes­
tic filing is a prerequisite for foreign filing). In 
2000, 145 patents issued by Argentina went to 
residents of Argentina, while 1,442 went to for­
eign residents.9 
Ownership. The 1990 Law on the Promotion 
of Technological Innovation No. 23.877 and the 
1995 Law on Higher Education No. 24.521 pro­
vided certain conditions for institutional owner­
ship and transfer of intellectual property result­
ing from the work of researchers.10 The 1990 law 
allows national research institutions to establish 
or outsource TTOs, but leaves the question of 
internal distribution of income up to institu­
tional policy. It allows for researchers to receive 
income beyond their government salaries from 
technology commercialization activities. The law 
also provides for government funding of TTOs 
for collaborations with (preferably small) busi­
nesses and establishes a fund for this purpose. In 
the 1995 law, Article 59 establishes the financial 
autonomy of national universities and their right 
to seek additional sources of revenue from the 
provision of services, products, contributions, 
fees charged, and any other resources, including 
technology transfer and commercialization. The 
law also allows national universities to form or 
own corporations.11 
However, the 1995 Law on Patents and 
Utility Models (24.481, modified by 24.572) es­
tablished that the ownership of inventions made 
by employees in the course of their jobs goes to 
the employer, in most cases. But the law also re­
quires the distribution of a share of the income to 
the inventor, and for researchers at national uni­
versities, it, in effect, gives joint ownership to the 
university and the centralized agency CONICET 
(Consejo Nacional de Investigaciones Cientificas 
y Tecnicas), which manages employment and pays 
salaries for most university-based scientists in the 
country. TTOs of individual institutions may es­
tablish individual agreements with CONICET 
for the assignment and management of particular 
inventions. CONICET does not, however, have a 
general policy on handling joint inventions.12 
Institutional capacities. As a result of owner­
ship laws, there is both some IP management and 
coordination capacity at the government level. 
TTOs exist at some universities, and IP manage­
ment is also contracted out to third-party man­
agement companies or centers. Among the most 
developed programs are:13 
•	 University of Quilmes 
•	 University of Cordoba 
•	 University of Litoral 
•	 Inis Biotech (the TTO for Instituto Leloir) 
•	 Some capacity for IP management is central­
ized at CONICET, within its Directive for 
Science and Technology Links (Dirección 
de Vinculación Científico Tecnológica). 
This lists on its Web site more than 60 pat­
ents registered in Argentina, 12 registered 
in other Latin American countries, and 
four registered in the European Union, the 
United States, and Canada14 
•	 The Constituyentes Technology Pole (Polo 
Tecnológico Constituyentes) was created 
in 1997 to facilitate technology transfer 
for several research institutions, includ­
ing the National University of General 
San Martín (UNSAM), the Atomic 
Energy Commission, (Cómision Nacional 
de Energia Atómica - CNEA), and the 
National Institute of Industrial Technology 
(Instituto Nacional de Tecnología Industrial 
- INTI) 
The Secretary of University Policies, which is 
part of the Ministry of Education, has established 
a Technology Network (Red de Vinculacion 
Tecnologica) that holds meetings and provides 
general information. Its main mission is to main­
tain professional networks. 
.2 Brazil 
IP protection. Brazil has a long history of IP rights, 
having first introduced a system of protection in 
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1809. Brazil was also an original signatory to 
the Paris Convention in 1884. Beginning in the 
1950s, Brazil pursued an aggressive science and 
technology policy designed in part to engen­
der economic development under an import-
substitution development policy. The previous 
Industrial Property Code (Law No. 5.772), dat­
ing from 1971, supported this policy by exclud­
ing patent protection for certain areas of tech­
nology, such as pharmaceuticals and chemicals. 
Following political and economic reforms, IP 
laws changed significantly in the 1990s. Brazil 
became a founding member of WTO and thus 
a signatory to the TRIPS Agreement in January 
1995. The Law on Industrial Property No. 
9.279 of 1996 entered into force in May 1997 
to implement TRIPS. It has since been amended 
several times. Patents are administered in Brazil 
by the National Institute of Industrial Property 
(Instituto Nacional da Propriedade Industrial 
- INPI).15 Article 10 of the Law on Industrial 
Property excludes from patentability materials 
existing in nature: “all or part of natural living 
beings and biological materials found in nature, 
even if isolated therefrom, including the genome 
or germplasm of any natural living being, and 
natural biological processes.”16, 17 
Plant varieties are protected under Law No. 
9.456, adopted in April 1997, and implement­
ed by Decree No. 2.366, in November 1997. 
They are also protected by the Ordinances of the 
Ministry of Agriculture No. 503, in December 
1997, and No. 8, in June 1999. Brazil has been a 
member of UPOV since May 1999.18 
In 2002, Brazil issued 666 patents to resi­
dents of Brazil and 1,366 to foreign residents.19 
Ownership. For purposes of invention 
ownership, researchers at universities and pub­
lic research institutes are not considered, under 
Brazilian law, to be different from other kinds of 
employees. The Law on Industrial Property gives 
inventors the right to apply for a patent, but gives 
employers the right to ownership of an inven­
tion by an employee that is “hired to invent,” 
according to the terms of their employment 
contract. The law thus differentiates between in­
ventions made in the course of employed work, 
inventions made separately from employed work 
(free inventions), and inventions that combine 
both (mixed inventions). Universities thus need 
to establish the type of inventions on a case-by­
case basis and can take title to those made in the 
course of employed work. According to Article 
93 of the Law on Industrial Property and spelled 
out in Presidential Decree No. 2.553, of April 
1998, inventors who are employees in public in­
stitutions are to receive remuneration from the 
income created by the patent, as an incentive or 
bonus for inventing. The exact share to be dis­
tributed is left to institutional policy, but is not 
to exceed one-third of the value of the invention. 
Terms of IP ownership and revenue sharing are 
further spelled out in implementing orders of the 
Ministry of Science and Technology, No. 88, of 
1998, and the Ministry of Education and Sport 
(No. 322 of April 1998).20 
Institutional capacities. As early as 1982, un­
der the former military regime, a central office for 
technological innovation was established at the 
National Council for Scientific and Technological 
Development to promote innovation at uni­
versities and encourage technology transfer to 
Brazilian industry. Thereafter, 12 Technological 
Innovation Centers were established at Brazilian 
universities to protect intellectual property and 
facilitate the university–industry interface. Today, 
more than 30 universities and research institutes 
operate TTOs.21 Among the largest and most ex­
perienced are: 
•	 the Agency for Innovation at Unicamp 
(Inova Unicamp)22 at the State University 
of Campinas (Unicamp)23 
•	 the USP Agency for Innovation (Agência 
USP de Inovação)24 at the University of Sao 
Paolo 
•	 the Brazilian Agricultural Research 
Corporation (Empresa Brasileira de 
Pesquisa Agropecuária - EMBRAPA),25 
which adopted an institutional IP policy in 
1996 and opened its IP Secretariat in 1998 
to handle intellectual property and tech­
nology transfer26 
•	 the Technology Development Support 
Center (Centro de Apoio ao Desenvolvim­
ento Tecnológico - CDT), created in 1989 
at the University of Brasília, and among the 
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earliest university centers for technology 
transfer 27, 28 
•	 the Secretariat for Technology Development 
(Secretaria de Desenvolvimento Tecnológico 
- Sedetec) at the Federal University of Rio 
Grande do Sul, formed by merging the op­
erations of a TTO and an incubator net­
work in 200029 
Patenting by Brazilian public sector institu­
tions has grown dramatically. In 2003, the top 
seven universities plus EMBRAPA received 153 
patents in just one year.30 In contrast, over the 15 
years between 1980 and 1995, all Brazilian uni­
versities and EMBRAPA received just 264 pat­
ents combined.31 
. Chile	 
IP protection. IP protection over technological 
inventions in Chile is based upon the Industrial 
Property Law (No. 19.039) of 1991. A 2005 
modification (No. 19.996) brings Chilean law 
into line with the minimum requirements in 
TRIPS and the IP requirements in the bilateral 
free-trade agreements concluded with the United 
States and the European Union. Chile has been a 
member of the WTO and a signatory to TRIPS 
since 1995. However, Chile is not a member of 
the PCT. In Chile, patents are administered by 
the Department of Industrial Property. 32, 33, 34 
Plant varieties are protected in Chile under the 
Rights of Breeders of New Varieties of Plants (No 
19.342) of April 1997. Chile joined UPOV in 
1996. 
In 2000, Chile granted 32 patents to resi­
dents of Chile and 569 to foreign residents. 
Ownership. The Industrial Property Law 
(No. 19.039) regulates the ownership of intel­
lectual property resulting from work conducted 
under contract or employment. A section spe­
cifically on universities stipulates that IP rights 
derived from the work of university employees 
belong to the university or its designee, since 
that inventive or creative work is understood to 
be part of the job obligation. However, certain 
limitations on the assignment of IP ownership 
are set by workers’ rights provisions in Chilean 
labor law, namely that universities cannot ask 
employees to completely waive the portion of IP 
rights due to them as inventors. Major Chilean 
research funding sources (such as FONDEF and 
CONICYT) now require IP protection of results 
by those organizations receiving funding, includ­
ing universities.35 
Institutional capacities. Among leading 
Chilean organizations with an organizational ca­
pacity for IP management are: 
•	 University of Concepción, with its Center 
for Industrial Property (Unidad de 
Propriedad Industrial)36 
•	 In 2003, the University of Chile formed 
the Central Commission for Industrial 
Property (Comisión Central de Propiedad 
Industrial)37 
•	 Fundación Chile, which coordinates inno­
vation and entrepreneurship projects based 
upon Chilean R&D, provides expertise and 
resources for IP management38 
•	 NEOS, a consulting company located in 
Santiago, provides professional IP services 
for universities in Chile39 
. China 
IP protection. IP law is widely viewed in China 
as a western import, with a first patent law adopt­
ed relatively recently in 1984 and a copyright law 
adopted in 1990. While protection and enforce­
ment under these has been of ongoing concern 
for outsiders, the internal political climate has 
been shaped by the desire to join WTO and the 
growing prowess of Chinese companies in science 
and technology. It is largely these internal forces 
that led to the strengthening of the patent law in 
1992 and in 2001. 
New plant varieties are protected under 
the Regulation on the Protection of New Plant 
Varieties, implemented in 1997. China joined 
UPOV in 1999.40 
In 2004, China granted 18,241 patents to 
residents of China and 31,119 patents to foreign 
residents.41 
Ownership. As early as 1985, just five years 
after Bayh-Dole passed in the United States, pro­
visional regulations issued by the State Council 
on Technology Transfer gave Chinese universi­
ties the right to manage and use the inventions 
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of university researchers, even though owner­
ship formally remained with the State.42 The 
government, however, has only recently encour­
aged universities to assert such rights. China 
adopted its Act for Promotion of Technology 
Transfer in 1996, later reinforced by the Decision 
on Reinforcing Technological Innovation and 
Realizing Industrialization of the State Council 
in 1999 and by the Opinion on Exerting the 
Role of Universities in Science and Technological 
Innovation issued jointly by the Ministry of 
Education and the Ministry of Science and 
Technology in 2002.43 The latter is often called 
the “Chinese Bayh-Dole Act.” In 2003, the 
Ministry of Education again clarified the rights 
of IP ownership by institutions undertaking re­
search sponsored by the government in its Key 
Points on Promoting Science and Technology of 
Universities.44 
Institutional capacities. Internal organiza­
tional capacity for IP management is most readily 
found at leading universities, such as: 
•	 Tsinghua University, with probably the 
most well-developed university TTO in 
China45 
•	 Beijing University 
The number of patent applications from 
across the full range of Chinese universities is 
significant. It quadrupled in the four years from 
1999 (with 988 applications) to 2002 (with 4,282 
applications).46 For comparison, U.S. universities 
reported total patent applications increasing less 
than two fold between 1999 (with 8,457 appli­
cations) and 2002 (with 12,222 applications).47 
However, some caution should be taken in inter­
preting these figures, since the practice of patent­
ing by Chinese academics appears to have been 
adopted as something of a proxy for published 
research. In fact, inventorship on patents is wide­
ly admitted as a criterion for academic promo­
tion. Significantly, far fewer Chinese university 
patents are being licensed or commercialized. 
Still, Tsinghua University reports having spun off 
more than 38 companies, generating annual sales 
of US$1.8 billion and actively incubating more 
than 200 companies at the Tsinghua Science Park 
during 2003 alone.48 
. Ethiopia 
IP protection. Ethiopia is an example of a coun­
try still largely outside of the global IP system. 
Ethiopia has a basic patent code, created in 1995 
by Proclamation No. 123 Concerning Inventions, 
Minor Inventions, and Industrial Designs, and 
instituted in 1997 by Regulation No. 12. The 
stated purpose is to encourage local innovation 
(mostly minor adaptations of existing technolo­
gies) and transfer in foreign technologies. The 
proclamation precludes the patenting of plants, 
animals, and essentially biological processes.49 
The country is an observer but not a signatory 
to WTO, and is thus not bound to compliance 
with TRIPS. Ethiopia protects copyright under 
its civil code.50 
PVP was introduced in February 2006 by 
Proclamation No. 481, Plant Breeder’s Rights. 51 
In 2000, the Ethiopian Intellectual Property 
Office received just seven patent applications 
and granted just one, to a foreign resident. In 
the same year it granted 19 industrial designs, 
12 to residents of Ethiopia and seven to foreign 
residents.52 
Ownership. There is no national framework 
and an apparent lack of clarity or transparency 
about the terms and conditions under which 
public research institution or individual inventors 
might be owners of any IP rights. 
Institutional capacities. The largest research 
organizations in the life sciences are Addis Ababa 
University, Alemaya University, the Ethiopian 
Health and Nutrition Research Center, the 
Ethiopian Agricultural Research Organization, 
the National Veterinary Institute, and the 
International Livestock Research Institute (ILRI), 
all producing locally or regionally marketable re­
search results. Only the Ethiopian Agricultural 
Research Organization has an IP unit in forma­
tion. The rest have no IP management units, and 
their scientists and staff have a very low level of 
awareness and knowledge about IP rights. The 
Ethiopian Intellectual Property Office has re­
ceived only a handful of patent applications from 
university researchers in Ethiopia, (primarily in 
agriculture, pharmaceuticals, and mechanics) 
and only one from the Ethiopian Agricultural 
Research Organization.53 
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IP protection. India’s history with IP law is deeper 
than that of many developing countries. The first 
patent law was adopted in 1856, and by 1911 
Indian patent law conformed to the standards 
of developed countries. Copyright, trade secrecy, 
and design laws have been in place equally as long. 
However, patent law was relaxed in 1970 under 
the import-substitution industrial policy, which 
encouraged economic development through the 
reverse engineering of western technologies. Since 
adopting market-oriented reforms and seeking 
WTO membership in the 1990s, reform in IP 
law has been rapid. India joined the WTO and 
became signatory to TRIPS in 1995. Patent law 
was strengthened in 1999 and again in 2002 to 
become compliant with TRIPS.54 Legislation that 
passed in 2005 reinstated the patenting of phar­
maceutical compounds, reversing legislation from 
1970 that limited patenting to the processes for 
the manufacture of pharmaceuticals.55 Today, an 
elite cadre of Indian pharmaceutical companies 
has emerged with the capacity to engage in glob­
ally competitive R&D, significantly influencing 
India’s internal IP policy debate. 
Plant varieties are covered by the Protection 
of Plant Varieties and Farmers’ Rights Act of 
2001.56 India has not joined UPOV. 
In 2004, India granted 851 patents to resi­
dents of India and 1,466 to foreign residents.57 
Ownership. In 2000, the Ministry of Science 
and Technology issued a ruling that gave title to 
intellectual property to those institutions that 
receive funding from the Ministry. While this is 
not a legislated policy, it signaled a milestone in 
an ongoing trend of shifting technology transfer 
activities away from the government to research 
institutions. This trend has been underway since 
at least 1995.58 
Institutional capacities. The bulk of intel­
lectual property and technology transfer expertise 
in the public sector remains located in govern­
ment agencies, particularly in the Council for 
Scientific and Industrial Research (CSIR), the 
Department of Science and Technology (DST), 
and the Department of Biotechnology (DBT). 
The Ministry of Science and Technology, the 
Indian Council of Medical Research (ICMR), 
and the National Research and Development 
Council (NRDC) are also involved in technology 
transfer activities.59 
Most academic intuitions still lack IP man­
agement capacity, with the exception of the lead­
ing Indian Institutes of Technology (IITs) and a 
few other universities. TTOs or centers are now 
found at: 
•	 IIT New Delhi 
•	 IIT Bombay 
•	 IIT Kharagpur 
•	 IIT Kanpur 
•	 IIT Guwahati 
•	 IIT Roorkee 
•	 IIT Chennai 
•	 Delhi University 
•	 Govind Ballabh Pant University of 
Agriculture & Technology, Pant Nagar 
•	 Bidhan Chandra Krishi Vishwavidyalaya 
•	 Jadavpur University60 
Only a small portion of the 277 Indian 
universities listed by the Association of Indian 
Universities have functioning TTOs.61 In April 
2005, a professional association for technol­
ogy transfer was launched—the Society for 
Technology Management (STEM).62 In April 
2006, the Minister of Science and Technology 
announced plans to set up an Indian Institute for 
Intellectual Property Management.63 
. Indonesia 
IP protection. Intellectual property is a relatively 
new concept in Indonesia. Indonesia signed the 
Paris Convention in 1950. It joined WIPO in 
1979. Industrial Designs were introduced by Law 
No. 5, Concerning Industry, in 1984. Patents 
were introduced by Law No. 6, Patent Law, in 
1989 and amended by Law No. 13 in 1997. 
Indonesia has been a member of WTO and a sig­
natory to TRIPS since 1995.64, 65 
In Indonesia, a plant variety can be protected 
by a patent if it fulfils the basic requirements for 
patentability. In addition, in 2001 the Indonesian 
parliament passed a Plant Variety Protection Act, 
based on the UPOV 1991 standards, to estab­
lish a PVP system.66 Indonesia has, however, not 
joined UPOV. 
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In 1996, Indonesia granted 16 patents to 
residents of Indonesia and 615 to foreign resi­
dents.67 In 2003, however, Indonesia granted 
2,902 patents, including both residents and 
nonresidents.68 
Ownership. The 2002 Law No. 18, titled 
National Systems for Research, Development, 
and Application of Technology, stipulates that 
institutions and universities in Indonesia should 
establish units for IP management and that they 
may use the income derived from the exploitation 
of intellectual property.69 
Institutional capacities. There are now, at 
least nominally, over 90 IP management units at 
institutes and universities throughout Indonesia. 
Leading centers of public sector IP management 
include: 
•	 more than 30 research institutes of the 
Agency for Agricultural Research and 
Development (AARD) have their technol­
ogy transfer needs handled by Kekayaan 
Intellectual dan Alich Teknologi (KIAT), 
established in 1999 
•	 Indonesian Institute of Science (LIPI) 
•	 University of Indonesia 
•	 Bandung Institute of Technology 
•	 Bogor Agricultural University (IPB)70 
. Jordan 
IP protection. Jordan joined the WTO in 1999, 
as the 136th member of the WTO. It became a 
member and signatory to TRIPS in April 2000. 
The Patents of Invention Law No. 32 was adopted 
in 1999. In 2001, Jordan signed the U.S.-Jordan 
Free Trade Agreement, which led to further 
IP reforms. Patents are issued by the Industrial 
Property Protection Directorate (IPPD) of the 
Ministry of Industry and Trade.71, 72, 73 
Plant varieties are protected under the Plant 
Varieties Law No. 24 of 2000. Jordan acceded to 
UPOV in October 2004. 
In 2004, Jordan granted four patents to 
residents of Jordan and 56 patents to foreign 
residents. 
Ownership. Jordanian law is flexible in its 
approach to commercializing technology devel­
oped in public sector institutions. Currently, a 
high-level comprehensive review is underway 
of all relevant legislation and supporting regu­
lations to outline areas that could be improved 
by an explicit act promoting commercialization. 
This legal and regulatory review will lead to spe­
cific improvements in their technology transfer 
infrastructure.74 
Institutional capacities. Few universities or 
research organizations have had time to adapt 
to the new IP legislation, and thus far only the 
Royal Scientific Society, the premier government 
research institution, reports having established its 
Technology Transfer Centre.75 
. Kenya 
IP protection. The application of IP regimes is 
not deeply rooted in the history of Kenya or in 
other countries of eastern Africa, and the coun­
try has typically responded to colonial influ­
ence or international developments. Kenya first 
introduced its Patent Registration Ordinance 
in 1914, which was modeled and dependent 
upon the British system. However, the Industrial 
Property Act of 1989 established the first inde­
pendent patent system in Kenya. Kenya joined 
the WTO and became signatory to TRIPS 
in 1995. The 1989 Act was superseded by the 
Industrial Property Act of 2001, which set up the 
Kenya Industrial Property Institute (KIPI)76 as an 
autonomous office to administer patents, utility 
models, trademarks, and service marks. Section 
26 of the Industrial Property Act includes stan­
dard TRIPS exemptions from patentability: 
methods for treatment of human or animal, 
diagnostic methods, any drugs or compounds 
necessary to combat threats to public health, and 
plant varieties.77 
PVP was established in 1972 by the Seeds 
and Plant Varieties Act and implemented un­
der the Seeds and Plant Varieties Regulations of 
1994. Kenya acceded to UPOV in 1999 under 
the terms of the 1978 Act. PVP is administered 
by the Kenya Plant Health Inspectorate Service 
(KEPHIS), under the Ministry of Agriculture 
and Rural Development.78 
In 2001, Kenya granted no patents to resi­
dents of Kenya and 33 patents to foreign resi­
dents. That year just two applications were re­
ceived from residents of Kenya.79 
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Ownership. A national policy for IP owner­
ship, beyond that stipulated in the employment 
and inventorship clauses of the Industrial Property 
Act, is largely irrelevant because public sector re­
search institutions make up most of the R&D in­
frastructure in Kenya. Many were founded with a 
mandate for conducting innovation and product 
development, since R&D is almost nonexistent 
in the private sector. Thus, public institutions are 
neither prohibited nor mandated to take owner­
ship; they are left to themselves to adopt institu­
tional policies and capacities to assert ownership, 
as long as the institutions operate according to 
the basic requirements of national IP law. 
Institutional capacities. The development of 
institutional IP management capacity has been 
motivated partly by reports that the University of 
Nairobi, the premier university in Kenya, has had 
to forego IP rights for some innovations due to a 
lack of clear policy and structures. These innova­
tions included a fermented milk product, a beer 
product, a disease-resistant pea variety, a pesticide 
compound, a database of medicinal plants, and a 
potential AIDS vaccine.80 The following research 
institutions are currently engaged in developing 
IP policies and creating IP offices: 
•	 University of Nairobi has recently adopted 
an IP policy that establishes an internal 
TTO.81 
•	 Moi University has established Moi 
University Holdings Ltd., a fully owned 
subsidiary with a TTO to manage the uni­
versity’s intellectual property.82 
•	 Jomo Kenyatta University of Agriculture 
and Technology (JKUAT) has drafted an 
IP policy and employs one IP manager. 
•	 At Kenya Agricultural Research Institute 
(KARI) a legal officer manages intellectual 
property. 
•	 The International Livestock Research 
Institute (ILRI) adopted an IP policy in 
1998 and has an IP office at its Nairobi 
center.83, 84, 85 
.10 Malaysia 
IP protection. Malaysia instituted a range of IP 
laws in the 1980s, including the Patents Act of 
1983 (Act No. 291). The Patents Act has been 
amended several times, both before and after 
Malaysia joined the WTO and signed TRIPS in 
1995. The Patents Act excludes from patentabil­
ity the same life-science subject matter excluded 
in TRIPS, including plant and animal varieties, 
essentially biological processes, and methods of 
medical diagnosis and treatment. Since the 1983 
Act, Malaysia has allowed product patents on 
pharmaceutical and agricultural chemical com­
pounds. The Intellectual Property Corporation of 
Malaysia Act of 2002 (Act No. 617) established 
the Intellectual Property Corporation of Malaysia 
as the new patent office. Malaysia joined the PCT 
in August 2006.86 
The Protection of New Plant Varieties Act 
of 2004 (Act No. 634) is largely compliant with 
UPOV, even though Malaysia has not yet joined 
UPOV.87 
In 2003, Malaysia granted 31 patents to resi­
dents of Malaysia and 1,542 patents to foreign 
residents.88 
Ownership. Under the Patent Act of 1983, 
employers, including publicly funded research in­
stitutions, are the rightful owners of intellectual 
property created by employees in the course of 
employment. However, there have been recent 
ministerial examinations of IP ownership issues 
in cases where government funding is involved. 
In 2003, the government announced the Second 
National Science and Technology Policy, which 
included the following clauses: 
•	 “to promote adoption of sound research man­
agement practices including intellectual prop­
erty management and commercialisation of 
research outputs in all PRls [public research 
institutes] and universities.” 
•	 “to enhance the management of intellectual 
property rights including patent advisory and 
other services.” 
•	 “to review existing legislation or to develop 
new legislation related to policy.”89 
In 2004, Malaysia’s Ministry of Science, 
Technology, and Innovation (MOSTI), at the 
prompting of the prime minister, began a review of 
incentive systems to attract and retain Malaysian 
scientists, including the availability of R&D fa­
cilities, financial assistance, and venture capital.90 
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The Ministry also considered IP policy options 
similar to those in the United States under the 
Bayh-Dole Act.91 The government then indicated 
that it would instead pursue a policy of three-way 
IP rights sharing: the government, research insti­
tute, and inventor would all jointly own research 
results.92 In a March 2006 announcement, the 
head of MOSTI announced, “research work un­
dertaken with government grants should be jointly 
owned by the Government, the respective university, 
as well as the scientists involved.”93 
Institutional capacities. Most universities 
and institutes established their internal IP policies 
under the Patent Act of 1983, asserting institu­
tional ownership of inventions made by employ­
ees and managing them accordingly. Currently, 
17 out of the 45 or so universities in Malaysia 
have established TTOs.94 IP management offices 
found at leading universities and research insti­
tutes include: 
•	 University of Malaya’s Technology Transfer 
and Commercialization Unit (UPTK) 
was founded in 1998 as part of the uni­
versity administration, but in 2001 it was 
transferred to the university’s Institute of 
Research Management and Consultancy 
(IPPP), which handles the full range of re­
search interactions with industry. 
•	 At Universiti Sains Malaysia (USM), the 
Research Creativity and Management 
Office (RCMO) handles many issues re­
lated to R&D relations with industry, in­
cluding IP marketing.95 Some aspects of 
patenting and commercialization are also 
handled by the Corporate and Sustainable 
Development Division (BPLK).96 
•	 Univeristi Teknologi Malaysia (UTM) is the 
premier engineering institute in Malaysia. 
In 1993, the university created a Bureau of 
Innovation and Consultancy to promote 
technology commercialization within its 
Research and Consultancy Unit, which has 
managed research relations with industry 
since 1981.97 
•	 Universiti Malaysia Sarawak (UNIMAS) 
has recently established the new Intellectual 
Property and Commercialization Unit 
(IPMCU) within the university’s Research 
and Innovation Management Centre 
(RIMC), which was formed in 2005 out 
of the previous Research Management 
Unit established in 2003.98 Some IP com­
mercialization services are also offered by 
the Centre for Technology Transfer and 
Consultancy (CTTC), formed in 1993 to 
facilitate collaboration between university 
experts and local industry.99 
•	 The Malaysian Palm Oil Board (MPOB) has 
been one of the most successful organizations 
in the country in using intellectual property 
to commercialize technology.100 MPOB of­
fers an extensive list of technologies available 
for transfer and commercialization, with 
licensing managed by the Licensing and 
Enforcement Division.101, 102, 103 
•	 The Malaysian Agriculture Research and 
Development Institute (MARDI) has a siz­
able technology transfer and commercializa­
tion unit and list of technologies available 
for transfer and commercialization.104, 105 
.11 Mexico 
IP protection. Mexican patent law has been 
in place since the early 1800s. Today, intellec­
tual property protection is governed under the 
Industrial Property Law, adopted in 1994 and 
amended in 1997 and 1999.106 Mexico joined 
the WTO and signed TRIPS in 1995. Mexico’s 
Industrial Property Law excludes from patent-
ability any essential biological process for the pro­
duction, reproduction, and propagation of plants 
and animals; biological and genetic materials as 
found in nature; animal species; the human body 
and its living components; and plant varieties.107 
Patents are administered by the Mexican Institute 
for Industrial Property (Instituto Mexicano de la 
Propriedad Industrial).108 
Mexico protects plant varieties through the 
1997 Federal Law on Plant Varieties (Ley Federal 
de Variedades Vegetales), under regulations imple­
mented in 2000 by the Ministry of Agriculture. 
Mexico joined UPOV in 1997, but joined under 
the terms of the 1978 Act.109 
In 2004, Mexico granted 162 patents to 
residents of Mexico and 6,677 patents to foreign 
residents.110 
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Ownership. In Mexico, Article 163 of the 
Federal Labor Law (Ley Federal del Trabajo), 
adopted in 1970 and reformed in 1998, gov­
erns the ownership of inventions made by 
employees.111 The law indicates that results of 
research are owned by the employer, who has 
the right to exploit patents. The employee, 
however, is to be given additional compensa­
tion, and in some cases the right of ownership. 
In all cases, the employee’s name is listed as in­
ventor. The Industrial Property Law, Article 14, 
reflects these protections of the employee. The 
2002 Law of the National Council of Science 
and Technology (Ley de Ciencia y Tecnología), 
Articles 47–59, discusses invention ownership 
in cases where the national science council 
(CONACYT) finances research and develop­
ment in universities or any other nongovern­
mental organizations and in the 60 or so public 
research institutes and agricultural R&D centers 
in Mexico. In both cases, the ownership of the 
results is determined according to the policies 
of the organization where the research is car­
ried out. Many organizations, like universities 
and large companies, have policies that indicate 
that the ownership of research results goes to 
the institution, but in most cases the inventor 
will get some share of the financial benefits. 
Usually in the case of universities, the research­
ers are named as the inventors on the patent but 
sign full ownership rights over to the university. 
Within universities, the distribution of benefits 
follows the terms of an internal agreement or 
institutional policies.112 
Institutional capacities. Development of 
institutional IP policies and discrete offices of 
IP management is minimal, but includes the 
following: 
•	 At the National Autonomous University of 
Mexico (UNAM), the General Counsel’s 
Office oversees IP policy and management. 
However, according to a critique in Nature 
Biotechnology, “there is no support, even at 
the university level, for patenting: the level of 
technology transfer is low… UNAM has nei­
ther sufficiently trained personnel, nor, appar­
ently, the interest to fight for its share on the 
patents.”113 
•	 Instituto Tecnológico de Estudios 
Superiores de Monterrey (ITESM) has en­
gaged in several projects involving technol­
ogy transfer in aerospace and expert systems 
engineering 
•	 CINVESTAV is engaged in a number of 
biotechnology projects and has mediated 
transfers of proprietary biotechnologies. 
.12 Philippines 
IP protection. IP protection has a somewhat 
deeper history in the Philippines than in some of 
its neighboring Asian countries. After achieving 
independence from the United States in 1946 at 
the end of World War II, the Philippines provid­
ed for the protection of inventions, utility mod­
els, and industrial designs under the Republic Act 
(No. 165) of 1947. Borrowing heavily from U.S. 
patent law, it provided 17 years of protection from 
the date the patent is granted and recognized pri­
ority based on “first to invent.” The Philippines 
joined the WTO at its founding in 1995 and be­
came a signatory to TRIPS. IP law was brought 
into compliance with TRIPS provisions in 1998 
with Republic Act (No. 8293), the Intellectual 
Property Code of the Philippines. This changed 
patent terms to 20 years from date of filing and 
recognized priority based on first to file. The Act 
also created the Intellectual Property Office of 
the Philippines. In accordance with TRIPS pro­
visions, the Act treats as non-patentable plants, 
animals, and essentially biological processes for 
the production of plants and animals.114 
Republic Act (No. 9168) of 2002, titled Act 
to Provide Protection to New Plant Varieties, 
provides for sui generis protection of plant vari­
eties and established the National Plant Variety 
Protection Board. The Philippines is not a mem­
ber of UPOV.115 
In 2003, the Intellectual Property Office 
of the Philippines granted 11 patents to resi­
dents of the Philippines and 1,160 patents to 
nonresidents.116 
Ownership. The Philippines has no enabling 
legislation to give ownership of inventions to uni­
versities or research institutes, effectively leaving 
them free to develop their own institutional IP 
ownership policies. 
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Institutional capacities. Policies and offices 
for IP management are being developed both 
centrally and at leading research institutions: 
•	 The Department of Science and Technology 
(DOST) has developed IP guidelines and 
the Technology Application and Promotion 
Institute (TAPI) to provide centralized 
services in technology transfer for pubic 
institutions.117 
•	 A central University Intellectual Property 
Office (UIPO) for the University of the 
Philippines was established in 1997 to co­
ordinate offices at its six semiautonomous 
campuses.118, 119 
•	 IP and technology transfer needs of faculty 
at the University of the Philippines, Diliman 
campus, is served by an intellectual property 
section within the Research Dissemination 
and Utilization Office (RDUO) of the 
Office of the Vice Chancellor for Research 
and Development. 
•	 The University of the Philippines, Manila, 
the main medical research university, has 
an intellectual property rights office in the 
Office of the Vice Chancellor for Research. 
•	 The University of the Philippines, Los 
Baños, has an intellectual property rights 
office in the Office of the Vice Chancellor 
for Research and Extension. 
•	 The Philippine Rice Research Institute 
(PhilRice) of the Department of Agriculture 
created a TTO in 2004. 
•	 The International Rice Research Institute 
(IRRI) adopted an IP policy in 1994 that 
specifies that IP protection will only be 
used selectively to serve the needs of farm­
ers in developing countries. IRRI coordi­
nates intellectual property for some biotech 
projects for other institutions with which it 
partners. 
Thus far, only a few dozen patents have issued 
to public sector institutions in the Philippines.120 
.1 Poland 
IP protection. Poland’s IP system is relatively 
mature, with the Polish Patent Office formed in 
1918. However, the intervening years of socialist
government had some effects, with Poland join­
ing the PCT only in 1990. Poland became a sig­
natory to TRIPS along with WTO membership 
in 1995. The Industrial Property Law of 2000 
(in force since August 2001) brought Polish pat­
ents and trademark law into compliance with 
TRIPS, and its amendment in 2002 brought 
Polish law into harmony with E.U. directives on 
biotechnology intellectual property, including 
patentability of biological materials, methods, 
and uses.121 
The Law on Seed Industry of 1995 conforms 
to UPOV, of which Poland has been a member 
since 1989.122 
In 2004, Poland granted 778 patents 
to residents of Poland and 1,016 to foreign 
residents.123 
Ownership. The Industrial Property Law, 
Article 11(3) stipulates that an employer or a 
contractor is the rightful owner of an invention 
produced under work for hire or contract, unless 
otherwise agreed upon by the parties involved. 
This gives universities flexibility to arrange for 
ownership through terms of employment and 
research agreements.124 In recent years the Polish 
government has been shifting R&D spending 
away from relatively inefficient industry research 
institutes and state-owned companies and toward 
universities.125 This shift in funding, however, has 
not been accompanied by any new policy specifi­
cally affirming or denying institutional ownership 
of IP rights resulting from research conducted 
with state funds. 
Institutional capacities. In practice, univer­
sities own the intellectual property resulting from 
research they conduct.126 IP management offices 
in Poland are still developing and are found most­
ly at the leading universities, including: 
•	 The Wroclaw Center for Technology 
Transfer (WCTT) formed in 1995 at the 
University of Wroclaw.127 
•	 The Technology Transfer Center (Centrum 
Transferu Technologii - CTT) formed 
in 1997 at the Cracow University of 
Technology. 
•	 The Centre of Innovation, Technology 
Transfer, and University Development 
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(CITTRU), formed in 2003 at Jagiellonian 
University.128 
•	 The Technology Accelerator and the Inno­
vation Center at the University of Lodz129 
formed in 2003 through a mentoring col­
laboration involving technology commer­
cialization and entrepreneurship established 
between the University of Texas at Austin 
and the University of Lodz. This was an 
offset commitment under an agreement be­
tween Lockheed Martin and the Polish Gov­
ernment for the purchase of F-16 fighters. 
•	 Poland has four regional Innovation Relay 
Centres (IRCs) hosted at university tech­
nology centers, such as the IRC South 
Poland, which is coordinated by the CTT 
at Cracow University of Technology.130 
The IRC Network was established by the 
European Commission in 1995 and now 
consists of 71 regional centers through­
out Europe. It seeks to support innovation 
and transnational technology cooperation 
through coordinated activities and a com­
mon technology database. 
.1 Russia 
IP protection. Russia has a history of intellectual 
property that dates to the time of the czars. The 
first patent law was adopted in 1812, and then re­
formed in 1896.131 During the Soviet period, the 
State effectively exercised monopoly power over 
all technological innovations, including those 
arising from universities and research institutes, 
with a Committee on Inventions and Discoveries 
issuing authorship certificates to inventors.132 
In 1991, the U.S.S.R. Law on Inventions radi­
cally departed from the Soviet system, creating 
a form of patent protection that gave exclusive 
rights of ownership to inventors. In 1992, follow­
ing the establishment of the Russian Federation, 
a range of IP legislation was adopted, including 
the Patent Law of 1992. The Committee for 
Patents and Trademarks was created, and in 1996 
it was changed to the current Federal Service for 
Intellectual Property, Patents, and Trademarks 
or ROSPATENT.133 In 2003, the Patent Law 
was amended to bring it into alignment with the 
provisions of TRIPS.134 As of 2006, the Russian 
Federation is still only an observer to the WTO 
and is thus not bound to compliance with 
TRIPS. 
The Russian Federation provides for PVP 
under the Law on Protection of Achievements in 
Plant Breeding, adopted in 1992 when the range 
of new IP legislation was introduced. In 1998, 
Russia became a member of UPOV under the 
terms of the 1991 Act.135 
In 2005, Russia issued 19,447 patents to resi­
dents of Russia and 3,943 to foreign residents.136 
Ownership. Attempts were first made to 
clarify the question of ownership by public re­
search organizations in 1998 with the Decree of 
the President No. 863 “On state policy for the in­
troduction of the results of scientific and technolog­
ical activity and objects of intellectual property into 
economic turnover,” and implemented in 1999 by 
Resolution No. 982 “On the use of the results of 
scientific and technological activity.”137, 138 While 
stating in principle that a research organization 
might take IP rights over inventions made un­
der work funded by the federal budget, in effect, 
the policies gave the Russian government first 
right to any intellectual property by giving the 
government rights to any military, dual-use, or 
other technologies deemed “of use to the State,” 
and by requiring all inventions made under 
federal funding to be recorded with the federal 
government. These conditions meant that very 
few publicly funded inventions were reported 
and that few patents were sought through offi­
cial channels.139 A fundamental shift in the gov­
ernment’s position, which provided clarity over 
the rights of the organization conducting the re­
search, only came about in the 2003 revision of 
the Patent Law. Article 9 states that the right to 
patent an invention created under state funding 
belongs to the contracted research organization, 
unless the research agreement specifies that the 
right belongs to the government.140 
Institutional capacities. Despite the State 
centralization and lack of formal IP rights un­
der the Soviet system, some attention was paid 
to developing mechanisms for the administrative 
management of technology transfer at the institu­
tional level. While technology transfers were free 
of charge, they did occur between public research 
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organizations and state companies in the Soviet 
Union and in other Soviet bloc nations. 
As a result, a significant number of univer­
sities and research institutes today have well-de­
veloped technology transfer policies and offices 
in place. In addition, a number of private, third-
party companies and centers have emerged to 
coordinate technology transfer services for mul­
tiple clients, including universities, institutes, and 
companies, within particular regions or particular 
fields of technology. Leading examples include: 
•	 the intellectual property and technology 
transfer department of the St. Petersburg 
State University, founded in 1967 as the 
Patent and Licensing Department (PLD) 
of the university141 
•	 the Puschino Center for Technology Transfer 
of the Puschino Scientific Center142 
•	 the Innovation and Technology Center of 
the University of Nizhny Novgorod143 
•	 the Patent Service Center of the Saratov 
State University144 
•	 the Obninsk Center for Science and 
Technology, which manages technology 
transfer and business development proj­
ects for the Institute of Physics and Power 
Engineering (IPPE), as well as for R&D 
centers in the Russian Ministry of Atomic 
Energy and the Russian Ministry of Science 
and Technology. 145 
•	 the Urals Regional Technology Transfer 
Center 146 
•	 the Southern Center for Technology 
Transfer 147 
In 2005, a professional association for tech­
nology transfer was launched in Russia and oth­
er former Soviet republics, called the Eurasian 
Association of Technological Transfer Managers 
(EATTM).148 
.1 South Africa 
IP protection. IP law in South Africa historically 
derives from U.K. law. South Africa’s first Patents 
Act (No. 37) of 1952 was modeled on the British 
Patents Act of 1949.149 It was superseded by the 
Patents Act No. 57 of 1978, which is in force 
today, though amended at least eight times.150 
South Africa signed the TRIPS agreement in 
1995. Patent Amendment Act No. 58 of 2002 
was largely responsible for bringing the provi­
sions of the Patents Act into line with TRIPS re­
quirements. The Act excludes from patentability 
“any variety of animal or plant or any essentially 
biological process for the production of animals 
or plants.”151 Patents in South Africa are adminis­
tered by the Companies and Intellectual Property 
Registration Office (CIPRO).152 
Plant varieties are protected in South Africa 
under the Plant Breeder’s Rights Act No. 15 of 
1976. South Africa became a member of UPOV 
in 1977 and still adheres to the 1978 Act. 
In 1995, the last year in which data was re­
ported to WIPO, 5,549 patent applications were 
received from residents of South Africa, and 
5,501 patent applications were received from for­
eign residents.153 
Ownership. The patent law of South Africa 
contains IP ownership terms typical of many 
countries, but it does not detail public sector 
employers’ rights of ownership or provide terms 
for publicly funded research.154 However, a na­
tional policy for the ownership of patent rights 
by public research organizations is currently in 
development.155 In the absence of such policies, 
the question of ownership has historically been 
shaped by institutional IP policies. But these are 
not uniform across or within institutions. While 
most universities prefer to take ownership of in­
tellectual property whenever possible, a relatively 
high level of their research funding (about 58%) 
comes from industry contracts, which typically 
stipulate industry control of IP rights resulting 
from the funded project.156 As a result, most uni­
versities maintain flexible policies and relinquish 
ownership of intellectual property as needed to 
obtain industry research funding.157 
The National R&D Strategy of 2002 con­
tained language recommending improved protec­
tion and commercialization of intellectual prop­
erty from public research.158 
In 2006, draft legislation embodying these 
recommendations was proposed: the Framework 
for Intellectual Property Rights from Publicly 
Financed Research. The Framework is largely 
modeled on the U.S. Bayh-Dole Act. It seeks to 
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unify IP policies across different government 
agencies that fund R&D and gives primary 
rights and responsibilities over intellectual prop­
erty to the funded research organization. The 
draft legislation also retains certain privileges for 
the government to use protected technologies 
and gives preference for licensing to domestic 
companies.159 
Institutional capacities. In order to sup­
port their important funding relationships with 
industry, a cadre of elite research universities in 
South Africa has developed significant IP policies 
and internal capacities for IP management. These 
include:160 
•	 University of Stellenbosch has a technology 
transfer officer in the Office of Research 
and has established Unistel, a wholly 
owned subsidiary, to commercialize re­
search through start-up companies. 
•	 University of Cape Town (UCT) has a well-
developed IP policy and an office called 
UCT Innovation with a staff that handles a 
range of activities, including management 
of research contracts, protection of intellec­
tual property, and technology commercial­
ization and entrepreneurship. 
•	 University of Pretoria and the Council for 
Scientific and Industrial Research (CSIR), 
the national research agency, have col­
laborated to form a private company, the 
Southern Educational Regional Alliance 
(SERA) Ltd., to handle licensing and com­
mercialization for both institutions. 
•	 The South African Medical Research 
Council has a technology commercial­
ization unit called the MRC Innovation 
Centre.161 
With the pending advent of the Framework, 
the government has also proposed a centralized 
office, the Innovation Fund Commercialization 
Office (IFCO), to assist public institutions with 
IP management and to help cover some of the 
costs associated with IP protection.162 
In 2002 a regional association for technol­
ogy transfer professionals was launched, called 
the Southern African Research and Innovation 
Managers (SARIMA).163 
.1 Tanzania 
IP protection. Like other east African coun­
tries, Tanzania inherited a colonial IP system 
from the U.K., including the Patent Registration 
Ordinance 217 of 1931. The patent ordinance 
was superseded by the Patent Act No. 1, adopted 
in 1987 and implemented in 1994. Tanzania 
joined the WTO and became signatory to 
TRIPS in 1995, but under the terms for devel­
oping countries it had until 2006 to become 
fully compliant with its provisions. In 1997, 
under the Government Executive Agencies Act 
No. 30, the Business Registrations and Licensing 
Agency (BRELA) was established to administer 
industrial property. Tanzania has been a mem­
ber of the African Regional Industrial Property 
Organization (ARIPO) since 1983.164, 165 
Tanzania is not a member of UPOV, but in 
compliance with its obligations under TRIPS, 
it adopted the Plant Breeder’s Right Act No. 
22 in 2002 to provide protection for new plant 
varieties.166 
In 1989, the last year for which data were 
reported, Tanzania granted 23 patents, all to for­
eign residents.167 
Ownership. Similar to other African nations, 
the Patent Act serves as the policy for IP owner­
ship. Public sector research institutions make up 
most of the R&D infrastructure in Tanzania; pri­
vate sector R&D is almost nonexistent. The pub­
lic institutions are neither specifically prohibited 
nor mandated by law to take ownership, but are 
left to adopt institutional policies and capacities 
to assert any ownership under the terms of na­
tional IP law. 
Institutional capacities. Several of the lead­
ing universities and research institutes have taken 
the first steps to establish institutional IP policies 
and are just beginning to set up IP management 
offices:168 
•	 Sokoine University of Agriculture, the first 
institution in Tanzania to develop an insti­
tutional IP policy, adopted in December 
2003 
•	 Dar es Salaam Institute of Technology 
•	 Tanzania Industry Research and Develop­
ment Organization 
•	 Tropical Pesticides Research Institute 
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.1 Uganda 
IP protection. After independence in 1962, 
Uganda maintained a patent system inherited 
from the U.K. until the Patents Statue No. 10 
was adopted in 1991. Subsequently, the Patents 
Act, Chapter 216 was passed and regulations 
were implemented in 1993. Section 3 created 
the Office of the Registrar of Patents and a pat­
ent registry office to administer the granting of 
patents. Uganda was a founding member of the 
WTO and became signatory to TRIPS in 1995. 
The Patents Amendment Act No. 7 of 2002 
brought Uganda into the PCT mechanism, but 
Uganda is still developing legislation to bring 
patent law into full compliance with TRIPS. 
Uganda has been a member of the African 
Regional Industrial Property Organization 
(ARIPO) since 1978.169, 170 
Although not a member of UPOV, Uganda 
is a member of the Organization of African Unity 
(OAU), which has advocated a separate set of 
standards for PVP in African countries. Uganda 
passed the Agricultural Seeds and Plants Act in 
1994 to provide for the registration of new plant 
varieties. 
In 2001, Uganda granted no patents to resi­
dents of Uganda and 34 patents to foreign resi­
dents. That year only two patent applications 
were received from residents of Uganda.171 
Ownership. No specific requirements, con­
straints, or distinctions are made in Ugandan law 
regarding the ownership of intellectual property 
by public sector research institutions or owner­
ship of intellectual property from work funded by 
the Ugandan government. As such, universities 
and research institutes are left to adopt institu­
tional policies and capacities to assert IP owner­
ship under the terms of national IP law. 
Institutional capacities. IP management 
in Ugandan institutions is, at best, embryonic, 
with the following developments reported for the 
country’s leading research institutions:172 
•	 The Uganda National Council for Science 
and Technology (UNCST) has plans to de­
velop an IP management policy and office 
that could serve as a central advisor on IP 
management issues for R&D institutions 
that lack such capacity. 
•	 The Ugandan Industrial Research Institute, 
which is very active in collaborating with 
local industry, has a single liaison officer in 
charge of IP issues. 
•	 Makerere University, the oldest and largest 
university in Uganda, has no IP manage­
ment policy or office. 
.1 Vietnam 
IP protection. Chapter II of Part Six of the 
Civil Code of 1995, on intellectual property 
and technology transfer, covers industrial prop­
erty and was the first legislation to introduce IP 
protections and include basic TRIPS provisions. 
Decree No. 63/CP of the Government, pro­
mulgated in October 1996, contained detailed 
regulations concerning Industrial Property.173 
Enacted in November 2005 and entered into 
force in July 2006, the new Intellectual Property 
Law has introduced comprehensive TRIPS-
compliant IP standards, with the decrees and 
circulars needed to implement this law likely 
to be out by the end of 2006.174 Vietnam en­
tered into a bilateral free trade agreement with 
the United States in 2004, which obliges it to 
protect U.S. intellectual property. Vietnam also 
joined the WTO in December 2006, bringing 
with it the formal commitment to comply with 
TRIPS obligations. 
Vietnam introduced PVP in 1995. However, 
only the new Ordinance on Plant Varieties of 
March 2004 made it a workable system. PVP 
is also included in the new Intellectual Property 
Law of 2006. Vietnam’s membership in UPOV is 
slated for late 2006.175 
In 2005, Vietnam issued 17 patents to resi­
dents of Vietnam and 756 to foreign residents.176 
So far, only about 14 instances of PVP have been 
granted in Vietnam, almost all going to foreign 
entities. There are currently 18 new applications 
for PVP, with some coming from domestic com­
panies and universities.177 
Ownership. In general, property rights are 
still weak in Vietnam. There are few mecha­
nisms in Vietnam to clarify and ensure the 
rights of ownership over technology created at 
universities and research institutes.178 The situ­
ation is further complicated because, despite 
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CHAPTER . 
increasing autonomy, universities are still in 
many respects regarded as part of the State ap­
paratus.179 Industry is also still in the process of 
being privatized, and in most cases the State still 
holds a large minority stake in, if not outright 
control of, private companies. 
Institutional capacities. Currently, univer­
sity researchers and administrators in Vietnam 
do not have much understanding of intellectual 
property. Their organizations largely lack IP man­
agement capacity, although some are beginning 
to seek patents and plant variety protections. 
Leading research institutions in the life sciences 
are beginning to orient toward intellectual prop­
erty as a tool for technology transfer. These insti­
tutions include: 
•	 The Institute for Biotechnology of 
the Vietnam Academy of Science and 
Technology, which does not yet have a 
formally adopted IP policy, has registered 
about 20 patents. Inventions and royalty 
distributions are decided on a case-by-case 
basis. 
•	 Hanoi Agricultural University’s Science 
Management Office has handled IP is­
sues for its researchers. Estimates are that 
university faculty members have registered 
three or four patents and six to seven trade­
marks, largely on new crop varieties.180 
•	 The Institute of Agricultural Genetics of 
the Ministry of Agriculture and Rural 
Development states that technology trans­
fer is an important goal of new research 
projects, particularly technology transfer to 
farmers, but it has not registered intellec­
tual property over any inventions. 
•	 The University of Technology of Hanoi: In 
the last five years, 20 of the leading techni­
cal and agricultural universities in Vietnam 
have signed 13,000 contracts worth VND 
1,188 billion (approximately US$74 mil­
lion). From 2000 to 2004, 22 Technology 
and Equipment Fairs, called Techmarts, 
were held in Vietnam, through which uni­
versities and research institutes sold more 
than 2,000 technology contracts worth 
up to VND 4,000 billion (approximately 
US$250 million).181 
. TREndS	And ConCLuSIonS	 
The 18 countries examined above provide a rep­
resentative cross-sampling of emerging and devel­
oping economies. They represent an enormously 
broad cultural, social, and economic landscape. 
Still, trends are discernable in the three areas 
reviewed: the availability of IP protections, the 
ownership of intellectual property over publicly 
funded research, and the institutional exercise of 
IP rights. 
.1 Trends in IP protection 
Trends in the availability of IP rights follow sev­
eral fundamental determinants. The first is the 
domestic science and technology capacity in the 
public and private sector and the level of eco­
nomic development, both of which serve to drive 
the formation of IP policies and the use of the 
IP system by residents. A second and somewhat 
correlated determinant is the history of IP laws 
within the country; this factor is more difficult to 
measure than the first. Some countries have had 
systems in place for over a century, particularly 
in Europe (Russia and Poland) and those that 
were major European, and particularly British, 
colonies (India and South Africa). This leaves a 
legacy of IP practices, even if IP rights have not 
been extensively used or enforced. Third, nation­
al agreements, in particular TRIPS and UPOV, 
have driven IP legislation in virtually every coun­
try reviewed. 
Roughly three tiers emerge when gauging 
the robustness of domestic IP systems (Table 1). 
The first tier consists of a handful of countries 
that have functioning IP policies and institu­
tions, along with substantial numbers of domes­
tic patent applications. These countries include 
the most-advanced innovators among emerging 
and developing economies, such as Brazil, China, 
India, and Russia. 
These countries all generate something in the 
range of 3,000 to 30,000 science and engineer­
ing articles per year. Their national patent offices 
grant 1,000 to 30,000 patents per year. Crucially, 
residents account for at least 50% of patent re­
cipients, signifying a significant level of domes­
tic innovation that is generated by national IP 
systems. 
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The second tier contains the bulk of middle-
income countries that have recently developed 
or improved their IP policies but that still grant 
most of their patents to foreigners. These include 
countries like Argentina, Indonesia, Malaysia, and 
Mexico. These countries have some research capac­
ity, evidenced by the generation of 300 to 3,000 
science and engineering articles per year. Their na­
tional patent offices are functioning, granting sev­
eral hundred to several thousand patents per year. 
Crucially, however, domestic inventors are receiv­
ing less than 10% as many patents as foreigner ap­
plicants. Thus, the patent system is primarily being 
used to protect imported technologies. Still, com­
panies and governments are typically seeking ways 
to better exploit the IP system’s R&D efforts. 
The third tier consists of the lowest-income 
countries, in which there is neither a strong IP 
system in place nor a great number of domes­
tic patents applicants. These include countries 
like Ethiopia, Kenya, Tanzania, and Uganda. In 
this survey, all of the representatives of the third 
group are in Sub-Saharan Africa. These countries 
have little research or technological capacity, gen­
erating less than 300, and on average less than 
100, science and engineering articles per year. 
Their national patent offices are not very active, 
granting less than 50 patents per year. Most sig­
nificantly, no patents are granted to domestic in­
ventors, only to foreigners. 
.2 Trends in IP ownership policies 
On the question of ownership over inventions 
developed from government-funded research, 
policies appear to be converging on the practice 
of giving the rights and responsibilities of own­
ership to research institutions, with some flex­
ibility for exceptions depending on the national 
context. This convergence typically stems from 
strengthening IP protections and/or increasing 
government spending on R&D, but it also grows 
out of an awareness of global policy trends and a 
desire on the part of governments to enhance the 
impact that their spending on R&D will have on 
economic development. 
The mechanisms through which policies on 
ownership of intellectual property arise are more 
diverse (Table 2). These include: 
• ownership clauses in patent law 
• ownership clauses in labor law 
• national R&D system laws 
• ministerial rulings 
In several countries (Jordan, Malaysia, South 
Africa) new policies are currently under review or 
exist in draft form. In a number of other coun­
tries, no explicit policy addresses IP ownership 
by universities or research institutes under public 
funding. In these cases, ownership questions are 
typically covered by the general ownership clauses 
of patent law, without specific reference to uni­
versities or research institutes, publicly funded 
R&D, or technology transfer. 
. Trends in institutional IP management 
The more than 80 specific institutions named in 
this survey have all to some degree developed an 
IP policy and management infrastructure. They 
cover many of the leading research universities 
and institutes in the countries surveyed. Many 
more IP management programs, in hundreds of 
other emerging and developing countries, could 
not be mentioned here. Still, the range of strength 
and sophistication in this representative sample is 
vast. Some operations efficiently review hundreds 
of technology disclosures and file dozens of pat­
ent applications a year; in others, IP policy is in 
draft form and no action has been taken to imple­
ment an IP management system. 
If anything, strong, sophisticated institu­
tional IP management is most strongly correlated 
with the underlying determinants of scientific 
and technological capacity, including, most im­
portantly, the amount spent annually on R&D at 
universities and in the public sector. Institutional 
IP management is more weakly correlated with 
the adoption of national-level policies explic­
itly encouraging IP ownership by public sector 
research institutions. In a number of cases, the 
practice of IP management has preceded policy 
changes governing IP ownership. 
. Conclusions 
While the call for policy reforms modeled on 
the U.S. Bayh-Dole Act has been made around 
the world, the particular policy reforms and 
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proposals exhibited in developing and emerging 
economies have varied. In some, the Bayh-Dole 
model is clearly discernible, but in many others 
the approaches to reform are more specifically 
adapted to local legal, political, and economic sit­
uations. Some national policies, such as those of 
China or those emerging in South Africa, clearly 
attempt to institute stronger IP protections in the 
economy and to emulate Bayh-Dole in the public 
sector. But many others merely make perfunctory 
efforts at conforming to TRIPS and only borrow 
the basic idea of encouraging institutional owner­
ship of IP. Some national policies set institutional 
ownership and management of IP as the default 
option among several possible modes of technol­
ogy commercialization. Others provide it as one 
alternative among multiple options, without a 
clearly defined preference. This survey noted one 
general trend: that strong IP protections and the 
institutional capacity to manage them grow in 
tandem, driven primarily by the amount of R&D 
being conducted and, secondarily, by the ability 
of the local economy to absorb new technologies 
into existing industry or an entrepreneurial sec­
tor. These insights may offer lessons for policy­
makers and practitioners seeking to use IP as part 
of an integrated strategy to drive economic devel­
opment through the public financing and com­
mercialization of innovation. n
auThoR’s noTe: By their nature, the policies and in­
stitutions reviewed in this chapter are constantly evolv­
ing and changing. The author invites any corrections, 
updates, and additional information, including policy 
studies or institutional case studies. New information 
will be used to update future reviews on this topic and 
may be added to the online version of the IP Handbook at
www.IPHandbook.org. 
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Creating Socio-Economic Benefits through Innovation 

susan K. finsTon, Principal and Founder, Finston Consulting, LLC, U.S.A. 
ABSTRACT 
This chapter examines the outcomes of technology trans­
fer policies adopted in the past 20 years by five middle-in­
come countries: Brazil, India, Ireland, Israel, and Jordan. 
The outcomes in those countries suggest that nations 
whose governments enable the assimilation of new tech­
nologies grow faster, create more jobs, and reduce poverty 
levels. The outcomes suggest also that a mixture of gov­
ernment and market strengths are needed to efficiently 
use technology transfer. Without this balance, technology 
transfer will have limited effects. 
1. InTRoduCTIon 
The founders of the United States understood the 
importance of innovation and took pains to pro­
mote and protect it in the U.S. Constitution: 
The Congress shall have power to lay and collect 
taxes, duties, imposts and excises, to pay the debts and 
provide for the common defense and general welfare 
of the United States; but all duties, imposts and ex­
cises shall be uniform throughout the United States; 
… to promote the progress of science and useful arts, 
by securing for limited times to authors and inven­
tors the exclusive right to their respective writings and 
discoveries. (U.S. Const. article I, § 8, cl. 8) 
The same principles embodied in this 
Constitution are used around the world today 
to encourage research and development. For ex­
ample, inventors and developers can apply for 
patent rights that give them exclusive use of their 
own innovations for a limited period of time. 
Patent rights are essentially “negative” rights: that 
is, they allow one party to exclude others from 
gaining benefit from an inventor’s work, but, of 
course, they cannot ensure that the invention will 
be profitable. In return for the patent right, the 
inventor discloses information in the patent that 
would enable a person who is “skilled in the art” 
(that is, knowledgeable in the field of the inven­
tion) to understand and replicate the invention 
for him- or herself. Patents thus seek to serve both 
the inventor’s and the community’s interests. 
We can see this dual effect in the case of a 
well-known American. George Washington was 
a mill owner and operator eager to improve his 
mill’s productivity. He was interested in new ag­
ricultural technologies, particularly in the Evans 
Mill System, patented by the prolific inventor 
Oliver Evans (U.S. Patent No. 3), and now rec­
ognized as the first mass production process. As 
president, Washington reviewed and signed all 
of the patents issued in 1790; and as the owner 
of the Mount Vernon Gristmill, Washington was 
one of the first to license the new technology. 
This automated mill produced high-quality flour 
using two men instead of six; the mill operated 
continuously and turned out greater quantities of 
flour than the traditional process in a fraction of 
the time. In addition to Washington, within two 
Finston SK. 2007. Technology Transfer Snapshots from Middle-Income Countries: Creating Socio-Economic Benefits through 
Innovation. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A 
Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. SK Finston. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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FINSTON 
years, over a hundred other U.S. mills were us­
ing the new Evans technology. Evans’ invention 
changed U.S. mills forever and boosted U.S. ag­
ricultural exports to Europe. It benefited not just 
Evans but the entire country, including George 
Washington.1 
Another example, predating Bayh-Dole, 
involving the contrasting paths of penicillin 
and streptomycin underscores the importance 
of incentives to ensure commercialization of 
science. Penicillin was first discovered in 1928, 
and is often cited as a laudable case where the 
innovator, Dr. Louis Pasteur, did not seek a pat­
ent or licensing for the drug. As a result, how­
ever, there was no commercial development of 
penicillin, for more than a decade, until World 
War II necessitated scale-up and mass manu­
facture of the drug.2 In contrast, streptomycin, 
developed by Dr. Salman Waksman at Rutgers 
University in the 1930s, was on a faster track, 
enabled by an early exclusive licensing agree­
ment with Merck.3 
Then as now, a climate that encourages the 
adoption of new technologies will also encourage 
increased rates of job creation, lower poverty lev­
els, and create greater opportunities for economic 
growth. We live in an unprecedented era, how­
ever, when the investment assets of companies are 
increasingly intangible, and particularly suited 
to forms of IP protection.4 Microsoft® founder 
Bill Gates concludes that the nature of the global 
economy increases the need for incentives to in­
novation given “the economic competition between 
nations going forward, particularly with regard to 
the rapid innovation and development in emerging 
countries … We need incentive systems that drive 
that innovation in an appropriate manner, because 
we can no longer compete exclusively on the basis of 
cost of labor.”5 This chapter looks at how technol­
ogy transfer policies have affected countries from 
three different regions (the Middle East, Asia, and 
Europe) in the past 20 years.
2.	 WHAT	IS	 TECHnoLoGy TRAnSfER? 
Technology transfer is the process of developing 
practical applications from the results of scientific 
research. Defined more broadly, technology 
transfer is anything that increases the capacity 
of people to benefit economically and/or socially 
from innovation. 
Technology transfer is a complicated process, 
and the journey from exploratory research to suc­
cessful product can be a long one. R&D falls into 
three categories or phases: 
•	 The primary objective of basic research is 
the advancement of knowledge for its own 
sake. This type of research is exploratory or 
investigative and is often driven by the re­
searcher’s curiosity, interest, and hunches. 
•	 The primary objective of applied research is 
to answer specific questions that have prac­
tical ramifications. These questions may or 
may not arise out of basic research. Applied 
research can be exploratory, but is usually 
more focused. 
•	 In commercial development, ideas arising 
from basic and/or applied research are used 
to create a product intended for commer­
cial sale. 
An example of an R&D process that in­
cludes all three phases is the discovery and de­
velopment of pharmacogenetic drugs: decoding 
the human genome (basic research) led to the 
identification and isolation of particular en­
zymes (applied research), which in turn led to 
the development and testing of drugs (commer­
cial development). This example suggests that 
governments have a significant role to play in 
identifying which areas of innovative research 
can and should be promoted (the initial re­
search on the human genome was a public ef­
fort). Governments also have a role in moving 
inventions from the theoretical level to the ap­
plied level (government-funded research drives 
a good deal of this movement) and in provid­
ing incentives to encourage the development of 
new products and processes arising out of ap­
plied research (for example, forms of intellectu­
al property). But as research moves further from 
basic research toward product development, the 
government’s role in directing this process di­
minishes. For the most part, the market distrib­
utes investment resources much more efficiently 
than the government. 
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.	 WHAT	 fACToRS	 pRoMoTE	
TECHnoLoGy TRAnSfER? 
The core elements of a robust technology transfer 
system are: 
1. a durable government commitment to science 
education, research, and related infrastruc­
ture. Governments create an enabling envi­
ronment for science and technology by in­
vesting in education and training (both at 
home and abroad, at secondary and univer­
sity levels), funding basic and early applied 
research, and improving technology-related 
physical infrastructure. 
2. broad rule-of-law protections, including 
strong IP protections. Rule-of-law protec­
tions give individuals the ability to enter 
into enforceable agreements or contracts 
with others; they promise predictable and 
timely judicial remedies in case these agree­
ments or contracts are breached. 
3. reliance on market forces as the engine for 
technology transfer. Market-oriented policies 
encourage risk taking and increased private 
sector investment. 
These three pillars of technology transfer are 
like the three legs of a stool: all are necessary, and 
none of them is sufficient by itself. However, it 
can be difficult to provide all three simultaneously. 
In the mid-20th century, the U.S. government 
thought it strongly supported science, rule-of-law 
protections, and market incentives, but it did not 
grant private rights to publicly funded inventions. 
The effect of this was to greatly weaken market 
incentives for investing in new technologies. Such 
rights only became part of the U.S. technology 
transfer regime with the passage of the Bayh-Dole 
Act of 1980.6 Once government-funded scientists 
were allowed to engage with those who had the 
skills needed to bring products to market, an ex­
plosion of innovation ensued, bringing remark­
able new products in health, agriculture, and other 
fields. 
.	 TECHnoLoGy TRAnSfER	 pRofILES 
The power of technology transfer is available to 
people everywhere, and it is a power that can 
facilitate not just a nation’s research abilities but 
its overall economy. Drawing on his experience in 
Bangladesh, David Sack, observed that: 
[W]ell-qualified local scientists generally prefer 
to remain in their home country if they can find 
meaningful employment in institutions where they 
can be productive. Well-functioning institutions con­
tribute to “brain-gain,” thus increasing the scientific 
and economic resources of a country as a whole.7 
No matter what stage of development a coun­
try is in, its government can train scientists and 
encourage them to remain at home by promoting 
a sensible, well-functioning technology transfer 
system. The remainder of this chapter provides 
brief profiles of five middle-income countries 
whose governments, over the past two decades, 
have supported science and education, created 
effective IP protections within a broader frame­
work of strong rule-of-law protections, and used 
the market to efficiently distribute investments 
in commercialization. These countries have de­
veloped successful innovation-intensive sectors 
like biotechnology and information technology 
that have, in turn, produced widespread social 
and economic benefits. The experiences of these 
countries can provide all of us with valuable les­
sons and insight into how to harness effectively— 
and fairly—the power of technology transfer. 
.1 Brazil 
The strength and durability of the Brazilian gov­
ernment’s commitment to science education and 
infrastructure are impressive. The State of São 
Paulo Research Foundation (Fundação de Amparo 
à Pesquisa do Estado de São Paulo, also known as 
FAPESP) has supported basic scientific research 
and graduate education at several universities in 
São Paulo for the last half-century. The federal 
Ministry of Health has funded two major pub­
lic research institutes: the Instituto Butantan and 
the Oswaldo Cruz Foundation. In recent years, 
the Instituto Bhutantan has been recognized for 
its role in the development of a hepatitis B vac­
cine.8 The Oswaldo Cruz Foundation has a long 
and distinguished history, including historic 
health and sanitation campaigns against bubon­
ic plague, yellow fever, and small pox,9 and the 
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foundation most recently announced advances in 
development of an algae-based microbiocide for 
use against HIV/AIDS.10 
However, Brazil lacks market-based incentives 
to drive private capital into commercial develop­
ment. As Michael Ryan observes, “The Brazilian 
public sector has made substantial investment into 
university and public laboratory research, thereby 
establishing the potential for biomedical technology 
innovations, but the lack of private sector R&D ca­
pabilities and lack of public-private linkages has tra­
ditionally prevented technology from being commer­
cialized into the marketplace.”11 Partly due to these 
weaknesses in its technology innovation system, 
the country’s economic growth in the 1970s and 
1980s faltered.12 Currently, two-thirds of R&D 
spending in Brazil is funded directly by the gov­
ernment (for comparison, only one-third of R&D 
spending in the United States is funded directly by 
the government), and only 18% of scientists and 
technicians work in the private sector.13 The dyna­
mism and flexibility of market forces were stymied 
by the government’s decisive intervention in the 
innovation process, and the resulting inefficiencies 
contributed to slow economic growth. 
Currently, a number of reforms are under­
way in Brazil to encourage private sector invest­
ment in R&D activities. As a result, there are 
more international patent applications being 
filed by Brazilian companies through the World 
Intellectual Property Organization (WIPO) 
Patent Cooperation Treaty,14 and new products 
are beginning to enter the market.15 This trend 
should strengthen the economy and provide 
Brazil’s people with more and better products in 
every economic sector. 
According to Ryan, Brazil was not alone in 
giving a dominant role to government in the pur­
suit of scientific and technological development. 
He cites a number of large developing countries 
that had also followed a policy of state-led eco­
nomic development. Many of these have since re­
vamped policies to promote greater private sector 
investment in the commercialization of new tech­
nologies. These include China, Mexico, Egypt, 
India, and Turkey. The lesson here is not that gov­
ernment should not provide funding to develop 
new technologies but that such funding should 
be focused on basic research (which functions as 
a kind of “seeding” for innovations). Applied re­
search and research focused on commercializing 
an innovation should rely more on investments 
from the private sector to ensure maximum ef­
ficiency and economic growth. 
.2 Israel 
Israel is another state with a commitment to long­
term investment in science and infrastructure. 
Recent investment data show that at least 50% 
of science funding in Israel comes from the State 
of Israel and international public sector sources.16 
Each of Israel’s ministries includes a chief scien­
tist,17 and Israel’s primary and secondary schools 
have a strong basic science curriculum.18 
Israel is a world leader in areas related to 
information and communications technology. 
These technological areas do not require capital 
investments to the same high degree as biotech­
nology and are characterized by short lead-times 
and low regulatory barriers to market entry. In 
fields such as biotechnology, however, Israel is 
not as innovative. As Avi Molcho observes, “Israel 
is among the world leaders in many fields of tech­
nology. It is a hub for innovative technologies in 
communications, semiconductors, information tech­
nology, and medical devices—innovation that has 
been translated into commercial success. While the 
same, if not greater, degree of innovation is found in 
Israeli life sciences research, this has yet to be trans­
formed into a more mature biotechnology start-up 
industry.”19 In fact, Israel’s patent prowess appears 
formidable: “Israel ranks first worldwide in the pro­
portion of life-science patents to the total number 
of patents written by Israeli inventors. The country 
ranks fourth in total number of biopharma patents 
granted, in terms of patents per capita, and 12th in 
the absolute number of biopharma patents.”20 Alla 
Katsnelson suggests that this is because patents 
are underutilized: “Israeli life-sciences patents com­
prise almost a third of the country’s total patents. 
What seems to be lacking is the ability to turn all 
this life-sciences-focused intellectual property into 
biotech products.”21 
The Milken report cites the lack of sufficient 
market incentives for commercialization of sci­
ence, 22 while others point to relatively weak levels 
200 | HANDBOOK OF BEST PRACTICES 







     
      
     
       
        
       
      
      
     
   
       
     
    
      
      
     
        
     
    
 
 
      
       
    
    
     
     
     
     
     
      
     
   
     
       
        
      
      
      
CHAPTER . 
of patent protection and data exclusivity.23 Some 
identify the market dominance of the generic 
pharmaceutical manufacturer Teva,24 as one rea­
son why Israel has not strengthened market and/ 
or IP incentives for international biotechnology 
companies to enter or remain in the market. 
Interestingly, Israel has maintained weaker 
levels of IP protection at the same time many 
of its neighbors, including Bahrain, Jordan, 
Morocco, Saudi Arabia and the United Arab 
Emirates (UAE), have strengthened their IP sys­
tems through WTO accession, bilateral free trade 
agreements and/or unilateral reforms.25 
Whatever the reason or combination of rea­
sons, Israel continues to suffer from a dearth of 
private clinical biotechnology research. David 
Haselkorn succinctly notes, “Not one single [multi­
national pharma] company has developed an R&D 
center here.”26 The Milken Institute goes farther, 
stating that the Israeli biotechnology sector is in 
decline, “as measured by the amount of venture 
capital funding.”27 
. Jordan 
Until the early 1990s, the Hashemite Kingdom 
of Jordan was best characterized as an aid- and 
remittance-based economy, with an estimated per 
capita gross domestic product (GDP) of about 
US$800. Over the past 15 years, however, the 
Jordanian government has increased its commit­
ment to science education and infrastructure, im­
proved its IP laws and the enforcement of those 
laws, and adopted a model of economic planning 
that relies on the private sector for job and wealth 
creation. The impact of these changes has been 
profound: the country has become more integrat­
ed into the world economy and enjoyed a more 
than five-fold increase in per capita GDP since 
the mid-1980s, reaching US$4,700 in 2006.28 
The growth of Jordan’s export-led pharmaceu­
tical industry is particularly remarkable. In 2001, 
production in the pharmaceutical sector totaled 
US$180 million; in 2002, it was US$210 mil­
lion; and in 2003, it reached US$275 million.29 
This was achieved both through higher levels of 
domestic IP protections and through trade ben­
efits provided by the World Trade Organization 
(WTO) and the United States–Jordan Free 
Trade Agreement.30 Jordanian pharmaceutical 
companies are beginning to invest more in research 
and product development. For example, local 
Jordanian companies Triumpharma and Advanced 
Pharmaceuticals are both investing in research to 
produce and patent drug delivery mechanisms. In 
addition, two new clinical research organizations 
have been established in the last three years.31 
Today, Jordan exports its pharmaceutical products 
to over 60 markets worldwide. 
In addition, Jordan has adopted market-
friendly policies that are attractive to interna­
tional pharmaceutical companies. Major in­
ternational pharmaceutical companies, such as 
Organon, Novartis, and Aventis, have worked 
with new Jordanian clinical research organiza­
tions and Jordanian hospitals to conduct clini­
cal trials. Since 2000, Jordanian companies have 
established licensing relationships with phar­
maceutical companies from Italy, Japan, Korea, 
Italy, Switzerland, the United Kingdom, and the 
United States. These foreign companies often rely 
on their Jordanian partners to provide marketing 
and distribution expertise in the Middle East. In 
return, Jordanian companies benefit from foreign 
investment by gaining a broader product base for 
sale, both at home and into export markets, and 
for the in flow of know-how and technology.32 
The government of Jordan continues to in­
vest in science and technology. Areas of invest­
ment include: natural products development; 
early diagnostics using monoclonal antibodies; 
applied microbiology in food; production of 
biogas, biofertilizers, pesticides, and yeast; and 
the development of new biotech equipment. 
Moreover, Jordan has recently established the 
King Hussein Cancer Center and Biotechnology 
Institute with support from the U.S. National 
Institutes of Health through the Cancer 
Biomedical Informatics Grid program. 
. India 
When it comes to adopting technology-friendly 
policies, few countries have faced as many chal­
lenges as India. R. A. Mashelkar, recently retired as 
the Director General (1995-2006) of the Council 
of Science and Industrial Research (CSIR), an 
early and persistent advocate for India’s adoption 
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FINSTON 
of technology transfer policies, calls India’s his­
tory with such policies “a series of missed bus­
ses,” in terms of lost opportunities for leveraging 
India’s intellectual assets in the global knowledge 
economy.33 
Many have cited India’s confidence in bio­
technology as rooted in its earlier success in the 
information technology (IT) sector. It is less well 
known, though, that patent protection also fu­
eled India’s original IT success, in the form of 
Dr. Sam Pitroda’s software patents.34 In 1980, 
prominent nonresident Indian and software 
guru Pitroda sold his first U.S. company and 
brought the profits to India to support his dream 
of installing telephones throughout rural India.35 
Telecommunications has been widely recognized 
in India as foundational to the entire industry sec­
tor known as “Information and Communications 
Technology (ICT),” as well as the related sub-sec­
tors known as “Business Process Outsourcing 
(BPO)” (which include back-office operations 
for multinational corporations, and call centers, 
among others) , and BioInformatics (the analytic 
processing of data generated as part of clinical re­
search in the life sciences and provided India’s 
initiation into biotechnology).36 Pitroda’s soft­
ware patents helped him to made his first fortune 
and provided the resources he needed to bring te­
lephony to rural India, laying the foundation for 
India’s IT revolution. 
Now the government of India is preparing to 
introduce comprehensive technology transfer leg­
islation in 2007. Under the bill, academic inven­
tors and their institutions would share royalties, 
and academic entrepreneurs will be encouraged to 
file patents to gain both increased research fund­
ing for their institutions and individual benefits 
for themselves, in the form of royalties. 37 The law 
would also include key mechanisms to bench­
mark patentable research undertaken by Indian 
academic and research institutions with support 
from the government of India.38 In the past year, 
product patent protection has been adopted and 
implemented in several fields, including pharma­
ceuticals. Patent processing reform has improved 
efficiency and reduced patent review times, and, 
increasingly, domestic companies are recommend­
ing that India adopt protection for commercially 
valuable clinical research dossiers (a protection 
known as data exclusivity).39 
India is engaged in a cooperative internal di­
alogue about how to implement these IP reforms. 
The Indian government continues to promote 
India as a global biotechnology R&D hub, and
the country has become a primary global loca­
tion for preclinical and clinical R&D. Most 
recently, the 2006 Ernst and Young European 
Attractiveness Survey placed India among the 
top five countries as a pharmaceutical and bio­
pharmaceutical R&D destination. Commercial 
biotechnology, which crossed the billion-dollar 
mark in 2005, has now reached nearly US$1.5 
billion, with 36% annual growth. 
. Ireland 
Over the past 20 years, Ireland has gone from 
“net brain-drain” to “net brain-gain” by system­
atically adopting pro-technology transfer policies 
and becoming a major importer of foreign direct 
investment in the area of life science. Ireland of­
fers strong patents and data exclusivity for terms 
of up to 11 years. There is substantial government 
support for science education and technology-re­
lated infrastructure, and the government’s cor­
porate regulatory policies ensure greater market 
orientation in terms of increased moderation in 
labor policies,40 reduced corporate taxation,41 and 
other reforms: 
Foreign direct investment in Ireland has been 
attracted by low rates of corporate tax. Today, Ireland 
has one of the world’s lowest rates of corporation tax, 
with the maximum rate for trading profits being 
12 percent. Other factors that help attract biophar­
maceutical companies to Ireland include the ready 
availability of the required specialist skills. Output 
from the third-level institutions is being continually 
refined to meet the sector’s needs. Further, the consid­
erable growth in the Irish economy over the past ten 
years has seen very significant repatriation of skilled 
people. In addition, Ireland is seen as a desirable ex­
patriate location with a minimum of bureaucratic 
obstacles and an excellent educational system that 
facilitates family relocation. The free movement of 
labor within the enlarged European Union has fa­
cilitated the swift acquisition of a further pool of 
skilled people.42 
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CHAPTER . 
As a result, Ireland has become more attractive 
to foreign investors for biotechnology and other 
high technology sectors43 and is also winning the 
global competition to attract and retain well-edu­
cated, creative workers.44 More than 170 compa­
nies employ 35,000 people in Ireland’s chemi­
cal, pharmaceutical, biopharmaceutical, medical 
device, and diagnostics industries.45 Together, 
these sectors generated more than US$52 billion 
in exports in 2005. Ireland’s per capita income 
has grown from about US$5,000 in 198646 to 
US$43,600 in 2006,47 a level of per capita in­
come that is comparable to that of the United 
States and the United Arab Emirates. 
.	 ConCLuSIon 
Technology transfer can improve lives by intro­
ducing innovations that directly contribute to 
improved public health, nutrition, and communi­
cations. Less obviously, but more importantly, the 
policies that promote technology transfer—such as 
an emphasis on personal rights and education— 
also promote economic development. Ideally, any 
positive changes in political and economic climate 
will create a self-perpetuating cycle: an improved 
economic environment and a general increase in 
education levels will lead to improved public health, 
which will in turn strengthen the economy. 
The above overview strongly suggests that 
such technology transfer works best when there 
is strong, consistent government support of basic 
research—including science education and tech-
nology-related infrastructure—and robust IP pro­
tection. Government policies should also strive to 
encourage market guidance and private sector in­
vestment in applied research and commercializa­
tion efforts. In this way, the strengths of the gov­
ernment and of the market can be synergistically 
applied to improve the lives of all of us. n 
susan K. finsTon, Principal and Founder, Finston 
Consulting, LLC, 3514 30th Street, NW, Washington, DC, 
20008 U.S.A. susan@finstonconsulting.com
For more background on Oliver Evans, the mechanized 
flour mill and other inventions, see www.greenbank-
mill.org/oliverevans.html. For more about Washing-
ton’s gristmill, see www.mountvernon.org/visit/plan/ 
index.cfm/pid/806/. 
2	 Public Broadcasting Service. A Science Odyssey: People 
and Discoveries. www.pbs.org/wgbh/aso/databank/
entries/bmflem.html. 
3 “An agreement was drawn up with Merck whereby the 
company provided chemical assistance, experimental 
animals for pharmacological evaluation of 
antibiotics, and large-scale equipment for producing 
any promising discoveries. In return, Waksman 
assigned Merck any patents resulting from research 
in his laboratory. Should any of the patents prove 
commercially successful, Merck was to pay the Rutgers 
Foundation a small royalty.” acswebcontent.acs. 
org/landmarks/antibiotics/trials.html. Streptomycin 
is broadly recognized as one of the important early 
antibiotics. In addition to being the first effective 
chemotherapeutic treatment for tuberculosis, it
also showed effectiveness against typhoid fever,
cholera, bubonic plague, tularemia, urinary tract
infections, and others. As Dr. Waksman recognized 
the importance of the new drug, he became 
uncomfortable with the agreement giving Merck 
exclusive rights, and Merck agreed to a renegotiated 
non-exclusive license and was granted a rebate on 
royalties to compensate the company for the cost of 
development of streptomycin. “Merck was praised for 
its generosity and Rutgers made licensing agreements 
with other drug companies.” 
4	 See Brief of Amicus Curiae BayhDole25, Inc., supporting 
respondent in Microsoft vs. AT&T, pp. 14–16. 
5	 26 January 2004 Keynote address by Bill Gates,
Chairman and Chief Software Architect, Microsoft
Corporation, at the Enterprising Britain Conference,
London, UK. www.hm-treasury.gov.uk/documents/ 
enterprise_and_productivity/enter_conf/ent_ 
entconf_gates.cfm. 
6	 For and extensive discussion of the debate over the 
issue of allowing exclusive rights to private actors to 
commercialize publicly funded research outcome, see 
BayhDole at 25: A Survey of the Origins, Effects, and 
Prospects of the Bayh Dole Act. www.bayhdole25.org/ 
resources.The author of this chapter is a founding board 
member of BayhDole25, a not-for-profit organization 
that promotes technology transfer in developing and 
developed countries through education and outreach 
activities. For more background and information on 
this organization, see www.bayhdole25.org.
7	 Sack DA. 2005. Letters: International Gaps in Science 
Publications. Science 309 (5739): 1325–1326. 
8	 Ferrer M et al. The Scientific Muscle of Brazil’s Health 
Biotechnology. Nature: Biotechnology 22(Suppl.):DC9,




9	 See supra note 9. Historic background on the first
hundred years of Oswaldo Cruz Foundation (originally 
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founded as the Federal Serum Therapy Institute).
World Health Organization (WHO) at www.who.int/ 
tdr/publications/tdrnews/news65/oswaldo-cruz.htm. 
10 Algae Gel to Combat HIV Infection. BBC News,
29 January 2007. news.bbc.co.uk/go/pr/fr/-/2/hi/ 
health/6266527.stm. 
11	 Ryan M. 2006. Brazil’s Quiet Biomedical Innovation 
Revolution: Drugs, Patents, and the “10/90 Health 
Research Gap.” Creative and Innovative Economy 
Center, George Washington University Law School:
Washington, DC.
12	 See supra note 5, p. 3 
13	 See supra note 5, p. 5 (citing a 2005 FAPESP report). 
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CHAPTER 3.5 
Benchmarking of Technology Transfer Offices and 

What It Means for Developing Countries
 
anThony d. heheR, Director, Associates for Economic Development, South Africa 
ABSTRACT 
At universities in both developed and developing coun­
tries, increasing emphasis has been placed on promoting 
technology transfer. Unfortunately, technology transfer is 
sometimes undertaken for the wrong reasons, especially 
in the mistaken belief that technology transfer will lead to 
substantial additional income for the institution. While it 
is important to protect intellectual property arising from 
research and to actively promote the transfer of research 
results, generating income should not be the primary ob­
jective in the transfer of technology. This is particularly 
important for health science, where there is a risk that 
research results, if not properly protected, will be inac­
cessible to private or public entities seeking to use the 
research for public benefit. 
International technology transfer benchmark data 
can be used to understand the implications of promot­
ing technology transfer and the likely outcomes of a tech­
nology transfer initiative. The benchmarks indicate that 
average income to an institution, after eight to ten years 
of activity, is likely to be a modest 1%–2% of annual 
research expenditure. The income is, moreover, highly 
uncertain and variable. Institutional and public sector 
managers must understand the nature of this income and 
the dynamics of the technology transfer process in order 
to manage this emerging discipline effectively, because 
unrealistic expectations can lead to dysfunctional policy 
decisions. The data and dynamic model presented in this 
paper are intended to promote better decisions. 
1. InTRoduCTIon 
The successful technology transfer programs of 
universities in Canada and the United States have 
prompted other countries to emulate them, and 
major technology transfer and commercializa­
tion support programs have been launched in 
Australia, Japan, the United Kingdom, and many 
other countries. The high-profile successes of rela­
tively few institutions have, however, generated 
unrealistic expectations. Additionally, it is not 
always clear that the success, measured in terms 
of income earned from commercialization, is pro­
portional to the magnitude of the investment in 
research. Without a well-funded, high-quality re­
search system, it is highly unlikely that a technol­
ogy transfer program will contribute significantly 
to economic or social development. Moreover, 
it is doubtful whether other countries can easily 
emulate the performance of the United States, 
due to differing social and economic conditions. 
The income-earning potential of technology 
transfer activities can, in fact, be a hindrance to 
effective programs. Technology transfer needs to 
be undertaken for good reasons, apart from the 
possibility of earning income. In health sciences 
and agriculture, in particular, appropriate IP (in­
tellectual property) protection may be essential 
to effectively exploit research results and ensure 
that the benefits are widely available to society. 
Whether exploitation of research is for commer­
cial or humanitarian uses, effective and appropri­
ate transfer of knowledge is still required, in ad­
dition to the normal academic requirements to 
publish. 
Heher AD. 2007. Benchmarking of Technology Transfer Offices and What It Means for Developing Countries. In Intellectual 
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. AD Heher. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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However, even with comparable investments 
in research, the performance of individual insti­
tutions is highly variable and unpredictable. This 
is true even for institutions that are comparable in 
size and maturity. A large portfolio of patents and 
licenses is required to give a reasonable probabil­
ity of a net positive income. A large portfolio may 
be possible at a national level but is problematic 
in smaller countries, and even more so for smaller 
institutions. Because the benefits of the innova­
tion system are captured largely at the national 
level, institutions need public sector support to 
reduce the institutional risk necessary to develop 
profitable investments. 
Technology transfer is, of course, only one el­
ement of the overall research and innovation val-
ue-chain. All elements must function effectively 
for an institution to derive economic and social 
benefits from its research. In addition to a strong 
research system, a university must offer academics 
adequate incentives to encourage their participa­
tion, particularly with regard to the crucial initial 
step of invention disclosure. Universities must 
possess adequate institutional capacity to take an 
idea, evaluate it, appropriately protect intellectual 
property, and then seek a path to commercializa­
tion through licensing or a spinout. 
It is widely recognized that monetary re­
turns are not, and should not be, the primary 
motivation for engaging in technology transfer. 
Increasingly, it is a public research organization’s 
social responsibility to ensure that research re­
sults are effectively transferred in a timely manner 
into the public domain for the good of society. 
The production of graduates and publication of 
research results remain the most important ways 
of affecting knowledge transfer; the more direct 
transfer of knowledge through technology trans­
fer is, however, an essential adjunct. Far from 
undermining conventional approaches, effective 
technology transfer can support and enhance tra­
ditional knowledge transfer. 
Technology transfer affects a society’s eco­
nomic well being directly and indirectly. In this 
chapter, both the conditions necessary for deriv­
ing economic benefit and the factors that influ­
ence the performance of a technology transfer 
office (TTO) are outlined. The data and models 
highlight the need for skilled technology transfer 
professionals. If a country is to profit from its in­
vestment in research, then training and capacity 
building at the institutional and national levels 
are key requirements. 
2. RESEARCH	And 	InnovATIon 
vALuE-	CHAIn 	BEnCHMARk dATA 
Universities and research institutions in North 
America have been benchmarking the research 
and innovation value-chain for a number of 
years.1 This data covers each step in the value 
chain, including expenditure on research; num­
bers of invention disclosures, patents, licenses, 
and spinout companies; income from licensing; 
and expenditure on IP protection. A few other 
countries are following a similar approach, facili­
tating cross-country comparisons. (A selection of 
the data is shown in Table 1.) 
To assist with comparisons across countries, 
benchmarks are generally converted to normal­
ized values. The most commonly used approach 
is to normalize in terms of total research expen­
diture, converted to equivalent U.S. dollars. This 
approach is called the adjusted total research 
expenditure (ATRE). The most commonly used 
reporting basis is per US$1billion ATRE or 
US$100 million ATRE. Table 2 presents normal­
ized values of the raw data in Table 1 based on 
US$100 million ATRE. For simplicity, only se­
lected variables are shown. This normalized data 
can be considered typical data for a small- to mid-
sized U.S. university or a large university in a de­
veloping country. 
The normalized data shows a remarkably con­
sistent pattern across different countries (summa­
rized in Table 3). While there are variations from 
year to year and from country to country, they 
are relatively small and statistically insignificant 
compared to the variations between institutions 
in one country. 
The data presented in Tables 1, 2, and 3 is 
for all research disciplines, as no desegregation 
to field of research was undertaken by any of the 
countries that conducted the survey. Although 
such results would be interesting, there is a lack 
of clear definition of the different fields, even 
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within one country, let alone across countries, 
making classification difficult. However, it is 
well recorded that medical and health-related 
research constitutes around 50% of all research 
expenditure. An analysis of individual results of 
commercialization efforts also shows that health-
related products make up around 50% of tech­
nology transfer outputs, so the available evidence 
indicates it is likely that the data for all fields is 
broadly representative for health sciences. Given 
that a relatively small proportion of total research 
is devoted to agricultural research, it is not possi­
ble to make similar conclusions about technology 
transfer in the agricultural sciences. Indications 
are, however, that it is likely to follow a similar 
pattern; there is little evidence that one field of 
research has significantly different results from 
another in terms of average performance, as indi­
cated in Table 3. 
A widely used proxy for the overall perfor­
mance of the technology transfer system is the to­
tal license income earned per year as a percentage 
of the total research expenditure. This measure is 
used in this chapter, and elsewhere, but it must be 
remembered that the measure is a proxy for a com­
plex system and does not, by itself, tell the whole 
story. License income as a percentage of research 
expenditure is often referred to, for simplicity, as 
the “return” from an investment in technology 
transfer. The concept represents one form of re­
turn, with returns to the economy through direct 
and indirect benefits being equally, if not more, 
important. The benefits to society, particularly in 
health and agriculture, are often far more impor­
tant than any financial return the institution may 
earn. The difficulty, however, is that the institution 
bears the costs of undertaking technology transfer, 
particularly, in terms of IP protection costs. The 
benefits, in contrast, may be enjoyed by the wider 
society, or even by another country. 
Over the years that data has been collected, 
the trend in total license income is instructive 
(the graph is shown in Figure 1). In the United 
States, the value has increased from 1.5% in 
the first year of surveys by the Association of 
University Technology Managers (AUTM) in 
1991 to around 3.5% in recent years, ignoring 
the anomalous peak during the dot-com boom in 
2000. Excluding medical research institutes and 
considering only universities, the figure is slightly 
lower, at around 3%. The available figures for the 
United Kingdom, Australia, and Canada are also 
plotted in Figure 1. Again ignoring anomalous 
figures in 2000/2001, averages are in the vicin­
ity of 1% to 1.5%. Interestingly, no evidence yet 
exists of other countries having the same rising 
trend that was observed in the United States in 
the early years. Whether a similar trend will oc­
cur in the years ahead, or whether there is a sys­
tematic difference between the United States and 
other countries, is still unclear. 
The average data set is misleading, however, 
and the full data set, showing individual institu­
tions, needs to be scrutinized. The AUTM data 
is excellent in this respect, as is the Australian 
survey. It is unfortunate that cultural norms in 
Europe tend to hide individual performance, as 
this impedes an understanding of the data. 
The characteristic distribution of this data is 
illustrated in Figure 2, which shows the returns of 
all reporting U.S. universities in rank order. The 
data is more easily understood when plotted on a 
logarithmic scale, as shown in Figure 3. The dot­
ted line in Figure 3 shows the approximate trend 
line for U.S. data. Figure 4 shows the same data 
for Canadian universities and Figure 5 shows 
the date for Australian universities, both with 
the U.S. trend line superimposed. The distribu­
tion of returns is remarkably consistent in these 
three reporting countries. The data for the United 
Kingdom shows a similar trend, but cannot be 
displayed in the same way because individual in­
stitutional performance is not reported. 
Table 4 summarizes the returns for the 
United States, Canada, Australia, and the United 
Kingdom in three bands. The first is for all report­
ing universities, the second for the lower 95%, 
excluding the upper 5%, while the last row shows 
the performance of the lower 50%. Excluding 
the upper 5% removes eight universities in the 
United States, two in Canada, one in Australia, 
and five in the United Kingdom. 
The affect of the skewness of the returns is 
evident: 95% of universities have returns of less 
than half the averages, while 50% earn only very 
small amounts from technology transfer. This 
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has important implications whether TTOs earn • The rate at which disclosures are converted 
enough to cover operating costs or if they need into a patent or license varies from 30% to 
to be subsidized. (This is discussed in more detail 50%. This is a relatively close correspon­
below.) dence with differences explainable by differ-
An important reason for undertaking bench­ ent national policies and support measures. 
marking is the understanding and insight that • The spinout-company rate shows a similar 
the process fosters. This is what Lundvall2 calls range, explainable by the greater emphasis 
a learning-by-comparing approach, and it is es- on company formation in Europe and in 
pecially important when using benchmarks in the United Kingdom, in contrast with the 
a different environment. Inherently, long-time emphasis in the United States on licensing. 
delays make innovation-system benchmark data The United Kingdom and Europe gener­
particularly difficult to collect and interpret. A ated four to six times more spinout com-
good understanding of the origins and structure panies in 2000/2001, but the number had 
is necessary to avoid misuse of the data. The mod- dropped in 2002, reflecting a much more 
el that has been developed here assists with the difficult venture-capital environment after 
interpretation of the raw benchmark data and the the dot-com bust. 
underlying processes it reflects. • A recent report in the United Kingdom, 
Analysis of the data is complicated by the however, has asserted that the reported 
existence of a few exceptional cases. In Australia, rate of spinout-company formation is 50% 
for example, the omission of a single equity trans- more than the real rate. If true, this would 
action in 2000 changed the income earned by make the United Kingdom data more com-
over 50%; while in 2001 and 2002, one univer­ parable to other countries and illustrates 
sity accounted for 66% of all income earned. In the importance of clear definitions when 
Canada, omission of two universities had a simi­ collecting benchmark data. 
lar impact, while in Europe omitting two uni­ • It is noteworthy that the total percentage of 
versities reduced the income by 70%. The affect invention disclosures that result in either a 
of a few large transactions makes measuring and license or a spinout is roughly similar in all 
interpreting the benchmark data more difficult, countries examined, at around 30% to 40%. 
particularly for projections and comparisons. • The staffing of TTOs shows interesting 
Some observations, with respect to the coun­ variations. The United States averages four 
try average data, are relevant: staff (per US$100 million ATRE), whereas 
• The invention disclosure rate of 40 to 50 Australia and Canada have eight to ten staff 
disclosures per US$100 million ATRE (per US$100 million ATRE). This reflects 
(or US$2 million to US$2.5 million of economies of scale in the United States, 
research expenditure per invention disclo­ as the average number of staff per institu­
sure) is remarkably consistent across coun­ tion is similar. Staffing levels in the United 
tries and over time. The most recent U.K. Kingdom, however, are six times higher 
data set is an exception and would seem than the United States per ATRE. This 
to indicate a difference in policy approach, reflects the emphasis on spinout-company 
with the invention disclosure rate increas­ formation (known to be much more peo­
ing by nearly 50% from 2001 to 2002. ple-intensive than licensing) in the United 
Not all disclosures are equal, however, and Kingdom and the strong national support 
in some instances a higher disclosure rate schemes that are in place. 
would appear to indicate a lower “quality” • The cost of operating a TTO can be esti­
of disclosure, as indicated by the fact that mated from the reported staffing levels and 
a smaller percentage of the disclosures are salary survey results, formal or informal. As 
converted to license or spinout opportuni­ shown in Table 5, these budgets fall into 
ties, as shown in Table 2. two categories and three groupings. For the 
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United States, Canada, and Australia, the 
budget for a small university is about 1% to 
2% of total research expenditure and 0.2% 
to 0.5% at the larger institutions. U.K. 
universities typically have budgets approxi­
mately double these figures. 
•	 The average returns shown in Table 4, cou­
pled with the typical budgets shown in Table 
5, enable an estimate of the profitability of 
the various classes of offices. These results 
are shown in Table 6. In the United States 
and Canada, the bottom 50% of all univer­
sities operate at a loss, and only the 50% to 
95% group are operating at a break-even or 
slightly profitable level. Only the top 5% 
are very profitable. It is this skewness that 
contributes to the all-too-common expec­
tations of unrealistic performance. In the 
United Kingdom and Australia, only a few 
universities are profitable, with over 95% 
operating at a loss. 
The similarity in performance among coun­
tries with different innovation systems and 
cultures indicates that the creative innovation 
process is inherently similar regardless of the en­
vironment. The single biggest factor that dwarfs 
all others is the expenditure on research, and it 
appears that no innovation system is significantly 
different with respect to the effectiveness with 
which ideas are generated and transformed. 
This is not to imply that active innovation 
support systems are not required. All the coun­
tries examined and reported in the benchmarks 
in Table 2 have strong systems of support and 
are actively involved in training and developing 
capacity to manage the research and innova­
tion process. Without such capacity, it is highly 
unlikely that the performance of any institution, 
region, or country will come even close to match­
ing the average benchmarks.3 
.  pHASInG	 of THE
InnovATIon-vALuE-CHAIn 
The benchmark data is masked by the long de­
lays inherent in the technology transfer process. 
Each step in the value chain takes a few years; 
typically six to ten years elapses from the mo­
ment of invention disclosure to the time when 
significant income can be generated from a li­
cense. These delays are depicted in Figure 6, and 
the impact of these delays is illustrated in Table 
7 and Figure 7. 
This phasing makes interpretation of the 
benchmark data difficult, because data for a par­
ticular year depends on activities that happened 
many years earlier. The total license income in 
any one year, for example, depends on the accu­
mulated sum of invention disclosure and patent­
ing activities from prior years and is independent 
of the disclosure rate in that particular year. For 
ease of analysis and reporting, ratios are used to 
measure the relationship between variables that 
may in fact be years apart. In a steady-state envi­
ronment, these ratios are correct, but the dynamic 
relationship must be understood. 
The data presented in Table 2 is therefore 
primarily useful as a steady-state approximation, 
particularly when used to make projections for 
a new institution or a country just establishing 
an innovation system. Misunderstanding these 
dynamics can contribute to false expectations of 
returns that are more properly based on observa­
tions of essentially steady-state data from mature 
systems. 
The dynamic model combines knowledge of 
the phasing of the value chain and the time du­
ration of the various steps with the steady-state 
benchmark data in Table 2. The primary purpose 
of the model is to provide estimates of the likely 
rate of return and cash-flow forecasts (institution­
al and national) of alternative innovation-system 
scenarios. As the parameters of any particular in­
novation system are not known in advance (and 
are difficult to measure even in retrospect), the 
main use of the model is as a “what-if tool” to ex­
plore alternative approaches and understand the 
impact of policy decisions. 
Table 7 illustrates one possible model based 
on a hypothetical institution expending US$100 
million in research expenditure per year for 20 
years. (The model is currency independent and 
whether this is US$ or any other currency makes 
no difference to the rate of return.) The model 
has also been used for actual institutions, where 
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past and future research expenditure is known or 
can be forecast. Any available data on past inven­
tion disclosures, patents, or licenses can be used 
as initial conditions; the model can incorporate 
as much past data as is available to generate 
forecasts. 
Figure 7 shows the results of using a range 
of parameters to represent the three main TTO 
operating models, called the income, service, 
or economic models. The choice of office op­
erating model depends on institutional and 
national policy, and upon capabilities and re­
sources. In practice, a mix of models is normal. 
Each model can be defined by a set of innova­
tion value-chain operating parameters. These 
parameters enable the future performance of an 
office (or country) to be calculated, including 
investment outlay required, patent prosecution 
costs, time to break even, and potential internal 
rate of return (IRR). The IRR is the estimated 
return to the institution from investing in es­
tablishing a TTO, including staff costs and IP 
protection expenses. 
The importance of the model is not the ac­
curacy of its predictions, which will, of course, 
be no better than the underlying parameters and 
assumptions underpinning their use. The prima­
ry benefit is in understanding the dynamics and 
relatively long timescales involved in technology 
transfer. The model can thus help avoid unrealis­
tic expectations and can also provide the basis for 
a series of intermediate benchmarks that can help 
ensure that the innovation system is moving in 
the right direction. Invention disclosure, for ex­
ample, is clearly an important early indicator to 
measure both the health and the vibrancy of the 
research system. 
. EConoMIC-IMpACT	ESTIMATIon 
The ability to calculate, or even estimate, the eco­
nomic impact of technology transfer activities has 
been actively debated for a number of years. The 
statement below from the AUTM licensing sur­
vey for fiscal year 1999 has been disputed, and in 
subsequent years AUTM has refrained from mak­
ing claims in the survey, suggesting instead on the 
need for ongoing research. 
“The economic impact of the licensing of 
technologies developed at academic institutions 
is remarkable. The responses from member in­
stitutions estimate that the licensing of innova­
tions made at academic institutions contributed 
over [US]$40 billion in economic activity and 
supported more than 270,000 jobs in Fiscal Year 
1999. In addition, business activity associated 
with sales of products is estimated to generate 
[US]$5 billion in United States tax revenues at 
the federal, state, and local levels.”4 
Despite contention over specific claims of 
economic impact, it is widely accepted that the 
process is of economic benefit in all countries that 
have active innovation systems and promote uni­
versity technology transfer. The many countries 
that are investing resources in technology trans­
fer development confirm that there is widespread 
confidence that the investment is worthwhile and 
generates a positive return. 
With considerable justification, developed 
countries use the overriding argument that, 
when a research program is already in place, 
technology transfer can result in significant ad­
ditional benefits for a small additional cost (as 
shown in Table 4). But in developing countries 
with smaller economies, less-developed innova­
tion systems, and many competing demands for 
resources, the situation is less clear. The bench­
mark data shows that the volume of innovation 
activities arising from research is directly pro­
portional to the amount of research funding. If 
additional investment in research is proposed on 
the grounds that it supports economic growth, 
some justification for this needs to be shown (for 
example, that there will be a positive return from 
that investment).
While there is some financial benefit to the in­
stitution performing the research, the benefit is, at 
best, around 1% to 2% of research expenditure, as 
shown in Tables 2 and 3, and is generally between 
0.5% and 1.5%. Income generation from tech­
nology transfer is therefore clearly not an adequate 
reason for an institution to invest in research. The 
financial benefits of technology transfer activities 
are captured primarily at the national economic 
level through business creation, with national re­
turns arising from direct and indirect economic 
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CHAPTER . 
effects. The data makes a compelling case for pub­
lic funding, not only of research itself, but also of 
technology transfer activities. 
Even when the public sector invests funds 
in research (whether for economic development 
reasons or otherwise), a research institution must 
invest in technology transfer activities over an ex­
tended period (eight to ten years) before a posi­
tive return can be expected. The highly uncertain 
and variable nature of the returns compounds 
these difficulties. Indeed, measuring the national 
economic impact of technology transfer is diffi­
cult and has been the subject of intense discus­
sion and debate. A simplistic model has been 
developed to illustrate the concepts and motivate 
the development of more comprehensive models 
(the approach used here follows that described by 
Pressman5). 
Universities report that the typical average 
royalty rate, from which license revenues are de­
rived, is within the range of 2% to 4%. Direct 
business activity generated by technology trans­
fer activities is therefore of the order of 25 to 50 
times the revenue received by the licensing insti­
tution. Using an appropriate multiplier (typically 
1.5 to 2.0), the overall direct economic impact 
can be estimated. This is not strictly an economic 
model. It is an estimate of the multiplier effects 
that are required to obtain a positive return. More 
work is needed to determine the actual multiplier 
effects that occur or are achievable. In addition to 
these benefits, the pre-production benefits associ­
ated with technology transfer activities have been 
shown to be significant.6 
This economic return is the direct return from 
the activities measured and managed by the insti­
tutions’ TTOs. There is strong evidence that the 
entrepreneurial culture resulting from the focus on 
technology transfer results in many other benefits 
that are neither captured nor measured by the in­
stitution, but which have an impact on the local 
economy.7 These are the indirect multiplier effects. 
Whether similar benefits will accrue in developing 
countries is difficult to say and requires more re­
search. Certainly, the factors noted by Tornatzky 
generate cause for concern. He noted that states 
with strong entrepreneurial support (such as 
Massachusetts and California) tend to draw 
entrepreneurial talent and opportunities from states 
with less support, resulting in a loss of economic 
benefits accruing to the states where the research 
was undertaken. This migration constitutes a leak­
age of benefits from states with less-well-developed 
entrepreneurial environments to those with a more 
nurturing environment. If leakages from poorer to 
richer states in the United States (in terms of entre­
preneurial support) have an impact in the United 
States, the effect in developing countries is likely to 
be even more pronounced. 
Figure 8 illustrates these concepts in an ex­
ample projecting the returns arising from the 
technology to an investment in research illustrat­
ed in Figure 7. These projections are, of course, 
sensitive to the assumptions made. The model 
shows, for example, that a positive national IRR 
can only be achieved if the indirect multiplier ef­
fects are at least three to four times more than the 
direct effects. This reinforces the need for a more 
in-depth understanding of innovation system 
dynamics so that these effects can be understood 
and measured. 
What is clear from the model is that the direct 
returns resulting from technology transfer are far 
from adequate to justify additional expenditure on 
research. In developing countries, the debate on 
whether higher expenditure on research is justified 
is intense and the model illustrates the need for 
more in-depth analysis and better economic data. 
.  vARIABILITy of 	BEnCHMARkS 
And 	RETuRnS 
The benchmark data from individual institutions 
(from all countries and over hundreds of institu­
tions) shows a very high variability from year to year 
and from institution to institution. This variabil­
ity is observed on all measures in the value chain: 
invention disclosures, patents, licenses, spinout 
companies, and income. The variations are up to 
two orders of magnitude, even for institutions that 
in other respects are similar. Some of these trends 
were illustrated in Figures 2, 3, 4, and 5. Analysis 
of the data by income, size of the institution, ma­
turity, or size of the TTO indicates that none of 
these variables is strongly correlated with efficiency 
or performance measures. The only significant
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correlation is that innovation output measures are 
proportional to the volume of research, as mea­
sured by expenditure on research. Even this figure 
is proportional only in aggregate over a large port­
folio, with strong institutional variations. 
Figure 9, for example, shows the variation 
in invention disclosure rate in terms of millions 
of dollars of research expenditure per invention 
disclosure, as a function of both the age of the 
office and the magnitude of research expenditure. 
Although in aggregate over time and across coun­
tries the figure is relatively constant, at the insti­
tutional level very strong variations occur, irre­
spective of the size or maturity of the institution. 
The European, United Kingdom, and Australian 
surveys show a similar distribution, so this is not 
unique to the United States. 
Figure 10 shows the variation in license in­
come (as a percentage of research expenditure) for 
U.S. and Canadian institutions. The graphs con­
firm the theoretical model presented above and 
demonstrate the ten-year lag before significant 
revenue is generated. But even after this portfo­
lio-establishing period, returns to offices of simi­
lar size and experience vary greatly. 
This high variability in returns has been not­
ed and studied.8,9,10 The variability in innovation 
returns appears to be inherent to the nature of in­
novation, but the variation in returns in early in­
termediate benchmarks (for example, invention 
disclosure rates) is not affected by the same fac­
tors. While still variable, this variability is less in­
herent and more manageable. Economic returns 
are determined by an unpredictable set of market 
factors, while the intermediate benchmarks are 
more controllable by the institution and TTOs. 
Institutional commitment, coupled with skilled, 
experienced staff, can significantly contribute by 
identifying opportunities and motivating inven­
tion disclosure, and, of course, by managing all 
the subsequent steps in the value chain. 
The impact that skilled staff could have on 
the overall innovation process and benchmark 
figures is a topic for further research. If best prac­
tices could be identified and disseminated, they 
could potentially increase innovation returns sub­
stantially. This is particularly relevant to smaller, 
more-isolated offices, and offices in developing 
countries where peer learning is absent. Strong 
professional networks are critical, and these need 
to be promoted and developed. 
Sherer and Harhoff11 performed an in-depth 
study on innovation returns. Based on their analysis 
of eight large patent portfolios in both the United 
States and Germany, the researchers concluded: 
“Our empirical research reveals, at a high level 
of confidence, that the size distribution of private 
value returns from individual technological innova­
tions is quite skew—most likely adhering to a log 
normal law. A small minority of innovations yield 
the lion’s share of all innovations’ total economic val­
ue. This implies difficulty in averting risk through 
portfolio strategies and in assessing individual orga­
nizations’ innovative track records. Assuming simi­
lar degrees of skewness in the returns from projects 
undertaken under government sponsorship, public 
sector programs seeking to support major technologi­
cal advances must strive to let many flowers bloom. 
The skewness of innovative returns almost surely per­
sists to add instability to the profit returns of whole 
industries and may extend even up to the macroeco­
nomic level. Although much remains to be learned, 
some important lessons for technology policy have 
begun to emerge.” 
The AUTM data confirms that this skewness 
is even more apparent in university portfolios, 
with an average of only one in 200 licenses gener­
ating more than US$1 million in revenue.12 This 
concurs with Sherer’s data: of the eight portfolios 
he analyzed, the three from universities all had 
higher levels of skewness than the industry port­
folios. This skewness is of particular relevance to 
smaller institutions and countries. 
This disparity in outcome, which can oc­
cur even between institutions of similar size, ca­
pability, and investment, can lead to problems. 
Without an in-depth understanding, the bench­
marks can result in dysfunctional policy decisions 
at both national and institutional levels. 
. IMpLICATIonS	 foR
dEvELopInG	CounTRIES 
Data on the actual performance of developing 
countries is not available, or at least none has 
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CHAPTER . 
been discovered in the course of conducting this 
research and making presentations in a number 
of countries.13 A limited set of data, which has 
been obtained by personal contact with a number 
of institutions, is available for South Africa. This 
data is shown in Table 8, together with projec­
tions of the possible outcome if South Africa was 
operating within the international ranges sum­
marized in Table 3. 
If South Africa was to attain an innovation 
performance similar to comparable institutions 
elsewhere, the entire South African higher-edu­
cation research system could be expected to 
generate 200 to 300 invention disclosures per 
year. After seven to ten years, such a disclosure 
rate should lead to a portfolio of around 500 ac­
tive licenses, two of which would be likely to be 
generating revenue of greater than US$1 million 
per year, with total revenue of US$5 million to 
US$10 million per year. 
Furthermore, the distribution of returns 
would almost certainly be skewed, even among 
the five or six major research universities, let alone 
the 15 smaller institutions. A few institutions are 
likely to perform relatively well, while the major­
ity are likely to operate at a net loss, even after 
ten or 15 years. Furthermore, the skewness and 
variability of returns means that it is not possible 
to predict who is likely to succeed and who will 
be considered to have “failed.” Given the finan­
cial constraints that exist in higher education 
institutions, continued institutional support for 
technology transfer is likely to be a risk, unless 
external support or stimulus is provided. 
In the United States, the Bayh-Dole act of 
1980 provided a major stimulus for technology 
transfer, but the difficulty of using a similar mea­
sure in South Africa is illustrated by the funding 
differences. In the United States, the proportion 
of research from federal funding is 61%, while 
industry contributes only 9% of total research 
funding.14 In South Africa, industry funding is 
58% and government funding makes up 28% of 
total research funding.15 This funding pattern has 
implications for IP generation and ownership, as 
well, and is an example of the differences that 
need to be considered when making projections 
based on international benchmarks. 
One argument that carries some weight is 
that the high levels of industry-sponsored re­
search in South Africa and other countries with 
a similar pattern of funding, represent consider­
able informal technology transfer embedded in 
research contracts. The true performance of these 
institutions, therefore, may be much higher than 
is indicated by the simple “AUTM-like” technol­
ogy transfer indicators. 
Whether the benchmarks from countries 
with large, well-developed research and innova­
tion systems will scale to smaller countries is at 
present unknown. More detailed analysis and 
measurement are required to determine appropri­
ate benchmarks and to construct a more robust 
and accurate economic impact model. 
. ConCLuSIonS 
The similar relative performance of higher-edu­
cation technology transfer systems in developed 
countries indicates that the creative innovation 
process is inherently similar and that no one 
country is significantly better in terms of the ef­
ficiency with which ideas are generated and trans­
ferred. The impact of a technology transfer pro­
gram is determined primarily by the magnitude 
of the expenditure on research and the length of 
time the program has been in operation, provided 
active innovation programs exist and well-trained 
technology transfer professionals are in place. 
These are essential requirements if institutions 
and countries aspire to attain international norms 
of performance. 
To avoid unrealistic expectations of the ben­
efits of technology transfer in smaller countries 
and institutions, this data set must be under­
stood. Effective models of the innovation system, 
preferably based on local data, can help predict 
budget requirements, the possible return on in­
vestment, and the timescales to attain these goals. 
Measurement of the local innovation system 
should commence at the earliest possible stage, 
because early indicators (such as the invention 
disclosure rate) can provide insight into how the 
remainder of the value chain is likely to develop. 
The long time-period required for individual 
institutions to derive benefits, and the fact that 
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the benefits are largely to the national economy, 
indicate that appropriate national support mea­
sures are needed to encourage innovation devel­
opment and to overcome institutional resistance 
in resource-constrained environments. Using an 
innovation-system model (where appropriate) 
to evaluate and quantify alternatives, further re­
search is needed to determine the most effective 
support measures. 
Institutions and innovation systems need to 
take into account the skewness and inherent vari­
ability of innovation returns. In the early stages, 
more emphasis needs to be placed on intermedi­
ate benchmark measures and less on such tradi­
tional measures as license revenues and spinout­
company formation. n 
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CHAPTER . 
Typical Ranges per $100m ATRE 
Invention disclosures 40 – 50 
Patents 20 – 30 
Licenses 10 – 15 
Spinout companies 1 – 5 
Income $1m – $3m 
(1% – 3% of research expenditure) 
Table 3: Research and Innovation Value Chain 
Group u.S. Canada Australia u.K. 
All universities 3% 1.60% 1.50% 1.10% 
Lower 95% 1.60% 0.80% 0.60% 0.55% 
No. of universities excluded
from average 
8 2 1 5 
Bottom 50% 0.28% 0.23% 0.08% 0.02% 
Note:“Group” refers to university rankings by percentage of license income, as indicated in Figures 2–5. 
Table 4: Average Returns in 2002
(license Income as % of Total Research Income) 
university size Budget (u.S./Australia model) 
Budget
(u.K. model) 
Small 1%–2% 2%–3% 
Medium 0.5%–1% 1%–2% 
Large 0.2%–0.5% 0.5%–1% 
Group u.S. & Canada u.K. & Australia 
Bottom 50% (of all universities) Loss Large loss 
50%–95% Break even–profitable  Loss 
Top 5% (of all universities) Very profitable Profitable 
Note:“Group” refers to university rankings by percentage of license income, as indicated in Figures 2–5. 
Table 6: likely Outcomes (Estimated Budget vs. likely Income) 
Table 5: Typical Technology Transfer Office Budgets
(As % of Total Research Expenditure)
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Table 8: Projections of TTO Activity for South Africa
International
ranges










Research expenditure (ATRE) per US$100m per US$100m US$500m 
Invention disclosures (total) 40–60 23 200–300 
Patents filed 20–30 6 100–150 
Licenses 10–15 4 60–100 
Start-ups 1–5 3 5–20 
Patent budget (as % income) 0.2%–0.5% 0.30% 
License income 1%–2% of total 0.1% of total US$5m–US$10m 
Size of staff 4–20 9 20–100 
Note: Projections are based on likely ranges from international benchmarks. 
Figure 1: license Income
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All universities (141) in Order by Percentage license Income 
US Trend 
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Figure 5: license Income for Australian universities for Fy 2002
(logorithmic plot) 





















































All universities (21) in Order by Percentage license Income 
US Trend 
US Trend 
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CHAPTER . 
Figure 7: Impact of Policy Choices on Performance 
2% 22% 33% 40% 44% 47%  48% 
yr 2 yr 3 yr 4 yr 5 yr 6 yr 7 yr 8 yr 9 yr 10 yr 11 yr 12 yr 13 yr 14 yr 15 
Service model (S) 
Income model (I) 





















IRR economic model 
IRR income model 
-13% 3% 13% 20% 24% 
IRR service model  -1% 7% 12% 
Figure 6: Typical Phasing of the Value Chain 
1 year 2 years 3 years 4 years 5 years 6 years 7 years 
Provisional 
Disclosure 
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Figure 8: Estimation of National Internal Rate of Return (IRR) 













Average royalty rate 3% 
GDP Multiplier 1.5 
Tax revenue direct 30% 
Indirect Multiplier 4 
Tax revenue indirect 25% 
Figure 9A: Disclosure Rate vs. Age of Office 
1975 1980 1985 1990 1995 2000 
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Source: IIPI Report on South African University Technology Transfer:  A Comparative Analysis, Jan 2004. 
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Figure 10B:TTO Age as a Determinate of licensing Income (Canada) 
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ABSTRACT 
This chapter reviews the options for effective public sec­
tor management of intellectual property (IP) in the life 
sciences, focusing on the need for a judicious, pragmatic 
choice of options along two axes: (1) deployment of 
exclusive rights over technology and (2) use of market 
mechanisms to bring a new technology to the public. 
The essence of public sector IP management is finding 
the right settings along these two axes that will deliver 
tangible outcomes in line with defined public-interest 
objectives. Experience shows that ex ante assumptions 
about how to gain optimal leverage from exclusive rights, 
and the appropriate degree of reliance on market mecha­
nisms, are unlikely to serve a public sector IP manager 
well. In clarifying objectives and the practical means of 
achieving them, pragmatic coordination between the 
practical and policy levels is essential. Public sector IP 
managers are more likely to be assessed against public 
interest expectations than their private sector colleagues. 
In IP management in the life sciences, policy and prac­
tice are ultimately two sides of the same coin; practi­
tioners cannot hope, expect, or plan to operate outside 
the broader policy perspective. Policy-makers therefore 
need to consider the actual practice of IP management 
when assessing a policy framework for innovation in 
the life sciences. IP managers should be open to using 
legal mechanisms flexibly for inclusion, or exclusion, as 
required to achieve their goals. Finally, managers should 
seek mechanisms to pragmatically structure and promote 
partnerships with those who have the resources necessary 
to bring life-sciences innovation to the public. Such part­
nerships may be centered in the public, philanthropic, or 
private sectors, but more likely fall into a hybrid mix of 
these categories. 
1. ovERvIEW	And 	ConTExT 
1.1	 Toward policy-rich practice and 
practice-informed policy 
Researchers, technology managers, and intellec­
tual property (IP) advisors who work in the life 
sciences and who use the IP system are not oper­
ating in a policy-neutral, strictly technical envi­
ronment. An overarching public interest in life-
sciences innovation means that the accumulated 
impact of many seemingly independent, individ­
ual choices will in fact have implications for how 
the IP system is perceived by policy-makers and 
will therefore help to determine policy directions. 
The practical choices made when managing IP 
rights therefore ultimately influence public policy 
debate. Indeed, given public expectations for life-
sciences innovation, choices over when and how 
to exercise IP rights are inevitably assessed from a 
policy point of view. 
Practitioners need to be sensitive to the poli­
cy environment and alert to the debates that swirl 
around two related aspects of public concerns: 
(1) the impact of life-sciences developments in 
themselves and (2) the impact when intellectual 
property is applied to life-sciences innovation. 
While this may frustrate legally trained practitio­
ners, how the IP system is used, and the perceived 
equities of access to the benefits of a life-sciences 
Taubman A and R Ghafele. 2007. Public Sector IP Management in the Life Sciences: Reconciling Practice and Policy—Per-
spectives from WIPO. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Prac-
tices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.
ipHandbook.org. 
© 2007. A Taubman and R Ghafele. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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technology, can affect public perceptions of the 
legitimacy of that technology. Juma and Konde 
write: 
Resistance to new technologies is likely to be re­
duced by changing perceptions of access to the new 
technologies as well as to their markets. This has not 
been the case with agricultural biotechnology, which 
involves worldwide exports with the potential for 
product displacement, while leaving wide margins 
of uncertainty for technology followers.1 
Moreover, the policy debate cannot oper­
ate in isolation from the practical realm. Policy­
makers need a robust, practical understanding of 
the technologies concerned, of the nature of life-
sciences innovation, of the overall trends in the 
IP landscape, and of the real-world impact of the 
actual exercise of IP rights. Only then can policy­
makers effectively balance concerns about equity 
of access with the proper exercise of exclusive 
rights. Optimal policy choices require the widest 
range of distilled, neutral empirical information 
about the use of intellectual property in relation 
to key life-sciences technologies. Indeed, the ex­
perience of practitioners contributes valuable in­
sights needed to guide and buttress policy debate 
over the future of life-sciences innovation. 
1.2	 Resolving the paradox: public 
interest through private rights 
Reconciling the public policy role of the IP system 
with the management and exercise of private IP 
rights addresses the central paradox of IP policy: 
what legal exclusions from the public domain are 
required to promote the public interest? And how 
can those exclusive rights, once granted, be best 
deployed for IP law to function as a public policy 
tool? Life sciences concern the basic human needs 
of food, health, and a safe environment. How 
then can IP rights be best managed to promote 
public welfare by making available the fruits of 
life-sciences innovation and spurring economic 
development? These benefits arise not from the 
mere presence of a formal system of assessing, 
granting, and enforcing IP rights, but from the 
judicious, skillful application of these legal mech­
anisms in practice. Positive welfare gains from 
IP mechanisms emerge from an accumulation 
of individual choices, not just from the abstract 
process of shaping a legislative framework This 
is most directly illustrated by the experience of 
managing rights held by public sector institutions, 
which can be held more immediately responsible 
than their private sector counterparts for securing 
tangible benefit gains directly from public invest­
ment in research and development. Thus, we see 
the emergence of public sector IP management 
as a distinct subset within the broader discipline 
of IP management. For instance, pharmaceutical 
public-private partnerships “must be as aggressive 
in the way they use IP as any commercial unit, but 
for a different purpose—namely to pursue their so­
cial objective of getting quality, affordable products 
to developing country patients.”2 
The optimal implementation of IP rights re­
quires a practical understanding of the full range 
of options for exercising exclusive rights and a ca­
pacity to assess and implement those options as 
part of a broader strategy. IP rights are exclusive 
in their formal legal character, but the modes of 
exercising such rights are highly diverse and will 
correspond to an institution’s broader objectives. 
A predetermined license template, for example, 
will not lead to best practice in IP management 
in the life sciences, because its use may effectively 
foreclose the full range of choices available and 
preempt the objective assessment of the implica­
tions of each option. A good manager will instead 
judiciously use IP mechanisms to leverage the re­
sources needed and obtain the freedom to oper­
ate, while prudently assessing the likely impact of 
various forms of IP rights exploitation. 
Workable public sector–management models 
do not normally entail an exclusive reliance on re­
lease into the public domain nor on wholly exclu­
sive licensing. While it is rare to see a life-sciences 
product delivered without some engagement of 
private sector actors responding to market signals, 
it is usually misleading to set the full product de­
velopment pipeline wholly in the public or private 
sectors. Given especially the necessarily stringent 
regulatory environment confronting the life sci­
ences and the need to garner resources for the full 
product development process, investments will 
likely draw on both public and private resources. 
Therefore, rather than employing simple public/ 
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private or open/exclusive labels, the full range of 
options available to public sector IP managers can 
be more usefully analyzed along two continuums: 
(1) degree of exclusivity, ranging from defensive 
publishing in the public domain through open 
source or commons-based constructs, and nonex­
clusive and exclusive licensing, to direct exploita­
tion of exclusive rights; and (2) degree of market 
engagement, from pure research, through mak­
ing some use of private resources in the develop­
ment pipeline, to various modes of outsourcing 
product development and the dissemination of 
a proven life-sciences technology, including spi­
noffs and transfer of rights to private firms. Even 
if a public sector IP manager’s core responsibility 
is to deliver welfare gains to the public in the form 
of accessible new life-sciences technologies, she or 
he is likely to have to assess the full range of op­
tions across these two spectra when formulating 
a practical strategy. These options are presented 
schematically in Figure 1 (which is also further 
discussed in section 4.2 below). 
1. 	 The meaning of global 
intellectual property 
Participation in the international patent system 
continues to grow and diversify in three overlap­
ping ways, each with direct ramifications for the 
field of public sector IP management: 
1. Greater geographical and cultural diversity. 
Membership in the Patent Cooperation 
Treaty (PCT) has shifted from an early 

























joint venture, etc.” 
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“Traditional”
private sector pipeline 
$ 
Public–private partnership 
with cross subsidization 
from market product 
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Source: A Taubman3 
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preponderance of developed and transi­
tional economies to a clear majority of de­
veloping countries. In terms of the actual 
use of the system, patent applicants from 
the developed world continue to predomi­
nate, but current trends reveal double-digit 
growth, sustained over five years or more, 
on the part of certain key developing coun­
tries. This trend, if sustained in the medium 
term, would significantly shift the center of 
international patent activity. PCT interna­
tional applications received from develop­
ing countries in 2005 rose 24.8% com­
pared to 2004, and constituted 6.9% of all 
filings. China, Mexico, and the Republic of 
Korea are among those countries register­
ing double-digit percentage increases in use 
of the PCT.3 (Figure 2) 
2. Greater use of the system by public sec­
tor and not-for-profit entities. In the 
life-sciences domain, these are as di­
verse as India’s Council of Scientific and 
Industrial Research, Empresa Brasileria 
de Pesquisa Agropecuaria (Embrapa), the 
Korea Research Institute of Bioscience 
and Biotechnology, the International 
Aids Vaccine Initiative, the Medicines for 
Malaria Venture, and CAMBIA. 
3. Growth in use of the system in life-scienc­
es technologies stronger than the general 
trend. For instance, PCT publications in 
the technical field represented by IPC Class 
A61K (Preparations for Medical, Dental, 
or Toilet Purposes) rose 5.1% in 2005. 
In the next highest field (G06F—Electric 
Digital Data Processing) the growth rate 
was 4.6%.4 
Public sector users of the patent system who 
are working in the life sciences face practical 
questions about how to manage a patent estate 
to advance their institutional objectives. While 
this has been the subject of a longstanding de­
bate in the developed world, it is increasingly a 
practical issue for developing countries as well. 
The rate of public sector patenting in life-sciences 
research in developing countries is growing expo­
nentially. These countries are, of course, starting 
from a small base, so the actual impact will be 
felt over time as international activity translates 
into distinct national rights. It is certain, how­
ever, that government agencies and other public 
sector institutions in developing countries will be 
increasingly responsible for managing a growing 
stock of life-sciences intellectual property result­
ing from investment of public resources, or from 
combined private and public sector inputs. These 
governments will assume the task in light of their 
overarching responsibility to promote the public 
interest through the management of this intel­
lectual property. Doing so entails working on 
a broader canvas than the mainstream manage­
ment of intellectual property the essential focus 
of which is to promote commercial outcomes. 
Such social or institutional responsibilities 
require that public sector IP managers develop 
and apply practical skills to manage intellectual 
property effectively. They may need to look be­
yond conventional, private sector methodologies 
to find appropriate ways of managing intellec­
tual property to ensure the desired public inter­
est outcomes. These might include ensuring the 
development and effective dissemination of new 
technologies to the public (for example, new 
pharmaceuticals), promoting economic and social 
development, creating skilled jobs, or enhancing 
urgent research funding. 
Effectively managing public interest IP is a 
task that requires judgment and acute sensitivity, 
acutely so in life-sciences domains. It requires ad­
vanced skills. There is a wide spectrum of possible 
approaches, and there are many distinct objectives 
that may be pursued. IP management to produce 
public health outcomes is particularly demand­
ing, yet vitally important for the public interest. 
1. Choices for public sector IP management 
While often debated in abstract terms, the impact 
of IP laws and IP rights is ultimately determined 
by a series of practical, yet critical, choices. For 
the public sector, these choices are increasingly 
guided by IP management policies. Tom Ogada 
has categorized these choices in terms of: 
•	 Who owns the intellectual property gen­
erated by government-funded research 
activities? 
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•	 How will revenues/benefits from the com­
mercialization of intellectual property be 
shared between the researcher/inventors, 
the department, the institution, and gov­
ernment funding providers? 
•	 Which, if any, government rights/stipula­
tions are attached to the commercialization 
of intellectual property generated under 
government-funded research? 
•	 In the case of privately funded research, who 
will own any resulting intellectual property? 
•	 Will spinout companies or licensing con­
tracts be used to transfer technology to the 
private sector for commercialization? 
•	 Who will manage IP assets, including the 
negotiation of licenses and royalty sharing? 
•	 To what extent will the institution encour­
age research commercialization through 
entrepreneurial activity? 
•	 How will the costs of IP protection and 
maintenance be paid? 
•	 How should any invention disclosure pro­
cedure be managed? 
•	 How will conflicts of interest between 
teaching/research duties and commercially 
driven projects be handled? 
To assist public sector IP managers and 
policy-makers in making these decisions, Ogada 
has authored Guidelines on Developing Intellectual 
Property Policy for Universities and R&D 
Institutions in African Countries.5 Other relevant 
Figure 2: PCT Applications of Select Research Centers
in India, the Republic of Korea and South Africa 
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TAuBMAN & GHAFElE 
World Intellectual Property Organization 
(WIPO) resources include: 
•	 Successful Technology Licensing. This booklet, 
written for use by business managers, technol­
ogy managers, and scientists who deal with 
licensing questions, aims to help its readers 
negotiate win-win licensing agreements, in 
which all parties receive and exchange ap­
proximately equal benefits and value. 
•	 Exchanging Value—Negotiating Technology 
Licensing Agreements: A Training Manual. 
This text focuses on the practical business 
needs and concerns of nonspecialists who 
have to deal with licensing in or licensing 
out of technology. The manual includes an 
outline for a program schedule and practical 
guidelines for creating and managing teams/ 
groups for conducting mock negotiations. 
(These are from a five-day practical workshop 
on negotiating technology licenses, includ­
ing a case study on tuberculosis vaccines.) 
•	 Advanced Distance Learning Course on 
Biotechnology and Intellectual Property. This 
addresses aspects of patenting biotechno­
logical inventions and the plant breeder’s 
rights systems, as well as IP in research and 
development, and the management and 
practical use of IP rights. 
2. BIoMEdICAL	InnovATIon 
And dEvELopMEnT 
2.1  Capturing the benefits of 
indigenous innovation 
Concentrating on technology transfer as a key 
innovation strategy, mainstream discourse on in­
novation and development tends to cast develop­
ing countries as recipients of technology produced 
elsewhere. While access to foreign technology is 
clearly integral to development, it is increasingly 
important to focus directly on capturing the in­
digenous innovation potential of developing coun­
tries.6 Given that developing countries hold signif­
icant traditional knowledge and genetic resources, 
this arguably applies in the life sciences more than 
in any other field. At least one of the lessons of 
the biopiracy debate is the need to ensure that 
custodian countries derive social and economic 
benefits from these vital feedstocks for life-science 
research. Accordingly, delivering on the promise 
of life-sciences innovation requires outcomes tai­
lored to the circumstances of individual countries. 
This means democratizing innovation to address 
neglected diseases that disproportionately afflict 
the developing world, or to respond to the agro­
nomic, environmental, and nutritional context of 
developing country agriculture. 
Many developing countries possess the hu­
man capital necessary for life-sciences innovation, 
and they seek the practical pathways to realize this 
potential, not only from the point of view of eco­
nomic development, but also from the broader 
perspective of public welfare. For instance, local 
health practitioners have extensive practical expe­
rience in traditional knowledge systems, as heirs 
of generations of “clinical trials.” In dealing with 
endemic diseases, the knowledge reserves of the 
health practitioners need to be drawn on more 
systematically as part of a sustainable, bottom-
up approach to development. The recent launch 
of the South African Indigenous Knowledge 
Systems (Box 1) places traditional knowledge 
policy squarely in the context of innovation pol­
icy and the equitable sharing of benefits. 
2.2	 Innovation and intellectual 
property—the practical context 
Debate continues over the overall role and impact 
of IP protection in relation to meeting the twin 
goals of fostering innovation and promoting the 
effective dissemination of the fruits of innova­
tion.8 Adopting the approach of this Handbook, 
this chapter does not enter into the debate be­
yond pointing out that the policy context is a 
highly dynamic one, greatly influenced by feed­
back from the actual and perceived impact of the 
accumulated choices of IP managers. It is clear 
that the effectiveness of the patent system for at­
taining these objectives depends on its practical 
context, which can be addressed on three levels:
1. the regulatory and administrative level (dis­
cussed in more detail below) 
2. the level of skills and capacity (As a com­
plex policy mechanism, the patent system 
requires skilled operators.) 
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CHAPTER . 
3. the level of individual users of the system: 
applicants, opponents, licensees, advisors, 
and advocates, with a special focus here on 
public interest users 
At the regulatory and administrative level, 
the key elements of a practically effective system 
include: 
•	 patent quality, construed here as the great­
est possible convergence between actual 
patenting outcomes and the public inter­
est as delineated in the principles of patent 
law, especially the conventional criteria for 
patentability 
•	 the transparency, clarity, and predictability 
that effective administration provides in 
terms of the practical accessibility of timely 
patent information, the clarity of scope and 
title, and functional patent quality 
•	 practical equity of access to the system, so 
that the skew of accessibility that favors al­
ready dominant private sector players can 
be reduced 
•	 persuasive deterrents and remedies against 
the misuse of patent rights once granted 
2. 	 System functionality and the capacity 
to make the system function 
In sum, much of the public welfare impact of the 
system and actual delivery of equity depend on 
system functionality—not merely on the formal 
legal settings that form the focus of international 
debate. Effective functionality depends on de­
ploying three special skill sets: 
1. The legal and policy skills required to draft 
and implement suitable legislation and 
policy mechanisms within the framework 
of international standards but also tailored 
to national needs and priorities 
2. The 	 technological know-how and legal 
skills required to draft patent documenta­
tion and to objectively assess the validity 
and legitimate scope of patents in patent 
examination and judicial processes 
3. Technological management skills, includ­
ing valuation of disclosed innovations 
in light of institutional goals (not just in 
terms of commercial value), assessment of 
potential technology development and dis­
semination pathways, and the formulation 
of patenting and licensing strategies 
As a rough generalization, capacity-building 
processes in developing countries have tended to 
focus on each of these skill sets in turn, beginning 
with a top-down legislative perspective. This has 
been most conspicuous in the decade of the im­
plementation of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS). 
This sequence of shifting priorities for capacity 
building reflects a natural evolution from a legalis­
tic view of implementation and a reactive, or defen­
sive, posture followed by a greater concentration on 
building administrative and institutional capacity, 
Box 1: Traditional Knowledge and Innovation in South Africa
 
South Africa’s Indigenous Knowledge Systems (IKS) Policy aims at “positive synergy between South 
African IKS and the South African National System of Innovation” through:
• the creation of a legal benefit-sharing framework 
• the establishment of a formal recording system for IK 
• legislation to ensure minimum standards in information and material transfer agreements 
with respect to IK research 
• the promotion of IK links with the science base by means of targeted funding instruments 
• amendments to patent legislation to enforce IK prior art declaration 
Source: WIPO.7 
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TAuBMAN & GHAFElE 
to the current growing emphasis on strategies that 
practically and proactively capture direct benefits 
from indigenous research capacity and comparative 
advantage in knowledge resources. This Handbook 
is emblematic of the culmination of this last trend. 
But capacity building must continue on these three 
tracks in parallel, mutually informing and reinforc­
ing one another, especially in the life sciences. In 
particular, the practical view from the bottom up 
should inform the view from the top down in a re­
spectful dialogue between policy-conscious practi­
tioner and practically informed policy-maker. 
2.	 The policy impact of effective users 
Clearly, it is the central role and responsibility of 
administrators to promote the effective and efficient 
functioning of the system as a system. But users are 
not just customers of the system; they function as 
active agents engaged in safeguarding patent quali­
ty: “users” have responsibilities as patent applicants, 
as patent opponents, as litigants, and as licensors 
or licensees. Adversarial legal processes have shaped 
much of the important detail of patent law. The 
costs and limitations of the existing administrative 
and legal systems have led to calls to more system­
atically include a user perspective on patenting out­
comes.9 The growth in life-sciences patent filings by 
government agencies and public sector institutions 
may lead to further blurring of the boundaries be­
tween administration and knowledge management 
within public sector agencies and to the implemen­
tation of a broader, more holistic array of innova­
tion policy settings. Ideally, the responsibility to ef­
ficiently manage IP portfolios will be understood in 
relation to the broader responsibility to contribute 
to public policy outcomes. This extra layer of opera­
tional and ethical complexity creates a distinct chal­
lenge for the public sector IP manager. Managers of 
private sector IP portfolios in the life sciences may 
need to consider ethical and social constraints, such 
as professional ethics and corporate social respon­
sibility programs, but this chapter concentrates on 
the public sector manager. 
2. 	 The public sector IP manager 
as a system user 
Since the informed, judicious management of life-
sciences IP is the most realistic way of boosting 
actual availability of vital life-sciences technolo­
gies, the public sector IP manager has fundamen­
tally important responsibilities. IP management 
is a practical craft, not a rigid legal discipline, 
difficult to capture in terms of checklists and 
licensing templates. This section reviews best 
practice for public sector IP managers in life-sci­
ences technologies. The discussion focuses on two 
broad categories of responsibility: policy-orient­
ed, or systemic, and outcome-oriented, or practi­
cal. Experience has shown that early assumptions 
about the right mix of exclusivity or openness of 
access, and the right proportion of a reliance on 
public resources and an engagement of private 
interests, are unlikely to be effective or even de­
fensibly fair. Public sector research programs that 
routinely consign publicly funded research to the 
public domain can attract just as much criticism 
as those programs that seek excessive exclusivity 
in the management of public-funded intellectual 
property. Inattentively letting research outcomes 
fall into the public domain can allow richer and 
more nimble private interests to benefit dispro­
portionately from access to this publicly funded 
knowledge. Public sector IP management must 
therefore be viewed with a strong pragmatic, em­
pirical perspective. Accordingly, an outcome-ori­
ented approach to public interest IP management 
includes: 
•	 promoting an in-house invention disclo­
sure under effective confidentiality rules 
•	 analysis of disclosures in the light of institu­
tional objectives 
•	 assessment of technologies against priori­
ties, categorizing them for public domain 
release or defensive publication, for open 
licensing, for nonexclusive licensing, or for 
a strategic in-house focus 
•	 review of the obstacles to the effective use 
and dissemination of the new technology, 
including resource limitations, regulatory 
obstacles, and constraints on freedom to 
operate in target markets, noting that de­
veloping countries generally have greater 
freedom to operate due to the relatively low 
levels of patenting 
•	 formulation of strategies, and identifica­
tion of potential partnerships, that aim to 
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bring a life-sciences innovation to targeted 
groups, which entails considering commer­
cial, technological, and regulatory issues, as 
well as an assessment of external require­
ments that include background intellectual 
property, project management capacity, 
technological and manufacturing capacity, 
regulatory process capacity, and investment 
capital 
•	 leveraging intellectual property holdings 
to: 
- promote the dissemination of techno­
logical knowledge 
- ensure the availability of improvements, 
further applications, and derivatives of 
licensed technology 
- secure access to regulatory data and 
background/platform technology 
- reserve rights for third-party use in hu­
manitarian applications 
- reserve exclusively licensed rights in the 
event that licensees fail to meet public 
interest performance criteria (such as 
low-cost or cross-subsidized distribution 
to target markets) 
- safeguard grant-back of background in­
tellectual property, project intellectual 
property, or regulatory dossiers in the 
event that licensees fail to meet public 
interest performance criteria 
-	 bolster institutional research capacity, 
through licensing fees, partnerships, ac­
cess to research tools and other platform 
technologies 
In the hands of the public sector IP manager, 
an IP portfolio is not necessarily viewed purely as 
a commercial asset, although commercial valua­
tion and product development and dissemination 
will normally be essential. An IP portfolio also 
functions as: 
•	 a transactional asset, used to promote, expe­
dite, and clarify the formation of technolo­
gy partnerships, and to define and structure 
specific contributions and expectations in 
partnerships 
•	 an institutional asset, used to leverage ac-
institutional goals, ranging from specific 
R&D expertise to research financing 
•	 a policy asset, used to influence choices of 
technology partners, including private sec­
tor partners in public–private partnerships, 
and to promote humanitarian or cross-sub­
sidized access to life-science technologies in 
developing countries or in other beneficiary 
groups 
The public sector IP manager in the life sci­
ences may also need to consider the public-policy 
expectations placed upon her or him, explicitly, 
implicitly, or even retrospectively. She or he 
should, in particular, consider the following poli­
cy-oriented or systemic responsibilities: 
•	 influencing positive innovation patterns, 
promoting the effective collaboration and 
open dissemination of upstream research 
findings, both for the inherent value of the 
knowledge as a public good and as a means 
of promoting the widest possible applica­
tion of upstream biotechnologies, such as 
research tools, diagnostic tools, and genetic 
modification technologies 
•	 promoting analysis, adaptation, and up­
take of practical-innovation structures that 
make effective use of diverse resources, such 
as strategic partnerships with other public 
institutions, public–private partnerships, 
and open collaborative mechanisms 
•	 good-faith participation in the patenting 
process, focusing on strategic and systemic 
outcomes, rather than on the tactical use of 
the system, and actively promoting patent 
quality 
•	 fostering an interdisciplinary approach to 
public policy formulation in the life sciences 
and a comprehensive view of the innovation 
process within the broader policy context 
•	 promoting open licensing models for re­
search or for humanitarian uses in pub­
lic health and agricultural development 
programs for the benefit of developing 
countries 
Exemplifying the crossover between policy 
cess to necessary resources to achieve and practice is the humanitarian licensing of 
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medical and agricultural research generated by 
universities or other public research institutions. 
“Humanitarian licensing” describes a range of 
public policy licensing strategies. These might 
include providing an open license to developing 
country technology users to sell derivative prod­
ucts back to commercial markets, as in the case of 
agricultural biotechnology. Humanitarian licens­
ing might also mean establishing reach-through 
rights reserving access to derivative innovations 
(for example, for use in licensing early-stage phar­
maceutical research). These practices may be seen 
as a movement to promote certain technology li­
censing norms, even to create de facto exceptions 
to patent rights in the life sciences. They might 
also be imagined as a suite of practical options 
for public sector technology managers to deploy 
in pursuit of institutional objectives. But the 
movement towards humanitarian licensing or re­
serving rights for humanitarian use still begs im­
portant questions at the core of public sector IP 
management: 
•	 How does the deployment of exclusive rights 
over life-science technologies promote the 
public welfare, and when is deployment of 
exclusivity contrary to humanitarian goals 
(the exclusivity axis)? 
•	 To what extent, and how, should public 
sector IP managers engage private interest 
and private sector resources to draw tech­
nologies through a demanding product 
development process, and when will hu­
manitarian interest be enough to impel a 
product through the product pipeline (the 
market axis)? 
See Box 2 for a recent exchange that high­
lights the broader range of options open to pub­
lic interest IP managers who have objectives that 
extend beyond the simple commercialization of 
research. 
.  puBLIC	poLICy Ip	 MAnAGEMEnT	
In THE	 LIfE	 SCIEnCES	 
IP management is not an end in itself, but an es­
sential part of a wider array of policy tools that 
need coordinated implementation to achieve 
desired outcomes. The efficiency and effective­
ness of IP management needs to be measured 
against broader objectives, including its ability 
to complement innovation policy and public in­
vestment in R&D infrastructure. Optimal use of 
intellectual property in the life sciences requires a 
well-managed IP system, clear policies about the 
ownership of intellectual property generated by 
the public sector or from public sector inputs, ad­
equate R&D resources and infrastructure, tech­
nology transfer centers at universities and other 
research institutes, and mechanisms to bring re­
search outcomes to the market. We focus on three 
elements in particular: 




2. Building functioning public institutions 
3. Managing public–private partnerships 
.1 The examples of Jordan and Indonesia 
.1.1 Overview 
This section reviews information gathered in field 
interviews with practitioners in biomedical in­
novation in two disparate developing countries: 
Jordan and Indonesia. Despite fundamental dif­
ferences in size, structure, resources, and geopo­
litical context, Indonesia and Jordan have both 
set up IP strategies to promote the social benefits 
of domestic biomedical innovation. The countries 
have sought the right institutional framework to 
link IP policy and IP management for the ad­
vance of public welfare. Indonesia is the fourth 
most populous country in the world and, after 
Brazil, is host to the greatest range of biodiversity 
worldwide. Jordan, with four million inhabitants, 
is a relatively small country with little biodiver­
sity, few natural resources, and no oil reserves. 
Both countries have strong potential for bio­
medical innovation. Indonesia’s opportunities are 
linked to the natural medicines market. Jordan’s 
pharmaceutical industry is the country’s second 
largest export earner, after textiles. 
Jordan’s pharmaceutical industry is making 
a structural shift from focusing solely on generic 
manufacturing to promoting biomedical inno­
vation. Six out of 12 Jordanian pharmaceutical 
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Box 2: Alternatives to Commercialization in Public Sector IP Management:
Four Points of View 
According to Tom Ogada, who is responsible for putting in place a formal policy for dealing with 
IP issues at Moi University,“an institutional IP policy serves to promote the generation, protection,
and commercialization of IP rights. Universities and R&D institutions are key generators of IP assets,
but there are many stakeholders involved in the process—researchers, students, private sponsors,
technology transfer units, national patent offices, the public, and so on. An IP policy is needed 
to harmonize the conflicting interests of the various stakeholders.” Thus, a university’s IP policy 
should aim to “create an environment that encourages and expedites the dissemination of new 
knowledge for the greatest public benefit, while protecting the traditional rights of scholars to 
control the products of their scholarly work. It should ensure that the financial or other benefits of 
commercialization are distributed in a fair and equitable manner that recognizes the contributions 
of the inventors and the institution as well as other stakeholders. It should promote, preserve,
encourage,and aid scientific investigation and research. It should sensitize students to IP and tap the 
creativity of the young. It should create incentives for researchers to conduct research and provide 
rewards for intellectual capital. In developing country universities, it should also stimulate research 
efforts to find solutions for pressing problems, such as medicines, clean water, and energy.” 
Dana Bostrom, Industry Alliances Office, University of California, Berkeley, adds that “most
university technology transfer offices do not have a primary goal of revenue generation. Professor 
Ogada captures the goals of technology transfer well, including: promoting the dissemination of 
knowledge, and assuring stakeholders that risks, benefits and credit are distributed equitably. The 
Association of University Technology Managers (AUTM) does not tend to use revenue generation 
as an indicator of benefit. Rather, [AUTM] uses information about how the university distributes 
revenue received under licenses to benefit the university community; how products which are 
brought to market benefit everyone;and how innovative,university-led licensing programs can push 
an industry or technology forward (among other measures). A blanket give-it-away approach, on 
the other hand, usually benefits large companies, who are able to create and patent improvements 
to the “free” intellectual property more rapidly than other organizations or individuals. For 
developing economies, or early-stage technology of all kinds, “free” can come with a heavy cost.
Although free intellectual property can still achieve the best outcomes for everyone, this strategy is 
best determined on a case-by-case basis. Without resources to sustain a free commons, often only 
those with resources can benefit from what was released. More than 500 new products became 
available last year as a result of licenses from U.S. and Canadian academic technology transfer 
efforts. More intangibly, universities benefit from the interaction with companies, to see how 
academic thinking and solutions can be applied to commercial problems. Ironically, universities 
also benefit from our academic community’s greater awareness of intellectual property; we live in 
a world where intellectual property plays a greater role, and companies, in their interactions with 
universities, demand greater accountability. Ultimately, universities are increasingly being asked to 
demonstrate to their community the benefit they provide in the knowledge economy.”
Gavin Moodie, Principal Policy Advisor at Griffith University, Australia, notes that “the 
fundamental question for a public university’s IP policy should not be: ‘How can the commercial 
potential of the property be maximized?’ but ‘How can the transfer of new ideas be maximized?’
Commercializing intellectual property is only one way—and often the worst way—to transfer new 
ideas. Concentrating on commercializing intellectual property encourages universities to overvalue 
their property, leading to protracted negotiations using lawyers and other intermediaries, which 
frustrates rather than facilitates the free flow of ideas necessary for research and innovation to 
flourish. Revenue from licensing intellectual property in fields other than biotechnology is a trivial 
(Continued on Next Page) 
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Box 2 (continued) 
proportion of university revenue. And, of course, licensing revenue isn’t all surplus or “profit”— 
with their business development managers, IP lawyers, and accountants, commercialization 
units are very expensive.They also impose heavy indirect costs on researchers who must explain 
their research and its implications to intermediaries. Joshua B. Powers reported in The Chronicle 
of Higher Education (September 22, 2006) that more than half of U.S. universities consistently 
lose money on technology transfer. And as the Australian policy and management consultant
John Howard observes, researchers and research organizations will, except in very rare 
situations, earn more from being paid for their work input in contracts and consultancies than 
from licenses and royalties flowing from intellectual property or from income earned in spinout
companies. I therefore suggest that—with the exception of biotechnology—public universities 
simply give away most intellectual property as a contribution to the general good. This could 
be subject to universities including in their IP licensing agreements a standard “blockbuster” or 
“jackpot” clause that provides that should their intellectual property contribute to blockbuster 
revenues of, say, $50 million over 10 years, there would be a sharing of revenue determined by a 
nominated commercial arbitrator.”
Bernardo Marcos Diez,Secretariat for Technology Transfer (New Technologies Research Group),
Faculty of Law, Universidad Nacional de Mar del Plata, Argentina, advised that the Governing 
Council of the University had “recently approved a regulation which defines the scope, players,
and procedures regarding the protection of any intellectual creation resulting from scientific or 
cultural research carried out within the university and/or with third parties.We have adopted an 
active IP awareness policy to reach those involved in this process, from the researchers, teaching 
staff, and students, to members of the decision-making bodies. We are running conferences in 
the different academic units in order to explain the objectives, implications, and advantages 
of IP protection, as well as of technology transfer between the university and external social/ 
commercial milieu.We have also applied to join the WIPO University Initiative in order to appoint
a coordinator and benefit from relevant IP reference materials. So we are in the early phase of 
what will be a lengthy process, but one which, it is already clear, will bring economic, scientific 
and developmental benefits, not only to our university, but also to our broader society.”
Source: WIPO Magazine.10 
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CHAPTER . 
companies have now developed patent portfo­
lios, several of which are potential blockbusters 
(remarkably, until recently most of these com­
panies made no use at all of the patent system). 
Indonesia is taking several measures to bolster its 
overall innovation strategy. It is, for instance, pro­
moting awareness among public research institu­
tions and the private sector of the opportunities 
in the natural medicines market. This market of­
fers annual growth rates as high as 20%. 
These countries are steadily increasing their 
IP holdings on indigenous research activities, 
particularly in the critical areas of the life sci­
ences: medical and agricultural research. As they 
do, broad public interest issues arise. How can 
or should private firms be encouraged to man­
age their IP holdings to contribute optimally 
to national social and economic development? 
Additionally, how can public sector or public-
funded IP estates be best managed to safeguard 
the public interest by capturing and equitably 
distributing the benefits of innovation? Finally, 
what broader institutional settings are needed to 
bolster public welfare outcomes from research? 
A public interest IP management perspective 
can help technology transfer centers at public 
research institutions find answers to these ques­
tions. Additionally, effective IP management en­
courages public–private partnerships that address 
humanitarian goals, in particular, the creation of 
affordable new medicines. 
The experiences of both Indonesia and 
Jordan illustrate the broader need for appro­
priate domestic institutional settings in order 
for the countries to be able to reap the benefits 
of biomedical innovation. Their experiences 
of Indonesia and Jordan also reveal the im­
portance of the interplay between investment 
in institutional infrastructure and the more 
diverse and tailored approaches to managing 
intellectual property within a public interest 
paradigm. The discipline of IP management 
has focused on the needs of firms. However, 
the high level of public concern with capturing 
public benefits from life-sciences research un­
derscores that countries, and public sector in­
stitutions, also need to make strategic decisions 
about the deployment of intellectual property 
on a broader base than the traditional focus of 
private firms. 
.1.2 Setting the regulatory framework 
IP law and practice cannot be viewed in isolation 
from the broader regulatory context. This is es­
pecially true in the field of life sciences, which is 
concerned with needs as basic as health, food, and 
the environment. Public interest IP management 
in biomedical innovation therefore needs to rec­
oncile public health needs with commercial goals, 
ideally helping to harness private sector resources 
to achieve public welfare outcomes. 
Indonesia and Jordan have effective IP leg­
islation in place, and both have undertaken ex­
tensive legislative programs to bring their laws 
into compliance with the TRIPS Agreement. 
Indonesia also adhered to the PCT in 1997, and 
Jordan has entered a bilateral trade agreement 
with the United States, which has implications 
for Jordan’s IP laws. In both countries, IP policy 
has been developed in an interdisciplinary way, 
as part of a broader public policy mix, rather 
than as a narrow, specialized discipline. Jordan’s 
Ministry of Planning is responsible for coordi­
nating public policies regarding innovation, and 
for measuring Jordan’s global competitiveness 
in achieving this goal. Jordan’s main innovation 
policy, King Abdullah II’s Vision 2020, proposes 
the strategic use of IP mechanisms to achieve 
society’s goals. Likewise, Indonesia coordinates 
intellectual property across policy portfolios, in 
cooperation with the Ministry of Research and 
the Directorate General of Intellectual Property, 
which screens research grants given to public re­
search institutions and conducts patent searches, 
supplementing the conventional literature review. 
Indonesia also provides funding to patent appli­
cants to make patent protection more affordable 
to local companies and public research institu­
tions, which is one way to address the issue of 
practical equity in access to the IP system. 
Jordan is reviewing possible legislative ini­
tiatives regarding the management of intellec­
tual property generated in public institutions. 
Indonesia has passed laws that give ownership 
over intellectual property generated within 
public research institutions to the institutions 
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themselves. This regulatory measure has been ac­
companied by the establishment of technology 
transfer offices (TTOs). Ten TTOs were created 
throughout the country with modest start-up 
capital. The offices have confounded some expec­
tations by establishing successful business opera­
tions in recent years. The Technology Institute of 
Bandung, for example, has struck international 
licensing agreements and research collaborations 
with local companies that are actively seeking to 
meet local needs. One public-private partnership 
resulted in the development of a new machine for 
harvesting local agricultural crops. 
.1. 	 Building accountable and 
effective public institutions 
The benefits of the regulatory framework will 
depend on establishing public institutions that 
are both accountable to the public and effective 
in serving it. These obligations go beyond the 
traditional institutional objectives of IP offices 
concerning administration of the patent system. 
Their responsibilities broaden into a wider policy 
role in the knowledge economy. IP mechanisms 
are actively harnessed to promote the overarch­
ing public interest. In both Indonesia and Jordan, 
the IP office reports to the ministries responsible 
for commerce and industry. This helps align IP 
policy with the countries’ overall economic and 
trade policy objectives. As in all countries, there 
are important choices to be made between the 
value of administrative independence, self-suf­
ficiency and direct accountability to political 
masters, and the benefits of linkages to a major 
policy ministry that can encourage high-level 
political attention to IP policy-making. In both 
Jordan and Indonesia, the IP offices focus on the 
operational challenges of using limited resources 
to serve diverse stakeholders. The two offices dif­
fer in size: Indonesia currently deals with a higher 
patent filing rate (4,303 applications in 2005); it 
was reported that Jordan had 200. But Indonesia 
confronts a problem experienced in many devel­
oping countries–that of finding and retaining 
suitably qualified technical staff to deal with the 
increasingly complex field of life sciences, effec­
tive examination capacity being one important 
safeguard of patent quality. 
.2 Managing public–private partnerships 
Life sciences R&D is often characterized by up­
stream, or basic, research conducted by public 
sector or academic researchers. Public sector in­
stitutions then depend on the private sector to 
take life-sciences innovations through the devel­
opment pipeline to yield finished products. Thus, 
life-sciences innovation pathways are increasingly 
characterized by an array of public–private part­
nerships. Those conducting early research and 
those investing in the product development phase 
will naturally have different approaches to the re­
lationship. But because life-sciences research has 
such a strong public interest element, close atten­
tion has been paid to how to manage intellectual 
property for specific public interest outcomes. 
Public sector research institutions are learning 
to pursue the option of leveraging their IP hold­
ings to ensure adequate returns from public in­
vestment in research, whether those returns are 
conceived in terms of narrow financial benefits or 
broader social ones. And public sector IP manag­
ers are trying to ensure that promising innova­
tions are not left on the shelf for want of practical 
mechanisms to garner the necessary resources— 
finance, expertise, regulatory approval capacity, 
product development, and manufacturing know­
how. TTOs, situated within universities, have 
also discovered the dual goal of helping to meet 
humanitarian needs and to mediating between 
academics and the market, which ultimately may 
determine a society’s capacity to nurture innova­
tion based growth. 
The interaction between the public and the 
private sector in health innovation can result 
in philanthropic achievements that also satisfy 
business interests. Successful examples of this in 
the field of public health include the Medicines 
for Malaria Initiative, the Drugs for Neglected 
Disease Initiative, PATH, One World Health, 
and the Bill and Melinda Gates Foundation. 
Publicly funded innovation provides an ad­
ditional mission and incentive system for busi­
nesses. A tension is usually perceived to arise 
between research and development. Research 
is often guided by the search for new insights; 
market interests are generally of secondary rel­
evance. In development, however, the market is 
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the defining element, since the substantial costs 
and risks associated with the development of new 
products and services can often only be justified 
by expected earnings.11 Currently, research tends 
to be concentrated in the public sector, whereas 
development is most often left to business. The 
relationship between research and development 
is usually mediated by the protection and subse­
quent exchange of intellectual property between 
the public and private sectors. This means that it 
is crucial to establish equity and negotiating sym­
metry between these sectors, bridging between 
distinct sets of goals and cultural settings. By 
using the IP system, public research institutions 
avoid giving away valuable knowledge without 
maintaining some leverage over how it is devel­
oped and disseminated, and without securing 
an adequate return, whether that return is in the 
form of money or social return. In this way, intel­
lectual property provides a mechanism to achieve 
equity with the private sector. 
Motivating researchers to patent innovation 
judiciously is an essential part of participating 
in the IP system, and institutions need to raise 
awareness about the necessity and advantages of 
an active but selective patenting strategy. Incentive 
structures for academics often help to pave the 
way from the research lab to the TTO. One way 
to achieve this is to allow academics to generate 
additional revenues from consulting agreements, 
royalties, and licensing agreements. Clearly, this 
should not provide businesses the opportunity 
to dictate the research agenda of public research 
institutions, nor should it compromise the funda­
mental freedom of research. Institutional policies 
need to protect these values. Nevertheless, relax­
ing the institutional restrictions on the interaction 
between the public sector and business in health-
related innovation might allow public research 
to generate new questions and find alternative 
approaches to a subject. Engagement in product 
development in health-related innovation has 
proven to be a valuable experience that enhances 
the quality of basic research. Faculty, for example, 
might develop innovative insights while resolving 
problems encountered in industrial consulting. 
Mansfield found that coauthorship by indus­
try and academics increased the overall research 
productivity in health-related innovation, con­
cluding that such activity can bring a new sense 
of urgency and reality to the public sector.12 In 
Sweden, for example, 10% of articles on health-
related innovation are coauthored by scientists 
working in the private sector.13 Government 
funding for such exchanges can provide a useful 
push to such initiatives. Austria illustrates how 
such a program can operate. In Austria, academ­
ics have the opportunity to spend a year or two 
in a company and then return to their university. 
They are guaranteed their post and granted fund­
ing for the exchange. 
To obtain the best outcomes for public 
health, researchers and institutions must under­
stand the value of intellectual property, commu­
nicate the worth of their intellectual property to 
potential trading partners, negotiate attractive 
licensing agreements, and enter agreements that 
will generate appropriate returns. IP manage­
ment comprises several components, including 
the prioritization and identification of research 
targets, decisions as to whether and which form 
of IP protection to seek, and methods to gain the 
attention of prospective investors/buyers of the 
product. 
Technology transfer centers within public re­
search institutions fill an important role in secur­
ing IP rights. They help researchers understand the 
need for intellectual property, give support in the 
application for IP protection, and help to transfer 
research results to the market. As in many other 
developing countries, the staff at these centers 
needs IP management training. In fact, a train­
the-trainers program is often needed to enhance 
IP management competencies. An exchange with 
IP management centers in the developed world 
may, in this context, be beneficial. 
To accomplish all of this, researchers and pub­
lic institutions need to identify potential licens­
ees, facilitate research collaboration, pool patents, 
and avoid unnecessary duplication. Other ways 
of encouraging public–private partnerships in­
clude commissioning research projects, operating 
joint research studies, financing doctoral studies 
with industrial laboratory funds (with due regard 
to the needs of the doctoral student to publish 
results), encouraging faculty consulting work, 
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and creating spinout companies. Establishing 
research clusters, in which public and private 
sector researchers and institutions work on com­
mon research projects, provides opportunities 
to exchange both tacit knowledge (know-how) 
and formal knowledge (such as publications and 
patents). Through the provision of a clear, trans­
parent regulatory framework and publication of 
basic research, anticompetitive problems can be 
avoided. 
From a health-equity point of view, the ef­
fectiveness of licensing agreements will depend 
on the conditions negotiated in these agreements 
and the overall innovation market. Licensing can 
lessen competition and raise anticompetition is­
sues, even when there is no cumulative aspect. 
Exclusive licensing arrangements may hamper 
public health if the cost reduction of one mar­
ket participant forces competitors to exit the 
market, or if the licensing agreement facilitates 
collusion.14 
Indonesia and Jordan both report positive 
experiences with public–private partnerships in 
biomedical innovation. Indonesia has developed 
an excellent framework for public–private part­
nerships. The Indonesian Science Foundation 
(LIPI) may be taken as a best practice example 
of public interest IP management. LIPI provides 
IP courses for its researchers, has developed its 
own in-house IP policy, and manages an active 
technology transfer center that has already issued 
several licenses. LIPI has also entered into allianc­
es with research institutions abroad, such as the 
Max Planck Institute, with whom jointly gener­
ated intellectual property is jointly owned. 
Technology transfer centers in Indonesia 
are attached to research institutions, such as 
public universities or research organizations. 
These technology transfer centers use different 
names, such as Gugus HaKI (IP Units), Sentra 
HKI (IPR Centers), Klinik HKI (IPR Clinics), 
IPR Management Office, or IPR, and Licensing 
Office. With the exception of the Eijkman 
Institute, all major public research institutions 
dealing with biomedical innovation have their 
own technology transfer center. The extent of the 
activities carried out by these centers varies from 
the most advanced, which provide assistance on 
IP licensing agreements, to those that assist pri­
marily with applying for IP protection or helping 
raise awareness about intellectual property among 
researchers. The statutes of Indonesia’s technology 
transfer offices suggest very clearly that intellectu­
al property held by public institutions should be 
licensed under a public interest paradigm. 
In Jordan, there are several examples of fac­
ulty–private sector biomedical R&D collabora­
tive projects, but the emphasis so far has been 
on research led by the private sector. Discussions 
reportedly continue regarding a suitable frame­
work for the ownership of innovation created in 
the public domain. The Royal Scientific Society 
of Jordan has an applied, rather than a research, 
orientation. 
Jordanian universities do not have TTOs to 
administer patent applications or negotiate licens­
ing agreements. However, companies increasingly 
refer to universities as subcontractors for specific 
biomedical tests. So far, the universities provide 
skilled labor and conduct some basic research. 
These activities appear to promise more institu­
tionalized partnerships and the beginning of a rela­
tionship between academia and the private sector. 
.  ConCLuSIonS: REConCILInG	 poLICy
And pRACTICE 
.1  Exclusivity or inclusion: public 
or private interest? 
The long history of patent law and patent policy 
has been a dynamic record of attempts to recon­
cile two complementary goals: 
1. The promotion of innovation by directing 
resources toward beneficial research and 
development 
2. The practical and equitable availability of 
the fruits of innovation 
Public interest IP management in the life sci­
ences is itself a search for practical means of achiev­
ing these twin goals. It seeks first to garner neces­
sary resources and then to focus them on finding 
technological solutions to neglected needs in the 
public health and agricultural domains. The tangi­
ble and intangible resources required for IP devel­
opment include know-how, research, and product 
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development capacity, clinical or field trial exper­
tise, regulatory infrastructure, background/plat­
form technologies, and the investment of public 
and private capital. IP management strategies will 
be effective if they help to apply these resources 
toward unmet needs. This requires finding these 
resources via new private resources (such as incen­
tives and market interventions) and via new public 
resources (additional funding and infrastructure 
development). IP managers must also work to 
better apply existing resources by leveraging access 
to technologies and by drawing on private sec­
tor development skills and R&D infrastructure, 
indigenous research and innovation capacity, and 
traditional medical knowledge. 
It is tempting to argue that the traditional 
conception of two distinct public and private 
spheres in the life sciences is breaking down. But 
it is more accurate to characterize it as a form of 
evolution, a broadening of the scope of inter­
action, and the creation of a far-broader policy 
canvas that can accommodate more geographical, 
cultural, and economic diversity in the use of the 
patent system. Figure 1 (see section 1.2 above), 
as discussed earlier, illustrates the options for IP 
management in pharmaceutical product develop­
ment. The figure illustrates how workable mecha­
nisms for bringing new biomedical innovations 
to the public may require (1) a range of strategic 
choices to engage or eschew market mechanisms 
to various degrees in order to secure the necessary 
resources and freedom to operate, rather than 
electing a wholly “public” or “private” technol­
ogy development and dissemination model, and 
(2) deployment of exclusive rights afforded by IP 
protection to greater or lesser degrees of exclu­
sivity and openness, ranging from direct exclu­
sive exploitation or exclusive licensing, through 
a range of options of decreasing exclusivity, to 
simple public-domain disclosure. 
Though it may seem counterintuitive, some 
public sector technology-development strategies 
may require exceptional degrees of exclusivity. This 
may be useful, for example, when seeking access to 
a private sector compound library or when nego­
tiating access to an existing regulatory dossier. In 
contrast, as the SNP consortium (single-nucleo­
tide polymorphism) and the human genome proj­
ect have demonstrated, private sector players may 
see commercial advantage in deploying nonexclu­
sive IP management structures, particularly for 
technologies that are considered precompetitive. 
No single template is likely to be anything but an 
indicative guide or catalog of options. Ultimately, 
good practice is good policy: the same exclusive 
right may be viewed very differently if it is held 
by a private firm, by a public sector agency, or by 
a private charity. Equally, the exclusive right will 
be viewed very differently depending on how it is 
deployed in practice.16 
.2 Fostering interdisciplinary IP policies 
Indonesia and Jordan provide complementary 
and contrasting examples of the role of judicious 
institutional settings in promoting investment in 
life-sciences research, tailored to the social and 
economic needs of developing countries. A coun­
try’s capacity to set up an effective institutional 
framework for public-interest-minded intellec­
tual property is the decisive factor. Used in an ef­
fective, informed and judicious manner, it creates 
a positive link between the exercise of exclusive 
commercial rights and a fairer distribution of 
the benefits of technological advancement, with 
strategies carefully tailored to a country’s level of 
wealth or economic development. n 
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ABSTRACT 
This chapter provides an overview of the current and 
potential impact of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) on 
low- and middle-income countries. The chapter also 
summarizes the findings of a meeting in New Delhi, 
India and explores the legitimacy of concerns about 
TRIPS. Access to health products relies on many fac­
tors, including the successful innovation of new tech­
nologies. Innovation, in turn, is a complex process, in­
volving many factors (intellectual property [IP] is just 
one) that influences product availability and price. 
Pointing to the growth of global and national pub-
lic–private product-development partnerships (PDPs), 
the chapter highlights one way these countries are seiz­
ing opportunities—and reveals how important effec­
tive IP management has become for them. Focused on 
high-priority diseases such as AIDS, malaria, and TB, 
PDPs require the development and implementation 
of sophisticated IP management policies and practices 
in both developed and developing countries in which 
PDPs operate. Finally, the chapter discusses the pos­
sible role of compulsory licensing and parallel trade. 
The value of these flexible options, provided by TRIPS, 
is yet undocumented and successfully implementing 
them represents a significant challenge. Crucially, coun­
tries have considerable freedom to control the effects of 
TRIPS on the availability of new health technologies. 
The countries can do this most effectively by building 
capacity for IP management and by formulating poli­
cies and practices, for courts, patent offices, and other 
institutions, that favor the poor. 
1. BACkGRound 
The Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS), under 
WTO (World Trade Organization), mandates a 
minimum set of IP (intellectual property) pro­
tection for patented pharmaceutical products. 
TRIPS raises questions about how new global 
standards for patent protection will affect innova­
tion, R&D investment, and product availability, 
especially for developing economies with signifi­
cant innovative capacities in health R&D (such 
as Brazil, China, India, and South Africa). To ex­
plore these issues, the Indian Council of Medical 
Research (ICMR), in India, and the Centre for 
Management of Intellectual Property in Health 
Research and Development (MIHR), based in 
the United Kingdom, convened an international 
meeting in New Delhi in December 2005, titled 
“Living with TRIPS: Innovation of New Health 
Technologies for the Poor.” This chapter summa­
rizes the findings of that meeting. A full report 
has been published elsewhere.1 
Attention has focused on India because of 
its established strengths in generic-drug pro­
duction, large prospective market for low-cost 
medicines, and potential cost advantages as an 
R&D base for multinational firms. These factors 
make India a bellwether for gauging the impact 
of TRIPS on health-product innovation and ac­
cess. Vigorous debates in India and elsewhere 
Eiss R, RT Mahoney and K Satyanarayana. 2007. Developing Countries and TRIPS:What Next? In Intellectual Property Man-
agement in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. R Eiss, RT Mahoney and K Satyanarayana. Sharing the Art of IP Management: Photocopying and distribution 
through the Internet for noncommercial purposes is permitted and encouraged. 
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EISS, MAHONEy & SATyANARAyANA 
preceded the implementation of TRIPS, and 
it is timely to follow up on some of the ques­
tions raised in that debate. Will TRIPS lead to 
monopolies on new drugs where, previously, 
imitation was possible? Will TRIPS encourage 
foreign investment for the health industry or 
create external constraints? Will TRIPS lessen 
interest, by developing country firms, in diseases 
of the poor where markets are uncertain, or will 
it motivate the development of innovative drugs 
against priority diseases in these countries? And 
will international product-development part­
nerships (PDPs) that are now generating a pipe­
line of drugs for poverty-related diseases find it 
easier to form partnerships with institutions and 
emerging suppliers in developing countries? 
2. puTTInG	 TRIpS 	In 	ConTExT 
Conclusively documenting the benefits or costs 
of TRIPS for developing countries may be impos­
sible. Innovation is a dynamic process influenced 
by many external variables. These include the lev­
el of government support for science and technol­
ogy, government programs to promote trade, the 
capabilities of national drug-regulatory agencies, 
and government efforts to enhance competencies 
in these and other areas. Despite the difficulties 
of measuring the effects of TRIPS, we can at least 
point to historical precedent, which suggests that 
strengthening intellectual property will increase 
foreign direct investment and flows of technology 
transfer, as long as essential preconditions exist 
(namely, supportive R&D environments, effec­
tive judicial systems to enforce patent law, and 
viable domestic and export markets). And while 
definitive measurements cannot be obtained at 
this time, it is possible to determine the most im­
portant trends to measure. 
Perhaps the most controversial issue sur­
rounding TRIPS is its impact on the price and 
availability of new medicines. If patents are ob­
tained and enforced in developing countries, 
TRIPS could reduce the availability of copies of 
patented medicines, thus adversely affecting a de 
facto price control on medicines in these coun­
tries. The manufacture of products that were 
unprotected by patents led to competition that 
played a key role in determining prices for HIV 
antiretrovirals in Brazil, India, South Africa, and 
other countries. 
Accordingly, the price effects of implementing 
TRIPS should be monitored closely, both in coun­
tries with strong generic industries and in coun­
tries relying on imports of generic substitutes. But 
there are other underlying structural impediments 
to access besides price. These include the equity 
and efficiency of health-care financing and drug/ 
vaccine distribution systems, the availability of evi­
dence-based analysis to improve current practice, 
and local community involvement. An instructive 
and often-cited example of delivery failure is the 
uneven access to medicines on the World Health 
Organization’s (WHO’s) list of essential drugs, of 
which less than 5% are on-patent. To accurately 
measure access requires carefully considering the 
historical and social contexts of drug delivery. 
Apart from the potential effects of patents on 
post-TRIPS pricing and availability, the compar­
ative therapeutic benefits of new chemical entities 
over available generics will have health implica­
tions. So, in assessing TRIPS over time, the rate 
of pharmaceutical innovation will be a key vari­
able in measuring the health impact of strength­
ened patent regimes. 
IP management skills will need to be devel­
oped so that TRIPS can be adapted to a nation’s 
advantage. Developing countries that choose to 
invest in science and technology must, of neces­
sity, address IP issues to participate in the interna­
tional marketplace. IP competencies will enable 
these countries to gain access to emerging tools, 
technologies, and resources. Indeed, an acute need 
exists to establish policies and procedures and to 
train staff in effectively managing intellectual 
property. Priorities include training in contract 
negotiation, statutory protection, patent search­
ing and filing, technology valuation and business 
strategy development, as well as the development 
and implementation of IP policies and strategies 
at the institutional level, especially within public 
research institutions and universities. To provide 
the most useful and most accurate information, 
evaluations of the costs and benefits of TRIPS 
should consider investments in capacity building 
as an important variable. 
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To 	REACH	 THE	 pooR 
Assessing the implications of TRIPS for the de­
velopment of new products to treat diseases of 
poverty is difficult. Technology transfer and inno­
vation, in general, are strongly viewed as ways to 
strengthen an economy; clearly, however, emerg­
ing pharmaceutical industries can do more than 
generate new knowledge, skilled labor, and mar­
kets. These industries can address social objectives 
by developing health-related products to meet lo­
cal needs. But will the emerging pharmaceutical 
industries in Brazil, China, India, and elsewhere 
become sources of new medicines for diseases that 
disproportionately affect low- and middle-in­
come nations? Early evidence suggests the answer 
is no. Pharmaceutical firms in India are focusing 
globally, exploiting their strengths to develop or 
improve therapeutic drugs for well-characterized 
medical conditions that exist in robust global 
markets. For example, based on projected sales 
growth, Ranbaxy Laboratories aspires to increase 
its percentage of revenue from sales to member 
countries of the Organisation for Economic Co­
operation and Development (OECD) from 20% 
in 2000 to 70% in 2007 (presentation at inves­
tors conference in Mumbai, September 2004). 
The public sector predominantly remains 
responsible for promoting the development of 
new technologies to meet local needs. For ex­
ample, the government of India is addressing this 
task by promoting investment in drug develop­
ment through several innovative schemes, such 
as increased R&D tax benefits and subsidies to 
support industry–university partnerships. The 
New Millennium Indian Technology Leadership 
Initiative, for example, supports local technology 
partnerships between publicly supported R&D 
institutes and industrial companies. Among 
health-related activities, the program supports 
the development of new targets, drug delivery 
systems, bioenhancers, and therapeutics for la­
tent mycobacterium tuberculosis to better man­
age India’s high disease-burden of tuberculosis. 
Researchers are also working to identify gene-
based drug targets for prevalent cancers in India. 
The program may serve as a model for supporting 
local public–private partnerships in other regions, 
especially as firms seek academic ties to enhance 
their R&D base in drug discovery. Importantly, 
when the public sector invests in product devel­
opment, it can control the intellectual property 
to help benefit the poor (for example, by setting 
conditions for how the covered technology is to 
be distributed or marketed). 
Equally important, the new global IP stan­
dards have emerged just as public–private prod­
uct-development partnerships (PDPs) are pio­
neering creative forms of IP management. PDPs 
use intellectual property as a negotiating tool for 
developing high-quality, affordable therapeutics 
and vaccines for diseases of the poor. For exam­
ple, the Medicines for Malaria Venture (MMV) 
has formed technology partnerships to develop 
an artemisinin-derived lead compound for ma­
laria. In explaining the success of the partnership, 
MMV points to its pragmatic approach to col­
laboration with the private sector, an approach 
made possible by the effective identification and 
management of intellectual property. Indeed, 
each PDP must adapt its IP strategies to the con­
tributions of its public sector and industrial part­
ners. Nonetheless, PDPs share the common goal 
of constructing deals that both provide incentives 
to the private sector and meet the social objec­
tives of the public sector. These deals are achieved 
through negotiated agreements on territorial 
markets, pricing structures for public and private 
markets, or field of use, among other areas. The 
synergistic relationships of PDPs are represented 
in Figure 1. 
4.	 TRIpS 	And puBLIC-HEALTH	
SAfEGuARdS 
TRIPS also raises issues related to compulsory li­
censing and parallel trade.2 These public-health 
safeguards are provided under the TRIPS agree­
ment and were reinforced by the Doha Ministerial 
Conference. In December 2005, the WTO 
Council permanently adopted a key policy on 
compulsory licenses that had existed as a waiver 
since 2003. The waiver has significantly improved 
the ability of developing countries without man­
ufacturing capabilities to import patented drugs 
from sources other than the originator company. 
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The waiver will become a formal part of the agree­
ment after WTO members ratify it. 
Production under compulsory licenses, how­
ever, presents some operational challenges. First, 
companies need to secure adequate know-how 
from the original manufacturer, or from else­
where, to recreate products. Second, the prod­
ucts must reach markets that are large enough to 
enable compulsory licensees to recoup develop­
ment and production costs. While compulsory 
licenses are potentially beneficial tools, develop­
ing countries can use other ways to help ensure 
that intellectual property does not create barriers 
to access. These include both conventional licens­
ing arrangements and, notably, the enactment of 
laws to permit and regulate the government’s use 
of patented inventions. Other options include 
the actions of patent courts to protect the public 
interest, the thoughtful management of genetic 
resources and traditional knowledge, and the ju­
dicious framing of competition law and policy. 
In sum, the international IP standards man­
dated by TRIPS allow member nations consider­
able discretion to enact laws and provisions that 
both meet treaty obligations and support national 
innovation policies and development priorities. 
5.	 ConCLuSIonS 
Issues discussed at the New Delhi conference 
and the analysis of those issues, presented in 
this chapter, have raised important consider­
ations for countries adapting to the TRIPS 
Agreement: 
•	 Intellectual property is one of several inno­
vation determinants in health R&D; when 
assessing impact, intellectual property 
must be considered in the context of other 
competencies. 
•	 Creatively managed, a global IP regime 
can be used in the public interest to im­
prove the access of poor populations 
to new medicines and public health 
interventions. 
•	 Countries aspiring to use TRIPS to national 
advantage must build institutional IP capa­
bilities and policies in order to participate 
in the global marketplace and benefit from 
emerging technologies. 
•	 TRIPS enables countries to establish na­
tional patent policies and practices that both 
meet treaty obligations and address nation­
al economic needs and social values. n 
Figure 1: Relationships within PDPs in Bringing 
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CHAPTER 3.8 
The TRIPS Agreement and Intellectual Property

in Health and Agriculture
 
JAyASHREE WATAL, Counselor, Intellectual Property Division, World Trade Organization, Switzerland
 
ROgER kAMPF, Counselor, Intellectual Property Division, World Trade Organization, Switzerland
 
ABSTRACT 
This chapter sets out the provisions of the Agreement 
on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) as related to intellectual property in health and 
agriculture and the policy work done in the World Trade 
Organization (WTO). The first part focuses on matters re­
lated to public health, including the protection of patents 
and undisclosed information. An overview is given of the 
three key instruments addressing the flexibilities available 
to Members of the WTO: the Doha Declaration on the 
TRIPS Agreement and Public Health, the Decision on the 
Implementation of Paragraph 6 of this Declaration, and 
the Protocol amending the TRIPS Agreement. The second 
part looks into TRIPS provisions relevant to agriculture 
and sets out the issues reviewed in the Council for TRIPS 
with respect to optional exclusions to patentability and the 
protection to be given to plant varieties. The second part 
also addresses work related to the relationship between 
the TRIPS Agreement and the Convention on Biological 
Diversity (CBD), including the suggested introduction of 
a disclosure requirement into the patent system, as well as 
the protection of traditional knowledge. In addition, two 
issues relating to geographical indications are taken up, 
namely, the ongoing negotiations on the establishment of 
a multilateral register of geographical indications for wines 
and spirits, and the extension of the higher level of pro­
tection currently available for wines and spirits to other 
products. To complete the picture, the third part discusses 
WTO programs aimed at enhancing capacities in the de­
veloping world with respect to the TRIPS Agreement. 
1. INTRODuCTION 
This chapter describes provisions of the Agreement 
on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) and the policy work done by the 
World Trade Organization (WTO) with respect 
to intellectual property (IP) in health and agri­
culture, as of July 2006. The chapter discusses 
WTO programs aimed at enhancing capacities in 
the developing world with respect to the TRIPS 
Agreement. 
The WTO came into existence in January 
1995. Its 149 current Members account for over 
97% of world trade, and around 30 other coun­
tries are negotiating membership. Decisions are 
made through the consensus of the entire WTO 
membership, and the TRIPS Agreement applies 
to all Members. 
The TRIPS Agreement establishes minimum 
levels of protection that each government has to 
provide to the IP of fellow WTO Members. By 
establishing these minimum levels, the WTO 
seeks to strike a balance between the long-term 
benefits and possible short-term costs to society. 
Society benefits in the long term when IP protec­
tion encourages creation and invention, especially 
when the period of protection expires and the 
creations and inventions enter the public domain. 
The Agreement contains provisions enabling 
governments to reduce short-term costs (for ex­
ample, through various exceptions to the rights 
conferred). The WTO’s dispute settlement sys­
tem is available to resolve disputes between WTO 
Members about compliance with TRIPS rules. 
Watal J and R Kampf. 2007. The TRIPS Agreement and Intellectual Property in Health and Agriculture. In Intellectual Proper-
ty Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen,
et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. J Watal and R Kampf. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged. 
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The Agreement covers five broad issues1: 
•	 how basic principles of the trading sys­
tem and other international IP agreements 
should be applied 
•	 how to give adequate protection to IP 
rights 
•	 how countries should provide for those 
rights to be adequately enforced in their 
own territories 
•	 how to settle IP disputes between Members 
of the WTO 
•	 how to accommodate transitional ar­
rangements during the new system’s 
introduction 
2. RElEVANT PROVISIONS OF
THE TRIPS AGREEMENT 
The TRIPS Agreement requires Member coun­
tries to make patents available for all inventions, 
whether products or processes, in all fields of 
technology without discrimination, subject to 
the normal tests of novelty, inventiveness, and 
industrial applicability. The Agreement also re­
quires that patents be available and patent rights 
enjoyable without discrimination as to the place 
of invention or whether products are imported or 
locally produced (Article 27.1). Although many 
aspects of the TRIPS Agreement could poten­
tially bear on health or agriculture, the sections 
on patents, test data protection, and geographical 
indications are perhaps the most relevant. 
There are three permissible exclusions from 
patent grant. One is for inventions contrary to 
ordre public or morality; this explicitly includes 
inventions that are dangerous to human, ani­
mal, and plant life or health or that are seriously 
prejudicial to the environment. The use of this 
exclusion is subject to the conditions that the 
commercial exploitation of the invention must 
also be prevented and that this prevention must 
be necessary for the protection of ordre public or 
morality (Article 27.2). 
The second exclusion is for inventions that 
are diagnostic, therapeutic, and surgical meth­
ods for the treatment of humans or animals 
(Article 27.3(a)). The final exclusion is for in­
ventions that are plants and animals (other than 
microorganisms) and essentially biological pro­
cesses (other than nonbiological and microbio­
logical processes) for the production of plants or 
animals. However, any country excluding plant 
varieties from patent protection must provide 
an effective sui generis system of protection. 
Moreover, the whole Provision is subject to re­
view four years after the Agreement comes into 
force (Article 27.3(b)). 
A product patent must confer the following 
exclusive rights on the right holder: making, us­
ing, offering for sale, selling, and importing the 
patented product. Process patent protection must 
give exclusive rights not only over use of the pro­
cess but also over products obtained directly by 
the process. Patent owners shall also have the 
right to assign, or transfer by succession, the pat­
ent and to conclude licensing contracts (Article 
28). Members may provide limited exceptions to 
the exclusive rights conferred by a patent, pro­
vided that such exceptions do not unreasonably 
conflict with a normal exploitation of the patent 
and do not unreasonably prejudice the legitimate 
interests of the patent owner, taking into ac­
count the legitimate interests of third parties, as 
well (Article 30). Finally, the term of protection 
available shall not end before the expiration of a 
period of 20 years counted from the filing date 
(Article 33). 
Members shall require that an applicant for 
a patent shall disclose the invention in a manner 
sufficiently clear and complete for the invention 
to be carried out by a person skilled in the art. 
Members may require the applicant to indicate 
the best mode for carrying out the invention 
known to the inventor at the filing date or, where 
priority is claimed, at the priority date of the ap­
plication (Article 29.1). If the subject matter of a 
patent is a process for obtaining a product, the ju­
dicial authorities shall have the authority to order 
the defendant to prove that the process to obtain 
an identical product is different from the patent­
ed process, where certain conditions indicating a 
likelihood that the protected process was used are 
met (Article 34). 
Compulsory licensing and government use 
without the authorization of the right holder 
are allowed, but they are subject to conditions 
254 | HAndBook of BEST pRACTICES 
 	 	 	 	 		 	
      
  
      
        
       
      
        
      
      
        
      
       
       
        
     
       
      
      
         
 
     
    
      
       
      
        
        
     
     
     
        
      
        
      
      
       
       
     
       
     
      
      
        
      
  
      
     
       
        
     
        
     
        
     
       
     
         
     
        
      
         
        
      
     
       
    
     
     
      
       
   
   





aimed at protecting the legitimate interests of 
the right holder. Mainly contained in Article 31, 
these conditions include the obligation not to, 
as a general rule, grant such licenses unless an 
unsuccessful attempt has been made to acquire a 
voluntary license on reasonable terms and condi­
tions within a reasonable period of time. The re­
quirement to pay adequate remuneration in the 
circumstances of each case, taking into account 
the economic value of the license, must also be 
observed, as must a requirement that decisions 
be subject to judicial or other independent re­
view by a distinct higher authority. Another im­
portant condition is that such use must be made 
predominantly to supply the domestic market. 
Some of these conditions are relaxed when com­
pulsory licenses are employed to remedy practices 
that have been established as anticompetitive by 
a legal process or in cases of emergency or public 
noncommercial use. 
The TRIPS Agreement also contains pro­
visions to protect undisclosed information. 
The Agreement requires that a person lawfully 
in control of such information must have the 
possibility of preventing it from being disclosed 
to, acquired by, or used by others without his 
or her consent in a manner contrary to hon­
est commercial practices. “Manner contrary to 
honest commercial practices” includes breach of 
contract, breach of confidence and inducement 
to breach, as well as the acquisition of undis­
closed information by third parties who knew, 
or were grossly negligent in failing to know, that 
such practices were involved in the acquisition 
(Article 39.2). In addition, undisclosed test data 
and other data that governments require to be 
submitted as a condition of approving the mar­
keting of pharmaceutical or agricultural chemi­
cal products that use new chemical entities must 
be protected against unfair commercial use. 
Members must also protect such data against 
disclosure, except where necessary to protect the 
public, or unless steps are taken to ensure that 
the data are protected against unfair commercial 
use (Article 39.3). 
For the purposes of the TRIPS Agreement, 
geographical indications identify a good as 
originating in the territory of a Member, or 
a region or locality in that territory, where a 
given quality, reputation, or other characteris­
tic of the good is essentially attributable to its 
geographical origin. The TRIPS Agreement re­
quires a standard level of protection to be avail­
able for all geographical indications (Article 
22). In essence, interested parties must have the 
legal means to prevent geographical indications 
from being used to mislead the public or in a 
way that constitutes unfair competition. Article 
23 provides a higher level of protection for geo­
graphical indications for wines and spirits: sub­
ject to a number of exceptions, they have to be 
protected even if use would not cause the public 
to be misled or constitute unfair competition. 
Information supplied by Members shows that 
countries employ a wide variety of legal means 
to protect geographical indications: ranging 
from specific geographical indications laws to 
trademark law, consumer protection law, and 
common law. The TRIPS Agreement and cur­
rent work in the WTO’s TRIPS Council takes 
account of that diversity. 
In some cases, however, geographical indica­
tions do not have to be protected or the protec­
tion can be limited. Among the exceptions that 
Article 24 allows are: continuous use of the geo­
graphical indication for at least 10 years preced­
ing 15 April 1994 or in good faith prior to that 
date; pre-existing trademark rights; and when a 
name has become a common (or “generic”) term 
for describing that type of product. 
3. ClARIFICATIONS AND FlExIBIlITy 
REGARDING TRIPS AND PuBlIC HEAlTH 
On the issue of TRIPS and public health (includ­
ing access to patented medicines), the WTO has 
adopted three instruments: 
•	 The Doha Declaration on the TRIPS 
Agreement and Public Health, November 
2001 
•	 The Decision on the Implementation of 
Paragraph 6 of the Doha Declaration on 
the TRIPS Agreement and Public Health, 
Geneva, August 2003 
•	 A Protocol amending the TRIPS Agreement, 
December 2005. 
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3.1	 The Doha Declaration on the TRIPS 
Agreement and public health 
The Doha Declaration on the TRIPS Agreement 
and Public Health2 responded to concerns about 
the possible implications of the TRIPS Agreement 
for public health, in particular, access to patent­
ed medicines. As mentioned earlier, the TRIPS 
Agreement allows countries to take various kinds 
of measures to qualify or limit IP rights, includ­
ing for public health purposes. However, some 
doubts had arisen as to whether the flexibility in 
the TRIPS Agreement was sufficient to ensure 
that it supported public health. It was unclear 
whether it promoted affordable access to existing 
medicines, while supporting research, and devel­
opment into new ones. 
The Declaration responds to these concerns 
in a number of ways. First, it emphasizes that the 
TRIPS Agreement does not and should not pre­
vent Members from taking measures to protect 
public health. It reaffirms the right of Members to 
use, to the full, the terms of the TRIPS Agreement 
that provide flexibility for this purpose. Through 
these important declarations, all WTO Members 
have signaled that they will not seek to prevent 
other members from using the provisions. 
Second, the Declaration makes clear that 
the TRIPS Agreement should be interpreted and 
implemented in a way that supports the right of 
Members of the WTO to protect public health 
and, in particular, to promote access to medi­
cines for all. Further, it highlights the importance 
of the objectives and principles of the TRIPS 
Agreement regarding the interpretation of its 
provisions. These statements thus provide impor­
tant guidance to both individual Members and, 
in the event of disputes, WTO dispute settlement 
bodies. 
Third, the Declaration clarifies some of the 
flexibilities contained in the TRIPS Agreement. 
It makes clear that each Member is free to de­
termine the grounds upon which compulsory li­
censes are granted. This is a useful corrective to 
views often expressed in some quarters that some 
form of emergency is a precondition for compul­
sory licensing. The TRIPS Agreement does refer 
to national emergencies or other circumstances of 
extreme urgency in connection with compulsory 
licensing, but this is only to indicate that, in these 
circumstances, the usual condition that an effort 
must first be made to seek a voluntary license 
does not apply. The Declaration makes it clear 
that each Member has the right to determine 
what constitutes a national emergency or other 
circumstances of extreme urgency. It also declares 
that public health crises, including those relating 
to HIV/AIDS, tuberculosis, malaria, and other 
epidemics, can represent such circumstances. 
With regard to the exhaustion of IP rights 
and a Member’s right to permit parallel imports, 
the TRIPS Agreement states that a Member’s 
practices in this area cannot be challenged un­
der the WTO dispute settlement system. The 
Declaration makes clear that the effect on exhaus­
tion of the provisions in the TRIPS Agreement 
is to leave each Member free to establish its own 
regime without challenge—subject to the general 
TRIPS provisions that prohibit discrimination 
on the basis of the nationality of persons. 
For Members of the WTO that are least de­
veloped countries, the Declaration agrees to pro­
vide them with an extension of their transition 
period until the beginning of 2016 for protect­
ing and enforcing patents and rights in undis­
closed information with respect to pharmaceuti­
cal products. This was given legal effect through 
a Decision of the TRIPS Council that extended 
the transition period for least developed countries 
until 1 January 20163 and another Decision of 
the General Council that waived the exclusive 
marketing rights provisions of Article 70.94 for 
the same period. In 2005, the TRIPS Council 
extended, to July 2013, the time given for these 
countries to implement other provisions of the 
TRIPS Agreement.5 
While emphasizing the flexibility in the 
TRIPS Agreement to take measures to promote 
access to medicines, the Declaration also recogniz­
es the importance of IP protection for developing 
new medicines and reaffirms the commitments of 
WTO Members in the TRIPS Agreement. 
3.2	 Paragraph 6 of the Doha Declaration 
In paragraph 6, the Doha Declaration recognized 
the problem of countries with insufficient or no 
manufacturing capacities in the pharmaceutical 
256 | HAndBook of BEST pRACTICES 
 	 	 	 	 		 	
       
      
        
      
        
     
       
       
       
     
       
        
       
     
       
       
      
     
   
 
 
        
      
       
       
    
       
       
      
       
     
       
      
     
 
       
       
      
       
       
       
      
        
       
     
      
 
     
         
        
       
        
         
       
      
         
        
       
      
       
        
     
       
        
      
    
CHAPTER . 
sector in making effective use of compulsory licens­
ing. Such countries could, under normal TRIPS 
rules, import under a compulsory license as there is 
no special problem with Members issuing compul­
sory licenses for importation as well as for domestic 
production. The problem, however, was whether 
sources of supply from generic producers in other 
countries to meet such demand would be avail­
able, particularly given Article 31(f) of the TRIPS 
Agreement, according to which production under 
a compulsory license in those other countries must 
be “predominantly for the supply of the domestic mar­
ket of the Member.” The problems facing countries 
with insufficient capacities in the pharmaceutical 
sector in accessing sources of supply were expected 
to increase as some countries with important ge­
neric industries were coming under an obligation 
to provide patent protection for pharmaceutical 
products as from 2005. 
In order to solve this problem, the WTO 
General Council adopted on 30 August 2003 a 
Decision6 that waives in certain circumstances 
Article 31(f ) and (h) of the TRIPS Agreement. 
This Decision was adopted in the light of a 
Chairman’s statement7 that set out several key 
shared understandings of Members on how the 
Decision would be interpreted and implemented. 
The Decision covers any patented pharmaceutical 
products, or pharmaceutical products manufac­
tured through a patented process, needed to ad­
dress public health problems recognized in para­
graph 1 of the Doha Declaration on the TRIPS 
Agreement and Public Health, including active 
ingredients necessary for the manufacture of phar­
maceutical products and diagnostic kits needed 
for their use. The Decision grants three waivers 
from the obligations set out in subparagraphs (f ) 
and (h) of Article 31 of the TRIPS Agreement 
with respect to pharmaceutical products, subject 
to certain conditions. The three waivers are: 
1. A waiver of the obligation of an exporting 
Member under Article 31(f ) of the TRIPS 
Agreement to the extent necessary for the pur­
poses of production and export of the needed 
pharmaceutical products to those countries 
that do not have sufficient capacity to manu­
facture them. This waiver is subject to cer­
tain conditions to ensure transparency in the 
operation of the system and that only coun­
tries with insufficient domestic capacity im­
port under it, and to provide for safeguards 
against the diversion of products to markets 
for which they are not intended. 
2. A waiver of the obligation under Article 31(h) 
of the TRIPS Agreement on the importing 
country to provide adequate remuneration 
to the right holder in situations where remu­
neration in accordance with Article 31(h) is 
being paid in the exporting Member for the 
same products. The purpose of this waiver is 
to avoid double remuneration of the patent 
owner for the same product consignment. 
3. A	 waiver of the obligation under Article 
31(f ) of the TRIPS Agreement on any de­
veloping or least developed country that is 
party to a regional trade arrangement at least 
half of the current membership of which is 
made up of countries presently on the United 
Nations list of least developed countries. The 
purpose of this waiver is to enable such coun­
tries to better harness economies of scale for 
the purposes of enhancing purchasing power 
for, and facilitating the local production of, 
pharmaceutical products. 
The above Chairman’s statement was designed 
to meet the concerns of those who feared that the 
Decision was too open ended and might be abused 
to undermine the benefits of the patent system. 
It recognizes that the paragraph 6 system set out 
in the Decision should be used in good faith to 
protect public health and not to pursue industrial 
or commercial policy objectives. It addresses some 
concerns relating to the risk of diversion, and it sets 
out ways in which any differences arising from the 
implementation of the system can be settled expe­
ditiously and adequately. The Decision also records 
that the 33 most-advanced countries have agreed to 
opt out of the system as importers, including since 
their accession to the European Communities, 
the 10 acceding countries.8 In addition, 11 other 
Members have agreed to use the system only as 
importers in situations of national emergency or 
other circumstances of extreme urgency.9 
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The Decision went into effect on 30 August 
2003, and since then a number of Members have 
modified their laws/regulations to enable exports 
under their legislation. As of July 2006, Canada, 
Norway, India and the European Communities 
have notified the WTO of these modifications.10 
3.3	 A Protocol amending the TRIPS Agreement 
Paragraph 11 of the August 2003 Decision called 
for the TRIPS Council to prepare an amendment, 
based, where appropriate, on the Decision that 
would replace its provisions. Agreement on such 
an amendment was reached on 6 December 2005, 
when the General Council adopted a Protocol 
amending the TRIPS Agreement and submitted 
it to WTO Members for acceptance. In substance, 
the amendment closely tracks the August 2003 
text. The Decision on the amendment was also 
taken in the light of a rereading by the General 
Council Chairman of the statement of August 
2003. The Protocol will enter into force upon 
acceptance by two thirds of the Members. The 
waiver provisions of the August 2003 Decision 
remain applicable until the date on which the 
amendment takes effect for a Member. 
4. WORK ON TRIPS PROVISIONS
RElATING TO AGRICulTuRE 
4.1	 Article 27.3(b) 
As mentioned earlier, Article 27 of the TRIPS 
Agreement defines which inventions govern­
ments are obliged to make eligible for patent­
ing and what they can exclude from patenting. 
Inventions that can be patented include both 
products and processes, and should generally 
cover all fields of technology. Part (b) of para­
graph 3 allows governments to exclude some 
kinds of inventions from patenting (for exam­
ple, plants, animals, and other “essentially biolog­
ical ” processes—but microorganisms and non-
biological and microbiological processes have to 
be eligible for patents). However, plant varieties 
have to be eligible for protection either through 
patent protection or a system created specifically 
for the purpose (“sui generis”), or a combination 
of the two. 
A review of Article 27.3(b) began in 1999 
as required by the TRIPS Agreement. The top­
ics raised in the TRIPS Council’s discussions 
included: 
•	 how to apply the existing TRIPS provi­
sions on whether or not to patent plants 
and animals, and whether they need to be 
modified 
•	 how to handle moral and ethical issues (for 
example, to what extent invented life forms 
should be eligible for protection) 
•	 how to deal with the commercial use of tra­
ditional knowledge and genetic material by 
those other than the communities or coun­
tries where these originate, especially when 
these are the subject of patent applications 
•	 how to ensure that the TRIPS Agreement 
and the Convention on Biological Diversity 
(CBD) support each other. 
With respect to the protection of plant vari­
eties, the meaning of effective protection for new 
plant varieties has been a part of the discussion 
under this review.11 The discussion has includ­
ed consideration of the kind of flexibility that 
should be available (for example, allowing tradi­
tional farmers to continue to save and exchange 
seeds that they have harvested). It is widely agreed 
that, while the standards of protection under the 
UPOV Convention would be considered ade­
quate for TRIPS purposes (with some differences 
of view about whether the 1978 or 1991 version 
is the most appropriate point of reference), WTO 
Members are not bound to apply UPOV stan­
dards as long as they can ensure effective protec­
tion of plant varieties.12 The privilege of farmers 
to replant, on their own holdings, propagating 
material of protected plant varieties that have 
been harvested is not in dispute, but no conclu­
sion has yet been reached about how much further 
the flexibilities might go and be consistent with 
TRIPS. There is no authoritative guidance in the 
WTO on these matters. However, the responses 
of some Members to a questionnaire about do­
mestic implementation of Article 27.3(b) are 
contained in a TRIPS Council document.13 
Following the 2001 Doha Ministerial 
Conference, the review of Article 27.3(b) has 
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been accompanied by parallel work on the rela­
tionship between the TRIPS Agreement and the 
CBD, as well as on protecting traditional knowl­
edge and folklore.14 
4.2	 Biodiversity and Traditional Knowledge 
Discussions on the relationship between the 
TRIPS Agreement and the CBD first began 
in the WTO in the Committee on Trade and 
Environment in 1995. They were brought into 
the TRIPS Council through the built-in review of 
Article 27.3(b) in 1999. In the Doha Ministerial 
Declaration under paragraph 19, the ministers in­
structed the Council for TRIPS “to examine, inter 
alia, the relationship between the TRIPS Agreement 
and the Convention on Biological Diversity, the pro­
tection of traditional knowledge and folklore.” The 
Hong Kong Ministerial Declaration of December 
200515 calls for the TRIPS Council to continue 
this work and for the General Council to report 
on it to the next ministerial meeting. 
In paragraph 12, the Doha Ministerial 
Declaration also addressed the question of out­
standing implementation issues (that is, out­
standing issues and concerns raised by develop­
ing countries about some existing WTO rules, 
including a number relating to biotechnology, 
biodiversity, and traditional knowledge). With 
regard to these issues, the work has focused on 
the relation between the TRIPS Agreement and 
the CBD. Some countries want a solution to the 
their related concerns to be negotiated as part 
of the ongoing Doha Round of trade negotia­
tions. Other WTO Members contend that there 
is no negotiating mandate on this matter and 
that it would not be appropriate to create one. 
Consultations on this issue have been held un­
der the auspices of the Director General of the 
WTO since the end of 2002. The Hong Kong 
Ministerial Declaration of December 2005 pro­
vided for the consultative process to be intensified 
further and for the Director General to report to 
each regular meeting of the Trade Negotiating 
Committee (TNC) and the General Council. 
This issue is one of the two outstanding imple­
mentation issues explicitly referred to in the text 
of the Hong Kong Declaration (alongside that of 
the extension of the protection of geographical 
indications). The General Council is to review 
progress and take any appropriate action no later 
than 31 July 2006. 
In the TRIPS Council sessions and at other 
discussions relating to the relationship between 
the TRIPS Agreement and the CBD,16 Members’ 
positions fall into three broad categories. First, a 
group of developing countries propose to amend 
the TRIPS Agreement to make obligatory dis­
closure in patent applications of (a) the origin 
of biological resources and/or traditional knowl­
edge used in the claimed invention, (b) evidence 
of prior informed consent under the relevant 
national laws/regulations/procedures, and (c) 
evidence of fair and equitable benefits sharing 
with those holding such resources or knowledge. 
Second, the European developed countries are 
willing to envisage some measure of disclosure of 
source or origin within the patent system, but not 
of access or benefit sharing. Those who agree with 
the disclosure approach differ on several other 
aspects, such as whether the requirement should 
be mandatory or voluntary, and under what in­
strument (the TRIPS Agreement or the Patent 
Cooperation Treaty of the World Intellectual 
Property Organization [WIPO]). There is also 
disagreement about the legal effects of wrongful 
disclosure or nondisclosure (invalidation of the 
patent or outside the patent system under civil/ 
criminal law). 
Third, other WTO Members are opposed to 
a disclosure requirement but are willing to engage 
substantively on the issue of how the shared ob­
jectives in these areas, such as the avoidance of 
erroneously granted patents and compliance with 
national access and benefit–sharing regimes, can 
most effectively be realized. They hold the posi­
tion that a national-based approach using tailored 
national solutions, including contracts, is suffi­
cient to ensure that the objectives of the CBD 
in relation to access and benefit sharing are met. 
They believe that it would be neither helpful nor 
desirable to involve the patent system. 
The TRIPS Agreement has no specific provi­
sions regarding traditional knowledge. Members 
are obliged to protect traditional knowledge 
when it falls under covered IP rights, and they 
are free to introduce a sui generis law to protect 
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it, as long as that does not conflict with TRIPS. 
They can similarly implement Article 8(j) of the 
CBD (to respect, preserve, maintain knowledge, 
innovations and practices of indigenous and lo­
cal communities and encourage the equitable 
sharing of benefits). Quite detailed work is going 
on in the WIPO Intergovernmental Committee 
on Intellectual Property, Genetic Resources, 
Traditional Knowledge, and Folklore. The ques­
tion of the appropriate forum for fleshing out the 
details of the subject comes up repeatedly in the 
TRIPS Council discussions. Some want to wait 
for WIPO to develop an appropriate framework 
so that it can be determined to what extent such 
protection can be included in TRIPS. Finally, as 
indicated above, the focus in the TRIPS Council 
is presently on the relationship between the 
TRIPS Agreement and the CBD, which covers 
some aspects of traditional knowledge. 
4.3	 Geographical indications 
Two issues relating to geographical indications are 
debated under the 2001 Doha Work Program: 
the establishment of a multilateral register of geo­
graphical indications for wines and spirits and the 
extension of the higher Article 23 level of protec­
tion beyond wines and spirits. 
4.3.1	 Multilateral register 
The agreed aim of the multilateral system of no­
tification and registration that is currently under 
negotiation is to facilitate the protection of geo­
graphical indications for wines and spirits. Work 
was initiated as early as 1997 and is mandated 
under TRIPS Article 23.4 and paragraph 18 (the 
first sentence of the Doha Declaration). The ne­
gotiations on this matter are being conducted in a 
Special Session of the council for TRIPS. 
Two main lines of argument have been 
advanced in the negotiations. The “joint pro­
posal” of Argentina, Australia, Canada, Chile, 
Dominican Republic, Ecuador, El Salvador, 
Guatemala, Honduras, Japan, Mexico, New 
Zealand, Paraguay, Chinese Taipei,17 and the 
United States18 suggests that the Council for 
TRIPS should decide to set up a voluntary sys­
tem under which notified geographical indica­
tions would be registered in a database. Those 
governments choosing to participate in the sys­
tem would have to consult the database when 
deciding on the protection of geographical indi­
cations and trademarks for wines and spirits in 
their own countries. Non-participating Members 
would be encouraged, but not obliged, to con­
sult the database. At the other end of the spec­
trum, the European Communities propose a 
TRIPS amendment to establish a system under 
which the registration of a geographical indica­
tion should lead to rebuttable presumptions of 
its protectability, except where a reservation has 
been lodged within a specified period, for exam­
ple, 18 months. Permitted grounds for a reser­
vation would include when a term has become 
generic or when it does not meet the definition 
of a geographical indication. In the absence of 
any reservation, a Member could not refuse pro­
tection on these grounds after the term has been 
registered. These proposals, together with a com­
promise proposal from Hong Kong, China, have 
been set forth side by side in a WTO Secretariat 
document.19 
Important differences remain, particularly 
on two key issues: (1) the extent to which legal 
effects at the national level should be consequent 
on the registration of a geographical indication 
for a wine or a spirit in the system and (2) the 
question of participation, including whether any 
legal effects under the system should apply to all 
WTO Members or only to those opting to par­
ticipate in the system. The Special Session has 
also discussed a range of other points, including 
questions of costs and administrative burdens 
for WTO Members, particularly for developing 
countries.20 
4.3.2	 Extension 
Article 22 requires protecting geographical indi­
cations for all goods. The issue here is whether 
to expand the higher level of protection under 
Article 23, currently required only for wines and 
spirits, to other products, including agricultural 
products and foodstuffs, handicrafts, and indus­
trial products. 
Paragraph 18 of the Doha Declaration notes 
that the TRIPS Council will handle work on ex­
tension under paragraph 12 of the Declaration, 
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which deals with implementation issues. As in­
dicated earlier, WTO Members interpret para­
graph 12 differently. Many developing country 
and European Members argue that the so-called 
outstanding implementation issues are already 
part of the “single undertaking” and therefore are 
also part of the negotiating agenda of the Doha 
Round. Others argue that these issues can only 
become negotiating subjects if the TNC decides 
to include them in the talks—and so far it has 
not done so. Presently, the topic is the subject of 
consultations under the auspices of the WTO 
Director General. At the Hong Kong Ministerial 
Conference, ministers requested the Director- 
General to intensify consultations on all out­
standing implementation issues, including the 
extension of the protection of geographical indi­
cations, and 31 July 2006 was set as the deadline 
for the General Council to review progress and 
take any appropriate action.21 
With regard to the substance of the TRIPS 
Agreement, Members remain divided, but there 
is a willingness to continue discussing the issue. 
The proponents consider, among other things, 
that progress on geographical indications would 
make it easier for them to agree to a significant 
deal in agriculture. The proponents see the higher 
level of protection as a tool to enhance rural de­
velopment, support quality production, and en­
able them to improve the marketing of products 
by differentiating them more effectively from 
other competing products. Consequently, the lat­
est proposal from the European Union calls for 
the TRIPS Agreement to be amended so that all 
products would be eligible for the higher level of 
protection in Article 23.22 To meet the concerns 
of other countries, the exceptions in Article 24 
would also apply, adapted as necessary. Opponents 
argue that the existing level of protection pursu­
ant to Article 22 is adequate. They caution that 
providing enhanced protection would be burden­
some and disruptive to existing, legitimate mar­
keting practices, that the interests of prior trade­
mark right holders and other third parties may be 
affected, and that considerable costs may result 
from the need to re-label their products. 
The issues raised and the views expressed in 
this debate have been compiled in a document 
prepared by the WTO Secretariat.23 The issues 
include, among others, those relating to the pro­
tectable subject matter (definition and eligibility), 
potential implications for administrative costs 
and burdens, and the impact of extension on (1) 
producers in and outside the area designated by 
geographical indications, (2) the relationship be­
tween trademarks and geographical indications, 
and (3) consumers. 
5. TRANSFER OF TECHNOlOGy 
Article 7 of the TRIPS Agreement reflects the ob­
jective that the transfer of technology should be 
promoted by the protection of IP. Some develop­
ing countries have expressed the view that more 
needs to be done to “operationalize” this notion. 
The TRIPS Agreement calls for more proactive 
measures to promote technology transfer and dis­
semination in the case of the least developed coun­
tries. Article 66.2 obligates developed countries to 
provide incentives for the transfer of technology to 
these countries. The effective monitoring of this 
obligation through regular reporting and TRIPS 
Council reviews was the subject of a political agree­
ment at Doha that was turned into the TRIPS 
Council Decision of February 2003.24 Reports un­
der this new mechanism, submitted at the end of 
2003, 2004, and 2005, are being studied by the 
Members that are least-developed countries. 
6. TECHNICAl COOPERATION AND
CAPACITy BuIlDING PROGRAMS 
Article 67 of the TRIPS Agreement obligates de­
veloped country WTO Members to provide, on 
request and according to mutually agreed terms 
and conditions, technical and financial coopera­
tion in favour of developing and least-developed­
country Members. This cooperation includes as­
sistance in preparing laws and regulations for the 
protection and enforcement of IP rights, as well 
as the prevention of their abuse. The coopera­
tion also includes support for the establishment 
or reinforcement of domestic offices and agencies 
relevant to these matters, including the training 
of personnel. On the basis of annual reports from 
developed-country Members, each autumn the 
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TRIPS Council reviews the technical cooperation 
that is being provided.25 
Considerable assistance is also provided by 
other intergovernmental organizations, notably 
WIPO, UPOV, the World Bank, and the WHO. 
Such organizations are annually invited to share 
information on their activities with the TRIPS 
Council.26 In addition, the WTO Secretariat’s 
technical cooperation program includes activities 
related to the TRIPS Agreement.27 These activi­
ties seek to help Members understand their rights 
and obligations—including the options and flex­
ibilities—under the TRIPS Agreement and rel­
evant decisions of WTO bodies. The cooperation 
program encourages Members to participate fully 
in the ongoing work of the WTO on TRIPS mat­
ters and emphasizes the importance of ensuring 
complementarity and cooperation with other in­
tergovernmental organizations, in particular the 
WIPO and the WHO. 
These activities include regional workshops 
on topical issues under discussion, examination, 
or negotiation in the TRIPS context, in particular 
TRIPS and public health, biotechnology, tradi­
tional knowledge, biodiversity, and geographical 
indications. These regional workshops, as well as 
specialized workshops held in the regions and 
Geneva, also aim to provide information that will 
assist developing-country Members in implementing 
and making effective use of the mechanism set 
out in the Decision on Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public 
Health. Upon request by developing- country 
Members, the WTO Secretariat regularly orga­
nizes national seminars or workshops devoted to 
IP matters. TRIPS issues also figure prominently 
in broader WTO training courses, seminars, and 
workshops held in Geneva and in developing 
countries. An important new component of the 
Secretariat’s capacity-building activities is the an­
nual joint WIPO/WTO colloquiums for teachers 
of intellectual property in Geneva, for partici­
pants from developing countries. This program 
seeks to enhance the capacity for teachers to train 
IP personnel in their own countries, by providing 
teachers with expertise on international aspects 
and allowing them to provide informed policy 
advice to their governments. n 
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10 Notifications about the use of the system will be 
accessible through a dedicated Web page on the WTO 
Web site: www.wto.org/english/tratop_e/trips_e/ 
public_health_e.htm.
11	 See document IP/C/W/369/Rev.1, paragraphs 51–60 
available at www.wto.org/english/tratop_e/trips_e/ 
art27_3b_e.htm.
12	 See document IP/C/W/369/Rev.1, paragraphs 61–66 
available at www.wto.org/english/tratop_e/trips_e/
art27_3b_e.htm.
13	 Document IP/C/W/273/Rev.1, available at www.wto. 
org/english/tratop_e/trips_e/art27_3b_e.htm. 
14	 Secretariat summary notes of the work done on these 
issues (IP/C/W/368/Rev.1, IP/C/W/369/Rev.1, IP/C/ 
W/370/Rev.1) are available at www.wto.org/english/
tratop_e/trips_e/art27_3b_e.htm.
15	 Document WT/MIN(05)/DEC. 
16 Summarized in Secretariat paper IP/C/W/368/Rev. 1. 
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17	 In the WTO accession document, Chinese Taipei is 
referred to as Separate Customs Territory of Taiwan,
Penghu, Kinmen and Matsu. 
18	 Document TN/IP/W/10 and Add.1. 
19 Document TN/IP/W/12. 
20 See Chairman’s report on the work done in 2005,
document TN/IP/14. 
21	 Paragraph 39 of document WT/MIN(05)/DEC. 
22 Document TN/IP/W/11. 




25 The most recent reports can be found in document
 
IPC/W/445 and addenda. 
26 The most recent information documents are in 
document IPC/W/456 and addenda. 
27 The most recent information can be found in document
IP/C/W/454. 
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CHAPTER 3.9 




HOWARd BREMER, Counsel Emeritus, Wisconsin Alumni Research Foundation, WARF, U.S.A. 
ABSTRACT 
This chapter provides an overview of some of the legisla­
tive bills that have profoundly affected the evolution of 
technology transfer and intellectual property (IP) rights 
in the United States. The chapter references provisions of 
the specific bills as codified in U.S. law and explains their 
goals and historical circumstances. While not an exhaus­
tive presentation of all of the bills that have contributed 
to laws governing IP, the codification references will pro­
vide a useful starting point for those researching the ap­
plicability of the laws to particular situations. 
1. INTRODuCTION 
In the United States, the fundamental basis for 
the transfer of technology as property lies in the 
U.S. Constitution. In an effort to protect the 
rights of its more creative citizens, the framers of 
the Constitution struck a compromise position: 
creators of intellectual property (IP) would own 
it and be able to exclude others from using it for 
a limited period of time. After this time period 
expired, the right to use the IP was extended 
to all. By agreeing to accept the “disclosure in­
ducement theory” of advancing science and the 
arts, the framers also allowed a creator of IP to 
deny others the use of that property for a lim­
ited period of time in exchange for disclosing 
the nature of the property to all. The conveyed 
right is expressed in article I, section 8, clause 8 
of the U.S. Constitution: 
The Congress shall have Power—
to promote the progress 
Of Science and useful arts, by securing 
for limited Times 
To Authors and Inventors the exclusive 
Right to their Respective Writings 
and Discoveries. 
2. u.S. PATENT SySTEMS 
The U.S. patent system finds its origin in the U.S. 
Constitution (art. I, § 8, cl. 8). The system de­
scribed therein is the primary vehicle for transfer­
ring IP from the university and nonprofit sectors 
to the private sector or, as is often the case, from 
the government to the private sector. Within its 
scope, the clause includes trademarks and copy­
rights. Indeed, all of these elements—patents, 
trademarks, and copyrights—are classified as in­
tellectual property and in the United States have 
the imprimatur of personal property rights. The 
terms and provisions governing these forms of 
IP are codified in various statutes: U.S. Code, 
title 35 for patents (35 U.S.C.); U.S. Code, title 
15 (15 U.S.C.), chapter 22 for trademarks; and 
U.S. Code, title 17 (17 U.S.C.) for copyrights. 
Detailed regulations governing the application of 
these statutes are found in title 37 of the Code 
of Federal Regulations (37 C.F.R.), chapters 
I and II. These laws and regulations outline 
Bremer H. 2007. U.S. Laws Affecting the Transfer of Intellectual Property. In Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K.,
and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. H Bremer. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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BREMER 
the obligations for obtaining and maintaining IP 
protection and for asserting the property rights 
that the laws convey. 
2.1 Specific legislation 
Two pieces of legislation, both of which were 
passed in 1980, are of particular interest. The 
first gave the government authority to engage in 
the transfer of federally owned or federally origi­
nated technology. The second gave the govern­
ment statutory authority to patent and license 
federally owned inventions and was instrumental 
in enhancing the nonprofit sector’s technology 
transfer function—especially for universities. 
The first law was the Stevenson-Wydler Act. 
Its reach expanded by amendments over a pe­
riod of years, the law is codified in title 15 (15 
U.S.C.), chapter 63 of the U.S. Code, under the 
heading “Technology Innovation.” Its funda­
mental purpose was to promote the utilization of 
technology owned by the federal government and 
generated with its help. The act accomplished its 
purpose by aiding the transfer of that technology 
to the private sector and to state and local gov­
ernments. The act initially called for setting aside 
0.5% of each federal laboratory’s budget to fund 
technology transfer activities; a later amendment 
required “sufficient funding to support technol­
ogy transfer activities.” 
The second law was the Patent andTrademark 
Amendment Act of 1980—known as the Bayh-
Dole Act. The terms and provisions of this act, 
as amended by the Trademarks Clarification Act 
of 1984, are codified in title 35 of the U.S. Code 
(35 U.S.C. § 200–212). The Bayh-Dole Act 
changed the presumption of title in and to in­
ventions made, in whole or in part, with federal 
monies at nonprofit organizations—including 
universities and small businesses—from the gov­
ernment to those entities. For the first time, the 
law established a uniform federal patent policy 
and provided the first statutory authority for the 
U.S. government to take title to and hold patents 
through its agencies. The regulations pertaining 
to the Bayh-Dole Act are found in the Code of 
Federal Regulations, title 37 (37 C.F.R.), part 
401; those regulations pertaining to the licensing 
of government-owned inventions are set forth 
in part 404, and those pertaining to inventions 
made by government employees are set forth in 
part 501. 
The Bayh-Dole Act also embraces any novel 
variety of plant that is or may be protected under 
the Plant Variety Protection Act, which is codi­
fied in title 7 of the U.S. Code (7 U.S.C.), chap­
ter 57, and includes sections 1545 and 2353 of 
title 28 (28 U.S.C. §§ 1545 and 2353), amend­
ments to title 27, sections 1551 and 1562 (27 
U.S.C. §§ 1551 and 1562) (the Federal Seed 
Act), and sections 1338 and 1498 of 28 U.S.C 
(28 U.S.C. §§ 1338, 1498). 
Because the Bayh-Dole Act depends upon 
the U.S. patent system to transfer technology 
from the nonprofit, university, and small business 
sectors, it is axiomatic that changes in the patent 
system and in the regulations governing that sys­
tem can affect the ability to protect and transfer 
technology. 
2.2 Patents and antitrust laws 
Many people classify patents as monopolies, a 
view that brings into sharp focus the issue of an­
titrust laws and patents, particularly the right of 
the patent holder to exclude. The passage of an­
titrust legislation in the United States was driven 
by the growth and expansion of business and 
the efforts of competitors to stabilize markets 
through price and quota arrangements. These 
activities made it clear that growing industrial 
combinations and monopolies would have to be 
controlled. 
As a result, in 1890 the Sherman Act was 
passed (codified at 15 U.S.C. §§ 1–7). The 
Clayton Act (codified at 15 U.S.C. §§ 12–29 
and 29 U.S.C. § 52) followed in 1916. As a 
supplement to the Sherman and Clayton acts, 
the Federal Trade Commission Act was passed in 
1914, amended in 1980 and1994, and reautho­
rized in 1996 (codified at 15 U.S.C. §§ 41–58). 
The Sherman Act prohibits the restraint of 
trade and monopolies. Antitrust law and patents 
oppose each other because according to the act, 
patents can contribute or be a part of an attempt 
to restrain trade or to establish a monopoly of 
“any part of the trade or commerce between the sev­
eral States (of the United States) or with foreign 
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nations.” Specifically, the substantive governing 
provisions are: 
•	 Section 1. Every contract, combination in 
the form of trust or otherwise, or conspiracy, 
in restraint of trade or commerce among the 
several States, or with foreign nations, is de­
clared to be illegal.… 
•	 Section 2. Every person who shall monopo­
lize, or combine or conspire with any other 
person or persons, to monopolize any part 
of the trade or commerce among the sever­
al States, or with foreign nations, shall be 
deemed guilty of a misdemeanor. 
It should be noted that under section 1, re­
straint of trade requires action by two or more 
parties, but monopolization requires action by 
just one party. 
In contrast to the broad language of the 
Sherman Act, the Clayton Act focuses on more 
specific trade abuses: price discrimination, the 
acquisition of one corporation by another, re­
strictions forbidding a purchaser of goods to 
deal in the goods of competition, and the use 
of interlocking directorates among large cor­
porations. The relevant, specific statutory lan­
guage is: 
•	 Section 3. …[I]t shall be unlawful for any per­
son engaged in [interstate] commerce, in the 
course of such commerce, to lease or make a sale 
or contract for sale of goods, wares, merchan­
dise, machinery, supplies or other commodities, 
whether patented or unpatented, for use, con­
sumption or resale within the United States or 
any Territory thereof or the District of Columbia 
of any insular possession or other place under the 
jurisdiction of the United States, or fix a price 
charged therefore, or discount from, or rebate 
upon, such prices, on the condition, agreement 
or understanding that the lessee or purchaser 
thereof shall not use or deal in the goods, wares, 
merchandise, machinery, supplies or other com­
modities of a competitor or competitors of the 
lessor or seller, where the effect of such lease, sale, 
or contract for sale on such condition, agreement 
or understanding may be to substantially lessen 
competition or tend to create a monopoly in any 
line of commerce. 
•	 Section 7. …[N]o corporation engaged in [in­
terstate] commerce shall acquire, directly or 
indirectly, the whole or any part of the stock or 
other share capital and no corporation subject to 
the jurisdiction of the Federal Trade Commission 
shall acquire the whole or any part of the assets of 
another corporation engaged also in commerce, 
where in any line of commerce in any section of 
the country, the effect of such acquisition may be 
substantially to lessen competition, or to tend to 
create a monopoly. 
The early historical perception that patents 
and antitrust principles are antithetical has been 
ameliorated over the years; today they are rec­
ognized as complementary tools that enhance 
competition. Nevertheless, the inherent right­
to-exclude conveyed by a patent forecloses third 
parties from practicing the invention patented, 
and patents can be used for various kinds of 
conveyances. (For example, patents can be the 
basis for exclusive, partially exclusive, or non­
exclusive licenses, bailments, or actual sales.) 
Attention must be paid to the nature of those 
conveyances and to the context within which 
and purpose for which they are generated and 
will be used. At present, patents, per se, are not 
viewed as conveyers of market power. But when 
coupled with other assets, or when patents are 
acquired in order to build a monopolistic posi­
tion (other than through internal research and 
development efforts), patents do contribute to 
market power. When combined with apparent 
predatory practices that restrain trade, such a po­
sition can invite antitrust scrutiny. For example, 
a violation of the Clayton Act would occur if a 
purchaser were forced to purchase certain mate­
rials or supplies from a specified supplier to the 
exclusion of a competitor—this is referred to as 
a tying arrangement. In terms of antitrust issues, 
this arrangement would be viewed as extending 
the scope of a patent by restricting the use of the 
patented invention to goods necessary for its op­
eration but not part of the patented invention. 
For example, the license (or franchise) under the 
patent might require the purchase of nonpatent­
ed items from the licensor as a condition for the 
license itself. Without the element of coercion, 
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BREMER 
however, the parties are free to enter into such 
a supply agreement. 
2.  Export Administration Regulations and 
International Traffic in Arms Regulations 
The Department of Commerce administers the 
Export Administration Regulations (EAR) to pro­
tect trade, while the Department of State adminis­
ters the International Traffic in Arms Regulations 
(ITAR) toprotectnational security.Theregulations 
apply not only to the transfer of physical items to 
persons and/or entities outside the United States, 
but also to the transfer of technology—whether 
or not it is associated with a physical item. The 
regulations also cover disclosure to foreign per­
sons while in the United States of technical data 
or information on controlled items, as well as to 
the training and offering of services involving con­
trolled equipment to foreign persons. 
The EAR can be found at title 15, sections 
730–74 of the Code of Federal Regulations. 
EAR regulations apply to and regulate the ex­
port of goods and related technology on the 
Commodity Control List (15 C.F.R. § 774, 
supplement 1). The ITAR can be found at 22 
C.F.R. 120–30. The regulations control the 
export of articles, services, and related techni­
cal data that are inherently military in nature. 
Regulated items are specified in the Munitions 
List at 22 C.F.R. 121. 
Additionally, the regulations restrict the ex­
port of goods and technology that could hamper 
the economic vitality of the United States or that 
might contribute to the military capability and 
potential of its adversaries. Because of global ter­
rorism, the latter has been particularly empha­
sized in recent years. 
IP, as represented by patents, know-how, 
trade secrets, and copyright can also be affected 
by EAR and ITAR. The Patent and Trademark 
Office asserts some control over the export of 
sensitive technology by issuing export licenses— 
in most cases, automatically, during the early 
consideration of a patent application, or upon 
request from the applicant. In some cases, the 
office will impose a secrecy order on a patent 
application that contains sensitive materials. 
In such cases, an applicant may prosecute the 
application so ordered in a special group in 
the examining corps, but the patent will not 
be issued until the restriction has been lifted. 
Corresponding applications can be filed and 
prosecuted in other approved countries to the 
point of acceptance, but the patent itself will 
not be issued. With the patented technology 
embargoed, the technology itself would fall un­
der the EAR or ITAR. 
Inasmuch as they embrace transfers of con­
trolled information (including technical data, 
physical items—inclusive of scientific equip­
ment—and verbal, written, electronic and/or 
visual disclosures of controlled scientific and 
technical information), the EAR and ITAR 
can affect university research and development, 
as well as university technology-transfer func­
tions, via patent licensing and/or other means. 
Because of the tradition of academic freedom 
and the open nature of research and develop­
ment in U.S. universities, the EAR and ITAR 
can be more difficult to administer; nevertheless, 
universities must comply with the regulations. 
Although EAR and ITAR cover virtually all of 
the same science and engineering fields that uni­
versities research and develop, compliance tends 
not to be viewed as essential. This is partly be­
cause of the open environment of universities. 
Control is more difficult, and neither the EAR 
nor the ITAR require an export license to dis­
close technical information to foreign nationals 
in the United States inside classes, laboratories, 
or conferences, or in publications, if the infor­
mation is in the public domain. Information is 
considered to be in the public domain if it is, at 
least in part, published and generally accessible 
to the public through unlimited and unrestricted 
distribution. This public-domain exemption, 
however, may not apply to all information that a 
university generates. There are circumstances in 
which a specific export license may be required 
or, particularly where a secrecy order has been 
imposed, export of the information and/or tech­
nology is illegal. 
Ancillary to the EAR and ITAR is the Treasury 
Department Office of Foreign Assets Control 
(OFAC). OFAC acts under presidential war­
time and national emergency powers and has the 
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authority of specific legislation to prohibit transac­
tions, including the provision of services, and freeze 
foreign assets under U.S. jurisdiction of targeted 
persons and entities. Individuals may not provide 
technologies or services to countries on OFAC’s 
list of embargoed entities or to specially desig­
nated persons without first obtaining licenses from 
OFAC and the state or commerce department. 
2.  The Cooperative Research and Technology 
Enhancement Act of 2004 
In 2004, the U.S. Congress passed the 
Cooperative Research and Technology 
Enhancement Act, (CREATE Act). The law is 
codified at 35 U.S.C. § 103(c) and applies to 
any patent (including reissued patents) granted 
on or after December 10, 2004. The law was 
designed to overrule a judicial decision that 
held that confidential information derived 
from another individual (termed secret prior art) 
could render an invention obvious and thereby 
preclude patentability of the invention. Since 
such an exchange of information tends to occur 
most frequently where researchers, engaged by 
different entities, are collaborating on a given 
research project, the decision was construed to 
have a “chilling effect” on collaborative research 
among different entities. The CREATE Act en­
ables two or more entities to obtain and sepa­
rately own patents containing claims that are 
not patentably distinct from each other (where 
one claim in one patent would be “obvious” in 
view of a claim in the other patent). To involve 
the provisions of the CREATE Act, the col­
laborative research must have been conducted 
under a Joint Research Agreement that was in 
effect on or before the claimed invention was 
made, the claimed invention must have been 
made as a result of activities undertaken within 
the scope of the agreement, and the application 
for patent for the claimed invention, initially or 
by amendment, must have disclosed the names 
of the parties to the agreement. 
2.5  Cooperative Research and 
Development Agreements 
Authority for Cooperative Research and 
Development Agreements (CRADAs) is found at 
35 U.S.C. § 3710(a). The purpose of CRADAs 
is to promote technology innovation in govern­
ment-operated federal laboratories and govern­
ment-owned, contractor-operated laboratories 
across all federal government agencies. The 
specific authorization language at 35 U.S.C. § 
3710(a) is reproduced below: 
(a)	 General authority. Each Federal agen­
cy may permit the director of any of its 
Government-operated Federal laboratories, 
and, to the extent provided in an agency-ap­
proved joint work statement or, if permitted 
by the agency, in an agency-approved an­
nual strategic plan, the director of any of 
its Government-owned, contractor-operated 
laboratories— 
(1) to enter into cooperative research and de­
velopment agreements on behalf of such 
agency (subject to subsection (c) of this 
section) with other Federal agencies; units 
of State or local government; industrial 
organizations (including corporations, 
partnerships, and limited partnerships, 
and industrial development organiza­
tions); public and private foundations; 
nonprofit organizations (including uni­
versities); or other persons (including li­
censees of inventions owned by the Federal 
agency); and 
(2) to	 negotiate licensing agreements under 
section 207 of title 35, United States 
Code, or under other authorities (in the 
case of a Government-owned, contractor-
operator laboratory, subject to subsection 
(c) of this section) for inventions made or 
other intellectual property developed at the 
laboratory and other inventions or other 
intellectual property that may be volun­
tarily assigned to the Government. 
Under a CRADA, the involved labora­
tory may grant, or agree to grant, in advance 
to a collaborating party patent licenses, or 
assignment, or options thereto, in any inven­
tion made, in whole or in part, by a laboratory 
employee under the agreement for reasonable 
compensation (35 U.S.C. § 3710a(b) enumer­
ated authority). 
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BREMER 
2.  Department of Energy/Nuclear Regulatory 
Commission inventions and atomic weapons 
The laws pertaining to this subject are codified at 
title 42 U.S. Code, beginning with section 2014 
and continuing with section 2181 (42 U.S.C. 
§§ 2014–181). The law specifically prohibits 
the granting of any patent for any invention or 
discovery for the utilization of special nuclear 
material or atomic energy in an atomic weapon; 
the law revokes any patent granted for such an 
invention or discovery. The prohibition extends 
even further to state that no patent granted shall 
confer any rights with respect to any invention 
or discovery insofar as it is used in the utilization 
of special nuclear material or atomic energy in 
an atomic weapon. 
2.  National Aeronautics and 
Space Administration 
The property rights for inventions made under 
the aegis of the National Aeronautics and Space 
Administration (NASA) or in contracts issued 
by NASA are codified at 42 U.S.C. § 2457. 
Generally, inventions made in the performance 
of any work under a contract with NASA shall 
be the property of the United States. The provi­
sions of 42 U.S.C. § 2457c extend beyond the 
obligation arising under contract with NASA to 
all patents that “have significant utility in the 
conduct of aeronautical and space activities sub­
ject to a patent applicant’s positive action to dis­
pute ownership by the United States.” A right 
of appeal presents an opportunity to obtain a 
waiver of rights by NASA (42 U.S.C. § 2457f ). 
Even if the agency waives its right of ownership 
in a given patent, the government will, never­
theless, retain or receive an irrevocable, nonex­
clusive, nontransferable, royalty-free license to 
practice the inventions of such patent on behalf 
of the United States or any foreign government 
pursuant to any treaty or agreement with the 
United States. 
2.  IP and international trade 
The applicable law under the general heading of 
IP and international trade can be found at 19 
U.S.C. § 1337 under “unfair practices in import 
trade.” Such issues fall under the aegis of the 
International Trade Commission. The provi­
sions under subsection (a), titled “Unlawful 
activities; covered industries; definitions,” are 
self-explanatory and are reproduced in Box 1. 
Moreover, 19 U.S.C. § 2242 requires the 
identification of countries that deny adequate 
protection or market access for IP rights before 
suitable action can be taken by the U.S. Trade 
Representative to counter, correct, or suspend 
the benefits afforded in trade and related activi­
ties to such a country. (The authorization for ac­
tions available to the Trade Representative can 
be found at 19 U.S.C. § 1526(c).) 
2.  Small Business Innovation 
Development Act of 1982 
Codified at 15 U.S.C. § 631, et sequens, the 
Small Business Innovation Development Act 
(SBIR) was intended to strengthen the role of 
small, innovative firms in federally funded re­
search and development and to utilize federal 
research and development as a base for tech­
nological innovation. An important feature of 
the SBIR is the directive for federal agencies 
to set aside a portion of each agency’s funding 
for small business R&D. The Bayh-Dole Act 
allows small businesses to retain title to inven­
tions made, in whole or in part, with federal 
funds. SBIR enhances the position of small 
business. 
2.10 Small Business Technology Transfer Program 
The Small Business Technology Transfer Program 
(STTR) (15 U.S.C. § 638) supplements the 
SBIR program. STTR requires a set-aside for 
applicable agencies to support cooperative re-
search-and -development projects involving 
small businesses and a nonprofit research insti­
tutions. STTR provides the latter with the op­
portunity to call upon the funding federal agen­
cy for technical assistance. IP rights between the 
United States and the recipient small business 
are required to be set forth in the funding agree­
ment, along with any right to carry out follow-
on research. 
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CHAPTER . 
Box 1: unlawful activities; covered industries; definitions 
(1)	 Subject to paragraph (2), the following are unlawful, and when found by the Commission to
exist shall be dealt with, in addition to any other provision of law, as provided in this section: 
(A)	 Unfair methods of competition and unfair acts in the importation of articles (other than
articles provided for in subparagraphs (B), (C), (D), and (E) into the United States, or in the
sale of such articles by the owner, importer, or consignee, the threat or effect of which
is— 
(i) To destroy or substantially injure an industry in the United States; 
(ii) To prevent the establishment of such an industry; or 
(iii) To restrain or monopolize trade and commerce in the United States. 
(B)  The importation into the United States, the sale for importation, or the sale within the
United States after importation by the owner, importer, or consignee, of articles that— 
(i) infringe a valid and enforceable United States patent or a valid and enforceable
United States copyright registered under title 17, United States Code; or 
(ii) are made, produced, processed, or mined under, or by means of, a process covered by
the claims of a valid and enforceable United States patent. 
(C)  The importation into the United States, the sale for importation, or the sale within
the United States after importation by the owner, importer, or consignee, of articles
that infringe a valid and enforceable United States Trademark registered under the
Trademark Act of 1946. 
(D)  The importation into the United States, the sale for importation, or the sale within the
United States after importation by the owner, importer,or consignee,of a semiconductor
chip product in a manner that constitutes infringement of a mask work registered
under chapter 9 of title 17, United States Code. 
(E)  The importation into the United States, the sale for importation, or the sale within the
United States after importation by the owner, importer, or consigner, of an article that
constitutes infringement of the exclusive rights in a design protected under chapter 13
of title 17, United States Code. 
(2) Subparagraphs (B),(C), and (D) of paragraph (1) apply only if an industry in the United States,
relating to the articles protected by the patent, copyright, Trademark, mask work, or design
concerned, exists or is in the process of being established. 
(3) For purposes of paragraph (2), an industry in the United States shall be considered to exist if
there is in the United States, with respect to the articles protected by the patent, copyright,
Trademark, mask work, or design concerned— 
(A) significant investment in plant and equipment; 
(B) significant employment of labor or capital; or 
(C)	 substantial investment in its exploitation, including engineering, research and 
development, or licensing. 
(4) For the purposes of this section, the phrase“owner, importer, or consignee” includes any agent
of the owner, importer, or consignee. 
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BREMER 
3. CONCluSIONS 
This overview of the laws and regulations gov­
erning IP in the United States provides a general 
orientation to the goals and historical concerns 
of the legislation. As these goals and concerns 
change, so will the laws addressing IP rights. 
Moreover, issues surrounding IP rights are ad­
dressed in many pieces of legislation, including 
authorization bills for funding various federal 
agencies. The effects of the legislation may be 
temporary or permanent, another reason for 
understanding not just the statutes, but also the 
motivation and reasoning behind them. n 
HOWARd BREMER, Counsel Emeritus, WARF-Wisconsin 
Alumni Research Foundation, 614 Walnut St. 13th floor, 
Madison, WI, 53726, U.S.A. hwbremer@warf.org 
22 | HANDBOOK OF BEST PRACTICES 







    
         
 






How to Gain Access to Patented Technology
 
caRlos MaRía coRRea, Center for Interdisciplinary Studies of Industrial Property and Economics (CEIDIE), 
Law Faculty, University of Buenos Aires, Argentina 
ABSTRACT 
Voluntary patent licenses are often difficult for institu­
tions to obtain, particularly those in developing coun­
tries. This chapter discusses why, how, and by whom 
compulsory patent licenses may be obtained and used. 
The main focus is on patented research tools rather than 
patented end products. 
1. InTRoduCTIon 
Some scientific discoveries and inventions, partic­
ularly in biotechnology, have no obvious practical 
application; to use the metaphor of a river, we 
might say that they are patented at a point up­
stream from practical application. Broad patent 
claims often hamper the development of down­
stream applications.1 For instance, in the United 
States, DNA sequences (genes) are legally consid­
ered to be chemical compounds and can there­
fore be patented. The gene’s functions, even those 
that are not yet known, can therefore be exploited 
only by authorization of the patent owner. 
One example of the problems that can oc­
cur when downstream researchers need to use up­
stream discoveries is the case of antigen MSP-1, 
an important candidate for the development of an 
antimalaria vaccine. The Program for Appropriate 
Technology in Health (PATH), which is work­
ing to develop such a vaccine, found that the 
antigen was protected by more than 20 partially 
overlapping patents. Extensive negotiations and 
a considerable amount of time and money were 
required to obtain permission to use it. A repre­
sentative of the program notes: 
Why does the IP landscape for MSP-1 not 
sort itself out through traditional channels such 
as technology transfer and the courts? Developers 
who want assurance of the rights to use MSP-1 
would have to obtain licenses from no less than 
eight organizations.Though theoretically pos­
sible, a licensing transaction of this type would 
take years, require significant staff time, and cost 
hundreds of thousands of dollars in attorney fees. 
While companies routinely make such efforts on 
behalf of commercial products, the economics 
of malaria vaccines make developers more reluc­
tant to invest in such cumbersome technology 
acquisition.2 
Several studies in the United States3 and else­
where4 have examined the potential impact of re­
search tool patents. Although the U.S. National 
Academies of Sciences found that private com­
panies and research institutions in developed 
countries are generally able to deal with the com­
plexities of patent law, it warned that “the patent 
landscape, which already is becoming complicated in 
areas such as gene expression and protein-protein in­
teractions, could become considerably more complex 
and burdensome over time.”5 A Swiss survey on the 
obstacles to research stemming from patent pro­
tection found that a majority of companies and 
Correa CM. 2007 Compulsory Licensing: How to Gain Access to Patented Technology. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. CM Correa. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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institutions favored the creation of either an ex­
ception for the clinical use of the patented subject 
matter or the granting of compulsory licenses.6 
Small companies and research institutions 
will likely be more adversely affected by upstream 
patents than will large companies or institutions. 
Entities in developing countries that lack the le­
gal, financial, technological and negotiating ca­
pacity to engage in complex negotiations, may be 
significantly constrained. For instance, a survey 
of 103 Indian pharmaceutical companies revealed 
that the most common reason firms decided to 
abandon R&D projects was because of restricted 
access to patented upstream technologies.7 
Some initiatives are being considered that 
would allow low-income countries access to tech­
nology under special conditions. The Science and 
Intellectual Property in the Public Interest proj­
ect (SIPPI) of the American Association for the 
Advancement of Science (AAAS)8 has promoted 
the idea that technology managers in developed 
countries should include legally enforceable pro­
visions in licensing agreements to preserve the 
possibility of sharing protected technologies 
with third parties for humanitarian reasons in 
developing countries.9 
Patented upstream technology can create bar­
riers to agricultural research,10 unless the use of 
the protected subject matter is permitted under 
a research exception or otherwise consented by 
the patent owner. Golden Rice, which has been 
genetically modified to contain pro-Vitamin A 
or beta-carotene, is a tool for combating vitamin 
A deficiency in developing countries. Syngenta 
Seeds AG negotiated access to all major technolo­
gies necessary for Golden Rice production11 and 
then granted the inventors of Golden Rice the 
right to sublicense breeding institutions in devel­
oping countries, free of charge, provided that the 
rice would be used only for subsistence farming 
and not for commercial purposes. Subsistence 
farming has been defined as any farm not gener­
ating income more than US$10,000 from the sale 
of rice. Syngenta is not interested in commercial­
izing Golden Rice in developed countries, where 
vitamin A deficiency is almost unheard of.12 
Other examples of removal of patent barriers 
through “humanitarian IP management” include 
Cornell University’s transfer of papaya-rings­
pot-virus-resistant papaya to Thailand; several 
projects brokered by the International Service 
for the Acquisition of Agri-biotech Applications 
(ISAAA); and the agreement between Yale 
University and Bristol-Myers Squibb regarding 
the patent on stavudine (d4T), a widely used 
HIV/AIDS antiretroviral drug. Humanitarian IP 
management could be expanded to involve re­
search and experimentation as well as the transfer 
of patented technologies. 
2.	 pATEnTS	And doWnSTREAM	
RESEARCH 
A compulsory license is an authorization given by 
a “national authority” to a natural or legal person 
for the exploitation of the subject matter pro­
tected by a patent; the consent of the patent title 
holder is not necessary. Compulsory licenses may 
be required to import or produce a given product, 
or to use a patented technology for research. They 
are especially important when there are no close 
substitutes for a product or process and a research 
exception is not available or is too narrow.13 
Compulsory licenses are granted in order to 
attain various public-policy objectives, such as: to 
address emergencies and public-health needs, to 
counteract anticompetitive business practices, or 
to permit the exploitation of a patent in cases of 
lack of working thereof. 
The right to use compulsory licenses was 
recognized in the World Trade Organization 
(WTO) Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) in 1994.14 
The Doha Declaration on the TRIPS Agreement 
and Public Health (the Doha Declaration), ad­
opted by the 4th WTO Ministerial Conference 
in November 2001,15 confirmed, inter alia, that 
each WTO member was free to determine the 
grounds under which it would grant compulsory 
licenses.16 
In the United States, compulsory licenses 
have been widely used for government use and in 
settlements for antitrust cases.17 Countries such as 
Zambia and Zimbabwe have recently issued com­
pulsory licenses to facilitate access to cheap medi­
cines; others, such as Malaysia and Indonesia, have 
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CHAPTER .10 
issued government-use provisions for the same 
purpose. A public non-commercial use provision 
is somewhat different from a compulsory license 
for commercial production. Public non-commer­
cial use provisions, which exist in many countries, 
authorize a government department to exploit, 
by itself or through a contractor, a patented in­
vention, without the consent of the patent right 
holder, as long as such exploitation is to provide 
a public service and for noncommercial purposes. 
Other countries, such as Brazil and South Africa, 
have threatened to grant compulsory licenses in 
order to obtain cheaper medicines.18 A compul­
sory license is likely to be less advantageous to the 
patent owner than a voluntary license. It is there­
fore to the advantage of patent owners to price 
their products fairly and grant voluntary patent 
licenses with reasonable terms and conditions. 
Compulsory licenses may be needed when 
patents restrict the freedom to operate (FTO) 19 
in a given field of R&D. Such licenses are subject 
to several conditions, notably that the licensee 
must remunerate the patent holder. These condi­
tions are examined in section 3 below. 
. CoMpuLSoRy LICEnSES	 foR	RESEARCH 
.1	 Who can apply? 
National laws normally allow companies, non­
governmental organizations, and research institu­
tions to apply for compulsory licenses. In some 
countries, licensees must first demonstrate that 
they have the technical or economic capacity to 
utilize the license properly. 
.2	 When can a compulsory 
license be applied for? 
Some types of compulsory licenses, such as those 
granted to remedy abuses, for example, lack of 
working, cannot be granted until four years after 
the date of filing of the patent application or three 
years from the date of the grant of the patent, 
whichever date comes second.20 These terms do 
not apply when the compulsory licenses are grant­
ed on other grounds, such as when public health is 
at stake, in emergency situations, or where neces­
sary to remedy anti-competitive practices. 
. 	 Prior negotiation of a voluntary license 
Except in the case of emergency, anti-competi­
tive practices, and government use, the potential 
compulsory licensee must first request a volun­
tary license on reasonable commercial terms from 
the patent owner.21 Such “reasonable commercial 
terms” must be consistent with standard com­
mercial practice and must ultimately be in accor­
dance with the requirements set by national law 
and by the competent authority. If such a volun­
tary license is denied, the potential licensee may 
apply for a compulsory license—though it may 
be necessary to prove that the patent owner has 
refused to grant a voluntary license within a rea­
sonable time period. 
Many patents for research tools are held by 
universities—where the initial invention has of­
ten been made—that sometimes decline to pro­
vide voluntary licenses to certain applicants or 
are unable to do so. The reasons for this may be 
multifold. One reason may be that the university 
has already granted an exclusive license; another 
reason may be that the university is in licensing 
negotiations with another party. Determining 
reasonable commercial terms when the patent 
owner is a university is also difficult. However, 
there are many universities with extensive experi­
ence in these matters, and their standard practices 
may serve as models. This is certainly one reason 
why universities should be encouraged to retain 
humanitarian-use rights.22 
. 	 How should the application be made? 
National laws govern both the substantive re­
quirements and the relevant procedures for ob­
taining a compulsory license. 
..1 The appropriate authority	 
In most countries, compulsory licenses are grant­
ed by the government’s executive branch. In oth­
ers, such authority lies with the judiciary branch. 
The services of legal professionals are not gener­
ally required, but may be advisable. 
..2 Grounds for the application	 
The appropriate authority should be provided 
with a reasoned justification for the application. 
The application should, to the greatest extent 
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possible, specify the legal provisions and grounds 
on which it is sought. Requests must abide by the 
restrictions set by national law.23 
The application should specify the scope and 
duration of the requested compulsory license. An 
application may request access to all of the sub­
ject matter covered by a patent, or it may request 
access to only certain elements of a patent, or cer­
tain uses of a patented invention. 
To avoid the trouble of having to file future 
license extensions, it is advisable to request the 
license for the full remaining term of the patent. 
.. 	 Identification of the applicant 
The applicant, if not a natural person, will nor­
mally have to submit copies of the relevant stat­
utes or bylaws. In addition, any person represent­
ing the applicant will have to demonstrate his or 
her capacity to do so. Depending on national law, 
the applicant may also have to provide evidence 
of sufficient economic or technical capacity to 
utilize the compulsory license (information about 
personnel, funding, activities, partnerships, pub­
lications, and so on). 
..	 Identification of patents 
The identification of the patents involved can be 
determined by indicating the product or tech­
nologies at stake. The compulsory license ap­
plication may refer to all patents relating to the 
products or technologies the applicant seeks to 
exploit. In other words, one application can re­
quest the rights to many patents. In the United 
States, there have been cases in which compulsory 
licenses were even granted for both current and 
future patents.24 
..	 Conditions of the 
compulsory license 
Remuneration. Governments have considerable 
discretion to define the level and kind of remu­
neration that the patent owner should receive. 
The general rule is that remuneration should be 
adequate, taking into account both the particu­
lar circumstances of each case and the economic 
value of the compulsory license.25 Following are 
some of the methods that have been used to cal­
culate remuneration:26 
•	 The 1998 Japan Patent Office (JPO) 
Guidelines (for government-owned drug 
patents) specify royalties that amount to 
2%–4% of the generic product price; this 
amount can be increased or decreased by as 
much as 2%, for a range of 0%–6%. 
•	 The 2001 United Nations Development 
Programme (UNDP) Human Development 
Report proposed a base royalty rate of 4% 
of the generic drug price. This can be in­
creased or decreased by 2%, for a range of 
2%–6%, depending upon various factors 
(how innovative the medicine is, or the role 
of governments in paying for research and 
development). 
•	 In accordance with the WTO Decision of 
30 August 2003, the 2005 Canadian gov­
ernment established royalty guidelines for 
compulsory licensing of patents to coun­
tries that lack the capacity to manufacture 
medicines. The royalty rate (between 0.02% 
and 4% of the price of a generic drug) is 
determined by a country’s rank in the UN 
Human Development Index. For most de­
veloping countries, the royalty rate is less 
than 3%. For most countries in Africa, the 
rate is less than 1%. 
•	 The tiered-royalty method is unusual in 
that the royalty rate is based upon the price 
of a brand-name drug, not the generic 
equivalent, in the high-income country in 
which the patent is owned. The base royalty 
(4% of the brand-name price) is adjusted 
to account for relative income per capita or, 
for countries with a particularly high bur­
den of disease, relative income per diseased 
person. 
These guidelines are used to determine roy­
alty rates for products, not research tools. For re­
search tools, royalty payments may be lower since 
no products are yet on the market. 
With regard to agricultural technology, a 
relevant precedent may be the determination 
of 1,1% of the net sales of products within the 
Multilateral System in the context of the stan­
dard material transfer agreement adopted, in 
June 2006, by the Governing Body of the FAO 
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International Treaty on Plant Genetic Resources 
for Food and Agriculture.27 
Finally, the act granting a compulsory license 
should specify time of payment, basis for the cal­
culation of fees or royalties, currency of payment, 
the bank account where the payment will be de­
posited, and other relevant details. 
Other conditions. In all cases, a compulsory 
license will be nonexclusive:28 that is, the patent 
owner or other voluntary or compulsory licensors 
may simultaneously exploit the patented inven­
tion or research tool. According to some national 
laws, the license may be revoked if not utilized 
within a certain term. Moreover, a compulsory 
licensor can request that a license be terminated, 
if and when the circumstances that first necessi­
tated the license cease to exist and are unlikely to 
recur.29 
.. Appeal 
A compulsory license may be delayed if the pat­
ent owner appeals the validity of the license or the 
level of remuneration that it grants.30 For this rea­
son, in some countries, a license can be put into 
effect even while appeal procedures are pending. 
.	 ConCLuSIonS 
The problems generated by patent infringement 
on downstream use of inventions, especially in 
developing countries, can be minimized through 
a number of approaches. Countries should adopt 
and enforce strict criteria of patentability and 
broad exceptions for research. If patents on re­
search tools limit FTO, the first step should be 
to negotiate voluntary licenses on reasonable 
terms and conditions, particularly as this may al­
low for the licensing of knowledge not disclosed 
in the patent. If it cannot be achieved, or proves 
too cumbersome or costly to do so, the next 
step should be to apply for compulsory licenses. 
Applicants need to be certain that they have the 
capacity to exploit the licenses and the financial 
ability to remunerate the patent holder or pat­
ent holders. Nonprofit research institutions may 
often find this particularly difficult because even 
with a compulsory license, commercial partners 
will need to be in place to produce and distribute 
products that were developed under compulsory 
licenses. This is one reason for further invest­
ments in capacity building and the establishment 
of strong institutional networks. n 
caRlos MaRía coRRea, Center for Interdisciplinary Studies 
of Industrial Property and Economics (CEIDIE), Law 
Faculty, University of Buenos Aires, Av. Figueroa Alcorta 
2263, 1st floor (1425), Buenos Aires, Argentina. ceidie@ 
derecho.uba.ar, and quies@sion.com. 
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(2000) limited the grounds on which compulsory
licenses can be granted as follows: “Neither Party 
shall permit the use of the subject matter of a patent
without the authorization of the right holder except in 
the following circumstances: (a) to remedy a practice 
determined after judicial or administrative process to be 
anti-competitive; (b) in case of public non-commercial 
use or in the case of a national emergency or other 
circumstances of extreme urgency, provided that such 
use is limited to use by government entities or legal 
entities acting under the authority of a government; or 
(c) on the ground of failure to meet working requirement,
provided that importation shall constitute working.”
(Article 4.20).
24 Correa C. 1999. Intellectual property rights and the 
use of compulsory licenses: options for developing 
countries. Trade-Related Agenda, Development, and 
Equity,Working Papers, South Centre, Geneva. Available 
at www.southcentre.org.
25 Article 31(h) of the TRIPS Agreement. The obligation to 
pay a remuneration is waived in the case of a compulsory
license granted under the system established by the 
WTO Decision of 30 August 2003 (incorporated as 
Article 31bis of the TRIPS Agreement, but still subject to 
ratification) to import pharmaceutical products in cases 
where theimportingcountryhasestablished that it lacks 
sufficient manufacturing capacity in pharmaceuticals.
Payment in these cases will only take place under the 
compulsory license granted in the exporting country. 
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26 Love J. 2005. Remuneration Guidelines for Non-Volun-
tary Use of a Patent on Medical Technologies. World 
Health Organization: Geneva. (WHO/TCM/2005.1), p
83–85. 
27 Correa C. 2006. Considerations on the Standard 
Material Transfer Agreement under the FAO Treaty on 
Plant Genetic Resources for Food and Agriculture. The 
Journal of World Intellectual Property 9(2): 137–65. See 
also the text of the adopted standard agreement at
ftp://ftp.fao.org/ag/cgrfa/gb1/SMTAe.pdf. 
28 Article 31(d) of the TRIPS Agreement. 
29 Article 31(g) of the TRIPS Agreement. 
30 The TRIPS Agreement specifically provides that “the 
legal validity of any decision relating to the authorization 
of such use shall be subject to judicial review or other 
independent review by a distinct higher authority in 
that Member” (Article 31(i)). 
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CHAPTER 3.11 
The Role of Clusters in Driving Innovation
 
PETER W. B. PHILLIPS, Professor, Department of Political Studies, University of Saskatchewan, Canada
 
CAMILLE d. RyAN, Postdoctoral Fellow, Faculty of Communication & Culture, University of Calgary, Canada
 
ABSTRACT 
The promise of biotechnology relies on new science that 
is increasingly complex and specialized and depends on 
sophisticated, global intellectual property rights systems. 
This complexity requires a more open system of knowl­
edge sharing than previous research and development 
programs. Studies suggest that successful innovation 
requires developing clusters of institutions, businesses, 
and personnel. “Location, location, location,” the battle 
cry for property realtors everywhere, is increasingly be­
coming the key phrase in studies of innovation dynam­
ics and knowledge-based growth. Offering an overview 
of recent research on clusters in Canada, this chapter 
suggests that governments have an important role to 
play in the process of cluster formation and that ensur­
ing a mix of “local buzz” and “global reach” is part of the 
recipe for success. 
1. INTRODuCTION 
Biotechnology has changed the discussion about 
research and development in agriculture and 
medicine. In the past, research tended to be dis­
tributed widely to meet agronomic and human 
health needs, but now we are seeing agglomera­
tions forming around the research, development, 
and commercialization of globally mandated 
technologies and products. Governments view 
this change as an opportunity to invest in and 
create comparative advantages or as a threat to 
their competitive status and ability to access new 
technologies. 
Theory and evidence suggest that competing, 
innovative companies and their related industries 
will tend to concentrate in a few locations. Most 
innovation involves a lot of learning-by-doing, 
which creates a barrier for imitators who want to 
use the innovation: they can do so only after they 
have gone through their own learning process. 
Furthermore, the cumulative impact of learning­
by-doing creates stronger competition in more-
innovative companies and sectors, thus erecting 
barriers to less-innovative actors. While basic 
science and inventions (usually codified through 
scientific journals and patents) can often be trans­
ferred at low or no marginal cost, know-how and 
experience are very difficult to transfer across long 
distances. Applied science (know-how) does spill 
over to others in the sector, but estimates suggest 
that the spillover benefits of tacit knowledge are 
limited to between ten and 100 miles of the epi­
center. This pattern is frequently seen in the inno­
vation corridors of Silicon Valley, Boston’s Route 
128, and Austin in the United States, Cambridge 
in England, Bangalore in India, and Saskatoon in 
Canada. 
Grossman and Helpman1 argue that techno­
logical spillovers limited to a specific location (due, 
for example, to climate or industrial structure) 
create an opportunity for endogenously gener­
ated comparative advantage. According to the au­
thors, countries that engage in technology-related 
Phillips PWB and CD Ryan. 2007. The Role of Clusters in Driving Innovation. In Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K.,
and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. PWB Phillips and CD Ryan. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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competitive activity can produce comparative 
advantage over time. If technological spillovers 
are geographically concentrated, then the initial 
and sequentially established conditions will af­
fect subsequent economic growth. Grossman 
and Helpman further argue that, as a result, the 
high-technology share of GDP and exports will be 
greater in first movers than elsewhere. In the ex­
treme, a country that inherits even a small techno­
logical lead could come to dominate world mar­
kets for high-technology products. A productivity 
differential then becomes self-sustaining. 
Gilpin2 argues that the new theories of eco­
nomic growth create a new role for the state. 
Governments can generate growth, and numer­
ous countries and regions have sought to do just 
that. By some counts, all large industrial econo­
mies, almost all major cities around the world 
and many smaller countries, cities, and regions 
have decided to invest in and nurture some form 
of a biotechnology cluster. There are literally hun­
dreds of putative biotechnology clusters around 
the world right now. 
2. BIOTECHNOlOGy, HEAlTH,
AND AGRICulTuRE 
Some 40% of the world’s market economy is based 
upon biological products and processes—mainly 
food, protein and fiber production, and human 
health.3 The security and the supply of food and 
fiber are threatened by increasing consumer de­
mand, shrinking cultivable land, limited water, 
and diminishing returns on existing technologies. 
Further, while great strides have been made in ex­
tending and improving the quality of life, disease 
remains a constant daily threat in many countries. 
Food-supply insecurities and unchecked disease 
go hand in hand in many low-income developing 
economies, yielding a dismal, Malthusian outlook 
for a large portion of the world’s population. 
Biotechnology has potential to transform 
food production and health. A number of key 
scientific discoveries since 1970 in the fields of 
genomics and proteomics (for example, gene se­
lection, gene splicing, and metabolic profiling) 
have opened up vast novel avenues of research, 
on new plants, animals, and microbes, that could 
have applications in medicine, agriculture, extrac­
tion, processing, and the environment. Despite 
some major obstacles, many scientists and policy 
advisors see great potential in modern, molecu­
lar-based biotechnology, especially through the 
new capacities to genetically modify plants and 
to detect and treat disease. In 2001, Daar and 
colleagues4 undertook a Delphi survey of more 
than 30 scientists and bioethicists from around 
the world to identify the top ten technologies 
that could address a wide range of problems in 
the developing world. The list included eight 
biomedical applications: molecular technologies 
for affordable, simple diagnosis of infectious dis­
eases; recombinant technologies to develop vac­
cines against infectious diseases; technologies for 
more-efficient drug and vaccine delivery systems; 
sequencing pathogen genomes to understand 
their biology and to identify new antimicrobi­
als; female-controlled protection against sexually 
transmitted diseases, both with and without con­
traceptive effect; bioinformatics to identify drug 
targets and to examine pathogen-host interac­
tions; recombinant technology to make therapeu­
tic products such as insulin and interferon more 
affordable; and combinatorial chemistry for drug 
discovery. It also included one agricultural use: 
genetically modified crops with higher yields and 
increased nutrients that resist biotic and abiotic 
stresses, and an environmental application: tech­
nologies for sanitation, clean water, and bioreme­
diation. If realized, these technologies would go a 
long way towards addressing the biggest food and 
health challenges of many developing countries. 
3. lIFE-SCIENCE INNOVATION SySTEMS
One opportunity or constraint, depending on how 
one looks at it, in achieving a better future is the 
relationship of innovation systems to life science 
research, development, and commercialization. 
In the classical model of innovation, relatively 
small groups of researchers (either in public labo­
ratories or in private research groups) engaged in 
a mostly self-contained, linear process of research 
and development, a process that ultimately led to 
commercialization through direct or contracted 
production and marketing. This type of structure 
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was exemplified by the research departments at 
Consolidated Edison, 3M, and Xerox, where ful­
ly dedicated research staff were given the freedom 
to investigate and invent new products for com­
mercialization by the host company. 
Much of the early life-science research also 
conformed to this model, except that it was often 
carried out in public laboratories (for example, 
the discovery of insulin by Banting and Best at 
the University of Toronto in 1922, the discovery 
of the structure of DNA for which Watson and 
Crick at Cambridge University received a Nobel 
Prize, and the creation of low-erucic acid, low 
glucosinolate rapeseed in Canada). While these 
individual efforts drew upon knowledge gener­
ated by others, most of them operated in relative 
isolation, with little formal or informal exchange 
of information during the discovery phase. This 
“standing on the shoulders of giants” model has 
generally been the basis for research efforts since 
the scientific and industrial revolutions of the 
seventeenth century. While the model may have 
been appropriate in earlier times, since many in­
novations were simply the product of inventors’ 
ingenuity, in more recent years, many institu­
tions, companies, and industries have used a dif­
ferent strategy to develop and exploit life science 
inventions. 
Indeed, the global life-science research ef­
fort has been significantly transformed. Two 
specific trends have led to this change. First, this 
new science has become increasing complex and 
specialized, which makes it increasingly difficult 
for isolated or independent scientists to realize 
breakthroughs or to pursue comprehensive re­
search programs. Instead, teams or networks of 
researchers pursue investigations. Second, intel­
lectual property (IP) rights have been extended 
into new subject areas and new jurisdictions. The 
United States started the process by extending 
patents through the Chakrabarty case in 1980 to 
living, single-celled organisms; patents were then 
extended through a series of subsequent decisions 
to whole plants, animals, and many human organs 
(but not the whole human being). Patent grant­
ing on living matter was internationalized over 
the past 20 years as other countries (for example, 
Australia, Canada, the European Union [E.U.], 
and Japan) either amended their own patent 
laws or issued judicial decisions extending rights. 
This IP rights system has been extended globally 
through the adoption of the Agreement on Trade-
Related Aspects of Intellectual Property (TRIPS) 
of the World Trade Organization (WTO), which, 
in 2006, began to require that all member states 
(virtually all countries) offer patents, plant breed­
ers rights, or some other sui generis system of pro­
tection for IP embodied in living matter. Private 
(and public) inventors have adapted rapidly to 
this new regime, patenting almost all of their 
inventions (including the tools of discovery and 
the resulting products). By 2005 there were an 
estimated 58,000 patents relating to biotechnol­
ogy tools and products in the United States, and 
a confusing array of rights claimed or allocated in 
other countries around the world. The increased 
role of profit seeking and the extensive use of for­
mal IP rights mechanisms such as patents have 
created barriers to the free exchange of knowl­
edge, which is now heavily scrutinized. 
The specialization of science and the fragmen­
tation of IP rights have forced scientists to col­
laborate and network more extensively to achieve 
research results (the Human Genome Project rep­
resents one type of widespread research network). 
Networks of institutions and researchers have 
evolved to handle the transfer, acquisition, and 
use of various forms of knowledge. Increasingly, 
research programs are not simply standing on 
others’ shoulders but instead are working side-by­
side through formal or informal collaborations 
or research networks. Sometimes these structures 
have grown organically; sometimes they have 
been actively supported and encouraged by gov­
ernment. Typically, they operate above the level 
of the company or the organization but below 
the global level; they are inherently regional and 
supraorganizational. 
4. NETWORKED KNOWlEDGE 
Networked knowledge exhibits three important 
attributes. First, it comes from a nonlinear re­
search system, perhaps best illustrated by a chain-
link model of innovation.5 In essence, a chain-link 
system embeds the traditional linear development 
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PHIllIPS & RYAN 
process in a series of feedback loops. At the core, 
new technology or product development still 
goes through a relatively linear process, begin­
ning with identification of the potential market, 
and involving successive efforts to design, adapt 
and adopt a new technology or product to the 
market need. But, unlike the linear model, where 
many of these steps were taken inside a closed 
R&D system (either inside a single company or 
involving only a few, formally aligned partners), 
the chain-link now involves extensive search and 
discovery functions, with innovators often going 
out beyond their own system to seek out exist­
ing knowledge or to undertake or commission 
research to solve specific problems in the innova­
tion process. At the root, such a system depends 
on the efficacy and efficiency of the relationships 
that link the often disparate actors together. 
Second, multiple types of knowledge are in­
volved in such a system. Malecki6 identifies four 
distinct types of knowledge: “know-why,” “know­
what,” “know-how,” and “know-who.” Each type 
of knowledge has specific features.7 Know-why re­
fers to scientific knowledge of the principles and 
laws of nature. It is almost always derived from 
research efforts undertaken in publicly funded 
universities and nonprofit research institutes and 
is subsequently codified, published, and made 
accessible in academic or professional journals. 
Know-what refers to knowledge of techniques; 
usually it can be codified and transferred through 
the commercial marketplace. Know-how refers to 
the combination of skills, analytical capacity, and 
intellectual, educational, and physical dexterity of 
individuals and systems to effectively combine the 
know-why and know-what to innovate. This ca­
pacity is often learned through education and tech­
nical training and perfected by doing. This makes 
it more difficult to codify and also more difficult 
to transfer to others. Finally, know-who, which 
“involves information about who knows what and 
who knows how to do what,”8 is becoming increas­
ingly important in biotechnology-based industry. 
The breadth of knowledge that is required to in­
novate has expanded to such extent that collabo­
ration has become indispensable. In today’s con­
text, know-who also requires knowledge of—and 
access to—private-sector knowledge generators 
who, at times, may hold back the flow of crucial 
enabling information, expertise, and knowledge. 
Know-who knowledge is seldom codified; instead, 
it often accumulates within an organization or, at 
times, in communities where a cluster of public 
and private entities are all engaged in the same 
type of research and development. These clusters 
often exchange technologies, biological materials 
and resources, and pursue common staff training 
or cross-training opportunities. 
Third, each of the above-mentioned types of 
knowledge is likely to be subject to some form 
of exchange costs. Different types of knowledge 
are likely to be delivered by different actors.9 
Depending on the nature of the knowledge 
(whether it is easily codified as well as the cost 
of exchanging it), the exchange may be an arms-
length market transaction (for example, contracts 
or spot markets) or may involve nonmarket or­
ganization (for example, intracompany transfer, 
development and use in the public sector or via 
collective institutions). 
The public sector is optimally structured 
to create know-why scientific knowledge for 
the public good. Private companies and mar­
kets are generally well suited to managing 
codified knowledge, often in the form of pat­
ents. Collective organizations are often best for 
delivering knowledge, such as know-how and 
know-who.10 Different domains, moreover, fa­
vor different formal or informal IP mechanisms, 
according to organizational objectives and abili­
ties. Academics developing pure science empha­
size publication and the use of copyright, while 
actors developing technology look to patents 
and trade secrets to protect interests. Collective 
institutions use less formal, open, pooled or net­
worked knowledge, controlling access through a 
shared language, a common culture, and exten­
sive collective experience.11 
In sum, to understand networks and net­
worked knowledge, we must consider the nature 
of the knowledge being developed and used, the 
transactional forms mediating the exchanges, 
and the institutional structure of the relation­
ships that manage the development and use of IP. 
Increasingly, networks or communities of innova­
tors are locating in aggregated clusters. 
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5. CluSTER THEORy 
“Location, location, location,” the battle cry for 
property realtors everywhere, is increasingly be­
coming the key phrase in studies of innovation 
dynamics and knowledge-based growth. Theories 
about how innovation occurs, and more specifi­
cally about how and why companies and other 
actors co-locate in clusters, are incomplete but 
continue to evolve. As our understanding of in­
novation grows, so does our ability to direct its 
revolutionary power. 
Widely used both in the academic literature 
and among economic development practitioners, 
the term cluster is helpful. The Oxford English 
Dictionary defines the generic term to mean 
a “group of similar things, especially such as grow 
together.” Although companies and various not-
for-profit entities in the same sector or product 
market have been observed since the beginning 
of recorded economic history to locate themselves 
in specific geographic regions (rather than spread­
ing out evenly across the geography or economy), 
the search for ways to encourage clustering has 
only recently begun. Economists first began to 
develop models to explain such agglomerations 
in the 1700s. By the mid-1800s, economists were 
beginning to develop new theories and undertake 
intensive analyses of the phenomena. While that 
work continued on and off into the 1900s, the 
rise to dominance of the neoclassical economic 
paradigm after 1950 pushed these studies (and 
related policy prescriptions) to the margins. 
That all changed in the 1990s. Beginning in 
the early part of the decade, economists began 
to refocus their attention on the microeconomic 
foundations of growth. After a decade of stagfla­
tion, new “conservative” governments shifted to 
a low-inflation macroeconomic stance and be­
gan to look for new microeconomic options to 
accelerate productivity and economic growth. 
Michael Porter’s well-timed release in 1990 of the 
Comparative Advantage of Nations12 reintroduced 
the concept of clusters, this time in a paradigm 
that posited that local competition is the primary 
dynamic behind cluster development and sustain­
ability. This concept dovetailed with the shift in 
strategies by governments. Since then, the general 
concept of “similar things… growing together” has 
been applied widely to economic and industrial 
policy around the world. 
Cluster theory is now a fabric of many 
threads drawn from economic geography, re­
gional economic innovation systems, national 
innovation systems, and knowledge transfer and 
social networks. While there is no consensus on 
a complete theoretical explanation for clusters, a 
few threads are becoming common to most ex­
planations of the phenomena. These return to the 
basic observations by Marshall,13 who identified 
three clear and straightforward sources of exter­
nal economies (Krugman14 calls them “centripetal 
forces”) that explained the location of some indus­
try: knowledge spillovers, related and supporting 
industry, and specialized labor markets. 
Much of the literature on clusters focuses on 
the potential for external economies to develop 
from information spillovers. Beyond the basic 
economies of scale in knowledge-based industry, 
external factors can significantly influence the in­
dustry due to “mysteries being in the air.”15 The 
literature on “national systems of innovation” (ini­
tiated by Lundvall16) posits that such systems in­
volve “that set of distinct institutions which jointly 
and individually contribute to the development and 
diffusion of new technology and which provide the 
framework within which governments form and im­
plement policies to influence the innovation process. 
As such it is a system of interconnected institutions 
to create, store, and transfer the knowledge, skills, 
and artefacts which define new technologies.”17 In 
other words, innovation now involves and gener­
ates significant externalities—innovators increas­
ingly rely on an array of formal and informal col­
laborators, and the efficacy of those relationships 
will determine their ability to successfully launch 
a new innovation. Mowery and Oxley18 point out 
that these systems must include more than the 
research actors. They also require public programs 
intended to support technology adoption and 
diffusion, as well as an array of laws and regula­
tions that define IP rights and manage discovery, 
production, and marketing. 
Studies have focused mostly on the role of 
universities in innovation systems. The traditional 
role of a university is to generate and diffuse basic 
or explorative knowledge and to develop a skilled 
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PHIllIPS & RYAN 
academic and technical labor force. However, 
these traditional roles (in terms of knowledge-
generation activity and culture) are evolving. As 
Cooke19 argues, a strong local science base needs 
to be complemented by a thick entrepreneurial 
culture in both the regional business and academic 
communities. Brown and Duguid20 suggest call­
ing these connections “communities of practice.” 
Not surprisingly, measuring such connections is 
complex and difficult because such knowledge is 
often tacit and nebulous. 
A similarly large amount of research has con­
centrated on evaluating extensive local and regional 
networks of related and supporting industry (of­
ten called “backward linkages”) and their access to 
large, sophisticated markets (“forward linkages”). 
Porter21 analyzed 2,500 potential clusters around 
the world based on the strength and value of their 
arrays of forward and backward linkages. The 
Innovation Systems Research Network, a consor­
tium of scholars examining 27 clusters in Canada, 
similarly evaluated the importance of industrial 
and supply-chain relationships on competitive­
ness and innovation. While these studies have 
shown that linkages are important, the evidence is 
still out on whether the linkages are a causal factor 
or are a result of effective innovation. 
Finally, a number of researchers have at­
tempted to evaluate the role of labor market 
dynamics for growth. These studies argue that 
when local labor markets expand and special­
ize, this creates incentives both for companies 
to co-locate and for specially skilled employees 
to migrate to those locations. This reduces the 
searching and negotiating costs for operating in 
the region. In addition, these labor force dynam­
ics sustain and support the flow of knowledge 
among actors. Zucker, Darby, and Brewer,22 for 
example, looked at the role of research stars such 
as high-impact academic researchers that were 
concentrated geographically, concluding that 
agglomerations of stars are positively correlated 
with greater local innovation. Stars appear to 
provide valuable signaling functions for capital 
markets to facilitate commercialization of new 
technologies and products. 
Metcalfe23 notes that Malerba’s 1991 study 
of Italy identified two discrete, independent 
systems of innovation. One, typified by the 
computer software industry, is based on flexible 
networks of small- and medium-size companies, 
often co-located in distinct industrial districts 
(such as Silicon Valley). These companies were 
both very volatile and growing rapidly. The oth­
er type of system, which perhaps better reflects 
current biotechnology systems, is based on 
universities, public research laboratories, and 
large firms performing and commercializing 
R&D—called “the triple helix” by Etzkowitz 
and Leydesdorff.24 It has been further argued 
that, regardless of the prevailing model, no 
institution can be self-contained in its techno­
logical activities.25 All companies, large or small, 
have to rely on knowledge from other sources. 
Systems that support a company’s ability to ac­
cess, absorb, and use external knowledge can be 
critical to the growth of companies, sectors, and 
regions. This is especially so in the early stages 
of a technology’s development or when a tech­
nology has a rapidly changing knowledge base, 
as is the case with biotechnology. 
Critics argue that the term cluster is vague 
and has become mere rhetoric. Markusen26 ar­
gues that the cluster literature involves “fuzzy 
concepts” based on “scanty evidence” that produc­
es “wimpy policy.” According to the OECD, the 
definition of a cluster “provides little guidance 
for narrowing the scope of inquiry in a meaning­
ful way.”27 Similarly, according to Martin and 
Sunley,28 “[Clusters have been] accepted largely 
on faith as a valid and meaningful way of think­
ing about the national economy, as a template or 
procedure with which to decompose the economy 
into distinct industrial-geographic groups for the 
purposes of understanding and promoting com­
petitiveness and innovation.” Finally, some critics 
argue that clusters can be interpreted to imply 
rising self-sufficiency, which may work against 
the economic benefits of specialization and 
open trade based on comparative advantage. 
6. CluSTER PRACTICE 
No matter how vague the term, this has not pre­
vented its rapid adoption. Economic development 
agencies in developed and developing countries 
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have applied Porter’s generalized approach to 
clusters, customizing it to their particular geopo­
litical region. More than 1,100 clusters have been 
examined in recent years,29 but few of these have 
examined the research components of health or 
agriculture, and only three major studies have fo­
cused on clusters in the life-science area. 
Ryan and Phillips,30 for example, identified 
and categorized 14 life-science clusters in seven 
countries in 2001, concluding that life-science­
based innovation clusters vary in scope and scale 
across the regions of Australia, Europe, and 
North America (see Table 1). Some clusters are 
discrete communities in which development and 
preservation are driven by clearly defined pub­
lic policy. The communities often have names 
signifying their status as an innovation cluster 
(for example, BioBelt, BioValley, and Innovation 
Place). Ryan and Phillips discovered that most 
clusters were based on a core of biomedical re­
search. In those that claimed to have an agri­
food focus, the effort was often only a small, 
relatively insignificant adjunct to the core. There 
are very few established clusters dedicated to ag­
ricultural or agricultural biotechnology other 
than Canada’s Innovation Place in Saskatoon, 
Saskatchewan; the Agri-Food Quality Cluster in 
Guelph, Ontario; and perhaps Adelaide Centre 
in Australia. In each case, a large percentage of 
the primary and supporting (private and public) 
actors are directly involved in food quality and 
agricultural biotechnology. 
Table 1: Selected life Science Clusters
 















Connecticut Bioscience Cluster 110+ 98% 1%
 
The Research Triangle Park (RTP),

Raleigh-Durham and Chapel Hill, North 145 92% 3%
United 
Carolina States 
BioBelt, St. Louis, Missouri and Illinois 1,183 90%+ 24% 
Biotech Beach, San Diego, California 700 90%+ 3% 
Innovation Triangle, Edinburgh, Dundee 
428 95% 2%
and Glasgow, Scotland 
Europe 




Qbio, Brisbane, Queensland 43 42% 5%
 
BioHub, Sydney, New South Wales 28 75% 18%
 
Australia Bio21, Melbourne, Victoria 24 0% 4% 
Adelaide, South Australia 25+ 65% 44% 
80– 
Perth, Western Australia 27 20%
90% 
Source: Adapted from Ryan and Phillips.31 
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PHIllIPS & RYAN 
Cluster models appear to be very different.32 
The United States focuses on commercial out­
comes and investment attraction, placing key 
multinational companies (some might call them 
national champions) at the center of their re­
gional clusters. In Europe, the public sector (uni­
versities and large research institutes) is the main 
driver. Canada’s key clusters tend to be commu­
nity led, while Australia appears to use a blend of 
cluster approaches. Phillips and colleagues33 ex­
amined the seven Canadian biotechnology-based 
clusters studied through the Innovation Systems 
Research Network.34 These seven communities 
represent a wide range of size, scope, foci and 
histories (table 2).35 
Consisting of both large pharmaceutical and 
small biotechnology companies, the Montreal 
cluster is the largest biotechnology cluster in 
Canada. It benefits significantly from provincial-
government programs and national research labs. 
Recent surveys identified 351 actors: 130 in hu­
man health, 26 in human nutrition, 12 in agri­
cultural biotechnology; and seven environmental 
companies; 171 service and supporting enter­
prises; one government lab; and four related uni­
versities. As of 2002, 29 companies in Montreal 
had patented 234 locally invented technologies, 
but 89% of the patents were owned by the eight 
largest companies. Growth in the region since 
1999—when only 14 companies had 66 patents 
in total—has been explosive. 
The Toronto cluster is a two-part cluster: one 
part is dedicated to core biotechnology activities 
and the other to biomedical devices. Anchored 
by the Medical and Related Sciences (MaRS) 
Discovery District, the University of Toronto (U of 
T), and the Health Network have also been identi­
fied as primary knowledge generators. A concen­
tration of companies is situated downtown while 
some skilled workers are concentrated in peripheral 
regions. It appears that once firms or organizations 
move from exploration to exploitation activities, 
they move to the neighboring cities of Etobicoke 
or Mississauga to take advantage of lower costs. 
This contributes to weak network coherence, al­
though Mississauga appears to be more cohesive. 
While the U of T has a significant number of stars, 
it has historically been considered unsuccessful in 
facilitating spinouts. This has been variously cited 
as the reason for limited local expertise in biotech­
nology financing. 
It is not yet clear whether London, Ontario 
has a distinct biotechnology cluster or whether 
the activity there is merely an extension of the 
Toronto cluster. With an established biomedi­
cal-devices competency that started in the 1970s, 
London would appear to be an early-stage, emerg­
ing biotechnology cluster focused on biopharma­
ceutical applications. Linkages among local actors 
appear to be weak, with most acknowledging that 
they are more connected to actors in the Toronto 
core than they are to one another. 
The Vancouver cluster, which focuses largely 
on biomedical biotechnology, is essentially a re­
search community with the University of British 
Columbia (UBC) at the core. UBC and, to a 
much lesser extent, Simon Fraser University, are 
home to almost 80 research stars who produce 
a wide array of IP. While there have been some 
spinouts from UBC, more than two-thirds of 
which have survived at least five years, the prime 
focus of the cluster is on developing IP rather 
than products. Government and industrial sup­
port has not fundamentally altered the cluster. 
Early research suggests that lifestyle may be one 
of the critical factors that sustains the university 
and attracts both companies and individuals to 
the region. 
The Saskatoon cluster is almost purely an 
agricultural-biotechnology cluster, focused pre­
dominantly on oilseed crops. While the univer­
sity is home to the largest number of researchers 
in the community, many of the stars and much 
of the IP that is developed and used have come 
from federal labs. NRC’s Plant Biotechnology 
Institute (NRC/PBI), the focus of considerable 
research collaboration, appears to share leadership 
with the local industry association, AgWest Bio. 
While the cluster is research focused, it has suc­
ceeded in commercialising world-first genetically 
modified plants, vaccines, and inoculants. Recent 
public investment in the university—including 
the Canadian Light Source Inc. (CLSI) synchro­
tron project and various genomics projects—has 
the potential to change the direction of the cluster 
over the coming years. 
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Table 2: Comparison of Canadian Biotechnology-Based Clusters
 
Cluster Focus Core actor(s) Stars Preliminary observations 
Montreal Pharmaceutical A handful of generic 70 • provincial government
and biotechnology and multinational- leads in terms of 
enterprise patent progressive policies
drug companies • 15 spinouts University 
of Montreal 
Toronto Biotechnology Medical and Related 47 • concentrated in 
and biomedical Sciences (MaRS) Toronto at exploration 
Centre; University stage; moved to 
of Toronto; and the peripheral regions 
Health Network (Etobicoke) at
exploitation stage
• limited network 
coherence 
London Biotechnology / University of 5 • early-stage 
biomedical devices Western Ontario; biotechnology cluster
(established in Robart’s Research • cluster or merely TO 
1970s) Institute; and Lawson ‘cohort’? 
Health Research • transportation 
Institute considered a weakness 
Vancouver Biotechnology University of British 80 • producer of IP, not
Columbia products 
Saskatoon Agricultural National Research 45 • research based 
biotechnology Council-Plant • new investments in 
Biotechnology genomics, Canadian 
Institute; AgWest Bio Light Source Inc.,
and University of 
Saskatoon may 
change direction 
Ottawa Biomedical and Gamma Dynacare 6 • more than 40 research 
biotechnology (Ottawa Life Sciences institutes 
Technology Park) • 18,000 people
employed in life 
sciences 
• 15–20 spinouts 
Halifax Pharmaceuticals, none min. • a variety of 
health, companies, with little 
nutraceuticals, product focus
information • not clearly a cluster
technology, and • weak networks 
biomedical 
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PHIllIPS & RYAN 
The evidence available to date suggests that, 
based on the traditional definition of the con­
cept, neither Ottawa nor Halifax are clusters. 
While Ottawa appears to have a large number of 
research institutes, its identifiable biotechnology 
cluster is quite small. As of 2002, there were only 
47 actors: 30 small biotech companies, six gov­
ernment labs, one connected university, and ten 
service/support organizations. Only two of the 
Ottawa-based companies had generated patents 
by 2002, and the University of Ottawa had only 
a few stars and limited success with patents (11 as 
of 2002). Meanwhile, Halifax hosts a variety of 
companies with little or no market focus. Actors 
are not focused on any specific technology or 
product application. Instead, some actors are in 
the heath sector (devices, pharmaceuticals, infor­
mation technology, and neutraceuticals), while 
others work on horticulture, environmental ap­
plications, and food quality. There is currently no 
obvious anchor organization, and actors in the 
region are loosely connected. In contrast to most 
other clusters, this one has seen little investment 
in infrastructure in the past few decades. Local 
surveys suggest that there has been little or no 
success in facilitating technology transfer, which 
has led to limited engagement between business 
and academic scientists. 
This review of Canada’s clusters offers a num­
ber of insights into cluster practice. Although bio­
technology-based industries have common, “deep­
er science” aspects, they appear to differ widely in 
terms of organization. The significant differences 
in size (Montreal versus Saskatoon), market focus 
(core biotech in Vancouver versus medical devices 
in Toronto), and cohesion (strong in Saskatoon 
and Montreal but weak in other centers) suggest 
that the way in which the cluster is organized—its 
position in a product or technology life cycle and 
how its actors interact—can vary widely. 
Phillips36 examined the dynamics of the 
Saskatoon-based ag-biotechnology cluster by fo­
cusing on knowledge flows. Wolfe and Gertler37 
suggest that a more-sophisticated approach to 
clusters is to consider them as regional systems 
of innovation that embody local interdependen­
cies (what Wolfe and Gertler call “local buzz”) 
and engagement with the broader international 
economy (“global reach”). A local buzz and glob­
al reach, or entrepôt, approach would highlight 
the balance needed between local, regional, na­
tional, and global capacities. Phillips38 analyzed 
the stocks, flows, and accomplishments of the 
Saskatoon innovation system through the mech­
anism of an entrepôt model. It looked at the 
community’s capacity to create knowledge, use 
knowledge, and commercialize new products. 
Saskatoon’s claim to fame is arguably the devel­
opment of canola (based on its record as the lead 
innovator and early adopter of all new traits over 
the past 40 years). Analysis showed, however, 
that a significant share of the applied research 
to develop the processes used in the creation of 
those varieties has been done in other countries. 
Moreover, much of the application-based re­
search (for example, uses for new oils) is happen­
ing elsewhere. This suggests that Saskatoon has 
actually operated in a niche of this global, knowl­
edge-based industry—as an entrepôt undertak­
ing and assembling the know-why, know-how, 
and know-who of varietal breeding and primary 
production—but that the bulk of the activities 
up- and downstream of that stage in the produc­
tion system are now, and may continue to be, 
carried on elsewhere. Figure 1 illustrates the re­
lationships between the global industry and the 
Saskatoon entrepôt.39 
7. CluSTERS AND IP MANAGEMENT 
Research is increasingly generating networked 
knowledge. This new asset potentially has new 
economic and commercial value, but it faces a 
new set of complex relationships and transaction 
costs. Recent research into cluster structures in 
the Saskatoon-based agricultural-biotechnology 
cluster suggests that one driver for agglomera­
tion may be the development of a cost-effec­
tive, efficacious system of IP management. This 
community has been host to a number of highly 
competitive multinational companies, has pat­
ented many critical life-science inventions, and 
has delivered a number of world-first technolo­
gies to the marketplace. Its experiences offer 
some insights into another possible objective of 
clusters. 
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In a perfect world with full information 
and no transaction costs, complete contracts to 
finance and undertake common research would 
be optimal. However, we know that transac­
tion costs (especially with highly fragmented IP 
rights) are nontrivial, and that the probability of 
having a commercial success in any given project 
is relatively low (usually, less than 10% of proj­
ects return the costs of investment). Hence, as 
transaction costs rise, full contracts become less 
likely. Furthermore, it tends to be difficult to 
measure the often-tacit inputs to research pro­
grams. Attributing respective contributions to 
success in the discovery process is also tricky. In 
addition, any resulting outputs often have very 
specific uses, which makes them hostage to their 
potential users. These factors can lead to a classic 
case of “hold up,” whereby investors may not be 
willing to invest because their bargaining power 
after any research breakthrough would be very 
Figure 1: The Saskatoon Biotechnology Entrepôt 
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PHIllIPS & RYAN 
low.40 While long-term contracts would be one 
way to resolve this conundrum, few contracts 
will be negotiated for one-time projects. An al­
ternate solution is to use social capital (for ex­
ample, norms and relationships) in a community 
or cluster. In essence, by using the cluster as the 
basis for a research relationship, the difficulties of 
negotiating one-time deals can be overcome: the 
research community operates as if it is engaged in 
repeated exchanges. Participants in a cluster thus 
often will not negotiate each deal as if it were 
a one-time event. Rather, they would be willing 
to leave some terms and conditions unspeci­
fied, on the (usually justified) assumption that 
the strength of overall community relationships 
would reduce the probability that any company 
or actor would act with guile. 
The Saskatoon-based agri-food research clus­
ter gives a sense of how clusters or regional systems 
of innovation can lower transactional costs.41 This 
community is credited with a series of world-mar­
ketfirsts (for example, agrobacteriumtechnologies) 
and product firsts (for example, herbicide-tolerant 
canola and flax). It took the lead in the develop­
ment of the concept for a National Agricultural 
Genome Centre (which, although unsuccessful 
in reaching that particular goal, ended up pro­
viding a model for Genome Canada) and leads 
four major genomics agri-food projects. Most of 
these initiatives were developed without formal 
ex ante contracts; instead, leaders in the commu­
nity developed the projects under the assumption 
that any gains and losses would be apportioned 
equitably, or at least that any short-term losses 
would be compensated by future joint projects. 
This apparent altruism is nothing more than an 
extension of the community’s business model, as 
Phillips and Khachatourians42 and Phillips43 show 
in their examinations of how Saskatoon became a 
national center for the generation, transmission, 
and consolidation of noncodified knowledge in 
the agricultural biotechnology industry. At the 
core of this community are Agriculture and Agri­
food Canada and the National Research Council. 
Both have extensive arrangements with each 
other, public universities, and private companies, 
which allow them to learn from their collabora­
tions, thereby adding further to the local stock 
of know-how knowledge and providing a vis­
ible, efficient point of entry for nonresidents to 
access know-how and know-who capacity. The 
public institutes also provide a home base for 
research stars, which, according to Zucker and 
colleagues,44 reduces the search costs for other 
researchers and subsequent commercialization. 
The largest single geographic concentration of 
stars and near-stars in the canola research world 
is located in Saskatoon, where 11 out of 69, 
or 16%, of the top scientists live and work.45 
Phillips and Khachatourians46 report that mul­
tinational enterprises (MNEs) and smaller com­
panies in Saskatoon were primarily attracted by 
the presence of key personnel in collaborating 
and competing organizations. Although the 
public and private institutions have changed in 
recent years, the social capital built up appears 
to continue to sustain collaborative activities. 
8. lESSONS FOR DEVElOPMENT
AND IP MANAGEMENT 
Knowledge-based development is inherently dif­
ferent from traditional industrial development. 
While a traditional industrial strategy that pro­
moted infant industry via protection made some 
sense in the industrial world, it is not clear wheth­
er it has any value in a knowledge-based world. 
This emerging global pipelines/local buzz 
cluster model of innovation poses some serious 
challenges for development policy. Much of the 
current biotechnology-development effort has 
a strong mercantilist orientation that focuses 
on self-sufficiency. Governments at all levels in 
many countries are actively using their tax and 
fiscal policy to encourage more local R&D and 
to attract global companies to relocate their 
R&D programs so that higher-value exports can 
be generated and imports replaced. This often 
involves preferential support for national cham­
pions or exclusive deals to encourage MNEs to 
relocate their activities. Usually governments do 
this without considering the corresponding rela­
tionships and interactions that knowledge-based 
companies require to succeed. If innovation can 
be thought of as limited to within a company or 
within a regional or national community, then 
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CHAPTER .11 
such a narrow approach might have some chance 
of succeeding. But the increasing complexity and 
fragmentation of knowledge and IP rights in 
the biotechnology sector suggests there likely is 
no single center that can effectively develop new 
biotechnologies or applications. Networking and 
partnerships are going to be the order of the day. 
And, if innovation is truly global, as appears to be 
the case in many of the life sciences, then narrow, 
mechanistic, self-sufficiency strategies may either 
simply fail or prove counterproductive. 
One key to success in these circumstances 
will be to invest in the institutions and mecha­
nisms that encourage the development of and 
access to the four knowledge factors (know why, 
know what, know how and know who), which 
provide the foundation of a research economy. 
A number of strategic options might be appro­
priate. First, effective mechanisms to protect and 
legally transfer IP across international boundar­
ies are the price of admission to collaborations. 
Second, clusters that are open to new knowledge, 
IP, and highly qualified personnel and compa­
nies will likely be more successful in creating and 
commercializing new biotechnologies or related 
products. Third, simply declaring that a region 
is a cluster is not enough. There must be some 
regional investment in infrastructure, as well as 
openness and/or support for the emergence of 
one or more anchor institutions. While private 
companies may have the greatest drive for com­
mercial development, governments often have 
only limited direct influence on their location 
and operation. Governments can strengthen 
their hand by considering how their universities 
or public research labs can be used to anchor the 
community. Ultimately, the goal should be to 
create some platform to generate mysteries in the 
air. Whatever forms this platform takes, it will 
need to generate both local buzz and tap into 
global pipelines. 
In short, innovation clusters are very attrac­
tive economic development and IP management 
tools, but they must be nurtured with an appreci­
ation for their partial and incomplete nature. Part 
of a global innovation system, they cannot thrive 
if cut off from the lifeblood of that system—ideas, 
skilled labor, and collaborative platforms. n 
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CHAPTER 3.12 
What Does It Take to Build a Local Biotechnology

Cluster in a Small Country? The Case of Turku, Finland
 
kIMMO VILJAMAA, Research Affiliate, University of Tampere, and Consultant, Advansis Ltd., Finland 
ABSTRACT 
There seem to be new biotechnology initiatives spring­
ing up in almost every country and every region, no mat­
ter how big or small. This is the case for both developed 
countries and many developing countries. At the same 
time, many studies seem to suggest that the industrial dy­
namics of the biotechnology sector strongly favor only a 
few globally important locations. These are characterized 
by well-established relations between small R&D compa­
nies and the presence of venture capitalists, big multina­
tional corporations, and service providers. The tendency 
of biotechnology clusters to form in certain locations 
raises some questions. Can all these new initiatives be 
successful? Can biotechnology research clusters develop 
and prosper on a smaller scale? The aim of this chapter 
is to discuss ideas for building successful biotechnology 
clusters in less-developed places. Using the example of 
Turku, Finland, the chapter analyzes how public policy 
and local activity can “fill the gaps” in the innovation 
system, thereby facilitating the emergence of a biotech­
nology industry. Although this case study is from a de­
veloped country, many developing countries face similar 
challenges to those Turku has faced. 
1. INTRODuCTION 
The economic literature of the past decade has of­
ten argued that innovation is the most important 
source of competitiveness, especially for high-
tech industries working within global markets. At 
the same time, it is widely known that particular 
industries tend to cluster in certain areas and that 
the clustering of knowledge is an important rea­
son for this phenomenon. 
Biotechnology, one of the most prominent 
new industrial sectors, is typically a very spatially 
clustered industry. Biotechnology companies are 
often located close to major universities, hospi­
tals, and research centers, and are sometimes as­
sociated with supportive bigger companies inter­
acting with small- to medium-sized enterprises. 
Moreover, the biotechnology sector usually makes 
extensive use of external services in R&D—test­
ing, financing, and marketing—which also tend 
to be located close by. 
Biotechnology activities also tend to con­
centrate strongly in specific areas of the globe. 
A few local concentrations (such as Cambridge, 
Massachusetts, and San Francisco/San Jose, 
California, both in the U.S.A.) are globally domi­
nant.1 In the past, biotechnology has been very 
much dominated by the United States and, to a 
lesser extent, by the United Kingdom.2 But the 
past decade has seen a huge increase in biotech-
nology-related development in many other places. 
Countries, regions, and cities all over the world 
have realized that biotechnology is the next big 
thing following the success of information and 
communication technologies (ICT). 
Previous studies have shown that the indus­
trial dynamics of the biotechnology sector, espe­
cially in biopharmaceuticals, strongly favor only a 
few globally important clusters characterized by 
well-established relations between small R&D 
Viljamaa K. 2007. What Does It Take to Build a Local Biotechnology Cluster in a Small Country? The Case of Turku, Finland.
In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger,
RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. K Viljamaa. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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companies, venture capitalists, big multination­
al corporations, and service providers. It would 
seem to be at least difficult, and perhaps entirely 
impossible, to develop an industry when some or 
most of these factors are missing. Nevertheless, 
the biotechnology industry is growing in many 
places that may at first seem unfavorable: in de­
veloped countries like Finland, but also in many 
developing countries such as India, China, Brazil, 
and South Africa.3 
This chapter analyzes how public policy and 
local activity can “fill the gaps” in the innovation 
system so that it is possible for a biotechnology 
industry to emerge and grow in seemingly unfa­
vorable places. The basic questions I will answer 
are: What policies and institutions best support 
the knowledge generation and dissemination 
processes of high-tech industries in smaller, more 
peripheral, or less developed regions? In other 
words, what are alternative ways of developing 
a favorable environment for the emergence and 
development of a local biotechnology concentra­
tion? What sorts of relationships between local 
actors encourage the development process? 
My argument is that it is possible, at least 
to some extent, to compensate for vital resourc­
es that may be missing in small economies and 
clusters. However, there seem to be several basic 
conditions for success. First, there has to be a sub­
stantial local knowledge base (often a university). 
Second, the national or regional innovation sys­
tem must compensate for any missing resources 
(public venture capital, R&D funding, services, 
and so on). Third, a network of capable local ac­
tors (public or private) must develop and strategi­
cally direct a local innovation system. 
To support the argument that it is possible to 
compensate for missing vital resources, the chap­
ter analyzes the recent development of the bio­
technology industry in Turku, Finland. The de­
velopment of the biotechnology sector in Finland 
during the past fifteen years has been largely due 
to active national innovation policies. In terms of 
numbers of biotech firms, Finland ranks tenth in 
Europe.4 The biotechnology industry in Turku has 
grown thanks to local activity, and Turku itself is 
home to the second-largest concentration of bio­
technology-related activities in Finland. 
The recent rise of biotechnology in Turku is 
largely due to the fact that it has drawn on de­
cades-old capabilities across a variety of sectors in 
food processing, pharmaceuticals, and materials 
sciences. Furthermore, local development activi­
ties and a national science and technology inno­
vation program have encouraged development. 
It remains to be seen whether or not biotech­
nology will continue to prosper inTurku. However, 
this study finds that active policy measures can al­
low smaller, more peripheral places to attract the 
interest of biotechnology entrepreneurs. 
2. THE BIOTECHNOlOGy INDuSTRy 
In this chapter, “biotechnology” refers to a broad 
range of life sciences (biosciences) and their uti­
lization in medicine, primary production,5 in­
dustry, and services. Biotechnology is a set of 
powerful tools that employs living organisms 
(or parts of organisms) to make or modify prod­
ucts, improve plants or animals, or develop mi­
croorganisms for specific uses. The Organisation 
for Economic Co-operation and Development 
(OECD) defines biotechnology as “the applica­
tion of science and technology to living organisms as 
well as parts, products, and models thereof, to alter 
living or nonliving materials for the production of 
knowledge, goods and services.” 
The development of biotechnology can be 
divided into three phases. Early first-phase bio­
technology includes traditional animal and plant 
breeding techniques, as well as the use of yeast in 
making bread, beer, wine, and cheese. The second 
phase started in the 1940s when biotechnology 
was introduced into modern industry. Modern, 
or third-phase, biotechnology includes the indus­
trial use of recombinant DNA, cell fusion, novel 
bioprocessing techniques, and bioremediation. 
This phase started in the 1970s, when new tools 
for modifying the genetic structure of living or­
ganisms were introduced.6 
Interestingly, new advances in the biosciences 
have blurred the boundaries between historically 
separate disciplines. Biology has begun to overlap 
with other fields, such as medicine, chemistry, 
informatics, and physics, thereby increasing the 
need for interdisciplinary research and bringing 
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different industries closer to each other. Many 
new technologies developed for molecular biology 
research, such as high-throughput DNA sequenc­
ing, protein structure determination, and gene ex­
pression analysis on “DNA chips,” are also used in 
ecology, agriculture, forestry, and the biotechnol­
ogy and pharmaceutical industries.7 
The nature of an industry greatly influ­
ences how it develops in any given location. 
Biotechnology is very demanding in terms of 
R&D. Bioscientific research is also time-consum­
ing and requires methods and instrumentation 
that are rapidly evolving and expensive.8 Because 
the cost of R&D is so high, funding becomes es­
pecially crucial for both universities and industry. 
Furthermore, many biotechnology innovations 
are based on basic research, which means that the 
time from innovation to market is very long. 
Cooke9 has observed that the focus of knowl­
edge creation has changed. In the past, the world 
of pharmaceutical R&D was dominated by large 
multinational companies (MNCs). However, 
there is growing evidence that university or public 
laboratory research with associated spinouts and 
dedicated biotechnology firms (DBFs) are now 
responsible for most knowledge generation and 
exploitation, while global MNCs are specializing 
in distribution and marketing. The combination 
of two factors—spatially highly concentrated 
R&D and global marketing and distribution 
strategies—means that the innovation system in 
biotechnology has become both highly regional­
ized and highly globalized. The tendency of bio­
technology activities to congregate means that 
local clusters of biotechnology activities are an 
important unit of analysis. 
3. ON INDuSTRy CluSTERING
AND KNOWlEDGE 
This chapter focuses on local concentrations of 
biotechnology-related activities. The first stud­
ies on the economics of territorial agglomeration 
were in the nineteenth and early twentieth centu­
ries: the works of Marshall.10,11,12 Traditional anal­
ysis of spatial clustering tries to analyze the advan­
tages that firms get by locating near to each other 
(localization economies). According to Malmberg 
and Maskell13 there are at least three factors that 
traditionally encourage spatial clustering: 
1. Reduced costs of producing and maintain­
ing a dedicated infrastructure and other 
collective resources 
2. Well-functioning 	 markets for specialized 
skills 
3. Reduced interaction costs for co-located 
trading partners 
In the last few decades, researchers have tried 
to explain the relationship between the spa­
tial clustering of firms and the innovation 
process. Several different approaches have 
been developed, including innovative mi­
lieu, new industrial spaces, spatial clusters 
of innovation, regional innovation systems, 
and learning regions.14 The topic has be­
come more relevant in recent years because 
technological change and globalization have 
led to intrinsic economic changes. 
Globalized markets, increased competition, 
and the development of information and 
communications technologies have forced 
companies to find new ways of increas­
ing their competitiveness. Furthermore, 
new scientific developments are occurring 
all the time. This combination of external 
pressures and opportunities makes for a 
very turbulent corporate environment.15 
Companies respond to these pressures in 
two ways: by specializing and by innovat­
ing. They outsource in areas where they 
are weak and try to maximize the profits 
of their core competencies through innova­
tion. Both of these strategies tend to create 
local as well as global connections. Many 
services and external functions have to op­
erate locally. This is typically because of the 
economics of scale that local clustering of 
associated actors brings; economies of time 
and smaller transaction costs are generated 
by trust and easy face-to-face interaction. 
Firms can increase their competitiveness 
by sharing an infrastructure and by shar­
ing supplier and service networks. In or­
der to facilitate knowledge generation and 
transfer, companies locate themselves near 
knowledge sources and each other so they 
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can make better use of local knowledge 
spillovers16 and informal types of social in­
teraction that form the basis for innovation 
and learning. 
The fact that knowledge, learning, and in­
novation are important if an industry is to 
retain its competitiveness suggests a fourth 
advantage to spatial clustering: 
4. Facilitation of knowledge spillovers, learn­
ing, and adaptation 
Local industrial structure with many firms 
competing in the same industry or collabo­
rating across related industries tends to be 
dynamic, flexible, and innovative; the ex­
istence of a local culture facilitates knowl­
edge transfer. The co-location of firms cuts 
the expenses of identifying, accessing, and 
transferring knowledge.17 There are several 
reasons why innovation capability is related 
to spatial clustering: 
•	 new knowledge. Usually difficult to 
codify and therefore difficult to trans­
fer. New knowledge is best transferred 
through repeated and frequent face-to­
face contacts. Innovation is therefore fa­
cilitated by geographical proximity. 
•	 knowledge exchange. Can happen 
through knowledge spillovers. On the 
other hand, most actors are unwilling to 
share crucial information when there is a 
danger that it could end up in the hands 
of competitors. Knowledge exchange 
may happen as a result of long-term co­
operation with universities and research 
institutions. 
•	 the availability of a high-level work­
force. A very important requirement for 
innovation. The mobility of labor, espe­
cially in Europe, is lower than the mobil­
ity of other resources, and so labor tends 
to concentrate in certain regions. 
All these knowledge-related factors are im­
portant because biotechnology typically has a 
much greater need for basic research and a highly 
educated workforce than does any other industry. 
It also tends to collaborate more with universities 
than do most other industries.18 
This chapter also investigates the process of 
cluster formation and the conditions that enable 
a local biotechnology cluster to emerge and grow. 
Much of the conventional wisdom regarding suc­
cessful industry clusters is based on studies of fully 
functioning innovation systems such as Silicon 
Valley.19 However, the conditions under which 
mature clusters operate are not, in many cases, 
present at the creation of new clusters. The history 
of each cluster is unique, suggesting that cluster de­
velopment is either path-dependent or heavily in­
fluenced by chance historical events.20 The current 
economic strengths of a particular region are often 
based on developments and activities that took 
place over the course of several decades. Examples 
of this phenomenon are the Research Triangle 
Park in North Carolina, U.S.A.,21 Silicon Valley, 
U.S.A.,22 and Oulu and Tampere, in Finland.23 
New clusters often develop thanks to pre-ex­
isting local expertise in related fields. Many places 
with ICT centers were founded in areas that al­
ready had expertise in electronics (for example, 
in Silicon Valley and Oulu). Therefore, it is im­
portant to understand both regional assets and 
the cluster formation process in order to develop 
policies that will support emerging clusters. 
Feldman and Francis24 have concluded that 
cluster formation appears to be characterized by 
three general stages.25,26 In the initial stage, there 
are typically few, if any, spinout companies, but 
there are some needed assets such as large com­
panies and universities. An exogenous shock that 
lowers the opportunity cost for entrepreneurship 
(such as a merger and acquisition or a change in 
the funding environment) tends to encourage ac­
tive entrepreneurship and the subsequent appear­
ance of new spinout companies. 
The second stage is typically characterized by in­
creased interaction between entrepreneurs and their 
environment.27 In this stage, the cluster self-orga­
nizes in order to better serve its own needs. Various 
institutions may be created to support the cluster, 
and these institutions may, in turn, stimulate further 
innovation and promote localized learning.28 
In the final stage, the success of the first 
spinouts and the synergy between them gener­
ate new possibilities for other firms in the same 
field. At the same time, an enhanced innovation
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CHAPTER .12 
environment develops around the cluster (con­
sisting of universities, technology centers, local 
policy-makers, service providers, and so on). At 
this final stage of cluster formation, a critical mass 
of resources provides locational advantages. 
4. INNOVATION AND INDuSTRy 
STRuCTuRE IN BIOTECHNOlOGy 
The geographical concentration of biotechnology 
is also the concentration of knowledge. Universities 
and R&D institutions are local concentrations of 
knowledge and expertise, and they can poten­
tially provide a workforce for local firms. Many 
knowledge spillovers are local, either because they 
are based on tacit knowledge or because people 
are usually well informed about developments in­
side their own local knowledge base. For example, 
Jaffe and colleagues29 show that most knowledge 
was used within a 50-mile radius of the university 
from which it originated. Also, the successful de­
velopment of biotechnology, especially in the early 
phases, seems to require a considerable amount of 
tacit knowledge, which itself often relies on short-
distance or face-to-face interaction.30 
The local existence of high-level knowledge 
and research seems to have more of an effect on 
the development of biotechnology clusters than 
do local knowledge spillovers. According to 
Cooke and colleagues,31 the biosciences do not 
typically make wide use of informal local tacit 
knowledge and face-to-face exchanges, informal 
networks, or other indirect region-specific assets 
that are often referred to as untraded interdepen­
dencies.32 Because biotechnology techniques are 
so specific and specialized, there is typically not 
much knowledge transfer through social ties or 
networking between firms. In the early phases of 
the creation of biotechnology clusters, localiza­
tion effects seem to be due to the so-called star 
scientists who are invaluable to R&D and tend to 
locate near their home universities.33 
Another factor in the creation of biotechnol­
ogy research clusters is the increasingly multidis­
ciplinary nature of biotechnology R&D. In many 
cases, development work requires a heterogeneous 
set of cognitive skills and, therefore, a need for 
transdisciplinary network relationships that are 
most easily found within a larger concentration 
of related activities.34 
What Cooke and colleagues call “exploi­
tation knowledge”—that is, the knowledge of 
how to use basic research for practical applica­
tions—is found in clusters for several reasons. As 
small DBFs rely on research scientists to translate 
noncodified knowledge so that it can be further 
developed into commercial products or services, 
people with experience in both research and in­
dustry tend to be magnets for new companies. 
In many cases, special services also play an 
important role. Business services and specialized 
expert services tend to locate close to key custom­
ers and thereby make these locations more attrac­
tive to new companies. I suggest that even if R&D 
companies trade very little knowledge with each 
other, they interact quite a bit with companies in 
fields like business expertise and services. 
Biotechnology companies tend to be located 
close to major universities, hospitals, research cen­
ters, and sometimes supportive larger companies 
that interact with small- to medium-sized enter­
prises. At least initially, most new ideas and spin-
outs seem to originate from universities. However, 
Feldman argues that even though universities 
seem to be necessary for the development of bio­
tech research clusters, the mere existence of a large 
knowledge base is not always enough.35 Orsenigo 
argues that the existence of a strong scientific base 
does not guarantee that new companies will start 
up or that an industry will emerge.36 There is also 
no firm correlation between the number of spin-
outs and either university financing or the num­
ber of patents applied for.37 
As a biotechnology research cluster develops 
from the “science stage” to commercial application, 
the cluster may become dependent on a few bigger 
anchor firms. Larger companies can act as pools 
of skilled labor and demand special inputs such 
as specific products and services that may benefit 
smaller spinouts.38 Large established companies 
can also act as sources for new entrepreneurial ac­
tivity in the form of spinouts or outsourcing. 
The mechanisms of co-location and spatial 
clustering seem to be especially strong in the 
biotechnology industry. However, the pres­
ence of favorable conditions (for example, a 
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VIlJAMAA 
strong science base and a working labor mar­
ket) is insufficient to explain why an industry 
develops in a particular region. Favorable condi­
tions in a particular locale may encourage the 
establishment of an industry, but its growth is 
determined by other factors: its structure, tech­
nological change, economic factors, and changes 
in the institutional base and local development 
policies. 
.1  Typical characteristics of successful 
biotechnology clusters 
Many studies and strategy papers have analyzed 
the factors that are needed for the biotechnology 
sector to prosper, and most of them have come 
to similar conclusions. They emphasize the role 
of a strong science base, a skilled workforce, sup­
portive infrastructure, and the availability of ser­
vices and financing. A British study39 identified 
the following factors for successful biotechnology 
clusters: 
•	 a strong science base 
•	 an entrepreneurial culture 
•	 a growing company base 
•	 the ability to attract key staff 
•	 the availability of financing 
•	 appropriate premises and R&D infra­
structure 
•	 the close proximity of business support 
services and large companies in related 
industries 
•	 a skilled workforce 
•	 effective networks (for example, associa­
tions and cluster councils) 
•	 supportive (national, regional and local) 
government policies 
Although many industries benefit from the 
factors listed above, they apply especially well 
to biotechnology. Biotechnology is a science-
driven business,40 which means that clustering 
often occurs in close proximity to key knowl­
edge centers, usually universities or public re­
search institutes conducting top-level research. 
Because this knowledge is very often tacit and 
tied to individual researchers or research groups, 
effective utilization requires close interaction 
between actors and multilevel partnerships. 
According to Cooke,41 because research 
tends to concentrate near the key magnets (that 
is, universities or public research institutes), it 
favors the development of a localized “biosci­
ences knowledge value chain.” (Agglomerations 
that are more than mere clusters of commercial 
firms with some links to local knowledge centers 
are called “megacenters,” which seem to be few 
and far between.) At the same time, the global 
“biotech boom” means that many countries and 
regions are investing in biotechnology. This leaves 
us with some questions: How successful can these 
initiatives be? Is it possible for smaller and more 
peripheral biotechnology clusters to survive? 
The development of a smaller biotechnology 
research cluster in Turku, Finland, offers some an­
swers to these questions. The primary data consist 
of detailed, interviews and analyses of industry sta­
tistics; the policy documents of national, regional, 
and city governments; and previous studies of the 
development of industrial activities in Turku, es­
pecially those conducted between the mid-1980s 
and 2004. Over a six-month period in 2002, 36 
detailed semistructured interviews were conducted 
with academics (scientists), policy-makers at vari­
ous levels, CEOs or R&D heads of companies, 
city officials, and actors in intermediary organi­
zations, such as economic development agencies 
and hybrid organizations for sectoral growth. 
5.	 THE CASE OF TuRKu: DEVElOPMENT OF
A SMAll BIOTECHNOlOGy CluSTER 
Turku is home to the second largest concentra­
tion (after Helsinki) of biotechnology activities in 
Finland.42 Other regions with dedicated centers for 
biotechnology development are Oulu, Tampere, 
and Kuopio. There are also many Finnish universi­
ties engaged in biotechnology-related research and 
education. The period 1996–2000 saw the sharpest 
rise to date in the number of new biotech firms in 
Finland. Turku underwent a similar growth spurt, 
with most new biotechnology companies emerg­
ing during the 1990s.43 Biotechnology companies 
that were started in the period 1998–2000 can be 
broadly categorized as biomedicine (37%), diag­
nostics (31%), biomaterials (13%), and “other” 
(19%).44,45 However, during the past few years,
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CHAPTER .12 
industry growth has almost stopped, and the num­
ber of companies has remained relatively constant. 
The Turku region is especially strong in bio­
pharmaceuticals, but its firms are also involved in 
diagnostics, biomaterials, and functional foods. 
In March 2006, there were approximately 80 
biotechnology-related companies in Turku, em­
ploying approximately 3,000 people. Two large 
pharmaceutical companies, Schering and Orion, 
conduct R&D in Turku, as do a number of smaller 
drug discovery companies, such as Tie Therapies, 
Hormos Medical (a subsidiary of QuatRx), and 
Juvantia Pharma Ltd. These firms, along with the 
universities and service companies, form a rela­
tively tight drug-development network. 
Although the growth of biotechnology in 
Turku has been very rapid, the roots of the in­
dustry are much older. The first drug companies 
(Leiras [a Nycomed Co.] and Farmos Ltd.) were 
established in the 1940s, as was Wallac Inc. (now 
part of the PerkinElmer group). These mid-sized 
companies cooperated with the universities when 
such cooperation was not common practice in 
Finland. A good example of this is the diagnostic 
company Wallac, which already cooperated with 
universities in the 1960s. Interactions with uni­
versity researchers were institutionalized in many 
ways, and this culture seems to have diffused to 
other companies.46 At the time Wallac also need­
ed a steady supply of professional employees, and 
the university cooperation provided a good op­
portunity for them to develop this resource. 
Older, larger companies have provided lo­
cal expertise in business and development activi­
ties, as well as labor pools for new spinouts. In 
fact, many key people in the universities and the 
smaller companies have worked for these larger 
companies at some point. Many ideas have also 
been exported by individual workers leaving their 
jobs and establishing new start-ups or by dedi­
cated spinout strategies of larger companies. 
Several studies have noted that in biotech, 
the performance, strength, and width of the sci­
entific base are perhaps the most important fac­
tors affecting industry development.47 Indeed, 
Turku’s scientific knowledge base did not emerge 
overnight: it has been developing since the 
1960s or 1970s. Moreover, the level of scientific 
research in biotechnology-related fields has been 
on par with top research around the world. The 
establishment of spinouts owes much to strong 
academic links with the United States. When 
the molecular biology revolution occurred in the 
1970s, many Ph.D.s and M.D.s from Turku did 
their postdoctoral research work in some of the 
best American laboratories. During their time 
abroad, they witnessed the birth of commercial­
ized biotechnology firsthand and saw the many 
ways that academics can become involved in the 
business of medical biotechnology. A few leading 
researchers subsequently returned to Turku and 
became intimately involved in the establishment 
of both the Center for Biotechnology and several 
promising start-ups. 
.1	 Strong national support for biotechnology 
research and business 
The Finnish model for supporting biotechnol­
ogy has been described as a “science-led strat­
egy from above.”48 In Finland, the national in­
novation system has played a significant role in 
developing the biotechnology sector. Various 
government agencies support science-based and 
resource-intensive businesses. The Academy 
of Finland funds basic research: TEKES (the 
Finnish Funding Agency for Technology and 
Innovation) funds applied research, develop­
ment, and knowledge transfer; VTT Technical 
Research Center conducts applied and contract 
research; and Sitra (the Finnish National Fund 
for Research and Development) used to provide 
venture capital funding for small high technology 
firms particularly in the 1990s.49 Furthermore, 
public programs, such as the regional Centers 
of Expertise, coordinate and focus resources in 
key industries in many cities. Many of the in­
stitutions and organizations affiliated with the 
national biotechnology innovation system are 
located in the Helsinki region. 
In the late 1980s, the Ministry of Education 
started the first biotechnology research program. 
Since then, public funding in the form of vari­
ous research and technology programs (especial­
ly those provided to universities by The Center 
of Excellence) and public venture capital have 
all increased tremendously. Roughly 40% of the 
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national R&D budget is spent on the bioscienc­
es. TEKES has invested some US$90 million, or 
27% of the total amount spent on biotechnology 
in Finland. The Ministry of Education has also 
created new centers of excellence in universities. 
These efforts have paid off: in 2000, nine of the 
26 most highly ranked university departments in 
Finland were in the field of biotechnology. 
In Turku, the impact of the national science 
and technology policy has been remarkable. Partly 
because local actors have been active in national 
development programs, the newly dedicated uni­
versity research units have received a lot of public 
funding. Public venture capital has also played a 
big part in the growth of new firms. However, 
in Turku, national institutions have been used 
as resources for local activity rather than initiat­
ing new activities themselves. Turku was not very 
visible in the biotechnology industry (compared 
with, for example, Helsinki) until the late 1980s. 
In 1987, the Ministry of Education launched a 
new biotechnology research program that was 
Helsinki centered, despite the fact that Turku had 
a biotechnology sector that was not much smaller 
than Helsinki’s. The Turku research community 
protested this “injustice,” and local informal 
initiatives, designed to increase the visibility of 
Turku’s biotechnology activities, were instrumen­
tal in developing a local biotechnology cluster.50 
.2	 Local networks and local initiatives 
facilitate cluster building 
The development of Finnish biotechnology has 
been aided not only by national policies but also 
by the local efforts of actors in business, academia, 
university administration, and city governments. 
Individuals have promoted change, whether or 
not they had strategic support from their own in­
stitutions; this is important to note because the 
role of individuals as instigators of change has of­
ten been overlooked.51 
The first changes in Turku’s innovation net­
work occurred in the mid 1980s. Particularly 
important was the first dedicated project for im­
proving biotechnology research, the South-West 
Finland Biotechnology Project (SWB), started 
in the mid 1980s. At approximately the same 
time (1986), the Foundation of New Technology 
(FNT) was established. This was a very informal 
organization, composed of approximately 30
people, most of them drawn from industry and ac­
ademia. The FNT was originally formed to estab­
lish Turku’s first technology center, DataCity.52 
The Turku Technology Center Ltd. region­
al development company is owned by the city 
of Turku (90%). It consists of two subsidiaries 
(100% ownership): Turku Bio Valley Ltd. and 
ICT Turku Ltd. The second stage of the tech­
nology center, BioCity, was built in 1989, after 
DataCity achieved some success. People with dif­
ferent needs joined for a common cause: the real 
estate business saw a new business opportunity; 
biotechnology firms saw an opportunity to gain 
more contacts and influence by cooperating with 
universities; and universities saw an opportunity 
to obtain better resources for research and edu­
cation. Because city governments played a cen­
tral role in planning five of the seven technology 
parks existing in Finland in 1989,53 it is interest­
ing that the city of Turku did not participate in 
the planning of BioCity. 
BioCity has been very important to Turku’s 
biotechnology cluster. It was not merely a physi­
cal structure but an ambitious new concept. Its 
founders wanted to create synergy between in­
dustry and academia by gathering a critical mass 
of researchers in various fields.54 This critical 
mass was achieved by establishing new facilities 
and labs that were jointly administrated by the 
University of Turku and Åbo Akademi. The uni­
versities entered the project not so much because 
they shared the founders’ vision but because they 
were suffering from a lack of resources. Today, the 
BioCity Turku research community consists of 
more than 50 research groups and more than 500 
people working in different fields. 
A recession in Finland in the early 1990s 
made local actors and the Turku city government 
look for new industries to develop. Compared 
with other mid-sized cities in Finland, like Oulu, 
Tampere, and Jyväskylä, Turku became active in 
the local economic development quite late. This 
was partly because of the local industrial struc­
ture—the impacts of economic restructuring 
in the 1970s and 1980s were not as severe as in 
many other cities. The Finnish recession and the 
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collapse of the Russian markets, which were im­
portant for many local industries, also made local 
authorities pay more attention to economic de­
velopment. Since then, the city of Turku has been 
very active in promoting new industries, particu­
larly biotechnology, and investing in infrastruc­
ture. The government has encouraged life-sci­
ences research and commercialization in Turku, 
partly because the city did not have pre-existing 
information-technology-related skills and indus­
try like many other midsize cities in Finland. 
Local authorities have supported the nation­
al Center of Expertise program, which organizes 
cooperation within the biotechnology sector in 
Turku. In general, local actors have taken advan­
tage of opportunities provided by national and 
regional policies regarding science and technol­
ogy. The use of biotechnology as a leading theme 
in city marketing should not be underestimated. 
. 	 Turku as a biotechnology cluster 
Turku has created a successful biotechnology 
cluster, but substantial efforts have been needed 
to guarantee its success. Below is an analysis of 
the aforementioned factors for successful biotech­
nology clusters, as they apply to Turku: 
•	 a strong science base. In recent interna­
tional evaluations, Turku’s science base was 
highly rated. 
•	 an entrepreneurial culture. Although many 
new companies have been created, there is 
no strong entrepreneurial culture. 
•	 a growing company base. The company 
base has grown rapidly in many fields in 
the latter part of the 1990s, but there have 
not been many new DBFs in the past few 
years. 
•	 the ability to attract key staff. So far, em­
ployees have come from within Finland. 
Many companies have noted that Turku is 
too small to be attractive. 
•	 the presence of investors. Missing are 
MNCs and international venture capi­
tal (VC), though domestic VC (especially 
public) has made up for a lack of interna­
tional VC. Recently, VC money has been 
less available and there have been substan­
tial problems in attracting financing. 
•	 infrastructure. Generally, the infrastructure 
for both research and business is very good. 
The public sector (especially the City of 
Turku) has recently supported the building 
of new infrastructure. This has been crucial, 
since university funding has been tight. 
•	 business support services and large com­
panies in related industries. Larger compa­
nies do not use local services very much. 
Many specialized services are in Helsinki 
and abroad. There are some good local ser­
vices but the number is still quite small. 
•	 a skilled workforce. The local universities 
have so far provided an adequate source 
of new employees. The region’s traditional 
strengths in pharmaceuticals and diag­
nostics provide some experienced people, 
though not enough. The city is too small 
to provide an adequate labor pool. There is 
also a lack of local business expertise. 
•	 effective networks. Local networks work 
effectively. Many of the networks arose vol­
untarily from local needs and have there­
fore been very active as opposed to policy-
led network initiatives, which often turn 
out to be rather artificial. Networks linking 
Turku with the rest of the globe are quite 
extensive and important for research and 
commercialization. 
•	 a supportive policy environment. National 
policy has been very important in providing 
financing for both research and commercial 
development. Local policy is increasingly 
supportive of infrastructure. University 
policies have neither helped nor hindered. 
Turku has been able to overcome the weak­
nesses mentioned above for two reasons: strong 
national support and the ability of local actors 
to exploit both internal and external resources. 
The factors contributing to Turku’s success can be 
summarized as follows: 
(A)	 A strong science base with local and
international networks 
•	 Expertise from older, medium-sized 
companies provided the cluster with the 
experience and skills that new univer­
sity-based start-ups often lack. 
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•	 Early on, companies established long­
term relationships with university re­
searchers, thereby developing a culture 
of collaboration. 
•	 Pre-existing scientific networks and 
cutting-edge research in medicine, bi­
ology, and chemistry compensated for 
the lack of local expertise and local in­
stitutions, such as business support ser­
vices, banks, consultancies, and venture 
capital funds. Strong research ties to the 
United States, for example, have been 
very important. 
•	 The difficulty of recruiting foreign em­
ployees has been at least partially com­
pensated for by the expertise of Finnish 
researchers who have spent time abroad. 
(B) National policies 
•	 Extensive research funding and educa­
tion supports the science base. 
•	 The TEKES technology programs sup­
port R&D. 
•	 Public VC partly compensates for a lack 
of foreign VC. 
•	 Local centers of expertise facilitate 
networking. 
(C) Local initiative 
•	 Local initiative has led to improved in­
frastructure, as well as improved organi­
zation in universities and R&D firms. 
•	 The success of Turku has been crucial in 
influencing national policy-makers to 
invest in biotechnology. 
•	 BioTurku has brought various actors to­
gether, thereby improving the integrity 
of the local biotechnology cluster. 
Despite its relative success in compensating 
for the missing success factors, Turku still faces 
problems. First, its small size makes it difficult 
to maintain local services. Lack of foreign VC is 
also a potential problem, because public support 
for biotechnology is limited. Technology trans­
fer mechanisms are still underdeveloped, even 
though there are close connections between uni­
versity researchers and companies. In addition, 
universities do not have a clear strategy for capi­
talizing on biotechnology research. The biggest 
problem, however, is that Turku lacks many parts 
of the value chain. There are few services, venture 
capitalists, and big MNCs with expertise in com­
mercialization and marketing. This is a problem 
because external links are usually more difficult 
and costly to maintain than internal ones, espe­
cially for small companies. 
6. DISCuSSION AND CONCluSIONS 
A small, peripheral biotechnology cluster can 
prosper under the right conditions. First, a strong 
local science base must already exist. Second, 
there must be a way to compensate for any miss­
ing links in the value chain. Turku has been fairly 
well able to provide adequate conditions for its 
biotechnology industry. Although its biotechnol­
ogy cluster is young, quite small, and in many 
ways peripheral, its development has been suc­
cessful because of the region’s strong science base 
and well-established strengths in medicine and 
diagnostics. Both national innovation policies 
and strong local initiatives have been important 
in overcoming obstacles. 
Several lessons can be learned from the 
Finnish experience. First, a good educational sys­
tem is important. There are many ways to com­
pensate for missing links in the value chain, but it 
is extremely difficult to build new entrepreneurial 
activity in biotechnology without a good local 
knowledge base. 
Second, human capital formation (in the form 
of educated people and research groups) should 
be drawn mostly from the local pool, though it 
is often necessary to bring in experienced people 
to work in R&D. It is difficult for developing 
countries to compete with major research centers 
in Europe and the United States. However, bio­
technology requires the best available scientific 
knowledge and expertise. If it is difficult to attract 
people from abroad, locals should go abroad to 
study, conduct research, and build international 
networks. It is easier to attract expatriates than it is 
to attract foreigners. 
Third, the development of clusters is path-de­
pendent and based on previous historical events 
and existing capabilities. It is extremely difficult 
to build new clusters from scratch. It is therefore 
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advisable to match research activities and start-up 
formations to the existing strengths of the region. 
In many countries, this may mean concentrating 
on specific fields, such as agriculture or health 
care, in which local expertise is strong. A strong 
health care system is important for the develop­
ment of biotechnology because it is a consumer 
of local products, a source of new ideas, and an 
environment for testing and clinical trials. It is 
also important to make good use of the R&D 
capacity and expertise of existing companies and 
universities. Many successful clusters in emerging 
technologies have been created around older but 
related industries. For example, the biotechnolo­
gy industry was created around pre-existing food 
and medical industries in Turku, and the semi­
conductor industry was created around a pre-ex­
isting electronics industry in Silicon Valley. 
Fourth, local and national policy support 
of emergent industries is important, especially if 
there are problems with the innovation support 
system. This support can take many forms: sub­
stituting public services for missing private ser­
vices, supporting research, building up a work­
ing education and research system, creating a 
favorable legal and economic environment for 
new start-up companies, and working to prevent 
“brain drain.” 
Fifth, the role of individuals, especially in the 
early stages of cluster formation, should not be 
underestimated. The Finnish experience demon­
strates that local networks of key individuals in­
crease the capabilities of the cluster as a whole and 
help different actors achieve consensus. Support 
for key individuals in enterprises, universities, 
and research institutes is therefore important, and 
networking should be promoted. 
There is indeed hope that smaller and more 
peripheral biotechnology clusters can prosper. 
However, it is also clear that strong, well-de­
signed policy support is needed to overcome the 
various setbacks that these small clusters tend to 
face. Of course, there still remains the question 
of how this should be accomplished. So far, the 
“Finnish way” has worked quite well, but it is 
always difficult to determine how well policies 
and practices will work in the future or how well 
they will work in other institutional environ­
ments. There also remain the perennial questions 
of how much a government should invest, and 
how much it would be ready to invest, in a new 
industry sector such as biotechnology. Success in 
such endeavors is not guaranteed. n 
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CHAPTER 3.13 




LITA NELSEN, Director, M.I.T. Technology Licensing Office, U.S.A. 
ABSTRACT 
Thischapterdescribesthestructure,policies,andoperations 
of the Technology Licensing Office at the Massachusetts 
Institute of Technology (M.I.T.). The chapter emphasizes 
the licensing office’s role in generating spinout companies 
and considers the importance of the biotechnology cluster 
within the state of Massachusetts and it’s surrounding re­
gions. Also discussed is M.I.T.’s approach to ensuring that 
licensing procedures maximize access to medicines and 
vaccines arising from M.I.T.’s research. 
1. INTRODuCTION 
The Massachusetts Institute of Technology 
(M.I.T.) is probably not a direct model for uni­
versities and research institutes just beginning 
their technology-transfer activities, whether in 
the United States or in developing countries. 
Instead, the institute is an example of what can be 
achieved by a mature organization that has built 
its patent portfolio and technology-transfer skills 
over the course of half a century. We, at M.I.T., 
live in an entrepreneurially advanced city, where 
technology-based companies originating from 
university research inventions have become an 
important part of the Massachusetts area’s econo­
my. M.I.T. and the other major research institu­
tions in the area, such as the Whitehead Institute 
for Biomedical Research, Harvard University, 
Massachusetts General Hospital, Brigham and 
Women’s Hospital, and Boston University, have 
helped to build this entrepreneurial cluster and 
have benefited from it. 
Nevertheless, other organizations can 
learn from our experiences, and M.I.T.’s 
Technology Licensing Office1 is both honored 
and pleased to help in the transfer of technology-
transfer practices. 
1.1 History and mission 
M.I.T.’s Technology Licensing Office is one of
the most active university patent and licensing
offices in the country. M.I.T. has had more than 
1,500 issued U.S. patents in its portfolio, many 
with foreign counterparts. 
M.I.T.’s technology licensing endeavors 
follow the mandate of the U.S. Congress who, 
in 1980, gave to universities title to inventions 
developed with federal funds through the Bayh-
Dole Act. Technology licensing from univer­
sities was greatly accelerated by Bayh-Dole, 
which allowed universities to own the patents 
arising from federally funded research, to grant 
exclusive licenses, and to charge royalties that 
could be shared with inventors. Since nearly 
90% of the basic research funds in U.S. univer­
sities comes from U.S. federal funds, the new 
law drastically changed the face of university 
technology transfer. 
The theory behind the law’s application 
to university research was based on Congress’ 
Nelsen L. 2007. The Activities and Roles of M.I.T. in Forming Clusters and Strengthening Entrepreneurship. In Intellectual 
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney,
L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. L Nelsen. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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NElSEN 
understanding of the embryonic nature of uni­
versity discoveries and inventions. Since universi­
ties do not develop products, early investment by
industry is needed to turn university findings 
into commercial realities. Typically, such invest­
ment involves high risk, since neither the prac­
ticality of the inventions nor their market utility 
has been proven. Patents, and particularly exclu­
sive licenses, can be used as incentives for first 
mover companies to make the investment: if the 
product were to succeed, the patent would pro­
tect the initial investor from competition for a 
period of time, rewarding the initial risk taking. 
Finally, the law provided an economic in­
centive for both universities and their research­
ers to patent their inventions and to participate 
in the technology-transfer process. Although 
the royalties gained from technology transfer 
are only a very small contribution to univer­
sity budgets (averaging about 3% of university 
research budgets for U.S. universities), there is 
enough economic return to support the pro­
cess—and considerable incentive for individual 
researchers. More importantly for the biotech­
nology industry, the technology-transfer process 
is an organized, effective method of transferring 
university findings via protected IP for the pur­
pose of forming a protected technology dowry 
for new companies. Investors in most technolo­
gy companies—and certainly in such high-risk/ 
high-investment fields as biotechnology—must 
have proof of the exclusive rights to patents and 
other forms of IP by the company before they 
will invest. 
Consequently, we use licenses to our IP 
to stimulate the development of our inven­
tions into products that serve the public good. 
Through our patenting, licensing, and copy­
right protections, we encourage companies to 
take the necessary risks to develop our inven­
tions into products and/or services that benefit 
humanity. Royalties derived from licenses sup­
port further research and are shared with inven­
tors. These, in turn, provide incentives for fur­
ther innovation. 
Each year, more than US$1.2 billion in 
sponsored research is conducted on the campus 
of M.I.T., at the Lincoln Laboratory, and at the 
Whitehead Institute for Biomedical Research. 
This research leads to more than 500 new inven­
tions per year. These inventions and software are 
marketed through M.I.T.’s Technology Licensing 
Office. The core of this office is a group of techni­
cally trained and business-oriented people. They 
work with industry, venture capital sources, and 
entrepreneurs to find the best ways to commer­
cialize new technologies. 
The Technology Licensing Office at M.I.T. 
began its operations many decades ago as the 
Patent, Copyright, and Licensing Office. It was 
reorganized in 1986 and became the Technology 
Licensing Office. It is administered by the Vice 
President for Research/Associate Provost and is 
now part of the academic arm of the university. 
Its mission statement declares that: 
The mission of the M.I.T. Technology Licensing 
Office is to benefit the public by moving results of 
M.I.T. research into societal use via technology li­
censing, through a process which is consistent with 
academic principles, demonstrates a concern for the 
welfare of students and faculty, and conforms to the 
highest ethical standards. 
This process will benefit the public by cre­
ating new products and promoting economic 
development. 
It will help M.I.T.: 
•  show tangible benefits of taxpayers support 
for fundamental research 
•  attract faculty and students 
•  generate industrial support of research 
•  generate discretionary income 
•  generate new job opportunities for 
graduates 
We will continue to be a world-class 
model of excellence in university technology 
licensing. 
1.2 Staffing 
The Technology Licensing Office is staffed by: 
•	 Director Lita Nelsen, chemical engineer­
ing background (BS, MS, MBA) with 20 
years experience in industry in the fields 
of medical devices, membrane separations, 
and biotechnology 
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•  Associate Director Jack Turner, electri­
cal engineering background (BS) with 18 
years of experience in industry 
•  seven technology licensing officers, all 
with degrees in engineering or science, 
each with one to two decades of industrial
experience; each is responsible for one of 
the seven technology areas: biotechnol­
ogy, chemistry, medical devices, semicon­
ductors, communications, software, and 
nanotechnology 
•  four technology licensing associates, all 
with BS degrees in science and little or no 
other experience; associates assist the tech­
nology licensing officers 
•  legal personnel: one corporate attorney, one 
junior lawyer, and one legal assistant; these 
staff members provide advice on licensing 
and particularly on corporate structure, 
manage outside attorneys for litigation, 
and manage M.I.T.’s trademark and end-
use software licensing; patent prosecution 
is handled by outside attorneys and patent 
agents 
•  financial and computer systems personnel: 
one financial manager, two accountants, 
one programmer, and one desktop support 
administrator 
•  office management and clerical support: 
office manager, compliance manager (gov­
ernment reporting), three secretaries, a re­
ceptionist, a files manager, and a file clerk 
1. Numbers of patents and licenses 
M.I.T. currently holds about 1,500 active U.S. 
patents and many corresponding foreign patents. 
About 150 U.S. patents are issued to M.I.T. each 
year. We have about 600 active licenses and issue 
around 100 new licenses every year. 
The gross annual revenue of the office is about 
US$40 million. Net revenue is about US$10 mil­
lion (after patent expenses, personnel expenses, and 
distribution of a portion of royalties to inventors). 
The majority of our licenses are to existing 
companies—both small and large. But about 
25% of the licenses are to new spinout compa­
nies, which are specifically formed to develop a 
licensed technology. 
2. THE ROlE OF THE TECHNOlOGy 
lICENSING OFFICE IN THE BuSINESS 
COMMuNITy 
2.1 The “virtual incubator” for spinouts 
Twenty to 30 new companies are spun out from 
M.I.T. each year. All of them are based on M.I.T. 
inventions and are built upon licenses to our pat­
ents and software. The companies based on our 
biomedical inventions form an important part of 
the biotechnology cluster in the Massachusetts 
area (see section 3 below). 
Our formal role in starting up new compa­
nies is confined to filing patents and negotiat­
ing license agreements with the companies, and 
although we will often take equity shares in the 
company as partial payment of royalties, we do 
not take board seats on the company or any man­
agement role. The purpose of these restrictions is 
to keep the company clearly separate from the 
university. We believe this separation is necessary 
for the university to concentrate on its mission of 
basic discovery research, dissemination of knowl­
edge, and education. Through these policies, the 
management of technology transfer essentially 
becomes a by-product of the academic process 
and will not distort the long-range mission of the 
institution. 
We can only achieve this mission through 
clear and transparent conflict-of-interest policies 
and procedures (see Box 1). The conflict-of-in­
terest rules may seem unusually strict, but this 
careful approach is necessary because of the very 
large number of companies spun out (more than 
250 since 1987). Management that allows excep­
tions to the rules would not be possible given 
this large number. Our task is not to use these 
rules as deterrents but to efficiently and cre­
atively craft arrangements within the rules. Put 
differently, our operating motto is “A firm wall 
between university and industry—but a wall with 
many doors.” 
We do not formally incubate these spinouts; 
we do not invest M.I.T. money in any of these 
companies; we do not allow the companies to use 
M.I.T. laboratory facilities; and we do not write 
their business plans nor do we participate in their 
management. 
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Box 1: M.I.T.’s Conflict-of-Interest Rules for Spinout Companies
(last Revised February 2005) 
1. Faculty member may consult but not be a line officer in any company. Consulting activities
should not use university resources and should not use students. 
2. Faculty member must distinguish direction of research at university from responsibilities at
company in which he/she owns equity. 
.  The university will not accept sponsored-research grants from the company if the faculty
member owns equity. 
.  No confidentiality of research results (anytime). All research must be publishable. 
.  Only patents, copyrights and tangible property can be licensed for compensation (no know-
how or trade secret licensing can be done since this would preclude open publication). 
.  Faculty members may not conduct the license negotiations (nor attend the negotiations). 
.  Consulting is third-party, between the faculty member and the company. No tie-in with the 
license. 
.  Only very minimum commitment of future inventions (those dominated by previously
licensed patents). No pipelining of improvements. 
.  Faculty member/founder who holds equity signs Conflict Avoidance Statement promising: 
• Not to accept research support from company
• Not to suppress dissemination of research findings
• Not to use students on company-related work at M.I.T. 
10. Arm’s length relationship between the university and the company 
• No M.I.T. monetary investment in the company
• No board seat 




11. Technology LicensingOffice enforces diligence terms,payment of patent costs,other license
obligations just like any other company. No special status for M.I.T. spinouts. 
12. Yearly departmental overview of faculty outside professional activities. 
Common sense: Emphasis on the spirit (not just the letter) of the rules, administered by people
with judgment and authority. 
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CHAPTER .1 
Our informal role, however, is much broader. 
We call it a “virtual incubation” function, which 
encourages and accelerates the formation and 
growth of our spinout companies. The initial 
license agreement itself includes contract terms 
that help. Our financial terms are quite generous 
for the first few years of operation, reflecting our 
understanding that new companies are often cash 
poor. Similarly, our royalties on products are low, 
because we know that the company will have to 
make substantial investments and develop and 
contribute substantial IP of its own before the 
product can be successfully commercialized. 
An important part of the license agreement— 
both for us and for the company—is that which 
defines the milestones, or diligence terms. These re­
quire companies to raise minimum amounts of 
capital and achieve progress in product develop­
ment. Milestones related to raising capital assure 
us that the outside market finds the company 
worthy of investment and that sufficient capital 
will be raised to fund product development. 
Our virtual incubation incorporates many 
other functions. We meet with inventors, help­
ing them to define the direction of the company 
and their own career aspirations. We introduce 
them to consultants, potential executives, and 
other advisors who can help them formulate their 
business strategy and write business plans. And, 
because of our long relationships with sources of 
investment capital, we can introduce inventors to 
venture capitalists and angel investors who may 
be willing to invest in the new companies. 
2.2  The role of students in 
entrepreneurship at M.I.T. 
The admission criteria for prospective M.I.T. 
students, particularly those for undergraduates, 
contribute to the entrepreneurial spirit at the in­
stitute and the ultimate impact of our graduates 
on the economy. In evaluating candidates for ad­
mission as undergraduates, we look not only for 
academic achievement (such as high grades and 
strong standardized test scores), but also for a cer­
tain quality of potential leadership—an intensity 
and focus that fosters achievement and also influ­
ences others. Young people who are strong po­
tential leaders often possess a self-confidence that 
allows them to think unconventionally and take 
risks—including the risk of joining (or forming) 
an entrepreneurial company. 
Our education of these students (and of their 
“big brothers and big sisters” in graduate school) 
stresses the fundamentals of science, rather than 
short-term applications. The students are in­
volved in leading-edge research projects early in 
the course of their studies. We seek to produce 
graduates who will have leadership capabilities 
based on a solid grounding in science and a fa­
miliarity with the state of the art. 
Role models in business are an important 
influence on these students during their years at 
M.I.T.. Many of the professors and many alumni 
who visit campus—and not a few of the students’ 
friends—have started companies based on M.I.T. 
technology. These entrepreneurs expose students 
to entrepreneurial thinking. The presence of 
strong role models is important for developing an 
entrepreneurial culture; the plethora of such role 
models at M.I.T. and in the Boston/Cambridge 
area leads others to think that “I can do it too”— 
and offers resources for advice and strategy. 
Finally, our culture at M.I.T. stresses that 
risk taking is necessary for achievement. And, 
importantly, that “failure is a learning opportu­
nity—not a black mark.” We assume that our 
students are good enough to take risks and suc­
ceed. They have sufficient talent, energy, and self-
confidence to recover rapidly from failure and to 
learn from failure to become more effective in 
their next endeavor. A willingness to take risks 
and the ability to learn from failure are critical 
for entrepreneurship. 
2.  Interaction with the business community 
A key part of the technology-transfer function at 
the university is to develop and maintain a wide 
range of contacts with the surrounding business 
community and to leverage these resources to 
help build our spinout companies. Our model 
for spinning out companies depends on a ma­
ture, entrepreneurial community surrounding 
the university. 
The geographic area of M.I.T. is the 
Cambridge/Boston area, which in many ways 
provides an infrastructure of support for spinout 
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NElSEN 
companies. High technology companies have been 
regularly spawned here for more than 40 years. 
As a result, there are many executives, lawyers, 
accountants, consultants, real estate managers, 
and other professionals who are experienced at 
working with new companies. And the commu­
nity is well connected. Networking organizations, 
such as the M.I.T. Enterprise Forum and the 
Massachusetts Biotechnology Council (MBC), 
keep people in contact with one another. 
Finally, the community has developed 
“knowledgeable money”: investors who contrib­
ute to spinout companies not only funds, but wis­
dom, guidance, and connections to management 
talent, business development opportunities, and 
follow-on money. A new breed of high-technol­
ogy angel investors—former entrepreneurs who 
founded and cashed out from successful compa­
nies—is now bringing wisdom, connections, and 
experience, along with money. 
There are also venture capital funds that 
specialize in technology-based spinouts. Many 
even subspecialize in biotechnology and have 
partners and associates with MD and PhD de­
grees in biology who are experienced in the bio­
technology industry. 
3. THE BIOTECHNOlOGy CluSTER:
ExPERIENCES FROM MASSACHuSETTS 
It is helpful for those who are involved in technol­
ogy transfer to be in proximity to others with sim­
ilar issues and challenges. The Boston/Cambridge 
area is one of the three main biotechnology clus­
ters in the United States. (Biotechnology clusters 
are geographical regions where a disproportion­
ately large number of biotechnology companies 
are located.)2 The other two biotechnology clus­
ters are: 
•	 the San Francisco Bay Area of northern 
California 
•	 the San Diego/La Jolla area of southern 
California 
Many factors have led to the formation and 
growth of the Massachusetts cluster, with research 
institutions playing a critical role. This cluster of 
more than 280 companies accounts for almost 
20% of the total number of U.S. biotechnology 
companies. Almost all of these companies started 
as small, entrepreneurial companies within the 
last two decades, the majority having been formed 
within the last 12 to 15 years. According to data 
from the Massachusetts Biotechnology Council, 
these companies now employ more than 30,000 
people. In addition, there are more than 220 
medical device companies in the area that employ 
an additional 25,000 people. 
.1 Key elements for a biotechnology cluster 
It all starts with early fundamental support of 
basic research by the U.S. government. Leading 
research institutions make the discoveries, devel­
op the IP, and train the scientists that form the 
biotechnology companies. Where the research 
institutions cluster, the new companies eventu­
ally form. The process continues with alliances 
developing between biotechnology companies 
and large pharmaceutical companies, which will 
often provide necessary testing, manufacturing, 
and distribution of the drugs discovered by the 
biotechnology companies. 
For a robust cluster to form, the area needs 
investment capital (and experienced investors), 
executive talent, trained scientists, and a host of 
supporting professionals—lawyers, accountants, 
real estate professionals, and others—who un­
derstand biotechnology entrepreneurship and
can help fledgling companies establish themselves. 
Good airports are critical, and local communities 
that are attractive to highly talented personnel and 
their families create a competitive advantage. 
The Boston/Cambridge area of Massachusetts 
has an unusually large concentration of world-
class research institutions (universities and re­
search hospitals) funded in large part by the U.S. 
government—particularly the National Institutes 
of Health (NIH)—to perform basic discovery 
research in biology and biomedicine. Together, 
Massachusetts research institutions received more 
than $2.1 billion in NIH research grants in fis­
cal year 2003, approximately 10% of the national 
total. 
From this research comes much of the 
“feedstock” for new biotechnology companies: 
new discoveries, IP, knowledgeable scientific
1 | HANDBOOK OF BEST PRACTICES 
       
     
      
	 	 	
       
     




     
    
     
   
     
    
    
      
       
  
      
      
      
      
      
      
     
     
      
      
      
       
   
 
	 	 	 	
CHAPTER .1 
advisors for new companies, and, importantly, 
well-trained scientists to staff the new companies. 
.2 The self-feeding cluster 
Even with a base of world-class university research 
and its resulting technology and IP, getting a clus­
ter started is difficult—there is no simple formula 
for doing so. But once started, a cluster begins to 
feed itself in a virtual cycle. The biotechnology 
cluster feeds itself through: 
• 	 role models. These are people who have 
founded companies and can offer examples 
of success and advice to new entrepreneurs. 
• 	 management/founders. Often new com­
pany management is recruited from other 
companies in the area. People who were 
employees of early companies in the cluster 
acquire the skills and interests to become 
founders of new companies. New compa­
nies also can recruit other skilled personnel 
from the older cluster companies. 
• 	 retention of new graduates. A cluster of 
biotechnology companies in an area en­
courages new graduates from nearby uni­
versities to seek employment in the area, 
consolidating skills. 
• 	 infrastructure support. The area’s patent 
attorneys, lawyers, accountants, recruit­
ers, real estate managers, consultants, and 
equipment suppliers develop special skills 
in biotechnology as they respond to the 
needs of the cluster. 
• 	 technology transfer. As the universities 
and other research institutions become 
more experienced in dealing with bio­
technology companies and biotechnology 
startups, they become more effective in 
starting new companies that strengthen 
the clusters. Successful technology licens­
ing and spinouts lead to revenue, which 
funds the filing of more patents and more 
opportunities. 
• 	 angel investors. Local angel investors bol­
ster the process, since they can offer their 
skills and experience in addition to their 
money. As clusters mature, founders of the 
early companies frequently become inves­
tors in new companies. 
At some point venture capital moves in. 
At the start of the Massachusetts biotechnol­
ogy cluster, there was little indigenous ven­
ture capital. Most venture capital money came 
from investment funds located in New York, 
California, and other states. With the growth 
of high-tech clusters in Massachusetts (both 
biotechnology and telecom), many of these 
funds opened new offices in Massachusetts, and 
many new venture funds were formed locally. 
Currently, the majority of new company financ­
ings in Massachusetts are led by venture funds 
with offices in Massachusetts. 
4. CONCluSIONS 
.1 The importance of clusters 
Many elements contribute to the success of a 
biotechnology cluster. Its origin and continued 
health depend on a continuing source of state-of­
the-art science, usually provided by universities 
and research hospitals funded for basic research. 
The source of this funding probably needs to be 
from government: no private institutions can af­
ford to fund sufficient speculative basic research 
to sustain the flow of discoveries necessary to sup­
port a cluster’s growth. 
Effective technology transfer is also neces­
sary. The legal infrastructure for transferring in­
ventions from universities must be in place (and 
relatively nonbureaucratic), and sufficient funds 
must be available for universities to file patents 
and protect their IP. 
The formation of new companies also re­
quires a business infrastructure in the communi­
ty. A simple legal system for company formation, 
consulting, accounting, and legal professionals to 
advise the company—as well as adequate physi­
cal space—are all necessary. Good transportation 
into the area is important, since investors and 
business partners need to visit the company. And 
investment capital is, of course, critical. 
Most of all, the formation of companies and 
the subsequent development of clusters requires 
talented people: world-class researchers to lead 
the discovery, trained and talented technology-
transfer professionals, entrepreneurial company 
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founders, scientists and managers to staff the 
companies, and knowledgeable investors who 
can both fund and guide the company. All will 
need the support of a variety of professionals in 
the community. It takes a whole community to 
build a biotechnology cluster—but once built, 
the cluster can achieve a self-sustaining life that 
strengthens itself and the community. 
4.2  The importance of policies for ensuring the 
availability of products for the poor 
M.I.T. usually files patents only in North America, 
Europe, and Japan (though occasionally we file in 
China, Singapore, Republic of China, and Korea 
for the electronics field). Thus, the biomedicine-
related patents we file are not often likely to affect 
the development and distribution of medicines 
and vaccines in developing countries. 
We are, however, mindful of the issues sur­
rounding the development and distribution of 
new health-related products for developing coun­
tries, and we consider both our patenting proce­
dures and our licensing terms when working with 
relevant technologies. For example, it may some­
times be advisable for patents to be filed in some 
developing countries so that local companies in 
those countries can protect their investments in 
further developing our technology. In other cases, 
we may choose not to file patents in those coun­
tries and may prohibit our licensees from doing 
so—or we may refrain from granting exclusive 
licenses in developing countries unless we feel 
exclusivity will enhance development and access. 
Other agreements could require preferential pric­
ing for the public sector of developing countries. 
There are no rigid written policies guid­
ing the way we handle technologies; instead, we 
leave our options open, creatively crafting agree­
ments to maximize access. However, the number 
of technologies arising from our research that are 
relevant to neglected diseases is relatively small, 
since we do not have a medical school nor a 
school of public health. Our experience with such 
technologies is relatively scant, as is our experi­
ence in crafting such agreements. We discuss our 
approach to those technologies in greater detail in 
another chapter. ■ 
LITA NELSEN, Director, M.I.T. Technology Licensing Office, 
Massachusetts Institute of Technology, Five Cambridge Center, 
Kendall Square, Room NE25-230, Cambridge, MA, 02142­
1493, U.S.A. lita@mit.edu
1	 web.MIT.edu/tlo/www. 
2	 See also in this Handbook, chapter 3.12 by K Viljamaa 
and 3.11 by PWB Phillips. 
3	 See, in this Handbook, chapter 1.3 by L Nelsen and A 
Krattiger. 
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CHAPTER 3.14 
Building Research Clusters: Exploring Public Policy

Options for Supporting Regional Innovation
 
peTeR w. b. phillips, Professor, Department of Political Studies, University of Saskatchewan, Canada 
caMille d. Ryan, Postdoctoral Fellow, Faculty of Communication & Culture, University of Calgary, Canada 
ABSTRACT 
Governments at all levels are showing great interest—and 
some are spending lots of money—in developing research 
clusters that they hope will benefit their local and nation­
al economies. Clusters are complex, however, and this 
chapter aims to help policy-makers maximize their ben­
efits. The chapter offers a taxonomy of countries and their 
potential for cluster development and explains a five-stage 
process for realistic cluster building. Stage one assesses ca­
pacities, resources, and opportunities. Stage two involves 
choosing an anchor strategy. In stage three, organizational 
and institutional leaders are identified to take the lead in 
developing the cluster. In stage four, proactive tactics are 
chosen. Stage five identifies the cluster’s lifecycle and the 
strategies needed to sustain it. Cluster building is knowl­
edge-based development, which is inherently different 
from traditional industrial development. For one thing, 
cluster building requires global links. Companies and 
skilled employees are less interested in fiscal incentives, 
public infrastructure, or other government support than 
in the innovation community and its networks. 
1. InTRoduCTIon 
Theory suggests that competing companies and 
their related industries often concentrate in a 
few locations and generate higher value, more 
jobs, and more innovation than companies that 
do not locate near clusters with companies in 
related businesses. Ultimately, those that do are 
benefiting from some traded or untraded interde­
pendencies: economies of scale in related or sup­
porting industries, economies of scope in labor 
and capital markets, or knowledge spillovers from 
competitors and collaborators.1 
Some analysts estimate that the benefits of 
scale, scope, and—perhaps most importantly— 
tacit knowledge spillovers are usually limited to 
between 10 and 100 miles of the epicenter of a 
community. Given that the cities, regions, and 
countries that host these clusters would likely 
benefit, all levels of government are greatly inter­
ested in doing whatever is appropriate to spur lo­
cal development of these clusters. 
While analysts do not agree about much, 
they generally accept that clusters are complex. 
Subject to industrial evolution, changes in global 
markets, the knowledge bases that drive them, 
and the geopolitical forces that influence their 
development and success, clusters are diverse and 
their characterizations are open to interpretation. 
Additionally, clusters go through cycles. There 
are periods when they require high reinvestments 
(public, private, or both) of money, time, and re­
sources. At other times they provide high payouts. 
No one cookie-cutter approach or measure can be 
employed to develop and manage a cluster. 
Assuming that the cluster is a dynamic phe­
nomenon and subject to a lifecycle, a number of 
important factors come into play when assessing 
and supporting innovative capacity. This chapter 
first examines a taxonomy of countries and their 
potential for cluster development. It then looks 
Phillips PWB and CD Ryan. 2007. Building Research Clusters: Exploring Public Policy Options for Supporting Regional Innova-
tion. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krat-
tiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. PWB Phillips and CD Ryan. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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at a five-stage process for cluster building. Stage 
one involves using an array of common analytical 
tools to assess a candidate for a cluster: these tools 
include an overview of discrete measures along 
with some more general analytical tools, such 
as social network analysis and emerging markets 
analysis. Stage two involves choosing one of the 
strategic options. Stage three identifies and mo­
bilizes actors or organizations within the region 
(public, private, and others) to take a lead in the 
cluster. Stage four involves choosing from a set 
of proactive tactics for encouraging companies 
to cluster. Stage five identifies the lifecycle of the 
chosen cluster and the strategies needed to sustain 
the initiative. 
2. THE	ConTExT 
According to Mashelkar,2 building indigenous 
technological capacity, in any context, requires a 
number of conditions: a conducive policy environ­
ment, entrepreneurship, promotion of a culture 
of innovation, access to technology (where neces­
sary, through international technology transfer), 
an educated and skilled workforce, and a “learn­
ing by doing” mentality. Although Mashelkar 
explores indigenous technological capacity ex­
clusively from a developing country perspective, 
his approach can be applied to examine, not only 
the disparities between developed and developing 
countries, but also disparities within and between 
developed countries as well. 
Morel and colleagues3 present a taxonomy to 
assess economic strength and innovation capacity 
in health and health-related organizations. Six di­
mensions (manufacturing capacity, domestic mar­
ket, export market, R&D, IP system, and drug 
regulatory system) are explored across three stages 
of development that, in combination, are used to 
measure the capacity for developing countries to 
progress in terms of innovation. We have adapted 
this taxonomy to assess the capacities of different 
groups of nations for supporting cluster develop­
ment and growth (see Table 1). 
Most countries can be relatively cleanly as­
signed to one of Mashelkar’s four quadrants. 
Quadrant I countries consist of leading indus­
trial nations, such as the United States, Canada, 
Australia, Japan, and E.U. countries. Quadrant II 
countries, which have relatively low per capita in­
comes but high innovative capacity, include Korea, 
China, Brazil, India, and some eastern European 
countries. Quadrant III includes resource-rich 
and resource-dependent countries such as those 
in the Middle East. Finally, Quadrant IV consists 
of developing nations, such as those in southeast 










Economic strength high low high low 
Innovative capacity high high low low 
Comprehensive cluster policies advanced emerging n/a n/a 
Incidence of formalized clusters high moderate low/none low/none 






Source: Adapted from Mashelkar4 and Morel5 and colleagues. 
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Asia countries, Sub-Saharan Africa, and south 
and central America. 
Quadrant I countries rank highly in terms 
of economic strength and science and technol­
ogy capacity: by most measures they have the 
lion’s share of the clusters and are the most ag­
gressive supporters of cluster development. A 
closer look at the United States shows that there 
are more than 160 clusters identified across 25 
states, with cluster activity ranging from nar­
rowly defined categories such as oil and gas (for 
example, Louisiana) or gun manufacturing (for 
example, South Dakota) to more broadly based 
categories such as biotechnology6 or life sciences.7 
Moreover, nine state legislatures in the United 
States have either written into law, or at the very 
least recommended, that the State apply a clus­
ter approach to economic development,8 while 
seven other states9 have nonlegislated, cluster-
based economic development strategies in place. 
In contrast, while Canada has no formalized na­
tional cluster policy,10 most of the provinces have 
examined and attempted to support clusters in 
their jurisdictions; there would appear to be at 
least 25 clusters or emerging clusters in nine sec­
tors across Canada.11 In Australia, a national clus­
ter policy has been proposed that advocates for 
strategic, proactive polices rather than the current 
laissez-faire approach, but the program has yet to 
be formally implemented.12 
On the opposite end of the continuum, 
Quadrant IV nations rank low in terms of eco­
nomic strength and innovative capacity. This is 
due to a range of limitations, including weak in­
frastructure and incomplete IP regimes. However, 
some cluster activity is emerging. Several small 
artisan or trade-type clusters (for example, the 
garment industry in Kenya) have emerged in 
Sub-Saharan African regions,13 but these clusters 
are characterized as low in terms of specialization 
and are often composed of networks of “petty 
commodity producers.”14 Another approach has 
been to create export-processing zones. Mauritius 
was the first African country to establish an ex-
port-processing zone (EPZ) in the early 1970s.15 
Meanwhile, in Asia, despite the financial crisis of 
the 1990s, countries such as Indonesia, Malaysia, 
and Thailand have encouraged significant 
economic development by emphasizing indus­
trial exports. 
The middle quadrants (II and III) include 
countries that have low to medium capacities 
in terms of economic strength and innovation. 
Clusters, if present, often exhibit low techno­
logical or industrial application. The exception 
is Korea. Although categorized as a Quadrant 
II country, it has developed significant cluster 
capacity in such specialized areas as movies and 
animation, information technology, and digital 
media.16 Similarly, China and India are growing 
in terms of economic strength and innovative 
capacity. In India, the United Nations Industrial 
Development Organization (UNIDO) and the 
national government support over 350 small-
scale industry (SSI), rural and artisan-based clus­
ters. India has also had some acknowledged suc­
cess in creating world-class clusters in Bangalore 
in biomedical research and software engineer­
ing.17 Some Middle Eastern countries, although 
ranked high in terms of economic strength, are 
often solely dependent upon the extraction and 
processing of natural resources such as oil and 
petrochemicals; scientific and technological ca­
pacity is limited in these countries.18 
In short, while clusters are both stronger 
and more prevalent in Quadrant I countries, all 
countries have the potential to benefit from clus­
ters. Every region needs to evaluate its capacities 
and opportunities, make strategic choices about 
which areas to nurture, choose specific tactics, 
and identify and support indigenous leadership. 
Such choices, moreover, will need to be tailored 
to the capacities and opportunities of the indi­
vidual countries and regions. 
2.1 Step 1: Evaluation 
The first and most important step in developing 
clusters is to assess capacities, resources, and op­
portunities. Given the importance of planning, 
the tools are surprisingly weak. No one tried-
and-true acid test for cluster capacity or potential 
exists. A number of methods have been used— 
ranging from ad hoc to formalized consulting and 
opinion formation, to valuing or analyzing cluster 
capacity through descriptive or institutional anal­
ysis, to empirical, statistical analyses of detailed 
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industrial data—but to truly understand or evalu­
ate the potential efficacy of a cluster likely requires a 
blend of quantitative and qualitative approaches. 
Given that clusters are to some extent self-de­
fining, one approach often used is to convene an 
industrial, expert, or community forum to iden­
tify common interests and opportunities. While 
useful for identifying actors, or at least companies 
that would willingly participate, these processes 
are simply a starting point. In the first instance, 
they will likely determine whether the necessary 
number of interested/engaged actors can foster 
effort to develop a cluster. The processes can also 
be valuable for identifying the scale and scope of 
current traded or untraded interdependencies, as 
well as for planning future development that may 
either require or generate greater connections in 
a community. They often run the risk, however, 
of becoming either subject to groupthink (where 
everyone goes along with the most important or 
loudest participant) or unfocused debates about 
what is, is not, could be, or should be happen­
ing locally. Every process needs to move beyond 
rhetoric. Depending on local capacities, two main 
approaches have been tried. 
One common analytical approach is to look 
at the institutional composition and leadership of 
the industry, supply chain, technology, or market. 
Generally speaking, clusters always represent a 
high concentration of people and activity within 
a particular region. Thus, a quantitative analysis 
of clusters would use measures that reflect those 
concentrations relative to benchmarks or other 
regions. A foundational theory that underlies any 
number of quantitative approaches is central place 
theory, a geographical theory that seeks to explain 
the size and spacing of human populations. The 
theory relies on the notion that centralization is a 
natural principle of human order and that nested 
hierarchies of people and institutions will fol­
low this principle.19 In the context of that the­
ory, many communities will seek to identify the 
community’s array of industry (for example, lead­
ing companies and suppliers), supply chain (the 
linked suppliers ranging from input industries 
through production to transportation, wholesale, 
and retail trade), and functional actors (finance, 
marketing, research, and labor services). 
Both of the above approaches can be used by 
all countries in all quadrants. As data becomes 
available (often only as a country becomes more 
developed), a number of other approaches can 
be used, including location quotient measures, 
shift/share analyses, and emerging-industry clus­
ter analyses. 
The location quotient (LQ) measures com­
petitiveness by comparing a region’s relative share 
of a particular activity to the share of that activity 
in some reference economy. This identifies spe­
cializations in a given regional economy. A com­
monly utilized economic-analysis method, it was 
developed in part to offer a slightly more com­
plex model to input/output analysis.20 A location 
quotient of less than one indicates that there is 
lower share of activity or nominal competitive­
ness within that region—in other words, the area 
has less than its share of activity or is less com­
petitive than the larger region or country. A loca­
tion quotient equal to one indicates the area has a 
share of activity in accordance with its share of the 
base. Finally, a location quotient greater than one 
indicates that the area is more competitive rela­
tive to other regions or the nation-state as whole. 
The location quotient can be applied similarly to 
regional wage levels relative to national or state 
levels. Additionally, the measure may be used to 
highlight policy impacts (for example, federal 
funding initiatives or support of science and tech­
nology) within a cluster or region. If a location 
quotient for support activities is significantly less 
than one, but the LQ for the cluster is greater 
than one, then there may be a case for reallocat­
ing effort more in line with natural competitive­
ness. The Boston Consulting Group adapted this 
methodology and examined year-to-year changes 
in location quotients to test the specialization of 
regions in particular industrial sectors. It arranged 
the results into four categories of clusters: stars 
(specialized with increasing specialization), ma­
ture (specialized with decreasing specialization), 
emerging (unspecialized with increasing special­
ization) and transforming (unspecialized with 
decreasing specialization). This methodology was 
then used to analyze Indiana’s cluster data: of the 
15 Indiana-based clusters identified, most were 
categorized as stars or “transforming.”21 
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Shift/share analysis is another technique used 
to determine how much of an area’s employment 
change is due to the nature of the national econ­
omy, the industrial mix, and local competitive­
ness. This approach makes it possible to separate 
growth into three components: national growth, 
industrial structure, and regional competition.22 
The shift/share analysis tool is composed of three 
components or equations. First, the national 
growth component measures the effect of nation­
al growth on a given local economy. Second, the 
industrial mix component identifies the relative 
growth or decline of local industries as compared 
to overall economic performance. Third, the dif­
ferential shift component measures the change 
in the local economy that is attributed to local 
economic advantages, such as natural resources, 
or disadvantages, such as low wages. Shift/share 
analysis was used to analyze the composition of 
the growth of the southern United States in the 
1980s.23 More recently, shift/share analysis has 
been used to assess the competitiveness level of 
Singapore’s exports.24 
Emerging cluster analysis is a broader tool. 
It begins by using employment levels to identify 
a dominant industry or a fast-growing, emerg­
ing industry. The measure compares employment 
and wage changes in an area’s cluster over a de­
fined period of time with the larger region, state, 
province, or even the nation. Overall, if the net 
change in employment and/or wages is greater 
than or equal to 100%, the cluster is considered 
to be emerging. However, if the change is be­
tween zero and 99%, the cluster is considered to 
be relatively stable. A cluster is considered mature 
when the percent change is less than zero.25 
Social networks analysis (SNA) is yet another 
diagnostic tool for cluster analysis. It is primarily 
used to collect and analyze data about relation­
ship patterns among individuals, though it does 
not simply examine the economic consequences 
of those relationships. According to Wellman, it 
is a powerful method for “explaining variances in 
resources, social behavior and socio-economic out­
comes.”26 SNA is guided by a focus on the dialec­
tical relationships between agents, nodes, and ac­
tors. It makes the invisible work visible.27 When 
applied to knowledge management, it can identify 
patterns of interaction and knowledge-exchange 
flows within a network. It shows how knowledge-
intensive work is done and can illustrate complex 
communication channels within a network. As a 
tool for analysis, SNA views “actors and actions … 
as interdependent” units and acknowledges that 
the “relational ties” between actors are “channels 
for transfer or flow of resources.” It can also pro­
vide “opportunities for or constraints on individual 
action,” which is antithetical to more traditional 
economic approaches.28 SNA helps to identify 
boundary spanners, gatekeepers, and knowledge 
bottlenecks, as well as under- and overutilized 
individuals or organizations. So many things are 
coordinated in networks (for example, work­
place environments, clubs, and memberships) 
that SNA appears to have almost universal ap­
plication. Indeed, multiple levels of analysis can 
be employed: the dyad, the node itself, or even 
the entire network. The entire incidence matrix 
(agent by agent or agent by event) can become 
the target of analysis, or it can merely become one 
variable in an adjacency matrix to explore correla­
tions between variables. 
A number of measures inherent in SNA help 
to illustrate realities that cannot otherwise be ob­
served in the social setting. Density measures how 
many potential linkages within a social setting 
(that is, pairings of different actors) are actually 
operational. Theory suggests that some nontrivial 
amount of density is required, but that too dense a 
community can stifle innovation and change. The 
concept of centrality refers to the importance of 
particular actors and the hierarchical nature of an 
entire network. In general, centrality measures are 
used to “… describe and measure properties of ‘actor 
location’ in a social network.”29 Centrality (applied 
to the node level) is a family of three measures, 
each answering a different theoretical question. 
High degree centrality refers to a high number of 
ties and the level of power or informal leadership 
capacity of an actor, agent or node. High closeness 
centrality builds upon high-degree centrality but 
also looks to the nature of the distance between 
nodes. Betweenness centrality identifies the critical 
route for flows in the network and the dominant 
node or agent that has more close relationships to 
other dyads. In terms of centrality, it is not just 
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how many connections an agent or node has, but 
how central its connected actors or agents are.30 
The power of a node or actor can be measured 
as a function of its position within a given net­
work.31 The eigenvector measure is useful for this 
analysis. An actor or agent who is high on eigen­
vector centrality is connected to many actors who 
are themselves connected to many actors, thus 
multiplying their risk and/or opportunity: this is 
their power indicator.32 While the data require­
ments for SNA can be large, there are a number 
of generally available proxies. Co-publications 
(bibliometrics) and co-patents (technometrics) 
are often used as proxies for social interactions 
among agents.33 
These discrete measures and analytical ap­
proaches have been employed to varying degrees 
in a number of regions or countries around the 
world. Table 2 provides a provisional assessment 
of analytical approaches and measures used to ana­
lyze regional competencies across a select number 
of regions worldwide. Upon closer examination, 
it appears that when multiple clusters are ana­
lyzed within a region, more analytical approaches 
are required or undertaken. Also, specialized or 
knowledge-based clusters often demand a more 
complex blend of analytical methods. For ex­
ample, Minnesota’s (low technology) industrial 
clusters were analyzed using location quotients 
and input/output analysis alone, while Iowa’s 
Table 2: Cluster Analysis Methods across Select Countries and Regions
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Calgary wireless cluster (6)
 
Mississauga’s ICT cluster (7)
 
Quebec photonics cluster (8)
 
Saskatoon’s canola research cluster (9)
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Sources: See endnotes for full list of sources.34 
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more-advanced technological clusters were ana­
lyzed using a combination of approaches. SNA 
appears to be less commonly used as a cluster 
analysis approach, at least partly because the pro­
cess can be resource and time intensive and fre­
quently requires gathering primary data, which is 
often not pragmatic from a practitioner’s point of 
view. Past practice suggests that input/output and 
institutional or descriptive-based analyses are the 
most commonly used approaches for exploring 
clusters. Additionally, the location quotient ap­
pears to be the quantitative tool most commonly 
used in this selection of regions or clusters. 
No matter what approach or tool is used 
to analyze a given cluster, the efficacy of such 
measures depends upon the quality of the data. 
Knowledge-based industries in particular, such 
as biotechnology, often are not adequately re­
flected in data collected through North American 
Industry Classification System (NAICS) codes. 
Furthermore, there is no consensus on where to 
draw lines or pull together multiple codes to best 
represent a cluster. Cluster boundaries, particu­
larly in advanced technology sectors, cannot be 
defined by conventional product-based industrial 
or sectoral boundaries. This limitation is particu­
larly important with respect to biotechnology. 
2.2 Step 2: Choosing a cluster strategy 
Table 3 outlines a chronological typology of clus­
ter definitions, beginning with Porter’s industrial 
approach. Different cluster approaches will have 
a different set of requirements, a different mix of 
leaders and tactics, and will fit better with some 
categories of countries than others. Economic de­
velopment agencies in developed and developing 
countries have usually applied Porter’s generalized 
approach to clusters, customizing it to the par­
ticular geopolitical region (see chapter 3.12 for 
examples). Indeed, despite the lack of consensus 
about what a cluster does and how it operates, 
Porter’s version of a cluster has been rapidly ad­
opted by practitioners from all over the world. 
Porter’s industrial managerial characteriza­
tion focuses heavily on the local and regional 
relationships between competing and collaborat­
ing companies, often without any specific indus­
trial, product, or technological core. These types 
of clusters appear to emerge and succeed where 
there are a number of highly competitive compa­
nies or competing supply chains that rely on the 
economies of scope and scale delivered by related 
and supporting industries. Porter emphasizes that 
the most successful clusters of this type have ei­
ther a direct local or a strong link to demanding, 
leading-edge consumers. Few centers in the world 
(especially in Quadrants II–IV but even in some 
of the more-advanced Quadrant I countries, such 
as Australia, Canada, and New Zealand) can meet 
this criterion. In this sense, these types of clusters 
have a greater chance of success in Quadrant I na­
tions, such as the United States, European Union, 
and Japan, all of which have large, wealthy, and 
demanding (that is, trend-setting) indigenous lo­
cal markets. 
The product/market, flagship company, and 
value chain models are all variations on cluster­
ing focused around a technology, product supply 
chain, or product market. As companies in these 
types of clusters seek greater efficiencies, they be­
gin to formally and informally acknowledge their 
local and regional interdependencies with other 
competing and completive companies. Over 
time, various types of nontrade interdependencies 
arise, which strengthen the collective. This model 
has perhaps more applicability to a wider range 
of countries because all economies, regardless of 
their local capacity, are fundamentally linked to 
a technology, product, or market through some 
form of supply chain or industrial structure. The 
difference in the three approaches is who takes the 
lead. In the product/market cluster there often is 
no single formal leader; instead, varying combi­
nations of companies and civic leaders will work 
to build the needed infrastructure, scale, and 
scope to realize the cluster’s potential. A number 
of clusters actually have sole leadership vested in a 
flagship company or national champion. The val­
ue chain model usually vests leadership in some 
“integrator.” This can vary widely depending on 
the nature of the supply chain: it can be the larg­
est enterprise in the chain; a logistics, wholesale, 
or retail actor; the owner of some key technology, 
infrastructure, or product in the chain; or it can 
be a leader of some industrial, technical, research, 
educational, or financial organization. This type 
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Table 3: Chronological Typology of Cluster Definitions and Examples
 
Cluster type Definition/description Example(s) 
Industrial/managerial 
characterization 
a geographic concentration of competing 
and cooperating companies, suppliers, service 




based on industrial interdependence (supply 
and demand linkages) 
Product/market focus 	 characterized as networks of production of Italian footwear 
strongly interdependent companies,knowledge cluster 
producing agents, and customers linked to each 
other in a value-adding production chain Australian wine 
cluster 
Flagship/company Multinational-enterprise-ledclusters/anchor; Monsanto-led 
act as flagships St. Louis, Missouri,
BioBelt Cluster 
Value chain (horizontal 	 includes final market producers, and first-, Silicon Valley 
and/or vertical)	 second-, and third-tier suppliers that directly 
and indirectly engage in trade (A value chain Boston Life 
cluster is an industry cluster identified as an Sciences Cluster 
extended input/output or buyer/supplier 
chain. The cluster comprises multiple sectors or 
industries.) 
system of market and nonmarket links between 
geographically concentrated companies and 
institutions (The links enable cooperation 
among suppliers and competitors on business 
processes, purchases, investments, strategies,
and technical research.) 
Networks	 most salient in a domain between the Biovalley (borders 
flexibility of markets and the visible hand of France,Switzerland,
organizational or political authority and Germany) 
Innovative entrepôt	 geographic specialization in a few linked Saskatoon canola 
stages in the innovation supply chain (for research cluster 
example, research, development, gestation, and (Canada) 
adaptation) 
Source: Adapted from Phillips37 
2 | HANDBOOK OF BEST PRACTICES 










of model would appear to be scalable to all of the 
categories. 
Finally, some clusters are defined by their role 
in developing useful knowledge. The networked 
model is increasingly common in large centers in 
Europe and the United States. Examples include 
world-scale universities (for example, Stanford/ 
UC Berkeley in San Francisco), critical research 
infrastructure (CERN in Switzerland), and of­
ten the head offices and research centers for large 
multinationals. Malerba38 identified two discrete, 
independent systems of innovation that would fit 
the networked model. Typified by the computer 
software industry, one system is based on flexible 
networks of small- and medium-sized companies, 
often co-located in distinct industrial districts (for 
example, Silicon Valley), and coordinated by a 
range of commercial venture-capital corporations 
and angel investors. Companies in these commu­
nities tend to be significantly volatile and rapidly 
growing. The other type of system, which perhaps 
better reflects the biotechnology world, is based 
on the universities, public research laboratories, 
and large companies that perform and commer­
cialize R&D. While clearly attractive, this model 
has limited scope to expand beyond the largest 
agglomerations. These are currently in the United 
States, the European Union, and Japan (and per­
haps in the larger research centers at Melbourne, 
Australia, and Toronto, Canada). In time, howev­
er, it could be attractive, especially to Quadrant II 
countries with large populations (such as China, 
India, and Brazil), which are increasingly focused 
on adopting, adapting, and increasingly develop­
ing new technology. 
An alternate “innovative entrepôt” model be­
ing adopted by some smaller, research-intensive 
communities concentrates on a narrower range of 
inventive areas and seeks to fashion some com­
parative advantages by being an expert in some­
thing in a particular location. While this model39 
requires most of the elements of the larger net­
worked clusters, it relies on small, nimble, highly 
specialized networks to create a comparative 
advantage for the region. This has particular ap­
peal to many communities because it does not 
require the scale of the networked model, and it 
can be adapted and adopted realistically in most 
countries. Scale is less important than focus and 
strong networking. The challenge of this model, 
however, is that it requires the capacity for a high 
degree of trade in people, knowledge, technolo­
gies, and products, making it less attractive to 
Quadrant III and IV countries where there re­
main significant economic, legal, social, cultural, 
and physical barriers to the flows necessary for 
such a model to work. 
2.  Step 3: Finding institutional and 
organizational leaders 
Actors provide varying levels of leadership based 
on the dominant activity of different stages of the 
industrial life cycle. Key actors in most clusters are 
often the university, public sector research labo­
ratories and institutions, and the private sector. 
The first two categories of clusters—Porter’s in­
dustrial managerial model and the product, mar­
ket, value chain approach—tend to be led by pri­
vate companies, while more innovative networks 
or entrepôts will have varying arrays of leaders, 
depending on the rate of innovation. Zilberman 
and colleagues40 undertook a conceptual analysis 
of agricultural biotechnology, proposing a five-
stage linear development process (including dis­
covery, development, gestation, production, and 
marketing), with different actors (universities, 
public labs, and corporations), taking the lead at 
different stages. In early stages, public labs and 
universities tend to lead, with corporations doing 
little beyond marketing any resulting products. 
The model suggests that as the technology ma­
tures, corporations contribute more and increas­
ingly take the lead. 
Almost all scholars and practitioners agree 
that competitive, profit-seeking companies are at 
the core of any cluster. While some clusters seem 
to be able to operate without a clear dominant 
player, many scholars have noted that some of 
the strongest clusters are formed around mul­
tinational enterprises (MNEs).41 Rugman and 
D’Cruz42 argue that MNEs frequently act as flag­
ships to lead, direct, coordinate, and manage stra­
tegic, value-added activities of collaborative com­
panies in combined business and social networks. 
According to their research, 14 of the world’s 20 
largest international MNEs (defined by revenues 
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and global presence) were largely home-based 
organizations with strong regional strategies and 
networks. Gassman and Gaso43 argue that regard­
less of whether the MNE is home-based or not, 
it can act as a broker of knowledge in a cluster. 
Some MNEs contribute information in disem­
bodied forms: they set up “listening posts” in 
many regions around the world and distribute in­
formation. Other MNEs transfer knowledge em­
bodied in new technologies, new processes, and 
new products. Regardless of the method, compa­
nies are a necessary condition for a cluster. 
The regional university can also directly or 
indirectly drive the evolution and success of a 
technology cluster. According to Niosi and Bas,44 
innovation in emerging technologies and indus­
trial clusters can be spurred indirectly through 
decentralized, horizontal policies that include 
the creation of both government laboratories 
and research universities. A source for skilled la­
bor, the university acts as a magnet (directly and 
indirectly) for “stars” and business. Moreover, 
its publications can be a conduit for local and 
nonlocal knowledge exchanges. The traditional 
role of a university is to generate and diffuse basic 
or explorative (know-why) knowledge and gener­
ate a skilled academic and technical labor force. 
However, these traditional roles are evolving. As 
Cooke45 argues, a strong local science base needs 
to be complemented by a rich entrepreneurial cul­
ture not only within the regional business com­
munity but also within the academic community. 
He further suggests that “… the science base is a 
magnet, even if only indirectly ... for biotechnology 
business.” This is supported in previous research, 
which found that the existence of a diversified, 
mainly academic, knowledge base is a prerequi­
site for successful, localized innovative activity 
in knowledge-based sectors like biotechnology.46 
Niosi suggests also that universities are a founda­
tional element of the “virtuous cycle” embedded 
within the cluster phenomenon—star scientists 
become entrepreneurs and spinout commercial 
ventures.47 
Regional leadership is not limited to just or­
ganizations and companies. Key individuals can 
be ambassadors or civic entrepreneurs for regions 
and/or act as catalysts for change. For example, 
Robert Mondavi altered the face of the wine in­
dustry when he founded the wine cluster in the 
Napa Valley in California. Wine producers were 
already in the region, but most guarded their op­
erations with secrecy. Mondavi opened the doors 
of his winery to tourists, customers, and competi­
tors alike, effectively transforming the regional 
wine industry into an open platform of pooled 
knowledge and diverse products that eventually 
spelled success for the region.48 
Finally, collaborative leadership has been an­
other powerful tool in some regions. For exam­
ple, the BioValley network (located in the Rhine 
valley where France, Germany, and Switzerland 
meet) was initiated in 1996 following the merg­
er of Ciba-Geigy AG and Sandoz AG, both of 
Basel, Switzerland, to form Novartis AG. The re­
gion had lost jobs from the merger, so advocates, 
both key individuals and existing organizations, 
led revitalization efforts. The original BioValley 
concept, developed by Georg Endress and Hans 
Briner, was to re-create the region as a “Silicon 
Valley” dedicated to biotechnology and chemical 
technologies. 
Cooperation or collaboration among public/ 
private actors and individuals is important for the 
innovation process. Cross-fertilization through 
partnerships, either in projects or in efforts to 
build innovative regions, alerts the public sector 
to market demands and provides companies with 
access to basic research. 
2. Step 4: Choosing tactics 
While many purposive, directed strategies can 
help, perhaps a cluster’s most important require­
ment is that the economic and business climate 
support market efforts. Because clusters involve 
both traded and untraded interdependences 
that can thrive only with strong underpinnings 
for market and social activity, centrally planned 
markets are unlikely to develop a true cluster. 
Minimally, a country needs to have the legal and 
social structures that create certainty for what 
would otherwise be risky transactions: the rule 
of law; effective and efficient mechanisms to 
protect and adjudicate property; the lowest pos­
sible barriers for entering or exiting any of the 
key input and output markets; the ability to trade 
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domestically and internationally; and effective 
tax, regulatory, and trade rules. Moreover, clusters 
tend to thrive best when at least a base investment 
has been made in education, training, and general 
community infrastructure. Clusters do not go in 
search of the lowest cost site; rather, they locate 
where things can get done. Unfortunately, such 
basic conditions are absent in many regions of the 
world, but especially in Quadrant IV countries. 
Any proactive measures to create a cluster with­
out most if not all of these basic preconditions 
would likely be useless. In some instances, one 
or more of these foundational conditions may be 
missing (or weak) and a cluster might emerge, 
but generally proactive efforts will only succeed if 
markets can function. 
Beyond ensuring an appropriate climate, an 
almost limitless array of proactive investments 
can nurture one or more cluster types. Some are 
more appropriate for some types of cluster than 
others. (Of course, there is no guarantee that the 
efforts will create the benefits envisaged.) A favor­
ite tactic is to start with a cluster’s core actors. All 
successful clusters appear to have a hub or anchor. 
Depending on whether the cluster is industrial/ 
managerial or product, technology, or supply­
chain-focused, this could be a set of competing 
companies, a leading company, a university, a 
public laboratory, or an industry association. If 
an anchor does not already exist, most regional 
planners and politicians will instinctively think of 
an investment-attraction program; virtually every 
jurisdiction in the world has someone marketing 
their location as a place to do business. But while 
expectations are often high, prospects are poor. 
Few companies are truly mobile. Most that are 
mobile would need inducements: large subsidies 
that could have a higher impact in other areas and 
that, in the end, would add little to job creation 
and wealth generation in the long term. In the 
absence of an obvious anchor, it usually makes 
more sense to build on potential local candidates 
than to try to lure others with subsidies. In lieu of 
a dominant companies, regions have sometimes 
been able to nurture Porterian or supply-chain 
type models, as long as they have been able to tap 
into distribution systems that provide access to 
global markets.
A second common model is to build poten­
tially attractive infrastructure on the assumption 
that “if we build it they will come.” Unfortunately 
for many of these ventures, infrastructure is only 
a minor attraction: “You will build it and they will 
not come.” Increasingly, infrastructure needs to 
be tailored to the specific needs of a user, so if it 
is built on speculation, it often can be far more 
costly than if it is built to suit. Having said that, 
industrial actors often cite infrastructure, in the 
form of labs, incubators, and sophisticated ma­
chinery that benefits a wide range of users, as a 
key reason for their presence in a community. The 
physical plans for any infrastructure may be less 
important in the long run than the business mod­
el. An operator of infrastructure—be it a research 
park, special laboratory, or experimental facil­
ity—will need to tailor the terms of access and 
use to ensure that highly volatile and competitive 
research and development programs are able to 
access the facilities at the right time and under 
the right terms (for example, clearly defined IP 
rules). In research today, timing and terms are of­
ten more important than cost. Nevertheless, there 
is no single infrastructure set that is necessary or 
sufficient to make any cluster work. 
Some think money is the key to the problem: 
If only more programs were created and more 
money made available, a cluster would emerge. 
It is true that money drives activity, but not all 
activity is desired. While in theory money is fun­
gible—it shouldn’t matter where it comes from— 
in practice money comes with strings attached. 
Who provides it and under what conditions can 
influence what others are able to accomplish with 
it. MNEs and other for-profit companies provide 
the lion’s share of capital in almost all markets, 
so engaging profitable operating enterprises is 
almost a prerequisite for creating a sustainable 
cluster. During growth phases, however, public 
and private venture capital can be a critical con­
tributor to the success of new technologies, prod­
ucts, and ventures. In the early stages of research, 
public funding tends to dominate, with private 
capital taking over as technologies, products, and 
processes mature and get closer to the market. In 
fact, public funds at later stages can be both good 
and bad. Government decision-making processes 
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(designed to ensure accountability and transpar­
ency) are generally inimical to effective and ef­
ficient financing: many companies ultimately 
supported by government grants or subsidies find 
the benefits are dissipated by slow decisions and 
inflexible terms. Furthermore, governments often 
have difficultly exerting the same influence as pri­
vate investors. For example, it is hard for most 
governments to change management in a venture 
they have invested in or to divest or write down 
their equity. Public funds tend to be most effec­
tive when they are partnered and leveraged with 
private funds or private management skills (for 
example, microcredit systems and public/private 
venture pools with private management). 
Locations lacking an anchor, an irresistible 
piece of infrastructure, and unlimited financial 
resources often look to their public research insti­
tutes or universities, especially in the early stages 
of developing a new technology area. Particularly 
with knowledge-intensive industries such as bio­
technology, universities’ public investment in 
R&D facilities is arguably a crucial precondition 
for a knowledge-based innovation system. Their 
capacity to create social capital, nurture and sup­
port stars, and provide a basis for collaboration 
and innovation—while harder but not impos­
sible to measure—is ultimately the real value of 
such investments. As previously mentioned, the 
regional university can drive (directly and indi­
rectly) the evolution and success of a technology 
cluster. Niosi and Bas49 assert that universities do 
four main things: they generate know-why knowl­
edge; they provide skilled, educated labor; they 
draw (directly and indirectly) stars and business; 
and they facilitate local and nonlocal knowledge 
exchanges (for example, publications and joint 
research). Many argue that a university’s most im­
portant output is the base that it provides for the 
“absorptive capacity” of an economy. While the 
university is vital, it will only be able to perform 
this function in conjunction with a number of 
other essential elements. First, there must be an ef­
fective mechanism to both practically and legally 
transfer knowledge. At a minimum, this requires 
a domestic research community with interna­
tional collaborations, companies with proprietary 
technologies, and an appropriate national system 
to legally protect IP. Second, there must be open 
and accessible labor markets for skilled and edu­
cated workers. Third, an institutional platform, 
such as a major national laboratory, a university, 
or a big research institute/program, is needed for 
community-based interaction and synergies to 
develop. These provide the foundation for ab­
sorbing global knowledge. Other elements, such 
as preferential financing and specialty commer­
cial services, may be important but appear to be 
second-order requirements. 
Ultimately, many theorists and practitioners 
are looking to “people policies” to nurture clus­
ters. People are at the heart of generating new 
ideas and technologies, people lead and work in 
companies and institutions, and people are the 
core of networks. Some clusters seek to build 
up their local talent by creating new educational 
and skills training programs focused on the mar­
ket needs of their local companies and clusters. 
Others work on building bridges to attach gradu­
ating students to the local labor market. These 
programs range in focus from technical train­
ing, entrepreneurial training, and mentoring to 
specialized advanced research techniques. Some 
clusters seek to attract highly skilled, educated, 
motivated, and experienced stars from elsewhere 
to populate their community and provide new 
ideas and leadership. Florida and Gates50 have 
suggested that the most vital and vibrant commu­
nities in the United States and Canada are those 
that value and support tolerance and talent. They 
suggest that creative, entrepreneurial people will 
tend to vote with their feet and move to com­
munities with the most accommodating lifestyle. 
Other researchers suggest that good climate, cul­
ture, civic amenities, tax levels, and other qual­
ity-of-life measures are vital to creating a cluster. 
There is, however, some contradictory evidence: 
attraction to clusters may be less about quality 
of life and more about the depth of local labor 
markets (for example, the potential of there be­
ing more than one employer for one’s specialized 
skills in the area) and the nature of the job (for 
example, one that is on the cutting edge of a tech­
nology or market).51 
A closely related people-policy strategy is 
to target local stars in a community. Zucker 
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and colleagues52 have noted that in the U.S. 
biotechnology field, academic and professional 
research stars (that is, those with a significant 
number of patents or publications) appeared to 
be instrumental in attracting major peer-reviewed 
grants, were key players in translating knowledge 
between academic and applied research, and were 
major contributors to the spinout of many new 
biotechnology companies. These stars assisted 
other researchers and industry. When the stars 
became affiliated with new spinouts, this signaled 
the presence of an opportunity to the market­
place. Some regions have attempted to collect 
more clusters of stars by collecting research exper­
tise in national centers of excellence in public labs 
or universities. These regions and stars have also 
provided added incentives for the scholars and 
scientists to engage in more external activities, 
on public and private boards and commissions, 
or through consulting work. Similarly, many 
communities promote or nurture civic entrepre­
neurs. Often in university, industry, or industry 
associations, these individuals undertake efforts 
to defend, explain, or inform the entire cluster 
to its members and others outside. These civic 
entrepreneurs are highly valued—they will often 
personify and coalesce a cluster’s spirit and aspira­
tions. The regional entrepreneurial culture is also 
considered important, but it is not clear whether 
it is an independent variable or is simply deter­
mined by local economic development. 
2.  Step 5: Sustaining a cluster 
through its life cycle 
Clusters appear to have life cycles. Sometimes 
strong centripetal forces pull activity to the 
community (for example, through knowledge 
spillovers and economies of scale and scope); at 
other times, centrifugal forces will dominate (for 
example, diseconomies and congestion costs).53 
Lundvall54 offered a neo-Schumpeterian model 
of industrial development that explains localiza­
tion patterns based on the degree of technological 
development: innovative clusters have the high­
est incentive to agglomerate, but markets become 
concentrated and profits stagnate as benefits de­
cline, costs rise, and products are standardized. 
Sustaining a cluster, therefore, is not ensured. 
Successful clusters continue to focus on innova­
tion (rather than on production efficiencies), 
which requires sustained investment in R&D. 
The cycle of investment and return in clusters 
has been explored also by Davis and Schaefer,55 
who outline a five-stage evolutionary process. In 
the first stage, assets are accumulated, with in­
vestments often coming from the public sector 
(for example, the recent worldwide infusion in 
genomics research). In the following stage, as­
sets are converted into business resources through 
entrepreneurial effort. Next, the cluster is estab­
lished and companies grow by exploiting new re­
sources and capabilities in external markets. Then 
as production and markets mature, collective 
efficiencies are realized. Finally, various market 
and non-market selection processes lead to lo­
cal specialization. Crone offers a more formally 
delineated and stylized five-stage cluster-devel­
opment model: precluster, protocluster, emerg­
ing cluster, established cluster, and restructuring 
or renewal states.56 According to Crone, these 
stages are not intended to constitute a determin­
istic life cycle model but to serve as an analytical 
tool. Rosenfeld57 alludes to yet another life cycle 
model in his exploration of clusters and cluster 
policy in less favored regions of the European 
Union. According to Rosenfeld, clusters progress 
from an embryonic stage through growth and 
maturity until they finally decay. The embryonic 
stage is stimulated through innovations, inven­
tions, or inward investment. During the growth 
stage, markets develop sufficiently to spinout and 
attract imitators and competitors; entrepreneur­
ship is also cultivated. In the maturity stage, the 
activities of the cluster have become more rou­
tine. More imitators enter the market, and lower 
costs become the key competitive advantage. The 
decay stage is when products or processes become 
expendable and are easily substituted in the mar­
ketplace by more cost-effective alternatives. 
Just as in the industrial life cycle, clusters dif­
ferentiate according to scale, scope, character, and 
activities. Regardless of how a cluster is character­
ized, it is still likely to be subject to the evolu­
tionary dynamics of markets. At any given point 
in the developmental cycle—cluster or indus­
trial—activities must shift. Different actors take 
HANDBOOK OF BEST PRACTICES | 2
  
     
	
 




   
   
 
  
    
       
     
     
     
   
      
        
   
PHIllIPS & RYAN 
on differentiated roles. At some points, activities 
may be concentrated or centralized within one 
institution. At other times, activities may be car­
ried out collectively by a number of actors work­
ing in collaboration. Such responses to global 
market signals and industry developments must 
be orchestrated to avoid the declining stage of in­
dustrial development or the decay of a cluster. 
.  ConCLuSIonS 
Cluster strategies would appear to be high-risk, 
high-return economic policies. While not all 
types of clusters are appropriate for all coun­
tries, most countries could attempt at least one 
or more options. If thoughtfully and prudently 
undertaken, the investments in analysis, strat­
egizing, building local leadership, and pursuing 
various tactics would generate positive social re­
turns even if a sustainable cluster did not devel­
op. Indeed, most of the options appropriate for 
clusters are also just good economic policy. One 
point that anyone interested in economic devel­
opment should keep in mind is that most sectors 
are becoming more knowledge intensive. Even in 
low specialized areas, such as garment industries 
in developing nations, technologies are being 
adopted to increase productivity and flexibility. 
In short, while clusters are attractive economic 
development tools, they must be nurtured with 
an appreciation for their partial and incomplete 
nature. Fundamentally, they are part of a global 
innovation system, and cannot thrive if cut off 
from the lifeblood of the system—ideas, skilled 
labor, capital, and competing and collaborating 
companies and organizations. 
Knowledge-based development is inherently 
different from traditional industrial development. 
While infant industry protection made some sense 
in the industrial context, it is not clear whether it 
has any value in a knowledge-based world. The 
imperatives of innovation pose some serious chal­
lenges for development policy. Many current 
development efforts have a strong mercantilist 
orientation, with a focus on self-sufficiency. In 
an effort to generate higher-value exports or to 
replace imports, governments at all levels in many 
countries are using their tax and fiscal policy to 
encourage greater local R&D or to attract global 
companies to relocate their R&D programs into 
their jurisdiction. This often involves preferential 
support for national champions or exclusive deals 
to encourage MNEs to relocate their activities. 
Usually governments do this without consider­
ing the corresponding relationships and interac­
tions that knowledge-based companies require 
to succeed. If innovation can happen within a 
company, companies, or a regional or national 
community, then such a narrow approach might 
have some chance of success. But if innovation 
is truly global, as appears to be the case in many 
of the life sciences, then narrow, mechanistic self-
sufficiency strategies may either simply fail or be 
counterproductive. This is why both companies 
and skilled employees are more interested in the 
innovation community than in fiscal incentives, 
public infrastructure, or other government sup­
port. By extension, a mercantilist policy that dis­
courages global links could not only fail to attract 
global companies but could also drive out local 
companies or researchers as they seek access to the 
global community. n 
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ABSTRACT 
This chapter presents the main forms of statutory intel­
lectual property (IP) protection with emphasis on utility 
patents, trademarks, geographical indications, copyright, 
and trade secrets. Basic questions with regard to who can 
get protection, the subject matter of each form of protec­
tion, statutory requirements, and certain exceptions. The 
chapter concludes with short sections on institutional as­
pects including employee agreements, how to mark the 
protected intellectual property, how to integrate the vari­
ous rights, and how to identify infringement. The authors 
conclude that the form of protection chosen for a given 
invention should be guided by the mission of the institu­
tion (whether public or private), the purpose of the work 
it conducts, and the nature of the invention, or other IP, 
that will be subject to IP rights protections. 
1. InTRoduCTIon: WHAT	IS	 
InTELLECTuAL	 pRopERTy? 
Intellectual property (IP), sometimes called in­
tangible property is any product of the human 
mind or intellect. Intellectual property can there­
fore be almost anything: a technical invention 
or an improvement of an earlier invention; it 
can be a unique name or logo, design, method, 
software, database, domain name, a chapter in a 
book (like this chapter), or an entire book (like 
this Handbook). The broad area of intellectual 
property is subdivided into different types, each 
clearly defined and protected through statutes 
or laws, which then can be protected by differ­
ent means. In the United States, for example, 
IP rights protection is even enshrined in the 
Constitution of the United States of America: 
The Congress shall have power … to pro­
mote the progress of science and useful arts, by 
securing for limited times to authors and inven­
tors the exclusive right to their respective writings 
and discoveries … .1 
By this clause the Constitution grants the 
rights to patent and copyright protection. Even 
though trademarks are not expressly protected 
by the Constitution, trademarks have a long his­
tory of use and protection in the United States 
and globally. Likewise, trade secret protection has 
long been accepted as a means for protecting IP 
rights. Other forms of IP protection include plant 
breeders’ rights. 
What makes these forms of IP protection 
particularly useful is that they have been able to 
adapt to the changing times. Even if the present 
technologies are different from the technology 
that was protected in Thomas Jefferson’s day, the 
means to protect are similar. But the essential 
nature of patents was “invented” well before the 
Constitution was written. They emerged in me­
dieval Europe where first rights were granted to 
individuals for what they owned, using a remu­
neration or an award as a means to encourage in­
dividuals to generate “property desired by them­
selves.” A more formal system of patents was born 
in the Venetian Republic where the first patent 
Dodds J and A Krattiger. 2007. The Statutory Toolbox: An Introduction. In Intellectual Property Management in Health and 
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. J Dodds and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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DODDS & KRATTIGER 
was granted in 1443 to a manufacturer of con­
veyors for loading and unloading ships.2 Two cen­
turies later, in 1623, the British Crown passed a 
patent law, then called the Statute of Monopolies. 
This law defined basic concepts that continue to 
influence to this day the interpretation of patents 
around the world. 
In the United States, the first patent law was 
adopted in 1790, shortly after the Constitution 
was ratified. The first U.S. patent was signed 
by President George Washington on July 31, 
1790 and was issued to Samuel Hopkins (of 
Pennsylvania) for his improvement of the pot­
ash manufacturing process. The invention saved 
what was then the country’s leading export 
industry. 
In the following chapters we will look briefly 
at issues related to the protection of intellectual 
property; Table 1 provides an overview of the 
main tools of IP protection. We especially focus 
on the law in the U.S., though in general terms, 
similarity exists throughout many parts of the 
world. Where international agreements regulate 
IP protection, that is noted. In national laws 
there are differences: some countries give broad­
er protection to intellectual property, others, 
narrower, but basically the forms of protection 
are similar, especially in member countries of the 
World Trade Organization (WTO), which ad­
here to the Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS). 
2. pATEnTS 
2.1 What is a patent? 
A patent, which usually refers to a utility patent,
can be granted to anyone who invents a new and 
useful process, machine, article, manufacture, 
composition of matter, or any new and useful 
improvement thereof. A utility patent is usually 
granted for a period ending 20 years after the fil­
ing date. A patent gives the inventor a right to 
exclude others from making, using, offering for 
sale, or selling the invention in the country where 
the patent is issued or importing the invention 
to the country where the patent is issued. In ex­
change for being granted a patent, the inventor 
agrees to disclose in the patent application, the 
invention in detail as well as the best mode of 
practicing the invention. The disclosure is pub­
lished normally 18 months after the filing but, at 
the latest, when the patent issues. Disclosing the 
invention to the public will help others to invent 
further, thus pushing technology forward for the 
benefit of the society. 
In the United States, there are three different 
kinds of patents: utility patents, design patents, 
and plant patents. Plant patents are essentially 
specific to the United States. In addition to these 
types of patents, several counties provide addi­
tionally utility model protection. Utility models 
are also called petty patents. Basically they allow 
the right holder to prevent others from com­
mercially using the protected invention during a 
limited time period. Therefore, a utility model is 
basically similar to a patent. The main difference 
is that the requirement of nonobviousness, or in­
novative step, is not as stringent for utility mod­
els as it is for patents. Moreover, the duration of 
the protection given by utility models is shorter 
than that given by patents. The duration depends 
on the country; usually the protection is between 
seven and ten years. In Estonia and Finland, for 
example, an invention can be protected by utility 
model for ten years, at most. 
In the United States, a utility patent can be 
filed as a provisional or a nonprovisional applica­
tion. A provisional patent application is a lower-
cost first patent application, which does not have 
to contain any claims. A provisional patent ap­
plication has a pendency of 12 months from the 
date of its filing. A provisional patent application 
cannot mature to an issued patent but it gives the 
inventor an early filing date, and the term patent 
pending is applicable. In order to benefit from the 
early filing date of the provisional application, a 
nonprovisional patent application has to be filed 
before the end of the 12 months pendency of the 
provisional application. It is possible to extend 
the period of patent life up to 21 years by first 
filing a provisional application and then later a 
nonprovisional one.4 
A design patent can be granted to anyone who 
invents a new, original and ornamental design 
for an article of manufacture. A design patent is 
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DODDS & KRATTIGER 
granted for a period of 14 years from the date of 
issuance. 
Certain countries provide protection called 
registered or industrial designs, which is similar to 
the U.S. design patent. In some countries, indus­
trial design provides protection of up to 25 years. 
Since April 2003, one can also get a Community 
Design in the European Union, which protects 
the design in all the member countries of the 
European Union for up to 25 years. 
Plant patents are a form specific to the United 
States. A plant patent can be granted to anyone 
who invents or discovers and asexually reproduces 
any distinct and new plant variety. Tuber-propa­
gated plants are excluded from plant-patent pro­
tection. For sexually reproduced (by seeds) or tu­
ber-propagated plants, one can get protection via 
the Plant Variety Protection Office administered 
by the U.S. Department of Agriculture. Several 
countries provide protection to sexually repro­
duced plant breeds through plant breeders’ rights.5 
It is important to note the distinction between 
plant patents and utility patents on plants.6 
2.2 Who can get a patent? 
According to the law in perhaps any country 
with patent law, only the inventor can apply for 
a U.S. patent. However, if the inventor is dead, 
a legal representative can make the application. 
Similarly, if an inventor assigned the right to his 
or her employer or any third party, that entity 
may file for the patent. In any case, it is impor­
tant that the true inventors are named in the pat­
ent application. If there is more than one inven­
tor, the inventors apply for the patent jointly. A 
person who contributed to the invention only 
financially cannot be a joint inventor. None of 
the inventors needs to be a U.S. citizen or live 
in the United States in order to be entitled to a 
U.S. patent. 
2.	 U.S. and “international” (PCT) patent 
applications 
A patent is territorial. This means that there is no 
such a thing as a world patent. A U.S. patent is 
valid only in the United States and the owner of a 
U.S. patent therefore can, based on the U.S. pat­
ent, only claim rights in the United States. 
The Patent Cooperation Treaty (PCT) is an 
international treaty harmonizing patent applica­
tion procedures in its member countries. Through 
a PCT patent application, the inventor can get a 
filing date with one application in all the member 
countries. Thirty months after the filing, the ap­
plicant has to decide in which member countries 
he or she actually wants and needs a national pat­
ent. The benefit of PCT application is that there 
is no need to file separately in all the countries; 
the procedure can be done by one application. 
Moreover, the PCT system gives the inventor ap­
proximately 30 months to shop around before 
deciding in which countries a national patent 
would be relevant. 
All the PCT applications will be published 18 
months from the filing if not abandoned before 
that. Usually, a U.S. patent application is published 
18 months after the filing, if nonpublication is not 
specifically requested. The applicant is entitled to 
request nonpublication if the application is not 
and will not be a subject of filing in any country 
publishing the patent application 18 months after 
filing. Nor may the invention be subject to a PCT 
application. When the patent has issued it will be 
published. Due to the publishing policy of PCT, 
some inventors prefer to file a U.S. patent and re­
quest no publishing, thereby keeping the inven­
tion secret until the patent issues.7 
2.	 First to file versus first to invent 
The United States is the only country in the 
world not applying the first-to-file concept. 
In the United States a patent is granted to the 
party that first invented. Because of this concept 
the U.S. patent system is known for its interfer­
ence practices. Interference is a proceeding con­
ducted before the Board of Patent Appeals and 
Interferences to determine priority on inven­
tion between a pending application and another 
pending application or unexpired patent. The key 
elements of determining priority are the date of 
conception, the date of reduction to practice, and 
diligence or lack of it. 
2.	 Subject matter of patents 
In the United States, statutory subject matter of 
a patent is defined as “any new and useful process, 
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machine, manufacture, or composition of matter or 
any new and useful improvement thereto.”8 
The Supreme Court acknowledged through 
legislative history that Congress intended that 
statutory subject matter includes “anything under 
the sun that is made by man.”9 
The Supreme Court has specifically identi­
fied three categories that are not patentable. Laws 
of nature, natural phenomena, and abstract ideas 
do not fall into any statutory class and they are, 
therefore, unpatentable. Furthermore, items from 
these categories are not patentable according to 
the national legislations of many other countries. 
Some national laws give further provisions for 
nonpatentable subject matter. For example, India 
does not allow patents on agricultural methods. 
The European Union and many other countries 
do not allow patents on methods to treat a hu­
man condition or surgical methods. 
Mathematical algorithms as such are abstract 
ideas when they stand alone and are not reduced 
to a practical application. However, when an ab­
stract idea is reduced to a practical application, the 
practical application of the abstract idea can be a 
useful, concrete, and tangible result and therefore 
patentable.10 In the United States, such applica­
tions of mathematical algorithms are increasingly 
patented as business-method patents. Business-
method patents are, however, not allowable in 
several countries; for example, the European 
Patent Office does not currently examine applica­
tions disclosing a business methods. 
2. Statutory requirements for patentability 
2..1 Novelty 
Because patents are granted to promote the prog­
ress of the useful arts, a product or process is not 
patentable unless it is new. A product or process 
is not new if all the claimed elements are pres­
ent expressly or inherently in a single piece of rel­
evant prior art. If a single piece of relevant prior 
art contains all the claimed elements, it is said to 
anticipate the product or process. An invention is 
not new and therefore not patentable, if “it was 
known or used by others in this country or patented 
or described in a printed publication in this or a for­
eign country …”11 Known has been interpreted to 
mean that the knowledge is accessible to the pub­
lic. An oral presentation may be enough to make 
the knowledge accessible to the public. Used in 
this clause means publicly accessible use. A ma­
chine that is operated in an open field is publicly 
accessible use even if no one sees the machine,12 
but a machine in a windowless building where 
no one can enter without swearing to secrecy has 
been ruled not to be public use.13 Printed publica­
tion has been very broadly interpreted to mean 
all material accessible to the public in tangible 
form.14 Oral communication is excluded, but if 
copies of a paper were distributed at a conference, 
they would be publications. However, if those re­
ceiving the copies were asked to keep the content 
of the communication secret, the paper would 
not be a publication. 
An invention is not patentable “if the inven­
tion was patented or described in a printed publica­
tion in this or a foreign country or in public use 
or on sale in this country, more than one year prior 
to the date of the application for the patent in the 
United States.”15 This section creates the one-year 
grace period, during which the inventor may de­
velop the invention further, market it, and pre­
pare a patent application. 
It is noteworthy that the U.S. patent sys­
tem is different from systems of the most other 
countries because of this grace period. In most 
other countries the inventor would lose the rights 
to patent if the invention were published before 
filing the patent. In European countries, for ex­
ample, a public disclosure is an absolute bar to 
patentability. Japan gives a six-month grace pe­
riod for filing a patent if the public disclosure was 
a presentation at a scientific meeting. 
2..2 Utility 
The purpose of granting patents is to promote the 
progress of the useful arts. Therefore, in order to 
be patentable an invention has to be useful. For 
a product or process to be useful it must, at least, 
work, although it does not have to work perfectly 
or even better than any competing products or 
processes. However, products or processes that 
are working but can be used, for example, only 
for immoral or illegal purposes are not consid­
ered useful. Also, products and processes that 
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DODDS & KRATTIGER 
are regarded as useless are not considered useful. 
A process for producing a steroid that had no 
known use, for instance, was found to be not use­
ful and therefore not patentable.16 
2.. Nonobviousness 
A new and useful product or process is not patent­
able unless it was nonobvious when it was made. 
The nonobviousness requirement is included in 
Section 103 of the Patent Act. Different from the 
novelty determination, the nonobviousness de­
termination does not include a strict identity re­
quirement. Therefore, prior art that does not dis­
close all the elements of the claim at issue might 
be relevant when determining obviousness. When 
making a decision of obviousness, the examiner 
has to determine the level of ordinary skill in the 
art at the time the invention was made. 
2. Experimental-use exemption 
U.S. patent law does not have a written research-
exemption clause, but current practices are based 
on case law, that is, on court decisions. The basic 
rule says the patentee shall not be allowed to pre­
vent experimentation using a patented product or 
process for bona fide research activities designed 
to further scientific knowledge. 
However, the experimental-use exception 
is very narrow, such that any research aimed at 
commercialization (with even the slightest com­
mercial implication) will not fall under the ex­
emption and will hence be subject to infringe­
ment liability. 
. TRAdEMARkS	And RELATEd RIGHTS 
A trademark is a word, phrase, symbol, design or a 
combination of those items, that distinguishes the 
source of one’s goods or services from the goods 
or services of others. A trademark can be valid 
only when it is used in, or in connection with, 
goods or services in the course of commerce. 
There are various types of marks that can be 
registered with the Patent andTrademark Office. In 
addition to trademarks17 and service marks (marks 
that indicate a specific service, such as a rental 
or leasing service), the Trademark Act provides 
for registration of collective marks, membership 
marks, and certification marks. Collective marks
are trademarks or service marks that are used by 
a member of cooperation, an association, or oth­
er collective group or organization. One type of 
collective mark is a membership mark. These are 
not trademarks in the ordinary sense. Membership 
marks do not indicate the origin of the good or 
service. The purpose of a membership mark is, 
rather, to indicate that the user of the mark is a 
member of a particular organization. 
There are generally three types of certification 
marks. First, there are marks that certify that the 
good or product is from a certain geographic re­
gion; for example Cognac for the distilled brandy 
from a certain region in France. Second, there are 
marks that certify that the goods or services meet 
certain standards, for example, quality standards or 
safety standards. Third, there are marks that certify 
that a member of a union or other organization per­
formed the work or labor on the goods or services 
and that the performer meets certain standards. 
In addition, one can register a trade dress of a 
good or service. Trade dress can, for example, be 
product design, packaging, or color. Trade dress 
of a service can be, for example, the overall look 
of restaurant. 
The most effective way to get trademark regis­
tration is to choose a mark that is fanciful or arbi­
trary. An example of a fanciful mark is EXXON—a 
made-up word—something that does not mean 
anything in itself. An example of an arbitrary 
mark is Apple used by Apple Computer—an exist­
ing English word that itself has no connection to 
computers. 
A mark that resembles another mark already 
in use in the United States cannot be registered 
because of the likelihood of customer confusion. 
Therefore, before filing a trademark registration 
it is important to perform a trademark search to 
discover whether the mark or a similar one is al­
ready in use. 
An important element of trademark law is 
the naked licensing doctrine. Quality assurance 
and protection of the public is a central purpose 
of the trademark law. Therefore, an indispensable 
condition of a valid trademark license is that the 
licensor controls the nature and quality of the 
good or service sold by the licensee under the 
2 | HANDBOOK OF BEST PRACTICES 
         
      
       
     
        
     
	
    
         
      
       
       
       





mark. Naked licensing results when the licensor 
does not adequately supervise the quality of the 
licensee’s products or services. Naked licensing 
can be regarded as abandonment of a mark and 
therefore leads to cancellation of registration. 
. GEoGRApHICAL	IndICATIonS 
A geographical indication is a sign used on goods 
that have a specific geographic origin and possess 
qualities or a reputation that are derived from 
that place of origin. Geographical indications are 
defined in the TRIPS agreement as a type of in­
tellectual property. WTO members provide legal 
means for interested parties to prevent the use of 
a geographical indication that indicates or sug­
gests that a good originates in a geographical area 
other than the true place or origin in a manner 
that is misleading to the public or constitutes an 
act of unfair competition. 
Most commonly, a geographical indica­
tion consists of the name of the place of origin 
of the goods. Agricultural products typically have 
qualities that derive from their place of produc­
tion and are influenced by specific local factors, 
such as climate and soil. Examples of geographi­
cal indications are Idaho (potatoes) and Roquefort 
(cheese). 
Whether a sign functions as a geographical 
indication is a matter of national law and con­
sumer perception. The TRIPS Agreement does 
not require that a WTO member extend protec­
tion to a geographical indication if that geograph­
ical indication is the generic name for the goods 
in that member country. Therefore, the word 
champagne is not registrable as a geographical in­
dication in the United States, because champagne 
is a generic term, in the United States, meaning a 
light-colored wine with bubbles. 
The United States offers robust protection 
for geographical indications, generally through 
registration as a certification mark. 
. CopyRIGHT 
A copyright is a type of intellectual property pro­
tection for authors of original works. Generally 
the categories of works that are protected are: 
•	 literary works 
•	 musical works, including words accompa­
nying music 
•	 dramatic works 
•	 pantomimes and choreographic works 
•	 pictorial graphic and sculptural works 
•	 motion pictures and other audiovisual 
works 
•	 sound recordings 
•	 architectural works 
A copyright protects an original work and al­
lows the author an exclusive right to: 
•	 reproduce the work exclusively 
•	 prepare derivative works 
•	 distribute copies or phonorecords by sale, 
transfer of ownership, lease, rent or lend 
•	 perform the work publicly 
•	 display 
An original work of authorship is immedi­
ately protected by copyright after it is fixed in a 
tangible medium. The duration of a copyright 
protection on or after 1978 is that of the author’s 
lifetime plus 70 years. If there are two or more 
authors, the term is 70 years after the death of 
the last surviving author. If the creation is a work 
for hire, and the works are created anonymously, 
the duration is 95 years from publication or 120 
years from creation, whichever is shorter. 
Only the author, or those deriving rights 
from the author, can claim the copyright. A copy­
right requires no registration or publication to be 
protected, but a copyrightable work is protected 
automatically when the creation is fixed in a tan­
gible form. 
Importantly, federal copyright registration is 
a legal formality intended to make a public re­
cord of the basic facts of a particular copyright. 
Copyright registration may be filed at any time 
during the life of a work. Even if registration is 
not a requirement for protection, registration 
brings several advantages. For example, before 
an infringement suit may be filed in the court, 
registration is required for a work of U.S. ori­
gin. Moreover, if registration is filed within five 
years of publication of the work, the registration 
will establish prima facie evidence, in court, of 
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validity and of the facts stated in the copyright 
certificate. Registration makes available to the 
copyright owner statutory damages and attorney 
fees, in case of an infringement suit, if the regis­
tration was made three months after publication 
of the work or prior to an infringement of the 
work. Registration also enables the U.S. Customs 
Service to protect the copyright owner against 
importation of infringing copies. 
To be copyrightable, a work has to be original 
and in a fixed medium. This means that a work 
has to be the independent creation of an author 
and that it has required a modest quantum of cre­
ativity. Being in a “fixed medium” means that the 
creation is in a tangible form: a short story is writ­
ten down, a song is recorded, and so on. A pure 
idea or concept cannot be copyrighted without 
description or illustration. 
An important question is whether software 
and databases can be protected. The last decades 
have seen a revolution in knowledge manage­
ment, library services, and information-resource 
database configurations. The use of integrated 
computer networks and the ability to produce 
and distribute information have had far-reach­
ing implications for IP (intellectual property) 
protection. In order to demonstrate IP laws and 
their application, another chapter discusses these 
aspects together with respect to geographic infor­
mation systems and remote sensing.18 
As mentioned earlier, the author of a work 
owns the copyright. In a case of work for hire the 
employer is regarded as the author and, therefore, 
the employee does not own the copyright. A work 
for hire is defined in copyright law as a work pre­
pared by an employee, within the scope of his or 
her employment, or a work specially ordered or 
commissioned for use as a contribution to a col­
lective work, a part of a motion picture or other 
audiovisual work, a translation, a supplementary 
work, a compilation, an instructional text, a test, 
answer material for a test, or an atlas, if the par­
ties expressly agree in a written instrument signed 
by them that the work shall be considered a work 
made for hire. 
Copyright protection subsists from the time 
the work is created in fixed form. The owner 
of a copyright can assign all his or her rights 
unconditionally to another. Alternatively, the 
owner can license the rights exclusively or non-
exclusively. If, at the time of creation, the authors 
intend to combine their contributions into insep­
arable or interdependent parts, the work is con­
sidered joint work and the authors are considered 
joint copyright owners. Each copyright owner has 
an equal right to exploit her or his rights. In such 
a case, a company can license or get an assign­
ment for the copyright of the whole work from 
only one of the authors. If at the time of creation 
the authors did not intend their works to be part 
of an inseparable whole, the fact that their works 
are later put together implicates the work as a col­
lective work. In such a case, each author owns a 
copyright in only the material she or he added to 
the final product. In this case, the company needs 
to have an agreement with each of the authors to 
convey the copyrights. 
It should be noted that in countries of the 
European Union, greater protection of data­
bases is provided than in the United States. The 
European Union Database Directive adopted by 
the European Parliament in 1996 sets out two 
rights for the makers of databases: 
•	 the right to prevent unauthorized acts of 
extraction from a database 
•	 the right to prevent unauthorized acts of 
reutilization of the contents of a database 
The first right is similar to that provided un­
der the U.S. Copyright Act. With this right the 
directive provides protection to a database but not 
to the underlying data, and the right is limited 
to databases containing a sufficient degree of cre­
ativity in the selection or arrangement of the data. 
The second right, however, provides for a sui ge­
neris right that prohibits the extraction or reuti­
lization of any database in which there has been a 
substantial investment in obtaining, verification, 
or presentation of the data contents. Under this 
second right, there is no requirement for creativi­
ty or originality. The protection is available for 15 
years from creation of the database. If substantial 
changes are made to the content of the database, 
the modified database will be protected a new 
term of 15 years. Protection under the directive 
is available only to nationals of member countries 
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CHAPTER .1 
of European Union. Other countries will obtain 
such protection only if they offer comparable 
protection to databases of a European national 
and if a bilateral agreement is reached. 
In the U.S. Copyright Act, there is a fair 
use exception that states that use of an author’s 
original creation is authorized for the purposes 
of criticism, comment, news reporting, teaching, 
scholarship, or research. Fair use takes into con­
sideration the purpose and character of the use, 
the nature of the copyrighted work, the amount 
and substantiality of the portion used in relation 
to copyrighted work as a whole, and the effect of 
the use on the potential market. There are four 
aspects to the fair-use exception: 
1. Classroom use. Certain educational estab­
lishments are allowed to publicly display 
and perform others’ works in the course 
of face-to-face teaching activities. But this 
exemption applies only to the use of legally 
acquired works. 
2. Copying in a library. In academic and 
research institutions, copying limited por­
tions of certain copyrighted works19 is not 
an infringement, provided that libraries (or 
their users) make single copies of the works, 
provided that all of the following apply: 
− only individual articles (for example, of a 
book) or small portions of a larger work 
be copied 
− the copies become the property of the 
person making the copies 
− the copies are used for private study, 
scholarship, or research 
− the copying is not done for commercial 
advantage 
−	 the library displays prominently a notice 
warning of copyright restrictions in ac­
cord with requirements published by the 
U.S. Copyright Office20 
Finally, it should be noted that no “interna­
tional copyright“ exists. But since most countries 
offer protection to foreign works under simplified 
international copyright treaties and conventions, 
a rule of thumb is that if a work could be pro­
tected as a U.S. domestic work, it is protected as 
a foreign work. There are cases, however, where 
foreign copyright law is less restrictive than the 
U.S. code, so the work may still be protected even 
though in the United States the work would be in 
the public domain. 
6. TRAdE	SECRETS 
.1 What can be a trade secret? 
Trade secrets are an important and widely used 
business asset in the United States. Both small 
and large businesses rely on trade secret protec­
tion, often without even realizing it. It has been 
estimated that 90 percent of inventions are pro­
tected by trade secrets. 
There are various kinds of trade secrets. The 
most popular example of a trade secret is the for­
mula for Coca Cola, which has been kept suc­
cessfully in secrecy now for more than 100 years. 
In addition to chemical formulas or processing 
methods, trade secrets can involve software, ac­
counting records, customer lists, plant designs, 
and so on. Although trade secrets may overlap 
with patentable subject matter, they go well be­
yond that. 
A generally accepted definition of a trade 
secret appears in the 1939 Restatement of Torts. 
The subject matter of a trade secret must be se­
cret. Matters of public knowledge or of general 
knowledge in an industry cannot be appropri­
ated by anyone as a secret, nor can matters that 
are completely disclosed by the goods one markets 
be trade secrets. Therefore, a trade secret is known 
only in the particular business in which it is used. 
.2 How are trade secrets protected? 
Intentional theft of trade secrets can constitute a 
crime under both federal and state law. The most 
significant federal law dealing with trade secret 
theft is the Economic Espionage Act (EEA) of 
1996.21 The EEA applies not only to thefts that 
occur within the United States, but also to con­
duct outside the United States, if the thief is a 
U.S. citizen or corporation, or if any act in fur­
therance of the offense occurred in the United 
States. All of the 50 U.S. states have enacted trade 
secret laws, most of which are some version of the 
Uniform Trade Secret Act (UTSA). 
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. To file a patent or to keep a trade secret? 
Before filing a patent one should always consider 
the possibility of keeping the invention in secre­
cy, because there are situations when one of these 
two protection methods is more useful than the 
other. 
There is no limitation in the time that a trade 
secret can protect the invention. On the contrary, 
a patent is normally enforceable for a period of 
20 years after the filing. If the subject matter is 
easy to keep in secret, if there will be no products 
being marketed that could be used to reverse en­
gineer the trade secret, then keeping trade secret 
might be worth considering. 
Sometimes it is very difficult to prove that 
someone has infringed a patent. For example, in­
fringement of a patent on a laboratory method 
might be difficult to prove, and, therefore, keep­
ing the method as a trade secret might be a better 
means of protection. 
In order to be patentable an invention has 
to be useful, novel, and nonobvious. There are 
no such requirements for trade secrets. The only 
“usefulness” requirement for a trade secret ac­
cording to the Restatement of Torts § 757, is that 
“it confers the owner an opportunity to obtain an 
advantage over competitors who do not know or use 
it.” Therefore, an improvement or a variation of a 
method, for example, can be a trade secret, but it 
might not be patentable. The field of trade secrets 
is much wider than that of patents. 
. Misappropriation of trade secrets 
Based on the definition given in the 1939 
Restatement of Torts, one who discovers a trade 
secret properly, for example, by analyzing a com­
mercial product embodying the secret, reverse 
engineering the secret, or by independent inven­
tion, is free to disclose it or to use it in his or her 
own business without liability to the owner. The 
cases rising from trade secret misappropriation 
are basically of three types: 
1. Cases in which a 	 trade secret is learned 
by improper means, as through industrial 
espionage 
2. Cases in which an employee knowing a trade 
secret is hired by a competitor to whom the 
employee discloses the trade secret, or the 
employee knowing the trade secret begins 
his or her own business basing it on the 
trade secret 
3. Cases in which a trade secret is disclosed 
during licensing negotiations, and the li­
censee later refuses to pay royalties but con­
tinues to use the trade secret22 
. 	oWnERSHIp of RIGHTS 
Ownership of rights is an important question with 
regard to licensing and transfer of the rights to 
another party. It may be that there are some rights 
belonging, for example, to an employee of an or­
ganization, that might interfere with the interest 
of the organization to license the rights further. 
In order to prevent misunderstandings related to 
such situations, it is worthwhile to think how the 
technology was created: Did the organization hire 
a consultant? What were the conditions of the 
agreements? Who sponsored the research? Where 
are the inventors now? 
.1 Ownership of patent rights 
Employed to invent. As a general rule, the inventor 
owns the patent rights to the subject matter of his 
or her invention, even if the inventor conceived it 
or reduced it to practice during his or her employ­
ment. The main exception to this rule is the em­
ployed-to-invent-exception. An employer owns the 
invention of the employee if the employee was em­
ployed to invent something or to solve a problem. 
Shop right. When an employee makes an 
invention or discovery that is outside her or his 
employment, but she or he uses the employer’s 
resources, the invention may be owned and pat­
ented by the employee, but the employer has a 
shop right to the invention. A shop right is a roy­
alty-free, nonexclusive, nontransferable, implied-
in-law license granted to an employer to use the 
employees patented invention. 
A shop right exists for the life of a patent, 
regardless of whether the employment contin­
ues or not. The employer having a shop right 
can make, use, and sell articles embodying the 
patented invention. The employer may, however, 
not sell articles outside his or her normal range 
of business. 
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Joint inventors. In the Code of Federal 
Regulations, the term joint inventor is defined as 
one who “must have made a contribution, individ­
ually or jointly, to the subject matter of at least one 
claim of the application.” To be legally named as an 
inventor, a person must have contributed to the 
discovery of the way of obtaining the wished-for 
results. Creating the idea of the general wished-
for result desired is not, by itself, sufficient to 
constitute joint invention. 
It is important to remember that any patent 
with a named inventor who cannot meet the legal 
test for the minimal requirement of inventorship 
will lead to that patent becoming invalidated. 
Similarly, if all joint inventors are not named, the 
patent is invalid. 
In absence of an assignment of the patent, 
the joint inventors are co-owners of the patent. 
Each of the co-owners has all the rights of a pat­
ent owner. This means that each of them may 
make, use, or sell the patented invention without 
the permission of or the need to account to the 
other joint owners. 
.2  Ownership of copyright 
As a general rule, a person who creates a work is 
the author and therefore owns the rights to the 
work. However, a work made for hire is an excep­
tion to this rule. If an employee within the scope 
of his or her employment prepares a work, the 
employer and not the employee is considered to 
be the author. 
8. pRoTECTInG	 THE	oRGAnIzATIon’S	 Ip 
.1  Notebook keeping 
Under U.S. law, a patent is granted to the first to 
conceive the idea for an invention, not to the per­
son who first files a patent application. Because 
of the first-to-invent concept, a notebook must 
be able to serve as essential evidence of the date 
of conception. In a case of interference, the note­
book might also be essential for proving diligence 
in developing the invention after the conception. 
For these purposes proper notebook keeping is 
important.23 All notebook entries should be made 
with permanent ink. The pages of the notebook 
should be numbered and filled consecutively, with 
no intervening pages left blank. Someone able to 
understand the work, but not participating in it, 
should witness all of the entries. 
.2  Employee agreements 
Employees make the majority of inventions pat­
ented in the United States. Therefore, it is im­
portant for an organization to establish practices 
related to inventions made by its employees. 
Employee agreements often contain clauses that 
require protection of trade secrets and confiden­
tial information, require the employee to assign 
inventions to the employer, require the employee 
to cooperate in disclosing inventive activity, and 
require the employee to cooperate in patent-pros­
ecution activities. Employee agreements can also 
include trailer clauses requiring the employee to 
assign inventions made for a certain period after 
leaving employment. 
Some states have recently enacted state stat­
utes attempting to prevent an employer from 
abusing his or her unequal bargaining power. The 
statutes are limiting the type of inventions that 
an employer can contractually require an inven­
tor to assign. 
.  Marking the protected intellectual 
property 
Patent marking. Patent law gives a patent owner 
an option to mark the patented product. Marking 
the product is not required, but owner failure to 
mark a patented product may raise a risk that the 
owner would not be able to collect damages from 
infringers during the time the product was not 
marked. An appropriate way to make the mark­
ing is: U.S. Patent No 5,555,555 or U.S. Pat. 
No. 5,555,555. After obtaining a filing date one 
can also use the marking: Patent Pending or Pat. 
Pending. 
Trademark marking. The designation TM 
indicates that a particular word, symbol, or logo 
is considered by its user to function as a trade­
mark. Similarly, the designation SM indicates a 
service mark. 
When a mark becomes registered with the 
U.S. Patent Office, the designation should change 
from TM or SM to the registered-mark symbol, 
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DODDS & KRATTIGER 
. Instead of this symbol, the mark owner can 
use the designation Registered in the U.S. Patent 
and Trademark Office or Reg. U.S. Pat & TM off. 
A marking Registered trademark is not appropriate 
because it could be misleading by not indicating 
where the mark is registered. It is important to 
indicate that the mark is registered with the U.S. 
Patent and Trademark Office, because the law 
provides that the owner of the mark is precluded 
from recovering profits and damages unless it can 
be established that the defendant had actual no­
tice of the registration. 
Copyright marking. The copyright symbol, 
, or the designations Copr. and Copyright are the 
proper legal notices for copyright protection. The 
copyright notice is usually included directly on 
the product or product label and typically takes 
this form: 
 ABC Corporation 2007. 
or 
© MIHR and PIPRA. All Rights Reserved. 
Failure to include the notice of copyright 
once was, but is no longer, fatal to the owner’s 
rights. Before the United States acceded to the 
Berne Convention, the author lost his or her 
rights if failing to include notice of copyright. 
It is still good practice, however, to include the 
traditional copyright notice where applicable. 
Very often a copyrighted work carries the notice 
All Rights Reserved, in addition to the copyright 
symbol. This is because the All Rights Reserved 
designation is required under the Buenos Aires 
Copyright Convention, which is important in 
several South American countries. 
. InTEGRATIon of Ip	RIGHTS 
A question that often comes up is whether a 
party can one have a patent and a trade secret 
simultaneously? At first sight it might seem that 
patents and trade secrets would exclude each 
other: patent application will become public, at 
the latest, when the patent is issued, and trade 
secret has to be kept in secrecy. Furthermore, 
the patent law requires the patent applicant to 
disclose the best mode of the invention in the 
patent application. It seems as if there would 
be no room for trade secret if one has filed a 
patent. 
This, however, is not the case. One can have 
a patent and also keep trade secret. One very 
common situation is that after filing a patent, the 
invention has been developed further and after 
filing, the development is kept secret. The pat­
ent law requires the inventor to disclose the best 
mode known when the patent is filed, but there 
is no requirement to disclose any improvements 
made later. In addition, sometimes trade secrets 
can be “negative know-how.” For example, in­
formation learned during research and develop­
ment that shows some formula or process does 
not work can be kept as a trade secret. It has 
been estimated that 80 percent of all license and 
technology transfer agreements cover proprietary 
know-how or trade secrets. 
Importantly, trademarks can prolong the pro­
tection of a patented good. The life of a patent is 
usually 20 years, while there is no limit to the life 
of a trademark as long as it is used. Many compa­
nies use trademarks to prolong the protection of a 
patented good. During the lifetime of the patent, 
the product is well protected, but if the company 
has also trademarked the product, the public will 
recognize the patented product also after expira­
tion of the patent. When filing a trademark for a 
patented product, the applicant should, however, 
remember that one cannot get trademark protec­
tion for any functional features. 
10. Ip	 InfRInGEMEnT 
Patent infringement can be either direct or indirect. 
Direct infringement is either literal or it takes place 
under the Doctrine of Equivalents. Direct infringe­
ment occurs when a party makes, uses, offers to sell, 
or sells any patented invention, within the United 
States, or imports the patented invention in the 
United States during the patent term without the 
patentee’s authorization during the term of patent. 
An infringement is literal when every limita­
tion recited in any claim in the patent appear in 
the alleged infringing product or process. If the 
alleged infringing product or process is missing 
on one of the claim limitations, there is no literal 
infringement. 
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CHAPTER .1 
In a case where the accused product or pro­
cess is missing a component or step of the claims, 
there can still be direct infringement, if the ac­
cused product or process has a component or step 
that is insubstantially different from the missing 
one. Such a case is known as infringement under 
the Doctrine of Equivalents. In such a case, the 
alleged infringing device (or method) substantial­
ly performs the same function, in the same way, 
with the same result as the patented invention. 
In addition to direct infringement, the pat­
ent law describes indirect infringement. Indirect 
infringement can be either induced infringement 
(knowingly aiding another in an act of infringe­
ment; aiding and abetting infringement) or a 
contributory infringement (knowingly selling an 
article that has no other use than as part of a pat­
ented invention).24 
A copyright is infringed if the defendant cop­
ied from the plaintiff’s copyrighted work. A plain­
tiff can prove copying through direct evidence of 
copying, or through circumstantial evidence that 
the defendant had access to the plaintiff’s work 
and the work is substantially similar to the work 
of the plaintiff. 
11. So I 	HAvE	InTELLECTuAL	 pRopERTy.
noW	 WHAT? 
Evidently, intellectual property is really only use­
ful if indeed the invention is used, applied, and 
incorporated into a productive process. This can 
be done either by those who own it or by au­
thorized third parties, called licensees. Inventing 
something new is important. Protecting such an 
invention might also be important. But bringing 
an invention from “bench to bedside” is undis­
putedly the most important. For this, IP protec­
tion might not always be the most efficient way as 
other chapters in this Handbook suggest.25 Equally 
important are the complex decisions regarding 
when, to whom, and how to license intellectual 
property in order to optimize both economic and 
humanitarian value.26 Suffice it to say that the 
form of protection chosen for a given invention 
should be guided by the mission of the institution 
and the purpose of the work conducted, as well as 
by the specific subject of the invention. n 
John dodds, Founder, Dodds & Associates, 1707 N Street 
NW, Washington, DC, 20036, U.S.A. j.dodds@doddsasso­
ciates.com 
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute, and Adjunct Professor, 
Cornell University, PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu 
1	 Article I, Section 8, Clause 8. 
2	 Some 30 years later, in 1474, the first patent law was 
enacted, called the “Inventor Bylaws,” also in Venice. 
3	 See, also in this Handbook, chapter 4.4 by JP Kesan, and 
chapter 4.6 by J Dodds, A Krattiger and SP Kowalski. 
4	 See, also in this Handbook, chapter 10.2 by RL Cruz. 
5	 See, also in this Handbook, chapter 4.7 by M Blakeney. 
6	 See Dodds et al., supra note 3. 
7	 See, also in this Handbook, chapter 10.7 by AM 
Schneiderman;chapter 10.8 by R Yin and S Cunningham;
and chapter 10.6 by AS Viksnins and AM McCrackin. 
8	 35 U.S.C. 101. 
9	 Diamond v. Chakrabarty. 447 U.S. 303 (1980). 
10	 State Street Bank v. Signature Financial Group. 47 U.S.P.Q.
2d 1596. This case was the most important case to 
establish the concept of business-method patents. As 
a result, during fiscal year 2001, the U.S. Patent Office 
was expecting to receive about 10,000 business-
method patent applications. This was in a year the 
U.S. Patent Office issued only 433 business-method 
patents. 
11  35 U.S.C. § 102(a). 
12 Rosaire v. Baroid Sales. Div. 218 F 2d 72. 
13 Kimball Int’l Inc. v. Allen Organ. Co. 212 U.S.P.Q. 584. 
14  Ritter v. Rohm & Haas Co. 271 F. Supp. 313. 
15  35 U.S.C. 102(b). 
16 Brenner v. Manson, 383 U.S. 519 (1966). 
17 See, also in this Handbook, chapter 4.3 by W Needle. 
18 See, also in this Handbook, chapter 4.8 by J Dodds, S 
Somersalo, SP Kowalski and A Krattiger. 
19 Musical works, graphic, pictorial or sculptural works,
motion pictures, or other audiovisual works are not
included in this exception. 
20 Note that libraries may make copies of entire works if 
the work cannot be obtained after a reasonable search 
and at a reasonable price. This exemption is also the 
basis of the fair-use doctrine that libraries may copy 
and place materials on course reserve. 
21 18 U.S.C. §§ 1831–1839. 
22 For further information on trade secrets, especially 
the licensing of trade secrets, see, in this Handbook,
chapter 11.4 by KF Jorda. 
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23 See, also in this Handbook, chapter 8.2 by JA Thomson. 
24 See, also in this Handbook, chapter 17.26 by M 
Goldman.
25 For example, see, in the Handbook, chapter 10.1 by S 
Boettiger and C Chi-Ham. 
26 See Sections 2 and 10 in this Handbook. 
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CHAPTER 4.2 
How to Read a Biotech Patent
 
CAROL NOTTENBURg, Principal/Patent Lawyer, Cougar Patent Law, U.S.A. 
ABSTRACT 
This chapter provides an annotated description of a sam­
ple U.S. patent. The U.S. patent is a convenient model 
because its format is well laid out and is similar to the 
required formats of patents granted in other major juris­
dictions, including Europe. 
INTRODuCTION
A patent is an exclusionary grant of intellec­
tual property (IP) rights, typically awarded by 
a government through a patent office, and ef­
fective for a limited period of time. Article 28 
of the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS), bind­
ing for member countries of the World Trade 
Organization (WTO), states that a patent owner 
has the right “to prevent third parties … from the 
acts of: making, using, offering for sale, selling or 
importing” the protected product. If the protect­
ed invention is a process, the owner can prevent 
third parties not only from using the process, but 
also from using, offering for sale, selling, or im­
porting “at least the product obtained directly by 
that process.” It is important to note that under 
TRIPS the patent owner does not have the right 
to practice her or his invention, only the right to 
prevent others from practicing it. 
The TRIPS Agreement requires the time 
limit of the patent (patent term) to be at least 
20 years. Most countries allow a 20-year term, 
starting from the date on which the application 
for the patent was first filed. Extensions of the 
patent term may be available in cases of regula­
tory or patent office delays that were imposed be­
fore a product is commercialized. Significantly, a 
patent grant is only legally binding in the country 
in which it was awarded. 
2. PATENT PuBlICATION 
Box 1 (at the end of this chapter) contains the 
front page of U.S. Patent No. 6,551,586,1 and 
Box 2 contains extracts of U.S. Patent No. 
5,723,765 (hereafter referred to as “the ’765 
patent”).2 A cursory review of the ’765 patent 
reveals that it has three main sections: 
•	 a front page, which presents bibliographic 
information (Box 2a, also at the end of this 
chapter), 
•	 text, which describes the invention (Box 
2b), and 
•	 claims, starting in column 35 (Box 2c), 
which define the limit of the protected 
invention.3 
2.1 Cover Page 
The cover page primarily contains bibliographic 
information, historical facts about prior patent 
applications, and identifying elements, none of 
which has any legal import for interpreting the 
Nottenburg C. 2007. How to Read a Biotech Patent. In Intellectual Property Management in Health and Agricultural Innova-
tion: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A.
Available online at www.ipHandbook.org. 
© 2007. C Nottenburg. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
commercial purposes is permitted and encouraged. 
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patent. The bracketed number adjacent to each 
data subsection is used by the patent office for 
internal identification purposes. 
At the top of the cover page is the vital iden­
tification of Patent No. 6,551,586 (Box 1): 
[12] 	nature of the publication. In this case,
United States Patent and, below, the first 
inventor’s name, Davidson et al.4 
[10] 	patent number. In the United States, the 
patent number is sequentially assigned by 
the patent office. Prior to early 2000, the 
patent number was the only publication 
number.5 
[45] 	date the patent was issued. This date (in 
this case, Apr. 22, 2003) is important for 
two reasons: (1) if the patent was not pub­
lished as a patent application, then this is 
the date it became public knowledge and 
thus prior art for non-U.S. jurisdictions;6 
and (2) in the case of applications filed 
in the United States prior to the General 
Agreement on Tariffs and Trade (GATT)
treaty (8 June 1995), as in this example, it 
is the date that initiates the patent term.7 
The remainder of the front page presents the 
main bibliographic data: 
[54] 	title of the patent. Should be representative 
of the content, is written by the inventors 
or their attorney and has no impact on the 
interpretation of the patent. In many cases, 
the title is wishful thinking. 
[75] 	 inventor(s)’ name(s) and place(s) of resi­
dence. For patent purposes, the order of 
the names is not important; the applicant 
determines the order, not the patent office. 
In the United States, the inventors and their 
assignees (see below) can independently 
practice or license all of the patent rights 
without the permission of the other inven­
tors. It is important to note that Australia 
and Europe, among other countries, have 
the opposite rule: an inventor cannot prac­
tice or license patent rights without the 
permission of the other inventors. 
[73] 	assignee(s) and his/her/their place(s) of 
business.8 An assignee is an owner of the 
patent because an inventor or inventors 
have signed over the rights to the inven­
tion. Typically, an inventor who is also an 
employee in a company or university is ob­
ligated to formally assign invention rights 
to the employer. In the United States, such 
assignment documents are recorded by the 
patent office and are publicly accessible, 
once the patent application is published. 
The identity of the owner of a patent is 
public knowledge, but the identity of those 
who have licensed a patent is not necessar­
ily available to the public. 
[21] 	application number. Assigned by the pat­
ent office 
[22] 	filing date of the subject patent applica­
tion. If there are no related U.S. applica­
tion data (see below), this date is used to 
determine the beginning of the 20-year 
patent term. 
[63]	 related applications. It is from these re­
lated applications that the patent claims 
priority. The United States is unusual in 
allowing applications to be refiled, either 
with or without new disclosure. A refiled 
application is called a continuation, or, if it 
contains new disclosure, a continuation-in­
part. U.S. Patent 6,551,586 was filed on 
27 November 1998 (field 21); however, an 
earlier application filed on Jan. 29, 1996 
(serial number 08/593,006) contained at 
least some of the disclosure of the subject 
patent; in other words, this patent is a con­
tinuation-in-part of the earlier application.9 
As the patent term begins from the filing 
date of the earlier application, this patent 
expires on 29 January 2016. 
[60]	 provisional applications. The filing date 
of a provisional application does not af­
fect the patent term, but it is critical for 
considering prior art that might affect 
patentability. 
[51] 	International Patent Classification (IPC)
code. A combination of letters and num­
bers.10 A patent application’s IPC code is 
assigned by the national or regional patent 
office that publishes it. The IPC is an indis­
pensable tool for patent-issuing authorities, 
potential inventors, attorneys, and others 
2 | HANDBOOK OF BEST PRACTICES 













      
       
       










	 	 	 	
 
	 	 	 	
 
	 	 	 	 	
 
CHAPTER .2 
concerned with the application or develop­
ment of technology.  
[52] 	U. S. Classification Code. Assigned by the 
U.S. Patent Office. 
[58]	 field of search. Contains the U.S. classifica­
tion codes that the examiner used to per­
form searches for prior art. 
[56] 	references. Subdivided into U.S. patent 
documents, foreign patent documents, and 
other publications that the examiner con­
sidered when evaluating the patentability 
of the claimed invention.11 
[no number] examiners. The names of the 
primary examiner at the patent office and 
the assistant examiner (if any). 
[74] 	attorney, agent, or firm. Representatives of 
the inventor or assignee. 
[57] abstract. A short description of the inven­
tion written by the applicant(s). The ab­
stract enables the patent office and the 
public to quickly determine the content of 
the patent. Although the “abstract shall not 
be used for interpreting the scope of the 
claims,” courts have taken it under consid­
eration on one or two occasions.12 
[no number] number of claims and draw­
ings. In this patent, there are eight claims 
and 13 drawings. 
2.2 Text of the patent 
The text of the patent is also called the disclosure
(In the United States, it may also be called the 
specification). According to the TRIPS Agreement, 
the invention must be disclosed “in a manner suf­
ficiently clear and complete for the invention to be 
carried out by a person skilled in the art” (Article 
29.1). Each country specifies its own require­
ments; the U.S. Patent Office requires a written 
description of the invention, a so-called enable­
ment, and a so-called best mode.13 
The layout of the patent varies somewhat 
from country to country. The United States and 
Europe have a similar required layout, except that 
(b) and (c) below are unique to the United States: 
a. title of the invention 
b. cross-reference to related applications 
c. statement regarding federally sponsored re­
search, if applicable 
d. background of the invention 
e. summary of the invention 
f. description of the drawings 
g. detailed description of the invention 
h. listing of relevant nucleotide and peptide 
sequences 
i. claims defining the scope of the invention 
2. Background of the invention 
The background is typically drafted for the patent 
examiner and a jury audience, in case the patent 
is ever litigated. It compares selected art in the 
field with the current invention and explains why 
the current invention is necessary. As one can see 
from downloading the full patent (and the extract 
on Box 2b), a large part of the background of the 
’765 patent explains the technologies of several 
relevant references. 
2. Summary of the invention 
The summary of the invention is distinct from the 
abstract and summarizes the scope of the inven­
tion (the claims). It often discusses the advantages 
of the invention or explains how it solves prob­
lems existing in the art. 
The summary of the ’765 patent discusses 
the invention as embodied in the claims. It also 
describes the specific advantages of the invention 
(see, for example, col. 1, lines 61–64; col. 2, lines 
1–6; and col. 2, lines 51–54; not shown here). 
The inventors believe that the advantages of their 
invention include: positive control of gene expres­
sion by an external stimulus without the need for 
continued application of the stimulus, the ability 
to grow plants under various conditions with ex­
pression of different phenotypes, and the ability 
to develop seed where a trait is desirable only in 
the first or in subsequent generations. 
2. Detailed description of the invention 
The detailed description of the invention is the 
most substantial section of the patent. It is made 
up of two sections: the first section (col. 2, line 
58–col. 8, line 40) explains the invention and how 
to practice it; the second section (col. 8, line 43 
to col. 20, line 33) provides specific examples of 
the invention. Many new readers mistakenly as­
sume that examples are intended to delineate how 
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NOTTENBuRG 
the invention must be practiced or used, but this 
is not the case. The examples are merely meant 
“to illustrate, but in no way to limit, the claimed 
invention.” While examples are not required by 
the patentability statutes, in practice the enable­
ment requirement is difficult, if not impossible, 
to satisfy for biotechnology inventions without 
examples. 
Paragraphs 1 and 2 describe the broadest 
concept of the invention, explaining how DNA 
constructs are used to create transgenic plants 
and then describing how the invention works to 
control gene expression. 
Paragraphs 3–11 (col. 4, lines–1-39) set forth 
some definitions of key terms. Definitions are ex­
tremely important in interpreting the scope of 
the claims. For example, this patent defines the 
term “plant-active promoter” as “any promoter that 
is active in cells of a plant of interest.” The pro­
moter can be derived not only from plants, but 
also from viruses, bacteria, fungi, and so on. This 
list only provides examples of sources from which 
promoters can be derived and the inventors do 
not intend it to be exhaustive. 
The next three paragraphs (col. 4, line 10– 
col. 5, line 47) describe preferred embodiments
of the invention. These are usually more limited 
versions of the broadest concept. They provide a 
“safety net” for the inventors in case the broader 
concept is not patentable. 
In paragraph 12 (col. 4, line 10), the pre­
ferred embodiment is a “transiently-active pro­
moter” (active only in late embryogenesis) and 
a “gene linked to this promoter” that is a “lethal 
gene.” The next two paragraphs describe an em­
bodiment in which a pair of transgenic plants is 
crossed to produce progeny that display an al­
tered phenotype, and an embodiment in which 
the recombinase is linked to an inducible pro­
moter. In addition, the paragraph provides a few 
examples of inducible promoters. 
The next several paragraphs (col. 5, line 
48–col. 7, line 48) define and give examples of 
some of the important elements of the claim
(transiently active promoters, genes whose ex­
pression results in a detectable phenotype, lethal 
genes, blocking sequences, repressor and re­
pressible promoters, and recombinase/excision 
sequences). These paragraphs support the scope 
of the inventors’ claim. In col. 6, lines 47-60, 
the inventors define “lethal gene,” then provide 
a single example (saporin-6, which acts by cleav­
ing the large ribosomal RNA molecule and thus 
inhibiting protein synthesis). Overall, the disclo­
sure in this patent is relatively thin. 
The next four paragraphs (col. 7, line 49–col. 
8, line 29) discuss the techniques that can be used 
to transform the target plant (col. 7, lines 62-65). 
This is a classic style of patent drafting and clearly 
indicates that the actual method used for trans­
formation is not critical. Other methods of in­
troducing the DNA constructs are described in 
paragraphs 21–23. 
Finally, paragraph 24 (col. 8, lines 30–40) 
discusses suitable plant species. The inventors do 
not believe that the process they describe need be 
limited to particular species. 
The next section presents the examples. 
Typically, the examples show how one or more 
specific embodiments of the invention could be 
put into practice. The examples may or may not 
be based on successful experiments performed 
by the inventors. If the experiments have been 
performed, the examples are called “working” ex­
amples; if not, the examples are called “prophetic” 
examples and are always written in the present or 
future tense. In the ’765 patent, examples 1–6 
(Box 2c) describe the cloning of three DNA se­
quences: (1) a lethal gene, saporin-6, under control 
of a late embryogenesis promoter, and separated 
by a blocking sequence, LOX; (2) a tet repressor 
gene under the control of a CaMV 35S promoter; 
and (3) a CRE (recombinase) gene under the con­
trol of a tetracycline-derepressible 35S promoter. 
Examples 7–10, which describe the introduction 
of the constructs into plants and activation of the 
system are written in a future tense because the 
relevant experiments were not performed as of the 
filing date of the application. 
2. Sequence listing 
The sequence listing includes all nucleic acid 
molecules mentioned in the patent application 
that are comprised of at least 10 nucleotides and 
all peptide sequences comprised of at least four 
amino acids. 
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The claims must “particularly point out and dis­
tinctly claim the subject matter which the appli­
cant regards as his invention.”14 The claims define 
the boundaries of the patent owner’s right against 
possible infringement. 
Each claim must be written as a single sen­
tence. A claim is presented in two parts, the pre­
amble and the body, with a transition word or 
phrase between them. 
•	 The preamble is an introductory statement 
that names the subject of the claim. For ex­
ample, the preamble of claim 1. is: “A method 
for making a genetically modified plant.” 
•	 The body of the claim describes the ele­
ments or steps that compose the claimed 
subject. In claim one, the body of the claim 
consists of the steps of “stably transforming 
…” and “regenerating …” 
The transition words or phrases between 
the preamble and the body of the claim indi­
cate whether the claim encompasses at least the 
listed elements or steps or whether the claim en­
compasses only the listed elements or steps. The 
transition word comprising means “including the 
following elements but not excluding others.”15 In 
claim one of the ’765 patent, comprising is used 
in two places: (1) in the preamble (“A method... 
comprising …”) and (2) in the body (“a … DNA 
sequence comprising …”). If someone were to use 
the patented method with small changes—addi­
tional steps or a DNA sequence with additional 
elements, for example—he or she would still be 
infringing on the claim. 
In contrast, the transition “consisting of” 
limits the claim scope to the recited elements or 
steps. If the claim were “a DNA sequence con­
sisting of ACGTGC,” a person would be able to 
make the DNA sequence “ACGTGCTA” with­
out infringing on the claim. 
The meaning of the transition phrase con­
sisting essentially of falls somewhere between the 
other two. It indicates that the patent does not 
regulate the use of variables that do not affect 
the basic and novel characteristics of the meth­
od or product. It is not often used in biotech­
nology patents. 
Furthermore, there are two kinds of claims: 
independent and dependent. An independent 
claim (for example, claims 1, 10, 19, 28, 37, 46, 
and 55) includes all necessary limitations and 
does not depend on nor include limitations from 
any other claim. Curiously, although dependent 
claim is defined in the patent rules of the United 
States, independent claim is not. U.S. patent rules 
state that a dependent claim must “refer[s] back 
to and further limit[s] another claim or claims.”16 
Moreover, a dependent claim “shall be construed 
to include all the limitations of the claim incorpo­
rated by reference.”17 
Claim 4. of the ’765 patent is an instructive 
dependent claim. Since claim 4. depends upon 
claim 1., the transiently active promoter is lim­
ited to the LEA promoter. All other elements of 
claim 1. remain intact and are not limited any 
further. 
Dependent claims serve several very impor­
tant purposes. In the first place, they help with 
so-called claim differentiation: in patent law, no 
two claims can have the same scope. Therefore, 
the transiently active promoter in claim 1. must 
encompass more than the LEA promoter men­
tioned in claim 1.; otherwise, claims 1. and 4. 
would have the same scope. Dependent claims 
are also written to protect specific embodiments 
of an invention. Should the main claim fail in a 
court case, a dependent claim may still stand. In 
addition, it is easier for a jury to have the alleged 
infringing activity clearly spelled out. 
3. CONCluSION 
Patent documents contain substantial information 
that has value to researchers, even if infringement 
isn’t an issue. While many patent documents are 
readily available on the Internet for free—gener­
ally from patent offices—they may not always be 
capable of being understood or appreciated. One 
reason for inaccessibility is that patent applica­
tions are written in a special style that does not 
follow the conventions of scientific or technical 
literature. To understand a patent document, a 
roadmap helps until the route is familiar. 
This chapter provides a roadmap for read­
ing a patent document. The various sections of a 
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document are explained in view of their purposes. 
The purposes especially delineate the amount and 
type of reliance that can be made of each of the 
sections. Each section contains its own set of use­
ful information. The importance of the claims is 
paramount for knowing the boundaries of the 
patent right, however, interpreting claims re­
quires more of a roadmap than this chapter pro­
vides. Even without a full appreciation of claim 
boundaries, much information may still be ob­
tained from patent documents. n 
CAROL NOTTENBURg, Principal/Patent Lawyer, Cougar 










3	 More typically, patents contain four sections with 
drawings comprising the last section. 
4	 In the United States, a patent application must be 
filed for in the name of the inventors. In most of the 
rest of the world, patent applications can be filed for 
in the name of the inventors or in the name of the 
assignee(s). 
5	 Patent applications are generally published 18 months 
after the earliest priority application date. Depending 
on the country, the publication number may or may 
not differ from the patent number. If the numbers 
are the same, a suffix is usually used to denote the 
status of the application. For example, in Europe, the 
publication and patent numbers are the same, but the 
suffix A is used to indicate an application and B is used 
to indicate an issued patent. 
6	 In the United States, inventions that are disclosed but
not claimed are prior art against other U.S. applications 
and patents, as of their filing date. 35 U.S.C. § 102(e). 
7	 Before the GATT treaty implementation, the patent
term in the United States was 17 years from the date of 
issuance. Under GATT, the patent term is 20 years from 
the earliest claimed priority date. 
8	 An assignee in the United States is called an applicant
in the rest of the world.
9	 Priority applications determine both patent term and 
which prior art can be applied in a patent examination.
A particular claim has a priority date as of the earliest
application that contains the patentable subject
matter. Art available after the priority date cannot
be cited against the claim. In practice, U.S. examiners 
rarely determine the priority date of a claim, whereas 
European examiners frequently review priority
applications to determine priority dates of claims. 
10 The IPC system is a hierarchical classification system 
administered by the World Intellectual Property 
Organization. For more information on international 
classifications and IPC, see WIPO’s Web site at
www.wipo.org. 
11	 In the United States, each individual associated with 
the filing and prosecution of a patent application (for 
example, inventor, patent attorney, assignee) has a 
duty to disclose all material information to the patent
office. 
12	 37 C.F.R. 1.72(b).
13	 The written description shows that the inventor has 
the invention in mind. The enablement describes the 
invention clearly enough that one skilled in the art
can understand it, make it, and use it without undue 
experimentation. In the best mode, an inventor 
discloses the most effective method of practicing or 
using the claimed invention. The patent office does 
not ask applicants whether or not they have disclosed 
the best mode, a question which usually only arises 
during litigation. 
14	 35 U.S.C. § 112.
15	 Equivalent words are having and including, but most
practitioners use comprising because it has become a 
standard term of art. 
16 37 C.F.R. 1.75(c). 
17	 See supra note 16. 
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WILLIAM NEEdLE, President and Founder, Needle and Rosenberg PC, U.S.A. 
ABSTRACT 
Trademarks, in the broadest sense, encompass a range 
of indicators for goods and/or services, including ser­
vice marks, collective marks, certification marks, trade 
names and trade dress. A trademark, which may be a 
name, symbol, feature, or design, functions as an indi­
cator of source and identifies and distinguishes a good 
or service, enabling customers to ascertain the quality 
of the good (or service) based on the trademark. Unlike 
other forms of intellectual property rights (for example, 
copyrights and patents), the rights extended by trade­
marks are not generated from the creative activity of 
an author or inventor, but rather via their use in com­
merce, and it is the customer’s association of the trade­
mark with a specific product (or service) that is the key 
factor in establishing rights. The relative effectiveness 
of a trademark depends on its degree of distinctiveness. 
By way of classifying trademarks, a hierarchy based on 
strength of protection, from fanciful to merely descrip­
tive, has been established. Whereas fanciful trademarks 
are inherently distinctive because they are terms invent­
ed solely for a specific purpose (for example, Kotex), 
descriptive marks (for example, Chap-Stick) must ac­
quire secondary meaning to become protectable. In the 
United States, trademarks are protected by both state 
and federal laws. Although federal trademark registra­
tion is not necessary to assert trademark rights, it af­
fords many advantages and benefits to the owner, and 
hence is by far the preferred means of protection. It is 
important to remember, however, that trademarks must 
always be maintained, protected, and correctly used. 
Their strength, and therefore value, is directly linked to 
public perception. 
1. INTRODuCTION 
This trademark primer is intended both to provide 
a general understanding for technology transfer 
practitioners and to introduce a protection tool 
for those who might, in the future, need to license 
trademarks for their own inventions or those of 
others. As trademarks are a distinct, legal form of 
intellectual property (IP), a working knowledge of 
trademarks will be useful for individuals who are 
active in the field of technology licensing. 
While trademarks, patents, and copyrights 
all are referred to as IP, they do, of course, serve 
different functions: patents protect inventions, 
trademarks protect unique product or service 
identifiers, and copyrights protect original artistic 
or literary works. While the meaning of inven­
tion is generally known, the distinction between 
a trademark and a copyright is often confused. 
As an example, the contents (for example, for­
mat, photos, text) of a periodical are protected 
under copyright law, but the title of a publication 
(such as Newsweek) is protected under trademark 
law. More information about these topics can be 
found on the World Wide Web.1 
Unlike patents and copyrights, trademarks 
(often called brands or marks) are regulated under 
federal and state laws. A mark may be registrable 
Needle W. 2007.Trademark Primer. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook 
of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online 
at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Third Edition, Part IV: Chapter 2.4). 
© 2007. W Needle. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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NEEDlE 
in the United States under the federal trademark 
legislation known as the Lanham Act (Title 15 of 
the U.S. Code of Federal Regulations). Federal 
registration provides protection throughout the 
United States. A mark may also be registrable in 
individual states; registration in a particular state 
is enforceable only inside that state. Registration 
is not required to establish rights in a mark; ac­
tual use in commerce is all that is necessary. A 
federal application can be filed in the U.S. Patent 
and Trademark Office (PTO) based only upon a 
good-faith intent that the mark will be used in 
interstate commerce, but a registration will not 
issue until actual use of the mark occurs in inter­
state commerce. Unregistered marks are protect-
able under common law but only in the market 
area in which they are actually used. 
2.	 TERMINOlOGy 
2.1 Trademark 
A trademark, or brand name, is any word, name, 
symbol, device, or any combination of these ele­
ments that is adopted for use in commerce by a 
manufacturer or businessperson to (1) identify the 
company or person’s goods or products, (2) distin­
guish those goods from goods manufactured or sold 
by another person or company, and (3) indicate 
the source of the goods carrying the trademark. 
Examples of what may function as a trade­
mark include the following: 
•	 a word or group of words, such as a slogan 
(Tide®, Cabbage Patch Kids®, Don’t Leave 
Home Without It®) 
•	 a logo, symbol, pictorial representation, or 
design (Nike’s Swoosh symbol, McDonald’s 
golden arches, the five interlocking
Olympic rings) 
•	 a combination of a word or words plus a 
symbol, pictorial representation, or de­
sign (the word Nestea plus its design, the 
phrase Cabbage Patch Kids plus its design
[see Figure 1]) 
•	 numerals, letters, or combinations thereof 
(Levi® 501® Original Jeans, IBM®, V8® 
[juice made by Campbell Soup Co.]) 
•	 the shape of a container or other packag­
ing (Coke’s bottle shape, the conical shape 
of the top of a Cross pen, the shape of 
Toblerone chocolate packaging) 
•	 color (The Home Depot’s orange, Owens 
Corning pink insulation) 
•	 sound (MGM’s lion roar, NBC’s chimes) 
•	 scent (“the high impact, fresh flower fra­
grance reminiscent of Plumeria blossoms” 
owned by Celia Clarke, doing business as 
Clarke’s OSEWEZ) 
2.2 Service mark 
A service mark is similar to a trademark; however, 
the service mark is used in the sale or advertising 
of services, rather than goods. A service mark is 
used to identify the services of one person and 
to distinguish them from the services of others, 
(McDonald’s® and Office Depot®). Service marks 
are afforded the same legal protection as trade­
marks and are registrable in the same manner and 
have the same effect. 
2. Trade name 
Normally, the name of a business entity is not 
registrable unless it is also used as a trademark 
or service mark, that is, in conjunction with the 
Figure 1: Sample Trademark 
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CHAPTER . 
goods and/or services of the business entity. A trade 
name is usually identified by its ending in the term 
Company/Co., Corporation/Corp., Incorporated/ 
Inc., or Limited/Ltd. (for example, McDonald’s 
Corp. [trade name] versus McDonald’s® restau­
rants [service mark]). Trade name infringement is 
actionable under federal and state laws. 
2. Trade dress 
Trademark protection has been expanded by courts 
beyond words, slogans, symbols, and other devices 
to protect distinguishing, albeit unregistered, fea­
turesofproducts.While tradedressoriginally referred 
exclusively to a product’s packaging or dressing that 
was not protectable by registration, the concept has 
grown to include product designs, for example, the 
decor of a chain of Mexican restaurants (“a festive 
eating atmosphere having interior dining and patio 
areas decorated with artifacts, bright colors, paint­
ings, and murals”) and even sales techniques, such 
as Original Appalachian Artworks’ simulation of 
adoption procedures and provision of birth certifi­
cates for the Cabbage Patch Kids® dolls. 
To recover damages for trade dress infringe­
ment, a plaintiff must prove by a preponderance 
of evidence that (1) the trade dress has obtained 
secondary meaning in the marketplace (that is, 
that the primary significance of the trade dress, in 
the minds of the public, is to identify the prod­
uct’s source rather than the product itself ); (2) the 
trade dress of the two competing products is con­
fusingly similar; and (3) the appropriated features 
of the trade dress are primarily nonfunctional. 
2. Domain names 
A domain name is a name that identifies one or 
more Internet addresses and is part of the URL 
for a Web site (examples are .com, .org, and .net). 
Domain names do not act as marks in identifying 
the source of goods or services, however, where 
a domain name is used as something other than 
merely an address, it becomes a trademark or a ser­
vice mark. For example, in Amazon.com, the do­
main name (.com) is functioning as a service mark 
because .com is part of the identity of the service of 
the Amazon.com Web site. For example, when the 
term Google® is used on the home page of Google 
or is used in advertising or promoting the Web 
site, it is being used to identify the source of spe­
cific services and, therefore, is acting as a service 
mark. Similarly, the domain name Amazon.com
also functions as a service mark because it, along 
with the service mark Amazon®, is used in advertis­
ing to designate the source of the services.2 
2. Certification marks 
Certification marks certify that products or servic­
es manufactured or provided by others have cer­
tain qualities. Vidalia® of Vidalia onions provide 
an example. According to Georgia’s Department 
of Agriculture, “The certification mark is intend­
ed to be used by persons authorized by the certifier 
and will certify that the goods in connection with 
which it is used are yellow Granex type onions and 
are grown by authorized growers within the Vidalia 
onion production area in Georgia as defined in the 
Georgia Vidalia Onion Act of 1986.”3 
2. Collective marks 
Collective marks are used by members of a group or 
organization to identify the goods it produces or 
services it provides. An example of a collective mark 
is ILGU® (International Ladies Garment Union). 
. SElECTION AND ADOPTION OF A MARK 
.1 Types of marks 
A hierarchy of marks exists within this protection 
system, with the more distinctive marks being af­
forded a wider scope of protection than the less 
distinctive ones. The order of marks from most 
distinctive to least distinctive is: fanciful mark, 
arbitrary mark, suggestive mark, and descriptive 
mark (see Figure 1). It is best to select a mark that 
is fanciful, arbitrary, or suggestive. As one might 
expect, the more distinctive the mark, the better 
the chance of protecting and registering it. 
A fanciful mark is one that is created solely for 
the purpose of functioning as a mark and has no 
other meaning. Examples are Xerox®, Pentium®, 
Kodak®, Exxon®, Clorox®, Kotex®, and Polaroid®. 
An arbitrary mark is one that comprises 
a common word or symbol that is arbitrarily
applied to the goods or services in question 
such that the word or symbol does not describe 
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NEEDlE 
or suggest the product. Nor would the words
normally be associated with the product. 
Examples are Command® (hair-care prod­
ucts), Shell® (gasoline), Apple® (computers), Ice 
Cream® (chewing gum), Guess?® (jeans), and 
Die-Hard® (batteries). 
A suggestive mark is one that suggests, but 
does not describe qualities or functions of a par­
ticular product or service. If the qualities are not 
instantly apparent from the mark, but with an 
exercise of imagination could convey the char­
acteristics or qualities of the product or service, 
the mark is “suggestive.” Examples are Crosstalk® 
(software), Stronghold® (nails), 7-Eleven® (retail 
store services), Coppertone® (tanning products), 
Rapid Shave® (shaving cream), Gleem® (tooth­
paste), Roach Motel® (roach bait), Woolite® (wool 
cleaner), and Honey Maid® (graham crackers). 
Arbitrary, fanciful, and suggestive marks are 
inherently distinctive and are given a high de­
gree of protection. 
A merely descriptive mark generally affords 
the narrowest scope of protection. The descrip­
tive mark immediately identifies or brings to 
mind the characteristics, qualities, ingredients, 
functions, composition, purpose, attribute, use, 
or other features of a product or service. A merely 
descriptive mark is not protectable because the 
word or words comprising the merely descriptive 
mark should be available for all competitors to 
use. It is sometimes difficult to distinguish a sug­
gestive mark from a merely descriptive mark. A 
merely descriptive term is protectable only when 
it holds a secondary meaning or distinctiveness, 
that is, the consumer accepts and recognizes it as 
denoting only one source (product or service) and 
the term is synonymous with that product or ser­
vice (and, thus, functions as a mark), rather than 
merely being a descriptor of the goods or services. 
Courts will often look to the following when de­
ciding whether a term is merely descriptive: 
• 	 the amount and manner of use of the term 
in advertising 
• 	 the volume of sales of products/services 
bearing the mark 
•	 the length and manner of the term’s use 
• 	 the results of consumer surveys 
Marks that have been found to be merely 
descriptive include: Chap-Stick® (chapped lip 
treatment), Shear Pleasure® (beauty salon), Hair 
Color So Natural Only Her Hairdresser Knows 
for Sure® (hair coloring), Beef and Brew® (res­
taurants), Hour after Hour® (deodorant), and 
Raisin-Bran® (cereal). To illustrate, the term bril­
liant would be merely descriptive for diamonds, 
suggestive for furniture polish, and arbitrary for 
applesauce. 
Finally, generic terms are the common name 
of a class of things and are, by definition, inca­
pable of indicating source and can never function 
as a trademark or service mark (examples of ge­
neric terms are blended whiskey, computer software, 
mouse, disk, or keyboard). 
In some cases, generic terms are those that, 
at one time, functioned as trademarks but 
that, as a result of widespread use, lost their 
ability to function as a source identifier and 
came to mean, to the general public, the prod­
uct itself (specifically) rather than merely one 
Figure 2: Types of Marks 
WEAkEST	pRoTECTIon STRonGEST	pRoTECTIon 
Fanciful Arbitrary Suggestive Merely Descriptive Generic 
s s s
s s 
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CHAPTER . 
manufacturer’s brand or version of the product. 
Such loss of distinctiveness in a trademark, so-
called genericide, happens when a mark, via 
misuse, becomes a generic term (for example, 
Frigidaire® becomes equivalent with refrigera­
tor) and thus, ceases to indicate the source and 
falls into the public domain where it is thereaf­
ter owned by no one. 
Such former trademarks are numerous, in­
cluding: aspirin, cellophane, cola, cornflakes, cube 
steak, dry ice, escalator, high octane, kerosene, lano­
lin, linoleum, mimeograph, Murphy bed, nylon, 
raisin bran, refrigerator, shredded wheat, thermos, 
trampoline, yo-yo, monopoly, and zipper. As an ex­
ample, the term escalator was first used as a trade­
mark (Escalator® [moving stairs]) but, over time, 
the public stopped using the term as a trademark 
(an adjective, or modifier, such as in Escalator® 
stairs) and started to designate any moving stairs, 
regardless of the manufacturer, as escalator and 
thus, the trademark term became the name of 
the product. 
.2 Preadoption investigation 
Once a mark is selected, but prior to its use, a 
thorough search should be undertaken to de­
termine whether the mark is available for both 
use and federal registration. Sources of informa­
tion on existing registered marks are discussed 
below. 
.2.1 	Records of the U.S. Patent and 
Trademark Office 
A prospective trademark user is charged with con­
structive notice of any identical or confusingly 
similar mark that is federally registered. A search 
of the PTO records can be conducted online on 
the PTO database,4 by hand in the office records, 
or by means of the Trademarkscan® database5 (File 
226)6 of Dialog services. Also, File 116 (brand 
names) of Trademarkscan can be searched. 
Private search companies undertake record 
searches for a fee. These companies include: 





The companies will search the federal reg­
ister and pending application records as well as 
phone directories, yellow pages, industrial direc­
tories, and state trademark registers in an effort 
to determine if a particular mark or a similar 
mark is already in use. 
Also, if use of the mark is contemplated in 
any foreign countries, the trademark and ser­
vice mark records of those countries should 
be searched. Searching of trademark records 
of countries such as Canada (File 127), France 
(File 657), Germany (File 672), and the United 
Kingdom (File 126) can be performed on the 
Trademarkscan database. 
.2.2 State trademark records 
The Trademarkscan database (for state records, 
File 246) can be utilized to search the trademark 
and service mark records of all states. 
Related information can be accessed using 
Internet searches. Network Solutions’ Web site12 
provides a convenient search tool to determine if 
a proposed mark is being used in a domain name 
and who owns it (the “WOSIT” button). One 
can also use a browser to search for directly con­
flicting Web sites or for business names across the 
country. The following sites are useful for such 
searches: 
•	 Big Book13 
•	 Switchboard14 
•	 GTE Superpages15 
•	 World Pages16 
•	 ZIP217 
. Misconceptions 
Below is a list of some common misconceptions 
about trademark protections: 
•	 The fact that an individual has incorporat­
ed, qualified to do business under a name, 
or registered the name in the assumed 
name records of a particular state does not 
automatically bestow to that individual 
the right to use the name as a mark. 
•	 A person does not have an absolute right 
to use his or her own name as a trade­
mark or service mark (for example, Old 
McDonald would likely be barred from 
using his surname as a trademark and 
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NEEDlE 
service mark for his own national chain of 
fast food hamburger franchises). 
•	 Registration in one state (or jurisdiction) 
of a mark for use as a trademark or service 
mark does not necessarily allow use of the 
mark elsewhere. 
•	 Even though a mark appears in an aban­
doned application or an expired registra­
tion, the owner of that mark may still be 
using it, and, thus, have protectable com­
mon law rights against a subsequent user. 
.	 REGISTRATION OF A MARK IN THE PTO 
.1  Process 
It is not necessary to obtain either a state or fed­
eral registration to be able to protect a mark, as 
rights in a mark are based upon use, not regis­
tration, of the mark. Generally, the owner of 
a mark is considered to be the first person or 
company to use a mark, or to file an intent­
to-use application in the PTO, for a particular 
product or service or for related products and 
services. However, registration of a mark in the 
PTO is highly recommended, as registration 
confers significant nationwide benefit upon the 
owner, even if the actual use in commerce of the 
mark is limited to a small geographic area—the 
term commerce is broadly construed to mean 
any commerce that may lawfully be regulated 
by the U.S. Congress. 
The Trademark Act (15 U.S.C. § 1127)
defines use in commerce as follows: 
The term use in commerce means the bona 
fide use of a mark in the ordinary course of trade, 
and not made merely to reserve a right in a mark. 
For purposes of this Act, a mark shall be deemed to 
be in use in commerce: 
(1)	 on goods when (A) it is placed in any
manner on the goods or their containers 
or the displays associated therewith or on 
the tags or labels affixed thereto, or if the
nature of the goods makes such place­
ment impracticable, then on documents
associated with the goods or their sale, and 
(B) the goods are sold or transported in
commerce, and 
(2) on services when it is used or displayed in 
the sale or advertising of services and the 
services are rendered in commerce, or the 
services are rendered in more than one State 
or in the United States and a foreign coun­
try and the person rendering the services is 
engaged in commerce in connection with 
the services. 
.2  Advantages of registration 
Registration of a mark on the Principal 
Register18 of the U.S. Patent Office allows
an owner to: 
•	 prevent registration of the identical or 
confusingly similar marks 
•	 secure injunctive relief and damages 
against infringers nationally in federal 
court (whereas unregistered marks may 
be protectable only in the specific market 
where they are used) 
•	 assert the registration in federal court as 
prima facie evidence of the validity of 
the registration, of the ownership of the 
mark, and of the right to exclusively use 
the mark in commerce 
•	 have the mark treated as incontestable af­
ter five years’ use 
•	 eliminate the defense of innocent adop­
tion by anyone using the mark after the 
date of registration, thereby affording na­
tionwide protection to registered marks, 
regardless of the areas in which the mark 
is actually used 
•	 prevent the importation of goods bearing 
infringing or counterfeit marks by record­
ing the mark with U.S. Customs 
.  Actual use versus intent-to-use 
applications 
A dual-application system exists in the PTO that 
permits the filing of trademark/service mark ap­
plications based upon an intent to use the mark, 
as well as applications based on actual use of the 
mark in commerce. However, while an applica­
tion may be filed based on a bona fide intent to 
use the mark, the applicant will still have to make 
actual use of the mark in commerce before the 
mark can be registered. 
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CHAPTER . 
The intent-to-use procedure encourages the 
early filing of an application because, while the 
application is pending, the applicant will have the 
benefit of constructive-use priority. Thus, subject 
to the mark actually being registered, the appli­
cant will have prior rights in the mark against 
all others nationwide (except for those who used 
the mark before the application was filed, or who 
filed an earlier application, or who had priority 
based on a foreign application). 
. Term of a federal registration 
Federal trademark/service mark registrations are 
valid for a period of ten years and are renewable 
for ten-year periods as long as the mark remains 
in actual use. 
Additionally, between the fifth and sixth year 
from the date of a federal registration, the regis­
trant must file a declaration or affidavit that the 
mark is still in use as of that date (as of the sixth 
year after registration). An affidavit of use must 
also be filed in the year prior to the end of each 
registration term. Failure to file such a statement 
will cause the registration to be canceled by the 
PTO. 
. State registrations 
A state registration does not confer the same 
rights and benefits as a federally registered mark. 
For example, a state registration is enforceable 
only within that state while federal registration 
provides nationwide protection and constructive 
notice.19 Usually there is no need to seek a state 
registration if the mark is registered in the PTO. 
A state registration should be obtained only if the 
mark is not registrable in the PTO. 
.	 INFRINGEMENT OF A MARK 
Protection of a mark, whether registered or 
not, involves actions against other marks that 
are likely to cause confusion. For a trademark 
owner to prevail against an accused party, nei­
ther the respective marks nor the respective 
goods or services need to be identical. Instead, 
likelihood of confusion (the test for trademark 
infringement) is determined by considering the 
following factors: 
•	 the strength or weakness of the
plaintiff’s mark 
•	 similarity of the marks in sound (for ex­
ample, SO found confusingly similar to 
Esso), appearance (Old Forester infringed by 
Old Foster), or meaning (Tornado for wire 
fencing held confusingly similar to Cyclone
[wire fencing]) 
•	 similarity of the product or services 
•	 likelihood that the prior owner will bridge 
the gap between the parties’ respective 
products or services 
•	 presence or absence of actual confusion (ac­
tual confusion obviously being the best test 
of whether there is a likelihood of confusion 
occurring between two conflicting marks) 
•	 defendant’s good faith in adopting the mark 
•	 sophistication of the potential purchasers 
(buyers of expensive goods may be more 
discerning purchasers and less likely to be 
confused between two similar marks for the 
same goods) 
•	 channels of trade (the goods/services are 
sold, or are not sold, in the same mar­
keting channels to the same general class
of customers) 
•	 similarity of the advertising media 
.	 THE “CARE AND FEEDING” OF MARKS 
Trademarks and service marks are valuable assets, 
so their proper use, maintenance, and protection 
should be a paramount concern of the owner. It 
is critical to avoid misuse of a trademark, which 
can destroy the legal significance of the mark, for 
example, misuse leading to genericide, with the 
unfortunate outcome of a valuable trademark 
becoming a generic term. There is also the neces­
sity of maintaining trademarks so as to avoid any 
possibility of creating unfavorable commercial 
impressions; solid, strong, and maintained trade­
marks are source indicators that attract business. 
Proper usage for trademarks and service marks 
will go a long way to protect marks and prevent 
genericide: 
•	 Always use the mark as a proper adjective that 
modifies a noun, such as Cabbage Patch Kids® 
dolls, Levis® jeans, Xerox® copy machines. 
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•	 Never use a mark in the possessive form, in 
the plural form, or as a verb. 
•	 Avoid prefixes, suffixes, additions, or dele­
tions of the mark. 
•	 Distinguish the mark in use from sur­
rounding text such as a distinctive typeface, 
quotation marks, all capital letters or, at the 
very least, capitalize the first letter of each 
word of the mark. 
•	 For marks registered in the PTO, use the 
symbol of registration, namely, ®, or the phrase Registered in the U.S. Patent and
Trademark Office or Reg. U.S. Pat. Tm. Off. 
•	 For unregistered marks, use either the in­
formal notice TM or SM (or the corre­
sponding symbols) or an asterisk indicating 
A trademark/service mark of XYZ Company. 
The following ditty was a prize-winning sub­
mission at the Coca-Cola Co., which should be kept 
in mind to promote the proper usage of any mark: 
Three laws bind the Kingdom of Coke.
 
This trio must never be broke:
 
The “C” should be tall,
 
Not possessive at all,
 
And the plural should never be spoke.
 
.	 lICENSES 
Never allow a third party to use your mark with­
out entering into a written license agreement, 
which, at a minimum, enables you to monitor 
and control the nature and quality of the goods 
or services in connection with which the mark is 
being used by the licensee. Otherwise, you may 
end up with a naked license,20 which could nega­
tively affect the distinctiveness of your mark, pos­
sibly leading to the de facto abandonment of the 
trademark. Also, provide in any license agreement 
for the licensee to notify you of potentially in­
fringing marks so that you may police your mark, 
as unauthorized uses of your mark will similarly 
negatively influence your scope of protection. 
An assignment of a mark must be in writing 
and, whether registered or not, must include “the 
good will of the business associated with the mark” 
or the assignment is invalid. The basis for this pro­
vision is that a mark is merely the symbol of good 
will (that is, the owner’s reputation for quality in 
connection with the goods or services sold un­
der the mark). An assignment of a mark without 
the accompanying good will is an assignment in 
gross21 and is invalid. Also, an intent-to-use ap­
plication cannot be assigned as there is nothing to 
assign until the mark is in actual use. 
.	 CONCluSIONS 
When properly managed, maintained, protected, 
and used, trademarks are a valuable form of IP 
rights. In a comprehensive and coordinated IP 
strategy, trademarks can augment other forms 
of IP rights protection, for example, patents 
and trade secrets, and therefore should not be 
overlooked as additional options in a layered IP 
portfolio. A single product, such as crop variety, 
can have multiple forms of IP rights protection, 
including patents, trade secrets, and trademarks. 
It is therefore important to understand what a 
trademark is, how to select a strong mark and es­
tablish rights, the importance of registration, and 
the necessity of policing the trademark, whether 
to maintain the integrity of licensees or to identi­
fy potential infringers. Finally, strong trademarks 
are distinct and specific indicators of source. 
Protecting this function, an owner never wants to 
find his or her mark in a dictionary. That would 
mean the mark had joined the ranks of the unfor­
tunate victims of genericide, like the yo-yo. n 
WILLIAM NEEdLE, President and Founder, Needle and 
Rosenberg PC, Suite 1000, 999 Peachtree Street, Atlanta, 
GA, 30309, U.S.A. bneedle@needlerosenberg.com 
1	 For copyright information, go to www.copyright.gov;
for patent information, go to www.uspto.gov/main/
patents.htm. The U.S. Patent and Trademark Office has 
a very informative Web site at www.uspto.gov/web/
menu/tm.html. 
2	 See www.uspto.gov/web/offices/tac/notices/ 
guide299.htm. 




6	 See library.dialog.com/bluesheets/html/bl0226.html. 
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18	 A trademark or service mark may be registered with the 
united states patent and trademark office on either the 
principal or supplemental registers. Arbitrary, fanciful,
and suggestive marks are on the principal register,
while suggestive marks with secondary meaning are on 
the supplemental register: “A certificate of registration 
of a mark upon the principal register provided by this 
act shall be prima facie evidence of the validity of the 
registered mark and of the registration of the mark,
of the registrant’s ownership of the mark, and of the 
registrant’s exclusive right to use the registered mark in 
commerce on or in connection with the goods or services 
specified in the certificate, subject to any conditions or 
limitations stated in the certificate.” 15 u.s.c. § 1057 (b). 
19 Constructive notice is a notice to the public of the 
registrant’s claim of ownership of the mark. 
20 Naked licensing means the licensing of trademarks 
without that trademark owner’s retaining the right
to approve the said use of the mark in connection 
with the licensee’s goods or services. As a result, the 
trademark would be deemed abandoned (Barcamerica 
International USA Trust v. Tyfield Imports, Inc., 289 F.3d 
589-598 [9th Cir. 2002]). 
21 Assignment in gross: A mark is a symbol of the mark 
owner’s goodwill in the goods or services associated 
with the mark. The rule both under the common law 
and the Lanham act is that a mark cannot be assigned 
apart from the goodwill in the mark. An assignment in 
gross is an assignment of a mark without the associated 
goodwill. This rule is intended to protect the public 
from the deception that might arise if the assigned 
mark becomes associated with goods or services 
of a different nature or quality than was previously 
the case. An assignment in gross is invalid, and the 
assignee acquires no rights by such an assignment. See
www.inta.org/index.php?option=com_content&task= 
view&id=174&itemid=132&getcontent=1. 
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CHAPTER 4.4 
The Statutory Toolbox: Plants
 
JAy P. kESAN, Professor and Director, Program in Intellectual Property & Technology Law, University of Illinois, U.S.A. 
ABSTRACT 
Different forms of intellectual property protection are 
available for agri-biotech inventions: utility patents, plant 
variety protection, plant patents, trade secrets, geographic 
indications, trademark, and copyright. Each form has its 
own strengths and weaknesses. In general, stronger protec­
tions require meeting more stringent requirements. The 
three most important regimes for agri-biotech inventions 
are utility patents, plant variety protection, and trade se­
crets. A careful consideration of the relative demands and 
benefits of each regime will allow custom-tailored ap­
proaches to suit the needs of the inventor and the nature 
of the invention. 
1. INTRODuCTION 
Several intellectual property (IP) regimes protect 
agricultural biotechnology. They may be used 
alone or in combination. In general, the easier it 
is to obtain a particular form of IP protection, 
the weaker the protection it affords. Conversely, 
the more robust the protection, the more strin­
gent are the requirements for obtaining it. This 
chapter provides an overview of the various forms 
of IP that are available for protecting agricultural 
biotechnology innovation. 
2. PATENT AND RElATED REGIMES 
Patent and somewhat patent-like IP protection 
regimes provide the most important protection 
for agricultural biotechnology innovation. In 
general, a patent grants an inventor of a novel, 
nonobvious, and useful invention an exclusive 
monopoly of fixed duration in exchange for 
public disclosure of the invention. Patent and 
related regimes offer the strongest IP protection. 
It is not mutually exclusive, and concurrent 
protection under multiple regimes is permitted. 
This section describes the utility patent, plant 
variety protection, and plant patent regimes, 
exploring the advantages and disadvantages of 
each regime. 
2.1 Utility patents 
The first regime, the utility patent, provides the 
most extensive coverage for inventions. In the 
context of agricultural biotechnology, the util­
ity patent may be obtained to protect everything 
from genetically modified seeds and geneti­
cally modified plants, to transformation meth­
ods. Under the U.S. statute governing utility 
patents: 
Whoever invents or discovers any new and 
useful process, machine, manufacture, or composi­
tion of matter, or any new and useful improvement 
thereof, may obtain a patent thereof, subject to the 
conditions and requirements of this title.1 
Plants are eligible subject matter for utility 
patent protection under the category of “compo­
sitions of matter.” 
Kesan JP. 2007. The Statutory Toolbox: Plants. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org. 
© 2007. JP Kesan. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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2.1.1 Scope of protection 
In the United States, utility patents grant a broad 
right to exclude others from making, using, offering 
to sell, selling, or importing into the United States, 
the patented invention.2 Unauthorized exploitation 
of the patented invention by others within the pat­
ent term constitutes patent infringement. The broad 
scope of protection afforded by utility patents pro­
vides great flexibility for tailoring protection to vari­
ous plant innovations. 
Utility patents may cover individual compo­
nents of a plant, including the plant’s genome, 
cells, cell culture, and tissues, as well as methods 
for making the plant. For example, Monsanto, an 
agrichemical corporation, holds U.S. patents on 
Roundup Ready® soybeans, which are genetically 
modified to withstand the company’s broad-spec­
trum herbicide, Roundup®. The company creates 
Roundup Ready® soybeans by inserting a gene 
sequence that allows the plant to survive the her­
bicide. Monsanto’s utility patents allow the com­
pany to claim protection not only for methods 
of producing the Roundup Ready® soybeans, but 
also for the DNA molecule that encodes the her­
bicide-resistant trait, for the herbicide-resistant 
plant cell, for the seed of the herbicide-resistant 
plant, and for the final Roundup Ready® soybean 
plant itself. 
A utility patent may also cover multiple va­
rieties at once. And if the applicant meets the 
disclosure requirements discussed below, the 
patent can cover an entire species or genus. 
Moreover, the scope of the protection is broader 
than the specific plant variety developed. Under 
the patent law’s doctrine of equivalents, trivial 
variations to an invention that may not fall 
within the literal terms of the claims of the pat­
ent may nevertheless infringe as an equivalent of 
the claimed invention. 
2.1.2	 Requirements for obtaining 
a utility patent 
To obtain the protection of a utility patent, an 
applicant must meet the highest threshold for ac­
quiring IP protection: an invention must be new, 
useful, and nonobvious.3 First, it is considered new 
if it is not already known to the public.4 An in­
vention fails to meet the novelty requirement if it 
was in public use, was described in a printed pub­
lication, or was covered in a preexisting patent. In 
the United States, there is a one-year grace period 
on the bar on public use and printed publication. 
Second, an invention must be useful, that is, ca­
pable of providing a specific benefit.5 Failure to 
identify a specific use for a gene sequence renders 
the gene sequence ineligible for patent protec­
tion. Finally, an invention must be nonobvious, 
that is, the invention is not obvious to a person of 
ordinary skill in the art. The nonobvious require­
ment takes into account the scope and content of 
the prior art and the level of ordinary skill in the 
pertinent art. Patent may be denied if the inven­
tion is a combination of previously known com­
ponents A, B, and C, and the idea to combine 
the components A, B, and C were obvious to a 
person of ordinary skill in the art. 
At minimum, a patent application must 
contain specifications and at least one claim. In 
the specifications, an applicant must disclose in 
writing what the applicant believes he or she has 
invented. The specifications must describe the 
invention in sufficient detail to enable others of 
ordinary skill in the pertinent art to practice the 
invention.6 For example, in an application claim­
ing DNA as the invention, a description of the 
DNA is adequate if it includes a definition of the 
physical properties, formula, chemical name, or 
structure of the claimed invention; a description 
that merely states that DNA is involved in the 
invention falls short of the requirement. In situ­
ations where the starting materials required to 
practice the invention are not readily available to 
the public, the applicant may also be required 
to place the materials in a depository in order 
to fulfill the enablement requirement. The writ­
ten description of the invention must also reveal 
what the inventor believes is the best way to 
practice the invention. 
The claims in a patent define the boundaries 
of a patentee’s right to exclude. The patent appli­
cation must therefore describe what the inventor 
claims as his invention, by including 
…one or more claims particularly pointing out 
and distinctly claiming the subject matter which the 
applicant regards as his invention.7 
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CHAPTER . 
Ideally, claims should be both broad enough 
to afford the patentee a wide scope of protection, 
and narrow enough to avoid invalidation by the 
prior art. In general, claim language that contains 
fewer limitations provides broader patent pro­
tection than claim language that includes many 
limitations. Consider the following two simpli­
fied claims for a bucket: 
A claim that reads: 
A bucket comprising a wooden circular bottom, 
wooden side walls, and a stainless steel handle 
provides narrower protection than a claim that 
reads: 
A bucket comprising a bottom, side walls, and 
a handle 
A competitor’s metal bucket with a square 
bottom would fall outside the claim language of 
the first example, but would infringe the second 
example by falling within its claim language. 
Additionally, claims may be classified as either 
independent or dependent. Independent claims 
generally are the broadest claims and do not re­
fer to any other claim in the patent. Dependent 
claims, on the other hand, incorporate other 
claims by reference and add additional limita­
tions. Consequently, dependent claims provide a 
narrower scope of protection than independent 
claims. Consider the following example: 
I claim: 
1. a 	 bucket comprising a bottom and side 
walls 
2. the bucket of claim 1 further comprising a 
handle 
3. the bucket of claim 2 wherein the bottom 
and side walls are wooden 
4. the bucket of claim 2 wherein the bottom 
is circular 
In this example, claim 1 is the independent 
claim. Claims 2 through 4 are the dependent 
claims that rely on claims that have come before. 
Ultimately, a patent covers only what the applicant 
describes and claims in the patent application. 
2.1.  Procedure for obtaining a patent 
a) Patent protection in the United States. In the 
United States, utility patents are administered by 
the Patent and Trademark Office (PTO), an arm 
of the U.S. Department of Commerce. The PTO 
receives and examines applications and has power 
to grant patents if it is convinced that the inven­
tion is new, useful, nonobvious, and meets other 
conditions and requirements as set forth in the 
statute.8 The first step in acquiring a patent is to 
file a patent application with the PTO. Thereafter, 
a series of communications between the applicant 
and the PTO follows. Six months to two years 
after the filing date of the patent application, the 
PTO will send communications to the applicant 
known as an Office Action. This communication 
notifies the applicant of whether the claims have 
been allowed and provides reasons for rejections of 
claims. The applicant then has a chance to respond 
to the PTO within a time specified in the Office 
Action, typically three months. The applicant may 
amend the application to overcome the rejections. 
Two to six months after the PTO receives the ap­
plicant’s response to the Office Action, the PTO 
may send another Office Action to the applicant 
or it may send a Notice of Allowance. A Notice of 
Allowance indicates that the PTO has allowed all 
of the claims in the application. A patent will issue 
after the applicant pays an issue fee. 
Once granted, utility patent protection lasts 
for a term of 20 years, measured from the date the 
patentee filed the application. It is not subject to 
exemptions from enforcement. During the term 
of the issued patent, the patent holder must pay 
periodic maintenance fees to the PTO. 
b) International patent protection: The Patent 
Cooperation Treaty (PCT).9 In the current glob­
al economy, an inventor may wish to procure pat­
ent protection for his or her invention in more 
than one country. A patent confers rights, how­
ever, only in the jurisdiction in which the pat­
ent application was filed. Outside of the country 
where the patent is issued, others are free to use 
the invention without incurring patent infringe­
ment liability. A patent that issues in the United 
States, for example, confers no automatic patent 
protection for the invention in France. To protect 
an invention internationally, an inventor must se­
cure a patent in each country in which he or she 
desires protection. 
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Many nations have adopted international 
agreements that make the process of obtaining 
multiple patents easier. One of these agreements is 
the Patent Cooperation Treaty (PCT). The PCT, 
administered by the World Intellectual Property 
Organization (WIPO), is an international agree­
ment that streamlines the process of securing 
patents for an invention in multiple countries. A 
patent applicant may seek simultaneous patent 
protection in multiple countries by filing a single 
application and designating the countries where 
protection is desired. While PCT does not alter 
the substantive requirements of patentability in 
each country, it does eliminate the duplicative ef­
fort wasted in filing separate patent applications 
for the same invention. 
An inventor who wishes to take advantage of 
the PCT, first files an application in his or her 
home patent office, designated the Receiving 
Office. The home office conducts an initial prior 
art search and gives the applicant the opportunity 
to request an international preliminary exami­
nation. The preliminary examination, while not 
binding, indicates the patentability of the inven­
tion, which may assist the applicant in deciding 
whether to commit to an expensive filing abroad. 
In the next step, called the “national stage,” an 
applicant has 30 months to convert the PCT ap­
plication into parallel patent applications in the 
countries in which he or she desires patent pro­
tection. From there, the patent application pro­
cess proceeds according to the procedures estab­
lished by each designated country. 
2.1. 	 Rights of the inventor 
A patent grants its owner the right to exclude 
others from making, using, offering for sale, and 
selling the patented invention without the patent 
owner’s permission. Patents are personal property 
and therefore may be licensed or assigned to oth­
ers, including companies. An assignment transfers 
the rights of the patent from the current owner to a 
new owner. In contrast, a license grants a revocable 
permission to engage in conduct that would other­
wise constitute patent infringement without trans­
ferring ownership of the patent. Licenses may be 
either exclusive (issued strictly to one licensee) or 
nonexclusive (issued to several licensees at once). 
2.2 Plant variety protection 
While utility patents provide the most robust pro­
tection for plant innovation, only a few countries 
afford utility patent protection for agricultural 
biotechnology. A more common regime is plant 
variety protection, also known as plant breeder’s 
rights. In general, plant variety protection pro­
vides a sui generis form of IP protection to breed­
ers of new varieties of plants. 
2.2.1	 International protection: UPOV– 
The International Convention for the 
Protection of New Varieties of Plants 
Many countries with a system for protect­
ing new varieties of plants have based it on the 
International Convention for the Protection of 
New Varieties of Plants (UPOV Convention).10 
Originally adopted in Paris in 1961 with the ob­
jective of providing IP protection for new plant 
varieties, the UPOV Convention has undergone 
several revisions, first in 1972, again in 1978, and 
most recently in 1991. The International Union 
for the Protection of New Varieties of Plants 
(UPOV), an intergovernmental organization 
headquartered in Geneva, Switzerland, adminis­
ters the UPOV Convention. 
The UPOV Convention defines a minimum 
scope of protection that enables plant breeders to 
prohibit the unauthorized exploitation of their 
protected variety. Under the UPOV Convention, 
the authorization of the breeder of an eligible 
plant variety is required to produce or reproduce, 
condition for the purpose of propagation, offer 
for sale, sell, export, import, and stock the propa­
gating material of the protected variety. Where the 
plant breeder has not had a reasonable opportuni­
ty to exercise his or her rights as to the propagat­
ing material, the same rights are extended to the 
harvested material of the protected variety. The 
rights also attach to varieties “essentially derived” 
from the protected variety, varieties “not clearly 
distinguishable from the protected variety,” and 
varieties that “require the repeated use of the pro­
tected variety.”11 The Convention explains that 
“essentially derived varieties” are those that 
…may be obtained, for example, by the selec­
tion of a natural or induced mutant, or of a soma-
clonal variant, the selection of a variant individual 
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CHAPTER . 
from plants of the initial variety, backcrossing, or 
transformation by genetic engineering.12 
To obtain plant variety protection, UPOV 
must examine an application to ensure that the 
proposed variety meets the conditions for protec­
tion. To qualify for UPOV protection, a plant 
variety must be: 
(i)	 distinct from existing, commonly known 
varieties, 
(ii)	 sufficiently uniform, 
(iii) stable, and 
(iv)	 new in the sense that they must not have
been commercialized prior to certain dates
established by reference to the date of the
application for protection13 
Once granted, UPOV dictates that plant 
breeder’s rights shall last for at least 20 years; for 
trees and vines, the term should endure for no 
less than 25 years from the date of the grant. 
UPOV also defines acts that are exempt from 
the plant breeder’s rights. The plant breeder’s per­
mission is not required for acts done privately and 
for noncommercial purposes, experimental use of 
the protected variety, and acts done for the pur­
pose of breeding other varieties. In addition to 
the compulsory exceptions, an optional excep­
tion allows farmers to save harvested seeds for 
replanting. 
Member nations of the UPOV Convention 
agree to adopt all measures necessary to im­
plement the plant breeder’s rights as outlined 
in the Convention and to extend to foreign 
nationals the same rights it provides to its own 
citizens. Implementation of the Convention 
entails the establishment of legal remedies and 
enforcement mechanisms for breeder’s rights, 
as well as the designation of an authority en­
trusted with the power to grant such rights to 
applicants. UPOV provides the basic frame­
work for plant variety protection. However, 
since countries are free to tailor their laws 
to domestic circumstances when implement­
ing the provisions of the UPOV Convention, 
different countries have adopted slightly dif­
ferent versions of the plant variety protection 
regime. 
2.2.2	 Protection in the United States: The Plant 
Variety Protection Act (PVPA) 
The United States is a member of UPOV, having 
implemented the UPOV Convention in 1981. 
Plant variety protection certificates, issued by 
the Plant Variety Protection (PVP) Office of 
the U.S. Department of Agriculture (USDA), 
supply patent-like protection for new varieties 
of seed-bearing plants and may be obtained to 
protect new plant varieties. Governed by the 
Plant Variety Protection Act (PVPA), rights are 
granted to 
[T]he breeder of any sexually reproduced or 
tuber propagated plant variety (other than fungi 
or bacteria) who has so reproduced the variety, 
[…] subject to the conditions and requirements of 
this Act.14 
The PVPA protects discrete varieties from 
unauthorized exploitation by others. Following 
the UPOV Convention, a PVP certificate grants 
its holder the right to exclude others from sell­
ing, offering for sale, reproducing, importing or 
exporting the protected variety, and from using 
the protected variety to produce (as distinguished 
from to develop) a hybrid or different variety. As 
per the UPOV Convention, protection under the 
PVPA extends not only to the protected plant 
variety, but also to “essentially derived varieties,” 
narrowly defined in the PVPA to include two 
generations of derivation. The PVPA defines the 
term as a variety that:
•	 …is predominantly derived from another 
variety (referred to in this paragraph as the 
“initial variety”) or from a variety that is pre­
dominantly derived from the initial variety, 
while retaining the expression of the essential 
characteristics that result from the genotype 
or combination of genotypes of the initial 
variety 
•	 is clearly distinguishable from the initial 
variety 
•	 except for differences that result from the 
act of derivation, conforms to the initial 
variety in the expression of the essential 
characteristics that result from the genotype 
or combination of genotypes of the initial 
variety. 15 
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KESAN 
Inclusion of essentially derived varieties 
within the limits of the breeder’s rights guards 
against acts that border on blatant copying. 
Essentially derived varieties delineate a zone of 
protection around the protected variety that 
captures plants produced by inducing minor 
changes to a protected variety. As an example, 
a hybrid variety of corn produced from a pro­
tected variety may exhibit cosmetic differences 
that make the hybrid distinct from its parent; 
but as an essentially derived variety, the hybrid 
nevertheless falls within the scope of PVP pro­
tection for the parent. 
As required by the UPOV Convention 
guidelines, the PVPA includes several excep­
tions that shield certain acts from infringe­
ment liability. Private noncommercial use of a 
protected variety does not constitute infringe­
ment.16 Saving seed for replanting “a crop for use 
on the farm” and sale of such seeds “for other 
than reproductive purposes” also do not consti­
tute infringement.17 Also, the PVPA explicitly 
provides a research exemption. The statute states 
that “use and reproduction of a protected variety 
for plant breeding or other bona fide research shall 
not constitute an infringement of the protection 
provided under this Act.”18 
Furthermore, though not an exemption from 
infringement liability, the PVPA is subject to a 
requirement that allows the secretary of USDA to 
declare a compulsory license allowing use of the 
protected variety for two years, in exchange for 
a royalty, if such action is deemed necessary for 
the public interest to maintain a sufficient food 
supply. The many exceptions to the PVPA allow 
others, under certain circumstances, to exploit a 
protected plant variety without the owner’s au­
thorization and therefore diminish the strength 
of plant variety protection. 
As a trade-off for the narrower scope of pro­
tection, the PVPA demands a lower threshold for 
obtaining protection. Unlike the utility patent, 
the PVPA does not call for rigorous disclosure 
of the claimed invention, nor does it impose a 
nonobvious requirement. Instead, applicants for 
a plant variety protection certificate must show 
that the variety qualifies for protection, must 
provide a description of the variety, and must de­
posit seed in a repository. 
To qualify for protection under the PVPA, a 
plant variety must be new, distinct, uniform, and 
stable. The statute defines each of these terms. 
First, a variety is “new” if “the variety has not been 
sold or otherwise disposed of to other persons” for 
more than one year before the date the applicant 
filed the application for PVP.19 
Second, a variety is “distinct” if 
… the variety is clearly distinguishable from 
any other variety the existence of which is publicly 
known or a matter of common knowledge at the 
time of the filing of the application. 20 
Moreover, 
… [t]he distinctness of one variety from an­
other may be based on one or more identifiable 
morphological, physiological, or other character­
istics (including any characteristics evidenced by 
processing or product characteristics, such as mill­
ing and baking characteristics in the case of wheat) 
with respect to which a difference in genealogy may 
contribute evidence.21 
Third, a variety is “uniform” when 
… any variations are describable, predictable, 
and commercially acceptable.22 
Finally, a variety is “stable” if
… the variety, when reproduced, will remain 
unchanged with regard to the essential and distinc­
tive characteristics of the variety, with a reasonable 
degree of reliability commensurate with that of vari­
eties of the same category in which the same breeding 
method is employed.23 
Once a plant protection certificate issues, 
the term of protection lasts for 20 years from 
the date of issue of the certificate, or 25 years 
in the case of a tree or vine.24 Unlike utility pat­
ents and plant patents, which must issue under 
an individual inventor’s name, a plant variety 
protection certificate may issue in the name of 
a corporation, which allows a corporation to file 
under its own name. Additionally, as a require­
ment for maintaining PVP, the certificate holder 
must periodically replenish the repository of 
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CHAPTER . 
seeds of the protected plant variety. The PVPA 
does not, however, require payment of mainte­
nance fees for the certificate. When compared 
to a utility patent, the scope of protection under 
the PVP regime is limited. But one advantage 
of the PVPA is the immediacy of protection: as 
soon as a plant variety protection application 
is filed and the fee is paid, provisional protec­
tion attaches to the plant variety. By marking 
the seed with protection notices “Unauthorized 
Propagation Prohibited” or “Unauthorized Seed 
Multiplication Prohibited,” the seed owner ac­
quires protection prior to the issuance of the 
plant variety protection certificate.25 
2. Plant patents 
Plant patent protection is the narrowest of the 
three patent and patent-like IP regimes available 
to agricultural innovation. The scope of protec­
tion extends only to asexually reproduced plant 
varieties. In general, the U.S. statute grants plant 
patents to one who 
… invents or discovers and asexually reproduces 
any distinct and new variety of plant, including cul­
tivated sports, mutants, hybrids, and newly found 
seedlings, other than a tuber propagated plant or a 
plant found in an uncultivated state…26 
For example, a person who discovers and 
asexually reproduces a new pineapple variety 
may obtain plant patent protection. If he or 
she later discovers a second variety of pineapple 
that is separated from the first by a single trait, 
the second variety may also obtain plant patent 
protection. 
The plant patent regime affords protection 
against unauthorized asexual reproduction of 
protected plant varieties. A plant patent grants 
its holder “the right to exclude others from asexu­
ally reproducing the plant, and from using, offering 
for sale, or selling the plant so reproduced, or any of 
its parts…”27 To qualify for plant patent protec­
tion, a plant must be produced asexually, through 
means such as grafting, cutting, budding, layer­
ing, and inarching. 
The cornerstone of plant patent protection 
is asexual reproduction, but asexual reproduction 
also severely limits the protection afforded and is 
therefore its Achilles’ heel. The asexual reproduc­
tion requirement effectively limits infringement 
to the narrow circumstance where stock from the 
patentee’s original parent plant is obtained and 
asexually reproduced. Independent breeding of a 
variety that closely resembles the subject of a plant 
patent escapes infringement liability. So too does 
seed propagation and sexual crosses of the plant, 
since such acts fall outside the scope of plant pat­
ent rights. Because its scope of protection is 
exceptionally narrow, a plant patent ordinarily 
should not be the sole source of protection for a 
plant innovation. 
The requirements for obtaining a plant pat­
ent are, arguably, the least strict of the three pat­
ent and patent-like regimes. In the United States, 
the Patent and Trademark Office administers 
both plant patent and utility patents. Like a util­
ity patent application, a plant patent application 
must meet the patent law’s nonobvious require­
ment. Applications for plant patents must also 
fulfill a disclosure and claiming requirement. The 
plant patent disclosure requirement may be met 
by a description that “is as complete as reasonably 
possible”28 and a color drawing of the plant. Plant 
patents need not disclose how to make or use the 
claimed invention. The claiming requirement re­
stricts the plant patent to a single claim to the 
whole plant. 
Plant patent protection shares some of the 
requirements for PVPA protection, but there are 
some differences. Like plant variety protection, a 
variety must be new and distinct—new, mean­
ing that the plant variety was not sold or used 
more than one year prior to the application date, 
and distinct meaning that the characteristics of 
the variety are clearly distinguishable from those 
of existing varieties. Unlike plant variety protec­
tion, however, plant patents do not require that 
the plant variety be uniform and stable. Whereas 
PVPA protection is unavailable for plants that do 
not breed true, such plants may receive protec­
tion under a plant patent. 
If the requirements are met, the PTO issues 
a plant patent, which offers a term of protection 
of 20 years from the date of patent application. 
Like a utility patent, there are no exceptions to 
enforcement. Also like a utility patent, the patent 
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KESAN 
holder must pay periodic maintenance fees to the 
PTO. 
3. OTHER FORMS OF
IP PROTECTION IN PlANTS 
.1	 Trade secrets 
Along with utility patents and plant variety protec­
tion, trade secret protection represents another es­
sential tool for protecting plant innovation. Most 
significantly, trade secret protection is available for 
inventions that do not otherwise qualify for pro­
tection under a patent or patent-like regime. 
In general, the purpose of trade secret protec­
tion is to uphold commercial morality by prevent­
ing the unauthorized use and disclosure of secret 
information, while leaving other parties free to 
independently develop the same matter. The sub­
ject matter protected by a trade secret coincides 
with the subject matter protected under patent 
regimes. Typically, protection attaches to infor­
mation that is used in business, gives a competi­
tive advantage, and has been kept confidential. 
Unlike patents, trade secret protection arises 
instantly and requires no formal application or re­
view process. Once trade secret protection is estab­
lished, it grants recourse against one who wrong­
fully acquires the secret information. To recover 
for trade secret misappropriation, however, the 
trade secret owner must show that the information 
was protected by reasonable measures to ensure 
the secrecy of the trade secret. The requirement 
of maintaining the confidentiality of the informa­
tion is critical: trade secret protection evaporates if 
the underlying information is no longer a secret. 
The cost of maintaining a trade secret is therefore 
largely the cost of maintaining secrecy measures. 
Keeping a trade secret may involve continuous and 
costly expenditures on measures to prevent the un­
authorized use or disclosure of the information. 
Unlike other IP regimes, trade secrets provide 
protection for an indefinite period rather than for 
a fixed term of protection. So long as the underly­
ing information continues to be a secret, the infor­
mation remains protected as a trade secret. Some 
trade secrets, most notably the secret formula for 
the beverage Coca-Cola, have been maintained as 
trade secrets for a very long time indeed. However, 
trade secret protection can end at any time, since 
once the underlying information is no longer a se­
cret, the trade secret protection disappears. Loss of 
trade secret protection may result from disclosure, 
successful reverse engineering, or independent 
development by others. Unlike patent protec­
tion, trade secret protection provides no recourse 
against one who reverse engineers or independent­
ly discovers the same matter. This uncertainty of 
protection is the risk borne by one who chooses 
trade secret protection. 
In the context of plant innovation, trade 
secret protection is a mixed bag. For seed com­
panies, protecting plant varieties under trade 
secrets alone may prove difficult. Maintaining 
the secrecy of information is challenging be­
cause crops are grown in open fields and seed 
is sold on the open market with no assurances 
of confidentiality. Hybrid seed varieties are the 
easiest to maintain as a trade secrets. Since the 
exact characteristics of the parental lines of a 
hybrid cross are difficult for others to ascer­
tain, the owner of the hybrid plant variety may 
maintain the parental lines as a trade secret and 
sell only the seed resulting from the cross of the 
parental lines. Trade secret protection might 
also be employed to protect know-how, or the 
methods and techniques of the plant breeder. 
Additionally, trade secret protection may be 
used to protect an invention during the patent 
examination period in order to protect an in­
vention until a patent issues. 
Most importantly, trade secret protection is 
instrumental for protection of innovations that 
do not otherwise qualify for protection under 
patent and patent-like protection regimes. Trade 
secret protection extends to the same subject mat­
ter covered by patents and requires only secrecy. 
Consequently, trade secret protection is vital for 
protecting matter where patent and patent-like 
protection is unavailable. 
.2	 Geographic indications, trademark, 
and copyright protection 
To a much lesser extent than patents (and to some 
extent trade secrets), the protection provided 
under geographic indications, trademark, and 
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copyright may also be used to protect plant in­
novations. The first of these three, the geographic 
indications regime, is not traditionally protected 
under U.S. law, but is recognized under a treaty of 
the World Trade Organization. Geographic indi­
cators communicate to consumers the association 
between a product and the territory from which it 
originates, which may indicate the product’s qual­
ity, reputation, or other characteristic. The most 
prominent example of geographic indicators is 
the designation given to wines, for example cham­
pagne and Bordeaux. Geographic indicators may 
be used to differentiate among plants originating 
from different territories. 
The second regime, trademarks, focuses on 
communicating to the consumer the association 
between a product and the source of the product, 
such as its manufacturer. This may reflect on the 
product’s quality or authenticity. Trademarks may 
differentiate one plant breeder’s product from an­
other breeder’s products, stopping competitors 
from using the good name a plant breeder has 
built in its popular varieties. The leading inter­
national treaties governing trademark protec­
tion include the Paris Convention, the Madrid 
Agreement, and the Madrid Protocol, all of which 
are administered by WIPO. 
The last of the regimes, copyright, protects 
works “fixed in any tangible medium of expres­
sion.”29 Copyright may be used to protect works 
of authorship such as descriptions of processes, 
training materials, and brochures, as well as ar­
tistic renderings of plant varieties and other an­
cillary materials. While copyright protects the 
expression of an idea, the copyright does not 
protect the underlying idea itself. Anyone is 
free to use the ideas contained in a copyrighted 
work. Therefore, while a copyright may protect 
the written expression that describes a new plant 
variety, the copyright does not offer protection 
for the plant variety itself. Internationally, the 
minimum substantive standards of protection for 
copyrights are set forth in the Berne Convention, 
a multinational agreement established in 1886, 
and in the Agreement on Trade Related Aspects of 
Intellectual Property Rights (TRIPS Agreement), 
an agreement administered by the World Trade 
Organization. 
4. CONCluSION 
In the context of agricultural biotechnology, sev­
eral IP regimes are available to provide protection 
for plant innovation. The three most important re­
gimes are utility patents, plant variety protection, 
and trade secrets. Through careful consideration of 
the relative demands and benefits of each regime 
in terms of the protection it offers for different 
types of plant innovation, individual approaches 
may be custom-tailored to suit the needs of the 
inventor and the nature of the invention. n 
JAy P. kESAN, Professor and Director, Program in Intellectual 
Property & Technology Law, University of Illinois, 504
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CHAPTER 4.5 
Plant Breeders’ Rights: An Introduction
 
williaM h. lesseR, Susan Eckert Lynch Professor of Science and Business, 

Chair of the Department of Applied Economics and Management, Cornell University, U.S.A
 
ABSTRACT 
Based on the averages, there is a good chance that your 
country has decided to fulfill its TRIPS (Trade-Related 
Aspects of Intellectual Property Rights) Agreement com­
mitments by selecting an “effective sui generis system” over 
patents for plants, something more commonly known as 
plant breeders’ rights. This chapter attempts to explain 
what plant breeders’ rights are by describing the organi­
zation and function of the plant breeders’ rights system. 
Covering the objectives, scope, protection requirements, 
and examination provisions, the chapter compares the 
plant breeders’ rights system with the patent system and 
attempts to clarify specific puzzling issues. These include 
concerns that the latest UPOV Act does not address farm­
er seed savings (the choice is left to individual countries, 
with virtually all countries choosing to allow seed saving). 
Plant breeders’ rights are less puzzling once the intent and 
structure of the system are understood. The system is, in 
fact, one with very specific, if narrow, objectives. 
1. InTRoduCTIon 
Guild members in mid-15th century Venice, 
averse to direct competition from former ap­
prentices, passed a law prohibiting the apprentice 
from entering the trade until about 18 years had 
lapsed. That edict, according to intellectual prop­
erty (IP) historians, marked the origins of pat­
ents. Indeed, the duration of a patent (20 years 
from date of filing the application) is said to be 
modeled after that apprenticeship period in long-
ago Venice. Yet some easily copied creations were 
not granted similar IP protection, in Venice or 
anywhere else, until many centuries had passed. 
Plants are one example of this. Food, fiber, and 
ornamental crops (F1 hybrids excepted) carry in 
themselves the ability to regenerate true to form, 
whether sexually or asexually. Anyone hold­
ing a seed or a cutting immediately possesses all 
the skills of the master to recreate the variety of 
plant from which the seed or cutting came. Yet 
not until 1930 (the U.S. Plant Patent Act) did 
legal restrictions apply to the use of plant ma­
terials for regenerative purposes, and even then 
protection only applied to asexually propagated 
plants (excluding tubers). An additional 30 years 
passed before a harmonized format for legisla­
tion covering IP protection for all plant varieties 
emerged. That is the International Convention 
for the Protection of New Varieties of Plants, or 
UPOV in its French acronym, an international 
treaty first adopted in 1961 and revised several 
times, the latest in 1991. The form of intellectual 
property created by UPOV is known widely, if 
informally, as plants breeders’ rights (PBR). This 
chapter describes the acts and modes of opera­
tion of PBR under UPOV-compatible national 
legislation. While every effort is made here to 
be complete and accurate, it would be impos­
sible discuss all of the considerations needed to 
appreciate every possible contingency. Persons 
wanting to learn more should refer to the text 
of UPOV and other official documents, such as 
Lesser WH. 2007. Plant Breeders’ Rights: An Introduction. In Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. 
© 2007. WH Lesser. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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at the UPOV Web site.1 The Handbook chapter 
PBR in the Developing World, discusses the ef­
fects of PBR laws and the available alternatives at 
the national level. 
2. WHAT	ARE	pLAnT	 BREEdERS’ RIGHTS? 
PBR is a patent-like system that allows the plant 
variety owner to prohibit specific unauthorized 
uses of the variety. PBR laws apply only to plants, 
and hence are among the class of sui generis sys­
tems, that is, special purpose systems. Laws ap­
plying to computer chips (that is, mask works … 
the set of templates used to manufacture chips) 
form another sui generis system. In fact, sui gene­
ris systems have been applied to everything from 
aeronautics to Xerox® machines. These systems 
differ significantly from patent laws. The differ­
ences between the two systems—and the similari­
ties—are explained below. 
PBRs, like patents and other forms of IP law, 
are forms of national legislation. That is, protec­
tion applies only in countries where protection 
has been sought and granted. Thus, the owner of 
a sunflower variety protected in the United States 
would have no legal control over how that vari­
ety was used inside Canada. Critically, however, 
the variety owner could prevent the importation 
into the United States of the variety, including (in 
most cases but depending on the specific coun­
try’s sui generis laws with regard to plant varieties) 
grain, plants, plant parts, and, in some countries, 
even manufactured products produced using the 
protected variety. In the case of a U.S. PVP-pro­
tected sunflower variety, the variety owner could 
not prevent it from being planted, grown, har­
vested, or sold inside Canada, but U.S. PVP-pro­
tected sunflower seed, sunflower meal, sunflower 
oil, and similar products could be prevented from 
entering the U.S. stream of commerce. 
PBR under the TRIPS Agreement (Agreement 
on Trade-Related Aspects of Intellectual Property 
Rights) is a component of the World Trade 
Organization (WTO). Signatories of WTO (cur­
rently about 150) are committed to comply with 
the TRIPS requirements of a harmonized mini­
mum level of IP rights protection. Although the 
TRIPS text is quite exhaustive in most regards, 
only a single sentence refers to PBR. Article 
27.3(b) reads, in part, that WTO members must 
provide plant variety patents, “an effective sui ge­
neris system,” or both. Most countries new to pro­
tecting plants are opting for PBR over patents. 
PBR is clearly a sui generis system, but what con­
stitutes “effective” is less clear. 
. WHAT	 RoLE	doES	upov	pLAy? 
If PBR is based on national law, what role does 
UPOV, an international convention, play? 
Essentially, UPOV establishes a framework law 
that may be adopted by countries into their own 
national laws. After having done so, a country 
could submit its national law to the governing 
body of UPOV for evaluation and, if the law was 
found to have similar critical elements, the coun­
try could become a UPOV-signatory nation. In 
practice, there is usually an informal assessment 
done by UPOV prior to final diplomatic submis­
sion. UPOV does provide a mechanism for har­
monizing national laws and providing standard­
ized definitions/interpretations of terms. UPOV 
also requires nondiscrimination against foreign 
applicants of other Union members (National 
Treatment, Article 4 of 1991 Act). However, that 
Article has largely been supplanted by the geo­
graphically broader national treatment require­
ments of TRIPS (Article 3). UPOV member states 
have training and other technical support avail­
able to them, although an annual membership fee 
based on national income is imposed. Countries 
can and do have PBR systems without joining 
UPOV, but little is known about their opera­
tion and few countries have implemented them. 
Since its inception, UPOV has adopted four acts 
(1961, 1972, 1978, and 1991). Members may 
at their discretion adopt a more recent Act, but 
older acts are closed. Presently, the 1991 Act is 
the only one now open to new members. There 
are some important differences between the 1978 
and 1991 acts, to which essentially all current 
members belong. These differences are discussed 
below. All terms and references here refer to these 
acts. There are some national-level differences, 
but for the most part identifying them involves a 
greater level of detail than is possible here. 
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.	 HoW	 do 	pBRS	 WoRk? 
PBR systems, like other IP systems, have three 
major components: 
1. Definition/identification of protectable sub­
ject matter 
2. Requirements that must be met to receive 
protection 
3. Rights of the variety owner 
.1 Identifying what can be protected 
As a sui generis system, protection is limited to 
plant “varieties,” but this term lacks a standard 
definition. The definition in the 1991 Act (Article 
1(vi)) reads in part: 
a plant grouping . . . 
•	 defined by the expression of the character­
istics … 
•	 distinguished … by the expression of at 
least one of the said characteristics and 
•	 [having] suitability for being propagated 
unchanged 
Beyond its technical relevance, this defini­
tion is significant since it departs from the lan­
guage of earlier acts. The 1978 Act lacked any 
such definition, while the 1961 Act (Article 2.2) 
refers to a variety as “any cultivar, clone, line, 
stock, or hybrid which is capable of cultivation….” 
Certainly, one purpose for defining variety is to 
distinguish what is protectable under UPOV 
from those “plant genetic resources” that fall 
under the Convention on Biological Diversity 
(CBD). As a general matter, a plant variety under 
UPOV would also be a plant genetic resource as 
defined by the CBD. Furthermore, the interna­
tional convention typically (but not universally) 
allows the more recent convention to supercede 
the prior one. The CBD was ratified in 1992 and 
went into effect in 1993. However, the CBD 
(Article 16.2) does provide for the “adequate and 
effective protection of intellectual property rights,” 
so PBRs would seem to operate independently of 
national laws enacted under the CBD, although 
exceptions could arise. There might be conflict, 
for example, over traditional farmer-bred variet­
ies, often referred to as landraces. Landraces are 
certainly genetic resources and, arguably, plant 
varieties. However, as a practical matter, hetero­
geneous landraces rarely satisfy the uniformity 
and stability requirements for PBR protection, 
so a conflict in practice seldom arises. This does 
not mean that a landrace is specifically excluded 
from PBR protection, or that one could not be 
protected. Rather, the UPOV protection re­
quirements demand more specific attention to a 
landrace (such as backcrossing), so the issue of 
whether, or not, landraces qualify for PBR pro­
tection actually seldom arises. As to UPOV, it 
is quite evident that the system is intended for 
planting materials, whether they are food crops 
or horticultural varieties, that will be sold on a 
commercial basis. 
Another area of potential overlap is with 
the offering of patents and PBR for a plant. The 
TRIPS Agreement specifically allows patents for 
plants, and, in the United States, both forms of 
protection have been available for some time. The 
matter has, however, not been so straightforward 
in E.U. countries, due to the adoption of the 
European Patent Convention (EPC). The EPC 
(Article 53(b)) excludes protection for “plant or 
animal varieties,” raising the question of just what 
the appropriate definition of variety is. Rulings 
on this question have seesawed back and forth 
for decades, but the current (and likely sustain­
able) rule is that a plant variety is in a fixed form 
regarding all of its characteristics. An invention 
that is applicable to a number of varieties is not 
a plant variety and is thus patentable. This inter­
pretation, while not binding in other countries, is 
of relevance since Article 53(b) wording has been 
adopted into the patent laws of a number of other 
countries. 
.1 Protection requirements 
To be eligible for protection under UPOV-based 
laws, a variety must be (Article 5, 1991 Act, 





These requirements are often abbreviated 
as DUS. Newness (or novelty) requires that the 
applicant variety has not been “sold or otherwise 
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disposed of to others” for more than one year in 
the country of application or for four years (six 
for trees or vines) elsewhere. This requirement 
assures that the public is not giving away exclu­
sivity rights to something already available, while 
recognizing that some limited use or testing will 
typically be required prior to application. 
Uniformity and stability necessitate a certain 
amount of backcrossing, so that the variety repro­
duces true to form across individual plants (unifor­
mity) and across generations (stability). Stability 
and uniformity serve the important function of 
making a variety identifiable after propagation. 
The two also serve important commercial needs. 
UPOV has sometimes been criticized for promot­
ing genetic uniformity through the stability and 
uniformity requirements. The text reads “suffi­
ciently uniform in its relevant characteristics” (Article 
8, 1991 Act) and “stable [in] its relevant character­
istics” (Article 9, 1991 Act). That is, stability and 
uniformity are required only to a degree, and only 
in certain characteristics. The requirements are 
variable and limited, beyond which a protectable 
variety can be as heterogeneous as is feasible from 
the prospective of UPOV. Commercial require­
ments may necessitate broader uniformity, but this 
is not relevant to UPOV. Rather, distinctness is the 
driving characteristic: “A variety shall be deemed 
to be distinct if it is clearly distinguishable from any 
other variety whose existence is a matter of common 
knowledge at the time of the filing of the application” 
(Article 87, 1991 Act). The wording in the 1978 
Act (Article 6.1(a)) is nearly identical, except for 
the inclusion of “by one or more important charac­
teristics.” That is, the variety must be distinguish­
able by one or more characteristics, such as flavor, 
color, or virus resistance. What characteristics are 
considered to be distinguishing ones is a matter of 
national interpretation. 
. Rights of variety owner 
Under the 1978 Act (Article 5.1), the permission 
of the owner is required for: 
•	 production, for purposes of commercial 
marketing 
•	 offering for sale or offering marketing rights 
to reproductive or vegetative propagating 
material 
To those activities, the 1991 Act (Article 
14.1) added the following activities for which 
permission of the owner must be given: 










•	 stocking for any of [these] purposes 
The specificity of these rights enhances the 
ability of the rights owner to exclude access, the 
only right granted by PBR and other IP rights 
systems. For example, under the 1991 Act, it is 
sufficient to show unauthorized reproduction, 
while the 1978 Act required proof of intent to 
“commercial[ly] market” the material. Similarly, 
under the 1991 Act (Article 14.2) protection is 
extended to “harvested materials, including entire 
plants or parts of plants.” This means, for example, 
that the blooms from an unauthorized propaga­
tion of a rose variety overseas can be barred access. 
Under the 1978 Act (Article 5.4), such an exten­
sion of protection was optional. Finally, under 
Article 14.3 in the 1991 Act, a signatory country 
may choose (but is not required) to extend pro­
tection to “products made directly from harvested 
material of the protected variety.” 
Two important exceptions to these rights 
exist. First, protected varieties may be used for 
breeding and experimental purposes (Article 
15.1, 1991 Act and Article 5.3, 1978 Act). This 
is a right mandated by UPOV, and typically re­
ferred to as breeders’ rights. The freedom to use the 
variety resulting from the breeder’s effort, how­
ever, differs between the two acts. It is an impor­
tant and arcane enough issue to warrant separate 
treatment. 
The second major exception to the rights 
listed above is the right of a grower (farmer) to 
retain the crop as a seed source for a subsequent 
season. This right is absolute under the 1978 
Act because, as there is no commercial market­
ing involved, it is not prohibited. The 1991 Act 
(Article 15.2) makes this right (typically known 
as the “farmer’s privilege”) optional. This Article 
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CHAPTER . 
is sometimes misconstrued as the elimination of 
the farmer’s privilege, when what it really does is 
allow each nation to choose. At present, almost 
all countries have chosen to retain the farmer’s 
privilege. A notable distinction is the European 
Union, which requires farmers to pay a royalty on 
saved seed. “Small” farmers are exempted. Note 
also that this right is completely different and 
separate from Farmers Rights as defined by the 
Food and Agriculture Organization of the United 
Nations (FAO). 
Under UPOV, the PBR protection period is a 
minimum of 15 years, which extends to 18 years 
for woody plants under the 1978 Act (Article 8). 
The 1991 Act (Article 19.2) extends the periods 
to 20 and 25 years respectively. 
..1 Testing (examination) methods 
According to the 1991 Act, “Any decision to grant 
a breeder’s right shall require an examination for 
compliance with the [protection] requirements” 
(Article 12, 1991 Act). The wording of Article 7, 
1978 Act, is similar. Signatory countries nonethe­
less have substantial latitude in how to conduct 
the examination. The distinctness requirement 
does, however, require a comparison with “any 
other variety whose existence is a matter of common 
knowledge at the time.” Thus, at a minimum, a 
national examination system must maintain (or 
have access to) a large database of variety descrip­
tions, both protected and not protected, includ­
ing varieties used both inside and outside the 
country. Beyond that, countries exercise consid­
erable flexibility. The E.U. nations, for example, 
carry out a two-year field trial where the applicant 
variety is compared to an established reference va­
riety. Distinctness is recognized only in specified 
characteristics by crop, and sometimes a quanti­
tative basis is defined by a “crop committee.” For 
example, an onion variety may be distinct in re­
sistance to sprouting if 3% fewer sproutings oc­
cur than in the reference variety after X months 
of storage. As a variation of this approach, some 
countries (such as Canada) require the applicant 
to conduct the growouts (field evaluation of the 
variety) under the supervision of the plant variety 
office. Most PBR offices are within a ministry of 
agriculture. Using the opposite approach is the 
United States, where growouts are rarely under­
taken. Instead, the claim of the applicant is essen­
tially taken at face value. Moreover, distinctness 
may be claimed in any characteristic, including 
in those of no practical value. Improper claims 
of distinctness are resolved in court between the 
parties. To date there have been few if any court 
cases resulting from improper claims. From an 
economic perspective, the U.S. approach is sim­
pler and less costly, while allowing more rapid 
access to new varieties. Because a variety is pro­
tected, however, does not necessarily mean it has 
agronomic merit. Cosmetic breeding (“cosmetic” 
traits do not contribute to the productivity of the 
crop, for example, flower color for pulses) raises 
costs, although the proliferation of available vari­
eties would reduce their market prices. Choosing 
a single approach, or choosing to adopt a combi­
nation system, is a significant national decision. 
The U.S. approach does rely more on an efficient 
and transparent court system, something not 
available everywhere. To emphasize that point, a 
study done of Argentina’s PBR act (one of the first 
in a developing country) determined that such a 
system of PBR would not be effective until the 
rights could be adequately enforced. 
..2 Initial and dependent varieties 
The 1991 Act (Article 14.5) does add a signifi­
cantly new component: that of essentially derived 
varieties. This component provides an exception 
to breeders’ rights: protected materials may still be 
used in a breeding program, but if the resultant 
variety is judged to be essentially derived, it can­
not be commercialized without the permission of 
the initial variety’s owner. Before considering the 
technical aspects of this article, it is perhaps help­
ful to consider several justifications. If the back­
ground or development breeder spends 15 years 
breeding disease resistance from a wild relative 
into a commercial variety, then under the 1978 
Act provisions, the resultant variety could be used 
as a basis of subsequent breeding, and within a 
few years competitive varieties would appear. The 
development breeder would then have difficul­
ty recovering the costs of the 15 years of work, 
meaning that, as a practical matter, background 
breeding would have to be left to the public 
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sector. The owner of a leading commercial variety 
would be in a similar situation regarding the in­
sertion of a genetically modified trait by another 
party. Under the 1978 Act, if herbicide resistance 
had been produced by cross-breeding patented 
genes into that leading commercial variety, then 
the resulting genetically modified herbicide-resis­
tant variety could be commercialized, with noth­
ing owing to the original variety owner. Yet that 
original variety owner would be prevented from 
using the patented genes in its breeding program, 
thus producing a distinct asymmetry of rights. 
Article 14.5 is intended to correct this imbalance 
by establishing two levels of protection: 
•	 Initial varieties are those on which essen­
tially derived varieties depend. If the initial 
variety is protected, these essentially derived 
varieties can be bred from an initial variety 
but not commercialized without permission 
from the variety owner. Essentially derived 
varieties are often referred to informally as 
dependent varieties. If the background-bred 
variety were an initial variety, any minor 
derivative varieties would be dependent 
and, in practice, could expect to pay roy­
alties. UPOV (Article 14.5(b), 1991 Act) 
uses terms such as “predominately derived.” 
•	 Other varieties retain the expression of the 
“essential characteristics.” Essentially derived 
varieties may be produced in a number of 
ways, including by selection, back-crossing, 
or transformation by genetic engineering. 
Several UPOV-associated committees have 
used words such as “the preponderance of ge­
netic material.” Just how initial and derived 
varieties are distinguished can be quite crit­
ical, but this may not be clearly determined 
until there are actual decisions settling dis­
putes revolving around this issue. We do 
know that many national PBR offices are 
treating the matter as an infringement, that 
is, the self-identified initial-variety owner is 
left to sue the purported dependent-variety 
holder, and it is up to the courts to resolve 
the counterclaims. This approach relieves a 
national office from having to making diffi­
cult distinctions, but could prolong the pro­
cess of identifying operational definitions. 
.	 HoW	 do 	pBRS	 CoMpARE	
WITH	pATEnTS? 
There are more similarities than differences be­
tween patent and PBR systems. Both operate by 
temporarily privatizing something that would 
otherwise have been freely available in the public 
domain. A fee can be assessed for access as well as 
for any rewards derived through market sales. In 
their particulars, however, critical differences exist 
between PBRs and patents. 
.1 Protection requirements 
Protection requirements for patents include nov­
elty, inventive step (nonobviousness under U.S. 
law), and utility (or industrial application). The 
concept of novelty in the two systems is simi­
lar, although most patent systems operate with 
absolute novelty, or no prior public disclosure. 
Inventive step in the patent system is similar to 
the distinctness requirement in the PBR system. 
Patents have always operated with a dependency-
type system similar to the initial variety concept 
in the 1991 UPOV Act, except that in the patent 
system there are no statutory (text-based) state­
ments about the dependency relationship or how 
dependency might be achieved. A dependent pat­
ent could, for example, be an improvement on 
an existing product or process or a new use for 
an existing product. The new product/new use 
could be protectable in its own right, so that nei­
ther owner could use the other invention without 
permission. These details are worked out between 
interested parties. 
The utility requirement, stated as simply as 
possible, means that some use for the product 
must be identified. When applied to patents for 
genes and gene fragments, the utility requirement 
has raised serious issues that generally do not exist 
for PBR. Protected varieties, as noted, are intend­
ed for sale and, under many examination systems, 
must display some practical merit. Uniformity 
and stability have no comparable requirements 
under patent law. 
.2 Protectable subject matter 
With respect to protectable subject matter, the 
patent and PBR systems are quite different from 
each other. Under patent acts, everything is pat­
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entable except for identified exceptions. One 
common exception is for “plant and animal vari­
eties.” PBRs cover all genera and species, with cer­
tain minimums under the several acts, as follows: 
•	 1978 Act (Article 4): on adoption, three 
rising to at least 24 genera or species within 
eight years 
•	 1991 Act (Article 3): for new members on 
adoption, at least 15 genera or species, rising 
to all genera and species within ten years 
. Other components 
PBR systems are distinct from patents in allow­
ing an option, under the 1991 Act, for farmers to 
save seed for subsequent seasons. Under patents, 
such actions would constitute infringement. The 
breeder’s right is statutory with PBR and hence is 
relatively clear in its scope. National patent sys­
tems do allow some research on patented inven­
tions, but the form and extent of research allowed 
is based on case law and so this is more difficult to 
assess. The difference in this matter between pat­
ents and PBR is one of clarity alone; however, this 
makes research use under PBR a more clear-cut 
process than for patented inventions. Provisions 
for farmer’s privilege (where allowed) and breed­
ers’ rights are generally considered to give hold­
ers of PBR certificates weaker protection than do 
patents. This helps explain why, where the choice 
is available, commercial breeders often prefer pat­
ents, or patents plus PBR, over PBR alone. 
Patents are, however, typically far more costly 
to apply for and to maintain. The difference is 
not in the application fees structure, which may 
in fact be lower for patents, but rather, a patent 
usually requires an attorney’s assistance to prepare 
the application. PBR applications are typically 
completed by the breeders. Adding the elaborate 
translation requirements under some patent laws, 
and the annual maintenance fees can also make 
patenting a costly process, compared with PBR. 
.	 ConCLuSIonS 
Although some legal ambiguity does still ex­
ist within PBR legislation, the objectives of the 
system are specific, and the laws and provisions, 
if clearly understood, are manageable. The PBR 
system shares several features with more conven­
tional patent systems, but the two systems differ 
in several crucial respects. As a sui generis system, 
PBR laws apply only to plants and plant materi­
als. But they work, like patents, to prohibit unau­
thorized use of these materials. 
UPOV establishes a framework to guide 
signatory nations in adopting PBR provisions 
in their own national laws. The acts have been 
amended several times; currently, most nations 
are operating under either the 1978 or the 1991 
versions. 
To be eligible for protection, a plant variety 
must demonstrate novelty, distinctiveness, uni­
formity, and stability. If protected, a potential 
user must seek permission from the owner before 
producing, selling, importing, or exporting the 
variety or, in some cases, products made from or 
with that variety. A few important exceptions to 
this apply; for example, a breeder’s exemption al­
lows researchers to use the variety for experimen­
tal purposes, and farmers are generally allowed to 
retain the variety for seed. In an important new 
component of the 1991 Act, if research produces 
a variety judged to be essentially derived from a 
protected variety, it cannot be commercialized 
without the permission of the initial variety’s 
owner. n 
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ABSTRACT 
In ever-increasing numbers, institutions are establishing 
technology transfer offices (TTOs). These offices serve a 
variety of functions, all of which must be integrated to 
cost effectively transfer technologies and to benefit the in­
stitutions. A critical function of the TTO is to proactive­
ly manage intellectual property (IP) issues pertinent to 
crops. Crops can be covered by more than one form of IP 
rights protection, often simultaneously. These rights pro­
tections include trademarks, trade secrets, plant and util­
ity patents, and plant variety protection (PVP). Closely 
related is the importance of careful and organized gene-
bank management, a critical component of an overall IP 
and tangible property management system. PVP provides 
one type of protection that allows TTOs to responsively 
serve clients and generate revenue. PVP is a form of IP 
rights protection for crops with potentially global appli­
cations, and either a PVP office, or a PVP subsection in 
the TTO, would be wisely established by an institution. 
In addition, this chapter provides important information 
to assist in establishing a national PVP office and in the 
selection and implementation of various types of IP rights 
protection for crops and germplasm. 
1. INTRODuCTION 
Plants affect people’s everyday lives in terms of 
quality and cost—the cost of food, feed, fiber, 
fuel, and other necessities. Plants provide raw 
materials for industry, such as vegetable oils, rub­
ber, and drugs and other health care items. By 
2020 the Earth’s population is likely to reach 9 
billion. To meet the increasing demand, annual 
global food production will have to increase to 
more than 3,000 million metric tons from the 
current 1,800 million metric tons. At the same 
time, productive farmland is, and will continue 
to be, diverted at an increasing rate to nonfarm 
uses, and access to water will continue to be a ma­
jor limiting factor for agricultural productivity. 
To address the challenge of meeting the 
needs of the world’s growing population, plant 
breeders are developing improved plants that 
can produce more, while using less land and less 
water. As trained professionals whose endeavor is 
developing plants that are genetically equipped to 
produce higher yields of quality products, plant 
breeders will contribute significantly to meeting 
these challenges. While producing higher yields, 
these improved plants will also be more resistant 
to pests and diseases, so they can potentially re­
duce the need for large (and expensive) applica­
tions of fertilizers and crop protection chemicals. 
Finally, these plants reduce the need for additional 
irrigation from precious water resources, thereby 
contributing to further conservation. 
The breeding of new plant varieties is thus 
an economically important activity that con­
tributes in many different ways to the social 
and economic well-being of societies. In many 
cases, new plant varieties are absolutely essential 
for human survival. However, there are many 
Dodds J, A Krattiger and SP Kowalski. 2007. Plants, Germplasm, Genebanks, and Intellectual Property: Principles, Op-
tions, and Management. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best
Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
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challenges associated with crop breeding. For 
example, experience has shown that a breeder 
has difficulty recovering his financial investment 
when he sells his initial supplies in the first years 
of a new variety’s life. The breeder’s competitors 
can secure supplies of propagating material and, 
in a short time, be in a position to compete with 
the breeder, thus profiting from the many years of 
effort invested by the breeder. In this way, the re­
wards of the plant breeder’s innovative efforts can 
be rapidly lost to himself or herself. The initial 
phase of protection is therefore critical, because 
developing new varieties in most plant species 
may take between ten and 20 years. 
These new varieties are crucial to the needs 
of modern society. They contribute to a varied 
diet and provide for a wide choice of ornamental 
and amenity plants. Generating sufficient variety, 
however, requires substantial investment in crop 
breeding programs. Accordingly, many countries, 
while continuing to invest in public sector plant 
breeding research, have established open free-
market systems in which exclusive rights of ex­
ploitation (patent-like protections) are granted to 
the breeders of new varieties of plants. 
This chapter presents a general overview of 
the types of IP protections that are available for 
plants. It then focuses on plant variety protection 
(PVP) as one key example of plant IP rights pro­
tection, an option that can be broadly applied to 
the needs of developing countries. 
2. DEFINITIONS 
Before discussing some specific issues in relation 
to crops, germplasm, and genebanks, it is impor­
tant to have a common understanding of what is 
meant by certain words: 
•	 breed. To develop new or improved strains 
of organisms, chiefly through controlled 
mating or pollination and the selection of 
offspring for desirable traits. 
•	 breeding line. Genetic group that has been 
selected and bred for special combinations 
of traits. 
•	 enhancement. The process of improving 
germplasm accessions by breeding, while re­
taining the important genetic contributions 
of the accessions. This process may entail 
simple selection. 
•	 gene. The fundamental physical and func­
tional unit of heredity. A gene is an ordered 
sequence of nucleotides in a particular po­
sition, on a particular chromosome, encod­
ing a specific functional product. 
•	 genebank. A genebank is a special facility 
that stores living samples of the diversity of 
crop varieties and their wild relatives. These 
samples are usually in the form of seeds or 
other plant parts. Some of the plants that 
genebanks hold are extinct in the wild. The 
value of the genetic resources conserved 
in genebanks encompasses not only their 
current use value and expected future use 
value, but also the option value associated 
with the flexibility to respond to some un­
known future events. 
•	 genetic resource. Often used as a synonym 
to germplasm, this is a seed, plant, or plant 
part that is useful in crop breeding, research, 
or conservation because of its genetic attri­
butes. Genetic resources are maintained for 
the purposes of studying, managing, or us­
ing the genetic information they possess. 
•	 improved material. An elite breeding line. 
•	 landrace. A population of plants, typically 
genetically heterogeneous, commonly de­
veloped in traditional agriculture from 
many years of farmer-directed selection and 
specifically adapted to local conditions. 
•	 public domain. Public ownership status of 
information not protected by patents or 
copyrights. 
•	 wild species. A species that has not been sub­
ject to breeding with intent to alter them 
from their wild state. 
3. IP ISSuES THAT AFFECT GENETIC
RESOuRCE MANAGEMENT 
It is useful to recall that plant breeding is a knowl­
edge-based activity. Consequently, it is a nonex­
haustive activity. In other words, the results of ap­
plying the knowledge are not decreased if shared 
with others. What is lost in sharing, however, is 
market value. In other words, a plant breeder who 
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has invested millions of dollars over many years 
cannot extract value if others appropriate the new 
variety and sell it at the mere cost of seed produc­
tion. The free distribution of varieties provides 
the breeder with no incentive to invest. IP sys­
tems remedy this situation by providing a level of 
protection to breeders. 
IP rights is a broad term for the various rights 
that the law provides for the protection of eco­
nomic investment in creative effort. The principal 
categories of IP protections relevant to agricultur­
al research are patents, plant variety rights, trade 
secrets, copyrights, and trademarks. 
.1 Patents 
Patents are a statutory form of protection that 
allows an inventor rights of exclusivity on the 
sale or use of his or her invention for a lim­
ited period of time, in a particular territory, 
in exchange for a full public disclosure of the 
invention. 
In the case of plants, there are two forms 
of patenting. The first is called a plant patent. 
It applies only to materials that are asexually 
propagated, such as pineapples and bananas. 
The second is called a “utility patent.” This does 
not protect the plant per se, but rather the in­
vention that is embodied in the plant (for ex­
ample, a method for conferring insect resistance 
through the incorporation of resistant genes into 
the plant). 
.2 Plant variety protection 
Plant variety protection (PVP) is another form of 
IP protection for plants. PVP gives the breeder 
exclusive rights to a new and distinct plant variety 
so that the breeder can exploit it. 
The breeder is defined by the 1991 UPOV 
(International Union for the Protection of New 
Varieties of Plants) Convention as the person 
who bred, or discovered, and developed a variety. 
Therefore, protection is not limited to breeders 
who produce a variety as a result of crossing par­
ent plants and selecting from the progeny. The 
term breeder also includes a person who discov­
ers a mutation and converts that discovery into 
a cultivated variety by a process of selective 
propagation. Discovery itself, however, does not 
constitute breeding. 
The PVP Act (PVPA), enacted in December 
of 1970 and amended in 1994, provides legal IP 
rights protection to developers of new varieties 
of plants that are sexually reproduced (by seed) 
or are tuber propagated. Bacteria and fungi are 
excluded. The PVPA is administered by the U.S. 
Department of Agriculture. 
A Certificate of Protection is awarded to an 
owner of a variety after an examination shows that 
the variety is new and distinct from other variet­
ies and is genetically uniform and stable though 
successive generations. The term of protection is 
20 years, for most crops, and 25 years for trees, 
shrubs, and vines. The owner of a U.S.-protected 
variety has exclusive rights to multiply and mar­
ket the seed of that variety. 
The characteristics of the PVP systems are 
summarized in Table 1 and are compared both 
to plant patents and utility patents. A detailed 
discussion of PVP and its global applicability is 
published by lakeney and colleagues.B 1 
. Trade secrets 
U.S. trade secret laws have been used to protect 
in-house breeding materials, such as the inbred 
lines of maize used as parents of hybrids. These 
laws do not, however, protect against indepen­
dent discovery or reverse engineering of products 
by the purchasers. 
It should be remembered, moreover, that ge­
netic resources have a dual property nature: they 
are physical material (tangible property) that may 
be associated with human-made improvements 
(IP). This dual nature is the reason for genetic re­
sources to be, on the one hand, physical property 
in the form of germplasm and, on the other hand, 
IP in the form of modified genetic information 
constituting inventions, trade secrets, and new 
plant varieties. 
. Copyrights 
Copyrights are becoming more important for pro­
tecting IP in the field of plant breeding because 
the databases that hold information about plant 
genes can often be copyrighted. Such copyrights 
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do not, however, affect trade in products devel­
oped using the protected information. 
. Trademarks 
Trademarks can be used to protect brand names, 
such as Monsanto’s Roundup Ready®. But trade­
marks protect only the names and other symbols 
denoting products or technologies, not the tech­
nologies themselves. Still, trademarks may give 
customers a proof of quality, and so they may be 
as important as variety protection. 
4. “NON-IP” MATTERS AFFECTING
GENETIC RESOuRCES MANAGEMENT 
As indicated above, there are tangible property 
rights that have a bearing on the ownership of 
genetic resources. The Convention on Biological 
Diversity (see below) affirmed the sovereign rights 
of nations over their genetic resources. Such own­
ership is a tangible property right on the owner­
ship of the actual material. 
There exist, however, a number of other 
non-IP matters that affect the day-to-day lives 
of genetic resource specialists working in the 
field. These most typically include indigenous 
knowledge issues and access to and transfer of 
materials. 
.1 Indigenous knowledge 
The formal IP system of patents, PVP, copy­
rights, and so on is based on a set of statutory 
(legislative) rules. The current system allows 
so-called prior art to be used as a way of deter­
mining whether novelty exists with regard to an 
invention. The current formal system does not 
adequately allow for indigenous knowledge to 
form the basis of prior art or allow indigenous 
people to be the inventors or breeders. This has 
led to significant controversy in the international 
community. Both WIPO (World Intellectual 
Property Organization) and UPOV are actively 
reviewing and debating this topic to try to devel­
op a mechanism that would prescribe a role for 
such knowledge within the formal system. One 
noteworthy example within a national program 
is the PVP Office of the Philippines’ mechanism 
for allowing the registration of descriptors for 
indigenous materials. These descriptors are re­
viewed as part of the examination process for 
awarding a PVP certificate. 
.2 Material transfer agreements 
When genetic resources are transferred, it is in­
creasingly common for them to be accompanied 
by an MTA. Such a document forms a contractual 
relationship between the shipper and the recipi­
ent. It is common for MTA agreements to attach 
terms and conditions regarding both the approved 
use of genetic resources and the rights to owner­
ship of such materials or their derivatives. 
MTA agreements can appear in a number of 
forms. While the most common is a conventional 
sheet of paper, it is also possible for the material 
to come with language included on the bag. The 
use of so-called bag-tag language is becoming in­
creasingly common. At issue, however, is whether 
the “shipper” who applies the MTA language ac­
tually owns title to the materials and has the right 
to allocate ownership rights. 
5. INTERNATIONAl TREATIES 
Generally, plant genetic resources are governed by 
national, regional and international laws, which 
regulate ownership, access, and benefit sharing. 
Internationally, these concerns are regulated by 
treaties such as the CBD, the International Union 
for the Protection of New Varieties of Plants 
(UPOV) Convention, the International Treaty 
of Plant Genetic Resources, and the Agreement 
on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS). 
.1 The Convention on Biological Diversity (CBD) 
The CBD is the central instrument related to 
international biodiversity. It broadly delimits 
the rights of states and other relevant actors over 
biological resources and affirms the sovereign 
rights of states to exploit their own resources 
pursuant to their own environmental policies. 
The sovereign rights of states over their own bio­
logical resources are limited by the recognition 
that these resources are a common concern of 
humankind. 
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The Convention also provides a broad frame­
work for member states’ policies concerning 
access, development and the transfer of technolo­
gies. It also acknowledges the necessity for all par­
ties to recognize and protect IP rights in this field. 
The Convention further recognizes both the de­
pendence of local communities on biological re­
sources and the roles that these communities play 
in the conservation and sustainable use of these re­
sources. Finally, it points to the need for equitably 
sharing the benefits that arise from the use of tra­
ditional knowledge, innovations, and practices. 
.2  UPOV 
The UPOV Covention is the only international 
treaty focusing on PVP. It recognizes not only the 
rights of individual plant breeders who have de­
veloped or discovered plant varieties that are new, 
distinct, uniform, and stable, but also accords cer­
tain rights to farmers. Under the 1978 version of 
the Convention, farmers are permitted to reuse 
propagating material from the previous year’s har­
vest, and they can freely exchange the seeds of pro­
tected varieties with other farmers. Plant breeders 
are also allowed to use protected varieties to breed 
and commercialize other new varieties. 
The latest revision of the Convention, ad­
opted in 1991, has further strengthened the 
rights of commercial plant breeders. These revi­
sions include the obligation for member states to 
provide protection to all plant genera and species. 
Furthermore, it extends breeders’ rights to all seed 
production of a protected variety, even though 
countries can decide on their own internal laws 
regarding this issue. In some cases, the revision 
grants to commercial breeders the rights to the 
harvested material of the variety and extends pro­
tection to varieties that are “essentially derived” 
from a protected variety. 
.  The International Treaty on Plant Genetic 
Resources for Food and Agriculture 
The International Treaty on Plant Genetic 
Resources for Food and Agriculture was adopted 
by consensus of the member states of the United 
Nations Food and Agriculture Organization 
(FAO) in November 2001. The Treaty envisions 
a multilateral system to facilitate access to key 
genetic resources, with minimal procedural and 
administrative costs. Initially, the treaty applies 
to 35 crops and some 80 forages that are un­
der the control of member governments and 
that are not subject to IP rights. Thus, the treaty 
includes practically all the crops that humanity 
depends on for its food supply. The treaty in­
vites all holders of listed plant genetic resources 
to join the multilateral system. The list itself can 
be changed with the consensus of the parties to 
the treaty. 
The multilateral system is intended to be ef­
ficient, effective, and transparent. It aims to ease 
access, not only to plant genetic resources for 
food and agriculture, but also to information 
about those resources, so that any benefits that 
may arise from their use can be shared fairly and 
equitably. 
In this context, it is worth dwelling briefly on 
the difference between farmers’ rights and farmers’ 
exemption/privilege. Because the terms are often 
used interchangeably, there has been significant 
confusion regarding their use. Farmers’ rights
is a term developed by FAO under the Revised 
Undertaking for Plant Genetic Resources. 
Resolution 5/89 of the treaty states, “…rights 
arising from the past, present and future contribu­
tions of farmers in conserving, improving and mak­
ing available plant genetic resources.” Resolution 
3/91 states that these rights are to be “implement­
ed through an international fund on plant genetic 
resources that will support plant genetic conserva­
tion and utilisation programmes, particularly, but 
not exclusively, in the developing countries….” 
The difference is further elaborated in the 
FAO Treaty. However, no specific future action 
is targeted here; instead, the treaty gives voice to 
a general equity objective. These areas are still the 
subject of much debate, and the mechanism with 
which to ensure both participation and benefit 
sharing has not yet been elucidated. 
The concept of farmers’ exemption or farm­
ers’ privilege in PVP legislation, on the other 
hand, hinges on the notion that a farmer has a 
right to “fair use” of his or her own produced 
seed. Most national legislations embrace this no­
tion of fair use, as do UPOV’s model laws, and 
allow farmers to use seed produced on their own 
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CHAPTER . 
farms for further sowing. Only if the farmer sells 
or trades the seeds is an infringement of the PVP 
holder’s rights committed. Article 15 of UPOV 
1991 states that: 
a) [Compulsory exception] The breeder’s right 
shall not extend to: 
(i) Acts done privately and for non-com­
mercial purposes; 
(ii) Acts done for experimental purposes; 
[…] 
b) [Optional exception] Notwithstanding 
Article 14, each Contracting Party may, 
within reasonable limits and subject to the 
safeguarding of the legitimate interests of the 
breeder, restrict the breeder’s right in relation 
to any variety in order to permit farmers to 
use for propagating purposes, on their own 
holdings, the product of the harvest that 
they have obtained by planting, on their 
own holdings, the protected variety or a va­
riety covered by Article 14(5)(a)(i) or (ii). 
. The TRIPS Agreement 
TRIPS was the result of an initiative by developed 
countries to introduce more stringent IP rights 
trade rules. The agreement sought to extend the 
security of IP rights internationally. Article 27.1 
of the TRIPS Agreement implies that patents 
may be available in biotechnology fields, a posi­
tion that Article 27.3 consolidates with regard to 
granting IP rights in biotechnology, particularly 
as it relates to plants. 
6. SPECIFIC ISSuES RElATED TO
GENEBANK MANAGEMENT 
A genebank manager addresses both the many 
technical aspects relevant to the use of genetic 
resources and issues related to the ownership 
of genetic resources. As outlined below, these 
issues usually come in different phases of the 
work. 
In accordance with the CBD, incoming 
material must be acquired with the consent of 
the nation that “owns” these resources. This 
is achieved through a germplasm acquisition 
agreement (GAA) or an MTA that clearly indi­
cates the rights that the owner is giving to the 
genebank in terms of using and distributing 
such materials. 
In-house materials may include those acquired 
prior to the CBD. These may be in the form of 
genebanks, botanic gardens, and so on. While the 
ownership of in-house materials is still conten­
tious, the law is clear that such materials may be 
used freely without prior permissions. It is very 
important here to distinguish between “genetic 
resources” collected in nature and “improved 
materials.” IP rights will attach only to the latter. 
Indeed, a sound knowledge of the biology of the 
materials and the ownership and legal rights as­
sociated with them is essential. 
Outgoing materials are those materials the 
genebank manager distributes to others, either 
for research, direct use, or for use in improve­
ment programs. This is often when problems 
arise. Carefully using appropriate MTAs is the 
most effective way to deal with these issues. The 
MTA should reflect a range of matters: interna­
tional law, policy of the organization, nature of 
the material, nature of the recipient, nature of the 
acquisition of the material, and conditions relat­
ing to incoming MTA on the material (see ex­
amples included in this Handbook). 
Genebank management has recently become 
a very sensitive issue. An organized, stepwise ap­
proach is vital for effectively managing a genebank 
and for avoiding difficulties. Potential ownership 
issues about genetic resources must be clearly ana­
lyzed, and documentation procedures for the ac­
quisition and distribution of such materials must 
be effective and thorough. 
The legal issues surrounding genebanks have 
changed dramatically over the last decade. Such 
changes will continue, and genebank manag­
ers must be alert to the effects of these changes. 
When appropriate, managers should seek profes­
sional advice about how these changes affect their 
respective institutions. Genebank managers must 
not, however, lose sight of their crucial social role: 
they guard and preserve the basic building blocks 
upon which human survival and food security de­
pend. They work not only for this generation but 
for generations to come. 
HANDBOOK OF BEST PRACTICES | 
   
     











      
        
    
        
      
        
      
     
     
        
      
         
           
       
DODDS, KRATTIGER & KOWAlSKI 
7.	 PVP: IP PROTECTION FOR CROP
VARIETIES
PVP addresses a specific need that applies broadly 
across the globe, in both developed and develop­
ing countries. So-called PVP regimes are imple­
mented in order to: 
•	 provide breeders (both public and private 
sectors) with an opportunity to receive a 
reasonable return on past investments 
•	 provide an incentive for continued or in­
creased investment in future breeding 
research 
•	 recognize the legal right of the innovator to 
be recognized as such 
•	 acknowledge his or her economic right to 
remuneration for his or her efforts 
In order to foster these laws and agreements 
within the global economy, UPOV was formed 
through a union of states. These states agreed to 
grant exclusive exploitation rights to the breeders 
of new plant varieties on an internationally har­
monized basis. UPOV developed a set of model 
laws that provided a general legislative framework 
for PVP. Indeed, some provisions of TRIPS re­
fer to the use of UPOV standards as an effective 
mechanism for complying with WTO standards.
One very effective aspect of this arrangement is 
the provision for mutuality, which allows cross 
protection between jurisdictions for states that 
are members of the UPOV system. Countries 
often use the model law produced by UPOV as 
a framework for developing their own legisla­
tive standards. This is not to say that the system 
is wrinkle free. For example, the differences be­
tween protected varieties and other forms of plant 
genetic material (including genetic resources and 
landraces) has yet to be established. 
The U.S. system is a useful model and be­
cause of the UPOV system’s efforts toward har­
monization, most of the provisions in the U.S. 
PVP system are consistent with those in other ju­
risdictions. It should be noted that many jurisdic­
tions have patent laws allowing for the protection 
of plants. This is complementary to the PVP leg­
islation. It is possible, and increasingly common 
in the United States, for protection to be taken on 
the variety, and, in addition, for a patent on the 
inventive nature of the product and/or process to 
be filed. Finally, the new variety name is usually 
trademarked. (For more information about the 
U.S. PVP system, see section 3.2.) 
The model law of UPOV, and effectively of 
all national legislatures, also allows a government 
to issue a compulsory use license. In effect, if a 
country has a compelling need to multiply a pro­
tected variety, then the government can issue a li­
cense for its use. The PVP holder would, however, 
still have the legal right to be given a reasonable 
royalty payment. 
To qualify as a protected variety, the plant va­
riety coming out of a breeding program must be 




The way in which these criteria are met is de­
scribed in more detail in section 7.3 below. 
.1 PVP application process 
PVP application forms and the supporting docu­
mentation, such as the UPOV crop guides, will 
guide the applicant (and examiner) through the 
steps of describing the history, breeding origin, 
and variety, making seed deposits, paying fees, 
and, if all is as required, obtaining a PVP certifi­
cate. If application materials exist, the relevant 
ministry of agriculture will have them; if applica­
tion materials are not available, this chapter pro­
vides information to help develop them. 
Anyone who is the owner, breeder, de­
veloper, or discoverer of a unique cultivar of a 
sexually reproduced or tuber-propagated plant 
may apply for PVP. This applies to any citizen 
in any UPOV member country. The applicant 
may be an individual, a public institution, or a 
corporation. 
The protection works by prohibiting a per­
son from selling, marketing, offering, delivering, 
consigning, exchanging, or exposing the variety 
for sale without explicit consent of the owner. In 
addition, a person is prohibited from soliciting 
an offer to buy the variety, or transfer or possess 
it in any manner. It is also illegal to import or ex­
port the variety, sexually multiply it, propagate it 
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CHAPTER . 
by tuber, use the variety in producing (as distin­
guished from developing) a hybrid, or condition 
the variety for the purpose of propagation. It is 
worth adding here that plant parts (flowers, pol­
len, and so on) are also protected. This is critical 
in reviewing infringement actions to determine 
where the material has been used. 
.2  Exemptions 
In general, there are two exemptions to the 
protection provided: 1) a research exemption 
and 2) a farmer’s exemption (also called farmer’s 
privilege).5 
A research exemption allows for breeding to 
develop a new variety; a farmer’s exemption allows 
for the saving of seed for the sole use of replanting 
the farmer’s land. However, if the farmer sells or 
trades the seeds, he infringes on the rights of the 
PVP holder. The controversies surrounding this 
provision turn largely on the definition of terms. 
It should be noted that neither plant patents nor 
utility patents provide these exemptions. 
.  Examination standards 
The owner must prove the distinctness, uni­
formity, and stability of the new variety. The bur­
den is entirely on the applicant. 
For distinctness, the applicant may: 
•	 list the single variety he or she believes is 
most similar to the new variety and de­
scribe how the new variety differs from it 
•	 list a group of varieties that are similar to 
the new variety and describe how it differs 
from varieties within that group 
•	 describe how the variety differs from all 
other known varieties in the crop kind 
The PVP office maintains databases of both 
public and private varieties of crops. The exam­
iner uses these and other sources to determine 
which, if any, varieties are indistinguishable from 
the new one. If the examiner finds varieties that 
appear to be indistinguishable from the applica­
tion variety, the applicant will be notified that 
supplemental data is necessary. To obtain addi­
tional data, applicants may perform additional 
field or greenhouse replications and may use 
DNA profiling and other analyses to substantiate 
distinctness. In the United States, the PVP office 
does not perform tests to confirm the distinct­
ness of a variety. That responsibility rests with the 
applicant. 
For uniformity, a statement must report 
the level of variability in any characteristic of 
the variety. Variation, which is predictable, de­
scribable, and commercially acceptable, may be 
allowed. 
For stability, a statement of genetic stability 
is required, showing the number of cycles of seed 
reproduction for which the variety has remained 
unchanged in all distinguishing characteristics. 
Special mention should be made of essential­
ly derived materials. Good examples are so called 
“sports.” If PVP protection has been obtained on 
a potato variety that has a red skin after decades of 
breeding, and then someone selects a field sport 
with a white skin, the new white skin material 
is determined to be essentially derived from the 
original variety and will be protected under the 
1991 UPOV act. 
.  Enforcement 
The owner of a protected variety may bring civil 
action against persons infringing on his or her 
rights, and the owner may ask a court to issue an 
injunction to prevent others from further viola­
tions. The owner of the protected variety must 
bring suit in such cases—the USDA will not take 
that action. In the United States, IP protection 
for plants is provided through plant patents, PVP, 
and utility patents. Plant patents provide protec­
tion for asexually reproduced (by vegetation) va­
rieties excluding tubers. PVP provides protection 
for sexually (by seed) reproduced varieties includ­
ing tubers, F1 hybrids, and essentially derived va­
rieties. Utility patents currently offer protection 
for any plant type or plant parts. A plant variety 
can also receive double protection under a utility 
patent and PVP. 
.  Contents of a complete application and 
exhibit forms 
A PVP application consists of a completed and 
signed form that includes Exhibits A, B, C, and E 
(Exhibit D is optional): 
A) Exhibit A (Breeding History) 
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B) Exhibit B (Statement of Distinctness, pre­
viously called “Novelty Statement”) 
C) Exhibit C (Objective Description) 
D)Exhibit D (Additional descriptive 
Information) 
E) Exhibit E (Statement of Ownership) 
Also required is a sample of at least 2,500 un­
treated viable seeds, capable of propagating the 
application variety, and, for a tuber-propagated 
variety, verification that a viable cell culture will 
be deposited. A check for the filing fee is also 
required. 
..1 Exhibit A: Breeding History 
The applicant is required to provide the 
following: 
•	 full disclosure of the genealogy back to 
publicly known varieties, lines, or clones, 
including the breeding method 
•	 details of subsequent stages of selection and 
multiplication used to develop the variety 
•	 statement of uniformity reporting the level 
of variability in any characteristics of the 
variety (commercially acceptable variability 
is allowed) 
•	 statement of genetic stability showing the 
number of cycles of seed reproduction for 
which the variety has remained unchanged 
in all distinguishing characteristics 
•	 information about the type and frequency 
of variants observed during reproduction 
and multiplication 
•	 information about the frequency of off-
types (in other words, impure lines) ob­
served or known to occur 
..2  Exhibit B: Statement of Distinctness 
The applicant is required to give a summary of 
the variety’s distinctness, stating clearly how the 
application variety may be distinguished from all 
other varieties in the same crop. If the variety is 
most similar to one variety or group of varieties, 
the applicant must (1) identify these varieties and 
state all differences objectively, (2) attach statisti­
cal data for characters expressed numerically and 
demonstrate that these are clear differences and 
(3) submit, if helpful, seed and plant specimens 
or photographs (prints) of seed and plant com­
parisons that clearly indicate distinctness. 
.. 	 Exhibit C: Objective Description of Variety 
The PVP office has prepared forms for the appli­
cant to provide a botanical description of the va­
riety for most crops. These forms list the botanical 
characteristics for a kind of crop and the degree 
of expression of each characteristic. These forms 
also provide a list of recommended varieties that 
the applicant should compare to the application 
variety. The applicant needs to complete the form 
for his or her variety as thoroughly as possible. 
..  Exhibit D: Optional Supporting 
Information 
The applicant may provide additional informa­
tion, specimens, and/or materials in support of 
the claims of the application. 
..  Exhibit E: Statement of Ownership 
The applicant is required to furnish a statement 
for the basis of the applicant’s ownership. The 
PVP office has prepared a form to simplify this 
requirement. The form also includes a statement 
to verify that the applicant is eligible to file for 
PVP in the United States. 
.  Steps needed to start and operate 
a national PVP office 
You may be reading this chapter because you are 
in the process of setting up a PVP office. If that 
is the case, then the topics below will help you ef­
fectively and efficiently establish the office. 
The basic operation of this office and its ac­
tions can be translated into the following steps: 
1.	 Setting up the office. The initial setting up 
of the office will have a physical component 
(obtaining the necessary space, equipment, 
and other physical resources) and a legis­
lative component (setting up the laws and 
regulations, and examining guidelines). 
2.	 Appointing the staff. A registrar for the 
PVP office, a number of examiners, and 
support staff, both clerical and technical, 
will need to be appointed. 
3.	 Training the staff. The PVP office staff 
needs to be trained in both the technical 
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processes related to the examination and 
the legal and clerical matters related to is­
suing and registering the certificate. 
4.	 Establishing the formal procedure. The of­
fice must set up formal procedures, such as 
law enactment, rule approval, and exami­
nation standards. 
5.	 Notifying the public that the office is func­
tional. Once the PVP office is functional, 
staff must inform the public that they may 
avail themselves of the services the office 
provides. 
6.	 Distributing information and application 
material. As part of the public awareness 
campaign, staff should make information 
and forms publicly available. In an increas­
ing number of jurisdictions, application 
forms are available online at the PVP office 
Web site. 
7.	 Informing and educating the public 
about how to apply. Attorneys and agents 
may need to be educated about the actual 
mechanics of preparing and submitting 
applications. 
8.	 Receiving application. The filing date is a 
critical component of the application pro­
cess, and detailed rules should inform ap­
plicants about the application filing date. 
9.	 Reviewing the applications. This is the 
heart of the process. Applications are re­
viewed (1) for compliance with general ap­
plications standards and (2) for technical 
content. 
10. Examinations standards and their applica­
tion. The 1991 UPOV act, the rules, and 
possibly the examiner’s manual provide an 
objective set of standards that can be ap­
plied to particular applications. The impor­
tance of such objectivity for the credibility 
of the system cannot be overstated. 
11. Communicating with the client. Effective 
communication with the applicant is abso­
lutely essential. All correspondence must be 
consistently dated, numbered, and sent by 
registered or certified mail. 
12. Communicating with policy-makers. 
When establishing the office, it will be 
crucial to keep in very close communi­
cation with senior policy-makers. The 
act and regulations will need legislative 
action, and they must also be consistent 
with other domestic laws. Regulations 
will also often need to comply with WTO 
requirements. 
13. Storing	 deposits. Facilities must be 
arranged for storing exhibits of the 
materials. 
14. Preparing certificates. A format and style 
must be established for the production and 
registration of PVP certificates. 
15. Dealing with disputes. The legislation and 
regulations will usually contain provisions 
allowing for applicants who are refused a 
PVP certificate to appeal the decision either 
through the PVP office and/or through the 
judicial system. 
16. Sample deposits. An appropriate, adequate 
system must be in place for applicants to 
deposit seed or plant materials. This facility 
may belong to the ministry of agriculture 
in most countries or may be managed by 
a related organization. The facility should 
meet appropriate international seed stor­
age guidelines and have adequate mecha­
nisms for safekeeping/security of the seed 
samples. 
8. CONCluSIONS 
It is clear that a PVP regime effectively harmo­
nized across different countries would significant­
ly lower the costs for users, and hence increase re­
turns on plant-breeding investments. This would 
undoubtedly lead to more varieties and more 
choices for farmers. A costly regime, on the other 
hand, discourages smaller national companies 
from filing for PVP protection and increases the 
cost of participating in foreign markets that, in 
turn, favors large multinational companies with 
the resources and infrastructure to operate across 
multiple national regimes. 
All of the IP protection mechanisms dis­
cussed in this chapter depend upon enforcement 
by national governments. If a law is only as good 
as its enforcement, then a regulatory body such 
as a PVP office is only as good as the people who 
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DODDS, KRATTIGER & KOWAlSKI 
implement the regulations. In order to reinforce 
national policy initiatives in many countries, a 
comprehensive, in-depth training program is 
recommended to equip personnel with the infor­
mation and experience required to establish the 
long-term health of a PVP system. This training 
could be combined with a coordinated effort to 
regionalize the PVP system through jointly train­
1 Blakeney M, JI Cohen and S Crespi. 1999. Intellectual 
Property Rights and Agricultural Biotechnology. In 
Managing Agricultural Biotechnology. Addressing 
Research Program Needs and Policy Implications (ed. JI 
Cohen). pp. 209-227. CAB International Press; Blakeney 
M. 1999. Agricultural Research and the Management
of Intellectual Property. In Managing Agricultural 
Biotechnology. Addressing Research Program Needs 
and Policy Implications (ed. JI Cohen). pp. 228-40. CAB 
International Press. 
ing administrators from a number of countries, 
which would increase cooperation and harmoni­
zation within the region. 
Of course, different people within the system 
require different training. As a starting point, all 
participants, whether officers, management, or 
even individuals in breeding companies, need to 
be brought to a certain minimum level of com­
petence in the application of the regulations. A 
general program, such as a Web-based training 




Modified from Helfer LR. 2002. Intellectual Property 
Rights in Plant Varieties: An Overview with Options for 
National Governments FAO Legal Papers Online, No. 31.
www.fao.org/Legal/Prs-OL/lpo31.pdf. 
The initial PVP Act of the United States was not UPOV 
compliant, but in 1980 the United States acceded to 
UPOV 1978 and later to UPOV 1991. A further jump in 
investment was seen after 1986 when the U.S. Patent
and Trademark Office established that plant varieties 
were patentable subject matter. 
Krattiger AF and RH Potter. 2002. The Status of Plant
Variety Protection Issues in the Asia-Pacific Region: An 
Overview. Asian Seed 9(5): 17–20. 
could help to achieve this goal. For management 
staff, tailored workshops could be used to expose 
staff members to areas of conflict and to increase 
their knowledge of the importance of PVP in the 
development of plant breeding businesses. These 
courses and workshops could be augmented by 
an internship program, in which selected indi­
viduals would be given more intensive training 
through collaboration with public and private 
institutions from countries with well-established 
PVP systems. These highly trained individuals 
5 Farmer’s exemption or farmer’s privilege should not
be confused with “Farmer’s Rights”. Farmer’s rights 
is a concept that became popular during the 1980s 
through the FAO Revised Undertaking for Plant
Genetic Resources (Resolution 5/89) in an attempt
to recognize and reward the “…rights arising from 
the past, present and future contributions of farmers 
in conserving, improving and making available plant
genetic resources…” (see www.fao.org/docrep/X0255E/
x0255e03.htm for a detailed history). The term now 
constitutes a central element in the International 
Treaty on Plant Genetic Resources for Food and 
Agriculture where it is called “Farmers’ Rights.” ftp://
ftp.fao.org/ag/cgrfa/it/ITPGRe.pdf.æ 
could form a core group that would then further 
develop staff expertise. n 
JOHN dOddS, Founder, Dodds and Associates, 1707 N 
Street NW, Washington., D.C., 20036, U.S.A. j.dodds@ 
doddsassociates.com 
ANATOLE kRATTIgER, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute; and Adjunct Professor, 
Cornell University. PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu 
STANLEy P. kOWALSkI, Visiting Scholar, The Franklin Pierce 
Law Center, 2 White Street, Concord, NH, 03301, U.S.A. 
spk3@cornell.edu or skowalski@piercelaw.edu
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CHAPTER 4.7 
Plant Variety Protection, International 

Agricultural Research, and Exchange of Germplasm:

Legal Aspects of Sui Generis and Patent Regimes
 
MICHAEL BLAkENEy, Director, Queen Mary Intellectual Property Research Institute, University of London, U.K. 
ABSTRACT 
This chapter outlines the range of plant variety protec­
tion regimes that currently exist internationally, includ­
ing the International Convention for the Protection of 
New Varieties of Plants, the Convention on Biological 
Diversity, the Agreement on Trade-Related Aspects of 
Intellectual Property Rights, and the International Treaty 
on Plant Genetic Resources for Food and Agriculture. The 
chapter commences with a history of intellectual property 
laws affecting plant breeding and the genetic modification 
of plants. It explores the trend toward the harmonization 
of international standards and concludes with an examina­
tion of the impact of these developments upon germplasm 
exchange, international agricultural research, and food 
security. 
1. INTEllECTuAl PROPERTy RIGHTS
AND AGRICulTuRE 
The first international intellectual property (IP) 
convention was the 1883 Paris Convention for 
the Protection of Industrial Property. In this in­
strument, agriculture was envisaged as an area of 
enterprise in which property rights could be se­
cured, thus Article 1(3) of the Paris Convention 
declared that: 
Industrial property shall be understood in the 
broadest sense and shall apply not only to industry 
and commerce proper, but likewise to agricultural 
and extractive industries and to all manufactured or 
natural products, for example, wines, grain, tobacco 
leaf, fruit, cattle, minerals, mineral waters, beer, 
flowers, and flour. 
Given the state of technology in 1883, the 
inclusion of these agricultural subjects within the 
Paris Convention was for the purpose of protect­
ing trademarks and indications of source. 
The first inclusion of biological agricul­
tural innovations in an IP statute was in the 
U.S. Plant Patents Act of 1930, which created 
a sui generis system confining protection to 
asexually reproduced plants, so confined be­
cause of the view that sexually reproduced va­
rieties lacked stability.1 The Act also excluded 
tuber-propagated plants principally because of 
a concern that protecting such plants would 
lead to monopolies in basic foodstuffs such as 
potatoes.2 Applicants for plant patents were 
required to asexually reproduce the plant for 
which protection was sought, to demonstrate 
the stability of the characteristics of the plant 
being claimed. Section 161 required that new 
varieties be “distinct.” The statute did not de­
fine this requirement, although the Senate 
Committee report accompanying the act stated 
that “in order for a new variety to be distinct it 
must have characteristics clearly distinguishable 
from those of existing varieties” and that it was 
not necessary for the new variety to constitute 
“a new species.”3 
Legislation similar to the Plant Patents Act 
was adopted in Cuba in 1937, in South Africa in 
1952, and in the Republic of Korea in 1973. 
Blakeney M. 2007. Plant Variety Protection, International Agricultural Research, and Exchange of Germplasm: Legal As-
pects of Sui Generis and Patent Regimes. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org. 
© 2007. M Blakeney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
HANDBOOK OF BEST PRACTICES | 01 
     
    
  
          
     
      
     
        
      
        
      
      
      
       
      
      
       
     
        
         
     
         
         
       
         
      
       
         
     
       
       
      
        
      
        
      
      
      
       
        
      
       
       
     
       
           






2. INTERNATIONAl STANDARDS FOR
SuI GENERIS PVP 
As with other categories of IP, a key role in the 
inclusion of agricultural innovations within the 
international regulatory regime was played by in­
dustry associations. The Congrès Pomologique de 
France, held in 1911, had called for special pro­
tection for plant varieties. This agitation contin­
ued in the 1920s and 1930s, culminating in the 
founding, in Amsterdam in November 1938, of 
the International Association of Plant Breeders for 
the Protection of Plant Varieties (ASSINSEL). At 
its Semmering Congress in June 1956 a resolution 
of ASSINSEL called for an international confer­
ence to promulgate an international system for 
the protection of new plant varieties. In February 
1957, the French government issued invitations 
to 12 western European countries4 to attend a dip­
lomatic conference in Paris in May of that year to 
consider establishing such a system. Participation 
was limited by the French to those states who were 
known to have similar concerns to it on this sub­
ject. The conclusions of the 1957 Paris conference 
were set down in its Final Act, adopted in May 
1957. This recognized the legitimacy of breeders’ 
rights and established as the preconditions for pro­
tection that a variety had to be distinct from pre­
existing varieties and sufficiently homogenous and 
stable in its essential characteristics. The act de­
fined the rights of the breeder and acknowledged 
the principle of the independence of protection. 
At the second session of the conference, held in 
Paris in late 1961, the International Convention 
for the Protection of New Varieties of Plants, or 
Union pour la Protection des Obtentions Végétales 
(UPOV), was adopted. Article 4(1) applied the 
Convention to “all botanical genera and species,” 
but it was envisaged that the Convention would 
have a gradual introduction. A list of 13 genera 
was annexed to the Convention: wheat, barley, 
oats or rice, maize, potato, peas, beans, Lucerne, 
red clover, ryegrass, lettuce, apples, and roses or 
carnations. Article 4(3) required each member 
state, upon entry into force of the Convention, 
to apply it to at least five genera from this list and, 
within eight years, to all the listed genera. 
Article 27 of the 1961 Convention provid­
ed for its periodic review, with the first revision 
scheduled for 1972. Within the first 19 years of 
its life, the UPOV Convention had attracted the 
accession of only 12 states. A reason identified for 
the reluctance of states to adopt the Convention 
was the stringency of its provisions, in particu­
lar the obligation of states to select either patent 
or UPOV-style protection for plant varieties, 
but not both. Article 2 of the Convention was 
amended to permit the accession of countries, 
like the United States, which had laws allowing 
for the double protection of varieties under both 
patent and UPOV-style sui generis laws. The list 
of genera, annexed to the 1961 Convention was 
removed. This list had contained mainly species 
from temperate climates. Under the new Article 
4, member states agreed to apply the Convention 
to at least five genera, rising to 24 genera within 
eight years. Additionally, a grace period was in­
troduced to permit the marketing of varieties for 
up to 12 months prior to submitting an applica­
tion for plant variety protection (PVP). 
A further broadening of the UPOV 
Convention occurred with the 1991 revision. The 
1991 Act requires states to protect at least 15 plant 
genera, upon becoming members, and to extend 
protection to all plants within 10 years (Article 
3(2)). In response to demands from breeders in 
developed countries, the 1991 Act removed the 
prohibition against dual protection. The 1991 Act 
recognized breeders’ rights to use protected variet­
ies to create new varieties. However, this excep­
tion is itself restricted to such new varieties as were 
not “essentially derived” from protected varieties 
(Articles 14(5) and 15). The drafters added this 
restriction to prevent second generation breeders 
from making merely cosmetic changes to existing 
varieties in order to claim protection for a new 
variety. The concept of essential derivation has, 
however, proved highly controversial in practice. 
Breeders have been unable to agree on a defini­
tion of the minimum genetic distance required 
for second generation varieties to be treated as 
not essentially derived from an earlier variety and 
thus outside of the first breeder’s control.5 
From the perspective of farmers, probably 
the most contentious aspect of the 1991 Act was 
the limitation of farmers’ rights to save seed for 
propagating “on their own holdings” the product 
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of the harvest that they obtained by planting a 
protected variety on their own holdings, “within 
reasonable limits and subject to the safeguarding 
of the legitimate interests of the breeder” (Article 
15(2)). Unlike the 1978 Act, the 1991 version of 
the farmers’ privilege does not authorize farmers 
to sell or exchange seeds with other farmers for 
propagating purposes. This is criticized as incon­
sistent with the practices of farmers in many de­
veloping nations, where seeds are exchanged for 
purposes of crop and variety rotation.6 
A number of developing countries have re­
sisted the adoption of the 1991 Act as the stan­
dard for PVP laws. The foreign ministers of the 
Organization for African Unity issued a statement 
at a January 1999 meeting calling for a morato­
rium on IP protection for plant varieties until 
an Africa-wide system had been developed that 
granted greater recognition to the cultivation 
practices of indigenous communities. 
3. THE uPOV SySTEM 
In most countries the implementation of 
the UPOV Convention requires domestic 
legislation. 
.1 Scope of plant breeders’ rights 
Generally, the plant breeders’ rights (PBRs) con­
ferred by domestic legislation modeled on UPOV 
are defined as the exclusive right to do or to li­
cense the following acts in relation to propagating 
material of the plant variety: 
•	 produce or reproduce the material 
•	 condition the material for the purpose of 
propagation 

• offer the material for sale 

•	 sell the material 
•	 import the material 
•	 export the material 
•	 stock the material for all of the purposes 
described above 
.2 Exceptions 
Excepted from these rights, under the UPOV 
Convention, are acts performed privately and for 
noncommercial purposes, for experimental pur­
poses, or for the purpose of breeding other plant 
varieties. As was mentioned above, seed saved by 
a farmer from harvested material and treated for 
the purpose of sowing a crop on that farmer’s own 
land is considered not to be an infringement by 
legislation based on UPOV 1991. 
Legislation may also provide that PBRs are 
not infringed when propagating material is used 
as a food, food ingredient, or fuel, or for any other 
purpose not leading to or involving the produc­
tion or reproduction of propagating material. 
Also, it may be provided that PBRs are ex­
hausted following the sale of propagating mate­
rial by a grantee unless there is a multiplication of 
the material after the sale. 
. Duration of plant breeders’ rights 
The general duration of PBRs, provided by leg­
islation implementing UPOV 1991, is to be 25 
years in the case of trees and vines and 20 years 
for any other plant type. This duration period 
commences on the date of grant of PBRs in the 
variety. Where a plant variety is declared to be es­
sentially derived from an initial variety, the total 
duration of protection for the dependent or es­
sentially derived variety generally can last for no 
longer than the duration of the protection of the 
initial variety. 
. Application for plant breeders’ right 
Eligible applicants are usually plant breeders who 
are citizens or residents of the country in which 
they are applying for the permit, if the variety is 
bred in the country. On the other hand, a coun­
try might permit anyone, domestic or foreign, to 
apply for a variety under the country’s laws. 
Ineligible applications will generally involve 
varieties previously sold in the country. 
. Form of application 
The form of application for PBRs will be pre­
scribed by the national legislation. It will provide 
that an application must contain: 
1. the name and address of the applicant 
2. the name and address of the agent, if any, 
making the application on the applicant’s 
behalf 
3. a statement to that effect if the applicant is 
the breeder of the variety 
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BlAKENEY 
4. if the applicant is not the breeder of the va­
riety, details of the applicant’s right to make 
the application 
5. a brief description, with a photograph, if 
appropriate, of a plant of the variety suf­
ficient to establish a prima facie case that 
the variety is distinct from other varieties of 
common knowledge 
6. the name, and any proposed synonym, for 
the variety 
7. particulars of the location at which and the 
manner in which the variety was bred, in­
cluding particulars of the names by which 
the variety is known and sold in the coun­
try and particulars of any PBRs granted in 
the country or in another country that is a 
signatory to the UPOV Convention 
8. particulars of any application for, or grants 
of, rights of any kind in the variety in any 
other country 
9. the name of an approved person who will 
verify the particulars of the application and 
who will supervise any test growing of the 
variety required under Section 37 of the 
Act and who will verify a detailed descrip­
tion of the variety; and 
10.such other particulars, if any, as are required 
by the approved form. 
. Application fee 
An application fee will usually be prescribed un­
der the legislation. 
. Acceptance or rejection 
The authority or official that is responsible for 
the administration of the relevant law will be 
required to decide, as soon as is practicable af­
ter an application is filed, whether to accept or 
reject the application. Where the authority or 
official is satisfied that the application is prior in 
time to any other application and that it com­
plies with the requirements of the legislation 
and establishes a prima facie case for treating 
the plant variety as distinct from other varieties, 
the application must be accepted. Upon accep­
tance, the applicant must be notified that the 
application has been accepted and public notice 
of the acceptance must also be given. Similar 
notification obligations apply when an applica­
tion is rejected. 
. Variation of application 
After an application for PBRs has been accepted, 
but before concluding the examination of that 
application, the authority or official may permit 
an applicant to vary an application, subject to the 
payment of a prescribed fee. 
An application is usually permitted to be 
withdrawn by an applicant at any time. If this 
occurs after public notice of the application, the 
authority or official must, as soon as is practical, 
give public notice of the withdrawal. 
. Detailed description of the plant variety 
Whenever it is practical, but not later than 12 
months after an application has been accepted, or 
within such further period granted by the author­
ity or official, the applicant is usually required to 
give a detailed description of the plant variety to 
which the application relates. Failure to supply 
this description will result in the application be­
ing deemed to have been withdrawn. The detailed 
description must be in writing and in an approved 
form, containing particulars of: 
1. the characteristics that distinguish the plant 
variety from other varieties, the existence 
of which is deemed a matter of common 
knowledge 
2. any test growing carried out 
3. any test growing outside the country that 
tends to establish that the variety will, if 
grown in the country, be distinct, uniform 
and stable; and 
4. other 	 such particulars that may be 
prescribed. 
.10 Objection to an application for PBRs 
The administering authority is usually obliged to 
give public notice of the detailed description as 
soon as is practicable after it has been received. 
A person may object to an application for PBRs 
if they can establish that their commercial in­
terests would be affected by the grant of PBRs 
to the applicant and that the authority cannot 
be satisfied that the various substantive require­
ments of the law have been met by an applicant. 
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The objection must set out the particulars of the 
manner in which the person believes his or her 
commercial interests would be affected and the 
reasons why the person considers that the author­
ity cannot be satisfied that the various substantive 
requirements of the law have been met. 
.11 Inspection of application and objections 
A person may, at any reasonable time, inspect an 
application for PBRs over a plant variety, or an 
objection lodged in respect to that application. 
Upon payment of a prescribed fee, a copy of an 
application or an objection to an application is to 
be provided. 
.12 Test growing of plant varieties 
In the case of an application that has been ac­
cepted, or an objection to such application, or 
a request for revocation of PBRs, the authority 
may require a test growing, or a further test grow­
ing, of the variety. In such case, notice may be 
required to be provided to all relevant persons. 
The notice, in addition to telling the applicant, 
objector, or grantee of the authority’s decision, 
must specify the purpose of the test growing and 
may require the person to supply the authority 
with sufficient plants or propagating material and 
with any necessary information to permit the au­
thority to arrange a test growing, or to make ar­
rangements for an approved person to supervise 
the test growing and to be supplied with plants 
or propagating materials. The expense of a test 
growing must be borne by the applicant, objec­
tor, or person requesting revocation of the PBR. 
Provision may be made for a test growing outside 
the country of a plant variety that was bred out­
side the country. 
.1 Provisional protection 
Where an application for PBRs is accepted, the 
applicant is taken to be the grantee of that right 
from the date that the application is received 
until the application is disposed of. During this 
period of provisional protection, the applicant is 
prevented from commencing any infringement 
action with respect to the PBRs, until such time 
as the application is finally resolved in the appli­
cant’s favor. 
.1 Declarations of essential derivation 
Where a person is the grantee of PBRs over a par­
ticular plant variety (the initial variety) and an­
other person is the grantee of, or has applied for, 
PBRs in another variety (the second variety) the 
grantee of PBRs in the initial variety may seek 
a declaration that the second variety is an essen­
tially derived variety of the initial variety. A plant 
variety is defined to be an essentially derived vari­
ety of another plant variety if: 
1. it is predominantly derived from the other 
plant variety 
2. it retains the essential characteristics that 
result from the genotype or combination of 
genotypes of that other variety; and 
3. it does not exhibit any important (as dis­
tinct from cosmetic) features that differen­
tiate it from that other variety. 
The application for essential derivation 
must be in an approved form and contain such 
information relevant to establishing a prima fa­
cie case of essential derivation. If the authority 
is satisfied, or not satisfied, as the case may be, 
that a prima facie case has or has not been estab­
lished, the applicant and the grantee of PBRs in 
the second variety must be informed and pro­
vided an opportunity to rebut the prima facie 
case. The authority may order a test growing 
in order to rebut a prima facie case of essential 
derivation. 
.1 Grant of PBRs 
Where an application for PBRs in a plant variety 
is accepted, the law will provide that following 
examination of the application. The authority 
must grant the right to the applicant where it is 
satisfied that: 
1. there is such a variety 
2. the variety is registrable within the law 
3. the 	 applicant is entitled to make the 
application 
4. the grant of that right is not prohibited by 
the law 
5. the right has not been granted to another 
person 
6. the 	 name of the variety complies with 
Section 27 
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7. propagating material of the variety has been 
deposited for storage, at the expense of the 
applicant, in a genetic resource center ap­
proved by the authority 
8. a satisfactory specimen plant must be sup­
plied to a prescribed herbarium; and 
9. all fees have been paid. 
PBRs are granted by the issue of a certificate 
in approved form. 
.1 Effect of a grant of PBRs 
If a person is granted PBRs over a plant variety, 
the grantee will take precedence over any other 
person who was entitled to make an application 
for the right in the variety. Such person is not pre­
vented, however, from applying for a revocation 
of rights or to seek administrative review of the 
authority’s actions in relation to the grant of PBR 
or to request the authority to make a declaration 
that the variety over which rights were granted 
was essentially derived from another plant variety. 
Where it has been determined that another per­
son was entitled in law or equity to an assignment 
of the right to make an application for the PBRs, 
that person may be entitled to an assignment of 
the PBRs. 
Where the relevant Minister for Agriculture 
considers it appropriate, PBRs may be granted 
subject to conditions. The Minister would prob­
ably take the advice of any Plant Breeders’ Rights 
Advisory Committee established under the law. 
.1 Revocation 
There may be provision for the revocation of 
PBRs, or a declaration that a plant variety is es­
sentially derived from another plant variety, if the 
authority becomes satisfied that facts had existed 
that, if known before the grant of the right or the 
making of the declaration, would have resulted in 
the refusal to grant the right or make the declara­
tion. Revocation may also result from a failure to 
pay prescribed fees. Within a prescribed number 
of days of the decision to revoke, the grantee or 
transferee of PBRs may be provided with particu­
lars of the grounds of proposed revocation. 
Applications for revocation may be made by 
a person whose interests are affected by the grant 
of PBRs over a plant variety or by a declaration 
of essential derivation. In the event of revocation 
or surrender of PBRs, particulars of revocation 
or surrender will usually be entered in the PBRs 
Register and published. 
.1 Compulsory licensing 
National laws usually require the grantee of PBRs in 
a plant variety to take all reasonable steps to ensure 
reasonable public access to that plant variety. This 
requirement is considered to be satisfied if propa­
gating material of reasonable quality is available 
to the public at reasonable prices, or as gifts to the 
public, in sufficient quantities to meet demand. For 
the purpose of ensuring reasonable public access, 
the law may permit the relevant authority to license 
an appropriate person to sell propagating material 
of plants of that variety, or to produce propagat­
ing material of plants of that variety for sale, during 
such period as the authority considers appropriate 
and on such terms and conditions (including the 
provision of reasonable remuneration to the grant­
ee) as the authority considers would be granted by 
the grantee in the normal course of business. 
A person may make a written request to the 
authority for the grant of a license where a per­
son considers that a grantee is failing to ensure 
reasonable public access to a plant variety and 
that failure affects that person’s interests. The re­
quest must set out particulars of the alleged fail­
ure and of the effect upon the person’s interests. 
The authority is then usually required to provide 
the grantee an opportunity within a prescribed 
period to satisfy the authority that the grantee is 
providing reasonable public access to a plant vari­
ety, or that he or she will comply within a reason­
able period of time. Where the authority decides 
to grant a license, a public notice will be issued 
identifying the variety, detailing the particulars of 
the license that is proposed to be granted and an 
invitation to persons to apply for a license. The 
authority is usually required to consider all appli­
cations and publicly notify the proposed licensee, 
as well as notifying each of the applicants. 
.1 Infringement of PBRs 
Generally speaking, PBRs in a plant variety are 
infringed by an unauthorized person: 
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1. performing acts that are included in the 
PBRs 
2. claiming the right to perform one of those 
acts; and 
3. using the name of a registered variety in 
relation to another plant or another plant 
variety. 
An infringement will not occur where the act 
complained of is exempted from the operation of 
the law. A defendant in an action for infringe­
ment of rights may counterclaim for revocation 
of the rights on the grounds that the variety was 
not a new plant variety or that facts existed that 
would have resulted in the refusal of the grant of 
those rights. 
.20 Remedies 
In an infringement action, a nominated court 
may grant an injunction subject to any terms 
that the court thinks fit and, at the option of the 
plaintiff, either damages or an account of profits. 
Where a person satisfies the court that at the time 
of the infringement he or she was not aware of 
that right, and had no reasonable grounds for sus­
pecting the existence of the right, it may refuse to 
award damages or order an account of profits. 
.21 Administration 
Most laws provide for the establishment of the 
Office of the Registrar of Plant Breeders’ Rights, 
which is responsible for the general administra­
tion of the Act and for the maintenance of the 
Register of Plant Varieties. 
The office of the Registrar will usually issue 
an official Plant Varieties Journal in which all 
public notices are to be published. 
.22 Genetic resource centers and herbaria 
The law may provide for the nomination of ge­
netic resource centers for the storage and mainte­
nance of germplasm material. 
4. PATENTS ON PlANTS, VARIETIES, SEEDS,
AND OTHER PROPAGATING MATERIAl 
As mentioned above, PVP laws were developed 
in response to industry calls for sui generis
protection of agricultural and horticultural in­
novations. However, a seed-saving exception for 
farmers was included as a public policy safeguard, 
an early reflection of food security concerns. Such 
a safeguard does not generally exist in patent stat­
utes, and this absence was an inducement for seed 
companies to shift their attention to the patent 
system as a means of protecting their innovations. 
This shift in attention also coincided with the de­
velopment of modern biotechnologies. 
Patent protection was not originally consid­
ered to be a particularly effective system for the 
protection of plant varieties. Prior to the develop­
ment of modern biotechnology, the breeding of 
a new variety could not be said to involve an in­
ventive step, and such innovations as were made 
could be considered to be obvious rather than 
inventive. However, with the extension of patent 
protection to recombinant DNA methods for 
producing transgenic plants and their resulting 
products, patents have been assuming increasing 
significance in PVP. The broader ambit of patent 
rights is one particular advantage of this form of 
IP protection, covering, as it does, plants, seeds, 
and enabling technologies. Plant variety rights 
are highly specific to the variety, and their scope 
is limited by reference to the physical (propagat­
ing) material itself, combined with the descrip­
tion of the variety given in the documentary 
grant of the rights. 
.1 European prohibitions on patentability 
Article 53(b) of the European Patent Convention 
(EPC) excludes plant varieties, as well as “es­
sentially biological processes” from the scope of 
patentable subject matter. This raises, in the first 
instance, the definitional distinction between 
plants and plant varieties. The UPOV Convention 
defines plant variety in terms of a plant group­
ing within a single biological taxon of the lowest 
known rank. The grouping can be: 
•	 defined by the expression of characteristics 
(such as shape, height, color, and habit) re­
sulting from a given genotype or combina­
tion of genotypes 
•	 distinguished from any other plant group­
ing by the expression of at least one of these 
characteristics 
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•	 considered as a unit with regard to its suit­
ability for being propagated unchanged 
The first consideration of the distinction be­
tween plant and plant variety by the Technical 
Board of Appeal of the European Patent Office 
(EPO) occurred in 1984 in the Ciba-Geigy de­
termination.7 This case concerned a plant that 
had been treated with a chemical compound to 
confer on the plant a degree of protection from 
the toxic side effects of certain herbicides. The 
Examination Division had refused the patent 
application on the basis of Article 53(c). This 
was reversed by the Technical Board of Appeal, 
which, applying the definition of plant variety 
in the UPOV Convention, stated that “Article 
53(c) prohibits only the patenting of plants or their 
propagating material in the genetically fixed form 
of the plant variety… Plant varieties in this sense 
are all cultivated varieties, clones, lines, strains and 
hybrids.”8 In this case the claims covered merely 
the application of a chemical treatment and not 
plant varieties as such. 
This approach was applied by the Technical 
Board of Appeal in the case Lubrizol (Hybrid 
Plants)9 where the Board held that “the term plant 
varieties means a multiplicity of plants which are 
largely the same in their characteristics (that is, homo­
geneity) and remain the same within specific toleranc­
es after every propagation or every propagation cycle 
(that is, ‘stability’).”10 The Board then ruled that as 
the hybrids in issue were not stable, they did not 
fall within the excluded category of plant varieties. 
TheEuropeanDirectiveontheLegalProtection 
of Biotechnological Inventions (the Directive) per­
mits the patentability of inventions concerning 
plants, where “the technical feasibility is not confined 
to a particular plant … variety.”11 Patent claims can 
therefore be made with respect to plant groupings, 
or as stated in Recital 31 to the Directive, 
Whereas a plant grouping which is character­
ized by a particular gene (and not its whole genome) 
is not covered by the protection of new varieties and 
is not excluded from patentability even if it com­
prises new varieties of plants. 
This qualification was addressed by the 
Technical Board of Appeal in Novartis/Transgenic 
Plant.12 The application concerned a patent 
containing claims to transgenic plants compris­
ing in their genomes specific foreign genes, the 
expression of which resulted in the production 
of antipathologically active substances, and to 
methods of preparing such plants. The EPO had 
denied registration. The denial was supported by 
the Technical Board of Appeal on the ground that 
Article 53(b) denied the patentability of an in­
vention that could embrace plant varieties. 
In its decision in December 1999, the 
Enlarged Board of Appeal indicated that it would 
favor the application because, in substance, it 
did not involve an application for a plant variety. 
This determination contains some useful guid­
ance on the legal definition of plant varieties. The 
Enlarged Board of Appeal noted that the defini­
tions of plant variety in the UPOV Convention 
and the Council of the European Union (EU) 
Regulation on Community Plant Variety Rights 
refer to “the entire constitution of a plant or a set of 
genetic information,” whereas a plant defined by 
a single recombinant DNA sequence “is not an 
individual plant grouping to which an entire con­
stitution can be attributed.” The Enlarged Board 
observed that the claimed transgenic plants in the 
application were defined by certain characteristics 
that allowed the plants to inhibit the growth of 
plant pathogens. No claim was made for anything 
resembling a plant variety. The board noted that 
in the case of PBRs, an applicant had to develop 
a plant group, fulfilling in particular the require­
ments of homogeneity and stability, whereas in 
the case of a typical genetic engineering inven­
tion, a tool was provided whereby a desired char­
acteristic could be bestowed on plants by insert­
ing a gene into the genome of a specific plant. 
The board observed that the development of spe­
cific varieties was not necessarily the objective of 
inventors involved in genetic engineering. 
.2 Patentability outside of Europe 
Outside of Europe the prohibition against the 
patenting of plant varieties is absent. In the 
United States, for example, the Federal Circuit 
resolved any potential conflict between patent 
protection and protection under the Plant Variety 
Protection Act in its decision in Pioneer Hi-Bred 
0 | HANDBOOK OF BEST PRACTICES 
         
 
      
      
       
     
       
     
     
       
     
       
      
     
        
      
       




      
      
      
     
      
 
	 	 	 	
       
        
        
      
        
       
     
      
        
        
     
        
      
       
        
     
    
      
      
CHAPTER . 
International Inc. v. J.E.M. Ag Supply Inc.13 The 
defendants objected that Pioneer had obtained 
both patent protection and certificates of protec­
tion under the Plant Variety Protection Act for 
the same seed-produced varieties of corn. The de­
fendants argued that the enactment of the Plant 
Variety Protection Act had removed seed-pro­
duced plants from the realm of patentable subject 
matter in the Patents Act. The Federal Circuit 
rejected this argument noting that the Supreme 
Court held that “when two statutes are capable of 
coexistence, it is the duty of the courts ... to regard 
each as effective.” 
The patenting of plant varieties in Canada 
was upheld by the recent Canadian Federal 
Court of Appeal case of Monsanto Canada v. 
Schmeiser.14 This case concerned the cultivation 
by a farmer of canola that contained chime­
ric genes conferring tolerance to glyphosphate 
herbicides. Monsanto had patented the canola 
and had marketed these genes in its product 
Roundup® Ready Canola. Schmeiser had cul­
tivated canola derived from plants on his land 
that he claimed had developed the tolerance 
from wind-borne genetic pollination. The trial 
court found that cultivation of a plant was not 
an infringement of patented genes contained in 
that plant; however, the majority of the Federal 
Court of Appeal agreed with Monsanto that this 
was infringing use. 
Counsel for Schmeiser raised the moral ques­
tion of whether it was right to manipulate genes 
in order to obtain better weed control or higher 
yields. The Federal Court of Appeal ruled that his 
was a question for the parliament to consider and 
that the court’s job was to “interpret the Patents 
Act as it stands.”15 The majority explained that, 
“Under the present Act, an invention in the domain 
of agriculture is as deserving of protection as an in­
vention in the domain of mechanical science. Where 
Parliament has not seen fit to distinguish between 
inventions concerning plants or other inventions, 
neither should the courts.”16 
As the minority judge pointed out that 
the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) of the 
World Trade Organization (WTO), in Article 
27.2(b), permits the exclusion of plants from 
patentability but that plant varieties might be 
patented. The Novartis determination, among 
others, argues that the addition or modification 
of genetic material to confer disease resistance is 
not the creation of a new plant variety. If the view 
of the majority in Schmeiser that the patenting of 
a cell confers exclusive patent rights over a plant 
in which that cell is included, then the Article 
27.2(b) exception becomes meaningless. 
The Joint Communication of the African 
Group to the TRIPS Council17 suggested that 
Article 29 of the TRIPS Agreement seemed to 
be the most suitable for an appropriate modifi­
cation to deal with the issue of patenting plant 
variety rights, by including the requirements for 
equity, disclosure of the community of origin of 
the genetic resources and traditional knowledge, 
and demonstration of compliance with applicable 
domestic procedures. Thus the Group suggested 
that Article 29 be modified by adding the follow­
ing as paragraph 3: 
Members shall require an applicant for a pat­
ent to disclose the country and area of origin of any 
biological resources and traditional knowledge used 
or involved in the invention, and to provide confir­
mation of compliance with all access regulations in 
the country of origin. 
. IP and the research exemption 
Plant breeders have tended to stress the necessity 
of being able to freely access genetic material, in­
cluding that which is IP protected. This is why 
the UPOV Convention contains a broad breeders’ 
exemption. Patent law tends to have a much nar­
rower research exemption, and it is often limited 
to noncommercial scientific or experimental use. 
The narrowness of the research exception in 
patents law is illustrated by the recent U.S. deci­
sion in Madey v. Duke University,18 which held that 
a university that undertook commercial research 
contracts could not avail itself of the defense. The 
ambit of the experimental research exception in 
patents law in the United Kingdom was examined 
in Monsanto v. Stauffer.19 In that case, Stauffer had 
developed a market variant, called Touchdown®, 
of Monsanto’s successful patented weed-killer 
Roundup® for which Stauffer had obtained provi­
sional clearance from relevant authorities. In order 
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BlAKENEY 
to obtain final clearances, Stauffer had established 
tests at its own research farm and also organized 
a series of tests outside the farm, where interested 
parties could observe the results. Monsanto moved 
for an interlocutory injunction, on the grounds 
of patent infringement, which was granted by the 
patents court, negating the ground that tests done 
outside the research farm to check the product 
in different soil and climatic conditions amounts 
to an experimental use. The Court of Appeal, 
although it agreed that tests done outside could 
not qualify for an experimental-use exception, ex­
empted all trials carried out at Stauffer’s research 
farm and at laboratories and greenhouses in the 
United Kingdom. The Court limited the inter­
pretation of the word experimental in accordance 
with the size, scale, recipient, and methodology of 
the experiment. This case has raised uncertainty 
as to how far university researchers can apply the 
experimental-use exception to agricultural field 
trials.20 
Another illustration of the relative narrow­
ness of the experimental-use exception in patents 
law, compared with PVP laws, is that while a 
protected plant variety is covered by a single ti­
tle, plant-related biotechnological inventions are 
likely to be protected by a patent and, in some 
cases, several patents. The patents may cover not 
just plants, but also seeds, genes, and DNA se­
quences. The effect of patents is to restrict access 
to the patented “products.” It has been argued 
that “locking up” genetic resources with patents 
is a bad thing because innovation in plant breed­
ing is cumulative and depends on being able to 
use as wide a stock of material as is possible. The 
International Treaty on Plant Genetic Resources 
for Food and Agriculture (the Treaty) introduced 
a number of provisions to deal with this concern. 
The provisions are laid out below. 
Apart from patents, the restrictions on access 
to breeding material may have causes other than 
IPRs. For one thing, some countries have cho­
sen to provide exception for certain categories of 
plant genetic resources they consider to be stra­
tegically important from the Multilateral System 
to be set up under the Treaty. Also, some devel­
oping countries have been exercising their rights 
under the Convention on Biological Diversity 
(CBD), administered under the United Nations 
Environment Programme (UNEP), to regulate 
access to their genetic resources, and in doing so 
have restricted the free flow of those resources. 
This practice may well be detrimental to those 
countries and others, in terms of long-term food 
security.21 
But beyond the issues of how specific IP 
rights privatize genetic material needed for 
breeding is the association of IP rights with the 
privatization of agricultural research, the shrink­
age of nonproprietary public sector research, 
and the increased concentration of ownership 
of breeding material, research tools, and tech­
nologies in the hands of a small number of giant 
corporations.22 Not only does this privatization 
trend toward greater restriction on access reduce 
the free circulation of breeding material, but it 
can also make public policy aimed at enhancing 
food security harder to put into practice. This is 
true because it is much more difficult for gov­
ernments to influence companies than the public 
institutions they partly or wholly fund. 
. 	 Ethical issues relating to the 
patentability of life-forms 
There is a substantial body of literature on the 
ethical implications of permitting the propertiza­
tion of the “building blocks of life” or at least to 
“reduce the value of life and nature to the merely 
economic.” The Joint Communication of the 
African Group to the TRIPS Council on tak­
ing forward the review of Article 27.3(b) of the 
TRIPS Agreement,23 stated that patents on life­
forms were unethical and “contrary to the moral 
and cultural norms of many societies in Members 
of the WTO.” The Joint Communication invoked 
the exception in Article 27.2 for protecting ordre 
public and morality as justification for outlawing 
patents on life-forms. 
An important question for which empirical 
work is required concerns the impact of oligop­
olization in the biotechnology market on the 
capacity of international institutions to provide 
public goods to developing countries in the ag­
ricultural sector. The proprietization of enabling 
technologies, as well as genetic resources, raises 
concerns about the capacity of the public agri­
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cultural research system to fulfill its public-good 
mission in contributing to the elimination of food 
insecurity. As Drahos observed, “in biotechnology 
and agriculture, it is likely that much research will 
end up as an international rather than public good 
and that it will be distributed according to complex 
licensing structures.”24 
In addition to the possible adverse impacts 
this market concentration might have upon the 
vigor of competition, the market dominance of 
these private corporations also has an important 
influence upon the sort of biotechnological re­
search that is undertaken. For example, to what 
extent will the dominance of private corporations 
in biomedical and agricultural research direct that 
research toward northern concerns and away from 
southern health problems25 and southern food 
priorities?26 Will the owners of IP rights in key en­
abling technologies make them available to public 
research institutions on affordable terms?27 
Article 27.2 of the TRIPS Agreement per­
mits members to disallow the exploitation of in­
ventions “which is necessary to protect ordre public 
or morality, including to protect human or plant life 
or health or to avoid serious prejudice to the environ­
ment… .” Member states would have to show that 
the commercial exploitation of the specific inven­
tion would be contrary to ordre public or moral­
ity. In light of the interpretation and application 
of the equivalent provision within the European 
Patent Convention, and recently reinforced in the 
Directive, it is unlikely that this exception would 
permit a general exclusion of living material from 
patentability. It is also questionable whether pat­
ent offices are the proper bodies to adjudicate 
the application of moral and ethical issues to the 
patent system.28 In any event, the patent offices 
have abstained from exercising moral judgments 
in this area. Thus, for example, in Greenpeace v. 
Plant Genetic Systems NV,29 in an opposition to 
an application for a patent directed to transgenic 
plants engineered to be resistant to the herbicide 
Basta®, Greenpeace argued that it was immoral, 
and therefore in breach of Article 53(a) of the 
European Patent Convention, to “own” plants 
that were the common heritage of humankind. 
The Appeal Board of the EPO sustained the 
Examination Division’s view that it was not the 
proper forum for discussing the advantages and 
disadvantages of genetic engineering. Similarly, in 
Novartis/Transgenic Plants30 the Extended Board 
of Appeal of the EPO considered the debate over 
genetic engineering to be too controversial for the 
board to sustain Greenpeace’s opposition to the 
patent. The Extended Board of Appeal noted that 
the Directive was an indication that the European 
Parliament considered there to be some benefit in 
genetic engineering. 
5.	 PVP, PlANT GENETIC RESOuRCES, AND
THE TRIPS AGREEMENT 
Access to the plant genetic resources of a country 
is governed by an evolving composite of national 
legislation pursuant to CBD, TRIPS, UPOV, and 
the Treaty. 
The interrelationship between these instru­
ments has been addressed by the Council onTRIPS 
pursuant to its review of Article 27.3(b), which 
commenced in 1999. At a March 2001 meeting of 
the Council on TRIPS, the chairman set out a list 
of key issues that had arisen in the review of Article 
27.3(b) (IP/C/M/26). These included: 
•	 technical issues relating to patent and PVP 
under Article 27.3(b) 
•	 technical issues relating to the sui generis 
protection of plant varieties 
•	 the relationship to the conservation and 
sustainable use of genetic material 
•	 the relationship with the concepts of tradi­
tional knowledge and farmers’ rights 
Article 27.3(b) of the TRIPS Agreement per­
mits the exclusion from patentability of : 
plants and animals, other than microorganisms, 
and essentially biological processes for the production 
of plants and animals, other than nonbiological and 
microbiological processes. However, Members shall 
provide for the protection of plant varieties either by 
patents or by an effective sui generis system or by any 
combination thereof. 
However, Article 27.3(b) provides no guid­
ance on what is meant by effective, the debate in 
the TRIPS Council having focused upon which 
sui generis systems satisfy the obligation. A sui 
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generis option in the IP context is usually taken to 
refer to a specially coined IP right, outside of the 
traditional categories of IP protection. UPOV has 
advanced its system as the principal workable ex­
ample of a sui generis PVP system. It is interesting 
to note that the drafters of the TRIPS Agreement, 
who felt free to import into the agreement provi­
sions from other named international instruments, 
such as the Paris, Berne, and Rome conventions 
and the Washington Treaty on Integrated Circuits, 
desisted from specifically importing provisions 
from the UPOV Convention in the area of plant 
varieties. 
The failure of the drafters of TRIPS to define 
what was meant by sui generis leaves considerable 
scope for nations in the range of legislation that 
they may implement in compliance with this pro­
vision. One option is to include the benefit-shar­
ing and informed-consent provisions of the CBD 
in a UPOV-style statute. A problem with doing so 
is that although the CBD provisions would apply 
in the countries that introduce them, they will not 
apply in countries that do not introduce them. In 
the countries that do introduce the provisions and 
also adopt an approach based on UPOV 1991 or 
patents, there is no guarantee of benefit sharing and 
informed consent, or even of the right to save seed. 
TheDohaMinisterialDeclarationofNovember 
2001, in Clause 19, provided: 
We instruct the Council for TRIPS, in pursuing 
its work programme including under the review of 
Article 27.3(b), the review of the implementation of 
theTRIPS Agreement under Article 71.1 and the work 
foreseen pursuant to paragraph 12 of this Declaration, 
to examine, inter alia, the relationship between the 
TRIPS Agreement and the Convention on Biological 
Diversity, the protection of traditional knowledge and 
folklore, and other relevant new developments raised 
by Members pursuant to Article 71.1. In undertaking 
this work, the TRIPS Council shall be guided by the 
objectives and principles set out in Articles 7 and 8 of 
the TRIPS Agreement and shall take fully into account 
the development dimension. 
.1	 Technical issues relating to patent 
and PVP under Article 27.3(b) 
The following technical issues are suggested by 
the terminology of Article 27.3(b): 
•	 What is a patentable invention for the pur­
poses of Article 27.3(b)? 
•	 What are microorganisms for the purposes 
of Article 27.2? 
•	 What are plant varieties for the purposes of 
Article 27.3(b)? 
•	 Should there be a research exception in re­
lation to patents over plant material? 
.1.1	 What is a patentable invention? 
IP law attempts to draw a distinction between 
inventions and discoveries. The latter are not 
protectable. This distinction may be made in the 
relevant legislation. For example, European laws 
based on the Directive, which specifically provides 
in Article 3.2 that “Biological material which is iso­
lated from its natural environment or produced by 
means of a technical process may be the subject of an 
invention even if it previously occurred in nature.” 
Of course, it is equally open to a court or a 
legislature to rule or provide that genetic material 
is not patentable, even in its isolated or purified 
form, on the grounds that it is a mere discovery. 
Indeed, nothing in the TRIPS Agreement obliges 
countries to deem the isolation of genetic mate­
rials to be inventions. A number of developing 
countries exclude the patentability of genetic 
materials (Mexico), or of materials existing in na­
ture (Argentina, Brazil, and the Andean Group 
Decision 486). 
.1.2	 What are microorganisms for the 
purposes of Article 27.3(b)? 
Article 27.3(b) permits WTO Members to ex­
clude from patent protection plants, animals, and 
essentially biological processes for the production 
of plants and animals. Members are specifically 
not permitted to exclude from patent protection 
microorganisms and nonbiological and micro­
biological processes. The language used in Article 
27.3(b) implies that a clear distinction can be 
made between plants and animals on the one 
hand and microorganisms on the other. However, 
there is no commonly accepted definition of mi­
croorganism, either in science or in patent office 
practice. The lack of any definition permits great 
variations between members in practicing this 
exclusion. 
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The practice of patent offices in developed 
countries suggests that there is no perceived need 
for a definition: the key issue for protection being 
not its subject matter, but whether or not the in­
vention meets the patent-granting criteria. 
An invention involving biological material 
will be regarded as lacking an inventive step if 
it: (1) merely identifies the biological material; 
and/or (2) merely identifies the natural function 
of the biological material. An invention will dem­
onstrate an inventive step if it takes the form of a 
significant technical application of an identified 
function of the biological material. This technical 
application must go beyond a mere simple rep­
lication of the natural function of the biological 
material, and the technical application must rep­
resent a significant technical advance on the prior 
art. What about processes and uses? 
An invention involving biological material 
will be regarded as being capable of industrial ap­
plication if it can be shown that the invention is 
capable of being used in a manner that provides a 
demonstrable public benefit. Public benefit means 
that the invention must be capable of being used 
in a manner conducive to public health and to 
social, environmental, and economic welfare. 
.1. 	 What is a plant variety for the 
purposes of Article 27.3(b)? 
As noted above, a crucial issue in the establishment 
of a sui generis regime would be the definition of 
the protected subject matter. Article 27.3(b) of 
the TRIPS Agreement requires the protection of 
“plant varieties,” but does not provide (as in the 
case of inventions) a definition thereof. Therefore, 
national laws have ample room to determine what 
is to be deemed a plant variety for the purposes of 
protection. Which are the possible definitions? 
The law may require certain characteristics for a 
protected variety that may not be essential for a 
scientific definition. 
.2	 Technical issues relating to the sui generis 
protection of plant varieties. 
Article 27.3(b) provides no guidance on what 
is meant by effective, the debate in the TRIPS 
Council having focused upon which sui generis 
systems satisfy the obligation. 
Sui generis systems are generally defined as 
those that fall outside of the traditional categories 
of IP protection and are created to deal with a 
unique category of creativity. The UPOV system 
has been urged by the industrialized group of 
countries as the principal workable example of a 
sui generis PVP system. In excess of 50 states have 
acceded to the UPOV Convention. 
Developing countries in the TRIPS Council 
have argued that the TRIPS Agreement is in ten­
sion with the CBD, particularly with the provi­
sions in the latter convention concerned with 
informed consent to biological materials and eq­
uitable benefit sharing following access. 
A communication to the WTO from Kenya, 
on behalf of the African Group, to assist the prep­
arations for the 1999 Ministerial Conference, 
suggested that: 
“After the sentence on plant variety protection 
in Article 27.3(b), a footnote should be inserted stat­
ing that any sui generis law for plant variety protec­
tion can provide for: 
(i) the protection of the innovations of indig­
enous and local farming communities in 
developing countries, consistent with the 
Convention on Biological Diversity and 
the International Undertaking on Plant 
Genetic Resources; 
(ii) the continuation of the traditional farming 
practices including the right to use, exchange 
and save seeds, and sell their harvest; 
(iii) preventing anti-competitive rights or prac­
tices which will threaten food sovereignty of 
people in developing countries, as is permit­
ted by Article 31 of the TRIPS Agreement. 
This African proposal is reflected, in part, in 
clause 19 of the Doha Ministerial Declaration of 
November 2001 mentioned above. 
In order to help countries devise an ap­
propriate sui generis system, the International 
Plant Genetic Resources Institute (IPGRI, now 
Bioversity International) came up with a list of 
key questions that decision makers should take 
into account.31 These are as follows: 
•	 What kind of domestic seed industry exists? 
•	 What kind of public breeding sector 
exists? 
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•	 What kind of seed supply system is in 
place? 
•	 To what extent is farm-saved seed used in 
the country? 
•	 What is the current capacity of breeders? 
•	 What do local breeders want to do in the 
next 5–10 years? 
•	 Are external inputs to agriculture low or 
high? 
•	 What are the country’s production needs 
and objectives? 
•	 What is the country’s biotechnology 
capacity? 
•	 What are the goals and realistic expecta­
tions of the biotechnology sector? 
•	 What kinds of strategic alliances will the 
country want to enter into in the next 5–10 
years and how involved will other countries 
be? 
The fact that the answers to these questions 
will vary widely from one country to another sug­
gests that, as with patents, one size is unlikely to 
fit all. 
6. THE INTERNATIONAl TREATy 
ON PlANT GENETIC RESOuRCES
FOR FOOD AND AGRICulTuRE 
Plant genetic resources for food and agriculture 
(PGRFA) were freely exchanged by the inter­
national agricultural research institutes of the 
Consultative Group on International Agricultural 
Research (CGIAR), as well as by their national 
counterparts, on the basis that they were “the com­
mon heritage of humankind.” This principle was 
embodied in the International Undertaking on 
Plant Genetic Resources for Food and Agriculture 
(the Undertaking) adopted by the Food and 
Agriculture (FAO) Conference in 1983. The 
Undertaking was adopted as a nonbinding con­
ference resolution. In subsequent years the prin­
ciple of free exchange was gradually narrowed 
by the impact of IP rights upon agriculture. In 
November 1989, the 25th Session of the FAO 
Conference adopted two resolutions providing an 
“agreed interpretation” that plant breeders’ rights 
were not incompatible with the Undertaking. The 
acknowledgment of plant variety rights obviously 
benefited industrialized countries that were active 
in seed production. In exchange for this conces­
sion, developing countries won endorsement of 
the concept of farmers’ rights. A further resolu­
tion in 1991 recognized the sovereign rights of na­
tions over their own genetic resources. Agenda 21, 
promulgated at the Rio Earth Summit in 1992 
called for the strengthening of the FAO Global 
System on Plant Genetic Resources. Resolution 3 
of the Final Act to the CBD noted that the ac­
cess to ex situ germplasm collections, such as 
those maintained by the CGIAR, and the realiza­
tion of farmers’ rights were the province of the 
Undertaking. The 1993 FAO Conference called 
on member states to harmonize the Undertaking 
with the CBD. Negotiations for revision of the 
Undertaking to take account of both the CBD and 
the TRIPS Agreement commenced in November 
1994 and were consummated with the adoption 
of the Undertaking as the Treaty. 
.1 	 The main objectives and innovations 
of the Treaty 
The objectives of the Treaty are stated in Article 1 
to be “the conservation and sustainable use of plant 
genetic resources for food and agriculture and the 
fair and equitable sharing of the benefits arising out 
of their use, in harmony with the Convention on 
Biological Diversity, for sustainable agriculture and 
food security.” 
Article 4 of the Treaty requires signatories 
“where appropriate” to “promote an integrated ap­
proach to the exploration, conservation and sustain­
able use of plant genetic resources for food and ag­
riculture.” Article 10.2 contains the agreement of 
the Contracting Parties to “establish a multilateral 
system, which is efficient, effective and transparent, 
both to facilitate access to [PGRFA] and to share, in 
a fair and equitable way, the benefits arising from 
the utilisation of these resources, on a complemen­
tary and mutually reinforcing basis.” Facilitated ac­
cess to PGRFA is to be provided in accordance 
with the conditions prescribed in Article 12.3. 
Paragraph (d) of this provision provides that the 
recipients “shall not claim any intellectual property 
or other rights that limit the facilitated access” to 
PGRFA, or their “genetic parts or components,” in 
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the form received from the Multilateral System. 
This, of course, does not prevent IP rights being 
claimed in relation to germplasm that is modified 
by the recipient. 
Article 13.1 recognizes that benefits accruing 
from facilitated access to PGRFA shall be shared 
fairly and equitably under this Article. Article 13.2 
envisages that this sharing of benefits includes 
the exchange of technical information, access to 
technology, capacity building, and the sharing of 
monetary benefits from commercialization. 
Article 28 provides that the Treaty would en­
ter into force 90 days after accession by 40 coun­
tries. Until that date, the Undertaking would 
remain operative. Having acquired the necessary 
accessions in March 2004, the Treaty entered into 
force in June 2004. 
The establishment of the Multilateral System 
was the principal innovation introduced by the 
Treaty. This asserts the primacy of national sov­
ereignty over biological resources, but, in fact, 
imposes limitations on countries on their ability 
to restrict access to other states. Facilitated access 
has to be provided to the crops, listed in Annex I, 
that account for a significant part of human nu­
trition. Member states are obliged to make avail­
able all passport data and, subject to applicable 
law, any other associated nonconfidential descrip­
tive information. In relation to material that is 
under development by farmers or breeders at the 
time when access is requested, the Treaty gives the 
country of origin the right to delay access dur­
ing the period of development. Two compromises 
were necessary to secure this right of access: first 
is the limitation imposed by Article 12 upon re­
cipients seeking IP rights in material obtained 
under the Treaty; second is the right of donors 
to receive some form of benefit sharing. Benefit-
sharing mechanisms under the Treaty include the 
exchange of information, access to and transfer of 
technology, capacity building, and the sharing of 
benefits arising from commercialization. 
The CGIAR Centres signed agreements with 
the FAO in 1994, placing the acquisitions to 
their germplasm collections after that date under 
the trusteeship of the FAO. Under the Treaty, 
new agreements were invited to determine that 
the access provisions of the Treaty would govern 
the Centres’ germplasm collections that fell with­
in Annex I list that were collected after the entry 
into force of the Treaty. 
.2 Farmers’ rights and food security 
Article 9 of the Treaty implements the proposal 
that was developed under the Undertaking for 
the recognition of farmers’ rights. The policy 
behind this recognition is stated in Article 9.1, 
namely that: 
The Contracting Parties recognize the enormous 
contribution that the local and indigenous com­
munities and farmers of all regions of the world, 
particularly those in the centres of origin and crop 
diversity, have made and will continue to make for 
the conservation and development of plant genetic 
resources which constitute the basis of food and agri­
culture production throughout the world. 
The principal contribution of traditional farm­
ers to agrobiodiversity has been their conserva­
tion of landraces, which are crop varieties that are 
primitive cultivars, developed by local farmers to 
deal with the local climate and diseases and to ca­
ter to local tastes and food-preparation practices.32 
This development may involve the interbreeding 
of locally occurring undomesticated plants with 
cultivated plants, as well as the exchange of differ­
ent genotypes among farmers and farms.33 
. Traditional knowledge and food security 
A significant contribution has been made by the 
knowledge of indigenous peoples and traditional 
farmers in the development of new crop types 
and biodiversity conservation. These groups have 
been an important agency in the conservation of 
plant genetic resources and the transmission of 
these resources to seed companies, plant breeders, 
and research institutions. The contributors have 
not typically been paid for the value they have 
delivered, whereas breeders and seed companies 
have resorted to IP rights to recover their devel­
opment expenditures. 
The economic value of biological diversity 
conserved by traditional farmers for agriculture 
is difficult to quantify. It has recently been sug­
gested that “the value of farmers’ varieties is not 
directly dependent on their current use in conven-
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tional breeding, since the gene flow from landraces 
to privately marketed cultivars of major crops is very 
modest”34 because “conventional breeding increas­
ingly focuses on crosses among elite materials from 
the breeders own collections and advanced lines de­
veloped in public institutions.” On the other hand, 
those collections and advanced breeding lines are 
often originally derived from germplasm contrib­
uted by traditional groups. 
An increasingly significant economic value of 
biodiversity is the extent to which it provides a 
reservoir of species available for domestication, as 
well as genetic resources available for the enhance­
ment of already domesticated species. The mod­
ern biotechnological revolution has enabled the 
engineering of desirable genetic traits from useful 
local species. It is estimated that about 6.5% of 
all genetic research undertaken in agriculture is 
focused upon germplasm derived from wild spe­
cies and landraces.35 
Traditional knowledge is particularly im­
portant in the development of farming systems 
adapted to local conditions and farming prac­
tices. This may enable the utilization of marginal 
lands, contributing to food security by enabling 
access to food in remote areas, as well as contrib­
uting to the management of the environment by 
preventing erosion, maintaining soil fertility, and 
maintaining agricultural biodiversity. 
Farmers in subsistence systems have tended to 
utilize a diverse selection of crop species in order 
to assure their annual harvests and thus to guaran­
tee a minimal level of production and to prevent 
food shortage. Seed production in many instances 
has been on the collection of and domestication 
of locally known wild varieties. Modern agricul­
tural practices depend on crop species that pro­
mote productivity and resistance to disease that 
can only be maintained with the continuous input 
of new germplasm. The diversity of landraces and 
the associated information on their specific quali­
ties contribute invaluable information to formal 
breeding processes. It has been noted that the loss 
of biological diversity is paralleled by the loss of 
traditional knowledge. Where a plant variety be­
comes extinct, then the entire body of knowledge 
about its properties is condemned to irrelevancy. 
An assumption of Article 9.1 is that the land-
races used by traditional farmers are a dynamic 
genetic reservoir for the development of new vari­
eties and for the transmission of desirable genetic 
traits. The traditional knowledge of local and in­
digenous communities is similarly perceived. As a 
means of remunerating these groups for their past 
contributions to the development of plant genet­
ic resources for food and agriculture production, 
there can be little argument, except about the 
quantum and distribution of this remuneration. 
Inevitably, any calculation of the equitable 
share that traditional farmers and indigenous 
communities might enjoy under a farmers’ rights 
or traditional knowledge regime will be arbitrary. 
However, the IP system is no stranger to arbitrary 
calculations, thus the 20-year length of a patent 
term is intended to provide an opportunity for 
the compensation of all inventors, whatever the 
area of technology. Similarly the 25-year exclu­
sivity, which the UPOV Convention provides for 
new varieties of trees and vines, takes no account 
of variations in R&D costs between the different 
varieties. 
The principal ways in which plant genetic re­
sources are translated into food and agriculture 
production is through plant breeding and plant 
patenting. Standing at the heart of a farmers’ 
rights regime is the concept of equitable benefit- 
sharing with farmers for their contribution to 
innovations in plant breeding and plant patent­
ing. It is estimated that about 6.5% of all genetic 
research undertaken in agriculture is focused 
upon germplasm derived from wild species and 
landraces.36 
Article 9.2 of the Treaty envisages that “the 
responsibility for realizing Farmers’ Rights, as they 
relate to Plant Genetic Resources for Food and 
Agriculture, rests with national governments” and 
that national legislation should include measures 
relating to: 
•	 protection of traditional knowledge rele­
vant to plant genetic resources for food and 
agriculture 
•	 the right to equitably participate in sharing 
benefits arising from the utilization of plant 
genetic resources for food and agriculture 
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•	 the right to participate in making deci­
sions, at the national level, on matters re­
lated to the conservation and sustainable 
use of plant genetic resources for food and 
agriculture 
Article 9.2 obliges the Contracting Parties to 
the Treaty “to take measures,” subject to their na­
tional legislation to protect and promote farmers’ 
rights. The content of these rights is defined in the 
balance of that provision and embraces the pro­
tection of traditional knowledge, equitable benefit 
sharing, and the right to participate in decision 
making. The Treaty leaves open the legal context 
within which farmers’ rights are to be enacted. 
Finally, Article 9.3 provides that the Article 
shall not be interpreted “to limit any rights that 
farmers have to save, use, exchange, and sell farm-
saved seed/propagating material.” 
National legislation on farmers’ rights tends 
to combine one of the versions of UPOV with 
some of the access principles of the CBD. The 
African Model Legislation for the Protection of 
the Rights of Local Communities, Farmers and 
Breeders, and for the Regulation of Access to 
Biological Resources, which was adopted by the 
Organization of African Unity (OAU), Heads of 
States Summit at Ouagadougou in June 1998, 
adopts a sui generis regime based on UPOV 1991. 
However, most national statutes prefer access leg­
islation combined with UPOV 1978 (for example, 
the Andean Community’s Common System on 
Access to Genetic Resources, 1996; Costa Rica’s 
Biodiversity Law of 1998; India’s Community 
Intellectual Property Rights Act of 1999; Kenya’s 
Seeds and Plant Varieties Act of 1975). 
7.	 ASSESSMENT OF THE RElATIONSHIP
BETWEEN IP AND FOOD SECuRITy 
The role of IP in eliminating food insecurity 
has to be placed in its proper policy perspective. 
Development experience over the last 50 years 
attributes rural poverty and food insecurity in 
developing countries to development strategies 
that overlooked the importance of the develop­
ment of the agricultural sector, particularly the 
production of staple foods.37 Thus the enhance­
ment of food security in developing countries re­
quires a package of policies that address the sup­
ply, distribution and consumption aspects of the 
food chain. The FAO has noted that the policy 
options that are available to poor countries are 
constrained by a number of factors including: (1) 
limited resources for public spending programs; 
(2) the dilemma between remunerative prices for 
producers and prices that a large number of poor 
households can afford, thus making the option 
of border protection less attractive despite high 
bound tariffs; (c) major constraints on foreign 
exchange availability leading to pressure to boost 
production of export crops.38 
Where IP could make its greatest contribu­
tion is in the incentivization of beneficial agri­
cultural innovations. Historically, the strongest 
incentives have been those arising from the mar­
keting of hybrid seeds that provide higher yields, 
with the commercial benefit to the seed marketer 
that the seeds of the offspring cannot be used by 
the farmer because these seeds do not breed true­
to-type. As is discussed above, the evidence for 
incentives to breeding research for crop plants 
is limited—in developing countries even more 
so—whether PVP and patenting will be useful in 
encouraging a national seed industry. Barton sug­
gests that a developing country “is probably best-
off adopting minimum compliance with TRIPS, 
which requires at least some form of sui generis pro­
tection for plants—although there is the possibility 
that a number of nations with similar agricultural 
conditions could combine their markets in some way 
that encouraged private investment. Moreover, use 
of UPOV-style laws might help in commercializing 
varieties developed by the public sector.”39 
The question of whether a developing coun­
try will adopt a sui generis PVP system or a pat­
ent-based system, to comply with Article 27.3(b) 
of the TRIPS Agreement will depend upon the 
technological sophistication of agricultural re­
search in that country. n 
MICHAEL BLAkENEy, Director, Queen Mary Intellectual 
Property Research Institute, Center for Commercial Law 
Studies, University of London, 13-14 Charterhouse Square, 
London, EC1M 6AX, U.K. m.blakeney@qmul.ac.uk 
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ABSTRACT 
The last decades have seen a revolution in knowledge 
management, library services, and information resource 
database configurations. The use of integrated computer 
networks and the ability to produce and distribute infor­
mation have had far-reaching implications for IP (intel­
lectual property) protection. In order to demonstrate IP 
laws and their application, this chapter will use, as its 
primary example, Geographic Information Systems and 
Remote Sensing (GIS/RS), a technology that presents in­
teresting and complex IP issues. 
1.	 InTRoduCTIon 
The management of databases and library vol­
umes is becoming increasingly complex. In many 
organizations, library staff are responsible for the 
storage and retrieval of information, as well as the 
development of new books or articles. Library 
staff face ever-increasing challenges regarding the 
intellectual protection (IP) rights that apply to 
these various materials. 
IP is a term that refers to creations of the 
mind: inventions; literary and artistic works; 
and symbols, names, images, and designs used in 
commerce. U.S. law allows for various sorts of IP 
protection. 
Much of this chapter focuses on a technol­
ogy that creates a unique IP management chal­
lenge: Geographic Information Systems (GIS) 
and Remote Sensing (RS). GIS/RS is a particu­
larly interesting example of intellectual property 
because it combines and interfaces a series of dif­
ferent component parts: hardware, software, and 
other protectable components (including maps, 
survey data, aerial photographs, information from 
land records, and so on). Each of these compo­
nents may carry its own IP protections and restric­
tions through various licenses. As a result, the final 
product will also have various IP protections and 
restrictions attached to it. In other words, GIS/ 
RS systems are affected by IP issues in relation to 
databases and software, as well as in relation to 
the technologies that create entirely novel sets of 
data. These are not always straightforward: for one 
thing, many different intellectual property and li­
censing terms appear to have overlapping mean­
ings. Box 1 at the end of this chapter provides a 
list of the most common technical and legal terms 
encountered in the context of data, databases, 
GIS, and software. 
In almost all countries, various forms of IP 
protection are available for the protection of data 
and data-related products. These are copyrights, 
trademarks and trade secrets. Thus: 
•	 Symbols, names, and images used in com­
merce can be protected by trademarks. 
•	 Creative works can be protected by 
copyrights. 
Dodds J, S Somersalo, SP Kowalski and A Krattiger. 2007. IP and Information Management: Libraries, Databases, Geograph-
ic Information Systems, and Software. In Intellectual Property Management in Health and Agricultural Innovation: A Hand-
book of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available 
online at www.ipHandbook.org. 
© 2007. J Dodds, et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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•	 Information can be protected by keeping it 
a trade secret. 
GIS/RS is protected by copyrights and trade­
marks and, to some extent, trade secrets. 
2.	 CopyRIGHT	And THE	 puBLIC	 doMAIn 
A copyright protects an original work and allows 
the author the exclusive right to: 
•	 reproduce the work exclusively 
•	 prepare derivative works 
•	 distribute copies by sale, transfer of owner­
ship, lease, renting, or lending 
•	 perform the work publicly 
•	 display the work 
Generally, the types of works that are pro­
tected by copyright are: literary works; musical 
works (including accompanying words); dramat­
ic works; pantomimes and choreographic works; 
pictorial, graphic, and sculptural works; motion 
pictures and other audiovisual works; sound re­
cordings; and architectural works. 
2.1 Public domain 
Works in public domain are not protected by 
copyright and are publicly available. They may 
be used by anyone, anywhere, any time, without 
permission or license. A work may enter into the 
public domain if its term of copyright protection 
has expired. In the United States, works of the 
U.S. government are all in public domain (Title 
17 U.S.C. § 105); they cannot be protected by 
copyrights. However, U.S. government employees 
may produce copyrighted work not created during 
the course of their official duties. If U.S. govern­
ment works are disseminated in foreign countries, 
such works may be copyrighted to the extent al­
lowed by the domestic laws of those countries. 
It is very important to note that authors are 
not required to give notice that their work is 
copyrighted. Therefore, it is the responsibility of 
the potential user to determine whether or not a 
work is in public domain. This may become an 
issue for example in a case where a private work 
has been included in a government publication 
by permission of its author. Under U.S. law, such 
private work is not in the public domain, and 
therefore one using the government publication 
may still need permission, or license, to use such 
private portions of the publication. 
2.2 Fair use exemption 
Section 107 of the U.S. Copyright Act states that 
an author’s original creation is subject to “fair 
use”: that is, the work can be used in special cases 
without permission for purposes of criticism, 
comment, news reporting, teaching, scholarship, 
or research. This exemption is one of the most 
important copyright limitations. De facto fair use 
should never be assumed. Fair use is determined 
on a case-by-case basis, taking into consideration 
the purpose and character of the use, the nature 
of the copyrighted work, the amount and sub­
stantiality of the portion of the work used in re­
lation to the work as a whole, and the potential 
effect of the use on marketing and distribution of 
the work.
2. Copyright registration 
Copyright is automatically granted at the creation 
of a work. Registration of the copyright with the 
U.S. Copyright Office is not necessary, but a copy­
right cannot be enforced, or damages collected for 
improper use, unless it is registered. Currently, the 
cost for registering a copyright is $30. 
2. Copyright duration 
In the United States, a work that is created and 
fixed in tangible form for the first time on or after 
1 January 1978, is automatically protected from 
the moment of its creation for the lifetime of the 
author, plus an additional 70 years after the au­
thor’s death. In case of a joint work, the term lasts 
for 70 years after the last surviving author’s death. 
For works made for hire, and for anonymous 
works, the duration of copyright is 95 years from 
publication or 120 years from creation, whichever 
is shorter. A work that was copyright registered or 
published with a copyright notice before 1 January 
1978 can be protected at most for 95 years from 
the date of securing. 
It is important to note that duration of copy­
right varies somewhat from country to coun­
try. In European Union member countries the 
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CHAPTER . 
copyright, generally speaking, protects the work 
for the lifetime of the author plus 70 years. In 
Japan the protection is generally lifetime plus 50 
years. In Mexico the protection is lifetime plus 
100 years. 
2. First sale doctrine 
The first sale doctrine, codified at 17 U.S.C. 109, 
limits the rights of copyright holders to control 
the distribution and display of copies of their 
works. The owner of a particular copy is entitled 
to “sell or otherwise dispose of the possession of 
that copy” and to “display the copy publicly ... to 
viewers present at the place where the copy is lo­
cated.” Therefore, the first sale doctrine gives the 
copyright owner the right to control only the first 
sale of the work. The owner of a lawfully made 
copy may in turn dispose of it by any means. The 
first sale doctrine is the legal basis for public li­
braries, which lend copies that they have previ­
ously purchased. The first sale doctrine does not, 
however, allow anyone except the copyright own­
er to make more copies. The Digital Millennium 
Copyright Act of 1998 authorizes the creation of 
digital copies for archival and preservation pur­
poses nonprofit libraries and archives. The right 
to distribute such copies requires authorization 
from the copyright owner. 
2. Copyright ownership 
Generally speaking, the author of a work owns its 
copyright. In case of work for hire, the employer 
is considered to be the author and the owner of 
the copyright. 
In the case of GIS/RS, if all work (including 
aerial photography and geographical data entry) 
is completed by the employees of a company 
under the terms of their employment, then the 
work-for-hire requirements would be fulfilled 
and the company would own any relevant copy­
rights. It is important that companies have writ­
ten agreements (with appropriate work-for-hire 
language) with any independent contractors that 
they hire. 
If, at the time of creation, the authors in­
tend to combine their contributions into an 
inseparable or interdependent whole, the re­
sulting work is considered a joint work and the 
authors are considered joint copyright owners. 
Each copyright owner has an equal right to ex­
ploit her or his copyrights. A company can li­
cense or obtain an assignment for the copyright 
of the joint work from only one of the authors. 
If, on the other hand, at the time of creation the 
authors did not intend their works to be parts 
of an inseparable whole, the resulting work is 
considered a collective work and the authors are 
considered collective copyright owners. A col­
lective copyright owner only owns copyrights 
for the material that she or he added to the final 
product. 
2. Work for hire 
A work for hire is defined in copyright law as 
that which is prepared by an employee within the 
scope of his or her employment, or a work spe­
cially ordered or commissioned for use as a con­
tribution to a collective work, a part of a motion 
picture or other audiovisual work, a translation, a 
supplementary work, a compilation, an instruc­
tional text, a test or the answer key to a test, or an 
atlas. The parties must expressly agree by signing 
a written instrument that the work shall be con­
sidered a work made for hire. 
In academic environments, the terms of em­
ployment typically require inventors to assign ex 
ante their patentable inventions (but not neces­
sarily their copyrightable works) to the univer­
sity. If a company hires consultants who are also 
academics, it is important that their consultancy 
contracts explicitly state that the contracting in­
stitution owns all work done by the consultant. 
The following is an example of such a clause: 
Property and Property Rights. Consultant 
agrees that any computer programs, software, 
documentation, copyrightable work, discover­
ies, inventions, or improvements developed by 
Consultant solely, or with others, resulting from 
the performance of Services pursuant to this 
Agreement, are the property of Contractor, and 
Consultant agrees to assign all rights therein to 
Contractor. Consultant agrees that the Services 
constitute a Work for Hire as such term is used 
and defined in the Copyright Act. This provision 
shall survive expiration and termination of this 
Agreement. 
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DODDS, SOMERSAlO, KOWAlSKI & KRATTIGER 
2. Assigning and licensing copyright 
The owner of copyright may transfer the copyright 
wholly or partially to another party. A transfer is 
usually done by an assignment or by licensing. 
With an assignment the copyright owner sells his 
or her rights to the assignee, while with a license 
the copyright owner retains the ownership but 
grants the licensee a right to use the copyright­
ed material according to the limitations in the 
agreement. 
It is important to realize here that copyright 
includes numerous rights (for example, a right to 
reproduce the work, a right to prepare derivative 
works, and a right to distribute copies). Therefore, 
the copyright owner can transfer the copyright via 
an assignment or a license partially or wholly. The 
copyright owner may, as well, transfer the copy­
right on an exclusive or a nonexclusive basis. The 
transfer of exclusive rights is not valid unless that 
transfer is in writing and signed by the owner of 
the rights. Transfer of a right on a nonexclusive 
basis does not require a written agreement. 
As an example, the author and copyright 
owner of a database, could transfer to a compa­
ny a right to copy and distribute the database. 
However, the author could also transfer a right 
for another company to make a derivative work 
using the database. Either of these rights granted 
could be exclusive or nonexclusive ones. Probably 
both of them would be made via a license. 
Works by the U. S. government, including 
maps, are not eligible for U. S. copyright protec­
tion. A map, in pictorial form, would not lose 
its copyright protection if its information were to 
be digitized and stored in an electronic database. 
However, a geographical information system 
whose data have never existed in a coherent pic­
torial form would be considered a compilation. 
2. Databases 
A compilation is only copyrightable if its facts 
have been selected, coordinated, or arranged in 
such a way that the resulting work, as a whole, 
constitutes an original work of authorship (joint 
work, see Section 2.6). Copyright is meant to 
reward originality, not effort. Therefore, not all 
databases are protectable under copyright law. 
An example of a compilation that did not have 
the requisite originality for being protectable un­
der the Copyright Act was a telephone catalog, for 
which the telephone company has simply selected 
names and arranged them in alphabetical order. 
Such a database is not original or creative and 
would not warrant protection.1 It is, however, 
important to note that there is no requirement of 
novelty; therefore, the data or information that is 
used for the compilation may well be known. The 
way to select, organize, and arrange the informa­
tion has, however, to amount to some minimal 
originality or creativity. 
Copyright Act Section 102(b) reads, in part: 
“in no case does copyright protection for an original 
work of authorship extend to any idea, procedure, 
process, system, method of operation, concept, prin­
ciple, or discovery, regardless of the form in which it is 
described, explained, illustrated, or embodied in such 
work.” This clause has been interpreted to mean 
that the individual data in a database are not pro­
tected under the Copyright Act. Therefore, even 
if a database may be copyrighted, a user may use 
data extracted from it. However, the original data/ 
images that were used to develop the new work 
must not be passed to any third party or used in 
a way inconsistent with the terms and conditions 
under which they were given. In order to prevent 
such use, the copyright owner usually includes 
preventing clauses into the licensing agreements. 
2.10 Maps 
Even if a map’s geographical features are not protect-
able by copyright law, the map may still be original 
enough to warrant copyright protection, depend­
ing on what information it includes, from which 
sources the information was collected, and how the 
information is represented in pictorial form. 
2.11 Photographic Images 
GIS/RS may use aerial photographs instead of 
maps. A photograph may be protectable under 
the Copyright Act if it exhibits a certain amount 
of uniqueness. The U.S. Court of Appeals, 11th 
Circuit, has stated that copyright law protects 
“the selection of lighting, shading, timing, angle 
and film” of a photograph.2 Copyright protection 
does not, however, extend to physical facts the 
photograph expresses. 
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Under U.S. law, spatial databases are granted 
fewer IP protections than even the most mun­
dane cloak-and-dagger international spy novel. 
Therefore, keeping the database a trade secret 
may be the best way to protect it. A generally 
accepted definition of trade secret appears in the 
1939 Restatement of Torts. The subject matter of 
a trade secret must be secret, and only known to 
those involved in the particular business in which 
it is used. Matters of public knowledge or of gen­
eral knowledge in an industry cannot be appro­
priated by anyone as his or her secret. Matters 
that are completely disclosed by marketed goods 
cannot be trade secrets, either. 
.	 Ip	 pRoTECTIon foR	SofTWARE 
.1 Protection 
A software program is potentially covered by two 
types of statutory IP protection:3 
•	 The software code is protected by copyright 
•	 The algorithm of the software, if original, is 
protectable in the United States (but not in 
most other countries) by patent 
Because software algorithms cannot be copy­
righted, it is possible for a third party to repro­
duce the flow and function of the software pro­
gram and (provided he or she did not derive the 
new code from the original code) legally use and 
sell the resulting software. 
Patents may offer better protection from 
competition, but they have several drawbacks: 
•	 Patents are expensive to file and prosecute 
(and software patents are often even more 
expensive than the average utility patent). 
Depending on the number of countries 
where patent protection is sought, the cost 
of a patent may amount anywhere from 
$10,000 and beyond. 
•	 The algorithm must be demonstrably 
original. 
•	 The patent laws of most countries do not 
cover software. 
•	 By the time the patent is issued, the pro­
gram may well have become obsolete. 
.2 Licensing 
Both copyrights and patents can be licensed for 
commercialization. Some software licenses in the 
United States are combined copyright-and-patent 
licenses. Generally, copyright-alone licenses for 
software are of limited value unless the program 
in question is very large and was developed over 
many years and is therefore difficult for a user to 
replicate. 
A number of different types of licenses are 
applicable to software: 
•	 end-use licenses. The licensee may use the 
software but not distribute it. These licenses 
are almost always nonexclusive. The licen­
sor may or may not provide a source code. 
•	 nonexclusive distribution licenses. The li­
censee may distribute the software, either as 
code or in hardware form (such as a semi­
conductor). The licensor usually provides a 
source code. 
•	 exclusive distribution licenses. The licensee 
will distribute the software to end-users and 
will also improve and support the software. 
The licensor always provides a source code. 
•	 open-source licensing. The software is 
provided free to users, usually over the 
Internet. There are many different forms 
of open-source licenses, each with different 
restrictions on use.4 Two of the most com­
mon are described below: 
•	 minimally restrictive. The licensee may 
use, improve, sell, and even establish pro­
prietary rights to any improvements he or 
she makes to the software, provided that he 
or she acknowledges the licensor’s owner­
ship of the copyright. 
•	 quite restrictive. The licensee may use and 
improve the software, but any improve­
ments or modifications to the software 
must be made available to other licensees 
under the same conditions. Any licenses 
the licensee grants to his or her improve­
ments must carry the same obligations and 
restrictions for the licensees; that is, the 
rights granted originally to the licensee who 
made improvements to the originally copy­
righted product has to flow through to the 
improved versions. 
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DODDS, SOMERSAlO, KOWAlSKI & KRATTIGER 
. Collaboratively developed software 
Software created for later distribution or com­
mercialization is a special case. Software programs 
often have a number of authors and frequently 
incorporate software that was written by third 
parties and obtained either formally (through 
license agreements or open-source licensing) or 
informally (such as through colleagues). 
Technology transfer offices should make sure 
ahead of time that they are legally able to license 
software programs, especially if they hope to 
grant exclusive licenses. In order to determine the 
legality of licensing, the following questions must 
be considered: 
•	 Does the potential licensor own the copy­
right for the primary software program? 
Are all authors obliged to assign their copy­
rights to the potential licensor? To ensure 
this, the potential licensor should: 
- have in place clear policies that delineate 
under which circumstances students and 
employees must assign their copyrights 
to the licensor 
-	 have written agreements with any other 
authors (such as consultants or students) 
that software produced under the con­
sulting arrangement will be assigned to 
the potential licensor 
•	 Is there any code in the program that was 
written by a third party? If so, the licensor 
should: 
- find out from whom or what the code 
was obtained and whether copyright per­
mission has been granted by this party; 
learn what restrictions, if any, have been 
imposed on making and/or distributing 
derivatives of the software that incorpo­
rate the original code 
-	 if the code was obtained from an open 
source, determine what type of open-
source license was involved and what 
restrictions have been imposed on the 
distribution of the code 
Technology transfer offices should take steps 
to educate creators of commercializable software 
about ownership issues. A lack of knowledge about 
IP rights may lead to an unmarketable product. 
The Uniform Computer Information 
Transaction Act (UCITA) standardizes the rules 
for licensing digital information, including soft­
ware. UCITA is, however, very controversial 
and at this point only two states (Virginia and 
Maryland) have implemented it. 
. Shrink-wrap and click-wrap licenses 
Shrink-wrap and click-wrap licenses are com­
mon in software licensing. Shrink-wrap licenses 
are enclosed in the plastic shrink-wrap packaging 
of software products; they inform the buyer that 
if he or she does not agree with the terms of the 
agreement, he or she should return the software 
and its packaging to the retailer. Click-wrap li­
censes appear on the screen before the software 
installation begins, and typically read: “Before 
downloading this software, you must read and agree 
to the following license terms and click the ‘I Agree’ 
button to accept.” In the United States, these types 
of licenses are enforceable. 
.	 InTERnATIonAL	ASpECTS 
Sometimes, data is obtained from multiple juris­
dictions, each with its own laws. IP protection 
for databases is stronger in Europe than it is in 
the United States. The European Union Database 
Directive, adopted by the European Parliament 
in 1996, grants two rights to the makers of 
databases: 
1. The right to prevent unauthorized use of 
the database 
2. The right to prevent unauthorized acts of 
extraction and reutilization of the contents 
of a database 
The first right, which is similar to that pro­
vided under the U.S. Copyright Act, protects da­
tabases that are sufficiently original in their selec­
tion or arrangement of data. This right does not, 
however, protect the data itself. 
The second right is a sui generis right that 
prohibits the extraction or reutilization of any 
database that has required a substantial effort 
to obtain, verify, or present. Under this second 
right, there is no requirement for creativity or 
originality. 
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A database is protected for 15 years from the 
date of its creation. If substantial changes are made 
to the content of the database, the modified data­
base will be protected for an additional 15 years. 
Protection under the directive is available only to 
nationals of member countries of the European 
Union. Other countries will obtain such protec­
tion only if they offer comparable protection to 
databases of European national and if a bilateral 
agreement is reached. 
.	 ConCLuSIonS	And TWo 
HypoTHETICAL	SITuATIonS 
Library and database management professionals 
are faced with a wide range of IP issues regarding 
who owns what and how and by whom various 
media can be used. There is no need to obtain 
permission to use a work if it is in public domain 
or if a license or agreement allows the intended 
use. Nor is it necessary to obtain permission to 
use facts from a copyrighted source, because the 
Copyright Act does not protect facts. However, 
charts, graphs, or figures that use these facts may 
be copyrighted. It is extremely important to know 
who the owner of a copyrighted work is: the po­
tential user needs to know whether it is a work 
for hire or a collective work. Also, it is important 
to carefully inspect the terms of any licensing 
agreement in order to determine what rights the 
licensee will have. In order to place these criti­
cal conclusions into perspective, Box 2 presents 
hypothetical examples of the various IP issues 
that emerge from library and database issues, and 
Box 3 offers examples from software development 
and use. n 
John dodds, Founder, Dodds & Associates, 1707 N Street 
NW, Washington, D.C., 20036, U.S.A. j.dodds@doddsas­
sociates.com 
susanne soMeRsalo, IP Specialist and Patent Agent, 
Dodds & Associates, 1707 N Street NW, Washington, DC, 
20036, U.S.A. s.somersalo@doddsassociates.com 
sTanley p. KowalsKi, The Franklin Pierce Law Center, 2 
White Street, Concord, NH, 03301, U.S.A. spk3@cornell. 
edu and skowalski@piercelaw.edu 
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute; and Adjunct Professor, 
Cornell University. PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu 
1	 Feist Publications Inc. v. Rural Telephone Service Com-
pany Inc. 499 U.S. 340 (1991) 
2	 See Leigh v. Warner Bros., Inc. 212 F.3d 1210,1215. [11th Cir.
2000] 
3	 This section is based on a text graciously supplied by 
Lita Nelsen, Director, M.I.T. Technology Licensing Office. 
4	 Further details on open-source licensing can be 
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DODDS, SOMERSAlO, KOWAlSKI & KRATTIGER 
Box 1: Common Technical and legal Terms Related to IP and Information 
author. either the person who creates a copyrightable work or the employer of the person who 
creates a copyrightable work as a work for hire (see Section 2.7) (The word author in copyright
law includes not only writers of novels, plays, and treatises, but also those who create computer 
programs, arrange data in telephone books, choreograph dances, take photographs, sculpt stone,
paint murals, write songs, record sounds, and translate books from one language to another.) 
book. a printed literary composition 
collective work. a work, such as an issue of a periodical, anthology, or encyclopedia, in which a 
number of contributions, each a separate and independent work in itself, are assembled into a 
collective whole 
compilation. as defined by Section 103 of the Copyright Act, “a work formed by the collection and 
assembling of preexisting material or of data that are selected, coordinated, or arranged in such a 
way that the resulting work as a whole constitutes an original work of authorship” 
copyright assignment. the giving away or selling, by the copyright owner, all rights to the 
copyright 
copyright license. a license by which an owner retains ownership to a copyright but allows 
another person to use or sell the copyrighted material under defined conditions (for example, for 
a certain purpose, for a certain period of time, or inside a limited geographical area) 
copyright. an intangible, incorporeal right granted by statute to the author (or originator, in the 
case of certain literary or artistic productions), whereby he or she is invested for a specified period 
of time with the sole and exclusive privilege of multiplying, publishing, and selling copies of the 
work 
creative works. works in which the content does not change, whether the work is in printed,
recorded, or electronic form (Materials such as books, sound recordings, downloadable songs,
downloadable ring tones, videocassettes, DVDs, audio CDs and films, are usually single creative 
works. Creative works that are serialized, that is, the mark identifies the entire work but the work is 
issued in sections or chapters, are also considered single creative works. A theatrical performance 
is also considered a single creative work, because the content of the play, musical, opera, or similar 
production does not significantly change from one performance to another.5) 
data. organized information often collected for a specific purpose and generally used as the basis 
for adjudication in case of litigation 
database or data bank. a computer-readable compilation of data and/or information, arranged 
for ease of search and retrieval 
design. the visual ornamental characteristics embodied in an article of manufacture 
electronic copy. a computer-readable copy of data or information 
facts. a statement or assertion of verified information about something that is the case or has 
happened (From a more legal perspective, a fact is an actual thing or happening [which must be 
proved at trial by presentation of evidence and which is evaluated by the finder of fact].) 
Geographical Information System (GIS). a computer system capable of assembling, storing,
manipulating, and displaying geographically referenced information 
image. a reproduction of the form of a person or object, especially a sculptured likeness (An image 
can be an original visual image or a copy of the original image; for example, it can be a digital 
image of a painting or a digital image made from a slide of the painting printed in a book.) 
joint work. collaboration between two or more authors in which their contributions are joined 
into a single cohesive work.
continued on next page 
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Box 1 (continued) 
patent license. an agreement between licensor and licensee allowing the licensee to practice the 
invention with agreed provisions while the licensor retains the ownership of the patent 
photograph. an image, especially a positive print, recorded by a camera and reproduced on a 
photosensitive surface 
public domain. the realm in which there are no laws that restrict a work from use by the public 
at large 
text. the body of a printed work, as distinct from headings and illustrative matter (on a page) or 
from front and back matter (in a book) 
trade secret. any valuable business information that is not generally known and is subject to 
reasonable efforts to preserve confidentiality 
transfer of copyright. the transfer of any or all of the copyright owner’s exclusive rights or any 
subdivision of those rights (Transfers of copyrights are normally made by contract; usually by a 
license or an assignment.) 
work. something that has been produced or accomplished through the effort, activity, or agency 
of a person 
work for hire/work made for hire. a work prepared by an employee within the scope of his or her 
employment or a commissioned work that all parties agree in writing to treat as work for hire 
(The real person, partnership, or corporation for which the work is prepared is considered to be 
both the author and the owner of copyright from the moment the work is created.) 
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DODDS, SOMERSAlO, KOWAlSKI & KRATTIGER 
Box 2: Hypothetical Example: library and Database Issues 
Let us imagine that a librarian is in the process of assembling a work that recounts and reflects 
upon a research institution’s 50-year history. In order to complete this project, the librarian will 
use various materials that may or may not carry IP restrictions: 
(A) photographic images stored in the institution’s archives for 20–50 years 
Although the organization has had physical custody of these images for as long as 50 years,
they are still protected by copyright.
(B) photographic images taken by staff members and donated to the library 
If the photos were taken in the course of the employee’s duties, they are the property of the 
institution. If taken outside of work, they may have been given to the institution with attached 
terms and conditions.
(C) photographic images of the institution taken by a commercial photographer 
The commercial photographer may have issued a use license to the institution, thereby 
preventing further use of the images.
(D) articles written by staff members, some of whom are now retired 
If the articles were written during the course of an employee’s duties, they are owned by 
the institution. If they were written after the employee’s retirement, the following questions 
should be asked: Did the employment or separation contracts assign copyright to one party 
or another? Is the information contained in the article based on knowledge that the author 
acquired while an employee? 
(E) a foreword written by a retired director general, who has been awarded a Nobel Prize 
The author owns copyright over the document and should sign a waiver or copyright
assignment document so that the material can be legally used. 
(F) reproduction of key research articles published by scientists in peer-reviewed journals 
It is very likely that the peer-reviewed journals requested and were granted the copyright over 
the authors’ material; the institution will therefore need permission from the owners of the 
journals to reproduce these articles. Such requests are almost always granted so long as there 
are no clear competition issues identified. 
(G) a text written by professional media consultants on the history of the institution 
The consultants should sign contracts indicating that all intellectual property developed 
during the term of the consultancy is property of the institution. 
(H) data (generated by the institution’s employees in cooperation with colleagues around the 
world) showing that the institution is still producing Nobel-Prize-quality data 
Care must be taken that the disclosure of data does not infringe on the IP rights of the 
scientists or their institutions. The terms of the agreement with the external scientists (there 
had better be one!) may also limit the institution’s data ownership and distribution rights. 
(I) a special 50-year anniversary logo 
The logo may be trademarked. 
In many cases, the most important IP protection is common sense. If the probability of a dispute 
over IP infringement is extremely low, the institution might choose to judiciously cut corners. 
The institution can, of course, seek protection for the final document, regardless of whether it is in 
print or electronic form. However, the IP protection of the final document must not infringe upon 
the IP ownership of its collective authors.
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CHAPTER . 
Box 3: Hypothetical Example: Software Issues 
Now,let us consider another example:a GIS/RS project to create maps that will assist in cultivating 
new plant varieties, conducted by an employee of a research university. In order to develop the 
project, the principal researcher has to deal with various types of materials, each with its own IP 
restrictions. 
(A) a soil map of country X (obtained from government X) 
The U.S. government does not, of course, have copyright on the maps it produces; this may 
or may not be the case for the IP laws of country X. It will be necessary to draw up a material 
transfer agreement (MTA) that delineates the specialist’s rights of use. The agreement might
include a reach-through clause that gives the government of country X rights over new 
materials created through the project. 
(B) a meteorological dataset (purchased from the Meteorological Office of country X) 
The principal researcher should check to make sure that there is no specific language in the 
license that would prohibit commercial use of the dataset (a research-only license) or restrict
its distribution. 
(C) photographic images of the area of interest (from a commercial source) 
As mentioned above, purchased materials almost always come with restrictions; see the 
previous paragraph. 
(D) information on the agricultural performance of a certain plant variety (obtained from an 
international development organization) 
Just because information comes from an international development organization does not
mean that it is not protected.The organization may require potential users of this information 
to sign a material transfer agreement.
(E) a topographical map of country X (obtained informally from a collaborating scientist) 
Informally shared information usually leads to IP conflicts. The employer of the collaborating 
scientist may have ownership rights to the map. If the employer is a U.S. university, it will 
probably protect its intellectual property and sell information only when it sees fit to do so.
There is also a chance that the government of country X has rights to the map.
(F) a software program bought by the principal researcher, using university grant money 
The software may have been licensed with an “educational use only” license 
(G) data collected in the field by the principal researcher 
Since the principal researcher is a university employee, the university may claim ownership 
over any data he or she collects.
(H) a data manipulation algorithm developed by the principal researcher during the course of his 
or her employment
As mentioned above, the university may claim ownership over the algorithm, since it was 
developed during the course of his or her duties as an employee of the university.
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CHARLES CLIFT, London, U.K. 
ABSTRACT 
The chapter discusses the meanings of data protection 
and data exclusivity in the context of the provisions of 
the Trade-Related Aspects of Intellectual Property Rights 
agreement. In addition, it outlines the relationship be­
tween data exclusivity and patent protection and briefly 
reviews the possible costs and benefits of introducing data 
exclusivity laws. Finally, the chapter explains that coun­
tries need to consider the costs and benefits when nego­
tiating bilateral trade agreements that might require the 
introduction of these laws. 
1. INTRODuCTION 
The development of a new drug or agrochemi­
cal, such as a pesticide, usually requires extensive 
testing, inside the laboratory or in the field, on 
animals, humans, plants, or the environment, de­
pending on the nature of the drug or chemical. 
The way in which these tests are undertaken are, 
at least in the later stages, governed by rules set by 
the regulatory authorities. These rules are designed 
to ensure the safety, quality, and efficacy of prod­
ucts being developed for use by humans or in the 
environment (in the case of agrochemicals). In the 
United States, for instance, this regulatory author­
ity is the Food and Drug Administration (FDA) for 
medicines and vaccines and is the Environmental 
Protection Agency (EPA) for agrochemicals. 
Meeting the requirements, which is nec­
essary for permission to place products on the 
market, involves a considerable cost. Studies on 
pharmaceutical industry data, albeit disputed by 
some, have suggested that the average total de­
velopment cost of a new drug is on the order of 
US$800 million, of which about 60% would be 
incurred in the conduct of trials (a substantial 
portion of these trials would be required for reg­
ulatory approval).1 In agrochemicals, it has been 
estimated that the average development cost is 
more than US$180 million.2 
Because of the size of the required investment 
in clinical test data, the pharmaceutical and ag­
rochemical industries argue that the use of such 
data by third parties (other than the regulatory 
authority) must be prevented. If the regulator, 
relying on test data provided by the originator 
company at great expense, allows an equivalent 
product to enter the market, originator compa­
nies would have no incentive to incur the heavy 
costs necessary to bring new products to market 
in the first place. In practical terms, a rule that 
prevents use of the data by a third party (or the 
regulator relying on that data to approve a third 
party’s generic product) also has the effect of pro­
viding exclusivity to the originator product. This 
is principally because the cost of replicating the 
investment in trials to satisfy regulatory require­
ments would be sufficiently prohibitive to deter 
a potential competitor. In the case of medicines, 
even if the cost were not prohibitive, there are 
also ethical concerns about repeating trials (that 
Clift C. 2007. Data Protection and Data Exclusivity in Pharmaceuticals and Agrochemicals. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. C Clift. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial 
purposes is permitted and encouraged. 
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ClIFT 
include an untreated control group) with a drug 
known to be efficacious. 
This chapter seeks to explain the quite com­
plicated issues related to data protection and data 
exclusivity and how they are treated in different 
jurisdictions. Particular consideration is given to 
the position of developing countries who are con­
templating, or being obliged to contemplate, data 
protection or exclusivity regimes. 
2. WHAT IS THE DIFFERENCE BETWEEN
DATA PROTECTION AND DATA
ExCluSIVITy? 
The modern debate about data protection and data 
exclusivity largely derives from differing interpre­
tations of what the agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) 
says on the subject. 
The relevant article (Article 39(3)) says: 
Members, when requiring, as a condition of 
approving the marketing of pharmaceutical or of 
agricultural chemical products which utilize new 
chemical entities, the submission of undisclosed test 
or other data, the origination of which involves a 
considerable effort, shall protect such data against 
unfair commercial use. In addition, Members shall 
protect such data against disclosure, except where 
necessary to protect the public, or unless steps are 
taken to ensure that the data are protected against 
unfair commercial use. 
There are unreconciled views on what this para­
graph, the subject of protracted discussion when 
the agreement was negotiated, means in practice. 
It is important to note that Article 39, as a 
whole, constitutes the section of the agreement 
“protection of undisclosed information” that re­
lates broadly to what are generally known as trade 
secrets. Article 39(2) is a general clause about 
World Trade Organization (WTO) members’ 
obligations with respect to trade secrets. Article 
39(3) covers such obligations in the particular 
case where such trade secret data are submitted 
to governments or government agencies as a pre­
condition for obtaining marketing approval. 
Article 39(3) essentially imposes three obli­
gations on governments: 
1. To protect data on new chemical entities, 
the collection of which involved consider­
able effort, against unfair commercial use 
2. To protect such data against disclosure, ex­
cept where necessary to protect the public 
3. To protect such data against disclosure, un­
less steps are taken to ensure that the data is 
protected against unfair commercial use 
The first obligation is simply about protect­
ing data submitted to regulatory agencies against 
unfair commercial use. No time limit is specified. 
Examples of unfair commercial use could include, 
for example, the government itself using the data 
for a commercial purpose or various kinds of dis­
honest commercial behavior. The World Intel­
lectual Property Organization (WIPO)3 provides 
a set of model provisions on protection against 
unfair competition. 
The second and third obligations concern 
protecting data against disclosure to third par­
ties, in the case of one or another exception. 
Although there is some lack of clarity, arising 
from the generality of the wording, about when 
disclosure would be justified by the exceptions 
(particularly in the third case), the essential 
point is that the obligation creates a presump­
tion that the regulatory authority would not dis­
close data, without due reason, to a third party. 
Again, no time limit is specified. The purpose of 
avoiding disclosure is to avoid unfair commer­
cial use. The third obligation implies, therefore, 
that disclosure is acceptable provided it can be 
ensured that disclosure will not lead to unfair 
commercial use. 
Most observers regard what is referred to in 
TRIPS Article 39 as “data protection,” dealing as 
it does with the protection of undisclosed infor­
mation or trade secrets. Article 39(3) does not 
create new property rights, nor a right to prevent 
reliance on the test data submitted by an origina­
tor for the marketing approval of an equivalent 
product by a third party, except where unfair 
commercial practices are involved. The article is 
an articulation of widely accepted legal precepts 
regarding trade secrets and unfair competition, 
not an invitation to create a new intellectual 
property right for test data. 
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CHAPTER . 
However, industry groups and some devel­
oped countries, for example, the United States 
and the European Union, have argued that Ar­
ticle 39(3) requires countries to create a regime 
of “data exclusivity,” a form of time-limited in­
tellectual property right. In the United States 
and countries in the European Union a data 
exclusivity regime for both medicines and ag­
rochemicals was adopted prior to the TRIPS 
agreement (for example, in 1984 in the United 
States and in 1987 in the European Union, for 
medicines). For a period of five years from mar­
keting approval of an originator product, no 
other company may seek regulatory approval in 
the United States of an equivalent product based 
on data submitted by the originator company 
without the latter’s approval. During the period 
of exclusivity, regulators cannot use (rely on) the 
originator’s data to approve a generic product, 
even if the product is demonstrated to be exactly 
equivalent in chemical composition and in its 
behavior within the body. 
The European Union now provides more ex­
tensive exclusivity, up to 10 years, for medicines. 
Unlike TRIPS provisions for data protection, 
data exclusivity regimes often extend beyond new 
chemical entities. For instance, in the United 
States only chemical entities never previously ap­
proved are entitled to exclusivity for a five-year 
period, but new uses or indications of an already 
approved entity are also entitled to exclusivity for 
three years. In the European Union, exclusivity 
is provided to new medicinal products, not just 
new chemical entities. Details of the European 
Union and United States regimes are described 
in Sanjuan.4 
In the United States, agrochemicals have 
been entitled to a ten-year exclusivity period; 
the period is five years for medicines. This dif­
ference exists because the act that introduced 
data exclusivity for medicines in 1984 (known as 
Hatch-Waxman) also introduced a provision al­
lowing for patent extensions of up to five years to 
compensate for the loss of patent life in meeting 
regulatory requirements (principally the time lost 
compiling the test data required by the FDA). 
Thus the term of data exclusivity for medicines 
was reduced as a trade-off. 
In addition, the United States provisions for 
agrochemicals allow for a further five years of ex­
clusivity during which the originator data may be 
relied on to approve a generic product, provided 
compensation for the use of the data is paid to 
the originator. 
In summary, a data exclusivity regime re­
lates to how long the regulatory agency may be 
prevented from relying on originator’s data to 
approve the products of potential generic com­
petitors. Data exclusivity does not relate to the 
question of disclosure to third parties and trade 
secrets dealt with in TRIPS Article 39(3) (and 
39(2)) in which no time limits are specified. 
3. DATA ExCluSIVITy AND PATENTS 
If the patent period has expired, or there is no 
patent on a product, data exclusivity will act in­
dependently to delay the entry of any generic 
companies wishing to enter the market until the 
period of data exclusivity is over. It should be not­
ed that in most cases the period of data exclusiv­
ity may have no material effect if it is within the 
patent period, because exclusivity is protected by 
the patent. 
However, the data exclusivity right is a 
much stronger right than a patent because, un­
like patent law, there are no exceptions or flex­
ibilities that allow governments to tailor the law 
to national circumstances. For example, there is 
no ability for governments to provide the equiv­
alent of a compulsory license, or data exclusivity 
may act as a barrier to compulsory licensing of a 
patent on the same product by preventing mar­
keting authorization for a compulsory licensee. 
Data exclusivity is attractive to originator com­
panies because unlike a patent, data exclusivity 
is automatic (rather like copyright). No fees are 
incurred for application or maintenance of the 
right, and there is more limited scope than ex­
ists in patent law for legal challenges, which are 
expensive to mount and to defend. For these 
reasons pharmaceutical companies are strong 
proponents of data exclusivity regimes. What­
ever the benefits, which depend on exclusivity 
extending beyond the patent term, the costs to 
these companies are very low. 
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ClIFT 
4. COSTS AND BENEFITS 
The claimed benefits of data exclusivity relate, to 
a great extent, to the additional incentives offered 
to companies in the long and expensive process 
of pharmaceutical R&D. Data exclusivity gives 
companies an incentive to extend the original use 
of the product (for example, to a wider popula­
tion, by age or geography, or in new indications 
for therapeutic use) where, for one reason or an­
other, no patent protection is available. Data ex­
clusivity provides an additional opportunity for 
originator companies to recoup their investments 
where marketing approval is given late in the pat­
ent life, so that the protection afforded extends 
beyond patent expiry. Experts argue that data 
exclusivity offers benefits to domestic innovators 
in developing countries, and, in particular, that it 
provides incentives for research to identify new 
uses for existing unpatented products and for 
originator companies to introduce products into 
developing countries, since, in effect, exclusivity 
would protect the companies from generic com­
petition. 
On the other hand, in developing countries 
where there is little or no innovative research ca­
pacity, the benefits of data exclusivity are likely to 
be limited. In those circumstances, data exclusivity 
would not promote R&D and the benefits to the 
companies themselves, and a potential addition 
to the R&D incentive, would be small because of 
the limited market potential in most developing 
countries. However, data exclusivity would allow 
additional periods of exclusivity for originator 
products, and it therefore would correspondingly 
delay the onset of generic competition. Specifical­
ly, exclusivity would preclude possible reductions 
in the cost of medicines in the developing country, 
keeping healthcare costs higher. 
Data exclusivity is likely to have the largest 
effect in countries where, for historical or other 
reasons, there are many products with no current 
patent protection that may gain rights to exclu­
sivity. For example, in many developing coun­
tries there are numerous medicines that are not 
patented (even if they are patented in developed 
countries). This is often the case in developing 
countries where TRIPS-based laws have only re­
cently been introduced (for example, India only 
introduced TRIPS-compliant laws in 2005 on 
the expiry of its transitional period allowed under 
TRIPS). In addition, even where there are pat­
ent laws, companies may not have considered 
the market sufficiently valuable to justify the ex­
pense and administrative cost of securing patents. 
In that case, the introduction of data exclusivity 
laws may bring into exclusivity drugs that would 
otherwise be open to generic competition. The 
perceived absence of strong patent protection 
in India, even after the law was revised in 2005, 
and the presence of a large number of products 
without patent protection due to the absence of 
product patent protection before 2005, is a major 
reason why the international pharmaceutical in­
dustry lobbied very hard for a strong data exclu­
sivity regime in India. By contrast, Indian com­
panies focusing principally on generics argued for 
a weaker data protection regime.5 
5. BIlATERAl TRADE AGREEMENTS 
Earlier drafts of the TRIPS agreement, which was 
in negotiation for nearly a decade before coming 
into force in 1995, contained, in addition to lan­
guage closely following the final form of Article 
39(3), text reflecting the U.S. five-year data ex­
clusivity regime, which had been enacted in 1984 
in the Hatch-Waxman Act. The North American 
Free Trade Agreement (NAFTA6), which was 
agreed in 1992, contained a close equivalent of 
Article 39(3) followed by a paragraph prevent­
ing the regulator from relying on the originator’s 
data for a reasonable period, normally meaning 
not less than five years. 
From the point of view of supporters of 
data exclusivity, the TRIPS agreement was, 
therefore, in this particular respect, something 
of a backward step. Although supporters of 
data exclusivity argued that exclusivity, taking 
account of the negotiating history, was what 
TRIPS Article 39(3) really meant, most observ­
ers have noted that the fact that a specific clause 
on data exclusivity along the lines of NAFTA 
was omitted from the final agreement indicated 
the opposite. If TRIPS had meant to sanction 
“data exclusivity,” it would have done so explic­
itly, as does NAFTA. 
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The United States in particular has sought, in 
post-TRIPS negotiations, to insert the language 
of NAFTA on data exclusivity, or even stronger 
provisions, in negotiating bilateral free-trade 
agreements with developing countries. Coun­
tries that have reached such agreements include 
Bahrain, Jordan, Morocco, Chile, the Dominican 
Republic, and the countries of Central America. 
Negotiations are ongoing with Thailand, Ecua­
dor, Peru, and Columbia. 
Most United States bilateral treaties involve 
agreement to the five-year rule as it is followed in 
the United States. In other cases, such as the Cen­
tral American Free Trade Agreement (CAFTA), 
approved in 2005, the five-year rule applies also to 
a product approved in another party to the agree-
ment—that is, marketing approval in Country A 
deters generic entry in country B for a period of 
five years. If the originator seeks marketing ap­
proval in Country B within five years, there will 
be an additional five years of data protection in 
Country B from the time of obtaining marketing 
approval, providing a maximum exclusivity of up 
to 10 years. CAFTA also obliges parties to pro­
vide extensions to the patent term on the grounds 
of unreasonable delays in granting a patent (for 
example, five years from filing) or unreasonable 
delays in procuring marketing approval. 
Developing countries need to consider the 
extent to which the demands for data exclusivity 
in bilateral trade agreements reflect the lobby­
ing of the pharmaceutical industry in developed 
countries, particularly the United States, where 
there are close and legally institutionalized links 
between the industry and negotiators, in partic­
ular through the Industry Trade Advisory Com­
mittee on Intellectual Property Rights (ITAC­
15). This Committee evaluates successive free 
trade agreements as to whether or not they meet 
the objectives of U.S. intellectual property-based 
industries. The committee’s objectives do not in­
clude consideration of what measures might be 
in the best interests of developing countries. 
6. CONCluSIONS 
This chapter has sought to explain the meaning 
of data protection and data exclusivity in the 
context of pharmaceuticals and agrochemicals. 
The protection of commercially valuable data 
held by governments is a duty of government, 
formalized in the TRIPS agreement, essentially 
to protect such data against unfair commercial 
use. Data exclusivity, by contrast, is a time-
bound form of intellectual property protection 
that seeks to allow companies to recoup the cost 
of investment in producing data required by the 
regulatory authority. The effect of data exclusiv­
ity is to prevent the entry of generic competitors, 
independent of the patent status of the product 
in question. The costs and benefits of data ex­
clusivity depend on the particular economic cir­
cumstances of countries. In developing countries 
with little innovative capacity, the benefits may 
be less obvious than the costs in terms of reduced 
competition in the market for medicines or ag­
rochemicals. These costs and benefits need to be 
considered in the context of bilateral trade agree­
ments, particularly with the United States, where 
data exclusivity is likely to be part of the package 
of intellectual property measures governments 
are asked to accept. n 
CHARLES CLIFT, 18 Parsons Green Lane, London, SW6 4HS, 
U.K. charlesclift@tiscali.co.uk 
1	 DiMasi J, Hansen R and Grabowski H. 2003. The Price 
of Innovation: New Estimates of Drug Development
Costs. Journal of Health Economics 22:151–185. 
2	 CropLife International. 2004. Position Paper: On the 
Protection of Safety and Efficacy Data for Existing and 
New Crop Protection Chemicals. CropLife International:
Brussels. www.croplife.org/librarypositionp.aspx?wt.
ti=Position%20papers. 
3	 WIPO. 1996. Model Provisions on Protection against
Unfair Competition. World Intellectual Property 
Organization: Geneva www.wipo.int/cfdiplaw/en/ 
trips/doc/unfair_competition.doc. 
4	 Sanjuan JR. 2006. U.S. and E.U. Protection of 
Pharmaceutical Test Data. Consumer Project on 
Technology: Washington, DC www.cptech.org/ 
publications/CPTechDPNo1TestData.pdf. 
5	 Satyanarayana K, S Srivastava and NK Ganguly. 2006.
Data Protection Issues in India. Indian Journal of 
Medical Research 123:723–726. medind.nic.in/iby/t06/
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Regulatory Data Protection in 

Pharmaceuticals and Other Sectors
 
TRevoR cooK, Partner, Bird & Bird, U.K. 
ABSTRACT 
Generating data to secure regulatory approval in sectors, 
such as pharmaceuticals and agricultural chemicals in 
which product safety and efficacy is paramount, has be­
come ever more extensive and expensive. There is thus 
a need to provide an incentive to undertake such data-
generation efforts by protecting the investment in them 
against free riding. Article 39.3 of the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS) 
recognizes as an intellectual property right the need for 
such protection in those sectors. This chapter discusses 
how certain jurisdictions, and in particular the European 
Community, have implemented the TRIPS requirement 
involving regulatory data protection regimes. Such protec­
tion is not provided by the patent system, which instead 
protects invention. 
1.	 InTRoduCTIon 
When a company or institution spends the time 
and money to demonstrate that a product is 
safe and efficacious, the investment pays off, in 
part, by protecting the data generated through 
this effort. This protection has become crucial in 
highly regulated sectors, such as pharmaceuticals 
and agricultural chemicals, where product safety 
and efficacy are paramount. The importance of 
protecting such data is reflected in their recogni­
tion by the Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS), Article 
39.3, as intellectual property (IP) rights. The need 
for such protection has arisen because the testing 
required to secure regulatory approvals has be­
come more extensive and expensive. Thus, greater 
incentives for undertaking such work are needed, 
especially since no other forms of protection may 
be available for a product that regulatory agencies 
have authorized for the market. 
The protection of data generated for regula­
tory purposes prevents direct or indirect use of the 
data filed in support of a marketing authorization 
by subsequent applicants seeking marketing au­
thorization for the same product. The protection 
applies unless the subsequent applicant has ob­
tained the consent of the party that first filed the 
data and obtained the original marketing authori­
zation. It is often uneconomic for subsequent ap­
plicants to generate their own data independently, 
so this exclusivity effectively confers a de facto
right in favor of the first applicant. However, the 
protection is for a limited time, so that subsequent 
applicants can use it after an appropriate period. 
This avoids the need for repetitive testing, which 
whether on animals or people, is undesirable both 
from economic and ethical points of view. 
2.	 REGuLAToRy 	dATA	pRoTECTIon
vERSuS	oTHER	foRMS	 
2.1	 How regulatory data protection differs 
from confidential information protection 
Although the protection of regulatory data has its 
origins in laws regulating confidential information 
Cook T. 2007. Regulatory Data Protection in Pharmaceuticals and Other Sectors. In Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Ox-
ford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. T Cook. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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(including trade secrets), and indeed is addressed 
in the same article of TRIPS that mandates the 
protection of confidential information, it is a 
separate right that requires separate analysis.1 The 
two types of IP right are different, and a balance 
between private and public interests struck in one 
should not affect how that balance is struck in the 
other. For example, while there would seem to 
be no compelling reason why the protection af­
forded to confidential information should ever be 
limited in duration, the term of regulatory data 
protection ought to be limited. 
Some experts might argue that there is no 
need for a separate legal regime to protect regula­
tory data because the data can be protected un­
der the law governing confidential information. 
Indeed, viewed from an English common law 
perspective, regulatory data is typically confiden­
tial in nature and is communicated to regulatory 
authorities with an obligation of confidence. 
However, trade secrets law has proved inadequate 
for protecting data filed with regulatory authori­
ties. First, the issue has not been about the disclo­
sure of data but about its use (although freedom 
of information considerations today make a lim­
ited measure of disclosures inevitable, which can 
undermine its confidential nature.) Second, it is 
unclear whether regulatory authorities in fact do 
“use” the data in a way that is subject to the law of 
confidential information, especially when officials 
merely rely on the existence of such data and do 
not actively refer to it. Third, even assuming that 
such reliance does constitute use, is there some 
“public policy” or “implied permission” defense 
that permits this use? 
On this third point the various Cimetidine
cases,2 each of which was decided effectively on 
public policy or implied-permission grounds, 
demonstrated the difficulties faced by those who 
file confidential regulatory data in the common 
law countries of England, Australia, and New 
Zealand. When regulators assessed in these cas­
es an application for approval of an equivalent 
medicinal product by a generic competitor, the 
original data filings could not be protected via 
traditional concepts of confidential information. 
The law of confidential information could not 
prevent the regulatory authority from referring 
to the originator’s file or from relying on the 
mere fact of the earlier authorization.3 Thus the 
decision of the House of Lords in the English 
Cimetidine case confirmed that the information 
was confidential and that a breach of confidenti­
ality would have occurred if the information had 
been disclosed to third parties or the informa­
tion used for purposes unrelated to the function 
of the regulatory authorities. But that was not 
the case. Instead, the regulatory authorities had 
been using the data to carry out the regulatory 
function. The legal decision went on to confirm 
that regulatory authorities have a right and duty 
to make use of such information. The court ob­
served that “the licensing authority should not be 
deterred from exercising its rights and powers so as 
to ensure public safety....” 
2.2 Regulatory data protection versus patents 
Some experts argue that the protection of innova­
tion in regulated areas, such as pharmaceuticals 
and agrochemicals, ought to be left to the patent 
system, and that no other system of protection 
is needed. This objection, however, fails to rec­
ognize that proving safety and efficacy for regu­
latory authorities is a very different matter from 
demonstrating that an invention is patentable. 
From a regulatory perspective, much of the re­
quired expenditure of time and money is directed 
to R&D that rarely yields patentable inventions. 
Indeed in some cases, patent protection for a 
product approved by regulatory authorities may 
be very weak or impossible to obtain, especial­
ly when the patent protection is not for a new 
chemical entity or other new active substance but 
is instead for a new physical form, new formu­
lation, new synthetic process, or new use of an 
old substance. Such “second generation” patents 
are at greater risk of successful attacks on their 
validity, because patent validity depends less on 
the work done to bring inventions to market, or 
to prove that inventions are safe and efficacious, 
than on the discovery of the invention in the first 
place. Such patent validity considerations are 
wholly unrelated to regulatory data protection, 
which may therefore provide the sole protection 
for a medicinal product. The ability of patents
to give only limited protection—and thus to 
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CHAPTER .10 
provide a limited incentive for completing the 
important work required to secure a marketing 
authorization—was recognized in the English 
patent case Merck & Co. Inc.’s Patents.4 Having 
found invalid certain patents for the medical uses 
of alendronate, a compound used to treat medi­
cal disorders of excess bone destruction, the trial 
judge observed: 
Accordingly I hold both patents invalid. I do 
so with some regret. Merck [has] only had a few 
years’ exclusive exploitation of alendronate. [The 
company] must surely have had to make a very con­
siderable investment and incurred considerable risk 
in bringing [the product] to market. And mankind 
is better off as a result. But the patent system does 
not confer monopolies on those who develop obvi­
ous or old products, even if they have never been 
exploited. A workable system for that might be a 
good idea, particularly in the field of medicine and 
analogous fields. 
The framework for such a workable system 
has existed for some time in the law of regulatory 
data protection, which in the United Kingdom 
provided longer effective protection than did 
the patents at issue in this case.5 However, the 
regulatory data protection system for medicinal 
products, at least in Europe and as mandated by 
Article 39.3 of TRIPS, provides for only limited 
compensation for the shortcomings of the patent 
system. This is because regulatory data protection 
is available only for data filed in support of a new 
active chemical and not (with one exception only 
recently introduced) for data filed in support of a 
new indication, new formulation, or new dosing 
schedule of an already-authorized active chemi­
cal. The exception, discussed further below, ex­
tends the total period of data protection for all 
uses of a medicinal product by one year, if one or 
more new therapeutic indications are authorized 
that are held to bring significant clinical benefits 
in comparison with existing therapies. To fail 
to protect data filed in support of a new indica­
tion, new formulation, or new dosing schedule 
of an already authorized active chemical has two 
baleful consequences. It not only discourages 
development work on existing medicinal prod­
ucts, but also encourages work on new medicinal 
products that may be no better in practice than 
those they replace. This robs from investments in 
public health since the “innovations” add no ben­
efit to the public but still require resources to be 
spent for new research and market authorization. 
Clearly, the pursuit of better IP protection in this 
case is a perverse incentive. A revised approach 
is needed, one that recognizes the differences 
between regulatory data protection and patents. 
In short, the former differs from patents in three 
ways: (1) its apparently shorter duration; (2) the 
lack of any need to comply with conventional 
concepts associated with patentability, such as 
novelty and obviousness; and (3) it protects only 
the regulated product. Table 1 lays out these dif­
ferences in more detail. 
Notwithstanding the fundamental con­
ceptual differences between the two systems of 
protection, some links between the systems have 
been created. The regime in the United States 
for granting authorizations for medicinal prod­
ucts (and as required to a degree, by many bilat­
eral trade agreements between the United States 
and third countries) provides that, when a pat­
ent protects a product, in most cases the term 
of regulatory data protection is extended for 30 
months or longer. In Europe, however, if there is 
no sample submission to the regulatory authori­
ties (which itself would constitute an infringing 
act under applicable patents in Europe), the mere 
application for a marketing authorization does 
not constitute an act of patent infringement. In 
fact, a marketing authorization may be granted 
to any party that complies with the applicable 
technical requirements without, thereby, infring­
ing any patent6. 
2. 	 Regulatory data protection versus 
other forms of marketing exclusivity 
Rights protecting regulatory data need to be dis­
tinguished from and contrasted with other types 
of marketing exclusivity conferred for other rea­
sons. Because both provide a form of market 
exclusivity, the distinctions are not always very 
clear. 
Internationally, one example of market ex­
clusivity that contrasts with regulatory data pro­
tection is the exclusive marketing rights conferred 
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under Article 70.9 of TRIPS for pharmaceuti­
cals and agricultural chemical products in those 
countries that did not provide full product patent 
protection for such chemicals when TRIPS came 
into force. 
Another type of marketing exclusivity is 
available in both Europe and the United States 
for orphan medicinal products. Because of their 
small potential market, these products require 
incentives for development over and above the 
norm. In a sense, the exclusivity for orphan 
medicinal products could be said to protect in­
directly the data submitted by the entity that 
secures the first such orphan-drug authoriza­
tion, but it goes much further. During the term 
of orphan-drug marketing exclusivity, a second 
applicant will not be able to obtain market au­
thorization even if it submits its own data. Thus 
orphan-product status does not simply protect 
regulatory data but confers true marketing 
exclusivity. 
As is to be expected for a right that has only 
recently been developed and is only now starting 
to be analyzed in detail, there was considerable 
international variation in the protection afforded 
to regulatory data. This was the case when the text 
of TRIPS was finalized in 1994 and it remains the 
case today in 2007. In consequence, Article 39.3 
leaves much latitude in relation to its national 
implementation (see Box 1). 
Table 1: Patents and Regulatory Data Protection Contrasted
 
Patent Data Protection 
Protects claimed compound and analogues, compound (and sometimes 
and/or uses, and/or formulations, formulation) which has an 
and/or synthetic processes authorization to market 
Prevents •	 manufacture, sale, use, or import grant to a subsequent
of a claimed product or the direct applicant of an authorization 
product of a claimed process to market based on 
originator’s data 
• use of a claimed process 
• indirect infringement 
Relevant excepted use - private and noncommercial use any use which does not
require an authorization to 
- use for purposes of securing market 
regulatory authorization 
- experimental use relating to the 
subject matter of the invention 
(outside the United States) 
Period of protection 20 years from application	 variable, but typically 
5–10 years from the first
authorization to market 
Requires patentability: novelty, inventive step, demonstration of safety and 
sufficiency, etc. efficacy 
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Box 1: Article 39.3 of TRIPS 
Propositions as to the scope of Article 39.3 TRIPS 
The importance of regulatory data protection and its international recognition as a sui generis 
type of intellectual property right are embodied in Article 39.3 of TRIPS.This embodiment, together 
with Article 39.1 and Article 39.2, (which are expressed in somewhat different terms and mandate 
the protection of confidential information) provides: 
1. In the course of ensuring effective protection against unfair competition as provided in 
Article 10 bis of the Paris Convention (1967), Members shall protect undisclosed information in 
accordance with paragraph 2 and data submitted to governments or government agencies in 
accordance with paragraph 3. 
2. Natural and legal persons shall have the possibility of preventing information lawfully within 
their control from being disclosed to, acquired by, or used by others without their consent in a 
manner contrary to honest commercial practices so long as such information: 
a) is secret in the sense that it is not, as a body or in the precise configuration and assembly 
of its components, generally known among or readily accessible to persons within the 
circles that normally dealt with the kind of information in question; 
b) has commercial value because it is secret; and 
c) has been subject to reasonable steps under the circumstances, by the person lawfully in 
control of the information, to keep it secret. 
Note: For the purpose of this provision, “a manner contrary to honest commercial practices” shall 
mean at a minimum practices such as breach of contract, breach of confidence, and inducement
to breach, and includes the acquisition of undisclosed information by third parties who know, or 
were grossly negligent in failing to know, that such practices were involved in the acquisition. 
3. Members, when requiring, as a condition of approving the marketing of 
pharmaceutical or of agricultural chemical products which utilise new chemical 
entities, the submission of undisclosed test or other data, the origination of which 
involves a considerable effort, shall protect such data against unfair commercial 
use. In addition, Members shall protect such data against disclosure, except where 
necessary to protect the public, or steps are taken to ensure that the data are 
protected against unfair commercial use. 
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To date, there have been no cases brought because in some regulatory systems the term 
under the WTO (World Trade Organization) new chemical entity is in practice limited to 
dispute-resolution mechanism in relation to “small molecules” (as opposed to the “large 
Article 39.3 to provide guidance. Nonetheless, molecules” that designate biotechnology 
the following propositions about the minimum products, such as therapeutic proteins, and 
thresholds of protection that it mandates can be are usually termed new active substances in 
advanced: such systems), the term ought to be regard­
• Article 39.3 addresses two issues: use of the ed as comprising new active substances. 
data in its first sentence and disclosure in the However, this does not mandate the pro-
second. However the data to be protected tection of new data, no matter how much 
are in each case the same. effort their origination has involved, for an 
old, or already authorized, chemical entity 
• In each case the data protected are required or active substance, although such protec­
“as a condition of approving the marketing tion ought to be regarded as desirable on 
of pharmaceutical or of agricultural chemi­ public policy grounds. 
cal products,” suggesting that this does not • In each case, the origination of the data 
require that data submitted for these prod- protected must “involve a considerable ef­
ucts for other purposes, or submitted as a fort.” This no doubt would cover safety and 
condition of approving the marketing of efficacy data, such as that generated in the 
other types of product, be protected. (The course of clinical trials for pharmaceuticals 
European Community, for example, also or field trials for agricultural chemicals, but 
provides for regulatory data protection in it leaves open the question of what other 
other fields, such as animal feedingstuffs data should also be protected on these 
and biocidal products but TRIPS does not grounds. 
recognize it). • In relation to prohibited use, the use must 
• In each case, the data protected are required be “unfair commercial use.” This expression 
“as a condition of approving the marketing of is not defined, but clearly excludes non­
… products which utilise new chemical enti­ commercial use, such as for public health 
ties.” The expression new chemical entity is and safety. As to commercial use, such as 
not defined. Thus this provision does not that made when a subsequent applicant re-
necessarily impose a patent standard of nov­ lies on the existence of such data (whether 
elty, and indeed it should not be expected or not actually referred to), or to be more 
that it do so, given the different nature of accurate, when the regulatory authority as-
the right. In any event, if one were to ap­ sesses the second applicant’s application in 
ply a patent standard of novelty, would this light of the data provided by the original 
be absolute (worldwide) or relative (local)? applicant, the issue is whether or not such 
TRIPS is silent on this issue with regard use is unfair. It is in this context that such 
to patents, and although over time there matters arise as the appropriate term of 
has been a trend to absolute novelty, it has protection and whether or not the protec­
by no means been universally adopted. It tion should be an exclusive right or merely 
should be noted that the term new chemical a remuneration right (and thus available for 
entity is widely used in a regulatory context. compulsory licensing). 
Accordingly, a new chemical entity could • In relation to disclosure, such data must 
be regarded as an active substance approved be protected except in two cases: where it 
for the first time within a particular regu­ is either “necessary to protect the public” or 
latory framework, since the same chemical where “steps are taken to ensure that the data 
may have activity within the context of dif­ are protected against unfair commercial use.” 
ferent regulatory frameworks. Moreover, Thus, in these two alternative cases there is 
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CHAPTER .10 
no absolute prohibition on the disclosure 
of such data. The first permitted exception, 
namely that of “[necessity] to protect the 
public” appears narrow in scope and should 
not properly be equated with transparency, 
which is the principle behind disclosures 
under freedom of information consider­
ations. Thus in relation to disclosures for 
purposes of transparency, TRIPS would 
appear to require that “steps [be] taken to 
ensure that the data are protected against 
unfair commercial use.” This would appear 
to require the regulatory authority not to 
treat information disclosed for such pur­
poses as detracting from the undisclosed 
nature of the underlying data. Indeed, in 
the European medicinal products regime, 
the Notice to Applicants expressly provides 
that the information set out in a European 
Public Assessment Report (EPAR) cannot 
be used to apply for a marketing authori­
zation for a medicinal product on a bib­
liographic or published data basis (see also 
Box 2 at the end of this chapter). 
The Background to and Negotiating
History of Article 39.3 TRIPS 
Before TRIPS came into force on 1 January 
1995, regulatory data was already protected 
throughout the European Community and in 
the United States by statutory provisions for 
both pharmaceuticals and agricultural chemicals. 
Since 1987, the member states of the European 
Community have provided protection for data 
filed in support of marketing authorizations for 
medicinal products, and since 1991 for data filed 
in support of marketing authorizations for plant 
protection products. Similarly since 1982, the 
United States has had its own regulatory data 
protection provisions for pesticides, and since 
1984, such provisions for medicines. Moreover, 
as discussed earlier, in both jurisdictions the case 
law had made plain the limitations of the law of 
confidential information as a means for protect­
ing regulatory data. 
Moreover, TRIPS was not the first multi­
national agreement to mandate that its Member 
States provide regulatory data protection. This 
honor fell to the North American Free Trade 
Agreement (NAFTA)7, paragraphs 5 through 7 of 
Article 1711 of which provide: 
5. If a Party requires, as a condition for ap­
proving the marketing of pharmaceutical 
or agricultural chemical products that uti­
lize new chemical entities, the submission 
of undisclosed test or other data necessary 
to determine whether the use of such prod­
ucts is safe and effective, the Party shall pro­
tect against disclosure of the data of persons 
making such submissions, where the origi­
nation of such data involves considerable 
effort, except where the disclosure is neces­
sary to protect the public or unless steps are 
taken to ensure that the data is protected 
against unfair commercial use. 
6. Each Party shall provide that for data sub­
ject to paragraph 5 that are submitted to 
the Party after the date of entry into force 
of this Agreement, no person other than the 
person that submitted them may, without 
the latter’s permission, rely on such data in 
support of an application for product ap­
proval during a reasonable period of time 
after their submission. For this purpose, a 
reasonable period shall normally mean not 
less than five years from the date on which 
the Party granted approval to the person 
that produced the data for approval to mar­
ket its product, taking account of the na­
ture of the data and the person’s efforts and 
expenditures in producing them. Subject to 
this provision, there shall be no limitation 
on any Party to implement abbreviated ap­
proval procedures for such products on the 
basis of bioequivalence and bioavailability 
studies. 
7. Where a Party relies on a marketing approv­
al granted by another Party, the reasonable 
period of exclusive use of the data submit­
ted in connection with obtaining the ap­
proval relied on shall begin with the date of 
the first marketing approval relied on. 
The “not less than five years” term of pro­
tection that the North American Free Trade 
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Agreement (NAFTA) accepts in Article 1711(6) 
as “reasonable” reflected, no doubt, the U.S. 
position regarding pharmaceuticals,8 but such 
a term is now widely regarded on the research-
based side of the pharmaceuticals industry as 
inadequate. However, the NAFTA formulation 
has a significant place in the history of regulatory 
data protection because it is the first to reflect the 
principles of regulatory data protection in treaty 
language and because its language parallels that 
found in TRIPS. 
.	 THE	 E.u. 	And 	u.S. IMpLEMEnTATIonS	 
of ARTICLE	 39.3 TRIpS 
.1 Background 
Although the obligations mandated under Article 
39.3 are generally expressed, it is instructive to 
consider how they have been implemented by the 
world’s two major trading blocks—the European 
Union and the United States—especially since it 
has become increasingly common for each to try 
to impose its own IP norms on trading partners 
through regional or bilateral trade agreements. 
.2 Pharmaceuticals 
A variety of national regulatory data protection 
regimes for pharmaceuticals have emerged. The 
regimes differ both in terms of the length of pro­
tection and the categories of data protected. For 
example, European Community Member States 
previously provided (depending on the coun­
try or the regulatory route followed) six or ten 
years protection for data filed in support of an 
authorization for a new pharmaceutical chemical 
entity, but none for data relating to a new indi­
cation for an already-authorized pharmaceutical. 
For new chemical entities authorized as phar­
maceuticals in the European Community after 
October 2005, second applicants may apply for 
a marketing authorization eight years after the 
first authorization is granted, but such authoriza­
tion cannot be granted less than ten years after 
the date of such first authorization.9 In each case 
the protection runs from the first authorization 
in the Community. Under the new system, the 
ten-year period is extended by a further year if 
authorization for a significant new indication for 
the pharmaceutical is secured before the eight-
year period expires. 
In the United States, a second applicant can­
not (assuming no patents cover the product) ap­
ply for such an authorization until five years af­
ter the first marketing authorization.10 Assuming 
a typical review period of 18 months, the result 
is a total effective protection period of six and a 
half years. However, the more usual situation is 
that the relevant regulatory authority (the U.S. 
Food and Drug Administration (FDA)) has been 
advised that one or more patents apply to the 
pharmaceutical in question, in which case the 
link between the regulatory regime and the pat­
ents regime comes into play (see section 2.2).11 
This link exists in the United States but not in the 
European Union. 
In the United States, a company wishing to 
market a generic version of a pharmaceutical by 
relying on the first applicant’s regulatory data 
must certify one of the following to the FDA: (1) 
no patent applies, (2) the relevant patent has ex­
pired, (3) approval is sought only after the patent 
expires; or (4) there is a patent but it is asserted to 
be invalid or not to be infringed. Once a generic 
manufacturer provides a certification that it con­
siders the patent to be invalid or not infringed (a 
“Paragraph IV Certification”), the manufacturer 
must notify the patentee, which then has an im­
mediate right to sue for patent infringement. A 
patent infringement action filed within 45 days of 
notice delays approval of the first generic authori­
zation for 30 months.12 The practical result of the 
linkage is thus to extend the effective regulatory-
data protection period by at least 30 months to 
seven and a half years, even when the Paragraph 
IV certification proves to be correct and the listed 
patent turns out to be either invalid or not in­
fringed. Thus at first sight the duration of protec­
tion in the United States for data filed in support 
of an authorization for a pharmaceutical as a new 
chemical entity may seem less than that afforded 
by the European Community. In practice howev­
er, the difference is much less, especially because 
of this patent linkage. 
Moreover, in the United States, data based 
on new clinical investigations (other than 
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bioavailability studies), relating to an already-au­
thorized product, that are essential to a further 
authorization (such as that required for a new in­
dication) are protected for three years. Although 
the protection for new data in support of a new 
indication for an old product is apparently more 
generous in the United States than in the European 
Community, which provides for an extension of 
only one year, it is important to appreciate that in 
the European Community the protection is ex­
tended for all indications and not just, as in the 
United States, for the new indication. 
. 	 Agricultural Chemical Products 
In general, the agricultural-data protection 
systems for authorizations in the European 
Community and the United States provides for 
a longer period of protection than for pharma­
ceuticals. They also give a considerably higher 
level of protection for new data used in relation 
to old active compounds than that mandated in 
the pharmaceutical systems. 
The system in the European Community, 
subject to special provisions for products already 
on the market when the system came into force, 
provides for ten years of Community-level pro­
tection for a new active compound.13 The system 
also provides ten years of protection at a national 
level (running from the first such authorization 
in the Community) for data filed in support of 
a formulated plant protection product contain­
ing an already authorized active compound. 
However, these periods of protection are subject 
to provisions intended to promote data regarding 
vertebrates to be shared, so that duplicate testing 
on animals can be avoided. Failing agreement on 
this issue, Member States are empowered to com­
pel sharing of such data, which typically involves 
arbitration over compensation. As a result of 
these compulsory licensing provisions, test data 
derived from vertebrate animals does not benefit 
from exclusivity. The conferred data protection 
can to this extent thus be seen as a remuneration 
right rather than an exclusive right. 
For pesticides, in the U.S. regulatory data for 
old and new products is protected for a ten-year 
period.14 For a further five-year period, others can 
use the data only when the would-be users have 
offered to compensate the first filer of the data (in 
the absence of agreement as to the level of com­
pensation, there are provisions for arbitration), 
but after this 15-year period there is no restric­
tion on use. Thus the protection for the last five 
years of the 15-year period of protection is not 
exclusivity but remuneration. 
. 	 Regulatory data protection in bilateral 
and regional trade agreements 
NAFTA is an example of a regional free trade 
agreement, but since the negotiation of TRIPS, 
both the United States and the European 
Community have entered into a number of bilat­
eral trade agreements with third countries. There 
have also been some regional trade agreements. 
Such agreements typically contain chapters ad­
dressing IP, including regulatory data protection. 
The approach of the European Community Trade 
Agreements, such as that with the Ukraine, is sim­
ply to require the trading partner to harmonize 
its laws with European Community standards. In 
contrast, the U.S. free trade agreements (FTAs) 
contain specific provisions to tighten up matters 
left vague by the TRIPS Agreement. Several FTAs 
are in force, including one with Australia. The 
texts of several others have been finalized, and ne­
gotiations are under way on a number of others.15 
The texts spell out the approach to be adopted 
in implementing the TRIPS standards. The obli­
gations, expressed as mutual obligations, usually 
require the other party to adopt at least some el­
ements of the U.S. implementation. This is the 
approach in the provisions concerning regulatory 
data protection. 
In most cases, the FTAs that the United 
States has negotiated specify minimum five-year 
periods of regulatory data protection for phar­
maceuticals and ten-year periods for agricultural 
chemicals. Some countries permit the granting 
of marketing approval based upon the existence 
of an approval for the same pharmaceuticals in 
another country. In some of these cases, the FTAs 
require the second country to protect the regula­
tory data filed in the first country for the same 
length of time as the first country does, or for 
an independent period.16 Protection is sometimes 
required for test data submitted in support not 
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only of authorizations for pharmaceutical prod­
ucts incorporating new chemical entities, but for 
any pharmaceutical product.17 In comparison, 
Europe offers such protection for new data filed 
in relation to an old active compound in a phar­
maceutical product only when such data is filed in 
support of one or more new indications that bring 
a significant clinical benefit. However, regulatory 
data protection in the European Community for 
data filed in support of an authorization of a new 
pharmaceutical chemical entity is longer than the 
minimum five years required under the FTAs. 
Several of the FTAs also require the parties to 
adopt the U.S. system for pharmaceutical prod­
ucts: the patent holder is notified of any attempt 
by a second applicant generic company to apply 
for a marketing authorization before patent ex­
piry.18 Indeed, in many cases, the regulatory au­
thority is prohibited from granting a marketing 
authorization before patent expiry.19 The impact 
of the FTA provisions requiring a link between 
marketing approval and patent protection, which 
is not mandated by TRIPS, depends very much 
upon the precise mechanism involved. Some 
mandate mere notification. Others mandate that 
no authorization be granted while patents con­
tinue in force, the effect of which is to increase 
considerably the effective period of protection. 
Moreover, unless they have an incentive to chal­
lenge patents in the form of their own brief pe­
riod of generic exclusivity as provided by the U.S 
system, they may be unlikely even to try, because 
all they will achieve is to clear the path for other 
generic competitors. 
.	 ConCLuSIonS 
Regulatory data protection provides an impor­
tant incentive for developing safe and efficacious 
pharmaceuticals and agricultural chemicals. It is 
an incentive that patents alone cannot provide. 
The obligations in TRIPS Article 39.3 concern­
ing the protection of regulatory data are broadly 
expressed and permit numerous flexibilities of 
implementation. However, the United States 
and the European Union, as the two major trad­
ing entities, have each developed specific imple­
mentations of these obligations, each with its 
own carefully crafted checks and balances. Each 
adopts a different approach to protecting regula­
tory data for pharmaceuticals and for agricultural 
chemicals. Each is also in the process of extending 
its specific approach to implementing these obli­
gations to some of its trading partners. They are 
doing this through trade agreements that specify 
the minimum standard of IP protection that the 
parties must afford. It is important, therefore, to 
be aware of the differences between the U.S. and 
European Community systems for protecting 
regulatory data for pharmaceuticals and agricul­
tural chemicals, the different checks and balances 
within such systems, and the reasons for and con­
sequences of such differences. Such differences 
make it dangerous to cherry-pick only certain 
aspects of such systems, or indeed to try to merge 
and harmonize their respective features into one 
system, for doing so is likely to result in an up­
ward harmonization that will produce a system of 
regulatory data protection that is more stringent 
than that provided by either system on its own. n 
TRevoR cooK, Partner, Bird & Bird, 15 Fetter Lane, 
London, EC4A 1JP, U.K. trevor.cook@twobirds.com 
1	 Article 39.2 TRIPS mandates the protection for confi-
dential information. There are, however, considerable 
disparities in the manner in which countries comply 
or enforce this protection (even within the European 
Community), in the remedies conferred (for example,
are they are enforced in the criminal or civil courts?),
and in the legal bases for such laws (are they contrac-
tual or, as tends to be the case in common law juris-
dictions, equitable? Or are they seen as a species of 
unfair competition, as tends to be the case in civil law 
countries?) 
2	 Smith Kline & French Laboratories Ltd. v Attorney
General FSR 418 (1989), In re Smith Kline & French 
Laboratories Ltd. 1 AC 64 (1990) (England), Smith Kline 
& French Laboratories (Australia) Ltd. v Secretary to 
the Department of Community Services and Health,
and Alphapharm Ltd. v Secretary to the Department
of Community Services and Health FSR 617 (1990),
relating respectively to New Zealand, England, and 
Australia. 
3	 Likewise in the United States, Ruckelshaus v Monsanto 
Co. (467 U.S. 986, 1019–20 (1984)) shows the reluctance 
of the courts to impose an unqualified restriction on 
regulatory authorities’ use of the data filed with them.
Ruckelhaus was analyzed extensively in the Australian 
Cimetidine case Alphapharm Ltd. v Secretary to the 
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CHAPTER .10 
Department of Community Services and Health [1990] 
FSR 617. 
4	 Merck & Co. Inc’s FSR, p. 498 (2003).
5	 However, one of the patents in issue in this case was for 
a new dosing schedule (seven days as opposed to one,
with a concomitant difference in dose), and neither 
the old regulatory data protection law in Europe, nor 
the current one that replaces it, protects new data in 
support of a new dosing schedule for an old active 
compound, as was confirmed under the old law in the 
unsuccessful challenge to the grant of a marketing 
authorization to a second applicant in The Queen on 
the application of Merck Sharp and Dohme Limited v 
The Licensing Authority (acting by the Medicines and 
Healthcare products Regulatory Agency, and Approved 
Prescription Services (U.K.) Ltd., Generics (U.K.) Ltd. and 
Arrow Generics Ltd. EWHC 710 (Admin, 2005) (Moses J,
28 June 2005). 
6	 The earlier regulatory data protection regime in Europe 
as introduced by the amendments made in 1987 by 
Directive 87/21/EEC to Directive 65/65/EEC allowed 
Member States the option not to confer regulatory 
data protection for medicinal product “after patent
expiry” and thus undermine the effect of regulatory 
data protection in such countries. However, although 
some countries, such as Denmark, initially availed 
themselves of this option, they rapidly abandoned 
it. The current regulatory data protection regime 
in Europe, which applies to active compounds the 
application for the first marketing authorization of 
which was made since November 2005, provides no 
such option. 
7	 NAFTA was signed on 12 August 1992 and entered into 
force (subject to transitional provisions) on 1 January 
1994. 
8	 Although, as observed in Section 3.2 where the 
pharmaceutical is the subject of a patent, this can in 
practice prove to be rather longer. 
9	 For specifics of the current European Community 
system for the regulatory data protection of medicinal 
products see Box 2 of this chapter.
10 See the Federal Food Drug and Cosmetic Act (21 U.S.C.
355), “New Drugs,” and in particular the amendments 
here introduced by the Drug Price Competition and 
Patent Term Restoration Act 1984 (Hatch-Waxman 
Act). 
11	 Such declarations are listed in the so-called Orange 
Book, the electronic version of which is available at
www.fda.gov/cder/ob/.
12	 There is an exception to this in the unlikely event that
a final judgment disposes of the patent in less than 30 
months. The U.S. system also provides an incentive to 
be the first applicant to file a Paragraph IV Certification:
no other such applicant can go to market until 180 
days after the first applicant to file such a certification 
goes itself to market or disposes of the patent in a final 
judgment.
13	 See Articles 13 and 14 of Directive 91/414/EC of 15 
July 1991 concerning the placing of plant protection 
products on the market. 
14	 See the Federal Insecticide, Fungicide, and Rodenticide 
Act (7 U.S.C. 136a),“Registration of pesticides.” 
15	 Details of those U.S. FTAs signed to date and the 
progress of the others can be found at www.ustr.gov/
Trade_Agreements/Bilateral/Section_Index.html. 
16 For example United States-Australia FTA Article 17.10,
CAFTA Article 15.10, United States-Jordan FTA Article 
4(22), United States-Bahrain FTA Article 14.9. 
17	 For example United States-Jordan FTA, Article 22 
Footnote 10, United States-Singapore FTA, Article 16.8. 
18	 For example United States-Chile FTA Article 17.10,
United States-Singapore FTA Article 16.8(4), CAFTA 
Article 15.10(3). 
19 For example United States-Singapore FTA, United 
States-Chile FTA, CAFTA, United States-Australia FTA,
United States-Morocco FTA. 
20 Namely, “any substance or combination of substances 
presented as having properties for treating or 
preventing disease in human beings” or “any substance 
or combination of substances which may be used in 
or administered to human beings either with a view 
to restoring, correcting or modifying physiological 
functions by exerting a pharmacological, immunologic 
or metabolic action, or to making a medical diagnosis.”
21	 Separate is here meant in the sense that an 
authorization secured under one system cannot form 
the basis for securing another authorization in the 
other system. One exception to this is provided by 
Article 3(3) of the Regulation, which allows Member 
States to apply the Article 10 abridged authorization 
procedure to grant a national authorization for a 
generic medicinal product of a reference medicinal 
product first authorized by the Community. 
22 The centralized system has long been obligatory for 
medicinal products produced by most biotechnological 
processes, and has with effect from 20 November 
2005 been obligatory also for medicinal products for 
human use containing a new active substance for the 
treatment of AIDS, cancer, neurodegenerative disorder,
and diabetes, and for medicinal products that are 
designated as orphan medicinal products. It is optional 
for other new active substances and for medicinal 
products shown by the applicant to constitute “a 
significant therapeutic scientific or technical innovation 
or that the granting of authorisation in accordance 
with [the] Regulation is in the interests of patients or 
animal health at Community level.”This latter provision 
provides a theoretical possibility of securing an entirely 
new period of data protection via the centralized route 
in relation to an active compound that has already 
been authorized via the national route.
23 See Article 14(11) and 89 of the Regulation, paralleling 
part of Article 10 of the Directive, as amended, and 
Article 2 of the amending Directive. 
24 See Article 6 of the Regulation, incorporating by 
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reference, inter alia, Articles 10, 10a and 10b of the 
Directive, as amended. 
25 Moreover by New Article 10(5) “… where an application 
is made for a new indication for a well-established 
substance, a non-cumulative period of one year of data 
exclusivity shall be granted,provided that significant pre-
clinical or clinical studies were carried out in relation to 
the new indication.” The precise application and scope 
of this provision (which was added at the final stage 
of the legislative process and for which there are no 
travaux preparatoires) is yet to be established.The EMEA 
takes the view that the expression well-established 
substance means that the product no longer benefits 
from data exclusivity, and that the new period of data 
protection can be granted independently at any time 
after the initial protection period has expired, but can 
only be granted once. 
26 Case C-368/96, R v Licensing Authority, ex parte Generics 
(UK) Ltd. 2 CMLR 181 (1999). 
27 The proviso under the old regulatory regime stated,
“However, where the medicinal product is intended 
for a different therapeutic use from that of the other 
medicinal products marketed or is to be administered 
by different routes or in different doses, the results of 
appropriate toxicological and pharmacological tests 
and/or of appropriate clinical trials must be provided.” 
28 In Case C-106/01, v R v Licensing Authority, ex parte 
Novartis the abridged authorization that the ECJ held 
to be lawful concerned a formulation of an active that
was suprabioavailable to the formulation that had 
been authorized for longer than the data protection 
period but was bioequivalent to a formulation for the 
same active that had been authorized for less than 
that period. In Case C-36/03, v R v Licensing Authority,
ex parte Approved Prescription Services the abridged 
authorization that the ECJ held to be lawful concerned 
a pharmaceutical form of an active compound that was 
different to the pharmaceutical form that had been 
authorized for longer than the data protection period 
but was the same as that for the same active that had 
been authorized for less than that period. In Case C-
74/03, SmithKline Beecham plc v Laegemiddelstyrelsen,
the abridged authorization that the ECJ held to be 
lawful concerned a different salt of the active moiety 
to that in the originally authorized product. 
29 Whether or not such a mechanism was in effect
implicit in the old regulatory regime was the subject
of a challenge to a Commission Decision under the 
old regulatory regime concerning a human growth 
hormone product in Cases T-15/04 & T-105/04 Sandoz 
GmbH v Commission of the European Communities.
However as the product in question (Omnitrop 
(somatropin)) has now received an authorization under 
the new regime, this litigation may well not continue. 
30 See www.emea.eu.int/pdfs/human/ewp/309702en. 
pdf and www.emea.eu.int/pdfs/human/bwp/
320700en.pdf for already-adopted general guidelines 
and the listing at www.emea.eu.int/htms/human/
biosimilar/biosimilardraft.htm for various draft
guidelines including specific draft guidelines as 
to recombinant EPO, G-CSF, human insulin, and 
somatropin. 
31	 C-440/93, R v Licensing Authority of the Department
of Health (Norgine intervening) ex parte Scotia 
Pharmaceuticals Ltd. 3 CMLR 657 (1995). 
32	 “The Parties acknowledge that, at the time of entry 
into force of this Agreement, neither Party permits third 
persons, not having the consent of the person that
previously submitted information concerning the safety 
and efficacy of a product in order to obtain marketing 
approval in another territory, to market a same or 
similar product in the territory of the Party on the basis 
of such information or evidence of prior marketing 
approval in another territory.” [Footnotes 17 and 18 in 
original Annex]. 
33	 “As an alternative to this paragraph, where a Party, on 
the date of entry into force of this Agreement, has in 
place a system for protecting information submitted 
in connection with the approval of a pharmaceutical 
product that utilizes a previously approved chemical 
component from unfair commercial use, the Party may 
retain that system, notwithstanding the obligations of 
this paragraph.” [Footnotes 17–19 in original Annex]. 
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CHAPTER .10 
Box 2: Regulatory Data Protection for Medicinal Products 
in the European Community (extracts) 
Introduction 
This section sets out in detail the provisions relating to regulatory data protection for medicinal 
products for human use in the European Community.20 Parallel provisions,which differ with regard 
to certain specifics involving regulatory data protection, apply to veterinary medical products.
The legal basis for such provisions changed as from:
•	 30 October 2005, the date by which Member States were mandated to bring the 
provisions of Directive 2004/27/EC amending Directive 2001/83/EC on the Community 
code relating to medicinal products for human use (for medicinal products in the national 
systems) into effect 
•	 20 November 2005, the date on which the relevant provisions of Regulation 726/2004
laying down Community procedures for the authorization and supervision of medicinal 
products for human and veterinary use (for medicinal products in the centralized 
Community system), and replacing those under Regulation 2309/93, comes into effect.
The relevant extracts from the Directive as amended are set out at the end of this Box. However,
it should be noted that certain aspects of the former provisions (notably the period of protection 
and the nonavailability of extended protection for new uses) continue to apply to medicinal 
products for which an application for authorization was submitted before such dates, and 
since much of the litigation concerning the scope and effect of the old provisions informs the 
interpretation of the new ones, it is appropriate also to bear in mind the old provisions when 
discussing the new ones. Moreover, it is convenient to analyze these issues by reference to the 
Directive, dealing with medicinal products in the national, decentralized, and mutual recognition 
systems, rather than by reference to the Regulation, which deals with the generally separate,
from a regulatory perspective,21 centralized system,22 because the substantive law in each case 
is the same as a result of the Regulation either repeating,23 or in some cases incorporating by 
reference the relevant provisions of the Directive.24 
This Box does not address the separate system of protection that may also be available in some 
cases under Regulation (EC) No 141/2000 (the Orphan Medicinal Products Regulation).
General Principles 
The regulatory data protection provisions for medicinal products operate by providing an exception,
after a specific period, to the requirement for someone seeking a marketing authorization for a 
medicinal product to provide the results of toxicological and pharmacological tests or the results 
of clinical trials for such medicinal product if such a medicinal product has already been the 
subject of an authorization. Thus these provisions enable the authorization of a generic version 
of an already authorized product after such period and without such data. Such an authorization 
may conveniently be termed an abridged authorization.
Term of Protection 
Where a medicinal product has been the subject of an authorization submitted before November 
2005, then the periods of protection under the old regime (old Article 10(1)(a)(iii)) apply, by which 
a product must have been authorized within the Community, in accordance with Community 
provisions in force, for not less than a six or ten-year period, and be marketed in the Member 
State for which the application is made. The ten-year period applies to medicinal products 
authorized under the centralized procedure of the Regulation and its predecessor, throughout
the Community, and also in respect of authorizations secured nationally in those Member States 
that elected to apply it, namely Belgium, France, Germany, Italy, Netherlands, Sweden and the 
United Kingdom The six-year period applies to authorizations secured nationally in other Member 
States. This is the regime that will continue in effect for abridged authorizations for some time 
to come. 
(Continued on Next Page) 
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Box 2 (continued) 
Where a medicinal product is the subject of an authorization submitted after October 2005, then 
the periods of protection under the new regime apply. By new Article 10(1), an application for 
an abridged authorization cannot be filed until a period of eight years after the first marketing 
authorization in the Community has been granted, but a product so authorized cannot be placed 
on the market less than ten years from the first marketing authorization in the Community.
This ten-year period is extended to 11 years when, during the first eight years, the marketing 
authorization holder obtains an authorization for one or more new therapeutic indications that,
during the scientific evaluation prior to their authorization, are held to bring a significant clinical 
benefit in comparison with existing therapies. The first requests for abridged authorizations 
under the new regime cannot be filed before November 2013.
Variations and line Extensions of an Already Authorized Medicinal Product:
New Indications, New Strengths, Pharmaceutical Forms, Administration Routes,
Presentations, and so on 
As noted earlier, the new ten-year period of protection available to medicinal products the subject
of an authorization submitted after October 2005 will be extended to 11 years where, during the 
first eight years, the marketing authorization holder obtains an authorization for one or more new 
therapeutic indications which, during the scientific evaluation prior to their authorization, are held 
to bring a significant clinical benefit in comparison with existing therapies.25 No such provision 
existed under the old regulatory regime, it having been established in the Generics case26 that new 
indications for an already authorized active did not secure a new period of protection running from 
the date of authorization of such new indication,and that accordingly an abridged authorization for 
a particular medicinal product could be granted with respect to all indications already authorized 
for that particular medicinal product as at the date of such abridged authorization. This case also 
established that new dosage forms, doses, and dosage schedules likewise did not secure a new 
period of protection running from the date of authorization of such new dosage forms, doses 
and dosage schedules, and that accordingly an abridged authorization for a particular medicinal 
product could be granted in respect of all dosage forms, doses and dosage schedules already 
authorized for that particular medicinal product as at the date of such abridged authorization. 
The decision in the Generics case was based on the determination under the old regulatory 
regime that the product the subject of the abridged authorization was properly to be regarded 
as “essentially similar,” as the term was used in Article 10(1)(a)(iii), to the originally authorized 
product, if it satisfied “the criteria of having the same qualitative and quantitative composition 
in terms of active principles, of having the same pharmaceutical form and of being bioequivalent,
unless it is apparent in the light of scientific knowledge that it differs significantly from the original 
product as regards safety and efficacy.” Subsequent cases under the old regulatory regime 
established that even where there might not be such essential similarity, the proviso to Article 
10(1)(a)27 allowed for bridging data to be filed, or for bridging data filed by the originator to be 
relied on, provided that the originally authorized product and the product that is the subject of 
the abridged authorization had the same active principle.28 
These principles have been retained under the new regulatory regime by virtue of new Article 
6 and Article 10(1). Article 6 clarifies the issues of interpretation addressed in the Novartis
and Approved Prescription Services cases by introducing the concept of the global marketing 
authorization which covers “any additional strengths, pharmaceutical forms, administration 
routes, presentations, as well as any variations and extensions.” Article 10(1) requires the applicant
for an abridged authorization to demonstrate that the medicinal product that is the subject of 
the application “is a generic of a reference medicinal product which is or has been authorized under 
Article 6 for not less than eight years in a Member State or in the Community.” The definition of 
generic medicinal product under Article 10(2)(b) preserves the concept of essential similarity as 
refined by ECJ case law in Generics and subsequent cases.
(Continued on Next Page) 
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Box 2 (continued) 
New Combinations 
New Article 10b replaces old Article 10(1)(b) and concerns medicinal products containing active 
substances used in the composition of authorized medicinal products but not hitherto used in 
combination for therapeutic purposes. In such a case, the results of new preclinical tests or new 
clinical trials relating to that combination shall be provided, but it is not necessary to provide 
scientific references relating to each individual active substance. The matter has not been the 
subject of litigation, but it has generally been accepted that, by virtue of this provision, a new 
combination has its own period of data protection calculated from the date of the first marketing 
authorization for that particular combination in the Community, as if that new combination were 
a new active substance. 
Biological Medicinal Products 
New Article 10(4) provides a framework that did not exist under the old regulatory regime.29 
It would enable guidelines to be established by which biological medicinal products could be 
authorized without full results of toxicological and pharmacological tests, or the results of clinical 
trials, on the basis of an earlier authorization for a “biosimilar” product. The EMEA is at present
developing such guidelines, but so far the only specific guidelines that have so far been published 
concern certain specified recombinant proteins.30 
Bibliographic Applications
New Article 10a replaces old Article 10(1)(a)(ii) and, as before, allows for an authorization to be 
sought without full results of toxicological and pharmacological tests or the results of clinical 
trials but which does not refer to an authorized reference product where “the active substances 
of the medicinal product have been in well-established medicinal use within the Community for a 
period of at least ten years, with recognised efficacy and an acceptable level of safety”. It is under 
this provision that authorization can, for example, be sought for medicinal products containing 
active substances such as aspirin for the relief of pain. The narrow scope of the provision was 
emphasized under an earlier version of the provision under the old regulatory regime in the 
Scotia case.31 
Relevant Provisions of Directive 2001/83/EC on the Community Code in Regard 
to Medicinal Products for Human use as Amended by Directive 2004/27/EC 
Article 6 
1. No medicinal product may be placed on the market of a Member State unless a marketing 
authorisation has been issued by the competent authorities of that Member State in accordance 
with this Directive or an authorisation has been granted in accordance with Regulation (EEC) 
No. 2309/93. 
When a medicinal product has been granted an initial marketing authorisation in accordance 
with the first subparagraph, any additional strengths, pharmaceutical forms, administration 
routes, presentations, as well as any variations and extensions shall also be granted an 
authorisation in accordance with the first subparagraph or be included in the initial marketing 
authorisation. All these marketing authorisations shall be considered as belonging to the 
same global marketing authorisation, in particular for the purpose of the application of Article 
10(1). 
Article 10 
1. By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the 
protection of industrial and commercial property, the applicant shall not be required to provide 
the results of pre-clinical tests and of clinical trials if he [or she] can demonstrate that the 
(Continued on Next Page) 
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Box 2 (continued) 
medicinal product is a generic of a reference medicinal product which is or has been authorised 
under Article 6 for not less than eight years in a Member State or in the Community. 
A generic medicinal product authorised pursuant to this provision shall not be placed on the 
market until ten years have elapsed from the initial authorisation of the reference product. 
The first subparagraph shall also apply if the reference medicinal product was not authorised 
in the Member State in which the application for the generic medicinal product is submitted.
In this case, the applicant shall indicate in the application form the name of the Member 
State in which the reference medicinal product is or has been authorised. At the request of 
the competent authority of the Member State in which the application is submitted, the 
competent authority of the other Member State shall transmit within a period of one month,
a confirmation that the reference medicinal product is or has been authorised together with 
the full composition of the reference product and if necessary other relevant documentation. 
The ten-year period referred to in the second subparagraph shall be extended to a maximum 
of eleven years if, during the first eight years of those ten years, the marketing authorisation 
holder obtains an authorisation for one or more new therapeutic indications which, during 
the scientific evaluation prior to their authorisation, are held to bring a significant clinical 
benefit in comparison with existing therapies. 
2. For the purposes of this Article: 
(a) “reference medicinal product” shall mean a medicinal product authorised under Article 6,
in accordance with the provisions of Article 8; 
(b)“generic medicinal product”shall mean a medicinal product which has the same qualitative 
and quantitative composition in active substances and the same pharmaceutical form as 
the reference medicinal product, and whose bioequivalence with the reference medicinal 
product has been demonstrated by appropriate bioavailability studies. The different salts,
esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance 
shall be considered to be the same active substance unless they differ significantly in 
properties with regard to safety and/or efficacy. In such cases, additional information 
providing proof of the safety and/or efficacy of the various salts, esters, or derivatives 
of an authorised active substance must be supplied by the applicant. The various 
immediate-release oral pharmaceutical forms shall be considered to be one and the same 
pharmaceutical form. Bioavailability studies need not be required of the applicant if he can 
demonstrate that the generic medicinal product meets the relevant criteria as defined in 
the appropriate detailed guidelines. 
3. In cases where the medicinal product does not fall within the definition of a generic medicinal 
product as provided in paragraph 2(b) or where the bioequivalence cannot be demonstrated 
through bioavailability studies or in case of changes in the active substance(s), therapeutic 
indications, strength, pharmaceutical form or route of administration, vis-à-vis the reference 
medicinal product, the results of the appropriate pre-clinical tests or clinical trials shall be 
provided. 
4. Where a biological medicinal product which is similar to a reference biological product
does not meet the conditions in the definition of generic medicinal products, owing to, in 
particular, differences relating to raw materials or differences in manufacturing processes of 
the biological medicinal product and the reference biological medicinal product, the results of 
appropriate pre-clinical tests or clinical trials relating to these conditions must be provided.
(Continued on Next Page) 
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Box 2 (continued) 
The type and quantity of supplementary data to be provided must comply with the relevant
criteria stated in the Annex and the related detailed guidelines. The results of other tests and 
trials from the reference medicinal product’s dossier shall not be provided.
5. In addition to the provisions laid down in paragraph 1, where an application is made for 
a new indication for a well-established substance, a non-cumulative period of one year of 
data exclusivity shall be granted, provided that significant pre-clinical or clinical studies were 
carried out in relation to the new indication.
6. Conducting the necessary studies and trials with a view to the application of paragraphs 1,
2, 3 and 4 and the consequential practical requirements shall not be regarded as contrary to 
patent rights or to supplementary protection certificates for medicinal products. 
Article 10a 
By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the 
protection of industrial and commercial property, the applicant shall not be required to provide 
the results of pre-clinical tests or clinical trials if he can demonstrate that the active substances 
of the medicinal product have been in well-established medicinal use within the Community 
for at least ten years, with recognised efficacy and an acceptable level of safety in terms of the 
conditions set out in the Annex. In that event, the test and trial results shall be replaced by 
appropriate scientific literature. 
Article 10b 
In the case of medicinal products containing active substances used in the composition of 
authorised medicinal products but not hitherto used in combination for therapeutic purposes,
the results of new pre-clinical tests or new clinical trials relating to that combination shall be 
provided in accordance with Article 8(3)(i), but it shall not be necessary to provide scientific 
references relating to each individual active substance. 
Article 10c 
Following the granting of a marketing authorisation, the authorisation holder may allow use 
to be made of the pharmaceutical, preclinical and clinical documentation contained in the file 
on the medicinal product, with a view to examining subsequent applications relating to other 
medicinal products possessing the same qualitative and quantitative composition in terms of 
active substances and the same pharmaceutical form. 
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COOK 
Box 3: Regulatory Data Protection Provisions of the united States-Australia 
FTA Articles 17.10: Measures Related to Certain Regulated Products 
1. (a) If a Party requires,as a condition of approving the marketing of a new pharmaceutical product,
the submission of undisclosed test or other data concerning safety or efficacy of the product,
the Party shall not permit third persons, without the consent of the person who provided the 
information, to market the same or a similar product on the basis of that information, or the 
marketing approval granted to the person who submitted such information, for at least five 
years from the date of marketing approval by the Party. 
(b)	 If a Party requires, as a condition of approving the marketing of a new agricultural chemical 
product, including certain new uses of the same product, the submission of undisclosed 
test or other data concerning safety or efficacy of that product, the Party shall not permit
third persons, without the consent of the person who provided the information, to market
the same or a similar product on the basis of that information, or the marketing approval 
granted to the person who submitted such information, for ten years from the date of the 
marketing approval of the new agricultural chemical product by the Party. 
(c)	 If a Party permits, as a condition of approving the marketing of a new pharmaceutical or 
agricultural chemical product, third persons to submit evidence concerning the safety or 
efficacy of a product that was previously approved in another territory, such as evidence of 
prior marketing approval, the Party shall not permit third persons, without the consent of 
the person who previously submitted information concerning safety or efficacy, to market
the same or a similar product on the basis of evidence of prior marketing approval in another 
territory, or information concerning safety or efficacy that was previously submitted to obtain 
marketing approval in another territory, for at least five years, and ten years for agricultural 
chemical products, from the date of marketing approval by the Party, or the other territory,
whichever is later.32 
(d)	 For the purposes of this Article, a new product is one that does not contain a chemical entity 
that has been previously approved for marketing in the Party. 
(e)	 If any undisclosed information concerning the safety or efficacy of a product submitted to 
a government entity, or entity acting on behalf of a government, for purposes of obtaining 
marketing approval is disclosed by a government entity, or entity acting on behalf of a 
government, each Party is required to protect such information from unfair commercial use 
in the manner set forth in this Article. 
2. With respect to pharmaceutical products, if a Party requires the submission of: (a) new 
clinical information (other than information related to bioequivalency) or (b) evidence of 
prior approval of the product in another territory that requires such new information, which 
is essential to the approval of a pharmaceutical product, the Party shall not permit third 
persons not having the consent of the person providing the information to market the same 
or a similar pharmaceutical product on the basis of the marketing approval granted to a 
person submitting the information for a period of at least three years from the date of the 
marketing approval by the Party or the other territory, whichever is later.33 
3. When a product is subject to a system of marketing approval in accordance with paragraph 1 
or 2, as applicable, and is also subject to a patent in the territory of that Party, the Party shall 
not alter the term of protection that it provides pursuant to paragraph 1 or 2 in the event that
the patent protection terminates on a date earlier than the end of the term of protection 
specified in paragraph 1 or 2, as applicable. 
(Continued on Next Page) 
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Box 3 (continued) 
4. Where a Party permits,as a condition of approving the marketing of a pharmaceutical product,
persons, other than the person originally submitting the safety or efficacy information, to rely 
on evidence or information concerning the safety or efficacy of a product that was previously 
approved, such as evidence of prior marketing approval by the Party or in another territory: 
(a) that Party shall provide measures in its marketing approval process to prevent those other 
persons from: 
(i) marketing a product, where that product is claimed in a patent; or 
(ii) marketing a product for an approved use, where that approved use is claimed in a 
patent, during the term of that patent, unless by consent or acquiescence of the 
patent owner; and 
(b) if the Party permits a third person to request marketing approval to enter the market
with: 
(i) a product during the term of a patent identified as claiming the product; or 
(ii) a product for an approved use, during the term of a patent identified as claiming 
that approved use, the Party shall provide for the patent owner to be notified of such 
request and the identity of any such other person. 
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RobeRT piTKeThly, University Lecturer, Said Business School; Fellow and Tutor in Management, St. Peter’s College; 
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ABSTRACT 
This chapter gives an overview of the aims of an IP (in­
tellectual property) strategy and discusses management 
issues involved in implementing such a strategy. Other 
chapters in this Handbook provide more-detailed infor­
mation about managing intellectual property; the purpose 
of this chapter is to provide an integrated framework for 
giving IP rights the balanced consideration they deserve. 
1. InTRoduCTIon 
IP (intellectual property) strategy can mean many 
things. In order to understand the relevance and 
implications of the term, we first need to look at 
what is meant by the terms intellectual property and 
strategy, how they work in combination, and the 
implications of an IP strategy for organizations. For 
some people, it means the tactics used to manage 
an IP rights program, with detailed attention to li­
censing, filing, and litigation strategies. For others, 
the term refers to a general business strategy that 
uses IP rights to manage technology. Still others 
might assume that an IP strategy is only a concern 
for large for-profit corporations and irrelevant to 
smaller or not-for-profit organizations. However, 
an IP strategy, and the informed use of IP rights, is 
important to organizations of all sizes. 
2. InTELLECTuAL 	pRopERTy 
IP rights are commonly regarded as simply a means 
of protecting innovation, with the assumption that 
this protection benefits the innovator.1 However, 
such a view emphasizes too strongly the private 
benefits that can accrue to IP rights holders while 
neglecting the important public benefits provided 
by an IP system. Viewed broadly, an IP rights 
system has several components that contribute to 
the system’s overall effectiveness. These roles need 
to be kept in balance, so that private interests do 
not dominate the public interest. Nor should 
public interests, considered in the short term, 
dominate the long-term private interests that 
drive the system. 
IP rights are beneficial in a number of ways. 
By providing incentives or rewards for innova­
tion, by packaging or defining intellectual assets, 
and by diffusing technical information and con­
trolling intellectual assets, they are a powerful en­
gine for innovation. In contrast to these utilitar­
ian functions, IP rights also can be seen to protect 
a natural, even moral, right of inventors to their 
creations, a view that has its origins in Lockean 
conceptions of property.2 
Whatever theoretical justifications are used to 
support them, the difficulty with IP systems is in 
striking the optimal balance between private rights 
and public benefits. From a public-policy perspec­
tive, this goal is elusive, and even after several hun­
dred years of debate by economists, political lead­
ers, and inventors, a precise way of balancing these 
competing concerns has yet to be found. 
Pitkethly R. 2007. IP Strategy. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of 
Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org. 
© 2007. R Pitkethly. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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PITKETHlY 
IP systems play a significant but uncertain 
role in policy measures used to encourage in­
vestment in innovation. Fritz Machlup is often 
cited, for example, to support the view that the 
uncertainty inherent in the patent system makes 
that system difficult both to implement and to 
abolish.3 But Edith Penrose made this same 
point seven years earlier in her study of the in­
ternational patent system: “If national patent 
laws did not exist, it would be difficult to make a 
conclusive case for introducing them; but the fact 
that they do exist shifts the burden of proof and 
it is equally difficult to make a really conclusive 
case for abolishing them.”4 Penrose was referring 
to the 19th century debate about patents, and 
Machlup and Penrose’s earlier discussion of the 
19th century patent system controversy dealt, in 
large part, with the debate over its abolition.5 
However, they observed in the same article that 
“little, if anything, has been said for or against the 
patent system in the 20th century that was not said 
equally well in the 19th.” That statement is also 
likely to be true for the 21st century. 
Indeed, despite the longstanding theoretical 
uncertainty about IP rights systems, they have 
proved remarkably resilient in the countries that 
have implemented them. It is arguable that IP 
rights systems are, so far as we can tell, better 
than any of the alternatives that have been pro­
posed over the years. Of course, this raises the 
possibility of interpreting IP strategy as that at 
the national not corporate level. In fact, there are 
many interesting examples that could be studied 
in support of this claim.6 The U.S. Constitution, 
for example, provided for IP rights from its in­
ception.7 And Japan’s rapid modernization from 
a feudal society in the 1850s to an industrialized 
nation by the early 1900s included the relatively 
rapid adoption of an IP rights system.8 Even in 
the United Kingdom, the gradually evolving 
patent system had a role to play in the first in­
dustrial revolution.9 Patent systems are known 
to support the interests of industrialized nations, 
and in most cases such systems also played a role 
in encouraging early industrialization efforts. 
This suggests that some form of IP strategy, at a 
national level, is relevant to all nations regardless 
of their level of industrialization. 
2.1 Organizational roles of IP rights 
Although the different justifications for IP systems 
and the different national strategies for implement­
ing them are worthwhile topics, this chapter has a 
more pragmatic goal, to help provide an under­
standing of the practical implications of the vari­
ous IP systems. Accordingly, it considers the four 
practical roles of an IP system. These are (1) acting 
as an incentive system for innovation, (2) packag­
ing intellectual assets, (3) diffusing technical infor­
mation, and (4) controlling intellectual assets. 
An IP system’s role of providing incentives or 
rewards for innovation is achieved through pro­
tecting that innovation by restricting use by oth­
ers. The restriction, by protecting the inventor, 
enables them to command monopoly prices and 
benefit from the innovation to a greater extent 
than would be possible without such protection. 
This has implications for strategy in that potential 
restrictions on use confer control, and that con­
trol can be exercised not just to limit but also to 
expand the market for an innovation. 
With technology-based innovation, IP sys­
tems also help package and define intellectual as­
sets. Intellectual assets, by definition, start as tacit 
ideas, literally embodied in the inventor. IP rights, 
and particularly patent specifications, facilitate 
these tacit inventions by providing a more eas­
ily transmissible and protectable embodiment for 
these intellectual assets. This ability to enable pre­
viously tacit or secret information to be identified 
and made the subject of transactions and com­
munications is a critical function of Intellectual 
property, and this dimension of IP rights has 
strategic implications. For example, this function 
facilitates licensing. Kenneth Arrow’s informa­
tion paradox, where transactions in confidential 
information are made more difficult where trust 
is absent, can be eased by the use of IP rights and 
the laws of contract.10 
An IP system—especially a patent system— 
plays a key role in diffusing technological 
information. The threat of free riders and 
competition may tempt an innovator to keep an 
invention secret. Historically, there have been 
cases, notably the Chamberlen family’s secret use 
of obstetric forceps in their medical practice for 
more than 130 years, where society has been denied 
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CHAPTER .1 
life-saving technologies because an invention was 
kept secret.11 Modern analytical methods and job 
mobility make such tactics less likely today, but 
an IP system still has an important role in both 
facilitating the publication of inventions and 
making information easier to find. The challenge 
is, of course, that an IP system must be arranged 
so that the rights granted to innovators do not 
end up costing the rest of society more by unduly 
hindering access to other innovations. 
Finally, intellectual property rights may be 
thought of as a means of, not just protecting, but, 
controlling, the underlying intellectual assets. This 
is particularly critical when IP rights are consid­
ered from the point of view of organizations or 
individuals with a concern for the public interest. 
The fact that IP rights give the power to prevent 
use means that they also give the right to license 
use, which enables IP rights holders to exert sig­
nificant control over their innovations. The ex­
tent of that control will depend on a number of 
other factors (see section 4 below). If an organiza­
tion ignores or fails to obtain IP rights, it risks 
abdicating control over an invention. In the case 
of a fundamental invention, this may have major 
strategic implications. 
This point is illustrated by the different ways 
in which penicillin and the subsequent cepha­
losporin antibiotics were protected by patents. 
When penicillin was discovered in 1929, chemical 
product patents were not available in the United 
Kingdom. At the time, some felt that the discovery 
and work associated with penicillin’s production 
should not be subject to patent protection. As a 
result, neither penicillin itself nor the initial pro­
duction methods were patented by the discoverer, 
Alexander Fleming, in London and the developers 
in Howard Florey’s team in Oxford. In contrast, 
the crucial factor in the widespread use of penicil­
lin in the latter part of the 1940s turned out to be 
the development of bulk fermentation methods 
of production, and these were patented by their 
inventors in the United States.12 As a result, the 
potential for control over the commercialization 
of penicillin largely belonged to the U.S. compa­
nies involved. Several years later, scientists from 
Florey’s research group in Oxford discovered and 
developed the cephalosporin group of antibiotics. 
Patents were obtained by the National Research 
and Development Organization (NRDC), which 
was then responsible for commercializing univer­
sity-based inventions.13 Using the royalties derived 
from licensing these patents, the two main inven­
tors, Guy Newton and Edward Abraham, set up 
two charitable trusts, the E. P. Abraham Research 
Fund and the Guy Newton Trust, which still to­
day support medical, biological, and chemical re­
search in Oxford. 
The point behind these two stories is that, in 
the first case, control and financial benefit were 
effectively ceded to subsequent developers of crit­
ical enabling technology. In the second case, pat­
ents were used to not only retain that control but 
also to put financial proceeds under the inventors’ 
control—in this case, for charitable purposes. A 
similarly significant financial decision was made 
by the NRDC many years later when it did not 
patent the initial discovery of monoclonal anti­
bodies by Georges Köhler and César Milstein.
In retrospect, this arguably forfeited several mil­
lion British pounds of potential royalty income. 
However, it is worth noting César Milstein’s com­
ment about his approach to patenting and licens­
ing his laboratory’s work: 
Within our laboratory we established a set of 
principles. The public interest should come first, the 
scientific interest of the inventors, second, and mak­
ing money should be considered only in the light of 
the first two priorities.14 
But did the first two principles receive the 
priority they could have had if there had been 
more interest in the commercial aspects of the 
laboratory’s work? Indeed, such principles do 
not preclude the use of IP rights. They simply 
suggest how the rights might be used. More im­
portantly, the public may benefit when those 
who are obliged to be concerned with the public 
interest exercise control over their innovations. 
Intellectual property represents one of the few 
means of control available to scientific and re­
search establishments, even for those organiza­
tions not directly involved in commercializing 
their research. 
More generally, it is much more useful
to consider IP rights as a means of control, 
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PITKETHlY 
rather than as a barrier to be placed in the path 
of the competition. 
. STRATEGIC MAnAGEMEnT THEoRy 
Having considered the roles that intellectual prop­
erty can play, the nature and scope of IP strategy 
should be considered. There are many definitions 
of strategy from a business perspective. A com­
mon, widely applicable definition is provided by 
business historian Alfred Chandler: 
Strategy can be defined as the determination of 
the long-run goals and objectives of an enterprise and 
the adoption of courses of action and the allocation of 
resources necessary for carrying out these goals.15 
The word objectives is used in the plural, and 
it is important to realize that organizations may 
have multiple objectives. Businesses tend to be 
thought of as unidirectional, as devoted solely to 
the pursuit of profit, or maximizing shareholder 
value. In reality, most organizations have mul­
tiple objectives and pursue more than just profit. 
In the case of not-for-profit organizations, this 
is usually explicit. Objectives such as widening 
access to medicines, eradicating disease, and im­
proving social conditions may constitute primary 
objectives for organizations, and these objectives 
may make profit seeking impossible. However, 
whatever the organization and whatever the ob­
jectives it sets for itself, the resources it has under 
its control must still be managed to best effect. 
For a company to say it will forego profit by not 
bothering to exploit a resource may sound accept­
able, if financially inefficient. For an organization 
to say it will forego the chance to save lives by not 
bothering to exploit a resource can hardly be seen 
in the same light. Indeed, if not-for-profit organi­
zations opt out of the global IP system, they may 
not be the biggest losers. This point once again 
highlights the importance of intellectual property 
and of understanding its challenge, which lies in 
the need to balance the management, control, 
and use of resources with the achievement of the 
organization’s objectives. Intellectual property 
is a resource. As such, it should not be thrown 
away—even with the best of intentions. As with 
many aspects of intellectual property, it is no 
surprise that the choices may not always be clear 
and are almost always controversial; the challeng­
es should be expected to be unexpected. 
A conventional view of business strategy 
might divide the subject into a consideration of 
the external environment, in which the business 
competes, and the internal resources it uses to 
compete. In the early 1980s, studies of strategy 
tended to concentrate more on external environ­
ment, including work originating in industrial 
organization economics. This work, emphasizing 
barriers to entry, by authors such as Bain16 and 
Mason,17 eventually led to Porter’s work on in­
dustry structure analysis.18 Porter considered IP 
rights primarily as examples of barriers of entry, 
though they also form “isolating mechanisms” 
necessary to preserve competitive advantage.19 
However, concentration on such external issues 
as the choice of where to invest and compete 
made the strategic analysis of the day less di­
rectly relevant to IP issues. In the latter half of 
the 1980s and 1990s, the development of the 
resource-based view of companies, with their 
internal focus on managing the resources of an 
organization, gradually drew the field of strategy 
closer to that of IP management.20 
The resources of the organization essentially 
comprise the organization’s staff, its financial re­
sources, any tangible assets, and the intangible or 
intellectual assets that the organization controls. 
The aim of strategy is to manage the resources 
available in order to achieve the objectives set. 
Since in most cases resources are tradeable as­
sets, any organization in possession of valuable 
resources is obliged to put those resources to the 
best use possible, even if they lack direct relevance 
to the organization’s immediate objectives. 
A publicly acknowledged failure to make 
the best use of a company’s assets may result in a 
bid for control of the company by those who feel 
they can extract more value from resources than 
managers have. Even with not-for-profit organi­
zations, not making the best use of the resources 
available is a serious failure. 
IP rights are one of an organization’s intangi­
ble resources, and thus they need to be exploited 
to the fullest extent consistent with the organiza­
tion’s objectives. How this should be done may 
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not always be clear, but what is certain is that no 
resource should just be given, or thrown, away. 
One final aspect of general strategic-man­
agement theory that is relevant to the study of 
intellectual property is the concept of managing 
added value. In any business where resources are 
employed and processed through a value chain of 
parties—each adding some small amount of value 
before the product reaches the end customer—the 
relationship between the organization and those 
with whom it buys and sells is crucial. Just as im­
portant is how the value created by the entire chain 
of parties is distributed among the parties in, or 
closely associated with, the chain. If the innova­
tor tries to capture the entire added value in the 
business, perhaps by using particularly effective 
IP rights, the innovator may find it impossible to 
get any distributors to sell the product. The inno­
vator might then be forced to rely on direct sales, 
resulting in a loss of competitiveness. Equally, if 
each business or licensor involved in a production 
chain insists on a substantial proportion of the 
final retail price, the royalty stacking produced 
may make the goods concerned uncompetitive. 
While the concept of the value chain is inherent 
in a number of strategic models, whether at the 
industry level21 or business-unit level, the “value 
net” advocated by Brandenburger and Nalebuff 
deals nicely with the issue of how value added is 
distributed over a network of parties involved di­
rectly, or indirectly, with a business.22 
In considering how to exploit and appropri­
ate the benefits of a given piece of intellectual 
property, consideration must always be given to 
how the dynamics of an industry, the access to 
complementary assets, and the strength of IP 
rights will affect the ability of any one party to 
appropriate the benefits of the innovation. 
. Ip	 STRATEGy 
Having identified IP rights and how they fit into 
the larger scheme of strategic management, the 
immediate question is what exactly an IP strategy 
requires beyond the general exhortation to make 
the best use possible of the resource. 
A simple taxonomy of IP strategy to di­
vide the field is needed, just as the larger field 
of strategic management is divided into internal 
and external resources. On the one hand, there 
are activities external to the organization that in­
volve interaction with other parties. On the other 
hand, there are internal activities concerned with 
management within the organization. The word 
strategy tends to invoke images of competitive ac­
tion, but the internal perspective on IP strategy 
must not be neglected in favor of the external, 
since both are directly concerned with the value 
and allocation of resources. 
A further distinction to be drawn is that be­
tween IP strategy and IP management. This might 
be likened to the difference between strategy and 
tactics; the difference is between the general prin­
ciples and aims that govern the courses of action 
(strategy) and the actual implementation of those 
courses of action (management). 
.1 External IP strategy 
The key components of an external IP strategy 
are the issues of exploitation and what might be 
termed litigation, licensing, and learning. In a 
sense, litigation and licensing are opposites, since 
one denies and the other allows what would oth­
erwise be an infringement of IP rights. The fact 
that both are choices within an IP rights holder’s 
range of strategies illustrates the power of con­
trol provided by an IP strategy. The possessor of 
an IP right has the power to stop, allow, or even 
encourage the use of that right, depending on the 
strength of the IP rights concerned. 
Regarding litigation, perhaps the main 
distinction to be drawn is between litigation 
tactics, for example, deciding in which country 
to litigate against multiple infringers or deciding 
which arguments to use. In contrast, litigation 
strategy involves, for example, deciding whether 
to resist or grant licenses to infringers, so that 
litigation can be settled before it reaches court. 
Especially where IP rights held overseas are 
infringed, IP rights holders may be persuaded 
to solve infringement by granting licenses to 
convert local infringers into licensees. This may 
not, however, always be the best course of action; 
certainly the best licensees may not always be 
found among former infringers. The infringers 
may have deliberately infringed with the aim of 
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PITKETHlY 
acquiring licenses on advantageous terms. Indeed, 
a focus on litigation strategy may encourage the 
IP rights holder to make poor decisions about 
whom to grant a license. Moreover, while a 
patentee’s options may be more limited when 
operating overseas, a litigation strategy should 
not be decided by the infringers but by the IP 
rights holder. Wherever possible, any decision 
about licensing should be driven by licensing 
considerations rather than by a desire to avoid 
litigation. For institutions and organizations 
whose main aim is to maximize the use of their 
innovations, litigation should be secondary—far 
behind exploitation and licensing. 
When seeking to exploit intellectual proper­
ty, an organization has at least three main options. 
First, it can sell the technology outright and exit 
from the field (except perhaps for providing tech­
nical advice during a transitional period). Or it 
might choose to exploit the technology in-house, 
using its resources to develop and market prod­
ucts and services. Finally, an organization could 
choose to license-out the technology. 
In all cases, the implications of each ap­
proach must be considered. The organization 
aims to make the greatest use of resources under 
its control. In the case of intellectual assets, such 
as a patented technology, a key question must be 
what resources are required to successfully exploit 
the technology. Teece has suggested that firms 
need more than IP rights: success in a competi­
tive market requires strong IP rights plus access 
to “complementary assets.”23 For most technolo­
gies, getting from laboratory to market or to the 
patient, recipient, or other beneficiary of the 
technology requires much more than just invent­
ing and announcing the technology. Process de­
velopment, testing, trials, approval, production 
engineering, production facilities, distribution 
chains, and marketing skills are just some of the 
resources required to exploit a technology. Not 
all organizations have the needed resources. Even 
those that do have the resources may only possess 
them in limited markets, putting international 
exploitation beyond their reach. So, if we assume 
that a new technology is well protected using IP 
rights, then the question remains as to whether 
the organization has the complementary assets 
needed to exploit the technology. Leaving aside 
the question of whether the innovator keeps most 
of the benefits from the innovation, the key issue 
is whether the innovation can be exploited to the 
fullest extent by the organization at which it was 
invented. 
Indeed, if a new invention gives substantial 
advantages over existing technologies, it can be 
assumed that the invention will be a technologi­
cal success. What cannot be known is whether 
the organization inventing it will be more suc­
cessful than its competitors in making the inven­
tion widely available. Organizations with limited 
resources, the case for all but the very largest 
multinational firms, are very unlikely to be able 
to exploit new products or services quickly. This 
means that the organization’s assets will have to 
be used or traded in order to acquire the needed 
resources. Especially for smaller organizations 
with limited staff, finances, and physical assets, 
the only resource likely to be sufficiently scaleable 
to expand to meet the resources needed for over­
seas exploitation will be the intellectual property 
associated with the invention. 
The returns from out-licensing technology are 
inevitably less than the potential proceeds from 
exploiting those assets in-house. But licensing can 
make access to markets and technical fields pos­
sible. Thus, the cost of such licensing may be well 
worthwhile, since the amount of value added will 
likely be substantial, relative to costs. Even for a 
not-for-profit organization, some form of con­
tract that effectively trades returns for opportuni­
ties to exploit is all but unavoidable. 
There are, however, two potential concerns 
with licensing agreements. Licensing is just one 
option on a continuum of possible interactions 
between organizations, ranging from sale, pur­
chase-through-licensing, and joint ventures and 
alliances to full acquisition and merger of the or­
ganizations. These options should be considered 
as alternatives to licensing if in-house exploita­
tion or outright sale of the technology is impos­
sible. For an organization with limited resources, 
licensing may be the easiest option, but it may 
not necessarily be the most efficient for maximiz­
ing control and returns available to the innovat­
ing organization. 
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CHAPTER .1 
Outright sale involves loss of control and, 
more importantly, may fix the returns available. 
As an alternative to an outright sale, some form of 
exclusive license may be preferable, since contracts 
can be written to include options enabling the 
innovator to benefit from unexpected increases 
in revenue and new opportunities to exploit the 
invention. This approach essentially applies the 
concept of real options to help the organization 
limit its downside risk, while still allowing the 
organization to take advantage of any unexpected 
upside advantage. Another way of achieving this 
real option effect is to license technology to a 
spinout company formed by the organization to 
develop the technology independently. Forming 
a spinout, however, requires raising additional 
financing from other sources, with the original 
organization recouping its investment from 
the eventual capital appreciation of its shares 
in the company. But the demands on those 
involved in the spinout are arguably greater 
than those involved with exploitation either 
through licensing or sale. That is true because 
the interests of investors, industry, and those in 
the organization must all be reconciled. Such a 
spinout strategy may, however, provide higher 
returns to the organization and, because outside 
investment could be generated, the strategy may 
enable exploitation on a scale that would have 
been impossible either by licensing or by selling 
the technology to existing companies. Spinouts 
can be used by any organization, including 
public sector organizations such as universities. 
Indeed, there are many examples of their use by 
technology transfer offices (TTOs).24 
The objective of all licensing or sale of intel­
lectual assets is for the organization to extract the 
maximum benefit from the innovation so that 
it can achieve its objectives. This means seeking 
the maximum benefit not just for immediate 
opportunities but also for future opportunities, 
such as overseas expansion. IP strategy cannot 
be short sighted, in terms of either markets or 
time. Just as a patent attorney drafting claims 
will frame them as broadly as the prior art al­
lows, enabling the full scope of patent protection 
to be obtained and not unnecessarily restricted 
as new uses of the invention develop, means a 
TTO should construct contracts and licensing 
arrangements to take advantage of all possibili­
ties. In fact, such practices should be a normal 
part of the responsible strategic management of 
an organization’s intellectual assets. 
One final aspect of licensing, equally impor­
tant to not-for-profit organizations, is the issue 
of learning, or technology diffusion. In a com­
petitive market, out-licensing by a technological 
leader will give access, not only to the technology 
licensed, but to learning opportunities.25 Where 
the aim is to diffuse technology as widely as possi­
ble, such dual access may be a positive advantage. 
On the other hand, where the aim is to maintain a 
competitive advantage over those who might learn 
by licensing-in, it may prove a considerable disad­
vantage that is not outweighed by the income that 
licensing brings. Licensors of intellectual assets 
may need to balance the effects of learning with 
the potential revenue from licensing. 
Finally, one sometimes neglected aspect of 
licensing concerns network externalities where 
the worth of a technology to users increases the 
more users it attracts. In such cases, even in a 
competitive situation, it may be preferable for an 
organization to license-out or otherwise make the 
technology available even at low or below cost, 
since this will generate a large user base and en­
courage further adoption of the technology. (An 
organization should, of course, be aware of any 
competition law restrictions that might be rele­
vant.) In such cases, the reluctance to license-out 
the technology may actually lead to a competi­
tive disadvantage, even though it is thought that 
the innovation is being protected and exploited. 
Once again, the lesson here is that the control 
that IP rights give is more important than the 
mere ability to prevent exploitation by others; too 
restrictive an attitude toward IP rights can act to 
an organization’s disadvantage. 
.2 Internal IP strategy 
IP strategy involves not just external issues but 
a variety of internal issues related to resources 
within an organization. A few of these issues that 
are particularly relevant to IP strategy are: valua­
tion, information, coordination, and education, 
including the management of researchers in their 
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roles as creators and preservers of intellectual 
property within an organization. 
.2.1 Valuation 
The valuation of intellectual property reflects the 
nature of the IP system in general. Despite the 
best efforts of economists, it is often arguable 
how valuable the IP system is for any general class 
of innovations. Likewise, despite the best efforts 
of managers and accountants, it is often unclear 
exactly how valuable a particular intellectual 
property right is, despite the fact that deciding 
to obtain or preserve the right implies a specific 
value.26 If organizations are to go to the expense 
of obtaining and protecting intellectual property, 
especially intellectual property that requires a 
complex application procedure such as overseas 
patent applications, then the considerable costs 
have to be justified. 
It is easy enough to justify long-established 
legal fees to preserve an established income 
stream, for example, from licensing a successful 
piece of intellectual property. However, far more 
often IP managers will be required to make deci­
sions about incurring costs for intellectual prop­
erty of unknown value. Such decision making in 
the early stages of the life of a patent, for example, 
is inevitably problematic because the decisions 
require speculation about the invention’s future 
prospects. After all, such predictions about the 
future can certainly be wrong. 
In response, two potential approaches can 
be taken. The first is simply to adopt a portfolio 
management view of innovation and to assume 
that, although much expenditure on R&D and 
IP protection may be wasted, there will be enough 
successes to more than pay for the failures. While 
this approach is adopted often by larger compa­
nies that can afford such an approach, such an 
approach is not easy to sustain when financial 
pressures mount and organizations are looking 
for short-term costs to cut. The consequence of 
such financial pressures are that companies oper­
ating near the margins of profitability may find 
that their IP rights coverage is patchy, reflecting 
fluctuations in their financial position. In unfor­
tunate cases, financial hardship coincides with 
the creation of a valuable innovation, which then 
is left unprotected and less exploitable than it 
might have been. 
The second approach is to adopt a case-by­
case analysis of each development, taking into ac­
count all the information that is available about 
the innovation’s future prospects. The key feature 
of such an analysis is the fact that the absence of 
current revenue early in the life of an invention 
should not count against it as much as its absence 
later in the invention’s life. Of course, it is easy 
to value a stable income stream once an inven­
tion has become successful. The essence of valu­
ing early-stage innovation is to be aware that such 
IP rights represent real options on the future extra 
income that might be derived from the IP rights 
that protect the invention.27 But calculating pat­
ent values, taking such real options into account, 
is not straightforward. In practice, patent attor­
neys and IP managers make implicit valuations 
of this sort whenever they justify preserving an 
IP right that is currently unproductive, as long 
as they foresee some chance of it producing an 
income stream in the future. 
In terms of evaluating alternative courses of 
action, some form of valuation is essential for 
assessing the potential outcomes against the po­
tential costs. Strategy is thus intimately linked to 
valuation. However, beyond such assessments, 
there is the more general issue of the values driv­
ing the objectives of the organization. Issues may 
exist where the values of the organization drive 
decisions that are not solely based on a financial 
analysis. That said, even where such plural stra­
tegic objectives and nonfinancial values are in­
volved, financial analysis might still be a perfectly 
valid basis for making many IP-related decisions. 
Valuation is a critical, unavoidable element of 
IP management and strategy. This, however, does 
not make valuation any easier to carry out reliably 
when making important strategic decisions. 
.2.2 Information 
One of the roles of IP rights is to diffuse informa­
tion. The patent system, for example, promotes 
the public benefit by forcing inventors to dis­
close their inventions to the world in return for 
the grant of patent rights. Of course, publishing 
such information has its drawbacks. Publishing 
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CHAPTER .1 
provides a source of information of great use to 
the organization and also of use to competitors. 
Besides publications, researchers should 
conduct patent searches along with literature 
searches. Though academic publications might 
be issued before related patent applications, of­
ten the patent application is the only, or the first, 
publication available related to a competing tech­
nology. In addition to establishing what already 
exists in the prior art, patent searching can give a 
very good view of the technological trajectory of 
organizations and thus has strategic importance 
for dealing with competitors or when negotiat­
ing licenses or other deals. Patent and other IP-
related information thus play, not just a technical, 
but a strategic role. 
Strategy is almost always formulated with re­
liance on imperfect information. Consequently, 
any access to information that can inform deci­
sions is a valuable resource. 
.2. Coordination 
Those involved in managing intellectual prop­
erty need coordination, and such coordination 
is essential to the strategic process of “allocating 
resources” identified in Chandler’s definition of 
strategy. The problem often encountered in the 
strategic management of intellectual property is 
that the range of people, skills, and qualifications 
required is such that no one person or group of 
people can easily carry out, in an integrated way, 
all the tasks required. The range of skills needed 
will include those of legal specialists, such as pat­
ent attorneys skilled in drafting and prosecuting 
patent and trademark applications; lawyers spe­
cializing in intellectual property who can assist 
with litigation or licensing contracts; and R&D 
managers who can provide suitable incentives 
and motivation to keep personnel involved in ob­
taining and protecting IP rights. Other person­
nel such as licensing managers, who may not be 
legally or technically qualified but have substan­
tial commercial experience, also have a significant 
part to play in managing intellectual property. 
Finally, senior managers are needed to guide 
and oversee the overall strategic management 
of the organization’s intellectual property. The 
person ultimately responsible for intellectual 
property in a company might come from a legal, 
business, or technical background. However, 
since it would be unusual for any one of such 
managers to have all the requisite skills to manage 
intellectual property, an essential feature of good 
IP rights management is good communication 
and coordination among those who, as a group, 
possess the requisite skills. Communication and 
coordination are key concepts to keep in mind 
when assembling staff to provide the skills for 
the organization. These concepts are especially 
important when making decisions about where 
to locate staff or find outsource specialists. 
For example, locating patent attorneys near 
to the R&D scientists the attorneys are meant to 
interact with will facilitate the process of patent­
ing and technology transfer. Conversely, isolat­
ing a specialist IP department from the strategic 
management of the organization will not help in­
tegrate the management of intellectual property 
into the strategic thinking of the organization as 
a whole. Compromises may have to be reached to 
reconcile conflicting demands of the R&D lab, 
IP legal department, and the organization’s head­
quarters. The aim, however, should be to enable 
R&D, IP law, general law, and general strategy to 
work together efficiently. 
.2. Education 
Finally, there must be a minimum level of IP 
awareness training for all staff, especially the ma­
jority who are not IP specialists. Such training is 
necessary to avoid employees compromising valu­
able intellectual property because they do not 
know, for example, that publication before filing a 
patent application invalidates the application. IP 
training can also serve to improve communication 
between researchers and IP specialists. Training 
sessions can provide a forum for publicizing the 
organization’s policy on incentives offered to em­
ployees to support the process of obtaining and 
preserving IP rights. Preliminary research results 
in the United Kingdom and of the common expe­
rience of those working as in-house patent attor­
neys show that, while most managers have heard 
of patents, they have only a limited knowledge 
of more-detailed information, such as what type 
of disclosure will prejudice a patent application. 
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PITKETHlY 
The aim of an organization’s IP awareness activ­
ity should therefore be to dispel such ignorance 
without trying to turn all employees into patent 
attorneys, thus ensuring that employees are rea­
sonably equipped to preserve the organization’s IP 
interests. 
.	 InSTITuTIonAL 	dIffEREnCES 
In	 Ip	 STRATEGy	 
Governments, public sector organizations, spin-
out companies, small and medium enterprises 
(SMEs), and large companies all need to pay at­
tention to IP issues. However, the issues that each 
will be concerned with will differ from institution 
to institution, as will the various IP strategies and 
practices the institutions adopt. 
.1 Governmental IP strategy 
In addition to having institutions to administer 
IP laws, most industrialized nations will need 
an IP policy, for dealing with trade-related IP 
aspects, as part of their general trade and indus­
try policies. However, any national government 
intellectual property or patent office has both an 
administrative role and an internal policy-mak­
ing and promotional role. The first IP systems 
in the U.K. resulted not from external trade 
pressure, but from the original goal of encour­
aging innovation. Today, battles commonly are 
fought to choose between trade pressures that 
protect external intellectual property and the 
perceived local, short-term advantages of mini­
mizing such protection and free riding on such 
external intellectual property. This conflict can 
lead to insufficient attention being paid to one 
of the original roles of IP systems: promoting 
innovation and diffusion of inventions. In the 
face of such distractions local innovators will fail 
to take advantage of the information that IP sys­
tems can diffuse (for example, through patent 
information systems) and will also likely fail to 
be influenced by, or even aware of, innovation-
promoting incentives. Thus, one of the most im­
portant things a government can do is to provide 
an effective, enforceable system for protecting 
and promoting local innovation that not only 
provides the infrastructure to administer the 
system and spread knowledge, but also actively 
promotes the use and benefits of the IP system 
to potential users. 
Such promotion can be carried nationally by 
the central government, as illustrated by the pro­
motional activities of the Danish patent office28 
and the traveling seminars of the U.K. patent of­
fice.29 Promotional activities can also be under­
taken at the local government level, as has been 
shown by the Tokyo metropolitan government’s 
IP center, which not only promotes IP aware­
ness but can even help pay for some IP work and 
applications.30 Obviously, exactly how awareness 
is promoted and which aspects of intellectual 
property are emphasized will vary from country 
to country. In any case, an IP system that po­
tential users are unaware of is guaranteed to be 
ineffective, since it will serve only the interests 
of the few who are aware of the benefits. 
.2 Public sector IP strategy 
IP strategy might appear to be of interest only 
to for-profit commercial organizations. Granted, 
the innovation-promoting role of IP rights may 
be less relevant for a public sector organization in­
volved in R&D as a matter of government policy, 
than for a private company seeking a commercial 
return. However, the controlling and intellec­
tual-resource-management aspects of IP strategy 
are nonetheless highly relevant to any institu­
tion—particularly public institutions that have 
a duty to manage their resources as best they can 
to achieve their public objectives. Government 
services, such as health services, government re­
search departments, university research laborato­
ries, and other public sector institutions involved 
in creating intellectual property will certainly 
need to formulate an IP strategy. They will need 
to ensure that staff are aware of the organization’s 
valuable IP assets and that these assets need man­
aging and preserving as much as any other as­
sets of the organization. An IP strategy can also 
help to ensure that any liabilities that might be 
incurred by the use—especially the inadvertent 
use—of intellectual property owned by other 
parties are minimized. 
Given, for example, the IP management 
functions within a university or government 
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CHAPTER .1 
research laboratory, an IP strategy is likely to 
emphasize protecting and exploiting intellectual 
property through licensing or spinout compa­
nies.31 Noncontractual and nonlitigious aspects 
of work, such as drafting patent applications, 
may be outsourced to patent attorneys in private 
practice. So one key role of a public organiza­
tion involved in R&D—especially collaborative 
R&D—will be to manage the IP elements that 
govern research contracts. 
In the case of public or charitably funded re­
search organizations, the absence of an IP strategy 
is likely to result in the organization effectively 
giving away its IP assets to others. Ignoring the 
need to manage IP resources is as serious a failing 
as neglecting to manage an organization’s physical 
or human resources. 
. Spinout and SME company IP strategy 
Small companies, especially those in the very early 
start-up phase of their existence, may not have the 
resources to employ any specialist staff (such as 
qualified patent attorneys). However, one might 
argue that companies at that stage of their exis­
tence have the largest portion of their overall val­
ue embedded in intellectual property. As such, an 
IP strategy is one of the most essential elements of 
a company’s overall strategy, and because of lim­
ited resources and information, the IP strategy 
will be difficult to formulate. Thus, because small 
companies lack resources and the complementary 
assets mentioned above, these companies, includ­
ing IP spinouts, run the risk of failing to appro­
priate returns from their innovations. 
To counter this potential loss of advantage, 
smaller companies need to spend what may seem 
like a disproportionate amount of their resources 
on protecting and exploiting their intellectual 
property. If necessary, these organizations should 
rely on external sources of advice and help to ac­
complish such protection and exploitation. A risk, 
which may be unavoidable at times, is that cash 
constraints may limit the ability of a company to 
protect and exploit its intellectual property. Thus, 
the company may be unable to reap as much of the 
benefit from its innovations as it otherwise might. 
By investing in the initial innovations to ex­
tract more value from them, a small company can 
use protected intellectual property to generate the 
financial and other resources needed to grow the 
business. A spin-out company may likely find it 
difficult to extract the maximum value from its 
innovations, especially if its IP rights are weak. 
However, as the company gradually increases the 
resources available to it, its ability to exploit subse­
quent innovations should improve. An IP strategy 
is not something that a small company cannot af­
ford to have, but rather something it cannot afford 
to be without. 
. Large-company IP strategy 
Large companies might be considered to have the 
simplest task when it comes to IP strategy, since 
they are likely to have enough resources to deal 
with IP issues promptly and, very often, in-house. 
But large companies face IP strategy problems 
that smaller companies or public institutions are 
unlikely to encounter. 
First, a large company is likely to have been 
built on the strength of its past technological 
successes. Most forms of intellectual property 
(apart from trademarks) have a limited lifetime, 
so past success is no guarantee of future suc­
cess. Indeed, the ability of a company to reap 
large financial rewards from out-licensing previ­
ously neglected IP assets may just be a prelude 
to the company’s demise, unless some of those 
proceeds from past success are invested in the 
future. Repeating success is never easy, especial­
ly in areas where technological uncertainty can 
undermine technical and commercial ability. In 
the absence of continued investment, decline is 
inevitable, since IP rights erode and technology 
gradually becomes obsolete. No company, how­
ever large, can afford to rest on its technological 
laurels. 
Second, communication and integration may 
present a challenge. One benefit of being a small 
company is that all the key personnel involved in 
IP issues probably work in the same building and 
interact with each other every day. For a large com­
pany, especially one with a separate in-house IP 
department, IP specialists must be continuously 
encouraged to communicate with those inventing 
and exploiting innovations within the company. 
Moreover, the IP department must communicate 
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PITKETHlY 
well with senior management and convince it of 
the importance of IP management. 
A third challenge is that IP departments 
within a larger company may be tempted to fo­
cus on internal department interests, rather than 
on the interests of the company as a whole. This 
might result in too many patent applications be­
ing filed or excessive licensing of technology that 
should instead be kept in-house. 
None of these challenges should force larger 
companies to outsource such IP management 
functions; they are just good reasons to make sure 
that IP is properly managed. In terms of commu­
nication alone, the benefits of keeping IP man­
agement functions in-house can be considerable 
if IP departments are managed well. 
.	 IMpRovInG Ip	 STRATEGy 
IP strategies inevitably differ with size and type 
of organization. As we have seen, the key ele­
ments of an IP strategy involve both external 
and internal factors. External factors include 
issues of licensing and litigation; internal fac­
tors include issues of valuation, information, 
coordination, and education. All these aspects 
of IP strategy should concern all types of insti­
tutions to some extent, though emphasis will 
vary. Public institutions may tend to concen­
trate more on licensing, information, and edu­
cation. Spinouts and small companies will be 
more concerned with external issues of licens­
ing and litigation, and, consequently, valua­
tion. Large companies will be concerned equal­
ly with all issues, and the companies may be 
more aware of IP issues due to their in-house 
IP departments. 
Each kind of institution can take basic ac­
tions to improve its own IP strategy. For govern­
ments, these might include: 
•	 promoting awareness of intellectual prop­
erty, from both a creator’s (potential in­
novators) and a user’s (potential infring­
ers) perspective 
•	 promoting use of information contained 
in patent and other IP databases to both 
source technology and inform further 
innovation 
•	 providing both central and local sources of 
advice and assistance with innovation ex­
ploitation, especially in overseas markets 
•	 providing basic education in innovation 
exploitation to IP lawyers (Although they 
may be the first point of contact for IP ad­
vice for many, they are generally only legal­
ly and not commercially trained. Having 
someone to whom companies could refer 
to for specific advice would help.) 
•	 organizing a network of innovation-
support centers to provide communal 
TTO/IP advice (Infrastructure to ex­
ploit innovations exists internationally; 
the problem in many countries is getting 
from the inventor to the overseas licens­
ee. Such centers might not be able to do 
all the work of normal TTOs, but would 
be able to coordinate IP exploitation
and protection.) 
•	 involving external trade organizations, 
which can help market technology overseas 
for those companies/organizations without 
the resources to do so 
•	 taking steps to enable organizations to 
use, protect, and exploit nontechnologi­
cal intellectual property—in particular 
copyright and trademarks, including col­
lective and certification trademarks and 
designations of origin—even where tech­
nological innovation is less common or 
absent 
For public sector institutions and research 
laboratories, basic actions to improve IP strategy 
might include: 
•	 promoting an awareness of intellectual 
property from the innovator’s perspective, 
including its value to the institution 
•	 promoting use of the information con­
tained in patent and other IP databases to 
inform further innovation 
•	 providing sources of advice and
assistance with intellectual property and 
innovation exploitation, especially in 
overseas markets 
•	 giving a manager within the organization 
specific responsibility for IP management 
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•	 combining the role of IP manager with 
that of TTO manager in order to control 
the exploitation of technology produced 
by the organization and to provide advice 
on research contracts with external orga­
nizations (This approach will work in an 
R&D-related organization) 
•	 taking action to facilitate good communi­
cation between IP generators and IP man­
agers, as well as between IP managers and 
those controlling the organization overall 
Spinouts and other small and medium enter­
prises could undertake these actions: 
•	 promoting awareness of the basics of IP law 
and IP exploitation among staff so that ev­
eryone knows what crucial errors to avoid 
•	 encouraging organizations to spend 
money in order to preserve and exploit 
commercially valuable intellectual prop­
erty, where doing so is obviously eco­
nomically justifiable 
•	 encouraging companies to use IP informa­
tion sources, such as patent and trademark 
databases, to supplement literature searches 
and to inform companies of competitors’ 
activities both at home and abroad 
•	 enabling companies to manage and provide 
incentives for those inventors who are the 
source of a company’s intellectual property 
and who may well be the source of future 
intellectual property 
•	 being prepared to form alliances and li­
censing deals to supplement the com­
pany’s resources and to exploit markets 
earlier than would otherwise be the case, 
especially in the early stages of a compa­
ny’s life, during which period resources 
are scarce (Such licensing should not be 
so late that competitors have sunk invest­
ments into developing their own compet­
ing technology, nor so early that the value 
of the company’s technology would not be 
fully appreciated or valued.) 
•	 being prepared for the exploitation of a 
succession of innovations (The company’s 
ability to fully exploit its inventions should 
gradually increase over time as proceeds 
from the exploitation of initial inventions 
are reinvested.) 
With public sector institutions and research 
laboratory scientists activities to improve IP 
strategy could include: 
•	 ensuring that laboratory notebooks are 
properly kept and that any publication is 
preceded by an assessment of patentability 
and commercial potential 
•	 ensuring that all research staff are aware 
of the basics of IP law, especially that 
publishing technology before an application 
is filed may preclude patent protection 
•	 ensuring that all research staff are familiar 
with IP-related staff in the organization 
or, if necessary, external TTO or patent 
attorneys who can provide expert advice 
at short notice 
•	 ensure that all scientists entering collabora­
tive agreements with other institutions have 
such agreements vetted by IP experts before 
they are signed 
Finally, larger companies will need to bear in 
mind the following points: 
•	 Even though a large company may have 
access to all the resources required for suc­
cessful IP exploitation, these may be ren­
dered useless by inadequate communica­
tion among the various people involved. 
Action should be taken to facilitate good 
communication between IP generators and 
IP managers, as well as between IP manag­
ers and those controlling the organization 
overall. 
•	 Intellectual property should be considered 
both a source of technology to exploit and 
a means of exploiting technology: a “Not 
Invented Here” attitude to externally 
sourced technology can be shortsighted. 
.	 ConCLuSIon 
IP strategy encompasses a far greater range of is­
sues than can be dealt with here. Strategic issues 
connected with intellectual property—in par­
ticular, the interaction between the strength of 
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PITKETHlY 
IP rights and access to complementary assets, as 
well as the specialist nature of the skills required 
to manage it—are particular to IP management. 
However, IP strategy can fit within a number of 
conventional strategic-management theoretical 
frameworks, particularly the resource-based view 
of the company, with its consideration of intan­
gible assets as a resource of the organization, and 
also game theoretical considerations of value-add­
ed distribution. As with any other resource, intel­
lectual assets should be used to best advantage to 
pursue the organization’s objectives. 
IP systems are always controversial, because 
they appear to be cases of means justifying ends: 
they use something generally considered undesir­
able (monopoly, even if temporary) to achieve 
something desirable (technical or commercial 
progress). Nonetheless, IP-rights systems are 
now institutionally embedded in many societies 
to such an extent that abolishing them or even 
weakening them would be extremely difficult 
without coordinated international cooperation. 
Such cooperation is highly unlikely to occur. 
Thus, whatever views are held of the system, or­
ganizations have no option, for now, but to work 
as best they can within it. 
The following is an essential tenet for any or­
ganization, including not-for-profit organizations: 
that if innovators do not use the IP rights at their 
disposal to try to influence or control the exploita­
tion of their own inventions, then others will do it 
for them. If this happens, the organization’s inven­
tions may be exploited in ways that do not conform 
or contribute to the organization’s objectives. n 
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Estimates of the Value of Holding European Patent
Stocks. Econometrica 54: 755–84. 
27.	 Pitkethly RH. 1999. The Valuation of Patents: A Review 
of Patent Valuation Methods with Consideration of 
Option-Based Methods and the Potential for Further 





30. See supra note 27.
31. Oxford 	 University’s technology licensing office is 
ISIS Innovation. It has developed a long track record 
of success in exploiting university-based research 
through a combination of licensing and the formation 
of spinout companies (www.isis-innovation.com). See,
also, in this Handbook, chapter 13.4 by T Cook. 
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CHAPTER 5.2 
IP Management Policy: A Donor’s Perspective
 
Zoë ballanTyne, Legal and Operations Adviser, the Wellcome Trust, U.K. 
daniel nelKi, Head of Legal and Operations, the Wellcome Trust, U.K. 
ABSTRACT 
This chapter describes how the Wellcome Trust, a ma­
jor charitable funder of biomedical research, manages 
intellectual property arising from Wellcome-sponsored 
research. The trust recognizes that the development of 
new health technologies requires the enlightened man­
agement of intellectual property through partnerships 
involving funders, scientists, institutions, and companies. 
This chapter explains how the charitable mission of the 
trust influences its decision-making process. The chapter 
includes case studies to illustrate the concerns of the trust 
and to identify key procedures. 
1. THE	 WELLCoME	 TRuST 
The Wellcome Trust is an independent, U.K.­
based biomedical research charity. In the year 
2006–2007, the trust will invest nearly US$1 bil­
lion in biomedical research, both in the United 
Kingdom and internationally. The Wellcome 
Trust was established in 1936 after the death 
of Sir Henry Wellcome. In his will, Sir Henry 
vested the entire share capital of a drug com­
pany he founded, The Wellcome Foundation, 
into the Wellcome Trust. The Wellcome drug 
company was absorbed, by a series of mergers, 
into GlaxoSmithKline, and, in the process, the 
trust diversified its investment portfolio. The 
trust no longer has a significant shareholding in 
GlaxoSmithKline but operates entirely indepen­
dently of the drug company. 
The mission of the trust is to foster and pro­
mote research to improve human and animal 
health (see Box 1 for a statement of the organi­
zation’s mission and general policy). Funding by 
the trust supports a wide range of work in the 
biomedical arena, including basic science, tech­
nology transfer, medical humanities, and public 
engagement with science. In order to support 
scientific research of the highest caliber, grant 
schemes include not only career-based schemes 
for scientists, from Ph.D. studentships to fellow­
ships, but project and program grants, equipment 
grants, and infrastructure initiatives. 
The majority of trust funding goes to research­
ers in U.K. academic institutions, but the trust has 
also always supported research for tropical diseas­
es, particularly in developing countries. Support 
schemes are available for U.K. researchers who 
wish to carry out tropical medicine research in the 
developing world, as well as for researchers, based 
in developing world institutions, who are conduct­
ing research in public health or infectious diseases. 
2. Ip	 MAnAGEMEnT 
When considering IP (intellectual property) 
management, the trust’s key aims are (1) to 
ensure that intellectual property arising from 
the research that it funds is prudently used to 
Ballantyne Z and D Nelki. 2007. IP Management Policy: A Donor’s Perspective. In Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. Z Ballantyne and D Nelki. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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BAllANTYNE & NElKI 
Box 1: Wellcome Trust Policy on Intellectual Property and Patenting 
Note that the policy is currently under revision and is expected to be approved in spring 2007.1 
Preamble 
The mission of the Wellcome Trust is to foster and promote research with the aim of improving 
human and animal health. This is the driving force behind all of the Trust’s activities, and the 
basis for its policy on the protection and use of intellectual property rights. The aim of this 
policy is to provide a clear statement for Trust-funded scientists on the Trust’s position on the 
protection and provide a clear statement for Trust-funded scientists on the Trust’s position 
on the protection and use of intellectual property through patents; and to inform other Trust
activities, particularly those relating to genomics. 
In developing this policy, the Trust has considered a wide range of issues, in particular the role of 
intellectual property rights in creating the best conditions for research and in translating that
research into tangible healthcare benefits. The Trust supports the appropriate protection and 
use of intellectual property where this will maximise healthcare benefits and enable biomedical 
research to flourish. 
In order for research advances to qualify for intellectual property protection, the legal criteria 
for patent protection must be fulfilled. This means that, to be patentable, the results of research 
must describe an invention that is: 
• novel, i.e., not described elsewhere before 
• non-obvious, i.e., involving a step sufficiently inventive that most people working in that field 
could not have predicted it
• capable of industrial application, i.e., described in such a way that it can be made or used. 
Patents, including those covering genes and their products, are no exception, and the Trust is 
supportive of these if there is sufficient information to indicate that the DNA sequences in 
question can be used to develop healthcare benefits. The Trust does not support the patenting of 
raw DNA sequences in the absence of such information. This is in line with EU law, which states 
that a gene sequence, whether partial or complete, is only patentable when it has been isolated 
and its function described.
The Trust is particularly concerned about patents and patent applications which are unreasonably 
broad and opportunistic, e.g., when there is limited functional data available to support those 
patent claims. The Trust may challenge such speculative patents if it believes that they are being 
applied for or used in ways that could be detrimental to research or limiting to the development of 
healthcare benefits. 
As a charity the Trust is under an obligation to ensure that useful results from the research that
it funds are applied for the public good. Technology Transfer at the Wellcome Trust aims to bring 
together researchers, universities, industry and investors to help ensure that promising lines 
of research yield practical healthcare benefits. Given the importance of these issues and the 
potential health gains which should flow from genomics research, the Trust will continue to keep 
this policy under review. 
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CHAPTER .2 
achieve health care benefits and (2) to maintain 
and promote a supportive environment for 
future biomedical research. The trust has 
historically taken an open and innovative 
approach to IP management, some examples of 
this are discussed below. 
Other donors, of course, will have different 
perspectives, mechanisms, and processes for 
achieving their respective missions. The trust’s 
approach to managing intellectual property 
has developed in a way that the trust considers 
appropriate for achieving its own objectives. This 
chapter is not intended to set out any form of best 
practice. The authors’ aim is simply to present 
experiences, from their work in technology 
transfer at the trust, that might be instructive 
to other practitioners. 
.  MAnAGInG InTELLECTuAL 	pRopERTy	 
fRoM TRuST GRAnTS 
The trust awards the majority of its grants based 
on its standard grant conditions.2 The trust does 
not normally seek to own intellectual property 
arising from the research it funds, but the trust 
does require a sponsored academic and research 
host-institution to establish agreements with 
personnel involved in the research that vest in 
the institution any intellectual property gener­
ated. Under the trust grant conditions, the in­
stitution must also have established systems for 
identifying and managing intellectual property 
generated under a trust grant (for example, a sys­
tem for invention disclosures and evaluation by 
the institution’s technology transfer office or the 
equivalent function). 
If trust-funded intellectual property is gen­
erated, the grant conditions require the host-
institution to consider whether protecting the 
intellectual property is an appropriate way for 
that research to benefit the public.3 The usual 
rationale for doing so is that attracting further 
research and development funding—which 
may likely be from a third-party commercial 
organization such as a venture capital company 
or a pharmaceutical or biotechnology compa­
ny—requires protecting the intellectual prop­
erty, often through a patent filing. Such patent 
filings offer a potential limited monopoly to any 
party who might wish to develop the intellec­
tual property. 
In some cases, of course, IP protection may 
not be the best way to obtain a public benefit. 
Instead, allowing immediate and unprotect­
ed access to the research results may directly
improve public health or enable other research­
ers to build upon the results with the aim, for
example, of aiding related health research 
through the creation of large data sets (see also 
section 7.1.3 below). Alternatively, the research 
results may be of insufficient value on their own, 
making patenting worthless. 
.1 Exploiting Intellectual Property 
Since part of the mission of the trust is to improve 
human and animal health, translating research 
successes into health care applications is essential. 
In the vast majority of cases, further development 
and investment in the results of trust-funded re­
search are necessary for it to have a health impact. 
Under the trust’s grant conditions, the host-insti­
tution has the responsibility to decide whether the 
exploitation of trust-funded intellectual property 
is an appropriate way to achieve public benefit. If 
the institution decides that exploiting the intellec­
tual property is appropriate, then before it grants 
any rights to the intellectual property, it must first 
seek the agreement of the trust on this matter. 
The trust’s consent would normally be contingent 
upon the institution accepting the trust’s standard 
revenue and equity-sharing terms. 
Under the trust grant conditions, if the trust 
reasonably considers that the institution is not 
adequately protecting, managing, or exploiting 
trust-funded intellectual property, the trust has 
the right to take over such activities instead. In 
addition, to ensure that potential grant recipients 
can adhere to the trust’s policies, the applicant(s) 
and institution are required to disclose at the 
grant application stage whether the research will 
use any technology or materials that are subject 
to agreements with third parties (such as com­
panies or other research institutions) that might 
affect the research institution’s ability to develop 
the potential trust-funded intellectual property as 
envisaged. 
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BAllANTYNE & NElKI 
.2 The consent process 
During the consent process, the institution pro­
vides as much detail as possible about the pro­
posed method of exploitation (such as draft li­
cense terms, material transfer agreements, and 
collaboration agreements). In the case of a pro­
posed transfer of intellectual property into a spin-
out company, the institution should provide the 
draft shareholders’ agreement and the company’s 
articles of association. The trust will assess on a 
case-by-case basis whether the terms set out an 
appropriate means by which the intellectual prop­
erty can achieve a public benefit. If the proposed 
development route and associated agreement 
terms are determined to be consistent with the 
trust’s public benefit objectives, the trust will nor­
mally enter into a benefit-sharing arrangement 
with the institution and with any other involved 
parties. This can include a percentage share of 
milestone and/or royalty payments. In the case of 
spinout companies, it will usually involve a share 
of the equity of that company. 
Because of its charitable status, the trust is 
required to assess any benefit-sharing terms and 
their public benefit impact. It is a fundamental 
principle of English charity law that any “private 
benefit” coming to an individual or company 
from a charity must be necessarily incidental to 
the public benefit resulting from the implementa­
tion of the charity’s objectives. Accordingly, where 
the trust’s charitable funding gives rise to valu­
able intellectual property and that value is to be 
shared with other parties, such as the researcher, 
the host-institution, and a licensee, it is impor­
tant that those parties receive only a portion of 
the total value of that intellectual property. The 
amount should be appropriately related to the 
amount that the party has contributed to the cre­
ation and further development of the intellectual 
property. The trust must also receive an appropri­
ate share of the value of the intellectual property 
that its funding helped create. 
Because most of the host-institutions that 
receive funding from the Wellcome Trust are 
themselves U.K. charities (for example, univer­
sities) and are governed by equivalent charity 
law, the research institutions themselves will 
consider the public and private benefit balance 
when establishing any IP exploitation agree­
ment. The consent process, therefore, is usually 
straightforward, since the proposed exploitation 
terms will likely be consistent with the trust’s 
objectives. 
. ExAMpLES 	of	 TRuST Ip	 MAnAGEMEnT 
.1 Material transfer agreements 
When a trust researcher requires biological ma­
terials from a third party, the consent of the 
trust is required if the relevant material trans­
fer agreement (MTA) grants any rights over 
trust-funded intellectual property. The trust 
has often encountered what it considers to be 
reach-through clauses in such agreements that 
give the provider of the material a payment-
free license, for commercial purposes, to any 
invention made through the recipient’s use of 
the materials. The trust considers this unac­
ceptable in a situation in which the provider of 
the materials makes no inventive contribution 
to new intellectual property created by the re­
cipient other than providing materials. In such 
situations, although a case-by-case approach 
is taken, the trust will often recommend that 
either (1) the license for such intellectual prop­
erty, to the provider, be limited to a nonexclu­
sive, noncommercial research license, or, (2) if 
the provider has significantly contributed to the 
new intellectual property and is considered to 
be a suitable partner for developing it further, 
the provider should be granted a time-limited 
option to negotiate a commercial, royalty-bear­
ing license (with the ability for the institution 
to license the invention to other partners, if 
license terms cannot be agreed to within the 
time period). However, where the recipient 
files patents on inventions that are directly and 
principally related to the materials, it is usu­
ally appropriate for the provider to be granted a 
nonexclusive license to use the patents solely in 
connection with the materials, so the provider 
can continue to use its own materials. Offering 
the provider a time-limited option to negotiate 
an exclusive license of such patents can be ap­
propriate in many cases. 
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CHAPTER .2 
.2 Pipeline agreements 
Pipeline agreements usually give a company an 
exclusive license to all future intellectual proper­
ty arising from, for example, an institution’s de­
partments. This type of arrangement is problem­
atic for the trust because should any trust funds 
be going into such a department, the automatic 
license prevents the trust from assessing, on a 
case-by-case basis, whether the proposed exploi­
tation plan of the new intellectual property is a 
suitable way of achieving a health-care benefit. 
The breadth of the pipeline arrangement often 
makes it unlikely that an automatic license to a 
company would be the most appropriate route 
of exploitation, particularly if the company’s 
resources are limited and the license field is 
much wider than that of the company’s focus. 
In such cases, the trust will normally agree with 
the relevant institution that, prior to granting 
any license of trust-funded intellectual property 
to the company under the pipeline agreement, 
the institution will request the trust’s approval 
of an exploitation plan and the license terms. 
However, such an arrangement may be consid­
ered acceptable if the pipeline arrangement is 
appropriately narrow, the anticipated intellec­
tual property can be well defined, the company 
in question is suitably qualified and resourced 
to exploit the relevant intellectual property, and 
revenue sharing terms with the host-institution 
can be agreed on in advance. 
. Licensing arrangements 
The trust commonly consents to the grant of 
exclusive license, or even the assignment of a 
patent, to a university spinout company. The 
trust recognizes that exclusive licensing or as­
signment will often encourage further invest­
ment in and development of trust-funded in­
tellectual property because it gives the investor 
or developer a competitive advantage. Where 
appropriate, the trust also uses co-exclusive li­
censing (the grant of licenses to a small num­
ber of partners—typically less than five) to bal­
ance incentives for commercial investment in 
product development, manufacturing, and dis­
tribution with wider public access to the new 
product. 
Sometimes, the patent in question is rela­
tively broad. It may address a number of diseas­
es, or it could be widely used by third parties to 
develop health-care applications without an un­
necessarily negative impact on their respective 
markets or applications. In such cases, the trust 
may conclude that there is a risk that a single li­
censee (especially in the case of a resource-limit­
ed, early-stage spinout) would be unable to fully 
exploit the patent across all applicable fields. In 
addition, if licensing is not carefully handled in 
such cases, there is a further danger that the re­
search fields would be unnecessarily inhibited. 
Thus, the trust would normally propose a pro­
gram of nonexclusive licensing, or careful, selec­
tive field-of-use licensing as a more appropriate 
means of achieving a public benefit. 
. puBLICATIonS 
The trust grant conditions require that the results 
of research funded by the trust be published in 
an appropriate form, although it is accepted that 
publication may be reasonably delayed to allow 
IP protection. The trust sees publication as a key 
process in maintaining an active, healthy research 
base and allows scientists to keep up-to-date with 
the latest discoveries, makes it possible for their 
research findings to be challenged and tested by 
their peers, and lets other scientists build upon and 
benefit from the new knowledge. Indeed, in the 
right circumstances, publication alone can there­
fore be a means of achieving a public benefit. 
In 2003–2004, the trust commissioned two 
reports on the scientific research publishing mar­
ket.4 They concluded that although many scien­
tific articles were available electronically, pub­
lishers’ access policies posed potential barriers to 
dissemination, and journal subscriptions were a 
heavy cost burden on institutional libraries and 
researchers. After these reports were issued, the 
trust added a new condition to its grants that 
requires all trust-funded researchers to deposit a 
copy of their scientific publications relating to 
trust-funded research into PubMed Central (a 
free-access, digital repository of full-text, peer-re­
viewed biomedical journals that was developed by 
and is maintained by the U.S. National Library of 
HANDBOOK OF BEST PRACTICES | 
  
     
	 	
	
      
      
     
       
     
        
        
       
      
      
    
       
     
      
      
     
      
       
       
       
       
     
     
       
       
       
      
       
       
    
   
     
       
       
      
     
       
      
    
       
        
       
     
     
      
      
     
      
     
      
      
     
     
      
     
       
       
       
      
     






BAllANTYNE & NElKI 
Medicine). The trust is also part of a consortium 
composed of medical-research charities and gov-
ernment-funding bodies that is funding and de­
veloping a U.K. counterpart of PubMed Central. 
This initiative aims to ensure that research is dis­
seminated as widely as possible and that both ac­
cess to articles and long-term preservation of the 
archive is ensured. 
.  Ip	 And	 TECHnoLoGy	
TRAnSfER AWARdS 
Technology Transfer at the trust makes trans­
lation awards to facilitate the development of 
early-stage health-care inventions to the point 
at which they can be further developed, usually 
by a commercial company. Funding through 
these awards aims to fill what the trust consid­
ers to be the funding gap between basic research 
outcomes in academic research and the point at 
which the research is sufficiently developed to 
attract investment by venture capital firms or 
potential commercial licensees. Trust translation 
awards may be made to companies, usually early-
stage spinouts, or to academic host-institutions. 
Funding for spinout companies is normally in 
the form of a program-related investment. With 
this type of funding—permissible for chari­
ties—a “charitable investment” is made into a 
specific research project with the primary aim of 
achieving the mission of that charity. Such fund­
ing provisions enable the trust to offer charitable 
funds to commercial vehicles where there is an 
ongoing research and development project for 
particular health care applications. While receiv­
ing a potential return on such a program-related 
investment is not the primary objective of mak­
ing such an award, it is nonetheless important 
(for balancing public and private benefits arising 
from charitable assets) for the trust to receive 
an appropriate share of any benefits that might 
result from the program-related investment. 
Accordingly, Technology Transfer normally 
structures its translation awards into companies 
as convertible loans rather than as grants.5 
Because of the critical nature of this stage 
of the development of a technology, appropri­
ate IP generation, identification, filing, ongoing 
monitoring, and prosecution are vital. As part of 
the application process for a translation award, 
Technology Transfer requires information about 
whether patents have already been filed, on the 
technology in question, or will be filed in the 
course of the funding. The application also typi­
cally requires disclosure of information about 
freedom-to-operate issues related to the relevant 
technology. 
For translation awards in areas of particular 
high-strategic interest or relevance to the trust, 
Technology Transfer may make strategic trans­
lation awards available. Through such awards,
Technology Transfer will often actively partici­
pate in project management, including the man­
agement of intellectual property that might arise. 
This involvement may even include assistance 
with finding commercial partners or further 
funding. Funding agreements tend to be much 
more customized for strategic translation awards, 
but a number of commonly used provisions have 
been developed to address IP issues that may 
arise. Two broad categories are addressed in these 
provisions: 1) keeping the research field open 
and 2) ensuring the appropriate management 
and exploitation of intellectual property for a 
health-care benefit: 
1) Keeping the research field open: 
(a) a prohibition on enforcing trust-funded 
intellectual property against universities/ 
research institutions carrying out non­
commercial research 
(b) the grant 	 or reservation of a license 
for research purposes (which may be 
sub-licensable) to the trust or relevant 
institution(s) 
2) Ensuring appropriate management and 
exploitation of intellectual property for a 
health-care benefit: 
(a)formation of an IP management group, 
comprising the researchers, independent 
experts, and representatives from the 
trust, to provide opinion and guidance 
on IP strategy 
(b) terms to ensure that the results of re­
search that have a potential developing 
country application are developed for 
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CHAPTER .2 
such purpose and made available in the 
developing world 
.1 Case studies 
.1.1 Typhoid vaccine 
With Trust funding, the company Emergent 
(Europe) Limited is testing its one-dose oral ty­
phoid vaccine in healthy Vietnamese adults and 
children in preparation for proof-of-concept and 
phase III studies in the southeast Asia region. 
Emergent owns the underpinning intellectual 
property in the vaccine. Typhoid has both a de­
veloped-world travellers’ market and a less-prof­
itable developing-world endemic market, so the 
Trust wanted to ensure that the developing world 
market would benefit from the development of 
the vaccine. Terms were therefore negotiated, 
giving timescales within which the vaccine has 
to be launched in developing world markets. If 
launch does not take place within the relevant 
timescale, and there are no concrete plans to do 
so within a reasonable time, the Trust can acquire 
the rights to manufacture and sell the vaccine in 
those countries. 
.1.2 Drugs for malaria 
The Trust, the Medicines for Malaria Venture, 
and the Singapore Economic Development Board 
agreed to fund the Novartis Institute for Tropical 
Diseases (NITD) to carry out a program of drug 
discovery in the field of malaria, the main aims 
being to find a one-dose cure for Plasmodium fal­
ciparum and a curative modality for Plasmodium 
vivax. Novartis agreed to make contributions in 
kind to the cost of the program. 
NITD owns, (or in the case of intellectual 
property generated by collaborators, has rights to 
acquire rights to), all intellectual property gener­
ated during the funded program, but the Trust and 
MMV have a noncommercial research license to 
enable basic research on any findings of the pro­
gram. If NITD decides not to file or prosecute 
such IP, the Trust and MMV may, so that valu­
able IP protection is not lost. In addition, NITD 
has agreed to covenants not to sue for infringe­
ment of the program patents any not-for-profit 
institutions that may carry out noncommercial 
research. NITD cannot develop and commercial­
ize products comprising Trust-funded IP without 
the consent of the Trust and MMV. Consent, not 
to be unreasonably withheld,  is subject to a ben­
efit-sharing arrangement. In the event that NITD 
puts development on hold for certain periods, or 
fails to make any sales into developing countries 
within a certain period following launch, the Trust 
and MMV have the option to take over the neces­
sary IP rights, to ensure that developing countries 
benefit from the outcomes of the research. 
.  Ip	 MAnAGEMEnT 	foR 
SpECIAL InITIATIvES 
The trust has been involved in a number of large 
initiatives to create data resources (principally 
DNA sequence information) for the scientific 
community. In each case, IP management has been 
considered from the outset as a key aspect of the re­
source. In the case of DNA sequencing, the trust’s 
position is that basic DNA sequence information 
should be placed in the public domain as soon as it 
is practical to do so without limitations on use. 
.1 Case Studies 
.1.1 The human genome project 
The Wellcome Trust Sanger Institute, which is 
largely funded by the Trust, took a major role in the 
Human Genome Project for its part in sequencing 
almost one-third of the human genome. The par­
ticipants in the Human Genome Project decided 
that all the information produced by public hu­
man-sequencing centers should be made immedi­
ately and freely available to the biomedical-research 
community, via the Internet, without seeking any 
IP rights and without restrictions on how the in­
formation could be used. These principles were 
enshrined in an agreement on human sequencing 
brokered at a strategy meeting sponsored by the 
Trust in Bermuda in February 1996 and extended 
to data on other organisms at a later meeting. 
.1.2 The SNP Consortium 
In partnership with several large pharmaceutical 
and technology companies, the Trust is a major 
funder of the SNP Consortium, which aims to 
HANDBOOK OF BEST PRACTICES | 1 
  
     







       
        
       
       
      
        
        
       
       
    
 
BAllANTYNE & NElKI 
produce a high-quality map of human genetic 
markers, known as single nucleotide polymor­
phisms (SNPs). An SNP is a site in DNA where 
there is a change in a single “letter” of the DNA 
code. Sometimes this change in a single letter can 
cause a visible effect or cause a disease, but even 
if there is no obvious effect, knowing the location 
of the change can still be useful. The SNP map 
may be used to identify specific genes involved 
in disease processes, to develop novel diagnos­
tic tests, and to predict individuals’ responses to 
medical therapy. 
As SNPs by themselves are only a small fac­
tor in the development of new drugs, the map 
was considered to be a precompetitive resource 
that would be of huge benefit to the biomedical 
research community. The consortium therefore 
agreed to put the SNP map into the public do­
main. Consortium members have access to the 
data on the same terms as other users: there is no 
preferential access. To keep the SNP map freely 
available to the public, the consortium filed pat­
ent applications on SNPs as evidence of dates of 
discovery (so that these would act as prior art to 
any subsequently filed patent). The patent appli­
cations would be abandoned prior to grant. 
.1. The international HapMap project 
The Trust, through the Sanger Institute, is a major 
participant in the HapMap consortium, which is 
made up of members from the United Kingdom, 
Japan, United States, Canada, Nigeria, and 
China. The HapMap consortium aims to build a 
map of haplotypes, or “blocks” of SNPs that are 
inherited together in humans, to aid in pinpoint­
ing genetic variations associated with disease. 
These data represent a valuable precompetitive 
resource for the biomedical research community, 
and it was decided to make SNPs and haplotypes 
available to the public as they were identified. 
There was a concern that in the early stages of 
the project, when data were not sufficiently dense 
to derive haplotypes, third parties could combine 
HapMap data with their own data and file patents 
on haplotypes. These filings could prevent the 
HapMap Project from continuing. Accordingly, 
data were initially released under a “click-wrap” 
nonexclusive license,6 which required researchers 
accessing the database to agree (by clicking a box 
on the HapMap Web page) to the following stan­
dard terms of access: 
1. not 	 to restrict access to or the use of 
HapMap data by others 
2. not to file composition-of-matter patents 
on SNPs, genotypes, or haplotypes based 
on HapMap data 
3. not to file patents containing claims to par­
ticular uses of any SNP, genotype, or hap­
lotype data based on HapMap data unless 
such claims do not restrict, or are licensed 
on such terms that do not restrict, the abil­
ity of others to use at no cost the HapMap 
data for other purposes 
4. to share data with other licensees only un­
der the same license 
The main disadvantage of this approach was 
that HapMap data could not be shared with oth­
er large-scale genomic databases. In December 
2004, following release of over 1 million SNPs 
by the HapMap project, a further release into the 
public domain of 1.6 million SNPs by Perlegen 
Sciences Inc. and the development of new hap­
lotype analysis tools, the consortium decided that 
sufficient data were in the public domain to consti­
tute prior art and that derivation of haplotypes and 
haplotype tag SNPs from HapMap data would be 
considered to be obvious and not patentable. The 
click-wrap license was therefore abandoned. 
.	 ConCLuSIonS 
The trust’s primary aim when considering IP 
management is whether it is an appropriate 
mechanism for achieving part of the trust’s mis­
sion, namely improving human and animal 
health. Practically, this translates into a focus 
on promoting a healthy research community 
and exploitation of research for health care out­
comes. By encouraging exchange of research re­
sults, making large-scale databases freely available 
for researchers, and discouraging restrictions on 
the research use of inventions, the trust aims to 
keep the research-base broad and to benefit from 
the exchange of ideas. The role for commercial 
(or noncommercial) exploitation is recognized 
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and encouraged, provided that there is a clear 
health care benefit as the ultimate outcome. The 
trust sees intellectual property as a useful tool for 
achieving these aims and encourages the intel­
ligent management of intellectual property by 
its grantees to ensure that trust-funded research 
achieves its full potential.  
The trust also recognizes that, on the whole, 
given the inherently varied nature of research 
and the diversity of health care applications that 
may arise, potential intellectual property emerg­
ing from trust funding should be considered on 
a case-by-case basis to determine how to best 
disseminate, protect, and develop the results. 
For this reason, the trust has a devoted group, 
Technology Transfer, to manage these processes 
and considerations. The trust is also in the ad­
vantageous position of being a significant funder 
in the area of biomedical research. This position 
offers the opportunity to contribute its perspec­
tive as a charitable funder to both governmental 
policies and institutional mechanisms for manag­
ing intellectual property. The trust’s collaborators, 
partners, and IP developers recognize the trust’s 
charitable motives and are usually accommodat­
ing to the trust’s IP policies and related goals with 
respect to health impacts. This accommodation is 
critical because the trust recognizes that the devel­
opment of new health technologies requires the 
enlightened management of intellectual property 
through partnerships of funders, scientists, insti­
tutions, and companies. n 
Zoë ballanTyne, Legal and Operations Adviser, Technology 
Transfer, the Wellcome Trust, 215 Euston Road, London, 
NW1 2BE, U.K. z.ballantyne@wellcome.ac.uk 
daniel nelKi, Head of Legal and Operations, Technology 
Transfer, the Wellcome Trust, 215 Euston Road, London, 
NW1 2BE, U.K. d.nelki@wellcome.ac.uk 
1.	 Please visit www.wellcome.ac.uk for the latest policy 
version. 
2.	 www.wellcome.ac.uk/doc_WTD004055.html. 
3.	 Trust-funded IP includes all IP created, exemplified, or 
developed in whole or in part from the research that
the Trust funds. Trust-funded IP does not normally 
include copyright in artistic works, books, articles,
scientific papers, lectures, or audio or visual aids to the 
giving of lectures or teaching.
4.	 The Wellcome Trust. 2003. Economic Analysis of 
Scientific Research Publishing. SQW Limited, A Report
Commissioned by the Wellcome Trust: London. www. 
wellcome.ac.uk/assets/wtd003184.pdf. 
The Wellcome Trust. 2004. Costs and Business Models 
in Scientific Research Publishing. SQW Limited, A Report
Commissioned by the Wellcome Trust: London. www.
wellcome.ac.uk/assets/wtd003182.pdf. 
5.	 www.wellcome.ac.uk/assets/wtx024257.doc. 
6.	 Click-wrap licenses are similar to the shrink-wrap 
licenses common with software. If one wants to access 
data online, one has to click a box that typically states 
something like “I agree to these terms” before one is 
let through to the online database.
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CHAPTER 5.3 
Making the Most of Intellectual Property:

Developing an Institutional IP Policy
 
sTanley p. KowalsKi, The Franklin Pierce Law Center, U.S.A 
ABSTRACT 
An institutional IP (intellectual property) policy forms the 
very foundation of IP management and, as such, serves as 
the starting point for a system of institutional best prac­
tices. The IP policy should be entirely consistent with the 
mission of the institution. Whether the role of the insti­
tution, as defined by its mission, is primarily disseminator 
of knowledge through teaching and publication, genera­
tor of research, technology transfer engine, or promoter 
of economic development through education and service 
and/or through technology transfer, the institutional IP 
policy should be drafted and enforced in a manner consis­
tent with the mission. Doing so will bring efficiency and 
clarity to IP management, since all the components of the 
policy, including IP ownership, patenting, confidentiality, 
and disclosure can be written into the policy. Moreover, 
the intellectual property will serve the mission in a way 
that strengthens the institution’s credibility, reputation, 
and public image. 
1. InTRoduCTIon 
Establishing an IP (intellectual property) policy 
is necessary for several important reasons. IP 
rights, including patents, copyrights, trademarks, 
and industrial property rights attach to research, 
administrative, and scholarly (including course-
ware) work products. Therefore, any public sector 
institution entering into research contracts with 
private sector entities will encounter IP issues. 
These matters will also need to be addressed in 
cases involving government-funding agreements, 
which often carry provisions for the disposition 
of intellectual property. 
Of course, most universities already have IP 
policies in place in a number of areas. Faculty and 
students have an interest in publishing scholarly 
works, and publishing carries with it copyright 
ownership issues. Most often publishers require 
assignment of copyright, but what about the in­
terests of the author or the institution? Lectures 
and course curriculam are also copyrightable. 
Who owns these? The faculty or the university? 
These same concerns govern other ostensibly 
more-complicated IP areas. For example, univer­
sities have an interest in owning or controlling 
the work product of nonacademic employees. Is 
there an operable work for hire doctrine that gov­
erns the country where the university is located? 
If not, agreements transferring ownership to the 
university must be in force. 
These kinds of issues will grow increasingly 
relevant for public sector research institutions as 
they become more involved with national and 
global IP systems. Indeed, for a university wishing 
to adopt a technology transfer program structured 
around licensing, a conceptually solid, pragmatic 
IP policy will be an essential building block for 
the program. It is the foundation upon which all 
other IP activities and initiatives are built. For de­
veloping countries, putting an IP policy in place 
is an especially important step for protecting their 
interests. When a university in a developing coun­
try commercializes an invention, an IP policy can 
Kowalski SP. 2007. Making the Most of Intellectual Property: Developing an Institutional IP Policy. In Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et
al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. SP Kowalski. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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be used to establish an equitable basis for resolv­
ing issues related to ownership, disclosure, and 
the distribution of income. In fact, the World 
Intellectual Property Organization (WIPO) has 
documented that universities and R&D insti­
tutions in developed countries, and also some 
countries in Asia and Latin America can generate 
significant income from sources such as: 
•	 royalties and fees from licensed patents 
from staff innovations and inventions 
•	 consultancy 
•	 research contracts 
•	 sponsored research 
•	 university-owned companies and joint 
ventures1 
Remember that it is too late to begin formu­
lating IP policy when negotiations about IP have 
already begun. As Lita Nelsen, Director of the 
Massachusetts Institute of Technology (M.I.T.) 
Licensing Office, observes, “Although policies will 
change over time as the program evolves, the ma­
jor issues must be decided in advance. Otherwise, 
a new program is likely to stall or fail altogether 
in an entangled committee indecision and policy 
ambiguity.”2 
2.  MATCHInG	 THE	MISSIon To Ip	 poLICy 
Certain steps should be considered when estab­
lishing an institutional IP policy. Initially, admin­
istrators of the institution will need to assess its 
mission. This will involve examining not only the 
university’s mission statement but also prioritiz­
ing the institution’s roles with respect to the mis­
sion. These may include: 
•	 disseminator of knowledge through teach­
ing and publication 
•	 generator of research
•	 technology transfer engine 
•	 promoter of economic development
through education and service and/or 
through technology transfer 
Such considerations will help establish an in­
stitutional IP policy that supports mission priori­
ties. For example, if the top priority is education 
and dissemination of knowledge, then IP policy 
should favor faculty ownership or release of in­
tellectual property into the public domain, with 
less emphasis on IP protection. If R&D activities 
are the institution’s top priority, then the insti­
tution should have greater control of intellectual 
property (for example, more-flexible licensing ar­
rangements with industry, to encourage industry 
funding, or more emphasis on industry needs). 
If the institutional mission emphasizes technol­
ogy transfer and commercialization, then even 
greater institutional control of intellectual prop­
erty may be most appropriate. This would involve 
IP strategies geared towards commercialization 
through inducing investment (exclusive licensing 
preferred), more-flexible royalty sharing with in­
ventors to induce disclosures, and choosing the 
best commercial partners for any given technol­
ogy. Finally, if the institutional mission priority 
is economic development, then a more-balanced 
IP ownership policy that promotes technology 
transfer, driven by economic development op­
portunities, may be preferred. Such an approach 
might focus on licensing regional companies and 
encouraging local spinouts by providing incuba­
tor facilities. Since economic policies will drive 
development and implementation of the IP pol­
icy that most supports economic growth, there 
should also be built-in flexibility to accommodate 
changes in economic climate. 
An exemplary case of an organization’s mis­
sion matching its IP policy can be found at the 
Drugs for Neglected Diseases Initiative (DNDi). 
Its mission statement proclaims that “[t]he mis­
sion of DNDi is to develop safe, effective and af­
fordable new treatments for patients suffering from 
neglected diseases, and to ensure equitable access to 
these.”3 This mission provides the framework for 
the institution’s IP policy (see Box 1). 
Note that DNDi explains how it “will pursue 
creative and innovative strategies to make the fruits 
of research projects readily available” in terms of its 
approach to managing intellectual property. This 
type of language provides for a flexible intellec­
tual property management style that is consistent 
with its core mission. Strong IP policies, such as 
DNDi’s, incorporate such language to allow the 
institution to operate without being constrained 
by its own IP policies. 
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.  foRMS	 of 	InTELLECTuAL	 pRopERTy/Ip	
RIGHTS	CovEREd 
Designers of an institution’s IP policy will need 
to define IP categories and the IP rights covered. 
Covered categories might include patents, copy­
rights, trademarks, industrial rights and designs, 
plants, computer software, video, multimedia, or 
courseware. 
It will be important for policy designers to 
understand the criteria the university will use to 
decide when to seek IP (generally patent) protec­
tion, and what happens if patent protection is not 
sought. To handle the latter, a procedure for waiv­
ing title back to inventors/authors in such an event 
needs to be developed. Furthermore, attention 
will need to be given to deciding which rights 
should be granted back to the university (grant­
backs), such as use for education and research. 
.  oWnERSHIp of
InTELLECTuAL	 pRopERTy 
Of course, issues relating to ownership are central. 
Such issues include the role of federal/local/state 
laws that directly relate to IP ownership, as well as 
the legal rights of employers/employees, contract 
obligations, and so forth. The prevailing customs 
of the country where intellectual property is de­
veloped also need to taken into account. There 
are a number of possibilities for ownership: 




III. Intellectual 	property and 	dndi’s Work: Basic 	principles 
In implementing the IP strategy, DNDi will adhere to the following basic principles: 
DNDi will ensure that the results of the work carried out under its auspices are disseminated 
as widely as possible and its products made readily available and affordable in developing 
countries.Where the acquisition of IP is not necessary to promote its mission and goals, DNDi 
will make all possible efforts to ensure that the results of its work are placed and remain 
in the public domain. However, it is possible that promoting DNDi’s mission and goals will 
sometimes require outputs to be protected by IP (see Sections IV and V). Given the costs 
involved, patenting is likely to be the exception rather than the rule. Other nonpatent types 
of IP such as confidential information (“trade secrets”) and copyrights will also need to be 
considered. 
To make the results of its work useful and encourage the research community to engage in 
additional or follow-on research in the field of neglected diseases, DNDi will seek—whenever 
possible and without undermining its rationale for acquiring IP—to disseminate its research 
through publications, presentations, the Internet (emulating the Human Genome Project),
and other appropriate channels. 
DNDi does not seek to finance its research and operations through IP rent revenues. Although 
they will constitute an exception rather than the rule, patents might be sought to strengthen 
DNDi’s ability to ensure control of the development process and to negotiate with partners. 
When IP is generated through DNDi-sponsored research projects, it should be used to achieve 
DNDi’s mission. To this end, DNDi will pursue creative and innovative strategies to make the 
fruits of research projects readily available to patients affected by neglected diseases. This 
will require avoiding prohibitively costly approaches, restrictive IP strategies, or other issues 
that may inhibit or delay the rapid adoption of the invention to the benefit of developing 
countries. 
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•	 inventor/author owns 
•	 university owns 
•	 company providing research funds owns 
•	 government providing research funds owns 
•	 public domain, that is, no one owns 
In designing an effective institutional IP pol­
icy, the inventor’s/author’s rights for IP assigned 
to the university should be clearly defined and 
could include a formula for sharing cash royal­
ties earned, sharing of equity interests taken by 
university in a spinout, or retention by inven­
tors/authors of personal rights to use intellec­
tual property they develop (generally these are 
copyrights). Normally, a university would own 
“any intellectual property that is made, designed, 
discovered or created by a member of staff, stu­
dents, guest researchers, etc., in the course of their 
employment and responsibilities or which makes 
significant use of the institution’s resources (in­
cluding institution-administered funds or R&D 
institution-funded time, facilities, or equipment) 
in connection with its development.”4 The policy 
of M.I.T., for example, states that the university 
owns all intellectual property that arises under re­
search grant funding or from significant use of 
M.I.T. facilities.5 In order to avoid potential dis­
putes, the policy should clearly state what consti­
tutes “institutional resources.” In the case of spon­
sored research, whether private or government, 
the usual approach to resolving ownership issues 
is to make them dependent on the terms of the 
grant, agreement, or prevailing law. Usually, the 
agreement would give the university ownership. 
It would also be a good idea to specifically address 
the ownership of intellectual property that stu­
dents and visiting researchers generate. At M.I.T. 
faculty researchers and visiting scientists (includ­
ing scientists who are assigned to M.I.T. for a 
limited period of time) must sign an Inventions 
and Proprietary Information Agreement prior to 
beginning work. It is highly recommended that 
universities have such IP forms.6 
An institutional IP policy should also con­
sider whether the institution will reserve a shop 
right in intellectual property created by faculty, 
students, and staff but not owned by the institu­
tion. (Under the shop right rule, an employer is 
granted an irrevocable, nonexclusive license to in­
ventions that originate with employees not hired 
to invent when such employees invent during 
working hours with the employer’s materials and 
facilities.7) Such intellectual property could in­
clude publications, software, theses, works of art, 
or student works. To address this issue, it will be 
important to ask for what purposes such a shop 
right is reserved. For example, would it be for in­
ternal use only, or, possibly, for Internet delivery 
for distance learning programs? 
An institutional IP policy should also cover 
stranded IP by establishing a default for intellec­
tual property not covered by the policy.8 In other 
words, what intellectual property is owned by the 
inventor, author, or institution? Despite efforts to 
be clear about these matters, disputes are prob­
ably inevitable. A carefully crafted institutional IP 
policy will therefore consider establishing an IP
disputes-resolution committee. It is better to set 
this up in advance of potential disputes so that it 
can be used to deal with problems as they arise. 
Indeed, an IP policy should seek to harmo­
nize the conflicting interests of all the stakehold­
ers. WIPO suggests that “in order to harmonize 
the various conflicting interests of stakeholders 
and achieve broad-based objectives, an intellec­
tual property policy for universities and R&D 
institutions should address some of the following 
issues: 
•	 coverage of intellectual property policy 
•	 ownership of intellectual property 
•	 disclosure of intellectual property 
•	 marketing, commercialization and licens­
ing of patents 
•	 distribution of income 
•	 rights and obligations of an inventor and 
the institution 
•	 other pertinent issues9 
Again, despite such efforts and the best in­
tentions of all involved, conflicts of interest will 
likely arise. For example, the goals of sponsored 
research may conflict with the aim of the univer­
sity to disseminate research results quickly and 
widely. Or there may be other legitimate but op­
posing goals between the institution and private 
interests that put researchers in conflict with their 
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employer. Universities and R&D institutions 
must therefore develop policies and procedures 
for the disclosure and management of conflicts 
of interests.10 
It is also difficult to ensure compliance with 
policies related to the disclosure of inventions. A 
comprehensive review procedure is often used in 
the private sector, but the resources and time re­
quired for such procedures make them impracti­
cal for the university. The best way to ensure com­
pliance, therefore, is to educate researchers about 
the potential value—to the university and them­
selves—of their discoveries. Enlightened self-in­
terest has always been an effective motivator. 
.  AdMInISTERInG	 THE	 Ip	 poLICy 
Identification of who shall administer and enforce 
institutional IP policy is another key ingredient 
of the policy. Possible administrators include: 
•	 vice president for research 
•	 technology transfer office 
•	 IP office 
•	 provost 
A patent committee that will address patent 
policy issues, and make decisions on patent fil­
ings, may also be established. 
. BuILdInG, 	IMpRovInG, 	And 
SELLInG	 THE	 Ip	 poLICy 
For more mature institutions, officials, at some 
point, will need to assess whether to design and 
implement a new policy or revise an old one. An 
initial step in this assessment might be to take a 
snapshot of “what is” so that the effectiveness of 
existing policies, contractual commitments, and 
legal constraints can be determined. 
When pursuing these efforts, it would be 
wise to gain the support of the highest levels of 
administration and to determine a path of least 
resistance for the process, perhaps via the fac­
ulty senate or the administrative committee. In 
addition, it will be critical to persuade faculty of 
the need to change the IP policy or to implement 
a new one. Gaining such backing will lend impor­
tance, urgency, and credibility to the endeavor. 
Policy developers may want to make available for 
comparison other universities’ policies in order to 
show that any suggested changes are not out of the 
mainstream. Providing such material, and oppor­
tunities for informed discussion and debate as to 
the pros and cons of suggested changes to the IP 
policy, will ease anxieties and highlight the ben­
efits the changes will provide. Indeed, throughout 
the entire process, it will be important to focus on 
the positive aspects that any changes to the policy 
may bring. 
The IP policy will have to be “sold,” both in­
side and outside the institution. Educating stake­
holder communities as to what the policy is and 
why it is will promote acceptance. However, to be 
successful, the proper pitch must be made. This 
will most likely involve: 
•	 making the policy comprehensible to the 
reader 
•	 providing incentives for participants 
•	 establishing IP management as a service to 
the community 
•	 applying the policy with consistency 
•	 showcasing the benefits 
One of the primary benefits of the policy will 
be shared licensing revenue, and a firm, cut-and 
-dried policy will be music to everyone’s ears. It 
should be straightforward with very few excep­
tions. M.I.T., for example, gives the inventor(s) 
one-third of net royalties (after taking 15% for 
administration and any unrecovered patenting 
costs for the case). The remaining funds are shared 
between academic departments and the university 
general fund under a formula involving patenting 
costs for unlicensed cases.11 WIPO’s recommen­
dations are equally clear: 
100% of the revenue goes to the institution un­
til all out-of-pocket expenses associated with protec­
tion and exploitation of the patent or copyright have 
been reimbursed. Such expenses include fees associat­
ed with patent filing and copyright registration and 
any other continuing costs associated with licens­
ing and other commercialization of the intellectual 
property. Thereafter, the net income is shared be­
tween the inventor and the institution; the general 
trend is that the inventor’s percentage share decreases 
whereas that of the institution increases as total net 
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revenue increases.  For example, one U.S. university 
gives the inventor 50% for the first $100,000 of net 
revenue, 40% for the next $300,000, 30% for the 
next $600,000 and 25% for net income in excess of 
100,000. 
.  M.I.T.’S	 Ip	 poLICy 
M.I.T. provides a vigorous example of institution­
al IP policy. The main missions of the institution 
are the dissemination of knowledge, education 
and research, but the institution also is commit­
ted to public service, which involves technology 
transfer, as is shown in this excerpt from M.I.T.’s 
IP policy (see Box 2). 
M.I.T.’s IP policy on ownership of intellec­
tual property is carefully laid out. For example, 
ownership of patents is either (1) assigned to 
M.I.T. if the invention occurs from sponsored 
research or is made with significant use of M.I.T. 
funds or facilities or (2) owned by the inventor(s) 
if the inventions are made on the inventor’s own 
time, without use of facilities, and are outside of 
the M.I.T. programs the inventor is assigned to 
work on. If appropriate, and with no outside ob­
ligations, M.I.T. will waive ownership to inven­
tors (see Box 2). 
This statement from M.I.T.’s IP policy 
clearly articulates the various foreseeable situa­
tions wherein IP ownership issues might arise. 
Significantly, these details are all placed within 
the purview of the overarching institutional mis­
sion of M.I.T. The policy goes on to explain, for 
example, that, with regard to copyrights to schol­
arly publications, textbooks, and course materi­
als, these copyrights are owned by the authors. 
However, M.I.T. owns “work for hire” made by 
staff. In other words, M.I.T. owns, by assign­
ment or as work for hire, copyrightable works 
developed by faculty and staff under sponsored 
research or with significant funds or facilities of 
M.I.T. 
For ownership of mask works and tangible 
research property, the policy is the same as for 
patents. The ownership of data is not specifically 
covered, but it is treated as M.I.T. owned un­
der the same situations as for patents and 
copyrights. 
Technology transfer, which is a by-product 
of M.I.T.’s primary missions of education and 
research, is conducted to fulfill institutional 
goals: 
•	 to foster continuing public support for 
basic research by showing public benefit 
(namely, new products) 
•	 to stimulate more industrial support for 
research 
•	 to foster community support by creating 
jobs and new companies 
•	 to help students learn entrepreneurial 
attitudes 
•	 to enable faculty to see the practical results 
of research 
.  SpECIAL	 pLAnT	ISSuES 
The International Maize and Wheat Improvement 
Center’s (CIMMYT) policy on intellectual prop­
erty12 is exemplary. The policy shows how a pub­
lic sector research institution involved in crop im­
provement seeks to achieve a balance between the 
institutions express mission of serving the greater 
global public interest and acknowledging issues 
relating to IP rights protection. The CIMMYT 
IP policy articulates these concerns, providing a 
coherent, comprehensive, and comprehensible 
statement that is the foundation of an institu­
tional IP policy that is consistent with and true to 
the institutional mission: 
As a publicly-funded international research 
institute, CIMMYT regards its research products as 
international public goods. Yet, in the current politi­
cal and legal environment, producing and keeping 
the products of its research in the public domain, 
free for use and development both by scientists and 
farmers, have become increasingly problematic. It is 
in this context that CIMMYT has examined, and 
will continue to examine, its policies and practices 
in regard to intellectual property rights. CIMMYT’s 
commitment to the resource-poor remains as strong 
and passionate as ever. As a direct consequence of 
this commitment, CIMMYT has a responsibility to 
be alert to changes in the political, legal and market 
environments. When necessary, CIMMYT must also 
be ready to adopt new tools and strategies in order to 
keep faith with its mission.13 
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CHAPTER . 
Box 2: M.I.T.’s Policy on Intellectual Property 
13.1 Intellectual 	property 
M.I.T. Policies and Procedures 
The aim of the Institute’s policy on patents, copyrights, and other Intellectual Property is 
to make available Institute technology to industry and others for the public benefit, while 
providing recognition to individual inventors and encouraging the prompt and open 
dissemination of research results. 
13.1.1 	ownership of Intellectual 	property 
With the exception of student theses as described below in Section 13.1.3 (Ownership of 
Copyrights in Theses), rights in patentable inventions, mask works, tangible research property,
trademarks, and copyrightable works, including software (“Intellectual Property”), made or 
created by M.I.T. faculty, students, staff, and others participating in M.I.T. programs, including 
visitors, are as follows:
 a) Inventor(s)/author(s) will own Intellectual Property that is:
 i) not developed in the course of or pursuant to a sponsored research or other agreement
(the faculty advisor, administrative officer, or the Office of Sponsored Programs contracts 
administrator can advise on the terms of the agreements that apply to specific research);
and
 ii) not created as a “work-for-hire” by operation of copyright law (a “work-for-hire” is defined,
in part, as a work prepared by an employee within the scope of his or her employment) 
and not created pursuant to a written agreement with M.I.T. providing for a transfer of 
copyright or ownership of Intellectual Property to M.I.T.; and 
iii) not developed with the significant use of funds or facilities administered by M.I.T.
(“significant use” is discussed in Section 2.1.2 of the Guide).
 b) Ownership of all other Intellectual Property will be as follows:
 i) ownership of Intellectual Property developed in the course of or pursuant to a sponsored 
research or other agreement will be determined according to the terms of such 
agreement;
 ii) ownership of copyrightable works created as “works-for-hire” or pursuant to a written 
agreement with M.I.T. providing for the transfer of any Intellectual Property or ownership 
to M.I.T. will vest with M.I.T.;
 iii) ownership of Intellectual Property developed by faculty, students, staff, and others 
participating in M.I.T. programs, including visitors, with the significant use of funds or 
facilities administered by M.I.T. will vest with M.I.T. 
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KOWAlSKI 
Importantly, with regard to access to germ-
plasm resources, CIMMYT encourages the avail­
ability of such resources in a manner consistent 
with its greater mission of serving the poor of de­
veloping countries. 
This commitment is reiterated several times 
in CIMMYT’s IP policy, which is clearly articu­
lated within the overall context of the guiding 
principles that establish the foundation of the 
CIMMYT global mission (see Box 3). 
This theme is repeated again in the CIMMYT 
IP policy, making CIMMYT’s mission the pre­
dominant determinative factor throughout the 
entire document (see Box 4). 
In addition to the provisions found in the 
CIMMYT IP policy, other provisions that would 
be applicable to plants and IP issues are related to: 
•	 genetically modified plants 
•	 essentially derived varieties 
•	 hybrid crops (issues relating to inbred pa­
rental lines) 
•	 designated and nondesignated germplasm 
as per the treaty, under the FAO 
•	 status of land races 
•	 freedom to operate 
•	 access issues relating to the Convention on 
Biological Diversity 
These issues relate directly to how crops are
actually improved, that is, by: 
•  conventional crossing of preexisting varieties 
•  introgression of genes from wild germplasm 
resources 
•  genetic engineering via plant transformation 
. ConCLuSIonS	 
The establishment—or revision—of institutional 
IP policies is a great tool for advancing internal 
institutional discussions on the role and function 
of intellectual property. Once finalized, an effec­
tive IP policy should fulfill three fundamental 
criteria: 
1. It should be based on and reinforce the core 
mission of the institution the policy serves. 
The mission drives IP management, not 
vice versa. 
2. It should indicate areas of flexibility that al­
low an institution to pursue creative deals 
and arrangements. 
3. It should be a succinct statement, as op­
posed to a detailed list of procedures. The 
latter can be accessed elsewhere, while the 
IP policy should be the basis of regularly 
updated IP strategies and serve as a guiding 
principle for the management of intellec­
tual property. 
Following the above criteria will allow you to 
successfully navigate the sometimes choppy seas 
of the IP system, and the end results of such a 
voyage will certainly be worthwhile. n 
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5	 See supra note 2. 
6	 web.mit.edu/policies/13.1.html. 
7	 A shop right is “an implied-in-law nonexclusive license 
of a patent from an employee to the employer. A shop 
right is generally implied when an employee who is not
specifically hired to invent uses the employer’s facilities 
to invent, usually while on the job. The shop right rule 
grants to such an employer the royalty-free right to 
use the invention of the employee. It is based on the 
employer’s presumed contribution to the invention 
through materials, time, and equipment.” (McCarthy JT,
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Box 3: CIMMyT Intellectual Property Policy 
Iv. oBJECTIvES And	opERATInG 	poLICIES





2. In the pursuit and management of intellectual property rights, CIMMYT will be 
guided by:
• its mission; and
• its special responsibilities to the resource poor arising from its role as a provider of 
   germplasm, technologies, and information. 
However, the CIMMYT IP policy does not leave the articulation of its mission and its 
views on IP issues so general. The policy also specifically states how it views IP issues 
within the context of the CIMMYT mission. Hence, the IP policy is built upon, and indeed 
interwoven with, the mission: 
IV, 4. On occasion, CIMMYT may enter into contracts that provide for the acquisition and 
management of confidential materials. CIMMYT may also seek to protect the products 
of its research by obtaining intellectual property protection through patents, plant
breeders’ rights, copyrights, trademarks, statutory invention registrations or their 
equivalent, and/or trade secrets to serve the resource poor in the following kinds of 
situations: 
1. to support public and private partnerships which pursue mission-based research or 
which develop and apply research results; 
2. to assure ready access by others to research products developed or funded by CIMMYT; 
3. to avoid possible restrictions arising from “blocking” patents and to ensure CIMMYT’s 
ability to pursue its research without undue hindrance; 
4. to facilitate the transfer of technology, research products and other benefits to the 
resource poor including, where appropriate, through commercialization or utilization 
of research products; and/or 
5. to facilitate the negotiation and conclusion of agreements for access to proprietary 
technologies of use to CIMMYT’s research and in furtherance of its mission. 
Box 4: CIMMyT Intellectual Property Policy 
IV, 8. In seeking intellectual property rights, CIMMYT will be guided by its commitment to 
serve the resource poor, rather than by opportunities to obtain recurring revenues.
To the extent that financial returns are generated via intellectual property, they will 
be used by CIMMYT to support its efforts to implement the FAO Global Plan for the 
Conservation and Sustainable Utilization of Plant Genetic Resources for Food and 
Agriculture, adopted by 150 countries in 1996. 
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RE Schechter and DJ Franklyn. 2004. McCarthy’s Desk 
Encyclopedia of Intellectual Property, Third Edition. The 
Bureau of National Affairs, Inc.: Washington, DC.). 
8	 Stranded IP is IP that is not covered by the formal 
policy. No policy is perfect, so certainly not all IP will 
be covered explicitly. If the IP is not covered, then there 
is a presumption that the university owns it, that the 
creator owns it, or that it must be reported to the 
technology transfer office and a determination made 
as to who owns it. 
9	 www.wipo.int/freepublications/en/intproperty/848/
wipo_pub_848.pdf. 
10 See also in this Handbook, chapter 5.8 by AB Bennett. 
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b. Jean weideMieR, Principal, Cambridge Licensing Law, LLC, U.S.A. 
ABSTRACT 
Several factors help to establish who owns a university 
invention and what rights the university may, or may not, 
have. These factors include whether (1) there are express 
or implied agreements to assign ownership, (2) the in­
ventor is employed by the university, (3) the invention 
was made within the scope of employment, and (4) where 
and when the invention was made. Under U.S. law, in­
dividuals own their inventions, except where there is an 
express agreement providing for assignment of owner­
ship of inventions to an employer or where an implied 
agreement to assign is found because the employee was 
hired or assigned to invent or solve a specific problem or 
served the employer in a fiduciary capacity. Therefore, in 
addition to implementing clearly delineated policies, it is 
critically important for a university to absolutely require 
all employees and visitors to sign invention assignment 
agreements (IAAs) on their date of arrival. It is unwise to 
rely on policy statements to determine whether or not a 
university employee owns his or her invention: univer­
sities should always obtain signed (express) agreements, 
and both the employee and the technology transfer office 
should retain copies. Research contracts with the govern­
ment and other sponsors should have a checklist item on 
the existence of IAAs for the principal investigator and 
other researchers (whether or not a university should 
have undergraduates routinely sign IAAs is up to each 
university). Upon termination of employment, personnel 
should be asked to sign an exit form indicating that they 
have disclosed all inventions falling within the terms of 
the IAA to the university licensing office. 
1. InTRoduCTIon 
Who owns an idea? A prototype? A patent? To a 
free-thinking university researcher, assigning in­
ventions to an employer could seem illogical. So 
what can a university administrator do to mini­
mize friction, between an employer and an em­
ployee, related to patent ownership? When is the 
law black and white? When gray? 
The starting point of the law is that individu­
als own their inventions, except: (1) where there 
is an express agreement providing for assignment 
of inventions to an employer; and (2) where an 
implied agreement to assign is found because the 
employee: 
(a) was hired or assigned to invent 
(b) was hired or assigned to solve a specific
problem 
(c) served the employer in a fiduciary (president 
of a commercial company, for example) 
Where no written agreement exists and no 
implied contract to assign is found, the inventor 
will own the invention, subject to the employ­
er’s “shop right” to use the invention if the in­
vention was made with the employer’s resources 
or facilities. The often-discussed, but frequently 
misunderstood shop right refers to an employee’s 
Weidemier BJ. 2007. Ownership of University Inventions: Practical Considerations. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Second Edition, Part VI: Chapter 1.2).
© 2007. BJ Weidemier. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
commercial purposes is permitted and encouraged. 
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obligation to accord an employer a royalty-free, 
nonexclusive license to practice the employee’s 
invention, if the employee, even if not specifically 
hired to invent, uses the employer’s facilities to 
make the invention. In other words, a shop right 
is an implied-in-law license of a patent from an 
employee to an employer. What differentiates the 
shop-right license from the agreements discussed 
above is that there is no assignment of patent 
rights from employee to employer; the employee 
retains full title to the patent. 
2. AppLyInG	 THE	RuLES 
But, how are these rules applied? Is a professor 
hired to invent? The following scenarios provide 
a framework for analyzing the practical applica­
tion of the above rules in the daily business of a 
university licensing office. 
2.1  Example 1: The unreasonable inventor 
The day Professor Z started work at the university, 
she signed a clear, unambiguous invention assign­
ment agreement (IAA; see Box 1 for a sample), 
along with his W-2 form. She signed a three-year 
federal contract to perform “research in the area of 
solar light bulbs.” She invented a solar light bulb 
while working in her university laboratory be­
tween 9 a.m. and 5 p.m. on a Wednesday. She has 
refused to assign the invention to the university, 
because as she says, “After all, it was my idea.” 
There is no question under the law that 
Professor Z must assign her invention to the uni­
versity. In order to compel the assignment of an 
employee invention, pursuant to a written IAA, 
an employer must show: (1) that the invention 
was conceived during the term of employment; 
(2) that the assignment was governed by a valid, 
binding, and enforceable contract; and (3) that 
all conditions in the assignment contract were 
met by the employer (Mosser Industries, Inc. v. 
Hagar).1 In this example, all of these elements 
could be demonstrated. 
To diffuse the situation, the university could 
suggest that Professor Z contact the university’s 
attorney or his own attorney. By seeking profes­
sional advice, Professor Z should become con­
vinced that this issue would not be worth fighting. 
In addition, the university may want to remind 
Professor Z of any university policy that rewards 
inventors with royalty revenue from the licensing 
of university inventions. 
2.2  Example 2: The unreasonable 
inventor you missed 
Professor Z invented her solar light bulb under 
the same circumstances as in Example 1 above; 
however, the personnel clerk was out sick with 
the flu on Professor Z’s first day of work, and the 
clerk’s substitute thought Professor Z only had 
to sign the W-2 form. Thus, Professor Z never 
signed an IAA. 
Because Professor Z received federal funding, 
37 C.F.R. § 401(14) applies regarding election 
of title by the contractor (the university) within 
two years of disclosure of the invention. At 37 
C.F.R § 401.14 (f ), the regulations also require 
the contractor to have written agreements with its 
employees (other than clerical and nontechnical 
employees) requiring (1) the disclosure of all sub­
ject inventions promptly and (2) the execution 
of all papers necessary to file patent applications. 
Unfortunately, the university is in breach of its 
federal contract covering Professor Z’s invention. 
Professor Z has hired an attorney, whose wages 
are being subsidized by Professor Z’s potential li­
censee, who has locked Z into a sweetheart deal. 
The university scrambles to locate a copy of its 
latest patent policy, which was revised and mailed 
to all faculty members last year, and that states: 
It is the policy of the university that individuals, 
through their employment by university, or by par­
ticipating in a sponsored research project, or using 
university-administered funds or facilities, thereby 
accept the principles of ownership of technology as 
stated in this policy. In furthering such undertak­
ing, all participants will sign invention assignment 
agreements … 
The patent policy also stipulates that inven­
tors/authors will own inventions/materials if they 
are (1) not developed in the course of or pursu­
ant to a sponsored research or other agreement; 
(2) not created as a work-for-hire by operation of 
copyright law and not created pursuant to a writ­
ten agreement with the university providing for a 
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CHAPTER . 
transfer of copyright or ownership to university; 
and (3) not developed with the significant use of 
funds or facilities administered by university. 
The university’s lawyer produces the often-
cited case of United States v. Dubilier Condenser 
Corp.,2 which states: 
One employed to make an invention, who 
succeeds, during his[or her] term of service, in ac­
complishing that task is bound to assign to his [or 
her] employer any patent obtained. The reason is 
that he [or she] has only produced that which he [or 
she] was employed to invent. On the other hand, if 
the employment is general, albeit it covers a field 
of labor and effort in the performance of which 
the employee conceived the invention for which he 
[or she] obtained a patent, the contract is not so 
broadly construed as to require an assignment of the 
patent. 
Another early case brought to the university’s 
attention is Solomons v. United States,3 which states: 
If one is employed to devise or perfect an instru­
ment, or a means for accomplishing a prescribed re­
sult, he [or she] cannot, after successfully accomplish­
ing the work for which he [or she] was employed, 
plead title thereto as against his [or her] employer. 
That which he [or she] has been employed and paid 
to accomplish becomes, when accomplished, the 
property of his [or her] employer. 
In this example, the key question in deter­
mining the ownership of the invention is wheth­
er Professor Z was hired to invent a solar light 
bulb, or whether her employment was “general.” 
Actually, in this case, on the fateful day she was 
hired ten years ago, no one had even remotely 
considered the idea of a solar light bulb. Professor 
Z was employed to teach several classes and to 
conduct research generally on solar power. Her 
first seven years of research were devoted to solar-
powered cars. 
The hired-to-invent rule clearly envisions 
that specific job assignments can change during 
the course of employment and the question of 
fact turns on the circumstances and current job 
assignment at the time of invention. Therefore, 
the change in focus of Professor Z’s research from 
solar cars to solar light bulbs over the ten-year 
period is relevant. “An employee, who undertakes 
upon the direction of his employer to solve a specific 
problem within the scope of his general employment, 
is as truly employed and paid for the particular 
project as if it had been described at the outset in 
the contract of employment” (Houghton v. United 
States).4 
In Standard Parts Co. v. Peck,5 Peck was em­
ployed to solve a particular problem, and a writ­
ten contract required him, “to devote his time to 
the development of a process and machinery for 
the production of the front spring now used on the 
product of the Ford Motor company,” in return for 
US$300 per month, plus several bonuses. The 
contract was silent on the matter of invention 
ownership, which became the subject of the law­
suit. The Court found the answer “inevitable and 
resistless”: the “process and machinery” contracted 
to be developed for the company belonged to the 
company, not to Peck, who was otherwise paid 
for his services. 
Whether the work statement in Professor 
Z’s federal contract is specific enough to cover 
the development of a solar light bulb would be a 
question of fact under a Standard Parts rationale. 
In Patent Law Fundamentals (Section 11.04, 
Rights of Employer and Employee Inter Se), the 
analysis goes one step farther; it is stated that 
“apparently” an employer would own inventions 
if an employee were “employed to plan and con­
duct fundamental and practical investigations and 
such lead directly to an invention,” so long as the 
employee’s area of activity was defined with “suf­
ficient specificity.” 
In Speck v. North Carolina Dairy Foundation, 
Inc. et al.,6 the inventors were professors and re­
searchers who developed a secret process; they 
had not signed IAAs. They were paid by the uni­
versity and acknowledged that the process was 
developed at the university using university re­
sources. The Supreme Court of North Carolina 
found that, although there were no signed IAAs, 
professors and researchers were hired to invent 
and their invention belonged to the university: 
“[T]hey developed the secret process ... while em­
ployed as teachers and researchers to engage inter 
alia in just such research and development for the 
University.”7 
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WEIDEMIER 
An even more recent university case is 
University Patents, Inc. v. Kligman et al.8 Dr. 
Kligman invented a Vitamin A preparation to 
slow the effects of skin aging. As with Professor Z, 
Dr. Kligman did not sign an IAA, nor did he sign 
an invention disclosure statement. Some univer­
sity resources were used, though Dr. Kligman was 
not as closely connected to the university as the 
inventors in the Speck case. Animal studies were 
conducted at the university by Dr. Kligman’s wife, 
Lorraine, pursuant to a Johnson & Johnson con­
tract, and a clinical study was performed at the 
university’s Aging Skin Clinic. 
University Patents, Inc., with whom the 
University of Pennsylvania had contracted to 
exploit its patents, relied primarily on the uni­
versity’s patent policy set forth in the employee 
handbook to prove an implied contract to assign. 
Under the University of Pennsylvania’s policy, 
all inventions resulting from work performed 
on university time or at university expense were 
owned by the university. 
Pennsylvania law is unclear on the question 
of whether an employee handbook can create an 
employment contract. The Court applied tradi­
tional patent assignment principles to the more 
controversial handbook concepts and found 
that the University of Pennsylvania’s handbook 
“clearly was not communicated as a definite offer 
of employment.”9 The opening comments in the 
handbook provided in part that, “we hope that 
this Handbook will serve as a useful traveler’s 
guide [emphasis added],” rather than as a contrac­
tual legal document. 
In April, 1991, the U.S. District Court for 
the Eastern District of Pennsylvania concluded 
that a “jury reasonably could find that an im­
plied contract to assign the patent in question was 
formed between Dr. Kligman and the University 
[of Pennsylvania].”10 The university conveyed and 
enforced its patent policy in a rather lax manner 
over the years, but the court found “[T]here is 
evidence, however scant, from which one could find 
that Dr. Kligman was aware of the Patent Policy 
since August, 1967, and manifested an intent to be 
bound by it.”11 The court cautioned that employ­
ers are advised not to rely on handbooks to gov­
ern the assignment of patent rights; rather, they 
should address such issues explicitly in an express 
IAA. However, the issue of whether professors 
and university researchers, as a class, are hired to 
invent when pursuing their field of research was 
not addressed. 
Although involving a different central issue, 
a third case, Regents of University of Colorado v. K. 
D. I. Precision Products, Inc.,12 stated that “[T]he 
subject of the University’s employment was research 
directed towards the obtaining of patents.” This 
supports the concept that university professors 
and researchers are employees hired to invent. 
But with regard to Professor Z in our earlier 
example, the law is not settled as to whether uni­
versity professors and researchers are hired to in­
vent. What is the likely outcome for Professor Z? 
In the university’s favor are the following points: 
•	 The failure to have Professor Z sign the IAA 
was a one-time error, not the result of a 
pattern of negligence. 
•	 All professors were recently mailed a copy 
of the patent policy. 
•	 Professor Z’s invention fell squarely within 
her federal contract’s statement of work. 
In Professor Z’s favor are these points: 
•	 She did not sign an IAA. 
•	 It was her first invention, and she had never 
gone through the procedure before. (see
Mainland Industries, Inc. v. Timberland Ma­
chine and Engineering Corp.13) 
As a practical matter, a university should 
tighten its process for requiring all regular em­
ployees and visitors to sign IAAs on their date of 
arrival. Before action is taken on new invention 
disclosures by the university licensing office, staff 
should double check the existence of such agree­
ments for particular inventors. Research con­
tracts, with the government and other sponsors, 
should have a checklist item referencing the exis­
tence of IAAs for the principal investigator and 
other researchers. 
2.  Example 3: Saturday afternoon 
conception at home 
Professor Z invents the solar light bulb in her 
driveway on Saturday afternoon after she incurred 
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a minor hit on the head falling off her son’s skate­
board. She refuses to assign the invention to the 
university because, “I invented it on my own 
time.” 
In this case, Professor Z properly signed the 
IAA on her first day of work. Ownership, in this 
case, would depend on the exact wording of the 
IAA. As a matter of policy, each university must 
decide what is fair and what is beyond the scope 
of the IAA. A university would be most pru­
dent to require inventors to assign this concep­
tion-at-home type of invention to the university. 
Otherwise, university sponsors would be short­
changed by the fact that the invention was con­
ceived in the driveway, even though the inventor 
most certainly relied for years on government-
funded background research at the university and 
the invention most certainly would have been in­
spired, at least in part, by that research. 
In Mainland Industries, the inventor was 
a salaried employee who did not work specific 
hours and did not sign an IAA. He was uncer­
tain whether the patentable idea was conceived 
at home or at the office. The court stated at 665, 
“the place where an invention is developed is not de­
terminative of whether the employer or the employee 
is entitled to a patent.” 
As a practical matter, most likely Professor Z 
will return to work at the university on Monday 
morning, will revamp her work schedule and list 
of priorities toward the goal of making Saturday’s 
idea into a working prototype, and will assign 
three graduate students to start implementing the 
idea. Professor Z is now clearly using university-
administered funds and facilities to develop the 
invention, and the university would own the pat­
ent rights, under the hypothetical IAA in Box 1. 
2. Example 4: The eclectic inventor 
Professor Z, instead of inventing a solar light bulb, 
as a diversion from her solar projects instead de­
velops a remarkable new fertilizer for tulip bulbs, 
after borrowing a colleague’s lab in the botany de­
partment and two research assistants on Tuesday 
afternoons. A frantic search of the records is fu­
tile; Professor Z never signed the IAA. 
The Dubilier case referenced in Example 
2 above presented a similar set of facts. Francis 
Dunmore and Percival Lowell were employed by 
the government in the radio section of the Bureau 
of Standards and performed research and testing 
in that laboratory. In the fall of 1921, Dunmore 
and Lowell were considering the problem of ap­
plying alternating current to broadcast receiving 
sets. This project was unrelated to the work of the 
radio section and not assigned to them by any 
superior. The employees took on the research in­
dependently and voluntarily. 
Dunmore and Lowell discovered a remote-
control system for airplane bombs and torpedoes 
and were permitted to pursue their work in the 
laboratory and to perfect the prototypes after 
disclosing their discovery to their section chief. 
Dunmore and Lowell did not sign IAAs, and no 
one advised them that they would be expected to 
assign their rights to the United States. Dunmore 
and Lowell instead assigned the invention to the 
Dubilier Condenser Corporation. 
The Supreme Court held that the work was 
not part of the work specifically assigned to them, 
and therefore, the employees had title. The gov­
ernment was granted the royalty-free right to 
practice the inventions, which is known as a shop 
right: when “a servant [employee] during his [or 
her] hours of employment, working with his [her] 
master’s materials and appliances, conceives and 
perfects an invention for which he [or she] obtains a 
patent, he [or she] must accord his master a nonex­
clusive right to practice the invention.”14 
In addition to the shop-right issue, Dubilier 
settled the question of whether the character of 
service calls for different rules regarding the rela­
tive rights of the government, as the employer, 
and its employees. The answer was no, the same 
principles of employer–employee apply. 
These court decisions are all good news for 
Professor Z. She would probably own her tulip 
bulb invention; the university would have a roy­
alty-free, nonassignable right to practice it. 
The controversy could have been avoided, had 
the personnel clerk been able to handle Professor 
Z’s paperwork. If Professor Z had duly executed 
the hypothetical IAA, the university would have 
owned the tulip bulb invention, because the sig­
nificant use of university-administered funds and 
facilities was covered in the standard agreement. 
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2. 	 Example 5: The precocious undergrad 
Professor Z is filled with joy. After years of lectur­
ing to a sea of bored, young faces, Jane, then a 
sophomore, appears in the professor’s advanced 
solar class. While chatting after class about 
Professor Z’s long struggle to harness the sun’s 
power in a 60-watt light bulb, Jane asks the key 
question, “Why not do it this way...?” Jane per­
forms a simple experiment demonstrating that her 
idea will work. Professor Z puts the lab at Jane’s 
disposal, and Jane spends every free moment for 
the next year in the lab developing a prototype. 
Undergraduates at the university are not 
routinely requested to sign intellectual property 
agreements unless they are employed as research 
assistants. Jane is not in need of employment 
while at school and never signed the agreement. 
Students were not issued copies of the patent pol­
icy, and frankly, Jane had not even considered the 
patent-ownership issue. 
When Professor Z filed an invention disclo­
sure with the university licensing office citing the 
federal research support and naming herself and 
Jane as co-inventors, problems arose. Jane refused 
to assign her invention to the university and de­
nied that Professor Z was a co-inventor. Professor 
Z ultimately conceded this issue after the univer­
sity’s patent counsel defined inventorship for her, 
and all agreed that Jane was sole inventor. 
In this case, as in University Patents, there is 
no signed IAA, and the university is relying solely 
on its patent policy. Under the hypothetical pol­
icy described in Example 2, the university would 
own Jane’s invention because of her use of signifi­
cant funds and facilities, regardless of the lack of 
a signed IAA. 
In a court battle, had Jane the financial re­
sources to fight it, the university would have had 
an uphill battle to prevail. Jane probably could 
not have been assumed to have had reasonable 
knowledge of the terms of the patent policy and 
its applicability to her, and so the university might 
be left with just a shop right. 
If Jane had signed the IAA, the result would 
be different; most likely the university would own 
the invention because of her significant use of 
funds and facilities. Whether or not a university 
should routinely have undergraduates sign IAAs 
should be a matter of thoughtful policy making 
for each university. 
2. 	 Example 6: The better-late-than-never 
agreement 
Professor Z did not sign the IAA on her first day 
of work. She invented the solar light bulb five 
years later, and coincidentally two weeks after the 
discovery received an IAA form, as part of a uni­
versity licensing office clean-up project, and she 
signed it. 
The courts are divided on whether continua­
tion of employment is adequate consideration for 
such an agreement when it is signed after the em­
ployer–employee relationship has been formed 
(see Mirafi, Inc. v. Murphy15). Any agreement 
after the employer–employee relationship has 
been formed must have new consideration to be 
enforceable; Harsco Corp. v. Zlotnicki16 held that 
an agreement to cover the assignment of inven­
tion to the employer, although not executed by 
the employee until after he made the invention, 
as agreement used past and present tenses and re­
ferred to entire term of employment. 
Regarding General Signal Corp. v. Primary 
Flow Signal, Inc. et al.,17 Dezsoe Halmi was em­
ployed by General Signal (GSC) and rose from 
the position of draftsperson to products develop­
ment manager. Mr. Halmi was employed for 15 
years before he was asked to sign an “Employee 
Confidential Information and Invention 
Agreement,” which he then signed. The agree­
ment required that he assign, to GSC, his inven­
tions made while working at GSC and for a six-
month period following employment. 
On April 5, 1983, five days after the six-
month period ended, Mr. Halmi recorded the 
conception of a universal flowmeter that was 
patented and then manufactured and sold by 
Primary Flow Signal, Inc., a company that Mr. 
Halmi established after leaving GSC. 
The court found that his continuing employ­
ment was adequate consideration for the inven­
tion agreement. The court also found that: 
The perfection of a flowmeter proved to be a 
painstakingly intricate process involving extensive 
testing. It is therefore difficult to believe that after 
a long and distinguished career with Plaintiff, Mr. 
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CHAPTER . 
Halmi in his musing five days after the trailer clause 
expired for the first time came up with the idea for 
the NTV. Although the word ‘Eureka!’ has allegedly 
been uttered by more than one inventor over the 
years, the concept at issue does not lend itself to such 
sudden discovery. 
The court concluded that the idea must have 
occurred to Mr. Halmi while employed at GSC, 
and, therefore, Mr. Halmi was in violation of the 
invention agreement. 
The university can take some steps to protect 
itself from situations where the IAA is not signed 
on the first day of employment, or for inventions 
not reported by employees who leave the univer­
sity. As mentioned in Example 2, various catch 
mechanisms can be put in place to ensure that 
IAAs are on file. If it is discovered that an em­
ployee has not signed an agreement, a carefully 
worded agreement, signed later, provides some 
assistance in many jurisdictions. The agreement 
should state that the consideration is the continu­
ation of employment and the continued use of 
university funds and facilities, and that the en­
tire term of employment is covered. Some addi­
tional consideration could be given, for example, 
the payment of the sum of US$10. Any royalty-
sharing right under the university’s patent policy 
should also be cited. 
On termination of employment, person­
nel should be asked to sign an exit form that in­
cludes a statement such as this: “I have disclosed 
all my inventions falling within the terms of the 
Invention Assignment Agreement to the univer­
sity licensing office.” 
2.  Example 7: The visiting scientist 
Professor Z corresponds regularly with her col­
lege classmate Martin Xcaliber, who is a tenured 
professor at another university halfway across the 
country. One hot summer day, Professor Z is feel­
ing stultified in her work and invites Professor 
Xcaliber to spend some time collaborating in her 
solar lab. He is compensated through funds from 
Professor Z’s federal contract. The collaboration 
succeeds, and Professor Xcaliber breaks through 
the impasse Professor Z had been struggling with 
for almost a year. He reduces his idea to practice 
that summer, and the invention is clearly novel and 
patentable. But he did not sign the visiting scien­
tist IAA from Professor Z’s university. His univer­
sity is claiming ownership and produces a valid, 
unambiguous IAA, which covers all inventions 
made during his period of employment, regardless 
of where conceived or reduced to practice. 
Again, the university is in a bit of trouble 
under its federal contract because this researcher 
did not sign an IAA. Once again, the university 
is left relying on a patent policy that states that 
the university owns inventions made by visiting 
scientists making significant use of funds or facili­
ties. Professor Xcaliber may never have seen the 
patent policy document. 
The university could argue that Professor 
Xcaliber should have known that Professor Z’s 
university would have some sort of patent policy 
and that he should have made reasonable inquiry. 
No case law was discovered relevant to this situa­
tion, but most likely Professor Xcaliber’s univer­
sity would own the invention, with Professor Z’s 
university getting a shop right. This might be a 
good case to negotiate for joint ownership by the 
universities. Another possibility for compromise 
is to recognize the contribution of both universi­
ties through a patent cost and license royalty-shar­
ing arrangement. Aside from the equities on both 
sides, as a practical matter Professor Xcaliber’s 
university may find itself on the other side of a 
similar situation in the future and may want to 
generate goodwill. 
2. 	 Example 8: The inventor who does not 
play well with others 
Professor Z was not asked to sign the IAA on 
her first day of work but, instead, five years lat­
er during the licensing office’s clean-up project. 
She replied, “My ideas and thoughts are not for 
sale.” Fearing that Professor Z may be upset, the 
department head and administration instruct the 
license office not to insist on the signing. 
Without upper-level pressure on the matter 
of Professor Z’s job security, the licensing office 
can only argue that: 
•	 The patent policy applies in any event, and 
Professor Z should sign the IAA merely to 
affirm. 
HANDBOOK OF BEST PRACTICES | 01 




       
    
        
      
       
        
        
       
     
      
        
     
          
     
       
      
        
      
       
       
     
         
 
   
 
WEIDEMIER 
•	 Licensing of inventions would be blocked by 
the potential of future ownership disputes 
between Professor Z and the university. 
•	 The university would take legal steps to 
pursue its ownership rights to inventions 
made by Professor Z falling within the pat­
ent policy. 
.	 ConCLuSIonS 
Under the hypothetical patent policy stated 
under Example 2, an employee of a university 
is required to assign to the university all inven­
tions made with university-administered funds 
and facilities if the employee signed a clear and 
unambiguous IAA. Even if no written contract 
exists, the university may own the invention. It 
is a question to be decided in view of the circum­
stances, and the contract may be implied from 
the relation of the parties. 
The principles underlying this policy have 
evolved from the line of court cases that, in the 
absence of a written agreement, hold that an in­
vention belongs to an employee-inventor unless 
the employee was hired to invent or assigned to 
solve a particular problem (Standard Parts Co. v. 
Peck18). In all of the cases, an implied contract 
to assign was found, because the employee had 
only accomplished what he was hired to do. The 
employer also owns the invention if the inventor 
owes a fiduciary duty to the company (see Great 
Lakes Press Corp. v. Froom,19 where the relation­
ship of president to company found to be one of 
special trust). 
Where no written contract and no implied 
contract to assign is found, the inventor owns the 
invention, subject to the employer’s shop right to 
use the invention if it was made with the employ­
er’s resources or facilities. 
One expert in IP law concluded that, “[T]he 
common expectations concerning university em­
ployment are not the same as the expectations con­
cerning employees within private industry.”20 It is 
this author’s opinion that the Speck court’s “classi­
fication of university faculty as persons hired to invent 
is contrary to the premises upon which higher educa­
tion is based.”21 The author suggests that professors 
are principally encouraged to acquire knowledge 
only through research. This conclusion is unsup­
ported by the case law, which does not distinguish 
between university and commercial employees; in 
fact, the cases of Speck v. K. D. I. Precision Products 
Inc. found specifically that university professors 
and researchers are, by definition, hired to invent. 
The Supreme Court stated that government em­
ployees are governed by the same rules as private 
industry employees in Dubilier. The logical exten­
sion of Dubilier is to treat university employees, 
the bulk of whom perform research under govern­
ment funding, equivalent to government research­
ers, and therefore, to be the treated the same as 
commercial employees. 
In Houghton, the employee-inventor argued 
that the hired-to-invent rule should not be ap­
plied to cases in which an employer, such as the 
government, does not seek a monopoly (the es­
sence of a patent). The Court responded vehe­
mently that: 
It is unthinkable that, where a valuable instru­
ment in the war against disease is developed by a 
public agency through the use of public funds, the 
public servants employed in its production should be 
allowed to monopolize it for private gain and levy a 
tribute upon the public which has paid for its pro­
duction, upon merely granting a nonexclusive license 
for its use to the governmental department in which 
they are employed. 
Ultimately, without a written agreement, the 
facts of each case determine ownership; a particu­
lar professor may or may not be found to have 
been hired to invent or to resolve a particular 
problem. As with any class of employees, proba­
bly no blanket statement can be made as to when 
university professors and researchers are consid­
ered to have been hired to invent. 
For managing intellectual property, inven­
tion, and ownership issues, the best approach is 
always to require employees and visitors in a posi­
tion to invent to sign IAAs as often as employees 
sign W-2 forms. n 
b. Jean weideMieR, Principal, Cambridge Licensing 
Law, LLC, 124 Mt. Auburn Street, Suite 200, 
North Cambridge, MA, 02138, U.S.A. Weidemier@
cambridgelicensing.com 
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WEIDEMIER 
Box 1: Invention Assignment Agreement 
Name (please print or type): 
In consideration of the sum of One Dollar ($1.00) and: 
• my past, present, and/or future employment at UNIVERSITY; and/or 
• my past, present, and/or future participation in research at UNIVERSITY; and/or 
• opportunities that have been made or will be made available to me to make significant use of 
UNIVERSITY-administered funds or facilities; and/or 
• opportunities to share in royalties and other inventors’/authors’ rights outlined in the “Guide 
to the Ownership, Distribution and Commercial Development of UNIVERSITY Technology,” 
A. agree to disclose promptly to UNIVERSITY and hereby assign all rights to all inventions,
copyrightable materials, computer software, semiconductor mask works, tangible research 
property and trademarks (“Intellectual Property”) conceived, invented, authored, or reduced 
to practice by me, either solely or jointly with others, that: 
(i) 	 are developed in the course of, or pursuant to, a sponsored research or other agreement in 
which I am a participant, as defined in Paragraph X of the UNIVERSITY Technology Policy 
Guide; or 
(ii) 	 result from the significant use of UNIVERSITY-administered funds or facilities as “significant
use,” as defined in Paragraph X of the UNIVERSITY Technology Policy Guide; or 
(iii) 	 result from a work for hire funded by UNIVERSITY, as defined in Paragraph X of the 
UNIVERSITY Technology Policy Guide; and 
B.	 agree to execute all necessary papers and otherwise provide proper assistance,at UNIVERSITY’s 
expense, during and subsequent to the period of my UNIVERSITY affiliation, to enable 
UNIVERSITY to obtain, maintain, or enforce, for itself or its nominees, patents, copyrights, or 
other legal protection for such Intellectual Property; and 
C. agree to make and maintain for UNIVERSITY adequate and current written records of all such 
UNIVERSITY Intellectual Property; and 
D.	 agree to deliver promptly to UNIVERSITY, when I terminate employment with UNIVERSITY 
for any reason, and at any other time as UNIVERSITY may request, copies of all written 
records referred to in Paragraph C, above, as well as all related memoranda, notes, records,
schedules, plans, or other documents, made by, compiled by, delivered to, or manufactured,
used, developed, or investigated by UNIVERSITY, which will at all times be the property of 
UNIVERSITY; and 
E. will not to disclose to UNIVERSITY or use in my work at UNIVERSITY (unless otherwise agreed 
in writing with UNIVERSITY): 
(i) 	 any proprietary information of any of my prior employers, or of any third party, such 
information to include, without limitation, any trade secrets or confidential information 
with respect to the business, work, or investigations of such prior employer or other third 
party; or 
continued on next page 
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Box 1 (continued) 
(ii) 	 any ideas, writings, or intellectual property of my own that are not included in Paragraph 
A, above, within the scope of this Agreement (please note that inventions previously 
conceived, even though a patent application has been filed or a patent issued, are subject
to this Agreement if they are actually first reduced to practice under the circumstances 
included in Paragraph A above). 
After the date hereof, this Agreement supersedes all previous agreements relating in whole or in 
part to the same or similar matters that I may have entered into with UNIVERSITY 
This Agreement may not be modified or terminated, in whole or in part, except in writing signed 
by an authorized representative of UNIVERSITY Discharge of my undertakings in this Agreement
will be an obligation of my executors, administrators, heirs, or other legal representatives or 
assignees. 
I represent that, except as identified on the reverse side hereof, I have no agreements with, or 
obligations to, others in conflict with the foregoing. 
Witness
Signature (to include first name in full) 
Date 
Note: This Agreement is completed and signed in triplicate and distributed in the following 
manner: original copy to the employee’s personnel file, second copy to the employee; third copy 
to the Technology Licensing Office. 
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ANNE C. dI SANTE, Director, Technology Transfer Office, Wayne State University, U.S.A. 
ABSTRACT 
Without inventors, there would be no technology to 
transfer. But without technology transfer professionals, 
there would be limited transfer of technology. Good rela­
tions between inventors and technology transfer profes­
sionals are therefore essential for the commercialization 
enterprise to succeed. Relationships should be established 
long before the transfer services of the technology trans­
fer office (TTO) are required. A healthy relationship will 
allow technology managers to negotiate both faculty and 
business concerns about licensing agreements. Making 
sure that the inventor is sympathetic to the aims of the 
TTO will also make it much easier for everyone to under­
stand how a technology may meet market needs, recognize 
potential licenses, and determine whether a licensee is ful­
filling its obligations. For all of these reasons and more, a 
TTO should always go the extra mile to educate, develop, 
and maintain good working relationships with inventors. 
1. INTRODuCTION 
The skills of the technology transfer professional 
are specific and unique to the profession and are 
crucial for the management and licensing of in­
tellectual property (IP). The successful transfer of 
a technology, however, cannot be accomplished 
without the inventor. The challenge for the tech­
nology transfer professional is to obtain full sup­
port for his or her efforts from the inventor, an 
individual over whom the technology transfer 
manager has no real control. In addition to gain­
ing inventor support, the technology transfer 
professional must expertly handle inventor rela­
tions, both with the technology transfer office 
(TTO) and within the university. The technol­
ogy transfer professional must also make sure 
that the inventor has realistic expectations about 
marketability. This chapter will describe both the 
various roles the inventor plays in the technol­
ogy transfer process and the technology transfer 
professional’s many responsibilities with respect 
to the inventor. 
2. INVENTOR AS CREATOR
OF TECHNOlOGy 
The essential role played by the inventor is to create 
and develop the technology that will be transferred. 
No one else will understand the technology as well 
as the inventor, so the inventor’s full cooperation 
in disclosure and participation in the technology 
transfer process is necessary. To develop the best 
working relationship possible with the inventor, 
the reputation of the TTO and of the technology 
transfer manager are important. Public relations 
within the institution are critical for sustaining 
these relationships and forging new ones. 
Di Sante AC. 2007. The Role of the Inventor in the Technology Transfer Process. In Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Second Edition, Part V: Chapter 2). 
© 2007. AC Di Sante. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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DI SANTE 
The technology professional should strive to 
ensure that the inventor hears of the TTO before 
coming up with a great invention. For many rea­
sons,1 the technology transfer professional needs 
to learn earlier, rather than later, about the inven­
tion. Academic faculty are now significantly more 
aware of the technology transfer process than they 
were a decade ago, but a manager should not as­
sume that this is enough to motivate faculty to file 
invention disclosures. The inventor must be fully 
aware of the importance of making timely disclo­
sure of an invention to the technology transfer of­
fice. However, educating faculty on the hazards of 
premature disclosure (including in publications) 
may mean more calls to the office about technol­
ogy not prime for licensing. It is easier to respond 
not yet than to explain that the big one got away. 
The technology transfer professional is chal­
lenged to develop systems that promote early 
information delivery, while remaining conscious 
of the specific academic environment of the uni­
versity and the pressures on faculty. The proce­
dures developed for information delivery must be 
relatively easy to access and use, since it is criti­
cal that the TTO receive not just timely but full 
disclosure of the invention. The technology man­
ager may also be faced with a faculty member’s 
concern about confidentiality. For example, the 
inventor may be willing to disclose to academic 
peers, even at another institutions, but may view 
the staff in the TTO as outsiders or as admin­
istrative bureaucracy. The technology transfer 
manager will need to ease these concerns to so­
licit complete participation of the inventor in the 
technology transfer process. 
3. ROlE IN THE PROTECTION PROCESS 
Once the decision to file a patent application has 
been made, the most frequent question a technol­
ogy transfer professional will hear is: “How much of 
my time will this take?” While one may be tempted 
to minimize the efforts needed, it is important 
to provide realistic estimates in order to prevent 
unrealistic expectations. Depending on the tech­
nology and the detail in the invention disclosure 
document, inventor input at the drafting and fil­
ing stages varies from minimal to substantial. 
The inventor and patent counsel should inter­
act early in order to form the critical relationship 
necessary for a solid patent application. The in­
ventor must be assured of confidentiality and con­
vinced of the value of providing a full disclosure 
of the technology to patent counsel. In addition 
to assisting in the drafting process, the inventor 
is needed for inventorship determinations. For 
example, many faculty equate inventorship with 
authorship, so they will list collaborating inven­
tors using the same criteria for naming authors on 
scientific manuscripts. Fortunately, patent counsel 
can assume the role of adjudicator for inventor-
ship matters, although the TTO may be required 
to enlist the assistance of department chairs and 
other university administrators for difficult cases.2 
The inventor must be a willing partner dur­
ing the actual prosecution of the patent applica­
tion, as well. While the concept of nonobvious­
ness can be difficult to grasp,3 a skilled patent 
attorney will work closely with the inventor to 
develop the responses necessary to overcome this 
type of rejection. The inventor should be encour­
aged to read the materials and provide answers 
to the attorney’s questions; after all, the inventor 
knows the field better than anyone else. Most fac­
ulty respond well to patent counsel’s translation 
of the rejection from “patentese” to plain English. 
Direct questions are easier for the inventor to ad­
dress than a general “please read and give me your 
thoughts on this” request. While it will cost more 
in attorney time to have patent counsel read, ana­
lyze, and develop questions to address an office 
action, the investment will prove worthwhile if 
needed responses are shared from the start. 
Filing a patent application and having a 
patent issue are not the only goals of the TTO. 
Nearly 100% of the time, the technology transfer 
professional will also need the inventor to actu­
ally transfer the technology to the licensee later in 
the process. In addition, once the patent is issued 
and the technology licensed, the inventor may 
take on the unofficial role of “infringement po­
lice officer” by recognizing when a product is sold 
that may infringe the patent. An inventor should 
be encouraged to report suspected infringement 
to the TTO, which can then assign responsibility 
for pursuing infringers. 
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CHAPTER . 
Developers of software and multimedia 
should be well educated about the use of copy­
right notices; it should be second nature for the 
appropriate notice to be placed in a new program. 
Of course, this depends on the specific copyright 
policy in effect at the institution. 
Biological materials with commercial poten­
tial are another form of IP not always associated 
with patent protection. The inventor must un­
derstand the difference between transfer to non­
profit research institutions and transfer to for-
profit institutions that may use the technology 
as a product development tool. It is important 
for the inventor to understand that the value of 
the material will be maintained if the release of 
the material is controlled. This control does not 
prevent the inventor from fulfilling the obliga­
tion to provide samples of the materials to those 
who wish to repeat experiments, as required by 
many scientific journals, or from meeting fed­
eral guidelines on the dissemination of research 
tools. In the management of biological materi­
als, it is essential for the technology transfer pro­
fessional and the inventor to design and agree 
upon a distribution plan that maximizes com­
mercial potential without negatively affecting 
scientific research.4 
4. ROlE IN THE TECHNOlOGy 
TRANSFER PROCESS 
The technology transfer process involves many 
steps, some occurring concurrently. An inventor 
participates at various levels in each step, although 
the degree to which the inventor is involved will 
depend on many factors, including university 
corporate culture and the players involved. 
.1 Marketing 
The technology transfer professional cannot ex­
pect to understand every industrial sector, mar­
ket, or niche into which technologies may fit. 
Most often, it is the inventor who will know 
both the academic and industrial players in 
the field. Additionally, the inventor may have a 
clearer understanding of unmet market need and 
whether the technology addresses this need. This 
information may allow the technology transfer 
professional to perform a general SWOT analy­
sis (strengths, weaknesses, opportunities, threats) 
with relatively minor market research. An inven­
tor can also prove to be a good source of other 
marketing information, such as market size, mar­
ket location, and competitive technology, both 
in academia and industry. While any numbers 
should be verified with an outside source, an in­
ventor can be a one-stop source of market in­
formation with which to get marketing efforts 
started. 
.2 Identification of potential licensees 
A manager can expect an inventor to be contact­
ed by potential licensees because of the inventor’s 
publications, meeting presentations, and indus­
trial contacts. Many inventors call friends in the 
industry to discuss their research. It is important 
to encourage the inventor to direct commercial 
inquiries to the TTO. The referral of these calls 
to the technology manager will help accomplish 
many objectives. First, it allows the technology 
transfer professional to manage the commercial­
ization of the technology by keeping tabs on 
commercial interest, allowing consideration of all 
potential licensees when making final decisions. 
Second, it establishes early in the process who will 
be the key licensee contact in making the licensing 
decision. Third, it keeps the inventor from selling 
the well twice. Fourth, by moving the inventor 
to a secondary role in negotiations, the inventor 
becomes insulated from licensing decisions, thus 
allowing the inventor and the industrial scientist 
to develop and maintain a relationship based on 
the interests of science—not business. Indeed, 
the industrial scientist hopefully will become the 
internal champion within the licensee for the in­
novation, with the first step in this process involv­
ing the inventor. 
. Information to the potential licensee 
Who provides what information to a potential li­
censee is partly intuitive. For example, the technol­
ogy transfer professional generally addresses issues 
regarding the patent application, IP policies, and 
licensing, while technical questions, prototypes, 
demonstrations, and materials for evaluation will 
most likely come from the inventor. With regard 
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DI SANTE 
to the latter, the inventor knows the technology 
best—what it can and cannot do—and thus is in 
the best position to share such information. The 
technology transfer manager may wish to en­
courage the inventor to brainstorm with his/her 
industrial counterpart on issues that may come 
up during scale-up. An inventor may become 
nervous about providing a full disclosure of the 
technology to industry. The technology transfer 
professional should work with the inventor to en­
sure that the time is right in the review process 
to provide full disclosure, and that the disclosure 
can be documented in some manner. 
. Licensing negotiations 
An inventor’s level of participation in licensing 
negotiations truly depends on the individual. 
The decision about how far to involve an in­
ventor rests on the shoulders of the technology 
transfer professional. The manager must weigh 
the inventor’s personality, interpersonal skills, 
and knowledge of business negotiations, as well 
as the inventor’s understanding of office policy, 
knowledge of the licensee, and ability to func­
tion as part of a negotiation team. The technol­
ogy transfer professional should be on guard for 
signs that the inventor is starting to sway to the 
side of the licensee during negotiations, which 
sometimes occurs. Often, the manager can re­
solve this by investing in discussions with the 
inventor to identify the underlying reason(s) for 
the inventor’s sympathy towards the licensee’s 
point of view. It is important for the inventor 
to agree to the deal breakers and to be prepared 
to walk away from the deal. If the inventor is 
apprehensive of business negotiations, he/she 
should remain on the sidelines. If this should be 
necessary, the technology transfer professional 
still should keep the inventor updated on the 
status of license negotiations in order to man­
age expectations and to preserve a good relation­
ship with the inventor. The inventor, in turn, 
should be encouraged to keep the technology 
transfer manager updated on what he/she may 
have heard from contacts within the company. 
The technology transfer professional should be 
notified of any technical updates that occur, es­
pecially during the negotiation period, since it 
may be important to promptly disclose this in­
formation to the company. It may be advanta­
geous to routinely schedule discussions with the 
inventor during negotiations. Such discussions 
can serve the dual purpose of a negotiation up­
date and a technical update. Prior to signing the 
agreement, the inventor should identify exactly 
what materials, know-how, and so on, must be 
transferred to the licensee. The inventor should 
also discuss with the licensee how this transfer 
is best accomplished. The licensee may wish to 
have access to the inventor once the agreement is 
in place, for example, by hiring the inventor as a 
consultant. The technology transfer professional 
must stay informed of these activities and verify 
that any obligations of the university under the 
agreement are fulfilled, and that any new rela­
tionships between the licensee and the inventor 
work within the framework of the license and 
institutional policies. 
. Licensee diligence and license compliance 
Following execution of the license, the inventor is 
a major source of information. It is extremely im­
portant for the TTO to develop systems to follow 
license compliance and diligence.5 In a perfect 
world, the technology transfer professional would 
maintain close ties with his or her counterpart 
at the licensee. Frequently, however, the inven­
tor will have more information than anyone else 
about technology development by the licensee. In 
most cases, contact with the scientific counterpart 
at the licensee is key for good information flow. 
Indeed, the relationship between the inventor and 
the scientific counterpart may provide the insight 
that will help the technology manager determine 
whether the licensee is diligently pursuing the 
technology’s development. The technology trans­
fer professional should encourage the inventor to 
inform the TTO of concerns about the voracity 
of the licensee’s efforts (or lack thereof ). Specific 
information about the likelihood of meeting tech­
nical milestones is also helpful. Encourage the li­
censee to involve the inventor (as an observer) in 
product development discussions. That way, the 
inventor will stay informed and may be able to 
help with any technical glitches that might arise 
when the licensee scales up the technology. 
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CHAPTER . 
. When things go well 
When there is an unqualified success in a tech­
nology transfer effort, the inventor, licensee, uni­
versity (including the TTO), and the public all 
benefit. The inventor might also experience fame 
and fortune, depending on the discovery. Positive 
feedback has the potential to reach other faculty 
and may encourage those who have not yet tested 
the waters of the TTO to disclose an invention. 
Conversely, success can also bring unwanted at­
tention, often related to the anticipated revenue 
stream. Disputes may arise about royalty distribu­
tions among the inventor, his or her department 
head, or dean. The university’s royalty distribution 
policy may be challenged. If significant revenue is 
expected, funds traditionally earmarked for one 
purpose might be considered for reallocation. A 
wise technology transfer professional will remain 
in touch with the inventor to ward off these oc­
currences and/or to be available for assistance, if 
needed. When challenges are raised, the TTO 
may be called upon for suggestions and may be 
engaged in the discussions, even if its preference 
would have been to remain neutral. 
. When things go badly 
The earliest signs that a license agreement is not 
proceeding as planned are usually given (inten­
tionally or not) to the inventor. The technology 
transfer professional, therefore, should counsel the 
inventor to recognize trouble spots. It is a good 
idea to provide pointers to the inventor about 
what to look for and when to contact the office 
to relate issues of concern. Better yet, the tech­
nology transfer professional should routinely stay 
in touch with the inventor in order to stay aware 
of the licensee’s R&D efforts. If a license is ter­
minated (for whatever reason), the inventor can 
help ensure that the institution retrieves from the 
licensee what is due. Should the technology man­
ager find himself or herself in the unenviable po­
sition of terminating a license, the inventor may 
be instrumental in establishing breach of diligence 
obligations. Managers should be cautious, how­
ever, of the overzealous phone call from the in­
ventor calling for the termination of a license. For 
example, an inventor who has difficulty moving 
past the point of research to product development 
may perceive progression from research to develop­
ment as a sign of an incompetent licensee. 
If litigation is a possibility, the technology 
transfer professional may wish to enlist the help 
of the university’s Office of the General Counsel 
to make sure that the inventor understands the 
process. Specifically, the inventor needs to know 
what is expected of him or her as inventor, and 
what is involved in such a proceeding. Litigation 
is complex and requires coordination and coop­
eration. Indeed, should the TTO need to litigate 
on a matter related to a license, the technology 
transfer professional and the inventor will both 
benefit from having previously established a long-
lasting, supportive relationship. 
5. INVENTOR AS ENTREPRENEuR 
With the increased emphasis on the role of tech­
nology transfer in economic development activity, 
managers can expect a change in the relationship 
when the inventor moves into the role of entre­
preneur. Many factors will influence the evolving 
relationship, including whether it is the inventor 
or the TTO pushing the entrepreneurial activity. 
Regardless, it is important for the inventor to rec­
ognize that the technology transfer professional’s 
fiduciary duty is to the university. In past cases of 
third-party licensing, the inventor’s interests and 
the university’s were closely aligned. But now the 
situation is different. Be diligent in notifying the 
entrepreneur about the university’s expectations 
for him or her to provide appropriate business 
and legal support. To prevent problems down the 
road from which it may be difficult to recover, the 
inventor-entrepreneur must understand the uni­
versity’s conflict-of-interest and conflict-of- com­
mitment policies. The technology transfer profes­
sional should encourage the inventor to provide a 
frequent flow of information to his or her depart­
ment chair and dean. Concurrently, the technol­
ogy transfer professional should also provide the 
appropriate information to the administration, 
department chair, and dean. The inventor-entre­
preneur must recognize that license negotiations 
with the company must be arm’s-length negotia­
tions and that they often require high-level ap­
proval, which may delay the execution of the 
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agreement for weeks. The inventor-entrepre­
neur has the potential to become a spokesperson 
for the university’s technology transfer efforts. 
Conversely, the inventor-entrepreneur could be­
come the strongest critic of such activity, depend­
ing on how these relationships are managed and 
balanced. 
6. MANAGEMENT ISSuES 
.1	 Other technology transfer roles 
for the inventor 
The inventor participates in many other technol­
ogy transfer activities throughout his or her aca­
demic career that occur without the involvement 
of the technology transfer professional. These ac­
tivities, such as consulting, educating/graduating 
students, publishing manuscripts, giving confer­
ence presentations, distributing posters, partici­
pating in a consortium, and becoming involved in 
sponsored research agreements, may be described 
as know-how transfer without a license. 
While the technology transfer professional 
may not be involved in any of these activities at 
the start, some (if not all, at some time) will af­
fect the technology manager’s efforts. In these in­
stances, it is best to take the education approach. 
When possible, educate faculty about the effects 
of publication or of signing away rights in con­
sulting agreements, and so on. Raising awareness 
about those effects means more inquiries to the 
TTO, but early input may prevent impossible 
situations later. 
.2	 Management of relationships 
It is imperative for the technology transfer profes­
sional to keep in mind the numerous groups the 
inventor needs to deal with in academia: patent 
attorneys, TTO staff, grants and contracts of­
ficers, department chairs, deans, sponsors, aca­
demic collaborators, licensees, and students, to 
name only a few. Remember, both the inventor 
and the technology transfer professional function 
within the organization’s corporate culture. In ad­
dition, the university’s corporate culture may be 
an island in the local culture, subject to frequent 
analysis and possibly criticism. 
It is important for the technology transfer 
professional to stay high on the inventor’s prior­
ity list of individuals with whom to nurture a re­
lationship. Faculty, however, are not universally 
evaluated by the number of disclosures submitted 
or patents awarded; publications and grants re­
main the priority. Remember this, and be assured 
that if the technology transfer professional un­
conditionally accepts the academic environment, 
an open, trusting relationship with the inventor 
will develop over time. 
The TTO may be enlisted to function as a go-
between, negotiator, or advocate for the inventor 
with any of the above groups. This is a challenging 
responsibility, since the TTO needs to maintain 
its own relationship with each of these groups as 
well. All potential outcomes and ramifications for 
both the inventor and the TTO (when assuming 
this role) need to be considered. 
. 	 Management of expectations 
A significant part of managing the relationship 
between the TTO and the inventor is making 
sure the inventor maintains realistic expectations. 
A former colleague coined this hypothetical dis-
closure-form question: “Please indicate the value 
of this technology: Is it worth millions, billions, or 
priceless?” And while this was suggested tongue 
in cheek, the sentiment does ring true. There is 
frequently a big disconnect between the inven­
tor and the TTO when it comes to an invention’s 
marketability. The challenge faced by the tech­
nology transfer professional is how to tactfully 
keep inventor’s expectations in line with realistic 
expectations. Soliciting an opinion from anoth­
er party may help. For example, the technology 
transfer manager may wish to enlist a trusted 
faculty member who has experience with trans­
fer technology. A patent attorney or an outside 
consultant can help deliver the news. Evaluations 
from industrial representatives may be the only 
validation an inventor will accept. A manager may 
wish to identify to whom the inventor best relates 
and enlist them to help. It is in the best interests 
of everyone to be realistic from the start. If the 
inventor’s value perception is skewed, his or her 
chair may also have skewed expectations, and the 
inventor’s dean may be overanticipating, as well. 
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In these situations, the technology transfer office 
spends a great deal of time (and political capital) 
explaining away unrealistic expectations and re­
defining what is reasonable to expect. Recovery 
from disappointed expectations may take years, 
and the gap between expectations and what was 
actually achieved could possibly end in an office 
reorganization. 
7.	 CONCluSIONS 
While the technology transfer professional is con­
stantly challenged to manage diverse technology, 
he or she is further challenged to effectively in­
teract with a diverse group of inventors. While 
these complex relationships and interpersonal 
dynamics may be overwhelming at times—both 
for the inventor and the technology transfer 
manager—working together can be extremely re­
warding. These interactions add an unanticipated 
dimension to the job of the technology transfer 
professional that is often enjoyable. n 
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Michael blaKeney, Director, Queen Mary Intellectual Property Research Institute, University of London, U.K. 
ABSTRACT 
This chapter explains how important it is for a research 
institute to audit both the intellectual property (IP) that 
it generates and the third party IP that its researchers uti­
lize. Such an audit will have the practical consequence 
of enabling the research institute (when appropriate) to 
secure ownership, maintain, and manage the IP for which 
it is responsible. 
1.  InTRoduCTIon 
For a number of years, intellectual property (IP) 
rights were considered private rights and not of 
concern to the public research community. A 
number of developments have changed this per­
ception. First, genetic materials have been priva­
tized, limiting the genetic materials available 
for public research. Second, IP rights have been 
asserted over enabling biotechnologies, which 
has the potential to thwart the ability of public 
research institutions to pursue modern biotech­
nological research. Third, funding for public re­
search institutes has been reduced, making them 
aware of their need to take an active role in IP 
management. Indeed, because of the above de­
velopments, public research institutes are now us­
ing their IP assets to bargain for access to private 
proprietary rights. 
The first step in IP management is to con­
duct an IP audit. This will identify the IP that 
the institution’s researchers generate, allowing 
it to be used as an asset and aiding in the 
identification of the IP of third parties. The lat­
ter is particularly important for the institution’s
ability to avoid liability for the misuse of third-
party IP. 
2.  METHodoLoGy 
The usual objectives of an IP audit are to identify 
relevant IP, establish the ownership of that IP, put 
in place procedures to manage the IP, and assist 
in the formulation and execution of the research 
institute’s IP policy. 
Of course, before any of these processes can 
begin, the scope of the audit must be determined. 
In some cases, an audit might be done to satisfy 
donor institutions or for external accreditation. 
On the other hand, it might be prefatory to the 
research institution’s collaboration with the pri­
vate sector. In each case, those commissioning the 
audit must determine the objectives. A decision 
will have to be made about who gets the results 
of the audit. It may be confined to the board, to 
donors, to management, or be made available to 
the public. 
The audit may be conducted through: 
•	 online surveys of senior administrative and 
research staff 
•	 follow-up interviews, by phone or in per­
son, with those staff 
Blakeney M. 2007. Conducting IP Audits. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org. 
© 2007. M Blakeney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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•	 analysis of contracts, material transfer 
agreements (MTAs) and other documents 
held at the central administration 
•	 analysis of relevant documents identified 
through interviews 
Before the audit, it is often useful to sensitize 
staff about the relevance of IP to the research insti­
tution’s operations. This can be achieved through 
workshops or distributing explanatory material, 
both of which can be done online. Surveys to 
identify agreements and activities with potential 
IP implications can also be administered online. 
Follow-up interviews will explore this informa­
tion and identify documents that need analysis. 
Of course, all of the institution’s contracts should 
be scrutinized for their IP implications. 
Keeping the results of the audit confidential 
will be essential for securing the full cooperation 
of the institute. After all, the audit might disclose 
matters that the institute may find damaging to 
its reputation. More positively, areas of education 
and training for staff may be identified and the 
results of the audit translated into best manage­
ment practices. 
.	 oWnERSHIp And ConTRoL	 of Ip 
.1 Introduction 
A key goal for any IP audit is helping to establish 
the research institute’s ownership and control of 
the audited IP. This requires examining all docu­
ments relevant to: (1) the legal status of the insti­
tute; (2) the obligations of personnel under their 
service agreements and employment contracts, to­
gether with their obligations under the institute’s 
IP policy; (3) agreements with research collabora­
tors; (4) agreements with funding bodies and do­
nors; and (5) documents relevant to the research 
institute’s status within any research network. 
The ability of a research institute to assert 
ownership and control over any IP depends upon 
its legal capacity. In the case of an incorporated in­
stitute, this will be set out in its constitution and 
bylaws (memorandum and articles of association). 
The laws governing the place of incorporation will 
usually govern these documents. But if the research 
institute has international status, its powers may 
be derived from a headquarters agreement between 
the host state, donor bodies, and the institute. 
Once it has the legal power to exercise do­
minion over property, including IP, the institute 
will also have the power to contract with its em­
ployees. Typically, IP clauses will be inserted in 
contracts of employment or in an institute IP 
policy or code referred to in the employment con­
tract. The simplest of these clauses will oblige an 
employee to comply with the institute’s IP policy, 
which will typically be available in printed form 
or on the institute’s Web site. 
For example, Washington State University’s 
IP policy states: 
All employees accept the terms of these policies 
as conditions of employment or gratis association. 
Employees shall agree to execute an assignment of 
their future patentable works and discoveries to the 
University. These policies may be modified by the 
administration with approval from the Board of 
Regents after consulting with faculty and staff of 
the University.1 
As indicated below, this policy obliges em­
ployees to notify their employers of any innova­
tions that might generate IP rights. For example, 
Texas A & M’s IP policy applies to: 
(i) all persons employed by the System; and
(ii) any persons using the System facilities un­
der the supervision of System personnel, in­
cluding but not limited to visiting faculty 
and adjunct faculty, unless special terms for 
management of the work of such individuals 
are negotiated by the System or the appli­
cable System component. System employees 
should not enter into intellectual property 
agreements related to outside employment, 
such as consulting or summer employment 
agreements, without affirmative notice to 
the prospective employer that the intellec­
tual property rights of the System cannot be 
subordinated to a third party consulting or 
employment agreement.2 
It will be up to the institution to decide what 
to do with such IP. In some cases, IP rights might 
be waived. More usually, there is a procedure to 
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CHAPTER . 
share the benefits of any exploitation of IP. The IP 
policy of Texas State University is typical: 
In those instances where the System licenses 
rights in intellectual property to third parties, the 
costs of licensing, including the costs to operate and 
support a technology transfer office and departmen­
tal or institutional intellectual property advisory 
committees, and the costs of obtaining a patent or 
other protection for the property on behalf of the 
Board shall first be recaptured from any royalties or 
other license payments received by the System, and 
the remainder of such income (including, but not 
limited to, license fees, prepaid royalties, minimum 
royalties, running royalties, milestone payments, and 
sublicense payments) shall be divided as follows: 
• 50% to creator 
• 50% to System 
With the prior approval of the Board … com­
ponent institution may include provisions in its 
Handbook of Operating Procedures to adjust the al­
location of royalties set forth herein, but in no event 
shall the creator receive more than 50% or less than 
25% of such proceeds. 
A similar situation will apply in research in­
stitutes operated by government departments. In 
each case the government department will have to 
decide whether any IP generated by its employees 
will be made available to the employee, whether 
it will be secured by the relevant department for 
exploitation or, alternatively, made available to 
the wider research community. 
.2 Headquarters agreements 
For international research institutes, the agree­
ment between donors and host governments will 
usually delineate the institute’s legal personality. 
It will usually be designated as “an autonomous, 
philanthropic, tax-free, nonprofit, nonstock, benevo­
lent corporation.”4 There will usually be a term for 
which the institute is to exist, such as 50 years 
from the date of incorporation, with a possibility 
for renewal. It will usually be indicated who owns 
the assets of the institute at the end of the term. 
Should an institute establish a collection of bio­
logical resources from other countries, biopiracy 
objections may arise if their ownership is lost at 
the end of the term. 
The headquarters agreement will usually in­
dicate the power of the institute to “receive and 
acquire by donation, grant, exchange, devise, be­
quest, purchase, or lease, either absolutely or in trust, 
contributions of such properties, real and personal as 
may be necessary to carry out the objects and pur­
poses” of the institute. This provision will have no 
operative effect, as the power will be conferred by 
incorporation.5 
. Incorporation 
Typically, a research institute will be incorporated 
under the law of the host country. This law will 
contain provisions about the types of corpora­
tions and their powers. Companies are usually 
divided into nonprofit and profit-making enter­
prises, and the ownership and assets structure 
of each may differ. Invariably, the voting rights 
of the company will be allocated by reference to 
shares. Management will consist of a board under 
a panel of directors and a chief executive officer. 
The powers of the company are usually set out in 
a constitution or a memorandum of association 
and detailed in its bylaws or articles of associa­
tion. These documents should be scrutinized to 
see what powers the institute has to own and to 
deal with IP. The documents will also explain the 
powers of the corporation’s officers to enter into 
transactions on behalf of the corporation. The 
procedures for terminating the existence of the 
institute and the disposal of its assets on termina­
tion should also be described. 
The constitutive documents of a corporation 
are commonly silent about the fate of intangible 
property, such as IP, that is generated by the cor­
poration during its life. This is because IP has only 
relatively recently become a corporate concern. 
However, where the tangible property is specifi­
cally disposed of, it is likely that the intangibles 
will follow the same route. 
. Charter of the institute 
Public research institutes commonly indicate their 
public service function in a governing charter. The 
board, under the corporation’s bylaws, will usu­
ally promulgate such a charter. As such, the char­
ter will be subordinate to the general operation of 
the articles of incorporation and confer no powers 
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that are greater than those defined by the articles 
of incorporation. 
. Personnel documents 
Typically, the personnel at a public research in­
stitute include national staff, internationally re­
cruited staff, visiting scientists, consultants, af­
filiate scientists, project scientists, collaborative 
research fellows, and doctoral and postdoctoral 
students. Asserting ownership and control over 
the IP that personnel may generate will depend 
upon the terms of their engagement. For conve­
nience, we can categorize these persons as staff 
and nonstaff. 
..1 Staff 
The ownership and control of IP generated or 
held by staff will be handled by a combination 
of personnel contracts and the institute’s person­
nel policies and procedures. These will usually be 
gathered in a personnel manual. Given the grow­
ing concern about IP staff, some institutes have 
been requested to sign an IP rights statement or 
a nondisclosure agreement. At the International 
Rice Research Institute (IRRI), for example, the 
statement is an IPR Agreement in which staff agree 
that “all inventions, improvements, data, processes, 
technologies, discoveries and other intellectual prop­
erties” generated by them, while employed by 
IRRI, “that relate to the research and development 
programs of IRRI or result from tasks” assigned to 
them “are the sole property of IRRI.”6 
Publication is a significant issue if a partner 
desires nondisclosure and the ethos of the insti­
tute is to publish its research. Premature publi­
cation in articles, research papers, and at confer­
ences and meetings may destroy the novelty of a 
patentable invention. This is in tension with the 
desire of researchers to place their scholarship into 
the public arena. The IP audit can be an oppor­
tunity to introduce staff to the impact of IP upon 
their research. When proprietary technologies are 
licensed from the private sector, the license agree­
ment may sometimes restrict publication until 
the commercial opportunities generated by the 
research have been evaluated. Nonresearch staff 
and board members should also be bound by a 
confidentiality obligation. 
This list of IP categories embraced by the agree­
ment is presumably intended to be informative and 
exhaustive for the staff members who sign it: 
•	 The IRRI IPR agreement obliges staff to dis­
close the listed categories of IP “promptly 
to IRRI.” A procedure for such disclosure 
should be established, identifying the per­
son or office to whom/which disclosure 
should be made. 
•	 The IRRI IPR agreement requires that 
employees assign relevant IP to IRRI and 
“do all things necessary, including executing 
documents” to assist IRRI in obtaining legal 
protection for its IP. This is a fairly effec­
tive means for IRRI to secure title to the IP 
generated by its staff. 
•	 The IPR agreement also obliges staff to use 
confidential information only in the perfor­
mance of duties for IRRI and not to disclose 
information to unauthorized persons both 
during employment with IRRI and for a 
five-year period after the termination of their 
employment. This provision appears to ef­
fectively impose confidentiality obligations. 
Staff includes those employed outside the in­
stitution, such as those working in the field or 
attached to other institutions. They are bound 
by their employment contracts and potentially 
by the IP policies of the external institutions for 
which they work. The legislation of the countries 
where they work may also apply. For example, a 
number of countries have enacted legislation to 
regulate access to biological materials that might 
become the subject of patent applications. A re­
search institute would be in breach of that law if 
it filed IP applications related to biological mate­
rial that was obtained without consent. 
Usefully supplementing the IPR agreement 
could be a reference to any institute policy on IP 
rights and a definition of those rights. Box 1 sets 
out a comprehensive definition of IP. 
..2 Non-staff 
Research institutes frequently host various cat­
egories of nonstaff, such as visiting scientists, con­
sultants, project scientists, collaborative research 
fellows, and students. Maintaining ownership 
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CHAPTER . 
and control of the institute’s IP can be a particular 
problem where non-staff are concerned. Without 
an agreement with them, the institute will be un­
able to assert control over IP that these visitors 
might generate or use. Indeed, problems have aris­
en from the uncertain status of visiting researchers, 
who in some instances have acquired patent rights 
over the subject of their research while a visitor. 
Accommodating researchers funded by outside 
donors has also been an issue. Uncertainty about 
the ownership of the research of such donors can 
be clarified in the institute’s IP policy. Accordingly, 
a number of countries commonly require nonstaff 
to execute an IP and confidentiality agreement. 
. Policy on IP 
Currently, public research institutes commonly 
formulate policies to deal with IP ownership 
and control. The policy is usually agreed to and 
approved at the board level. As a general prin­
ciple, the institutes emphasize the free availabil­
ity of the information, inventions, and biological 
material that they develop. Institutes are obliged, 
however, to seek IP protection to ensure the avail­
ability of advanced biological technologies or bio­
logical materials for developing countries. Some 
institutes declare that they may seek to protect 
technologies or materials that they develop for 
their client communities. Protection may also be 
pursued to prevent third parties from obtaining 
IP rights over their innovations. For example, by 
filing a provisional patent application, knowledge 
about an institute’s innovations will be placed in 
the public domain. This is intended to destroy the 
novelty—and hence the patentability—of inno­
vations that are required for the benefit of devel­
oping countries. This will prevent such inventions 
from being appropriated by the private sector. 
Box 1: Intellectual Property
 
Intellectual property means information, ideas, inventions, innovations, art work, designs, literary 
texts and any other matter or thing whatsoever as may be capable of legal protection or the 
subject of legal rights and includes the following protections:
•	 patents 
•	 confidentiality (for information which is of a kind and which has been communicated in such 
a way as to give rise to a duty of confidentiality) 
•	 copyright vesting in literary works (including computer programs), dramatic works, musical 
works, artistic works, films, sound recordings, multimedia works, broadcasts, published 
editions, and certain types of performances 
•	 registered trademarks 
•	 unregistered trademarks used or intended for use in business 
•	 registered designs and designs capable of being registered 
•	 rights of breeders for new plant varieties 
•	 rights associated with designs 
• rights related to databases 
• other rights resulting from intellectual activity in the industrial, commercial, scientific, literary,
and artistic fields 
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A number of public research institutes include 
their IP policy within a policy on partnership with 
the private sector. These research institutes will of­
ten concede that to ensure that developing coun­
tries have access to biotechnology-derived products 
and advanced biotechnologies, it may be necessary 
to enter into special agreements that stipulate some 
limitations on distributing derived and associated 
materials. Within the context of this policy, the in­
stitute may assemble a list of IP that it is willing to 
share with the private sector in exchange for access 
to its IP, under mutually acceptable terms. 
.	 IdEnTIfICATIon of Ip	GEnERATEd
By 	A	RESEARCH	InSTITuTE 
.1	 Background 
An IP audit obviously has to identify all the IP 
generated by the research institute, whether ex­
isting in a registered or unregistered form. This 
requires analyzing questionnaires completed by 
management and research staff, as well as the 
examination of contracts, MTAs, licenses, col­
laboration agreements, memorandums of under­
standing, collaborative work plans, employment 
contracts and other legal arrangements. This will 
allow the auditor to: (1) clarify the terms under 
which IP is being accessed; (2) determine whether 
the terms of access impose restrictions on the in­
stitute’s ability to distribute products and services 
produced with the help of this IP; (3) identify 
ownership of relevant IP; (4) identify the source 
of IP in order to identify areas in which IP access 
and ownership issues may have to be reexamined 
to ensure compliance with the institute’s current 
IP policy; (5) assess the importance of the IP to 
the institute’s activities; and (6) identify all new IP 
being developed at the institute (specifically, the 
IP opportunities perceived by the institute, for its 
own and third-party IP). 
Typically, an audit will identify the following 
main types of IP: 
•	 patents and know-how associated with the 
biological assets of the institute 
•	 patents and industrial design rights 
•	 IP associated with agricultural equipment 
developed by the institute 
•	 copyright, database rights, and know-how 
associated with publications, computer 
programs, and databases generated by the 
institute 
•	 copyright databases and know-how devel­
oped from the functional genomics research 
undertaken at the institute 
•	 trademarks 
•	 industrial designs 
.2	 Patentable biological assets 
The principal biological assets located at a scien­
tific research institute will include: 
•	 germplasm collection 
•	 DNA collection 
•	 biological tools for gene discovery 
•	 enabling technologies (for example, marker 
genes and probes) 
•	 advanced mapping populations 
•	 near isogenic lines 
•	 introgression lines: mutants (characterized/ 
uncharacterized); BAC library 
•	 introgression lines 
•	 gene pyramids 
•	 advanced lines from conventional breed­
ing: conventional lines; new plant types 




•	 transgenic lines 
These biological assets represent a consider­
able investment by the institute, its partners, and 
collaborators. Insofar as they contain potentially 
patentable or licensable information, they also 
represent various levels of added value, utility, 
and inventiveness. 
. 	 Patents, utility models, and 
industrial design rights 
A medical or agricultural research institute is like­
ly to develop equipment and tools that need IP 
protection. 
. 	 Technological know-how 
Not all IP is protected through a system of regis­
tration. An important unregistered category of IP 
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CHAPTER . 
in medical research is confidential information. It 
is often an adjunct to registered IP rights. For ex­
ample, patent protection is conferred in exchange 
for the disclosure of enough information in a pat­
ent application to permit the invention, which 
is the subject of the application, to be used. To 
protect its competitive advantage, the applicant 
inevitably will withhold information about how 
to effectively commercialize an invention. This 
information, or know-how, may include plant 
design and setup, training, marketing plans, cus­
tomer lists, and accounting and survey methods. 
Similarly, a protected trademark is of limited com­
mercial utility without an associated scheme for 
advertising, licensing, franchising, and marketing 
the goods or services under that mark. Ensuring 
the quality control of the licensed goods will usu­
ally entail the application of trade secrets. 
At the center of the attempt to protect con­
fidential information are efforts to restrain the 
disclosure of trade secrets by former employees or 
researchers. A particular difficulty in these cases is 
distinguishing between information that can be 
regarded as the skilled employee’s or researcher’s 
own expertise and other information gained dur­
ing employment, such as secret industrial formu­
lae or processes, which may properly be regarded 
as the employer’s. Generally speaking, if the in­
formation in question can fairly be regarded as a 
separate part of the employee or researcher’s stock 
of knowledge that a person of ordinary honesty 
and intelligence would recognize, the informa­
tion would be considered to be the property of 
the employee. In applying this objective test, the 
courts have tended to look, among other things, 
at the nature of the employment, the nature of 
the information, and whether the information 
was capable of being isolated from other un­
protected information. Chemical formulas and 
recipes and engineering drawings and designs 
are usually considered to be discrete categories of 
undisclosed information that fall within the cat­
egory of protectable confidential information. 
National laws protecting confidential infor­
mation differ. Article 39 of the Agreement on 
Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) administered by the World Trade 
Organization (WTO) deals with the preservation 
of confidential test data submitted to government 
approval agencies. Given the long approval pro­
cess, particularly for pharmaceutical products, the 
opportunities for wrongful appropriation of such 
data by competitors was self-evident. Accordingly, 
Article 39 (3) provides that: 
Members, when requiring, as a condition of 
approving the marketing of pharmaceutical or of 
agricultural chemical products which utilize new 
chemical entities, the submission of undisclosed test 
or other data, the origination of which involves a 
considerable effort, shall protect such data against 
unfair commercial use. In addition, Members shall 
protect such data against disclosure, except where 
necessary to protect the public, or unless steps are 
taken to ensure that the data are protected against 
unfair commercial use. 
. 	 Biological assets protectable 
as plant varieties 
New plant varieties developed by agricultural re­
search institutes may be protectable under plant 
breeders’ rights legislation. Such varieties can 
also be patented in the United States but not in 
Europe. 
. 	 Rights associated with publications, 
computer programs, and databases 
Copyright arises in relation to publications, CD-
ROMs, databases, online displays, and software. 
Governing the protection of works created within a 
country, copyright laws are territorial. But through 
international agreements a particular country’s 
laws can be respected outside its territory. Most 
countries are signatories to the TRIPS Agreement, 
which affirms the Berne Copyright Convention 
and adds some additional protection. 
Most copyright laws provide protec­
tion for printed works, such as books, confer­
ence proceedings, research reports, and jour­
nals. Copyright protection is also available for 
research notes, provided that these are in writ­
ten form. Copyright protection is also available 
for films, photographs, sound recordings, and 
CDs. Under the Berne Convention and TRIPS 
Agreement, computer programs are treated as 
if they were literary works. Finally, copyright 
protection is available for online materials and 
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BlAKENEY 
screen displays. The period of copyright protec­
tion is conventionally 50 years from the date of 
a work’s publication. 
..1 Publications 
Copyright will exist in the textual material, pho­
tographs, graphic designs, diagrams, charts, and 
the compilation or arrangement of a publication. 
A research institute will publish scientific books 
(including monographs, conference proceedings, 
manuals, and field guides); discussion papers; 
proceedings of conferences, meetings and work­
shops; technical bulletins; and scientific posters. 
..2 CD-ROMs 
A number of different copyright interests may 
arise for material on a CD-ROM. Copyright 
may arise with respect to text, artistic works (such 
as photographs, drawings, diagrams), musical 
works, sound recordings, and films, as well as 
in relation to the compilation of material con­
tained in the CD. An institute may produce CD­
ROMS as part of its training materials. For ex­
ample, the asynchronous Internet-based courses 
in Experimental Design and Data Analysis and 
in Agricultural English, created and administered 
by IRRI, are available on CD-ROM. When ma­
terials have not been generated at the institute, 
the audit should ascertain whether permission 
or clearance has been obtained from the author 
or original source prior to publication. The au­
dit should also determine whether the author or 
original source is acknowledged. When material 
appearing on CD-ROM is generated at the in­
stitute, the CD-ROM should carry a copyright 
notification with respect to the compilation and 
the individual elements of the CD. 
.. Video materials 
Video materials produced for the purpose of train­
ing are copyright protectable. Thus video materi­
als produced at the institute should acknowledge 
it as the source and carry a copyright notice. If 
desired, this could be accompanied by a notice 
authorizing reproduction or copying of the ma­
terial provided the institute is acknowledged as 
the source. If videos are produced involving ma­
terial generated from outside the institute, then 
procedures have to be put in place to obtain copy­
right authorization and copyright indemnities. 
.. Copyright databases and know-how 
The various research projects undertaken or un­
derwritten by an institute generate considerable 
bodies of data. Under current copyright law, raw 
data or information is not protectable. But legis­
lation is being considered in a number of coun­
tries that would allow databases and possibly raw 
data itself to become the subject of sui generis, or 
special, IP protection. However, while raw data 
contained in databases may not be copyright 
protected, the way in which information is ex­
pressed can offer some protection. For example, 
a passage of text, a diagram, or chart contained 
in a database may be protected by copyright. 
It is also possible that in certain circumstances, 
where sufficient originality or creativity in the 
arrangement of data is present, the database as 
a whole may be protected by copyright on the 
basis that it is a compilation. Because individual 
components of the database may be protected 
by copyright, there must be mechanisms and 
procedures to ensure that the database does not 
contain material that infringes the copyrights of 
others. IP rights are of particular concern when 
the creation of a database is collaborative. In this 
case, when copyright exists in individual entries 
it may be unclear whether the copyright belongs 
to one collaborator or to all the collaborators 
jointly. Moreover, when material is contributed 
from diverse sources, each collaborator may be­
come liable as an infringer—even if only one of 
the collaborator infringes the copyright of a third 
party. 
To deal with some of these copyright issues, 
the Document by Bioversity International recom­
mends that the copyright notification page con­
tain a general notification hyperlinked to a page 
of specific copyright notifications. These would 
identify which part, or center, of the institute owns 
copyright in the relevant material. The document 
suggests the following general notification: 
This site is protected by international copyrights 
in the design of the site including the layout, ty­
pography, and graphics reproduced herein, and in 
the expression of the information contained herein, 
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CHAPTER . 
whether as a compilation, literary or artistic work 
or otherwise. 
The form of the specific copyright notifica­
tions recommended in the Bioversity International 
document is: 
Copyright [full name of copyright owner] [year 
of creation of work] in [describe] as [compilation/ 
published edition/literary work/artistic work] or 
otherwise. 
.. Online materials 
The copyright principles that apply to printed 
works and CD-ROMs apply equally to online 
materials. Thus an institute would have to secure 
permission and indemnities to use copyrighted 
material that it displays on its Web site. 
IP approval for hypertext links to other World 
Wide Web sites has recently raised some copy­
right concerns. If the institute’s home page links 
to a large number of Internet resources, it should 
be ensured that the proprietors of those online 
resources have no objections to those linkages. 
Copyright issues are also raised by mirroring 
and framing. Mirroring occurs when a site is du­
plicated on another server. Framing occurs when 
one Web site imports material from another site 
and makes it part of its own site. When such fram­
ing or mirroring occurs, it is essential that copy­
right clearances and indemnities are obtained. 
.. Computer programs 
Copyright subsists in both source and object 
codes of computer programs. Where commercial­
ly available programs are used or are incorporated 
in larger programs developed by the institute, li­
censes are available from the suppliers of those 
programs. It should be noted that a license to use 
commercially available software will not necessar­
ily authorize the development or improvement of 
that software. The development or improvement 
of commercially available software for the pur­
poses of, for example, facilitating or improving 
the accessibility of information stored on a data­
base will infringe the copyright unless a license to 
develop the program has been obtained. Where 
programs are written in-house by institute em­
ployees, copyright problems do not arise. 
In order to provide evidence that computer 
programs have been generated in-house, it is rec­
ommended that when institute personnel gener­
ate such material they complete a declaration of 
originality. Such a declaration could be made in 
electronic form in order to facilitate and central­
ize collection and storage. 
. Trademarks 
Research institutes commonly seek trademark 
protection for their names and key research 
products. The acronym and name of a research 
institute, for example, could be registered in 
Class 16 of the Nice Trademark Classification 
in relation to “research and educational mate­
rials.” Registrations can be obtained in each 
country in which research is undertaken. When 
an institute makes products such as seeds, these 
could be registered in Class 30, in relation to 
“[plant] variety/breeding lines.” Trademarks 
can also be sought for equipment and tools, for 
example in Class 7, which covers agricultural 
equipment. 
. Confidential information 
Research data compiled in institute projects by 
institute researchers may be protectable as con­
fidential information. To be protected, the in­
stitute has to impose confidentiality through 
confidentiality agreements with employees and 
researchers. These will inform them that the in­
stitute attaches the quality of confidence to its 
research data and to its research methods. For the 
most part, a public research institute will waive 
its rights to the confidential information that it 
generates in its research findings. However, for 
agreements according to which the institute 
undertakes to share unpublished research find­
ings and data with its collaborators, some en­
forcement of confidentiality agreements will be 
necessary to ensure that the research findings 
are shared and not dissipated. As awareness of 
IP protocols becomes more widespread, research 
collaborators will begin to insist upon an enforce­
able confidentiality regime. It will be increasingly 
important, therefore, to put in place mechanisms 
and procedures that ensure that confidential ma­
terial is not publicly disclosed. 
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. 	 Biodiversity rights 
The Convention on Biological Diversity (CBD) 
seeks to establish an international program for the 
conservation and utilization of the world’s biolog­
ical resources, as well as for the “fair and equitable 
sharing of the benefits arising from the utilization 
of genetic resources.” A similar policy animates the 
International Treaty on Plant Genetic Resources 
for Food and Agriculture. For example, the CBD 
contains provisions dealing with access to genetic 
resources. Article 15 requires contracting parties 
to “endeavour to create conditions to facilitate ac­
cess to genetic resources for environmentally sound 
purposes” by other contracting parties accord­
ing to mutually agreed terms and conditions on 
the basis of “prior informed consent.” A detailed 
code of access to biotechnology is prescribed in 
Article 16. Access and transfer are to be “provided 
on terms which recognize and are consistent with 
the adequate and effective protection of intellectual 
property rights.” The Article provides that devel­
oping countries that provide genetic resources 
shall be granted “access to and transfer of technol­
ogy which makes use of those resources.” In addition, 
Article 19.2 provides for the grant of access on a 
fair and equitable basis and on mutually agreed 
terms to contracting parties, “particularly devel­
oping countries, to the results and benefits arising 
from biotechnologies based upon genetic resources 
provided by those contracting parties.” Additionally, 
Article 8(j) of the CBD envisages that where the 
knowledge, innovations, and practices of indig­
enous and local communities are utilized, the 
benefits arising from their utilization should be 
shared equitably. 
A number of developing countries have in­
troduced legislation that seeks to enact the ben­
efit sharing provisions of the CBD. Thus, when a 
patentable invention results from institute germ-
plasm that is contributed by indigenous persons 
or local communities, or that is collected as a re­
sult of the utilization of the knowledge of those 
persons or communities, a compensation liability 
may arise. Indigenous groups and local commu­
nities have begun to insist upon the collection of 
samples under the terms of bioprospecting agree­
ments, which invariably define the distribution of 
benefits from any royalties that may result from 
patents. In a number of developing countries, the 
use of bioprospecting agreements is becoming 
mandatory. 
.	 THIRd-pARTy Ip	 
.1	 Patents and know-how associated 
with biological technologies 
Most research institutes will have third-party pro­
prietary technology licenses. The basis of the pro­
prietary claims made by most of the licensors will 
be the confidentiality of the biological materials 
or know-how that is licensed to the research insti­
tute. Additionally, patented research technologies 
may be licensed. 
The salient features of these licenses are: 
•	 permissible use of the licensed material 
confined to scientific research 
•	 confidentiality of licensed material to be 
preserved 
•	 all information concerning improvements 
in the material or inventions associated with 
the material to be reported to the licensor 
•	 research progress to be reported 
periodically 
•	 use of material only by identified institute 
scientists 
•	 advance copies of manuscripts of publica­
tions to be provided to licensor 
The various obligations these agreements 
with third parties impose emphasize the impor­
tance of an IP management facility at a research 
institute. 
.2	 Genetic material 
Medical and agricultural research increasingly 
utilizes genetic material provided to an institute 
under an MTA or confidentiality agreement. The 
terms of that MTA may restrict how that mate­
rial can be used. For example, it may be on the 
condition that IP rights are not sought in rela­
tion to that material, or that it is not used for 
commercial purposes. Sometimes the MTA will 
require that material derived from the supplied 
material should also be supplied under those con­
ditions. In each of these cases, the responsibility 
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CHAPTER . 
to observe those conditions will be imposed on 
the institute; it will be the purpose of the audit 
to identify these obligations and document how 
they are being managed. 
On occasion, genetic material is made avail­
able informally by a scientist from a third party, 
acting without the authority of that third party. 
In this case, the unauthorized use could involve 
the research institute in liability. Consequently, 
the audit should identify the terms of all acces­
sions of third-party genetic material. 
. 	 IP rights associated with equipment 
utilized by a research institute 
A number of items of research equipment ob­
tained from commercial suppliers may generate 
IP obligations. For example the Bio-Rad Biolistic 
PDS-1000/He apparatus is often supplied to re­
searchers at IRRI subject to an agreement that it 
be used “for research purposes only.” The Hybaid 
PCR Express Thermal Cycler is also subject to a 
license “to practise the PCR process for internal re­
search and development.” 
.	 Ip	MAnAGEMEnT	STRuCTuRES 
An IP audit should analyze the management of 
IP at a research institute from the perspective of 
the adequacy of the management structures and 
procedures. It should also consider IP manage­
ment in terms of the staff’s awareness of IP obli­
gations. Finally, the institutional mechanisms for 
dealing with institute and third-party IP should 
be examined. 
.1	 IP management culture 
A critical feature of effective IP management is 
the existence of a research culture in which IP 
awareness is communicated to researchers. In 
order to ascertain the extent of IP knowledge 
and of IP management practices within an in­
stitute, questionnaires could be administered to 
administrative and research staff. To supplement 
the general IP consciousness-raising activities 
mentioned above, it would be very useful for staff 
to be provided with an IP handbook, containing 
a general primer on IP, as well as all relevant IP 
documents and procedures. This IP handbook 
could also be made available online and accessed 
from the institute’s Web site. 
.2	 Office of IP coordination 
As IP becomes increasingly significant for sci­
entific research, establishing an IP coordination 
office or officer for an institute becomes more 
important. This office, which may be within the 
research institute or located within the offices of 
a third-party subcontractor, would be responsible 
for coordinating both IP administration and pro­
cedures within the institute. The IP office would 
also be responsible for external IP liaison. The 
coordination of IP procedures would include 
securing the IP compliance of staff and visitors; 
ensuring the inclusion of IP provisions in relevant 
third-party agreements; ensuring the utilization 
of appropriate MTAs by the institute, both as a 
recipient and distributor of germplasm and bio­
logical tools; maintenance of a central repository 
of IP documents; maintenance of the institute’s 
IP database; and raising awareness of about IP is­
sues. Externally, an IP coordinator could provide 
an IP dimension to negotiations with research 
collaborators and act as a liaison with IP officials 
of other institutes. 
The IP coordination office would ensure that: 
•	 staff and visitors sign and adhere to IP and 
confidentiality agreements 
•	 copyright permissions and indemnities are 
secured for various publications 
•	 Copies of MTAs and other IP agreements 
are filed centrally and provided to appropri­
ate staff members 
•	 Proper research records are made, main­
tained, and filed 
•	 the MTA granting procedure is coordinated 
•	 the IP provisions of other agreements are 
supervised 
•	 the institute’s legal advisers are updated on 
IP matters 
. 	 Research records 
Establishing provenance for research is central to 
any policy of securing and exploiting the IP rights 
that might be generated from an institution’s
research. The practice of maintaining laboratory 
notebooks with consecutively numbered pages 
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that are signed at the end of each day by the su­
pervising scientist is normal in private enterprise, 
but may be alien to the research culture at a pub­
lic research institute. However, without this sort 
of management practice, it would be difficult to 
contest a first to invent dispute under patent law. 
Similarly, it would be difficult to identify the 
technological know-how brought by a scientist 
to the institute and to distinguish it from that 
which has been developed at the institute. This 
is important in delineating the respective confi­
dential information of a staff member and the 
institute. 
. Material transfer agreements (MTAs) 
Guidelines and procedures for the approval of 
material transfer agreements could efficiently di­
rect the management of IP in a scientific research 
institute. For germplasm designated under the 
International Treaty on Plant Genetic Resources 
for Food and Agriculture, an established procedure 
already exists. Some of the Consultative Group 
on International Agricultural Research (CGIAR) 
genebanks distinguish between designated germ-
plasm and germplasm that they themselves have 
developed, which is accordingly regarded as non-
designated. Separate MTAs are being developed 
by research centers to deal with the distribution 
of this material. 
.	 ConCLuSIonS 
Modern scientific research often requires expen­
ditures to enable the generation of protectable IP. 
The institute will have to decide whether this IP 
will be placed into the public domain or regis­
tered, either to pursue commercial exploitation 
or to prevent its privatization by unauthorized 
third parties. Before any of these actions can be 
taken, however, the research institute must iden­
tify the IP that its researchers generate or utilize. 
An effective IP audit is therefore an important 
tool for supporting the research objectives of the 
institute. n 
Michael blaKeney, Director, Queen Mary Intellectual 
Property Research Institute, Center for Commercial Law 
Studies, University of London, 13-14 Charterhouse Square, 





4	 See, for example: www.irri.org/publications/chandler/
pdfs/Appendices.pdf. 
5	 See, for example: www.irri.org/about/images/Memora
ndum%20of%20Understanding.pdf. 
6	 For an example of a standard research agreement
along these lines, see Oklahoma State’s template for 
a sponsored research agreement at: www.vpr.okstate. 
edu/Forms/Forms%202003/Spon%20Res%20Agmt.
doc. 
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CHAPTER 5.7 
Conflict of Interest and Conflict of Commitment
 
Management in Technology Transfer
 
alan b. benneTT, Associate Vice Chancellor, Office of Research, University of California, Davis; 
and Executive Director, PIPRA, U.S.A. 
ABSTRACT 
The potential for personal interests to influence institu­
tional decisions in universities and public sector research 
institutions continues to grow. This is because of the in­
creasing activity in intellectual property (IP) management 
and technology transfer undertaken by these institutions. 
The activities have the potential to generate both personal 
and institutional financial gain, making conflict of inter­
est and conflict of commitment issues unavoidable. This 
chapter explains the nature of these conflicts and discusses 
the policies, regarding conflict of interest, of several uni­
versities, offering them as potential models for crafting 
these indispensable policies. 
1. INTRODuCTION 
Universities and public research institutions have 
been characterized historically by their selfless ef­
forts to expand knowledge for the public good 
rather than for private gain. This has contributed 
to a high level of public trust in the integrity of 
these institutions, and they are seen as providers 
of unbiased information. This institutional integ­
rity rests on the personal integrity of the people 
employed by or associated with that institution, 
which collectively represent the greatest asset of 
the institution. Indeed, any erosion of institu­
tional integrity or of the public’s trust can have 
devastating consequences in terms of public sup­
port for the institution. 
One significant danger with regard to com­
promising the integrity of a university or public 
research institution is the potential for personal 
interests (often financial) to adversely affect an 
employee’s professional judgment when exercis­
ing a university duty or responsibility, for exam­
ple, the direction and conduct of research. The 
potential for a divergence between an individual’s 
institutional obligations and his or her private or 
personal interests can become a conflict of inter­
est: and a perceived conflict of interest can be as 
damaging as a real one. 
The potential for personal interests to influ­
ence institutional decisions is greater today be­
cause every institution is doing more in the area 
of IP management and technology transfer, and 
because these activities have the potential to gen­
erate both personal and institutional financial 
gains, conflict of interest issues are a constant 
concern. Indeed, in today’s modern research uni­
versities, the missions of which explicitly include 
the transfer of research to commercial partners, 
conflicts of interest are practically unavoidable. 
These conflicts need to be managed in ways that 
allow institutions to meet their technology trans­
fer mission without compromising their integrity 
and the public’s trust. 
Another closely related pitfall is the pressure 
that technology transfer and commercialization 
activities place on employees’ primary allegiance 
to their institution. In an era when researchers are 
encouraged to actively participate in technology 
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BENNETT 
transfer—and even in the development of new 
companies—it is necessary to ensure that the em­
ployee’s primary professional loyalty is to the insti­
tution rather than to a private, extramural activity. 
When outside activities cross boundaries in ways 
that compromise, or appear to compromise, the 
employee’s primary allegiance to the institution, 
a conflict of commitment exists. Because both 
conflicts of interest and conflicts of commitment 
are potential pitfalls in the technology transfer 
process, both are addressed in this chapter. Some 
universities address both conflicts in a single com­
bined policy (for example, Stanford University), 
while most treat conflicts of interest and conflicts 
of commitment in separate policies. 
2.  ConfLICT	 of 	InTEREST	RELATEd To 
Ip	MAnAGEMEnT 
Fundamentally, a conflictof interest is any situation 
in which there is a conflict between an individual’s 
private interests and his or her professional obli­
gations such that an independent observer might 
reasonably question whether the individual’s pro­
fessional actions or decisions are affected by his 
or her private interest.1 It is important to note, a 
conflict of interest exists whether or not decisions 
are made that are influenced by personal interests. 
The conflict only indicates the potential for mak­
ing biased decisions—not any likelihood of doing 
so or any a priori misconduct. One should also 
note that the precise definitions of conflict of in­
terest are guided by national and local laws, re­
search sponsor policies, and institutional policies; 
thus the definitions may vary widely depending 
on the geographic and institutional context. 
The potential for financial conflicts of inter­
est for individual researchers increases dramati­
cally when an institution begins to actively sup­
port and promote the transfer of research results 
for commercial applications.2 In many cases, the 
commercial development of early-stage research 
results can be carried out best by a start-up 
company. Typically, the university researcher is 
either a founder of or a consultant to the com­
pany and has substantial financial interests in the 
company. This gives rise to a personal conflict 
of interest, and any future decisions on research 
directions, assignment of research topics to stu­
dents, the supervision of clinical trials, or any 
influence over institutional IP licensing deci­
sions by the researcher/entrepreneur should be 
viewed through the lens of the institution’s con­
flict of interest policies. Again, it is important to 
note that the existence of the personal financial 
interests should not, in themselves, but in gen­
eral the conflict should be openly disclosed and 
any future activities and decisions by the con­
flicted individual reviewed and managed by the 
institution. 
The potential for a researcher to have a sig­
nificant financial interest in an outside potential 
licensee can be quite high, particularly if the 
licensee is a start-up company founded by the 
researcher/inventor. When the researcher partici­
pates in the licensing negotiations or even in dis­
cussions with the institutional licensing officer, 
the researcher is in a conflict of interest position: 
the researcher has the potential to influence an 
institutional licensing decision in which he or 
she has a direct financial interest. In California, 
such a position constitutes a criminal conflict of 
interest under the Political Reform Act of 1974. 
As a consequence of the Act, the University of 
California developed detailed guidelines and 
guidance on the disclosure and management of 
conflicts of interest in licensing. These guidelines 
permit participation in licensing negotiations by 
an inventor, even when he or she has a disqualify­
ing personal financial interest. As the guidelines 
observe, such participation “is appropriate and 
represents a useful contribution, because the transfer 
of University technology to industry is in the pub­
lic interest and is consistent with the University’s 
mission.”3 Such participation, however, requires 
an appropriate intervening substantive review, 
called a Licensing Decision Review, which deter­
mines whether licensing decisions are inappro­
priately influenced (see Box 1). Although these 
guidelines for managing conflicts of interest in 
licensing are very specific to the laws of the State 
of California, they raise and consider a number 
of important issues that are both generic and spe­
cific to technology transfer. 
An additional level of conflict of interest has 
also emerged as a result of universities taking an 
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CHAPTER . 
Box 1: university of California Guidelines for a licensing Decision Review 

What is licensing Decision Review? 
Licensing Decision Review means there is a review by a noninterested person or persons before 
a proposed licensing decision goes to the final decision maker for approval. The review must be 
based on an independent consideration and assessment of the facts of the case. The Licensing 
Decision Review body, composed of qualified staff with appropriate expertise, knowledge, and 
professional judgment, must independently check the original data and analysis upon which the 
selection of licensees proposed by the licensing professional and other licensing decisions were 
made and make its independent recommendations concerning the decisions.
Who conducts the licensing Decision Review? 
Each University of California campus and laboratory was directed in a June 18, 2001, letter to 
chancellors and laboratory directors from Provost King and Senior Vice President Mullinix to 
establish a plan for conducting intervening substantive review of licensing decisions (in this case,
called Licensing Decision Reviews), whether those licensing decisions are made in the systemwide 
Office of Technology Transfer (OTT) or at a campus or Laboratory Authorized Licensing Office. Each 
local Licensing Decision Review plan, including the processes,mechanisms,and bodies (individuals 
or committees) established to carry out Licensing Decision Reviews may accommodate local needs 
and circumstances, but must be responsive to the direction provided in that letter and, consistent
with these Guidelines, must be filed with the OTT. 
Source: University of California.4 
active role in IP licensing, particularly to start-up 
companies. Typically, the university will accept eq­
uity in a company in lieu of upfront license issue 
fees, which gives the university itself a financial in­
terest in the company. This leads to an institution­
al conflict of interest. Such institutional conflicts 
of interest have been particularly problematic in 
research involving human subjects, so institution­
al policies are being developed to ensure that the 
financial interests of the researcher and the institu­
tion do not create a conflict of interest in enrolling 
and ensuring the safety of human research sub­
jects. Stanford University’s Institutional Conflict 
of Interest Policy provides a concise approach to 
ensuring that all human-subject institutional re­
views include a review of whether the university 
has any financial interests in drugs or devices un­
der study or financial interests in the company 
that is sponsoring the research (See Box 2).5 
.	 ConfLICT	 of 	CoMMITMEnT	RELATEd 
To Ip	MAnAGEMEnT 
Faculty and researchers working in educational 
and research institutions are expected to give 
primary allegiance and professional commitment 
to the institutions that employ them and devote 
primary energy to teaching and research. Even 
so, most institutions value their staff’s contribu­
tions to professional and public service, including 
pro bono work and paid consulting. In addition, 
public institutions increasingly value the role of 
employees in technology transfer and its contri­
bution to economic development. Effective tech­
nology transfer inevitably requires faculty and 
researchers to actively participate in the commer­
cialization process, which often includes taking 
an active role in starting up new companies that 
are capable of developing and exploiting univer­
sity inventions. These multiple institutional goals 
create the potential for a conflict of commitment 
between the institution’s primary educational and 
research mission and the institution’s interest in 
effectively supporting economic development 
and technology transfer through the external ac­
tivities of its faculty and researchers. 
Conflicts of commitment typically require 
determining the appropriate balance of time al­
location between institutional and external ac­
tivities—the critical test is that external activities 
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The goal of this policy is to preclude situations in which human-subjects research is carried out
at Stanford or by Stanford researchers involving organizations in which the University holds 
ownership equity or rights to equity that is not publicly traded. The fundamental assumption 
underlying the policy is that such situations present a significant risk to the perceived objectivity 
of the research. The policy requires that the Office of the Dean of Research be informed of all such 
situations and provides that, after a review of the facts and circumstances, the Associate Dean of 
Research may either arrange the divestment of the University’s holdings through the Office of 
Technology Licensing or, if that cannot be done, refuse to allow the research to proceed. 
DISCuSSION AND DETAIl 
1. Review by the 	office of Technology Licensing (oTL) of all human-subjects research protocols 
proposed by 	university 	principal Investigators: 
At the request of the Office of the Dean of Research, the Stanford Research Compliance 
Office has established a procedure that requires all new human subjects research protocols 
submitted for regular or expedited review to the IRBs to indicate (1) the nature and source(s) of 
all drugs, devices, or biologics (e.g., vaccine products, gene therapeutics) which will be used in 
the proposed research and (2) the source(s) of all funding to be used in supporting the research.
Per this procedure, the information provided is then reviewed by the Director of OTL to identify 
situations in which the proposed research involves (1) the use of drugs, devices, or biologics 
that make use of Stanford-owned intellectual property or (2) funding from nonpublicly traded 
organizations in which Stanford owns equity or the right to acquire equity through a licensing 
agreement. 
2. Review by the 	office of the 	dean of Research of all protocols that might be 
subject to this policy: 
Per the procedure described above, the Director of OTL flags for further review by the Office 
of the Dean of Research all proposed new human subjects research proposals involving the 
use of drugs, devices, or biologics that make use of Stanford-owned intellectual property or 
are funded in whole or in part by nonpublicly traded organizations in which Stanford holds 
equity or the right to acquire equity through a licensing agreement. Based on the facts and 
circumstances identified in this review, the Associate Dean of Research will (1) require OTL to 
divest that equity on behalf of the University or (2) prohibit or require modifications to the 
proposed human-subjects research which would remove any possibility for the University as an 
institution, or any University department, to benefit as a result of the conduct or outcomes of 
the proposed research. In the event the University’s financial interest is in the form of royalties 
payable as a result of exclusive technology licensing rights, OTL will inform the Associate Dean 
of Research, who will determine on a case-by-case basis the significance and management, if 
appropriate, of the potential institutional conflict of interest. 
3. Monitoring compliance: 
The University’s Internal Audit Department will periodically review a sample of human subjects 
research protocols to ensure that all situations in which a potential exists for institutional 
conflict of interest have been properly identified and all risks to human subjects have been 
properly mitigated. 
4. Responsibilities of the 	dean of Research: 
The Vice Provost and Dean of Research is the University officer responsible for interpreting and 
overseeing implementation of and compliance with this Policy. Questions may be addressed 
to the Assistant Dean of Research. 
Source: Stanford University.6 
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CHAPTER . 
should not detract from their primary institu­
tional responsibilities. Institutions vary widely 
regarding permissible external activities, which 
may reflect differing institutional priorities as 
well as whether the institution is public or pri­
vate. Stanford University, for example, integrates 
both conflict of interest and conflict of commit­
ment into a single policy that specifies the appro­
priate balance of time commitment to external 
activities to be approximately one day per week 
(see Box 3). 
.	 STRuCTuRE	 of 	A	ConfLICT	 of 
InTEREST/CoMMITMEnT	 poLICy 
The development of institutional conflict of in­
terest and conflict of commitment policies is a 
critical step in developing technology transfer 
capabilities and programs. Developing the policy 
will require identifying and articulating institu­
tional priorities and determining the appropri­
ate balance between institutional interests and 
the interests—both internal and external—of its 
researchers. In addition, the effort will require 
an in-depth analysis of the requirements placed 
on the institution by national or local laws and 
by the policies of agencies that sponsor research 
in the institution. The elements of a conflict of 
interest/commitment policy are outlined below; 
actual policies take many forms. 
.1 The purpose of the policy and applicability 
The preamble of the policy should reiterate the 
primary mission of the institution and indicate 
in general terms how the institution views the 
balance between internal and external activities 
and the potential for developing conflicts. For 
example, the Washington University in St. Louis 
Conflict of Interest Policy is presented, in part, in 
Box 4. 
The preamble should identify to whom the 
policy applies. In some cases, the policy may be 
broadly applicable to all institutional staff, while 
in other cases different policies may be required 
for teaching faculty, for clinical faculty, and for 
nonfaculty staff. Whatever the case, the applica­
bility of the policy needs to be clearly stated early 
in the policy document. 
.2 Definitions 
Definitions of key terms are typically provided to 
ensure the policy’s clarity. For example, the defi­
nition of “significant financial interests” should 
be explicit with regard to applicable instruments 
of monetary value such as stocks and stock op­
tions. It should also explicitly state the extent to 
which such interests extend to the researcher’s 
spouse, children, or domestic partner. Examples 
of terms that have been useful to define at our the 
University of California include: 
• business entity 
• clinical research 
• compensation 
• conflict of interest 
• gift 
• intellectual property 
• investigator 
• management plan 
• research 
• select officials 
• significant financial or other interest 
. Policy 
The policy statement should clearly describe ac­
ceptable and prohibited activities, requirements 
for reporting and disclosure, and processes for 
evaluating and managing specific situations that 
are not directly addressed by the policy. 
. Process, roles, and responsibilities 
The policy should clearly describe the institu­
tional processes for disclosing external activities, 
if there is a requirement to do so, as well as de­
scribing the processes for seeking a review and 
evaluation of conflict of interest disclosures. Most 
institutions have one authorized official with this 
responsibility and a committee that participates 
in evaluations. The policy should describe the 
processes for appointing the relevant commit­
tees and identify the institutional officials with 
responsibility for conflict of interest evaluations 
and management. 
. References and links to source documents 
Finally, a conflict of interest/commitment policy 
does not exist in isolation but typically relies on 
the synthesis of a number of source documents, 
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BENNETT 
Box 3: Summary of Stanford university’s Faculty Policy on 

Conflict of Commitment and Interest
 
1.	 Faculty must maintain a significant physical presence on campus (main or overseas) throughout
each quarter they are on active duty. 
2.	 Faculty must not allow other professional activities to detract from their primary allegiance 
to Stanford. For example, a faculty member on full-time active duty must not have significant
outside managerial responsibilities nor act as a principal investigator on sponsored projects 
that could be conducted at Stanford University but instead are submitted and managed 
through another institution. 
3.	 Faculty must foster an atmosphere of academic freedom by promoting the open and timely 
exchange of results of scholarly activities, ensuring that their advising of students and 
postdoctoral scholars is independent of personal commercial interests, and informing students 
and colleagues about outside obligations that might influence the free exchange of scholarly 
information between them and the faculty member. 
4.	 Faculty may not use University resources, including facilities, personnel, equipment, or 
confidential information, except in a purely incidental way, as part of their outside consulting 
activities or for any other purposes that are unrelated to the education, research, scholarship,
and public service missions of the University. 
5.	 Faculty must disclose on a timely basis the creation or discovery of all potentially patentable 
inventions created or discovered in the course of their University activities or with more than 
incidental use of University resources. Ownership of such inventions must be assigned to the 
University regardless of source of funding. The inventor will share in royalties earned. 
6.	 Faculty must disclose to the University whether they (or members of the immediate family, as 
defined below) have consulting or employment relationships with, and/or significant financial 
interests (also defined below) in, an outside entity before the University will approve the 
following proposed arrangements involving them between such entities and Stanford: a) gifts;
b) sponsored projects; c) technology licensing arrangements; and d) certain procurements. In 
such cases, approval by the school dean will be required prior to entering into each proposed 
arrangement. 
7.	 In situations in which the objectivity of a faculty member could reasonably be questioned, the 
dean of a school may establish an independent oversight committee to take steps including 
(but not limited to) the following: to review the appropriateness of the proposed research to be 
conducted at Stanford, to oversee the conduct of the research, and to ensure open and timely 
dissemination of the research results. Such oversight committees will be required for all clinical 
trials raising questions of conflict of interest. 
8.	 On an annual basis all faculty members must certify to their school deans their compliance 
with Stanford’s policies related to conflict of interest and commitment. They must also disclose 
information about their (and their immediate family members’, as described below) financial 
relationships with outside organizations that are sponsors of their teaching or research 
programs or are otherwise involved in current, proposed, or pending financial relationships with 
the University that involve the faculty member. In addition, faculty must disclose to their school 
dean on an ad hoc basis current, proposed or pending situations that may raise questions of 
conflict of commitment or interest, as soon as such situations become known to the faculty 
member. 
9.	 School deans shall establish procedures to ensure timely review of their faculty’s annual and ad 
hoc disclosures of potential or apparent conflicts, and to ensure (in consultation with the Dean 
of Research office) the appropriate management of such conflicts. Such procedures may involve 
representatives from the school’s faculty as part of a reviewing body. School deans will file their 
own annual disclosures and certifications of compliance with the Dean of Research. 
10. The Dean of Research shall approve each school dean’s plans for implementing this policy,
interpret policy provisions in consultation with school deans, respond to faculty wishing to 
appeal school deans’decisions, and report to the Committee on Research annually on the status 
of this policy and its implementation. 
11.	 Should a faculty member wish to appeal a decision made by the Dean of Research, he or she may 
present the appeal to the Provost, who will consider the case in consultation with the Advisory 
Board. 
Source: Stanford University.7 
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Box 4: Excerpt of Washington university’s Conflict of Interest Policy 
The faculty and administrators at Washington University recognize a shared responsibility to 
ensure that they conduct themselves in an unbiased manner and serve the goals of the University.
It is thus the responsibility of the University and its employees to guard against conflicts of 
interest that might compromise the integrity and objectivity of the University community.
It is understood that the faculty, as developers of knowledge, have a unique opportunity and 
responsibility to disseminate that knowledge to the public. By adopting this Conflict of Interest
Policy, the University reaffirms the value of collaboration with industry as a means of fostering 
public access to the practical benefits of University research. By adopting this Conflict of Interest
Policy, the University also (i) demonstrates its commitment to the ethical principles that guide 
University research and (ii) establishes a mechanism to safeguard University and faculty integrity 
and objectivity so that University/industry interactions can optimally benefit society.
Source: Washington University. 8 
policies, and laws. These sources should be listed 
and hyperlinked from the policy. 
.  ConCLuSIonS 
In addition to the legal reasons to develop and 
enforce rigorous conflict of interest and conflict 
of commitment policies, the fundamental 
reputation of the institution rests on setting 
and maintaining high ethical standards. As 
Johns Hopkins University’s policy states: 
“public confidence in the University’s integrity 
undoubtedly ranks among its greatest assets.”9 
Although technology transfer activities are only 
one of many areas in which the potential for 
conflict of interest exists, the interface between 
the mission of the university and the demands 
of industry and of private sector collaboration 
is a rich breeding ground for such potential 
conflicts. As an institution becomes engaged 
with the private sector and with technology 
transfer, the adoption of a thoughtful conflict 
of interest and conflict of commitment policy is 
essential. Not only is the policy itself an essential 
administrative tool, but the analytical process of 
developing the policy will reveal the institution’s 
priorities. The process will also clarify what the 
university considers the appropriate balance of 
allowed and prohibited activities for achieving 
the university’s mission(s). In the United 
States, there has been a convergence of norms 
in conflict of interest/commitment policies 
that is driven by our legal framework and by 
the policies of national research sponsors. It 
is likely, however, that other countries facing 
very different demands for research-based 
economic development may find that the U.S. 
approach does not conform to their regional and 
institutional needs. n 
alan b. benneTT, Associate Vice Chancellor, Executive 
Director, PIPRA, Office of Research, University of 
California, Davis, 1850 Research Park Drive, Davis, CA, 
95616, U.S.A. abbennett@ucdavis.edu 
1	 Chinn J and EC Kulakowski. 2006. Conflict of Interest
in Research. In Research Administration and Manage-
ment (eds. EC Kulakowski and LU Chronister). Jones 
and Bartlett Publishers: Sudbury, Mass. pp 511–21. 
2	 Garton JD. 2002. Conflicts of Interest and Technology 
Transfer. AUTM Technology Transfer Practice Manual,
Part XIII, Chapter 2. AUTM: Northbrook, Ill. 
3	 University of California. 2001. Guidelines on Managing 
Potential Conflicts of Interest in Licensing. www.ucop. 
edu/ott/staff/ott00-05b.pdf. This and other conflict of 
interest and conflict of commitment policies are also 
available via the online edition of this Handbook. 
4	 Slightly edited and based on supra note 3. 
5	 An online tutorial on conflict of interest from Columbia 






















         
       
       
        
      
       
		
   
      
 




Ten Things Heads of Institutions Should Know about

Setting Up a Technology Transfer Office
 
liTa nelsEN, Director, M.I.T. Technology Licensing Office, U.S.A. 
ABSTRACT 
Technology transfer is a rewarding process for the uni­
versity, researchers, students, the business community, 
the public, and the professionals who make it all happen. 
Technology transfer brings new products, services, and 
jobs. But it is a complex process, one that requires sus­
tained dedication at every level. This chapter offers advice 
about some of the most important policy and strategy 
issues: five are economic issues and five relate to imple­
mentation. The chapter concludes with a discussion of 
technology transfer pitfalls caused by unrealistic expecta­
tions. The chapter emphasizes the role of senior manage­
ment in changing the IP (intellectual property) culture, 
the need for transparent conflict-of-interest policies, and 
the importance of sufficient autonomy and infrastructure 
support for technology transfer officers. 
1. InTRoduCTIon 
The widely touted success of technology trans­
fer from U.S. universities has attracted interest 
from universities and research institutes around 
the world. Such diverse countries as Germany, 
the Republic of China, South Africa, the United 
Kingdom, and many others have changed their 
laws and policies, modeling them after U.S. prac­
tices, to allow universities and faculty members to 
manage and transfer intellectual property (IP). In 
the United States, smaller universities and research 
institutes are looking to imitate the successes of 
their larger counterparts. Such changes are moti­
vated primarily by two economic interests: 
1. enhancing economic development by trans­
ferring new technologies to local industries 
2. obtaining financial support from industry 
to support university programs 
The advice offered in this chapter aims to pro­
vide to heads of a research institutes and universi­
ties perspective on what challenges to expect when 
setting up a technology transfer office. These “Ten 
Things” are based on almost 20 years of experi­
ence in the Technology Licensing Office of the 
Massachusetts Institute of Technology. The ideas 
expressed in this chapter reflect also my long-time 
experiences with the Association of University 
Technology Managers (AUTM), including a 
stint as president, during which I watched many 
North American technology transfer programs 
grow. The ideas expressed here have been influ­
enced by my experiences visiting with universi­
ties in almost 20 different countries and learning 
about their technology transfer activities. 
2. THE	LIST	 of TEn 
Many items in the list of ten may surprise you 
(Box 1). The economic five may sound dis­
couraging even, but that is not the intention. 
It is to encourage a realistic time frame and 
the sustained investments in time and money 
are needed to reap the substantial societal and 
Nelsen L 2007.Ten Things Heads of Universities Should Know about Setting Up a Technology Transfer Office. In Intellectual 
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. L Nelsen. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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NElSEN 
Box 1: Ten Things to Know about Setting up a Technology transfer Office 
The economic five 
1. Technology transfer will not make your university rich. A successful program will make a 
small profit but will not support the university. It will, however, provide many other benefits 
to the institution and the community. 
2. Building a robust technology transfer program takes sustained financial investment.
Investments are required to develop a patent portfolio, attract expert talent, and train office 
professionals.
3. It will likely take eight to ten years before your program stops losing money—and it may
never make your institution any substantial amount. It takes time to build an IP portfolio,
establish contacts, and develop skills in technology transfer. Following the set up, the TTO 
may begin to make money. 
4. It may take two decades or more before a university technology transfer program (including
entrepreneurial spinouts) substantially affects the local economy. Impact in regional 
economic development takes 20 to 30 years. Expecting substantial returns in a few years 
leads to underinvestment and disappointment. 
5. The ultimate impact may be very large—both economically and culturally—for the university,
its graduates, and the community. 
The implementation five 
6. Sustained effort requires visible support—fiscal and otherwise—from senior administration.
Senior management must not only lead the way, but also sustain the effort to change the 
culture of research and investment.
7. only senior administration can set the mission, policies, and priorities for the program. Clear 
mandates will help technology transfer professionals choose among competing priorities 
and the ever-present trade-offs between business and academic values. These policies will 
ultimately help to define the university. They need to be clearly stated, and supported from 
the top, so that technology transfer professionals can make the best decisions and withstand 
pressure from competing interests. 
8. Clear policies on Ip	 ownership, the roles of researchers in interactions with industry, and
other ground rules should be set up before the program begins. Working out such policies 
in the middle of making deals leads to confusion and bureaucratic lethargy, slows down the 
learning process, and hurts a university’s reputation for being able to consummate deals. 
9. Conflicts of interest, both real and perceived, are inevitable. Clear policies and a well-
understood review and appeal process need to be put in place early. Much can be learned 
from the experience of others in the technology transfer field. Again, support from senior 
administration is critical. 
10.Technology transfer is a talent-based business. It is difficult to find people who can speak the 
two languages of academia and industry and who also have the creativity to craft agreements 
that meet the needs of both sides. One should not underestimate the combination and level 
of skills required.These skills and experiences are very different from those needed to conduct
research. 
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CHAPTER .1 
economic benefits of a successful technology 
transfer program. A few TTOs have performed 
atypically and these provide exceptions to the 
principles described, especially with respect to 
the economic five. But these exceptions depend 
mostly on luck and planning—they cannot be 
counted on. The issues are discussed in more de­
tail following the list. 
The sections that follow discuss more 
fully the promise of technology transfer, the 
economic issues and expectations involved 
with technology transfer, and implementation 
matters. 
2.1  The promise of technology transfer 
There is little doubt about the ultimate potential 
of university technology transfer programs when 
it comes to accelerating the adoption of new tech­
nologies, enhancing entrepreneurship, creating 
new medicines and other products, creating jobs, 
and adding prosperity through economic devel­
opment. The clustering of high technology and 
biotechnology companies around major univer­
sities has been well described, and AUTM and 
others have documented the creation of hundreds 
of thousands of jobs directly related to university 
licenses and startups. 
Within universities, robust technology 
transfer programs also have many important 
benefits that are quite separate from royalty 
income (royalty income as used here includes 
royalties from licenses to university intellec­
tual property and monetary return from equity 
holdings in spinout companies formed around 
university intellectual property). Among others, 
these include: 
•	 productive interaction with the industrial 
community: ideas shuttling back and forth 
between the academy and the private sector, 
which often increases the quality of research 
•	 increased industrial support of university 
research 
•	 more willingness from central and local 
governments to support university research 
for economic development 
•	 student exposure to the world of industry 
and to the commercial opportunities of re­
search (including training in entrepreneur­
ship), thus influencing their future career 
aspirations and ultimately impacting the 
country’s economy 
•	 financial support from grateful alumni 
and other entrepreneurs who have grown 
wealthy from companies started from uni­
versity research 
Such programs can have a major impact on 
the economy of the surrounding regions—and 
not only directly from entrepreneurial spinout 
companies from the university. The entrepre­
neurial ferment and capability resulting from 
university spinouts leads in turn to the formation 
of many other new companies. Larger companies 
also often move to the region to take advantage of 
relationships with entrepreneurial companies and 
the skilled employee base. 
2.2 Expectations in setting up a program 
Despite the promises of successful technology 
transfer programs, when communities and their 
universities try to start new technology transfer 
programs or to accelerate existing ones, the road 
is rocky. Unrealistic expectations are a major 
cause of failure and frustration. Universities of­
ten expect their programs not only to bring in in­
dustrial sponsorship for research but to provide 
royalty income and entrepreneurial spinouts that 
will support the entire university. 
Unfortunately, government expectations are 
often equally unrealistic. Some governments, for 
example, have expected royalty income from tech­
nology transfer to replace government support of 
their universities. Too often, local and national 
governments believe that just a few years of fi­
nancial support for technology transfer—coupled 
with pressures on universities to produce measur­
able impacts—will almost instantly create thriv­
ing clusters of biotechnology,1 software, or tele­
com companies akin to those in Boston, Silicon 
Valley, or San Diego. 
A more realistic picture, however, is pro­
vided by almost a quarter century of technology 
transfer experience in the United States under 
the Bayh-Dole Act of 1979, which allowed uni­
versities to own patents from federally funded 
research. 
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2.2.1 Licensing income 
Income from royalties and equity in spinouts is 
measured most easily. Data from the AUTM sur­
vey of U.S. universities (not including hospitals 
and research institutions for fiscal year 2002 shows 
that total gross royalties (including income from 
equity) for 158 universities was US$959 million. 
This from a research expenditure base of over US
$32 billion during that year! 
Thus, even before subtracting expenses for 
patenting and staff costs, technology licensing 
and spinout equity income averages less than 
3% of the amount universities spend on research. 
And the income distribution is skewed: ten uni­
versities in the United States (6.3% of the total) 
account for almost 60% of the total royalty in­
come for all U.S. universities. 
The income distribution is skewed because a 
good fraction of the total U.S. university income 
from technology licensing is from a few block­
busters: single inventions that yield very high 
royalties (millions or tens of millions of dollars 
per year, often for over ten years, until the patent 
expires). These blockbusters are few and far be-
tween—there are no more than two or three ones 
each year in the United States. 
It is therefore unwise to look to technology 
licensing and income from spinouts (royalties or 
equity) to support the university. 
2.2.2. Program profitability 
Building a program to break-even profitability 
takes time and money. Again, the North American 
experience is instructive. Studies have shown that 
it can take a technology transfer program eight to 
ten years or more to reach profitability, although 
most programs become profitable if the effort to 
build them is sustained.2 
If measured only by royalty income, uni­
versities with smaller research bases have a 
more difficult time breaking-even. Less research 
means fewer inventions, lowering the statistical 
probability of a blockbuster invention. Fewer 
opportunities for licensing also mean that the 
technology transfer staff gains less experience 
and learns the craft more slowly. Small tech­
nology transfer programs, therefore, may have 
to be sustained financially for a long period 
of time, with the revenue shortfall justified by 
their nonroyalty contributions to the university 
and community. 
Finally, it should be noted that new technol­
ogy transfer programs are too often starved— 
both for money to file patents and for staff. A 
university frequently expects its program to 
somehow bootstrap itself into profitability and 
expansion. An “anorexic” program, however, 
climbs the learning curve—and reaches profit­
ability—much more slowly and has a much low­
er impact on the university and the community 
along the way. 
Thus, the university must have a well- 
thought-out, long-term financial plan for build­
ing its technology transfer office. The plan should 
be based on expected benefits—both financial 
and especially, nonfinancial—and on what the 
university can afford during the decade or so it 
takes to build a mature program. 
2.2. Regional economic development 
Governments most frequently support technol­
ogy transfer in universities directly because they 
hope that entrepreneurial spinout companies 
will revivify the regional economy surround­
ing the university. This is not an unfounded 
hope—a number of regions have demonstrated 
the success of such programs over time. But it 
takes time: more than ten years for more than a 
few spinouts to be formed, and as long as 20 to 
30 years before a substantial cluster of techno­
logically-based companies forms—and this only 
when such development has been purposefully 
planned and robustly supported financially. (The 
Research Triangle region in North Carolina, 
U.S.A., is one such success—after about a quar­
ter century!) 
Thus, government programs that support 
technology transfer for four to five years and 
then expect the programs to be self-support­
ing and surrounded by a flourishing cluster 
of companies are unrealistic. It will not hap­
pen that fast. Building a regional economy 
based on entrepreneurialism is a slow, gradual 
process. 
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CHAPTER .1 
. IMPlEMENTATION 
.1  The role of the upper administration: 
culture change 
Founding a successful technology transfer pro­
gram means changing a culture. Researchers must 
become aware of how useful and rewarding it is to 
identify potentially commercializable inventions 
from their research. They also need to see the 
benefits of cooperating with industry to transfer 
such technology. For most researchers this will be 
a new way of thinking, and some will feel that it 
threatens the very purpose of the university. 
This change in culture must start from above. 
The upper administration needs to clearly delineate 
the purpose and potential benefits of a technology 
transfer program—not only to the individual and 
the university but to the community at large. The 
administration of the university can thus allay mis­
trust by making it clear that technology transfer 
will not be allowed to distort traditional academic 
principles: investigator-initiated fundamental 
research, uncensored publication, and open ex­
change of information within the university. 
.2  Defining the mission 
The upper administration and the faculty must 
define the mission and priorities of the technology 
transfer office: Is it primarily to produce licensing 
income? Or industrial support of research? Is the 
mission primarily to get technology developed for 
the public? Or is it primarily to generate startups 
and regional economic development? 
There are inevitably trade-offs among these 
potential primary missions. Unless priorities are 
explicitly set, the practices of the technology 
transfer office may well diverge in time from the 
best interests of the university. Surprisingly, even 
in the United States, with a quarter century of 
experience in university technology transfer, dis­
cussions about mission and priorities rarely are 
held between university management and the 
technology transfer office. 
.  Setting the ground rules: 
policies and practices 
The technology transfer office—and the research­
ers, companies, and investors that it deals with 
on a daily basis—must all know the ground rules 
before work can begin. The growth and learning 
process of the office will by stymied if each new 
invention or license-in-negotiation must be run 
through a committee. Accordingly, policy guide­
lines concerning such issues as IP ownership; the 
rights, duties, and obligations of the faculty in 
regard to technology transfer; sharing of revenue 
and equity with inventors; use of university fa­
cilities by companies; and related issues should be 
clearly defined as early as possible. 
New offices will find that there are many 
guides available from experienced universities to 
help them write their ground rules—but only the 
administration and faculty of the university can 
decide which rules make the most sense for their 
particular institution. 
.  Conflicts of interest 
Technology transfer inevitably brings conflicts of 
interest.3 The challenge is to manage them. 
For the university itself, conflicts may exist 
between the goals of maximizing royalty income 
and promoting publication, between commit­
ments to fostering spinout companies (for ex­
ample, by allowing the use of university facilities, 
staff, or even students) and preserving university 
resources or between strong IP ownership poli­
cies or indirect cost rates and attempts to bring 
in more research support from industry. One big 
conflict of interest arises when university admin­
istrations are called upon to make exceptions to 
long-standing policies in order to bring in a big 
program; the exception itself may be only mar­
ginally harmful to the university, but the will­
ingness to make an exception for enough money 
or for a very senior person can be a dangerous 
precedent. 
For faculty members, conflicts of interest may 
involve time commitments (often called conflict 
of commitment). For example, conflicts may arise 
between time spent in university teaching and re­
search and time spent with the spinout company. 
Faculty may also be tempted to withhold research 
data from university research efforts because of 
potential usefulness to the company for the data 
to remain secret—or because of harm to the com­
pany publishing might cause. Using students on 
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company projects presents another potential con­
flict of interest, as does company use of university 
equipment. A conflict of interest also arises when 
a researcher has to decide whether his or her new 
patent belongs to the university, to him- or her­
self, or to the spinout company. 
Even a national government can find itself 
with a conflict of interest: Does it want to sup­
port basic research in its university, keeping its 
scientific community at a world-class level in the 
pursuit of new frontier technology for the com­
ing decades, or should it shift its support to prac­
tical research that is more likely to quickly usher 
in new transfer technologies, new spinout com­
panies, and regional economic development? 
For universities and their faculty members, 
written policies that are well thought out and 
consistently applied can avoid many conflicts of 
interest. There are, inevitably, gray areas or ap­
peals for exceptions that will intensify with time 
as the technology transfer program matures. The 
university needs to define a clear chain of com­
mand for ruling on most of these issues. Only 
rare exceptions should find their way to oversight 
committees; otherwise the process bogs down in 
the interminable wait for committees to be as­
sembled and convened. Twenty years of experi­
ence suggests that exceptions to policy should be 
granted very, very rarely. It is difficult in a uni­
versity to make an exception for one researcher 
without soon being called upon to make a simi­
lar exception for the next one—and policies soon 
erode and become meaningless. 
. Talent 
Technology transfer officers need an unusual 
combination of qualifications: 
•	 an understanding of state-of-the-art re­
search (though not necessarily as a practi­
tioner), often over a fairly broad range of 
technologies in a multidisciplinary uni­
versity. (This usually requires a solid back­
ground in science or engineering.) 
•	 an understanding of the language of indus­
try (Officers must be familiar with markets, 
how technology is developed into products, 
•	 at least a minimal understanding of venture 
capital, spinout formation, and smallcom­
pany operation 
•	 more than a passing familiarity with patent 
law 
•	 an understanding and sympathy with how 
academia operates, academic principles, 
and the career development paths and aspi­
rations of students and professors 
•	 outstanding written and verbal communi­
cations skills in both formal and informal 
situations 
•	 good negotiation skills—or the innate tal­
ent, intelligence, emotional control, and 
“people skills” needed to learn them 
•	 ability to deal with multiple constituencies 
with conflicting objectives, most of whom 
one has no authority over 
•	 ability to deal with highly ambiguous, con­
fusing situations 
•	 both the drive and creativity to solve com­
plex multidimensional problems and arrive 
at win-win solutions 
•	 drive to get the job done, or follow 
through 
•	 very high personal integrity and the wis­
dom to avoid situations that get close to 
the line on ethics—no matter how profit­
able the situation may be to the univer­
sity, a faculty member, or the licensor. A 
university’s reputation is priceless. It must 
not be endangered by unethical behavior—
or naiveté. 
And finally: 
•	 the willingness to work at a university sal­
ary because of the inherent satisfactions of 
the technology transfer job: great technol­
ogy, complex and always-interesting issues, 
the satisfaction of seeing new companies 
form and new technologies reach the mar­
ket, and, above all, the opportunity to con­
tribute to the university, its students, and 
the community 
People who embody all of these qualifica­
accounting and finance principles, and de- tions are indeed difficult to find, but one should 
cision-making processes.) not underestimate the need for a very high level 
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CHAPTER .1 
of talent. My experience in hiring and supervising 
technology transfer professionals have taught me 
that it is a talent-based business—some can do it 
and some cannot. Those who can will perform 
many times better than those who cannot. They 
will also build much better relationships with re­
searchers and the business community over time, 
thereby enhancing the office’s effectiveness. 
In choosing staff, some formal qualifica­
tions in technology and business are a sine qua 
non. These qualifications, unlike personal char­
acteristics, can be easily be checked on a résumé. 
Whether the technical background is at a bach­
elor’s or Ph.D. level is relatively unimportant, 
provided that the person is very bright and can 
understand how research is done and how uni­
versities operate. Unfortunately, until the candi­
date has taken the job, it is difficult to determine 
whether an individual has the creativity, interper­
sonal skills, ability to deal with ambiguity, and 
drive to completion that the job requires. 
Staff should be given sufficient clerical and 
infrastructure support and sufficient autonomy 
so that they can do their jobs well. Clearly written 
policies help define the limits of that autonomy. 
Good training coupled with oversight supervi­
sion—but not micromanagement—allows the 
talented professional to learn and grow on the job 
while bringing his or her talents to bear on the 
tasks at hand. Plus, he or she can make decisions 
and get deals done quickly, without waiting for 
multiple levels of approval at each point along the 
way. 
They must also be given adequate clerical 
support. Clerical support seems trivial: it is not. 
Regrettably, technology transfer is not only a tal­
ent-based business but also a paperwork-intensive 
business. If good computer systems and clerical 
help are not available, your very talented technol­
ogy transfer professionals will spend far too much 
of their time on clerical work—which is both 
wasteful and demoralizing. n 
liTa nelsen, Director, M.I.T. Technology Licensing Office, 
Massachusetts Institute of Technology, Five Cambridge 
Center, Kendall Square, Room NE25-230, Cambridge, 
MA, 02142-1493, U.S.A. lita@mit.edu
1	 See, also in this Handbook, chapter 3.11 by PWB Phillips 
and CD Ryan, and chapter 3.12 by K Viljamaa. 
2	 Brandt KD, EJ Stevenson, JB Anderson, CL Ives, MJ Pratt
and AJ Stevens. 2005. Do Most Academic Institutions 
Lose Money on Technology Transfer? Boston University.
Poster Session, AUTM Annual Meeting, 2005. 
3	 See, also in this Handbook, the chapter 5.7 by A 
Bennett.
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CHAPTER 6.2 
Establishing a Technology Transfer Office
 
TERRy A. yOUNg, Director of Research Development, University of South Dakota, U.S.A. 
ABSTRACT 
Technology transfer does not just happen. Transferring 
knowledge and innovation from a public research organiza­
tion to the private sector for commercial application and 
public benefit requires a formal mechanism—a technology 
transfer office (TTO)—to protect and license intellectual 
property. Establishing a new TTO is no trivial matter, and 
the decision to create one should be made within the con­
text of a long-term plan that takes into consideration the 
following questions: (1) Does “research commercializa­
tion” align with the institution’s mission? (2) Do the qual­
ity and quantity of research within the institution warrant 
the establishment of a TTO? (3) Is the institution willing 
to make a long-term commitment to required institutional 
changes and to adequately invest in resources and people? If 
the answer to all of these questions is yes, then it is time to 
develop a clear TTO business plan. In this effort, a strong 
dose of patience will help. An often-quoted rule of thumb 
in professional circles suggests that even under the very best 
circumstances, TTOs do not become successful for seven 
to ten years after they are established. This chapter provides 
practical advice for creating a proactive TTO and also of­
fers historical examples from around the globe of TTO 
launches. 
1. THREE FuNDAMENTAl QuESTIONS 
Before initiating a planning process for a new 
TTO, a research organization must first address 
three fundamental questions. 
1.1 	 Does “research commercialization” 
align with the mission? 
If the institution’s primary mission is education, 
or if its mission does not support research as a 
primary institutional focus, establishing a TTO 
may not be warranted. Without a strong research 
focus, the organization would do well to find 
alternatives for meeting the occasional need for 
technology transfer services. 
With more than twenty years of experi­
ence, the international Association of University 
Technology Managers (AUTM)1 has identified 
four key reasons for public research organizations 
to advance academic technology transfer: 
•	 facilitate the commercialization of research 
results for the public good 
•	 reward, retain, and recruit high-quality 
researchers 
•	 build closer ties to industry 
•	 generate income for further research and 
education, and, thus, promote economic 
growth 
If these reasons make sense for your institu­
tion, then it may be time to set up a TTO. 
1.2 	 Do the quality and quantity of research 
warrant the establishment of a TTO? 
All technology transfer opportunities flow from 
research. The 2003 AUTM Annual Licensing 
Survey™ indicates that, on average, one formal 
disclosure of invention was made for every US$2 
million in research activity at research universities 
in the United States. One U.S. patent application 
Young TA. 2007. Establishing a Technology Transfer Office. In Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. 
© 2007. TA Young. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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YOuNG 
was filed for every US$5 million in research expen­
ditures, and one technology transfer or licensing 
agreement was executed for every US$8.5 million 
in research expenditures.2 These statistics indicate 
that public research organizations review many 
more innovations (disclosures of invention) than 
are acted upon. Clearly, substantial research is re­
quired to generate technology transfer opportuni­
ties. Using the above averages, a TTO in a public 
research organization with a research budget of 
US$100 million might expect to record 50 disclo­
sures of invention, 20 patent applications, and 11– 
12 license agreements per year. An institution must 
therefore determine whether its research volume is 
sufficient to warrant investing in a new TTO. 
The quality of research accomplished within 
an institution is another critical variable. This may 
be affected by an institution’s ability to recruit and 
retain world-class researchers who are at the cutting 
edge of science and engineering advancements. 
Furthermore, pursuing basic research may generate 
fewer opportunities than would applied research. If 
the estimated quantity and quality of research are 
below the AUTM averages cited above, the institu­
tion should use alternative means to address its oc­
casional need for technology transfer services. 
1. 	 Is the institution willing to make 
a long-term commitment to the TTO? 
Time may be the greatest predictor of success 
for a TTO. In other words, the longer a TTO 
operates, the better will be its cumulative results 
and performance measures. This makes sense in­
tuitively: as innovations, patent applications, and 
license agreements are added cumulatively each 
year to the institution’s portfolio, there is a greater 
chance that a fraction of these will eventually gen­
erate returns. Technology transfer practitioners 
suggest that it typically takes five or more years 
for technology that is licensed to an industry 
partner to result in a marketable product. Thus, 
according to these practitioners, TTOs require 
seven to ten years to be successful, regardless of 
how one chooses to measure success. Institutions 
should expect similar experiences and be prepared 
to subsidize the office for many years to come. A 
commitment to support a TTO is more than a 
two- or three-year financial obligation. 
1. 	 If the institution does not meet 
the four criteria, then what? 
If the research organization does not, in its initial 
planning processes, answer yes to the fundamen­
tal questions, the following alternative models, 
which have proven successful globally, can be 
used: 
•	 An external organization, which can be not 
for profit or for profit, contracts with the 
institution to manage the occasional disclo­
sure of invention on an ad hoc basis. There 
are many examples of these organizations 
utilized in smaller research organizations 
globally. 
•	 An individual or small internal office 
could review, filter, and rank disclosed 
innovations and an external for-profit 
company could implement commercial­
ization of the most promising opportuni­
ties. Consider the model offered by Baylor 
College of Medicine Office of Technology 
Administration and BCMT Technologies 
in Houston, Texas, both in the United 
States.3 
•	 One TTO could serve a consortium of 
several public research organizations in a 
region. The Chinese Northern Technology 
Exchange Market offers a good example of 
this approach.4 
•	 One office, funded by the national govern­
ment or a philanthropic institution, could 
serve as a TTO for several public research 
institutes. Examples include the U.S. 
National Institutes of Health Office of 
Technology Transfer5 and the Innovation 
Fund Commercialisation Office in South 
Africa.6 
2. All GO? DEVElOP A
TTO BuSINESS PlAN 
When the four fundamental questions have been 
satisfactorily explored and a TTO has been decid­
ed upon, both short- and long-range plans should 
be developed, much as a for-profit organization 
would develop its business plan. At the very least, 
an executive-summary plan addressing the essen­
tial elements should be crafted. 
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CHAPTER .2 
2.1. Developing a mission statement 
First, the TTO should establish a transparent 
mission statement developed in concert with its 
constituents (including but not limited to its 
administration, inventors, and external clients, 
including potential industry partners). TTO mis­
sions may focus upon three primary objectives or 
combinations thereof: (1) service, (2) economic 
development, or (3) income.7 
2.1.1 Service mission 
The TTO can be considered a service unit to the 
researcher, similar to an institution’s human re­
sources office or a contracts and grants office. In 
this model, the institution may not share with the 
office a percentage of the income from successful 
commercialization. Instead, it fully subsidizes the 
office—just like any other internal department. 
Researcher satisfaction typically is high because 
all innovations receive TTO attention and work. 
2.1.2 Economic development mission 
Institutions inspired by the goal of economic de­
velopment see their primary mission in terms of 
creating jobs and economic growth in the local 
community—and perhaps the region, state, or 
nation—through spinout companies and through 
licensing to local companies. A cluster of compa­
nies (centers of excellence) may be created around 
a core area of technology. Significantly, a recent 
Milken Institute study on the high-tech economy 
concludes that “research centers and institutions are 
indisputably the most important factor in incubat­
ing high-tech industries.” The same study found 
that 29 of the top 30 high-tech clusters in the 
United States were home to a comprehensive re­
search university.8 
2.1.  Income mission 
As expected, earning income from the transfer of 
innovations to commercial concerns is nearly al­
ways the primary focus of the operation with in­
come as its main objective. Such institutions are 
very selective, identifying innovations with the 
highest potential and quickly abandoning others. 
Not surprisingly, this can lead to overall research­
er dissatisfaction; this is not usually the case with 
institutions that have a strong researcher-service 
orientation. Institutions with higher income lev­
els from licensing are typically teaching/research 
hospitals at which the possibility of an outstand­
ing commercial success is more realistic. 
Of course, TTOs do not focus on a single 
mission but combine their vision in ways that best 
satisfy their own constituents. The mission state­
ment serves as a guide for implementing these 
goals and sets forth the activities expected from 
the new TTO. A short and simple mission state­
ment might be: The TTO serves to assist research­
ers in the transfer of the institution’s research results 
to industry for commercial application, economic 
development, and public benefit. TTOs must be 
careful to avoid “mission creep.” This can occur 
when TTOs are charged with managing activi­
ties not directly related to commercializing in­
novations (research administration, institutional 
export regulation requirements, conflict of inter­
est compliance, and other tasks not within its 
stated mission). 
Finally, while TTOs are business offices 
within academic institutions, the mission state­
ments of these offices increasingly announce a 
societal role. As the managers of institutional 
innovations for commercial use, do TTOs also 
have a social responsibility to improve the well­
being of humanity? The answer is a resound­
ing YES! Social responsibility and a contribu­
tion to societal wellbeing must fit within the 
TTO’s mission. These can easily be incorpo­
rated into the service mission of the office and 
the institution. Indeed, public research agencies 
should be in full support of the United Nations’ 
Millennium Development Goals.9 Furthermore, 
given that the current debate opposes corporate 
profit flowing to a range of important social 
goals—sustainable development, the health of 
the environment, the indigenous farmer, and 
free or low-cost treatment of AIDS, malaria, 
and other diseases in developing countries of the 
world—public research institutions must make 
sure to align themselves with societal welfare. 
The TTO mission statement is a powerful place 
to announce these aims. 
There are many ways to balance these goals 
with commercialization. One relatively simple 
way would be to carefully craft license agreements 
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to ensure that social benefits for developing coun­
tries are incorporated into the grant section. For 
example, a grant for an improved agricultural va­
riety could require the corporate licensee to sell 
seed for commercial production with royalty or 
added-value premium pricing but to indigenous 
farmers in developing countries at cost (or at least 
without requiring them to pay royalty to the uni­
versity or the added-value premium charged by 
the company to commercial producers). 
2.2 Policies and procedures 
The system for managing innovations should 
be easily understood, and transparent policies 
should guide the implementation of the institu­
tion’s mission statement. Defining the ownership 
of intellectual property (IP) resulting from insti­
tutional research must be at the very heart of the 
institution’s policy. A disposition of ownership 
can take many forms, but the disposition must 
be defined clearly without question or ambigu­
ity. In some countries, ownership is defined by 
national law. In other countries, each institution 
holds the prerogative to determine the ownership 
of research results: the government, the inventor, 
the institution, or two or more of these parties. 
In the United States, for example, each research 
institution is free to determine how ownership 
is allocated, with the exception (under the U.S. 
Patent and Trademark Law) that if the innovation 
is developed with government sponsorship, own­
ership lies with the institution. Regardless of the 
approach the institution chooses or is compelled 
to adopt, technology transfer is impossible with­
out a clearly defined, written policy concerning 
ownership (including written assignment of title, 
when required). 
Even after more than 20 years of proactive 
technology transfer practice in North America 
and throughout the globe, debate continues 
about the best model of IP ownership for aca­
demic institutions and other public research 
organizations. The inventor-owned model and 
the institution-owned model both have posi­
tive and negative attributes, as seen in the ex­
amples of success in both the United States 
(institution-owned, except for the University 
of Wisconsin) and Canada (inventor-owned in 
many institutions). Several countries in various 
parts of the world have moved recently to the 
institution-owned model (Japan, Germany, and 
the United Kingdom, for example). It seems 
clear that either approach can work well. 
However, a disturbing trend has been seen 
in the recent laws of various countries just enter­
ing the technology transfer arena. In some cases, 
the new national laws require that the ownership 
of IP arising from sponsored research be shared
between the research sponsor and the institu­
tion. Ownership is shared equally to begin with, 
but later becomes negotiable (such a provision 
is stated in Brazil’s new technology transfer law 
of 2005). Such an arrangement is not viable, as 
these countries will find as they seek to imple­
ment a national technology transfer regime. In 
seeking to be politically correct and not offend 
the country’s corporate sector, the governments 
have created a situation in which neither par­
ty wins: the transfer of research results will be 
blocked by the inability of either party to main­
tain exclusivity. This will create an impenetrable 
barrier that will prevent any corporate partner 
from investing the energy and money necessary 
to take an embryonic technology to market. The 
result will be impasse; the transfer of technology 
will by stymied. 
Obviously, policies should address a multi­
tude of other issues that are critical to the suc­
cess of technology transfer programs, such as roy­
alty-income distribution, the disclosure process, 
assignment of responsibility for seeking patent 
protection, researcher and institutional conflict 
of interest, dispute resolution, management of li­
censees’ contractual performance, management of 
equity interests in spinout companies, and many 
more requirements. As examples, the policies for 
most research-intensive universities in the United 
States and in many other countries are found on 
the AUTM Web site.10 
2. Financing the TTO 
As previously established, an institution’s new 
TTO will require subsidies for years under the 
very best of circumstances. However, as different 
countries have discovered, there are many differ­
ent funding models. 
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2..1 Australia’s models 
In Australia, public research organizations, within 
a relatively unregulated environment, are respon­
sible for financing their own technology transfer 
operations. Two primary models have emerged: 
(1) the formation of an external company, and 
(2) the establishment of an internal institutional 
department or office. Using the company model, 
the corporation generates cash flow through a va­
riety of related business activities such as consult­
ing, conference management, and professional 
development courses. The proceeds enable the 
company to support the organization’s technol­
ogy transfer function. In some cases, a university 
has provided seed funding to initiate the compa­
ny’s operations. 
In the internal-office model, the organization 
provides funding directly to the TTO, which is 
then considered one of the organization’s cen­
tral administrative functions. The amount and 
adequacy of TTO funding depends upon how 
important innovation management is to the 
central administration and upon the TTO’s abil­
ity to demonstrate the benefits it brings to the 
institution.11 
2..2 India’s model 
No formal legislation for organizing and financ­
ing TTOs exists in India. However, during the 
last ten years, most technical universities and 
research institutes independently established or­
ganizations to interface with industry. Such orga­
nizations perform many of the technology trans­
fer activities typically assigned to TTOs in other 
countries. Some of these autonomous entities 
were initiated with seed funding provided from 
state governments or the central government. For 
example, the Indian Institute of Technology in 
Delhi established the Foundation for Innovation 
and Technology Transfer (FITT) with a corpus 
grant equivalent to US$400,000 from the Indian 
Ministry of Human Resource Development. In 
other cases, TTOs were formed by funds appro­
priated by a governing board of the autonomous 
university or research institute. 
In all cases, such support is provided only for 
a limited time. These organizations are expected to 
attain self-sufficiency, working as “profit centers” 
with a well-managed business plan. As in Australia, 
income may be derived from service charges levied 
for business-development activities that may have 
little to do with managing the innovations from 
the research institute (for example, industrial con­
sultancies and other business services provided to 
small and medium enterprises). In addition, each 
center typically receives a percentage of the roy­
alty income for the technology transfer transac­
tions it manages for the public research organiza­
tion.12 In April 2005, the Society for Technology 
Management (STEM) was formally launched as 
India’s professional technology transfer society, in­
cluding institutional and individual members.13 
2.. Japan’s model 
In 1998, the Japanese government enacted legis­
lation to create government-approved university 
TTOs. Once a TTO was approved, the govern­
ment would provide two-thirds of its operating 
cost, up to the equivalent of US$300,000 per year 
for five years; the universities or other university-
related organizations were expected to match gov­
ernment support by contributing one-third of the 
funding. At the end of the five-year period, the 
TTOs were expected to be able to sustain them­
selves without the income streams resulting from 
commercialization. However, when the Japanese 
government realized that such expectations could 
not be achieved, it extended its direct subsidy of 
a portion of the cost of TTO operations, includ­
ing the direct allocation of funds to secure pat­
ent applications for selected top-tier or so called 
Super TTOs. Furthermore, in 2004, Japanese law 
gave all national universities independent legal 
status, allowing them to participate in these TTO 
initiatives. 
Finally, a number of Japanese TTOs quickly 
discerned that the funding from the government 
was insufficient to support their operations. They 
therefore created associated for-profit companies 
that facilitated the creation of spinout companies. 
Faculty members were asked to invest in these 
companies, which commercialized university 
R&D. Now, several faculty-owned companies 
associated with university TTOs exist to assist 
the commercialization of R&D through spinout 
companies. This provides incentives for faculty 
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members to disclose their inventions, because 
they have a personal stake in the commercializa­
tion company. The government and universities 
realize, however, that this expanding strategy will 
require new support systems, such as incubators 
and risk capital, in order for these Japanese insti­
tutions to become entrepreneurial universities.14 
2.. People’s Republic of China 
In 1998, inside China, only Tsinghua University 
and Peking University in Beijing operated TTOs. 
Today, most public research organizations in 
China have a TTO. These were originally sup­
ported by the Chinese government, but as China 
moves from a state-planned economy to one that 
is more market based, this TTO funding model 
is changing. Most of the TTOs today operate as 
associated private companies, solely owned by the 
corresponding university and initially supported 
with university funds. As private companies, 
these TTOs are very active in business-develop­
ment services, such as setting up incubators, as­
sisting small- and medium-sized enterprises to 
prepare business plans, helping develop spinout 
company requirements, investing in new spinout 
companies with university-based venture funds, 
and so on. Most often, the TTOs negotiate for 
significant equity shares in new university spin-
out companies and may wholly own some spin-
out companies. Eventually, the TTOs—often 
called technomarts—are expected to become 
self-sufficient from their equity holdings and the 
income received from licensing and other related 
business-development activities.15 
2.. South Africa 
South Africa has made government support for 
research and innovation a key part of the national 
economic-development strategy. In August 2002, 
South Africa’s government approved a new na­
tional R&D strategy, and discussions continue 
for implementing the new strategy, including na­
tional funding for technology transfer. Funding 
for commercialization activities and patents is 
critical, but a major capacity-building and devel­
opment effort is under way. This effort will build 
upon capabilities that exist in a few universities 
and public research councils. 
South Africa is seeking to build strong links 
between its emerging technology transfer system 
and its research system. This means building 
a new culture of innovation inside the research 
community and ensuring that all benefits of re­
search (including noncommercial and social 
benefits) are understood and exploited. To sup­
port this integrated approach, the Southern 
African Research and Innovation Management 
Association (SARIMA) was formed in 2002 to 
assume the lead role in national efforts to build 
capability in research and innovation. SARIMA 
is supported by the government, participating 
academic institutions, and U.S. and European 
philanthropic donors.16 
As part of its national strategy, the South 
African government established its Innovation 
Fund to promote technology innovation, which 
has increased networking and cross-sectoral col­
laboration. The fund has invested South African 
Rand ZAR650 million in more than 100 proj­
ects. Many of these have produced patents and 
in some cases spinout companies. Most recently, 
the government established the Innovation Fund 
Commercialisation Office (IFCO), a centralized 
office to provide one-stop support for protecting 
and commercializing intellectual property rights 
for all of the nation’s public research organiza­
tions. IFCO complements existing technology 
transfer offices in South African public research 
organizations.17 
2.. United Kingdom 
Shortly after the 1998 report White Paper on 
the United Kingdom’s Competitiveness, issued 
by the government of the United Kingdom, 
many policy initiatives and government funding 
streams were established to stimulate cooperation 
between the researchers at universities and the 
country’s industrial entrepreneurs. This coopera­
tion significantly changed the way universities in 
the United Kingdom organize their technology 
transfer activities. Several prominent universi­
ties created separate companies to commercialize 
IP, especially innovations that were thought to 
have potential to serve as foundations for spinout 
companies (university companies or UNICOs18).
Nonetheless, the majority of universities also have 
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internal TTOs that collaborate closely with the 
sponsored-research office and with the UNICOs 
to develop industry relationships. The growth 
and development of TTOs have been stimulated 
more recently by direct government funding to 
universities for this third stream activity via the 
Higher Education Innovation Fund in England 
and Wales (HEIF)19 and the Scottish Executive 
Expertise, Knowledge, and Innovation Transfer 
Programme (SEEKIT).20 
Initially, HEIF financial support was awarded 
to institutions through competitive solicitation. 
Today, the government distributes HEIF funds 
directly to universities through a formula funding
process that is based upon numerous criteria, in­
cluding but not limited to institutional research 
capacity (quantity and quality) and TTO perfor­
mance measures.21 
2.. Russian Federation 
A major initiative began in 2002 to establish 
TTOs in leading universities in the Russian 
Federation. This was led by the U.S. Civilian 
Research and Development Foundation (CRDF) 
of Arlington, Virginia, in cooperation with the 
Russian Ministry of Education. The 19 universi­
ties participating in the so-called Basic Research in 
Higher Education (BRHE) program were identi­
fied for R&D development and technology trans­
fer focus. Funding was provided primarily by the 
John D. and Catherine T. MacArthur Foundation 
through CRDF and the Russian Federation 
Ministry of Education. In 2003, CRDF and 
the Ministry held a joint competition in which 
BRHE universities submitted proposals to estab­
lish TTOs with dedicated funding. Four univer­
sities were selected by CRDF to receive funding 
for TTO establishment, which provides a good 
example of financing TTOs through a third-
party philanthropic source. The awards ranged 
from US$75,000 to US$150,000 and were paid 
out over three years. Most recently, the U.S. 
Department of Commerce and the Russian 
Ministry of Education and Science executed a 
bilateral agreement that included establishing 
the U.S.-Russian Innovation Council on High 
Technologies. The first meeting of the council was 
convened in Moscow in June 2005. One of the 
four focused working groups established by the 
council will address the role of universities and re­
search organizations in the process of innovations 
and commercialization. This will include con­
sidering how to establish and finance TTO op­
erations in the Russian Federation. Finally, most 
research in the Russian Federation is conducted 
by the research centers of the Russian Academy 
of Science. Many of these centers have extensive 
technology transfer operations funded internally 
and directly by government allocations made to 
research centers at the academy.22 
2.. The United States 
No government funding for TTOs is provided to 
universities inside the United States, and there are 
no national universities. However, the Bayh-Dole 
Act of 1980, enacted as PL 96-817 and codified in 
the U.S. Code of Federal Regulations23 provides 
a legal basis for TTO funding. The act states that 
income recorded from commercializing govern-
ment-funded-research results can be utilized for 
only three purposes: (1) to fund the administra­
tion of the technology transfer function (TTO), 
(2) to provide a share of income to the inventor as 
an incentive to participate in technology transfer, 
and (3) to support education and further R&D 
at the institution. 
The act does not specify the percentages of 
income to be allocated for these three purposes. 
Universities are free to determine how to allocate 
commercialization income as they see fit. Most 
institutions have set aside a portion of the income 
stream to fund the TTO: allocations for TTO op­
erations usually range from 10% to 25%. Typically, 
after allocating a portion of commercialization 
income to support the TTO, the university di­
rectly subsidizes the TTO from internal sources 
during the first years of its operation. Then, as 
income is realized from license agreements, the 
subsidy required from the university for the TTO 
operations is reduced over time. Eventually, the 
institution expects that the income stream gen­
erated by the TTO will eventually eliminate the 
need for direct university subsidy. As mentioned 
above, several years are required for a TTO to be­
come entirely self-supporting from the allocated 
income. In a few rare cases, a TTO has become 
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self-sufficient early in its growth from a successful 
project that immediately generated a large stream 
of royalty income. Finally, it should be men­
tioned that other public research organizations 
in the United States (such as federal laboratories) 
are funded directly through a set-aside of the an­
nual appropriation provided to departments of 
the executive branch of government, such as the 
U.S. departments of defense, energy, and com­
merce (see Federal Laboratory Consortium for 
Technology Transfer24). 
2..10 Assessing the options 
The previous examples demonstrate how TTO 
funding models vary around the globe. Each 
model has developed to fit the cultural, political, 
and economic conditions of the corresponding 
country. Two themes are found in most interna­
tional models: 
1. The TTO typically is allocated a percentage 
of the income stream from the commercial­
ization of innovations. 
2. The TTO is expected to eventually become 
self-supporting from this allocation of in­
come and perhaps other related income-
generating services. 
Despite a new axiom (discussed in sec­
tion 2.5), many countries or regions may have 
no choice but to establish a regional or inter-
institutional model, for the reasons presented, 
with regard to the costs of establishing a TTO 
and the quantity and quality of an institution’s 
research results. The greater the distance from 
the regional office to the institutions the office 
serves, however, the greater are the challenges 
for identifying research results with commercial 
potential, protecting such results, and finding 
corporate partners for commercialization. Here 
are a few recommendations that, when followed, 
can diminish the negative impact of physical 
distance: 
•	 Within each institution served by a regional 
office, an individual must be identified to act 
as the institution’s liaison with the regional 
TTO. (This individual would have other re­
sponsibilities as well.) Having a specific point 
of contact is necessary for coordinating even 
the simplest administrative tasks. Ideally, 
this individual should not be a rector, vice 
president, provost, or dean, but rather a sec­
ond-tier administrator who reports to such 
institutional authorities. 
•	 The best communication infrastructure 
possible must be in place between the re­
gional TTO and the institutions it serves, 
including, but not limited to, video-confer­
encing capabilities when possible. 
•	 Key staff of the regional TTO must make 
regular, frequent visits to each of the insti­
tutions it serves in order to have adequate 
face-to-face contact. 
•	 Transparency in the operations of the re­
gional TTO is essential. Transparency re­
quires: (1) sharing costs between served 
institutions on a negotiated and equitable 
basis (if the regional office is not fully gov­
ernment supported), and (2) equal treat­
ment and consideration toward all in­
stitutions served by the TTO (that is, no 
favoritism shown to any one institution). 
For 13 years I directed a TTO that served 
ten academic institutions within the Texas 
A&M University system. At one time during 
those years, the TTO sought to serve smaller 
Texas universities outside the A&M system. 
The greatest challenge I found in seeking to 
manage such a broad program was that despite 
all efforts on the part of the TTO against it, 
favoritism was perceived by the institutions 
served. Such perceptions are likely unavoidable 
and simply must be managed. Once one of the 
served institutions records a significant success, 
the other institutions want to know and under­
stand why they have not achieved, or are not 
achieving, similar success. Individuals who per­
ceive that their institutions have been slighted 
will frequently blame the “failure” on the TTO 
and its staff. Over the years, I spent many hours 
addressing this issue in high-level meetings with 
institutional officers and system-level officials, 
even though the TTO office and staff sought 
to be impartial. Thus, a regional TTO must be 
prepared to address this critical issue, or the col­
lective approach is likely to fail. 
2 | HANDBOOK OF BEST PRACTICES 
         
	 	
        
       
        
        
         
       
   
      
      
      
          
       
      
        
       
    
      
      
     
     
     
  






2. Staffing the TTO 
Staffing a newTTO is a major challenge. Engaging 
the right individual or individuals to operate the 
office often is the factor that determines failure or 
success. In the United States, the number of TTOs 
began to increase in the 1980s, and selected to di­
rect the new TTOs were individuals from various 
backgrounds including high-level administrators, 
staff from other departments (contracts and grants 
staff, for example), clerical staff, scientists, attor­
neys, businesspeople, and so on. Significant de­
bate went on in the 1980s and 1990s as to which 
combination of skills was most desirable for direc­
tors and licensing associates to possess: scientific 
skills, legal skills, or business skills? At the same 
time, many offices evolved from simple one- or 
two-person operations to complex operations 
with many different positions to address specific 
job tasks, such as general administrative manage­
ment, clerical support, accounting support, para­
legal services, and project management (evalua­
tion, marketing, licensing, and so forth). 
For the university contemplating a new of­
fice, two would be the fewest number of positions 
to start with: 
•	 a director/licensing associate. In an ideal 
world, a person charged with setting-up a 
new office should have significant business 
experience (marketing, management, and 
business development), combined with a 
science or engineering education. Generally, 
neither scientists nor attorneys have the 
business acumen necessary to establish, or­
ganize, and manage a TTO. The director/ 
licensing associate should have excellent 
communication skills to effectively market 
innovations and to work successfully with 
both internal constituents (researchers and 
administration) and external constituents 
(potential corporate licensees). 
Unless the new TTO recruits an expe­
rienced technology transfer professional, 
the new director/licensing associate should 
be trained before operations begin. There 
are many opportunities for workshops 
and other training events internation­
ally, through such organizations as AUTM 
and the Licensing Executives Society 
International.25 Additionally, internships 
are available in numerous countries, for 
instance, in the United States, the Special 
American Business Internship Program 
(SABIT) is offered by the Department of 
Commerce.26 AUTM offers scholarships 
for training, such as the Howard Bremer 
Scholarship and the Developing Economies 
Scholarships (five awards). Each of these 
scholarships is offered annually through a 
competitive solicitation process. 
•	 clerical support. TTO operations require 
significant clerical and administrative sup­
port. TTO activities generate tremendous 
volumes of paper in the form of patent ap­
plication drafts, license agreements, project 
summaries, and marketing materials, as 
well as daily correspondence with attor­
neys, potential licensees, and researchers. 
Project files and docketing systems must be 
prepared to manage the progress of ongo­
ing work on each innovation, which not 
only requires clerical support but also ap­
propriate computer and electronic database 
resources. The telephone rings constantly 
with calls from inventors and potential 
corporate partners. Additionally, Web 
sites must be created and maintained, and 
incoming e-mails can be overwhelming. 
Excellent clerical/administrative assistance 
for the director is essential when establish­
ing a new TTO. 
When helping countries and institutions 
to establish TTOs, I have frequently heard this 
question: “Should we hire an in-house attorney 
to file patent applications for the institution?” 
Generally, in-house counsel retained for the 
drafting and filing of patent applications is not 
recommended for the following reasons: 
•	 By and large, the breadth of an institution’s 
research is too wide to be within the techni­
cal expertise and knowledge of any one pat­
ent attorney. Furthermore, the cost of hiring 
several attorneys with the relevant technical 
skills to address this breadth is not cost ef­
fective. Exceptions to these conclusions 
may be Centers of the Consultative Group 
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on International Agricultural Research 
(CGIAR) or similarly focused research in­
stitutions with narrower institutional re­
search results. 
The claims of a patent application form 
the basis for products and companies. 
Especially in human-health research, tens 
and even hundreds of millions of dollars 
are spent to bring an embryonic technol­
ogy to market. Such investments depend 
upon and are protected by the strength and 
enforceability of the patent rights to the 
subject technology. An institution would 
be extremely shortsighted to cut its pat­
ent application costs by using an in-house 
attorney made to be responsible for too 
many fields of technology. Given the high 
stakes, it is far better to secure the best pos­
sible patent counsel available to draft the 
strongest claims possible for the subject 
invention. 
Corporate licensees prefer to use the best 
counsel available to back their investments, 
and they may not have full confidence in 
the capabilities of an in-house attorney. 
In today’s litigious world, use of outside 
counsel creates a third-party buffer, an 
entity that must take responsibility for 
conducting thorough prior art claims, 
meeting filing deadlines, drafting the best 
claims possible, and managing the patent 
prosecution process from start to finish in 
the most professional manner. If problems 
arise along the way, as they often do, the 
institution is best served by having the 
attorney’s firm, and not the institution, be 
responsible for all of the constituents: the 
inventor, the institution, and the licensee. 
It is not advisable, when things go wrong, 
for the university to be in the position of 
defending the patent prosecution with in-
house counsel. 
Finally, many institutions have legal coun­
sel in an office of the general counsel (or simi­
lar name) that can offer assistance to the 
TTO, from time to time, for contractual 
Many TTOs in the United States—includ­
ing the TTO of the Texas A&M University sys-
tem—have hired an in-house paralegal specialist, 
rather than in-house counsel, to manage the in­
terface between the institution and its patent at­
torneys engaged under contract. The paralegal is 
responsible for ensuring that all documents are 
properly executed and filed with the attorney 
firm, for maintaining “suspense files” or tickler 
files to provide a backup system to ensure that 
no filing deadlines are missed at domestic and in­
ternational patent offices, for filing copyright ap­
plications for software and other works on behalf 
of the institution and its faculty, and for main­
taining a relational database of all official project 
documentation. 
2. Organizing the TTO 
During the initial growth of the technology trans­
fer industry in the United States in the 1980s and 
1990s, TTOs were located in a variety of admin­
istrative units within public research organiza­
tions, including (1) offices of general counsel, (2) 
business administration offices, (3) offices of the 
vice president for research, and (4) contracts and 
grants offices. Over time, however, TTOs typical­
ly were placed within the research administrative 
unit of the institution, which usually reports to 
the vice president for research. In many cases, an 
individual serves as the organization’s officer for 
research and technology transfer, combining the 
functions within one administrative unit. 
Additionally, as TTO offices grew in the 
United States and other industrialized countries, 
the offices diversified to create individual operat­
ing divisions to manage focused tasks: 
• general administrative office management 
• clerical support 
• project management services through a li­
censing associate (responsible for evaluat­
ing inventions, marketing, coordinating 
industry relations, and negotiating license 
agreements) 
• accounting services (responsible for man­
aging general fiscal operations, as well as 
accounts receivable from licensees, and ac-
questions, contract enforcement, and other 
legal issues. 
counts payable to consultants, patent attor­
ney firms, and other service agents) 
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CHAPTER .2 
•	 paralegal services (responsible for manag­
ing the volumes of correspondence and 
carrying out discussions with patent attor­
ney firms, executing and notarizing legal 
documents, and docketing critical dates to 
ensure filing deadlines are met) 
•	 marketing/public relations (responsible for 
managing Web sites and producing bro­
chures, press releases, and other marketing 
materials, as well as organizing frequent 
promotional events for researchers and 
industry) 
More entrepreneurial offices may even create 
divisions to establish new spinout ventures, in­
cubators, university venture funds, and the like. 
Obviously, new TTOs may utilize existing units 
outside the office to manage some of these ac­
tivities—such as working with a university com­
munications office to produce marketing materi­
als—until such time as the growth of the office 
warrants a dedicated person inside the TTO. 
As has been suggested, TTOs have taken vari­
ous organizational forms, in addition to the tradi­
tional stand-alone unit or department within the 
public research organization. These include (1) 
an external company owned by or closely affili­
ated with the institution to manage its technol­
ogy transfer activities, (2) a service or consulting 
contract with a third-party company to manage 
occasional innovations disclosed by researchers, 
(3) one office serving multiple institutions in a 
region under collaboration agreements, and (4) a 
government agency serving as a TTO for univer­
sities and other research organizations in a region, 
state, or nation. 
How to choose? This chapter suggests a new 
“TTO axiom” to help guide planners toward the 
most effective organizational form: The closer the 
TTO is physically to the scientists and researchers it 
serves, the more effective it will be. The reverse is 
also true: TTO effectiveness diminishes the further 
it moves physically from its customer base. This latter 
holds true even in our age of e-mail, instant text 
messaging, and other video, voice, and digital com­
munication techniques. None of these techniques 
can replace frequent face-to-face communication 
needed between the TTO staff and its inventors, 
or the ability to call, on short notice, meetings be­
tween project stakeholders—inventors, TTO staff, 
academic administrators, potential licensees, and so 
forth. At times potential corporate partners arrive 
at the TTO with little or no advance notice, and 
getting the inventor to join the group for a meet­
ing, lunch, or dinner obviously is not possible if 
the individual is in a faraway city. Moreover, simple 
administrative and logistical requirements in man­
aging innovation suggest that physical proximity 
is important. Consider the example of an inventor 
receiving a call from the attorney-of-record on a 
patent application saying that the inventor’s signa­
ture is needed on an affidavit before the end of the 
day. Such a situation could only be addressed if the 
TTO were on-site. 
3. OPERATIONS 
The degree to which TTOs participate broadly 
in research, technology transfer, and industry 
relations varies widely from institution to insti­
tution and from country to country. The degree 
of participation depends upon many factors, the 
most important being the entrepreneurial culture 
of the institution and of the region or nation. 
Institutional culture is determined most often by 
the attitude and degree of support from the presi­
dent or chancellor of the institution. Some entre­
preneurial chief executive officers have expanded 
their initial TTO operations to include activities 
in support of their industry partners. This can 
create closer connections to the corporate sec­
tor, such as the development of spinout-company 
business plans by a university’s college of business 
administration; the creation of university-based 
technology business incubators, and/or research 
and science parks; organizational venture funds, 
and so on. Constituents of a new TTO, however, 
expect the following minimal activities: 
•	 Assist faculty and researchers in identifying 
research results that have commercial value 
and document the discoveries through a 
disclosure process. The disclosure-of-inven­
tion form should be simple and make it easy 
for the inventor to document the discov­
ery; more detailed information can be ob­
tained through interviews and subsequent 
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YOuNG 
•
interactions with the inventor. The com­
plexity of the disclosure form should never 
be a deterrent to faculty participation in the 
technology transfer process. 
Evaluate commercial potential of disclosed 
basis through their professional network­
ing activities. 
• Once one or more industry partners are 
identified for an innovation, negotiate 
legal contracts (license agreements) with 
innovations. A TTO exists to find com- these industry partners to transfer IP 
•
mercial applications for technology and 
partners to realize the commercial poten­
tial, not to judge the value of the science. 
Such evaluations may be the most difficult 
of all tasks for a TTO. There are many ap­
proaches to invention evaluation.27 The 
evaluation process lays the foundation for 
future decisions about IP protection and 
marketing. 
Determine whether or not to protect IP 
rights in the innovation; secure funding 
for filing patent, trademark, or copyright 
applications; and manage the protection 
rights in the innovation in exchange for 
royalties or other consideration. The goal 
is to negotiate a fair arrangement that facili­
tates and assists the commercial partner in 
successfully developing and marketing the 
product, rather than simply seeking to ne­
gotiate the absolute highest fees and royal­
ties in the agreement. Developing industry 
partnerships can lead to many unexpected 
benefits, such as sponsored research, stu­
dent employment opportunities, consult­
ing opportunities, and even philanthropic 
donations to the institution. 
process. The challenge of securing fund­
ing for protection of intellectual property 
internationally—especially when seeking 
protection in highly industrialized coun­
tries where the primary markets for the ex­
pected products lie—is often overwhelm­
ing and perhaps even impossible in many 
developing economies because of the tre­
mendous expense. Yet, there may be very 
small or nonexistent commercial markets 
• Maintain and manage administrative func­
tions in support of the primary functions 
of IP protection and technology transfer. 
These functions can include accounting, 
royalty distributions, licensee performance 
management, and patent application 
management. 
• If the TTO decides not to pursue IP pro­
tection and commercialization of an in­
novation, implement a process to ensure 
•
for the innovation in the country of origin, 
which can present a serious dilemma. The 
only solution in many cases is to first secure 
protection in the country of origin, thereby 
“buying time” under the requirements of 
the Patent Cooperation Treaty (PCT)28 to 
find a corporate partner to pay the patent 
costs internationally as a business expense 
in the license agreement. 
Conduct market research to identify po­
tential industry partners, and then market 
the innovations. Research has shown that 
in the United States, the primary source 
for identification of licensees is the inven­
tor. In industrialized countries, inventors 
typically are familiar with the market­
place29 in their area of scientific expertise; 
they may even know their counterparts in 
industry (potential licensees) on a personal 
that others have an opportunity to pursue 
protection and commercialization, if they 
chose to do so. The “others” will most often 
be inventors. 
4. ExEMPlARy TTOS AND CONCluSION 
In 2000, Dr. Louis Tornatsky conducted a study 
for the National Governors Association in the 
United States to identify the common practices 
of the most exemplary TTOs in the country. The 
study highlighted seven characteristics that were 
common to most exemplary offices: 
1. A clearly stated TTO mission 
2. Transparent TTO policies and procedures 
3. Entrepreneurial staffing and an entrepre­
neurial environment 
4. Customer-friendly relations with both inter­
nal and external constituents by TTO staff 
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CHAPTER .2 
5. A highly supportive university administra­
tion and community (local, regional, and 
national) 
6. Strong TTO links to potential industry 
partners 
7. TTO access to risk, or venture, capital30 
TTOs exist in all shapes and sizes around the 
world, ranging from a part-time individual at a 
small research organization, to offices with several 
hundred professionals (such as the University of 
California system), to a contracted third-party or­
ganization that manages an occasional innovation 
with commercial potential. Furthermore, sources 
of TTO funding, the organizational structure of 
the office, the scope of activities, and many other 
operational factors vary from office to office and 
from country to country. 
The most compelling forces that determine a 
TTO’s characteristics and performance have been 
a primary focus of this chapter: the volume of re­
search activity within the institution and the qual­
ity of the research results. Research is the source 
from which all innovations and opportunities for 
TTO management originate. Public research or­
ganizations contemplating the creation of a TTO 
should always first consider whether the research 
quantity and quality of their institutions justify 
the endeavor. n 
TERRy A. yOUNg, Director of Research Development, 
Office of Research and Sponsored Projects, University of 
South Dakota, Vermillion, South Dakota, 57069, U.S.A.
terry.young@usd.edu. 
1 www.autm.net. 
2 The survey is published online at www.autm.net/
surveys/dsp.surveyDetail.cfm?pid=16. The survey can 
be accessed by members of AUTM at no cost. Non-
members may purchase the survey on the AUTM 





7 These concepts were first presented by Jim Serverson 
at the 1999 AUTM Central Regional Meeting in 
Minneapolis, Minnesota 
8	 DeVol R. 1999. America’s High Tech Economy.The Milken 
Institute: Santa Monica, California. 
9	 www.un.org/millenniumgoals/. 
10	 www.autm.net. 
11	 Electronic communication with Claire Baxter,University 
of Sydney, and Colin Melvin, Queensland University of 
Technology, 17 November, 2002. 
12	 Electronic communication with Parameshwar P. Iyer,
Center for Scientific and Industrial Consultancy, Indian 
Institute of Science, Bangalore, 22 November, 2002;
and A. K. Sengupta, Foundation for Innovation and 
Technology Transfer, Delhi, 25 November, 2002.
13	 Chandrashekhar G. 2005. Society Set Up for Managing 
Technology The Hindu Business Line.25 April,2005.www.
blonnet.com/2005/04/25/stories/2005042501221300. 
htm. 
14	 Electronic communication with Akio Nishizawa,
Tohoku University, Sendai, Japan. 18 August, 2005. 
15	 Personal visit to China as principal investigator on 
project sponsored by U.S. State Department and 
Chinese State Intellectual Property Office. Intellectual 
Property Rights and Technology Transfer Exchange 
Program, October 26–November 9, 2002. 
16 Electronic communication with Tony Heher, University 
of Cape Town, South Africa. 21 November, 2002; and 
Rosemary Wolson, University of Cape Town, South 





21	 Electronic communication with Isabell Majewsky,
Connect Midlands, University of Warwick, U.K., 21 
August, 2005. 
22 Electronic communication with Marilyn Pifer, Civilian 
Research and Development Foundation, 15 August,
2005; and personal experience as an appointed 
member of the U.S.-Russian Innovation Council on 
High Technologies.
23 Another source of the Bayh-Dole act: (i) AUTM offers 
a description of the Act, with a link to the actual 
legislation: http://www.autm.net/aboutTT/aboutTT_ 
bayhDoleAct.cfm. (ii) When you click on the AUTM link,






27 See, also in this Handbook, chapter 9.3 by R Razgaitis,
and chapter 9.2 by RH Potter. 
28	 www.wipo.int/pct/en/texts/articles/atoc.htm. 
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ALISON F. CAMPBELL, Managing Director, KCL Enterprises Ltd., U.K. 
ABSTRACT 
Technology transfer has an important role to play in the 
today’s world, where access to know-how and knowledge 
are valuable economic commodities. A technology trans­
fer office (TTO) can be set up in many different ways. 
The TTO should be tightly aligned with its supporting 
institution’s missions and goals. Available external re­
sources will affect the TTO’s strategy and its operational 
structures, so it is important to consider the TTO’s exter­
nal environment. Income generation is typically one of 
the main objectives for the TTO, but technology transfer 
is valuable also because of its capacity to facilitate innova­
tion and broker the exchange of knowledge for society’s 
benefit. This chapter discusses the key elements involved 
in building a TTO—from structure and staffing to ex­
ternal engagement—and how to lay the foundations for 
success. A number of European models and trends are 
described to provide greater context. 
1. INTRODuCTION 
There is no “right” way to set up a technology transfer 
office (TTO), but success does require considering 
some key issues. This chapter discusses how to estab­
lish and run a TTO, and, drawing on experiences 
from a number of such offices, the chapter provides 
case studies to illuminate these issues. Emerging 
trends in funding TTOs are also discussed. 
2. FOuNDATIONS 
Any technology transfer office should be aligned 
with and supported by the institution it serves. 
The TTO’s mission should be consistent with the 
institutional mission, and the TTO’s approach 
and activities should support and add value to the 
institution. The TTO and the institution should 
agree upon what adds value, because financial re­
turns alone are an insufficient measure of value 
for universities viewing their commercial activities 
strategically and contextually. Long-term returns, 
such as sustained partnerships, cultural change, 
job creation, and societal well-being should be 
part of the value provided by TTOs. These long­
term returns supplement shorter-term, more tan­
gible returns such as income, access to resources 
and expertise, and program delivery. This point 
has been emphasized by the U.S. technology 
transfer association, the Association of University 
Technology Managers (AUTM) and the U.K. 
association for technology transfer (UNICO1), 
which have disseminated data and case studies of 
how technology and knowledge transfer can ben­
efit society.2 
Deciding whether the TTO should un­
dertake pure commercialization or broader 
knowledge transfer is important for developing 
an operational strategy. In a knowledge-based 
economy, access to know-how and use of knowl­
edge (outside of the environment in which the 
knowledge was gained) is a valuable commod­
ity.3 The U.K. Research Councils define such 
knowledge transfer as: 
Campbell AF. 2007. How to Set Up a Technology Transfer Office: Experiences from Europe. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. AF Campbell. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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[T]he two-way flow of people and ideas be­
tween the research environment and wider economy, 
[which] thereby contribute[s] to national prosperity, 
the quality of life of U.K. citizens, and cultural en­
richment of our society. Knowledge Transfer encom­
passes the systems and processes by which knowledge, 
expertise and skilled people transfer between the 
research environment (universities, centers and in­
stitutes) and its user communities in industry, com­
merce, public and service sectors.4 
While the public good is always a part of a 
TTO’s agenda, some have made income genera­
tion the prime objective. Others base their agenda 
on public benefit or economic development. De­
ciding upon the TTO’s objectives will determine 
how the office should be configured, resourced, 
and operated. (Examples are presented at the end 
of this chapter.) 
The senior management of the host insti­
tution must actively support establishing these 
foundations. To do so, managers will need to 
understand the relevance of technology transfer 
to the institution. Understanding the TTO life 
cycle is essential for helping the TTO office to 
encourage academics to participate in technology 
transfer and will help maintain support when re­
turns seem slow or when a partnering decision 
appears unappealing on the surface. Such an un­
derstanding involves vision from both partners 
in the transfer and an ongoing dialogue between 
principals. In particular, it should be clear to all 
parties that, while technology transfer may be an 
extra income stream, it should not be relied upon 
to generate significant revenue for institutional 
planning. At Isis Innovation (Oxford University), 
perhaps one of the best-known European exam­
ples of technology transfer success, the gross in­
come from technology transfer is about 0.005% 
of annual turnover. This is based upon annual 
turnover for the University of UK£530 million, 
gross income from technology transfer activity of 
UK£2.7 million, and net income from technol­
ogy transfer (after the costs of undertaking the 
business), UK£260,000 (2005–2006 figures). 
National and regional policies and objectives 
also should serve as a framework for shaping the 
office and directing priorities. When TTOs benefit 
from funding for local development, for example, 
they have been able to secure partnerships and 
fund specific activities of interest to the local re­
gion. In the Aachen region of Germany, for ex­
ample, regional imperatives have engineered local 
economic development to ensure that an exhaust­
ed traditional coal mining region transitions into 
a high-technology center for innovation. Special 
initiatives and funding have encouraged the de­
velopment of new businesses within the region. 
The scientific institute in Julich (Fachhochschule 
Aachen5) has been central to this redevelopment, 
having been built up to offer a variety of support­
ing technology-transfer services, including con­
sultancy, provision of facilities, and the brokering 
of business advice. 
An early step in setting up the TTO—and 
an essential ongoing activity—is identifying and 
fostering relationships with stakeholders. This 
group will include academics, representatives of 
the business and user community, and regional 
and governmental offices. The most important 
group at the outset is the internal community. 
Successful and meaningful technology transfer is 
demand driven, so it is important to understand 
the external partner’s needs. If the internal aca­
demic community does not support the technol­
ogy transfer process, there will be scope for failure 
at various stages of the process. Although time 
consuming for the technology transfer manager, 
he or she should be seen in the academic depart­
ments being served. This visibility will accelerate 
culture change and help integrate the TTO into 
the fabric of the university. The institutional mes­
sage must be one of support and encouragement 
for engaging in technology transfer. TTO staff 
must work with academics at all levels to educate 
them in entrepreneurial behaviors at the macro 
and micro scales. This work could include train­
ing in how to engage with business and respond 
to its needs, how to act as consultants, and how 
to identify partnership or licensing opportunities. 
All academics will need to be aware of the intel­
lectual property (IP) rights process, including 
disclosure, confidentiality, types of protection, 
and so forth. Such awareness training may be de­
livered by the TTO itself or in partnership with 
external providers. For example, IP specialists, 
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lawyers, and research sponsors are often willing 
to provide limited training. In the United King­
dom, government funding of universities consor­
tia has established a number of enterprise centers 
for such training. 
Incentive schemes for academic staff need to 
be carefully considered; policies should be imple­
mented early. Experience has shown that acknowl­
edging an employee’s participation in technology 
transfer and sharing some of the financial reward 
are clear incentives to encouraging engagement in 
technology transfer. Siegel and colleagues6 high­
light the importance of faculty reward systems— 
along with removing cultural barriers and staffing 
the TTO, the reward system is one of the three 
key factors for success in technology transfer. 
3. STRuCTuRING THE TECHNOlOGy 
TRANSFER OFFICE 
.1 Personnel 
The core element for successful technology trans­
fer is people. Technology transfer is a “contact 
sport,” so managers must have the ability to en­
gage with people at all levels and across national 
boundaries. Managers need to understand the 
potential of their offerings and be highly flexible. 
Technology transfer managers need to be capable 
of engaging equally well with academics and busi­
ness; they must be both inward and outward fac­
ing. Business skills are important but hiring an 
MBA graduate is not essential. The office should 
be led, however, by an individual who under­
stands the details of running a business. Staff with 
work experience in the relevant business/user sec­
tor who can appreciate its requirements and tailor 
opportunities accordingly are also very useful. To 
build up an understanding of the potential for 
new opportunities, the technology transfer man­
ager needs to win the confidence of academics, 
which is why it is helpful for the TTO to be em­
bedded in the institution and for the office to be 
perceived as part of the institution. Staff should 
be able to spend time with academics to better 
understand what they can offer to the business 
and user community—as well as how these op­
portunities can best be developed for mutual gain 
by the institution and the community. Similarly, 
staff must actively engage with businesses to bet­
ter understand market needs and gain agility in 
matching proposals with the institution. 
An effective TTO is a team with complemen­
tary abilities. There is no one rule for the type of 
background that TTO staff need; much can be 
learned on the job and through specific training. 
However, if the office will be brokering opportu­
nities in particular technical areas, then it is wise 
to recruit technical specialists. They will need to 
be able to use technical language with academ­
ics and customers, understand an opportunity 
and its applications, research areas of interest to a 
partner, and translate their ideas into an offering 
that business professionals will understand. Not 
all TTOs need to be large. A core viable unit at 
the outset may have three staff members, two of 
whom have business and technical skills and have 
or can develop expertise in IP rights and commer­
cialization. The third staff member would provide 
administrative support. Often it is hard to resist 
the seduction of employing specialist staff in pref­
erence to administrative staff. However, an office 
that does not have access to appropriate adminis­
trative support will always be inefficient. 
Specialist advice can be outsourced (for ex­
ample patent and legal counsel). A growing 
number of legal firms have experience with the 
academic technology transfer sector, and they can 
provide a service that responds to the needs of 
this sector—both in terms of the type and level 
of advice and in the cost of counsel. When op­
tions have not been identified, a discussion with­
in technology transfer networks will often reveal 
a number of suitable choices. While most offices 
use external legal advisors, a growing number of 
TTOs now employ in-house advisors, which may 
be desirable but naturally depends on whether 
the volume and complexity of work make such 
an appointment financially sensible. 
Free business advice—which can be useful— 
is abundantly available to TTOs. Peer advice, in­
cluding participation in technology transfer net­
works, can be invaluable. Other sources include 
funders of research (for example, Wellcome Trust, 
the Centre for the Management of Intellectual 
Property in Health Research and Development 
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(MIHR), and the Bill and Melinda Gates Foun­
dation) and government and regional bodies. 
Business itself is an eager ally of the academic in­
stitution and the TTO. Often, experienced peo­
ple will give their time to advise on specific issues 
or to become part of an advisory group. Many are 
delighted to be asked, and few refuse to help. 
.2 Building skill sets 
As technology transfer has become a recognized 
profession within many countries, an inventory 
of best practices has accrued. There are many 
opportunities to build core skills in the team 
through networking, training, and literature. 
Some ways to improve the skills of the office will 
be free, through personal networks and mentors, 
for example. Secondments, where a member of 
one organization spends time in another, and in­
ternships with business and other TTOs are an 
attractive way to bolster skills, gain understand­
ing, and share best practices. Such arrangements 
always work two ways, and both parties in the 
arrangement will normally be keen to participate. 
For the most part, however, specific training is 
needed for a team to acquire core skills and—as 
business needs and the landscape evolve—attain 
new ones. In Europe, the most prominent net­
working forum is the Association of European 
Science and Technology Transfer Professionals
(ASTP)7, a professional membership organiza­
tion for technology transfer managers that hosts 
conferences across Europe. For technology trans­
fer training, Praxis (a not-for-profit organization) 
offers a full range of courses that are delivered by 
practitioners.8 Emphasizing experiential learning 
and networking, Praxis offers training both for 
new entrants and for more experienced profes­
sionals. Its courses are open to international dele­
gates. In the United Kingdom, UNICO has pub­
lished a series titled UNICO Practical Guides in 
a handy, readable format that provides in-depth 
advice on the range of technology transfer activi­
ties, from student IP rights to legal agreements 
and company formation.9 There are also numer­
ous guides available both for purchase and free of 
charge. The MIHR Handbook of Best Practices for 
Management of Intellectual Property in Health10 is 
a good example of the latter. 
. Managing information 
When setting up an office, adequate attention 
must be paid to information management. It is 
crucial to establish business processes at the out­
set. Technology transfer is naturally a long-term 
prospect, and key information on IP rights and 
legal agreements must be captured, organized, 
and maintained for a long time. The life of a 
patent, for example, may last for up to 20 years. 
Naturally, so will the license obligations. More­
over, most litigation requiring access to initial 
documents comes after a successful product is 
on the market, often several years after patent 
filing and licensing. Without adequate access 
to records, patent positions may not be sustain­
able and income may be lost. To develop busi­
ness, project and contact information must be 
captured and shared across the organization, so 
a CRM (customer relationship management) 
style of database is desirable. It can be purchased 
off the shelf or developed internally. Each ap­
proach has its own strengths and weaknesses. A 
number of producers and many TTOs who have 
tried different systems are happy to share their 
expertise. 
. Budget 
An office without an appropriate budget will 
struggle. As described above, technology transfer 
requires a complex combination of activities and 
skills. All technology transfer outcomes involve a 
transaction based on hard or soft IP rights (that 
is, patent or know-how). Invariably, the transac­
tion will be by way of a legal agreement, which 
requires legal drafting (or use of template agree­
ments) and negotiation skills. The transaction will 
have a financial component that must be clearly 
understood, and it will be based upon IP rights 
and/or access to resources that will need to be 
valued and protected. This means that someone 
must understand what elements can and need to 
be protected. The drafting and filing of a patent 
application are best done in conjunction with a 
patent agent, and there is a requirement for on­
going patent prosecution. All of these activities 
require funding; however, some costs may be 
recovered through a business deal or by passing 
them onto a partner. 
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. Business model 
Offices tend to be departments within institu­
tions or subsidiary companies. As a department, 
the TTO is embedded in the institution and has 
its interests clearly aligned with institutional ob­
jectives. TTO staff will be on par with academic 
colleagues. Running technology transfer through 
a subsidiary company, however, may encour­
age a positive perception of technology transfer 
and demonstrate the seriousness with which it 
is viewed by the institution. A subsidiary com­
pany gives more operational flexibility and the 
ability to structure staff remuneration packages. 
Debates over TTO staff pay and incentives are 
frequent, and it is increasingly common to award 
performance-related pay and bonuses for meet­
ing targets. This works well when the targets can 
be easily defined and measured and when reward 
is against outcomes rather than activities. How­
ever, this reward system skews behavior in favor 
of reaching those targets, so care needs to be 
taken to ensure that reward systems are properly 
cast to promote core business objectives. This is 
another reason why the TTO should have clear 
objectives that can be easily communicated to its 
staff—regardless of whether they are employed 
by the company or by the university. As a final 
twist on the internal/external TTO, staff do not 
necessarily need to be employed by the company; 
they may be employed by the university (and sub­
jected to the university pay and pension scheme 
structure) and then seconded to the company. 
Chain of command and accountability must 
be clear. A departmental TTO should report to a 
senior university staff member. A company will be 
responsible to a board, which may be chaired by a 
university senior staff member. In either case, the 
TTO will be accountable to the university gov­
erning body and will be expected to produce at 
least annual reports of activity. For both types of 
organizational structure, it will be helpful to have 
a group of advisors inside and outside of the in­
stitution. The advisors can bring new experience 
to the organization and act as internal and exter­
nal champions. Advice on the most tax-efficient 
structures for establishing and running the TTO, 
for example, may help to determine whether it 
should be treated as a department or as a separate 
business. Governance should be considered where 
a company is formed and may be accomplished 
by forming a board with nonexecutive directors 
and/or an advisory board. 
A final option is to outsource technology 
transfer to an independent third party. Outsourc­
ing minimizes investments and the risks for the 
institution but also reduces the returns to the 
institution since the partner will take the lion’s 
share of them. Such models are usually predicat­
ed upon income, and so the partner will likely 
pursue activities directed towards high-value, in-
come-generating opportunities rather than tech­
nology transfer for the broader public good. 
4. TRENDS IN TECHNOlOGy
TRANSFER OFFICES 
The landscape of technology transfer activity is 
changing. As Campbell11 discusses, the United 
Kingdom is particularly progressive. Universities 
are creating innovative partnerships and devel­
oping expertise in technology transfer to secure 
financial investment and build future returns. 
Research funders are looking for initiatives to fill 
gaps in the technology transfer process. 
Sheffield University is an interesting model. 
It lacked the funding needed to fulfill its tech­
nology transfer ambitions, so the director of the 
TTO set about developing a relationship with ex­
ternal experts, an initiative that led to establishing 
a separate company: BioFusion PLC (Sheffield, 
U.K.).12 With a ten-year exclusive agreement with 
Sheffield University to commercialize all Univer­
sity-owned medical IP rights, BioFusion is run 
independently of the University and its TTO. In 
2005, BioFusion listed on the Alternative Invest­
ment Market (AIM) of the London Stock Ex­
change, raising UK£8.23 million. The University 
is one of the shareholders. This funding allows the 
company to manage and fund both existing and 
new portfolio companies within the life sciences 
area. BioFusion has made clear its intention to de­
velop similar relationships within the sector. With 
the increasing interest in technology transfer as an 
area for external investment, academic technol­
ogy transfer companies have been able to secure 
funding when there is a clear income-generation 
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model. The most prominent example is Imperial 
Innovations of Imperial College, London. With 
a solid track record in commercialization and a 
robust pipeline of spinout companies, Innova­
tions (and in turn Imperial College) has benefited 
from private institutional investment and intends 
to become a publicly listed company. Of course, 
this model of external funding does not work for 
all TTOs because it applies only to those organi­
zations with potentially high investment returns. 
This will not be the case for most technology or 
knowledge transfer activities because most offices 
are brokering partnership deals to bring cash to 
a university for specific research rather than to 
generate unencumbered income. At Imperial, 
knowledge transfer and research partnership de­
velopment has remained within the institution; 
Innovations concentrates on the cash-generating 
activities of licensing and spinouts. 
5.	 ExAMPlES OF TECHNOlOGy TRANSFER
OFFICE MODElS 
At King’s College London (KCL), technology and 
knowledge transfer is managed within one orga­
nization, KCL Enterprises Ltd., a wholly owned 
subsidiary of the university. KCL Enterprises is 
responsible for new opportunities and research 
support, which bring all the external business fac­
ing and research funding activities together. This 
combining of functions weaves the activities of 
the organization together and creates an extend­
ed, integrated team. Established 12 years ago, the 
initial team was a small technology transfer unit 
of staff specializing in the protection and com­
mercialization of college IP rights. Over time, the 
research grants and contracts office of the univer­
sity was incorporated into the organization. The 
company has since grown to 50 people and now 
encompasses business development, consultancy, 
work placement, marketing, technology transfer, 
spinout company incubation, and research sup­
port. The mission of the organization is to lever­
age the intellectual capital of the university to 
generate income and benefit society. The business 
development team underpins the activities of the 
company; specialist functions take on the leads 
appropriate to them. Eight business development 
managers specialize in different sectors and are 
co-located in both Enterprises and their relevant 
academic departments. Their objectives include 
developing collaborative research with business 
and promoting enterprise within King’s and ex­
ternally. The technology transfer team focuses on 
the identification, management, and exploitation 
of IP. They are skilled in patent prosecution, due 
diligence, and drafting and negotiating license 
agreements, and are supported by a team dedi­
cated to mentoring and incubating new company 
spinouts from the university. The expansion of the 
team has been possible through funding from the 
university and from government, both of which 
recognize the increasing importance of the knowl­
edge economy and applied research. Particularly 
active in promoting knowledge transfer, the U.K. 
government has established a specific stream of 
funding, the Higher Education Innovation Fund, 
which is available to universities within England. 
This has allowed many universities to develop 
knowledge transfer capabilities and capacity. It 
also allows them to take some risks in finding 
mechanisms to encourage and capture new op­
portunities at the institutional level. 
The government has been keen to encourage 
development of knowledge transfer through the 
public sector research establishments within the 
United Kingdom. An early leader in this sector is 
Medical Research Council Technology (MRCT), 
a wholly owned subsidiary of the Medical Re­
search Council (MRC). This technology transfer 
company grew from a team of four MRC staff in 
1990 to a company that currently employs more 
than 60 people and that this year saw a windfall 
of over UK£140 million in income from royalty 
sales. MRCT in many ways is a unique example 
of technology transfer, but in other ways it points 
the way for others to follow. MRCT became a 
separate entity by merging with another applied- 
research activity of the MRC, thus gaining staff 
and expanding its technology transfer offerings 
to include applied-development laboratories. Its 
expansion was enabled through a record of good 
work and the vision and support of its parent insti­
tution. While the amount of income it generates 
is unusual, the sources of the income are typical: 
a suite of related technologies and their various, 
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CHAPTER . 
carefully crafted exploitation. (This case still sup­
ports the general notion—discussed by Scherer 
and Harhoff13—that big wins in commercializa­
tion come from only a few deals.) Continuing its 
expansion into applied research, MRCT has de­
veloped new activities to add value and speed the 
uptake of academic IP. One approach has been 
to create a drug discovery team that identifies 
academic IP and develops licensing leads in in­
dustry. U.K. funders and international initiatives 
have also tried to expedite the process. For ex­
ample, Cancer Research Technology (CRT) has a 
drug development laboratory, and the Wellcome 
Trust offers Translational Awards for developing 
early-stage opportunities into more commercially 
attractive offerings. International approaches 
include Medicines for Malaria Ventures, which 
brings public, private, and philanthropic sec­
tor partners together to fund and manage the 
discovery, development, and registration of new 
medicines to treat and prevent malaria in disease-
endemic countries. 
A push for technology transfer in the past 
ten years has created more than 20 technolo­
gy transfer offices across Switzerland. To build 
critical mass, the two universities of Bern and 
Zürich jointly own a subsidiary nonprofit tech­
nology transfer company that they established 
in1999: Unitechtra. With a staff of seven and 
serving two other research institutes, Unitechtra 
has a clear mission to contribute to the economy, 
facilitate research uptake for the public good, 
develop mutual beneficial close ties with indus­
try, motivate and retain academic staff, and, 
ultimately to increase income to the institutes. 
These objectives are pursued through activities 
that include the commercialization of research 
results, the negotiation of research agreements, 
support for the creation of new spinout compa­
nies, and training and education for scientists 
in the field of technology transfer. As a natural 
next step in the evolution of Swiss technology 
transfer, in 2003 the Swiss Technology Transfer 
Association (swiTT14) was formed. A network 
organization, it aims to bring together TTOs 
and specialists in the field to improve the provi­
sion of services and to share information and 
resources. The Swiss Network for Innovation 
(SNI) and the Swiss federal government provide 
funding to swiTT. 
6. CONCluSION 
TTOs can be set up in a variety of ways, but in 
all cases it is helpful to draw on external skill re­
sources where possible. Possessing clarity of pur­
pose and building the right foundations is es­
sential for planning the operations of the TTO. 
Making money will always be a consideration 
when setting objectives, but technology transfer 
adds value in other important ways: as a resource 
to facilitate innovation for the public good and 
as a way to broker the exchange of knowledge 
between the business and public sectors for soci­
ety’s benefit. Transferring knowledge across such 
disciplines as the humanities, law, and social sci­
ences is as important as transferring knowledge 
and technology across the applied sciences, and 
TTOs should be set up to have the flexibility 
to accomplish this broader knowledge-transfer 
objective. n 
ALISON F. CAMPBELL, Managing Director, KCL Enterprises 
Ltd., King’s College London, Capital House, 42 Weston 
Street, London, SE1 3QD, U.K. alison.campbell@kcl.ac.uk 
1	 For the transcript visit www.unico.org.uk/prodben.doc,
and for the slides visit www.unico.org.uk/prodben. 
ppt. 
2	 AUTM. 2006. AUTM Better World Project. AUTM:
Northbrook. www.betterworldproject.net. 
3	 Arnesse F and A Cohendet. 2001. Technology Transfer 
Revisited from the Perspective of the Knowledge-
Based Economy. Research Policy 30:1459–1478. 
4	 U.K. Parliament. 2006. Research Council Support




6	 Siegel DS, D Waldman and A Link. 2003. Assessing the 
Impact of Organizational Practices on the Relative 
Productivity of University Technology Transfer Offices:




10 Mahoney R. (ed). 2003. MIHR Handbook of Best Practices 
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CHAPTER 6.4 
How to Set Up a Technology Transfer 

System in a Developing Country
 
caRlos feRnandeZ, Director, Strategic Studies, Foundation for Agriculture Innovation (FIA), Chile 
ABSTRACT 
This chapter reports the results of a recent study of the 
current state of technology transfer in Chile, including 
recommendations for the development of a new technol­
ogy transfer system. Currently in Chile, few commercially 
viable technologies are transferred from research institu­
tions to the private sector. This means that many univer­
sities should review their role and implement innovative 
ways of contributing to society. 
1. InTRoduCTIon 
In emerging economies, existing R&D capabilities 
tend to be highly concentrated within universi­
ties and public research institutes. In Chile, about 
85% of scientists are formally linked to universi­
ties, and the Chilean government contributes an 
estimated 80% of funds spent on R&D. 
In early 2004, the Ministry of the Economy 
entrusted Fundación Chile, a private, indepen­
dent, nonprofit research organization located in 
Santiago, with studying the technology transfer 
units at Chile’s universities.1 The ministry’s aim 
was to find ways to improve the mechanisms for 
transferring the results of R&D performed at 
Chile’s universities and research institutes to the 
private sector. In order to carry out this study, 
Fundación Chile assembled a team of six local 
specialists and three foreign experts.2 
First, Fundación Chile set out to assess the 
current state of university technology transfer 
in Chile. Interviews and surveys were conduct­
ed at seven universities that together currently 
conduct 51% of all university research proj­
ects in Chile. Surveys were also conducted at 
four technology transfer offices (TTOs) located 
within business incubators associated with these 
universities. 
Second, a workshop was held involving 
specialists from the Ministry of the Economy, 
CORFO (Corporación de Fomento de la 
Producción),3 CONICYT (Comisión Nacional de 
Investigación Científica y Tecnológica),4 and the 
team of experts assembled by Fundación Chile. 
The first day, the workshop focused on the cur­
rent condition of technology transfer at universi­
ties and research institutes in Chile (see Section 2 
in this chapter). The second day, the participants 
discussed their experiences of technology transfer 
in other countries. The participants then created 
guidelines for technology transfer from Chile’s 
universities and research institutes to its commer­
cial sector. 
The assessment of Chile’s current conditions 
and the guidelines created by the workshop par­
ticipants were used to develop a proposal for the 
creation of a new national technology transfer 
system (described in Section 3). 
Fernandez C. 2007. How to Set Up a Technology Transfer System in a Developing Country. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. C Fernandez. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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FERNANDEZ 
2.	 THE	CuRREnT	STATuS	 of 
TECHnoLoGy TRAnSfER	In CHILE	 
2.1	 The role of universities within 
the national R&D context 
Traditionally, universities have fulfilled two pri­
mary societal functions: educating students and 
conducting research. In recent years, however, 
universities have had to fulfill an additional func­
tion: promoting the commercialization of the 
results of their research. This expansion has re­
quired changes, not only in policy and allocation 
of resources, but also in academic culture itself. 
In an ideal environment, many mecha­
nisms link the academic and business worlds. 
Researchers exchange information through semi­
nars and publications, and there are informal and 
formal ties between researchers in various types 
of institutions. Additionally, academics work as 
consultants and as company board members and 
are involved in professional training, contract re­
search, and the spinout and incubation of new 
businesses. And, of course, universities educate 
the researchers of the future. 
In Chile, however, the lack of systematic 
policies for technology transfer has hindered pro­
ductive interaction between the academic and 
business worlds. This, in turn, has led to other 
challenges: 
•	 There are few incentives for academic re­
searchers to participate in technology trans­
fer and commercialization. 
•	 Academic culture does not see technology 
transfer and commercialization as “legiti­
mate” activities. 
•	 The academic and business worlds have 
different ideas about technology transfer: 
different short- and long-term visions, dif­
ferent expectations about how resources 
should be used, and different priorities 
when it comes to meeting shared targets. 
For the past 20 years, Chile’s growth has been 
sustained by industries exploiting the country’s 
rich natural resources. Technology transfer during 
this period mostly occurred by importing capital 
and by receiving foreign investment, virtually ex­
cluding the local innovation system of Chile. As 
a result, both the formation of innovative compa­
nies and the development of an entrepreneurial 
culture in Chile were inhibited. 
In Chile, around US$480 million is spent 
annually in R&D; only about one-fifth of this 
money comes from private sources. Universities 
carry out some 58% of ongoing R&D projects 
in Chile; 4,800 specialists—or three out of ev­
ery five scientists and engineers in Chile—work 
on such projects. Only 6% of those working in 
R&D do so in a private company.  
Furthermore, no more than 13% of the na­
tional budget for R&D goes toward commercial 
development activities. The rest goes to basic and 
applied research projects. In contrast, about 60% 
of the R&D expenditure in developed countries 
supports development activities, and only 40% 
goes to basic and applied research. 
In a recent study, Benavente5 suggests that 
joint activities between universities and the pri­
vate sector should receive more financing from 
government and that TTOs should to be estab­
lished in order to promote the commercial ap­
plication of university research results. 
2.2	 A survey of technology transfer 
units at universities in Chile 
The results of the surveys conducted by Fundación 
Chile of seven universities and four technology 
transfer offices are summarized in the following 
nine items: 
1. IP-protection activities in universities. The 
concept of intellectual property embodies 
the right of ownership protected by law to 
intangible (that is, intellectual) works or 
information, or representations of informa­
tion such as literary works, trademarks, lo­
gos, data, and know-how. In Chile, intellec­
tual property can be protected by patents, 
copyrights, trademarks, industrial designs, 
or rights for plant varieties. Like any other 
goods or assets, intellectual property can be 
bought, sold, or licensed. 
The surveyed universities were asked 
what specific IP protection activities (such 
as signing confidentiality agreements or ap­
plying for IP protections) they engaged in 
each year. Most of these activities involved 
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CHAPTER . 
agricultural, health, and energy technolo­
gies. The total number of such activities 
for all eleven institutions was fewer than 
100. Signing confidentiality agreements 
accounted for almost half of the activities; 
filing applications for patents accounted for 
another quarter. The remaining quarter pri­
marily involved copyright and plant-variety 
registrations. Only about four confidential­
ity agreements were signed per institution 
per year.  
2. Communications between universities and 
the private sector. At 73% of the institu­
tions surveyed reported that their technol­
ogy transfer offices (TTOs) and/or investi­
gators contacted private companies. Other 
methods of contacting companies included 
publications and the Internet (55%), fairs 
and exhibitions (36%), and technology 
brokers (27%). 
3.Procedures for evaluating potential tech­
nologies. Formal evaluations (those that 
do not rely solely on the opinions of the 
research team) are the best way for uni­
versities to determine which technologies 
should be transferred to private companies. 
However, only one of the seven universities 
surveyed claimed to have a formal proce­
dure for evaluating technologies. Three of 
the four TTOs associated with the incuba­
tors did have such a procedure. 
4.Policies regarding ownership of research 
results. It is important to clearly define who 
owns the rights to research results. Only 
three of the seven universities surveyed had 
a formal institutional policy regarding the 
ownership of research results. None of the 
TTOs associated with the incubators had 
such a policy. 
5. Policies regarding conflicts of interest.
TTOs need to have the resources to man­
age potential conflicts of interest. Only two 
of the eleven offices surveyed had a specific 
policy regarding conflicts of interest. 
6. Distribution of income generated by tech­
nology transfers. On average, the universi­
ties distributed revenues from technology 
transfers as follows: 
- 38% to the researchers 
- 15% to the research units (departments) 
- 18% to the central administration 
- 8% to the technology transfer office 
- 21% to other actors 
The offices associated with incubators dis­
tributed revenues as follows: 
- 37% to the research units and to the 
researchers
 
- 12% to the central administration
 
- 10% to its own transfer office
 
- 41% to other actors
 
7. Networks for collaboration. 	The surveys 
reveal that institutions do not collaborate 
with each other to any appreciable extent. 
For example, of the universities surveyed 
only half of them belong to networks with 
other universities, and only two of them 
are part of networks with business organi­
zations. Of the offices associated with incu­
bators, only one participates in a network 
of research centers. 
8. The influence of technology transfer on 
university researchers’ careers. Four of the 
seven universities stated that technology 
transfer has no influence on their research­
ers’ academic careers. Two of the seven 
noted that successful technology transfer 
may raise researchers’ salaries, and one of 
the seven reported that it influences pro­
motion decisions. The technology trans­
fer experience of potential candidates for 
academic jobs has no influence on hiring 
at any of the seven universities surveyed. 
Therefore, it is not surprising that 78% of 
the university investigators participating in 
Fondef projects consider this fund only as 
a source of financing for their own projects 
and Institutions.6 
9. Spinouts and startups. Over the last 19 
years, the 11 surveyed technology transfer 
units have created a total of 28 compa­
nies using the results of their institutions’ 
R&D. Of these new companies, two-thirds 
are spinouts and the rest are start-ups. 
Over 13 years, from 1991 to 2003, 
Fondef. has financed a total of 159 R&D 
projects: 
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FERNANDEZ 
- Agriculture 37 projects 
- Fisheries and Aquaculture 35 projects 
- Forestry 34 projects 
- Mining 17 projects 
- Education 13 projects 
- Other 23 projects 
A total of US$126 million was invested 
in these projects, of which only 28% was 
contributed, in money or in kind, by com­
panies or other institutions interested in 
using the technologies produced by these 
projects. 
These 159 projects led to the creation 
of 33 companies, 13 business units, and 
12 new lines of business in existing com­
panies. Two-thirds of these institutions are 
still operating today. By the end of 2002, 
these projects had generated an accumu­
lated sales total of US$8.9 million. 
These results show that technologies de­
veloped by Chilean universities lead to very 
few start-ups or spinouts. 
2. 	 The current state of university 
technology transfer in Chile 
The existence of TTOs in Chilean universities is a 
recent phenomenon. The capabilities of these offic­
es are still limited. Generally, they have small staffs. 
Many have yet to establish essential policies regard­
ing the formal disclosure and evaluation of technol­
ogies, the ownership of intellectual property, and 
conflicts of interest. Most have little experience in 
such areas as technology management, IP protec­
tion, and commercial agreement negotiation. 
Academics are not encouraged to engage in or 
initiate technology transfer to the productive sec­
tor. Moreover, very few university projects result in 
commercially viable innovations, so few technolo­
gies leave the universities, and few spinouts or start­
ups are created. Therefore, many universities see 
little reason to set up technology transfer offices.
.	 A pRopoSAL	 foR	A	 nATIonAL	
SySTEM	 of TToS 
The participants in the cross-disciplinary work­
shop proposed the creation of an institutional 
consortium, the members of which would share a 
central TTO. Each institution in the consortium 
would also have a local TTO to assist in relation­
ships between researchers and private companies, 
as well as with technology marketing. The consor­
tium would represent the interests of the member 
institutions and operate with the double aim of 
improving Chile’s technological capabilities and 
developing a national entrepreneurial culture. 
The consortium would be a private, nonprof­
it organization, governed by a board of directors 
made up of representatives from the member in­
stitutions. These offices would be established us­
ing public funds; once they are operational, they 
would support themselves with fees they earn for 
the services they provide. 
.1	 A business model for the TTO system 
The central TTO would need to have the capacity 
to manage 20 to 30 technology transfer projects 
annually. The TTO system would be involved in 
these projects from gestation to final commer­
cialization. The system would also be required 
to participate in the analysis of about a dozen 
completed Fondef and FDI projects, in order to 
identify opportunities for the commercialization 
of the technologies they have developed. 
The central TTO system would require an an­
nual budget of approximately US$650,000. The 
member institutions would make annual con­
tributions based on the volume of research that 
each has conducted. The TTO would also charge 
member institutions an ex ante fee for each proj­
ect based on its size and complexity. Furthermore, 
the TTO system would receive fees from compa­
nies that it assists, as well as from other users of 
its professional services. The institutions belong­
ing to the consortium also would be expected to 
pay annual dues for the right to participate in 
the consortium. During the system’s first three to 
five years of operation, any additional financing 
needed would come from public sources; how­
ever, this public subsidy would be granted only if 
the TTO system continued to receive positive an­
nual performance evaluations. The consortium’s 
board of directors would be responsible for secur­
ing outside financing for the TTO system. 
The TTO system’s financial manage­
ment would be based on annual accounting (an 
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CHAPTER . 
examination of the system’s total income and ex­
penses) and separate accounting (an examination of 
the income and expenses relating to each individ­
ual project). The following formula for the distri­
bution of royalties is recommended: the university 
distributes one third of net income to the inventor 
and another third to the inventor’s department or 
research unit; this formula is aligned with inter­
national practices. The remaining third typically 
goes to the university’s general fund, but may go to 
other specified funds, including the TTO system’s 
own fund. Royalties would be distributed after the 
end of each fiscal year. General expenses such as 
salaries, rent, office equipment, and general travel 
would be paid for by the TTO system’s fund. Any 
project-specific expenses (such as the legal fees in­
volved in a patent prosecution) would be paid for 
by royalties that accrue from the licensing of the 
corresponding technology. The board of directors 
would review this distribution of funds annually 
and modify it as necessary. 
.2 Central and Local TTOs 
.2.1 Contracts between central and local TTOs 
The central TTO would supervise and work to­
gether with each of the local TTOs to protect 
and market the technologies resulting from R&D 
conducted at member universities and insti­
tutes. The contracts between the central and lo­
cal TTOs would need to include the following 
information: 
•	 Policies outlining: 
- the legal supervision of the consortium 
by consortium members 
- the ownership of intellectual property 
- the distribution of income from the de­
velopment of intellectual property 
- conflict of interest resolution and what 
obligations each party has to the others 
•	 terms and conditions for the formal eval­
uation of inventions with commercial 
potential 
•	 plans for marketing and licensing the 
inventions, both domestically and 
internationally 
•	 plans for a follow-up system to track the 
success of inventions 
•	 plans to disseminate and communicate the 
results of the TTO system 
•	 plans to establish national and internation­
al strategic alliances in technology develop­
ment and commercialization 
.2.2 Function of the central and local TTOs 
The main functions of the central TTO would be 
to: 
•	 evaluate the results of R&D projects ex­
pected to have commercial potential 
•	 apply for patents and other forms of IP 
protection 
•	 market technologies 
•	 provide expertise and technical assistance 
to the local TTOs 
•	 establish national and international strate­
gic alliances in areas important for success­
ful technology transfer 
The main functions of the local TTOs would 
be to: 
•	 facilitate interactions between their in­
stitutions and industry (duties would in­
clude developing research contracts, iden­
tifying collaborative research projects, and 
consulting) 
•	 educate academic investigators about op­
portunities and techniques for marketing 
research results 
•	 stay abreast of new technologies developed 
at their institutions and identify marketing 
opportunities for these technologies 
•	 serve as a contact point between the central 
TTO and the institution 
•	 help researchers gain funding for R&D 
projects 
As the local TTO gains experience and be­
comes more effective, it may take on other func­
tions, such as offering its services to other institu­
tions (for example, local business incubators) that 
are not part of the national consortium. 
. Human resources and infrastructure 
A fully functioning TTO system would have the 
following personnel needs, some of which could 
be fulfilled by outsourcing, either for the long 
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FERNANDEZ 
term (as would be appropriate for the office’s legal 
experts) or on a short-term basis (as would be ap­
propriate for consultants hired to conduct market 
studies, for example). 
..1 Central TTO personnel 
The central TTO would need to employ skilled 
individuals to fill key roles: 
Director. The director would need proven 
leadership skills; excellent ability to create net­
works and establish alliances; business vision; ex­
perience in technology management; knowledge 
about national and local laws and regulations; 
and an understanding of the national university 
system, the national innovation system, and the 
status of local industry. In addition, the director 
would need a minimum of ten years’ experience 
in a relevant field, and good written and spoken 
English. 
Program managers. International experts 
recommend that the central TTO initially be 
staffed by program managers. This encourages 
specialization and focused searching. It also takes 
advantage of the synergies that can be generated 
via networks. Program managers would need to
have within their ranks: 
•	 a Ph.D. in biological sciences and/or bio­
technology with both laboratory experience 
and experience in product development, a 
minimum of ten years of professional ex­
perience, and good written and spoken 
English 
•	 a Ph.D. in the engineering sciences with 
broad knowledge of the product develop­
ment process, at least ten years of profes­
sional experience, and good written and 
spoken English 
Project analysts. The central TTO would 
need at least two economists and/or engineers. 
They would need to have completed at least some 
graduate studies, with a minimum of five years 
of experience in the profession, and good written 
and spoken English. 
..2 Local TTO personnel 
The local TTOs would need a staff composed of: 
•	 a director or manager 
•	 two or three professionals with graduate 
degrees, preferably Ph.D.s, with at least 
five years of professional experience in ei­
ther biological sciences/biotechnology or 
engineering 
•	 project analysts 
The volume and type of R&D being carried 
out at each university or institute would determine 
the size of the office and the discipline(s) in which 
its staff members would need to specialize. 
.. Office support staff and infrastructure 
The central and local TTOs would need an ad­
ministrative and support staff. At minimum, each 
office would need a computer for each profes­
sional, a printer, local and international commu­
nications networks, filing space for documents, 
and the space and equipment to make formal 
presentations. 
. Policies 
The TTO consortium would design collectively 
the key policies regarding the technology transfer 
process, and these policies would form an integral 
part of the consortium’s charter or proposal. They 
should clearly establish the terms of IP owner­
ship, the distribution of income, and the resolv­
ing of conflicts of interest: 
Ownership of IP rights. The universities or 
institutes participating in the technology transfer 
consortium would need to have uniform guide­
lines for assigning IP ownership. Uniform practic­
es help to reduce transaction costs, increase trans­
parency, and facilitate utilization of intellectual 
property protected by third parties. Government 
agencies could encourage members to agree on 
common guidelines through “codes of practice” 
or by making adherence to certain guidelines a re­
quirement for receiving funds from the state.
Distribution of income. Fair distribution of 
income generated from technology commercial­
ization is common practice around the world, 
and it is a powerful incentive for the various play­
ers in the technology transfer process. There are 
many options for how to distribute such income, 
and the options taken would have to depend on 
institutional and national context. 
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Resolving conflicts of interest. The consor­
tium members would need to include clear policies 
and procedures for resolving potential conflicts of 
interest in the initial proposal for the creation of 
the technology transfer system. 
. Early phase 
Planners/developers of the TTO consortium 
would need to consider a few issues early on in 
the creation of the national system: 
•	 Skills at different levels would need to be 
developed. 
•	 The concept of the national TTO system 
would need public support so that the cen­
tral TTO could assume a leading role by 
establishing its own trademark. 
•	 Initially, the TTOs could help address their 
institutions’ weakness through training 
and educational efforts that would provide 
them with the necessary skills. 
. ConCLuSIon 
A foundation of innovative technology compa­
nies and the development of an entrepreneurial 
culture will drive the development of new indus­
try and enhance the global competitiveness of 
Chile’s economy. The author believes these goals 
can be best achieved through a TTO system such 
as the one proposed in this chapter. Such a system 
could provide a full range of technology transfer 
functions for the main universities and research 
institutes in Chile in the most economically ef­
ficient manner. n 
caRlos feRnandeZ, Director, Strategic Studies, Foundation 
for Agriculture Innovation (FIA), Loreley 1582, La Reina, 
Santiago, Chile, carlos.fernandez@fia.gob.cl 
1	 Fundación Chile. 2004. Design of a Model for Technol-
ogy Transfer Applicable to Chile. The Ministry of Econo-
my sponsored this study.
2	 The selection of foreign experts began with a request
to the Association of University Technology Managers 
(AUTM) of which Fundación Chile is a member. AUTM 
is the leading professional association in technology 
transfer, with about 3,200 members worldwide. The 
foreign experts who were chosen have been actively 
involved in the design and implementation of different
transfer offices—in their home countries and abroad:
Alan Bennett, Executive Director of the University of 
California system’s Office of Technology Transfer; Niels 
Reimers, an international consultant and formerly the 
Director of Stanford University’s Office of Technology 
Licensing; and Pedro Palominos, Director of Spain’s 
Consultoría Tecnológica de Instituto Robotiker. The 
local team consisted of Eduardo Bitrán, Director 
General of Fundación Chile; Sergio Burdiles, Project
Head in Information Technologies at Fundación Chile;
Joaquín Cordua, Manager of Fundación Chile’s Human 
Capital and Information Technologies Area; Carlos 
Fernández, Head of Regulations for Fundación Chile’s 
Agribusiness Area; Michael Moynihan, Director of 
Research for Biogenetic S.A.; and Gabriela Paiva, from 
the law firm Paiva Associates. 
3	 CORFO is a government organization that promotes 
the productivity and competitiveness of the Chilean 
economy. www.corfo.cl/.
4	 CONICYT is a government organization that promotes 
science and technology development. www.conicyt.cl/.
5	 www.expansiva.cl.
6	 Santibáñez E. 2003. Intellectual Property, University and 
Business. Presentation at the WIPO-ECLAC Regional 
Expert Meeting on the National System of Innovation:
Intellectual Property, Universities and Enterprises.
Santiago: Chile. 
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CHAPTER 6.5 
Practical Considerations for the Establishment

of a Technology Transfer Office
 
John dodds, Founder, Dodds & Associates, U.S.A.
 
susanne soMeRsalo, IP Specialist and Patent Agent, Dodds & Associates, U.S.A.
 
ABSTRACT 
The establishment of a technology transfer office (TTO) is 
a complex undertaking, so it is important to decide—be­
fore the office is established—about its operational scope, 
how the office will be funded, how it will be managed, 
and for what kind of issues the office should develop a 
policy. This chapter provides basic information that is 
indispensable for running effective TTOs. The chapter 
explains what physical and human infrastructures are 
needed, outlines the responsibilities and powers of TTOs, 
emphasizes the importance of technology evaluation, and 
stresses the centrality of good communication and nego­
tiation skills. 
1.	 InTRoduCTIon 
The last decade has seen tremendous growth in 
the use of IP (intellectual property) protection 
in business ventures, particularly those concern­
ing biotechnology. As a result, more and more 
institutions are establishing technology transfer 
offices (TTOs) to assist in the legal transfer of 
technology. These offices serve a variety of func­
tions, such as evaluating research results in regard 
to potential commercialization, advising on IP 
protection, filing and prosecuting patent applica­
tions, assisting in funding issues, conducting fea­
sibility studies, and so on. 
Starting a TTO is a complex and costly en­
deavor. The project must receive the support of 
administrators and scientists, and it must get off 
to a dynamic, effective start and focus on those 
who will use it. First impressions count. 
It is important to define the TTO’s scope of 
operations—as well as how it will be funded and 
managed—from the outset. Because several years 
can pass before any revenues or royalties would be 
collected from IP transfers, the office has to op­
erate with the highest possible efficiency. Success 
or failure will depend mostly on the human re­
sources and physical infrastructure available to 
the office. 
2.	 pHySICAL	InfRASTRuCTuRE 
The location of the TTO is critical. An office that 
is located close to the scientists’ workplace is most 
efficient and the proximity will help to establish 
cooperation and trust between the scientist/re­
searchers and the TTO staff. Most TTOs start 
in either a research office or an administration 
building. 
Elements of physical infrastructure that 
might be required include but are not limited to: 
•	 office space (presumably either leased or 
rented). In cases of universities, locating 
the office on campus may make it easier 
for scientists to contact the TTO; on the 
other hand, an off-campus location might 
better serve potential licensees. Such fac­
tors as the need for confidentiality, meet­
ing rooms, and so on, should be take into 
consideration. 
Dodds J and S Somersalo. 2007. Practical Considerations for the Establishment of a Technology Transfer Office. In Intel-
lectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT 
Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. J Dodds and S Somersalo. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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DODDS & SOMERSAlO 
•	 office furniture, including desks, chairs, fil­
ing cabinets, conference tables, decoration, 
carpets, and so on. If budgets are very tight, 
acquiring salvaged or second-hand furni­
ture can save money. 
•	 computer systems, including PCs, printers, 
cameras, speakers, and so on. A high-speed 
modem or DSL line is critical. 
•	 phone equipment able to handle confer­
ence calls, call transfers, and voice mail. 
•	 a photocopier. If budgets are tight, se­
lecting a small copier or a second-hand 
machine can save money. Remember that 
photocopiers are notorious for frequent 
and inconvenient breakdowns. 
•	 general office supplies, including pencils, 
pens, paper and staples. Keep a good office-
supplies catalog handy. Every office needs 
a good coffee and tea service; guests appre­
ciate this simple, yet thoughtful, form of 
hospitality. 
•	 a library of limited scope. It is useful to 
have a few key handbooks, such as Black’s 
Law Dictionary1 and McCarthy’s Desk 
Encyclopedia of IP. 2 CD-based IP manuals 
can be handy references as well as being 
easy to use and to store; a computer could 
be dedicated for utilizing this resource. 
•	 online legal databases, both paid-service 
(such as LexisNexis®3 and WestLaw®4) and 
others that are free of charge.5 
•	 various software packages. A standard of­
fice package should be adequate, at least at 
first. It must contain anti-virus, firewall pro­
tection, and disk-maintenance software. 
.	 HuMAn 	InfRASTRuCTuRE	 
And TALEnTS 
Human infrastructure is even more important 
than physical infrastructure. A TTO needs to have 
employees with expertise in intellectual property, 
business, law, contracting, and negotiation. People 
will be needed to fill the following positions to op­
erate a typical TTO: 
•	 office director (usually a scientist with ex­
tensive business experience rather than a 
lawyer) 
•	 administrative assistant 
•	 licensing specialist 
•	 attorney (either in-house or contracted 
from outside) 
•	 students (often local law students) 
A TTO’s daily operations touch on a num­
ber of different fields. An office should therefore 
have access to external specialists for advice: an 
advisory panel, hired consultants, or colleagues. 
The types of specialists that are needed usually in­
clude, but are not limited to: 
•	 patent attorneys or patent agents (depend­
ing on the field of invention) 
•	 general legal counsel 
•	 licensing specialists 
•	 marketing specialists 
•	 database specialists 
•	 drawing and design specialists 
One of the most important skills relates to 
communication and negotiation. An office direc­
tor should possess these communication and ne­
gotiation skills: 
•	 good interpersonal skills (especially impor­
tant when interacting with inventors) 
•	 good interaction skills for dealing with en­
trepreneurs in the private sector, the public 
sector, and small and large businesses 
•	 good spoken and written language skills 
•	 formal experience in negotiation 
.	 THE	SCopE	 of THE	 offICE 
With the goal of providing comprehensive IP ser­
vices as effectively as possible, the responsibilities 
and powers of the TTO should be established at 
the outset. 
.1 Patenting and other protections 
Patenting work may involve searching, freedom to 
operate, filing, maintenance, and so on. If patent­
ing is a key duty of your office, it may be worth­
while to consider hiring a patent agent. Either 
way, it is essential to have a clear understanding 
of the various protection options including: 
•	 utility or design patents 
•	 filing a national patent application 
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CHAPTER . 
•	 filing in foreign countries 
•	 filing provisional patent applications to 
get initial protection and later filing non-
provisional, national or even international 
applications under the Patent Cooperation 
Treaty (PCT). 
Offices may need to consider the options 
case by case with each invention or the office 
may have a default process for most invention 
disclosures. Some offices, for example, file a rela­
tively cheap provisional patent application in 
the United States, in each case, and then market 
the technology for the year that the provisional 
patent is valid, before spending more money on 
patent prosecution. If it seems that there are in­
terested licensees, you may then file national or 
international applications. This is, of course, only 
one strategy among many. 
The TTO should also consider the role of 
trademarks and service marks in its operation. 
Product branding is a very important element 
of global marketing, but trademark protection is 
often underused. It may be wise even to protect 
the mark of the TTO itself. Copyrights are a very 
simple and cheap form of protection for books, 
papers, and databases; the latter is becoming 
common in genomics as a cost-effective form of 
IP coverage. Trade secrets are the cheapest form of 
coverage: they are free! Of course, relying on only 
trade secret protections, a TTO runs the risk that 
someone will reverse-engineer and IP-protect the 
invention so the TTO cannot use it! 
.2 Policy development 
It is important to have an internal office policy 
that addresses the following questions: 
•	 How will licensing revenues be shared? 
•	 Can the office accept equity in a company 
as part of licensing-related transactions? 
•	 Should the office represent competing 
technologies? 
A TTO must develop a system for identifying 
and dealing with possible conflicts of interest and 
questions of ethics. For example, it will need to 
anticipate such questions as should a staff mem­
ber be allowed to license an invention to a com­
pany for whom he or she works as a consultant? 
TTOs should consider assembling an ethics and 
conflicts panel to regularly review office actions. 
A policy development document should 
guide the institution in developing its own IP 
policies. 
. Licensing 
Licensing is the heart, the essence, indeed the 
very bread and butter of a TTO. Remember that 
the flow of information and materials is two-way: 
some staff will access the IP of others through li­
cense agreements, and the TTO will be licensing 
its technologies through license agreements. 
. Invention marketing 
Great technologies do not sell themselves. TTOs 
need good marketers and should pay them on a 
contingency basis. Do not underestimate the role 
of the inventors in identifying potential licensees. 
. Negotiations support 
Negotiation is an art form that takes skill, prac­
tice, patience, and sharp wits. TTO personnel 
should consider taking courses to improve their 
negotiating skills. Alternatively, the TTO can 
hire negotiating experts. Whatever is done, TTOs 
should watch out for legal loopholes. 
. Technology evaluation and assessment 
One of the challenges facing any TTO, especially 
at the beginning, is deciding which inventions to 
protect, and to what extent. No office has the re­
sources to patent all inventions, especially if they 
are not likely to generate revenue for some time. 
As a rule of thumb, ten invention disclosures may 
lead to one patent, and one license might come 
from ten patents. In other words, only 10% of 
patents provide royalties. It is critical, therefore, 
that the TTO invest in only those inventions 
that are both truly innovative and appear to have 
commercial value. Remember that some great 
scientific advances cannot be marketed. At the 
same time, some simple inventions have huge 
commercial value. 
TTOs usually have an internal committee 
that reviews invention disclosures for commer­
cial viability and gives feedback to inventors. If 
the TTO manager needs to tell a scientist that 
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DODDS & SOMERSAlO 
his or her invention will not be patented, good 
communication skills are critical. Obviously, the 
manager does not want to discourage an inventor 
from coming forward again in the future with an­
other idea that may be commercially viable. 
As a result, TTO staff should be prepared 
to spend time, effort, and money when deciding 
what to protect. The decisions should be influ­
enced by a product’s market potential—not by 
the excellence of the science behind it nor the de­
sires of the inventor. Remember, the goal is not 
simply to patent inventions but to strategically 
patent inventions with commercial potential. 
The TTO director must make sure he or 
she is fully aware of the TTOs legal rights before 
starting the negotiating process. It would be un­
fortunate to invest in a technology and later find 
out it cannot be licensed. 
.	 Monitoring royalty incomes and potential 
licensing infringements 
Once a technology has been licensed, the TTO 
has to make sure that the licensee pays the royalties 
it has agreed to. The licensing agreement should 
give the licensor (the TTO) the right to audit the 
licensee, and this right should be exercised.6 
The office must also monitor potential licens­
ing infringements. This is not an easy task: the office 
may have to monitor companies that are using com­
peting technologies, as well as minor distributors 
who might sell patented products out of ignorance. 
. 	 A note on confidentiality 
The nature of the IP business means that all em­
ployees of a TTO must observe strict confidenti­
ality and always adhere to office policy on such 
matters as conflict of interest. These consider­
ations should be taken into account during the 
hiring process, and the office’s operations should 
always be fully documented. 
. ExpEnSES 
The costs of evaluating, protecting, and maintain­
ing IP coverage are substantial and might include 
the following: 
• patent and trademark search fees 
• patent and trademark filing fees 
• PVP fees 
• maintenance fees 
• copyright filing fees 
• issue fees 
• attorneys’ fees 
• drafting fees 
In the United States, the cost of a trade­
mark (including attorneys’ fees) is approximately 
US$1,200–2,000. A provisional patent applica­
tion costs US$2,500–8,000, and a nonprovi­
sional application costs US$6,000–30,000. The 
cost of filing and maintaining a patent globally 
is approximately US$500,000. The TTO direc­
tor must keep in mind that the filing of an inter­
national patent will make it necessary to use the 
services of a translator and that translation fees 
add up fast. 
. kEEpInG	 up To dATE 
It is important for the TTO to keep a close eye 
on developments in technology and markets. In 
order to stay informed, TTO employees should 
be active members of professional associations, 
such as the Association of University Technology 
Managers (AUTM) and the Biotechnology 
Industry Organization (BIO). 
Another aspect of keeping up to date relates 
to obligations with contracts and agreements. 
Producing and reviewing contracts and agreements 
is a large part of the work of the TTO manager. 
Therefore, it is important to establish a portfolio 
of standard contract and agreement templates that 
can be customized as needed. 
It is often tempting to cut costs by using 
standardized forms and agreements. However, it 
is important to note that such standardized docu­
ments are rarely drafted in favor of the person ini­
tiating the deal. If standard forms and agreements 
are used, a lawyer should review the final versions 
and point out any specific clauses that need to be 
further negotiated. 
. offICE	 oRGAnIzATIon 
A number of organizational matters need to be 
addressed in the early stages of the establishment 
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of the TTO. These include creating a staffing plan 
and an employment handbook, incorporating (if 
necessary), and establishing procedures for han­
dling federal and state filing requirements, taxes, 
and payroll. 
•	 staffing plan. A coordinated and coherent 
staffing plan should provide details of lines 
of authority, job descriptions, and work 
plans for each day. Early planning will pre­
vent future headaches. 
•	 employment handbook. The staff employ­
ment handbook must state the company’s 
policies regarding confidentiality, eth­
ics, and conflicts of interest, among other 
topics. 
•	 procedures for federal and state filing re­
quirements. The local representative of the 
Secretary of State may be able to provide as­
sistance with filing such documents as work 
permits, pension plans, occupancy permits, 
fire inspection permits, and so on. 
•	 plan for incorporation. The office may wish 
to (or need to) become an independent le­
gal entity. In the United States, such inde­
pendent offices (often called research cor­
porations) have charitable, or “501(c)(3),” 
tax status. 
•	 tax strategy. It is money well spent for a 
TTO to hire a good accountant and a good 
audit firm. 
•	 payroll plan. The TTO director must re­
main aware of federal and state tax policies. 
It is wise to hire a good accountant and a 
good audit firm to oversee such matters. 
CHAPTER . 
12. ConCLuSIonS 
A TTO serves many masters and has a range of 
different functions. An effective and efficient of­
fice needs employees with good business, legal, 
technical, and contracting skills. And it is impor­
tant to establish the office’s scope and to develop a 
comprehensive office policy as soon as possible. 
This chapter provides only a basic template 
for a TTO. Naturally, each office will have unique 
needs that will need to be addressed—creativity 
and a good team spirit will make it much easier 
to do so. n 
John dodds, Founder, Dodds & Associates, 1707 N Street 
NW, Washington, D.C., 20036, U.S.A. j.dodds@dodds
associates.com 
susanne soMeRsalo, IP Specialist and Patent Agent, 
Dodds & Associates, 1707 N Street NW, Washington, D.C., 
20036, U.S.A. s.somersalo@doddsassociates.com 
1 Gardner BA, ed. 1999. Black’s Law Dictionary. West
Group, St. Paul, MN. 
2 McCarthy JT, RE Schechter and DJ Franklyn. 2004.
McCarthy’s Desk Encyclopedia of Intellectual Property,




5 See also, in this Handbook, chapter 14.3 by H Thangaraj,
RH Potter and A Krattiger. 
6 See also in this Handbook, chapter 15.1 by HH Feindt. 
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CHAPTER 6.6 
Administration of a Large Technology Transfer Office
 
sally hines, Administrative Services Manager, Office of Technology Licensing, Stanford University, U.S.A. 
ABSTRACT 
This chapter describes the organizational management of 
a technology transfer and licensing office based on the 
experience of Stanford University’s Office of Technology 
Licensing (OTL). It consists of a director, seven licensing 
associates, eight licensing liaisons, one copyright licensing 
specialist, and an administration staff. The administrative 
staff comprises an assistant to the director, an administra­
tive services manager, a manager of information systems, 
receptionist(s), a manager of compliance and assistant, 
and an accountant and assistant. The industrial contracts 
office is part of OTL and consists of a manager and three 
associates. 
1. BACkGRound 
The mission of the Stanford University Office of 
Technology Licensing (OTL) is to promote the 
transfer of Stanford University’s technology for 
society’s use and benefit, while generating unre­
stricted income to support research and educa­
tion. Thus, the primary focus of OTL has not 
been to maximize income generation, but to fa­
cilitate putting into use for society’s benefit the 
innovations developed at Stanford University. 
In the early years, staffing levels were kept 
very low to control total expenses. There were 
only two people on staff for the first five years 
of operation. A third person was added in FY 
1974–75 and total staffing was three people for 
the next six years. Today, the OTL has the follow­
ing employee composition:1 
• director (1) 
• assistant to the director (1) 
• licensing associate I (0) 
• licensing associate II (1) 
• licensing associate III (6) 
• marketing, software and copyright specialist (1) 
• licensing liaison I (0) 
• licensing liaison II (8) 
• administrative services manager (1) 
• administrative support personnel (7) 
The benefits to Stanford resulting from the 
formation and operation of the OTL have been 
many. Although it took many years for substan­
tial net revenues to be obtained, at the end of FY 
2005–06, the OTL had received total revenues 
of US$1 billion and had total operating expenses 
of US$45 million. In its 36 years of operation, 
the OTL has contributed US$591 million to 
Stanford and its inventors 
2. pERSonnEL	ISSuES 
Reporting to the director are the licensing associ­
ates, administrative services manager, marketing, 
Hines S. 2007. Administration of a Large Technology Transfer Office. In Intellectual Property Management in Health and 
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Second Edition, Part II: Chapter 3). 
© 2007. S Hines. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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HINES 
software and copyright specialist, manager of 
compliance, accountant, manager of the industrial 
contracts office, and the director’s assistant. Each 
of the licensing liaisons supports one licensing as­
sociate; the liaisons report directly to the associ­
ates. The manager of information systems reports 
to a senior licensing associate. The receptionists 
report to the administrative services manager. 
Professional staff are divided into licensing 
liaison and licensing associate positions (Table 
1), whereas Figure 1 shows the organigramm. 
Complete job descriptions are provided in Box 1, 
at the end of this chapter. 
2.1 Licensing associates 
Each licensing associate has a specific area of ex­
pertise (see OTL Web site2). Many of the Stanford 
licensing associates have been recommended to 
OTL by other universities or individuals in the 
field. There are no lawyers in the licensing associ­
ate category. 
•	 The technology licensing associate I handles 
routine cases (with supervision) and par­
ticipates in the negotiation and preparation 
of more complex cases. Some experience in 
at least one of the following is necessary: li­
censing, negotiation/contracts, marketing, 
or patents. 
•	 The technology licensing associate II handles 
a variety of complex cases and requires a 
high degree of technical and business ex­
pertise, a familiarity with the legal issues in­
volved, and at least four years of applicable 
experience. 
Table 1: Main Professional licensing Positions
 
Position Job Description (corresponding appendix) 
Licensing liaison I	 Direction from supervisor, assist with marketing, routine 
amendments, patent prosecution, database management;
position is 75% clerical 
Licensing liaison II	 With some supervision, market new inventions, including 
carrying out market research and preparing abstracts; docket
administration; coordinate and monitor patent activities;
inventor meeting scheduling; handle administrative/clerical 
responsibilities in support of licensing associate 
Licensing associate I Evaluate and handle licensing with respect to standard and 
nonstandard cases with some guidance 
Licensing associate II	 Evaluate and handle licensing with respect to nonstandard 
cases with independence; take appropriate, independent
action in a majority of situations 
Licensing associate III Evaluate and handle independently the licensing of complex 
cases; appropriately handle a variety of IP 
Note: Standard cases involve nonexclusive licenses and template-type agreements. Nonstandard cases 
require creativity in resolving issues. Complex cases require unusual creativity in resolving new issues. 
See also Box 1 at the end of this chapter for job descriptions. 
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•	 The technology licensing associate III is re­
served for individuals handling major cases 
where licensing potential is estimated to 
be in the millions of dollars. Because of 
the magnitude of the cases, the work has 
a significant impact on the university and 
involves much coordination and complex 
decision making. Eleven or more years of 
applicable experience and/or two years of 
experience at the OTL are required. After 
an individual has been with the office for 
five years (and has reached the associate III 
level), he/she has the privilege of using the 
title senior associate. 
2. 2 Licensing liaisons 
Stanford OTL has two levels of licensing liai­
sons. The licensing liaison I level requires more 
direction from the licensing associate than the 
licensing liaison II level. There are many ways 
to find good people. Probably the best ways are 
referrals, ads on various Web sites, and through 
licensing organizations such as the Association 
of University Technology Managers and the 
Licensing Executives Society. 
.  ConCLuSIonS	And 
THE	 nEEd foR	 SopS 
Running and administering a technology trans­
fer and licensing office is a challenging task from 
many perspectives, ranging from policy to strat­
egy. As Nelsen3 describes them, one of the key 
aspects are rigorous, consistent, and authoritative 
administrative approaches and procedures. This 
chapter described the approach of one entity, 
Stanford University’s OTL. 
CHAPTER . 
It is important to keep yearly statistics about 
the office and collect them in a database for 
analyzing the progress of the office and for use by 
other entities. Such data for Stanford University’s 
OTL are published annually and are available on 
the OTL Web site.4 
Finally, in order to ensure smooth operations, 
each member of the staff of the office is trained 
in and has access to the Standard Operating 
Procedures (SOP’s) through the OTL Intranet. 
These SOP’s consist of step-by-step instructions 
about procedures for handling various docu­
ments. Two sample SOPs are included in Box 2. 
It is important to note, however, that the SOPs 
are evolving, and each tech transfer office should 
develop its own operating procedures, adjusted to 
institutional policies and the prevailing adminis­
trative procedures. n 
sally hines, Administrative Services Manager, Stanford 
University, Office of Technology Licensing, 1705 El Camino 
Real, Palo Alto, CA, 94306 U.S.A. sally.hines@stanford.edu 
1	 The information provided here is current as of the pub-
lication date. As with any technology transfer office,
structure, job descriptions and responsibilities, and the 
number of persons employed change over time. 
2	 otl.stanford.edu.
3	 See, also in this Handbook, chapter 6.1 by L Nelsen,
which provides relevant information for heads of 
research institutes and research hospitals, whether 
private or government supported.
4	 otl.stanford.edu/about/resources.html. 
5	 Note that SOPs are rarely shared with third parties 
because they are highly specific for the particular 
institution and environment in which an office 
operates.
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CHAPTER . 
Box 1: OTl licensing Job Descriptions 
Technology licensing associate I 
The Licensing Associate works with the inventors (Stanford professors, graduate students,
and research staff) and with prospective licensees. The Licensing Associate evaluates, obtains 
proprietary protection, markets, and negotiates the terms and conditions of the licensing 
agreement with industry. 
The Licensing Associate I typically performs the following functions: 
•	 Evaluation and analysis of new invention disclosures (initial review; meeting with inventor(s);
identify industry reviewers; make contact, send materials, follow-up; collect and evaluate 
information; and make decisions and provide necessary notifications) 
•	 Licensing (Develop licensing strategy; identify potential licensees; negotiate terms; prepare 
draft agreements; and close the deal) 
•	 Patent-related activities (selection of attorney;make decisions regarding when and where to file 
patent applications; and manage inventory of unlicensed cases from a financial perspective) 
•	 License Agreement Monitoring/Relations with Licensees (ensure compliance with diligence 
terms; prepare and execute amendments; process terminations; and hold meetings with 
licensees to monitor progress in Licensed Product(s) development) 
•	 Professional Development (participate in professional associations; attend association 
conferences; and take training classes) 
The Licensing Associate I level handles (with supervision) standard and nonstandard cases,
where agreements tend to be modifications of established patterns. The Licensing Associate also 
participates in the negotiation and preparation of more complex cases. 
Some experience is necessary in at least one of the following: licensing, negotiation/contracts,
marketing,and patents. Approximately four years of work experience is preferable. A minimum of a 
BS/BA degree in a science or engineering field—or equivalent applicable experience—is required. 
Technology licensing associate II 
The Licensing Associate works with the inventors (Stanford professors, graduate students,
and research staff) and with prospective licensees. The Licensing Associate evaluates, obtains 
proprietary protection, markets and negotiates the terms and conditions of the licensing 
agreement with industry. 
The Licensing Associate II typically performs the following functions: 
•	 Evaluation and analysis of new invention disclosures (initial review; meeting with inventor(s);
identify industry reviewers; make contact, send materials, follow-up; collect and evaluate 
information; and make decisions and provide necessary notifications). 
•	 Licensing (develop licensing strategy, identify potential licensees, negotiate terms, prepare 
draft agreements, and close the deal. 
(Continued on Next Page) 
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Box 1 (continued) 
•	 Patent related activities (selection of attorney;make decisions regarding when and where to file 
patent applications; and manage inventory of unlicensed cases from a financial perspective) 
•	 License Agreement Monitoring/Relations with Licensees (ensure compliance with diligence 
terms; prepare and execute amendments; process terminations; and hold meetings with 
licensees to monitor progress in Licensed Product(s) development) 
•	 Professional Development (participate in professional associations; attend association 
conferences; and take training classes) 
The Licensing Associate II independently handles a variety of nonstandard cases and would be 
considered an experienced professional. These positions require a high degree of technical and 
business expertise, a familiarity with the legal issues involved, and approximately four years of 
applicable experience (for example,scientific,research,marketing,business development,patents,
and licensing). A minimum of a BS/BA degree in a science or engineering field is required. 
The Licensing Associate II is a position in which qualified professionals may enhance their career 
experience and move up the OTL career development ladder to a Licensing Associate III. The 
Licensing Associate II must be able to participate as a member of the OTL team, while continually 
assuming increased responsibility and independence. 
Technology licensing associate III 
The Licensing Associate works with the inventors (Stanford professors, graduate students,
and research staff) and with prospective licensees. The Licensing Associate evaluates, obtains 
proprietary protection, markets and, negotiates the terms and conditions of the licensing 
agreement with industry. 
The Licensing Associate III typically performs the following functions: 
•	 Evaluation and analysis of new invention disclosures (initial review; meeting with inventor(s);
identify industry reviewers; make contact, send materials, follow-up; collect and evaluate 
information; and make decisions and provide necessary notifications) 
•	 Licensing (Develop licensing strategy; identify potential licensees; negotiate terms; prepare 
draft agreements; and close the deal) 
•	 Patent-related activities (selection of attorney;make decisions regarding when and where to file 
patent applications; and manage inventory of unlicensed cases from a financial perspective) 
•	 License Agreement Monitoring/Relations with Licensees (ensure compliance with diligence 
terms; prepare and execute amendments; process terminations; and hold meetings with 
licensees to monitor progress in Licensed Product(s) development) 
•	 Professional Development (participate in professional associations; attend association 
conferences; and take training classes) 
The Licensing Associate III level would be reserved for individuals handling major cases (for 
example, Cohen/Boyer or FM Sound) where licensing potential is estimated to be in the millions 
(Continued on Next Page) 
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Box 1 (continued) 
of dollars. Because of the magnitude of these cases, the work has significant impact on the 
University and involves much coordination and complex decision making (for example, participating 
in decisions on whether to pursue major litigation). 
In order to qualify for the level of Licensing Associate III, an individual is required to have 11 or 
more years of applicable experience and/or two years of experience at the Office of Technology 
Licensing. 
A Complex Case has one or more of the following attributes: 
•	 Requires exceptional good judgment and special attention because of the following: exceptional 
number of patent applications/patents involved; the level of royalty revenue (potential or actual);
and/or the number of licensees involved 
•	 Involved in litigation in which Stanford is either responsible or intimately involved and where 
Stanford’s involvement presents a significant liability or revenue opportunity for Stanford 
•	 New and complex intellectual property issues are involved in the licensing such that creative 
solutions must be developed 
•	 The case has either the potential to generate $3–5 million or costs $1 million (in litigation costs or 
claims against Stanford) or has a major impact to OTL’s licensing program 
Examples of complex cases include: 
•	 Sondius Program:the technology consists of a portfolio of patents,trademarks,copyrighted works;
licensees include a start-up, major corporation, and other companies, and the licensed fields 
of use are varied; the revenue potential is considered significant; Stanford invested significant
resources into the development of the technology; the potential of litigation is relatively high. 
•	 ARIM Portfolio: involves 20 patents and copyrighted technologies licensed exclusively and 
nonexclusively to many companies; licensing strategy is to make the technology broadly available 
while encouraging investment in the technology. 
•	 Phycobiliprotein: Complicated license strategy (exclusive license to two companies, converting 
one of these two licenses to a nonexclusive); sued one licensee; generating over $3 million/year 
in royalties with the extensive management and monitoring of the licensees because the chain 
of distribution is often unclear; auditing; each license is separately and individually negotiated. 
The Licensing Associate must have demonstrated exceptional good judgment, breadth of knowledge 
of patents, copyrights, and trademarks, and the ability to independently resolve complex issues and 
deal with unusually difficult situations. The Associate must use exceptional creativity in structuring 
win-win licenses in difficult and complex cases.Typically, complex cases present issues that have not
been dealt with in the past and, therefore, require particularly creative solutions. 
(Continued on Next Page) 
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HINES 
Box 1 (continued) 
licensing liaison I 
With close supervision from Licensing Associate: 
•	 Assist in the marketing of inventions to industry, including identifying potential licensees,
initiating contact, preparing and distributing promotional materials 
•	 Research library and computer database resources to identify potential licensees in the 
invention field of use 
•	 Help monitor performance of licensees to ensure diligence provisions are met 
•	 Prepare routine amendments to agreements, give notice and process termination of 
agreements when required 
•	 Assist in the coordination and monitoring of patent filing and prosecution 
•	 Prepare financial and status reports and complete other tasks in the analysis and marketing of 
inventions as assigned and designated by Licensing Associate 
•	 Keep highly organized and indexed files (both paper and computer database) to track 
evaluation, patenting, marketing, and maintenance functions for inventions 
•	 Extensive database management including entry of information on new inventions, keeping 
people, company records, and patent information up to date, and entry of license agreement
data 




Assist with general office-support tasks as needed for the efficient operation of the office. It





College level training highly desirable, preferably in science or engineering. Demonstrated strong 

oral and written communication skills. Ability to take initiative, to prioritize workload, and to 

work independently. Exceptional organizational and analytical skills. Attention to detail. Interest/

experience desirable in technical marketing. Ability to use PCs, familiarity with databases 

(preferably 4th Dimension) and software programs Microsoft Word and Microsoft Excel.
 
licensing liaison II 
With some supervision from Associate, Licensing Liaison is responsible for marketing and 
invention management assistance. The Licensing Liaison will work with the Licensing Associate 
(with some supervision and good judgment on the part of the Licensing Liaison): 
•	 Marketing, including identifying potential licensees through market research, initiating 
contact, preparing and distributing promotional materials 
(Continued on Next Page) 
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CHAPTER . 
Box 1 (continued) 
•	 Market research using library and computer database resources 
•	 Preparation of invention abstracts for database 
•	 License Agreement monitoring ensuring compliance with diligence provisions and financial 
terms of the agreement 
•	 Patent-related activities including coordinating and monitoring patent filings and prosecution.
Coordination of inventor signatures on documents and licensee input 
•	 Responsible for all sponsor compliance ensuring that all regulations and obligations are 
fulfilled 
•	 Prepare financial and status reports and complete other tasks in the analysis and marketing 
of inventions as assigned and designated by Licensing Associate 
•	 Preparation and execution of royalty sharing and nondisclosure agreements 
•	 Processing of dropped cases and follow through 
•	 Secondary administrative support and database entry for Associate 
•	 Keep highly organized and indexed files (both paper and computer database) to track 
evaluation, patenting, marketing, and maintenance functions for inventions. 
•	 Schedule inventor meetings 
•	 Assist with general support tasks, including reception, as needed for the efficient operation of 
the office.This position will have administrative/clerical responsibilities in support of licensing 
associate 
Qualifications: 
No licensing experience is required, but at least three years of experience as a paralegal or 
other relevant experience is preferred. BS/BA strongly preferred. Experience with intellectual 
property preferred. Ability to take initiative, to prioritize workload, follow-up consistently, and 
work independently. Good communication skills (oral and written) important. Exceptional 
organizational skills and attention to detail required. Experience with databases, word processing,
and spreadsheet software required. 
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Box 2: Standard Operating procedures5 
list of SOPs 
Invention 	disclosures 
Conceptual Disclosures 
Preliminary Disclosure Information Entered into Database 
Disclosure Notification of Government and Other Sponsors 




Enter RSA Data into Database 
Compliance—Government and 	other Sponsors 
Government Sponsors 
Disclosure Notification of Government Sponsors 
Transmit Compliance Information to the Government
Copy Distribution 
Corporate and Other Sponsors 
Disclosure Notification of Corporate and Other Sponsors 











Develop List of Companies 
Marketing Letter—Have Inventors Review/Comment
Confidential 	disclosure Agreements (CdA)
Send Two Original CDAs to Potential Licensee(s) for Signature 
File Stanford’s Original Agreement
License Agreements
Negotiate the Terms of the Agreement with Potential Licensee(s) 
Agreement Signature Procedure 
Enter License and License Terms into Database 
Copy Distribution 




Receiving Stock Certificates from Company 
(Continued on Next Page) 


















    
	 	 	 	 	 	 	 	  
  
 
      
   
 
 





Box 2 (continued) 
Tabled 	dockets
Assess whether Invention Belongs in “The Pound”

Steps for Sending Invention to “The Pound”

Consider Re-Marketing While in “The Pound”

To Remove from “The Pound”
 
Terminated Agreements
Letter to Terminate Received/Issued 
Update “Terminated” Safe Documents 
Termination-Letter Distribution 
dropped 	dockets 
Decision to Drop a Docket
off-Site Storage
Files to Be Archived for First Time 
Files to Be Re-filed at Off-Site Storage 




Sample SOPs for license Agreements4 
negotiate the terms of the agreement with potential licensee .................................Associate
 
A Royalty-Sharing Agreement should be completed when a patent is filed or when a license 
negotiation is initiated.
(See also Exhibit L, titled 1st Licensee Meeting Checklist and Exhibit M, titled Parameters of 
an Exclusive License Agreement [not included in the Handbook].) 
1.1 Term Sheet............................................................................................................. Associate/Team
 
Associate and Team determine the desired:
• 	 financial terms 
• 	 BATNA (Best Alternative to No Agreement) 
• 	 walk-away conditions for the agreement 
• 	 type of license (non-exclusive, field exclusive,

     or exclusive) 

Associate either generates a term sheet (See Terms Sheet example [not included in 
the Handbook]) or requests a proposal from a licensee. For all field and fully exclusive 
licenses, Associate receives a development plan from licensee.
Associate and company representative agree on financial terms. 
(Continued on Next Page) 
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Box 2 (continued) 
1.2	 License Agreement ......................................................................................................... Associate
 
Once term sheet is agreed upon, enter financial terms, and docket-specific 
information, into standard License Agreement (see standard document license 
agreements on OTL Intranet; not included here). Utilize clauses library and input
from Team as needed. Keep Director informed, particularly if the license contains 
nonstandard provisions.
1.3	 Conflict of Interest Review........................................................................................... Associate
 
Prepare Conflict of Interest Memo if inventor has a financial stake in the company or 
other relationships with the company, including:
• has equity
• is or will be a consultant 
• is or will be on the Scientific Advisory Board 
• is or will have sponsored research or collaboration with company 
a.	 Ask inventor to send their COI memo to Deans describing relationship with 
company and how any potential conflict of interest would be managed. Suggest
inventor check out the COI Web site of their respective institution (for Stanford 
University, see www.stanford.edu/dept/DoR/ad_hoc.html). ................... Associate 
b.	 Obtain approval required by School Dean and Dean of Research before signing 
the Agreement. ............................................................................................ Associate Tracks 
2.	 Agreement Signature 	procedure 
Signature order not critical; if OTL signs first, include a deadline for the agreement to be 
returned.
2.1	 Director reviews and approves final draft of agreement. ....................................Director
 
2.2	 Prepare two original agreements for execution. ...................................................... Liaison
 
2.3	 Licensee signs (preferably first). .................................................................................. Licensee
 
2.4	 Director signs for OTL. ......................................................................................................Director
 
2.5	 Return one original to Licensee. .................................................................Associate/Liaison
 
3.	 Enter license and license terms into the database ...................................... Liaison/Associate 
Be sure to add all necessary information, including:
- To License record 
• All standard fields 
• Equity (if applicable)
• Office of Scientific Research funds (if applicable) 
• Corporate contact
• Entity size 
• License-specific notes 
(Continued on Next Page) 
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CHAPTER . 
Box 2 (continued) 
- To License Terms:
• All royalty terms 
• Progress report terms and 
• Diligence terms or reminders to self 
4.	 Copy 	distribution ......................................................................................................Receptionist

• Original to SAFE file 
• Routing copy, which is routed to:
1. OTL Accounting; then 
2. OTL staff; then 
3. Receptionist for scanning 
• Personal copy to Associate (Associate should notify receptionist

   if he/she already has a personal copy).
 
5.	 processing and filing Stanford’s original agreement 
5.1 After license terms entered: ........................................................................................ Associate
 
• If license issue fee was received, forward check to OTL Accounting
   for processing.
• If license issue fee was not yet received, have OTL Accounting send invoice
to Licensee. 
5.2	 Notify inventors of license agreement, verify their address and  update 4D.
................................................................................................................................. Associate/Liaison 
5.3	 If inventor requests a copy of the license agreement and there are no confidentiality 
provisions in the agreement that prevent this: ..................................... Associate/Liaison 
• The inventor must sign and return an Inventor Confidential  Disclosure    
   Agreement.
• File original inventor CDA in SAFE and stamp “CONFIDENTIAL” on the copy of  
the agreement before sending it to the inventor.
5.4 When licensed, notify patent attorney to: .................................................................. Liaison

• Pay large entity fees.
• cc licensee on correspondence with the patent office
  (for exclusive licensees only).
6.	 Amendments 
Amend for “minor” changes; rewrite agreement if major changes.
6.1	 Prepare up to two amendments per agreement, rewrite  agreement thereafter.
................................................................................................................................Associate/Liaison 
6.2	 Associate and team determine desired terms and conditions. .......Associate/Liaison
 
(Continued on Next Page) 
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HINES 
Box 2 (continued) 
6.3	 Follow same signature procedures for original agreements 
(see Section 2, above) .....................................................................................Associate/Liaison 
6.4	 Update 4D license and license terms, if necessary. ..............................Associate/Liaison
 
6.5	 Original Amendment filed in SAFE; Associate keeps a personal copy.
................................................................................................................................Associate/Liaison 
7. Terminated-agreements process ........................................................................................... Associate
 
(See SOP section “Terminated Agreements” for further instructions [not included in the 
Handbook].) 
Sample SOPs for Invention Disclosures 
1.	 OTL/Associate receives new paper disclosure..................................................... Associate/Liaison
(for online disclosures, go to 3) 




2.	 Preliminary disclosure information entered in database ..................................................Director
 
2.1	 Assign docket number, associate initials and title...................................................Director
 
2.2	 Give copy of disclosure to Front Desk. ........................................ Assistant to the Director
 
2.3	 Create correspondence folder and give folder to Associate. ......................... Front Desk
Give copy of disclosure to Compliance Manager.
(See SOP section “General Administrative Filing” [not included in the Handbook].) 
2.4	 Review, sign and witness disclosure, then give it to Liaison for 
processing...........................................................................................................................Associate 
2.5	 Enter all remaining information from invention disclosure form into 





• E-mail address 
• Phone number 
• Fax number 
• Department (please verify using Stanford Directory) .....................................Liaison
 
Also check each Database box that corresponds to a special affiliation or situation
(e.g., HHMI or SRC). 
(Continued on Next Page) 
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CHAPTER . 
Box 2 (continued) 
2.6	 If invention is sponsored, and sponsor is already listed in the database:
enter sponsor name and contract number in the sponsor portion of the 
docket screen. .........................................................................................................................Liaison 
If no sponsor or “None” listed: double check with the inventor.
 
If an inventor is an HHMI employee: HHMI should be included as a sponsor.
 
If an inventor is a VA employee: VA should be included as a sponsor.





2.7 	 If sponsor not already in database, obtain copy of any nonfederal sponsored 
agreement from Industrial Contracts Office, Office of Sponsored Research, or inventor 
and put agreement in file. Then enter sponsor information/terms into database.
Verify sponsor requirements and communicate them to Compliance Manager as 
needed. (See SOP section “Compliance: Government & Other Sponsors” [not included 
in the Handbook].) ................................................................................................................Liaison 
3.	 oTL receives new online disclosure, and 	database notifies 	director ............................Director
 
3.1	 Director assigns docket to Associate and generates database e-mail to
Associate/Liaison team. ...................................................................................................Director 
3.2	 Print out attachment(s) included with Director’s e-mail, if any, for
correspondence file...............................................................................................................Liaison 
3.3	 Review disclosure (found in the Database Disclosures view):
• Add/update inventor and sponsor information in Database, as needed
• If no sponsor or “None” listed: double check with inventor
• If inventor is a Howard Hughes Medical Institute employee: HHMI should
be listed as a sponsor
• If inventor is a Veteran’s Administration employee: VA should be listed
 as a sponsor
• Approve docket and generate database e-mail to director
• Print out disclosure 
3.4	 Director creates docket and sends 4D e-mail to Associate/Liaison team. ......Director 
3.5	 Once docket number has been assigned by Director, write docket number in upper 
right-hand corner of printed disclosure and give original disclosure (with printouts of 
attachment(s), if any) to Front Desk to create correspondence folder................Liaison 
3.6	 Database notifies Compliance Manager of new disclosure..............................Database
 
4.	 oTL notifies government and other sponsors of Stanford’s action on the disclosure
(See SOP section “Compliance: Government & Other Sponsors” [not included in the 
Handbook].) ............................................................................................................ Compliance Manager 
(Continued on Next Page) 
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Box 2 (continued) 
5.	 Associate docket review 
5.1	 Read disclosure and arrange to meet with Inventor(s) within 1 month. .......Associate
 
Have the disclosure signed by inventor(s), witness, and Associate. 
If there was a material transfer agreement (MTA): copy the MTA from
Industrial Contracts Office files and review for any IP requirements. 
Confirm whether inventor(s) plan to publish or present, including online. 
Enter status note (in Database Notes view) that describes inventor 
meeting and docket evaluation. 
(See also Exhibit B: 1st Inventor Meeting Checklist; [not included in the Handbook].) 
5.2	 Evaluate disclosure for patentability and commercial potential. Evaluation
may include input from:
• Biological or Physical Sciences Team
• Patent attorneys
• Industry contacts
• Technical Experts (for example other faculty, Niodesign Network)
• Full marketing ............................................................................................. Associate/Team
 
5.3	 If not provided with disclosure,obtain marketing abstract information from inventor 
or create marketing abstract........................................................................ Associate/Liaison
(See Exhibit D: Marketing Abstract [not included in the Handbook].) 






• Stage of Development
• Continuing Research





• EPIC if applicable
• Patent Bar date......................................................................................... Associate/Liaison
 
5.5	 Make preliminary domestic/foreign filing decision—defer if more research required
................................................................................................................................... Associate/Team 
5.6	 Send out standard royalty sharing agreement (RSA) memo if:
• Invention is being marketed
• Patent application is filed
• RSA not needed if invention is being dropped prior to marketing..............Liaison
 
(See SOP Section “Royalty Sharing Agreements” [not included in the Handbook].) 
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Training Staff in IP Management
 
sibongile pefile, Group Manager, R&D Outcomes, Council for Scientific and Industrial Research (CSIR), South Africa
 
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University,
 
Chair, bioDevelopments-International Institute, and Adjunct Professor, Cornell University, U.S.A. 

ABSTRACT 
This chapter provides an overview of training opportuni­
ties that developing country institutions can explore to 
start to address problems related to a smooth implemen­
tation and execution of all intellectual property-related 
aspects (policy, management, procedures, and so forth). 
The chapter offers to institutions guidelines for evaluat­
ing training needs and reviews different kinds of training 
programs, identifying the pros and cons of each. IP man­
agement training is a long-term investment, but a cost-ef­
fective one, leading to better utilization of third-party IP 
resources, more effective internal IP management policies 
and procedures, and higher efficiency in regard to out-
licensing and partnership development. The chapter em­
phasizes the importance of strategic and practical training 
programs related to participants’ responsibilities within 
an organization. Finally, multidimensional case studies 
are provided to illustrate the myriad issues that may arise 
with respect to the management of intellectual property. 
1. InTRoduCTIon 
Whether technology comprises new products and 
services, or improvements of existing ones, and 
whether it is simple or sophisticated, technology 
is an important contributor to socio-economic 
development. The processes by which knowledge 
and technology are transferred ensure that tech­
nologies can be applied in virtually all industry 
sectors. But technology and knowledge transfer 
capabilities in developing countries are not meet­
ing local needs for socio-economic development 
and for driving progress in such critical industry 
sectors as health and agriculture. Despite an ac­
tive research environment, developing countries 
have been less effective in exploiting research out­
puts, especially intellectual property. Institutions 
in developing countries face numerous problems 
in managing their own intellectual property.1 
These include a limited understanding of the IP 
system and how it can be applied in the public 
sector research environment, a low appreciation 
of the benefits that can be derived from manag­
ing institutional intellectual property, and inad­
equate human and financial resource capacity to 
invest in institutional IP management policies 
and resources. 
In IP management, the importance of practi­
cal training events cannot be overemphasized. For 
this reason, we have included, at the end of this 
chapter, a few brief case studies that can be used 
for training purposes (Box 1 at the end of this 
chapter). These case studies will allow the par­
ticipants to play roles (that is, role-play situations 
that arise in the day-to-day management of intel­
lectual property) and, most importantly, will al­
low participants to see how their specific roles in 
real life affect (directly or indirectly) deal-making 
activities. Even for those who are not involved in 
deal-making, this practical approach is especially 
useful as it enables participants to view their re­
spective tasks in broader contexts and thus better 
understand their roles and responsibilities, as well 
as their importance in the process. 
Pefile S and A Krattiger. 2007. Training Staff in IP Management. In Intellectual Property Management in Health and Agricul-
tural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. S Pefile and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged. 
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PEFIlE & KRATTIGER 
2. A 	STRATEGy foR	 Ip	MAnAGEMEnT	
CApACITy 	BuILdInG 
2.1	 Analyze institutional goals 
Deciding upon a program to build IP manage­
ment capacity begins with a thorough analysis 
of institutional goals, recent policy changes, and 
required adjustments in the institutional strategy, 
with respect to IP management. Institutional ca­
pacity in IP management means a range of things: 
including clear and transparent policies (conflict 
of interest, licensing, patent, and so forth); es­
tablished procedures (for example, for incoming 
and outgoing materials, laboratory notebooks); 
and people at nearly every level of the organiza­
tion being well informed on how the procedures 
work, and why. It is essential to identify weak­
nesses and strengths of the IP management sys­
tem within an institution in order to take better 
advantage of existing organizational structures. 
This means identifying where the weakest links 
are. A training program then will assist staff in 
better understanding and helping the institution 
to achieve its goals. 
2.2	 Identify training needs 
The next step is to identify the competencies re­
quired to accomplish the overall goals. This re­
quires an analysis of the required proficiencies, 
existing deficiencies, and the causes of the defi­
ciencies. In general, the training requirements 
of staff members are summarized in Table 1. In 
order to ascertain specific needs, the following 
question should be answered: 
•	 What knowledge and skills are required 
for optimal operation of the IP office and 
therefore required among IP management 
staff? 
•	 What IP-related knowledge and skills are 
required for the research staff? 
•	 What are the communication gaps with re­
spect to intellectual property both within 
the institution and with third parties? 
•	 What are the particular elements of the IP 
policy that seem least well understood and 
implemented? 
•	 What resources are required to bring knowl­
edge and skills to the required levels? 
Information on training needs can be gath­
ered in various ways: 
•	 interviews. one-on-one or group format; 
face-to-face or by phone; formal interviews 
and off-the-record discussions 
•	 focus groups. conversations among teams 
of workers from across the organization 
•	 questionnaires and surveys. anonymous 
or not 
•	 document analysis. a study of policies, 
strategies, and management procedures (for 
example, employment agreements, grant 
documents, and other contracts) 
•	 observation. 
2.  Develop strategies to achieve 
training goals 
Ranking the training goals and determining 
how to meet the highest-priority training needs 
is difficult. A well-developed plan should have 
specific and realistic objectives, include measur­
able and achievable outcomes, schedule clear 
time frames for all activities, and should un­
dergo regular monitoring and evaluation.2 Of 
course, different people have different under­
standings, vested interests, and preferences, so 
a lot of soft negotiation will be required. It may 
be helpful to work with a third-party training 
provider who, if they understand the organiza­
tion, can take a more objective view and assist in 
better designing the training program to meet 
institutional goals. 
.  Ip	 TRAInInG	 pRoGRAMS 
Initially, individuals interested in IP training were 
limited to a small collection of course offerings 
available through staff members of organizations 
that, due to their practical experience in the field, 
were able to share their know-how. But intellec­
tual property as a field of study is growing in im­
portance as institutions value it more and more. 
In addition to the essential practical training of­
fered by institutions such as the Centre for the 
Management of Intellectual Property in Health 
Research and Development (MIHR), formal 
training in IP management is also available from 
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Table 1: Generalized Training Needs of Different Staff Groups
 
CHAPTER . 







• maintaining good laboratory records 
• a basic understanding of the types of IP agreements,
especially in the context of exchanging research material and 
information 
• the importance of confidentiality, especially with respect to 

publishing and delivering academic presentations 

• when to disclose intellectual property to the relevant office 
• institutional IP policy guidelines and procedures 
• the importance of IP management and management functions 
• IP protection processes and procedures; the investments 

required to manage intellectual property effectively (include 

key decisions required at different stages of intellectual 

property and research development)
 
• implementing IP policies, processes, and procedures 
• an appreciation of the role of technology in addressing socio-
economic needs 
• overview of IP management from the generation of intellectual 
property to its exploitation and application 
• awareness building 
• understanding of science (some domain understanding of 

certain fields of science an added benefit)
 
finance 
• understanding of IP policy guidelines, namely, systems and 
processes to handle IP payments and receipts, for example,
royalties; the administration of benefits to researchers and the 
institution 
human resources 
• IP policy guidelines and interface with other institutional 
policies such as, conditions of service, recruitment, conflicts of 
interest and commitment, contracting with clients, and so on 
legal services 
• IP policy guidelines 
• IP contracts and agreements 




• IP negotiation 
grant and contract research 




• IP policy guidelines 
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PEFIlE & KRATTIGER 
MIHR.3 The online version of this Handbook will 
list many other such programs and places. 
IP training opportunities can be divided into 
two distinct disciplines: law and IP management, 
which includes deal making as the central focus. 
.1 IP law 
Although most training programs begin by cover­
ing IP law, it is more appropriate to present this 
topic at the end of the course. A brief overview at 
the beginning might be appropriate, but placing 
emphasis on it at the beginning diverts attention 
from the more important issues, namely what an 
institution is doing with its intellectual property 
and with the intellectual property of third par­
ties. Therefore, a training program really ought to 
begin with the central issue, which is deal making 
for most institutions. 
IP law is concerned with statutory regimes 
for the legal protection of IP rights. IP law studies 
normally include: 
•	 patent law. the study of patents for inven­
tions, including international and regional 
treaties that form part of an international 
legal framework in patent law 
•	 copyright law. the study of principles and 
standards of protection under national and 
international copyright and related rights 
treaties 
•	 trademark law. the study of legal provisions 
relating to trademarks in national, interna­
tional, and regional IP treaties 
•	 industrial design law. the study of laws 
pertaining to the registration and protec­
tion of original and innovative designs. (In 
some countries, design patents go under 
different names, such as “utility model” in 
France and the law for “minor inventions” 
in Australia.) 
Other training opportunities exist in areas 
such as: 
•	 legal aspects of traditional knowledge and 
biodiversity 
•	 legal aspects of electronic commerce 
Many law faculties offer training for becom­
ing a patent lawyer. Typically, patent lawyers are 
responsible primarily for preparing and pros­
ecuting patent applications, conducting patent 
searches, patent infringement and litigation, and 
preparing and filing applications for patent and 
other IP protection. During the course of per­
forming these duties, patent lawyers are required 
to communicate with counsel and guide clients 
on legal issues in this field. 
.2 IP management 
On the other hand, IP management courses train 
individuals to become IP practitioners. An IP 
practitioner may not necessarily have formal edu­
cation or training related to intellectual property 
but would have work experience and some infor­
mal training in the field. IP management is the 
convergence of basic IP law, business and research 
management, and institutional policy adminis­
tration. IP practitioners need to know the IP field 
well enough to make appropriate strategic and 
management decisions about the protection and 
exploitation of institutional intellectual property. 
Furthermore, IP practitioners are expected to: 
develop institutional IP policy, advise on when, 
where, what, why, and how to protect intellec­
tual property; identify useful intellectual property 
from their institutions; establish institutional sys­
tems and processes to manage intellectual prop­
erty; assess the value of intellectual property; re­
port on IP activities; and build awareness of the 
importance of intellectual property within the 
research community. Essentially, the IP practi­
tioner serves as a bridge between science and the 
outside world. Such an individual should know, 
therefore, how to articulate issues effectively to 
different stakeholders and when to seek profes­
sional counsel for highly technical matters. 
. IP law vs. IP management training 
Important issues to consider when deciding on 
which type of IP training program would be ap­
propriate for staff members include: 
•	 training costs. It is important that the 
institution receive value for its training 
investment. 
•	 duration of training. Legal training in IP 
law takes several years; short courses in IP 
management take weeks or months. 
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•	 institutional needs. While it is not unheard 
of for IP lawyers to be involved in IP man­
agement activities, normally, these lawyers 
are focused on legal issues. Institutions 
can outsource legal functions to local law 
firms. Depending on the type and volume 
of work, institutions need to determine 
whether their IP managers require a legal 
qualification in addition to the scientific 
and research management background that 
most IP practitioners possess. 
•	 access to and availability of training op­
portunities. Unless an institution organizes 
an internal IP training program, the institu­
tion often relies on the training schedules of 
other programs. Some training opportuni­
ties may take place at awkward times in the 
organization’s business cycle. Furthermore, 
it can be exceedingly costly for developing 
country institutions to fund individuals to 
attend a one- or two-day training course 
overseas as is often the case with such IP 
training programs. 
•	 size of institution and volume of IP activ­
ity. Large institutions with a significant, 
growing IP portfolio may need an IP law­
yer in addition to an IP manager. For most 
institutions, however, an IP practitioner 
may be adequate. 
. Training locations 
A growing number of IP training programs are 
available on the market. The list of programs 
below is by no means exhaustive; an Internet 
search of the topic will certainly yield many more 
results. 
..1 IP law 
Degree programs or courses in IP law are offered 
by numerous universities in both developing 
and developed countries. The World Intellectual 
Property Organization (WIPO), along with the 
University of South Africa (UNISA) offer a dis­
tance-learning course in IP law. 
..2 IP management 
Highly regarded IP management courses are of­
fered by: 
•	 MIHR4 
•	 AUTM (The Association of University 
Technology Transfer Managers)5 
•	 NTTC (National Technology Transfer 
Center)6 
•	 WIPO Worldwide Academy7 
•	 NIH (United States National Institutes of 
Health) Office of Technology Transfer8 
•	 PIIPA (Public Interest Intellectual Property 
Advisors, Inc.)9 
. Designing training programs 
A training strategy should begin with a clear mis­
sion and provide measurable training objectives 
through which progress can be monitored. The 
training program should facilitate the achieve­
ment of the institution’s goals for promoting 
and commercializing products that emerge from 
research. 
Training-program development can be bro­
ken down into ten essential steps as illustrated in 
Figure 1. Note that training is a continuous and 
iterative process. 
. Elements of a good training program 
Given the many different types of training pro­
grams available, how does one distinguish good 
training opportunities from those with little 
value? Key considerations to bear in mind when 
planning an IP training program include: 
•	 relevance to practical issues. For example, 
whereas for lawyers, the course may well 
center around the law, in most cases em­
phasis on legal aspects, especially patent 
law, for IP management practitioners is too 
strong. Rather, equal emphasis should be 
placed on deal making, which should run 
like a thread through training programs for 
technology transfer managers. 
•	 reputation of trainers and programs. Over 
the years, certain programs have built a 
good track record and are often recom­
mended by former course participants. It 
is useful to seek the views of past trainees 
and trainers about courses attended and the 
value derived from those course. 
•	 qualifications and experience of trainers.
Some training programs provide a biogra-
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phy of trainers and presenters. The biog­
raphies provide useful information about 
the trainer’s knowledge and expertise in 
the field, as well as experience in providing 
training to a given audience. 
training topics and relevance. It is pos­
sible to rapidly appraise the usefulness of 
the training opportunity by carefully ex­
amining the training subject matter. To 
maximize the benefit of the training op­
portunity, course content should be cur­
rent, provide new knowledge, and show 
relevance to the training needs of the se­
lected audience. 
method of instruction. To ensure effective 
learning, training should incorporate dif­
ferent methods of instruction. Lecturing is 
the most common form of instruction (al­
though this may not be the most effective). 
Demonstrations, group discussions, role-
playing, and simulations are other methods 
of instruction that can be used to maximize 
which training programs to invest time and 
money in. 
• training material. The merit of a course 
can be evaluated based on the quality and 
relevance of training material offered prior, 
during, and after the event. Pre-training 
material is important for introducing the 
topic and preparing the trainee. Post-train­
ing material should reinforce the training 
and provide trainees with reference mate­
rial that will be useful for applying the new 
knowledge. 
• post-training support. Support after the 
training event is important. In most cases, 
the real training takes place in the work en­
vironment, which is where the learning can 
be applied and utilized. Trainees may not 
always be certain of themselves; when it is 
possible for trainees to ask questions and 
reaffirm learning, the chances of applying 
the new learning successfully are greater. 
•
•
the training opportunity and maintain the 
audience’s interest. Programs that use dif­
ferent instruction methods and a mix of 
student-teacher interactions tend to be the 
most effective and offer the greatest benefit 
to the trainee. 
training environment. The location and 
environment of the training site is of major 
importance to the trainee and the trainer. 
The training environment should not in­
terfere negatively with the learning pro­
cess. Venues and facilities need to be eas­
ily accessible and conducive to learning. 
Without a suitable setting, the training will 
be compromised. 
training schedule and session plans. A well-
designed session plan will focus on topics 
that the audience needs to know. Session 
objectives should be clearly stated, the tar­
get audience identified, and the schedule 
should communicate the method and con­
tent of presentations and the time available 
for questions and discussion. A detailed 
analysis of the training schedule ahead of 
time will reveal whether or not the program 
is well planned and inform choices about 
Different forms of training programs exist, 
and some programs will be more valuable than 
others; if possible, trainees should experience 
a range of opportunities. Post-training reports 
should not only detail the outcomes of a given 
training program but also explain how the train­
ing experience will change work practice. The 
measures that management can use to monitor 
development should be clear. The institution 
paying for the training should be able to measure 
the outcomes of the training experience. Long­
term outcomes should address the competency 
gaps identified in the needs analysis and should 
be evaluated using measurable indicators. Long­
term outcome measures would include: 
• increased research outputs 
• more efficient resources utilized for IP man­
agement activities 
• improved financial performance of the 
organization 
• portfolio performance 
Short-term outcome measures include:10 
• improvements in skills performance 
• improvements in the efficiency of conduct­
ing procedures and tasks 
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PEFIlE & KRATTIGER 
•	 showing an understanding and appreciation 
of performing tasks in a prescribed way 
Table 2 introduces the different types of train­
ing and examines the pros and cons of each form. 
Box 2 presents an outline of a workshop plan. 
.  ConCLuSIonS 
The chapter provided an overview of training op­
portunities that can enable developing-country 
institutions—or indeed institutions anywhere in 
the world—to strengthen staff competencies and 
thus build internal IP management capacity. The 
chapter offers to institutions guidelines for evalu­
ating training needs and reviews different kinds 
of training programs, identifying the pros and 
cons of each. 
The adage “reading is learning, seeing is be­
lieving, and doing is knowing” is particularly ap­
propriate in the context of training and capacity 
building. Accompanying this chapter are several 
case studies for short courses, each presenting a 
different challenging IP management scenario. 
Case studies give trainees opportunities to envi­
sion how a technology transfer project might be 
carried out. 
Finally, a detailed workshop plan that pro­
vides comprehensive steps is important. Such 
an IP management training course so that it can 
then be successfully implemented, while engag­
ing, educating, and motivating participants. n 
sibongile pefile, Group Manager, R&D Outcomes, 
Council for Scientific and Industrial Research (CSIR), PO 
Box 395, Pretoria 0001, South Africa. spefile@csir.co.za. 
anaTole KRaTTigeR, Research Professor, The Biodesign 
Institute at Arizona State University, Chair, bioDevel­
opments-International Institute, and Adjunct Professor, 
Cornell University, PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu
1 CIPR. 2002. Integrating Intellectual Property Rights and 
DevelopmentPolicy.DFiD:London.www.iprcommission.
org/papers/pdfs/final_report/Ch7final.pdf. 
2 OPM.2006.Guidelines for Conducting Diversity Training.









10 Boydell T and M Leary. 2001. Identifying Training Needs.
Chartered Institute of Personnel and Development:
London. pp. 8–10. 
11	 Although the case studies are based on real occurrences,
the scenario has been adapted to protect the privacy 
of all organizations and individuals involved. 
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Table 2: Pros and Cons of Different Types of Training Programs
 
Type of
training Pros Cons 
Short • trainee not absent from work for extended • no formally recognized 
courses periods qualification 
• training opportunity focused and aimed at • course content shallow 
professional development • course coverage possibly 
• can be inexpensive unfocused 
• teaching specifically targeted to adult • value of learning 
learners experience dependent on 
• possible to be selective and choose only the 
most relevant training courses 
the extent to which the 
trainee can apply the new 
knowledge 
Full-time • often leads to a formal qualification • trainee absent for a 
courses • course content detailed and the learning longer period 
intense • training might be costly 
• direct access to training material, lecturers, • not all of the course 
and other resources content relevant to the 




• greater chances that trainee will complete 
course within the stipulated period 
Part-time • trainee not away for extended periods • overall training period 
courses • learning in segmented modules enabling 
trainee to apply new knowledge in a more 
possibly longer than full-
time course 
structured manner • overall cost of releasing 
trainee from work not
necessarily cheaper 
• possibility that trainee 
may take longer to 
complete course due to 
flexibilities built into the 
course 
Distance • flexible learning schedule • need for good time-
learning • trainee can be situated anywhere 
• training material is normally in a form 
that makes it readily available for future 
reference 
management skills and 
the discipline to study 
• trainers and training 
resources less accessible 





(Continued on Next Page) 
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PEFIlE & KRATTIGER 
Type of
training Pros Cons 
Internship • can be customized for the individual 
• practical experience 
• greater exposure for trainees through 
secondments to different organizations 
• training in depth and teacher/trainee 
exchange better, resulting in a potentially 
better cost benefit to the institution 
supporting the training 
• overall training experience typically varied 
with broader exposure 
• may necessitate extended 
absence 
• can be costly 




• training customized and contextualized 
• greater control over course content
• training intense and in depth 
• can be structured to cater to the different
needs of different groupings within the 
research community 
• greater number of individuals can be 
exposed to a single training episode 
• assists with creating an internal culture of 
learning and understanding intellectual 
property 
• helps to develop institutional IP networks 
and systems 
• post-training assistance is normally 
available 
• the institution must pay 
unless training is funded 
• for the duration of the 
course, productivity may 
be lower 
• institutions need to be 
involved in the planning 
and implementation of 
the event; in some cases,
institution may need 
to assign staff member 
to assist with training 
arrangements 
Table 2 (continued) 
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CHAPTER . 
Box 1 : Case Studies for use in Training 
EyEBoRn™ 	oRBITAL	 IMpLAnT	 
Your local research and technology institute (RTI), in collaboration with a clinical research 
organization (CRO), a group of surgeons and the local university, have developed an 
orbital implant to replace eyes lost due to disease or injury. The Eyeborn™ implant is to be 
launched as a commercial product at the next International Ophthalmology Conference.
The central aim of the project, supported by an angel investor, is to develop an improved 
and more cost-effective orbital implant. The hydroxyapatite material from which the 
implant is made, allows tissue and blood vessels to grow into the porous ceramic. Since the 
eye muscles are attached to the orbital implant, mobility of the implant is synchronized 
with that of the normal eye. Once a polymer prosthesis, or cap, with artwork of an iris 
and a pupil is placed over the implant, it is often difficult to discern a difference in the 
eyes in appearance and movement. This means patients who receive an implant appear to 
have normal ocular function. Presently, your product offers a more affordable, high-quality 
alternative to existing implants. It will benefit a larger percentage of the poor population,
and, because of the lower cost, will be more accessible to government hospitals and clinics.
Presently at government hospitals, patients that have lost an eye are given either a silicon 
eyeball or nothing at all. 
Background 
• A local patent has been granted for the eye orbital. 
• There is a patent application for the orbital eye inserter. 
• RTI owns the intellectual property. 
• You have approached a local company to do the manufacturing. 
• You would like to sell the product nationally and internationally. 
• You would like to ensure that the product is available at an affordable price at all local public 
health facilities. 
• You have a three-year window of opportunity to get your product on the market and to secure 
a sustainable market position. 
Tasks 
• Determine whether or not you will file international patents, stating where, how and why. 
• Determine how benefits will be shared with the consortium of researchers. 
• Identify any other forms of IP you may consider protecting. 
• Summarize what commercialization vehicle you will use and why. 
• Identify your key partners to help you get the product on the market. 
• List agreements you require with your partners. 
• Describe your business model for supplying private and public sector health facilities. 
(Continued on Next Page) 
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PEFIlE & KRATTIGER 
Box 1 (continued) 
THE	 SMART-LoCk 	SAfETy 	SyRInGE 
The Smart-Lock Safety Syringe provides improved protection against needle stick injury 
and contamination. The device has an added benefit of being easier to use and providing 
more accurate measuring. 
Background 
• The Smart-lock Safety Syringe 	 technology is a new disclosure by your institution’s 
researchers. 
• A prototype has been developed. 
• The market for syringes in your country is highly competitive and saturated. While there are 
no Smart-Lock Safety Syringes on the market, there are many different other types of syringes 
available. 
• You have been promised significant distribution opportunities for your product in francophone 
Africa, provided you establish a factory in one of the countries. Most countries in this region 
have weak IP protection systems. 
• To manufacture the Smart-Lock Safety Syringe is a highly technical process; the know-how or 
the process resides with the small group of researchers at your institution. 
Tasks 
• Develop an IP protection strategy for the Smart-Lock Safety Syringe detailing: 
- whether or not you wish to protect your intellectual property (if not, go to the next task);
if so: 
- where to protect the intellectual property (taking into consideration national, regional,
and international patent systems)
 
- when to start applying for IP protection
 
• Given your answers to the questions above, develop a business plan that details how you 
intend to exploit your intellectual property . In the summary of the plan, address the following 
issues: 
- partnerships and partnership agreement conditions
 
- other agreements required
 
- technology and knowledge transfer arrangements
 
- your business model
 
(Continued on Next Page) 
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CHAPTER . 
Box 1 (continued) 
AvEnGInG	 MonTEzuMA’S	 REvEnGE! 
The purpose of this case study is to consider basic strategies related to the building of 
public–private partnerships, the pooling of resources, building on comparative advantages,
and achieving the dual goals of social needs and commercial objectives. Specifically,
trainees will be addressing the issues of licensing across public and private sectors that are 
attempting to meet needs in developed and developing countries.
In this case study, trainees are encouraged to develop creative ways in which public and 
private sectors can combine their resources, segment markets, and address the specific 
needs of different constituencies (developed and developing countries). 
Background 
Viajes BioTech Inc.11 is a small biopharmaceutical company in North America, founded by Jose 
(Pepe) Herrera, a Mexican immigrant to the U.S. Prior to establishing the company, Pepe worked 
for his mother’s travel agency while he was studying for his doctorate degree at the Autonomous 
University of Cancun, Mexico, and visited all corners of the world. During these times, he often 
had intestinal discomfort and returned with diarrheal diseases. His doctoral thesis focused on 
such diseases, and he collected many Escherichia coli specimens from around the world. After 
making good money during the dot-com boom, he set up Viajes BioTech Inc. in San Diego, United 
States, to build on his Ph.D. research with the primary purpose of alleviating the suffering of the 
many millions of travelers to the developing world. 
The Research To-Date 
E. coli heat-labile enterotoxin (LT) is composed of catalytic A and noncatalytic homo-pentameric 
B subunits and causes diarrheal disease in humans and animals. In order to produce a nontoxic 
LT for vaccine and adjuvant development, two novel derivatives of LT were constructed by a site-
directed mutagenesis of A subunit; Ser63 to Tyr63 in LTS63Y and Glu110, Glu112 were deleted in 
LT delta 110/112. Mice immunized with the purified mutant LTs (mLTs) either intragastrically or 
intranasally elicited high titers of LT-specific serum and mucosal antibodies.These results indicate 
that substitution of Ser63 to Tyr63 or deletion of Glu110 and Glu112 eliminate the toxicity of LT 
and both mutants are immunogenic to LT itself. Therefore, both mLTs may be used to develop 
novel antidiarrheal vaccines against enterotoxigenic E. coli. 
Note that the particular strain used in this research originated from a sample collected from 
a campesino at a clinic in Pepe’s grandparents’ hometown, Chulula, outside San Cristobal de 
las Casas in the State of Chiapas. Whenever he visited his family at Christmas and Easter, Pepe 
would spend a few days helping in a clinic in that village. Campesinos are generally poor farm 
laborers. 
Business Model of Viajes BioTech Inc. 
The company focuses on the development and commercialization of a vaccine for diarrheal 
diseases that occur predominantly in developing countries but that have a significant market in 
developed countries among travelers for both business and leisure.
Viajes Biotech Inc. counts some 50 highly trained staff and has laboratories able to produce 
nonGMP pilot lots of the vaccine but has no clinics or production facilities.
(Continued on Next Page) 
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PEFIlE & KRATTIGER 
Box 1 (continued) 
The company owns the key intellectual property for the vaccine in the form of a single 
dominating patent (but a series of continuations in part are still at the patent office in the United 
States). Pepe still has another two months to file for (PCT Patent Cooperation Treaty) applications 
in foreign jurisdictions, having marked all possible boxes in the application. Money, however, is 
relatively tight, and it is not clear whether the expense is warranted. 
Because the infections are extremely rare in most developed countries, it is difficult to test
the vaccine in those countries. Thus Viajes BioTech Inc. is seeking a partner in the developing 
world to assist in the clinical trials. Pepe, having lived the first 25 years of his life in Mexico, also 
wants to find a way to extend the benefits of the vaccine to people in the developing world. 
During his recent vacation trip over Christmas to the South African vineyards, Pepe visited 
a former fellow student of his, Koreen Ramessar, who works on muscular dystrophy at the 
Department of Human Genetics at the University of Cape Town medical school. Koreen heard 
of the advances her classmate had made with his vaccine and introduced him to the director of 
IIMR, the International Institute of Medical Research in Colombo, Sri Lanka. The current director,
D.C. Mokhobo, is originally from Cape Town and was visiting her family over the festive season. 
Pepe and Dr. Mokhobo of IIMR had dinner just before New Year’s Eve and agreed, in principle,
on a joint effort to develop the vaccine further whereby Viajes BioTech would focus on introducing 
the vaccine into developed countries, and IIMR, through appropriate partnerships, would focus 
on developing countries. 
The International Institute of Medical Research, IIMR 
IIMR is an autonomous international nonprofit organization headquartered in Colombo, Sri 
Lanka. It maintains a network of laboratories and research centers hosted by a series of leading 
research institutions across the developing world.The institute also carries out research, teaching 
and training in its facilities. The entity does not have its own clinics but arranges for clinical 
studies through collaborating centers in developing countries.
Tasks 
General 
To develop a framework agreement between a public (IIMR) and a private entity (Viajes BioTech 
Inc),sketching the outline of a business plan,with particular focus on the IP strategy,incorporating 
all the available tools, as appropriate. 
The Teams 
Pepe and Dr. Mokhobo each requested the relevant people in their institutions to work out the 
details on how the scheme could be made to work to benefit both parties. Two teams were 
created: 
• One team represents the business development and marketing side of Viajes BioTech Inc.
• Another team represents the R&D program of IIMR and also includes the deputy director for 
International Cooperation. 
The Specifics 
First, meet in your own team for 60 minutes to determine the issues that need to be addressed.
Specifically, think of the needs of your entity to ensure that the primary policy of the entity is 
(Continued on Next Page) 
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CHAPTER . 
Box 1 (continued) 
respected in the deal. Also think of the needs of the other party. For example,Viajes BioTech must
find a way of making a return on its investment. IIMD, on the other hand, does not sell things 
and will need to think of marketing alliances and licensing, as well as obtaining the funding to 
conduct the work. 
Second, the teams meet together and compare ideas, issues, and approaches. Note that this 
is not primarily a negotiating exercise. Begin by developing the overall business plan for how the 
vaccine would be tested and commercialized, both in the developing and developed worlds.Then 
develop a coherent IP strategy that reinforces the business plan. 
Remember that your bosses have made the policy decision, in principle, to get this venture 
going. Your task is to flesh out the framework for how it could work in practice. Hence the other 
party is not a hostile team but, essentially, in the same boat as you are. Also, you are not required 
to develop a detailed investment plan with cash flow and royalty rates; rather, the principles of 
the deal are to be developed. 
The Assumptions 
• The time required to develop the vaccine for clinical trials is 9 months. 
• Clinical trials will take two years to complete if all goes well. 
• The cost for clinical trials across five countries is estimated to be US$20 million. 
• The cost of production for 1 million units is US$10 million. That cost could be reduced to US$5 
million if produced in a high quality laboratory in India. Note that these costs do not include 
marketing and distribution costs, commissions, advertising, and so forth. 
• The total market in the United States, Europe, and Japan for business and leisure travelers is 
estimated by Viajes BioTech Inc. to be approx. five million units per year in the first five years,
increasing to 15 million units per year thereafter. Viajes BioTech Inc. estimates that travelers 
are willing to pay up to US$25 per shot/unit. 
• The total market in the major cities in Asia, Africa, and Latin America is estimated to be at
least 100 million units per year. 
• Viajes BioTech Inc. already invested US$7.5 million in the vaccine. The next round of financing 
will be launched in three months and the company needs to show a sound business plan and 
potential for significant profits, if it is to convince its current and prospective new investors of 
putting up an additional US$30 million or so over the next three years. 
The Report to Your Bosses 
Specific issues you should address in your report (in the form of a slide presentation lasting no 
more than 10 minutes), should include: 
• Who supplies the vaccine for clinical trials? 
• In which countries outside the U.S.A. should Viajes BioTech Inc. file for patent protection? 
Remember that each such filing will cost some US$25,000 including translation and filing 
fees. 
• What other form of IP protection should be sought? When, where, and why? 
• Who is liable for untoward events with the vaccine in clinical trials? 
• Who should own potential new intellectual property generated from the clinical trials 
conducted by IIMR? 
• Means by which the vaccine could be (1) produced, (2) marketed, and (3) sold in the developing 
world. 
• How will you deal with third-party technologies that may have to be licensed-in for the 
production of the vaccine? 
(Continued on Next Page) 
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PEFIlE & KRATTIGER 
Box 1 (continued) 
• Are there any issues of compensating Mexico for use of the E. coli strain that led to the vaccine? 
If so, what might they be and how could they be resolved? 
• Prior review of the labeling of the vaccine for sale in any market. Include an explanation of why 
there should be review. 
Additional Considerations 
• Should your group require specific technical,strategic,and legal advice, it can be made available 
for a limited time. However, the external advisors will only respond to well-formulated and 
relatively specific questions. 
• Invent whatever additional information you feel you may need, but be sure to specify such 
assumptions (amount of capital needed, types of IP protection sought and obtained, terms 
of the commercial licenses required, the way that regulatory issues are addressed, and so on).
Make reasonable assumptions, given the milieu of your activities. 
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Box 2: Sample Workshop Plan 
objectives 








• To develop knowledge and skills in strategic IP management, focusing on the fundamentals 
of IP rights: licensing issues and negotiating joint venture agreements that seek to enhance 
the availability of research results for health products.
Workshop emphasis 
The workshop will focus on providing participants basic/intermediate/ advanced [indicate which] 
level training in IP management. 
Background 
Many developing country institutions lack the human capital and capacity required to design 
and implement IP management systems that serve the IP management needs of academic 
institutions. Without meeting the need to provide training to personnel in IP management, the 
execution of IP management practices is less likely to succeed. The proposed capacity-building 
initiative will focus on developing learning experiences that have immediate relevance to the 
participant’s occupation and experience, thus providing the basis for activities that lead to 
institutional IP management development.
partners 
Acknowledge the organizations collaborating on or sponsoring the training. 
Workshop format 
• Tutorial work and presentations 
• Case studies and role-play 
• Materials for reading and future reference 
Training topics 
• The fundamentals of intellectual property management. This component will provide the 
basic principles of intellectual property protection processes and an overview of IP regimes. 
• IP strategies and methodologies. The purpose is to teach participants the approaches to 
negotiation, establishing agreements, licensing, technology transfer processes, and business 
development. 
• Technology transfer management. An overview of technology management functions and 
strategies is provided. 
• Commercialization. Provide instruction on how to develop a commercialization plan, include 
discussion of the key components of such a plan and guidance on aspects such as negotiation,
deal structuring, and venture fund sourcing. 
(Continued on Next Page) 
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PEFIlE & KRATTIGER 
Box 2 (continued) 
Teaching and learning methods 
The teaching techniques selected are designed to enable trainees to gain knowledge through 
traditional tutoring methods and from each other’s experiences. 
• lectures. knowledge transfer using conventional teaching techniques (direct instruction) 
• presentations. “guest speakers” including IP professionals representing private and public 
sector industries 
• case studies. interactive practical exercises that encourage participants to apply the knowledge 
they have acquired to solve complex intellectual property issues 
• role play. exercises that expose trainees to strategies and approaches in operation in various 
IP management disciplines 
Workshop content and curriculum 
The teaching content of the workshop will be developed in consultation with key partners. The 
suggested agenda for a four-day workshop is presented below. 
day 1. Refresher on IP processes and regimes: An overview of IP processes 
day 2. IP management practices 
• current practices and issues in IP management 
• licensing fundamentals
 
day 3. IP management strategies: Managing an IP portfolio
 
day 4. Technology transfer strategies and commercialization 

• fundamentals of technology transfer 
• fundamentals of commercializing intellectual property 
Training materials 
• slide presentations 
• case studies 
• role-play supplies 
• reading material 
• CD of reference material and Web-based links 
Accreditation 
Participants will receive acknowledgement for full attendance of the training program. 
Tutors 
Tutors will include: 
• three to four keynote speakers 
• lecturers and presenters 
• facilitators of interactive activities 
(Continued on Next Page) 
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Box 2 (continued) 
Who should attend 
This training program is directed at professionals in health R&D interested in acquiring skills in IP 
management. The target audience includes:
• technology transfer office staff 
• research managers and scientists 
• senior management
venue 
Accommodation will be provided at preferential rates. Refreshments and meals will also be 
provided. 
Costs 
Participants will be required to pay their own travel costs. Participants will be required to make a 
single payment [or other payment plan] when registering for the workshop. 
Entry limitations 
Entrance will be granted to the first 20 applicants who complete registration. 
Subsequent training and support 
Post-workshop activities will include issues identified during the training-needs analysis and also 
take into account responses received following a workshop survey among participants. 
Workshop evaluation
The assessment measures will be determined first by the specific objective of the workshop, and 
second, by the expectations of participants. Evaluation measures will include: 
• relevance of the workshop to participants 
• choice of tutors 
• professional diversity of trainees 
• duration of workshop 
• balance between theory and application 
• training techniques 
• discussion and exchange 
• documentation 
Suggestions for further improvement will be sought from trainers, trainees, and observers. 
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The National and International Experiences of AUTM
 
kAREN HERSEy, Visiting Professor of Law, Franklin Pierce Law Center, U.S.A. 
ABSTRACT 
Developing and implementing best practices in intellec­
tual property (IP) management requires several critical 
inputs, and building networks is among the most im­
portant. The experience of the Association of University 
Technology Managers (AUTM) serves as an excellent 
example of how to build and maintain such networks. 
The important lessons learned as AUTM grew and ex­
panded its networks are broadly applicable to building 
dynamic, productive, and sustainable networks anywhere 
in the world. Furthermore, since AUTM is an association 
of individual, rather than institutional or organizational 
members, it functions all the more as a catalyst for net­
working. Networking provides two important benefits. 
First, it facilitates relationships between individuals with 
varied experience, expertise, and skill sets, encouraging 
individuals to contribute to each other’s professional 
expertise. Second, the network itself contributes to the 
overall quality of group performance. Working through 
networks, practitioners exchange ideas and experiences to 
form best practices that become performance standards 
for individuals and their institutions. Networks thereby 
contribute to building IP management capacity at both 
the individual and institutional levels, and this capacity 
building then feeds back to further support and expand 
the network. This chapter considers the networking prac­
tices established by AUTM. It charts the organization’s 
growth over a period of 30 years from a small group of 
U.S. and Canadian patent managers to an association of 
more than 3,400 members from countries on every con­
tinent.1 As the story of AUTM demonstrates, networks 
can begin locally and gradually expand to operate on a 
national, regional, and even international scale. However, 
as AUTM has shown, the organization itself must begin 
with—and steadfastly maintain—a clear and focused 
central mission. 
1. INTRODuCTION 
Networking among peers in any profession gener­
ally provides two important benefits. It encourag­
es relationships between individual practitioners, 
some of whom may be highly skilled while others 
are less so. Regardless of the proficiency levels of 
individuals, each one contributes to the experi­
ence of every other. Whether individuals func­
tion as mentors or apprentices, the one-on-one 
interactions raise the level of each person’s exper­
tise and professionalism. Moreover, networking 
contributes to the overall quality of group perfor­
mance. By working through networks, practitio­
ners exchange ideas and experiences, developing 
best practices that become standards for perfor­
mance. The Association of University Technology 
Managers (AUTM) provides a shining example of 
how this process can benefit an organization. The 
history of the AUTM provides a solid case study 
of the usefulness and power of networking. 
2. FORMING A NETWORK
TO SOlVE PROBlEMS 
AUTM began its journey as a direct result of 
networking. Coming together as a small group 
to solve a set of common problems in the mid­
1970s, a handful of individuals formed a net­
work that would eventually grow into AUTM. 
Midway through 2006, the total membership 
Hersey K. 2007. Building Networks: The National and International Experiences of AUTM. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. K Hersey. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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HERSEy 
stood at 3,494. The organization plays a global 
role in developing academic technology transfer 
as a unique profession. 
AUTM, or more accurately its antecedent, 
the Society of University Patent Administrators 
(SUPA), did not start out to establish a new pro­
fession. Rather, it started as a loose organization 
of individuals, notably not institutions, who saw 
a need to work together to solve problems. The 
problems of the day were specific to the then-cur­
rent university patenting situation in the United 
States. A jumbled array of inconsistent patent 
policies among U.S. government agencies fund­
ing research at U.S. universities made for a dif­
ficult landscape for early practitioners of univer­
sity technology transfer. At the same time, a few 
experienced individuals recognized that other 
issues involving patenting and licensing periodi­
cally emerged in their daily activities as university 
licensing professionals. Patenting and licensing 
concerns were not commonly understood by the 
colleagues of these individuals. Although there 
were relatively few U.S. universities engaged in 
technology transfer in the mid-1970s, there was 
enough activity to suggest a need for an associa­
tion of individuals who could help each other. In 
the beginning, AUTM (SUPA, at the time) was 
chartered to create networks of individuals who 
would find solutions to problems arising from the 
complex legislative landscape in the United States 
and who could provide useful interpersonal link­
ages to help understand and deal with the com­
plexities of patent licensing. 
3. EARly DAyS: DEVElOPING THE MISSION 
Early efforts to draw new members into the fledg­
ling organization could succeed only if organizing 
filled a need. Articulating a mission was then, as 
now, indispensable to creating sustainable net­
works. While the word networking was not com­
monly used in those days, the enumerated pur­
poses for establishing the organization included, 
among others, “generating self-help programs to 
enable universities to establish an in-house patent 
technology and licensing capability” and “effect­
ing interchange of views amongst university patent 
administrators.” These goals certainly match the 
modern concept of networking. These early efforts 
to articulate a useful mission were successful: at 
its first annual meeting in 1976, some 51 indi­
viduals paid a $30 fee to join SUPA. 
No two networks are alike, nor is the pro­
cess by which they are formed. Each network is a 
unique creation formed by different people for dif­
ferent purposes. Each grows according to the ac­
tivities its members choose to focus on. Often, the 
role a network takes on is influenced by external 
factors that simply happen. Such was the case with 
SUPA. Its unexpected ability to wield influence 
through its networking capacity became apparent 
early on, as its members were rallied to gather sup­
port for the most significant piece of legislation to 
affect university technology transfer in the United 
States: the Bayh-Dole Act.2 By using the organi­
zation as a pulpit from which information about 
the Bayh-Dole bill could be broadcast, SUPA was 
able to give members the information they needed 
to urge their own congressional representatives to 
support the bill. The organization gained public 
recognition from this early experience of energiz­
ing its member network. It continues to play a 
role in virtually all U.S. federal policy efforts that 
involve technology transfer at universities. 
4. ExPANDING GEOGRAPHIC BOuNDARIES 
Today, AUTM’s membership is an ethnically 
and culturally diverse group with individuals 
from around the globe. This diversity is due, 
in part, to another external factor that played 
an unanticipated role in expanding the AUTM 
network. While there was no overt intention to 
reach beyond U.S. boundaries during SUPA’s 
formation in 1974 and 1975, the organization 
embraced Canadian institutions nearly from the 
start. It happened quite naturally that Canadian 
members were included because of their person­
al connections and relationships to SUPA’s orga­
nizers and also, perhaps, because a mailing list 
was used that reached across the United States/ 
Canadian border. The outreach encouraged a 
contingent of six Canadians to attend SUPA’s 
first annual meeting in 1976. By 1978, SUPA 
had its first Canadian trustee, and a concerted 
effort was made to extend information about 
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CHAPTER 6.8 
SUPA to licensing practitioners in Canadian 
universities. Another reason for AUTM’s inter­
national membership had to do, no doubt, with 
the omission of any geographical or national 
limitations in early membership requirements. 
Membership was open to “any individual who has 
some responsibility for the administration of inven­
tions and/or intellectual property at an institution of 
higher learning….” Although not part of the early 
planning, the fact of early Canadian involvement 
paved the way for AUTM to grow as an inclu­
sive, rather than exclusive, global network. By not 
limiting its membership, SUPA was providing av­
enues along which global networking could begin 
to develop. 
5.	 DEVElOPING A NETWORKING
STRuCTuRE 
Early decisions to structure AUTM as an asso­
ciation of individual, rather than institutional or 
organizational members, laid the foundation for 
the organization as a catalyst for networking. The 
first step in developing its networking capacity 
was to use regionalization as the best mode for 
organizing subgroups, rather than using public/ 
private, big/small or other classification schemes. 
Organizing by U.S. geographical regions (East, 
Central, West), and then forming a Canadian 
region, promoted networking in several im­
portant ways. It helped individuals in the same 
geographical region to become acquainted with 
one another and provided opportunities for dis­
cussing issues that were common to their region. 
Closer regional associations also promoted faster 
and more-satisfactory resolutions of ownership 
and licensing issues where faculty and students 
in neighboring institutions actively partnered in 
research. Organizing in regional cohorts also laid 
the groundwork for local summer meetings that 
AUTM introduced in 1992. The purpose of the 
new format of regional summer meetings was ex­
pressly to provide small, informal meeting venues 
that were more conducive to forming personal re­
lationships than were general meetings attended 
by the membership at large. 
In 1978, the organization took a second step 
to expand opportunities for member networking 
by adopting a category of affiliate membership. 
Individuals can be admitted as affiliate members 
if they are, “engaged either directly or indirectly in 
activities relating to the administration of intellec­
tual property… and [their] organization interacts 
with institutions of higher education or teaching 
hospitals.”3 An important reason for introducing 
the affiliate-member category was to provide an 
opportunity for regular members to make con­
tacts with prospective licensees, as well as with 
service providers such as patent counsel. Through 
these opportunities, members could begin to de­
velop personal networks among companies con­
sidered to be customers. AUTM recognized that 
networking could be used as a marketing tool to 
build relationships with potential customers. The 
decision to do so had a tremendous impact on the 
growth of the organization. 
Through trial and error, AUTM adopted 
an internal structure to support its networking 
goals. Initially, the management structure did 
not include any position dedicated to enriching 
networking activities. But as the organization’s 
membership grew and its educational activities 
expanded, it became clear that AUTM had to 
pay closer attention to specific member needs. 
Over a period of two years, between 1993 and 
1995, AUTM reorganized and made networking 
a fundamental focus of its organization. This was 
accomplished by adding two new positions to the 
board of trustees: a vice president for member­
ship and a vice president for communications. 
Further strengthening its commitment to the 
networking needs of its members, the organiza­
tion added a vice president for affiliate members 
to the AUTM board in 1997, and in 2000, the 
organization created a vice president for interna­
tional relations position. AUTM has made other 
recent changes at the trustee level to support and 
bring greater emphasis to its network. A vice 
president for public policy supports the efforts of 
AUTM’s members to speak in a collective voice 
on relevant policy matters. In addition, because 
the organizing of the annual meeting and the 
data gathering function, overseen by the Metrics 
and Survey Committee, have emerged as the pri­
mary interests of the organization’s membership, 
these two functions (formerly under a single vice 
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president) are now represented on the AUTM 
board by two separate vice presidents. 
6. MEMBER NETWORKING 
While supporting networking through the orga­
nizational structure is an indispensable activity, 
more than structure is needed to instill network­
ing as a seamless part of a member’s experience. 
Over the past 30 years, AUTM has pursued dif­
ferent avenues to reach this goal: 
•	 The AUTM Web site went online in 1995. 
It provides members with online access to 
shared information. Networking is spe­
cifically addressed through a MEMBER 
CONNECT capability that allows mem­
bers to find and communicate directly with 
one another through email.4 
•	 The AUTM Newsletter provides informa­
tion and articles of current interest. The 
newsletter is now delivered six times a year 
electronically, and members receive weekly 
updates by email. 
•	 Educational courses are held throughout 
the year to provide professional education 
to both new and more experienced mem­
bers. These courses directly contribute to 
the overall quality and influence of the 
AUTM member network. 
•	 Special interest groups (SIGs) encourage 
members with particular interests to meet 
together to discuss issues and solve prob­
lems. Each SIG meets in conjunction with 
AUTM’s annual meeting. 
•	 Summer meetings are held in each AUTM 
region, with networking opportunities 
forming a major element of program plan­
ning. Special workshops promoting net­
working have been included in both sum­
mer and annual meeting programs. 
•	 Activities at AUTM’s annual meeting that 
support its networking goals include: 
- logistical and space planning to facili­
tate networking breaks, which serve to 
support prearranged and impromptu 
meetings 
-	 social events specifically arranged to 
promote relationship building, such as 
sporting events, receptions, group din­
ners, and a special reception for new 
members to facilitate their first AUTM 
networking opportunity 
-	 specific time set aside for each AUTM 
region to meet 
- one afternoon dedicated to SIG meetings 
- the Networking Fair, first held in con­
junction with the 2000 annual meeting, 
providing a forum for members to meet 
with affiliate members looking for new 
licensing opportunities (The fair enables 
members to build their own marketing 
networks and has become a major an­
nual meeting event.) 
- the Innovation Showcase, introduced at 
the 2006 annual meeting, gives AUTM 
members an opportunity to formally 
present new and promising technolo­
gies to AUTM’s network of affiliate 
members (The 2006 showcase pro­
duced several relationships with poten­
tial licensees. As another successful ex­
ample of promoting networking among 
AUTM’s members and their customers, 
the showcase will be repeated at the 
2007 annual meeting and after, as in­
terest warrants.) 
Forming an integral part of the AUTM struc­
ture, most of these efforts continue today. 
Metrics are one way to measure the impor­
tance of organizational activities to members and 
to gauge the success of the organizational efforts 
to support those activities. An AUTM survey 
conducted in 2005 was especially instructive, 
as it measured the importance of networking to 
AUTM members. The survey results indicated 
that networking with colleagues was cited as a 
primary reason for joining AUTM by 22% of 
respondents; and 51% of respondents cited net­
working with colleagues as the reason for remain­
ing an AUTM member. Networking was by far 
the most important reason for retained member­
ships. Thirty-eight percent of respondents se­
lected networking as the second most important 
reason for joining AUTM. It is clear from the 
survey that working to build successful member 
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CHAPTER 6.8 





AUTM has long debated how to extend its 
member network beyond the United States and 
Canada to include relationships with technol­
ogy transfer professionals in other countries. 
The importance of learning from counterparts 
in Europe, Asia, South America, and elsewhere 
was always regarded as an important goal. 
Memberships were routinely accepted from 
individuals from any country who fit the reg­
ular-member or affiliate-member definitions. 
However, member surveys and questionnaires 
through the 1980s up until the mid-1990s 
showed that most Canadian and U.S. members 
were not engaged in enough global activities to 
warrant placing the question of how to “interna­
tionalize” on the AUTM agenda. 
As globalization increased during the 1990s, 
the situation changed. More institutions were 
doing business abroad, and there were more and 
more requests for memberships from foreign 
countries (although foreign members still account 
for only a small fraction of all AUTM member­
ships). It is probably fair to say that a major factor 
in AUTM’s thrust onto the global stage was the 
publication of two important works by the orga­
nization in 1994: the AUTM Technology Transfer 
Practice Manual and the first annual AUTM 
Licensing SurveyTM. These enhanced the organi­
zation’s reputation for leadership in technology 
transfer, both at home and abroad. Requests for 
translation rights to the practice manual made 
it clear that AUTM had provided a practical 
resource for technology transfer professionals 
regardless of nationality, and the AUTM licens­
ing survey provided a model that other countries 
and geopolitical units could look to in measuring 
their own technology transfer activities. 
Despite growing international interest, 
AUTM responded slowly. This hesitation was 
due not to any lack of interest in networking 
with international colleagues, but rather to cau­
tiousness about selecting the structure for the 
interaction. Any networking organization that 
begins regionally but wishes to expand must 
consider how the expansion fits in with the its 
mission. The organization must decide whether 
it can expand without compromising that mis­
sion and whether, in the case of AUTM, it 
should attempt, as a wider organization, to ex­
tend beyond its borders, or leave it to disparate 
national regions to do so individually. AUTM 
wrestled with these questions throughout the 
1990s. It considered proposals for international 
growth that ranged from marketing materials 
worldwide, under the AUTM brand, to fran­
chising. The organization weighed the options 
of establishing an “international region,” that 
would mirror the United States and Canadian 
regions, with establishing a looser type of struc­
ture where networking, sharing of educational 
materials, and joint meetings would form the 
basis for AUTM’s international relationships. 
The path toward finding an appropriate inter­
national role for AUTM formally began with its 
agreement in 1997 to partner with Science Alliance 
in sponsoring a conference in Amsterdam aimed at 
European participation. The success of this con­
ference resulted in similar conferences sponsored 
jointly by AUTM and Science Alliance in 1998 and 
1999. Partly as a result of networking at these con­
ferences, Europe formed its own organization, the 
Association of European Science and Technology 
Transfer Professionals (ASTP) while UNICO, 
among others, was formed in Britain. In a sense, 
then, AUTM’s approach to internationalizing was 
determined not by AUTM, but by the individuals
who would people the new international organi­
zations. Those individuals answered the question 
for themselves. They would have most to gain, in 
terms of networking and education, by forming 
their own independent organizations to focus on 
regional issues. And as these organizations now be­
gin to grow their own networking capacities, they 
may find AUTM’s experience useful. 
This is not the end of the story, however. 
Although AUTM had decided neither to fran­
chise itself nor to form an international region, 
international interest in AUTM’s educational and 
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networking activities was growing. Without com­
promising its initial mission of education, net­
working, and influencing academic technology 
transfer directions in the United States, AUTM 
added a vice president for international relations 
to its board of trustees in 2000. In the same year, 
AUTM hosted its first independent international 
conference in Edinburgh, Scotland, attracting 
182 participants from 18 countries. 
7.2 Networking for a global impact 
AUTM’s current challenge is to meet the net­
working and educational needs of colleagues in 
developing countries. A first major step in this 
effort has been to offer very low-cost electronic 
memberships (US$10 per year) to colleagues in 
developing countries. Electronic memberships 
give these members electronic access to AUTM’s 
publications and news updates and provide 
these members with opportunities to partici­
pate directly in AUTM activities—all without 
paying the higher costs associated with regular 
memberships. In an effort to build a global net­
work of partnerships, AUTM is seeking to form 
sustainable relationships with organizations 
such as MIHR (Centre for the Management of 
Intellectual Property in Health Research and 
Development) and WIPO (World Intellectual 
Property Organization). 
7.3 Networking as part of strategic planning 
While network building has been central to 
AUTM’s organizational efforts from its inception, 
in many respects networking among members has 
naturally happened without robust or direct plan­
ning. Nonetheless, as a result of recent changes 
in AUTM’s strategic planning, networking will 
command a center stage with two strategic goals: 
(1) to specifically identify and gather a number of 
essential skills and best practices that have been 
learned through AUTM’s networking activities, 
and (2) to add a new networking component 
that will establish networks with other organiza­
tions that have related interests. The latter goal 
is explained as an effort “[to] develop a network­
ing map of key organizations, both for-profit and 
not-for-profit, and individuals with whom AUTM 
wishes to collaborate.”5 
8. CONCluSIONS 
Network building by any professional organiza­
tion or association comes from a unique combi­
nation of individual member preferences, goals 
adopted by the organization, and factors that hap­
pen randomly. Thus, the experience of AUTM is 
unique simply because there is only one AUTM. 
It is not unique, however, in terms of adopting 
networking practices and activities that are driven 
by the fundamental interests of its members and 
that seek to encourage both learning and mentor-
ship based on shared experiences. This goal repre­
sents a universal maxim of network building that 
can be applied across the world, in both devel­
oped and developing countries. Strong member 
networks build quality and integrity by adopting 
best practices that have been tested and found to 
be successful. Building networks both among its 
members and with aligned organizations provides 
the credibility an organization needs if it aspires 
to a leadership position in its sphere of operation. 
The AUTM experience may be helpful for others 
seeking to reach those goals. 
Networks, as groups of like-minded, mis­
sion-driven professionals, can be formed at dif­
ferent geographical levels in order to serve vari­
ous functions. This multilevel approach allows 
organizations to address different aspects of their 
respective missions: 
•	 Local networking creates opportunities to 
work with colleagues who are in the imme­
diate vicinity. They might be working on 
similar problems, and so such networks can 
build synergistic collaborations. 
•	 National networking can be a useful 
mechanism for working with colleagues 
to encourage national legislation that 
addresses IP and technology transfer. 
National networking can also be useful 
for designing and implementing systems 
for appropriate IP management, training, 
and education. 
•	 Regional networking provides opportuni­
ties to work with neighboring countries 
in coordinated research and development 
endeavors and related IP management and 
technology transfer initiatives and includes 
building AUTM-like organizations. 
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CHAPTER 6.8 
•	 International networking will become in­
creasingly important as globalization ad­
vances. Building networks with colleagues 
from around the world will provide op­
portunities for many forms of technology 
transfer and for building IP management 
capacity. n 
kAREN HERSEy, Visiting Professor of Law, Franklin Pierce 
Law Center, 2 White Street, Concord, NH, 03301, U.S.A. 
khersey@piercelaw.edu 
1	 The author gratefully acknowledges the contribution 
to this chapter by Jon Sandelin. (Sandelin J. 2004.
Association of University Technology Managers: 30 Years 
of Innovation. Association of University Technology 
Managers: Northbrook, Ill.) While the work is not
quoted herein except as noted, it provided a history of 
AUTM that would not have been otherwise available. 
2	 35 U.S.C. § 200–212 (1980, 1984). 
3	 See AUTM Bylaws,Article IV:Categories of Membership:
Affiliate Members. www.autm.net. 
4	 www.autm.net. 
5	 AUTM Strategic Plan, adopted by the board of trustees,
1 March 2006. www.autm.net. 
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CHAPTER 6.9 
How to Select and Work with Patent Counsel
 
MICHAEL L. gOLdMAN, Partner, Nixon Peabody LLP, U.S.A. 
ABSTRACT 
Public sector technology transfer offices (TTOs) are in 
the business of “moving” technology from research and 
development to eventual commercialization in order to 
advance their missions of serving the greater public good. 
Intellectual property (IP) management is integral to this 
process, and integral to IP management is patenting. 
Maximal captured value for public sector technologies 
will be greatly affected by the quality and scope of the pat­
ent coverage and this, in turn, is greatly influenced by the 
quality of work done by patent counsel. It is therefore es­
sential for a TTO to select a patent attorney whose work 
will enhance the institution’s prospects for obtaining op­
timal licensing arrangements. From selection to hiring to 
ongoing interactions, it is important for the TTO and 
the patent counsel to develop and maintain a good work­
ing relationship. Central to this relationship is ensuring 
that patent counsel can prepare and prosecute patent ap­
plications in a manner that achieves positive results cost 
effectively. This is a complex process, and there are many 
responsibilities that both counsel and the TTO must 
assume. In addition, patent attorneys can provide gen­
eral counseling: resolving inventorship issues, providing 
licensing and agreement support, and settling disputes. 
The TTO will be the patent attorney’s actual client and 
function as the interface between counsel and the institu­
tion. By selecting qualified patent counsel and then devel­
oping a good relationship, a TTO can ease its workload 
and facilitate its mission. Therefore, retaining a skilled 
patent attorney and one that is well suited to the particu­
lar needs of the TTO is an essential element for operating 
a viable technology transfer program. The search for such 
an attorney must be approached thoughtfully. 
1. INTRODuCTION 
Technology transfer offices (TTOs) at a univer­
sity or other academic institution have only one 
product to sell—technology. The value attributed 
to such technology is influenced heavily by the 
quality and scope of the patent coverage. If a pat­
ent is drafted poorly or does not provide adequate 
coverage for the technology and reasonable exten­
sions thereof, licensing opportunities may either 
be lost or greatly devalued. Unlike manufactured 
goods, patents are not made by machines—they 
are prepared by people, in other words patent at­
torneys or patent agents. As a result, patents will 
vary in style and quality as a function of who pre­
pares them. Due to the possibility of such vari­
ability, it is important to select carefully a pat­
ent attorney whose patent work will enhance the 
institution’s prospects for obtaining profitable li­
censing arrangements. Guidelines on making this 
selection are suggested in this chapter. 
Once suitable patent counsel is selected, it is 
important to develop a good working relationship 
between the patent counsel, the technology trans­
fer manager, and any other individuals involved 
in these processes. One aspect of this developing 
relationship involves ensuring that patent counsel 
can prepare and prosecute patent applications in 
Goldman ML. 2007. How to Select and Work with Patent Counsel. In Intellectual Property Management in Health and Ag-
ricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Part IV: Chapter 1). 
© 2007. ML Goldman. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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a manner that achieves good results in a cost-ef­
fective fashion. Beyond that, however, it is im­
portant to recognize that patent attorneys can 
provide general counseling, resolve inventorship 
issues, provide licensing and agreement support, 
and resolve disputes. Suggestions on how TTOs 
can work effectively with patent counsel in all 
these areas are also provided. 
By selecting qualified patent counsel and de­
veloping a smooth working relationship with him 
or her, TTOs can develop a resource that will ease 
their workload and facilitate their ability to handle 
difficult situations. Inevitably, when patents are 
well prepared and prosecuted, they become more 
valuable, and licensing income may be enhanced. 
Making an appropriate selection of patent counsel 
and developing a good working relationship with 
him or her is one of the essential elements to oper­
ating a viable technology transfer operation. 
2. SElECTING PATENT COuNSEl 
2.1 The patent attorney 
Patent attorneys must be registered with the 
U.S. Patent and Trademark Office (PTO) in or­
der to practice before that governmental agency. 
Obtaining such registration is not like register­
ing to vote. Patent attorneys must pass a written 
examination given by the PTO. In addition, pat­
ent attorneys must have a degree in science or en­
gineering or a sizable amount of course work in 
those areas. 
The PTO registers both patent attorneys 
and patent agents. Those with law degrees and 
admission to a state bar are registered as patent 
attorneys, while individuals who are not lawyers 
are registered as patent agents. In a law firm (as 
opposed to in a university setting) the practice of 
a patent agent is usually limited to preparing and 
prosecuting patent applications before the PTO. 
Patent attorneys also handle these responsibilities 
and, additionally, may litigate patent disputes, 
prepare and negotiate license agreements, and 
provide legal advice. Because patent agents usu­
ally handle only a limited scope of work within 
a law firm, a TTO is best served by selecting a 
patent attorney as its primary contact. 
Names of patent attorneys can be obtained 
from a variety of sources. Like most profession­
als, patent attorneys are best located by seeking 
references and by “word-of-mouth.” Listings in 
a telephone book and the PTO’s register of pat­
ent attorneys are potential sources; however, they 
provide no basis for distinguishing between the 
listed individuals. The local bar association or 
intellectual property (IP) law association may 
be somewhat better resources, because these or­
ganizations would have some knowledge about 
individuals’ reputations in the community and, 
presumably, would recommend someone with a 
solid reputation. 
As members of the Association of the 
University of Technology Managers (AUTM), 
technology transfer managers are an excellent 
source of counsel who have experience with aca­
demic institutions and have provided quality as­
sistance to peers in other TTOs. A few calls to 
the TTOs of other institutions should result in 
names of recommended individuals. 
Local companies are another source of pat­
ent counsel recommendations. Companies with 
their own in-house patent attorneys are likely to 
use attorneys in private practice for some proj­
ects, so in-house patent attorneys are likely to be 
a very good resource. In companies with no in-
house patent attorney capability, the individual in 
charge of research, development, or engineering 
or the company’s general counsel are likely to be 
working with outside patent counsel and should 
be able to provide recommendations. 
2.2 Evaluating the Patent Attorneys 
Once the names of some patent attorneys have 
been obtained, the technology transfer man­
ager is ready to begin the evaluation of those 
recommended. The following items are offered 
as criteria to be considered when determining 
which attorney will best meet the needs of the 
institution: 
•	 size of the attorney’s firm 
•	 scope of the attorney’s legal experience 
•	 the attorney’s experience with academic 
institutions 
•	 the attorney’s technological background 
•	 the firm’s location 
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2.2.1 Size of the firm 
One consideration is the size of the firm with 
which the attorney is affiliated. Large firms will 
have a critical mass of patent attorneys and the 
resources to handle whatever problems the insti­
tution might encounter. These resources include 
large libraries, access to databases, staff to main­
tain and utilize the resources, and so on. The staff 
of patent attorneys at a large law firm is likely to 
include individuals with biotechnology, chemi­
cal, mechanical engineering, software, and elec­
trical engineering backgrounds, so that the firm 
can handle work in virtually any technology. In 
addition, these attorneys will collectively have 
experience in patent prosecution, litigation, IP 
counseling, interferences, and licensing. As a re­
sult, a large law firm is generally able to handle 
most any legal problem that confronts a technol­
ogy transfer manager. On the other hand, small­
er firms might have the advantage of lower cost 
while having individuals with the skills needed 
to service the institution. Although firm size is 
a consideration, its significance should not be 
overstated. The technology transfer manager will 
be working with individual attorneys, and, there­
fore, the attorney’s capabilities should receive the 
bulk of the manager’s attention during this eval­
uation process. 
2.2.2 Scope of legal experience 
A manager should know the patent counsel’s 
scope of legal experience. Because a significant 
portion of the work required by TTOs involves 
preparation and prosecution of patent applica­
tions, the attorney selected should have a solid 
patent prosecution background. Careful scruti­
ny of an individual’s capabilities in prosecuting 
patent applications is appropriate. Ask how long 
the attorney has been doing such work, how 
many applications he or she has prepared and 
prosecuted, and so on. Make sure the attorney 
does a significant amount of original patent-ap­
plication drafting as opposed to prosecuting cas­
es that originated overseas. Ask to review patents 
that the attorney prepared and the files of issued 
patents he or she prosecuted (these are publicly 
available after the patent issues or the patent ap­
plication publishes). The technology transfer 
manager should also examine whether the
attorney being considered has experience in 
other areas, such as litigation, interferences, li­
censing, and counseling. There will inevitably be 
times when a TTO will need such skills. 
2.2. Experience with academic institutions 
It is also beneficial for the patent attorney se­
lected to have experience representing academic 
institutions. Attorneys with such a background 
are comfortable working with TTOs as clients 
and in dealing with faculty. Unfortunately, such 
experience includes the ability to prepare patent 
applications under the seemingly constant pres­
sure of filing a case prior to publication. Another 
facet of expertise in handling patent matters for 
academic institutions is the ability to work with 
faculty who have little knowledge about IP and 
have a variety of undertakings competing for 
their time and attention. Lastly, the attorney 
needs to be acquainted with procedures com­
monly used by TTOs to delay or minimize costs. 
For example, patent counsel should be familiar 
with the Patent Cooperation Treaty procedure 
for foreign filing in order to delay payment of 
national filing fees in the selected foreign coun­
tries. Further, patent counsel without experi­
ence working with universities may not know 
that a reference to government rights should be 
inserted in the specification. Rapport and mu­
tual respect between patent counsel and faculty 
inventors are also crucial to cost-effective, strong 
patent protection. 
2.2. Technological background 
Another selection criterion is the extent that pat­
ent counsel’s technological background matches 
the needs of an academic institution. Larger in­
stitutions may have work in myriad technologies 
from electrical engineering to biotechnology. As 
a result, such institutions must retain different 
attorneys with these backgrounds (or a firm with 
such attorneys). On the other hand, a smaller 
institution, such as a medical center, may only 
need an attorney with a biotechnology or medical 
background. In selecting patent counsel, TTOs 
should evaluate their needs technologically and 
find someone with a matching background. 
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2.2. The firm’s location 
How close are patent counsel’s offices to the in­
stitution? Generally, it is preferable to use a local 
attorney if he or she is otherwise satisfactory. If 
there is no local attorney with the necessary legal 
and technical expertise, however, proximity must 
give way to quality. If a manager needs to go out­
side the local vicinity to find a patent attorney 
with suitable credentials, the manager should try 
to structure the relationship so that the attorney 
has maximal opportunities to visit the institu­
tion. For example, if possible, the technology 
transfer manager should give the attorney more 
than one project to work on at a time so that he 
or she can come to campus, talk to the inventors, 
and handle the matters in a cost-effective fash­
ion. Personal meetings between TTO personnel 
and patent counsel are important for fostering a 
good working relationship, and making it easier 
for the technology transfer manager and office 
staff to receive advice. When personal meetings 
are not possible or cost effective, a patent attor­
ney outside the local area should be able to work 
effectively with the technology manager and the 
institution’s faculty by telephone, fax, e-mail, and 
overnight courier. 
2. Selecting one firm vs. many 
Another criterion to consider in retaining pat­
ent counsel is how many individuals or firms 
the technology transfer manager should select. 
This depends on the volume of work generated 
at the institution. The technology transfer man­
ager must, of course, select enough individuals 
or firms to handle the institution’s work volume. 
On the other hand, it is preferable to use as few 
firms as possible to ease administrative require­
ments on the TTO. It is also easier to establish 
a good working relationship and to ensure that 
the institution’s procedures are followed when 
only a few firms are used. Nevertheless, it may 
not be a good idea to use only one firm, be­
cause that firm may not be able to handle cer­
tain projects for any of a variety of reasons. For 
example, the legal profession has rigorous con­
flict of interest standards that prevent attorneys 
from representing one client in an action against 
another client. In patent matters, conflict of 
interest issues are complicated by the need to 
avoid representing clients with technologically 
similar inventions. It is difficult to anticipate 
conflict of interest issues; they may never arise 
or may arise years after patent counsel is first 
retained. Another potential problem is that the 
counsel or the firm selected may not, at some 
distant time in the future, have the capacity 
to handle a particular project. This may occur 
because the attorney or the firm are otherwise 
engaged or lack the required technical expertise. 
Rather than dealing with a conflict of interest 
or a lack of capacity situation on a crisis basis, it 
may be better to select and work with a back-up 
firm that can handle such projects. 
2. Conditions of representation 
Once the technology transfer manager has se­
lected patent counsel, the conditions of rep­
resentation should be established. In many 
jurisdictions, lawyers are required to establish 
such a relationship in writing through a retainer 
letter. 
One purpose of the retainer letter is to es­
tablish contact people on both sides to handle 
administrative matters, particularly billing is­
sues. The TTO should select the person from its 
staff who is most likely to interact with patent 
counsel as counsel’s contact person. The retained 
attorney or law firm will designate the attorney 
who will prepare and send out bills. It may also 
be appropriate to use one attorney as the point 
of contact between the institution and the law 
firm. That person can act as ombudsman with­
in the law firm to ensure that the institution’s 
special needs or requirements are met. It is still 
a good idea, however, to know which attorney 
will be taking primary responsibility for particu­
lar projects and to ensure that the individual is 
qualified. 
The retainer letter should also establish 
billing procedures. Because most law firms 
work on an hourly rate basis, the retainer let­
ter should specify billing rates for the attorneys 
likely to be handling the institution’s work. 
There is an occasional desire to utilize alterna­
tive billing procedures, such as fixed fees or fee 
and equity combinations. Further, some TTOs 
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choose to pay their counsel a monthly retainer 
fee to cover routine counseling and advice. This 
makes TTO personnel and faculty less reluctant 
to contact counsel with small but important 
questions. The terms of any special fee arrange­
ment should be stated in the retainer letter. The 
retainer letter will also specify billing cycles. 
Generally, bills are rendered by most law firms 
every month. 
Another feature of the retainer letter will 
be a specification of the bill content. An accept­
able bill will include, on a daily basis, an indica­
tion of which attorney worked on a particular 
project, the amount of time spent daily on that 
project, and what that work involved. This will 
make clear the services for which the TTO is 
being charged. Block bills containing a narrative 
of all work done on a particular project without 
specifying which attorney did that work, how 
much time the attorney spent on a particular 
task, and when that task was done should not 
be accepted. 
TTOs should also prepare their own retain­
er letter for newly selected patent counsel. In 
the institution’s retainer letter, the TTO should 
state what it expects from counsel. One impor­
tant point that this letter should stress is that 
the TTO—not the faculty—is counsel’s client. 
This is a seemingly simple concept, because the 
TTO is receiving and paying the attorney’s bills. 
Nevertheless, things can become confusing in 
academic settings where patent counsel is work­
ing heavily with faculty members who generally 
operate as “free agents” with respect to the in­
stitution. It is easy for such faculty members to 
regard patent counsel as their attorney and to 
begin asking the attorney to handle their other 
projects without approval from the TTO. In 
such situations, patent counsel should refer such 
requests back to the TTO. The TTO’s retainer 
letter should emphasize this point and inform 
counsel that charges for unauthorized work will 
not be paid. To diminish further the possibil­
ity of such a problem, the TTO should empha­
size to faculty that patent counsel represents the 
TTO—not the individual faculty member— 
and that any patent work the faculty member 
wants carried out should be channeled through 
the TTO. 
3. WORKING WITH OuTSIDE
PATENT COuNSEl 
.1 Allocation of work 
Having selected patent counsel, the TTO should 
begin to establish a working relationship with 
that attorney. Determining how work is to be al­
located between patent counsel and the TTO is 
an important starting point in establishing such a 
relationship. Generally, the less work that is sent 
to the attorney, the lower the TTO’s legal fees. 
On the other hand, the more work the TTO re­
tains for itself, the less time its staff will have for 
other matters. It is, therefore, important for the 
TTO to assess how its resources are to be utilized 
and then to distribute its workload accordingly. 
.2 Evaluating the invention disclosure 
Quite often, a TTO will receive an invention dis­
closure from a faculty member while the underly­
ing research is ongoing. An evaluation must then 
be made to determine whether the matter is ripe 
for filing a patent application.11 The TTO should 
consider: 
•	 the invention’s commercial value 
•	 whether there will soon be a public disclo­
sure regarding the invention 
•	 whether that publication will enable those 
skilled in the art to practice the invention 
•	 whether meaningful protection can be 
obtained at this stage of the invention’s 
development 
Generally, the TTO should make an initial 
effort to decide whether (and when) a patent ap­
plication should be applied for on a particular 
technology. However, where resolution of this is­
sue becomes legally and technically complex, pat­
ent counsel should be consulted. 
Another important consideration with re­
spect to a newly submitted invention is whether 
that invention warrants an investment in patent 
protection. This decision should be made by the 
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TTO that has experience in marketing and valu­
ing technology. 
.  Pre-filing patentability evaluation 
Once the TTO makes a preliminary decision to 
proceed with obtaining patent protection, it is 
advisable to make a pre-filing patentability evalu­
ation. An initial evaluation of this type can be 
conducted by the TTO if it has access to comput­
er-search databases or is willing to work directly 
with an outside search firm. Generally, computer 
searching is appropriate for biotechnology and 
chemical inventions. On the other hand, devices 
are best searched by manually reviewing the U.S. 
Patent and Trademark Office’s collection of pat­
ents in the relevant area. The TTO, of course, 
must have the staff to conduct and/or evaluate 
such searches. 
One possibility to increase staff assistance in 
a TTO is to use engineering, science, or law stu­
dents on a part-time basis for such work. When 
utilizing such part-timers, however, it is recom­
mended that their role be restricted to gathering 
information for evaluation by patent counsel or 
a staff person who has experience in evaluating 
patentability. Staff persons making initial pat­
entability evaluations need to acquire a working 
knowledge of patentability standards and what 
is considered prior art (in other words, subject 
matter capable of preventing issuance of a pat­
ent). An ideal way to gain such an understand­
ing is to attend AUTM programs on the subject. 
Other organizations also have basic courses about 
patents and patentability. Ultimately, however, 
knowledge is best obtained over time by working 
with (and learning from) patent counsel. 
A TTO that does not have the staff to make 
an initial patentability evaluation should send 
disclosures out to patent counsel who can then 
arrange for a patentability search and make an 
evaluation. This, of course, is the most expensive 
route, because patent counsel is taking respon­
sibility for obtaining a patent search, evaluating 
that search, and providing a recommendation. 
Many TTOs, however, utilize this approach be­
cause their staffing resources are committed to 
marketing and technology transfer. 
.  Preparation and prosecution of 
a patent application 
Once a patentability search has been obtained and 
a decision is made to proceed with preparation 
and prosecution of a patent application, patent 
counsel will bear the bulk of work responsibility. 
Nevertheless, the TTO should act to facilitate the 
process (to minimize costs and to ensure that there 
is valuable IP to license). This can be achieved in a 
number of ways. 
..1 Inventor participation 
The TTO should make introductions between 
patent counsel and the inventor(s), personally or 
by mail. The TTO should insist that the number 
of meetings between counsel and the inventor(s) 
be held to a minimum. In most cases, one meet­
ing to discuss the invention and one meeting to 
discuss a draft application is sufficient. Brief tele­
phone conferences can be used to fill in gaps left 
by such meetings. 
It is important to impress upon the inventor(s) 
the need to cooperate with counsel’s requests for 
information. The inventor should furnish any 
draft journal article to facilitate preparation of 
written examples for the patent application. If 
the article does not provide sufficient information 
for examples, the inventor will be requested to 
provide additional experimental write-ups. This 
often requires a fair bit of work, but the inven­
tors are much better able to do this than patent 
counsel. Moreover, having the inventors under­
take this task (as opposed to patent counsel) will 
reduce cost. 
For biotechnology and chemical inventions, 
patent applications will frequently be faced with 
a rejection (35 U.S.C. §112, 1st paragraph: fail­
ure to disclose and explain the invention in de­
tail) because the application’s disclosure does 
not support the broad scope of protection being 
sought. To overcome this problem, the scope of 
protection may have to be narrowed to an often 
unacceptable extent. Applications based on little 
more than draft publications are particularly sus­
ceptible to such problems, because publications 
generally report only the work actually carried 
out by the researcher; it does not usually discuss 
alternatives or way in which the invention can 
0 | HANDBOOK OF BEST PRACTICES 
        
 
	 	 	
       
        
       
         
    
        
      
     
 
	
        
       
      
        
     
       
        
     
       
        
       
       
        
      
        
     
        
       
   
	 	
        
     
        
     
       
      
         
      
       
      
       
 
	 	 	 	 	
	 	 	 	
       
        
CHAPTER . 
be expanded. To obtain a broad scope of protec­
tion, the inventor(s) will be requested to assist 
patent counsel by providing information about 
how the invention can be utilized. The TTO 
should impress upon the inventor(s) the impor­
tance of their cooperation in this regard so that
commercially valuable patent rights are obtained 
in a timely manner. 
..2 Duty of disclosure 
It is important for the TTO to understand the 
duty of disclosure to the PTO. Under this duty, 
patent applicants must disclose all information 
that a reasonable examiner would consider im­
portant in deciding whether a patent should is­
sue. Inventors must not submit inaccurate data 
and must disclose all patents, publications, and 
other disclosures (such as prior art) which would 
be relevant to patentability. This includes the in­
ventor’s own efforts to disseminate information 
as well as those of others. Published abstracts and 
information disseminated at poster sessions must 
also be disclosed. This duty is not extinguished 
upon filing of the application. If the inventor dis­
covers prior art after his application for patent has 
been filed, he has a continuing duty to submit 
such information to the PTO. 
The TTO will need to advise patent counsel 
which aspects of an invention it considers to be 
valuable. The attorney can then frame the pat­
ent claims in a way that will provide the desired 
protection and enhance licensing opportunities. 
It would be prudent for the TTO to monitor 
what is being claimed initially and throughout 
prosecution to ensure claim scope expectations 
are met. 
.. Office Actions 
After the application has been filed, the PTO will 
eventually issue an “Office Action” that must be 
responded to by patent counsel. Generally, coun­
sel will need input from the inventors when pre­
paring this response. The technology transfer 
manager can assist in this process by stressing 
to the inventors that a prompt response to the 
attorney’s request for information or additional 
experimental data is imperative. If a response to 
the PTO Office Action is filed without all the 
information requested by counsel, it is likely that 
the PTO will mail another Office Action; thus 
requiring the TTO to incur the expense of fil­
ing another response, which includes the infor­
mation that should have been put into the prior 
response. 
In responding to Office Actions, extensions 
of time can be obtained by payment of additional 
fees. To minimize costs, there should be limited 
use of such extensions. 
.. Foreign filing 
After an application is on file in the United 
States, counsel will eventually inquire whether 
the case needs to be filed overseas. Decisions on 
foreign filing require consideration of whether: 
•	 the return on foreign filing justifies the 
expense 
•	 such filing is going to be considered valu­
able by domestic licensees 
•	 the invention has sufficient value to attract 
a licensee in a particular foreign country 
There are, of course, other factors that must 
be considered in deciding whether to foreign 
file, but they are beyond the scope of this chap­
ter. A technology transfer manager should pro­
vide the attorney with plenty of advance notice 
about foreign-filing plans. This will enable the 
necessary papers to be prepared without a last-
minute rush. 
.. Further research and new data 
After an application is filed, inventors often 
breathe a sigh of relief and assume that they are 
done with patent applications. They then con­
tinue their research without informing the TTO 
or patent counsel of any developments. This is 
unfortunate, because such later work can be the 
basis for further (and, indeed, often more valu­
able) patent protection. The technology transfer 
manager should impress upon the inventors the 
need to keep either patent counsel or the TTO 
apprised of future developments. 
. Maintenance fees and annuities 
Once patent protection is obtained in the United 
States or overseas, it is necessary to decide who 
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will be responsible for paying maintenance fees 
and annuities. The TTO can undertake this 
task itself or work directly with an annuity ser­
vice. On the other hand, it can rely upon pat­
ent counsel and counsel’s docketing system to 
handle this task. 
4. WORKING WITH PATENT COuNSEl ON
OTHER MATTERS 
Working with patent counsel should not be thought 
of only in terms of preparing and prosecuting pat­
ent applications. There are a number of other areas 
where counsel can provide valuable assistance. 
.1  Dispute resolution 
Quite frequently, inventorship disputes arise in 
academic settings. These issues are best resolved 
before any patent application is filed. 
Inventorship disputes may arise between 
faculty members and their graduate students. 
Sometimes, graduate students are merely “a pair 
of hands” who simply follow instructions from 
the faculty member. In other situations, the stu­
dent conceived or helped conceive the invention. 
To make a proper inventorship determination, it 
is necessary to interview the parties and to review 
their documents to ascertain each inventors’ con­
tribution. Patent counsel should have a level of 
expertise in resolving inventorship disputes that 
will make all parties involved feel that their views 
have been properly considered. 
Faculty often collaborate with scientists at 
other institutions or companies. Such collabora­
tion is rarely undertaken with an eye toward pat­
ents. However, once a decision is made to go for­
ward with a patent application, disputes can arise 
regarding who will be named as inventors. Again, 
patent counsel can be useful in investigating the 
situation and providing an opinion on how to 
resolve the matter. This is particularly important 
when dealing with a collaborating institution or 
company, because, in order to maintain what has 
been up to that point a good working relationship 
with the collaborating institution, the technology 
transfer manager may choose to use patent counsel 
as an advocate to resolve conflicts. Moreover, early 
involvement of patent counsel in any such dispute 
will enable the attorney to position the dispute to 
the advantage of the client—the TTO. 
.2  Preparation and negotiation of 
agreements 
Patent counsel can also provide TTOs with sup­
port in the preparation and negotiation of licenses 
and other agreements. Some TTOs have a great 
deal of experience in these efforts and do not need 
to use patent counsel for such services. On the 
other hand, other TTOs lack this experience and 
should strongly consider involving patent counsel 
in these activities. For instance, counsel can pre­
pare agreements, review draft agreements from 
potential licensees or the TTO, provide selected 
clauses for inclusion in any agreement, and ne­
gotiate with potential licensees. Involving patent 
counsel in such negotiations is particularly criti­
cal where discussions are centered around sub­
stantive patent issues, such as the scope of patent 
protection available, and whether the potential 
licensee has rights in the subject technology due 
to a dispute over inventorship or over who was 
first to invent. Patent counsel should be involved 
in such negotiations to help persuade potential li­
censees that the client has a meritorious position. 
At the very least, patent counsel should be kept 
apprised of the substance of any license negotia­
tions so that any changes needed to enhance the 
quality of the application can be promptly made. 
.  Interference proceedings 
Issues of priority of invention (who was first to in­
vent) are resolved in the PTO through proceed­
ings known as interferences. Often, these issues 
become apparent during license negotiations as 
discussed above. Alternatively, the inventors may 
become aware of similar work by others when 
they attend conferences. No matter how this in­
formation becomes known, it is important that 
patent counsel be kept apprised. This enables the 
attorney to undertake a strategy that will put the 
TTO in the most advantageous position possi­
ble in any interference proceeding. The attorney 
should be involved in such situations at a very 
early stage and should meet with the inventors to 
discuss strategy. In the event that an interference 
is declared, such a proceeding is like a mini-patent 
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CHAPTER . 
litigation. This is a complex proceeding, and pat­
ent counsel will need to be involved. Indeed, the 
attorney should be the institution’s representative 
in any such proceeding. 
. Getting questions answered 
Lastly (and most importantly), patent counsel 
can serve a TTO by being available to answer 
simple questions on IP matters. Most patent 
counsel are willing, without charge, to help a 
technology transfer manager in patent awareness 
efforts by giving seminars to groups of institution 
faculty or participating in special events such as 
invention fairs relating to the technology transfer 
program. By providing such advice to that office 
and faculty, patent counsel can help ensure that 
protection for valuable technology is not lost but, 
instead, enhanced. 
5. CONCluSIONS 
The mission of public sector research institutions 
is research and development of technological ad­
vances that will eventually provide benefits to the 
public, especially in terms of health and nutrition. 
IP management (of which patenting is integral) ad­
vances this mission by facilitating the development 
and commercialization of public sector innova­
tions. Therefore, for public sector TTOs, the prod­
ucts that they will want to disseminate will be their 
technology and the patents covering this technolo­
gy. To ensure that the greatest value is realized from 
the fruits of the institutions’ research scientists, it is 
essential that good patents are drafted, prosecuted 
and maintained. Therefore, it is of the utmost im­
portance to select the institution’s patent counsel 
carefully. This will involve evaluating several key 
factors, such as size of the attorney’s firm, scope of 
the attorney’s legal experience and capabilities, the 
attorney’s experience with academic institutions 
and technological background, and the firm’s geo­
graphic location. Once counsel is selected, a good 
working relationship with him or her should be ac­
tively pursued. This will require defining the condi­
tions of representation, the allocation of work, and 
the dynamics and management of patent counsel’s 
relationship with its client (the TTO) and also with 
the institution’s administration, staff and scientists. 
By carefully taking all of these steps, the TTO can 
ensure that quality patents are obtained and man­
aged in a cost effective and timely manner. n 
MICHAEL L. gOLdMAN, Partner, Nixon Peabody LLP, 
Corner of Clinton Ave. and Broad Street, P. O. Box 
31051, Clinton Square, Rochester, NY, 14603, U.S.A.
mgoldman@nixonpeabody.com
1 See also in this Handbook, chapter 9.1 by L Nelsen and 
chapter 9.3 by R Razgaitis 




   
       
 
        
       
       
     
     
           
 
     
       
CHAPTER 6.10 
How to Hire an IP Attorney and Not Go Bankrupt
 
JOHN dOddS, Founder, Dodds & Associates, U.S.A. 
ABSTRACT 
As a result of the growth in intellectual property (IP) pro­
tection, more and more institutions are establishing tech­
nology transfer offices (TTOs) to spearhead or support 
the effective transfer of technology. These offices serve a 
variety of functions, all of which must be integrated in 
order to transfer the technology cost effectively and to 
benefit the institution. One responsibility of a TTO is to 
provide services: from strategy development to contracts 
and agreements; from patenting to trademark protec­
tion; and from conflict-of-interest analysis to negotiation 
support. In all of these areas, legal inputs are important, 
and few offices will have the necessary range of in-house 
expertise. Gaining access to and developing relationships 
with attorneys are important elements in any strategy to 
set up effective TTOs. This chapter provides important 
information for deciding how to select and work with an 
attorney (or attorneys) who will provide IP backstopping 
to the TTO. 
1. INTRODuCTION 
The process of hiring an attorney to represent 
your IP interests can be complex and costly. It 
is therefore important that your office finds dy­
namic, effective, and user-oriented representation 
from the beginning—first impressions really do 
count. The support of administrators and scien­
tists to the technology transfer office is critical, 
especially in the first few months and years of its 
operation. Hiring the right lawyer can really help 
you achieve your IP goals. 
The technology transfer office (TTO) serves 
many masters and has a range of functions; this 
makes it very important at the outset to clearly 
define the scope of the office and the ways in 
which work will be analyzed and implemented. 
2. THE ATTORNEy-ClIENT RElATIONSHIP 
The legal relationship between a lawyer and a cli­
ent is protected under a special set of legal rules 
that encompass the concepts of “client confiden­
tiality” and “legal privilege.” This umbrella of 
confidentiality and legal protection from disclo­
sure is an important part of the relationship, that 
allows attorneys and clients to deal with sensitive 
issues without compromising a client’s privacy. 
This confidentiality can be particularly important 
when a staff member of a client company wishes 
to discuss a matter that involves disclosing poten­
tial wrongdoing but does not want to risk having 
the disclosure made public. It is important early 
on in the relationship for the client to understand 
the nature of this special relationship and use it 
effectively for the benefit of the TTO. 
3. THE SCOPE OF THE TTO AND ITS
lEGAl-REPRESENTATION NEEDS 
Establishing the scope of the work for the TTO 
is an important initial step. The TTO should 
be able to provide a comprehensive IP service 
without being overwhelmed with work and 
Dodds J. 2007. How to Hire an IP Attorney and Not Go Bankrupt. In Intellectual Property Management in Health and Ag-
ricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. J Dodds. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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DODDS 
obligations. The types of issues that need to be 
debated and resolved will affect the type of legal 
representation required and should include the 
ten items discussed below (see also Box 1). 
.1 Strategy development 
A critical initial role of the lawyer should be to 
work closely with the TTO to develop an IP 
strategy that delivers benefits most effectively to 
the institution or company (more about this will 
be explained below). Early decisions on the goals 
and strategies of the institution or company will 
save funds later (for example, money can be saved 
by not filing applications deemed frivolous to the 
goals of the TTO). Helping the client to decide 
goals and strategies may be one of the most criti­
cal jobs for the lawyer, whose assistance in devis­
ing the new strategy is crucial to the long-term 
success of the IP office. Ensuring that expenses 
are incurred only in those areas that fit the strat­
egy is also crucial. 
.2 Patenting 
The area of patenting includes patent searches, 
work related to freedom-to-operate, prior art 
searches, patent filing, patent maintenance, and 
so forth. 
In your discussions you need to think about 
whether the type of patenting done by the TTO 
will involve utility or design patents, or utility 
patents on plant. When should provisional appli­
cations rather than nonprovisional applications 
be used? If in doubt, use a provisional applica­
tion to buy yourself a year to seek partners and 
develop interest in the concept. (You also need to 
be aware of the Patent Cooperation Treaty pro­
visions and when to apply them in order to file 
for multicountry coverage.) It is vital to involve a 
patent attorney in these steps of the process and 
to be guided by him or her as to the nature of the 
subject matter. Try to develop a portfolio of ex­
perts that can be called upon to advise you when 
patents are being sought in their particular areas 
of expertise. 
. Trademarks and copyright work 
The trademark area is often significantly under­
used. Product branding is an important marketing 
element in a global environment. Think of the 
brand value of names such as Coca-Cola® and 
Kodak®. Again, use the guidance of the lawyer 
when choosing for inventions, their names, lo­
gos, slogans, and so forth, so as to minimize costs 
later when dealing with potential infringement 
actions. 
Copyright is a simple and cheap form of pro­
tection; it is useful for books, papers and databas­
es. In the genomics area, more attention is being 
given to using database protection as a cost-effec­
tive form of IP coverage. The use of this type of IP 
in the overall strategy development of an office is 
critical. As an example, companies such as Celera 
Genomics and Human Genome Systems have 
used highly effective copyright and contract law 
provisions to protect and exploit their databases 
on sequence data. 
. Trade secrets 
Protecting innovative ideas from becoming pub­
lic knowledge is the cheapest form of coverage— 
it is free! And not very popular with IP lawyers! 
The downside of this IP approach is that you must
keep your secret a secret. If you do not, you risk 
having someone reverse engineer your invention 
and patenting it. Then you could be precluded
from using your own invention! Protecting a se­
cret in a commercial environment is really not 
as simple as one might imagine, and substantial 
effort is required to maintain secrecy, or to li­
cense it.1 
. Plant variety protection 
An important area of IP specifically applied to 
sexually propagated plant species is plant variety 
protection. Separate chapters in this Handbook
deal with the topic in detail.2 
. Contract and agreement development 
Develop a good portfolio of standard agreements 
and templates that can then be customized as need­
ed and as appropriate. But take care to fully cus­
tomize the required content. Use a lawyer to review 
them and ensure that your interests are covered. It 
is tempting to think that once you have used one 
agreement you can just use the same for others with­
out consultation—this is a mistake! 





      
       
      
     
       
        
     
         
        
     
        
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
  	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
  	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	
  	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
	
  	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	









      
CHAPTER .10 
. Policy development 
You will need to create an internal office policy 
document, which may well assist the institu­
tion in developing its IP policy and guidelines.
Obtain a lawyer to review and comment on prog­
ress during the initial strategy development stage. 
Remember, it is hard to go against something
that is included in the policy document. Again, 
this is a crucial area since the policy of the TTO 
can be used as a tool in both negotiations and 
litigation. 
. Conflict analysis 
Consider using a lawyer and an ethics-and-conflicts 
panel to regularly review the TTO’s actions regard­
ing potential conflicts. Conflicts are a surprisingly 
common problem, especially where staffs develop 
consulting contracts, serve on boards, and so forth. 
Having a review panel is also valuable when faculty 
or staff develop competing technologies. Effective 
rules must be established so that support of one pat­
ent does not affect a competing patent, a situation 
that would breach a fiduciary relationship. 
Box 1: Scope of TTO Activities—The Easily Forgotten Items 
Legal  One of the key outputs from your lawyer should be legal documentation. 
documentation:  Do not measure the volume of paper as an indication of output. Instead, 
focus on a limited amount of high-value text such as opinion letters, con-
tracts crafted, and so forth. 
keeping  It is very important for the TTO to maintain an active surveillance of keep-
up to 	date:  ing abreast of changes. The lawyer can be used to “police” agreements and 
technologies. This can be an important way to identify infringers and po-
tential licensees. 
Legal Matters A wide range of legal matters needs to be addressed early on in the estab-
Linked to 	office lishment of the TTO. These include, but are not limited to, the following: 
organization: 
■	 Staffing contract: This should lay out a staff line-of-authority plan and
work definitions. The employment contract needs to be reviewed by a
lawyer. 
■	 Staff employment handbook: This must include matters related to con-
fidentiality, ethics, and conflict of interest.The lawyer should review and
give input on this. 
■	 Governmental and state filing requirements:Your local equivalent of the
Secretary of State can help on this. Requirements include work permits,
pension plan provisions, occupancy permits, fire inspection permits, and
other documents. 
■	 possible incorporation of the entity: The TTO may wish or may need to
form a separate legal entity. In the U.S., many of these offices are known
as research corporations and have charitable, so-called 501(c)(3) status.
This is the domain of the lawyer. Seek his or her counsel before you
proceed. 
■	 Tax matters: Be aware of all U.S. federal and state tax matters if you are
in the U.S. (Other countries have local, regional, and/or national laws)
Hire a good accountant and audit company. They are as important as
your lawyer. 
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DODDS 
.  Licensing 
The bread and butter of a TTO is licensing. The 
flow of information, ideas and materials is two-
way. Some staff members will be accessing the 
IP of others through license agreements, and the 
TTO will be licensing technologies through li­
cense agreements. Be careful, you will be bound 
to abide by any agreements that you sign! Make 
sure a lawyer reviews all major-deal documents. 
You may also wish to seek advice from a lawyer on 
creative arrangements for licensing your technol­
ogy. Such arrangements may involve using your 
IP as an investment by contributing to a joint 
venture. Consider hiring a lawyer or technology 
transfer company to do this on a contingency or 
partial-contingency basis. 
.10 Negotiations support 
Successful negotiating is an art that takes skill, 
practice, and sharp wits. Lawyers are trained in 
the skills and use them each day. Moreover, the 
representational responsibility of a lawyer can 
make him or her an excellent advocate for the 
TTO. Under certain circumstances, you may 
wish to use a lawyer as your negotiator. 
.11  Strategy development and technology 
assessment 
The area of strategy development and technology 
assessment is one of great importance. It is per­
haps the area to which money spent on lawyer 
fees can be applied most effectively. If your TTO 
strategy is ill conceived, all efforts in the other as­
pects of your office are redundant. 
One of the key challenges facing any TTO, 
especially in the early stages, is trying to decide 
which inventions to protect and to what extent 
the protections should apply (that is, in which 
countries or fields of use). Costs and fees are such 
that no individual entity has the resources to pat­
ent all inventions. Typically, ten invention disclo­
sures will lead to one patent, one license will come 
from ten patents, and royalties will come from 
10% of the patents. That is why the lawyers’ input 
here is so vital. Use patent attorneys to help you 
evaluate the potential market for an invention. 
It is critical to spend your money wisely and 
try to evaluate only those inventions that are truly 
innovative and that appear to have commercial 
value. Remember that some great science has no 
market, and some simple inventions have huge 
commercial value. 
Most often, TTOs set up an internal com­
mittee, or panel, to review invention disclosures 
and give feedback to inventors. Use the lawyer as 
a part of this evaluation process. 
4. THINKING OuTSIDE THE BOx 
The lawyer can be used highly effectively to think 
of innovative ways of capturing value from an IP 
portfolio. Patenting may not be a viable option in 
some areas, and the use of creative instruments of 
copyright, trademark, and contract law may be vi­
able, and even preferable, alternatives to consider. 
.1  Outsourcing services 
An effective technology transfer office should 
consider building access to a set of contracting 
agents, who can provide external skills that can 
be counted on for needed advice or service. This 
might be achieved through the maintenance of 
an advisory panel, through a series of consulting 
contracts, or through a well-functioning personal 
(business) network. The lawyer can play a criti­
cal role in setting up such outsourcing arrange­
ments. Before outsourcing services, consider the 
following: 
•	 Hiring patent attorneys: Choose an attor­
ney with a range of qualifications and spe­
cializations tailored to the nature of the in­
vention portfolio. A chemical engineering 
background might be helpful for advising 
on a natural products patent, for example, 
whereas a background in biological engi­
neering might prove better for handling a 
patent on a biolistic gun. 
•	 Retaining general legal counsel: Find 
someone who knows the big picture but 
who understands the science of the inven­
tion and the client as well. Be guided by 
the attorney as to the big-picture issues. 
.2  Costs and fees 
The cost of evaluating, protecting, and maintaining 
IP coverage is not insubstantial. A wide range of 
 | HANDBOOK OF BEST PRACTICES 
       
         
        
	 	 	 	 	 	
         
         
          
        
        
        
       
       
        
       







fees is payable in relation to IP protection. The types 
of fees a TTO may face include the following: 
•	 patent and trademark search fees 
•	 patent and trademark filing fees 
•	 plant variety protection fees 
•	 maintenance fees 
•	 copyright filing fees 
•	 issue fees 
•	 attorney fees 
•	 drafting fees 
These fees can be substantial. In the United 
States you would pay US$1,200–$2,000 for a 
trademark, US$2,500–$8,000 for a provisional 
patent application, and US$6,000–$30,000 for 
a nonprovisional application. A patent filed and 
maintained worldwide over its entire life will cost 
about US$500,000 in fees. When retaining a law­
yer to negotiate for you, don’t neglect to negotiate 
your legal fees! 
. Use of form agreements and contracts 
Lawyers often do not like the use of standard forms. 
The forms are designed to be party neutral. The ob­
ligation of a lawyer is to act on the client’s behalf, 
which is why lawyers react adversely to such forms. 
the final version to comment on any specific clauses 
that need to be negotiated and agreed upon. 
5.	 CONCluSIONS–AND A NOTE
ABOuT CONFIDENTIAlITy 
The importance of confidentiality and trust can­
not be underestimated. The inventions of the 
clients, the nature of the business, and so forth, 
requires that all TTO employees observe the 
strictest rules in relation to confidentiality and 
conflict-of-interest matters. The hiring of person­
nel should take this into account. Moreover, full 
and adequate documentation about confidential­
ity and conflict-of-interest issues, in relation to 
the TTO’s operations, should be used to further 
strengthen compliance with the rules. The lawyer 
has a special relationship to the TTO and can be 
used as a valuable resource to deal with difficult 
and delicate matters. Attorney privilege is a legal 
strength to be used to your advantage. ■ 
JOHN dOddS, Founder, Dodds & Associates, 1707 N 
Street NW, Washington, D.C., 20036, U.S.A. j.dodds@ 
doddsassociates.com
At times, it is tempting to use standard forms 
1	 See also in this Handbook, chapter 11.5 by K Jorda. 
and agreements to keep costs low. The situation can 
2	 See also in this Handbook, chapter 4.7 by M Blakeney be resolved by using standard forms and agreements and chapter 10.11 by W Pardee. 
where appropriate, and then having a lawyer review 
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CHAPTER 6.11 
Technology Transfer Data Management
 
ROBERT g. SLOMAN, CEO, Inteum Company LLC, U.S.A. 
ABSTRACT 
A technology transfer office must be able to manage enor­
mous amounts of dynamic data. This chapter examines 
how electronic file systems can meet this need, focusing 
on the importance of shared communication links and 
the benefits of using advanced spreadsheet applications 
developed by the private sector. It considers the relative 
merits of spreadsheets, flat file databases, and relational 
databases, and highlights the numerous benefits of a net­
work solution. The chapter explains how to ensure data 
integrity and manage “analysis paralysis” in such systems, 
and it offers a self-questionnaire to guide decisions about 
adopting a software management solution. 
1. INTRODuCTION 
Managing a technology transfer office (TTO) re­
quires strong administrative, technical, and com­
munication skills. To make informed decisions, a 
tremendous diversity of information needs to be 
captured and analyzed. A TTO’s ability to handle 
this information is complicated by how rapidly 
new information becomes available. Moreover, 
the average academic TTO usually has limited 
funds and staff with which to create such a so­
phisticated data management system. 
Meeting these challenges and making time­
ly, informed decisions can be very rewarding. 
However, as workflow increases, the ability to 
maintain a high standard of decision making can 
be compromised. If the TTO is a closed system, and 
no additional professional or support resources can 
be acquired to deal with the additional workflow, 
other solutions must be found. These solutions will 
very likely involve fundamentally changing how 
the office uses its available tools. 
Fortunately, being one or more generations 
behind in implementing data management and 
decision support software systems does not trans­
late into years of catch-up for the TTO. TTOs 
can reap the rewards of corporate investment in 
these areas. For more than a decade, companies 
have collectively spent many millions of dollars ex­
perimenting with executive decision-support soft­
ware and management information systems that 
were designed to get information to organizations 
quickly and thus increase efficiency and facilitate 
rapid response. These objectives apply equally well 
to TTOs. 
Airline-booking applications are good exam­
ples of large, end-user friendly, real-time informa­
tion systems. Much has been learned about soft­
ware design since the first implementation of such 
systems, resulting in more accessible applications 
that conform to the workflow logic of the end user. 
While early linear programming efforts proved 
Sloman RG. 2007. Technology Transfer Data Management. In Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
California, U.S.A. Available online at  www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Part II: Chapter 4).
© 2007. RG Sloman. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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inaccessible to end users, modern software applica­
tion design is event driven and object oriented. 
As computer prices have plummeted, the pow­
er and sophistication of hardware computing have 
increased dramatically. Decommissioning exotic 
mainframe computers because of their exceptional 
maintenance and professional support costs, com­
panies are now implementing enterprise computing 
models on local area networks (LAN) of worksta­
tions, sharing resources from a file server.1 The com­
puting advances pioneered in the corporate realm— 
specifically, improved efficiency, reliability and work 
throughput—are now available to TTO managers. 
2. PHySICAl OR ElECTRONIC FIlES? 
2.1 Considerations 
A resource for shared information should be ac­
cessible to those who need the information in or­
der to make decisions. Often, technology transfer 
and intellectual property (IP) management deci­
sions depend on a mix of variables, including in­
formation about the inventors, their ongoing re­
search programs, the companies interested in the 
technology, the relevant patent applications and 
their status, and the amount of money invested in 
each technology transfer case. In this complex en­
vironment, electronic data management systems 
provide the most rapidly adaptable support tool. 
Physical files suffer from some fundamental 
limitations. In a TTO, records (or documents) are 
generally filed by case or technology according to 
the manager’s guidelines. The technology transfer 
manager will probably find physical files limited 
and difficult to maintain because there will be only 
a single physical copy—unless staff members make 
multiple copies of files and place them in related 
areas. The person doing the filing makes a judg­
ment about where best to file each document. This 
is why a manager may routinely find information 
in the “wrong place”—or not find it at all. A man­
ager may apply certain rules for filing documents, 
but the rules are generally complex and loose, and 
therefore are frequently bent or misapplied. Often, 
a technology transfer manager must review an en­
tire file to find the information in question. Another 
problem with physical files is the time it takes for 
information to be processed and correctly filed. If 
files are not up-to-date, a technology transfer man­
ager may be forced to wade through stacks of pa­
perwork to find a needed piece of information. 
With an electronic system, however, a job 
packet can be quickly delegated to an officemate. 
All case-related data and activities can be transferred 
easily, with instructions, to another manager or to 
support staff. This is the electronic equivalent of 
handing a physical file to a person with the neces­
sary instructions and briefing information. With a 
physical file, the recipient may miss relevant action 
items. However, with an electronic file, the previous 
manager can easily transfer a variety of action items 
associated with that case to the new manager. 
Of course, one of the most compelling reasons 
to use a state-of-the-art data management system is 
the unprecedented ability to interrogate enterprise-
wide data creatively. A manager can now rapidly for­
mulate questions that in a physical file environment 
would be unthinkable due to the time required to 
assemble and analyze the information sets. 
2.2 Connectivity 
The key to achieving connectivity through net­
worked computing environments is to create 
shared communications links, including e-mail 
facilities and a shared information pool. No alter­
native method achieves the degree of connectiv­
ity offered by a networked environment. Indeed, 
networked computing environments can develop 
connectivity between the files themselves in a way 
that is not possible with physical files. For ex­
ample, a technology transfer manager can check 
to see if contact has been made with a particular 
company or individual, regardless of what case 
that contact is associated with. The labor required 
to accomplish this task with physical files would 
be prohibitive. 
3. FINDING THE BEST TOOl FOR THE JOB 
3.1 Computer applications 
3.1.1 Spreadsheets 
Financial modeling tools, called spreadsheets, 
were the first applications developed for the PC. 
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CHAPTER 6.11 
Since the release of Visicalc™,the first widely used 
spreadsheet, many generations of powerful ana­
lytical tools have been developed. (A secondary 
market has developed for templates. These add 
utility by providing spreadsheet layouts and built-
in algorithms, enabling plug-and-play simplicity. 
Unfortunately, few of these templates are useful 
for the technology transfer professional.) 
When a technology transfer manager is seek­
ing to generate graphs from data for reports, the 
spreadsheet has no equal. Users can create relation­
ships between different spreadsheets, allowing data 
to be shared and linked from one sheet to another. 
However, users who have tried to create complex 
links between several layers of spreadsheets know 
that this can be a complex task, tantamount to 
programming. Unfortunately, because of the soft 
nature of the links, they can become corrupted. 
One corrupt spreadsheet cell, or one with a pilot 
error,2 can be copied into other spreadsheets with 
catastrophic results. Such errors, moreover, are dif­
ficult to trace. 
Of course, spreadsheets are useful for budget­
ing and license revenue forecasting. They are well 
understood and provide dramatic visual outputs, 
such as graphs. The modern spreadsheet is capable 
of conducting “what if?” scenarios that can be par­
ticularly useful when attempting to forecast patent 
maintenance fees, for example. Some of these pack­
ages also contain rudimentary database-like func­
tions that create screens for data entry. However, 
the sheer size and complexity of spreadsheets make 
them difficult to program. In addition, they do not 
compare favorably in this area to purpose-built da­
tabase products. 
Some very sophisticated, complex systems us­
ing Microsoft’s Excel® and other software products 
have been developed by TTOs. Sharing these sys­
tems is encouraged, since the time required for de­
signing linked spreadsheets suitable for managing 
the forecasting and budget processes is daunting. 
3.1.2 Flat file databases 
Flat file databases create an environment where 
the user can create records with data about a 
particular class of event or package of informa­
tion. For example, records on a technology and 
the data elements directly related to it may be 
contained in a single record. Patents, however, 
would be in a separate database file. In a flat file 
database, therefore, a user would need to consult 
first one database and then the others in order to 
connect the data in meaningful ways. Because a 
programmer or user can change the data structure 
of a particular table, these databases are quite flex­
ible. Moreover, they can also be changed with­
out upsetting relations with other databases. In 
short, flat file databases have the benefits of de­
sign simplicity, ready recognition by end-users, 
and flexibility. 
Though navigation is straightforward in a flat 
file database, the burden is on the user to look 
in the right place. There are other disadvantages. 
Generally, the end user must purchase a flat file da­
tabase engine and then design his or her own sys­
tem. Experienced users of flat file databases work 
out routines and patterns of interrogation at which 
they become adept; new users, however, may have 
a problem navigating around these systems with 
sure-footedness. 
In addition, reporting from a flat file database 
is difficult because the links required to bring infor­
mation together can be as complex as those used to 
link cells in spreadsheets. If a technology transfer 
manager is contemplating a flat file database struc­
ture, she or he should consider preferred report de­
sign and useful templates, which will reduce some 
of the complexity. 
3.1.3 Relational databases 
Relational databases contain a group of tables 
with various aspects of the information base cod­
ed together or hard-linked to other tables. A data-
input screen may draw on a number of tables to 
show information in a pseudorelational mode. In 
a truly relational database design, however, there 
must be one or more linking fields between tables. 
Technology transfer managers require access 
to data on finances, faculty, patent prosecution, 
and marketing contacts, among other things. Each 
functional data element might be contained in a 
separate data management resource, but this would 
be inefficient. In programming parlance, access to 
backroom (detail) data is important, but technol­
ogy transfer managers increasingly value data that 
can be easily navigated without any knowledge of 
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SLOMAN 
the underlying data structure. A relational database 
system can accommodate this need. 
Relational database systems permit the ma­
nipulation of larger sets, such as the technology 
portfolios for each manager and each department, 
among myriad other selectable criteria.Transferring 
sets of physical files would require a review of the 
file and, probably, a briefing from a previous man­
ager. With a relational database, one can transfer 
the entire project from one manager to another, 
enabling a more efficient transfer of action items 
and information than is possible with physical files. 
This maximizes the use of professional management 
talent, for example, if one manager needed to focus 
attention on other urgent projects, such as infringe­
ment support, cases could easily be temporarily re­
deployed with a relational database tool. 
The inherently rigid structure and connectivity 
of data in a relational database gives unprecedented 
power to look at the data and business models in 
different and creative ways. Exception reports, run 
with some frequency, can rapidly show where data 
gaps exist, which can drive administrative proj­
ects. Managers can forecast expenses and revenues 
to isolate a variety of parameters and determine if 
divisions are real. The ability to conduct nearly in­
stantaneous audits can help managers plan office 
activities, and this connectivity also enables a su­
pervising manager to evaluate the performance of 
technology transfer managers using data manage­
ment systems. 
Some argue that a disadvantage of a relational 
database is that it uses a rigorous data structure that 
does not allow variability. However, a rigid data 
structure is essential if a technology transfer man­
ager wants to get reliable results from an electronic 
interrogation. To accommodate the real need for 
free-form annotations, it is possible to provide 
note or memo fields in which special details can 
be recorded. Indeed, a technology transfer manager 
should look for a balance between rules and flex­
ibility when selecting or designing a relational data 
management system. 
In some relational database models, connec­
tivity is enhanced by regularly downloading recent 
data that can be read and interpreted by all office 
members. This works best when the office eschews 
a hierarchical structure. If the office director,
managers, and support staff are electronically briefed 
about cases and contacts, then meetings can proceed 
more efficiently, and briefing sessions can be short­
ened or eliminated. When meetings do occur, it is 
more likely that decisions can be made with confi­
dence; those who are not directly involved in the 
case may still have sufficient information to contrib­
ute useful ideas. Also, when support staff is kept cur­
rent they can plan their workflow more efficiently. 
In relational database design, there are rules 
that describe how data should be “normalized.”3 
Rigid rules dictate elegance and resource efficiency. 
For transaction-based databases, the design can be 
optimized to increase the speed of recording a sales 
transaction or stock movement. Alternatively, the 
design can be optimized for ready access to a large 
pool of related data. This latter version most con­
forms to the needs of a technology transfer man­
agement information system. The reason is simple: 
technology transfer decisions are based on complex, 
variable information. A technology transfer manag­
er requires access to a range of information, includ­
ing IP status, commercial contacts, expenses, and 
other information. The transaction- and related-
data design paradigms, however, need not be mu­
tually exclusive. In other words, even if the demand 
for data interconnectedness dominates, the goal of 
high-speed response need not be abandoned. 
When thinking about the complexity of tech­
nology transfer data management requirements, 
the relational database is the engine of choice be­
cause it requires less data entry and can be easier 
to maintain and audit. With expert programming 
code, a relational database can quickly present the 
information a technology transfer manager needs. 
Because the complexity of the data sets requires 
these powerful and capable computing tools, the 
commercial databases used by the technology 
transfer community are all relational or pseudo-
relational database engines. 
One perceived disadvantage of licensing an 
independent vendor’s technology transfer manage­
ment system is that the vendor controls the struc­
tural design. That is, during the next generation 
of offerings, additions will invariably arise, and 
the end user is not able to modify the data struc­
tures as needed. Viewed from the perspectives of 
the vendor and licensee, there are excellent reasons 
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CHAPTER 6.11 
for this limitation. The cost of developing the code 
generated for such applications frequently involves 
many thousands of dollars, as well as years of care­
ful thought and programming. The investment in 
programming code of this type can cost in excess 
of US$200,000! 
3.2 Network solutions 
All of the above database tools can be shared over 
a local area network (LAN). However, only rela­
tional databases can function reliably in multiuser 
mode, with a number of users accessing the same 
data pool simultaneously, without fear of data 
corruption. For example, on a LAN, if a technol­
ogy transfer manager were to open a spreadsheet 
file that someone else had on his or her screen, the 
manager would either receive an error message 
indicating that the file was in use or be advised 
that it was available in read-only mode. In the 
later scenario, any changes made would be lost. 
More accurately, they would be saved but then 
overwritten by the person who had the file open 
first and saved it. Flat file databases may be prob­
lematic in the same way. 
Relational databases have built-in record lock­
ing and transaction-tracking features that control 
the access to shared files and the procedures used to 
update data. Many TTOs associate networks with 
the Internet. This chapter, however, is addressing 
LANs, a computing environment where one com­
puter acts as the file server for client workstations. 
LAN technology has advanced dramatically in the 
last several years, with a number of well-supported 
systems available. Even for small TTOs, the advan­
tages of using a LAN in combination with a rela­
tional database are remarkable. 
3.3 Data portability 
Most software applications are able to export 
and import data. The advantages of data por­
tability are evident. If a technology transfer 
manager can enter data in one application and 
transport it in an organized fashion to a differ­
ent application, data doesn’t have to be entered 
twice. Rekeying data not only wastes time but 
also increases the likelihood of data integrity 
problems if data is recorded differently in 
two places (for example, if the date of receipt 
of funds from a licensee or the response due 
date for a patent application office action is
wrongly entered). 
It is important to use the most appropri­
ate tool for a given job. Relational databases 
are the best all-around data management tool. 
Spreadsheets are a good tool for financial analy­
sis and graphics. A technology transfer manager 
may choose to use a relational database engine to 
store data and then export data to a spreadsheet 
for manipulation and graphing. 
Relational database engines are at the core of 
all commercially available accounting packages. An 
increasing number of commercially available ac­
counting packages are designing their database file 
structure to be compatible with DBase®. DBase data 
file structures, in turn, are an example of so-called 
XBase data structures. When the data structures 
between two applications are equivalent or com­
patible, fewer steps are required to translate data 
between them. So, if an accounting package with 
DBase-compatible data structure is used, it would 
be advantageous to choose a management informa­
tion system with a compatible data file structure. 
DBase data file structure is currently supported 
and promoted by two of the leading proprietary 
relational-database engine suppliers. Accordingly, a 
technology transfer manager should be aware that 
not all relational database engines are compatible 
with DBase. 
3.4 Data distribution 
Data distribution means providing rapid access 
to current information to precisely those people 
who require it to make informed decisions. The 
ease with which data can be queried will deter­
mine how often the database is used by the tech­
nology transfer staff. With the power of relational 
database engines and the connectivity of a LAN, 
designs that can be easily interrogated by end us­
ers are now possible. 
The technology transfer manager should view 
the investment in the acquisition of a system and 
the time spent in data entry as an asset in produc­
tion. This system data should be fully utilized by 
the technology transfer manager to coordinate 
office activities and generate reports sequentially or 
on an ad hoc basis. 
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SLOMAN 
3.5 Paradigms for data management 
The main design paradigms for technology transfer 
management information systems are driven either 
by (1) committee andadministrationor (2) end-user 
functionality. System designs that are driven by the 
former usually prioritize the design of report out­
puts. Administration, for example, may announce, 
“We want a monthly report showing which patent 
applications are due for a maintenance fee, sorted 
by the technology licensing manager.” As a result, a 
table structure may be defined and a report written 
to support this management objective. But while 
defining objectives is important, this approach may 
create conflicts in terms of data structure. To create 
a design of this type requires the consideration of 
all the ways the data may be interrogated, while at 
the same time avoiding massive data duplication, 
rekeying, or excessive look-up requirements that 
slow a system down. 
If the system is designed around the very spe­
cific interrogatory output paradigm, the administra­
tive objectives will be supported, but the ease of use 
for end users will be diminished. When a manage­
ment information system provides little end-user 
functionality, it will not be kept as current as one 
that does. With daily functionality, end users more 
easily navigate around other parts of the system. 
Even though most users will spend 80% or more 
of their time in a single module, they will be famil­
iar enough with navigation techniques to find their 
way to other relevant sections when the need arises. 
A technology transfer manager may want to 
opt for a system designed first for the end user, but 
with powerful and flexible administrative report 
functions. The design goal should be to create a 
system that acts as a partner in real time, so that 
data is entered as the workday unfolds. If users en­
ter the data as they move along during their day, 
data entry is more current and accurate. In addi­
tion, the time burden decreases and the sense of 
accomplishment is enhanced. 
4. DATA INTEGRITy 
4.1 Assigning data-entry tasks 
For day-to-day contact functions, users should 
have the flexibility to use the system in a way that 
supports their work habits. Relying on technol­
ogy transfer managers to complete data entry on 
their patents and licenses may not be the most 
effective use of their time. Rather, this task could 
more efficiently be delegated to the individual 
responsible for administering the contracts or to 
an experienced administrative staff person. It is 
desirable that a single individual be delegated the 
responsibility of entering specific sections of the 
data (for example, the data on patent prosecution 
and revenues and expenses for each technology 
or case). This approach reduces the likelihood of 
errors and data duplication. In general, a manage­
ment information system should allow an admin­
istrative support staff member to easily complete 
such data entry. 
4.2 Auditing 
It is preferable to conduct audits of the informa­
tion in all environments. Reports can accomplish 
this function and can be set up to run at certain 
intervals or to run on an as-needed basis. In ad­
dition, for truly mission-critical information, re­
ports should be created and submitted to outside 
professional service providers for periodic review. 
An example might be generating reports from the 
database with current information about a par­
ticular patent prosecution and presenting that 
report, or portfolio of reports, to the patent at­
torney. Staff could then request that the attorney 
update the report. 
One direct and immediate benefit of this ap­
proach is improved data integrity. Another benefit 
is that service providers may come to understand 
how much information about a university’s tech­
nology transfer assets, patent applications in this 
case, is valued. 
If a technology transfer manager is interested in 
implementing such a review, doing so on a rotating 
basis, rather than as a direct audit of all records, may 
be sufficient and would reduce incremental costs. 
5. ANAlySIS PARAlySIS 
The term analysis paralysis is being used here to 
describe a period of time when an office shuts 
down operations, virtually stopping all services, to 
allow the staff time to update, analyze, modify, and 
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CHAPTER 6.11 
discuss the technology data. This process can be an 
excellent educational experience for an entire of­
fice staff. Generally, teams should be planned in 
advance and assigned a batch of technology or case 
files to find answers to predefined questions. This 
process can help define the office’s future mode 
of operations and may uncover areas in need of 
attention. If the entire staff is engaged in the pro­
cess, a sense of team building may be achieved. 
Through this process, a technology transfer 
manager may be able to anticipate questions from 
the university’s administration. Moreover, if all 
technology staff are involved in the production and 
interpretation of the data, experts among the staff 
may emerge in different fields. And finally, periodic 
analysis of data results allows for a faster response 
when a quick, unexpected analysis is needed. This 
“time out” might seem an impossible goal, but the 
rewards can far outweigh the cost. 
6. EVAluATING SOFTWARE SOluTIONS 
If a technology transfer manager is going to adopt a 
software management set of solutions, this author 
suggests taking the process to its most advanced 
state possible. In determining suitability, a number 
of questions should be asked (see Box 1). 
The decision to design a system or acquire 
a commercially available software package to
manage technology transfer data should be based 
on the TTO’s needs. Like all computer solutions, 
the system will be only as good as the people
Box 1: Key Questions for Decision Makers in Evaluating Software Solutions
 
1. How suitable to the task is the software solution? 
The solution recommended in this chapter is not cheap, especially when a technology transfer 
manager considers the cost of a LAN, a commercially available package, and training.
2. Is adopting the software solution worth the investment of both money and staff time? 
Only the technology transfer manager can answer that question, taking into consideration 
all variables of the university and the TTO. A technology manager may want to consider the 
following advantages of incorporating a software solution: 
a) Managers with ready access to current data can work faster and with greater accuracy and 
can make decisions with increased confidence. 
b) Staff will be more likely to bring important issues to the attention of the supervising 
technology transfer manager, and necessary interventions will more likely occur. 
c) As a training tool for new technology licensing managers, the software tools described in 
this chapter can create an environment where staff can work more efficiently, with fewer work 
projects falling behind schedule. 
d) Software solutions can increase responsiveness to clients and the ability to analyze workflow 
and make appropriate resource allocations. 
3. Why is time being spent in entering the data (as opposed to completing the 
day-to-day functions)? 
One possible response to this question is that data entry creates a work environment where 
relevant data can be readily accessed when needed by users, managers, and support staff so 
informed decisions can be made in a timely fashion. 
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using it. Therefore, a final consideration when 
purchasing or developing any system is the likeli­
hood that staff will actually use the software. It 
is not necessarily true that staff who collectively 
design a system will be more likely to use it. This 
may sound counterintuitive, but it is based on 
our real-world experience. 
7.	 CONCluSIONS 
A key element in developing a data management 
system is setting clear goals of effective data man­
agement. The technology transfer manager should 
have information to support the essential tasks of 
the office staff in both tactical and strategic modes. 
Tactical support means ensuring ready and cur­
rent access to information about all aspects of a 
particular case. The strategic mode demands the 
presentation of information that can illuminate 
trends and assist in office organization, workflow 
distribution, and planning. Other examples of 
such data use include revenue forecasting and 
cash-flow planning. While cash flow may not be 
a prominent issue yet in all academic TTOs, the 
cost of doing business in the field of technology 
transfer is increasing rapidly, and cash-flow plan­
ing may soon become imperative. 
Data management tools should act in con­
cert with the goals of managers and adapt to the 
way managers work, instead of requiring users to 
adopt a certain pattern of processing information. 
Regimentation of data is important, but this need 
not create a barrier to end users. 
It also is important to think ahead and design 
an application for the future. As programming 
tools and desktop computers have become more 
powerful, workgroup software with event-driven, 
rather than programming-driven, applications have 
emerged in full graphical user interface presenta­
tion formats. The industrial relational-database lit­
erature reveals that the focus of applications devel­
opment is moving away from the exotic hardware 
of the mainframe and minicomputer and toward 
the client-server model of distributed computing 
environments such as LANs. 
The TTO management experience is relatively 
fresh, and the cost of failing to professionally man­
age data is not yet widely recognized. Examples of 
such costs include large, unpaid obligations that 
persist because of inefficient methods for collecting 
revenues, or poor management of a technologies 
portfolio. Both of these situations could result in 
real costs to the TTO, although it may take several 
years for this to become evident. 
With a properly designed and implemented 
software solution, a manager can decide with 
greater confidence that the data needed to sup­
port a decision are at hand. Allowing managers 
and staff to be more responsive to clients, data 
management systems solutions can also dramati­
cally enhance the general professionalism of an 
office. n 
ROBERT g. SLOMAN, CEO, Inteum Company LLC, 8826 
NE 124th Street, Kirkland, WA, 90834, U.S.A. robs@in­
teum.com 
1	 A file server is a high-powered personal computer 
linked by communication cables to computer worksta-
tions. The file server provides storage of shared data 
files and software applications, as well as printer shar-
ing capabilities. 
2	 A spreadsheet “pilot error” is a data entry error made 
in an algorithm or data cell that causes erroneous 
results. 
3	 “Normalized” data has been organized into relation-
ships in a way that seeks to minimize duplication of 
data and maintain data integrity. 
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CHAPTER 6.12 
WIIPS™:Whitehead Institute Intellectual 

Property System (A Relational Database for 

IP Management and Technology Transfer)
 
aMina haMZaoui, Associate Director, Intellectual Property, The Whitehead Institute for Biomedical Research, U.S.A. 
We are pleased to announce that the Whitehead 
Institute for Biomedical Research in Cambridge, 
Massachusetts, U.S.A., has kindly allowed 
MIHR and PIPRA to distribute the Institute’s 
proprietary WIIPS™ Database. This database 
offers tangible benefits to improve the function 
and efficiency of any technology transfer office 
(TTO). In accordance with the non-profit mis­
sions of MIHR, PIPRA, and the Whitehead 
Institute, the sharing of WIIPS™ will be free of 
charge and is primarily aimed at assisting devel­
oping country TTOs. 
WIIPS™ is a relational database designed to 
automate essential intellectual property man­
agement and technology transfer functions. It 
simplifies recordkeeping and generates useful 
reports for technology disclosures, patent ap­
plications, joint invention agreements, licenses, 
and material transfer agreements. In addition, 
the system stores essential information on every 
inventor, owner, and licensee who has interacted 
with a given TTO. Thus, the system effectively 
automates all recordkeeping, and offers imme­
diate and accurate information on the status of 
every case, including documentation, patenting 
and licensing information. Not only will it al­
low TTOs to better manage volumes of IP data, 
it will also increase productivity and accuracy, 
since WIIPS™ allows for easy communication 
among staff members. The system is easy to 
learn and use and comes with detailed system 
documentation. In addition, WIIPS™ provides 
complete financial control, with financial audit 
trails and automation to meet the compliance 
requirements that are often required of TTOs. 
WIIPS™ can be used to manage all the financial 
aspects of the TTO, allowing better control of 
patent-filing costs. The system permits effective
monitoring of expenses and legal bills, thus 
helping to ensure timely expense reimburse­
ment and accounts receivable management, 
and it facilitates faster royalty calculation and 
distribution. 
In order to better adapt WIIPS™to the 
needs of TTOs, users will be authorized to copy 
and modify the software, and/or to re-write the 
accompanying user guide, as long as any modi­
fied products mention that the product is based 
on WIIPS™ and has been modified by the user. 
Users may also make and use as many copies of 
WIIPS™ as are required. 
The relational database and the user guide 
can be downloaded for free, subject to the terms 
of a license, from the online version of the 
Handbook at www.ipHandbook.org as of August 
2007. The database requires that users are run­
ning Microsoft® Access® on a Windows XP or 
higher system. 
Hamzaoui A. 2007. WIIPS: Whitehead Institute Intellectual Property System: A Relational Database of IP Management
and Technology Transfer. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best
Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org. 
© 2007. A Hamzaoui. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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HAMZAOuI 
As a non-profit, research and educational or­
ganization with focus on research in the biomed­
ical field, the Whitehead Institute is pleased to 
further MIHR and PIPRA’s missions of dissemi­
nating information and tools of best practices 
in technology transfer and intellectual property 
management, and we are keen to contribute to 
these commendable efforts. n 
aMina haMZaoui, Associate Director, Intellectual 
Property, Whitehead Institute for Biomedical Research, 
Five Cambridge Center, Cambridge, MA, 02142, U.S.A.
hamzaoui@wi.mit.edu 
0 | HANDBOOK OF BEST PRACTICES 




   
         
 
     
CHAPTER 6.13 
Organizing and Managing Agreements and Contracts
 
ROBERT POTTER, Senior Associate, Agriculture & Biotechnology Strategies, Inc, Canada
 
HILd RygNESTAd, Managing Director, Rygnestad Canada, Canada
 
ABSTRACT 
Agreements and contracts are not just pieces of paper to 
be signed before money changes hands; they are vitally 
important documents. If an organization hopes to prop­
erly fulfill the terms of its contracts, to say nothing of 
negotiating future contracts, it must have a system for or­
ganizing and managing its contracts. Such a system must 
make data accessible as well as keep it secure. Resources 
and tools should be incorporated wherever possible to de­
sign and implement a system within the available budget. 
After it is implemented, the effectiveness of the contract 
management system should be continuously monitored 
and evaluated. 
1.	 InTRoduCTIon 
Social and cultural differences can cause people, 
even good friends, to misunderstand each other. 
Written agreements and contracts are therefore 
critical in that they formalize the details of a deal 
and ensure that all parties concerned understand 
their rights and obligations. For these reasons, a 
contract is not just a piece of paper that must be 
signed before money changes hands, but a vital 
document throughout the life span of the rela­
tionship between the parties to a deal. 
It is important for a company or institution 
to be able to organize and manage contracts to 
know what its existing contractual obligations are. 
After all, there is no use negotiating a wonderful 
deal for a piece of technology if your organiza­
tion does not have the rights to the technology 
(or has already licensed rights to certain parts of 
the technology). Even worse, you will not be able 
to sign a deal at all if you cannot find out whether 
you have the rights to use a technology. Both of 
these situations require that your organization can 
quickly determine where you stand with existing 
contractual obligations related to the technology 
that is being developed. 
This chapter will consider the life span of 
a contract from the point of view of what is re­
quired to manage the rights and obligations un­
der that contract. Life span is defined as the entire 
process (or the stages) from the initial idea of a 
deal to the expiration of the contract or of its ob­
ligations (Figure 1). 
2.	 REquIREMEnTS	 of 	A	ConTRACT-
MAnAGEMEnT	SySTEM 
Agreements and contracts have a life span and 
the needs for contract management will change 
over time: during negotiations, for active con­
tracts, and after a contract has expired or been 
terminated. 
2.1 Requirements during negotiations 
Contracts begin as a potential relationship be­
tween two or more parties. Ideally, the parties 
negotiate an agreement that ends in a signed con­
tract, but the agreement may be put on hold, or 
Potter R and H Rygnestad. 2007. Organizing and Managing Agreements and Contracts. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. R Potter and H Rygnestad. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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POTTER & RyGNESTAD 
even dropped completely, if the parties cannot 
agree or if the agreement process is somehow de­
railed. The level to which pre-signing activity needs 
to be captured in a contract-management system 
depends on the parties involved and the way the 
deal was initiated and brought to a close. The fol­
lowing questions need to be considered: Would it 
be valuable (for the parties involved or for future 
negotiators) to have the history of the negotiation 
on record? Did communications during the nego­
tiations have any bearing on the final deal? Will 
the negotiations (especially if they do not lead to 
an agreement) affect potential future deals?1 The 
staff that were a part of the negotiations will likely 
be able to answer these questions. Generally speak­
ing, in a small organization, it may not be criti­
cal to formally record such information. However, 
in larger organizations a high staff turnover and a 
larger number of contracts often translates into a 
shorter “institutional memory” and a greater need 
for formally recording the information. 
2.2 Requirements for active contracts 
It is important to store a signed contract securely; 
however, it is also critical that the staff respon­
sible for implementing the terms of the contract 
have access to the documents, so that they can 
ensure that all rights are enforced and obligations 
honored. For example, licenses fees must be paid 
and reporting dates must be met. In addition, 
a contract may oblige one of the parties to dis­
perse funds, to follow up diligently on product 
development, to grant rights to derived materi­
als to third parties, or to obtain such rights from 
third parties. The methods of storing and access­
ing contracts will largely depend on the size and 
resources of the organization, and is discussed in 
detail in a later section. 
2.3 Requirements after contract expiration 
When a contract expires or is terminated before 
its due date, the parties involved often still have 
various legally binding obligations toward each 
other. For example, all parties are typically bound 
by confidentiality clauses that last longer than the 
contract period. There may be other obligations, 
as well, such as the obligation for one party to 
give up the rights to original or derived materials. 
The extent to which each party fulfills its obli­
gations may directly affect the success of future 
deals, so both administrative and management 
staff must be familiar with the obligations of all 
parties. To facilitate this information sharing, the 
requirements of a contract-management system 
are as much about enabling access as they are 
about secure storage. 
3.	 dESIGnInG	A	ConTRACT-
MAnAGEMEnT	SySTEM 
A contract-management system can be based on 
many components such as institutional memory, 
hard-copy filing, electronic filing, or a computer­
ized database. However, a system composed of a 
combination of these components is more robust. 
Moreover, since it is not entirely dependent on 
any one technology, the reassignment of staff, a 
flood in the archive room, a fire in the computer 





(for example confidentiality) 
“Dead” 
Active 
(fully executed, signed) 
Expired Final Obligation
  Pending    Terminated
 (prior to expiration) 
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room, or a failure of the database tool will not 
cause a catastrophic loss of information. 
Determining the right blend of components 
requires input from all levels of the organization. 
The staff knows how the current system works, or 
why it does not work, and can offer suggestions 
for improving the management system. All users 
of the management system should be involved 
during system design to ensure successful imple­
mentation: when users are involved in the design 
and take ownership of the system, it becomes a 
useful tool rather than a resource-costly burden. 
Designing a contract-management system is 
more than picking a software tool and its starts by 
finding the balance between accessibility and data 
security that meets your organization’s require­
ments. The desired design is subsequently guided 
by available resources such as existing tools, per­
sonnel, and information technology infrastruc­
ture. In the end the desired design is adapted to 
meet the available budget. 
3.1	 Requirements: Accessibility 
versus data security 
When designing a contract-management system 
it is important to find the balance between mak­
ing the system accessible and maintaining data 
security. 
3.1.1 Accessibility 
One of the main purposes of implementing a 
contract-management system is to minimize 
reliance on one or a few persons to manage the 
organization’s contracts and associated obliga­
tions. This requires a certain level of accessibility 
to contract documents as well as any other related 
information. 
Hard-copy filing systems. Maintaining and 
using hard-copy systems do not require users to 
have specialized technology skills, but hard-copy 
systems may be difficult to organize and update. 
If several people are involved in the management 
of contracts and storage of documents, there 
may be no central point allowing timely access 
to required information including original docu­
ments. No matter what other storage techniques 
are used, hard-copy originals must always be 
stored in a secure manner and kept on hand. 
Electronic filing systems. With electronic filing 
systems documents can be made easily accessible, 
especially if they are stored on network-accessible 
media. Documents are transferred to electronic 
media such as scanned computer files and can be 
copied and updated much more easily than for 
hard-copy files. An electronic filing system can be 
stored centrally and accessed directly from a stor­
age location or viewed remotely over a computer 
network. 
Database. An electronic filing system makes 
it easier to retrieve documents when these need to 
be reviewed. However, it still remains time-con­
suming to search for specific information and to 
get an overview of all contracts and agreements. 
Computer-based databases, including simple 
ones kept as spreadsheets and text documents, 
are useful because they are more easily searchable 
than hard-copy files. Databases should record the 
following information for each contract and re­
lated documents: 
•	 Name and address of contract parties 
•	 Dates of execution and expiration 
•	 Length of the confidentiality term 
•	 Deadlines by which products or informa­
tion must be delivered 
•	 Deadlines by which funds must be 
transferred 
•	 Keywords or a brief summary describing 
the scope of the contract 
•	 Electronic links to the document(s) 
Searchable databases have several fundamen­
tal advantages. They can: 
•	 Reduce the time and resources needed to 
find physical or electronic documents 
•	 Incorporate searches of electronic docu­
ment texts provided these have been made 
searchable through a process of Optical 
Character Recognition (OCR) 
•	 Produce automatic reminders of expiring 
contracts and upcoming deadlines 
•	 Help identify potential conflicts of interest 
before new contracts are signed 
When properly designed, searchable data­
bases can help staff find the proverbial needle in 
a haystack. Not only can databases retrieve any 
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POTTER & RyGNESTAD 
and all documents that contain a particular term, 
but they can be designed to automate searches of 
such information as outstanding payments, over­
due reports, or upcoming deadlines. 
System access. All employees will need a dif­
ferent level of access to the system, depending on 
their job duties. An employee who scans docu­
ments and inputs data will probably require a 
lower level of access than one who needs to ac­
cess specific records or information. For example, 
a system can be designed so that it only displays 
the details of selected contracts to authorized us­
ers. Staff can generate statistics on overall perfor­
mance (such as the number of contracts finalized, 
payments made, or reports overdue) without be­
ing granted access to sensitive material. In a Web-
enabled application external parties can even have 
direct access to information related to their own 
obligations, thereby reducing the number of re­
quests handled by the contracts-management 
office. 
A contract-management system that com­
bines electronic filing of documents with a search-
able database can also be designed such that it is 
accessible by users at a central point or from a 
workstation on an internal network (Intranet) in 
one location or over a Virtual Private Network 
(VPN) linking different geographical locations. 
Access over a network is a benefit as long as the 
connections are secure and reliable with minimal 
downtime. This is particularly important if the 
whole system is stored off-site with no central ac­
cess point on-site if the network is down. 
3.1.2 Data security 
Regardless of the measures put in place, a con­
tract-management system will be labored with 
security problems related to both loss of data and 
access by unauthorized users. 
Data loss. Regardless of how you store your 
data, it can be lost due to fire, flood, theft, or 
a number of other catastrophes, so it is impor­
tant to take steps to guard against data loss. 
Preventative measures include safes, fire alarms, 
sprinkler systems, burglar systems, and fire- and 
waterproof filing cabinets. The chances of data 
loss are minimized further if hard-copy and 
electronic systems are maintained in separate 
locations. It is also a good idea to keep a backup 
electronic copy in an off-site location. Off-site 
storage and backup services can be purchased 
and/or managed commercially or by other de­
partments in your organization. These service 
providers should guarantee that they have appro­
priate measures in place to prevent unauthorized 
access and accidental data loss. 
Unauthorized access. Lockable storage fa­
cilities, filing cabinets, and safes generally pre­
vent unauthorized access to hard-copy mate­
rial. Electronic material and databases may be 
at greater risk of unauthorized access than hard-
copy materials, especially if they are stored off 
site. Network traffic should be encrypted and 
usernames and passwords should be used to make 
sure only authorized persons can input, view, or 
alter data. 
Information technology support. In-house 
computer support is essential because of increased 
reliance on information technology. If an orga­
nization lacks the resources to employ full-time 
computer support personnel, it must train some 
staff members to deal with common computer 
problems. More complex technical problems will 
need to be addressed by a reliable and responsive 
external party. 
3.2 Available resources 
The next step after having determined your orga­
nization’s requirements for accessibility and data 
security is to determine how available resources 
will affect the system design and implementation. 
When taking available resources into account the 
original plan often needs revising to include is­
sues such as: newly discovered needs, change in 
staff expertise, new technologies, and declining 
available funds. 
3.2.1 Identify existing tools and procedures 
The first step is to identify all–if any–tools that 
already exist and are used currently for contract 
management within the organization. Such tools 
could be filing systems, procedures, spreadsheets, 
or more-advanced databases and reminder sys­
tems. These tools can be used as models for de­
signing components of the new system. As noted 
before, current contract managers can shed useful 
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CHAPTER 6.13 
light on tools and procedures that work, but also 
those that do not work, as this information is of­
ten more useful. 
3.2.2 Select new tool 
Low-technology solutions. A contract-manage­
ment system is more than a software tool such 
as a database, and, with some limitations on 
accessibility and security, low-technology solu­
tions can still be viable solutions if resources 
are particularly limiting. Some organizations 
use hard-copy filing systems with continuously 
updated hard-copy summary sheets for each 
contract. The summary sheet is good for quick-
reference but may lack accessibility. As noted 
before, a backup system is important to avoid 
data loss. 
Simple databases. Other organizations de­
sign and maintain computer-based databases 
in their simplest forms, for example in spread­
sheets or text documents. This improves acces­
sibility, enables a quicker overview, and can be 
supplemented with some form of reminder sys­
tem for upcoming deadlines and obligations. 
Database software packages. Some organiza­
tions decide to use internal or external expertise to 
design a more complex database tool in software 
packages such as Microsoft® Access or FileMaker® 
Pro. These software packages provide a user-
friendly front-end for designing and maintaining 
databases. More advanced approaches could in­
volve other software such as Oracle®, MySQL™, 
Microsoft® SQL Server, and DB2®. Using these 
packages allows for tools to be designed more to 
order and is a good option if an organization has 
some level of internal expertise with the software 
of choice. 
Off-the-shelf tools. There are software packages 
designed for contract management that are more 
or less ready for use off-the-shelf. It is important 
to make sure that the software has the necessary 
features. Although off-the-shelf tools can usually 
be customized to some extent, it may make more 
sense for an organization to redesign its proce­
dures than to try to make an off-the-shelf tool 
perform tasks that the system was not designed 
to handle. 
Custom built tools. Another option is to have 
tools custom built. A provider tailors an applica­
tion to the client’s needs. The more complex the 
tool, the more time and resources will be required 
for its design and implementation—and the 
higher the cost. The implementation of custom­
ized software should be expected to cost roughly 
twice as much as the software tool itself. It is im­
portant to remember that more advanced (and 
more expensive) tools are not always the best or 
most cost-effective solution. 
Numerous companies provide software 
systems for managing intellectual property as-
sets—including filing patents (mostly U. S. 
patents) and licensing inventions. A number 
of these systems are customizable, including 
software packages that either the clients or the 
company must modify to fit their own needs. 
All of the systems are quite expensive to pur­
chase. They are likely to be most useful to larger 
research institutions and research-based compa­
nies. You can find a list of providers and links 
to their Web sites in the endnotes following this 
chapter.2 
Finally, there are many other options for 
less- specialized, less-expensive document man­
agement system. A simple search will turn up 
20 or 30 companies that provide such software. 
It is quite possible that future versions of com­
mon operating systems or office productivity 
suites will include such applications. However, as 
discussed in this chapter, contract management 
is much more than just storage and retrieval of 
documents. 
3.2.3 Personnel considerations 
When transferring information from the old sys­
tem to the new, considerable time will be needed 
to locate existing documents, convert them to 
electronic files, and enter the corresponding data 
into a database. At the same time, new contracts 
must be entered into the system. After the initial 
transfer is completed, keeping the filing system 
and database up to date must be considered as a 
time-consuming task. If a system design change 
becomes necessary, time will also have to be allot­
ted for accomplishing this task. 
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The amount of staff training that is required 
by a change in management system will depend 
on the complexity of the system and on existing 
staff skills. Staff may be trained in such skills as 
filing, data entry, reporting, and day-to-day prob­
lem solving. Providers of commercially purchased 
management systems usually offer employee 
training sessions for an additional fee. 
3.2.4	 Select information 
technology infrastructure 
The choice of Information Technology (IT) infra­
structure is largely guided by the balance between 
accessibility and security discussed above. A con­
tract-management system might include some or 
all of the following items: 
•	 Physical storage facilities. Fire- and flood-
proof filing cabinets that can store hard-
copy originals, or system-backup media, 
that do not require frequent access 
•	 Computer/server. A computer or server 
with the necessary software that stores all 
electronic documents and the database 
tools —in other words, the central collec­
tion point. The organization should obtain 
professional IT advice and continued IT 
support to ensure data security. 
•	 Backup system. A system in the form of 
another computer or storage medium that 
automatically backs up the information 
in the contract-management system on 
an hourly, daily, or weekly basis, depend­
ing on how frequently data is updated. If 
automatic backups are impossible, manual 
backups should be performed, for example, 
on backup drives or other storage media, 
and the copies stored safely away from the 
central collection point. 
•	 Scanning capability. Scanning hardware 
and software, with or without optical 
character recognition capabilities that can 
convert documents into searchable elec­
tronic media. 
•	 Network. Computers connected to the 
central collection point also with profes­
sional IT support that can ensure stable ac­
cessibility as well as data security over the 
network. 
•	 IT and system support. Support both for 
maintaining network infrastructure and 
for running the system. If the system is 
designed in-house, details of operations 
should be extensively documented in order 
to make future maintenance and develop­
ment easier. If the system is purchased off 
the shelf or designed by an external devel­
oper, the service provider should provide 
on-site or telephone support 
3.2.5 	 Budget considerations 
Finally, the desired system requirements, such 
as accessibility, data security, existing tools, 
personnel resources, choice of system tool, and 
information technology infrastructure must be 
compared to the available budget. Trade-offs 
will be necessary and each organization must de­
termine which needs are absolute requirements 
and which are only desirable. While it is often 
tempting to cut back on such expenditures as 
training and support for users, it is important to 
note that the system investment will be a waste 
of money and resources if it is not used to its 
capacity. 
Some organizations have the resources to 
think big and to implement systems with more 
capability than is needed at the outset, thereby 
delaying the cost of frequent upgrades. Where 
possible, an organization should plan for success 
and institute a system that seems too big now, as 
it will likely appear too small in a few years time. 
An organization with tighter budget restrictions 
should aim for a system that will serve its cur­
rent needs and implement a smaller or cheaper 
system, but try to ensure that there is room to 
expand it later. 
3.3 Monitoring benefits of the new system 
Because it is costly to implement a new contract- 
management system, and because the cost must 
be justified to senior management, it is impor­
tant to be able to measure the benefits of the new 
system. Many, if not all, of the benefits can be 
tracked and monitored automatically by the most 
advanced systems. Table 1 outlines the baseline 
data that should be established and against which 
benefits can be measured. 
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Table 1, below, provides only examples; each 
organization will want to monitor itself according 
to its own criteria. Monitoring the benefits of a 
new system not only helps to justify its expense 
but also helps to identify aspects of the system 
that need revising. 
4. ConCLuSIonS 
Managing contracts and agreements is not glam­
orous, but it is vital—especially if the organi­
zation is involved in complicated technology 
transfer deals with many rights and obligations. 
Ideally, a contract-management system should be 
Baseline Data Measurable Benefits 
Time and resources spent searching and 
managing contracts 
Additional staff time available for 
performing other tasks due to more-efficient
contract management 
The value of successful proposals, less the 
value of unsuccessful proposals 
Increase in the value and number of 
successful proposals, due to less time spent
researching potential conflicts with existing 
contracts 
The value of invitations to submit proposals 
Grounds for successful and unsuccessful 
proposals 
Improved reputation with collaborators,
funding bodies, boards, and contractors 
Resources spent or committed 
without contract 
Minimized exposure due to nonexistent or 
expired contracts 
Number of deliverables that are not
submitted according to contract 
Fewer deliverables not submitted according 
to contract 
Number of delayed reports. 
Resources committed to preparing reports 
Time and resources saved because reports 
(whether scheduled or ad hoc) are processed 
timely and with minimal effort 
Penalties for delayed payments Money saved because payments are 
processed on schedule. 
Number of times that confidentiality terms 
are broken 
Confidentiality terms are adhered to 
Table 1: Examples of Criteria that Can Be used to Measure 
Benefits of a New Contract-Management System 
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established before any contracts are negotiated.
The sooner a functional system is implemented, 
the easier it will be to keep it updated. 
Identifying the system requirements starts 
with balancing accessibility against data secu­
rity throughout the life span of a contract. This 
is followed by considerations for the available 
resources, including personnel and budget. The 
contract-management system should be planned 
and implemented with the full involvement of all 
levels of the organization to make sure that it be­
comes a useful tool and not another administra­
tive burden. 
Smooth contract management is almost in­
visible, but the marks of poor management are all 
too evident: lost deals, a poor corporate reputa­
tion, and, in the worst case, lawsuits. Investing 
resources in management is like any preventive 
measure: you will really never know how much 
time and money it has saved you. n 
ROBERT POTTER, Senior Associate, Agriculture & 
Biotechnology Strategies, Inc., 106 St John Street, PO Box 
475, Merrickville, Ontario, K0G 1N0, Canada. rpotter@ 
agbios.com
HILd RygNESTAd, Managing Director, Rygnestad Canada, 
179 George Street, Apt. 306, Ottawa, Ontario, K1N 1J8, 
Canada. hild@rygnestad.net
1	 If negotiations are aborted, there may still be certain 
obligations that affect future deals. These include 
confidentiality agreements. Being aware of other 
types of information about the party with which 
negotiations were aborted, for example reasons for 
failure or specific problems encountered, may also be 
useful when future deals are being contemplated.
2	 Knowligent has developed IP-Portfolio (an IP 
management system) and many lab-management
software modules. www.knowligent.com/.
Computer Packages provides customized solutions for 
managing IP portfolios and collecting royalties. www.
computerpackages.com/. 
Inteum LLC is the maker of Inteum C/S® (the successor 
to a widely used system called DEALS), a program 
that manages the entire technology life cycle from 
negotiations to final obligations. www.inteum.com/. 
InfoEd supplies module-based software for managing 
sponsored research programs, including technology 
transfer modules. www.infoed.org/. 
O P Solutions Inc. provides software to the IP legal 
industry, including software for patent and trademark 
filing and prosecution management.www.opsolutions. 
com/. 
Master Data Center provides IP management
software, including installation of software systems 
and maintenance services. www.masdata.com/. 
Knowledge Sharing Systems LLC makes TechTracs, a 
complete management system covering sponsored 
research, patent filing, and compliance with licenses 
and agreements. www.knowledgesharing.com/. 
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CHAPTER 6.14 
Monitoring, Evaluating, and Assessing Impact
 
sibongile pefile, Group Manager, R&D Outcomes, Council for Scientific and Industrial Research (CSIR), South Africa 
ABSTRACT 
Much has been written about the socio-economic ben­
efits and competitive advantage achieved by developed 
countries as a result of investing in scientific research and 
technological innovation. For developing and emerging 
economies, sustainable development is dependent on 
establishing and supporting R&D institutions that not 
only perform good science, but also effectively share their 
knowledge and technology outputs. Both the extent to 
which a return on an investment is realized from R&D 
activities and the magnitude of the resulting impact on 
intended beneficiaries are important to funders, policy­
makers, taxpayers, government officials, development 
agencies, and the research institutions themselves. This 
chapter provides guidance on building organizational 
capacity to plan, monitor, evaluate, and assess the im­
pact of R&D investments. It should be noted that the 
chapter does not address measuring the performance of a 
Technology Transfer Office to manage intellectual prop­
erty, but rather focuses on determining the socio-eco­
nomic impact of transferred knowledge and technology. 
1. InTRoduCTIon 
Much has been written about the socio-economic 
benefits and competitive advantage that devel­
oped countries achieved by investing in scien­
tific research and technological innovation.1 For 
developing and emerging economies, it is recog­
nized that sustainable development depends on 
establishing and supporting R&D institutions 
that both perform good science and share their 
knowledge and technology outputs.2 A return 
on R&D investment, and the magnitude of that 
return, is important to policy-makers, tax pay­
ers, government officials, development agencies 
and, of course, those funding the research and 
the research institutions themselves. This chapter 
provides guidance on building organizational ca­
pacity to plan, monitor, evaluate, and assess the 
impact of R&D investment on society and in 
the market. It should be noted that the chapter 
does not evaluate the performance of Technology 
Transfer Offices in managing intellectual prop­
erty, but rather focuses on determining the socio­
economic impact of transferred knowledge and 
technology. 
R&D institutions in developing countries 
operate with limited financial resources for 
R&D and even less funding for technology and 
knowledge transfer. The socio-economic chal­
lenges experienced by developing countries put 
more pressure on R&D institutions, requiring 
them to effectively and efficiently address local 
social and economic development needs through 
the transfer and adoption of innovative science. 
To this end, a key responsibility of research in­
stitutions in developing countries is to make re­
search outputs available for use by society and 
local industry. It is therefore critical that research 
institutions not only generate relevant research, 
but also transfer and diffuse research results in 
a way that maximizes impact. A well-developed 
Pefile S. 2007. Monitoring, Evaluating, and Assessing Impact. In Intellectual Property Management in Health and Agricul-
tural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA:
Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. S Pefile. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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and comprehensive monitoring, evaluation, and 
impact assessment framework is necessary to 
measure efforts by institutions to meet R&D 
objectives. Such a framework can assist research 
institutions in: 
•	 improving the efficiency of research re­
source allocation 
•	 improving the standard and effectiveness of 
project decision-making 
•	 directing future research plans more 
effectively 
• obtaining evidence of resource mobilization 
•	 prioritizing research based on the level 
of economic returns and positive social 
impact 
Technological innovation transforms an idea 
generated during research into a new or improved 
product that can be introduced into a market, a 
new or improved operational process used in in­
dustry and commerce, or a new approach to a so­
cial service.3 Monitoring, evaluation, and impact 
assessment should be conducted throughout the 
R&D continuum described below: 
•	 research and technology generation. Basic 
research, applied research, and experimen­
tal development are included. 
•	 technology development. During this 
stage, knowledge from research is com­
bined with practical experience to direct 
the production of a new product. 
•	 technology adaptation. This entails pilot­
ing technology and simulating real-life 
conditions for the production of the tech­
nology are typically involved. 
•	 technology transfer. An important com­
ponent of technology transfer is IP (intel­
lectual property) management. Typically, 
institutions manage IP protection, routes 
to commercialization or transfer, and con­
tractual arrangements that facilitate the 
transfer of intellectual property from the 
lab to the market. 
•	 technology adoption and diffusion. This 
stage of the process is key, for it signifies 
the point that products, transferred to the 
market, achieve depth and spread widely. 
Technology adoption is measured at one 
point in time and is associated with the use 
of transferred technology; technology dif­
fusion is the spread of a technology across a 
population over time. 
A robust monitoring, evaluation, and impact 
assessment framework should demonstrate trans­
parency and confer accountability. It is therefore 
important that systems enable institutions to 
document, analyze, and report on research and 
technology transfer performance effectively. 
2. THE	fRAMEWoRk 
There are different methodologies and processes 
for monitoring, evaluation, and impact assess­
ment. An impact assessment study can be custom­
ized and structured to suit the information and 
reporting requirements of an institution and its 
stakeholders. Figure 1 illustrates a comprehensive 
monitoring, evaluation, and impact assessment 
framework. (The components of the diagram are 
described in greater detail in subsequent sections 
of this chapter.) 
2.1 Diagnosis 
For many developing country institutions, the 
public expects the research to provide solutions to 
health, food security, sanitation, water, poverty, 
and environmental challenges. As institutions in­
vest their limited resources in these important ar­
eas, their research efforts must be focused so that 
the resulting impact on society and the economy 
is optimal. Institutions, therefore, must be able 
to articulate the problem that the science sets 
out to address. The needs assessment conducted 
at the start of a project defines the problem and 
provides baseline data for the ex ante evaluation. 
At the diagnosis stage of the process, questions 
should include: 
•	 Who is responsible for collecting perfor­
mance information? 
•	 What information is being collected? 
•	 When and how often is the performance 
measure reported? 
•	 How is the information reported? 
•	 To whom is the performance measure 
reported? 
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The needs assessment should also seek to 
determine: 
•	 What is the nature and scope of the prob­
lem requiring action? 
•	 What intervention may be made to amelio­
rate the problem? 
•	 Who is the appropriate target population 
for the intervention? 
The outcome of the diagnosis should be a 
document that: 
•	 defines baseline information 
•	 sets project targets 
•	 states assumptions 
•	 specifies measurement indicators 
•	 could be tied with ex post evaluation, that 
is, evalulation after the project has ended 
2.2 Planning 
Once the problem has been identified, a plan 
should be drawn up to explain how the research 
will address the challenges. A logical framework 
can be used to structure the various activities and 
specify means and ends. Information in a logical 
framework should include: 
•	 why a project is being conducted 
•	 what a project is expected to achieve 
•	 how the project is going to achieve these 
results 
•	 what external factors are crucial for the suc­
cess of the project 
•	 how the success of the project can be assessed 
•	 where the data required to assess the success 
of the project can be found 
•	 what the project will cost 
This information is then used to complete 
the matrix summarizing information, which is 
required both to design and evaluate the activity. 
Table 1 illustrates such a matrix. 
A logical framework (logframe) is a useful tool 
for the assessor and has the following advantages: 
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•	 It makes the project appraisal transparent 
by explicitly stating the assumptions under­
lying the analysis and by allowing a check 
on the proposed hypotheses and expected 
results in an ex post analysis. 
•	 It deals explicitly with a multitude of so­
cial goals and does not require reducing the 
benefits into one figure. 
•	 It is understandable to nonscientists. It 
can therefore be used as a tool to clarify 
the trade-off among objectives and, thus, 
specify the decision-making process. 
•	 It is flexible with regard to information and 
skill requirements. It can incorporate social 
cost, benefit analysis, use input, output tables, 
and partial models. It can also be used with 
rudimentary information skills, albeit at the 
cost of more hypotheses and uncertainties. 
2. Implementation 
Implementation is the actual evaluation; it en­
tails data collection, analysis, and reporting. 
Evaluation is systematically assessing a situation 
at a given point in time, whether that point is in 
the past, the present, or the future. Put another 
way, an evaluation is the periodic and systematic 
assessment of the relevance, performance, effi­
ciency, quality, and impact of a project, in rela­
tion to set objectives and goals. Evaluation seeks 
to investigate and determine whether: 
•	 the intervention is reaching the intended 
target audience 
•	 the intervention is being implemented as 
envisioned 
•	 the intervention is effective 
•	 the costs of the intervention, relative to ef­
fectiveness and benefits, is lower than the 
benefits 
Different monitoring and evaluation systems 
can be used. The method chosen mainly depends 
on the following considerations: 
•	 What should be measured? The evalua­
tion should be based on the project design. 
Stakeholders should agree about how the 
crucial project issues should be measured. 










Inputs • Nature and level of • Sources of information • Initial project
resources assumptions 
• Necessary cost 
• Planned starting date 
Outputs • Magnitudes of outputs • Sources of information • Assumptions affecting 
the input-output• Planned completion • Methods used 
linkage data 
Purpose • End-of-project status • Sources of information • Assumptions affecting 
the output-purpose • Methods used 
linkage 
Goal • Measures of goal • Sources of information • Assumptions affecting 
achievement the purpose-goal • Methods used 
linkage 
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•	 For whom should it be measured? The us­
ers of the evaluation results should be iden­
tified and the results should correspond to 
their expectations. 
•	 For what purpose should it be measured?
This determines the sensitivity of the mea­
sures and the degree of accuracy needed. 
•	 How should it be measured? Consensus 
is needed between the evaluator and pro­
gram/project managers on whether a pro­
posed measure truly indicates a change in 
the desired direction. 
•	 How should the data be collected? The de­
sign of the evaluation system should be de­
termined and the desired level of accuracy 
in the information agreed upon. 
•	 When and in what form is the informa­
tion needed? It should be available when 
needed in a usable format. 
•	 Who collects, analyzes, and presents the 
information? This is necessary to adapt the 
monitoring and evaluation system to the 
management realities of a program/proj­
ect. Managers should not underestimate 
the time needed to analyze and present the 
information. 
The specific questions that an effective evalu­
ation should answer are: 
•	 Is the program effective in achieving its in­
tended goals? 
•	 Can the results of the program be explained 
by alternative explanations that do not in­
clude the program? 
•	 Does the program have effects that were 
not intended? 
•	 What are the costs of delivering services 
and benefits to program participants? 
•	 Is the program an efficient use of resources? 
Deciding which evaluation process to use de­
pends on numerous factors, such as set objectives, 
available time, skills, and resources. To guide your 
choice, Table 2 summarizes data collection de­
signs and their different characteristics. 
Typically, data collection methods include 
checklists, scoring models, cost-benefit analyses, 
surveys, and case studies. The best approach is to 
use several different methods in combination, bal­
ancing quantitative and qualitative information. 
Ongoing monitoring and evaluation pro­
cesses measure: 
•	 technical aspects: physical input-output of 
goods and services 
•	 institutional aspects: organizational and 
managerial aspects, including customs, 
tenure, local organizations, and cultural 
setting 
•	 socio-cultural aspects: broader social impli­
cations, resource and income distribution, 
and employment opportunities 
•	 commercial aspects: business and financial, 
securing supplies, and market demand 
•	 economic aspects: economic efficiency, 
costs and benefits 
•	 environmental aspects: biological and phys­
ical effects 
2. Rediagnosis and replanning 
Should the results of a monitoring and evaluation 
exercise indicate that a project is not going ac­
cording to plan, then rediagnosis and replanning 
is required. Rediagnosis and replanning require 
the measurement process to be continually im­
proved, and changes in the measurement process 
should be aligned with changing needs and pri­
orities.4 Program replanning and rediagnosis may 
also require going back to prior steps in the plan­
ning process to review whether: 
•	 the problem is well defined and described 
•	 the objectives are adequately implemented 
•	 a revised-impact model has been 
developed 
•	 the target population has been redefined 
•	 the delivery system has been redesigned 
•	 there are revised plans for monitoring im­
pact and efficiency 
Research programs are dynamic, and evalu­
ations should take this into consideration. 
Naturally, the longer the research project lasts, 
the greater the likelihood that a given project 
will require modification and adjustment. Table 
3 summarizes the design, implementation, and 
assessment requirements of research projects at 
different stages of maturation. 
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2. Ex post evaluations 
These take place at the end of a research project, 
when the effects and results of the project can 
be tracked and used in adoption studies. At this 
stage, the evaluation: 
•	 assesses the project’s performance, qual­
ity, and relevance, immediately after its 
completion 
•	 works best when a pre-project baseline had 
been defined, targets projected, and data 
collected on important indicators 
•	 is often done by professional and external 
evaluators 
•	 requires that classical criteria be broadened 
to include user satisfaction 
•	 should be an integral part of project 
implementation 
•	 demands advanced preparation 
•	 uses a blend of interviews, field visits, ob­
servations, and available reports 
•	 provides lessons that can be systematically 
incorporated into future activities, for 
example ex ante evaluation, as well as proj­
ect planning 
•	 is usually only done for more important, 
innovative, or controversial projects 
Essentially, ex post evaluations determine im­
pact and are used to demonstrate accountability. 
The evaluations sum up the lessons learned from 
the project. They provide a firm foundation for 
future planning and for establishing the credibili­
ty of public sector research. They can also be used 
to justify an increased allocation of resources. 
2. Recommendations 
The recommendations that arise from evaluation 
studies should assess the information collected. 
Evaluations should also review: 
•	 what turned out differently than expected 
•	 which part of the strategy produced the de­
sired results and which did not 
•	 whether a cross-section of views were 
sought and accommodated 
Table 3: An Assessment Planning Guide
 
Innovative programs Established programs Fine-tuning 
Conceptualizing • problem description 
• operationalizing 
objectives 
• developing intervention 
models 
• defining extent and 
distribution of target
population 




• developing evaluation 
model 










• designing program 
modifications 
Implementing • formative research and • program monitoring • R&D program 
development and accountability refinements 
• implementation studies • monitoring
monitoring program changes 
Assessing • impact studies • impact studies • impact studies 
• efficiency analyses • efficiency analyses • efficiency analyses 
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•	 with whom the findings need to be shared 
•	 in what form the results should be 
presented 
There are various uses for evaluation find­
ings. The outcomes of an evaluation can be cat­
egorized into three basic types: direct, indirect, 
and symbolic.5 Evaluation outcomes are direct 
when information or findings are applied directly 
to alter decisions and results in an operational 
application. Indirect use refers to a more intel­
lectual, gradual process, in which the decision 
maker gleans a broader sense of the problems 
addressed by a project or program. Indirect use 
of study results produces a strategic or structural 
application of outcomes. Symbolic use refers to 
situations where the evaluation results are accept­
ed on paper, but go no further. Unfortunately, 
many evaluation studies end up as symbolic ini­
tiatives. It is imperative that technology transfer 
assessments do not end up simply as academic 
exercises. When an assessment is not practically 
applied or used, not only is the effort wasted, but 
future programs may continue to repeat mistakes 
and waste money. 
2. Impact assessment 
An impact-assessment study aims to determine 
causality and to establish the extent of improve­
ment for the intended beneficiaries. Impact 
assessments are time sensitive and, there­
fore, studies should be conducted periodically 
throughout the duration of a project. An im­
pact study should measure the rate of adoption 
for technologies that have been made available 
for social or industry use. Such studies should 
assess the technology’s level of use by targeted 
beneficiaries and estimate the benefits of R&D 
investments. By following these guidelines, im­
pact studies should be able to determine the 
impact of technology generation and transfer. 
Impact assessments should also seek to mea­
sure both intended and unintended outcomes, 
taking into account behavioral change among 
potential users and beneficiaries. The resulting 
effect on productivity and quality of life should 
be measurable and, therefore, evaluated and 
reported. 
When conducting an impact study, the im­
pact is assessed by gathering information on the 
number of users, degree of adoption, and the ef­
fect of the technology on production costs and 
outputs. Studies should be conducted at different 
levels (for example, household; target population; 
regional and national; and at primary, secondary, 
or economy-wide sector levels.) 
There are different types of impacts. 
Production and economic impact measure the 
extent to which the project addresses: 
•	 risk reduction 
•	 yield increases 
•	 cost reduction 
•	 reduction in necessary inputs 
•	 employment creation 




Socio-cultural impact measures the extent to 
which the project contributes to: 
•	 food security 
•	 poverty reduction 
•	 status of women 
•	 increases in knowledge and skill level 
•	 number and types of jobs 
•	 distribution of benefits across gender and 
geographical locations 
•	 changes in resource allocation 
•	 changes in cash requirement 
•	 changes in labor distribution 
•	 nutritional implications 
Environmental impact measures the project’s 
effects on: 
•	 soil erosion and degradation 
•	 silting 
•	 compact soil 
•	 soil contamination 
•	 water contamination 
•	 changes in hydrological regimes 
•	 effects on biodiversity 
•	 air pollution 
•	 greenhouse gases 
Institutional impact measure effects on: 
•	 changes in organizational structure 
•	 change in the number of scientists 
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•	 change in the composition of the research 
team 












•	 new techniques or methods 
2. Tools 
Different tools are used to measure performance 
over time. These include (1) secondary analysis 
of data, (2) the screening of projects and research 
orientations by peers and experts in the field, (3) 
qualitative descriptions of case studies and anec­
dotal accounts, and (4) matrix approaches, which 
provide rich information and help to rationalize 
and simplify choices. 
Examples of the matrix approach include: 
•	 systemic methods. can be used to imple­
ment an evaluation (This method is not re­
ally suitable for evaluating and can be very 
difficult to implement.) 
•	 financial methods. namely, cost-benefit 
measures that take into account marketable 
outputs and commercial resources (It is of­
ten difficult to collect the information, and 
some factors cannot be financially assessed.) 
•	 technological forecasting methods. en­
tail the use of scenario methods and allow 
for the causality chain to be reversed (This 
method also allows for forecasting and takes 
into account social transformations.) 
•	 quantitative indicators. for example, sci­
ence and technology indicators and mea­
surement, pure descriptiveness, and se­
lection integration (Indicators provide 
fundamental scientific output measures.) 
To help select the most appropriate study 
method,Table 4 maps the desired impact of a study 
against the assessment method and technique. 
2. Indicators 
Developing indicators is a critical step in the eval­
uation process. Ultimately, indicators drive im­
pact assessment and influence how the assessment 
is conducted. In summary, there are three evalua­
tion methods used to assess impact. These can be 
(1) qualitative, such as peer review, (2) semiquan­
titative, such as tracking scientific evidence, or (3) 
quantitative, such as econometric measures. The 
evaluation method selected should depend on the 
evaluation objectives of the study and the needs 
of each stakeholder (Table 5). The strengths and 
drawbacks of each tool are presented in more de­
tail in Table 6 (at the end of this chapter). 
.	 CHALLEnGES And	kEy	
SuCCESS fACToRS 
Monitoring, evaluation, and impact assessment is 
a complex field. The conditions, methodologies, 
and projects described here present various chal­
lenges that need to be factored into the evalua­
tion and impact study. These challenges include 
the relatively unpredictable nature of research 
and technology transfer events. Certain research 
outcomes are discrete and are thus difficult to 
measure, track, and document. Moreover, there is 
no single, accurate method to objectively evaluate 
R&D performance. There are also institutional 
challenges. Effective communication between 
stakeholders can be a problem, partly because of 
the difficulty of maintaining data quality. And 
because assessments tend to focus on measuring 
more immediate, short-term benefits, there is 
the risk of overlooking some of the longer-term 
benefits of R&D. This issue is also related to de­
termining the frequency of assessment studies. 
For example, the European Union has adopted 
a system that calls for three impact assessment 
studies: an ex ante study at the start of the proj­
ect, a project-end assessment, and an ex post study 
three years after the completion of the project.6 
The frequency of the study may affect its tem­
poral focus. Of course, without establishing the 
commitment and resources to collect, process, 
store, and make accessible key performance data, 
nothing can be accomplished. trans-Technology ­
fer managers need to develop the infrastructure 
necessary to have valid and reliable performance 
information and use this data for decision-mak­
ing. They should take the time to develop a 
shared understanding with funders about the role 
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Table 4: Impact Assessment Methods and Techniques
 
Impact Type Method Technique 
Intermediate impact Survey, monitoring Simple comparison/trend 
• Institutional changes analysis 
• Changes in the enabling 
environment 
Direct product of research Effectiveness analysis using Simple comparison: target vs.
logical framework actual 
Economic impact Econometric approach, Production function, total 
(micro, macro, spillovers) surplus approach factor productivity, index 
number methods, and 
derivatives 
Socio-cultural impact Socioeconomic survey/ Comparison over time 
adoption survey 
Environmental impact Environmental impact Various 
assessment • Qualitative 
• Quantitative 
Table 5: A Summary of the Evaluation Needs of Different Stakeholders7 






Review of entire system X X X X 
In-depth review of component X X X 
Ex ante evaluation of program/ 
project 
X X X 
Ongoing evaluation/ monitoring 
of research activities 
X X X 
Ex post evaluation of a research 
program/project 
X X X 
Impact assessment X X X X 
 | HANDBOOK OF BEST PRACTICES 















    
 
  
   
 
    
 
   
 
 
   
  
    
   




   
  
 
   
  
  
   
 





of public R&D within the national innovation 
system. Such efforts may make it possible to alle­
viate shortages of essential financial, human, and 
knowledge resources. 
It is essential to identify the key factors that, 
if in place, will improve the effectiveness of an 
assessment framework. Managers must strive to 
have in place as many of the following key success 
factors as possible: 
•	 leadership commitment 
•	 a desire for accountability 
•	 a conceptual framework 
•	 strategic alignment 
•	 knowledgeable and trained staff members 




•	 a positive and not punitive culture 
•	 rewards linked to performance 
•	 effective data processing systems 




•	 adequate resources and the authority to 
deploy them effectively. 
.	 ConCLuSIon 
An effective evaluation system should strengthen 
an institution’s ability to maintain leadership 
across the frontiers of scientific knowledge. The 
system should enhance connections between fun­
damental research and national goals, such as im­
proved health, environmental protection, pros­
perity, national security, and quality of life. Such 
an evaluation system also will stimulate partner­
ships that promote investments in fundamental 
science and engineering, as well as the overall 
more effective use of physical, human, and finan­
cial resources for social and economic benefit. 
As a way of benchmarking progress, it is 
helpful to examine how other organizations mea­
sure impact. Impact measures are a sure way of 
knowing that science is delivering on its objec­
tives and that R&D projects are having their in­
tended effect. Without a measurement process, 
institutions cannot justify their efforts in R&D, 
IP management, commercialization, and tech­
nology transfer in relation to their economic and 
social goals. 
Finally, it is essential to take the time to di­
gest, reflect upon, and learn from an impact-as­
sessment process. Lessons can be learned from 
both successes and mistakes, and these lessons 
should not only be used to take corrective action 
but also to improve future performance. n 
sibongile pefile, Group Manager, R&D Outcomes, Council 
for Scientific and Industrial Research (CSIR), PO BOX 395, 
Pretoria 0001, South Africa. spefile@csir.co.za
1	 Macfarlane M and J Granowitz. 2002. Report to Science 
Foundation Ireland: Technology Transfer for Publicly 
Funded Intellectual Property. Columbia University: New 
York; Rivette K and D Kline. 2000. Rembrandts in the 
Attic–Unlocking the Hidden Value of Patents. Harvard 
Business School Press: Cambridge, Mass. 
2	 Idris K. 2003. Intellectual Property: A Power Tool 
for Economic Growth. World Intellectual Property 
Organization, WIPO Publication No.888; Alikhan S.
2000. Socio-Economic Benefits of Intellectual Property 
Protection in Developing Countries. World Intellectual 
Property Organization, WIPO Publication No. 454(E);
Dickson D. 2007. Technology Transfer for the Poor 
(editorial), SciDev.Net; 16 January 2007. Moreira M A.
2007.Technology Transfer Must be Relevant to the Poor 
(opinion), SciDev.Net; 16 January 2007. www.SciDev.Net
(click on Dossiers, Technology Transfer). 
3	 Main definitions and conventions for the measurement
of research and experimental development (R&D): A 
summary of the Frascati Manual 1993. OECD. Paris. 
4	 U.S. Department of Energy Office of Policy & Office of 
Human Resources and Administration. 1996. Guidelines 
to Performance Management. Washington, DC. 
5	 Mackay R and D Horton. 2003. Expanding the Use of 
Impact Assessment and Evaluation in International 
Research and Development Organizations. Discussion 
Paper, ISNAR. 
6	 Anonymous. 2003. Assessing EU RTD Programme 
Impact; Collecting Quantitative and Qualitative Data 
at Project Level: Designing Suitable Questionnaires 
for Measurement of EU RTD Programme Impact
Study Contract No XII/AP/3/98/A. www.evalsed.info/ 
downloads/sb1_research_development.doc. 
7	 Interest depends on the activity and the role of the 
stakeholder concerned. 
HANDBOOK OF BEST PRACTICES | 







    
  






     


































































































































































































































































































































































































































































































































































































































































































































































































































































































        
 
 








   
  
 
   















































































































































































































































































































































































































































































































































































































































































































































































































































































HANDBOOK OF BEST PRACTICES | 1 
CHAPTER .1 
     
 
 







   
     
PEFIlE 













































































































































































































































































































































































































































































































































to Support Partnerships 

        
    
       
   
     
        
       
        
       
      
      
       
       
       
         
       
        
       
      
       
        
     
     
      
     
	 	
	
      
      
      
        
         
        
    
       
      
    
      
   
         
 









RichaRd T. Mahoney, Director, Vaccine Access, Pediatric Dengue Vaccine Initiative,
International Vaccine Institute, Republic of Korea
 
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University; Chair,
 
bioDevelopments-International Institute and Adjunct Professor, Cornell University, U.S.A.
 
ABSTRACT 
Public-sector research institutions can use a variety of 
agreements to protect and manage intellectual property. 
These agreements are powerful tools to foster competition 
in the private sector and reduce prices for consumers in 
developing countries. This chapter provides an overview 
of the following types of major agreements—confidential­
ity, material transfer, development (in which the licensee 
is responsible for further development), co-development 
(in which two parties collaborate on continued develop­
ment), and distribution—explains the functions of those 
agreements, and suggests strategies for their effective use. 
The chapter also discusses the meaning and usefulness of 
the standard elements and formulas found in such agree­
ments. It explains the meaning and significance of the 
terms and language used and discusses such key issues as 
product liability, fees and royalties, and arbitration. The 
chapter emphasizes the importance of establishing and 
maintaining trust when negotiating and implementing 
agreements. 
1. InTRoduCTIon 
One important goal of public sector licensing 
should be to promote competition between pri­
vate companies. Monopolies and high prices are 
not caused by patents themselves but by how pat­
ents are managed, so the goals of the public sec­
tor can be served by using licensing strategies that 
foster competition and reduce prices. 
Many kinds of agreements are used to pro­
tect and manage intellectual property (IP). These 
include agreements for confidentiality, material 
transfer, development (in which the licensee is 
responsible for further development), co-develop­
ment (in which two parties collaborate on contin­
ued development), and distribution. 
Most agreements are between two parties, 
but some may involve three or more parties. The 
public sector agency or the negotiating party may 
provide the first draft of an agreement for nego­
tiation. Whoever writes the first draft often has 
the advantage, so public sector agencies should, 
whenever possible, take the initiative to prepare 
the agreement. Regardless of who provides the first 
draft, the proposal should adhere to the principle 
of good negotiations: offer an agreement that you 
would be willing to sign, if you were the other 
party. A good agreement benefits both parties. For 
an agreement to work, the two parties must trust 
each other and maintain this trust throughout the 
implementation of the agreement. With a high 
level of trust, moreover, a request to renegotiate 
by either party may be better received should cir­
cumstances change. Finally, since enforcing inter­
national agreements through legal remedies may 
be difficult, such agreements should be considered 
solemn commitments that must be observed. 
2. THE	 uSE	And 	LIMITATIonS	 of 
TEMpLATE	AGREEMEnTS 
The chapter provides a number of template or 
sample agreements for each major type of contact. 
Mahoney RT and A Krattiger. Agreements: A Review of Essential Tools of IP Management. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. RT Mahoney and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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MAHONEY & KRATTIGER 
The online version of this Handbook also provides 
many agreements from different institutions from 
countries around the world. Each of these agree­
ments can be downloaded in Microsoft Word or 
Adobe PDF formats. 
Evidently, no template agreement can be nor 
should be considered as the “correct” or “best” 
agreement. Any agreement must embody, specifi­
cally, the deal that has been struck between the par­
ties, and a good deal for all parties will depend on 
the purpose of the deal and the context in which 
the deal takes place. The template agreements are 
merely intended as illustrations and possibly be­
come a starting point for discussions and negotia­
tions. In the discussion of the agreements in the 
Section 3, special reference is made to humanitar­
ian-use clauses where appropriate and relevant. 
It should be noted that template agreements 
are useful when used judiciously and as a start­
ing point in the total process that ends in a fi­
nal agreement between or among the parties. A 
template agreement may be more or less com­
plete, but clauses will always have to be changed, 
deleted, or added. It is useful, however, for any 
organization to develop its own template agree­
ments that include the major elements that are 
regularly used. The final draft agreement should 
be reviewed by the institution’s counsel before 
signature (and in some cases even before sending 
it to the other party for review). 
TheonlineversionofthisHandbook1 will include 
a section with several hundred actual downloadable 
agreements from many different institutions. 
. MAJoR	 TypES	 of 	AGREEMEnTS 
Two parties establishing a long-term working 
relationship could sign a series of agreements, 
or they could sign one or two agreements that 
combine several agreements within them. The 
following list appears roughly in the order that 
agreements would be signed when two parties are 
engaged in the development and distribution of a 
new or improved product. 
.1 Confidentiality agreements 
Confidential information will probably be part 
of discussions to establish business relationships 
involving proprietary health products. Such con­
fidential information could concern laboratory 
data and other research data, sources of materi­
als, methods of production, the nature of licensing 
agreements, detailed design of specialized equip­
ment, staff-training requirements, countries in 
which the developer would like to sell the product, 
and so on. It is wise to conclude a confidentiality 
agreement before entering into serious discussions 
about a relationship with another party. Aside 
from the obvious aim of protecting confidential 
information, such an agreement ensures that both 
parties are treating the discussions seriously. An 
agreement to convey and protect confidential in­
formation is a measure of the willingness of both 
parties to proceed. This is especially important for 
the party receiving confidential information. They 
should be able to ask any reasonable question and 
expect a fairly detailed response. Without a confi­
dentiality agreement, the other party can refuse to 
provide information that they consider sensitive. 
It is more difficult to negotiate a confidentiality 
agreement after negotiations have begun, espe­
cially if trust has been damaged.2 
.2 Materials transfer agreement 
Before agreeing to sign a license for further prod­
uct development, a potential licensee may wish to 
evaluate the new material(s) or products to see if 
it works well in his or her hands. Although licen­
sors should be willing to provide samples, they 
have an interest in assuring that the prospective 
licensee does not misuse the samples. Misuse 
might involve passing on a portion of the sample 
to a third party or using the sample to generate 
additional material for future use without con­
cluding a license. It is generally recommended 
that public-sector research organizations use ei­
ther a Simple Letter Agreement3 or the Uniform 
Biological Materials Transfer Agreement and the 
Implementing Letter format developed by the 
National Institutes of Health.4 In cases where 
large numbers of materials need to be transferred 
on a regular basis, such as by plant breeders, a 
simple material transfer agreement, such as that 
developed by with the International Network 
for Genetic Evaluation of Rice (INGER),5 vari­
ous national agricultural research and extension 
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CHAPTER 7.1 
systems in Asia and the International Rice 
Research Institute (IRRI) might be most appro­
priate (Box 1: see also Appendix of this Handbook
at the end of Volume 2, page 1853). 
3.3 Invitations to collaborate 
To achieve its product-development goals, a re­
search institute will often need to collaborate with 
another organization. This need may arise at any 
point, from laboratory studies through licensure 
and distribution. For example, when a public-sec­
tor research program requires prototype products 
for clinical trials, it will probably need to find a 
partner because most public-sector research centers 
lack high-quality production facilities. Likewise, 
for many neglected diseases in developing coun­
tries, highly specific, highly sensitive, affordable 
diagnostics are unavailable, and so collaboration 
might be needed when diagnostics are required 
for surveillance or clinical trials. Collaborators are 
such an important part of successful development 
that public-sector research institutions should 
have a thorough process for identifying them. 
Collaborators may be sought through Invitations 
to Collaboration, which should be widely distrib­
uted in international journals or other media, in­
cluding the Internet and an organization’s Internet 
home page. Summaries of the goals of the collabo­
ration might also be included in the invitation. 
Responses to an invitation should be reviewed ac­
cording to well-defined criteria, and all applicants 
should receive a report on the outcome of the pro­
cess. An open and transparent process (with ap­
propriate protection of confidential information) 
will establish a reputation for fairness. Sometimes, 
sole sourcing for one of the collaborating entities 
may be appropriate because of the undisputed ca­
pability of one organization to undertake the work 
rapidly, effectively, and inexpensively. Cases of sole 
sourcing, however, should be clearly documented, 
and management should be able to explain clearly 
why the sole-source route was chosen (see Box 2). 
Once a collaborator has been identified, it will be 
timely to negotiate a co-development agreement.6 
3.4 Co-development agreements 
If research and development have reached a stage 
at which further extending the work requires 
additional capabilities that a public-sector research 
institution either lacks or does not wish to allocate, 
then the institution will want to enter into a co-
development agreement with a partner identified 
through the Invitation to Collaboration process. 
Co-development agreements vary widely with 
regard to the extent to which the original owner or 
product developer retains control over the prod­
uct. A lone inventor with no development capa­
bility may have very little control over what hap­
pens to the product once a co-developer is brought 
into the picture. On the other hand, a large firm 
that has completed virtually all of a product’s de­
velopment, and only needs, for example, to clini­
cally test the product at a new dosage, may retain 
almost complete control (in such cases, the firm 
may simply execute a subcontract with the clini­
cal-testing organization). A co-development agree­
ment will define the nature of the final product or 
other output sought, the role of each party in the 
development process, the resources (financial, per­
sonnel, and institutional) each party will invest, 
the process by which the project will be managed, 
the interim goals (milestones) and timetable, and 
provisions for sharing in the success or failure of 
the effort. Of particular importance is the project-
management system. It is common to establish a 
project-management committee comprising staff 
from each party. The number of members from 
each party, the authority of the committee, the 
frequency of meetings, and the requirements for 
written reports will be specified in the agreement 
(see the Appendix of this Handbook for a sample 
co-development agreement).7 
3.5 Technology licensing agreement 
These are the most common types of agreements 
negotiated by universities. It allows one party to 
use, make, or sell products involving the intellec­
tual property of the other party. The agreement 
has terms defining the length of time the license is 
valid; the markets (territory) in which the licensee 
can make, use, or sell the product; whether or not 
sublicenses are permitted; the nature and amount 
of up-front fees and royalties; and whether or not 
the licensor has rights to any improvements de­
veloped by the licensee. Many other terms can ap­
pear in a licensing agreement. See Appendix for a 
HANDBOOK OF BEST PRACTICES | 677 
  
     
    
        
      
	 	
     
        
        
       
     
        
      
     
      
     
        
       
       
   
       
      
      
     
       
        
      
       
        
         
         
       
      
       
        
        
      
         
     
    
       
  
	 	 	
	 	 	 	 	
	 	
 
MAHONEY & KRATTIGER 
sample technology-license agreement, and Sections 
11 and 12 in this Handbook contain many chap­
ters dealing with specific elements of licenses. 
. Distributorship agreement 
Distributorship agreements permit the licensee to 
receive a product from a licensor or to purchase 
a product from a third party for distribution in 
a defined market under a number of conditions 
involving price, quantities, quality, labeling, roy­
alties, and so on. The agreement often allows the 
distributor to arrange for clinical trials, submit 
required documentation to the national licens­
ing authority, and prepare and carry-out product 
promotion. A public-sector research institute, for 
example, may arrange for a diagnostic to be man­
ufactured by a commercial company that may not 
be interested in marketing the diagnostic in any 
or all territories.
Because they place a valued product in the 
hands of a second party, distributorship agree­
ments are treated very carefully, especially the 
negotiation and implementation phases of such 
agreements. In cases of drugs, vaccines, and diag­
nostics, a license grants the licensee the right to 
obtain a regulatory permit to sell the product in a 
given market. If the license should be terminated 
because the licensee does not perform or loses in­
terest in the product, the licensor and a new li­
censee may find it difficult to get a new permit 
from the regulatory authority. They may have to 
repeat many expensive activities with the attendant 
delays. One way to address this potential problem, 
if local law permits, is to require the regulatory 
license to be transferable to a third party selected 
by the licensor. A distributorship agreement can 
also be the first step in building a long-term re­
lationship that can lead to technology-licensing 
agreements and additional co-development agree­
ments. The Appendix of this Handbook contains a 
sample distributorship agreement. 
. STAndARd ELEMEnTS	 of AGREEMEnTS 
.1 Recitals, preamble, and whereas clauses 
Laying out the broad motivations and goals of 
the parties, this opening section is important, 
particularly in agreements between public and 
private sector agencies. It documents that the 
parties believe their motivations and goals are 
complementary, and because the objective of an 
agreement is to have a win-win outcome, this sec­
tion should set the right tone and clearly state the 
parties’ reasons for entering into the agreement. 
If a dispute ever arises between the parties, the 
information in this introductory section could be 
invaluable should the dispute end up in arbitra­
tion or litigation. 
.2 The parties 
The parties are those persons, companies, or in­
stitutions that willingly enter into an agreement. 
Most often, there are two parties, but the number 
may be more than two. The agreement may be 
between two institutions or two individuals, or 
an institution and an individual. It is important 
to note that if one of the parties is an institu­
tion, then the entire institution is bound by the 
agreement. 
Note that the incorporated names of the in­
stitutions involved, as well as their headquarters, 
are included in the parties’ names and addresses 
list. Some organizations have regional offices or 
subsidiaries with authority to enter into agree­
ments. The addresses here may be different from 
the addresses to which notifications or data must 
be sent. 
. Definitions 
Any agreement is built around the meaning of the 
written words. Many words or phrases are legal 
“terms of art” that do not require definitions if 
the usage is standard within the corresponding 
field. Including a definition section enables a 
lawyer, in drawing up an agreement, to use the 
language of the agreement precisely, clearly, and 
consistently without deviation in either the forms 
of terms or their meanings. For example, as a legal 
term of art, the term infant refers to any child up 
to the age of adulthood—not just a baby—and a 
“foreign corporation” is one incorporated in any 
jurisdiction, not necessarily another country. If 
there is any doubt whether a term will be under­
stood, it is advisable to define it, in order to avoid 
any confusion later. 
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Confidential information disclosed in tangible 
form is managed very carefully. The informa­
tion is placed in a secure, locked filing cabinet 
or in a password-protected computer and marked 
“CONFIDENTIAL.” Only those staff covered by 
the confidentiality agreement have access to the 
material. Either they should complete a check- 
out form when they remove the material, or, with 
digital materials, a record should be made of the 
materials being accessed. Orally transmitted in­
formation should be put in writing soon after 
it is provided and the written form checked in 
and out as appropriate. Scientists commonly dis­
cuss research findings freely and seek to publish 
them early. However, if the generation of intel­
lectual property is an important goal, scientists 
will have to consider how they can disseminate 
their findings while helping to produce the in­
tellectual property. One way to overcome this 
difficulty is for IP management offices to swiftly 
evaluate whether to patent a new discovery. Some 
technology transfer offices can complete such an 
assessment in 30 days, which does not unrea­
sonably delay the presentation or publication of 
the work. It should always be remembered that 
confidential information has commercial value 
and its improper release can cause substantial 
damage. The original owner of the confidential 
information could seek financial damages for the 
unauthorized release of confidential information. 
Divulging confidential information might also be 
grounds for terminating the agreement. 
. Territory and exclusivity 
In a licensing agreement, the territory is the geo­
graphic region in which the licensee is permit­
ted to make, use, or sell the product. Applying 
mainly to distribution agreements, a territory can 
be a part of a country, a whole country, several 
countries, or the whole world. Exclusivity deter­
mines whether the licensee will have to share the 
territory with one or more other licensees of the 
same products. Licensors grant nonexclusive li­
censes to stimulate competition among licensees 
and to provide alternate distributors in case one 
licensee fails. For health products, a licensor rare­
ly grants anything but an exclusive license when 
the license is for the limited territory of a single 
country. One reason for this is the cost and time 
required to obtain the approval of the national li­
censing authority. Few licensees would be willing 
to take on this burden if others could freely take 
advantage of their costs for obtaining regulatory 
approval. 
In general, licensees want the most territory 
and the highest level of exclusivity. This gives 
them the greatest opportunity to exploit mar­
kets, seek profits, and keep competitors away. 
Moreover, it generally lowers the licensee’s risk. 
With an unproven licensee, it is prudent to limit 
both territory and exclusivity to the minimum 
necessary for the project to succeed (at least ini­
tially). It is a licensor’s nightmare to spend several 
years working with a licensee only to have that 
licensee fail to develop the product’s market. A 
compromise middle ground is for the licensor to 
grant increasing levels of territory and exclusivity 
as the licensee achieves various performance mile­
stones. For example, the licensee could receive a 
license to a new territory after successfully com­
pleting a marketing plan for that territory and 
investing some base levels of funds to implement 
the plan. Or a licensee could be required to pay 
a separate license fee for each additional territory 
granted. The amount should be large enough to 
ensure that the licensee will want to protect the 
amount paid by actually developing the market 
in the new territory. A good rule of thumb is that 
a license should be granted only when it is prob­
able that the licensee will be able to develop that 
market. A key consideration for the licensor is to 
calculate the minimum market size necessary to 
reach its financial goals with the product. One is­
sue with exclusive licenses is that they de facto 
form monopolies, which can make it difficult for 
the public sector to obtain the product at an af­
fordable price. 
. Product liability 
Product liability is increasingly important. Once 
an issue primarily of concern in the United 
States, product liability is becoming a problem 
in Europe as well as the rest of the world. It af­
fects many aspects of the health product business, 
from the conduct of clinical trials to product 
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MAHONEY & KRATTIGER 
prices, which are increased to cover the cost of 
liability self-insurance. 
All health-product manufacturers and dis­
tributors should be concerned about the safety of 
their products. There is a chance that a product 
will harm an individual. Preventive products (for 
example, vaccines) are the cause of greater con­
cern than therapeutics, since the former are given 
to healthy individuals. When a health product 
harms an individual, it is reasonable for that per­
son to be compensated for the injury. The form 
of compensation, however, will vary depending 
on the country. Unfortunately, in developed 
countries, “product liability” has, to some extent, 
become a kind of lottery: individuals seek huge 
awards based more on the ability of the company 
to pay than on the actual losses. Sometimes the 
awards are so large that the very survival of the 
company is threatened. This situation has made 
companies quite defensive regarding liability, af­
fecting their willingness to enter new markets and 
to develop new health products. 
When negotiating a license, the key ques­
tion with respect to liability is: who should accept 
product liability and for what? For some matters 
the answer is clear. A manufacturer, for example, 
should be responsible for adhering to good man­
ufacturing practices and should be responsible 
for any injury caused by errors in the production 
process. A public sector licensor will usually ex­
pect the licensee to assume most of the liability 
because the licensee sells the product. A licensor 
may, as a condition for granting the license, make 
acceptance of liability by the potential licensee, 
which places a special burden on the licensee to 
assess carefully the product’s potential liability 
implications. It is extremely rare for a licensor to 
be brought into a liability suit. If accused, it is 
even rarer for a licensor to be found liable. 
Even if a licensee holds the licensor harm­
less, doing so would not prevent the licensor from 
being named in a suit. The costs of defending a 
suit, especially in the United States and Europe, 
can be very large—sometimes almost as dam­
aging as a liability judgment itself. The licensor 
should therefore request, and have this specified 
in the agreement, that the licensee meet all costs 
incurred, within reasonable limits, by the licensor 
in defending a liability case. Insurance is available 
to cover just the legal costs of defense. The licen­
sor should ask for proof that the licensee has ob­
tained liability insurance and that the insurance 
is kept in force. Liability is an extraordinarily im­
portant issue, and public sector research groups 
are well advised to obtain high-quality profes­
sional advice. 
. Up-front fees and royalties 
A license transfers value. The up-front fees and 
royalties, therefore, are the agreed price repre­
senting that value. Since licenses are not trad­
ed in open markets, where the price can be set 
through supply and demand, each negotiation is 
unique and reflects the evaluations of each party. 
A licensor will have several considerations. First, 
the licensor will want, at a minimum, to recover 
the expense, or some reasonable portion of the 
costs, already invested in the product. Second, 
the licensor will want to generate a steady flow 
of income. 
Up-front fees have to balance two issues. 
First, they should be high enough, if possible, to 
meet the licensor’s need for short-term income 
and to assure that the licensee is seriously seek­
ing to develop the product. Second, they should 
not be so high that they limit the ability of the 
licensee to invest in the product and make it a 
success. Other factors to consider are the ex­
pected life of the product and the lifetime of the 
IP rights being granted. The shorter the life of a 
product (because other, better products are ex­
pected to emerge quickly), the less the licensor 
can ask for up-front fees and, to a lesser extent, 
royalties. If the license is based on a patent, at 
the end of the patent’s life the level of royalties 
may decrease or the license may even expire. The 
term of the license is more complicated when the 
license is for know-how. A reasonable but com­
plicated approach for such licenses is to have the 
royalty diminish with time and eventually reach 
zero when both parties agree that the know-how 
is no longer valuable. Such an event might oc­
cur when the licensor stops using the know-how. 
But if the know-how is essential for successfully 
manufacturing and selling the product through­
out its lifetime, there is no reason for the royalty 
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CHAPTER .1 
to change. Also, a licensor may make continual 
changes in the know-how and pass those on to 
the licensee. In this situation, royalties may be 
collected for a very long time.8 
Having said all this, it is important to remem­
ber that the goal of the licensing strategies dis­
cussed here is to maximize benefits for the public 
sector. Possible up-front fees and royalties should 
be seen simply as two ways to extract value for the 
public sector—and perhaps not the most desirable 
ways. 
. Arbitration 
Successful agreements are based on trusting re­
lationships, and both parties in an agreement 
should work to maintain trust in implementing 
the agreement. Some agreements, usually those 
negotiated between two parties in the same coun­
try, can allow for disputes to be settled in court. 
The more common practice, however, is to use 
arbitration. The issues for consideration here are 
the number of arbitrators, how they are chosen, 
their operating rules, the location where the ar­
bitration shall take place, which party shall bear 
the costs of the arbitration process (or what share 
each party will bear), and whether the arbitration 
should or should not be administered by an arbi­
tration institution. 
In one formulation, three arbitrators are 
used. Each party chooses one, and the two ar­
bitrators, so chosen, choose the third. The third 
arbitrator serves as the chairperson of the panel. 
The arbitrators may operate according to various 
rules. An international set of rules is a common 
reference, and many arbitration institutions have 
their own arbitration rules. In addition, most 
countries have laws that govern arbitral proceed­
ings conducted within their territory. These laws 
should be carefully considered when choosing the 
arbitral locale. Location is also important because 
of costs. If arbitration occurs at the offices of one 
party, the other party will have to incur costs to 
be present for the proceedings. Cost allocation 
can be specified in the agreement, or the arbitra­
tors can allocate the costs. Arbitration can be very 
costly, which further emphasizes the need to en­
sure that the initial negotiations are as thorough 
and specific as possible.9 
. Term and termination 
Term and termination clauses specify the term 
over which an agreement is to last. The beginning 
date can be either a specified calendar date or, 
more usually, the date on which the last signature 
is applied. A specified date might apply when cer­
tain calendar-specific tax matters are important 
or when it is essential to ensure that one party 
does not delay initiation of the agreement. 
Termination is a much more complex issue. 
A standard termination provision should include 
cases in which one party breaches a part of the 
agreement. The party that feels there has been a 
breach by the other party will be required to send 
a notice of breach. Usually, a period of time is 
provided during which the supposedly breach­
ing party can correct the breach or prove that a 
breach has not occurred. Also, since circumstanc­
es can change, it may be desirable to allow one or 
both parties to terminate the agreement follow­
ing the expiration of a defined notice period (for 
example, 60 days). It may be desirable to define 
the circumstances under which such termination 
is allowed. 
.10 Jurisdiction, warranties, notices 
The agreement will specify that, in the case of a 
dispute, laws will apply in a particular country, 
state, or province. The jurisdiction will usually be 
that of the licensor, although there may be rea­
sons to have a neutral third location. 
Each party to the agreement should warrant 
that it has the authority to do what is contained 
in the agreement. For example, if the agreement 
is a patent license, the licensor will warrant that 
it owns the patent and that it is not aware of any 
infringement of the patent. Conversely, this war­
rant may include that the licensee cannot hold 
the licensor liable for any unknowing infringe­
ment that may be discovered. Warrants are of­
ten symmetrical (that is, each party warrants the 
same things). 
An agreement will specify the name, address, 
and other contact information of the individuals 
or positions within each party to which official 
communications should be directed. The notice 
clause may also specify whether fax and electronic 
documents are acceptable. 
HANDBOOK OF BEST PRACTICES | 1 
  
     
 	 	 	
      





      
        
       
         
         
       
	
 
MAHONEY & KRATTIGER 
.11 Other potentially important clauses 
In certain types of agreements or jurisdic­
tions, the following clauses may be of particular 
importance: 
.11.1 Illegal/unenforceable provisions 
In some jurisdictions, it might be advisable to in­
clude certain limitations: 
Should any court of competent jurisdiction later 
consider any provisions of this Agreement to be in­
valid, illegal, or unenforceable, such provisions shall 
be considered severed from this Agreement. All other 
provisions, rights, and obligations shall continue 
without regard to the severed provision, provided 
that the remaining provisions of this Agreement are 
in accordance with the intentions of the Parties. 
.11.2 Statement of completeness 
Many organizations have more than one agree­
ment with a specific third party in place. If that 
is the case, then the formerly existing agree­
ments should be cited whenever possible and re­
viewed for consistency with any new agreement. 
Alternatively, the agreement may be limited to the 
purpose that has previously been defined. Typical 
language could read: 
The above constitutes the full and complete 
Agreement on this Purpose by and between the 
Parties. 
.11. Subject law 
In the subject-law section, the Parties clarify where 
they wish to have an agreement interpreted and 
adjudicated. Such a determination is not always 
necessary but can make future interpretation less 
difficult, particularly if the Parties are located in 
different countries. Typical language is: 
This Agreement shall be interpreted, construed 
and adjudicated under the laws of _____ province 
[or state, canton, etc.] _____ within the nation of 
_____. 
.12 Signatories 
Representatives with authority to bind their re­
spective institutions are the persons who should 
sign agreements. It is advisable to include the 
person’s title to make clear that the person is 
representing the Party and not signing the agree­
ment as an independent entity. 
In some cases, more than one representative 
from each party should sign an agreement. For ex­
ample, when materials are transferred to a labora­
tory of a specific scientist, it is important to ensure 
that the scientist is fully aware of the obligations so 
the scientist may be included as a signatory. 
Further, in a university setting, different de­
partments or even legal entities may have certain 
responsibilities over in-licensing and out-licens­
ing. For example, an office of sponsored pro­
grams may be responsible for incoming materi­
als, whereas a foundation that commercializes 
university inventions may also have a stake in the 
agreement. In such cases, there may be signatories 
representing at least three entities, one of which 
may include the chief scientist. 
. ConCLuSIonS 
No agreement will ever be perfect. Evidently, 
there are good and not-so-good agreements (and 
even poorly written ones or highly ineffectual 
agreements). The better ones may take longer to 
negotiate, but the good news is that each time 
an agreement has been successfully developed by 
two parties, the process gets easier. Taking time to 
think through and discuss the terms of an agree­
ment helps foster communication between the 
partners. Such an activity, especially if carried out 
early on, sets the project on a path for success. In 
any case, the critical aspect of any agreement is 
what the parties do after the agreement has been 
signed; an agreement should always be seen as 
just the beginning of a long and mutually benefi­
cial relationship. n 
RichaRd T. Mahoney, Director, Vaccine Access, Pediatric 
Dengue Vaccine Initiative, International Vaccine Institute, 
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818, 
Republic of Korea. rmahoney@pdvi.org 
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute; and Adjunct Professor, 
Cornell University, PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu 
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CHAPTER .1 
1	 www.ipHandbook.org. Included there are many actual 
agreements including confidentiality, material transfer 
(for germplasm, biological resources, materials for 
testing, research tools, and experimental animals),
IP licenses for copyright, software, trademarks, trade 
secrets, and various forms of exclusive, coexclusive and 
nonexclusive licenses, as well as the Model Provisions 
for an Equitable Access and Neglected Disease 
License developed by the working group, based at
Yale University, convened by Universities Allied for 
Essential Medicines. Other chapters in this Handbook
also contain sample agreements including nonasserts,
invention disclosure, licensing checklist, and more.
Please refer to the index for a list of agreements. 
2	 See, also in this Handbook, chapter 7.2 by SP Kowalski 
and A Krattiger. 




5	 The swift program at Cornell University and IRRI 
collaborated at the time for the INGER Training-
Workshop on IPR, 17-18 July, 2001, Maruay Garden Hotel,
Bangkok, Thailand. 
6	 See, also in this Handbook, chapter 17.10 by KR 
Schubert.
7	 Ibid. and chapter 7.4 by MB Steinbock. 
8	 See, also in this Handbook, chapter 5.4 by BJ 
Weidemier. 
9	 See also, in this Handbook, chapter 15.3 by E-J Min. 
10 Mahoney RT (ed.). 2004. Handbook of Best Practices 
for Management of Intellectual Property in Health 
Research and Development. MIHR: Oxford, U.K. 
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Box 1: Material Transfer Agreement for the Genetic Evaluation

of Rice to and from INGER Collaborators
 
The International Rice Research Institute, MCPO Box 3127, Makati City 1271, Philippines (“IRRI”),
provides the “Material”
under the following terms and conditions: 
1. The Material provided is not intended for the exclusive use of any single organization. 
2. IRRI requires written notification if the recipient distributes the Material to a third party. 
3. Recipients may not seek any form of intellectual property rights protection on the Material 
without prior written consultation with IRRI. IRRI reserves the right to refuse to grant such 
permission.
4. Use of the Material will be publicly recognized when and where appropriate, and recipient will 
provide IRRI with reports on its use of the Material on a reasonably frequent basis. 
5. IRRI does not warrant or guarantee the title, quality or correctness of the Material being 
supplied and will not be held liable for the Material or its use. 
6. IRRI provides the Material on acceptance of the terms and conditions of this MTA. Recipient’s 
retention of the Material shall be deemed to constitute acceptance. 





Date       
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Box 2: Invitation to Collaboration 
Development of a Health Product A 
objective
The Public Sector Research Centre (PSRC) is seeking collaborative relationships with one or 
more organizations capable of completing the following tasks for prototype health products:
industrial development, manufacturing, clinical testing, and licensure by national regulatory 
authorities.
Health Product A can be produced in a number of different ways. The PSRC believes that one or 
more of these production methods could be viable for commercial scale-up. 
The 	public Sector Research Centre
[insert a description of the PSRC including governance, funding, research programs, goals,
history, capabilities, etc.] 
participating Scientists
The following scientists have played a leading role in the development of methods for 
synthesizing Health Product A as described in the attached documents. [attach copies of 
relevant publications] 
and their collaborators. 
Mode of 	operation
The PSRC has the ability to mobilize assistance for the health-product development process by a 
variety of means including financial, technical, and in-kind support. 
Companies should contact the PSRC to initiate an agreement on a development project.
The following issues are open for discussion with respect to a collaboration 
agreement: 
•	 Product development including consultation on details of manufacture, adjuvanting,
packaging, heat stability, etc. 
•	 Cost sharing of the manufacture of sufficient health product for Phase I through Phase III 
trials. 
•	 Assessment and planning for the introduction of the health product into private-sector 
markets. 
•	 Assessment and planning for the introduction of the health product into public-sector 
markets. 
(Continued on Next Page) 
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MAHONEY & KRATTIGER 
Box 2 (continued) 
•	 Development of regulatory standards through interactions with national regulatory 
authorities and the World Health Organization. 
•	 Conduct of Phase I through Phase III trials in developed and developing countries in a variety 
of populations.
•	 Obtaining regulatory approval in developed and developing countries. 
Intellectual 	property Rights
Details on patent applications will be discussed with interested parties following execution of 
a suitable confidentiality agreement. The PSRC possesses extensive know-how, which will be 
essential for the cost-effective implementation of a health-product development program. 
desired 	product
The envisaged health product is expected to consist of _______________________. Further 
information on specific methods for health product manufacture is provided in the attached 
documents. 
In the developing world, the principal use of the product is expected to be _________________
______. In the developed world, the health product may find use in _______________________.
See the following dossier for further discussion of potential market. 
Submission of Expression of Interest
At this time, a letter containing the following information is requested:
•	 the nature of your interest in this project 
•	 if you wish, a summary of the capabilities and experience of the organization 
•	 names of other collaborators or partners 
•	 an indication of the types of assistance/collaboration desired from the Institute 
Interested parties are requested to write to the PSRC ____________________________________
__________. Submissions are requested prior to _______________________. 
For further information, contact either [name 1] _______________________or [name 2] _______
________________ of the PSRC at telephone _______________________ or fax _______________
________ or write to them at [e-mail address] _______________________or the above address. 
Review and Contracting 	procedure
Interested parties will be contacted to arrange for meetings and development of collaborative 
agreements. 
Background on Health 	product A and Collaborating Scientists
Health Product A is involved in acute, chronic, and _______________________. Health Product A 
is widespread in both developing and developed countries and infects _____________________.
Infection persists throughout life. Health Product A transmission is primarily by _____________ 
__________. 
(Continued on Next Page) 
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Box 2 (continued) 
Health-Product-A–associated diseases are significant causes of morbidity and mortality.
For example, in developing countries ______________________________________________.
In developed countries, it leads to significant morbidity_______________________. 
Short biographies of collaborating scientists [include as an attachment] 
Market Potential for Health Product A 
Scientific and other References 
Source: Mahoney10 
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Confidentiality Agreements: A Basis for Partnerships
 
sTanley p. KowalsKi, Franklin Pierce Law Center, U.S.A.
 
anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University; Chair, 

bioDevelopments-International Institute and Adjunct Professor, Cornell University, U.S.A.
 
ABSTRACT 
Confidentiality agreements (also called nondisclosure 
agreements, confidential disclosure agreements, and se­
crecy agreements) are contracts that govern the disclosure 
of confidential information by one party (the disclosing 
party) to another party (the receiving party). Confidential 
information is exchanged for a promise of secrecy. The 
disclosure may be unilateral, bilateral or multilateral. 
Confidential information disclosed in a confidentiality 
agreement might pertain to scientific research results and 
data, chemical compositions and formulas, software de­
velopment information, recipes, laboratory methodology, 
and manufacturing techniques trade secrets (in the form 
of valuable know-how and/or show-how). The confiden­
tial information has value precisely due to the fact that is 
known to only a few, that is, open disclosure will be inju­
rious to this value. Confidentiality agreements often pre­
cede licensing negotiations or the acquisition of IP (intel­
lectual property) rights and serve to strike an appropriate 
balance between the needs of the disclosing and receiv­
ing parties. A confidentiality agreement can either stand 
alone or be included as part of a broader agreement. An 
appropriately drafted confidentiality agreement should 
contain a list of standard provisions and exceptions. In 
special cases, where the disclosing party wishes to care­
fully protect the confidential information, the agreement 
might also include extra strong clauses and articulated 
security provisions. 
1. InTRoduCTIon: BuILdInG	 TRuST 
Before entering into a relationship, a level of 
trust between the parties must be established. 
This trust is the basis for a confidentiality agree­
ment, which is often the first step in developing 
a mutually advantageous relationship. For exam­
ple, a confidentiality agreement often precedes 
licensing negotiations or the acquisition of intel­
lectual property (IP) rights. 
Depending on the perspective, whether a per­
son or party is disclosing or receiving confidential 
information, the disclosing party will want the re­
ceiving party to maximize protection whereas the 
receiving party will want to minimize constraints. 
However, the disclosing party often wants to dis­
close information, for example, as a first step in 
licensing negotiations or other business develop­
ment activities, or as required by a know-how li­
censing agreement. But even the receiving party 
may see problems in terms of future constraints 
imposed by the agreement and its ability to use 
the received information. In the end, a confiden­
tiality agreement is intended to strike an appro­
priate balance between the needs of a disclosing 
party and the needs of a receiving party. 
Confidential information is often passed 
from one party to another when materials are 
transferred, during collaborations, and in some 
types of licensing agreements. A confidential­
ity agreement is the simplest form of almost any 
agreement, and confidentiality clauses generally 
form an integral part of most other agreements. 
But confidentiality agreements are also entered 
into separately for the sole purpose of disclosing 
confidential information, although perhaps they 
Kowalski SP and A Krattiger. Confidentiality Agreements: A Basis for Partnerships. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. SP Kowalski and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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KRATTIGER & KOWAlSKI 
are used less often for that purpose. It is important 
to note that obtaining third-party confidential in­
formation may not always be a good option. The 
knowledge could block important future research 
or otherwise adversely affect the business of a re­
ceiving party. 
2.	 ConfIdEnTIALITy 	AGREEMEnTS	 
dEfInEd 
Confidentiality agreements (also called nondis­
closure agreements, confidential disclosure agree­
ments, and secrecy agreements) are contracts that 
govern the disclosure of confidential information 
by one party (the disclosing party) to another 
party (the receiving party). The disclosure may be 
unilateral, with one party disclosing confidential 
information to only one other party; bilateral, 
with two parties mutually disclosing information; 
or multilateral, with three or more parties disclos­
ing information among themselves. 
With regard to a confidentiality agreement, 
confidential information is exchanged for a prom­
ise of secrecy. Confidential information is infor­
mation that is of value precisely because it is not 
generally known to competitors or to the public. 
Such information might pertain to scientific re­
search results and data, chemical compositions 
and formulas, software-development information, 
recipes, laboratory methodology, manufacturing-
techniques trade secrets (in the form of valuable 
know-how and/or show-how), and so on. What 
matters, within the context of the confidential­
ity agreement, is that the information is of value 
due to its state of being relatively unknown, and, 
therefore, open disclosure would be injurious to 
this value. 
.	 kEy pRovISIonS 
As stated above, confidentiality agreements come 
in many different forms and lengths and should 
be adapted to the particular circumstances and 
legal environment.But they all have the same es­
sential components and purpose: to ensure that 
a privileged communication to a third party is 
treated as confidential. But, along with the stan­
dard terms of any agreement, such as boilerplate 
contract terms, confidentiality agreements in­
clude a number of terms that are important. Box 
1 provides a fairly typical confidentiality agree­
ment used by a university. 
The following agreement is a sample of a 
one-way, or unilateral, confidentiality agreement. 
Two-way agreements, through which two parties 
mutually disclose confidential information follow 
the same approach in principle, except that both 
parties usually have the same obligations to each 
other. Specific samples of unilateral and bilat­
eral agreements from different organizations are 
available for download on the Handbook’s Web 
version. 
.1 Disclosing party 
It should be noted that the disclosing party does 
not necessarily need to be the party who actually 
owns the confidential information. The disclos­
ing party may instead be a party that lawfully pos­
sesses the information and is legally permitted to 
disclose it. 
.2 Receiving party 
Receiving parties, particularly in large organi­
zations, are parties to a confidentiality agree­
ment. The receiving party may thus be a series 
of individuals, depending on the complexity 
of the disclosure. In such cases, confidentiality 
agreements, and disclosures, are made at differ­
ent stages whereby, initially, one individual or 
a small department receives the confidential in­
formation. For example, if the receiving party 
is not confident that the information is really 
worth binding the entire large institution to an 
agreement, an individual may be nominated to 
receive the confidential information as a first 
step before subsequent agreements are executed. 
Unless otherwise articulated in the confidential­
ity agreement, every person within the organi­
zation that is named as a party may share the 
confidential information with every other per­
son within the same organization. However, as 
per specific disclosure provisions in the agree­
ment, disclosure may be limited to persons who 
“need to know,” or to certain departments, or to 
only scientists within a specific research group, 
for example. 
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Box 1: unilateral Confidentiality Agreement 
This Agreement, effective on _________ (“Effective Date”),
 
is by and between _________________________(“Disclosing Party”),
 




with offices at ________________________.
 
The Disclosing Party intends to disclose certain Confidential Information to the Receiving Party 

for the following purpose (the “Purpose”):
 
Now, therefore, in consideration of the Disclosing Party making such confidential information 

available to the Receiving Party, the Receiving Party hereby agrees as follows:
 
1. As used in this Agreement,the term “Confidential Information”means any technical or business 
information furnished by the Disclosing Party to the Receiving Party in furtherance of the 
Purpose in connection with the Purpose, regardless of whether such information is specifically 
designated as confidential and regardless of whether such information is in written, oral,
electronic, or other form. Such Confidential Information shall include, without limitation, trade 
secrets, know-how, inventions, technical data or specifications, compilations of information,
records, testing methods, business or financial information, research and development
activities, product and marketing plans, and customer and supplier information.
2. Confidential Information shall not include disclosed information to the extent that the 
Receiving Party can demonstrate that such disclosed information: 
(a) was in the public domain prior to the time of its disclosure under this Agreement; 
(b) entered the public domain after the time of its disclosure under this Agreement through 
means other than an unauthorized disclosure resulting from an act or omission by the 
Receiving Party; 
(c) was independently developed or discovered by the Receiving Party without use of the 
Confidential Information; 
(d) is or was disclosed to the Receiving Party at any time, whether prior to or after the time 
of its disclosure under this Agreement, by a third party having no fiduciary relationship 
with the Disclosing Party and having no obligation of confidentiality with respect to such 
Confidential Information; or 
(e) is required to be disclosed to comply with applicable laws or regulations, or with a court
or administrative order, provided that the Disclosing Party receives prior written notice of 
such disclosure. 
3. The Receiving Party agrees that it shall:
(a) maintain all Confidential Information in strict confidence, except that the Receiving 
Party may disclose or permit the disclosure of any Confidential Information to its 
directors, officers, employees, consultants, and advisors who are obligated to maintain 
the confidential nature of such Confidential Information and who need to know such 
Confidential Information for the purposes of this Agreement; 
(b) use all Confidential Information solely for the purposes of this Agreement; and 
(c) upon the conclusion of the Purpose, or earlier at the request of the Disclosing Party, return 
to the Disclosing Party all originals, copies, and summaries of documents, materials, and 
other tangible manifestations of Confidential Information in the possession or control of 
the Receiving Party.
(Continued on Next Page) 
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KRATTIGER & KOWAlSKI 
Box 1 (continued) 
4.	 The term of this Agreement is for the duration of one (1) year from the Effective Date 
(“Termination”).
5.	 The obligations set forth in this Agreement shall remain in effect for a period of five (5) years 
after Termination, except that the obligation of the Receiving Party to return Confidential 
Information to the Disclosing Party shall survive until fulfilled. 
6. The Receiving Party acknowledges 	that the Disclosing Party claims ownership of the 
Confidential Information disclosed by the Disclosing Party and all intellectual property rights 
in, or arising from, such Confidential Information. No option, license, or conveyance of such 
rights to the Receiving Party is granted or implied under this Agreement. 
In Witness whereof, the Parties hereto have caused this Agreement to be executed. 
DISCLOSING PARTY RECEIVING PARTY 
Signature: _________________________ Signature: _________________________ 
Name: ____________________________ Name: ____________________________ 
Title: _____________________________ Title: _____________________________ 
Date: _____________________________ Date: _____________________________ 
. Purpose of the confidentiality agreement 
As with any agreement the definition and de­
scription of the purpose are important for any 
confidentiality agreement, with the aim of avoid­
ing confusion and later disagreement. The text 
could read: 
… to evaluate XXX technology of the Disclosing 
Party, or 
… to evaluate entering into a sponsored research 
agreement, or 
… to evaluate the information to assess entering 
into a license agreement 
Such language provides an additional caveat 
as to how the confidential information may be 
used within the context of the confidentiality 
agreement. That is, in addition to who may be a 
receiving party and what the confidential infor­
mation entails, purpose further specifies, or re­
stricts, how the information may be used. 
. Limitations on disclosure 
Information received under a confidentiality 
agreement cannot be disclosed to a third party 
that is not a party to the agreement, even if such 
disclosure takes place under a separate agreement. 
There are also examples when a receiving party 
believes that the disclosing party has a separate 
confidentiality agreement with a third party. This 
might tempt the receiving party to disclose the 
confidential information to this third party, per­
haps mistakenly believing that the third party 
might already have had access to the particular 
confidential information from the disclosing par­
ty. Such disclosures to third parties are not per­
mitted (unless specifically allowed). 
. Important exceptions 
Confidentiality agreements usually contain ex­
ceptions to the receiving party’s obligation to 
maintain the confidence of the confidential 
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CHAPTER .2 
information. These clauses are not generally 
points of negotiation. Different agreements may 
include different exceptions, though the follow­
ing five are fairly typical: 
1. The information that was in the public do­
main prior to the time of its disclosure. 
2. The information was already known by the 
receiving party. 
3. The information entered the public do­
main after the time of its disclosure under 
the agreement through means other than 
an unauthorized disclosure resulting from 
an act or omission by the receiving party. 
4. The information 	 was independently de­
veloped or discovered by the receiving 
party without use of the confidential 
information. 
5. The information is or was disclosed to the 
receiving party at any time by a third party 
having no fiduciary relationship with the 
disclosing party and having no obligation 
of confidentiality with respect to such con­
fidential information. 
6. The information is required to be disclosed 
to comply with applicable laws or regula­
tions, or with a court or administrative or­
der, for example, a subpoena for produc­
tion of the information pursuant to a grand 
jury proceeding. 
The fourth point is particularly important for 
academic research establishments. The following 
example serves to illustrate the point: Yuri works 
at a university in the biochemistry department. 
He has no connection with, nor knowledge of, 
a particular set of confidential information. Yuri 
independently develops an innovation that relies 
on the same general knowledge as that of another 
researcher, Irina, at the same university but in 
the department of physical chemistry. With that 
general knowledge, Yuri developed his invention 
that concurrently leads to valuable data. Nearly 
identical data had been obtained by Irina under 
a confidentiality agreement from the BioChem 
company. That confidential data has been previ­
ously obtained by Irina. 
Evidently, both professors, Yuri and Irina are 
employed at the same university but in different 
departments. Yet Irina’s confidentiality agree­
ment is between BioChem and the university as 
a whole since the Office of Sponsored Programs 
signed it on behalf of the university. Since Irina 
never shared the data with Yuri, Yuri may be un­
der no obligation of confidentiality in regard to 
the specific data he developed himself. 
Referring now to the fourth point in the list 
above, if a provision is included in the confiden­
tiality agreement such that information indepen­
dently developed or discovered by the receiving 
party (someone at the university) without the use 
of the confidential information will be an excep­
tion to confidentiality, then Yuri is under no ob­
ligation to keep the information secret. If this ex­
ception were not included in Irina’s confidentiality 
agreement with the BioChem company, then Yuri 
would not be able to publish information about his 
innovation without placing Irina at risk of breach 
of the confidentiality agreement with BioChem. 
Once Yuri made his data public, Irina likewise is 
no longer under an obligation to keep her data se­
cret (providing it is identical) since the data is now 
public. This is perhaps the single most important 
exception to keep in mind when drafting confi­
dentiality agreements for research institutions. 
.	 oTHER	 poSSIBLE	CLAuSES	 
Nongrant of rights. In some confidentiality agree­
ments, the disclosing party will state that there is 
no confusion about the intent in disclosing confi­
dential information. This is to prevent the receiv­
ing party from later claiming that, by disclosing 
the confidential information, the disclosing party 
implied the granting of, to the receiving party, addi­
tional rights or licenses. This limitation could read: 
Nothing contained in this Agreement shall 
be construed as an obligation to enter into any 
further agreement concerning the Project or 
Confidential Information, or as a grant of license 
to the Confidential Information, other than for the 
Project. 
Limitations to disclose. Certain limitations may 
apply to the amount of information to be dis­
closed. Language such as the following can be 
included in specifying such a limitation: 
HANDBOOK OF BEST PRACTICES | 
  






        
    
    
      




KRATTIGER & KOWAlSKI 
The amount of Confidential Information to be 
disclosed is completely within the discretion of the 
discloser. 
Limitations on the use of the information. 
Certain agreements contain a specific clause that 
states certain limitations on the receiving party’s 
use of the confidential information, for example: 
The receiving Party may not use the Confidential 
Information for commercial or noncommercial re­
search (or for the production of prototypes; or for 
obtaining regulatory approvals) without the prior 
written approval of the disclosing Party. 
Representation. In some cases, a receiving party 
may demand representation. Language such as the 
following can be included to address this issue: 
Discloser of Confidential Information represents 
that the disclosure of information is not in viola­
tion of any commitment or obligation to any former 
employer, present employer, or any other party and 
that discloser has the right to make such a disclosure 
and to make the promises and agreements expressed 
herein. 
Such representations are sometimes used 
when individuals disclose information. 
Requirements for documentation. There are no 
standards as to whether disclosed confidential in­
formation should be documented. Especially in 
an academic setting, where disclosing and receiv­
ing parties are scientists and converse by phone 
and e-mail, such a requirement would, in many 
cases, be ignored or forgotten. However, if in­
cluded, the following clause may be used: 
To the extent practical, Confidential Information 
shall be disclosed in documentary or tangible form 
marked “Proprietary” or “Confidential.” In the case 
of disclosures in nondocumentary form made orally 
or by visual inspection, the discloser shall have the 
right or, if requested by the recipient, the obligation 
to confirm in writing the fact and general nature of 
each disclosure within a reasonable time after it is 
made. 
Extra strong clauses.1 Occasionally the 
disclosing party may want the confidential­
ity agreement to provide as much protection as 
possible. This will be the case when information 
to be disclosed is of great value and importance 
to the disclosing party. Under such circumstanc­
es, the disclosing party can include extra strong 
clauses in the agreement. These provisions will 
not alter basic obligations articulated in the agree­
ment, but rather clarify and emphasize the grav­
ity of said obligations. Examples of extra strong 
clauses could include: 
•	 The receiving party is forbidden to use the 
disclosed confidential information to make 
inventions or other valuable developments. 
•	 If the receiving party uses the disclosed con­
fidential information to make inventions or 
other valuable development, then all rights 
to such shall be assigned to the disclosing 
party. 
•	 The receiving party will not attempt 
to replicate the disclosed confidential 
information. 
•	 The receiving party will not engage in de­
tailed research for the purpose of investigat­
ing the details and aspects of the disclosed 
confidential information. 
•	 The receiving party will not use the dis­
closed confidential information in a 
manner that either confers commercial 
benefit on the receiving party or places 
the disclosing party at a commercial 
disadvantage. 
Security.2 Security is, naturally, a critical consider­
ation in any confidentiality agreement. Common 
provisions in agreements state that the receiving 
party must treat the disclosed confidential infor­
mation with the same degree of security as it does 
its own confidential information, or there can be 
a clause that specifies reasonable and proper mea­
sures to safeguard and ensure security. However, 
if the disclosing party wants to make certain 
that a specific level of security is established and 
maintained, then the following types of provi­
sions might be included in the confidentiality 
agreement: 
•	 Disclosed confidential information must be 
stored in designated, locked storage spaces. 
•	 Only designated individuals can have access 
to the disclosed confidential information. 
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•	 Copying the disclosed confidential infor­
mation is strictly prohibited. 
•	 Disclosed confidential information cannot 
be taken from the premises. 
•	 Any viewing of the disclosed confidential 
information must be duly recorded in a 
log. 
•	 All disclosed confidential information docu­
mentshaveunique identifiernumbers andall 
are marked, in red, “CONFIDENTIAL.” 
.	 ConCLuSIonS 
There are two simple rules to keep in mind when 
dealing with confidentiality agreements (and, in 
fact, with any agreement): First, if there is no trust 
between the parties, then perhaps it is best not 
to proceed with the agreement, no matter how 
simple the agreement may be. On the other hand, 
a confidentiality agreement may be a rational first 
step in developing the trust needed to build a re­
lationship that may lead to further collaboration 
and new opportunities. Second, by entering into 
CHAPTER .2 
a confidentiality agreement with another party to 
receive their confidential information, it is im­
portant to ensure that everyone in the organiza­
tion who has access to the confidential informa­
tion is well informed of the obligation to keep it 
confidential. n 
sTanley p. KowalsKi, Franklin Pierce Law Center, 2 White 
Street, Concord, New Hampshire, 03301, U.S.A. spk3@ 
cornell.edu and skowalski@piercelaw.edu 
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute; and Adjunct Professor, 
Cornell University, PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu 
1	 This section is based on UNICO. 2006. UNICO Guides:
Confidentiality Agreements. UNICO; Cambridge, U.K.
www.unico.org.uk. The UNICO Guide provides ad-
ditional and valuable discussions on confidential-
ity agreements, including a range of template agree-
ments. 
2 	 Ibid. 
HANDBOOK OF BEST PRACTICES | 

        
         
       
     
     
        
      
          
         
      
              
  
     
                 
                  
              
    
CHAPTER 7.3 
Specific Issues with Material Transfer Agreements
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ABSTRACT 
In the health and agricultural sciences, biological mate­
rials were once freely and widely exchanged. But more 
and more, these materials have gained commercial value. 
Public sector institutions, as well as private companies, 
have recognized, therefore, that proprietary protection of 
these materials may be necessary. Material transfer agree­
ments (MTAs) are legal instruments that define terms 
for the transfer of tangible biological materials between 
or among two or more parties. MTAs are bailments that 
transfer possession but not title: the party who transfers 
the materials retains full ownership; the party who receives 
the materials holds them in trust. Transfer is governed by 
contract, ideally specifying the term of the transfer, how 
the materials may and may not be used, and other related 
issues, such as confidentiality. In addition, an MTA may 
contain licensing provisions for the transfer of embedded 
intellectual property (IP) rights (patent rights). Hence, 
an MTA can be a hybrid instrument, covering the trans­
fer of both tangible property (via bailment and contract) 
and intangible property (via licensing of patent rights). 
Biological materials transferred using MTAs include re­
agents, cell lines, antibodies, research tools, insertional 
mutant populations, genome sequence databases, novel 
vectors, and plant genetic resources. Due to divergent 
institutional priorities, material transfers between the pri­
vate and public sectors are generally more complex than 
those between public sector institutions. 
1. INTRODuCTION 
There is a long history of sharing biological
materials, such as plant germplasm or genetic 
stocks, and for the most part this has been done free­
ly and often without any form of a legal agreement. 
This has not typically been the case in health re­
search, where reagents, cell lines or antibodies that 
have potential therapeutic implications have been 
transferred under specific agreements that define 
the terms of the transfer. In both agricultural and 
health research, the increasingly sophisticated re­
search approaches that rely heavily on access to 
biological or bioinformatic resources created by 
other researchers have dramatically increased the 
need for researchers to share research tools. This 
trend has been advanced further by the investment 
of federal agencies (notably the National Science 
Foundation [NSF] and the National Institutes 
of Health [NIH]) and private companies in the 
development of genomic resources that are in­
tended primarily as vehicles for further discovery 
of gene function and/or gene regulation. These 
types of biological and bioinformatic resources 
(such as insertional mutant populations, genome 
sequence databases, and novel vectors) are the 
most problematic with regard to sharing, because 
they are the research tools that can lead to po­
tentially valuable discoveries, invariably leading 
to the question of who will own or control those 
downstream discoveries. 
The NIH considers the sharing of research 
tools so important to future research progress that 
the agency issued strong guidelines on the ap­
propriate terms for transfer of research materials 
that contribute to, or result from, NIH-funded 
Bennett AB, WD Streitz and RA Gacel. 2007. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org.
© 2007. AB Bennett, WD Streitz and RA Gacel. Sharing the Art of IP Management: Photocopying and distribution through 
the Internet for noncommercial purposes is permitted and encouraged. 
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BENNETT, STREITZ & GACEl 
research.1 Similarly, the NSF has issued guide­
lines for data and materials release and requires 
investigators to describe the timing, constraints, 
and means of release of materials developed, par­
ticularly for programs (such as the Plant Genome 
Research Program) that focus on the generation 
of research resources and tools.2 
Plant genetic resources represent another area 
of increasing concern regarding how freely these 
resources can be exchanged. Even those plant ge­
netic resource centers that are most committed to 
the free exchange of germplasm now utilize spe­
cific agreements to govern the transfer of seeds, 
if only to specify that the recipient cannot seek 
intellectual property (IP) rights on the materials 
(the African Rice Center, WARDA; Box 1 [see 
end of chapter])3 or to ensure that the recipient 
understands that there is no warranty on the 
transferred material (Tomato Genetics Resource 
Center; Box 2 [see end of chapter]). 
Scientists have traditionally shared research 
materials freely, and, indeed, an important criteri­
on for scientific publication has been the ability of 
other researchers to experimentally reproduce and 
thereby test published results. The ability to repli­
cate results will often rely on access to the under­
lying biological materials or information, but that 
access is not assured today. So what has changed? 
Probably the most significant change has been the 
narrowing of the gap between fundamental re­
search and commercial developments, particularly 
in health research, but also in agriculture.4 Materi­
als that at one time would have been useful almost 
exclusively for fundamental research purposes are 
increasingly seen as having direct commercial val­
ue, and this trend has generated a new breed of 
researchers and companies that focus on leveraging 
novel research tools to discover new commercially 
valuable traits, genes, or compounds. Particularly, 
in the case of companies, they may be reluctant 
to share their “crown jewels” without making sure 
that their business interests are protected. As a re­
sult of the Bayh-Dole Act, many universities ac­
tively use the patent system as a means to transfer 
research results to industry. In addition, universi­
ties increasingly conduct research that is sponsored 
by industry. As a consequence, they may have con­
cerns similar to those of private companies. So a 
company that traditionally had little concern over 
a university’s use of its property may now be ap­
propriately concerned that its proprietary materials 
may lead to valuable inventions or even to fueling 
a competitor’s business interests. Universities and 
nonprofit research institutions have also become 
much more aware and protective of research mate­
rials. The result has been a slow but steady evapora­
tion of unrestricted transfers of research materials 
between scientists, in general, and particularly be­
tween industry scientists and those in universities. 
With growing regularity, the sharing of re­
search materials takes place under material trans­
fer agreements (MTAs). MTAs are legal agree­
ments (bailments) that govern the transfer of a 
tangible property between parties. For example, 
the University of California, Davis, executed over 
470 MTAs in 2005, and this number had been 
increasing every year since 2001. At the same 
time, the complexity of MTAs is increasing dra­
matically, with restrictions and obligations poten­
tially reaching far beyond the material itself, to 
data or inventions made using the material and/ 
or to derivative materials. As a consequence, each 
MTA has begun to take on the complexity of a li­
cense agreement, and a high level of skill and time 
are required to ensure that the MTA can be ex­
ecuted without compromising key principles and 
will not conflict with other agreements. Hence, 
an MTA can be a hybrid instrument: covering the 
transfer of both tangible property (via bailment 
and contract) and intangible IP (via licensing of 
patent rights). To complicate things even further, 
provisions of an MTA may stipulate how any fu­
ture IP rights, arising from the use of the materi­
als transferred, will be allocated. 
Because MTAs are contractual agreements 
between two or more parties, the agreements 
typically do not have the geographic or tempo­
ral limitations of patented technologies (patents 
are territorial, issued by countries, with limited 
terms, typically 20 years from filing) and, con­
sequently, can be much farther reaching than 
the scope of patent rights. It is interesting to 
note that an evaluation of the property rights 
associated with “GoldenRice” indicated that 
44 patented products or processes and at least 
15 materials, many of which were governed by 
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CHAPTER . 
MTAs, were potentially used in its development.5 
In navigating the intellectual and technical prop­
erty landscape surrounding “GoldenRice,” Po­
trykus reported that the restrictions imposed by 
one MTA had been particularly problematic.6 
Just as universities are experiencing an in­
crease in the use of MTAs for receiving and dis­
seminating materials, so are companies. One large 
pharmaceutical company indicated that it had 
six administrators dealing with more than 1,000 
MTAs in the year 2000 and that many of these 
agreements required lengthy negotiations. Some 
companies have questioned whether it is worth 
their while to exchange research tools with uni­
versity scientists at all.7 In our own experience, 
agreements for transfer of research materials from 
industry to the university often have a low priority 
for attention within company legal departments, 
particularly because such transfers are often only 
incidental to, or may actually compromise, their 
main commercial interests. We estimated that 
10%–25% of MTAs received from industry for 
incoming materials to the University of California 
were never executed because the terms compro­
mised fundamental academic principles or created 
legal obligations that the university cannot fulfill. 
An example of a deal-breaking term in an MTA is 
one that specifies that the provider maintain own­
ership of data resulting from use of the materials. 
This term could prevent publication or prevent 
the continuation of the very research that the ma­
terial was intended to advance. Thus, universities 
in general are in a situation in which the exchange 
of research materials is of increasing and indeed 
critical importance, but both universities and pri­
vate companies are having difficulty finding easy 
ways to share these resources. As Eisenberg sum­
marized “Although there are many points on which 
they disagree, most people from each of these quarters 
seem to agree that the problem is growing rather than 
diminishing.” 8 
2. WHAT IS A MATERIAl
TRANSFER AGREEMENT? 
Fundamentally, an MTA is a bailment, that is, 
a transfer of tangible property without transfer 
of title. Under such an agreement, the provider 
maintains ownership of the property transferred. 
Transferred property is held by the receiving party 
according to terms stipulated in a legally bind­
ing contract. The contract, therefore, governs the 
transfer of tangible biological materials between 
two or more parties. In addition to the tangible 
property rights being owned by the provider, the 
material(s) may be the subject of a patent or pat­
ent application. In this case, the MTA may need to 
account for the transfer of IP rights as well as the 
transfer of tangible material. Transfer of IP rights 
would be in the form of a license, for example, to 
make, use, sell, and so forth, that is, a license is 
permission to do what would otherwise violate the 
provider’s IP rights. This chapter deals with mate­
rials that are intended to be used for research pur­
poses, usually in the absence of planned research 
collaboration between the provider and recipient. 
Such a collaboration could be accommodated by 
a separate collaboration agreement that would ac­
company the MTA. The MTA defines the rights 
of the provider and recipient with respect to the 
materials and derivatives of the materials. 
At most institutions, researchers themselves 
are not authorized to sign either outgoing or in­
coming MTAs for their institutions. The MTAs 
must be reviewed and approved by an autho­
rized institutional official. Agreements that are 
not signed by an institutional official may not 
be valid or enforceable. These functions usually 
reside in the Office of Research Administration 
(Sponsored Programs) or the office that manages 
IP and technology transfer for the institution. Be­
cause the researcher utilizing the material(s) is ul­
timately responsible for fulfilling the obligations 
of the MTA, most MTAs require the signature of 
the recipient of the material acknowledging their 
recognition of their responsibilities and duties un­
der the agreement. 
3. STRuCTuRE OF A MATERIAl
TRANSFER AGREEMENT 
An MTA can range in size from a few hundred 
words on one page to several thousand words on 
more than a dozen pages. The NIH’s “Simple Let­
ter Agreement for the Transfer of Materials” (Box 
3 [see end of chapter]) is an excellent example of 
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BENNETT, STREITZ & GACEl 
a short, easy-to-understand, one-page MTA. The 
Simple Letter Agreement requires no negotiation 
and is used by academic institutions throughout 
the United States to transfer materials, and, in the 
case of research consortia composed of multiple 
academic or nonprofit institutions, this type of 
agreement can be modified to provide an umbrella 
for easy transfer of materials between consortium 
members. On the other end of the spectrum, a 
complex and lengthy MTA from a company will­
ing to provide innovative and highly proprietary 
materials can take years to negotiate. 
The standard MTA used by the Davis campus 
of the University of California (Box 4 [see end of 
chapter]) represents an MTA that a university would 
use to provide materials to another university. An 
MTA, regardless of its length and complexity, may 
incorporate many if not all of the following: 
•	 a preamble 
•	 definitions 
•	 a description of use of the materials 
•	 confidential information 
•	 IP rights 
•	 warranties 
•	 liability and/or indemnification 
•	 publication 
•	 governing law 
•	 termination 
•	 signatures 
•	 exhibits or appendices 
.1 The preamble 
The preamble of an MTA is like an abstract of 
a manuscript or a prologue to a novel. The pre­
amble lays the groundwork for the MTA and 
sets the stage for the legally binding terms and 
conditions that follow. The preamble identifies 
parties to the agreement and specifies the MTA’s 
effective date. It may also include the addresses 
of the parties. It may even contain recitals or 
whereas clauses describing the material, the goal 
of the research, and the intent of the parties. 
.2 Definitions 
An MTA may have a separate section to define spe­
cific terms such as materials, use of the materials, 
modifications, or inventions. On the other hand, 
an MTA may define these terms as they first ap­
pear within the agreement. In a third approach, 
an MTA may define the terms that will be used 
throughout the agreement in a separate section 
for definitions and define the terms that are used 
only in one or two sections as they first appear 
within the agreement. 
The definition of materials should be limited 
to that of the actual materials being transferred, 
including progeny and unmodified derivatives, 
and should not include substances or inventions 
created by the recipient of the materials. Progeny, 
as defined in the Uniform Biological Material 
Transfer Agreement (UBMTA), are unmodified 
descendents of the original material. Progeny can 
include a virus from a virus, a cell from a cell, 
or an organism from an organism. Unmodified 
derivatives, according to the UBMTA, are sub­
stances created by the recipient that constitute an 
unmodified functional subunit or an expression 
product of the original material that was provid­
ed. Unmodified derivatives can include purified 
or fractionated subsets of the original material; 
progeny or products thereof; subclones of un­
modified cell lines; transcription and translation 
products, such as RNA and protein derived from 
provided DNA; reverse transcription and reverse 
translation products, such as DNA synthesized 
on a template using provided RNA; monoclonal 
antibodies secreted by a hybridoma cell line; and 
chemically synthesized copies. Since a provider 
usually asserts ownership of materials, the defini­
tion of materials should not overreach to modi­
fications, derivatives, crossbred progeny (in ani­
mals), mutants, or other substances that are not 
being provided by the provider. 
. Use of the materials 
An MTA specifies how the recipient can and can­
not use the material. Usually, the MTA contains a 
blank space for the researcher to include a descrip­
tion of the research use with the material. Some­
times an MTA has a separate appendix with a very 
detailed description of the intended research use. 
An MTA will usually prohibit the recipient from 
using the materials in a manner other than that 
intended by the original research. An MTA will 
also typically prohibit provider’s material from 
being tested in humans and used in plants and 
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CHAPTER . 
animals consumed as food. Other prohibitions 
may include using the material in research that 
has IP obligations to third parties, or with other 
materials from third parties, or transferring the 
material to third parties or even to other research­
ers within the recipient’s institution. Finally, most 
MTAs have prohibitions for the material to be 
used for commercial purposes. 
. Confidential information 
Often, providers of materials include, on the 
MTA form, proprietary or confidential informa­
tion. Therefore an MTA may contain a provision 
to protect the provider’s confidential informa­
tion. Confidential information can be defined 
as “information, data, or material, in written or 
other tangible form related to the material, that 
is identified as confidential at the time of disclo­
sure.” However, confidential information should 
not include information that is: 
•	 generally known to the public at the time 
of disclosure to the recipient 
•	 already in the recipient’s possession at the 
time of disclosure by the provider 
•	 disclosed to the recipient on a noncon­
fidential basis by a third party having the 
right to make such disclosure 
•	 independently developed by the recipient 
without the use of the confidential infor­
mation disclosed by the provider as evi­
denced by written records 
•	 required to be disclosed by law or govern­
mental rule or regulation 
The MTA should include language to make 
clear to the provider that the above information is 
not considered confidential. 
An MTA may also specify that the recipient 
of the confidential information treat it as confi­
dential and maintain it in confidence for a certain 
period of time. A long period of nondisclosure, 
for example, over five years, may be very difficult 
for a university to manage. Generally, an MTA 
may require that all confidential information 
be marked “Confidential” and be reduced to 
writing. Reducing confidential information to 
writing places an additional administrative bur­
den on both parties, but it does make it easier for 
the recipient to know precisely what information 
must be kept confidential. 
The MTA may stipulate that the recipient 
can disclose the provider’s confidential infor­
mation only to the recipient’s own personnel 
who have a need to know and who use the 
confidential information. The MTA may also 
require that the recipient take the same steps 
and use the same methods to prevent the un­
authorized use or disclosure of the provider’s 
confidential information as the recipient would 
take to protect its own confidential informa­
tion. Requirements such as these are generally 
appropriate when confidential information is 
being exchanged. 
. Intellectual property 
Nearly every MTA will address IP matters such 
as the disclosing of inventions, the prosecuting 
of patents and plant variety protection certifi­
cates, and the granting of options and licenses. 
IP rights language is perhaps the most challeng­
ing language to negotiate. An MTA may con­
tain overarching IP language that can reach to a 
researcher’s and/or institution’s past inventions 
and future inventions, which may have little or 
nothing to do with the materials provided, and 
could impact the researchers ability to continue 
doing related research. 
The MTA may specify that the recipient 
disclose, assign, and/or license any inventions to 
the provider, free of any royalties and fees. While 
most institutions will agree to certain licensing 
rights, they are generally unable to assign an in­
vention because doing so may violate: 
1. the Bayh-Dole Act if the invention resulted 
from research funded by the U.S. federal 
government 
2. the Tax Reform Act of 1986 by possibly 
jeopardizing the U.S. federal tax-free status 
of bonds that were issued to build or im­
prove research facilities 
3. the Principles and Guidelines for Recipients 
of NIH Research Grants and Contracts on 
Obtaining and Disseminating Biomedical 
Research Resources, by restricting the ac­
cessibility of research materials 
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BENNETT, STREITZ & GACEl 
4. an 	 institution’s own principles, policies, 
and practices if the invention was not de­
veloped for the public benefit 
5. other laws, regulations, rules and policies 
It is generally reasonable to grant a limited 
subset of IP rights to the provider of the materi­
als. For example, to the extent that the recipient 
is legally able to do so, the recipient could grant 
a nonexclusive royalty-free research license to any 
inventions that necessarily use or necessarily in­
corporate the material and are conceived and first 
actually reduced to practice in the performance of 
the research. The recipient, in many cases, may be 
able to grant a first right or an option to negotiate 
a non-exclusive or exclusive commercial license to 
such inventions. In some cases, when a provider 
provides innovative and valuable compounds, a 
recipient may have to grant a nonexclusive, roy­
alty-free research license to such inventions if the 
provider is concerned about being blocked from 
practicing new uses for its materials especially 
when the provider is performing or sponsoring 
similar research. 
. Warranties 
An MTA nearly always stipulates that the mate­
rial does not come with any warranties. A typical 
warranty clause, usually written in capital letters, 
may read: 
PROVIDER MAKES NO REPRESENTA­
TIONS AND EXTENDS NO WARRANTIES 
OF ANY KIND, EITHER EXPRESSED OR 
IMPLIED. THERE ARE NO EXPRESS OR 
IMPLIED WARRANTIES OF MERCHANT­
ABILITY OR FITNESS FOR A PARTICULAR 
PURPOSE, OR THAT THE USE OF THE 
MATERIAL WILL NOT INFRINGE ANY 
PATENT, COPYRIGHT, TRADEMARK, OR 
OTHER PROPRIETARY RIGHTS. 
The language is nearly always written in up­
percase letters to make the clause stand out. 
. Liability and indemnification 
An MTA usually stipulates that the recipient of 
the materials assumes all liability for damages 
that may arise from the recipient’s use, storage 
or disposal of the material, and modifications. In 
addition, many providers will stipulate that the 
recipient indemnify, hold harmless, and defend 
the provider against any claims, costs, or other 
liabilities that may arise as a result of recipient’s 
use, storage, or disposal of the material. A num­
ber of state institutions, for example in Alabama, 
Georgia, Kentucky, New York and other states, 
are prohibited from indemnifying other parties 
and must limit their indemnification to the ex­
tent permitted by state law. In addition to recipi­
ent liability, some MTAs will make the providers 
liable for losses, claims, or demands made by the 
recipient, or made against the recipient by any 
other party, that are due to the provider’s negli­
gence or misconduct. 
. Publications 
An MTA should enable the recipient of the ma­
terials to publish or present the results of the 
recipient’s research using the materials without 
the approval of the provider. An MTA can re­
quire that the recipient send the provider a copy 
of any proposed manuscript, abstract, poster 
session, or presentation prior to such publica­
tion or presentation so that the provider can 
review it, provide any comments, or request 
the removal of the provider’s confidential in­
formation. A review period of 30 to 45 days is 
sufficient for most providers and is acceptable 
to most academic recipients. The MTA may 
require that the publication or presentation 
be delayed for an additional period of time to 
allow for the filing of patent applications. An 
additional period of 30 to 45 days is sufficient 
for most providers. An MTA can also require 
the recipient to acknowledge the provider for 
providing the materials in any publications or 
presentations. 
. Governing law 
An MTA may specify that it is governed by 
the laws of a particular jurisdiction, state, or 
country. This may present a problem in cases in 
which the provider and the recipient are located 
in separate jurisdictions, states, or countries. 
Most providers and recipients will agree to be 
silent on governing law. 
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CHAPTER . 
.10 Termination 
An MTA should specify an expiration date for the 
agreement. Otherwise, the recipient’s obligations will 
continue forever. The parties should be able to ter­
minate the MTA earlier by providing advance, writ­
ten notice. When the MTA expires or terminates, 
the recipient is generally required to stop using the 
material and may be required to return or destroy 
any remaining material. A termination clause may 
also delineate certain obligations that survive termi­
nation. These surviving obligations may be related to 
areas dealing with confidentiality, IP, warranties, lia­
bility, and indemnification. The MTA can always be 
extended by the mutual agreement of both parties. 
.11 Signatures 
The signature section is usually the last part of an 
MTA. A typical MTA may have the signatures of 
the following individuals: 
•	 the authorized official of the organization 
or company receiving the materials 
•	 the researcher receiving the material 
•	 the authorized official of the organization 
or company providing the materials 
•	 the researcher providing the material 
Some MTAs may require only the signature(s) 
of the authorized official and/or the researcher of 
the recipient of the materials. Researchers may sign 
as acknowledging, reading, and/or understanding 
the MTA but should not sign as legal parties to the 
MTA. Doing so could place them at risk of being 
personally liable and being sued in a court of law. 
.12 Exhibits or appendices 
An MTA may include an exhibit or appendix that 
is attached to the end of the agreement. In many 
cases, the attachment is a detailed description of 
the research, a protocol, or a long list of materials. 
Sometimes confidential information is put in the 
exhibits or appendices so that it can be redacted 
more easily than if it were put into the agreement. 
4. MATERIAl TRANSFER BETWEEN
uNIVERSITIES 
Sharing of materials between university scientists 
is generally less problematic than transfers between 
industry and academia, primarily because the 
cultures and motivations of each institution in­
volved in the exchange are similar. In the United 
States, most universities readily transfer materials 
for academic research purposes under terms that 
typically have no restrictions other than a require­
ment not to transfer the materials to third parties 
without approval or notification. These transfers 
are often accomplished using the NIH-facilitated 
UBMTA9, the NIH’s Simple Letter Agreement, 
or an equivalently benign agreement. The UBM­
TA incorporates a very narrow definition of the 
material to be transferred and the agreement does 
not give a provider rights beyond the “original 
material, progeny and unmodified derivatives.” This 
narrow definition and the lack of “reach through” 
to new materials and to new research results is the 
hallmark of agreements between universities that 
greatly facilitates these transfers. 
When a problem does occur in a transfer be­
tween academic institutions, it is usually because 
the material has been exclusively licensed and the 
terms of that agreement impose some constraints 
on the institution providing the material. Howev­
er, this problem is usually avoidable, particularly if 
such exclusive licenses specifically reserve the right 
to use the materials for internal research purposes 
and to transfer the materials for research at other 
academic institutions. For example, the University 
of California routinely incorporates the following 
clause into its exclusive license agreements: 
Nothing in this Agreement will be deemed to 
limit the right of The Regents (i.e. University) … 
to make and use the Invention … and associated 
technology and allow other educational and non­
profit institutions to do so for educational and 
research purposes. 
5.	 MATERIAl TRANSFER FROM PRIVATE
COMPANIES TO uNIVERSITIES 
Material transfers between private and public sec­
tor institutions are typically much more complex 
than transfers between two universities and are 
much more prone to failure, particularly when 
the transfer is from a company to a university re­
searcher.10 What are some of the features of these 
MTAs that create difficulties, particularly for 
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BENNETT, STREITZ & GACEl 
universities? Contrary to popular belief, the pri­
mary issues for most universities do not concern 
the ability to profit from licensing future inven­
tions, but center on: 
•	 a few fundamental academic principles 
•	 the need to avoid incurring unfunded fi­
nancial obligations 
•	 the need to avoid creating conflicting legal 
obligations with third parties 
These issues primarily reflect most universi­
ties’ concern with protecting the fundamental 
mission of the institution and their low tolerance 
for financial or legal risk. 
.1 Dissemination of research results 
The single most obvious and fundamental prin­
ciple for the university and university researchers 
is to preserve the unrestricted ability to publish 
their research results. The freedom to publish can 
be restricted by MTAs when the provider requires 
editorial rights in a publication or the right to ap­
prove and, by inference, to disapprove a publica­
tion. Publication restrictions can show up in MTAs 
in indirect ways as well. For example, the material 
itself may be specified as confidential, making a 
meaningful publication impossible. Of particular 
concern are the serious consequences that a pub­
lication restriction can have on students, whose 
future depends so heavily on publication. Clearly, 
this is one principle a university cannot compro­
mise and the principle is so widely recognized that 
one would think it would not even be on the table 
for discussion. However, it occasionally is. 
Typically, the material provider’s underlying 
concern is not to restrict academic publication 
but to protect its confidential information relat­
ed to the material and to preserve patentability 
of inventions. Both are legitimate concerns and 
can usually be met by agreeing to remove a com­
pany’s confidential information from publica­
tions and to delay publication for a limited time 
(usually 60 to 90 days) to permit the evaluation 
of potentially patentable inventions and to file 
patent applications, when appropriate. Univer­
sities readily agree to these types of provisions, 
but further restrictions on publication rights are 
typically nonnegotiable. 
.2 Rights in research results 
Universities also need to preserve the ability of 
their researchers to use their own research results 
in future research. This may seem obvious, but 
if a provider of material insists that it own the 
results of research conducted with its material 
(sometimes including data, inventions, and re­
ports), researchers and universities can lose all 
access to these products of their own research, 
making it difficult, if not impossible, to perform 
any follow-on research. An example of how this 
appears in an MTA would be a case in which 
a provider asserts ownership of new substances 
created by the university researcher while using 
its proprietary material, sometimes reaching to 
substances or compositions that don’t contain 
the original material in any form (often referred 
to as reach through rights). This type of provi­
sion could have an impact on publication as 
well, since many journals require that materi­
als discussed in a paper be made available for 
replication of the research. Yet in this case such 
availability would be controlled by the material 
provider, not the researcher. In many cases, a 
for-profit provider may have a legitimate reason 
to insist on retaining ownership of any modifi­
cations of its original material. For example, if 
a vector that took years to create could now be 
easily modified to incorporate new functions, 
the provider would be understandably reluctant 
to relinquish rights to improvements that can 
now be relatively easily incorporated. In these 
cases, it may not be appropriate or possible to 
share this material. However, in many cases this 
kind of provision is the result of a provider us­
ing too broad an approach to ensure no pos­
sible loss of its own rights. Negotiations can 
often identify a balanced solution in which 
the provider is assured that it maintains own­
ership of its proprietary material, and while a 
recipient may own the narrow improvement it 
created, the provider would still own the origi­
nal material if it continued to be included as a 
component. 
. Conflicting legal obligations 
Perhaps the most difficult issue presented by 
MTAs is the potential for entering into agree­
0 | HANDBOOK OF BEST PRACTICES 
         
     
      
       
        
       
      
       
         
       
      
       
     
       
        
       
      
        
       
       
        
         
     
        
       
       
       
     
       
         
       
       
         
      
       
       
      
       
         
      
        
      
       
         
       
     
       
         
   
	 	 	 	 	
    
       
         
         
        
       
        
        
       
     
       
      
       
       
      
        
     
      
     
       
        
      
       
       
       
    
     
      
       
     
        
       
      
      
	 	
     
CHAPTER . 
ments that create conflicting legal obligations. 
This situation routinely arises because, while the 
material is coming from one source, the funding 
for the research is usually provided by a differ­
ent source, typically public agencies but also, po­
tentially, other private companies. To the extent 
that the MTA and relevant funding sources carry 
IP obligations, it is easy to see how conflicts can 
arise. While such obligations are typical of pri­
vate research support, public funding also carries 
legal IP obligations to the government. The most 
prominent of these obligations includes require­
ments in the United States under the Bayh-Dole 
Act, such as, a prohibition on assigning title to 
inventions to third parties, the provision of a 
nonexclusive license to the government to prac­
tice or have practiced the invention on behalf of 
the government, and the right of the government 
to march in. Clearly, the university cannot enter 
into an MTA that creates a new obligation that 
is in conflict with such obligations of law or its 
contractual obligations to others. For example, 
if access to a particular research tool or material 
requires that the provider be offered an exclusive 
license to inventions, then this restricts the proj­
ect from receiving any other material or research 
funding that carries a similar obligation—exclu­
sive access to inventions from the same project 
can be given only once! The university and its re­
searchers need to be very careful in determining 
how important are specific inputs to the project, 
and they may need to decide which IP rights can 
be apportioned to research sponsors and/or ma­
terial providers and prioritize those rights. It is 
clear from the complexity of inputs to research 
projects and the increasing complexities of own­
ership of research tools and materials, that access 
to the full set of tools for certain projects may 
simply be impossible. This situation is analogous 
to that which has been described as the “tragedy 
of the anticommons” where the fragmentation of 
IP ownership becomes so complex that no single 
entity can acquire all the rights it needs to devel­
op products.11 In a similar sense, the fragmented 
ownership of research materials or information 
can impact the practical ability to conduct fun­
damental research or at least to do so using the 
most efficient research tools. 
. Public benefit of university research 
Universities, particularly public universities and 
those whose research is supported largely by pub­
lic funds, have an obligation to see that their inno­
vations are made available to the public in a dili­
gent and timely manner. In the United States, this 
obligation is based on the Bayh-Dole Act, which 
has a stated objective “to promote … public avail­
ability of inventions,” as well as on the philosophi­
cal missions of most universities. One means of 
accomplishing availability is through the licensing 
of inventions to private companies that can invest 
the often substantial additional R&D effort re­
quired to produce real products. The public ben­
efit obligation can be compromised by MTAs that 
require the granting of a nonexclusive, royalty-free 
license to inventions back to the provider. If the 
company were not interested in commercializing 
the invention, the existence of its nonexclusive, 
royalty-free license could prevent other companies 
from entering into a license, because they would 
lack the exclusivity needed to allow them to invest 
in the development of the technology, effectively 
“shelving” the technology. A solution that is often 
acceptable is involves linking such a license very 
narrowly to inventions that are dependent on the 
company’s material. These inventions represent 
the company’s legitimate business interest and 
are inventions that, typically, only the company 
providing the material would be in position to 
commercialize. While broader language seeking a 
license to inventions less closely linked to the ma­
terial will not necessarily prevent a university from 
signing an MTA, such language should certainly 
provoke a careful evaluation of the situation. 
. Fair consideration 
Most universities seek a financial return in ex­
change for the commercial use of their research 
results. Public institutions, in particular, are 
concerned that the public funds that are used 
to support the institution should not be used to 
indirectly support private companies. These con­
siderations color the expectations of universities, 
particularly if the provider of a material seeks free 
license to resulting inventions. Here, the interests 
of the university’s administration and researchers 
may diverge, with researchers needing, primarily, 
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BENNETT, STREITZ & GACEl 
to gain access to the material to advance their 
research and with the administration seeking to 
preserve the fundamental principles of the uni­
versity and avoid costly legal battles. Where inter­
ests are divergent, the situation can become very 
complex. In our experience, a common underly­
ing interest of all parties is to enable and acceler­
ate research progress, and in most cases solutions 
can be developed that satisfy the essential needs 
of all parties. Unfortunately, developing these so­
lutions can take a long time and, as mentioned 
earlier, for many private companies, negotiating 
MTAs for university researchers is a low priority 
in relation to the many IP-related transactions 
that may be more critical to the company’s pri­
mary business interests. 
6. CONCluSIONS 
Overall, the transfer of materials between re­
searchers has been getting more difficult, and it 
appears that the days of open exchange of mate­
rials, particularly from researchers in industry to 
academic researchers in the life sciences, are over. 
While some domains of free exchange continue 
to thrive, and some funding agencies and foun­
dations are actively promoting open exchange of 
materials, these are becoming exceptions rather 
than the rule. Both universities and private com­
panies have legitimate interests, which they are 
trying to support when engaging in material 
transfers. When these interests collide, it can be 
difficult to find common ground. However, the 
mutual interest of both research-based private 
companies and of universities is to support re­
search advances; and when both parties keep this 
overarching objective in mind, material transfers 
usually are possible. ■ 
ALAN B. BENNETT, Associate Vice Chancellor, Executive 
Director, PIPRA, Office of Research, University of Califor­
nia, Davis, 1850 Research Park Drive, Davis, CA, 95616, 
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CHAPTER . 
Box 1: Material Transfer Agreement (MTA) for plant genetic resources held 
in trust by the Africa Rice Center (WARDA)1 
The plant genetic resources (hereinafter referred to as the “material”) contained herein are being 
furnished by Africa Rice Center (WARDA) under the following conditions: 
•	 Africa Rice Center (WARDA) is making the material described in the attached list available as 
part of its policy of maximizing the utilization of material for research, breeding and training.
The material was either developed by Africa Rice Center (WARDA); or was acquired prior to the 
entry into force of the Convention on Biological Diversity;or if it was acquired after the entering 
into force of the Convention on Biological Diversity, it was obtained with the understanding 
that it could be made available for any agricultural research, breeding and training purposes 
under the terms and conditions set out in the agreement on 26 October 1994 between the 
Africa Rice Center (WARDA) and the Food and Agriculture Organization of the United Nations 
(FAO). 
•	 The material is held in trust under the terms of this agreement,and the recipient has no rights 
to obtain Intellectual Property Rights (IPRs) on the material or related information. 
•	 The recipient may utilize and conserve the material for research, breeding and training and 
may distribute it to other parties provided such other parties accept the terms and conditions 
of this agreement.
•	 The recipient, therefore, hereby agrees not to claim ownership over the material, nor to seek 
IPRs over that material, or its genetic parts or components, in the form received. The recipient
also agrees not to seek IPRs over related information received.
•	 The recipient further agrees to ensure that any subsequent person or institution to whom 
he/she may make samples of the material available, is bound by the same provisions and 
undertakes to pass on the same obligations to future recipients of the material.
•	 Africa Rice Center (WARDA) makes no warranties as to the safety or title of the material,nor as 
to the accuracy or correctness of any passport or other data provided with the material.Neither 
does it make any warranties as to the quality, viability, or purity (genetic or mechanical) of the 
material being furnished. The phytosanitary condition of the material is warranted only as 
described in the attached phytosanitary certificate. The recipient assumes full responsibility 
for complying with the recipient nation’s quarantine and biosafety regulations and rules as to 
import or release of genetic material.
•	 Upon request, Africa Rice Center (WARDA) will furnish information that may be available in 
addition to whatever is furnished with the material. Recipients are requested to furnish Africa 
Rice Center (WARDA) with related data and information collected during evaluation and 
utilization.
(Continued on Next Page) 
1. This MTA covers materials which are being transferred before the entry into force of the International Treaty on 
Plant Genetic Resources for Food and Agriculture. The Treaty envisages that Africa Rice Center (WARDA) will enter 
into an agreement with the Governing Body of the Treaty, once the Treaty enters into force. Africa Rice Center 
(WARDA) has indicated its intention to conclude such an agreement with the Governing Body. This agreement, in 
line with the Treaty, will provide for new MTAs and benefit-sharing arrangements for materials transferred after 
the entry into force of the agreement. The attention of the recipient is drawn to the fact that the details of the 
MTA, including the identity of the recipient, will be made available to the public. 
2. This does not prevent the recipients from releasing the material for purposes of making it directly available to 
farmers or consumers for cultivation, provided that the other conditions set out in this MTA are complied with. 
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BENNETT, STREITZ & GACEl 
Box 1 (continued) 
•	 The recipient of material provided under this MTA is encouraged to share the benefits accruing 
from its use, including commercial use, through the mechanisms of exchange of information,
access to and transfer of technology, capacity building and sharing of benefits arising from 
commercialization. Africa Rice Center (WARDA) is prepared to facilitate the sharing of such 
benefits by directing them to the conservation and sustainable use of the plant genetic resources 
in question, particularly in national and regional programs in developing countries and countries 
with economies in transition, especially in centers of diversity and the least developed countries.
The material is supplied expressly conditional on acceptance of the terms of this Agreement.
The recipient’s acceptance of the material constitutes acceptance of the terms of this Agreement. 
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CHAPTER . 
Box 2: Material Transfer Agreement (MTA) for requesting plant 
materials from the C.M. Rick Tomato Genetics Resource Center (TGRC) 
THIS AGREEMENT is made by and between The Regents of the University of California (“THE REGENTS”) 
on behalf of the C. M. Rick Tomato Genetics Resource Center (“TGRC”), and _______________________
_____________________(“RECIPIENT”). THE REGENTS asks that the RECIPIENT agree to the following 
before the RECIPIENT receives the plant materials requested from the TGRC. 
1. The TGRC will make substitutions, as necessary, for items that are currently unavailable for 
distribution. For large requests, the TGRC may delete some items, as needed, to reduce its workload 
and accommodate other requests. The TGRC will provide a packing list detailing which accessions 
(“MATERIAL”) have been shipped.
2. The MATERIAL is provided free of charge and, except as stated herein, without restrictions by the 
TGRC to support research, breeding, and/or educational projects involving tomato. The RECIPIENT 
may distribute the MATERIAL to third parties under an MTA that includes the language of terms 3,
4, 5, and 6.
3. THE REGENTS MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER 
EXPRESSED OR IMPLIED, REGARDING THE FITNESS OR MERCHANTABILITY FOR A PARTICULAR 
PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
4. The MATERIAL has not been thoroughly evaluated by the TGRC.THE REGENTS MAKES NO WARRANTIES 
OF ANY KIND, EXPRESSED OR IMPLIED, REGARDING THE ACCURACY OF THE INFORMATION 
PROVIDED BY THE TGRC; THE QUALITY, HEALTH, OR PHYTOSANITARY CONDITION OF THE MATERIAL;
OR THE GENETIC IDENTITY OF THE MATERIAL, INCLUDING ITS ORIGIN, PURITY, TRUENESS TO TYPE,
GENETIC BACKGROUND, AND THE PRESENCE OR ABSENCE OF ANY TRANSGENES. The RECIPIENT 
is responsible for verifying that genetic identity is correct in its own plantings, and the RECIPIENT 
will notify the TGRC of any potential problems it observes with the MATERIAL, such as aberrant
segregation, incorrect phenotypes, unexpected traits, or other problems.
5. Unless prohibited by law, the RECIPIENT assumes all liability for damages it incurs and for claims 
by third parties which may arise from the RECIPIENT’s use, storage or disposal of the MATERIAL.
RECIPIENT shall hold harmless, defend, and indemnify THE REGENTS against any claims, costs 
or other liabilities which may arise as a result of the RECIPIENT’S use, storage or disposal of the 
MATERIAL. 
6. The RECIPIENT shall acknowledge the TGRC as the supplier of the MATERIAL in any publications 
which result from the RECIPIENT’s use of the MATERIAL, and shall provide the TGRC with copies of 
the relevant publications. 
7. Before the TGRC can send the MATERIAL,the RECIPIENT or other authorized official of the RECIPIENT’s 
organization, must sign and deliver this MTA by mail, facsimile, e-mail or in person to the TGRC at
the following address: 
c. M. Rick Tomato genetics Resource center
Department of Plant Sciences (Mail Stop 3) Tel.: +1-530-754-6059 
University of California, Davis Fax: +1-530-752-9659 
One Shields Avenue tgrc@ucdavis.edu 
Davis, CA 95616, U.S.A. http://tgrc.ucdavis.edu 
ceRTificaTion by RecipienT oR oTheR auThoRiZed official:
I have read and understand the conditions outlined in this Agreement and I agree to fully abide by 
them in the receipt and use of the MATERIAL. 
Signature, Name and Title: ____________________________________________________________ 
Institution:_______________________________________________________Date:______________ 
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BENNETT, STREITZ & GACEl 
Box 3: Simple letter Agreement for the Transfer of Materials 
In response to RECIPIENT’s request for the MATERIAL ______________________________________
_____ the PROVIDER asks that the RECIPIENT and the RECIPIENT SCIENTIST agree to the following 
before the RECIPIENT receives the MATERIAL:
1. The above MATERIAL is the property of the PROVIDER and is made available as a service to the 
research community.
2. THIS MATERIAL IS NOT FOR USE IN HUMAN SUBJECTS.
3. The MATERIAL will be used for teaching or not-for-profit research purposes only.
4. The MATERIAL will not be further distributed to others without the PROVIDER’s written consent.
The RECIPIENT shall refer any request for the MATERIAL to the PROVIDER. To the extent supplies 
are available, the PROVIDER or the PROVIDER SCIENTIST agree to make the MATERIAL available,
under a separate Simple Letter Agreement to other scientists for teaching or not-for-profit
research purposes only.
5. The RECIPIENT agrees to acknowledge the source of the MATERIAL in any publications reporting 
use of it.
6. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in 
nature and may have hazardous properties. THE PROVIDER MAKES NO REPRESENTATIONS AND 
EXTENDS NO WARRANTIES OF ANY KIND,EITHER EXPRESSED OR IMPLIED.THERE ARE NO EXPRESS 
OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR 
THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK,
OR OTHER PROPRIETARY RIGHTS. Unless prohibited by law, RECIPIENT assumes all liability 
for claims for damages against it by third parties which may arise from the RECIPIENT’S use,
storage or disposal of the MATERIAL except that, to the extent permitted by law, the PROVIDER 
shall be liable to the RECIPIENT when the damage is caused by the gross negligence or willful 
misconduct of the PROVIDER.
7. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and 
regulations.
8. The MATERIAL is provided at no cost, or with an optional transmittal fee solely to reimburse the 
PROVIDER for its preparation and distribution costs. If a fee is requested, the amount will be 
indicated here: ______________ 
The PROVIDER, RECIPIENT and RECIPIENT SCIENTIST must sign both copies of this letter and return 
one signed copy to the PROVIDER. The PROVIDER will then send the MATERIAL.








Name of Authorized Official: _____________________________________________________ 

Title of Authorized Official:______________________________________________________ 

Certification of Authorized Official: This Simple Letter Agreement has 
 / has not [check one] 
been modified. If modified, the modifications are attached.
(Continued on Next Page) 
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Box 3 (continued) 
Signature of Authorized Official Date 

RECIPIENT INFORMATION and AUTHORIZED SIGNATURE 

Recipient Scientist: ____________________________________________________________ 





Name of Authorized Official: ____________________________________________________ 

Title of Authorized Official:______________________________________________________ 





Certification of Recipient Scientist: I have read and understood the conditions outlined in 

this Agreement and I agree to abide by them in the receipt and use of the MATERIAL.
 
Recipient Scientist Date 
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BENNETT, STREITZ & GACEl 
Box 4: Material Transfer Agreement with the university of California, Davis 
This Agreement is made this _____ of ________________, by and between THE REGENTS OF THE 
UNIVERSITY OF CALIFORNIA, as represented by its Davis campus, (“UC DAVIS”), having an address 
at the Office of Research, Technology and Industry Alliances, Technology Transfer Services;
University of California, Davis; 1850 Research Park Drive, Suite 100; Davis, CA 95616-6134, and ___
________________ (“RECIPIENT”), having its principal place of business at ____________________ 
(collectively “the PARTIES”). 
RECIPIENT has requested from UC DAVIS the MATERIAL defined in Section 1.B. below for the 
RESEARCH USE defined in Section 1.F. below by the RECIPIENT INVESTIGATOR(S) defined in Section 
1.G. below. In consideration of the supply of MATERIAL from UC DAVIS to RECIPIENT, the PARTIES 
agree as follows: 
1.	 definitions 
A.	 “ORIGINAL TRANSFERRED MATERIAL”: The physical material actually delivered to the 
RECIPIENT by UC DAVIS, as identified in Exhibit A attached hereto. 
B.	 “MATERIAL”: ORIGINAL TRANSFERRED MATERIAL, PROGENY, and UNMODIFIED 
DERIVATIVES. 
C. “PROGENY”: Unmodified descendant from the MATERIAL. Examples include but are not
limited to: virus from virus; cell from cell; and organism from organism. 
D. “UNMODIFIED DERIVATIVES”: Substances created by the RECIPIENT that constitute an 
unmodified functional sub-unit or an expression product of the ORIGINAL TRANSFERRED 
MATERIAL. Examples include but are not limited to: purified or fractionated sub-sets 
of the ORIGINAL TRANSFERRED MATERIAL; PROGENY or products thereof; subclones 
of unmodified cell lines; transcription and translation products (e.g., RNA and protein 
derived from provided DNA); reverse transcription and reverse translation products (e.g.,
DNA synthesized on a template using provided RNA); monoclonal antibodies secreted 
by a hybridoma cell line; and chemically-synthesized copy or copies. 
E.	 “MODIFICATIONS”: Substances created by the RECIPIENT that either contain or 
incorporate the MATERIAL or were created through the use of the MATERIAL. 
F.	 “RESEARCH USE”: The scientific RESEARCH USE specified in Exhibit A. 
G. “RECIPIENT INVESTIGATOR(S)”: The RECIPIENT’s scientific investigator(s) specified in 
Exhibit A. 
H. “CONFIDENTIAL INFORMATION”: Information, data or material in written or other 
tangible form related to the MATERIAL that is identified as confidential at the time of 
disclosure. CONFIDENTIAL INFORMATION does NOT include information that is: 
(i) generally known to the public at the time of disclosure to the RECIPIENT; 
(ii) already in RECIPIENT’s possession at the time of disclosure by UC DAVIS; 
(iii) disclosed to RECIPIENT on a non-confidential basis by a third party having the right
to make such disclosure; 
(iv) independently developed by RECIPIENT without the use of the CONFIDENTIAL 
INFORMATION disclosed by UC DAVIS as evidenced by written records; or 
(v) required to be disclosed by law or governmental rule or regulation. 
(Continued on Next Page) 
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Box 4 (continued) 
2.  Terms and conditions 
A. Use 
i.	 The RECIPIENT shall use the MATERIAL solely for the RESEARCH USE. Any other use of the 
MATERIAL by the RECIPIENT is expressly prohibited without the prior written consent
of UC DAVIS. In addition, the RECIPIENT agrees to use the MATERIAL in compliance with 
all applicable statutes and regulations, including, but not limited to, those related to 
research involving the use of animals or recombinant DNA. The MATERIAL may not be 
used on any human subjects or for commercial purposes or any other use other than the 
RESEARCH USE. 
ii. RECIPIENT will not analyze the MATERIAL for chemical composition or physical structure 
or have or allow any component of the MATERIAL to be analyzed or make any use of any 
such analysis. The RECIPIENT will not alter the chemical structure of the MATERIAL in 
any way. 
B.	 Tangible Property Ownership: UC DAVIS retains ownership of the MATERIAL, including any 
MATERIAL contained or incorporated in MODIFICATIONS. 
C. Confidentiality: Any CONFIDENTIAL INFORMATION disclosed by UC DAVIS to RECIPIENT 
shall be treated as confidential and maintained in confidence by RECIPIENT for five (5) 
years after disclosure. RECIPIENT shall not disclose any CONFIDENTIAL INFORMATION of 
UC DAVIS, except to its own personnel who have a need to know. Without limiting the 
foregoing, RECIPIENT agrees to take the same steps and use the same methods to prevent
the unauthorized use or disclosure of CONFIDENTIAL INFORMATION of UC DAVIS as it takes 
to protect its own CONFIDENTIAL INFORMATION or proprietary information. 
D. Distribution: RECIPIENT agrees NOT to transfer the MATERIAL or MODIFICATIONS to anyone 
other than to one who works under the direct supervision of the RECIPIENT INVESTIGATOR 
within the RESEARCH USE without the prior written consent of UC DAVIS.
E. Disclosure, Inventorship, and Intellectual Property Rights 
i.	 Disclosure: The RECIPIENT shall promptly notify UC DAVIS of any potentially patentable 
discoveries or inventions made through the use of the MATERIAL, whether or not made 
within the specified limits of the approved RESEARCH USE.The RECIPIENT shall promptly 
supply UC DAVIS with a copy of the invention disclosure. 
ii. Inventorship: Inventorship shall be determined according to United States patent law. 
iii. Intellectual Property Rights: Collaborative efforts of UC DAVIS and the RECIPIENT may 
create inventorship rights under United States patent law as well as under the law 
of any applicable jurisdiction in which a party or the PARTIES may elect to file patent
application(s). Each party shall own its undivided interest in joint inventions. The 
PARTIES shall cooperate in discussing and securing intellectual property rights to protect
potentially patentable inventions. 
iv. No Implied Rights: The RECIPIENT acknowledges that the MATERIAL is or may be the 
subject of a patent application. Except as provided in this Agreement, no express or 
implied license or other rights are provided to the RECIPIENT under any patents, patent
applications, trade secrets or other proprietary rights of UC DAVIS, including any altered 
forms of the MATERIAL made by UC DAVIS. In particular, no express or implied licenses or 
other rights are provided to use the MATERIAL, MODIFICATIONS or any related patents of 
UC DAVIS for commercial use or any other use other than the RESEARCH USE. 
(Continued on Next Page) 
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BENNETT, STREITZ & GACEl 
Box 4 (continued) 
F.	 Warranty and Licenses: 
i.	 Any MATERIAL delivered pursuant to this Agreement is understood to be experimental 
in nature and may have hazardous properties.UC DAVIS MAKES NO REPRESENTATIONS 
AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED.THERE 
ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A 
PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY 
PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. 
ii. If the RECIPIENT desires to use the MATERIAL or MODIFICATIONS for profit-making 
or commercial purposes, the RECIPIENT agrees, in advance of such use, to negotiate 
in good faith and conclude a license agreement containing terms typically required 
in license agreements executed by UC DAVIS. It is understood by the RECIPIENT that
UC DAVIS will have no obligation to grant such a license to RECIPIENT, that future 
licensing rights, if any, may be subject to preexisting contractual obligations of UC 
DAVIS, and that UC DAVIS may grant exclusive or non-exclusive commercial licenses 
to others. 
G. Liability: The RECIPIENT assumes all liability for damages that may arise from its use,
storage or disposal of the MATERIAL and MODIFICATIONS. UC DAVIS will not be liable to 
the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the 
RECIPIENT by any other party, due to or arising from the use, storage or disposal of the 
MATERIAL and MODIFICATIONS by the RECIPIENT. The RECIPIENT agrees to indemnify, hold 
harmless and defend UC DAVIS against any claims, costs or other liabilities which may 
arise as a result of RECIPIENT’S use, storage or disposal of the MATERIAL. 
H. Publication of Research Results: The RECIPIENT may publish or present results of research 
relating to the MATERIAL, provided the RECIPIENT provides UC DAVIS with a copy of any 
proposed manuscript, abstract, poster session or presentation at least thirty (30) days prior 
to such publication or presentation. UC DAVIS shall review such publication or presentation 
for CONFIDENTIAL INFORMATION or patentable material and may request a delay of the 
proposed publication or presentation for up to an additional thirty (30) days to allow for 
the removal of CONFIDENTIAL INFORMATION or the filing of patent application(s). Unless 
UC DAVIS directs otherwise, any publication or presentation reporting the research carried 
out with the MATERIAL shall contain proper referencing in academic journal format,
acknowledging UC DAVIS as the source of the MATERIAL. 
I.	 Termination: 
i.	 Date: This Agreement will terminate on the earliest of the following dates: 
(a) on completion of RECIPIENT’S current RESEARCH USE with the MATERIAL; 
(b) on thirty (30) days’ written notice by one party to the other; or 
(c) ( ) years from the date of execution of this Agreement by UC DAVIS. 
ii. Surviving Obligations: Obligations with respect to Tangible Property Ownership (2.B.),
Confidentiality (2.C.), Distribution (2.D.), Disclosure, Inventorship, and Intellectual 
Property Rights (2.E.),Warranty and Licenses (2.F.), Liability (2.G.), Publication of Research 
Results (2.H.), and this Section (2.I.ii) shall survive termination. 
iii. Return of MATERIAL: As directed by UC DAVIS, RECIPIENT shall stop using the MATERIAL 
and shall return or destroy any remaining MATERIAL on the termination of this 
Agreement. 
(Continued on Next Page) 
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CHAPTER . 
Box 4 (continued) 
J.	 Applicable Law:The validity and interpretation of this Agreement and legal relations of the 
PARTIES in the performance of this Agreement shall be governed by the laws of the State 
of California without regard to conflicts of law provisions. 
K. Notice: Any notice required under this Agreement will be considered properly given and 
effective on the date of the postmark if mailed by prepaid postage first-class certified mail;
on the date of delivery if delivered in person; or on the date of receipt if mailed by any global 
express carrier service that requires the recipient to sign the documents demonstrating 
the delivery of such notice. Notice shall be given to the designated authorized official at
the address provided below: 
FOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA: 
Authorized Official: Executive Director, 
Technology and Industry Alliances 
Address: Technology Transfer Services,
Office of Research, 
Technology and Industry Alliances, 
University of California, Davis 
1850 Research Park Drive, Suite 100 













This Agreement constitutes all the agreements between the PARTIES, both written and oral 
with respect to the subject matter hereof. All prior agreements respecting the subject matter 
hereof, either written or oral, expressed or implied, between the PARTIES are hereby canceled. 
(Continued on Next Page) 
HANDBOOK OF BEST PRACTICES | 1
   
     
  
       
 










BENNETT, STREITZ & GACEl 
Box 4 (continued) 
THE REGENTS OFTHE UNIVERSITY OF CALIFORNIA RECIPIENT 
Name: Name: 
Associate Director, Technology Transfer Services Title:
Date: Date: 
UC DAVIS INVESTIGATOR and RECIPIENT INVESTIGATOR acknowledge reading and understanding 
this Agreement and shall abide by the terms and conditions thereof. 





1. ORIGINAL TRANSFERRED MATERIAL: 
2. RESEARCH USE: 
3. RECIPIENT INVESTIGATOR (name): 
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How to Draft a Collaborative Research Agreement
 
MaRTha baiR sTeinbocK, Deputy Assistant Administrator, Office of Technology Transfer, 
U.S. Department of Agriculture, Agricultural Research Service, U.S.A. 
ABSTRACT 
A collaborative research agreement has five major parts: 
(1) statement of objectives, (2) statement of work, (3) gen­
eral provisions, (4) budget, and (5) list of materials. This 
chapter provides a step-by-step discussion of the issues 
that need to be addressed in each part of the agreement, 
emphasizing the importance of crafting an agreement 
that is mutually beneficial and, above all, clearly written. 
Whereas all parts of any agreement are important, for col­
laborative research agreements, extra care should be taken 
in describing the objectives and work of the collabora­
tion, the research plan, and the mechanisms for agreeing 
on changes in the research plan. Partnerships grow and 
change; this invariably leads to the need for amendments. 
Arguably, many of the best collaborative research agree­
ments need numerous amendments in order to reflect the 
evolving needs of the parties involved. 
1. InTRoduCTIon 
The objective of writing a collaborative research 
agreement is to clarify for both parties what they 
are trying to accomplish together and to clearly 
set forth the rules that will govern the collabora­
tive effort. A good partnership must be mutually 
beneficial, and an effective collaborative research 
agreement will help both parties understand and 
accept mutual benefit as a goal. Of course, sim­
ply writing that an agreement is mutually benefi­
cial does not make it so. An effective agreement 
must be based on an actual win-win relationship, 
one that is truly mutually beneficial. So to start 
with, the concept of the collaborative research 
project must involve a research project through 
which both parties benefit from the work that 
will be done. 
A poorly written agreement can tear apart an 
otherwise harmonious relationship. On the other 
hand, a well-written agreement, in which all par­
ties understand their responsibilities, will build 
and strengthen a productive scientific relation­
ship. An effective agreement will be clear both to 
the researchers doing the research work and to the 
managers of both parties. And a well-written col­
laborative research agreement can lay the ground­
work for moving the results of research toward 
commercialization. 
For the sake of simplicity and to facilitate dis­
cussion of the issues involved, the chapter focuses 
on one scenario: developing a research agreement 
between a National Agricultural Research System 
(NARS) government laboratory and a private 
company. Many of the points made are equally 
valid for collaborative research agreements be­
tween other types of entities. 
2. pARTS	 of 	An AGREEMEnT 
Most collaborative research agreements have five 
general parts. The agreements can be somewhat 
flexible in the terminology they use. The names 
Steinbock MB. 2007. How to Draft a Collaborative Research Agreement. In Intellectual Property Management in Health and 
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
This chapter was authored as part of the official duties of an employee of the U.S. Government. Copyright protection for 
this work is not available in the United States (Title 17 U.S.C § 105). The views expressed are those of the author and do 
not necessarily represent those of the U.S. Department of Agriculture. 
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assigned to the subparts are not terribly impor­
tant. What is important is that the agreement 
covers each the following points: 
1. statement of objectives 
2. statement of work 
3. general provisions 
4. budget 
5. list of materials 
The first part of the collaborative research 
agreement is commonly called the statement of 
objectives. This explains the overall setting of the 
agreement. It describes what the parties want to 
accomplish together and why the collaboration is 
important. 
The second part of a well-drafted collabora­
tive research agreement is called the statement of 
work. This may sometimes be called the research 
plan. It describes the research that the parties pro­
pose to conduct and includes which approaches 
will be undertaken and which methodologies 
will be used. Most importantly, this part of the 
agreement specifies who is responsible for what 
and specifies the due dates for completing each 
part of the research project. 
The third part of an effectively written col­
laborative research agreement is called the general 
provisions. These are sometimes known as the 
legal provisions. They cover a series of impor­
tant details, the mechanisms of collaboration, 
and the rules by which the collaboration will be 
conducted. 
The fourth part of a agreement is the bud­
get. This part sets forth the resources that each 
party needs and contributes to the collaborative 
research project. 
For collaborative research agreements in which 
biological or other materials (germplasm, plant 
parts, biotech components, and so forth) are passed 
from one party to the other for use in the project, 
the agreement typically includes an additional sec­
tion called the list of materials. This section is of­
ten attached as an appendix to the agreement. In 
some cases there may be more than one appendix, 
since the materials being used and transferred may 
change over the course of the project. 
In its simplest form, the list of materials 
should provide a unique name for each item 
that is sent to the project, as well as the quantity 
of each item and the dates those materials were 
transferred from one party to the other. By updat­
ing the list of materials each time new materials 
are sent from one of the collaborating researchers 
to the other, all parties are assured of having a 
current and complete list. 
2.1 Statement of objectives 
The statement of objectives should be concise 
and clear. Use terms that nonscientists will read­
ily understand and avoid the excessive use of sci­
entific jargon. The statement of objectives should
explain the real-world issues that the collabora­
tive research agreement will address. It should 
articulate both the what and the why of the col­
laboration. When someone outside of the science 
community reads the agreement, they should be 
able to tell why the parties believe it is important 
to undertake the collaboration. In addition, the 
statement of objectives should clearly specify the 
scientific goals of the collaboration. Care should 
be taken to differentiate long-term goals, which 
may happen years after the agreement is complet­
ed, and short-term goals, which will be accom­
plished by the end of the agreement. 
Consider the following examples from two 
statements of objectives from actual agreements: 
•	 Good: to develop, test, and evaluate trans­
genic tomatoes expressing the “N” gene, 
which encodes for resistance to tobacco 
mosaic virus. 
•	 Not as good: to determine basic breeding bi­
ology, including ploidy levels of a resistance 
biotype of Lolium. 
The first one is quite well written. It clearly 
and specifically explains the objective. From this 
clear statement, most readers will get a feel for 
what the agreement hopes to accomplish. 
The less well-written statement vaguely states 
the goal. Phrases like basic breeding biology do 
not really mean much unless they are further 
defined, and terms like ploidy level may not be 
well understood by the nonscientific community. 
Remember, the goal of the statement of objectives 
is to set the stage for the agreement by clearly stat­
ing what the parties hope to accomplish. 
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CHAPTER . 
2.2 Statement of work 
The next part of a well-written collaborative re­
search agreement is what is often referred to as 
the statement of work. This is by far the most 
important part of the agreement. Sometimes, the 
statement of work is attached to the agreement 
as an appendix. This is not to diminish its im­
portance in any way. It is merely a convenience 
to have this research plan slightly separated from 
the general body of the agreement. The advantage 
of having it self-contained is that it will be easier 
for the scientists to relate to it, and in the event 
of modifications to the work plan, it can be more 
easily amended. 
The statement of work contains the scien­
tific objectives, methodologies, and approaches. 
It should be broken down into subsections, with 
each section explaining what “partner A” will 
do and what “partner B” will do, with the time 
frames and benchmarks specifically laid out. 
In drafting this section of a collaborative re­
search agreement, the parties must work together 
closely. The other parts of a collaborative research 
agreement can be initially drafted by a technol­
ogy transfer officer and/or intellectual property 
management officer and then can be exchanged 
between the partners for review, comment, and 
negotiation. But the collaborating researchers 
themselves should prepare a first draft of the 
statement of work, which can then be edited by 
the technology transfer officer. This is because the 
collaborating scientists are the ones who really 
understand the complexity of what is to be un­
dertaken, and it is the scientists who must fully 
embrace the plan that is developed. 
Within the statement of work, there should 
be a section stating the project’s scientific objec­
tives. With complicated or longer projects, there 
may be many objectives and subobjectives. In 
such cases, the use of a numbering or outlining 
system makes the objectives clear and readable. 
Each objective in the statement of work 
should be followed by a description of the meth­
odologies and approaches to be used to address 
the scientific questions involved. Further, each 
objective must include very clearly what each 
partner (the institute scientists and the com­
pany scientists) will be doing, separately and 
collaboratively. This statement of responsibilities 
is perhaps the most critical element of a research 
agreement because without a clear understand­
ing of responsibilities, the partners may have 
unrealistic expectations and become frustrated. 
If it is unclear who will be doing each piece of 
experimentation, both parties may be sitting 
back, waiting in vain for the other to produce 
something. It cannot be stressed enough that it is 
very important to break down each of the scientific 
objectives of the statement of work into tasks and 
clearly state who is responsible for each. 
Another point to consider is to quantify the 
work that is to be done. It may not be necessary 
to use exact numbers (for example, the types and 
replications of an experiment or the number of 
test tubes you will be using), but do insert gen­
eral guidance about the size and scope of the col­
laborative research. For example, if you are go­
ing to do a feeding study and will be using 30 
mice per replication, state that in the agreement. 
That way both parties will be clear as to the or­
der of magnitude of the data types that are to be 
generated and the level of resources needed for 
their part of the work. Researchers often believe 
they understand what the other has in mind, but 
without written descriptions, such assumptions 
often lead to misunderstandings. For example, if 
an institute researcher says he or she will “field 
test” a new variety, he or she may have in mind 
a half-hectare plot necessary to generate enough 
plants for a publication, while the company sci­
entist has in mind 100 hectares. So, be as clear 
as you can about the sizes or numbers of replica­
tions and other quantifiable aspects in the state­
ment of work. 
Another aspect that is very important is to 
build-in time frames and benchmarks. Generally, 
you want to have built into the statement of work 
at least an indication of when each party should 
have completed their responsibilities under each 
objective or subobjective. Often researchers will 
object that time-frame specifics make them feel 
pressured, but such a plan will help the collaborat­
ing scientists make progress in an orderly fashion. 
It also helps prevent one party from having to wait 
for the other and causing lost time. Time frames 
are important to make the experimentation run 
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smoothly and they help the partners garner the 
resources that will be needed to move the project 
along. 
Benchmarks are important to help measure 
work progress. They specify that at a certain point 
both parties expect certain pieces of data to have 
been generated, certain parts of the experiments 
to have been completed, or certain questions to 
have been answered. You will want to write these 
goals as benchmarks. In a larger agreement, with 
multiple objectives and multiple people involved, 
sometimes there may be activities that will flow 
sequentially (one has to be completed before 
another can begin). Other research may be oc­
curring simultaneously in parallel experiments. 
In these complicated situations, project-manage­
ment software can be helpful when preparing the 
statement of work. 
A collaborative research agreement can grow 
to be a lengthy document. However, you should 
not think that it is like a grant application that 
can be 20, 30, 40 or more pages. A collaborative 
research agreement is not designed to convince 
an outside party that the work is worthwhile, nor 
does it aim to show that either of the collaborat­
ing scientists are high-quality researchers. Rather, 
it should clearly spell out the respective research 
that the partners will be doing. So, a statement of 
work should only be as long as it needs to be to 
ensure that both parties know what is expected of 
them. A typical agreement will be 10–15 pages, 
and the statement of work is often no more than 
two or three pages. 
. GEnERAL	pRovISIonS 
The next part of a collaborative research agree­
ment is the general provisions. This is the body of 
the agreement that covers the how of working to­
gether and provides mechanistic guidance to the 
scientists at the institute and at the company, as 
well as to managers. Normally, an institute or an 
entity has a standardized set of general provisions 
that has been reviewed by their legal counsel and 
that can serve as a starting point for negotiating 
agreements. Each person studying this chapter 
should consider developing such template agree­
ments. In the process of such development of 
template agreements, a person can often begin to 
fully understand which points are negotiable and 
which legal provisions are required by organiza­
tion policy or law. At the same time, collaborative 
research agreements should be as user-friendly as 
possible and avoid unnecessary stipulations. 
There are a wide range of typical general 
provisions. These include a public disclosure/ 
publication policy, which addresses how the par­
ties will communicate with each other and the 
outside world; reports; confidentiality issues; the 
important issues of intellectual property manage­
ment and technology transfer from the institute 
to the company; regulatory approvals; indemnity 
and liability statements; dispute resolution plans; 
and provisions for termination. This part of the 
agreement should also spell out an amendment 
procedure and name the persons responsible for 
the agreement, both managerially and scientifi­
cally, at the institute and the company. 
.1 Publications 
Public disclosure is a crucial part of any research 
agreement. Science is driven by the need to pub­
lish, and scientific careers depend on such publi­
cations. Public disclosure, including publication 
in patent literature, keeps innovation going. The 
phrase public disclosure is a broad term that in­
cludes many types of disclosure of research re­
sults. Public disclosure can include any form of 
public dissemination of research results: articles, 
abstracts, poster sessions, both informal and for­
mal seminars, talks, information posted on the 
Internet, and grant applications. Most organiza­
tions that enter into collaborative research agree­
ments will want to put some limitations on the 
right to public disclosure. Such a delay in public 
disclosure may be necessary to ensure that patent 
applications can be filed for discoveries made un­
der the agreement. 
A publication clause should protect the inter­
ests of both parties. Generally, there is a statement 
that both parties reserve a right to review and 
comment on all public disclosure by the other 
party. Typically, a specific time frame (usually 60 
or 90 days) is set up for such a review. Often there 
is also a provision written into the collaborative 
research agreement stating that one party requires 
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the other party to delay public disclosure of proj­
ect-derived information for a specific length of 
time to allow for patent preparation or exclusive 
use by the other party. The bottom line is that 
a well-written agreement should clearly state all 
such limitations of public disclosures. 
.2 Confidentiality 
Another aspect of the general provisions involves 
confidential information, sometimes called confi­
dential business information, or CBI. It is impor­
tant for the collaborative research agreement to 
differentiate between two types: (1) confidential 
information that a party brings into the project 
and that predates the agreement, and (2) confi­
dential information that is generated under the 
agreement and that the parties generated while 
working together and conducting project experi­
ments. A collaborative research agreement should 
specify how both types of information are to be 
handled by the parties. 
For information that is created by one of 
the parties prior to or outside the scope of the 
agreement, you may find it helpful to use the 
terms commonly found in a confidentiality or 
nondisclosure agreement. Like any confidenti­
ality agreement, these clauses should specify a 
time limit during which the information is to be 
kept confidential. Typically, such time limits are 
between two and five years after the end of the 
collaboration or from the point the information 
is generated. If the parties have an earlier signed 
nondisclosure or confidentiality agreement, that 
document may simply be referenced in the col­
laborative research agreement or the collaborative 
research agreement can state that it replaces the 
confidentiality agreement. 
The confidential treatment of information 
generated under the project will be closely tied 
to the treatment of intellectual property (IP) and 
tangible property. 
. Intellectual property 
Perhaps the most important section of the gener­
al provisions deals with the intellectual property 
and tangible property (TP) provisions. This sec­
tion is important because what motivates most 
collaborative research is the potential for gaining 
access to such IP/TP as may be created under 
the collaborative research agreement. For an in­
stitute, working with a company is an effective 
way to transfer technology. Many believe that it 
is the most effective and efficient way for research 
results to move from the laboratory, through a 
development process by the company partner, 
and finally into the marketplace. Without such 
provisions, the benefits of collaboration may be 
lost. 
The first step in drafting this section is to 
clearly define IP and TP rights. 
IP rights are rights under various types of 
statutory protection. These IP rights include the 
intangible property rights obtained from: 
•	 issued patents and patent applications 
•	 plant variety protection (or a breeder’s 
rights) applications and granted certificates 
•	 copyrights (including software) 
•	 trade secrets 
•	 trademarks and service marks 
TP rights are the second broad class of prop­
erty rights. These include ownership rights in 
various classes of biological materials, germplasm, 
databases, business plans, research plans and pro­
tocols, laboratory notebooks, and the like. They 
involve the ownership of things that one can 
touch, see, taste, smell, and hear. 
The second step in dealing with IP/TP issues 
is to establish who owns what. The collaborative 
research agreement should clearly state that all 
IP/TP contributed to the collaborative research, 
but predating the project, should be owned by 
the party who contributed its use to the project. 
This is why there should be a clear inventory of 
all IP/TP that either party contributes to the 
project. 
For example, if the company has a genetic 
construct or a genomics database that the collab­
orators will use, then whether or not these con­
tributions are covered by a filed or issued patent 
or some other sort of statutory protection, these 
contributions need to be clearly identified in the 
agreement. Similarly, if the institute brings germ-
plasm lines, a site-specific promoter, or a transfor­
mation vector into the project, these too should 
be identified and documented in the agreement. 
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In this way, collaboration can be promoted be­
cause each party recognizes and acknowledges 
the other party’s ownership of the contributed 
materials. 
After establishing an inventory (in the list of 
materials) of the IP/TP that is brought into the 
project, the next step is to clearly establish how 
the ownership of new property discovered under 
the project (new IP/TP) will be determined. In a 
typical collaborative research project there is the 
potential for three classes of new IP/TP: 
1. New IP/TP that is solely discovered by the 
institute researcher 
2. New IP/TP that is solely discovered by the 
company researcher 
3. New IP/TP that is jointly discovered by 
the institute researcher and the company 
researcher 
In collaborative research, many of the discov­
eries fall into class three. A well-written collab­
orative research agreement will address how and 
by whom the ownership determinations are to be 
made in cases in which the IP/TP is discovered by 
one party or the other. 
Globally, patent laws differ. Under the 
patent laws of nearly all countries outside the 
United States, inventorship is determined by 
whomever files the patent first (and has been in­
volved in the discovery process). In the United 
States, inventorship is determined by first-to­
invent and ownership follows inventorship, 
that is, ownership goes to whoever files first. 
This is the so-called first-to-file approach. It is 
therefore necessary for a collaborative research 
agreement to address the matter of ownership 
determination, or refer to the national laws of 
the partners. 
Normally, inventorship is determined when 
the patent attorney talks with the researchers. If 
a patent is being sought in the United States, 
great care must be taken to include on the pat­
ent application only the actual inventors (those 
researchers who make the creative, intellectual 
contributions to the discovery). If someone who 
is not an inventor is named as an inventor on the 
patent application, this will prevent the issuing 
of a legitimate U.S. patent. 
In a first-to-file country, the rules for the de­
termination of actual inventorship are different. 
As in a first-to-invent country, ownership follows 
inventorship. So, whoever files first will be listed 
as the inventor and as the owner. Clearly, it is im­
portant to understand the rules of the country in 
which the patent filing is taking place. Yet it must 
be remembered that if the new IP/TP is to be 
protected in the United States (and other first-to­
invent countries), regardless of where the research 
takes place, the rules of first-to-invent apply to all 
patent filings. 
In general, if only employees of the institute 
are listed as inventors, then the institute owns the 
invention. If only employees of the company are 
listed as inventors, then the company owns the 
invention. However, if at least one employee of 
the institute and one employee of the company 
are listed as inventors, then the invention is joint­
ly owned by both the institute and the company. 
Regardless of whether the patent filing is in a 
first-to-invent country or a first-to-file country, 
it is important to address the matter of patent 
ownership in a well-written collaborative research 
agreement. However, equally important than pat­
ent ownership are the rights that are granted un­
der the patent. 
A key part of the IP provision is what the 
agreement is actually promising in terms of 
the granting of licensing rights, or the “grant.” 
Normally, the parties enter into a collaborative 
research agreement in order to obtain access to 
the discoveries that flow from the collaborative 
project. 
The scope of the grant must be considered 
very carefully. For example, if the scientists are 
conducting mer research and are seeking a tech­
nology for disease resistance, it is possible that 
the technology may apply to other plants as well. 
Thus, the collaborative research agreement should 
be clear that the grant is for a license for mer only 
(or for some other agreed-upon subset of plants). 
This will be a key point in the negotiation of the 
agreement. Normally, one party will want a very 
broad grant of rights and the other party will keep 
trying to narrow the grant. 
The next thing to consider is whether the 
grants will be for an option to a license or an actual 
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license. There are pros and cons to both approach­
es. Granting an option, with a preset fee struc­
ture, is sometimes all that will be requested, be­
cause such an option allows both parties adequate 
time to thoroughly evaluate the invention before 
signing an actual license. On the other hand, one 
party may strongly prefer a direct grant of a li­
cense, with the business licensing terms clearly 
spelled out, because this reduces the amount of 
uncertainty. 
Granting an option normally makes a great 
deal of sense because it is very difficult to pre­
dict what IP/TP will be generated. Further, it is 
difficult to predict the value of such new IP/TP. 
Therefore, agreements that give a direct grant of 
a license and fully spell out the license terms can 
lead to a gross miscalculation of the new IP/TPs 
worth, either undervaluing it or overvaluing it. If 
the IP/TP is overvalued, this would likely act as a 
disincentive for future development of such IP/ 
TP. If the new IP/TP is significantly undervalued, 
this may act as a block on the future relationship 
of the parties because one party has been treated 
unfairly. 
With either approach, the collaborative re­
search agreement should include time frames 
during which the party who receives the option 
to a license must decide whether it wishes to ex­
ecute its option and take a license. The option 
grant should not be open ended. This will allow 
another licensee to be sought if the collaborating 
party does not wish to develop and market the 
new IP/TP. 
Likewise, it is important to specify the li­
cense grant’s level of exclusivity. Is the license (or 
the option to a license) for an exclusive license or 
a nonexclusive license? Is the license exclusive by 
country or region? Is the license limited by crop? 
By product? By time? Or, is the license more gen­
eral? Most companies (and many other collabora­
tors as well) will want some sort of exclusivity in 
their license (or option to a license). It may be 
adequate for such a collaborating partner to have 
an exclusive right for some specified time period, 
or for a certain well-defined field of use, or for a 
certain licensed territory, or for a combination of 
these. Most organizations are reluctant to put their 
resources into an agreement if the organization is 
not assured of an exclusive license because their 
competitors may also seek a license. 
The negotiation of the grant of intellectual 
property is a key part of the collaborative research 
agreement. Take time to think it through clearly 
and come up with a solution that meets the needs 
of both parties. 
. Amendments 
The last part of the general provision section is 
the amendment process. Strong partnerships 
grow and change; therefore, agreements need 
to be amended. In fact, many of the best col­
laborative research agreements need constant 
amendments. It is not unusual for a collaborative 
research agreement to be amended as often as ev­
ery six months or every year. This is because the 
researchers often identify dynamic, new opportu­
nities that the partners want to explore together. 
Thus, a well-written agreement can be amended 
so that the statement of objectives, the statement 
of work, and the budget reflect the new needs. 
All amendments should in writing and signed 
by the proper authorities as an appendix to the 
agreement. Guard against informal amendments 
that may sneak in as the project gains momen­
tum and the researchers become excited. If they 
are not written down, such amendments can lead 
to disputes and litigation. So make it clear to ev­
eryone that all significant changes in the research 
must be written and appended to the agreement. 
. Termination 
All agreements should have a specific date upon 
which the cooporation ends. Termination clauses 
may be added that stipulate when and under what 
conditions each party may elect to terminate the 
agreement before the end date. The end date may 
be extended through the amendment process, if 
both parties agree. This is common in successful 
collaborations. 
. BudGET 
The fourth section of a well-written collaborative 
research agreement is the budget. There is a ten­
dency to view this as the most important section 
because it documents the funding that the parties 
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contribute. This, however, is an improper em­
phasis. While it is true that public sector agricul­
tural research is grossly underfunded, and there­
fore funds obtained from collaborating partners 
have an extremely important place in the overall 
research budget, collaborative research should 
never be viewed principally as a way to raise rev­
enues. Collaboration is much more than that. 
Concentrating only on research funding over­
looks both the use of the agreement as a means of 
technology transfer and as a way to build an intel­
lectual synergism that can result when researchers 
collaborate. 
Developing the budget must begin with a 
clear statement of work. This will help determine 
for the collaborators the amount and the timing 
of the resources required for the collaborative 
project. This is the starting point. There must be 
enough funding to undertake the project without 
detracting from other projects that are already 
underway. 
Staff time should be considered, as well as 
tangible resources (such as space and equipment 
that will be required to support the project). For 
example, if one partner will need to recruit gradu­
ate students, technicians, or other personnel, then 
salary and benefit costs for the new staff must be 
included. Also, do not overlook in-kind contri­
butions that a collaborating partner may be able 
to provide. A company, for example, may have 
very specialized equipment, expertise, formula­
tion technology, or access to facilities that would 
be extremely costly for an institute to procure on 
its own. The value of such in-kind contributions 
should be noted in the budget. 
The budget for a collaborative research agree­
ment should be absolutely clear as a research bud­
get and be totally separate from any sort of licens­
ing revenue that might be projected. The budget 
should also specify when the payments will be 
made and clearly indicate when the contributed 
in-kind resources will be provided. 
. LIST	 of MATERIALS 
The final section of a collaborative research agree­
ment is the list of materials. As with the budget, 
this section provides a clear listing of the TP that 
each party provides to the project. This is critical 
because all such materials were developed outside 
of the project and are owned by one partner or 
the other. They are not new TP that will be di­
vided according to the granting clauses. Rather, 
materials that are included in the list of materi­
als are fully owned by one of the collaborators. 
Sometimes items listed in the list of materials 
have IP rights associated with them; sometimes 
they do not. 
In truly collaborative research, the list of ma­
terials may have to be amended on a regular basis. 
This will require the agreement to be amended 
easily (as noted above). A well-written collabora­
tive research agreement, the list of materials will 
dynamically respond to the emerging needs of the 
researchers. 
. ConCLuSIon 
Collaborative research agreements can be ex­
tremely beneficial to both partners. No single 
entity ever has adequate money, resources, and 
intellectual capacity to do all the research it might 
want to do. Forming partnerships can be an effec­
tive and economical way of accessing resources. 
Collaborative research agreements, moreover, are 
often the first step in establishing longer-term 
partnerships. They can be effective technology 
transfer tools, as well. The benefits are much more 
than monetary. Taking the time to think through 
and discuss the terms of the collaborative research 
agreement helps foster communication between 
partners and sets the project on a path for suc­
cess. Indeed, good partnerships spur creativity 
and help innovation to serve the public welfare. 
Lastly, it should be said that writing and 
negotiating a collaborative research agreement 
might seem like a very difficult process. In fact, a 
first attempt to write such an agreement usually 
is difficult. The good news is that each time one 
does it, the process gets easier. n 
MaRTha baiR sTeinbocK, Deputy Assistant Administrator, 
Research Operations and Management, Office of Technology 
Transfer, USDA-ARS, Room 4-1158, 5601 Sunnyside 
Avenue, Beltsville, MD, 20705, U.S.A. martha.steinbock@ 
ars.usda.gov
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CHAPTER 7.5 
Drafting Effective Collaborative Research 

Agreements and Related Contracts
 
e. RichaRd gold, Director, Centre for Intellectual Property Policy, McGill University, Canada 
Tania bubela, Assistant Professor, School of Business, University of Alberta, Canada 
ABSTRACT 
Best practices in IP (intellectual property) management 
are built on a foundation of licensing and contracting 
expertise. A contract defines a bargain that parties enter 
into, and, as such, defines the relationship and the expec­
tations of the parties. It is therefore critical to carefully 
draft contracts that clearly, and objectively, indicate the 
intentions of the parties. Avoid stilted, legalistic jargon 
when drafting contracts; instead, strive for direct, simple, 
and accurate language. In written agreements, be sure to 
include the terms and provisions covering the grant itself, 
such as payments, dispute resolution, intellectual prop­
erty emerging from the R&D, IP ownership and confi­
dentiality, and other related legal terms and definitions. 
However, remember that generic templates do not exist. 
The relationship and goals of the parties will define how 
the agreement is structured. The actual document will 
also vary, depending on whether the parties are public or 
private sector entities, on whether the license is a collab­
orative-research agreement or a sponsorship agreement, 
and on the business and legal culture. 
1. InTRoduCTIon 
Human relationships are the engine of innova­
tion; they drive the creative use and management 
of intellectual property (IP). Patents, trademarks, 
and copyrights provide mechanisms through 
which actors in the private and public sectors can 
build relationships, coordinate activities, assign 
responsibility, and allocate the benefits arising 
from innovation and its distribution. The con­
tract links these actors and the various IP regimes. 
Contracts, which define in legal terms the form 
relationships take, mediate the interaction among 
those with knowledge, skills, and/or resources in 
order to create something new, improve what al­
ready exists, or distribute what has already been 
created. In this chapter, we first discuss some of 
the basic tenets of good contract drafting, that is, 
emphasizing clarity and simplicity and avoiding 
the slavish use of standard-form contracts, which 
may contain provisions unsuitable to specific 
contracting cultures and contexts. Later in the 
chapter, we discuss sound drafting practices for 
research contracts and for more complex collab­
orative research and sponsorship contracts. 
Because contracts are about relationships— 
with all the ambiguities, pitfalls, and excitement 
of human relationships—contracts are difficult 
to capture on a dry document composed by law­
yers. A written contract can never fully describe 
a relationship nor the full set of contractual ar­
rangements that embody the relationship. The 
extent to which judges and arbitrators interpret­
ing a dispute rely on the written document it­
self—in contrast to the external evidence about 
the relationship between the parties—varies from 
jurisdiction to jurisdiction. For example, in com­
mon law jurisdictions, contractual interpretation 
tends to be more contextual, with greater allow­
ance made for external evidence about the broad­
er relationship. The civil law, however, tends to 
Gold ER and T Bubela. 2007. Drafting Effective Collaborative Research Agreements and Related Contracts. In Intellectual 
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. ER Gold and T Bubela. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged. 
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focus more on actual contractual wording and 
the dictates of the civil code. However, irrespec­
tive of jurisdiction, the written contract is the 
strongest objective manifestation of the inten­
tions of parties as they enter into a relationship. 
Parties can most easily avoid disputes if the 
contract describes, as fully and simply as possible, 
the bargain made by the parties. This notion has 
important consequences for contract document 
drafting. Long-winded sentences, boilerplate 
provisions and impossible-to-understand defini­
tions only complicate lives and understanding in 
a futile attempt to remove doubt concerning, and 
ambiguity of, complex and evolving relationships. 
Such lengthy documents are not only unreadable 
by the actual signatories to the contract but do 
little to provide guidance to the business people 
and judges who may eventually have to settle dis­
putes based on those documents. 
Instead of thinking about contractual docu­
ments as an attempt to pin down every last aspect 
of a relationship between parties in complex legal 
jargon, this chapter suggests a different approach, 
one drawn from the experience of large corporate 
law firms: explain the provisions of the bargain 
as simply as possible, in a logical sequence, us­
ing plain language. By explaining the bargain in 
a clear and accessible manner, not only are the 
chances better that the parties will comply with 
the essence of the contractual relationship, but 
also business people and judges will resolve dis­
putes in conformity with the fundamental inten­
tions of the parties. 
Undoubtedly there is temptation to use stan­
dard form contracts and boilerplate provisions to 
lower transaction costs and legal fees, but in the 
end, the use of poorly written or inappropriate 
contractual provisions may lead to greater costs, 
rather than save money. That is not to say that 
every contract need be drafted from scratch; the 
use of contractual precedents is a judicious use 
of legal resources. Select precedents that are well 
written and constructed. Parties to the contract 
should question the relevance of each provi­
sion to the bargain within the appropriate cul­
tural context. When using clauses from standard 
form contracts, the key question to ask is: do you 
understand the language and does it accurately 
describe the arrangements between the parties, 
given the cultural and legal context? 
1.1	 Explaining the bargain: 
The art of contract drafting 
If one were to read court decisions about con­
tracts, one would soon see that judges struggle 
not as much to determine what the documents 
say, as to determine the nature of the relation­
ships underlying the contracts. When judges 
find this difficult because the contract docu­
ment is confused and convoluted, they are more 
likely to misinterpret the original agreement 
between the parties. Such misinterpretations 
lead to decisions that run against the allocation 
of responsibilities and benefits that the parties 
originally intended, increasing uncertainty and 
undermining the business rationale for the con­
tract. What judges seek to find in contractual 
documents are objective indications of what 
the parties intended to do: Who was to take on 
what risks? Who was to benefit from the results 
of the contract? How were the parties to deal 
with disputes and controversies? Judges want 
to understand what the parties bargained for so 
that they can figure out who should do what, 
when, and where. 
A good contractual document is one that sets 
out the bargain as clearly and simply as possible; 
a bad document is one that muddles it with too 
many words, arcane language, and legal mumbo 
jumbo. The job of a lawyer is to identify the es­
sence of the relationship so that the parties and 
judges understand exactly what the business deal 
is about. This involves setting out the contract in 
a structured way that focuses on the essential ele­
ments of the bargain. 
The simplest contract is one in which one 
party promises to deliver something to another 
in return for something (monetary or otherwise). 
If a dispute arises, the parties agree to follow a set 
procedure (such as arbitration or mediation) or to 
sue in court (litigation).1 This progression should 
be defined in the contract (for example, mediation 
procedures, followed by binding arbitration). 
Further, the agreement should clearly explain 
how one party is to deliver something to the other, 
the heart of what Article 1 should cover. Article 
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2 should deal with payment: to whom should 
the payment be made? in what currency? in 
which form (electronic, bank draft, for example) 
and when? One could also add a few sentences 
dealing with late payments: will there be inter­
est charged and, if so, how much? how would a 
currency crisis (for example, currency cannot be 
exported out of the country) be dealt with? The 
third article deals with resolving problems: steps 
to be taken if the receiving person is unsatisfied 
with what was delivered, either in terms of qual­
ity or quantity; how the parties would resolve the 
conflict; what the first person should do if he or 
she is not paid. The parties can agree to litiga­
tion or arbitration but may first prefer to set up 
a mechanism through which they can elevate the 
problem to senior management who, presumably, 
want to avoid the costs and embarrassment of go­
ing to court or arbitration. 
The key to drafting these articles is to keep 
the essence of the bargain clear and as uncompli­
cated as possible. Sentences should be short, free 
of vague adjectives, and be written in the active 
voice. The vocabulary should be accessible both 
to business people (with technical knowledge but 
limited legal knowledge) and judges (with lim­
ited technical knowledge but with extensive legal 
knowledge). Use correct grammar and a simple 
vocabulary. If the document would get low grades 
from a secondary school teacher, do not use it. In 
fact, sometimes legal disputes turn on grammar. 
One recent commercial dispute in Canada, worth 
$2 million (Canadian), was resolved on the basis 
of a rogue comma.2 
After the parties explain the main provisions 
of the bargain, the parties will need to define
words and phrases used in the contract. The par­
ties should include clauses that take into account 
the local law that applies to the contract. These 
clauses can have important implications for the 
bargain, and so writing them requires expert le­
gal knowledge. Such clauses can deal with what 
would happen if there were natural disasters or 
labor strikes, or how much leeway is given with 
regard to time lines, or how to calculate exchange 
rates. This information must be relevant to the lo­
cal area, however, because the detailed legal rules 
of one place, say California, U.S.A., may be quite 
different from the detailed legal rules in another 
place, say Uttar Pradesh, India. 
Written contractual documents depend 
to a large extent on local customs. That is, the 
contract can be meaningful only within the set 
of business practices and norms that exist in the 
place where the contract is to be performed. As 
practices and norms vary tremendously, so do the 
contractual documents that serve to reflect con­
tractual relationships. So, for example, contrac­
tual documents in the United States tend to be 
very detailed and long, while a contractual docu­
ment on a similar topic will be shorter and much 
less detailed in Germany. Exporting one style of 
contractual document from one place to another 
can be risky, since the business people and courts 
will have difficulty interpreting a document writ­
ten for a different place with different customs. 
This is another good reason to avoid a slavish de­
votion to standard-form contracts and why this 
chapter does not include a sample contract with 
boilerplate provisions, but instead sets out only 
the main elements of a contract. 
Of course, when the parties are from two dif­
ferent places, say Uttar Pradesh and California, 
the parties must adopt a more generic style of 
contractual language that reflects, to the extent 
possible, the practices in both jurisdictions. This 
is not principally for legal reasons; the contractual 
document will be interpreted in accordance with 
the laws and customs of only one of the jurisdic­
tions. Rather, the effort to reflect both cultures is 
important to maintaining business relationships, 
since people from both places must feel comfort­
able with the contractual document. 
Finally, it is helpful to recognize that, while 
legal systems abound, there are two principal 
ones that govern most commercial contracts: 
the common law and the civil law. While some 
countries use hybrid legal systems (for example, 
Oman, Puerto Rico, and Indonesia), most con­
tracts dealing with collaborations and research 
will be subject to one or the other of these two 
systems. Usually, common law countries are for­
mer colonies of the United Kingdom and follow 
the English legal system, while civil law countries 
are generally the former colonies of continental 
European powers. 
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Common law and civil law systems are usual­
ly similar in result, but there are differences in law 
and in practice that could ambush the unwary. 
For example, for a common law contract to be en­
forceable there must be an exchange of something 
of value, called consideration. Consideration can 
be in the form of money, return promises, action, 
or forbearance. On the other hand, civil law does 
not require consideration. Therefore, a failure 
to provide consideration (for example, a license 
with no payment and no obligation of confiden­
tiality) may not be enforceable in the common 
law. Another difference between the two legal 
systems is that the civil law imposes background 
obligations of good faith as well as more limits on 
what can be the subject of a contract than does 
the common law. However, these differences are 
relatively rare. They are unlikely, in most cases, to 
affect collaborative or research agreements great­
ly. The bigger difference is one of style: common 
law contractual documents tend to be longer and 
more detailed, while civil law contractual docu­
ments tend to be short and refer to the civil code 
for more detail. 
1.2 Contracting to innovate 
Contractual documents that deal with innovation 
should follow the general rule of contracts: explain 
the bargain in simple, straightforward sentences. 
Clarity and simplicity are, once again, the keys to 
a successful contractual document. If the contract 
is well drafted, neither the institutions involved 
nor judges will misunderstand the responsibilities 
of the parties involved. Following the rule does 
not, of course, avoid all conflict, but minimizes it 
and provides business people and courts a frame­
work within which to resolve disputes. 
1.2.1 The license 
Traditionally, a license is a grant of permission for 
a party to enter onto the physical property of an­
other, that is, an agreement not to hold the party 
liable for illegal trespass. With respect to intel­
lectual property (IP), a license is a promise not 
to sue a party for actions that would otherwise 
constitute infringement. In other words, a license 
is permission to make use of another’s IP under 
carefully laid out conditions and terms. 
There are a variety of contracts, and associated 
documents, that relate to intellectual property. A 
basic license is the simplest of these contracts. The 
first article of a basic license should describe the 
rights being licensed (patent rights, copyright, 
trade secret rights, data-use rights, and so on) and 
the scope of the license (limitations on geography, 
users, and time). Article 1 should provide suffi­
cient detail so that the business people and judges 
understand as clearly as possible both the nature 
and the limitations on what is being licensed. 
Article 1 should also discuss any ancillary license 
(for example, a license back or cross-license). 
The second article should deal with payment. 
Is there, for example, an up-front fee? Are there 
royalty payments and, if so, how long will roy­
alty payments have to be made? How and when 
should payments be made? The third article will 
set out the dispute-resolution mechanism: arbi­
tration, courts, and/or some form of mediation. 
One should supplement these articles with an 
explanation of what brought the parties together 
and what their goals are. The contract also should 
either acknowledge or reject relevant local laws 
regarding liability for problems that may arise 
(those within the parties’ control, such as failure 
to pay, and outside their control, such as flood 
or fire). The contract should clearly state which 
country’s (or state’s) law applies and so on. The 
parties should take care in setting out definitions 
and should include these at the end (or in the 
introduction, if one prefers). The other issues can 
be dealt with in a concluding article that would 
include mundane, but essential topics, such as 
how the parties are to notify one another. 
Other forms of contractual documents deal­
ing with intellectual property expand the license 
agreement and may, in addition to the basic li­
cense, include articles dealing with matters such 
as information exchange, staff, and IP rights (as 
in a consortium research agreement). 
1. Types of contracts 
Just as there are no real limits to the bargains we 
can make, there is no limit to the type of con­
tracts we can create. As circumstances change, 
new technologies are introduced, and business 
people and lawyers try to identify new niches, we 
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encounter new ways of contracting. The imagina­
tion is the only thing that limits what a contract 
can be about. Therefore, instead of trying to cover 
all possible forms of contracting with respect to 
innovation—an impossible task—we will concen­
trate on a discussion of the main types and leave it 
to the reader to imagine different scenarios. Since 
the key is, as always, to be clear and transparent, 
one can adapt the basic forms of contractual ar­
rangement covered here to other circumstances. 
The remainder of the chapter concentrates 
on two types of contracts: research contracts and 
collaborative research or sponsorship agreements. 
The collaborative research and sponsorship agree­
ments are the more complicated and incorporate 
most of the basic terms of the research contract. 
Heeding the warning against using standard-
form agreements, the discussions below will con­
centrate on some of the principal issues that arise 
in the various types of contract. However, one 
must adapt the contractual arrangements to the 
fundamental underlying relationship and not get 
overly caught up in presenting minutiae. 
2.	 RESEARCH	ConTRACTS 
A research contract is one in which a researcher 
seeks to obtain the rights to use some knowledge 
(be it patented or protected as a trade secret) to 
advance his or her research project. That is, the 
rights obtained are an important ingredient in the 
carrying out of a research project, whether at a 
public, not-for-profit, or for-profit institution. 
A basic outline of a research contract would 
include the following: 
•	 Article 1: the license 
•	 Article 2: payment terms and process 
•	 Article 3: problem escalation and dispute 
resolution 
•	 Article 4: intellectual property emerging 
from research (where applicable) 
•	 Article 5: confidentiality and publication 
rights 
•	 Article 6: legal terms, such as what to do 
in case of an “act of God” or other inter­
vention, timing issues, and notification 
procedures 
•	 Article 7: definitions 
The simplest form of research contract would 
begin, in Article 1, with a holder of intellectual 
property granting a license (that is, promising not 
to sue for infringement) to a researcher in order to 
allow the latter to make use of a certain technolo­
gy for a defined research use. Generally, however, 
research contracts are more complex, and the li­
cense forms only one part of the broader research 
contract. The contract may include a promise to 
provide a sample of the material. 
Material transfer agreements are discussed 
more fully elsewhere,3 but it is worth noting that 
these agreements are not only particularly sig­
nificant for research, but are also often the most 
problematic of contracts to negotiate. There are 
real worries about the sharing of research materi­
als and results in a research environment that is 
increasingly industry funded, competitive, and fo­
cused on commercializing research results. These 
agreements also give rise to significant practical 
difficulties, such as the time and labor needed to 
prepare and transfer research materials, and the 
need to internationally ship biological material.4 
The research contract may call for a payment 
(often nominal, to cover expenses) in cash as well 
as in-kind (for example, a promise not to do or 
disclose certain things). The contract may also 
discuss how to resolve disputes over exactly what 
was licensed (for example, slight variations on the 
initial technology), payment amounts (how to 
handle the production of material that was never 
used), and so on. 
That is the basic bargain. With a clearly 
written contract, one has already avoided most 
possible conflicts. There remain, however, a few 
contentious issues that we cover here in more 
detail. These include publication rights, confi­
dential information, tricky licensing concerns, 
payment, and rights to the results of the research 
performed. 
2.1 Publication rights 
It is seldom the case that a technology is solely 
protected by patents that are available for review 
by the public, and it is bad business practice to 
use only patents if other forms of business protec­
tion are also available. Therefore, when a party 
licenses the use of a certain technology, that party 
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often must provide associated confidential infor­
mation. To protect the party against the disclo­
sure of this information, he or she often asks for 
a right to approve any publications. In addition, 
if the research may result in new information that 
may affect the technology owner’s interests (the 
research shows that the technology does not work 
or works better than expected), the technology 
owner may wish to have time to prepare for this 
eventuality prior to any public disclosure. This 
also would lead the owner to seek the right to ap­
prove publications. 
Given the interests of technology owners 
to guard against uncontrolled disclosures, these 
owners may insist that a clause be added to the re­
search contract providing that the researcher may 
only publish articles after first getting permission 
from the technology owner or after first giving 
the technology owner enough time to prepare 
itself for the publication. Delays of three to six 
months for the technology owner to review pub­
lications to ensure that no confidential informa­
tion is disclosed are reasonable, provided that the 
article’s author is permitted to submit the article 
to the journal for a confidential review during 
this time. As normal peer-review processes usu­
ally take at least this much time, it provides little 
inconvenience to the author. 
If the technology owner also has the right to 
new inventions coming out of the research (usu­
ally this only happens in a sponsored-research 
setting, which will be discussed later), then the 
owner may also reasonably request a publication 
delay in order to assess the publication for any 
disclosure that could threaten the patentability of 
the new invention. 
2.2 Confidential information 
Patents often represent only a part of a technol­
ogy, for example, an early prototypical embodi­
ment of an invention. The remainder, such as 
secrets and know-how, are protected under most 
legal regimes as trade secrets or as confidential 
information. In addition, the research conducted 
under a contract may result in the creation of 
new confidential information. The person who 
possesses confidential information can only pre­
vent others from disclosing it, for example, to a 
competitor, if a confidential relationship exists 
between the person and the party to whom the 
information was initially disclosed. One of the 
best ways of ensuring this protection from disclo­
sure is through a contract. 
The obligation to maintain confidentiality 
will often be reciprocal. The technology owner 
may seek to include a confidential information 
clause in the research contract to prevent the re­
searcher from disclosing confidential information 
initially disclosed by the owner. The researcher 
may wish to insert this type of clause into the 
contract to protect the results of his or her re­
search effort. 
It is important to pay attention to how broad­
ly one defines the term confidential information. A 
narrow definition can be clear, but may leave out 
important information. A broad definition may, 
on the other hand, prevent the parties from get­
ting on with their work. Therefore, both parties 
to the research contract should review the defini­
tion carefully and make sure it is clear to them. 
There are several mechanisms that can increase 
clarity. First, one can limit confidential informa­
tion to material that is clearly identified (because 
it is marked confidential) or limit confidential 
information to clear and discrete categories of 
information (for example, business plans or cus­
tomer lists). Caution should be used in accepting 
an open definition (for example, “Confidential 
Information includes but is not limited to … .”), 
especially where there is no requirement that the 
confidential information be specifically marked 
as such. In addition, some courts may strike 
down an overly broad confidentiality provision. 
This is because they sometimes see these provi­
sions as contrary to public policy, since they limit 
competition. 
Overall, the scope of what is held to be confi­
dential should not be so broad as to prevent pub­
lication of research results and the use of research 
by others. Moreover, since what should be kept 
confidential will depend on how the information 
is to be used, no single definition will apply well 
in all cases. 
The contractual provisions dealing with con­
fidential information should make clear to whom 
the information may be disclosed (for example, 
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other researchers, including graduate students in 
the same and other institutions, and so on). Care 
should be taken to ensure that the obligations 
would not prevent doctoral students or post-doc­
toral fellows from publishing theses and making 
presentations. 
The confidentiality provisions should also 
include a sunset clause that would end the ob­
ligation of confidentiality under a variety of cir­
cumstances, including situations where the infor­
mation is made available to the public through 
no fault of the receiving party and cases where a 
court requires that the information be disclosed. 
Finally, the contract should set out how 
much care must be taken by the person receiving 
the information to keep it confidential. For ex­
ample, must the receiving party lock away the in­
formation in a safe, or can he or she leave it filed 
in office filing cabinets? This is important, since 
it establishes the level of precaution the receiving 
party must undertake to protect the information, 
and how the party ought to address inadvertent 
disclosures. The agreement should also specify 
what information the recipient of information is 
entitled to keep after the expiration of the con­
tract and what must be returned or destroyed. 
2. The license 
The researcher’s freedom to carry on research us­
ing a patented, or otherwise protected, invention 
is determined by the scope of the license. A li­
cense may be narrow and provide only for a de­
fined field of use, such as use in conjunction with 
certain vectors, or the license may be broad and 
cover all research. The broader the scope, the more 
freedom the researcher has to conduct research. 
The researcher needs to recognize the coun­
terintuitive fact that receiving a license to an in­
vention does not guarantee that he or she is en­
titled to use the invention. The researcher may 
need, for example, regulatory approval, or may 
need to license other inventions from the same 
or different providers. It is therefore critically im­
portant for the researcher to determine, normally 
with the assistance of the licensor, how he or she 
will be able to legally use the invention. 
A license can be a nonexclusive license, a 
sole license, or an exclusive license. A technology 
owner who grants a nonexclusive license is per­
mitted to grant the same or a similar license to 
anyone else (however, the owner may not grant 
someone else a sole or exclusive license). Unlike 
a nonexclusive license, an exclusive license incor­
porates two promises. The first is the license itself, 
that is, a promise not to sue the researcher for pat­
ent infringement. The second is a promise by the 
technology owner to neither use the invention 
himself or herself nor grant a license to anyone 
else. Coexclusive licenses, prevent the owner from 
granting a license outside of an identified group. 
A sole license is similar to an exclusive license ex­
cept that the technology owner retains the right 
to use the invention herself or himself. Normally, 
the greater the degree of exclusivity requested, the 
greater the royalty paid by the researcher, since 
fewer sources of revenue are available to the tech­
nology owner. In an academic setting, researchers 
usually require only nonexclusive licenses. In the 
private sector, especially where a technology is key 
to developing a particular application, a research 
organization may need an exclusive or co-exclu­
sive license that justifies the investments needed 
to bring the technology to the market. This is of­
ten the case if the research organization faces a 
significant risk or the market for the technology 
is expected to be small. 
Some inventions in the biotechnology field, 
such as genetic inventions and platform technol­
ogy, tend to represent upstream inventions: these 
are inventions that are needed in a large variety 
of settings and applications. Granting exclusive 
or sole licenses over all applications (generally re­
ferred to as fields of use, in-license agreements) 
for these types of inventions is not recommended. 
Indeed, the Organisation for Economic Co-op­
eration and Development (OECD) has recently 
issued best practice guidelines for licensing ge­
netic inventions that emphasize the general 
preference for nonexclusive licensing for genetic 
technologies.5 However, we can infer that non­
exclusive licensing is more broadly preferred, 
especially for platform technologies. One study 
indicated that exclusive licensees often fail to ac­
tually invest the necessary funds to move a tech­
nology forward.6 This may happen if the licensee 
lacks funds or loses interest in developing the 
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technology. Thus, strong exclusive relationships 
are generally not the best way to advance research 
or commercialization. 
If an exclusive license is necessary, particu­
larly with respect to very early-stage research, it 
is best to narrowly define fields of exclusive use 
for the invention so that the technology owner 
has the flexibility to permit researchers in other 
fields with different applications the freedom to 
conduct research. Where an exclusive license is 
required, the parties should draft the license to 
include provisions that enable the technology 
owner to take back the rights granted in certain 
circumstances. These circumstances might in­
clude the failure of the research organization to 
develop the invention in the manner described in 
the license agreement, failure to fully exploit all 
aspects of development for the invention, or fail­
ure to sublicense as appropriate. These take-back 
provisions should address, for example, the loss of 
the license, the conversion of the exclusive license 
into a nonexclusive license, or the reduction in 
scope of the exclusive license. 
To preserve the freedom of researchers, in 
general, to engage in research for humanitar­
ian purposes, licenses should, whenever possible, 
explicitly recognize the rights of third parties to 
conduct humanitarian research. This can be ac­
complished by having one of the parties retain 
the right to provide licenses to others who plan 
to carry on such work. The parties may even go 
so far as to impose an obligation to do so in spe­
cifically defined circumstances. When seeking to 
include this type of provision, a lawyer should be 
consulted in the relevant country to make sure 
that the obligation is enforceable, especially in 
case of bankruptcy. 
One important, but occasionally overlooked, 
element of a license is a description of the orga­
nizations and people that are entitled to benefit 
from the license. Without such a list, the default 
is that the license will apply only to the licensee. 
Where the research is being used by researchers 
at several institutions, or several locations, or 
by research teams from multiple corporate en­
tities within the same family of companies, the 
license must be drafted so as to permit all of the 
researchers to use the technology. To accomplish 
this, the license should specifically permit the re­
search organization signing the license with the 
right to allow others to use the invention through 
a sublicense. On the other hand, the technology 
owner will often want to ensure that this group 
does not become too large. Thus, it is in both par­
ties’ interests to specifically define the group to 
which access to the inventions will be provided. 
In addition, the license should identify all coun­
tries where the researcher requires access to the 
invention. 
2. 	 Payment 
In general, those who receive a license for an in­
vention pay a combination of up-front fees and 
ongoing royalties for the right to use the inven­
tion. Where the technology is a research tool and 
the market for the technology consists primarily 
of those conducting research, a market price will 
be charged. In the case of research agreements, 
however, it is standard practice to either not 
demand these fees or to set them at a rate that 
compensates the technology provider for out-of­
pocket expenses. There are other cases where a fee 
will normally not be requested, such as where the 
license is provided as part of a cross-license ar­
rangement or where the parties wish to contract 
for the provision of know-how related to research 
that falls within existing research exemptions. 
Where payment is required, the amount of the 
fees depends on many factors, including the scope 
and nature of the license, the type of invention, 
and whether the researcher is sponsored by the 
private or the public sector. In general, care must 
be taken in establishing up-front fees, especially 
where these fees may present a barrier to access. 
2. 	 Rights to intellectual property 
created through research 
Research conducted using licensed innovation 
may itself result in patentable inventions. Some 
of these inventions may relate to the licensed-in 
technology. For example, they may constitute a 
modified or improved form of the original tech­
nology, or they may be substantially different. If 
the research agreement is silent on the ownership 
of these new inventions, then the researcher or 
the researcher’s employer, or a combination of 
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the two, would be entitled to hold a patent over 
it, depending on the IP policy of the particular 
research institution. This means that the original 
technology owner would, in the absence of any 
agreement to the contrary, normally have no IP 
right to this new invention and, therefore, no 
right to use the new invention, let alone control 
access to it. This situation can be changed through 
an appropriate assignment, through grant-back 
clauses, or through license provisions in the re­
search contract. 
2..1 Ownership 
In the research setting, ownership of intellectual 
property developed using licensed-in technology 
should generally remain with the researcher or 
the researcher’s employer. This is especially true 
where the research takes place at a university or 
public research center and where public funds are 
used to conduct research. Thus, reach-through 
license agreements, in which the original technol­
ogy owner claims rights to research resulting from 
the use of licensed inventions, should generally be 
avoided. 
The situation is different for sponsored re­
search where the researcher is essentially hired to 
conduct research for the original technology own­
er. In this case, it is appropriate for the researcher 
to assign IP rights to the technology owner, since 
the default rule would leave the intellectual prop­
erty in the researcher’s hands. Where there is an as­
signment, the researcher should ensure that other 
researchers, graduate students, and postdoctoral 
fellows working on the project understand this 
and agree to transfer intellectual property to the 
original technology owner. 
The contract should also set out whether the 
researcher or the original technology owner has 
the responsibility to file and maintain patents for 
the new inventions. Normally, this would fall on 
the party who ends up with the patent or who 
holds an exclusive license to the invention. 
2..2 License back 
The research contract would not normally include 
a license back from the researcher to the original 
technology owner for inventions made during the 
course of the research. This is because the risk and 
responsibility for new inventions rests with the 
researcher, not the original owner. The situation is 
slightly different with respect to improvements to 
licensed-in inventions. In this situation, the origi­
nal technology owner may wish to have access to 
those improvements both for his or her own sake 
but also for the sake of his or her other licensees. 
It may be appropriate for the researcher to license 
back improvements on a nonexclusive basis to the 
original technology owner, to the extent that this 
is necessary for the owner and his or her other 
licensees to continue using the (improved) inven­
tion. A reasonable royalty may be required. The 
scope of the license back should not be so large as 
to prevent the researcher from licensing the im­
provement to other parties. 
2. 	 Alternative structures for 
research relationships 
Researchers will often require access to many 
inventions to accomplish their work. Indeed, 
a researcher may be required to purchase many 
licenses to carry out a particular research proj­
ect. The need for multiple licenses, referred to as 
patent stacking, can lead to problems, because 
the costs, in terms of both time and money, as­
sociated with obtaining those licenses to a large 
number of patents simply is prohibitive. In order 
to avoid potential problems, license agreements 
need to ensure that the total royalty burden faced 
by the researcher is reasonable. This can be ac­
complished by setting a maximum total royalty 
burden that the researcher must pay to all licen­
sors. To the extent that the total royalty burden 
exceeds that amount, the researcher would pay 
the technology owner a pro rata amount of the 
total royalty burden. The owner may wish, how­
ever, to set minimum royalty rates. 
Alternatively, licensors and licensees may 
wish to contemplate creating patent pools, pat­
ent clearinghouses, or other open-source means 
to ensure that researchers at both public and pri­
vate institutions have access to basic technology. 
License agreements would then be standardized 
and ensure access to a variety of inventions at a 
reasonable cost. 
A patent pool is an arrangement in which 
“two or more patent owners agree to license certain 
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of their patents to one another and/or third parties.”7 
Patent pools bring together patent holders in a 
specific area of innovation, such as a viral genome, 
to facilitate the efficient use and development of 
a technology. The patents are pooled because the 
arrangement allows inventors in the pool to use 
all their patented inventions under favorable li­
censing terms. The group then shares any benefits 
that may materialize from this arrangement. The 
motion picture industry, aeronautics firms, and 
those developing new DVD technology have all 
successfully used patent pools to advance their re­
spective technologies.8 
There are many challenges to setting up a pat­
ent pool. For example, patent pools may trigger 
anti-competition laws.9 Second, researchers may 
choose not to join in the patent pool because, 
even though these pools reduce research transac­
tion costs and spread risk, they also decrease the 
potential for large profits. Thus, parties need to 
strike the right balance between research goals 
and profit motives.10 
Open source patent systems share the goal 
of promoting the free dissemination of research 
between inventors and the public, in contrast to 
the creation of marketplace monopolies. Open 
source systems can be directed at end products 
or research tools used to develop products. There 
are several functioning examples of open source 
patent systems. One such initiative is the Public 
Patent Foundation (PPF). It facilitates the cre­
ation of free zones in which patents are pooled 
and made freely available to other participants.11 
The PPF accomplishes this by granting nonex­
clusive and royalty-free licenses to participants. 
Another example is the Biological Innovation 
of Open Society (BIOS). It involves technolo­
gies that have already been granted patent rights. 
Focusing on research tools rather than on final 
products, BIOS (like PPF) has established licens­
ing terms to achieve their specific goals.12 One 
final example of an open source patent system is 
the Tropical Disease Initiative (TDI). With this 
system, inventions are not necessarily subject to 
patent rights. TDI’s aim is to maintain an ac­
cessible Web database to facilitate research and 
development and to make research information 
readily accessible to researchers.13 
.	 CoLLABoRATIvE	RESEARCH	And 
SponSoRSHIp 	AGREEMEnTS 
While the research contract normally provides a 
one-way flow of technology from the technology 
holder to a researcher, more complex arrange­
ments exist. This section considers two of them: 
the collaborative research agreement and the 
sponsorship agreement. 
A collaborative research agreement involves 
multiple partners, often a mixture of private and 
public sector actors, working together on a par­
ticular research project. The partners each con­
tribute an amount of money, skilled talent, and 
technology to a central pot that they then har­
ness to conduct research. Usually, the private sec­
tor actor either obtains the intellectual property 
to the resulting research or, more often, a prior­
ity right to license that intellectual property. By 
adding additional players and providing a more-
complex ownership scheme for the resulting tech­
nology, collaborative research agreements form a 
more-complex transaction than the one-way flow 
of technology in the research contract. 
A basic collaborative research agreement 
would include the following 
•	 Article 1: joint obligations to participate in 
the collaborative research effort 
•	 Article 2: a high-level description of what 
each party brings to the research project 
(money, technology, material, skills) with 
cross-references to articles 3, 4 and 5. The 
details of each party’s contribution may be 
attached as an appendix to the agreement. 
•	 Article 3: payment terms and process 
stipulations 
•	 Article 4: licenses from the various parties 
to use pre-existing technology (including a 
mechanism to add additional technology) 
•	 Article 5: a list of materials needed to be 
transferred to conduct the research 
•	 Article 6: provision for who holds intellec­
tual property emerging from the research 
•	 Article 7: licenses to technology emerging 
from the research (including who has the 
right to license-out the technology) 
•	 Article 8: allocation of financial returns 
from the use or license of emerging tech­
nology and payment terms 
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CHAPTER . 
•	 Article 9: addition and removal of collab­
orative team members 
•	 Article 10: management structure that will 
be used to supervise the research and re­
search results 
•	 Article 11: problem escalation and dispute 
resolution 
•	 Article 12: confidentiality and publication 
rights 
•	 Article 13: legal terms, such as what to do in 
case of an “act of God” or other intervention, 
timing issues, and notification procedures 
•	 Article 14: definitions 
A sponsorship agreement is a research contract 
instigated by an actor, usually in the private sec­
tor, for the benefit of that actor. In some ways, it 
is research for hire. However, when the research­
er or research organization being hired is in the 
public sector, the agreement normally also creates 
knowledge for that organization or the research 
community in general. As in the collaborative re­
search agreement, the sponsor will normally, in 
addition to providing a license to original tech­
nology, pay for the research and retain certain IP 
rights in the outcome of that research. 
The basic structure of a sponsorship agree­
ment includes the following: 
•	 Article 1: a description of the research to be 
conducted by the researcher 
•	 Article 2: payment terms and process 
stipulations 
•	 Article 3: the license to any technology nec­
essary to conduct the research 
•	 Article 4: any materials needed to be trans­
ferred to conduct the research 
•	 Article 5: ownership of intellectual prop­
erty emerging from the research 
•	 Article 6: any license to use technology re­
sulting from the technology 
•	 Article 7: problem escalation and dispute 
resolution 
•	 Article 8: confidentiality and publication 
rights 
•	 Article 9: legal terms, such as what to do in 
case of an “act of God” or other interven­
tion; payment schedules and other timing 
issues; and notification procedures 
•	 Article 10: definitions 
Both collaborative research and sponsor­
ship relationships are complex and so the nature 
of these relationships will be context dependent. 
This means that one should avoid the automatic 
use of standard-form agreements and ensure that 
the contract is context specific. The more com­
plex the contract, the greater the need for clarity 
and structure. 
.1 Confidential information 
The discussion that follows presumes the reader 
understands the content of the previous discus­
sion with respect to research contracts, and thus 
only highlights areas of particular importance 
and adds provisions not required for the ordinary 
research contract. The reader is thus advised to 
read carefully the previous section on research 
contracts before continuing further. 
A research sponsorship or collaborative 
research relationship is designed to build new 
knowledge and new inventions. While some of 
these inventions may be patented, others may 
be held as trade secrets. In the latter case, the 
agreement should normally establish how to en­
sure trade secret protection. In virtually all col­
laborative research or sponsorship agreements, 
all parties will be obliged to maintain confi­
dentiality, in order to protect both what was 
brought into the research project and what is to 
be produced through the research partnership. 
Unlike standard research contracts, it is highly 
likely that, with both collaborative research 
and sponsorship agreements, information will 
likely flow back and forth between a number of 
parties, perhaps in different jurisdictions. The 
agreement must therefore clearly provide for 
information sharing and for a mechanism to 
keep track of who has accessed what informa­
tion and when. Such provisions will not only 
help maintain control over the information, 
but make it easier to identify which party is 
responsible for any security lapses, should they 
occur. It is also important, in cross-jurisdic­
tional agreements, to ensure that confidential 
information provisions are enforceable in all 
relevant jurisdictions. 
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The parties should carefully describe what 
should be done at the end of the project with 
confidential information that is brought into or 
created through the project. Thus, the agreement 
should specify whether, at the end of the research, 
other participants in the research project are en­
titled to use the confidential information brought 
into the project by another party. Similarly, the 
parties must determine who will be entitled to 
use information created through the research pro­
gram and for what purposes. 
In order to ensure that confidential informa­
tion can be licensed to others, it is also important 
for the agreement to stipulate which of the parties 
is entitled to make decisions about the licensing 
of the information. In the absence of such a pro­
vision, it will be difficult to transfer confidential 
information developed through the research pro­
gram to eventual licensees of the technology. 
.2	 License to contributed 
patented technologies 
Participants in a research project will likely bring 
with them not only confidential information, but 
patented technology for use in the course of the 
research. Given the evolving nature of complex 
research projects, the parties are unlikely, at the 
beginning of the project, to know exactly which 
technology they will each need to contribute. To 
handle this problem, the agreement should list 
the technology and associated patents that need 
to be included in the project. The parties should 
establish a mechanism through which additional 
technology (and associated patents) can be added, 
for example, a committee that formally approves 
the addition of new items to the technology and 
patent list. By establishing such a mechanism, 
the contract provides transparency to the partici­
pants and yet includes flexibility to adjust to new 
developments. 
.2.1 License scope and nature 
Unlike a standard research contract, which li­
censes technology to one party, in the collabora­
tive research agreement and occasionally in the 
sponsored research agreement, the license will 
need to extend to all research participants at all 
institutions. Therefore, the agreement needs to 
describe the set of persons who are entitled to use 
the technology, as well as set out a mechanism to 
add additional researchers and institutions who 
may later join the project. 
Normally, material or information contrib­
uted through a sponsorship or collaborative re­
search agreement will be licensed on a nonexclu­
sive basis to those carrying out the research. It is 
good practice to include these provisions even in 
countries where a formal research exception exists, 
given both ambiguities in the law and differences 
between the legal rules in different countries. The 
parties should ensure that the scope of the license 
is sufficiently broad as to accommodate changes 
in research direction. 
Where there are multiple parties to an agree­
ment, the contract should provide a mechanism 
through which participants can withdraw. This is 
particularly important for bankruptcy issues that 
otherwise could plague ongoing research. Such a 
mechanism can also address any changes in sta­
tus of one of the participating institutions (for 
example, a subsidiary company merging with its 
parent company). These agreements should nor­
mally state that the remaining parties are entitled 
to continue using material or information and 
should also stipulate the process for adding new 
parties to the collaboration, subject to national 
bankruptcy and competition laws as well as other 
contractual obligations. 
Once again, one must recognize that a license 
by itself does not guarantee that the licensee or 
other parties named in the agreement can actually 
use the invention. 
.2.2 Payment 
As licenses granted to researchers actively con­
tribute to the research effort, they are usually 
provided either free of charge or at a reasonable 
rate. 
. 	 Rights to intellectual property 
created through research 
One of the most important goals of the spon­
sorship or collaborative research arrangement is 
to develop a new technology that can be com­
mercialized. Because of this, some of the key 
IP provisions in these agreements relate to the 
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CHAPTER . 
intellectual property produced through the re­
search, rather than to existing inventions. 
..1  IP rights associated with 
the sponsorship agreement 
If a sponsor wishes to alter the default legal pro­
vision that the researcher or employer retains IP 
rights to research results, the agreement ought to 
clearly specify the respective ownership stake of 
each of the parties in inventions resulting from 
the research. The sponsor and researching organi­
zation ought also to specify which of them has the 
power to make decisions about the licensing of 
these inventions. This need not be the same as the 
ownership entitlements, although it frequently is. 
The parties should also specify which of them has 
the responsibility to file and maintain patents, 
with respect to the inventions. In normal cases, 
the sponsor holds the IP rights and the obligation 
to maintain patents. 
..2	 IP rights associated with the 
collaborative research agreement 
The ownership of intellectual property that re­
sults from a research collaboration can be dif­
ficult to determine. Often the institutions have 
different sets of rules governing the ownership 
of intellectual property. Some institutions may 
leave intellectual property in the hands of their 
researchers and students, while others will claim 
ownership to the intellectual property. In reality 
the issue of ownership is more complicated, since 
ownership rules often depend on who funds the 
research (that is, the government, a philanthropic 
foundation, or the private sector). Furthermore, 
on a practical level, it may be difficult to assess 
which party has the greater claim to inventions 
made during the course of the research. 
In the above circumstances, the parties 
would be well advised to specifically address the 
question of which of them will obtain ownership 
of patents and other IP rights. If the parties fail 
to address this issue, they risk blocking further 
development and use of research results arising 
from the collaboration. Ownership may also be 
particularly important with respect to avoiding 
seizure by others, as in the case of bankruptcy. 
The parties ought also to specify which of them 
has the responsibility to file and maintain patents 
over those inventions. 
A related issue is which party or parties will 
have the power to make decisions about the fu­
ture use of intellectual property, including deci­
sions concerning licensing out technology devel­
oped during the course of the research program. 
What is important here is not actual ownership, 
but which party has control over the use and fur­
ther licensing of those inventions. 
In general, no matter which party or parties 
own the technology and associated intellectual 
property, all of the parties ought to have the right 
to use the developed technology on a nonexclu­
sive basis for internal use and the use of their sub­
sidiaries. There may, however, be cases where such 
an arrangement is not practical or effective (for 
example, when the parties do not plan to work 
on the technology after the research project and 
prefer to license it exclusively to a third party). 
The power of a party with the right to grant 
licenses to others should not be unconstrained. 
For example, the collaboration agreement should 
normally provide that licenses over research tools 
or platform technology developed through col­
laboration should be nonexclusively licensed. If 
that is impossible, and the collaboration agree­
ment provides that resulting technology can be 
licensed exclusively, there should be limits. An 
exclusive license should preserve the right of all 
collaborating researchers, and preferably all re­
searchers anywhere, to continue conducting re­
search on the technology and using it in a teach­
ing environment. Second, any exclusive license 
should ensure that further development and use 
of the technology is not blocked. This can be ac­
complished through the use of provisions that 
enable the collaboration to nullify licenses in 
certain well-defined circumstances (for example, 
the failure of the future license holder to develop 
the technology in the manner described in the 
license agreement, to fully exploit all aspects of 
development for the technology, or to sublicense 
as appropriate). The nullification provision can 
take the form of a loss of the license, the conver­
sion of the exclusive license into a nonexclusive 
license, and the reduction in scope of the exclu­
sive license. 
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GOlD & BuBElA 
Just as the issues of technology ownership 
should be separated from control of the technol­
ogy, so should the issue of ownership be separated 
from that of revenue allocation. What is critical 
is that the agreement clearly states how licens­
ing and other revenue is to be divided among the 
collaborators. 
.	 ConCLuSIon 
The best contractual document is one that, once 
signed, is never looked at again. This can be the 
case when the parties have so well described their 
relationship that it is obvious who is to do what 
and who bears the risks. In the unfortunate and 
rare situation where a dispute arises, a clearly 
drafted contract is essential for assisting both the 
business people administering the contract and 
the judges that may be called upon to interpret it 
to find an appropriate and fair solution. 
The basic elements of a bargain between par­
ties, whether with regard to a simple research 
contract or to more complex sponsored research 
or collaborative research agreements, determine 
the structure, language, and length of a contrac­
tual document. The goal of the contract drafter is 
to capture the main components, laying them out 
in order of importance to the overall relationship 
between the parties. While legal detail cannot be 
ignored, it should take second place to clear draft­
ing practices. n 
e. RichaRd gold, Director, Centre for Intellectual Property 
Policy, McGill University, 3664 Peel Street, Montreal, H3A 
1W9, Canada. Richard.gold2@mcgill.ca 
Tania bubela, Assistant Professor, School of Business, 
University of Alberta, 3-30D Business, Edmonton, T6G 
2R6, Canada. Tania.bubela@ualberta.ca
1 See, also in this Handbook, chapter 15.3 by EJ Min. 
2 Robertson G. 2006. A $2-Million Comma? Au Contraire,
Rogers Tells Aliant. Globe and Mail 16 October, 2006: B1. 
3	 See, also in this Handbook, chapter 7.3 by A Bennett,
WD Streitz and FA Gacel. 
4	 Walsh JP, C Cho and WM Cohen. 2005. View from the 
Bench: Patents and Material Transfers. Science 309:
2002–2003. 
5	 In order to address these concerns, OECD member 
countries agreed to Guidelines for the Licensing of 
Genetic Inventions used in health care. The guidelines 
set out principles and best practices for those in 
business, research, and health systems who enter 
into license agreements for genetic inventions used 
for human health care. The guidelines are targeted 
at those involved with innovation and the provision 
of health services, particularly those involved in the 
licensing of the inventions. Overall, the guidelines seek 
to foster the objectives of stimulating genetic research 
and innovation while maintaining appropriate access 
to health products and services. www.oecd.org/
document/26/0,2340,en_2649_37437_34317658_1_1_ 
1_37437,00.html. 
6	 Colyvas J, M Crow, A Gelijns, R Mazzoleni, RR Nelson, N 
Rosenberg and BN Sampat. 2002. How Do University 
Inventions Get Into Practice? Management Science 48:
61–72. 
7	 U.S. Department of Justice and the Federal Trade 
Commission. 6 April 1995. Antitrust Guidelines for the 
Licensing of Intellectual Property. 4 Trade Reg. Rep. CCH.
See also Goldstein JA,TJ Ebersole and MC Guthrie 2005.
Patent Pools as a Solution to the Licensing Problem of 
Diagnostic Genetics. Drug Discovery World Spring:86-
90.
8	 Clarke J, J Piccolo, B Stanton and K Tyson. 2000.
Patent Pools: A Solution to the Problem of Access in 
Biotechnology Patents? United States Patent and 
Trademark Office: Washington, DC. www.uspto.gov/ 
web/offices/pac/dapp/opla/patentpool.pdf. 
9	 Ibid. 
10 Verbeure B, E Van Zimmeren, G Matthijs and G Van 
Overwalle. 2006. Patent Pools and Diagnostic Testing.
Trends in Biotechnology 24: 114–120. 
11	 Feldman R. 2004. The Open Source Biotechnology 
Movement: Is It Patent Misuse? Minn. J.L. Sci. & Tech. 6:
117–167. 
12	 Ibid. 
13	 Maurer S, A Rai and A Sali. 2004. Finding Cures for 
Tropical Diseases: Is Open Source an Answer? Minn. J.L.
Sci. & Tech. 6: 169–175. 
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CHAPTER 7.6 
The Use of Nonassertion Covenants:
 
A Tool to Facilitate Humanitarian Licensing,

Manage Liability, and Foster Global Access 

anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University;
Chair, bioDevelopments-International Institute and Adjunct Professor, Cornell University, U.S.A. 
ABSTRACT 
Nonassertion covenants (nonasserts for short) grant per­
mission to third parties to practice a patent they would 
otherwise infringe. Legally, nonasserts are patent-in­
fringement settlement agreements that are designed and 
drafted with the purpose of preemptively resolving future 
infringement disputes. Nonasserts can take three forms: 
(1) an agreement between two parties, (2) an agreement 
among several parties, or (3) a public statement. A non-
assert can specify the release of only certain patent rights 
or fields of use, or it can be broad and specify release 
for entire patent families, including future inventions in 
a certain area. Public statements effectively place rights 
to patents, or elements thereof, into the public domain. 
Nonasserts nevertheless need to specify, precisely, which 
rights are granted in order to avoid ambiguity that could 
lead to equitable estoppel. 
Nonasserts can have wide-ranging implications in 
terms of enhancing public sector R&D. One application 
could be with patent rights covering research tools that 
are critical for accelerating the development of essential 
biotechnological applications. Specifically targeted non-
asserts can also be effective instruments for industry to 
permit the use of patented inventions anywhere in the 
world, provided such use is for the express purposes of 
addressing specific humanitarian needs in developing 
countries. This could have broad-ranging and signifi­
cant positive impact, as this approach reduces trans­
action costs, encourages innovation to help the poor, 
and accomplishes this without any loss of commercial 
opportunities. 
1. InTRoduCTIon 
The concept of a nonassert agreement, or nonasser­
tion covenant (NAC),1 has become well known 
in 2006 in the context of open-source software. 
During that year, several major software com­
panies such as Sun Microsystems and Microsoft 
Corp. announced that they would not seek to 
enforce any of their enforceable patents with re­
spect to defined portions of products related to 
certain Web-based applications. Similarly, IBM 
proclaimed that it would not assert its rights with 
respect to 500 of the company’s patents on open-
source software implementations. Similarly, the 
Massachusetts Institute of Technology (M.I.T.) 
and other public entities also use nonasserts in 
the biotechnological areas. 
The use of nonasserts spans a broad range 
of applications. This chapter presents the main 
types of nonasserts, provides sample language 
from actual nonassert agreements, and discusses 
the broader implications of the use of nonasserts 
to respond to the overwhelming need for new ap­
proaches in humanitarian licensing as public in­
stitutions strive to bring about global access. 
2. 	foRMS	 of nonASSERTS 
A nonassert is an implied license. Put differently, 
a nonassert is an agreement that certifies that the 
party or parties to the implied agreement will not 
Krattiger A. 2007. The Use of Nonassertion Covenants: A Tool to Facilitate Humanitarian Licensing, Manage Liability, and 
Foster Global Access. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Prac-
tices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.
ipHandbook.org. 
© 2007. A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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KRATTIGER 
assert or defend certain rights that they possess. 
Such rights are typically related to patents. A 
nonassert can take one of three forms: 
•	 an agreement between two parties 
(bilateral) 
•	 an agreement among several parties 
(multilateral) 
•	 a public statement (proclamation) 
When drafting a nonassert, the owner of the 
intellectual property rights who pledges that it 
will not enforce its rights should use precise lan­
guage to specify which rights exactly will not be 
enforced and whether or not any field-of-use re­
strictions will apply. If the terms are left vague 
or ambiguous, the ambiguity could leave open 
the possibility of equitable estoppel at some time 
in the future.2 This means that a person or party 
could overcome an infringement action and be­
come an unintended beneficiary of the nonas­
sert, continuing to use the intellectual property 
with impunity (perhaps on the grounds that the 
nonassert was misleading and that the unintended 
beneficiary would be materially prejudiced if the 
patentee could assert his or her rights). 
Box 1 provides a sample of a public nonassert 
statement from the software industry and Box 2 
gives a public nonassert statement from biomedi­
cal area. 
. THE	 BEnEfITS	 of 	nonASSERTS 
Nonasserts are an important instrument of indus­
try for promoting open standards or for the es­
tablishment of industry standards. In the form of 
public statements, nonasserts provide a number




Published: September 12, 2006 | Updated: February 15, 2007 
Microsoft irrevocably promises not to assert any Microsoft Necessary Claims against you 
for making, using, selling, offering for sale, importing or distributing any implementation to 
the extent it conforms to a Covered Specification (“Covered Implementation”), subject to the 
following. This is a personal promise directly from Microsoft to you, and you acknowledge 
as a condition of benefiting from it that no Microsoft rights are received from suppliers,
distributors, or otherwise in connection with this promise. If you file, maintain or voluntarily 
participate in a patent infringement lawsuit against a Microsoft implementation of such 
Covered Specification, then this personal promise does not apply with respect to any Covered 
Implementation of the same Covered Specification made or used by you. To clarify,“Microsoft
Necessary Claims” are those claims of Microsoft-owned or Microsoft-controlled patents that
are necessary to implement only the required portions of the Covered Specification that are 
described in detail and not merely referenced in such Specification. “Covered Specifications”
are listed below.
This promise is not an assurance either (i) that any of Microsoft’s issued patent claims covers 
a Covered Implementation or are enforceable or (ii) that a Covered Implementation would 
not infringe patents or other intellectual property rights of any third party. No other rights 
except those expressly stated in this promise shall be deemed granted, waived or received by 
implication, exhaustion, estoppel, or otherwise. 
“Covered Specifications” […] applies to the identified version of the following specifications.
New versions of previously covered specifications will be separately considered for addition 
to the list. 
[List of Specific Web services] 
Source: Microsoft Corporation.3 
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Box 2: Nonassertion Covenant from the Biomedical Area 
for Tuschl I siRNA Patent Applications 
In order to facilitate widespread distribution of an important class of research reagents,
the Massachusetts Institute of Technology, the Max Planck Gesellschaft zur Förderung der 
Wissenschaften e.V., The Whitehead Institute for Biomedical Research, and The University of 
Massachusetts (“the Patent Owners”) now announce that they will not assert the patents 
listed below against companies that sell or use DNA vectors which induce production of siRNA 
endogenously, provided that such vectors are only used for research purposes, and provided 
that the RNA that mediates RNA interference is not isolated from the transformed cells. The 
Patent Owners intend to enforce the patents listed below against any use not specifically 
listed above. 
The patents included in this announcement are listed below. Further continuations,divisionals,
issued patents, and reissuances are included as well. 
“RNA Sequence-Specific Mediators of RNA Interference”

by David P. Bartel, Phillip A. Sharp, Thomas Tuschl and Phillip D. Zamore
 
• Australia Serial No. 2001249622, Filed March 30, 2001 
• Brazil Serial No. P10107536-5, Filed March 30, 2001 
• Canada Serial No. 2404890, Filed March 30, 2001 
• European Patent Convention Serial No. 01922870.9, Filed March 30, 2001 
• Israel Serial No. 151928, Filed March 30, 2001 
• Japan Serial No. 2001-573036, Filed March 30, 2001 
• Korea Serial No. 200270123832, Filed March 30, 2001 
• New Zealand Serial No. 522045, Filed March 30, 2001 
• Patent Convention Treaty Serial No. US01/10188, Filed March 30, 2001 
“RNA Sequence Specific Mediators of RNA Interference”
• United States of America Serial No. 09/821,832, Filed March 30, 2001 
• United States of America Serial No. 10/255,568, Filed September 26, 2002
Source: M.I.T.4 
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of advantages over traditional open-standards 
committees or institutions: 
1. Through nonasserts, the standards devel­
opment is streamlined and the standards 
implementation proceeds faster since free 
licenses promote adoption. Importantly, 
nonasserts can be issued unilaterally with­
out the need for any complex negotiations 
with third parties (such as open-standards 
committees). 
2. Commitments not to enforce certain pat­
ent rights can be highly specific or broad, 
or both. Under the somewhat stringent 
U.S. antitrust laws, broad industry col­
laborations may not be permitted in an 
environment where multiple competitors 
meet in the same place.
3. Also related to antitrust concerns is the lim­
itation on specific price or terms whereby 
price fixing and market manipulation al­
legations may arise. Standard-setting ini­
tiatives among competitors always entail 
the potential for incurring significant legal 
risk. 
4. Nonasserts in the form of public statements 
carry no enforcement cost. In essence, they 
are self-executing. Once proclaimed, no legal 
staff time is required to negotiate licenses. 
Everyone gets the same deal and the deal is 
free. 
The result of the acceptance and use of non-
asserts in the software industry is that a growing 
“patent commons” has emerged supporting open-
source software. 
In agricultural biotechnology (agri-biotech) 
applications and health-related research, nonas­
serts are also emerging as an elegant solution to 
certain well-defined problems. These solutions 
include: 
•	 A tool for the management of liability. 
License agreements carry certain liabilities 
even if the agreements contain all the nec­
essary safeguards and warranties. This is 
especially the case with agri-biotech appli­
cations where little certainty exists, because 
discussions on global liability and redress 
regimes are ongoing.5 
•	 Access to research tools. Nonasserts can 
provide access to patented research tools, 
for example (as illustrated in box 2 below), 
by removing intellectual property barriers 
that would otherwise inhibit the research 
tool’s use by those who most need but can 
least afford it. Specifically, nonasserts can 
provide access to critical research tools for 
use in designated institutions that con­
duct R&D specifically to address needs 
in developing countries. But the use of 
nonasserts goes further: even drugs or 
vaccines could be manufactured in coun­
tries where such drugs or vaccines (or pro­
cesses) have been granted for the express 
purpose of producing them for develop­
ing countries. 
•	 Reduction of high-transaction costs as­
sociated with negotiating bilateral or 
multilateral licensing agreements. The 
negotiation of any license agreement is a 
time-consuming endeavor. In cases where 
the license is for humanitarian purposes in 
particular, the licensor generally gains no 
material benefits and often places the nego­
tiation of such agreements at the bottom of 
the priority list. Nonasserts, even bilateral 
ones, are relatively easy to negotiate as they 
primarily require agreement on two fairly 
simple aspects: 
− listing of the patents (or other forms of 
intellectual property protection) 
− specific permitted use, or limitations to 
the permitted use, or both 
To be clear, nonasserts are not a form of a 
patent pool. This distinction is important with 
regard to liability management associated with 
the commercialization of products, particularly 
in the drug, vaccine, and food biotechnology 
areas. A patent pool is an explicit granting of 
right to other parties. A nonassert, on the other 
hand, is a pledge not to sue someone who would 
otherwise infringe on a right. As such, a nonas­
sert can also be viewed as a preemptive infringe­
ment-settlement agreement, granting permission 
to practice the patent in spite of the actual legal 
infringement thereof. 
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Box 3 provides a sample nonassert that is 
based on an actual agreement signed by two U.S. 
institutions, a company and a university. In the 
case of humanitarian licensing, certain restric­
tions may be included such as the limiting of use 
to not-for-profit humanitarian purposes for the 
exclusive benefit of people in developing coun­
tries or even to for-profit entities solely for hu­
manitarian purposes in developing countries. 
. ConCLuSIonS 
From a legal perspective, nonasserts are preemptive 
patent-infringement settlement agreements that 
are designed and drafted with the purpose of re­
solving future infringement disputes. Nonasserts, 
therefore, in essence, release certain patent rights 
into specified sectors. These sectors are often the 
public domain when it comes to software and of­
ten bilateral agreements in applications related to 
health and food biotechnology. But there are no 
reasons really why nonasserts could not become a 
more widespread tool in fostering important ad­
vances and innovation to address needs in devel­
oping countries. 
Bilateral nonasserts should find much more 
common use as the problems with equitable es­
toppel are almost moot. Due to privity (in oth­
er words, the degree of relationship between or 
among the parties), the closer the relationship, 
the less likely will be the potential for misunder­
standings that could trigger equitable estoppel. 
Hence, an agreement between two parties, or an 
agreement among several parties, is a sufficiently 
close relationship to permit communications to 
resolve any misunderstandings or ambiguities, 
much as with a license agreement. 
But a patentee’s public declaration of non-
enforcement of a patent via a nonassert can have 
wide-ranging implications in terms of enhanc­
ing public sector R&D. This would be the case 
especially with patent rights covering research 
tools, and particularly in the United States due 
to limitations on research exemptions, which are 
critical for accelerating the development of es­
sential biotechnological applications in both the 
health and agri-business areas. Carefully drafted, 
targeted nonasserts permitting the use of these 
tools—anywhere in the world—for developing­
country–public-sector R&D institutions (and/or 
for commercial purposes for the exclusive use to 
address humanitarian needs could therefore have 
broad-ranging and significant positive impact. 
This approach reduces transaction costs, encour­
ages innovation to help the poor, and accom­
plishes this without much cost, time, or loss of 
commercial opportunities. n 
acKnowledgeMenTs 
Thanks go to Stanley Kowalski for having brought to my 
attention the important issue of equitable estoppel. 
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevelop­
ments-International Institute and Adjunct Professor, Cornell 
University. PO Box 26, Interlaken, NY, 14847, U.S.A. 
afk3@cornell.edu 
1	 They are also called nonassert agreements (when be-
tween two parties) or Covenant Not to Sue. 
2 “Equitable estoppel [is] an equitable defense to a claim 
of patent infringement available when a defendant
has prejudicially relied on the patentee’s misleading 
conduct concerning his intentions to enforce a patent.
The Federal Circuit [has] adopted a three-part test
for equitable estoppel, under which the defendant
[being sued in an action for patent infringement] 
must show: (1) The patentee, through misleading
conduct, led the alleged infringer to reasonably infer 
that the patentee did not intend to enforce its patent
against the alleged infringer. (2) The alleged infringer 
relied on that conduct, and (3) Due to its reliance, the 
alleged infringer would be materially prejudiced if the 
patentee is allowed to proceed with its claim. When an 
alleged infringer establishes the defense of equitable 
estoppel, the patentee’s claim is entirely barred [that
is, an alleged infringer may continue to practice the 
patented technology].” McCarthy JT, RE Schechter 
and DJ Franklyn, 2004. McCarthy’s Desk Encyclopedia 
of Intellectual Property: Third Edition; The Bureau of 
National Affairs, Inc.: Washington, DC. 
3	 www.microsoft.com/interop/osp/default.mspx; see 
also www.oasis-open.org/committees/security/ipr.php
for other samples. 
4	 http://www.web.mit.edu/tlo/www/industry/non 
assert_statements.html.
5	 See also in this Handbook, chapter 17.18 by RY Boadi. 
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KRATTIGER 
Box 3: Nonassertion Covenant in the Form of a Bilateral Agreement 
Date: 21 March 2007 
To: Institute 
From: Company
Subject: Nonassertion Letter under U.S. Patent No. X,XXX,XXX 
Thank you for your interest in using Patented Technology owned by Company in your endeavors 
aimed at improving the health and well-being of people in developing countries of the world.
Company is willing not to assert its rights under Company Patented Technology you requested,
as further described below. 
As background, Company’s understanding is that your work aims at the development of _______ 
_____ for use in __________. Company is willing to not assert Company U.S. Patent No. X,XXX,XXX 
nor any of the patents’ foreign counterparts, divisionals or continuations in part, or any other 
rights that Company may have now, or hereafter, related to the technology contained in the 
patents specified against Institute, or their trustees, directors, officers, employees, affiliates, their 
agents, licensees, or successors in interest.
This Nonassertion Letter is limited to the aforementioned Patent and provided that such patented 
technology is used solely for the production of ___________.
In consideration for Company’s Nonassertion Letter as described herein, Institute, their affiliates,
agents, licensees and successors of interest, agree to not assert any patent or patent application 
against Company, it affiliates, agents, licensees, or successors that would prevent Company, its 
affiliates, licensees, agents, licensees, or successors or customers of each, from practicing, for any 
purpose(s), under the claims in the Company patents specified above. Upon change of control of 
Institute or assignment by Institute to any party or entity, Institute shall concomitantly impose 
the obligation to implement this Nonassertion Letter to Company with respect to such acquirer 
or affiliate. 
COMPANY MAKES NO EXPRESS OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER,
INCLUDING (1) THE CONDITION OF THE INTELLECTUAL PROPERTY THAT IS THE SUBJECT
OF THE NONASSERT, (2) THE MERCHANTABILITY AND FITNESS OF ANY MATERIAL, RESULT,
OR PRODUCT FOR A PARTICULAR PURPOSE, (3) NONINFRINGEMENT OR MISUSE OF ANY 
INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY, OR (4) SAFETY OF EMPLOYEES,
WORKERS OR PURCHASERS OF PRODUCTS MADE USING THE COMPANY PATENTS.
Accordingly, Institute and their affiliates, agents, licensees, successors, and customers shall 
have sole discretion, responsibility and full liability for their activities, provided for under this 
Nonassertion Letter, including the research, design, manufacture, and potential sale of products 
pursuant to this Letter. Institute shall hold Company, and its affiliates, officers, employees, and 
consultants harmless from and against any and all claims, suits, obligations, causes of action,
liability, costs and damages, injuries to persons (including those that may result in death) or 
property (including, without limitation, loss of use), product liability claims, claims for damage 
to the environment or from the use, handling, or storage of materials and any other claim,
whatever the cause may be, based upon, arising out of, or related to the acts or omissions of an 
Institute and/or its affiliates and/or any of their employees, officers, employees, and consultants 
or other persons acting on behalf of the Institute or under Institute’s control, in connection with 
the Institute’s execution, delivery, performance of, or failure to perform, or practice of its rights 
granted under this Nonassertion Letter.
Please indicate your acceptance of the terms in this Nonassertion Letter by signing two copies 
and returning one fully executed copy of the original to me at your earliest convenience. 
Best regards and all the best in this endeavor,
Company Officer 
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ABSTRACT 
Intellectual property (IP) is inherent to many of the 
research, teaching, and extension functions of the uni­
versity, and IP issues can occur in all phases of the cor­
responding programs. A research program may utilize IP 
generated and protected by others in its planning and 
execution phases. As a research program advances, de­
cisions made regarding disclosure of results may affect 
whether or not discoveries made by the program can 
eventually be protected. 
A successful research program will generate discov­
eries—and therefore IP—and decisions must be made 
regarding whether to protect, and how to deploy, those 
discoveries. The decisions must consider the manage­
ment of IP as well as the goals and priorities of the re­
search program and the university. It is also important to 
consider IP in the teaching and extension functions of 
the university, including the creation or use of written 
materials, software, networked resources, or designs. 
IP and IP issues are not the sole or even the primary 
focus of a university. However, failure to properly consid­
er IP issues can lead to frustrating and costly problems. 
Fortunately, realistic and efficient management of IP in 
research, teaching, and extension requires only a mini­
mal working understanding of the issues and an ability 
to access on-campus assistance in dealing with them. 
This chapter presents basic information that any sci­
entist should know about IP, discusses the importance 
of IP management in a scientist’s work, and reviews ad­
ditional sources of information regarding IP. We hope, 
this chapter will assist the reader in avoiding simple yet 
costly errors in IP management. 
1. WHy you 	SHouLd 	LEARn 	ABouT	 Ip	
And TECHnoLoGy TRAnSfER 
1.1 Faculty and staff 
A working understanding of intellectual property 
(IP) is needed to realistically evaluate and man­
age IP issues and make informed decisions, from 
starting and running programs to deciding how 
best to handle the resulting inventions. Lack of 
basic information regarding IP and technology 
transfer issues can result in problems that are 
costly in terms of time, opportunity and money. 
You must take an active role in decisions regard­
ing IP management within your program. This 
will have an impact on the directions you provide 
to undergraduate and graduate students, post­
doctoral fellows, and/or technicians working in 
your program. 
Ignoring IP management issues will not make 
them go away. Failure to manage IP and make in­
formed decisions are de facto decisions that may 
result in outcomes that are undesirable and irre­
versible. Errors made by students and staff in your 
program can materially affect IP issues. Regardless 
of whether you knew of the errors when they oc­
curred, you may still be ultimately responsible. 
Acquisition of the basic information re­
garding the management of IP by faculty and 
staff need not be difficult or time consuming. 
You are not expected to become an expert in IP 
Mutschler M and GD Graff. 2007. Introduction to IP Issues In the University Setting: A Primer for Scientists. In Intellectual 
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. M Mutschler and GD Graff. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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MuTSCHlER & GRAFF 
management and technology transfer, just to be 
sufficiently aware of the issues so that you can 
use the resources available to avoid problems and 
maximize your opportunities. This chapter pro­
vides many links in the text to important online 
resources. Pertinent additional resources are listed 
in the endnote.1 
1.2	 Graduate students, postdoctoral 
fellows, and technicians 
Obtaining a basic understanding of IP is an im­
portant part of your training, whether your fu­
ture career lies in government, academia or in­
dustry. Basic IP training is important to how you 
will proceed in your research. Do not assume that 
your advisor or supervisor—or the technology 
transfer office (TTO)—can reverse the effects of 
IP errors you make. Your status as a student or 
postdoctoral fellow, and thus your status of be­
ing “in training,” does not alter the regulations 
regarding the use of IP protected by others or the 
requirements that must be met for any inventions 
you generate to be properly handled. In fact, ba­
sic IP training is important in the direction of 
staff you may be responsible for supervising in 
the course of your activities. 
1. 	 Difficulties caused by 
a lack of IP knowledge 
Depending on the nature of the error, misjudg­
ments in handling IP issues can result in dif­
ficulties protecting your discovery or licensing 
your invention. Even if these difficulties are sur­
mountable, they can be extremely frustrating, 
time consuming, and costly. Errors may even 
result in the complete loss of opportunity to 
protect your discovery, or in a severe narrowing 
of the scope of protection obtained. Reduction 
or loss of opportunity to market your discov­
ery/invention can result. In fact, you may even 
suffer a reduction or loss of opportunity to use 
your own discovery or incur liability due to an 
inadvertent infringement of IP protected by 
others. However, with proper IP protection and 
management, you can decide how to handle the 
intellectual property you create as you see fit 
and make sure that you receive the rewards that 
mean the most to you. 
1. 	 Applying basic information 
As university faculty, staff, and students, you are 
not expected to become experts in the manage­
ment of IP. However, acquisition of some basic in­
formation about management will allow you to: 
•	 make informed decisions day to day, to 
avoid errors that are time consuming and 
costly 
•	 know when to contact IP/TT personnel 
•	 interact efficiently and successfully with the 
university’s technology transfer staff 
•	 achieve your goals 
Furthermore, remember that there is most 
definitely a lack of sufficiently trained personnel in 
the field of university IP management and technol­
ogy transfer, and thus considerable employment 
opportunities exist if this area appeals to you. 
Further information. To find out more about 
employment opportunities, see the Association of 
University Technology Managers (AUTM) Web 
site: www.autm.net/directory/job_list.cfm. 
2. unIvERSITy 	InTELLECTuAL	 pRopERTy
And TECHnoLoGy TRAnSfER	 poLICIES 
A university will have a policy covering intellec­
tual property that will be available to all university 
personnel. All personnel are required to operate ac­
cording to this policy. The university home page is 
a central site for searching for university policy on 
many topics. Your university may also have a pol­
icy office, a technology transfer office or research 
foundation, and a office of university counsel. 
2.1	 Bayh-Dole and university policy 
The policy of any U.S. university must conform 
to the obligations imposed by the Bayh-Dole 
Act (Public Law 96-517). The Bayh-Dole Act is 
intended to promote investment by the private 
sector in commercialization of federally funded 
research discoveries for the public good. It in­
cludes preferences for small businesses and for 
manufacturing in the United States. Under Bayh-
Dole, a university is required to file patents on 
those inventions they elect to own and to encour­
age collaboration with industry to promote the 
utilization of inventions. 
 | HANDBOOK OF BEST PRACTICES 
         
     
     
      
        
      
      
       
      
       
      
        
         
 	 	 	
  	 	
 	 	
      
      
       
     
     
     
         
      
       
        
       
       
    
      
       
       
         
      
       
 
		 	 	
 	 	 	 	 	 	
	 	 	 	 	
      
      
      
       
      
        
        
      
      
       
     
       
 
CHAPTER .1 
Rights retained by the government under 
Bayh-Dole include a nonexclusive license to 
practice the patent and march-in rights. March-
in rights allow the government to “march in” and 
take over an invention if commercialization of 
an important invention is not being executed 
with due diligence by a university or licensee. 
The government has not, to date, invoked 
march-in rights, but it is possible that someday 
march-in rights could be applied. One situation 
that could warrant such action might be one in 
which a drug or vaccine is needed to control a 
pandemic. 
Further information. To find out more about 
the background of Bayh-Dole as well as its implica­
tions for university IP policies in the U.S., see the 
Web site of the Council on Government Relations 
(COGR), “The Bayh-Dole Act: A Guide to the 
Law and Implementing Regulations,” October 
1999. To find our more about similar legislation 
in developing countries see chapter 6.1.14 by 
Gregory D. Graff titled “Echoes of Bayh-Dole: 
A Survey of IP and Technology Transfer Policies 
in Emerging and Developing Countries” in this 
Handbook. 
2.2	 Ownership of intellectual property 
A central part of IP policy at any organization 
concerns the ownership of intellectual property. 
The approach differs somewhat between corpo­
rate and university contexts. 
2.2.1 Typical corporate policy 
In industry, employment contracts regarding 
the issue of IP ownership are binding. A com­
pany usually holds total ownership of ideas and 
inventions, while an employee’s salary is consid­
ered the compensation to an employee/inventor 
for his or her “inventing services” rendered to the 
firm. Noncompete clauses are often included in 
employment agreements and apply when an em­
ployee leaves the company. 
2.2.2 Typical university policy 
In the university, employment contracts or IP 
agreements are likewise binding with regard to 
the issue of IP ownership. University policy cov­
ers all personnel, including faculty, postdoctoral 
fellows, technical staff, graduate students, and 
visiting scholars. The employee contracts usu­
ally assign property rights in all IP to the uni­
versity, but the inventor(s) typically are given 
a significant share in any revenues that are 
earned, typically in the range of 25% to 50% 
of royalties. One major exception to the policy 
of assigning IP rights to the university involves 
copyrighted materials (with some exclusions). 
In addition, the IP agreement covers inventions 
and creations in the individual’s area of employ­
ment. Thus, if a molecular biologist invents a 
better lawn mower at home in his or her free 
time without use of university resources, that 
invention would not be included under the em­
ployment agreement. 
.  THE	 unIvERSITy TECHnoLoGy
TRAnSfER	 offICE 
.1	 A university’s IP, licensing, or technology 
transfer office executes its IP policy 
The university’s IP or technology transfer office 
is your most important source of information 
and assistance. The structure and functions of 
such an office may differ somewhat from insti­
tution to institution. Most often the technol­
ogy transfer office will be in or affiliated with 
the office of research, although in some cases it 
may be an independent foundation owned by 
or affiliated with the university. Most university 
IP or technology transfer offices will evaluate in­
ventions and pursue appropriate protection for 
them. Some offices will also market or license 
the inventions. 
The technology transfer office will indicate 
what materials you must provide so that the trans­
fer manager can service your needs. Reasonable 
expectations regarding this process will make it as 
efficient as possible and prevent misunderstand­
ings. The technology transfer personnel will not 
be experts in your area of endeavor. You must 
provide them with detailed information regarding 
the creation and characteristics of your invention. 
Expect that creating this documentation—and 
working with the IP/tech transfer personnel to 
create the documents supporting a utility patent 
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MuTSCHlER & GRAFF 
or other forms of IP protection—may require as 
much time and effort as creating a collaborative 
grant proposal or a major publication. 
Further information. For general informa­
tion about university technology transfer offices 
see the following: 
•	 G Graff, A Heiman and D Zilberman. 
2002. University Research and Offices 
of Technology Transfer, California 
Management Review, vol. 45, no. 1. are. 
berkeley.edu/~ggraff/Graff-Heiman ­
Zilberman-CMR-2002.pdf 
•	 EM Rogers, J Yin and J Hoffmann. 2000. 
Assessing the Effectiveness of Technology 
Transfer Offices at U.S. Research 
Universities, Journal of the AUTM. www. 
autm.net/pubs/journal/00/assessing.html 
.2	 The mission of the IP or 
technology transfer office 
The mission of a technology transfer office as the 
responsible agent, fiduciary, or trustee for the 
university’s intellectual property is to: 
•	 foster creativity and inventiveness at the 
university 
•	 support the university’s educational and re­
search missions 
•	 enhance and protect the IP interests of the 
university and its employees 
•	 manage IP for the benefit of the university’s 
research and educational enterprise and its 
inventors 
The roles of the office—in providing for the 
protection and commercial development of in­
ventions—are typically to: 
•	 determine what type of protection, if any, is 
possible and desirable for an invention 
•	 evaluate commercial potential of an 
invention 
•	 obtain the appropriate intellectual property 
protection 
•	 locate suitable commercial development 
partners or research and developmen col­
laborators and market the intellectual prop­
erty to them 
•	 negotiate and manage licenses over the in­
tellectual property 
.  Ip	And TECHnoLoGy TRAnSfER	
ISSuES	 THAT	MAy 	AffECT	 unIvERSITy 
SCIEnTISTS	 on 	A	 dAILy 	BASIS 
Important issues and agreements that may af­
fect university faculty or staff members include 
the documentation of work with appropriate re­
cordkeeping methods, the use of materials and 
methods originating elsewhere, dealing with col­
laborators outside the university, executing legally 
binding agreements, and publicly disclosing re­
search results. 
.1	 Documenting work: Notebooks, films, 
electronic information, and beyond 
Work must be efficiently and fully documented. 
Documentation can of course be important for 
the preparation of publications, reports, and 
grant proposals, and it can be essential for the 
preparation of documentation supporting an ap­
plication for IP protection and for supporting IP 
rights in the rare event that they are challenged. 
The types and quality of documentation are im­
portant, but there are ways this can be done ef­
ficiently, so that proper documentation is not an 
undue burden. 
Further information. For good examples 
of guidelines for keeping notebooks, see the 
following: 
•	 Cornell Center for Technology, Enterprise, 
and Commercialization, “Lab Notebook 
Guidelines.” www.cctec.cornell.edu/cctec/ 
researchers/protocols/guidelines/index.cfm
•	 Northwestern University, Technology 
Transfer Program, “Maintaining Laboratory 
Notebooks.” www.northwestern.edu/ttp/ 
investigators/lab_notebooks.html
•	 Florida State University, Office of IP 
Development and Commercialization, 
“Notebook Guidelines.” www.techtransfer. 
fsu.edu/notebookguidelines.html
.2	 Using materials or methods 
originating elsewhere 
The issue of using materials or methods originat­
ing elsewhere arises in a number of ways or under 
various circumstances including the use of copy­
righted material and the use of protected mate­
rials or processes. Using protected materials and 
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CHAPTER .1 
processes in research could end up affecting your 
freedom to operate (FTO). 
.2.1 Using copyrighted material 
There are standard rules governing the use of 
copyrighted materials in publications, teaching, 
and research. University libraries can provide in­
formation regarding the use of copyrighted ma­
terials for such purposes as class readings and re­
serve lists. A university’s information technology 
(IT) or computing policy may cover, specifically, 
the use of copyrighted material on course Web 
pages. Often the university counsel rather than 
the technology transfer office handles copyright 
issues on campus, including the acquisition of 
copyrights on materials owned by the university. 
.2.2 Using protected materials or processes 
Protected materials and processes vary widely, 
depending upon the field of endeavor. They can 
include such things as: 
•	 vectors used in genetically engineering 
organisms 
•	 enzymes, reagents, and other supplies used 
in a laboratory 
•	 computer programs 
The use of protected materials or processes 
leads to the question: Do you have full freedom 
to operate in your research program, or do unrec­
ognized, unresolved FTO issues exist? 
4.2.3 Freedom to operate 
Freedom to operate indicates that you are “free” to 
use all of the materials, methods, and other re­
sources needed for your programs and projects 
and that this use does not infringe on the prop­
erty rights of others. Just as your invention may 
be protected because you are using some form 
of intellectual property, the inventions of oth­
ers may also be protected. Use of such protected 
inventions of others, without permission, might 
constitute infringement of their rights. The legal 
and appropriate use of protected inventions may 
require a formal agreement or license with the 
inventors. 
Published does not mean unprotected! A 
publication by the scientist about a discovery or 
invention merely indicates that if there is protec­
tion, the application for that protection predates 
the publication. You must be aware of IP protec­
tion of any materials or processes you use in your 
programs and projects. 
A research exemption might apply to your use 
of the materials or methods in your work at the 
university, but this cannot be assumed in all cases. 
In U.S. patent law there is no formal research ex­
emption for university research. However, there 
are strong social norms in place such that pat­
ent owners have virtually never exercised their 
property rights against university researchers for 
conducting academic research. There are several 
practical limitations that prevent patent lawsuits 
from being filed against university researchers: 
•	 In most cases it is a benefit to patent hold­
ers to have academics testing, validating, 
and refining the technologies they already 
own. 
•	 It may be difficult to define what damages 
are suffered by the owner of a patent if the 
technology is used in an academic research 
project. 
•	 Because establishing a clear precedent 
against research use of patented technolo­
gies by universities could open the door 
for widespread litigation against universi­
ties—thereby slowing down the pace of 
academic research and draining public re­
sources—patent owners generally view the 
pursuit of such cases as detrimental to their 
own long-term interests, or, if more short­
sighted, simply conclude that it is highly 
unlikely that any judge or court would 
want to establish such a precedent by rul­
ing in their favor. 
Thus, there is something of a de facto research 
exemption for university research. 
FTO problems resulting from the use of oth­
ers’ proprietary materials and methods are more 
likely to show up further downstream, such as 
when you attempt to patent and commercialize 
the results you obtained. Your technology and any 
patents you might receive are likely to be domi­
nated by their patents. If your invention embod­
ies their technology (for example, if you create a 
HANDBOOK OF BEST PRACTICES | 1 
  
     
       
        
        
        
       
       
      
       
        
        
       








  	 	
 
 
MuTSCHlER & GRAFF 
plasmid that contains their promoter), then they 
may be able to stop you from commercializing 
your invention altogether. 
To prevent or at least to be cognizant of such 
risks, consider freedom to operate issues when 
you start using any new method or material, not 
after your project is completed. After all, a patent 
holder is not obligated to give you a license. If in 
doubt whether freedom to operate issues apply to 
your work, contact your technology transfer of­
fice representative. 
Examples of FTO issues are, in fact, com­
mon in the university setting. Be aware of ma­
terials or methods that can be used for research 
purposes only. Examples of this can be found in 
the fine print in molecular biology supply cata­
logs. Likewise, be aware of limitations in an 
agreement allowing use of protected materials or 
processes. The agreement may limit you to use 
for research purposes only, or it may restrict you 
to a certain range of use for commercial prod­
ucts, affecting your ability to protect and com­
mercialize any inventions that may result from 
your work. 
It is advisable to search the patent literature 
just as you would search for recent publications 
in your line of research. While this might seem 
tedious or redundant, in fact there can be impor­
tant fringe benefits. Someone may have already 
made the discovery or invention you are pursu­
ing. If a patent already exists, you can study it 
to determine whether your project can proceed 
as planned, should be modified, or if you should 
seek a license to the patented invention. In addi­
tion, patents can be an excellent source of infor­
mation. Since an application must fully disclose 
the invention, including the best method for its 
practice, a patent document may provide more 
detail on how to reproduce a result than a peer-
reviewed research publication. 
Further information. Your technology 
transfer office representative or university coun­
sel should be approached regarding concerns or 
questions on freedom to operate, as ultimately it 
is a legal question. Other chapters of relevance in 
the Handbook are: 
•	 Intellectual Property Freedom to Operate: 
The Law Firm’s Approach and Role, by 
GM Fenton, C Chi-Ham and S Boettiger.
www.ipHandbook.org
•	 Freedom to Operate: The Preparations, by 
SP Kowalski. www.ipHandbook.org 
•	 Freedom to Operate Strategies: Why the 
Public Sector Needs to Learn How to 
Manage Risk, by A Krattiger. www.ipH­
andbook.org 
. Dealing with outside collaborators 
It can be critical to discuss and document col­
laborative agreements in the development of a 
project. Consider which part of the work will be 
performed by each cooperator, how responsibility 
and credit will be shared, and who will be authors 
on publications. It is best if such questions are 
considered at the onset of a project and are re­
assessed as the program continues. Problems are 
most likely to occur if this is put off until a dis­
covery is made. 
..1 Material transfer agreements 
A material transfer agreement (MTA) is a legal 
agreement used when giving material to others 
that limits the rights they have to use the mate­
rial and lists their obligations with regard to use 
of the material. In short, it details the conditions 
of the agreement between the owner of protected 
IP and the party wishing to use it. An MTA is 
executed if you want to use material or methods 
protected by others or if others want to use mate­
rials or methods protected by you. An MTA must 
be crafted carefully since it will be legally bind­
ing. And it must be created and signed before the 
transfer of the material in question occurs, not 
after the fact. 
Consult with your technology transfer repre­
sentative regarding any MTA needed for obtain­
ing other’s materials or for the release of your ma­
terials. However, different offices of the university 
may manage MTAs for incoming materials (often 
sponsored programs or the research office) and for 
outgoing materials (often the technology transfer 
office). 
Further information. To learn more about 
material transfer agreements see the following: 
•	 Cornell Center for Technology, Enterprise, 
and Commercialization, “Material Transfer 
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•	 Northwestern University, Technology 
Transfer Program, “Material Transfer 
Agreements (MTAs).” www.northwestern. 
edu/ttp/investigators/material_transfer. 
html 
•	 Council on Government Relations 
(COGR), “Material Transfer in Academia.” 
www.cogr.edu/docs/MTA_Final.pdf 
..2	 Confidentiality and 
confidentiality agreements 
A confidentiality agreement is a legally binding 
agreement regarding the disclosure and use of 
confidential proprietary information. A confi­
dentiality agreement should be in place before 
either sharing proprietary information with an­
other party or seeking proprietary information 
from another party. 
Consideration of confidentiality agreements 
can be different in a university setting than in an 
industry setting. A faculty or staff member may 
be asked to sign a confidentiality agreement if 
he or she is consulting for a company outside of 
the university. In this situtation, the individual
signs, and is obligated by the agreement, not the 
university. Faculty and staff are not empowered 
to obligate the university under a confidentiality 
agreement and attempting to do so may make 
them personally liable. The offices that are autho­
rized to sign these agreements and create a legal 
obligation for the university are typically in the 
technology transfer office (signatory authority for 
licenses, agreements, contacts, and so forth deal­
ing with inventions) or an office such as spon­
sored programs or the office of research (signa­
tory authority for outgoing grant proposals and 
agreements accompanying incoming funds from 
the funded grants). 
For example, the representative of a company 
interested in possibly licensing intellectual prop­
erty handled by the technology transfer office 
would sign a confidentiality agreement before ob­
taining detailed information on the technology. 
Drafting and obtaining signatures on the confi­
dentiality agreement is handled by the technology 
transfer office for the inventor. This helps assure 
that the agreement is properly drafted, and that 
the correct individuals sign the agreement. 
. What constitutes public disclosure? 
A public disclosure is made when an inventor 
reveals previously undisclosed (that is, secret) 
information to members outside the circle of 
inventors and the personnel they directly super­
vise. There is interplay between the need for se­
crecy, in order to be able to protect an invention, 
and the need to reveal information to operate 
a program within a university where disclosure 
and transparency are the norm. The presence 
of various functions important to the univer­
sity—educating students, publishing, efforts to 
acquire grant funding, and others—which are 
generally not part of a corporate environment, 
might have ramifications regarding disclosure. 
Among the many different vehicles for disclosure 
are lectures, discussions, seminars, group meet­
ings, annual reports, grant proposals, and radio 
and TV interviews. 
Unintended public disclosure can have major 
ramifications for protection of intellectual prop­
erty. The more valuable the invention, the harder 
companies will search for any inadvertant disclo­
sure that will invalidate IP protection. 
Further information. A good discussion of 
disclosure by publications and by posting online 
can be found in these online publications: 
•	 GP Malilay, AM Mueting and AS Viksnins. 
1996. Prior Art: Silent Time Bombs that 
Can Blow Away Your Licensing Deals. 
Journal of the AUTM, pp 18–28. www. 
autm.net/pubs/journal/96/3-96.html 
•	 SJ Braman. 1996. Are Your Patent Rights 
Disappearing over the Internet? Journal 
of the AUTM, pp. 29–31. www.autm. 
net/pubs/journal/96/4-96.html 
.  So you (THInk you) 	HAvE	An 
InvEnTIon! GREAT! WHAT	 nExT? 
.1 Overview 
There are a few things that are important to un­
derstand about working with the technology 
transfer office. Foremost, it is essential for the 
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MuTSCHlER & GRAFF 
inventor to be actively involved in all of the phas­
es of the protection and marketing of the inven­
tion. There are two main reasons for this: first, the 
inventor has unique, detailed knowledge that is 
critical to the characterization and description of 
the invention and the drafting of the patent and 
its claims; and second, inventors often have useful 
leads, such as company contacts, that will assist 
in the marketing of the invention. Collecting the 
information and documentation needed to draft 
a disclosure and a patent application takes time 
and effort on the part of the inventor, something 
on the order of the time and effort required to 
write a major publication or grant proposal. If 
you expect to seek patent protection for your in­
vention, you need to make the commitment and 
create time for it. This will make the process run 
far smoother. 
It is helpful to remember that the breadth 
of research covered at a university is often far 
greater in scope than that at even the largest of 
companies. At the same time, university technol­
ogy transfer offices have less staffing than analo­
gous offices in industry. As a result, a technology 
transfer officer at a university may be dealing with 
more inventors and a broader scope of inventions 
than his or her counterparts in industry. Input 
from the inventor will directly assist the technol­
ogy transfer staff in bringing projects to successful 
completion. 
Cooperative, responsive inventors often have 
the best experiences, since they enable the tech­
nology transfer staff to provide prompt and com­
plete service. 
The steps in the technology transfer process 
follow a typical pattern: 
•	 disclosure: starting the process of protect­
ing/marketing an invention 
•	 evaluation: deciding whether the invention 
should be protected and, if so, how 
•	 protecting: proceeding with an application 
(also called prosecution) 
•	 marketing: finding a licensee 
•	 licensing: making a deal 
.2 Invention disclosure 
The inventor’s role in disclosure is to provide in­
formation, including: 
•	 a description of the invention 
•	 details about the funding of the research 
that led to the discovery 
•	 an explanation of why the invention may 
be important or valuable in industry 
•	 reasons why companies might be interested 
in the invention 
•	 the identity of the inventor (or inventors) 
•	 a description of how the invention was 
made 
Remember, a clear, detailed disclosure allows 
the technology transfer staff to serve you better 
and faster. 
The technology transfer officer’s role in dis­
closure is to help the inventor fully describe the 
invention by considering the material provided 
and asking questions to elicit further informa­
tion or details. In the process of discussing the 
disclosure and deciding upon a protection and 
licensing strategy, the technology transfer officer 
will conduct an intellectual property audit. This 
will reveal whether there is any preexisting IP that 
may affect the process. 
Further information. Details regarding the 
disclosure process, including forms, can often be 
found on a university’s technology transfer office 
Web site. Some examples include: 
•	 Cornell University, Center for Technology, 
Enterprise, and Commercialization, 
“Invention Disclosure Process.” www.cctec. 
cornell.edu/cctec/researchers/disclosures/ 
index.cfm 
•	 University of California, Office of 




The purpose of evaluation by the TTO is to de­
termine what the technology does and what its 
commercial potential may be. For example: 
•	 Is it a research tool, software, compound, 
new method, diagnostic, or therapeutic? 
•	 Does it fill an unmet need, or fill a need 
better than current methods? 
•	 What is the size of the potential market or 
markets? 
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•	 Would it have competition from other 
technologies in those markets? 
•	 What companies are in those markets? 
•	 Who is investing in those markets? Why 
would investors be interested in the 
technology? 
Answering these questions will enable the 
TTO to estimate the commercial value of the 
technology. 
. Deciding whether and how to protect 
After disclosure and evaluation of an invention, 
decisions must be made as to whether to protect 
the invention and, if so, how. These decisions are 
made jointly by the inventor(s) and the technol­
ogy transfer office, based upon all of the technical 
and legal information available and based upon 
economic considerations. 
Some disciplines routinely employ a par­
ticular form of protection for the technology 
generated in that discipline. Examples include 
copyrights on writings; patents on vaccines, 
medicines, chemicals, engineered processes and 
materials; design patents on figures, graphics, or 
artwork; and plant patents or plant variety certifi­
cates (PVCs) on new varieties of plants. 
In some areas, protection has long been possi­
ble but not routinely employed by universities. For 
example, plant patents have been available since 
1930; however, prior to 1982 the apple breeding 
programs at the Geneva Agricultural Experiment 
Station in New York developed and released apple 
varieties without protecting them. These unpro­
tected cultivars include a number of widely grown 
varieties, such as Empire (1968), Jonagold (1972), 
and Liberty (1978). However, cultivars released 
after 1982 were protected using plant patents and 
are generating returns to the inventors and their 
research units. These protected cultivars include 
Freedom (1983), Empress (1988), Royal Empire 
(1990) and Fortune (1995). 
In some areas, the possibility of protecting 
IP is a more recent development. For example, 
before changes were made in the interpretation 
of U.S. patent law beginning in the 1980s, it was 
not possible to protect inventions involving mod­
ified life forms with utility patents. 
It is important to realize that the laws, inter­
pretations of laws, and strategies used in protect­
ing intellectual property develop and change over 
time. It is the responsibility of the technology 
transfer office to keep abreast of these develop­
ments and to advise and assist university inven­
tors as needed. 
. Marketing and licensing 
An invention will not generate financial returns 
for a program unless it is successfully marketed 
and licensed. Depending on the nature of an in­
vention, the personnel of the technology transfer 
office may or may not have a comprehensive list 
of potential licensees for the technology. The in­
ventors may play a critical role in providing such 
information. 
Depending on the invention, and the com­
panies interested in the invention, the license 
granted may be exclusive (made to only one com­
pany, with that company holding all rights to sub-
license) or nonexclusive (made to more than one 
company). In some cases, a license to a company 
transfers rights to the invention for just a limited 
subset of its potential uses, rather than for any 
and all possible uses. The decision as to the na­
ture of the license granted (that is, the uses it will 
cover) is made by the technology transfer office in 
consultation with the inventor, and is thoroughly 
negotiated with the licensee. 
There are other options as well. In some cas­
es, the university, through the technology transfer 
office, encourages use of the invention in the de­
velopment of a new start-up venture. 
Patents require periodic servicing, such as pe­
riodic payment of fees to the U.S. Patent Office 
(PTO), which is managed by the technology 
transfer office. The technology transfer office also 
manages the license: receiving and distributing 
payments, billing the licensee, and monitoring 
whether the terms of the license are being re­
spected by the licensee. 
If an invention is valuable, it is not unusual 
to find companies infringing the property rights 
over it by using the invention without a license. 
If this is determined to be occurring, the tech­
nology transfer office will take the lead in rectify­
ing the matter, seeking assistance as needed from 
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the inventor. This involves a series of steps, from 
contacting the infringing company and request­
ing that it either cease infringement or obtain a 
proper license, to filing a law suit. The more valu­
able the invention, the more likely it is that some 
company will test the resolve of the university to 
assert its IP rights. Such situations occur regu­
larly, but they are manageable, given the proper 
expertise on the part of the technology transfer 
office and other legal counsel representing the 
university. 
Marketing and licensing is obviously a large 
and complicated endeavor. The best information 
regarding this process can be obtained from rep­
resentatives in the technology transfer office. 
. TypES	 of 	InTELLECTuAL 
pRopERTy pRoTECTIon 
.1	 Overview 
Types of IP protection tend to be specific to par­
ticular kinds of creations or technologies, but 
they are not always mutually exclusive. There are 
instances when an invention may be protected by 
more than one type of IP. 
The types of protection vary in many features 
including: 
•	 requirements to acquire the protection 
•	 cost 
•	 type of technology covered 
•	 type of protection afforded 
•	 length of time provided 
A full study on any one type of IP protection 
would be a book in itself. What follows is a brief 
introduction to each of the types of IP protec­
tion that might be of possible use to a university 
researcher. 
.2	 Patents: utility patents, design patents, and 
plant patents 
A utility patent is what most people think of when 
they hear the word patent. A utility patent is a 
grant of a property right by the U.S. government 
to the inventor for a term of 20 years. 
The applicant is required in the patent ap­
plication to fully disclose the invention, and, 
in so doing, to fully describe the best means of 
practicing the invention so that an expert in the 
relevant field of technology (one skilled in the art,
in patent terminology) can actually make and use 
the invention relying only upon the information 
presented in the application. 
Subjects of patents can be any of the 
following: 
•	 mechanical devices: a machine or device 
•	 processes: methods of doing or creating 
something, for example, a diagnostic or 
therapeutic method 
•	 articles of manufacture: the paper clip is the 
classic example 
•	 compositions of matter: a new formulation 
of plastic, a new alloy, a new medicinal 
compound 
•	 improvements in any of the above 
Certain characteristics are required for an in­
vention to be patentable. The invention must, of 
course, be of proper subject matter. It also must 
be novel. The invention must be something that 
would not be obvious to an expert in the field. 
And the invention must have some useful appli­
cation industrially or commercially (that is, the 
invention is not trivial). 
There are two types of patent applications: a 
regular application and a provisional application.
(A provisional application merely starts the ball 
rolling and gives the inventor one year to file a 
regular application.) 
Once granted, a U.S. patent gives the owner 
of the patent the right to exclude others from 
making, using, offering for sale, or selling the 
invention in the United States or importing it 
to the United States for the term of the patent. 
It is important to remember that patents are 
country specific. For instance, a patent granted 
by Canada gives the owner of that Canadian pat­
ent similar rights within Canada. It is up to the 
inventor and their technology transfer office to 
decide in which countries to apply for foreign 
patents (which foreign filings to make). In those 
countries where rights are not sought or granted 
over a technology, it is, in effect, left to the public 
domain (unless some other means of protection 
is utilized.) 
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The inventor or inventors must be listed on 
the patent application. The question of inventor­
ship—Who is the inventor?—is sometimes a point 
of contention, so consider this carefully. The 
rules used under U.S. patent law to determine 
who is an inventor for purposes of patent protec­
tion are very different from the means generally 
used to determine who should be an author on 
a publication. Inventorship depends specifically 
on the claims of patent. A person who gives piv­
otal advice, even just once, in the course of a re­
search project could be an inventor. A technician 
doing much of the work under supervision, but 
not making decisions, would probably not be an 
inventor. However, if the technician made unex­
pected observations or suggestions critical to the 
development of the invention, he or she might 
well be an inventor. Advice from the university 
IP/technology transfer office may be useful in 
cases in which inventorship is unclear. 
Further information. To learn more 
about inventorship, see SH Lieberstein. 1998. 
Relevant Concepts in Determining Difficult 
Disputes Over Ownership. Journal of the AUTM.
www.autm.net/pubs/journal/98/lieberstein.html. 
.2.1 Utility patents 
A utility patent is costly in terms of time and ef­
fort. The time and effort you spend on filing and 
prosecuting a utility patent could be equivalent to 
the time and effort you would spend on produc­
ing a major publication or a large collaborative 
grant proposal. 
A utility patent is also costly in terms of mon­
ey. The cost of a U.S. patent application typically 
ranges from about US$15,000 to US$30,000, al­
though it can cost more. Costs of foreign patent 
applications depend on the country but typically 
are within a similar range in Germany, England, 
France, Australia, and Japan. After a patent is is­
sued, there are patent maintenance costs to cover. 
At times, there are additional costs for defending 
the application or the patent. The more valuable a 
property is, the more likely it is to be challenged, 
either as an interference (issuance of a conflicting 
patent claiming some of the same technology) or 
as an infringement (actions of a company using 
the technology without permission). 
At most universities, patent costs are ini­
tially borne by the office of technology transfer, 
but they are the first thing to be reimbursed once 
revenues begin to come in when an invention 
is licensed. It is crucial to consider whether a 
license on the invention is even likely to return 
more than the costs of applying for, maintaining, 
and defending the patent; otherwise, perhaps a 
less costly form of protection should be used. A 
good rule of thumb is that if the technology is not 
worth defending, one should not be applying for 
a patent. Consultation with a technology transfer 
representative can help to determine if a utility 
patent is the appropriate means of protecting the 
invention. 
Further information. For useful information, 
in increasing order of detail and complexity, on 
the requirements and protection afforded by util­
ity patents, see the following: 
•	 L von Bargen Mueller. 1995 (with revi­
sions by JT Sorensen, 2002). An Inventor’s 
Guide to Patents and Patenting, AUTM 
Educational Series No. 1 
•	 American Bar Association, “Inventor’s 
Committee: Short Description of the 
Patent Process.” www.abanet.org/intel­
prop/comm106/106patent.html 
•	 U.S. Patent and Trademark Office, 
“Frequently Asked Questions about 
Patents.” www.uspto.gov/web/offices/pac/ 
doc/general/faq.htm 
•	 U.S. Patent and Trademark Office, “A Guide 
to Filing a Utility Patent Application.” 
www.uspto.gov/web/offices/pac/utility/ 
utility.htm
•	 American Bar Association, “Comprehensive 
Information on Patents.” www.abanet.org/ 
intelprop/comm106/106general.html 
.2.2 Design patents 
A design is a visual ornamental feature, such as 
a logo, embodied in, or applied to, some article 
of manufacture (for example, a mug, sweatshirt, 
or poster), the shape of a bottle or the shape of 
headlights of a car. Design patents protect new, 
original, and ornamental designs for an article 
of manufacture. The design patent protects the 
appearance of design on the item, and not the 
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structural or utilitarian features of the item—that 
is, the design of the logo, not the cloth of the 
sweatshirt or the ceramic of the mug. The term of 
protection in the United States is 14 years from 
the date the grant is awarded. 
A design patent application must include: 
•	 a preamble stating the name of the appli­
cant, the title of the design, and a brief de­
scription of the nature and intended use of 
the design 
•	 drawings or photographs of the design 
claimed (Since this is the critical part of the 
design patent, the PTO site listed below 
has considerable detail about this portion 
of the application.) 
•	 a written description of the elements 
of the design, shown in the drawing or 
photograph 
•	 a written description of the features of the 
design 
•	 the single claim for the design 
•	 an executed oath or declaration by the 
applicant 
Further information. To learn more about 
design patents, see the Web site of the United 
States Patent and Trademark Office, “Frequently 
Asked Questions (FAQ) about Design Patents.” 
www.uspto.gov/web/offices/pac/design/desfaq. 
html. 
.2. Plant patents 
A plant patent protects a distinctive new variety 
of an asexually reproduced plant. Asexual repro­
duction is the creation of identical genetic copies 
of a plant without using genetically reproducing 
seeds. Asexual reproduction includes the use of: 
•	 root cuttings 







...and methods such as:
 
•	 grafting and budding 
•	 division 
•	 layering 
•	 tissue culture 
•	 nuclear embryos 
Most plants covered by plant patents are 
horticultural crops, such as apples, raspberries, 
and almonds, or ornamentals, such as rhododen­
drons, roses, and tulips. For historical reasons, 
tuber crops, such as potatoes and Jerusalem arti­
chokes, were specifically excluded from consider­
ation. For the purpose of plant patents, algae and 
macro fungi are allowed; bacteria are not. 
A plant patent application must meet the 
same requirements of utility patents. The plant 
to be protected must have been developed or dis­
covered by the applicant. It must fulfill the re­
quirements for novelty and nonobviousness. The 
plant cannot have been sold or released in the 
U.S. more than one year prior to the date of the 
application. 
A plant patent must include a complete de­
scription of the botanical features of the plant 
and the characteristics that distinguish that plant 
from known, related plants. A drawing or photo­
graph of the plant showing its most distinguish­
ing characteristics and text describing what is be­
ing shown in the drawing or photograph help to 
document the plant’s novelty. 
Once granted, the plant that is protected 
includes mutants, hybrids, and genetically trans­
formed plants. The grant lasts for 20 years from 
the date the application is filed. During this pe­
riod, the plant patent protects the inventor’s right 
to exclude others from asexually reproducing, 
selling, or using the plant so reproduced. As with 
utility patents, when the plant patent expires, the 
subject matter of the patent (that is, the plant va­
riety) enters the public domain. 
Further information. To learn more about 
plant patents, see the Web site of the United 
States Patent and Trademark Office, “General 
Information about Plant Patents.” www.uspto. 
gov/web/offices/pac/plant/. 
. Plant variety protection 
Plant variety protection (PVP) is a means for 
protecting sexually reproduced plant varieties. 
Plant variety protection is a form of IP admin­
istered and granted by the U.S. Department 
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of Agriculture (USDA), rather than the U.S. 
Patent Office. This is basically the U.S. version 
of plant breeders rights, as agreed upon interna­
tionally under the convention known as UPOV 
(International Union for the Protection of New 
Varieties of Plants). A PVP grants 20 years of pro­
tection (for new varieties of plants) from date of 
issue (and 25 years for trees and vines). A PVP 
cannot be granted for uncultivated plants or ma­
terials found in nature. 
PVP regulations require that the plant culti­
var to be protected must be: 
•	 novel or new: cannot have been sold in the 
United States for more than one year 
•	 distinct: is clearly different from other com­
mon varieties of the crop 
•	 uniform: has no more variability than other 
varieties of the crop 
•	 stable: remains unchanged when repro­
duced, particularly with regard to the dis­
tinctive characteristics of the variety 
In the application for the PVP, the applicant 
provides the genealogy of the variety and describes 
the variety and its novelty. A public deposit of 
seed of the variety is also required. 
Protection provided by the PVP applies to 
the single variety claimed. The PVP prevents oth­
ers from selling, sexually or asexually reproduc­
ing, or distributing without a license from the 
holder of the PVP. Since the mid-1990s, a PVP 
also prevents others from producing a hybrid va­
riety using the claimed variety as a parent. 
Exclusions to the protection include use of 
the cultivar in breeding, by farmers saving seed 
for their own use, and for the sale of limited 
amounts of seed. 
Further information. To learn more about 
plant variety protection, see the Web site of the 
USDA Plant Variety Protection Office. www. 
ams.usda.gov/science/PVPO/pvpindex.htm. 
. Copyright 
Copyright provides legal protection of an original 
work set down in a fixed form or medium of ex­
pression. The term of protection for works owned 
by corporate entities is the lesser of 95 years from 
publication date or 120 years from the creation 
of the copyrighted work. The term of protection 
for works owned by individuals is the life of the 
author plus 70 years. 
Items that can be copyright protected 
include: 
•	 literary works 
•	 musical works, including accompanying 
words 
•	 dramatic works, including any accompany­
ing music 
•	 pantomimes and choreographic works 
•	 pictorial, graphic, and sculptural works 
•	 motion pictures and other audiovisual 
works 
•	 sound recordings 
•	 architectural works 
Examples of things that cannot be copyright 
protected include: 
•	 ideas or concepts 
•	 lists showing no originality 
•	 titles, names, short phrases, and slogans 
•	 type styles 
•	 factual information 
•	 public domain information 
•	 works not fixed in tangible form 
A copyright gives to the holder the right to 
reproduce one or more copies of the protected 
work. Notwithstanding copyright protection, 
other parties, such as archivists, educators, and 
members of the media may reproduce protected 
works for certain types of use known as fair use. 
The copyright also gives certain limited rights to 
distribute or disseminate copies, prepare deriva­
tive works (including translations), and perform 
or display publicly (with exceptions for instruc­
tional use, broadcasting, and religious services). 
Excluded from the fair use are digital movies, dig­
ital games, and similar products since the entry 
into force of The Digital Millennium Copyright 
Act in late 1998. 
At most universities copyright issues are 
handled by the university counsel, rather than 
the technology transfer office, with possible ex­
ceptions for some technologies, such as software, 
involving both copyright and utility patents for 
protection. 
HANDBOOK OF BEST PRACTICES | 
  










     
     
      
      
      
     
     
      
     
	
       
       
     
        
     
     
      
       
       
         
          
       
 
MuTSCHlER & GRAFF 
Further information. To learn more about 
obtaining copyrights or using copyrighted mate­
rial, see the following Web sites: 
•	 Cornell University, “The Copyright 
Information Center.” www.copyright.cor­
nell.edu
•	 Stanford University Libraries, “Copyright 
and Fair Use.” fairuse.stanford.edu 
•	 Indiana University and Purdue University 
Indianapolis, “Copyright Management 
Center.” www.copyright.iupui.edu
•	 Library of Congress, United States 
Copyright Office. www.copyright.gov 
. Trademark 
A trademark is essentially a brand name, which is 
used to identify or distinguish in the marketplace 
one company’s goods from another’s. A trademark 
includes any word, name, symbol, or device, or 
any combination of these. Many of the products 
we buy sport trademarks, from Sunkist oranges 
and Coke, to Levi Strauss jeans, Dell computers, 
and Intel microprocessors. 
There are other types of “marks” as well. The 
service mark is similar to the trademark, but the 
service mark identifies a service or the source of a 
service, rather than goods or the source of goods 
(for example, a cleaning service, rather than mops 
and brooms). A certification mark identifies a “re­
gional or other geographic origin, material, mode 
of manufacture, quality, accuracy, or other charac­
teristics of goods and services.” A collective mark
is a type of trademark or service mark used by 
the members of a collective group and indicates 
membership in the organization. 
Trademarks, and the other types of marks, are 
handled by the U.S. Patent Office. Application 
involves filing a form, along with a drawing of 
the mark to be protected and specimens of the 
mark. (The specimen will be a prototype of the 
design, such as a label or tag, which incorporates 
the mark.) Before one files an application, it is 
advisable to run a search to check that the mark 
is not already registered. With proper mainte­
nance (use, renewal, and so on) a trademark can 
be perpetual. 
At most universities, the university counsel 
handles trademark and service mark applications. 
Properties that many universities protect by copy­
right, design patent, and perhaps trademark, are 
the university’s name, logo, and other symbols, 
such as a mascot. Some universities—particular­
ly those with well-known sports programs—earn 
considerable funds through the licensing of their 
protected names and logos for merchandise. 
A department wanting to use the university 
logo, for example, on a T-shirt being designed 
for an upcoming symposium, must first obtain 
permission from the office that is responsible for 
trademarks and such. 
Further information. To learn more about 
trademarks, see the Web site of the U.S. Patent and 
Trademark Office, “Basic Facts about Trademarks.” 
www.uspto.gov/web/offices/tac/doc/basic/. 
. Trade Secrets 
A trade secret is secret or confidential informa­
tion that gives the company that possesses the 
information an advantage over companies that 
do not possess it. Trade secrets can protect any 
information that provides a competitive ad­
vantage. Examples include a process, method, 
composition, or recipe. The recipe for Coca-
Cola syrup, and many other food and beverage 
products are protected as trade secrets. A trade 
secret has a far longer term of protection than a 
patent. A trade secret is in force as long as the 
secret information is kept secret and not made 
publicly available. 
A trade secret protects information, quite 
simply, by keeping it secret. Trade secrecy laws 
make it illegal for someone to obtain the secret 
by misappropriation (for example, breaking into 
the vault in which the secret is kept). Of course, 
a product must be able to be used or marketed 
without revealing the secret to be protected as a 
trade secret (for example, the product must not 
be able to be reverse engineered). If someone in­
nocently, independently discovers the same in­
formation, they can use it without infringement. 
Indeed, the second discoverer could in fact apply 
for a utility patent, in some instances. 
By university policy, no secret research is 
conducted at the university, but an invention that 
results from research could, in some instances, 
be protected by trade secret at least temporarily, 
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pending an application for another form of
IP protection. 
. Bailment Law 
Some inventions can be marketed without the 
formal protection of a patent or other form of IP 
protection though the use of bailment law. Under 
this approach, control over use and dissemination 
of the invention is obtained by careful use of ma­
terial transfer agreements and licenses. Where ap­
plicable, this method reduces paperwork and the 
costs of preparation and application for patents 
or other forms of protection. The method would 
require careful coordination with the technology 
transfer representative. 
Further information. To learn more about 
bailment law, see PM Simpson, Jr. 1998. Use 
of Bailment in Transferring Technology from a 
University. Journal of the AUTM. www.autm.net/ 
pubs/journal/98/simpson.html. 
.  SuMMARy 
Managing the IP issues that arise in the course 
of university research and teaching functions 
is important. Though sometimes the issues are 
complex, the management of these issues can be 
handled efficiently, reducing time commitment. 
The goal of this chapter is to provide basic infor­
mation to enable university scientists/inventors 
to manage intellectual property and technol­
ogy transfer issues. The university scientist need 
not be an IP expert. The ability to protect some 
forms of IP is fairly recent, having undergone or 
even still undergoing rapid changes in interpre­
tation and strategy. Being knowledgeable and 
capable in these areas is the task of those uni­
versity personnel in the technology transfer of­
fice and the outside legal experts who work with 
the university on IP and technology transfer. 
Researchers/inventors should consider how they 
want to handle IP issues during day-to-day work 
and know whom they should contact when they 
have new IP or technology transfer issues. They 
should not hesitate to use these resources when­
ever needed. n 
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CHAPTER 8.2 
How to Start–and Keep–a Laboratory Notebook:

Policy and Practical Guidelines
 
JENNIFER A. THOMSON, Professor, Department of Molecular and Cell Biology, University of Cape Town, South Africa 
ABSTRACT 
A laboratory notebook is an important tool that goes well 
beyond research management and can have important 
implications for issues ranging from intellectual property 
management to the prevention of fraud. This chapter dis­
cusses the key elements of a laboratory notebook, types 
of notebooks, what should be included in the notebook, 
ownership issues, archiving, and security. The chapter 
provides sample notebook pages that illustrate some of 
the recommended practices. 
1. WHAT IS A lABORATORy NOTEBOOK? 
Although you may think you will remember what 
you did and why you did a certain experiment in 
a week’s time, YOU WILL NOT! And nor will 
anyone else in your laboratory. Hence the need 
for laboratory notebooks. In short, a laboratory 
notebooks is: 
•	 a daily record of every experiment you do, 
think of doing, or plan to do 
•	 a daily record of your thoughts about each 
experiment and the results thereof 
•	 the basis of every paper and thesis you 
write 
•	 the record used by patent offices and, in the 
case of disputes, courts of law (in the event 
you file patents on your findings) 
•	 a record that would enable successive scien­
tists, working on the same project, to pick up 
where you left off or reproduce your results 
2. TyPES OF lABORATORy NOTEBOOKS 
The following items explain a few important 
things to know about lab notebooks and how 
they may be used: 
•	 Hardbound books with numbered pages 
show that no pages have been deleted or 
added. 
•	 In companies or institutions aimed 
mainly at producing patentable prod­
ucts, carbon copies of each page are of­
ten required. In addition, each page may 
have to be signed and dated both by the 
scientist and by an independent witness 
within two weeks of work being done. 
This scientist should be someone who is 
likely to be traceable in some years time, 
if needed, to confirm reading and coun­
ter signing. The witness should not be 
likely to be named as a co-inventor in a 
patent application. The counter-signato­
ry should sign and date each page of the 
notebook to confirm that she or he has 
read and understood the entry and is sat­
isfied that the entry has been accurately 
and correctly written. 
•	 It is advisable to keep different note­
books for different projects or different 
aspects of the same project. Notebooks 
should be clearly identified on the out­
side cover. 
Thomson JA. 2007. How to Start—and Keep—a Laboratory Notebook: Policy and Practical Guidelines. In Intellectual Prop-
erty Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. JA Thomson. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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3. WHAT GOES INTO A
lABORATORy NOTEBOOK? 
On the front cover of the notebook should be a 
description of what is contained in it (for exam­
ple, cloning of the X gene and characterization 
of its product). The first and last dates of entry 
should also be written on the front cover. 
The following items explain a few important 
things that need to be recorded inside the lab 
notebook. Remember, everything must be writ­
ten in ink or other permanent medium. 
•	 a detailed account of every planned and ex­
ecuted experiment with the amount of de­
tail that would enable a scientist “skilled in 
the art” to determine what had been done, 
why it had been done, and what the results 
were 
•	 dates accompanying every entry, account, 
or record 
•	 protocols, reagents, lot numbers in each 
entry, and where appropriate, sketches, de­
scriptions, and so on 
•	 explanations of the significance of each 
experiment, as well as the observations, re­
sults and conclusions of the experiment 
•	 details of each experiment (Remember, 
what may seem trivial or obvious at the 
time your experiment was conducted, may 
later be of critical importance.) 
•	 personal comments (It is a living docu­
ment, so stamp it with your own person­
ality. Comments such as “SUCCESS AT 
LAST!! THIRD TIME LUCKY :)” are 
highly appropriate. However, do not make 
sweeping statements, such as, “This proce­
dure is worthless” or “We infringe X’s patent 
with this procedure.” Statements like this 
could affect the future patentability of your 
research. 
•	 photographs, computer generated data, 
and so forth should all be stuck into your 
notebook in such a way that they will not 
come loose (see Figure 1). If the format of 
these data is too large for your laboratory 
notebook, sign and date such data and file 
them in a loose-leaf ring file that can clearly 
be identified. Record the location of these 
documents in your notebook. 
•	 cross-references (If you have already de­
scribed an experiment earlier, or if you have 
used a standard protocol and have not devi­
ated from the previous descriptions of the 
experiment for your current one, you may 
reference the earlier information instead of 
writing it out again. For example, if you are 
starting a new experiment on page 48 and 
are using the same protocol as already de­
scribed on page 22, write on page 48, “fol­
lowing the protocol as described on page 22 of 
this laboratory notebook.”) 
•	 using preprinted forms can save time, if 
your experiments involve common, stan­
dard procedures (see Figure 2) 
•	 information with regard to any data that 
has been electronically captured (These data 
should be accessible to any scientist “skilled 
in the art.” Such electronic data should be 
backed-up and archived weekly.) 
Corrections must be made by drawing a sin­
gle line through the entry (see Figure 3). If you 
leave more than four lines at the bottom of a page, 
cross through the area to indicate that those lines 
were unused (see Figure 4). Never use Whiteout. 
Remember, laboratory notebooks and their 
contents are confidential and of great value. 
Store them in safe places and report any loss or 
theft to your supervisor immediately. When you 
leave your laboratory for any length of time, in­
form your supervisor of the whereabouts of your 
laboratory notebooks. When you leave the insti­
tution permanently, ensure that your notebooks 
are handed over to your supervisor. 
4. WHO OWNS THE NOTEBOOK? 
The person or organization who is paying the bills 
owns your laboratory notebook. In most cases 
this will be the company, university, or research 
institute who employs you or your supervisor. 
In the case of universities, you will probably 
find that employees enter into a contract that 
stipulates that all inventions developed while 
employed are the property of the university. 
Universities, and some companies, have agree­
ments that income generated from discoveries 
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CHAPTER .2 
made by employees and/or students, will be divid­
ed between the institution and the discoverers. 
5.	 HOW DO yOu KEEP COPIES OF
lABORATORy NOTEBOOKS? 
Some laboratory notebooks come equipped with 
carbon copies. These types are the best and safest. 
If your notebook is not of this type, you should 
make photocopies of the complete notebook. But 
why do you need copies? 
•	 Once you have completed a laboratory 
notebook, your supervisor will probably 
want to keep the original. You will there­
fore need copies to help you in completing 
your research. You will often need to check 
back on what you did a few months ago. 
•	 You might leave your institution before 
you have time to write up your research for 
publication or patenting. You will need a 
copy of your notebook to enable you to do 
this. Your supervisor will also need a copy 
to ensure correctness of data and interpre­
tation. (The latter is just one reason why 
it is so important for you to comment on 
your data in your lab notebook, making 
suggestions, interpretations, and so forth.) 
•	 Another scientist might have to take up 
where you left off. Although your supervi­
sor will have your lab notebook, your suc­
cessor will also need to have a copy to help 
her or him continue your work. It will be 
essential that your results can be repeated. 
6. HOW DO yOu ARCHIVE yOuR
lABORATORy NOTEBOOK? 
Archiving means keeping your notebooks in a 
system that allows easy access. Your supervisor or 
institute will probably have an archival system in 
operation for this purpose. Here are some recom­
mendations for archiving: 
•	 The best option is a lockable bookcase, or 
cupboard, or a locking file cabinet. 
•	 Label your notebook along the spine with 
your name, the project, and the start and 
end dates for the notebook. 
•	 Make sure your supervisor knows where 
your notebooks are stored! 
7.	 HOW DO yOu PROTECT yOuR
lAB NOTEBOOK? 
It is essential to protect the security of your re­
cords. Here are some important practices to 
follow: 
•	 When you leave the lab each day always 
leave your lab notebook where your su­
pervisor can find it, preferably in the same 
place. It is not necessary to lock it away 
every night, although it is a good habit to 
form. 
•	 Lock your lab when you are the last person 
to leave. If you are not sure whether anyone 
else will return to the lab, play safe and lock 
it. People will soon learn to keep their keys 
with them! 
•	 If your supervisor allows you to keep past 
notebooks, make sure she or he knows 
where they are. 
8. CONCluSIONS 
A laboratory notebook is an important tool that 
goes well beyond research management, and 
keeping good records has implications for issues 
ranging from intellectual property management 
to the prevention of fraud. Institutions should 
have a comprehensive policy that should be rig­
orously implemented (see Box 1 for guidelines for 
a notebook policy). n 
JENNIFER A. THOMSON, Professor, Department of Molecular 
and Cell Biology, University of Cape Town, Private Bag, 
Rondebosch 7701, South Africa. jennifer.thomson@uct.ac.za 
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THOMSON 
Box 1: laboratory Notebook Policy 
The following policy is a document originally prepared by SWIFFT at Cornell University in
the context of its collaboration with the centers of the Consultative Group on International
Agricultural Research (CGIAR). The policy itself is based on actual policies that are in effect in
several leading research centers and companies, but has been adapted to reflect the specific
needs of public sector research institutions. 
Background
Many public organizations are entering a new era and are considering protecting their own
inventions and engaging in research with other organizations, both public and private. These
new relationships, often based on collaborative research agreements, may require precise
documentation of certain activities and results. Laboratory and research practices will frequently
need to be carefully formalized and noted in ways that will allow future IP auditors to review
the authenticity of results and certify the dates of occurrences. Such practices are important for
potentially patenting possible discoveries made by these institutions or by their collaborators,
especially when seeking patent protection in the United States. 
Recording procedures are generally spelled out with respect to standard laboratory notebook
practices. These procedures inform all staff about the process for daily establishing and
maintaining of laboratory records that could become primary evidence for the resolution of
disputes or litigation. In court, dates of invention, description of an invention, and research
techniques can be established through carefully kept laboratory notebooks. 
In order to achieve the goal of maintaining court-ready documentation, a bound laboratory
notebook, in whatever format, must be: 
•	 an honest representation of the research work done by the researcher 
•	 regularly written (daily recording is normally recommended) 
•	 routinely witnessed (at least weekly) by another scientist 
•	 duplicated when completed, if the researcher would like a working copy 
•	 archived in a secure place and/or by a secure method. 
The policies and procedures outlined below can be modified to suit almost any organization’s
needs and existing IP policies and to harmonize the lab notebook policy with other institutional
tools. It is essential, however, that any laboratory notebook policy be consistent with other
laboratory procedures, that all research staff be well trained in the execution of the policy, and
that the adopted policies be systematically enforced. 
laboratory Notebook Policy
The purpose of this policy is to ensure that the institution is sufficiently protecting its inventions,
research, and products, so that discussions or allegations during disputes or litigation are based
on documented fact. This includes such things as the date of an invention or a description of
the invention or research, the dates or research techniques that were used, and the like. In order
to do this, the laboratory notebook, in whatever format, must be an honest representation of
the research work done by the institution, and must be acceptable to a court, the U.S. Patent
and Trademark Office, and other offices whose charge is regulating statutory protection of IP.
Therefore, certain standards apply to each type of notebook. 
Guidelines 
1. General 
All ideas and data must be entered into the laboratory notebook. Entries must be complete
enough that another scientist would have little or no trouble understanding and repeating the
experiments. 
(Continued on Next Page) 
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Box 1 (continued) 
Each page must be signed, and dated each day, by the scientist running and recording the
experiment, and signed and dated by a witness, if not immediately, then at least within one week
of the scientist’s signature.
In deciding the exact procedures to follow, it is important to keep in mind that any type of
laboratory notebook must achieve two goals: 
1. Reflect its own integrity 
2. Corroborate information independent of the person doing the research 
Thus, the condition of the laboratory notebook must reflect that it is a clear and accurate
representation of activities that have taken place in the lab and that none of the information
has been falsified: any changes made to the recorded information should be clear and obvious
and the new information should be able to be compared with the old; and the notebook should
be completely in tact, with no pages missing or illegible. A witness who has not been involved in
the experiment, by signing and dating the notebook, must attest (by virtue of signing) that the
information, experimentation, and/or ideas that occurred were recorded on the date indicated. 
2. Types of laboratory notebooks 
A. Hardbound notebook 
•	 Laboratory notebooks are checked out from the designated librarian in the department or
office specified and returned to the designated technician immediately upon being filled,
to be microfilmed. 
•	 When signing out a new laboratory
notebook, the researcher will notice 
that the laboratory notebook is 
numbered, is permanently bound,
has index pages (Figure 5) and that
all pages are prenumbered. 
•	 The researcher should enter a new 
experiment in the index each time a
new experiment is started. 
•	 Use each page in order. Leave no 
blank pages between experiments. 
•	 Record enough information so that a
scientist “skilled in the art” could pick up your laboratory notebook and easily determine
what had been done, why it had been done, and what the results were. Entries should
include procedures, reagents, lot numbers, where appropriate, sketches, descriptions, and
so on. The purpose and significance of the experiment as well as observations, results, and
conclusions should be made clear. Remember, what may seem trivial or obvious at the time
experiments are conducted, may later be of critical importance. 
•	 If procedures have already been described in an earlier experiment or have used a
standard protocol, and the researcher has not deviated from the previous descriptions of
the experiment for the current one, the researcher may reference the earlier information
instead of writing it out again.For example, if the researcher was starting a new experiment
on page 42, and was using the same protocol as already described on page 25, he or she 
(Continued on Next Page) 
Figure 5: An Index at the Back Makes 
your Notebook More useable 
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Box 1 (continued) 
could write on page 42, “Following the protocol as described on page 25 of this laboratory
notebook.” 
•	 All data should be entered, in ink, directly into the laboratory notebook. 
•	 Corrections should be made by drawing a single line through the entry. Erasers or whiteout
should never be used. The researcher should initial each lineout, and if possible, add next
to each lineout a note of explanation, such as, “wrong data.” The researcher should never 
tear pages out of the laboratory notebook. Pages may be copied for the researcher’s own
use, but never removed. 
•  At the end of each day the researcher should put a line or a cross through any unused
space on that day’s page(s) in the laboratory notebook. If a blank line is left between
paragraphs, there is no need to lineout the one line, but if a number of lines have been
left at the bottom of the page, they should be marked through. This could prove it was
impossible to enter additional information in the laboratory notebook, in those empty
spaces, at a later date. 
•	 If additional information, such as a machine-generated table or graph, an original photo, or
autorad, is part of the experiment and is small enough to be attached in the notebook, the
information should be attached using a permanent adhesive or nonremovable tape. The
researcher should sign his or her name over the border of the attachment, crossing over
onto the laboratory notebook page. Signing in this way would clearly show, if at any time
in the future the attachment had been removed. 
•	 If the additional data is too large for the laboratory notebook (for example, a computer
printout that is a few pages long), such additional data can be signed and dated;
countersigned and dated by the witness; and given an appropriate ID number. The
researcher should note on such additional data which laboratory notebook and which page
number the additional data is referenced. Then, in the laboratory notebook the researcher
should reference the additional data’s ID number and note the secure-storage location
where the additional data is being held. Preferably, a drawer with a set of files that are
always used to store oversized information should be used. A summary of the data can be
placed in the laboratory notebook.The same sort of procedure should be followedwith any
samples that are to be kept. 
•	 Each original page of the laboratory notebook must be signed and dated by the researcher
and by a witness. A witness should be someone who has read each entry, who is competent
to understand what he or she has read, but who is not a co-inventor. Each research group
should designate a person who is responsible for assigning permanent witnessing partners.
However, if the assigned witness is not available when needed, another person who fulfills
the appropriate criteria may be used. 
•	 If any changes are made after pages are signed or witnessed, the changes must be initialed
and dated by both the researcher and a witness. Care should be taken to use the current
date when signing or witnessing a laboratory notebook. 
•	 Ideas should be recorded in the laboratory notebook, as these may be important in
determining a date of invention. 
•	 It is important to return completed laboratory notebooks to the designated person as soon
as possible to ensure a duplicate copy of the laboratory notebook is captured on microfilm 
(Continued on Next Page) 
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CHAPTER .2 
Box 1 (continued) 
or other permanent media. This process will be expedited so that the notebook can be
returned quickly to the researcher. A laboratory notebook can be retrieved at any time
during the microfilming process, if needed. Upon completion of the microfilm process, the
laboratory notebook will be returned to the researcher,for use as reference in the laboratory,
or put into permanent storage at the researcher’s request. One microfilmed copy will be
kept in the library for access at any time. One other copy of the microfilm copy will be put
into secured storage in the designated location. 
B.  Hardbound notebooks containing electronically captured data 
•	 At laboratories where a large amount of data are generated and stored in the computer, a
written laboratory notebook, with all of the guidelines referred to above, is still required. In
this setting, however, much of the data referred to in the laboratory notebooks may exist
in electronic files. The laboratory notebooks should contain a summary of the information
in those files and also give the name of the file (and format) in which the data are stored. 
•	 The electronic data should be backed up and archived weekly. A new and separate file
should be provided as a place to store data. Details of these files and the back-up procedure
should be described to all researchers and managers in a memo. These backed-up files
should never be opened except for litigation or U.S. Patent Office matters. 
C. Hardbound notebooks generated by computers 
•	 The same guidelines apply to hardbound notebooks generated by computers as for
hand-written laboratory notebooks. The difference is that rather than purchasing a
laboratory notebook and writing in it, research activity is documented electronically. The
documentation is printed out on a regular basis and then bound to form a laboratory
notebook. The printed material should be clearly labeled with the information that will
appear on the front of the bound book and sent to the appropriate person or department
for binding. Once bound, the laboratory notebook will be assigned a number, recorded, and
returned to the researcher or archived, upon request. 
•	 Each experiment is to be described and each page should be numbered and signed,
countersigned, and dated. Each week these experiments are to be saved in the special data
file as described in a memo. Also, as with hardbound notebooks, data such as small graphs,
photos of gels, and so on, which can be attached to the laboratory notebook page should
be attached using the same methods as described above. 
•	 Eventhoughitmaybeaconvenientwayofrecordingexperiments,electronicdocumentation
is not the recommended way, for a variety of reasons. If a number of experiments from
different days are printed on one page, for example, and the page is only signed and dated
after the last entry, it may be difficult or impossible to pinpoint dates of specific activity,
especially an exact date of invention. 
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w. MaRK cRowell, Associate Vice Chancellor for Economic Development and Technology Transfer, 
University of North Carolina at Chapel Hill, U.S.A. 
ABSTRACT 
Documentation of research is a critical aspect of best 
practices in IP management. This is true because research 
and development activities that give rise to inventions 
must be thoroughly documented in order to successfully 
manage patents, including determining patentability, 
drafting and prosecuting patent applications, and later, 
if the need arises, protecting patents against third party 
challenges, for example, a patent interference proceed­
ing. Maintaining, for each invention, a complete record 
of who made the invention, when it was made, and how 
it was made, must therefore become a formal component 
of a university’s policy and training programs and must be 
carried our according to specific protocols. An organized 
and methodical approach to documentation will support 
patent management, provide a readily accessible source 
of critical information, ensure the capture of maximum 
value of inventions, and protect patent portfolios against 
challenges when, and if, the need arises. 
1. InTRoduCTIon 
Documentation of inventions is an extremely 
important issue, and yet this relatively straight­
forward activity is one of the most forgotten, 
overlooked or, simply, carelessly neglected aspects 
of invention management. A lack of attention to 
this activity can result in the loss of patent rights 
that the applicant would otherwise possess. The 
facilitate understanding among researchers of the 
importance of keeping good records. In addi­
tion, the technology transfer office must establish 
fail-safe systems for documenting and diligently 
pursuing the invention disclosures that the office 
receives. 
Why is record keeping so important? In a 
research environment, good research records are 
essential for a number of reasons—including for 
assisting the institution in meeting its progress- 
reporting requirements to research sponsors, for 
documenting expenditures, and for promoting 
research integrity. However, for the technology 
transfer manager, U.S. patent laws provide an 
altogether different reason for promoting good 
practices in invention documentation. 
Among the first lessons that U.S. technol­
ogy managers learn is that the patent laws dictate 
that a patent is awarded to the first party to in­
vent. In the United States, unlike virtually every 
other country, priority of invention is established 
by the first-to-invent rule. However, the major­
ity of nations follow a priority rule by which the 
party who is first to file is entitled to a patent. 
What this means, then, is that a contest can en­
sue between parties who dispute priority of an in-
technology transfer office has a responsibility to vention, that is, who was actually first to invent. 
Crowell WM. 2007. Documentation of Inventions. In Intellectual Property Management in Health and Agricultural Innova-
tion: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A.
Available online at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Second Edition, Part VI: Chapter 2).
© 2007.WM Crowell. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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Such a contest is adjudicated by the U.S. Patent 
and Trademark Office (PTO), Board of Patent 
Appeals and Interferences, in an administrative 
proceeding called a patent interference. The patent 
interference proceeding determines who was the 
first to invent, has priority, and thus is entitled to 
the patent. 
So, when two competing patent applications 
claim the same subject matter, the PTO declares 
an interference, that is, the patent applications 
“interfere” with each other. Each inventor then 
seeks to prove priority of invention, and reliable 
evidence is sought that can document which party 
was, in fact, the first to invent. Under U.S. patent 
law, the inventive process, by definition, begins 
with conception of an invention and proceeds 
to reduction to practice (either actual construc­
tion of the invention or filing of a patent applica­
tion with the PTO). To comply with patent law, 
the first party to conceive a patentable invention 
must carry out certain activities to proceed with 
reasonable diligence toward the development and 
patenting of an invention. In other words, it is 
possible that the first to conceive an invention 
can fail to prevail in an interference proceeding if 
he or she did not diligently work toward reduc­
tion to practice of the invention or did, in fact, 
diligently work toward reduction to practice but 
cannot produce any documentation as evidence to 
prove having done so. Therefore, an inability to 
prove who is the first to conceive, or a lack of 
evidence to refute a charge that an inventor was 
not diligent in pursuing an invention, can lead 
to the loss of valuable patent rights to which the 
inventor and institution may otherwise have been 
entitled. 
Therefore, within the notoriously complex 
context of an interference proceeding, careful 
documentation of inventions and the inventive 
process, from conception to reduction to practice, 
will be extremely important in order to prevail if 
such legal challenges arise. In addition to inter­
ference proceedings, patents are, not infrequently, 
challenged on such grounds as incorrect naming 
of inventors or newly raised references that chal­
lengers argue should have been submitted to the 
PTO as proof of prior art at the time of the patent 
application. In such situations, research records 
can be invaluable for documenting who contrib­
uted to the invention and the critical dates and 
facts of conception and reduction to practice of 
the invention; these dates would refute the claim 
that raised references identified relevant prior art 
if the records documented conception and reduc­
tion to practice (invention) as having occurred 
before the raised references. This example under­
scores the importance of maintaining clear, me­
ticulous chronological records. Nothing will sub­
stitute for comprehensive records if, and when, 
complex legal challenges to a patent or patent ap­
plication arise. Always assume that there could be 
trouble, and assemble records accordingly so as to 
protect valuable investments in research, develop­
ment, and commercialization. 
2.  THE	pRACTICAL	IMpoRTAnCE	 of
RECoRd kEEpInG 
In reality, there are occasions on which an inven­
tion disclosure form (IDF) itself, or possibly a 
grant application, will be the first viable record 
that a researcher has adequately, and diligently, 
proceeded through the inventive process, from 
conception of the invention through to reduction 
to practice. In such cases, the technology trans­
fer office must ensure that such records are safely 
stored, properly witnessed, and readily available 
when the need arises. A lot depends on such care 
being taken, and an investment in managing 
and maintaining records will pay off in the long 
term. 
U.S. patent practice places immense impor­
tance on witnessed records when two or more 
parties claim the same invention. For example, an 
applicant involved in an interference proceeding 
must be able to prove the date of conception (the 
date when the inventor formulated in his mind a 
definite and complete idea of the invention) and 
the date of reduction to practice (the date when 
the conceived invention was actually built, with 
every element of the conceived invention) even if 
it is not yet commercially perfected. It is critical to 
make clear to staff that the IDF used by the tech­
nology transfer office must avoid using language 
that refers to date of first conception or date of first
reduction to practice. Should legal adjudications 
 | HANDBOOK OF BEST PRACTICES 
         
      
         
       
      
          
        
       
    
        
       
     
      
     
   
       
    
      
        
       
       
       
        
       
       
      
        
      
        
         
 
     
      
      
      
      
     
     
        




arise, such a statement could be construed to be 
an admission that no earlier conception or reduc­
tion to practice occurred (when in fact it has), sig­
nificantly damaging the institution’s position in a 
priority contest. Instead, the IDF should simply 
ask that the location of records documenting con­
ception and reduction to practice be identified. 
In addition to documenting the dates of 
conception and reduction to practice, the PTO 
interference proceeding may turn on the dili­
gence shown by the contending inventors. In 
this situation, the inventors’ witnessed records 
must demonstrate that the invention’s develop­
ment, including the act of filing a U.S. patent 
application, was pursued in a reasonably diligent 
manner, pursuant to the statutory requirements 
of U.S. patent law. In an interference proceed­
ing, the party that can prove that it was the first 
to conceive will likely be awarded the patent. If 
one party proves it was the first to conceive of an 
idea, but a second party conceived of the idea and 
pursued reduction to practice in a more diligent 
manner, the second party may prevail in the in­
terference proceeding. 
In the private sector, most industrial research 
is carried out under guidelines that impose strict­
ly enforced record-keeping practices as a matter 
of routine practice. Often, these records are made 
on a daily basis, dated, witnessed, and stored. If 
researchers working under such conditions are the 
inventors named on a patent application involved 
in an interference proceeding, proving the date of 
conception and reduction to practice should be 
without ambiguities and informational gaps and, 
hence, relatively simple and straightforward. 
On the other hand, research record keeping 
in universities can be lax to the point of slop­
piness, and, in such cases, much more challeng­
ing to organize and manage. Laboratory research 
tends to be conducted at any and all hours of the 
day, and researchers often find it difficult to find 
the resources, witnesses, or other means by which 
documentation can be facilitated. Furthermore, 
the culture of some universities is such that prac­
tices of this type historically have been viewed 
as inappropriate or unnecessary. Researchers may 
neither understand, appreciate, nor wish to be 
inconvenienced by attending to detailed and 
chronologically consistent documentation, and 
thus simply perceive such a requirement as an­
other annoying administrative burden. Indeed, 
in some laboratories, directors of research might 
push staff to maximize time at the bench and 
minimize time at the desk; record keeping will 
inevitably suffer as a result of such prioritization 
of time. And in some cases, graduate students 
who come and go, and who work on research 
projects, believe, or perhaps are told, that labora­
tory notebooks belong solely to the students. If 
important facts about the conception or reduc­
tion to practice of an invention are included in 
such notebooks, the documentation may not be 
available (that is, it has “walked away” with the 
student) at some future date when a patent is be­
ing challenged. 
Despite any difficulty that universities may 
face with strict record-keeping protocols, the im­
portance of this activity cannot be overlooked. 
Most research universities now have active pat­
enting and licensing programs, and sound re­
search documentation and record keeping is 
an essential component of successful programs. 
This cannot be ignored or left to chance; there 
is just too much at stake, and the stakes only get 
higher. 
. GuIdELInES	 foR	RECoRd kEEpInG 
Good laboratory record-keeping practices should 
not be driven merely by IP (intellectual property) 
concerns. Good laboratory records have long been 
viewed as “good science,” and good laboratory 
records can be extremely helpful if a lab should 
ever face charges (however specious) of scientific 
misconduct. Essentially, the same record-keeping 
practices that are considered good science and ap­
propriate for responding to scientific misconduct 
charges are also good practices for purposes of 
managing, securing and protecting IP rights.1 
The following guidelines for record keep­
ing are contained in the North Carolina State 
University manual of patent and copyright pro­
cedures and are highly recommended: 
1. A good practice is to use bound notebooks 
for records. Entries should be made on 
a daily basis. The use of a “diary format” 
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provides a day-to-day chronology. (This 
can be extremely important in document­
ing diligence or other important issues.) 
2. Use the notebook to record a conception (a 
complete description of a means to accom­
plish a particular purpose or result, ideally 
including all elements of a conceptualized 
invention), laboratory data, drawings, or 
other observations. Each entry should be 
dated, headed with a title, and continued 
on successive pages. 
3. Entries in the notebook should be made in 
ink. Under no circumstances should entries 
be erased or “whited out”; a line should be 
drawn through text or drawings that are 
being deleted, and the corrected material 
should be entered. Any blank spaces on 
pages should be drawn through. 
4. Any material that cannot be incorporated 
into the notebook should be glued in and 
referred to in a notebook entry. 
5. All entries in the notebook should be signed, 
dated, and witnessed (by at least two peo­
ple) at the time they are made. Witnesses 
should have read the entered material and 
be capable of understanding it but be im­
partial observers of the work and have no 
direct stake in the outcome. The witnesses 
could be, for example, colleagues from an­
other laboratory in the same department. 
An extremely important or unusual discov­
ery or observation (a potentially patentable 
invention) may warrant having more than 
two witnesses. Multiple inventors may not 
serve as witnesses for each other. If impor­
tant records lack the requisite witness sig­
natures, the records should be signed as 
soon as possible after the records are cre­
ated. Even a witness signature made days 
or weeks after the record was created is evi­
dence that the document existed prior to 
the date on which signature was made. 
6. Laboratory heads should set aside a time for 
all in their laboratory staff to stop working 
at the bench (or, in agricultural research, 
the greenhouse or field) and record entries 
into their notebooks. This time should be 
carefully and consistently observed. Be sure 
to invite individuals who can witness the 
entries immediately after they are made. 
7. In the event that notes are kept on a com­
puter, be sure to make the appropriate en­
tries into the computer system at the end of 
each day. Each daily entry should be print­
ed out, signed, and witnessed, following the 
same procedure as that recommended for 
written notebook entries. The final printed, 
signed, and witnessed document should be 
glued into a notebook. 
8. Identify a safe method for storing and mon­
itoring the records. Research data related to 
pending or issued patents should not be 
destroyed. Therefore, a retrievable archive 
system needs to be organized, implemented 
and maintained. Such an investment will 
pay for itself many times over in the event 
of a patent dispute. 
. ConCLuSIonS 
In general, best practices in documenting labora­
tory research serves two purposes: scientific and 
legal (IP management and patenting). These pur­
poses are not mutually exclusive, and indeed there 
is considerable overlap, as the means to the two 
objectives are entirely consistent. Best practices in 
documentation will provide the researcher with 
a clear record for assembling publications, grant 
proposals and, in the event of fraud or miscon­
duct allegations, a clear record for establishing the 
facts. Similarly, a best practices approach to docu­
menting research will greatly facilitate managing 
issues related to IP management and patenting. 
This could include, but is not limited to, patent 
application drafting and prosecution, patent chal­
lenges by third parties, and evidence production 
for patent interference proceedings. Each of these 
will require documentation of research and devel­
opment activities. Documentation policy must, 
therefore, be carefully and thoughtfully institu­
tionalized, as part of every university’s required 
protocols. Such procedures and requirements 
should be an integral part of overall IP manage­
ment and training that the technology transfer 
office provides to the university administration, 
staff, and scientists. A lot of value might be at 
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stake. The investment in building capacity and 
appropriate IP management systems will pay off 
in the long term. n 
w. MaRK cRowell, Associate Vice Chancellor for Economic 
Development and Technology Transfer, University of 
North Carolina at Chapel Hill, Box 4000, 312 South 
Building, Chapel Hill, NC, 27599-4000, U.S.A.
Mark_Crowell@unc.edu
See, also in this Handbook, chapter 8.2 by JA Thomp-
son. 
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CHAPTER 8.4 
Invention Disclosures and the Role of Inventors
 
dAVId R. MCgEE, Executive Director, Technology & Industry Alliances, University of California, Davis, U.S.A. 
ABSTRACT 
This chapter is intended to assist intellectual property pro­
fessionals, in working with inventors, to develop a high-
quality invention disclosure and, eventually, to prosecute 
a patent application. Major topics include the importance 
of data records, utility and reduction to practice of inven­
tions, understanding prior art (including the inventors’ 
own art), and determination of inventorship. 
1. INTRODuCTION 
Invention disclosure is more than the simple 
completion of an institutional or corporate 
form to satisfy some policy requirement. It 
includes a complete description of something 
novel and nonobvious given in such a manner 
that anyone of ordinary skill in the particular 
art could reproduce the invention. The disclo­
sure represents the first official recording of the 
invention and, if done properly, can establish 
an irrefutable date and scope of the invention. 
Often the disclosure document has been used 
to defeat challenges to dates of invention, in­
ventorship, invention scope, and prior art. 
Conversely, improperly written invention dis­
closures many times have resulted in disastrous 
losses of patent rights. 
This chapter explains the nuts and bolts of 
invention disclosures (as well as some of the nu­
ances), beginning with the responsibility of sci­
entists to disclose inventions even before they are 
made and ending with the use of disclosures to 
create defensible patents. 
2. CONCEPTION OF AN INVENTION 
The term invention is occasionally confused with 
the term idea. According to the U.S. Code of 
Federal Regulations, (37 C.F.R. §501.3(d)), an 
invention is defined as “any art, machine, manu­
facture, design or composition of matter, or any new 
and useful improvement thereof, or any variety of 
plant, which is or may be patentable under the pat­
ent laws.” An idea, by definition, is limited to a 
thought, existing only in the mind; an idea may 
or may not be patentable as a concept. Only in­
ventions can be patented, not ideas. 
In the legal sense, the conception of an in­
vention occurs when someone has mentally de­
veloped an idea that is novel, nonobvious, and 
exists in enough enabling detail that someone 
of ordinary skill in the relevant area of science 
could practice the invention. Conception does 
not necessarily require actual reduction to prac­
tice of the invention, but it does require that the 
invention be thought through completely. The 
degree to which the conceptualization is incom­
plete should not be such that it is renders the 
invention inoperable. 
Commonly, a complete conception occurs 
over a lengthy period of time and may involve 
McGee DR. 2007. Invention Disclosures and the Role of Inventors. In Intellectual Property Management in Health and Ag-
ricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. DR McGee. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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MCGEE 
other contributors. The date on which such con­
ception is deemed to be complete, that is, it satis­
fies all aspects required of an invention (novelty, 
nonobviousness, and enablement), is considered 
to be the date of invention. The date of inven­
tion may be, but is not required to be, either the 
actual date of reduction to practice of the inven­
tion or the filing date of the patent application 
(constructive reduction to practice). 
3. INVENTORSHIP 
Those individuals who contribute to an enabling 
concept are known as the inventors. Inventorship 
is, therefore, restricted to the intellectual concept. 
It does not extend to those persons who may re­
duce the invention to practice but did not con­
tribute to the invention’s conception. 
Inventorship relies on specific claims ul­
timately approved by the patent office for the 
granted or issued patent. Since patent prosecu­
tion most commonly involves changes to the 
claims filed with the application, the inventors 
may change. 
One of the most frequently misunderstood 
and contentious issues between scientists and the 
intellectual property (IP) professional is the con­
fusion between inventorship and authorship. As 
described above, inventorship is a legal determi­
nation based on the contribution to the enabling 
concept embodied in at least one allowed claim. 
An individual who has spent extensive time and 
effort in the laboratory reducing an invention to 
practice is not an inventor in any sense unless he 
or she has also contributed to at least one claim. 
Teams of scientists conduct most research. 
As such, research team members are constantly 
discussing technical aspects of the research; over 
a period of time, an idea may emerge that has 
been jointly developed. From the idea, an inven­
tion may be described. Frequently, conflicts arise 
when an author is not included as an inventor on 
a patent application and believes that the work 
performed in actual reduction to practice should 
mean that he or she be designated as an inventor. 
Unintentionally including a noninventor or ex­
cluding an inventor can usually be corrected in the 
patent office. However, intentionally including a 
person as an inventor who did not contribute to a 
claim is patent fraud and would render the patent 
invalid if discovered. Intentionally excluding an in­
ventor could likewise render a patent invalid. 
It is the responsibility of potential inven­
tors to make a good faith effort to determine 
who among themselves are actual inventors. 
Ultimately, inventorship must be examined by 
the patent attorney of record to ensure that the 
inventors included on the patent filed are, in 
fact, inventors. 
4. PREPARING THE INVENTION
DISClOSuRE 
.1 Education of inventors before they disclose 
The IP professional should never assume that the 
scientists in his or her organization are aware of 
when, how, to whom, and why to properly make 
an invention disclosure. As with many other busi­
ness practices, acceptance of the patenting process 
begins at the top of the organization. If top man­
agement does not endorse patenting, then no one 
else will either. An effective education program, 
concerning the policies, practices, and practical 
understanding of the patent process, is a must for 
staff of the organization. The program must be 
continuous, since new staff will not be aware of 
the process, and existing staff will need to review 
the process on a frequent basis. The best time to 
educate new employees is during their orientation 
programs. Instruction should be supplemented at 
regular periods during the year to all potential in­
ventors. Only the technology transfer office (TTO) 
is really qualified to educate these scientists. 
.2 Duty to disclose 
It is essential that employees be aware of and fol­
low the employer’s policy for duty to disclose an 
invention. Many organizations have a policy that 
requires all employees to disclose to the employer 
all inventions made during the course of employ­
ment. Depending on the specific policy, the duty 
to disclose may extend beyond employment to 
include inventions made outside of employment, 
such as inventions made while consulting for an­
other company or at home. 
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. When the inventor calls 
For the TTO to succeed, inventors must be con­
fident that their inventions are going to receive 
a thorough evaluation of their patentability and 
commercialization potential. Nothing will alien­
ate an entire cadre of inventors more quickly and 
completely than if the TTO treats inventions 
superficially or capriciously. The TTO must give 
careful attention to every invention disclosure, re­
gardless of its content. 
..1	 Understanding your institution’s IP 
policies and your country’s IP laws 
The IP official must be the expert on his or her 
company and institutional IP policies and prac­
tices. These policies and practices must be care­
fully and patiently explained to each inventor. 
Likewise, all laws pertinent to any aspect of IP 
must be understood by the TTO and communi­
cated whenever needed to the inventor. 
..2	 Understanding the inventor’s 
timing of public disclosures 
One of the most common complications accom­
panying an invention disclosure is a publication or 
a pending publication. If publication is imminent, 
then a provisional patent application may be the 
only recourse to avoiding loss of patent rights. In 
the United States, a grant application is not consid­
ered a publication until the Notice of Grant Award 
is sent. Therefore, it is essential to completely un­
derstand the nature and content of the intended 
publication in order to determine whether or not 
it will actually contain an enabling disclosure of 
the invention. It also is necessary to know when 
the invention will be disclosed. Abstracts for sci­
entific meetings are now commonly e-mailed to 
participants months before the meeting date. 
Depending on the specific invention, an abstract 
may easily be an enabling disclosure, so it is im­
portant to question each inventor to determine if 
and when a publication and/or abstract may oc­
cur. Many times a disclosure (such as a speech) 
does not provide enough detail to constitute an 
enabling disclosure. The TTO should obtain cop­
ies of all speeches, technical presentations, pend­
ing grant applications, and so forth, and maintain 
these with the patent file wrapper. 
. Getting the big picture 
When an invention is disclosed, the IP profes­
sional should clearly understand not only the 
technical details of the invention but also how 
the new invention may relate to other inventions 
as a portfolio. Additionally, the inventor may be 
prolific and so it is important to know if there are 
additional invention disclosures anticipated by 
the inventor and, if so, whether those should be 
combined with the invention disclosure at hand. 
This knowledge could greatly influence whether 
and/or when to file a patent application and 
what the scope of the patent application may be 
in light of other existing or expected invention 
disclosure forms. The inventor must provide the 
IP professional with his or her plans to continue 
conducting research related to the invention. This 
is especially important if the invention has not 
been reduced to practice. 
If the invention disclosed is incomplete be­
cause the inventor has not completed an enabling 
concept, or if reduction to practice is necessary 
to determine enablement, then the inventor 
must be clearly told what deficiency is present. 
The invention disclosure form will be held by the 
IP professional with no action taken until the in­
ventor provides a complete disclosure. Periodic 
follow-up with the inventor is advisable to en­
sure that he or she remembers to provide the in­
formation necessary to complete the invention 
disclosure form. 
. Inventorship versus ownership 
The duty to disclose should be not be confused 
with the assignment of an invention. Disclosure 
of an invention means merely that the invention 
has been described in complete (that is, enabling) 
detail. Assignment means that ownership of, that 
is, legal title to, the invention has been given by 
the inventor to another party (for example, the 
employer). Employers commonly combine the 
duty to disclose and the assignment of inventions 
on a single form to be signed by the new employ­
ee upon reporting to work. But this is not always 
done, so the actual language must be carefully re­
viewed. The combination of the duty to disclose 
and the assignment of invention into a single, 
signed document is convenient in case there are 
HANDBOOK OF BEST PRACTICES | 1 
     
	 	 	 	 	
       
         
        
      
          
      
        
      
      
       
        
      
     
       
      
    
     
 
 
 	 	 	 	 	
MCGEE 
ever any questions later during a patent prosecu­
tion of the ownership of an invention. 
For certain government organizations, the 
duty to disclose may go beyond mere policy com­
pliance and have additional legal consequences if 
timely and complete disclosure is not made. 
. When the invention disclosed is co-owned 
Collaborative research projects between separate 
entities are common. Usually these projects are 
described in a contract, grant, or interinstitution­
al agreement. These documents will usually con­
tain one or more sections that address co-inven­
torship and co-ownership of IP developed during 
the term of the agreement. Nothing should be 
assumed about the ownership of IP before thor­
ough review of the agreement has been complet­
ed. Once ownership has been determined, the 
other party may need to be notified upon receipt 
of an invention disclosure form and prior to filing 
a patent application. Frequently, the other party 
will have an opportunity to participate in some 
manner during the IP process. 
If an invention has been made by co-inven­
tors and at least one of the co-inventors is from 
a second entity, and if there is no contractual 
agreement between the entities, then a decision 
has to be made as to whether to inform the sec­
ond entity of the invention disclosure form. 
Prior to disclosure, it would be advisable for the 
two institutions to sign a two-way confidentiality 
agreement to avoid public disclosure and subse­
quent loss of rights. Additionally, in first-to- file 
countries, the first party should file a patent ap­
plication prior to notifying the second party. 
Subsequent agreements, such as an interinsti­
tutional agreement, can be made to define each 
party’s rights and determine how patent prosecu­
tion costs will be shared. 
5. WHEN TO DISClOSE AN INVENTION 
It is good practice to disclose an invention as soon 
as it is an invention. Filing an invention disclosure 
declares the invention, the inventors, and the date 
of invention. Even if a patent application is never 
filed, a properly completed invention disclosure 
may be able to provide some protection against 
subsequent patent applications filed by other par­
ties that could prohibit the first party from being 
able to practice something it invented. This pre­
caution may be especially helpful in the United 
States, where first to invent takes precedence over 
first to file. Most importantly, without a timely
disclosure, no decision can be made about wheth­
er or not to file a patent application to preserve IP 
rights. Occasionally, a delay in disclosure may be 
appropriate, for example, if the inventor is con­
tinuing to conduct experiments that may provide 
better enablement or broader utility, which would 
provide broader claims should a patent be sought. 
However, the decision to delay filing an invention 
disclosure should be made in consultation with 
appropriate IP managers. 
If an inventor is unable or resistant to com­
pleting an invention disclosure form (See Box 1 at 
end of chapter for a sample invention disclosure 
form.), then an interview with an IP professional/ 
TTO officer of the same institution for the pur­
pose of disclosure may be required. Completing 
an invention disclosure without the inventor’s 
input is not recommended, however, since the 
inventor is, naturally, more familiar with the in­
vention than anyone else. If a patent application 
is prepared from an invention disclosure that has 
been obtained from an interview, the patent ap­
plication may take longer and cost more to pre­
pare. Ultimately, each inventor must critically 
review and affirm that the invention has been 
correctly and completely described in the patent 
application. In the United States, each inventor 
must sign a declaration affirming that the inven­
tion has been correctly and completely described, 
in order to meet the filing requirements of the 
U.S. Patent Office. 
In some countries, patent offices do not re­
quire filing an invention disclosure in order to 
file a patent application. Under certain circum­
stances, however, other government agencies may 
require that invention disclosures be filed. 
.1 Where to submit an invention disclosure 
Invention disclosures may be submitted wherever 
the employer’s policy dictates, for example, with 
a company’s own IP department or outside patent 
counsel or with an academic institution’s TTO. 
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In the United States, patent law provides 
for a disclosure document program that allows 
an inventor to submit an invention disclosure to 
the U.S. Patent and Trademark Office (PTO). 
The program is described in detail in the Code 
of Federal Regulations (37 C.F.R. §1.2.1(c)). It is 
especially beneficial to individual inventors who 
are not affiliated with an employer, because the 
program provides evidence of disclosure that may 
avoid the necessity of disclosing, to witnesses, in­
formation the inventor wishes to keep confiden­
tial. The U.S. PTO will keep the invention dis­
closure for two years and then discard it unless it 
is referred to in a pending patent application. The 
disclosure document program is not a substitute 
for filing a patent application and provides no fil­
ing date for a patent application. 
.2 Confidentiality of an invention disclosure 
To avoid the potential undesired publication 
of an invention prior to filing a patent applica­
tion, all invention disclosures should be submit­
ted confidentially. When disclosure is made by 
an employee to a fellow employee, it should be 
clearly understood that the disclosure is to be 
kept confidential. As such, the disclosure would 
not be considered a publication in most cases. In 
very large institutions, the presumption of con­
fidentiality may not exist. Consequently, if chal­
lenged by an outside party, such disclosure may 
be deemed by the patent to have not been a confi­
dential disclosure but a publication. Even within 
an organization, therefore, it is always important 
to verify confidentiality prior to disclosure and to 
execute a confidentiality agreement, if needed. 
. Content of an invention disclosure form 
There is no set format for an invention disclosure 
form; however, there are certain types of required 
information common to all invention disclosure 
forms. Examples of the forms can be easily ob­
tained from the Internet by selecting any search 
engine and entering invention disclosure in the 
search box. Numerous forms from institutions all 
over the world are available.1 All the forms have 
certain things in common: most request similar 
kinds of information. Box 2 at end of chapter lists 
items that appear commonly on the forms. 
.	 uSE OF lABORATORy NOTEBOOKS AS
INVENTION DISClOSuRES 
Laboratory notebooks are frequently relied upon 
to ascertain the actual date of invention and to 
identify the inventor. Unfortunately, most lab 
notebooks are incomplete, illegible, and not wit­
nessed, or witnessed erratically—if they are kept 
at all. However, if kept appropriately, a labora­
tory notebook can easily suffice as an invention 
disclosure. The information must at least include 
a detailed description of the invention and signed 
and dated pages by the inventor and appropriate 
witness(es). The actual discovery (that is, the in­
vention) must be clearly explained. 
IP professionals should educate scientists 
about the need for complete disclosure if the note­
book is to be useful at all. The scientists should 
also be trained to avoid writing off-hand remarks 
in the notebook (for example, “this was an obvi­
ous experimental approach” or “I used an obvious 
extension of Dr. X to conduct this research” or 
“there is a paper that is prior art to my research”). 
Such notebook disclosures would be discoverable 
during litigation and could result in loss of patent 
rights. As always, scientists should be counseled 
to completely disclose the invention and to pro­
vide only absolutely truthful disclosure. 
7.	 ASSIGNMENT FORM 
An assignment is the transference of legal title to 
an invention. Assignment of all inventions may 
be made in advance of any discovery by execut­
ing a general assignment agreement. During pat­
ent filing, assignment of an invention may be re­
quired by the patent office. The employer should 
obtain a second assignment of the specific inven­
tion being filed as a patent application because 
it provides the patent office with a simple, clear 
assignment record. However, if an inventor can­
not be reached or is unwilling to provide a signed 
assignment, then the original general assignment 
agreement can serve as evidence of assignment of 
that invention. 
Under U.S. patent law, all assignments for 
patent applications and issued patents must be 
recorded. This requirement may vary in other 
countries. 
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.1	 What to do in the absence of a previous 
assignment when there is a duty to disclose 
Occasionally during the preparation of a pat­
ent application, the IP professional discovers 
that there is no record of assignment. A signed 
acknowledgement of an employee’s duty to as­
sign may also be lacking. These are serious is­
sues, because ownership of a patent is joint and 
severable; any owner can act independently of a 
co-owner. In other words, co-owners can sepa­
rately practice an invention or license it without 
a co-owner’s permission. Therefore, obtaining 
clear assignment of an invention is extremely 
important. 
.2	 Obtaining signatures for duty to assign 
and assignment documents 
As soon as it is discovered that an inventor has 
not fulfilled the duty to assign or has not executed 
an assignment document, the TTO officer should 
promptly review the organization’s policies to see 
if they are clear. In addition, he or she should look 
for other records that may include the employ­
ee’s signed acknowledgment of compliance with 
corporate or institutional policies. For example, 
employee policy handbooks frequently contain 
sections relating to IP. It is common practice for 
human resources departments to obtain from 
employees written acknowledgement that they 
have read, understand, and will comply with all 
policies. This written acknowledgement may be 
useful if an inventor does not wish to provide a 
written assignment for an invention. 
Next, the IP professional should contact 
the inventor, in person if possible, and explain 
why an assignment is necessary. If a duty-to-dis­
close agreement has not been signed, then the 
IP professional should explain to the employer 
why signing a duty-to-disclose agreement is 
important. If the institution has a policy that 
provides inventors with compensation, such as 
royalties, then the IP professional should go over 
those policies as well. He or she should have the 
agreements ready to be signed in duplicate and 
provide the inventor with a copy. (The original 
should be kept on file.) Explain that additional 
assignments for any future inventions will be 
needed and why. 
It is advisable not to ask anyone to sign an 
agreement upon which the signature date is dif­
ferent than the actual date of signing—it may un­
dercut the validity of the document. The agree­
ment can, however, specify an effective date in the 
text that predates the signature, providing that no 
intervening and conflicting agreements have been 
executed. 
8. DIlIGENCE WHEN FIlING A PATENT
AFTER RECEIVING THE INVENTION
DISClOSuRE FORM 
Because the U.S. PTO has a first-to-invent rule, 
U.S. patent practice includes an obligation of 
diligence to proceed with the filing of a patent 
application once an invention is completed. A fil­
ing delay can, under certain circumstances, result 
in a loss of patent rights. This most commonly 
occurs when a second, independent party invents 
and files a patent application after the first party’s 
date of invention, but before the first party’s filing 
date. If a lack of diligence by the first party can 
be shown, the second party may prevail and win 
the patent filing. Obviously, diligence in filing is 
rendered a moot issue in first-to-file countries. 
9. uPDATING A SuBMITTED INVENTION
DISClOSuRE FORM AND COMBINING
DISClOSuRE FORMS 
Frequently, when an invention disclosure form 
is submitted, it represents ongoing research. As 
such, it may not meet the standards of patent-
ability or commercialization potential to warrant 
a patent filing. Regardless, an IP professional 
should receive the invention disclosure form and 
assess whether or not to file a patent application. 
Alternatively, he or she could hold the invention 
disclosure form in anticipation of receiving new 
data or matter from the inventor. The inventor 
may then file a subsequent invention disclosure 
form as an addendum to the first form. Invention 
disclosure forms on related matter, if combined, 
may greatly strengthen a patent application with 
broader claims. 
If the second invention disclosure form con­
tains the best method of practicing the invention 
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CHAPTER . 
or new matter, then the date of invention may be 
that of the second invention disclosure form and 
not the first. 
10. PATENT PREPARATION FROM THE
INVENTION DISClOSuRE FORM 
A properly completed invention disclosure form 
will greatly enhance the ability and speed with 
which the patent attorney is able prepare the pat­
ent draft. Expediting this process can dramatical­
ly lower attorney fees. To aid in the process, the 
attorney should receive a complete copy of the 
invention disclosure form, copies of all referenc­
es, clear instructions about the most important 
aspects of the invention that need to be claimed 
in the patent application, and an explanation 
of why these aspects are important. The patent 
attorney will be able to craft a patent applica­
tion properly only if the client clearly describes 
its strategic objectives within the context of the 
invention. 
Most inventors are unfamiliar with the pat­
ent prosecution process, and so the IP profession­
al should clearly describe the process to the inven­
tor and explain how he or she will be expected to 
assist in it. The inventor should be introduced to 
the patent attorney, and the employer should take 
care to ensure that a good, productive working 
relationship is established between the inventor 
and the patent attorney. The inventor is the ex­
pert and will need to provide the patent attorney 
with substantial assistance in drafting the inven­
tion background, the technical description of the 
invention, and access to any known references. 
After filing, the inventor will likely assist the pat­
ent attorney in providing technical rebuttal for 
issues raised by the patent office. Depending on 
the particular patent application, the inventor’s 
involvement can occasionally require a substan­
tial amount of time. 
Patent counsel will prepare and file the pat­
ent application based on the invention disclosure 
form. It is the responsibility of the patent coun­
sel to prepare a complete and enabling disclosure 
of the invention. Most often the patent attorney 
will discuss the invention at length with the in­
ventor, in order to ensure that all its features are 
understood. During these discussions, the patent 
attorney will develop the broadest claims pos­
sible without becoming an inventor. 
11. MAINTAINING INVENTION
DISClOSuRE FORMS 
Each TTO should establish a database of inven­
tion disclosures and a secure-storage facility where 
original copies of invention disclosure forms are 
filed. A fireproof file cabinet is a good example 
of such a facility. Invention disclosure forms 
should be retained for the life of any related pat­
ent. Duplicate copies should be stored off-site. 
An outside patent firm will frequently provide 
this service. The disclosure document program at 
the U.S. PTO will maintain an invention disclo­
sure form only for two years, unless the invention 
disclosure form is referenced in a pending patent 
application. 
12. INVENTOR’S CERTIFICATE 
An inventor’s certificate may be filed in lieu of 
a patent application. The certificate will contain 
a detailed description of the invention and most 
of the components of a patent application. An 
inventor’s certificate is, therefore, similar to an 
invention disclosure form. However, unlike an 
invention disclosure form, the inventor’s certifi­
cate is part of a legal process (established in ac­
cordance with each country’s respective patent 
laws and procedures) to publicly recognize the 
inventor(s) as an inventor for a defined invention 
as of a specified date. 
An inventor’s certificate is not a patent and 
does not provide any of the IP protection rights 
provided by patenting. Instead, many countries 
commonly use certificates to provide a monetary 
reward for an invention for which no patent is 
intended. 
13. MARKETING INTEllECTuAl PROPERTy 
THROuGH AN INVENTION DISClOSuRE 
It is common practice among academic institu­
tions to market IP using the information con­
tained in invention disclosure forms. Because 
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the invention disclosure form contains enabling 
detail of an invention, premature disclosure of 
such information prior to filing a patent appli­
cation could destroy patent rights. Care must be 
taken to provide only general, nonconfidential 
information that does not include any enabling 
information. If a patent application has been filed 
but not yet published, then the filing date or pat­
ent application number should not be disclosed. 
Unauthorized parties can use these numbers to 
obtain confidential information about a pending 
application. If the patent application has been 
filed, then including information contained in 
the pending application is acceptable. The dis­
closed information in marketing abstracts made 
available for previously unpublished patent appli­
cations should be updated after the application is 
published. It is inadvisable to include inventors’ 
names in marketing abstracts as points of contact; 
instead, the name of the licensing professional 
should be used. 
Many institutions provide nonconfidential 
abstracts of IP on Web sites, which usually orga­
nize the abstracts and contact information into 
databases by technology area. These databases 
can be efficiently marketed by technology area 
through mass e-mailing or mailings to potential 
licensees. n 
dAVId R MCgEE, Executive Director, Technology and 
Industry Alliances, University of California, Davis, Office of 
Research, Technology Industry Alliances, 1850 Research Park 
Drive, Davis, CA, 95616, U.S.A. drmcgee@ucdavis.edu 
1 For example: http://research.ucdavis.edu/homecfm?id
=OVC,2,1025. 
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Box 1: Sample invention disclosure form 
[Insert Institution or Company Name Here] 
CONFIDENTIAl 
1.	 TITlE OF INVENTION:
2. OVERVIEW OR PuRPOSE OF INVENTION:
3. BRIEF DESCRIPTION OF INVENTION: 
Provide a brief abstract of the invention including novel embodiments of the invention. 
4. DETAIlED DESCRIPTION OF INVENTION: 
Provide in plain language a numbered list of what attribute(s) you, the inventor, believe is/are
useful about the invention. 
Provide a complete, enabling description of the invention. Include all descriptions, steps,

processes, and other data and information necessary, so that someone of ordinary skill in the

art could reproduce and practice this invention. If the invention is a composition of matter,

provide a complete formulary and any other information necessary to completely and accurately

describe the composition. If the invention requires software that has been developed as part

of the invention, provide a detailed program flow chart and copies of the software. Provide

detailed drawings and a description for any apparatus.

Attach additional sheets if necessary.
 
5.	 BACKGROuND (Optional):
If known, describe the state of the art as set forth in patents or journal references (identify
by patent number or journal citation, if possible) and indicate how the invention overcomes
any disadvantages to or problems in this art. Attach additional sheets if necessary. Also attach 
complete copies of the references.
If any inventor knows of any art relevant to the invention, please provide such information
through description below with appropriate literature references. All cited references should
be attached to the invention disclosure form. 
(Continued on Next Page) 
HANDBOOK OF BEST PRACTICES | 
     
 
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	
	 	 	 	
 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	




	 	 	 	 	 	 	 	 	 	 	 	 	 	 	






	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
	 	
 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	






	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	





Box 1 (continued) 
6. CONCEPTION: 
Provide the date upon which a complete, enabling concept was known by the inventor(s). 
Invention conceived on: 
First written record: 
7. FIRST DISClOSuRE TO OTHERS: 
Provide the complete names and anyone to whom you have disclosed your invention in enabling




Indicate how the disclosure was made (for example, orally or through a presentation, report, or
publication). Provide copies of any documents or other media you used to make the disclosure. 
8. FIRST REDuCTION TO PRACTICE: 
Provide the date of first preparation or isolation of compound molecule or microorganism; date
of first use of process, or date of construction of apparatus. 
Date: 
9. FIRST SAlE OR PuBlIC uSE OF INVENTION: 
Describe and provide the date of any sale or public use made, or planned to be made, of your
invention in the United States or in any foreign countries. Provide details of any sale, use or
disclosure. The description should tell whether or not the use was for testing purposes, and
if there was an effort or intention to maintain secrecy around the invention after the use
commenced. 
10.PROGRAM OR CONTRACT: 
Was the invention made during the course of your work on a specific program, grant(s) or
contract? 
Yes	 No	 
If no, provide an explanation of how and where the invention was made.

If yes, provide below the name and applicable number of the funding agency.
 
Fund source	 Grant or contract number 
(Continued on Next Page) 
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Box 1 (continued) 
11. CONTACT INFORMATION 
Provide the specified information about the inventor(s). 
Signature of inventor: Date: 






Signature of inventor: Date: 







The invention was described to me by the above inventor(s), the description was examined and
clearly understood. 
Signature of witness: Date: 
Printed name: 
Affiliation: 
Signature of witness: Date: 
Printed name: 
Affiliation: 
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Box 2: Information requested typically in 
an invention disclosure form 
Inventor 
This should include the complete name of the inventor and his or her employer affiliation and
complete mailing address. 
Invention 
An invention should include a title of the invention, a short abstract, and a detailed description of
the invention.The advantages of the invention should be clearly described.The inventor(s) should
include as many features, embodiments, and uses of the invention as possible. 
Date of invention 
This is the date the invention was conceived in enabling detail. U.S. patent law (35 USC §104)
provides for the establishment of a filing date when an invention is made abroad, as long as
certain provisions are met: 1) the inventor must be domiciled in the United States or a North
American Free Trade Agreement [NAFTA] or World Trade Organization [WTO] country; 2) the
invention has been conceived in either the United States or a NAFTA or WTO country; and 3) the
inventor must be serving in a NAFTA or WTO country on behalf of one of those countries. Such a
provision may or may not be available in countries other than the United States. The provision
may have no significance at all for first-to-file countries. 
Date of actual reduction to practice, if applicable (may be the date of invention)
Actual reduction to practice is not required but is helpful when preparing the patent 
application. 
Applicable research funding sources, if any
It is very important to know whether the invention has been funded by an entity, other than the
inventor’s employer, that may have ownership/licensing rights. 
Date of public disclosure of the invention
This may be critically important if the date creates a statutory bar for patenting. If the date is in
the future, then it provides a timeframe within which a decision of whether or not to file a patent
application has to be made. Copies of any publications (for example, manuscripts, handouts,
posters, electronic presentations, and slides) should accompany the invention disclosure form.
In addition, any relevant supportive scientific references should be copied in full and attached to
the invention disclosure form. 
References 
The inventor should include complete references and photocopies of any other related science he
or she is aware of that could potentially be cited by the patent examiner as novelty-destroying or
as rendering the invention obvious. There is no duty for the inventor or the attorney of record to
conduct a literature search to determine whether there is any prior art to the present invention.
But if the inventor or the assigned institution is made aware of any such art, then it must be
disclosed to the patent office. There is no duty to provide the patent office with an opinion of the
relatedness of any reference cited to the patent office. The examiner is responsible for making
such a determination. 
The inventors should be instructed not to provide written admission, directly or indirectly,
that any reference is prior art. In some countries such a statement is viewed as an irrevocable
admission that the reference is true prior art that renders the present invention as non-novel
and/or obvious. 
(Continued on Next Page) 
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Box 2 (continued) 
list of potential competitors/licensees
Since inventors are knowledgeable in the area of science related to the invention, they are usually
also knowledgeable about who is working in that area. This is valuable information, since it
provides direction in finding potential competitors,potential licensees,and potential areas of prior
art that can be reviewed before filing a patent application to help determine patentability and
claim drafting. Also, one can build a better patent portfolio by reviewing patents and file wrappers
filed by another institution or company. 
Witnesses 
Usually, at least two witnesses are required on an invention disclosure form. A witness should
be scientifically competent to understand the details of the invention and not directly affiliated
with the research being disclosed (for example, an inventor on the invention disclosure form or a
principle investigator of the research). 
Signatures of all inventors
It is critical that at least one of the inventors has signed the invention disclosure form, otherwise,
the form cannot be considered to have been perfected. The TTO at the institution should try to
obtain original signatures from each of the inventors as soon as possible. 
Receipt of electronically filed invention disclosure forms
Faxedsignaturesaregenerallyacceptedworldwideas sufficient evidenceof anexecuteddocument.
Electronic signatures do not yet have such wide acceptance. Consequently, it is recommended that
invention disclosure forms not be sent electronically without the subsequent conveyance of an
original, signed copy. 
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CHAPTER 9.1 
Evaluating Inventions from Research Institutions
 
LITA NELSEN, Director, M.I.T. Technology Licensing Office, U.S.A. 
ABSTRACT 
The patenting strategies of research institutions are based 
on three key decisions. The first involves whether or not 
to file a patent. This decision must be based on sound 
information about the market, the uniqueness and use­
fulness of the invention and/or technology, the likelihood 
of being able to obtain patent protection, factors related 
to the inventor, and the potentially paradoxical impact 
of patenting on the institution’s social and humanitarian 
responsibilities. The second decision involves whether to 
market the invention to established companies or to de­
velop a spinout business. The third involves how much to 
charge for a license. Related to all of these decisions is the 
key question of whether patenting is the most effective 
route to global access. Negotiating licensing agreements 
that are fair to the research institution, the private com­
pany, and developing countries can be challenging be­
cause research institutions may have difficulty determin­
ing fair market values. In addition to outlining a process 
for obtaining these values, this chapter offers some rough 
numbers for guidance. In general, the author concludes 
that it is far better to conclude a deal than to wait for 
the best agreement while fighting interminably for perfect 
financial terms. 
1. INTRODuCTION 
This chapter discusses how to evaluate new in­
ventions arising from research at universities and 
other research institutions. It considers early, 
“university-stage inventions” arising out of ba­
sic research, rather than development projects. 
Most of these university-stage inventions will 
require substantial investments in both money 
and time to develop them into marketable prod­
ucts. Such investments will usually be very risky; 
neither the practicality of the technology nor its 
ultimate market acceptance will be known with 
any certainty. 
It is assumed that the research institution’s 
interest is primarily in the social functions of 
technology transfer: bringing new medicines 
and other useful products into public use, en­
hancing the competitiveness of industry by 
encouraging the use of new technology, and 
enhancing economic development and job cre­
ation. Revenue from royalties is assumed to be 
a secondary consideration. (Even in the United 
States, the Bayh-Dole Act, which gave U.S. re­
search institutions the right to own and license 
out inventions from government-funded re­
search, was enacted in the cause of economic 
development—not as a mechanism for fund­
ing the institutions. Twenty-five years later, the 
revenue produced, though useful to the institu­
tions, makes up on average only a small per­
centage of their research budgets.) 
2. THE EVAluATION PROCESS 
Technology transfer offices evaluate early-stage 
inventions in order to make three decisions: 
1. whether 	 or not to file a patent on the 
invention 
Nelsen L. 2007. Evaluating Inventions from Research Institutions. In Intellectual Property Management in Health and Ag-
ricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. L Nelsen. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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2. whether to market the invention to existing 
companies or try to do a spinout 
3. what to charge for the invention 
Fortunately, these three decisions do not usu­
ally have to be made at the same time. And, of 
course, if the answer to the first question is no, 
then the other two questions are moot. 
2.1 Decision 1: Whether or not to file a patent 
It is assumed that money for filing patents is avail­
able but limited. The decision to file a patent 
should take into account answers to the following 
questions: 
1. Is this invention likely to get awarded a pat­
ent with broad enough claims to protect a 
product or a product line—not just a mi­
nor variation of an existing technology? 
2. If patented, will this invention likely attract a 
licensee or investment for commercialization 
that will produce enough of a return to the 
institution to justify the patenting expense? 
3. Is patenting the right route to maximize so­
cial access to the technology? 
The answer to the first question on patent-
ability is fairly easy to determine with relative 
(though not absolute) certainty. If time allows, a 
search of the literature that includes past and pub­
lished pending patents will reveal prior art. When 
possible, this search is best done by a professional 
search librarian working side-by-side with one 
of the inventors. If potentially important prior 
art is found, a patent agent may be called in to 
evaluate its significance and the likely claims to 
be achieved by patent filing. The prior art search 
may also turn up dominating patents that may 
have to be taken into account. 
The second question—will the technology 
attract investment for commercialization if it is 
patented—is far more difficult than the first to 
answer with any certainty. Market research stud­
ies take both time and labor. If the technology 
transfer office receives many invention disclosures 
(at the Massachusetts Institute of Technology 
[M.I.T.] we receive about 450 disclosures per 
year), there will not be enough resources to per­
form a market research study on every one. In 
addition, there may not be enough time for such 
a study before publication (particularly in aca­
demic institutions with a policy against delaying 
publication for patenting or other commercial 
reasons). The requirement for confidentiality be­
fore patenting also limits the depth of any market 
research study. 
Finally, it must be realized that the more in­
novative the invention, the harder it is to get good 
market feedback. Potential users of new technol­
ogy cannot easily judge the value of something 
they have never thought about before. Business 
histories are replete with gross underestimations 
of the potential of innovative products (for exam­
ple, photocopy machines and home computers). 
Innovative inventions from basic research in uni­
versities should expect to suffer similar challenges. 
So what is a technology licensing office to do? 
Below are some questions to consider. They 
will be answered, for the most part, through dis­
cussions with the inventors, some library work 
perhaps, some discussions with potential users 
or investors maybe, and the experience and judg­
ment of the technology transfer staff. 
2.1.1 The market 
It will be important to try to answer these ques­
tions about what the market for the invention 
might be: 
•	 What need does this invention satisfy? Is 
this a major, well-recognized need or a mi­
nor one? 
•	 How is this need being met now? Or is it 
satisfied at all? 
•	 What size is the market? Huge, large, small, 
miniscule? (As will be discussed later un­
der pricing, more precision here is not usu­
ally needed by the patent holder, although 
much more precision will be needed by the 
licensee or investor.) 
•	 Is the market already established, or will it 
need developing? 
•	 Is this a growing field or a dying one? 
2.1.2 The technology 
The institution will need answers to these ques­
tions about the new and existing technology and 
how to develop the invention: 
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•	 How would this technology change how 
the market presently addresses the need? 
•	 Is the new technology not only different 
from what is already available, but better? 
If better, what are the major benefits it 
offers? 
•	 How certain is it that the technology will 
work? Can this be demonstrated to a po­
tential licensee or investor? 
•	 How long and how much money will it 
take to develop the invention into a com­
mercial product? 
2.1. Likely degree of patent protection 
Answering the following questions will help deci­
sion makers determine whether obtaining a pat­
ent is worth the expense: 
•	 Did the prior art search (or what is known 
about the state of the science) indicate that 
broad claims are likely? 
•	 Is the invention at such an early stage in 
product development that the patent will 
expire before products reach the market? 
(Sadly, many have seen their patents expire 
just as the market began rapid growth.) 
•	 Is the field moving so quickly that patents 
are irrelevant? By the time the patent is­
sues, will the invention be obsolete? (This is 
not uncommon for software patents in the 
United States.) 
•	 Can practice under the patent be detect­
ed, thus allowing for patent enforcement 
against infringers? (It may be impractical 
to enforce the patent if the manufacturing 
method is simple and requires no special 
materials, and the invention is not evident 
in the final product.) 
2.1. The inventor 
Inventor participation in the development of 
university-stage technology is usually critical. 
The inventor is most familiar with the technol­
ogy and is most likely to have a vision for its use. 
Some inventors (particularly students or research 
associates) may wish to leave the research institu­
tion and join (or help form) a company. Most 
professors or senior researchers, however, will 
probably choose to stay at the research institu­
tion, although they may consult or work part 
time for the company developing the invention. 
On the other hand, if the inventor has no 
interest in seeing the technology developed and 
will not help to market the patent, these tasks can 
be hopeless. 
The following questions should be considered 
to decide how effective the inventor might be in 
finding a licensee or investor for the technology. 
As we shall see, not all of the findings should be 
documented! 
•	 Is the invention in the inventor’s major field 
of research? If not, is he or she at all familiar 
with the market’s needs for the invention? 
•	 Does the inventor have business connec­
tions in the field of the invention? 
•	 Is the inventor famous? (It’s a lot easier to 
market a patent with a Nobel Laureate’s 
name!) 
•	 Will the inventor be cooperative in meet­
ing with potential licensees or investors to 
share his or her vision of the invention’s po­
tential and the means of developing it? 
•	 Does the inventor have realistic expecta­
tions about the magnitude and uncertainty 
of the development task and the potential 
financial returns? 
•	 Can relationships with investors or compa­
nies proceed reasonably or is the inventor 
too naïve or overly paranoid? 
2.1. Social responsibility 
In terms of public policy, patents are two-edged 
swords. They can protect investments very effec­
tively. Moreover, the licensing of university pat­
ents has been shown to stimulate much earlier 
investment than the placement of inventions in 
the public domain. They can also bring much-
needed revenue to research institutions (although 
the revenue potential of university-stage inven­
tions has been much exaggerated). On the other 
hand, patents can limit investment in new tech­
nologies when the patent holder (or exclusive 
licensee) does not invest in all of the fields that 
can use the patented technology. Patents can also 
sometimes be used to maintain high prices on 
necessary products by excluding competition. 
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NElSEN 
As a side note, patents are particularly para­
doxical in the development and distribution of 
drugs and vaccines for diseases in developing 
countries.1 Indeed, if effective drugs and vac­
cines for all diseases in developing countries ex­
isted and could be manufactured at low cost, a 
social philanthropist might wish that no patents 
existed, since in theory the absence of patents 
would allow competition, leading to lower prices 
and wider availability. But in the absence of effec­
tive drugs and vaccines, patents may be necessary 
to ensure profits for pharmaceutical companies, 
thus encouraging commercial investment in the 
research, development, and clinical testing of 
new drugs and vaccines. This paradox puts a spe­
cial burden on technology transfer professionals. 
When licensing health- and agriculture-related 
patents from nonprofit research institutions, 
technology transfer professionals must try to pat­
ent strategically to protect profits in developed 
countries and encourage commercial research and 
development. At the same time, they must use 
mechanisms to assure that the poor can access the 
final products. 
When deciding whether patenting a new in­
vention is in the public interest, the following is­
sues, among many others, should be considered: 
•	 Is this technology self-evidently useful 
without substantial further investment in 
development? Will it be widely used even 
if it is not patented but put in the public 
domain? 
•  If the answer to the previous questions 
is yes, can the patent-holding institution 
nonetheless devise a nonexclusive licens­
ing strategy that allows revenue to be gen­
erated without impeding the use of the 
technology? 
•	 If the technology requires substantial high-
risk investment, and therefore patent­
ing and exclusive licensing is warranted, 
should patents be foregone in developing 
countries to encourage generic competi­
tion? (This approach is reasonable, under 
some circumstances, for health and agri­
cultural patents.) 
•	 Can the patent holder require sublicensing 
of other mechanisms to promote low-cost 
manufacture and distribution in the public 
sector of developing countries? 
•	 If the drug or vaccine is expected to be used 
only in developing countries, with little 
or no market in developed countries, will 
market aggregation through patenting and 
limited licenses create a sufficiently profit­
able market that will encourage develop­
ment and clinical testing? 
•	 Should the patent holder carve out free use 
of a patented research tool for nonprofit re­
search institutions? 
2.1. Local considerations 
The decision to patent depends, to some extent, 
on the institution and its geographic location. 
For example: 
•	 In under-developed regions (of both de­
veloped and developing countries), tech­
nologies well-suited to local industry and 
the technology skills of the region, espe­
cially, may be promoted to create jobs and 
strengthen the local economy. 
•	 Public institutions, more than private in­
stitutions, may emphasize technologies 
that will enhance local economic develop­
ment—particularly if technology transfer 
is one of the metrics that legislators use 
to decide how generously to fund a given 
institution. 
•	 Medical institutions may decide to patent a 
product with a relatively small market, be­
cause of the potential benefit to patients. 
In all, this set of challenges is formidable. 
For any given invention, most of the answers 
will be guesses at best; still, these should be edu­
cated guesses, and the judgment of the technol­
ogy licensing office may be all that is available. 
Both the technology licensing office and, even 
more importantly, the senior administration of 
the institution must realize that a decision to 
file a patent is a decision to take a risk. Patents 
are expensive, and patent budgets are limited. 
Nonetheless, decision makers must realize that 
although it is easier to say no than yes, the sin 
of omission—not filing a patent on a technology 
that later becomes important—may be worse 
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CHAPTER .1 
than the sin of commission, the filing of a pat­
ent that is never licensed. Decision makers should 
consider that if the requirements for patenting are 
too stringent, then only a few of the inventions 
submitted to the technology licensing office will 
be accepted for patenting. This will be discourag­
ing to researchers and will result in fewer inven­
tions reported in subsequent years. 
2.2  Decision # 2: Whether to market the 
invention to existing companies or license 
to a spinout 
Licensing to an existing company has many ad­
vantages over licensing to a spinout (a new com­
pany specifically formed to develop the licensed 
technology). An existing company already has its 
infrastructure in place, including management. 
The company usually has sufficient funds to de­
velop the invention, and its financial health often 
can be readily assessed. The company also usually 
has distribution channels, and its brand name and 
market access will make final distribution of the 
product easier and more effective. From the re­
search institution’s point of view, the license agree­
ment is much easier than spinout agreements, and 
potential conflicts of interest are far less likely. 
This is not to say that licensing to an existing 
company has no difficulties and disadvantages. 
For one, it is difficult to get the attention of an 
existing company (particularly a large one) with 
new but unproven inventions. Existing compa­
nies have already set their research agenda and 
priorities, and a new technology needing devel­
opment could cause disruption. It is also difficult 
to find within a large company a “champion” who 
will enthusiastically support a new technology 
that is not his or her own when it runs into the 
inevitable problems in development. 
The single biggest disadvantage of licens­
ing to an existing company is the risk that the 
company will lose interest in the technology, or, 
perhaps worse in the case of an exclusive license, 
that it will retain some interest in the invention 
but that the project will be given less priority and 
inadequate resources. When things do go wrong, 
it is often difficult for large companies to identify 
the right person to provide information or to ne­
gotiate a change in the license agreement. 
The advantages and disadvantages of licens­
ing to a spinout are almost the reverse of those 
for licensing to an existing company. At the be­
ginning, at least, the spinout will be dedicated 
to developing the invention as its first priority. It 
will also usually be working very closely with one 
or more of the inventors; moreover, the research 
institution itself knows the people involved. The 
financial arrangements of the license may include 
both shares of stock and royalties, giving some­
what more assurance that the institution will get 
at least some return from its license. And, if the 
company’s strategy does diverge from the origi­
nal technology (or the technology doesn’t work), 
although there will not be any royalties on the 
patent, the equity shares may become liquid and 
reward the research institution for its role in start­
ing the company. 
Spinout companies represent a substantial 
risk of conflict of interest, which can be on the 
part of the inventor/researcher or on the part of 
the institution itself. Frequently, both the inven­
tors and the institution will own stock in the 
company. This can lead to an unhealthy interest 
in the company’s fortunes—the parties involved 
may encourage the institution to make conces­
sions on future IP, to sequester data from publica­
tion, or to misuse institutional resources or staff 
time. The situation is exacerbated if the institu­
tion also invests its own funds in the company. 
Thus, research institutions need well-crafted and 
well-enforced conflict of interest policies if they 
plan to engage in spinning out companies around 
their technologies. 
Spinout companies are also fragile. They 
must find management talent and raise invest­
ment money. They are highly dependent on the 
talent of the management team, and a bad hire 
can set the company back for a year or more. A 
spinout company often has difficulty in market­
ing and developing distribution channels. In hard 
economic times, further investment may be very 
difficult to attract, and the research institution’s 
equity shares may become valueless due to a 
down round of investment or a low-price sale to 
an acquiring company, made in desperation. And, 
because of the complexity of equity investments, 
the technology transfer agreement is likely to be 
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NElSEN 
considerably more difficult to negotiate than a 
conventional license. 
The advantages and disadvantages of conven­
tional licenses and spinouts will be different for 
different inventions. A spinout may be preferred 
when the following criteria are met: 
•	 The invention is a platform technology that 
may lead to not just one but many products. 
It is difficult to justify the risk of a spinout 
when only a single product is envisioned. 
Also, a spinout company is more likely to 
try to exploit the full range of potential ap­
plications of the technology, while an es­
tablished company will more likely focus 
on a single addition to its existing product 
line. 
•	 There is no existing industry making similar 
products. It is difficult for a new company 
to compete in an established market unless 
the technology is overwhelmingly superior. 
•	 The market is large enough to justify the risk. 
This is particularly true for technology requir­
ing substantial investment in development. 
Since the failure rate of spinouts is often 
high, investors expect a very large return on 
their investments from the winners. A small 
market, therefore, will not be sufficient. 
•	 Strong intellectual property (IP) protection 
exists in the country in which the spinout 
exists and/or in the major markets to which 
it intends to export. Patents are the prima­
ry protection for small companies against 
larger companies that enter a market after 
a technology is proven successful. Without 
them, the market strength of a large compa­
ny that is the second to enter the market can 
overpower the innovating small company. 
•	 At least one credible inventor will join the 
company as founder, consultant, and/or 
employee (the most important criterion). 
Without this human technology transfer,
it will be almost impossible to raise invest­
ment money and much more difficult to 
develop the technology. 
In reality, the choice between a convention­
al license and a spinout often is made for the 
technology transfer office. If the inventor is not 
interested in contributing to the spinout, it is un­
likely to be successful. On the other hand, if the 
inventor wants to form a spinout and there are 
no clear reasons why this is impractical, then it is 
not advisable for the technology transfer office to 
“take the baby from its parent” and give the job 
to an existing company. Such an act would likely 
cause political problems in the research institu­
tion and could also discourage future inventors 
from reporting their inventions. 
2.  Decision #3: What to charge 
for the invention 
Although research institutions may engage in 
technology transfer primarily for social benefit, 
most nonetheless expect to reap a reasonable fi­
nancial return from those licenses. The company 
expects to make a profit from the product with the 
proviso that concessionary terms may be appro­
priate for critical public goods where the markets 
are small, or the ability to pay is very limited. 
Under the usual (profit sector) conditions, 
how does a technology transfer office decide 
what is a reasonable return from licensing a 
particular invention? Unfortunately, all too 
many technology licensing offices spend far too 
much time trying to evaluate the total value of 
embryonic inventions in some supposedly sci­
entific manner. Calculators are kept running 
on Net Present Value calculations and other 
more abstruse formulae, when the major inputs 
to the formulae—cost of developing the tech­
nology, cost of manufacture, the market adop­
tion cycle, and the ultimate market size—are 
all unknown and cannot even be reasonably 
estimated. Thus, the calculations often fulfill 
the “garbage in/garbage out” axiom, producing 
largely meaningless results. 
Fortunately, technology transfer offices are 
almost never asked (or able) to sell a technology 
outright for a single lump sum. (Few companies 
or investors would be willing to pay any substan­
tial sum up front for unproven technologies even 
if the research institution was willing to make the 
offer.) Thus, the full worth of an invention need 
not be calculated at the time the technology is 
transferred. License agreements and spinout agree­
ments share the risk of this uncertainty between 
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CHAPTER .1 
the research institution and the company through 
a combination of payments, some at the begin­
ning of the license and others later, depending on 
future sales or the company’s future success. 
In a conventional license to a company, the 
financial components of the license may include 
(among possible other terms, such as sublicens­
ing fees): 
•	 a license issue fee: a negotiated amount pay­
able at the time the license is executed 
•	 license maintenance fees: annual fees, usu­
ally creditable against royalties in any year 
where royalties are payable (Thus, the li­
cense maintenance fees function as “mini­
mum royalties” in years when the product 
is sold.) 
•	 patent cost reimbursement: almost always 
required by universities 
•	 milestone fees: usually applied only when 
the technology is very risky and requires 
significant investment (Meeting a mile­
stone—such as approval for clinical testing 
or regulatory approval for sale—validates 
the technology, allowing the research in­
stitution to expect more rewards after the 
relatively low initial license fees.) 
•	 running royalties: usually a percentage of 
sales (Major value is expected here, but 
it is contingent on the technology’s suc­
cess and on the market’s acceptance of the 
product.) 
In a license to a spinout company2, the finan­
cial components may include: 
•	 a license issue fee 
•	 license maintenance fees 
•	 patent cost reimbursement 
•	 milestone fees 
•	 running royalties 
•	 shares of stock (in other words, equity) in 
the company 
Shares of stock may or may not be the ma­
jor source of return for the research institution. 
Equity in the company is certainly the riskiest 
component for the institution. In harsh economic 
climates, the company may have a difficult time 
reaching liquidity (that is, public stock trading 
status or acquisition by a larger company). In ad­
dition, if the company has to raise more money 
later from investors and its progress-to-date has 
not been good (or the economic climate for in­
vestment is bad), the company may have to ac­
cept funding in a “down round investment” that 
makes the initial stock almost worthless. 
If both running royalties and stock are taken, 
then each is usually lower than if the deal were 
“pure cash” or “pure equity.” In addition, license 
fees are usually lower than from a large compa­
ny, since a new company will typically be cash 
poor and will need to use its cash to develop the 
technology. 
The main point for both conventional licens­
es and spinouts is that if the technology is suc­
cessful the major financial returns will be from li­
cense fees and/or equity. With both conventional 
licenses and spinouts, the returns are linear. That 
is, once a running royalty rate is set (for example, 
4% of net sales), then the formula will make “ap­
propriate returns” regardless of whether the sales 
of the final product are US$100,000 per year or 
US$100 million per year: 
•	 If the sales are only US$100,000 per year, 
then the company pays the research institu­
tion only US$4,000 per year; a small but 
fair number, since the sales have not been 
high. 
•	 If the sales are US$100 million per year, 
then the research institution receives US$4 
million per year, reflecting the large success 
of the product. 
Similarly, if the research institution takes 
100,000 shares of founders stock from a total of 
one million shares of founders stock issued, rep­
resenting 10% of the company, in exchange for 
the technology (the total number of shares, one 
million in this case, is totally arbitrary: the per­
centage of the total is what counts), then: 
•	 If the share price at liquidity is US$50 per 
share (reflecting a successful company), then 
the university will receive US$5 million. 
•	 If the share price is low, reflecting a “despera­
tion acquisition” price of only US$0.50 per 
share, then the research institution will get 
only US$5,000. (This is not unheard of.) 
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It is worth reiterating that the research insti­
tution does not need to know the total value of 
the technology at the time of licensing/spinning 
out, because the linearity of running royalties 
and/or equity determines the amount the insti­
tution will receive. The acquiring company (or 
spinout), however, must have a much better es­
timate of the final value of the technology and of 
the cost of developing it, since the spinout must 
balance the cost and risk of developing the prod­
uct within the market against expected sales and 
profit returns. Fortunately, industrial concerns 
and financial investors have better resources for 
making these estimates. 
3. SO, WHAT ARE THE NuMBERS? 
This section is a risky one to both write and read. 
People often ask for numbers, but the problem is 
that there are no typical numbers, because there are 
no typical deals; each one is unique. The section 
does, however, attempt to provide some guidance 
on numbers. Those presented here are all based on 
personal experience with U.S. and U.K. institu­
tions and all depend on the following: 
•	 the importance of the technology to the fi­
nal product 
•	 the type of product 
•	 the uniqueness of the technology and the 
final product 
•	 the typical profitability of that type of prod­
uct and/or the industrial sector 
•	 whether the IP is the key IP for the com­
pany or only a small piece of its holdings 
•	 the strength and breadth of the IP 
•	 whether the IP includes:
 
-	only present patent rights 
-	additional know-how for which the 
research institution can command re­
turn (most know-how is in the public 
domain) 
-	a “pipeline” to future technology and 
patents from the research institution (a 
dangerous precedent if the pipeline is 
too wide) 
•	 whether the company will have to license 
blocking patents from third parties 
•  the state of development of the technology 
•	 how much and how long it will take to de­
velop it 
•	 the cost of development in the country in 
which the company resides 
•	 the state of the economy—including the 
state of the stock market and the investment 
climate in both the country of origin and, if 
different, the country of the licensee 
•	 the negotiating power of the research insti­
tution relative to the company 
•	 the negotiating skill of the research 
institution 
The amount of equity the university gets will 
depend on all of the above variables, as well as on 
the extent to which the research institution “in­
cubated” the technology and spinout company 
before the technology left the institution. For 
example, the amount (or percent) of equity will 
be lower if the university merely licenses the aca­
demic-stage invention to a newly incorporated 
company and higher if the university invests in 
showing proof of practical concept or in develop­
ing a prototype of the final product. The level of 
equity will be highest if the university assists in 
forming the company itself, devising and writing 
the business plan, hiring the management team, 
helping the company raise money, and even al­
lowing the company to be housed in the labora­
tories of the research institution for the compa­
ny’s first year or two of life. 
With those caveats, the typical ranges are 
given in Box 1 for license fees and royalties for a 
conventional license, based on U.S. experience, 
with the further caveat that some deals fall out­
side of these ranges. 
4. CONCluSION 
The task of evaluating and pricing early-stage 
technology is more art than science. (This is 
true for negotiation too.) Success requires a 
general knowledge of product development, 
manufacture, and markets, plus knowledge of 
the pricing for comparable technologies (when 
the information is available), plus experience. 
Technology transfer offices primarily learn 
from their own experiences and by studying the
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experiences of similar institutions. If the offices 
can attract and retain both talented staff and 
commitment from their administration, they 
will get better with time. 
No deal will be perfect. Some will fail. It is 
important to remember, however, that it is far 
better to conclude a deal with a company that 
will competently develop the product than to 
wait for the best deal or to fight interminably for 
the best financial terms. Only when the technol­
ogy is developed and brought to market will the 
public benefit. And that is ultimately why uni­
versities and their technology licensing offices are 
in business. n 
LITA NELSEN, Director, M.I.T. Technology Licensing Office, 
Massachusetts Institute of Technology, Five Cambridge 
Center, Kendall Square, Room NE25-230, Cambridge, 
MA, 02142-1493, U.S.A. lita@mit.edu
1	 See also in this Handbook, chapter 1.4 by L Nelsen and 
A Krattiger.
2	 See also in this Handbook, chapter 13.1 by A Brown and 
J Soderstrom. 
Box 1: M.I.T.’s license Fees and Royalties 
(u.S. dollars) 
Conventional license (without equity) 
•	 License Issue Fee: $10,000–$200,000 
•	 Annual license fee (minimum royalties): $20,000–$200,000 (often beginning low and increasing 
by year until the amount reaches a plateau) 
•	 Milestones (when present): $0,000–$1,000,000 (the latter when Food and Drug Administration
approval for marketing is gained for a major drug) 
•	 Running Royalties: 0.%–% (the lower range for process improvements or commodity products;
the higher range for noncommodity products and patents with product claims) This may be still
higher for software and for composition of matter patents on drugs. 
Based on U.S. and U.K. experience, the following division of equity is typical for a spinout after it has 
raised $1 million in investment. It assumes lower license fees and royalties: 
Spinout Company Equity Shares After $1 Million of Investment 
Venture investor: ........................................................................................ %
 
Research institution’s share based on IP alone: ................................. %–%
 
(If) Research institution does extensive incubation: ........................ 10%–1%
 
Research institution total: ....................................................................... 1%–22%
 
Employee stock option pool: ................................................................... 20%
 
Founding entrepreneurial team: ............................................................ 2%–2%
 
If no incubation was provided by the research institution, then the entrepreneurial team’s share may 
be 0%–%. 
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Technology Valuation: An Introduction
 
ROBERT H. POTTER, Senior Associate, Agriculture & Biotechnology Strategies, Inc., Canada 
ABSTRACT 
This chapter explains the basics of the various ways of 
estimating value of a new technology, focusing on the 
importance of agreeing on the value before finalizing a 
technology transfer deal. Indeed, value is simply the ne­
gotiated amount arrived at between two parties. Although 
there are many ways to place a value on a technology, 
most licensing deals focus on royalty amount, since it 
spreads the risk between the technology provider and the 
developer. The percentage assigned to royalty has to be 
negotiated. Several factors will affect royalty value: level 
of market demand, the improvement the technology can 
bring to the final product, whether or not other invest­
ments will be needed to develop the final product, and, 
most importantly, the predicted rate of uptake in the 
marketplace. Some understanding of these factors, or at 
least the procedures used to estimate them, will enhance 
one’s ability to negotiate a deal that will both help bring 
the technology to market and nurture the relationship be­
tween the parties, thus facilitating any future technology 
transfer deals. 
1. INTRODuCTION 
What is value and what are valuation techniques? 
Value is what a willing buyer and a willing seller 
have agreed upon as the basis for the exchange 
of property or, in our case, intellectual property 
(IP) rights. The critical point is finding a particu­
lar value that is agreeable to both the buyer and 
the seller. The first task, and the most difficult 
one, is assigning realistic values (that the partners 
can agree on) to the various factors in the system. 
Simply put, valuation is the process of estimating 
a mutually agreed upon value for a product or an 
intellectual property that will enable its transfer 
from seller to buyer. People use many techniques 
to reach this value. A perfect valuation scenario 
would be one where both the buyer and seller 
walk away each thinking it got the best deal. 
Although we may not realize it, we use valu­
ation techniques every day. For example, an indi­
vidual might not hesitate to pay US$6 for a ham­
burger, but would certainly not be willing to pay 
US$50 for the burger. This is because we perceive 
the value of a burger to be within a limited range. 
The benefits we derive from a burger are not ex­
pected to cost more than the money we are will­
ing to spend; otherwise, one will eat elsewhere. 
From the buyer’s point of view, the cost, benefit, 
and competing alternatives determine what we 
will pay, and, therefore, determine a value. That 
value will change depending on where we are, 
how hungry we are, and how far the nearest bet­
ter alternative is. From the seller’s point of view, 
the questions are: How much can I charge for the 
burger? What is the demand for my burgers? How 
many different alternatives are there? How is my 
product distinct and superior to the alternatives? 
This chapter provides background knowledge 
on technology valuation that is particularly rel­
evant to IP rights in agriculture. The chapter aims 
to heighten readers’ awareness of the important 
Potter RH. 2007. Technology Valuation: An Introduction. In Intellectual Property Management in Health and Agricultural In-
novation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. 
© 2007. RH Potter. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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POTTER 
issues and methods involved in technology valua­
tion when negotiating the sale of rights to a new 
technology as well as in other circumstances. 
2. VAluATION OF
INTEllECTuAl PROPERTy 
Much energy has been spent determining meth­
ods for valuing intellectual property, technology, 
or products. All available approaches require dif­
ferent amounts of data and serve different pur­
poses (limitations are inherent regardless of the 
approach taken). A brief overview of the most 
common approaches to technology valuation is 
provided in this chapter. More detailed discus­
sions are found elsewhere in the Handbook.1 
The valuation of intellectual property tends 
to be very complex, since the task of valuation 
involves determining the present value against a 
future technology or product. Various methods 
have been developed that use greater or lesser 
amounts of economic theory. In the end, as the 
value will usually be a negotiated figure, what is 
most important is to find a method that both par­
ties agree will produce a value they can accept. 
The most common method of valuation is a 
process of discounted cash flow, which calculates 
the present value of future revenues. Present value
reflects the price a purchaser of the intellectual 
property is willing to pay now, in order to receive 
anticipated cash from future sales of the product. 
Different variables and factors can be built into 
this, such as the risk of the technology not deliv­
ering promised returns, but obviously it is hard to 
accurately estimate the future cash flows from in­
tellectual property or from an undeveloped, un­
tested technology. The closer one comes to a final 
product, the more realistic will be the estimate 
of future cash flow. Waiting until near the end of 
product development to negotiate royalties can, 
however, give rise to serious problems in reaching 
a negotiated settlement. 
Most valuation models rely on market data, 
which, at best, can provide only a range of prob­
able values. For a revolutionary new product, di­
rect market data is often unavailable and proxies
(or existing products on the market) are used as 
substitutes. The complexity of valuation arises 
from the challenge of identifying useful, appro­
priate proxies. The more appropriate data one 
uses, the more accurate the valuation will be. 
Furthermore, the individual and specific val­
ue of assets will vary widely. Understanding how 
these specific values are statistically distributed 
will greatly help estimating value, since including 
a probability of receiving a specified return aids 
decision making. Wherever an individual compo­
nent has a range of possible values, knowing the 
statistical distribution over this range can make 
the overall valuation more accurate and also allow 
one to estimate the probability that this value will 
actually be achieved. 
The following sections identify several valua­
tion approaches and provide a short explanation 
of each. To illustrate this, each approach is ex­
plained with reference to a fictional, ongoing ne­
gotiation, between the University of Costa Rica 
and Mer Seeds SA de CV, over a commercial-use 
license for a root-rot-resistant gene isolated at the 
university. The gene has been transferred into a 
line of a root crop called mer, which Mer Seeds 
intends to cross with their elite breeding lines. 
2.1 Cost approach 
The cost approach is based on covering costs of 
developing a new product. Using this approach, 
the University of Costa Rica would seek to charge 
a one-time fee to cover all research and possible 
patenting costs for isolating the gene and produc­
ing the transgenic root-rot-resistant mer. While 
this approach is a highly relevant one for pricing 
an article produced for sale, the approach is rarely 
used to assign a value to a piece of intellectual 
property, because the cost to develop something is 
not usually related to the value of any intellectual 
property it contains. One version of the approach 
is to calculate anticipated future costs of develop­
ing similar technologies—in effect, using the pro­
ceeds from the sale of this technology to pay for 
developing the next one. This approach, however, 
is highly subjective and difficult to justify. 
Still, knowing the cost of development of 
a particular technology is often useful and rel­
evant when calculating the relative inputs of par­
ties into a joint venture. If, instead of licensing 
a technology, an institution enters into a joint 
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CHAPTER .2 
venture to develop a product, initial investments 
into the joint venture often control the share 
assigned to each party. A university or research 
institution may not have adequate financial re­
sources to develop a product from a technology, 
but the institution could justifiably claim a share 
of a joint venture based on the investment in the 
project up to that point, as well as the product’s 
potential value. 
2.2 Income approach 
A pure income approach is carried out by discount­
ing future anticipated revenues (cash flows) sev­
eral years into the future. In our scenario, this ap­
proach is used when the University of Costa Rica 
asks Mer Seeds SA de CV how much it would 
be willing to pay now for a certain return in the 
future (for example, US$10 million in 10 years 
time). The big drawback to this approach is that 
there may be no sales, market, or cost data from 
which to predict future revenues. Furthermore, 
the method relies heavily on allocation of risk: de­
termining what the chances are of a disappointing 
return (or even of no return at all) and who should 
take this risk, the university or the company? Risk 
estimates are crucial for determining whether to 
invest in a new technology, but they are too often 
based on little more than gut feeling. 
2. Market approach 
The market approach requires finding a similar or 
comparable technology to the one being evaluat­
ed. In our scenario, the University of Costa Rica 
would look for other root-rot-resistant mer plants 
on the market and determine how much farmers 
are using and paying for the seed. So, the valua­
tion would rely on finding sufficient data about 
similar transactions to arrive at an accurate esti­
mate of the value of the new product. The inher­
ent weakness of this approach is the difficulty of 
obtaining data for a truly novel product. 
2. Hybrid approaches 
The more common approach is to use a hybrid 
of income and market methods of valuation. 
This combines the benefits of market compara­
bility and the business community’s familiarity 
with the income approach. In our example, Mer 
SA de CV would use its experience with similar 
products to estimate what farmers would pay and 
how quickly the market for the seed would grow 
to produce the estimated income. This method 
is usually applicable where there is prior experi­
ence and sufficient information. Where products 
are being developed in-house (for example, in a 
large company that performs all or most of the 
research and development), calculating the net 
present value of a new product is based on this 
hybrid method. Decisions on funding products 
are made by estimating a certain minimum net 
present value. 
2. Royalty rate method 
Because royalties give the inventor a return on 
sales of the final product, royalties are often used 
to share the risk between the inventor and the de­
veloper. Parties often use a royalty rate that has 
been agreed upon in the past for similar technolo­
gies; that rate is then applied to anticipated rev­
enue streams. Because of the risk-sharing nature 
of this method (if the product does not become a 
success, the royalty amount is low), this is a com­
mon approach to licensing technology. But the ap­
proach does not always result in a valuation of the 
technology itself. Indeed, royalty rates are often 
determined arbitrarily, with little or no relation to 
the added value the technology may give to the 
product. For example, in our scenario, if an ini­
tial collaborative research agreement between the 
University of Costa Rica and Mer Seeds limits the 
university to a maximum royalty of 5% of gross 
revenues, then, if the technology increases the 
value of Mer seed products by more than that, the 
university loses. Another problem with arbitrarily 
applying royalty rates, in this case, is that if Mer 
Seeds were to combine several traits in one variety, 
then the company might be unable to afford to 
pay 5% royalties to each technology provider if 
the combined added value was insufficient. 
3. THE PRODuCTION SySTEM 
To accurately value a new technology, the existing 
production system must be understood in order 
to see where the new technology will be applied. 
While agricultural systems vary due to climate 
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and local soil conditions, data do exist on input 
(costs) and output (benefits)—as in any field. 
Because of the complex interrelationships among 
agricultural markets, competition is hard to es­
timate, but data does exist upon which to base 
assumptions. As modern agricultural products 
rely more and more on biotechnology, a relatively 
new field, for which there is little information 
and substantial risk that there will be no product 
at all, valuation becomes more difficult. To illus­
trate the complexities of agricultural systems, we 
use an input/output or cost/benefit model based 
on the harvest of mer (see Figure 1). 
The diagram depicts average returns per 
hectare of mer in Latin America. Input costs, 
such as for seed, fertilizer, and pesticide, have 
been derived by converting to U.S. dollars from 
the average costs in Latin America of those items. 
Similarly, yield in metric tons (MT) was calcu­
lated by taking conservative yield figures and 
deducting average post-harvest and pest losses 
to arrive at the final yield per hectare for the av­
erage mer farmer. Returns are divided between 
those from mer that is consumed domestically 
(Domestic) and those from mer that is exported 
(Export). On the basis of this model, production 
costs are US$90 and returns are US$220. A new 
product that reduces inputs (pesticides, in this 
case, of root-rot-resistant mer) can be calculated 
to increase returns by the amount that the pes­
ticides cost. 
4. VAluING IP RESOuRCES 
Sometimes, all of the IP resources of a company 
or institution need to be valued. Valuing these re­
sources can provide a value for the whole compa­
ny, including its intellectual property and physi­
cal resources, or it can reveal the input a company 
is investing in to developing a product, excluding 
Figure 1: Hypothetical Cost/Income Model 
for Mer Production in latin America 
















(2 x US$80) 
US$160 
(3 x US$20) 
Note: The online version of the Handbook (www.ipHandbook.org) contains a downloadable Microsoft® 
Excel spreadsheet, which readers can use for modeling cost/income scenarios. 
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CHAPTER .2 
the technology that is being negotiated. In our 
hyphothetical example, Mer Seeds can point to 
the intellectual property that it already owns, for 
example, existing mer varieties, to show that the 
company is investing significant resources into 
developing the new product and also to show that 
the gene being obtained from the university will 
be worth only a portion of the total added value. 
Knowing such figures is relevant for joint venture 
negotiations. 
One complication in these calculations is the 
need to value nonformal intellectual property: the 
know-how, experience, and expertise that reside 
in the company, and in its employees, and that 
may not be protected by patents and trademarks. 
Institutions that consider only the value of formal 
intellectual property stand to lose from overlook­
ing this form of intellectual property. 
.1 Excess earnings/residual value 
The excess earning/residual value approach places 
a valuation on an entire business, rather than a 
single technology. The approach is appropriate 
only if a company has just one major-platform 
technology and its business is based purely on 
products related to that technology. Using a pe­
riod of five or more years immediately prior to 
the valuation date, a percentage return is assigned 
to the average annual value of tangible assets used 
in a business. This return is deducted from aver­
age earnings of the business for the same period, 
and the remainder, if any, is considered to be the 
amount of the average annual earnings from the 
intangible assets of the business. Since this meth­
od is based on past data, it is not necessarily useful 
for valuing a novel technology, but it may be used 
to value a company’s existing technologies. which 
will allow for the determination of how much 
of an input one side is making in a negotiation. 
For example, Mer Seeds could use this method to 
value its existing germplasm in order to show that 
the varieties coming out of the transgenic project 
are just as much due to their germplasm as to the 
transgene. The main flaw in this model, however, 
is the assumption that excess earnings above and 
beyond the return on tangible assets are solely at­
tributable to intangible assets. Such thinking can 
lead to an error in valuation because it assumes 
that the business is maximizing the exploitation 
of all of its intellectual property. 
.2 Technology factor method 
The technology factor method is a modification of 
the income or excess earnings approaches that 
addresses the shortcomings of these approaches 
by directly measuring the contribution of the 
technology to the total revenue of the business. 
The technology factor method can be used on 
one technology at a time to eliminate the limita­
tions of the excess earnings method, in which the 
whole set of intangibles are valued and lumped 
together. The technology factor method might be 
applicable to Mer SA de CV if it sold many more 
agricultural products than just mer seeds and if 
most of these products had a relatively low tech­
nology input (for example, if the company dis­
tributed many agricultural chemicals produced 
by large multinational corporations). In this case, 
an overall picture would not give the true worth 
of the value of the company’s germplasm. 
. Options pricing method 
The options pricing method estimates the value of 
the technology at the point it is considered to be 
successful and then calculates the probability of its 
preliminary successes along the path to commer­
cialization. In the root-rot-resistant mer example, 
basic research has already been done, but there are 
still the possibilities that the technology will not 
work in the field, that farmers will not be prepared 
to buy it, or that a competitor will offer a better 
product (such as a very cheap fungicide). It is also 
possible that transgenic mer will not be approved 
for biosafety or food safety reasons. The probabil­
ity of success at each step in the process is very 
hard to calculate, but with each step, the value of 
the technology effectively rises as the risk of failure 
diminishes. To use this model for early estimates 
of value, the technology must be well defined and 
the statistical analyses of historical data must be 
significant enough to allow the appraiser to assign 
probabilities to the technology as it proceeds from 
one step to the next. This method is applicable 
to start-up companies during their initial rounds 
of financing, and also for companies developing 
high-risk technologies, such as pharmaceuticals. 
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. Technology risk/rewards method 
The technology risk/rewards method uses the value 
of roughly comparable technology-based busi­
nesses as a proxy for the value of patents, and 
then subtracts from this number the amount of 
cash needed to further develop the technology to 
a commercial stage. Thus, Mer SA de CV would 
first calculate the value the company could gain 
from the technology and then look at the invest­
ment needed to bring the technology to market. 
Using this number, the company would decide 
whether to commercialize the product and wheth­
er paying the University of Costa Rica could be 
afforded. One drawback of this method is the 
assumption that the value of technology-based 
companies reflects only the value of the technol­
ogy, which ignores many other factors. 
5. ADOPTION 
One very important factor in determining the 
market value of a product is how much of the 
product is sold or used and at what rate demand 
for the product develops and increases. A prod­
uct’s success depends not just on the number of 
people who try it once, but on the number of re­
peat users. This is referred to as the adoption pro­
cess, in which a product goes from being new in 
the marketplace to being an established product 
(or, in some cases, obsolete). 
Figure 2 is a generalized adoption curve 
for a hypothetical new technology or product. 
Importantly, the rate at which a product is taken 
up has a great effect on the revenue that goes to 
the developer of the product. In this case, as of­
ten happens, initial uptake is low, and adoption 
grows slowly as people become aware of the prod­
uct, try it out, and use it. Early adopters show 
the product’s potential value, and gradually other 
consumers begin to use it. As more users see the 
benefits, the product spreads throughout the 
market. When the new product approaches full 
market penetration, the rate of uptake slows— 
there are always people who are either very late 
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in adopting or will never adopt the product. At 
some point other competing products may enter 
the market and reduce market share, or newer 
technologies may arise that replace the product 
completely. The actual curve, therefore, will be 
more complex than Figure 2 suggests. 
In reality, farmers are likely to be wary of ini­
tially investing heavily in an agricultural product, 
such as a new seed variety. Some will try it out 
on part of their land and, if they feel it is worth 
the investment, they might then plant more of the 
seed. Other farmers may see this and decide to try 
out the seed themselves. Once a certain amount 
of the seed is being grown, the adoption rate will 
increase. However, there will almost always be 
some farmers who will either delay adoption or 
not adopt at all, because they prefer traditional 
methods, are unwilling to change, or perhaps be­
cause their land is of such poor quality that the 
increased yield does not cover the increased price. 
Calculating the value of a product by mak­
ing sales projections (the income approach) must, 
therefore, consider not just the total area of land 
on which a seed could be used, but also include 
a realistic sense of the rate at which the coverage 
area will expand to reach the total. Meanwhile, as 
other products will also likely become available, 
the original product will be unlikely to retain its 
area indefinitely. 
6. CONCluDING REMARKS 
As the discussions above indicate, no universal 
method for technology valuation exists. In fact, 
different methods will often be used within one 
organization. The method chosen depends on the 
kind of technology in question and whether one 
is a technology buyer or a technology seller. In the 
end, however, what most matters is the accuracy 
of the estimations and assumptions about whether 
a product will be a success and how much people 
will pay for it. Estimating the size of the potential 
market and the adoption rate for the product are 
both important in this process. 
Negotiating is a big part of arriving at a value 
for your technology, but remember that develop­
ing intellectual property into commercial prod­
ucts through in-licensing and out-licensing is not 
a zero-sum game. Both buyer and seller are look­
ing to get something good out of the deal. And 
these are the much-sought win-win deals. n 
ROBERT H. POTTER, Senior Associate, Agriculture & 
Biotechnology Strategies, Inc., 106 St. John Street, PO Box 
475, Merrickville, Ontario, KOG 1N0, Canada. rpotter@ 
agbios.com
1 See, also in this Handbook, chapter 9.3 by R Razgaitis. 
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Pricing the Intellectual Property of Early-Stage 





RichaRd RaZgaiTis, Senior Advisor, CRA International, Inc., U.S.A. 
ABSTRACT 
This chapter introduces technology managers to certain 
key issues and to six methods of valuation and pricing. 
The value of a technology to a buyer (licensee) depends 
upon how it is to be commercially employed, taking 
into account the cost of development, the time the tech­
nology takes to generate returns, the extent of such fi­
nancial returns, and the risk involved in the process. At 
the time of a licensing/sale transaction of an early-stage 
technology many, perhaps all, of such factors need to 
be assessed and quantified by making judgments about 
how the future will unfold with respect to the technolo­
gy being developed. This assessment and forecast assess­
ment are the essence of all pro forma business models. 
Valuing license rights for early-stage technologies is in 
this sense no different than making other future busi­
ness forecasts, though the details may differ because the 
forecast time horizon may be longer, the uncertainties 
may be greater as to the market size and profitability, 
the operating performance of the technology as it will be 
used in commercial operation may be less well defined, 
and other factors. The price paid for a technology trans­
ferred between parties is the amount of money (present 
and future) and/or the financial value of noncash assets 
given in exchange for the transfer of the technology, 
which can only occur if both the seller (licensor) and 
buyer (licensee) have by some process reached a com­
mon, present understanding of value that makes agree­
ment possible. 
A key consideration in valuing a technology and arriving 
at a price is determining what is to be provided or trans­
ferred between the parties. This may include exclusive or 
nonexclusive rights to specified patents, know-how, and 
copyrights (IP [intellectual property] rights), technical 
data, rights to future-seller improvements, rights to subli­
cense, and the like. The price can consist of any combina­
tion of a variety of types of consideration, including run­
ning royalties, fixed payments, common stock (equity), 
R&D funding, lab equipment, consulting services, grant 
backs, or access to other proprietary buyer resources. 
Although sometimes used, cost-basis pricing is a poor ba­
sis of valuation, because it fails to consider a technology’s 
value based on future commercial applications: the market 
pays for value to be received, not the cost to create. This 
chapter introduces and explains six methods for valuation 
and pricing that are based, to one degree or another, on 
the market’s expectation of value. 
•	 Method I: The Use of Industry Standards Method 
looks at the range of published royalties (and other 
forms of payment) from technology licenses with­
in an industry category and uses that information 
to guide valuation of a technology currently under 
consideration. 
•	 Method II: The Rating/Ranking Method looks 
at several existing license agreements for similar 
technologies, comparing and ranking a technol­
ogy currently under consideration against the 
existing license agreements in terms of stage of 
Razgaitis R. 2007. Pricing the Intellectual Property of Early-Stage Technologies: A Primer of Basic Valuation Tools and 
Considerations. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Prac-
tices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Second Edition Part II: Chapter 4). 
© R Razgaitis. 2007. All rights reserved. Photocopying and distribution of this chapter through the internet is permitted 
provided that: (1) this complete copyright notice is included; (2) no derivative works or changes to this text are made; (3) 
the chapter is copied in its entirety as a single, complete stand-alone work and not be combined with any other text, im-
ages, graphics, or works; and (4) no compensation is sought or received for any such copies. www.razgaitis.com. 
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development, scope of IP protection, market size, 
profit margins, and other such factors. 
•	 Method III: The Rules of Thumb, such as the 25% 
Rule (and Other Rules) Method, which appor­
tions anticipated profits from the commercial use 
of the technology between the seller and buyer. 
•	 Method IV: The Use of Discounted Cash-Flow 
Analysis with Risk-Adjusted Hurdle Rates Method 
seeks to split expected returns but adjusts basic 
profit and loss accounting terms to take into ac­
count the timing of investments and returns and 
the risks borne by both parties. The method intro­
duces a discussion of the different possible struc­
tures of payments that are possible, as they affect 
both timing and risk. 
•	 Method V: The Advanced Tools Method applies 
statistical methods, such as Monte Carlo simula­
tions, to discounted cash-flow models to test the 
influence of various value assumptions and license 
terms on the possible outcomes of a deal. 
•	 Method VI: The Auctions Method allows in­
terested parties to bid on the technology, based 
upon their own independent efforts at valuing the 
technology, thus comparing their respective valua­
tions, identifying the highest valuation, and strik­
ing a price based on that highest valuation. 
pREfACE 
Although we will consider each of the valuation 
methods one at a time, doing so does not sug­
gest that only one method is to be used in any 
given valuation, nor does having six methods 
mean that all should be used in every situation. 
Depending on the circumstances it is likely to be 
advantageous to consider more than one method 
in any particular valuation. Yet, not all methods 
work equally well in all circumstances, and there 
is always the practical consideration of the com­
mensurate level of valuation analysis appropri­
ate to the magnitude of the potential licensing 
opportunity. 
The context of the valuation and pricing 
discussed in this chapter and with the valuation 
methods is licensing (sale) generally known as op­
portunity licensing, as distinct from licensing in 
litigation contexts. In litigation matters there is 
normally a very narrow focus on certain claims 
of certain patents that have been infringed as of 
a particular date with respect to specified prod­
ucts and which patents are known to be valid, 
enforceable and infringed. On the other hand, 
opportunity licensing of early-stage technology 
is normally performed prior to a licensee’s com­
mercial use, includes deal elements other than a 
narrow enumeration of certain patent claims, and 
anticipates the potential future use for a range of 
products, applications, and markets. 
This chapter is necessarily a short introduc­
tion to a complex subject. The author has writ­
ten three published books that give a much fuller 
treatment of these valuation and pricing matters 
than is possible here. Two of the books are cur­
rently in print and available from online sources 
such as Amazon® and are recommended for those 
who are charged with valuation and pricing of 
technology. 
•	 Valuation and Pricing of Technology-Based 
Intellectual Property, Dr. Richard Razgaitis, 
published by John Wiley & Sons, 2003. 
•	 Dealmaking Using Real Options and Monte 
Carlo Analysis, Dr. Richard Razgaitis, pub­
lished by John Wiley & Sons, 2003. 
•	 Early-Stage Technologies: Valuation and 
Pricing, Dr. Richard Razgaitis, published 
by John Wiley & Sons, 1999 (now out of 
print, and supplanted by the 2003 valua­
tion and pricing book). 
Finally, the views expressed here, as in my 
above writings, are solely those of the author, and 
are not intended to represent the views of CRA 
International or that of any professional society 
of which I am a member or officer. 
1.	 InTRoduCTIon 
One of the most interesting and challenging 
tasks facing a licensing manager is determining 
the value and price of its specific opportunities. 
This chapter provides an overview of useful tools 
and methods for this purpose and offers general 
observations on licensing practices.1 Because each 
valuation situation depends on numerous, case-
specific factors, such generalizations may not ap­
ply universally, so readers are encouraged to be 
cautious when drawing parallels or imagining 
similarities. 
Pricing, of course, is a crucial issue in the 
commercialization process. The customer for 
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CHAPTER . 
early-stage technologies can be viewed as a value-
added reseller. Resellers will be induced to buy 
(license), if and only if they believe that they can 
conduct all the value-added activities needed and 
sell the result to their customers at a price signifi­
cantly greater than what they paid to acquire the 
rights. 
When selling rights to early-stage technolo­
gies, there are (usually) significant uncertainties 
facing both the owner of the technologies and the 
licensee. These uncertainties include important 
issues such as: 
•	 Does the technology really work in a pro­
duction setting as opposed to inside a clois­
tered laboratory? 
•	 What product development and manufac­
turing activities will need to be conduct­
ed—and at what cost—to bring the tech­
nology to commercial maturity? 
•	 Will there be any commercially valuable 
patent protection to bar copycats? 
•	 What product do end users really want 
from the technology, and how much will 
they be willing to pay? 
•	 What regulatory requirements will need to 
be satisfied? 
•	 How much better is this technology than 
what is already available? 
•	 Will competitors develop an even better 
way of meeting the end user’s needs? 
One way to begin to get around the pric­
ing issue is to use royalties. The advantage of the 
royalty (and equity) concept is that it spreads, 
to some degree, these uncertainties and risks be­
tween the parties. Under a royalty (or equity) ar­
rangement, technologies that ultimately become 
wildly successful in the marketplace will return 
high financial rewards to both the licensee and 
the licensor in some direct proportion to the 
degree of commercial sales achieved. This helps 
remove some of the anxiety of determining the 
right price—but not all of it. 
Technologies that lead to highly profitable 
outcomes for a licensee typically warrant a higher 
royalty rate on behalf of the licensor. Similarly, 
smaller returns (with all relevant factors consid­
ered) warrant a lower rate. By fixing a royalty rate, 
an equity split, or any combination of royalties 
and equity, the technology transfer manager is 
apportioning the total financial reward between 
the creating organization and the commercial­
izing organization. That split should depend on 
the relative value-creating contributions of both 
parties. 
Determining a fair royalty depends on a 
present understanding of the commercial use 
and economic impact of the licensed technol­
ogy. From this perspective, it is better, when 
feasible, to defer setting the royalty rate to the 
time, or closer to the time, of commercial intro­
duction. When licensing early-stage technology, 
this means that the license or option agreement 
would leave the royalty rate unspecified. The par­
ties would commit to engage in good-faith nego­
tiations on this matter at a later date, preferably 
when a projected income statement based on 
more robust market and manufacturing projec­
tions was available. 
But prospective licensees generally look 
at this approach with disfavor. They argue that 
the royalty rate is an important factor in reach­
ing a decision about licensing the technology in 
the first place. Further, the licensees argue that 
they cannot commit substantial product- and 
market-development investments and risk fac­
ing a carnivorous licensor seeking unreasonable 
compensation at the eleventh hour. And there are 
also some good reasons why a technology seller 
might not prefer to defer royalty negotiations. 
Depending on the final royalty values, the seller 
might have elected to pursue a different commer­
cialization approach (taking equity in a spinout 
or pursuing industry-wide nonexclusive licens­
ing) or to find a different licensee willing to pay 
more for the opportunity. 
Further, if a market window has closed, a 
reversion of rights back to the seller because of 
an inability to agree on financial terms may be 
of little business value. Clearly, it is in the inter­
est of both parties to conduct royalty negotia­
tions based on accurate projections of a license’s 
economic impact. Agreements reached before 
the impact is known are more likely to be dis­
appointing to either the licensee or licensor. A 
disappointed licensor will normally not have any 
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RAZGAITIS 
recourse as long as the licensee fulfills its end of 
the deal. A disappointed licensee, however, can 
come back to the licensor and threaten to drop 
the license unless it gets some relief from a royalty 
rate that the licensee later perceives as too high. 
The licensor can decline such a request, but it 
could be put in a difficult bargaining position be­
cause of the cost, delay, and risk associated with 
finding another licensee, and because the term 
of years remaining under the patents may have 
been reduced significantly while in the hands of 
the original licensee. A royalty rate determined 
well before commercial introduction can thus be 
viewed as a royalty cap by the buyer, regardless 
of what is called for in the agreement. Of course, 
the buyer cannot count on a seller agreeing to 
such a downward renegotiation in royalty rate; 
the buyer may face the choice of proceeding to 
commercialization under the agreed terms, or 
dropping its license and losing its own invest­
ment in the technology. 
Parties seeking win-win arrangements 
should seek ways to make these negotiations as 
fair as possible, even while each party is looking 
out for its institution’s interests. This requires 
as much economic information as possible and 
some tools for using that information. Presented 
in the sections below are tools and consider­
ations in determining such splits of the com­
mercial reward. To set the stage, consider the 
following excerpt from an actual letter received 
by a venture capitalist: 
“… we are asking for Forty Million Dollars 
($40,000,000), which will provide the capital 
needed … . As planned, at the end of the two-year 
period, we will have ramped up to 100% with an 
expected pre-tax profit of $211,832,258.”2 
Now, is this a good deal? Even more impor­
tantly, what methodology could be used that 
would lead to a fair price for such an opportunity 
and form the basis for a rational decision? 
Although the general principles in this chap­
ter apply to both a licensee (buyer) and a licen­
sor (seller), this chapter primarily looks at these 
matters from the point of view of the licensor. 
The form of an agreement is not detailed in this 
chapter; many differing approaches as to royalties 
and equity are possible. This topic is sufficiently 
complex to warrant coverage in other chapters in 
this Handbook.3 
2.	 GETTInG	STARTEd 
Prior to delving into this discussion, it is help­
ful to review the definitions of two key, related 
terms.4 
•	 value: an amount considered to be a suit­
able equivalent for something else 
•	 price: the sum of money or goods asked or 
given for something 
In this chapter, price will mean the quantifi­
cation or specification of value. Price should be 
the expression, in monetary and other forms of 
consideration, of what the technology manager 
believes is an appropriate starting point for dis­
cussions and ultimately represents a fair exchange 
for the institution’s willingness as a licensor to en­
ter into a commercial agreement. 
This requires that the technology transfer 
manager determine, from the outset, what the 
institution is willing to provide as its end of the 
bargain. Table 1 summarizes ten sources of value, 
from the perspective of a licensor of early-stage 
technologies. 
Item No. 1 is the key source of value pro­
vided by the licensor for a typical early-stage 
technology agreement—the right to practice the 
technology described by the intellectual property 
(IP). The licensor may also provide something 
within the categories of Item Nos. 2, 3, and 4. 
Item No. 5 is usually a left-pocket/right-pocket 
grant: if the licensor agrees to pay the patent costs 
for the licensee, then the licensee reimburses the 
licensor for these costs, dollar for dollar.5 
From the perspective of licensors of early-
stage technologies, Item Nos. 6, 7, and 8 are 
strictly the responsibility of the licensee and are, 
thereby, not part of what is granted. Although the 
costs associated with these boxes may be small 
on average, the risks of a very significant cost as­
sociated with them on a given deal are both so 
large, and primarily or solely under the control 
of the licensee, that it is imprudent for a licensor 
to bear them (this is discussed in greater detail in 
Section 6.4). 
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The last two Items, Nos. 9 and 10, may in­
volve the licensor in some way; most often, how­
ever, the licensor will grant only a willingness to 
assist the licensee in these activities on a cost-re­
imbursement basis. 
Generally, therefore, the licensor of early-
stage technologies is offering Item No. 1 and, 
possibly, Item Nos. 2–4. Within each of these 
boxes, figuratively speaking, are yet smaller boxes 
that further define the contents of the grant. For 
example, in Item No. 1 the license may be exclu­
sive for all fields and territories for all patents in 
the technology package, for a specific application, 
for a specific territory, for a specific term (such 
as five years, after which time the licensor can 
license others), or exclusive but for one other li­
censee (a limited exclusivity, sometimes referred 
to as a second-source approach), and so on in a 
limitless array of possibilities and combinations. 
Each of these options will have a different eco­
nomic value; accordingly, each should bear a dif­
ferent price. Such issues are sometimes referred to 
as aspects of value (see Section 6.2). 
As the licensor, a technology transfer man­
ager needs to determine what boxes (and contents 
thereof ) the institution is offering as its package. 
Table 1: Ten Sources of Value Relating to IP (Intellectual Property) Rights
 
1. Rights to practice the • IP rights included
technology (patents, • Field/territory 
trade secrets, copyrights, • Degree of exclusivity
trademarks) • Duration 
2. Commercial data Production drawings, material balances, operating 
statements, training or technical assistance 
3. Future improvements From licensor, from licensee, from other licensees, rights 
to, payment(s) for 
4. Right to sublicense Conditions for, split of fees, improvements/grant backs 
5. Patent expenses Maintenance costs, patent prosecution, foreign filing 
6. Defense of patents Oppositions, interferences, declaratory judgment actions,
claims of ownership 
7. Infringement issues Studies and opinions, freedom to practice, suits against
infringers, suits by third parties 
8. General indemnity Product liability, ownership issues 
9. Quality control Testing, laboratory services, trademark policing 
10. Regulatory approval National regulatory agencies and listings such as the FDA,a
and EPA,b and TSCAc 
a U.S. Food and Drug Administration
b U.S. Environmental Protection Agency
c Toxic Substances Control Act 
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It is a very good practice to document the con­
tents of the package in some detail for internal 
purposes, and perhaps in a more succinct fashion 
for initial discussions with prospective licensees. 
For example, part of a licensing package could 
include product prototypes or customized test or 
development fixtures, as well as data unpublished 
or not yet published that provides additional in­
formation on potential applications, costs, or ar­
eas of potential improvement. 
Similarly, the technology professional should 
document in detail what the institution is seeking 
from the licensee as fair exchange. Some items to 
consider in determining this exchange are: 
•	 royalties (often termed running royalties) 
•	 other cash payments (an upfront cash 
payment, progress payments, or annual 
minimums) 
•	 common stock or partnership interests (as 
partial or total offset for royalties) 
•	 R&D funding at the institution to advance 
the technology or other R&D objectives 
•	 lab equipment 
•	 consulting agreement(s) 
•	 improvements to inventions (so-called 
grant backs) 
•	 access to proprietary and/or technical data 
related to the invention 
There is a long list of sources of consider­
ation that the institution may wish to seek from 
the licensee. By thinking through these items 
and writing down those that are desirable from 
the institution’s point of view, the technology 
transfer manager can develop a rational frame­
work for expectations. From a negotiating per­
spective, following this process can prevent the 
institution from being perceived as a nibbler: 
that is, an organization that is always thinking 
of something more that it should get for the 
deal. 
.	 THE	ConTExT	 of pRICInG 
The seller’s pricing expresses belief about value. 
Such belief arises from considering the innate eco­
nomic benefit associated with the use of the tech­
nology being offered, the competitive alternatives 
available to a prospective buyer, and an overall 
negotiation strategy. 
As mentioned earlier, there are an unlimited 
number of combinations that could be agreed to 
by the licensor and licensee. It is impractical to 
price all these combinations and offer a price list. 
Instead, a price is needed for what is considered 
to be a basic deal that is of interest to the insti­
tution and that the technology manager believes 
will be of interest to a licensee. 
In the process of discussing an opportunity 
with prospective licensees, a licensing profes­
sional will learn that there are different items that 
each licensee wants and different values that each 
licensee places on what it has to grant (surprising­
ly, not all companies view money the same way; 
there can be a big difference between funding 
R&D and upfront cash, or between upfront cash 
and royalties, and so on). As new information is 
learned, the technology transfer manager should 
be prepared to reenter the pricing methodology 
and reconsider assumptions and elections. The 
technology transfer manager will also learn about 
the competitive alternatives that prospective li­
censees have use of the institution’s technology. 
At the same time, the manager will analyze the 
institution’s alternatives should the licensee say 
no. 
In a free market, all participants can decide 
what they think a product is worth and com­
municate this to others. From this process, the 
technology transfer manager should be able to 
learn relevant facts that may cause the price to be 
reassessed. It should be remembered that partici­
pants in a free market do not consider themselves 
compelled to communicate what is good or un­
dervalued about what the institution has to offer. 
In most instances, a technology transfer manager 
will only hear (or primarily hear) the bad news 
related to a product; some of it may be true, and 
some may even be relevant. 
Negotiating strategy is also important. 
Although this subject is outside the scope of this 
chapter, two pricing negotiation-strategy poles il­
lustrate the significance of negotiating strategy: 
•	 fixed-price seller: The seller has made a best 
effort at determining a value that repre­
sents what it believes is a fair value to both 
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parties. This price is its bottom line, and it 
offers the product to all prospective buyers 
as a here-it-is, here-is-what-it-costs, take-it­
or-leave-it proposition. 
•	 price maximizing seller: The seller seeks to 
identify only those prospective buyers who 
express interest in the opportunity, which 
is initially priced at or near the maximum 
reasonably conceivable value because it is 
expected to be adjusted downward, per­
haps substantially, due to the back and 
forth of what are likely to be extensive 
negotiations. 
There is, of course, a continuum of perspec­
tives between these polar positions. The fixed 
price approach (as an idealization), has the ap­
peal of deal simplicity and speed, but may have 
as its result (a) no buyers and therefore no deal 
or (b) a deal with a buyer who would have been 
readily willing to pay more had it just been asked. 
The price-maximizing approach is really about a 
seller offering some flexibility on price and deal 
elements to attract potential buyers to engage in 
a negotiation that leads to mutual learning. In 
some respects this second approach could be bet­
ter described as the deal-probability-maximizing 
approach because it offers an adjustability of pric­
ing and deal elements not available in the fixed-
price approach. However, the initial pricing of 
this second approach has to be within a range that 
buyers can conceivably find reasonable; otherwise 
buyers can be dissuaded from even initiating due 
diligence. The most important point to remember 
is that pricing is a process, not a one-time event. 
.	 CoST	AS	A	BASIS	 foR	 pRICE 
Cost is a very poor basis for pricing, although it 
is sometimes used. To get a sense of using cost of 
development as the deal price, consider the fol­
lowing: suppose an institution and its sponsors 
have invested $10 million in a particular tech­
nology that at long last has been determined not 
to work well enough to be used commercially. 
What are the chances of going out into the world 
of commerce and saying: Have I got a bargain. 
Because this technology doesn’t really work, we 
are not going to ask for any profit. It is yours for 
only the $10 million we have sunk into it. The 
market will not value what the institution paid 
to develop the technology, not because it is un­
sympathetic to the institution’s investment (and 
plight), but because what is important to the 
market (the buyer) is the value of the product, 
not the costs of development. If the product does 
not work, it has no value. What the institution 
has invested in its development is gone. 
Consider the other extreme: An individual 
buys a lottery ticket for $1. It turns out to be 
the sole winning ticket in a $10-million lottery. 
Now, someone shows up and says: I’ll give you 
$2 for your winning ticket, which will double 
your money. Is this a good deal? Again, the cost 
of the lottery ticket is irrelevant in this example. 
Rather, its worth after selection is what some will­
ing party would pay to gain the benefits of owner­
ship. For all the losing tickets together, no ratio­
nal buyer would pay even a dime. For the one 
winning ticket, in this example, a rational buyer 
would offer millions of dollars, but not more than 
$10 million. 
In the world of manufactured-commodity 
goods, costs and price are often closely related. 
Historically, pricing in such circumstances was 
determined by multiplying the costs of manufac­
ture by an industry-standard multiplier. A typical 
historic multiplier was simply the factor 2, so the 
price would be double the cost of manufacture.6 
But in the case of high-cerebral content 
products, such as intellectual property, cost is 
an inappropriate basis. If Picasso was alive and 
you approached him to buy a painting, would 
you ask: What did it cost you to make this paint­
ing? Consider another example. The late Sammy 
Cahn received (it is believed) approximately 
US$40,000 for granting the producers of the 
movie, Die Hard II, the right to play his song 
“Let it Snow” in the movie’s opening scenes to set 
the mood for the holiday season. Cahn had sold 
rights to “Let It Snow” many times. Cahn did 
not write any new music for the movie; he prob­
ably did not even provide the producers a copy 
of the sheet music. So what did the producers get 
for their $40,000? They bought merely the right 
to use something already existing. How was the 
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RAZGAITIS 
$40,000 determined? That is what the two parties 
dealing at arm’s length said it was worth, not an 
amount based on a person-hours of labor calcula­
tion as Cahn’s appropriate value for the rights to 
use the song. 
The market pays for value, not cost. In re­
tail software sales, the actual cost of the CD, the 
manual (if not on the CD), and the packaging 
is typically less than 10% of the price. Why are 
software companies seeking and able to sell their 
products for more than 10 times their costs? The 
answer again is that it is value, not cost, that the 
market buys. 
Cost, however, does come into play when 
considering a prospective licensee’s alternatives 
to entering into an agreement. A prospective li­
censee could seek to develop its own technology 
by inventing around the institution’s protection 
to accomplish the same purpose. If the prospec­
tive licensee was convinced that it could do so in 
a very short period of time with a parity outcome 
for, say, $1 million, then the licensee would rea­
sonably determine that the institution’s technol­
ogy was not worth much over $1 million, which 
is what its costs would be to get what the institu­
tion has without buying what the institution is 
selling.7 
When it comes to cost, it is the costs for the 
prospective licensee that are considered. Whether 
the seller’s costs for developing the technology 
were $10 or $10 million is basically irrelevant. 
Another important, usually misunderstood, 
point is how to determine the seller’s costs. In 
the lottery ticket example, the costs are easily 
known—it is printed on the ticket. But in the 
case of technology development, such costs are 
very difficult to estimate. Consider the variety 
and range of questions to be answered: Have we 
collected all the direct costs back to the very be­
ginning of the development? Do we even know 
how to define the beginning? Did we include the 
value of all the contributions made to the proj­
ect by products, services, insights, intellectual 
property, and so on, that were contributed at no 
recorded cost to the project? Have we excluded 
costs associated with development efforts that are 
not being offered to prospective licensees? Have 
we deducted “bad judgement” costs (which no 
reasonable R&D program should have spent)? 
Or should such “misspent” costs be recognized as 
a natural part of R&D? When parties talk about 
the seller’s costs, they are usually talking about a 
number residing in some seller cost account used 
to track certain kinds of investments, and not the 
result of a carefully considered analysis of all the 
activities and value invested by the seller. 
.	 pRICInG	 METHodS 
If cost is not a good way to determine price, 
what is? Sections 5.1–5.6 of this chapter consider 
methodologies for answering this question. These 
methodologies include: 
•	 Method I: The Use of Industry Standards 
•	 Method II: The Rating/Ranking Method 
•	 Method III: Rules of Thumb, such as the 
25% Rule (and Other Rules) 
•	 Method IV: Use of Discounted Cash-Flow 
Analysis with Risk-Adjusted Hurdle Rates 
•	 Method V: Advanced Tools 
•	 Method VI: Auctions 
The goal of these following discussions is to 
develop tools and thinking. Producing an “an­
swer,” to the question posed at the beginning of 
this section is not the goal of this discussion, be­
cause the world of technology rights makes it im­
possible to determine a price in the abstract. 
.1 The Use of Industry Standards Method 
Having dismissed cost as a basis for pricing, the 
next most logical approach is to use industry 
standards; the reason for this is that such an ap­
proach serves decision makers well in many other 
areas of experience. 
Suppose you want to rent office space. The 
coin of that realm is commonly expressed as dol­
lars per square foot per year (DSFY). Ranges for 
DSFY in the United States are from about US$1 
to more than US$50. However, when consider­
ation is restricted to a particular city and a region 
within that city (downtown/prime, downtown/ 
periphery, outer belt, suburbs, inner-city ware­
house district, and so on), the DSFY range will 
shrink remarkably, say to US$6 to $12. Then, 
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when one further specifies level of amenities 
(Bigelow®carpets versus linoleum), and what is 
included in the rate (utilities, janitorial services, 
parking, security, partitioned office layout versus 
open and bare) the range narrows even further, 
say US$10.25 to $11. So it is with many other 
goods and services, from haircuts to paper clips. 
Why can’t this approach work for rights to 
early-stage technology? The problem is primar­
ily the absence of a track record for comparable 
products bought and sold under known (or 
knowable) terms. In the office space example, 
there are many properties, many buyers (lessees), 
and many sellers (lessors). This results in many 
transactions of relatively standardizable terms 
agreed to by parties that had numerous alterna­
tives to entering into the agreement, which were 
considered and evaluated before signing. It is the 
tangibility of what is purchased, the frequency 
of purchases, and the public knowledge of the 
purchase that makes it possible to apply industry 
standards. 
In the case of early-stage technology licens­
ing, it is often unclear what products can or will 
be ultimately introduced. The number of similar 
transactions on which to determine price are too 
few, and frequently it is impossible (or difficult) 
to know what price other licensees/licensors have 
paid in similar deals. Nonetheless, there does exist 
some public and private data on early-stage-tech­
nology licensing and in many instances some­
thing useful can be learned from it. 
One example of published financial data for 
licensing agreements is that obtained by survey­
ing. Among the more famous examples are tables 
published based upon transactions between a 
Japanese company and a non-Japanese company. 
Prior to liberalization of Japanese foreign ex­
change regulations in the 1980s, foreign parties 
licensing technology to Japanese parties were re­
quired to receive government approval of licens­
ing terms. The Japanese government published 
annual statistics related to licensing. A typical 
table is shown in Table 2. In some respects, this 
table is more complete than most since it includes 
upfront payments and minimum royalties. As is 
typical of such tables, there is a frequency of oc­
currence entry for selected royalty-rate ranges for 
each of several categories of technology licensed. 
The best way to assess how useful such a table 
might be is to think about how its existence would 
lead a technology transfer manager to reach some 
decision about the price of something. 
Consider the pricing of a medical device such 
as a blood glucose monitor. Reviewing Table 2, 
the closest category is probably electrical, but is 
this really what was meant by electrical? What 
does this table reflect for upfront payments? Half 
of the agreements contained a provision for up­
front payments, and half did not.9 Now what? 
What guidance does this table give about whether 
to have such a payment and its amount? What 
is the modal (most common) value for running 
royalties? None! Now what? Should the royalty 
be priced at zero? The percentage of cases the roy­
alty was negotiated within the shown ranges can 
also be determined using Table 2, but where does 
the institution’s product fit? Finally, look at the 
minimums row. What can a technology transfer 
manager do with this information? 
The problem is actually even worse. The 
agreements that comprise the table each includ­
ed a whole panoply of exchanges, only some of 
which were summarized in Table 2. How can a 
technology transfer manager shrink all of these 
different considerations down to just one num­
ber, a royalty rate, and compare the institution’s 
opportunity with these published outcomes? 
Further, there can be instances of royalty base 
ambiguity. Staying with the hypothetical medi­
cal-device example and our bold assumption that 
“electrical” data may have some relevant teaching, 
we can envision instances where the entire device 
being sold is covered by the licensed subject mat­
ter, whereas in other cases the license could be 
about a limited feature or function within a much 
more extensive device. In such cases, how was the 
royalty-rate data used by the parties? Did they 
agree in both of these cases to use the selling price 
of the complete medical device, or did they in the 
second instance agree to use as the royalty base 
some smaller amount than the full selling price 
of the device because of the limited application 
to a single feature or function? There is no way 
to tell from the table. There are also other con­
cerns about this table. It is limited to technology 
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transferred into Japan in the early/mid-1970s. 
And what relevance would these rates have for li­
censing technology to be used in the U.S.? 
A more recent industry standard survey is 
available, which also offers more distinguishing 
categories.10 One of the tables is shown in Table 
3—does it provide the technology office manager 
more useful information? 
Again, use the test. How would this data 
help a technology transfer manager make a deci­
sion? Consider the categories of pharmaceuticals, 
general manufacturing, and other. Each royalty-
range category has an entry for each of these. 
Unfortunately, all that can be discerned is that 
most royalties are in the range of 0%–10% and 
that pharmaceuticals are generally higher than 
manufacturing. One wonders about the category 
of telecommunications. Does this mean that 
all royalties for this industry fall in the range of 
10%–15%? (No, as it turns out: there was only 
one survey respondent.) The paper from which 
Table 2 has been prepared contains a lot of good 
information, but a technology transfer manager 
should recognize its limitations as a guide for set­
ting a royalty. 
None of this discussion is intended to dis­
parage the efforts of those gathering and pub­
lishing this data. Determining effective ways of 
Table 2: use of Industry Standards to Determine Royalties





of Technology Chemical Metal Machinery Electrical Others 
Required 100 54 223 119 231
Initial payment 
Not required 65 37 187 119 220 
< 2% 5 6 16 32 28 
2% > x < 5% 42 24 119 55 126 
Running 
5% > x < 8% 12 8 112 24 119 
royalties 
> 8% 7 4 24 11 17 
Others 48 28 80 54 69 
None 51 21 59 62 92 
Minimum Required 38 19 116 35 186 
payment Not required 127 72 294 203 265 
Subtotal 165 91 410 238 451 
No fee, royalty 16 4 11 2 15 
Total 181 95 421 240 466 
Source: Science & Technology Agency8 
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CHAPTER . 
valuing (pricing) technology is extremely diffi­
cult, and this author cherishes every scrap of in­
formation found. Everyone’s efforts to extricate 
and publish anything that might help technolo­
gy professionals in this valuation process are ap­
plauded. The goal here is simply to caution the 
reader about the limitations of using industry 
standards for setting royalties and other license 
considerations. 
Let us now consider, as examples, other 
sources of financial information about license 
agreements. The references that follow should not 
be taken as recommended norms or standards, 
but illustrations of information that can be found 
by investigation. 
Lita Nelsen of M.I.T. has published a table 
of standards that is an example of more useful 
data than the above broad Japanese license agree­
ments. The table below represents a narrower 
class of licensors (M.I.T. and similar universities) 
and provides a narrower distinction of categories 
as well as a narrower range of typical royalties. A 
recast version of data she has published is shown 
in Table 4. 
Table 3: A Recent Royalty Data Set Obtained by Survey 
(licensing-out royalty rates by industry royalty rate category) 
Primary 









Aerospace 40.0 55.0 5.0 
Automotive 35.0 45.0 20.0 
Chemical 18.0 57.4 23.9 0.5 0.1 
Computer 42.5 57.5 
Electronics 50.0 45.0 5.0 
Energy 50.0 15.0 10.0 25.0 
Food/Consumer 12.5 62.5 25.0 
General Manufacturing 21.3 51.5 20.3 2.6 0.8 0.8 2.6 
G o v e r n m e n t / 7.9 38.9 36.4 16.2 0.4 0.6 
University 
Healthcare Equipment 10.0 10.0 80.0 
Pharmaceuticals 1.3 20.7 67.0 8.7 1.3 0.7 0.3 
Telecommunications 100.0 
Other 11.2 41.2 28.7 16.2 0.9 0.9 0.9 
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Clearly Nelsen’s data covers wide ranges in 
royalty rates, from 0.1% to 20%, a factor of 200. 
Even within one category, the range between the 
high and low ends can be a factor of five or more. 
Further, it is likely that there exist “outliers” from 
such ranges that M.I.T. would license at rates be­
low the bottom end of the range and perhaps, for 
major breakthroughs and extensive IP portfolios, 
may expect values above the top of the range. The 
data illustrates another trend that appears in other 
examples: those products and industries with tra­
ditionally high operating margins (profits), such 
as pharmaceuticals and software tend to exhibit 
higher royalty rates compared with, say, the ma­
terials industry. 
Other authors have published tables of roy­
alties for the purpose of establishing reasonable 
expectations of both licensors and licensees. Table 
5 is a table published by Corey and Kahn for the 
medical industry.12 
The table’s context is well defined (early-stage 
technologies out of research labs), the categories 
are comparatively precise (diagnostics in vivo), 
and it includes guidelines on up fronts and mini­
mums. However, note that there is an important 
economic difference between the ends of the roy­
alty ranges given: 1% versus 3% or 2% versus 
10%, and so on. Unless the technology transfer 
manager understands where the institution’s op­
portunity fits in the range identified, it is difficult 
to know where to begin. Further, not every oppor­
tunity falls within even these broad ranges. Some 
opportunities will have only negligible value; oth­
ers could be unusually valuable opportunities. 
Tom Kiley has published another medical 
industry table that deals with exclusivity granted 
(Table 6).14 
Kiley appears to suggest that for nonexclusive 
rights, the royalty should be about half of the ex­
clusive royalty. (See section 6.3.2 for more on the 
50% rule.) According to Kiley, inventions in sup­
port of a pharmaceutical (drug) warrant higher 
royalties (7%–15%, as his generalization) than 
drug delivery, diagnostic and therapeutic mono­
clonal antibodies (2%–7%), perhaps reflecting 
another two-to-one ratio. 
Published price lists are another source of 
industry standards for pricing. Sometimes a 
company simply announces its royalties. One ex­
ample, shown in Table 7, was published by one 
licensor for nonexclusive licenses for its LCD dis­
play patent. 
Another example of such published rates 
is, or was, IBM’s licensing terms. In the 1980s 
and early 1990s, IBM established a licensing 
practice—essentially a price list—that offered to 
license essentially all of its 34,000 patents world­
wide for a 1% royalty each for computer uses (pat­
ents only, nonexclusive only), up to a maximum 
of 5% for all 34,000.17 This practice does not 
establish 1% as a minimum per patent royalty; 
rather it reflects IBM’s practice at one time that 
a licensee can choose any one from IBM’s massive 
portfolio for a rate of 1%, any two for 2%, and so 
on. Further, because IBM does not make public 
its license agreements it is unknown what pay­
ment structure or amount was finally agreed to 
with licensees. 
The main point about the LCD and IBM 
examples is that such published lists can lead to-
expectations and, to the degree that the opportu­
nity the technology transfer manager is pricing 
fits any published examples, this may influence 
the thinking of prospective licensees. In some 
cases, such proposed pricing can create a widely 
accepted norm in the respective industry, mak­
ing it difficult for the seller to price above such a 
norm if the subject matter is perceived to be in a 
similar category. Licensees, like licensors, look to 
this method of industry standards (or norms or 
comparables). However, they may look to a dif­
ferent population of examples such as their own 
internal catalog of extensive deals that they have 
completed in the past to establish their expecta­
tions for financial terms. 
Yet another source of industry standards 
are court determinations of reasonable royalties 
awarded in patent infringement lawsuits. Table 8 
offers a summary from a paper by Mike Carpenter 
who analyzed a series of judgments.18 
The main limitations of such data are that 
the result is very specific to the litigated sub­
ject. In addition, the maturity state of the tech­
nology is normally far beyond what may be 
considered as early-stage technology. Further, 
adjudicated reasonable royalty rates are almost 
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Table 4: Example Table of Royalties Developed by Experience 
by a university licensing Office11 
Product Royalty (%) Comments 
Materials processes 1–4 0.1%–1% for commodities; 0.2%–2% for processes 
Medical equipment/devices 3–5 
Software 5–15 
Semiconductors 1–2 Chip design 
Pharmaceuticals 8–10 Composition of materials 
12–20 With clinical testing 
Diagnostics 4–5 New entity 
2–4 New method/old entity 
Biotechnology 0.25–1.5 Processa/nonexclusive 
1–2 Processa/exclusive 
a Expression systems, cell lines, growth media/conditions 
Table 5: Royalty Rates for the Medical Industry13 





Reagents/process 1–3 Patent costs 2,000–10,000 
Reagents/kits 2–10 Patent costs 2,000–10,000 
Diagnostics in vitro 2–6 5,000–20,000 2,000–60,000 
Diagnostics in vivo 3–8 5,000–20,000 2,000–60,000 
Therapeutics 4–12 20,000–150,000 20,000–150,000 
Medical instrumentation 4–10 5,000–150,000 5,000–20,000
(yr. 1)
10,000–25,000
(beyond yr. 1) 
HANDBOOK OF BEST PRACTICES | 2












        
   
    
   
   
RAZGAITIS 
always unrepresentative of arm’s-length rates, as 
they represent royalties for patents known to be 
valid and infringed—conditions not typical of 
early-stage technologies. This litigation-particular 
outcome example is also quite dated, but dated­
ness is a factor here in all of the prior examples 
as well, and is innate to any historical collection 
of data.20 Still, a court case usually contains a 
wealth of information about how such rates were 
determined, and of course, the information is in 
the public record. Einhorn has published a much 
more current summary of reasonable royalty de­
terminations by a court.21 One can also search 
LEXIS® for even more current data. The key is 
to find a comparable technology, stage of devel­
opment, market impact, and so on. When some­
thing comparable exists and is published, this can 
be very helpful. 
The most valuable tool for determining in­
dustry standards for this method are published 
agreements for similar technologies licensed by 
similar institutions. As Ashley Stevens explains, 
publicly-traded companies will file license agree­
ments that may have a significant economic im­
pact on the value of the company with the U.S. 
Securities and Exchange Commission (SEC).22 
The Internet now enables very effective searching 
of disclosures made by publicly-traded companies. 
Table 6: Proposed Standard Royalties15 
Exclusive (%) Nonexclusive (%) 
Development rDNAa drug 7–10 3–4 
Approvable rDNAa drug 12–15 5–8 
Therapeutic mAbb 5–7 3–4 
Diagnostic mAbb 3–4 1–2 
Drug delivery component 2–3 0.5–2 
a Recombinant DNA 
b Monoclonal antibodies 
Table 7: Price list for an lCD Display Patent16 
Vehicles 0.125% 
VCRs, and so on 2% 
Meters, gauges, and so on 3% 
Telephones, and so on 4% 
Calculators, and so on 5% 
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CHAPTER . 
Several organizations offer, as a service, summa­
ries of categories of such filings and copies of spe­
cific agreements. An example, taken from a talk 
by Mark Edwards, is shown in Figure 1.23 
These data are unusual in that they show many 
of the forms of upfront consideration received by 
universities for having licensed their biotechnol­
ogy. Underneath such summaries, however, are 
specific agreements now numbering in the thou­
sands, copies of which can be found with some 
research. It is from such published agreements 
that one can gain a better understanding of what 
was agreed to, at least once, by two parties for 
something similar to what is being offered.24 
One example of such a specific agreement is 
the license between the University of Houston 
(UH) and DuPont for the so-called 1-2-3 super­
conductors developed by Professor Wu of UH. 
The State of Texas required that this agreement 
be placed in the public domain. The agreement 
details the payments DuPont agreed to make to 
gain rights to UH’s superconductor technology: 
US$1.5 million in cash upon execution of the 
agreement, an additional US$1.5 million upon 
issuance of the U.S. patent, and a third US$1.5 
million upon the second anniversary of the U.S. 
patent. The agreement has many other interest­
ing details, and it would be wise to study this 
agreement and learn as much as possible about its 
background and current status. 
To sum up, using this industry standards 
method of setting prices has both positive and 
negative aspects: 
Positive aspects of the industry-standards 
method include: 
•	 The values used as the basis are based on the 
market. 
•	 No calculations are required (beyond per­
haps taking averages and medians or other 
statistical methods). 
•	 One has some confidence of being in the 
range of some believed-to-be comparable 
reference points. 
Potential negative aspects include: 
•	 Published information is inevitably dated, 
and such datedness could have a mate­
rial effect on the present value of a similar 
deal. 
•	 The segmentation provided by surveys is 
normally too coarse (electrical, mechanical, 
telecommunications, and so on). 
Table 8: Other Tables of Royalty Rates Based on litigation Outcomes19 
Product Royalty (%) Date Citation 
Rotary wing aircraft 2 1976 192 USPQ 612 
Sleeping bag 5 1967 156 USPQ 403 
Digital data transmitter 7.5 1978 200 USPQ 481 
Oscilloscope 10 1977 193 USPQ 385 
Computerized teaching aid 12 1978 199 USPQ 178 
Toilet paper perforator 20 1977 195 USPQ 125 
Airline baggage cart	 100a 1977 196 USPQ 129 
a of profit 
HANDBOOK OF BEST PRACTICES | 2
     
         




   
 
RAZGAITIS 
Figure 1: Royalty and Other IP Revenue Data Based 
on SEC-Filed and SEC Agreements 






































Source: Recombinant Capital (Mark Edwards). AUTM presentation 1993. 
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• The values published normally do not pro- The industry standard method works best 
vide sufficient information to determine when one deals in one technology/industry seg­
what IP rights were provided, or to deter­ ment, especially when there are a significant 
mine their significance or their strength. number of deals involving multiple buyers and 
• The royalty basis (or base) is not always ex- competitive sellers, much as in the real-estate 
plicitly defined. rental market discussed above. The examples giv­
• The connection of the license to the size en here are not intended to provide representative 
and margins of the buyer’s market oppor­ technology values but to illustrate some of data 
tunity is not explicitly known. sources that exist. 
• A wide range of royalties is reported for In summary, price is a very tricky idea. It oc­
each classification, with no clear means of curs “between the ears” of the technology transfer 
discerning why some opportunities were manager, as well as between the ears of prospec­
higher valued and some lower. tive licensees. As you can see, it is affected by all 
• Often no information on upfront pay- the other things that affect a person’s judgment. 
ments, minimums, or due-diligence provi- For those who doubt this, an experiment has 
sions is available, all of which can be im­ been published that illustrates this point.25 Two 
portant components of value. groups of students were asked to review identical 
• The licenses often contain other provisions notebooks containing descriptions of seven con-
that directly affect the total value of the sumer products. They were each asked to respond 
deal and are reflected in the royalty rate. to each product by specifying what they would 
• One cannot uncover a historical agreement be willing to pay for the item. A summary of the 
for exactly the same technology as that of findings is shown in Table 9. 
current interest, between comparable par- Everything was identical in the two settings 
ties, at a comparable stage of development. (A and B), except for one small thing. In setting 
So one is commonly performing some in- B, there were Mastercard® logos left lying on the 
terpretation of available data to apply to table. Even though all the participants understood 
one’s present situation. that they were not buying the items in the book, 
Table 9: Price is a Tricky Idea: What Would you Be Willing to Pay?26 
Consumer products book Mean in setting A Mean in setting B (B-A)/A 
Dress 1 $27.77 $41.50 49% 
Dress 2 $21.09 $33.91 61% 
Tent $69.95 $77.73 11% 
Men’s sweater $13.91 $20.64 48% 
Lamp $28.36 $40.41 42% 
Electric typewriter $131.45 $165.36 26% 
Chess set $35.29 $43.15 22% 
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RAZGAITIS 
and there was no discussion as to how such items 
could or should be paid for, the mere presence 
of the logos influenced the group B students 
significantly. 
The point of relating this experiment is that 
everything about the technology transfer manager, 
the institution, the inventors, and so on, are po­
tential influences on what a licensee will conclude 
is a fair price. 
Consider these two different settings for the 
same invention. In setting A, the prospective 
licensee goes to Nowheresville, has to drive four 
hours because there is no air service, steps in 
cow dung as he gets out of his car, meets the 
inventor who has no front teeth and exhibits 
an annoying habit of scratching his underarms, 
and discusses the invention in the Greasy Spoon 
Cafe. In setting B, the prospective licensee goes 
to Mostfamousuniversity, where he is intro­
duced to the distinguished inventor (who has 
previously won a Nobel Prize) at the exclusive 
faculty club and a well-known, well-respected, 
high-ranking public official stops buy and says 
hello during lunch. 
Remember, in this thought experiment the 
institution is selling the same invention in both 
settings. Even though the prospective licensee is 
not a student and is not buying consumer prod­
ucts as in the example above, the principles are 
the same. The licensee will likely be influenced 
by the setting and circumstances, which may be 
completely unrelated to the underlying value of 
the opportunity. 
In the first act of a wonderful play by Arthur 
Miller called The Price, the owner of a house full 
of furniture is frustrated when the dealer he has 
invited to bid on all of it delays giving him a 
price. Instead, the dealer spends a lot of time 
understanding the context of the sale (and learns 
that the building is about to be demolished and 
that the seller has no time or patience to sell the 
items piece by piece). He intermittently (and 
politely) points out certain blemishes in objects 
that would otherwise have been perceived as 
very valuable. When the seller finally demands 
to hear the price, the very old man who plays 
the buyer simply says, “Because the price of used 
furniture is nothing but a viewpoint, if you don’t 
understand the viewpoint, it is impossible to un­
derstand the price.” The view from the buyer’s 
position always affects the price he is willing to 
pay. 
One other point needs to be made about 
price. It is often the lever used in negotiations. 
Often each party to a negotiation uses price as 
a lever to get other things. There is a wonderful 
ancient saying on how buyers tend to negotiate, 
“Bad, bad says the buyer, but then he goes his 
way, then he boasts.” 
.2 The rating/ranking method 
This method applies the elements of any defini­
tion: the specification of a genus plus the distinc­
tion of a differentiator. 
First, the technology transfer manager 
must find the genus (or family) for the in­
stitution’s technology that he or she is seek­
ing to price. Places to look include the pub­
lished agreements discussed earlier, friends in 
the network of the Association of University 
Technology Managers (AUTM) and the 
Licensing Executives Society (LES), consul­
tants, and the institution’s files of negotiated 
deals. Ideally, a technology transfer manager 
should find at least one or possibly two or 
three comparable deals from such a search. 
Second, this method uses some form of rat­
ing table to score (differentiate) the deal that 
is now being priced based on the known price 
of the comparable deal(s). To do this, a tech­
nology transfer manager must select a list of 
relevant factors. Tom Arnold and Tim Headley 
published a useful, extensive list of 100 possible 
factors in an article in Les Nouvelles.27 One hun­
dred factors, however, are far too many to evalu­
ate, which is perhaps why the most well-known 
enumeration is the Georgia Pacific factors, so 
called because the factors were annunciated in a 
lawsuit involving the Georgia Pacific company 
and have since been widely cited with respect to 
litigation matters. The results of a survey pub­
lished by LES asked respondents which of the 
primary Georgia Pacific factors they used to as­
sess an opportunity when either licensing in or 
licensing out. Table 10 gives a summary of these 
findings. 
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Other approaches may use only three or four 
factors to simplify the analysis, such as (1) com­
prehensiveness of the IP protection, (2) the stage 
of development (or, conversely, the magnitude of 
licensee investment) to bring the technology to 
the market, (3) the size and value of the market 
that is expected to be won by the licensee, and 
(4) the sustainability of the innovation wrought 
by the subject technology in view of competitive 
alternatives both present and anticipated. 
Once one has chosen the key factors, the 
technology transfer manager, or preferably a 
commercial assessment team, scores the subject 
opportunity compared to the reference agree­
ment found above for each factor selected on 
some scale. This can be done by employing a 1 
to 5 scale, with a 3 as being indistinguishable to 
the comparable agreements, 4 meaning the sub­
ject opportunity is better (more valuable) with 
regard to this particular factor, 5 meaning much 
better, and so on. It is usually a good idea to also 
include a weighting factor so that each consider­
ation is not treated equally. This is illustrated in 
Table 11. 
The result is a weight-averaged score. 
Anything greater than 3.0 would suggest that the 
subject opportunity is better than the examples 
being considered as a standard, anything less than 
3.0 suggests it is worse. If a technology transfer 
manager has two or three standards available, it 
may be possible to use this method to bracket the 
opportunity. 
Although this method is straightforward, 
there are some important limitations. What is a 
true comparable? Each agreement is a snapshot 
in time, no two technologies are really identi­
cal, the market is almost never the same, and 
the negotiators and organizations will likely be 
Table 10: Example of Georgia Pacific Factors used in Rating/Ranking28 
Importance of Factor licensing Ina licensing Outa 
1. Nature of protection 4.3 4.2 
2. Utility over old methods 4.2 4.2 
3. Scope of exclusivity 4.1 4.1 
4. Licensee’s anticipated profits 3.0 3.4 
5. Commercial success 3.7 3.4 
6. Territory restrictions 3.7 3.5 
7. Comparable license rates 3.6 3.7 
8. Duration of protection 3.3 3.1 
9. Licensors’ anticipated profits 2.6 3.1 
10. Commercial relationship 2.6 3.6 
11. Tag-along sales 2.1 2.1 
a A ranking of 5 corresponds to most important; 1 to least important. 
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different. In addition, there are many tradeoffs 
and exchanges in every agreement; a technology 
transfer manager cannot simply compare one 
single aspect, such as a royalty rate, and look 
at it without considering what else was in the 
agreement. What about the differentiating fac­
tors selected? Does a technology transfer man­
ager really know what the important ones are for 
this opportunity? What does a 4 really mean in 
economic terms? Finally, what does a technolo­
gy transfer manager do with the result? Suppose 
the technology transfer manager determines 
that the institution’s opportunity scores a 3.8 
compared to the standard. Now what? Does the 
technology transfer manager set expectations for 
the royalty at 27% better than the standard, as 
determined by ((3.8–3.0)/3.0)? Is the up front 
now 127 instead of 100? Are the minimums 
64 instead of 50? Does the diligence require­
ment provide that the licensee must be on the 
market in 31 months instead of 40 months? Is 
the premium on late payments 3.8% instead of 
3%? There are no simple answers to any of these 
questions. Still, performing this ranking against 
multiple standards and thinking through the re­
sults generally allows one to better understand 
Table 11: Method II: The Rating/Ranking Method
 
Factors Score (1 to 5) x Weighting Factor Weighted Score 
Stage of
development 










Compared to 3.0 
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CHAPTER . 
the helpfulness of this rating/ranking method in 
a specific circumstance. 
The approach also yields at least two other 
benefits. First, it prepares the technology transfer 
manager for marketing, negotiating, and sharpen­
ing his or her thinking about what the important 
economic factors are relating to the opportunity. 
It gives the manager a greater self-awareness. A 
second benefit is that it provides a way of dialogu­
ing with the internal stakeholders and beneficially 
incorporating some of their insights. 
The rating/ranking method can also be 
used for selecting a commercialization path. 
When developing a commercialization strategy, 
there are countless possibilities: exclusive versus 
nonexclusive licenses, licensing versus equity in 
a new start-up, going with a company in indus­
try A as the exclusive licensee or in industry B, 
commitment to the industry leader versus a small 
company who seeks to upset the industry, and so 
on. The rating/ranking method can help a man­
ager sort out the advantages and disadvantages of 
each of the alternatives. It can also be used with 
respect to different potential licensees/partners by 
taking into account the particular benefit(s) of 
the technology to such licensee; the method can 
help a seller differentiate among multiple poten­
tial candidates to identify those who would ap­
pear to have the most to gain from the license and 
would therefore be the likeliest to enter an agree­
ment and possibly pay the most. These and other 
criteria can help a technology transfer manager 
decide upon the best commercialization path. 
. 	 Rules of thumb, such as the 25% 
rule (and other rules) 
..1 The 25% rule 
One of the most widely cited tools of valuation is 
the 25% rule. It has various manifestations, but 
when most managers invoke it they usually mean 
either of the following: 
1. The royalty in dollars should be one fourth 
of the savings in dollars to the licensee by 
the use of the license subject matter. 
2. The royalty in percent of the net sales price 
should be one fourth of the profit, before 
taxes, enjoyed by the licensee as a result of 
selling products incorporating the licensed 
subject matter. 
Although this looks simple, it is not. One of 
the key issues is the degree to which the licensed 
subject matter accomplishes the savings or pro­
duces the profit. For example, an invention incor­
porated into a process may produce a savings of 
$1 a unit. However, when one examines in detail 
how such savings are attained, it may be that sev­
eral other technologies developed and possessed 
by the licensee need to be exploited in order to 
realize the full $1. In such a case, does the licen­
sor deserve 25 cents, or should the savings be 
discounted in some way before the one-fourth 
fraction is computed? The issue seems to hinge 
on whether the invention opens the door to an 
otherwise locked room called: I can save you $1, 
or whether the invention is a link in a multilink 
chain that together combine to save $1.29 
In the second (profit) manifestation of the 
rule, things get even more complicated. Although 
net sales is generally a straightforward term to ap­
ply, profit before tax is subject to many interpre­
tations. Normally, the royalty rate is applied to 
the royalty basis defined by net sales as follows: 
net sales price is the gross invoice price charged 
minus allowances for returns, and minus cash and 
other discounts granted, charges for packaging 
and shipping, and sales and excise taxes.30 
For the purposes of this rule, there is no 
comparable generally accepted definition of profit
before tax. Indeed, one of the basic problems is 
determining what an appropriate income state­




= net sales 
Less: cost of goods sold (COGS)31 
= gross margin (or gross profit) 
Less: overheads (or G&A, for general 
and administrative) 
Less: sales (or sales and distribution) 
Less: other 
Less: R&D 
= Profit before tax (or EBIT, earnings
before interest and tax) 
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The trouble usually starts below the gross-
margin calculation. What overheads should be 
attributable to this opportunity? Should all the 
overhead costs currently being experienced by 
the licensee be included in the calculation, even 
though including these may reward the licensee’s 
inefficiencies? Will the cost-of-sales allocation, 
which is across many products now being sold, 
overcharge the appropriate sales allocation for the 
subject opportunity? What is “other,” and why is it 
being used to draw down the profitably before the 
application of the royalty? And finally, what con­
stitutes R&D, and should it draw down profits as 
calculated for determining a reasonable royalty? 
Underneath these questions is the difficulty 
of obtaining reasonable estimates for each of the 
numbers. Annual reports from companies that 
sell products like the one the institution is licens­
ing are good places to start. Table 12 shows sum­
maries of two large materials companies, one U.S. 
company and one European company, based on 
their income statements published in annual re­
ports. Although the numbers reflected in Table 
12 represent real data, for the purposes of this il­
lustration, the company names have been noted 
as U.S. Co. and Europe Co., respectively. 
As discussed earlier, one of the issues in ap­
plying the 25% rule is where to apply it. If it is 
applied to the EBIT line ($18,352,000, in the 
United States company example), it is asserted that 
the deductions above that line (COGS, SD&A, 
and R&D) are appropriate for determining the 
true profitability associated with the commercial­
ization of the new opportunity being licensed. 
Consider whether it is appropriate to subtract 
R&D from available profit. If it is not subtracted, 
we would get, by this rule, one fourth of 12% 
(11+1) or a 3% royalty. This is a lot better for the 
licensor, since it is 12 times the 0.25% one gets by 
using what remains after R&D is subtracted. But 
should R&D be included in the subtraction? The 
argument for including it is that R&D is a neces­
sary business expense for the enterprise; without 
such investments, the licensee would not have the 
high-value, competitive products it needs to sus­
tain its operations, and, by implication, would be 
unable to successfully commercialize the subject 
opportunity. 
On the other hand, these expenses are in­
vestments for future payoffs to the company for 
which the licensor may not enjoy the benefits. 
Suppose the U.S. company had elected, in the 
year reported, to increase its R&D investment by 
$18,351,000 to pursue an antigravity invention. 
This would have left the grand sum of $1,000 
on the EBIT line, corresponding to one-ten­
thousandth of a percentage point (of sales). Why 
should a licensor’s fair share of profits depend on 
the company’s management pushing an R&D 
project to develop an antigravity material or, for 
that matter, any other product? 
Above or below the EBIT line are even more 
subjective costs. If they are associated with the 
company’s core operations, they may be appro­
priate. But what if they are associated with buying 
that new hunting lodge in Montana? Or buying 
up Brazilian rain forests? What about restructur­
ing, which may be synonymous for the present 
cost of past folly? Again the same kinds of argu­
ments exist on both sides. And again, what about 
that favorite term in accounting statements: “oth­
er.” Other than what? 
If the licensor agrees that all of the expenses 
shown are appropriate allocations against earn­
ings, it leads in this particular year to a negative 
number. Now what? Does the institution pay the 
licensee a royalty to commercialize the institution’s 
product? The point of this discussion is that each 
cost below the sales line should be analyzed in the 
context of the subject technology to determine if 
the EBIT percentage shown reasonably predicts 
the licensee’s profitability in the present case. If 
not, adjustments to such costs should be made to 
correct the base on which the rule is applied. 
The second example in Table 12 (European 
Co.) presents other problems. For competitive 
reasons, many companies conceal details in their 
statements. They may also use different terminol­
ogy. In Europe, sales is normally called turnover, 
interest can be finance charges, and so on. This 
example shows a gain from investments.32 Should 
the licensor receive the benefit of a higher royalty 
because the Europe-based company made money 
in one year on a good investment? Probably not. 
But if the company had lost money on invest­
ments, wouldn’t the licensee argue that such loss 
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should be subtracted as an appropriate business 
expense? So, what about the gain? 
Another way to obtain income statements 
is to use Ibbotson and Associates33 and Robert 
Morris Associates (RMA) publications.34 RMA, 
for example, annually publishes income state­
ments of categories of companies by Standard 
Industrial Classification (SIC) code. Continuing 
with our two materials company examples, Table 
13 shows the data available from the 1991 edition 
for SIC #2395. 
In the first two columns are shown summa­
ries for 11 smaller companies and 17 larger com­
panies, based on assets. The right three columns 
provide three years of data for all of the compa­
nies in the database. Even when focusing on just 
the operating profit row, this gives five choices on 
which to apply the one-fourth rule: 4.1%, 4.7%, 
Table 12: Example Applications of the 25% Rule 
Annual Report, 1991 
u.S. Co. 
Annual Report, 1991 
Europe Co. 
US$, in % UK £ in % 
thousands millions 
Sales 1,249,512 100 “Turnover” 454.0 100 
COGSa 643,357  52 Other Inc.  2.2 
Gross margin 606,155  48 456.2 
“S,D,&A” 447,607  36 “Operating costs” 405.0 89 
R&D 140,196 11 EBIT 51.2  11 
















a Cost of goods sold (all “direct” costs of making the product)
b Earnings before interest and taxes
c Earnings before tax 
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7.8%, 8.4%, and 10.4%. How does a technology 
transfer manager choose? Taking an average yields 
about 1.5% as the royalty. Is this fair? Unlikely. 
The root problem is getting good numbers 
for the profitability associated with the subject 
opportunity. A prospective licensee will almost 
surely make such a calculation. Yet a licensor will 
find it very difficult to get access to such infor­
mation. The problem with published numbers 
of business enterprises—such as annual reports, 
10Ks, RMA publications, Ibbotson, and other 
sources—is that the numbers are “smeared” over 
many different products, each with widely vary­
ing profitability. And once a product has been 
introduced, a company is inclined to keep it in 
the marketplace as long as it contributes to over­
head, meaning it at least covers its cost of goods 
sold (COGS). In short, dogs in the company’s 
profit portfolio bring down the returns of the 
stars. Basing a valuation on such numbers will 
therefore always be a very tricky business. It also 
ignores a company’s willingness to pay more for 
a new opportunity, such as licensing a particu­
lar technology from which new products can be 
made. As a technology transfer manager becomes 
more experienced in various business sectors, he 
or she will better understand the economics of 
such variables—especially the company’s interest 
in the opportunity of a new technology—allowing 
for better valuations (see Method IV: Discounted 
Cash-Flow Analysis with Risk-Adjusted Hurdle, 
section 5.4). 
One possible remedy to these difficulties is to 
request that the licensee provide a pro forma (pre­
dictive) income statement for the subject oppor­
tunity. In many cases, the licensee will refuse on 
Table 13: Another Example Application of the 25% Rule35 













Net sales 100.0 100.0 100.0 100.0 100.0 
Gross “profit” 29.9 21.8 25.4 33.8 32.5 
“Op-exp” 21.5 17.7 20.7 26.0 22.1 
“Op profit” [ 8.4 4.1 4.7 7.8 
“Other” 1.2 0.8 1.0 1.8 1.6 
“Profit before tax” 7.2 3.3 3.0 5.9 8.7 
Now what? 1.5%? Average 
10.4 ] 
a Operating without a mine or quarry crushing, grinding, pulverizing, or otherwise preparing 
clay, ceramic and refractory minerals; barite, and other miscellaneous minerals, except fuels. Also 
includes crushing slag and preparing roofing granules. 
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the grounds that such information is trade-secret 
information and that providing it, even under 
confidentiality terms, is forbidden. In other cases, 
the licensee may provide it. If so, it is a virtual 
certainty that what will be provided is the lower 
range of possible outcomes. Also, such pro forma 
statements may have certain cost allocations in­
corporated by rule or custom that may be argu­
able (either way) for getting to a figure to which 
the parties will apply the 25% rule. 
Licensors sometimes call the 25% rule the 
“one-third rule.” Licensees, on the other hand, 
sometimes argue that claiming even one-fourth 
of the profit is overreaching, given such issues 
as the technology’s early stage of development, 
weak patent protection, high market risks, 
the extraordinary value of intangible assets to 
be applied by the licensee, and so on. Clearly, 
the many numerous factors that go into value 
(summarized earlier) must always be considered 
when applying rules of thumb. Perhaps the high 
risk associated with commercializing a specific 
opportunity means that only one-tenth is fair. 
And if the technology is only a small part of a 
very complex whole, with many other patents 
and proprietary technologies required of the li­
censee and a royalty base on the selling price 
of such a complex whole product, then a value 
much less than one-tenth can be reasonable. 
This last point relates to the always-relevant dis­
cussion of the royalty base that is being used 
with the royalty rate to determine the royalty 
payment. If the licensor’s technology enables 
substantially the entire product, then the sell­
ing price of the entire product is normally the 
base. If the licensor’s technology is only part of 
the entire product, then the parties may elect 
to still use the selling price of the entire prod­
uct, but discount the royalty rate in recognition 
of that fact. Returning to the issue of whether 
25% is the appropriate apportionment, if the 
commercial introduction of a well-developed, 
whole technology package for an attractive mar­
ket opportunity is certain, then a value higher 
than 25% may be appropriate. 
Despite these complexities, the 25% rule is 
well known and widely cited. One example is a 
citation by the court in Gore vs. Internal Medical 
Prosthetics where the judge stated, “As a general 
rule of thumb, a royalty of 25 percent of net prof­
its is used in license negotiations.”36 However, in 
the famous case of Polaroid vs. Kodak, the judge 
awarded a reasonable royalty that amounted to 
slightly more than 60% of the infringer’s antici­
pated profits. The “Ten Sources of Value” (Table 
1) and the rating/ranking factors must always be 
kept in mind, as should the overwhelming sig­
nificance of differing risk perceptions of the same 
opportunity. If the licensee sees an opportunity 
as extraordinarily risky, then 25% of the profits 
will appear far too high. If the licensor sees it as 
picking the low-hanging fruit of something that 
can be readily commercialized by a license, 33% 
or more will seem reasonable. So, one should 
not take this “rule” suggesting there is a univer­
sal agreement that the value of “25%” covers all 
situations. 
For more information, a summary of the his­
tory of the 25% rule is included in William (Bill) 
Lee’s paper.37 Our observations relating to the use 
of this rule are summarized below: 
Positive aspects of the 25% rule method: 
•	 Has a “feel-right” tug in certain circum­
stances 
•	 Can be the basis (principle) of early 
agreement 
•	 Appropriately tied to profitability 
•	 Widely accepted (at least in the sense that 
lots of people have heard of it) 
Difficulties with the 25% rule method: 
•	 The lower you go below the top line of an 
income statement or model, the more sub­
jective (that is, inauditable and arguable) it 
gets, for example, what is appropriate over­
head? What are appropriate sales costs? 
•	 The calculation, depending on how it is 
performed, can have the effect of rewarding 
licensee business inefficiency. 
•	 Very difficult to get good income statement 
numbers that are not smeared over many 
businesses and products. 
•	 The licensed subject matter (normally) rep­
resents only a part of the sales price; com­
plex considerations are needed to decide 
whether to discount or not. 
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•	 There can be significant year-to-year vari­
ability in available income statement 
numbers. 
•	 No help on upfront fees. 
•	 There is no inherent assessment of the po­
tential importance of third party IP and 
technology to a licensee’s use of the subject 
technology. 
One key piece of advice: If you use the 25% (or 
one-third) rule, use it only to develop the calcula­
tion of the royalty rate to be based on sales—never 
permit the royalty to be calculated on an as-you­
go basis as a percentage of earnings before tax. 
..2 The 50% rule 
Duke Leahey has outlined a 50% rule that is re­
lated to the 25% rule:38 
•	 At the point of product introduction, about 
50% of the total risk of product failure 
remains. 
•	 If the inventing organization brings the 
technology to the state of product intro­
duction, it is entitled to 50% of the total 
reward (profit). 
•	 If the commercializing organization partic­
ipates in premarket development costs and 
risks, it is entitled to more than 50% of the 
total reward. 
From this perspective, the 25% rule repre­
sents a 50:50 participation in premarket risk. 
Accordingly, the 50% rule suggests that to deter­
mine a fair apportionment of profit one should 
assess the extent to which the premarket risks and 
costs will have been borne by the licensor and li­
censee when the product finally gets marketed. 
Unfortunately, this is not easy to do. 
When did the invention begin? In most 
cases, the inventing organization and individual 
inventors endured a long, costly gestation that 
was the essential primordial ooze from which the 
invention emerged. It is therefore unfair to the 
licensor to add a $5,000 patent application and 
a $10,000 project that fleshed out a few numbers 
and contend such expenditures are equivalent to 
the $1 million required cost asserted by a licensee 
to bring the technology to the market as the basis 
for determining the relative, premarket contribu­
tions of licensor and licensee. 
A second version of the 50% rule appears 
to be applied primarily in the area of software 
and reflects the very significant pre- and post-
commercial involvement by university and 
R&D organizations in certain situations. When 
software is commercialized, many activities 
can be the responsibility of either the licensee 
or licensor. These include: performing all the 
bug fixes and compatibility tests of the original 
code, developing user interfaces, creating soft­
ware manuals, making copies for distribution, 
packaging, finding customers, delivering copies, 
hot-line help for routine questions, resources for 
in-depth questions, new bug fixes, updates and 
improvements, product advertising, sales and 
distribution, more bug fixes, and so on. In some 
instances, the licensee and licensor will divide 
these responsibilities so that when credit for 
cost/risk of creating the product is ascribed to 
the licensor, then the resulting split is 50:50. 
But there is no simple way of saying how 
such a split in responsibilities warrants 50:50. At 
one extreme, for example, the owner/developer 
of the software product could do everything re­
quired for commercial use, including advertising 
and other promotional activities, and elect to hire 
marketers purely on a commission basis to assist 
in direct sales. (This is commonly necessary when 
selling software that costs in excess of several 
thousand dollars). In such a case, the marketer 
is playing only a limited role in the commercial 
process, basically as a manufacturer’s rep and may 
be paid a commission, ranging from 10%–20%. 
Taking a figure of 15%, this means the revenues 
from sales have been effectively split 85:15 taken 
as a percentage of sales in this example of a differ­
ent rule of thumb. 
At the other extreme, the creating organiza­
tion can enter a license at an early stage in de­
velopment and turn over a hard drive contain­
ing code that works but is not yet complete as a 
product. In this case, the licensee has to finish the 
code; develop all the user-friendly tools; intro­
duce the product to the market; perform all the 
promotions, sales, and distribution; handle the 
customer; and so forth. Here, the licensee may 
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agree to pay a royalty in the range of 10%–25% 
(or even much less). Taking again a figure of 15%, 
this means that the revenues from sales have been 
split 15:85. 
By using the 50% rule, or a 50:50 split of 
revenues, a licensor agrees to perform an addi­
tional 35% share more of services than in the 
15:85 example (or the commercial partner is 
doing an additional 35% share more of ser­
vices than in the manufacturer’s rep example 
of 85:15). As you can see, it is unhelpful to 
rely too heavily on such numbers. Indeed, like 
any other type of licensing, once a technology 
transfer manager has gone through a significant 
number of deals, he or she will be able to recog­
nize what deserves a 50:50 split, as well as the 
appropriate split for the level of involvement in 
particular cases. 
. 	 Discounted cash-flow analysis 
with hurdle rates 
Method III introduced the concept of apportion­
ing profit by examining each party’s contributions 
and risks incurred in creating such profit. Method 
IV is a more sophisticated way of performing such 
considerations. This method consists of deter­
mining future cash flows, then discounting these 
cash flows by accounting for the time over which 
those amounts are to be received and by the as­
sociated risk of receiving such cash flows. For this 
reason, this method is sometimes known as the 
discounted cash flow (DCF) method. When all 
such cash flows have been discounted, they can 
be added to determine net present value (NPV). 
The key to this method is the application of the 
risk-adjusted hurdle rate (hereafter designated by 
k) or the factor based upon perceived risk that is 
used to discount the future cash flows and will be 
referred to here as the “risk-adjusted hurdle rate” 
(RAHR). In effect, k is used to determine how 
the profits (or cash) resulting from the commer­
cialization of the subject opportunity should be 
apportioned. 
..1 Defining risk 
First, let us consider what is meant by risk. There 
are technical risks, market risks, and the infamous 
other risks, such as market erosion or the changing 
tastes of consumers. What are some technical 
risks? Although it may not be obvious, a key 
technical risk has to do with whether the technol­
ogy works. For many reasons, a lot of inventions 
simply do not work. Sometimes the invention 
works, but only under very carefully controlled, 
glacially slow procedures with tiny quantities in 
clean rooms carried out by very experienced sci­
entists using technicians with dexterity and intel­
ligence that is hard and very costly to duplicate. 
If a product needs to be made in high volumes at 
low cost, there is a huge risk in taking something 
that works in the cleanest of clean-rooms and get­
ting it to work in a factory. 
In the category of market risk, a competitor 
may develop a superior product based on anoth­
er technology. Customer requirements can also 
change dramatically. Tastes can change, and antic­
ipated profit margins can erode or disappear. And 
customers, despite all the market assessment, can 
simply decide not to like a product. Remember 
New Coke? Remember Corfam? Sinclair and 
Commodore computers? An appetite-suppress­
ing candy with the unfortunate name of Ayds? 
Finally, all sorts of external events can sink 
an enterprise. Some raw material that the licens­
ee needs to use or a product that it plans to sell 
can become illegal or so constrained by regula­
tion that there is no cost-effective way to use it 
or sell it. Other industries can undergo upheaval 
to the mortal detriment of a licensee. Remember 
the oil embargo? The shortage of DRAM chips? 
Nuclear power? A key trade secret could be sto­
len. The patent office could deny patentability or 
grant broad rights to a blocking patent owned by 
a third party. 
..2 Developing a risk-reward model 
Investors use a risk-reward model to guide their 
investment decision making. It is commonly 
expressed in some form of a graph such as the 
one shown in Figure 2, where increased risk de­
mands an increased required rate of return (k), 
also known as the hurdle rate. The job of a busi­
nessperson is to convert the investments made in 
the company into returns that equal or exceed 
the rates of return expected by such investors. So 
the floor for a businessperson’s expected returns 
HANDBOOK OF BEST PRACTICES | 
     
 
 
       
       
         
       
        
        
          
       
       
         
       
        
    
    
RAZGAITIS 
is normally the company-specific, average cost of 
capital (a combination of debt and equity). What 
makes a particular project investment good or 
bad at the stage of making the investment is the 
perception of whether the returns will be attrac­
tive in relation to its risks, the latter of which are 
determined by the company’s prescribed reward-
risk relationship. 
From the point of view of the prospective 
licensee, one of the basic value questions is the 
degree of risk that has been eliminated by the 
licensor’s R&D and other activities. The greater 
the risk reduction, the greater the perceived value 
(or, in other words, it is less likely that a discount 
will be applied to the perceived potential value of 
the license). From the perspective of the licensor 
and, particularly, the professor-inventor, this sug­
gests that additional R&D will increase both the 
likelihood and the economic value of a license. 
But this is only true if the licensor’s R&D activi­
ties are successfully applied to commercial risk-re­
ducing activities. Investment in R&D that is di­
rected toward improved scientific understanding 
and publication of an invention may or may not 
reduce risks associated with commercializing a 
product of interest to a licensee.39 Not all motion 
is progress. This is yet another reason why costs 
are irrelevant in assessing value. Figure 3 summa­
rizes the key steps of this method. 
First, a determination must be made of the 
earnings before interest and tax (EBIT). This is 
done in the same fashion (and with the same un­
certainties) as with Method III (see Table 12). 
Next, a provision is made for a royalty payment 
as yet another cost of the licensee. Initially, this 
value is simply a guess. Later, it will be adjusted to 
make the overall returns attractive to the licensee. 
Next, a provision is made for taxes. Throughout 
the 1980s and 1990s, a value of 40% was typi­
cal for combined state and federal taxes; some­
what lower projections are now sometimes made 
for the future. This results in earnings after tax 
(EAT—an easy acronym to remember). 
But the EAT for a project is rarely the 
amount of cash it throws off. One reason is that 
to calculate earnings, we have subtracted from 























3% is the historic figure people require to defer consumption 
+ 4% inflation = 7% T bill 
Risk-free rate of return (T= bills) 
Company-specific average cost of capital 
Good investment 
Bad investment 
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revenues some non-cash costs such as deprecia­
tion. To get a cash figure, we need to make three 
additional adjustments to earnings: (1) the total 
depreciation expenses deducted from revenues to 
reach EBT must be added back since they are not 
a current-year cash expense; (2) the current-year 
cash investment (such as plant and equipment) 
needed to produce the revenues flowing from the 
technology must be deducted; and (3) the year­
by-year increase needed in networking capital 
(current assets, such as cash, receivables, and in­
ventory, less current liabilities, such as payables— 
all of which tend to increase with increasing sales) 
must be subtracted. The result is net cash flow in 
current-year dollars for the projected period, nor­
mally at least 10 years of sales, or a total of 15 or 
more years from the effective date of the license 
agreement. 
Next, each years’ cash flow is reduced by di­
viding each cash flow by the term (1+k)n, where k
is the hurdle (or discount) rate, and n is the year 
from now in which the projected cash flow oc­
curs.41 In order to perform this calculation, esti­
mates must be made for revenues and all relevant 
costs and investments year by year. This can be a 
formidable exercise to a first-timer, but after the 
technology transfer manager has done this a few 
times, timidity flees and the manager will find 
him- or herself boldly arguing about projected 
costs of sales in the year 2020. Table 14 provides 
an example calculation taken from Gordon Smith 
and Russell Parr.42 
In the example shown in Table 14, a com­
pany is considering whether to buy a license for 
a specialty product to add to an already existing 
commodity product. The royalty line showing 
12.6% of sales is based upon the sales of the li­
censed, specialty product only. The NPV of the 
combined net cash is shown as US$19,684. The 
12.6% was used because this NPV is identical to 
















Discount cash by NPVa = $ in year n 
(1 + k)n 
3 
Embody risk in “k” 
4 
Choose “k” 
a Net present value equals “All the future benefits of ownership compressed into a single payment.” 
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RAZGAITIS 
Table 14: Commodity Corp. Discounted Cash-Flow Analysis
(uS$, in thousands) 
% 1991 1992 1993 1994 1995 % 
Commodity sales 100 100,000 105,000 110,250 115,763 121,551 
Specialty product sales 100 1,000 5,000 20,000 45,000 60,000 
Total sales 101,000 110,000 130,250 160,763 181,151 
Cost of commodity sales 68 68,000 71,400 74,970 78,719 82,564 
Cost of specialty product 45 450 2,250 9,000 20,250 27,000 
sales 
Total cost of sales 68,450 73,650 83,970 98,969 109,654 
Depreciation expense 2,632 2,813 3,051 3,446 3,699 
Gross profit 30 29,918 33,537 43,229 58,348 68,198 38 
Selling, general and 24 24,240 26,400 31,260 38,583 43,572 24 
administrative 
Royalty payment at 12.6% 126 630 2,520 5,670 7,560 
of sales 
Operating income 5 5,552 6,507 9,449 14,095 17,065 14 
Provision for taxes 2,499 2,928 4,252 6,343 7,679 
Net income 3 3,054 3,579 5,197 7,752 9,386 5 
Depreciation expense 2,632 2,813 3,051 3,446 3,699 
Gross cash flow 6 5,685 6,392 8,248 11,198 13,085 7 
Less— 
- Additions to working 1,200 1,800 4,050 6,103 4,158 
capital 
- Capital expenditures 2,632 3,632 4,763 7,901 5,046 
- Net cash flow 2 1,853 960 (565) (2,805) 3,881 2 
- Discount rate 0.9333 0.8115 0.7057 0.6136 4.9718 
- Present value 1,730 779 (399) (1,721) 19,296 
Total net present value (in uS$, in thousands) 19,684 
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the NPV of not taking a license for the specialty 
product. Therefore, a royalty of 12.6% would be 
the most the company would pay to gain this ad­
ditional product. 
The key aspect of the above calculation is 
the specification of a value for k. Before delving 
into how a value for k might be selected, a bet­
ter understanding of what k does to a calculation 
is required. Figure 4, which shows a pro forma 
net-cash-flow projection for a license, can help us 
take our first steps to understanding k. 
At time zero, the license agreement is signed. 
During each of the first and second years, the li­
censee spends $1 million in combined upfront 
fees and technology development and project 
costs. In the third year, these costs grow to $2 
million, and in the fourth year, as scale-up and 
production costs are incurred, they grow to $3 
million. So, by the end of the fourth year, and 
before any sales occur, the licensee has spent $7 
million. Although sales begin in the fifth year, 
there is still a net investment required of $2 mil­
lion and again of $1 million in the sixth year. At 
the seventh year, the licensee finally reaches the 
stage where the technology does not require an 
additional current-year net cash investment. In 
this model, the licensee has had to sink a total of 
$10 million to get to this point (7+2+1), and in 
the seventh year, the project results in a net cash 
inflow of $1 million. Note that for most projects, 
the amounts of initial investment required are 
generally able to be estimated with more certainty 
than are the later-arriving profits. 
Now, the market for the product is expect­
ed to take off and there is a significant growth 
in expected cash generated until the product 
peaks in the 12th year. Sales begin to decline 
in the 15th year, and finally end after the 19th 
year when the product is withdrawn from the 
market because it is no longer economically 
competitive. 
Adding all the cash flows above the line, 
from the seventh through the 19th years, shows 
a cumulative $136 million. Thus, it took a rela­
tively certain $10 million investment to get an 
expected return of $136 million.43 Putting this 
another way, a $10-million investment starting 
today and extending over a period of the next six 













1 2 3 4 5 6 7 8 9 10 11 12 
Patent expires 
Exit the business 
Patent issues 
1st commercial sales 
year 
13 14 15 16 17 18 19 20 
Profit pressure
at maturity 
Total net cash flow = $126m 
Investment required = $10m 
Project years 
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years, will yield a substantial $126 million net 
over the next 19 years.44 
Figure 4 ignores inflation and all the risks as­
sociated with the production of those future cash 
flows. In accounting for inflation, a k value of 2%– 
8% (depending on our views of the future) might 
be used to reduce all the cash flows to the same 
basis so that when the return is netted against the 
investment the calculation is made using same year 
dollars, at time zero. If a k value of 7% is selected, 
each of the shown cash flows would then be di­
vided by the term 1.07n, where n is 1, 2, 3, and so 
on, up to 19 for each year of the projection. 
However, in addition to inflation, risk must 
also be assessed and accounted for. The licensee’s 
expenditures of money are comparatively cer­
tain. The returns are not. If the licensee takes 
the view that investments and returns should be 
discounted by the company’s cost of capital, and 
such cost is, say, 15% (which includes the effects 
of inflation), then the cash flows of Figure 4 result 
in the curve shown in Figure 5. 
This shows that the early-year cash amounts 
are reduced slightly (the curve and bars are close 
in the first and second years). As time progresses, 
there is a compound discounting of cash amounts 
until the cash contributions calculated by the 15% 
discount factor in the 19th year are almost neg­
ligible. This is because the mathematics assumes 
a compounding of risk with each succeeding 
year (in other words, more things can go wrong 
as more time progresses). Remember that a k of 
15% in this model is more than the presumed 
rate of inflation. This is why the term hurdle rate 
is used for k. If the projected cash flows cannot be 
attractive using 15%, then this investment does 
not jump this hurdle and should not be made. 
What Figure 5 shows is that, for a k of 15%, 
the $126 million of nominal net cash is really 
only $17.25 million of time zero (now) cash. 
This $17.25 million value is called the net pres­
ent value (NPV) at a hurdle of 15%. The NPV 
means that, for a risk value of 15%, including in­
flation and all the things that can go wrong, the 
decision to invest in this opportunity will pro­
duce, in time, the equivalent of $17.25 million 
of today’s dollars. By definition, this means it is 
worth making the investment, unless the licensee 













1 2 3 4 5 6 7 8 9 10 11 12 
NPV (15% of $126 million) ,
is $17.25 million, which corresponds to
the sum of all the values associated
with this curve, 
13 14 15 16 17 18 19 20 
$17.25 million is the 
maximum a licensee 
would pay for the 
right to such future 
cash flows if its 
perception of risk 
corresponds to a
k of 15%. 
Project years 
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CHAPTER . 
has an even better NPV opportunity at the same 
or lower level of risk. 
Figure 6 shows the impact of various hurdle 
rates on the same cash values shown in Figure 5. 
The original cash profile shown was for 
a hurdle rate of 0% and assessed this opportu­
nity at $126 million net in nominal dollars. If 
a k value corresponding to a near risk-free alter­
native investment opportunity of 7% is selected 
over the period, then the opportunity is assessed 
at $49 million (again, and always, in today’s dol­
lars). When a hurdle rate of 15% is selected, cor­
responding to a low but real risk, this is further 
reduced to $17 million. Finally, when this oppor­
tunity is believed to contain significant technical, 
market, and other risks corresponding to a risk-
adjusted hurdle rate (RAHR) of 30%, the NPV is 
reduced to $1.6 million. 
The key idea of NPV is that, once the ap­
propriate value for k has been selected by the 
licensee, then the licensee should be motivated 
to acquire rights to any properties that have a 
positive value of NPV, provided the company has 
sufficient resources to pursue every positive NPV 
opportunity. Otherwise, the licensee will select 
the most positive opportunities available. In any 
case, the licensee will still want to buy the rights 
to the opportunity for as little as possible, even 
less than the values used in computing the NPV 
in the first place: “Business is about paying tens 
for fifteens.”45 
.. Determining k (the hurdle rate) 
Now, how is k determined? The discussion of 
Method I noted that established market prices 
exist for certain standard kinds of items, such as 
office floor-space rentals, and for standard forms 
of debt instruments, such as federal securities of 
varying maturity. U.S. Treasury securities, having 
essentially no “business” risk, have the lowest k
values. For example, as of 13 April 2001, the k
value ranged from 4.33% on two-year treasuries 
to 5.16% on ten-year treasuries. Bonds offered 
by corporations generally have higher k values, 
depending upon the perceived risk as character­
ized by various bond-rating agencies. However, 
all such rates are for broadly based investments, 
not a specific commercialization project, so they 













1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
NPV (0%, $126m) 
NPV (7%, $49m) 
NPV (15%, $17m) 
NPV (30%, $1.6m) 
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are normally believed to be substantially less risky 
(because the companies exist, their markets are 
known, their competitors positioned, their tech­
nology understood, and their businesses typically 
are somewhat diversified). 
Unfortunately, there is no such table of values 
available for technology licenses. As was the case 
when contrasting office space rentals and tech­
nology commercialization opportunities, the lat­
ter do not fall into sufficiently precise categories 
with large numbers of published values to permit 
standard ks to be established. 
Figure 7 illustrates another type of risk con­
sideration: business start-up risk. This is based 
primarily on a book by Jeff Timmons.46 
A number of terms are used to characterize 
the stages of development; at times, these terms 
can be confusing and contradictory. In general, 
for capital sought prior to initial sales, the hurdle 
rate required by risk-capital providers is very high, 
50%–100% (or even more). Once sales exist and 
a market can be characterized, and assuming the 
results are favorable, the hurdle rates can decline 
dramatically down to 30%–40% (depending 
upon assessments of competitive response, mar­
ket saturation, cost of expansion, and so on). The 
hurdle rates used for genuine start-up situations 
are usually far higher than those used by an exist­
ing company, and they reflect the increased risks 
associated with all the activities needed to create a 
business ex nihilo. 
So, what is a reasonable way to categorize 
hurdle rates? There is no simple answer to this 
question. However, to provide some insight the 
broad generalizations of Box 1 are offered for five 
categories of risk.47 
Most licensing situations with existing 
companies will fall into Categories II and III, 
corresponding to hurdle rates in the range of 
25%–40%. Start-up situations or companies 
contemplating a spinout structure normally re­
quire hurdle rates in excess of 40%, even to 50% 
or higher. However, as was discussed in connec­
tion with the 25% Rule, every licensing opportu­
nity has case-specific factors that affect both value 
and, our present concern, risk. Just because an 
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invention relates to an existing manufacturing ca­
pability with a known technology area, a poten­
tial licensee may see the risk associated with such 
specific invention as warranting a RAHR higher, 
or lower, than given in the Box below. 
Figure 8 applies these five risk categories to 
our original cash flow example of Figure 4. 
If this opportunity corresponds to Category 
III, the NPV ranges from a negative $800,000 
(for a k of 40%) to a positive $1.6 million (30%). 
So, what originally looked like a simple decision 
of making a total investment of $10 million to 
net a total of $126 million is actually a close call. 
If the risk of this opportunity corresponds to a 
hurdle of 40%, this investment cannot be justified 
because the NPV is negative. Recall that, when 
this model was created, (an unstated) upfront 
payment and progress payments were assumed 
by the licensee to the licensor, as were continu­
ing royalties that reduced the cash flows to those 
shown. Both were part of the $10 million invest­
ment. From the point of view of the licensee, this 
negative NPV should be a stimulus to reconsider 
all such IP payments to see if the negative NPV 
can be made positive. 
.. Reducing risk/enhancing value 
In any event, there are at least two other possibili­
ties for reducing IP payments. First, the perceived 
risk may be reduced by working with prospective 
licensees who are either already commercially ap­
plying technology similar to the subject opportu­
nity or selling like or similar products. The point 
here is that companies perceive risk differently 
depending upon their technology base and their 
existing customers. If, by this redirecting of mar­
keting activity, a different prospective licensee’s 
assessment of risk is now 30%, then there is the 
potential to gain as much as an additional $1.6 
million beyond those payments embedded in 
the cash-flow calculation. That is a very dramatic 
increase in value. Furthermore, the likelihood of 
getting the royalties is increased because it is more 
likely that such a licensee will succeed (all other 
things being equal—and they never are). 
A second approach to dealing with negative 
NPV outcomes is to consider what R&D and/or 
market development activities can reduce the risk. 
The real technical risk of some key aspect of the 
technology may be known by the inventors to be 
much less than that perceived by prospective buy­
ers. A carefully directed, internally funded R&D 
program tackling commercial objectives can sig­
nificantly reduce such risk. Of course, it is always 
possible that such results will go the other way. 
The key idea is to spend small amounts of money 
on critical, commercially relevant experiments— 
and not just gather ever-more publishable data 
Box 1: What Is Reasonable k?
 
Unfortunately, the answer is: whatever the market says it is. 
What does the market seem to be saying?
I.	 Low risk (assuredly fits into an existing manufacturing line and market) 10% to 20%; if required 
to maintain base product life, then k could be much lower, or even discarded
II. New product (existing manufacturing capability, known technology) 25% to 35% 
III. New product and technology (still in existing business) 30% to 40% 
IV. New business, product ready for sale (no R&D required) 40% to 50% 
V. New business, seed funding, R&D stage 50% to 70% (or more) 
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Figure 8: Who Are Prospective licensees 













1 2 3 4 5 6 7 8 9 10 11 12 
Patent expires 




13 14 15 16 17 18 19 20 
Profit pressure
at maturity 
Applied to our previous
net cash-flow model, what would 
an investor conclude? 
Category k NPV 
RF........................... 7%............................ $49m 
I............................... 10%–20%............... $33–$8m 
II. ............................ 25%–35%............... $4.2–$0.1m 
III> ......................... 30%–40%.............. $1.6– $(0.7)m 
IV. ........................... 40%–50%.............. $(0.7) – $(1.4)m 
V. ............................ >50%....................... <$(1.4)m 





Only if you paid me! 
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sets. Some have described this process as doing 
the last experiment first. In general, it is a very 
good idea. 
Another tool in such a risk-reduction ap­
proach is leveraging government funding. It can 
be argued that government funding should be 
used to reduce the risk of significant commer­
cial opportunities so that the private sector can 
apply it to create high-valued companies and 
jobs. Commercial funding necessarily has some 
relatively immediate market application and in­
troduction. However, there are other sources of 
“research” funding sometimes available that push 
forward certain knowledge frontiers that could 
have as a consequence the development of know­
how that supports the subsequent commercial 
development needed for a specific licensing 
opportunity. 
In addition to reducing risk, one can work 
to directly enhance value. One tool to accom­
plish the latter is to form partnering relationships 
with other R&D organizations that, by pooling 
technology resources and market awareness, can 
sometimes significantly increase the NPV per­
ceived by prospective licensees. Even when the 
NPV is already positive and a prospective licensee 
is interested in negotiating rights, remember that 
a licensor always has alternatives. For example, 
the technology could be pushed closer to mar­
ket either by internal investment or by partnering 
with another R&D organization to increase the 
value. The technology transfer manager should 
make such investment decisions by calculating 
the prospective increase in value discounted by 
the risk of success. 
This risk-adjusted hurdle rate approach can 
be used for exclusive and nonexclusive licenses, 
as well as for licenses by field (or product) and 
territory. In each case, the cash-flow projections 
need to reflect the anticipated commercial out­
come given the structure of the agreement. For 
example, if the licensing strategy is to have two 
competing licensees in all fields and territories, 
then the magnitude of the total sales attainable 
by each licensee is probably less than if there 
were to be one exclusive licensee. However, the 
gross margins, or profitability, may remain large, 
since each licensee will not face a large number 
of competitors. The net result is likely to be that 
each licensee will pay less royalty, but together 
they could (and should be if such an approach is 
considered) pay more total royalties.48 More de­
tails on DCF models are provided in the Wiley-
published book by this author.49 
.. Possible payment structures 
Running royalty structures. There are many pos­
sible royalty structures. Because the royalty rate 
depends upon the economic value associated 
with specific products, if there are multiple prod­
ucts, then a separate royalty could be established 
for each product or product area within a single 
agreement. There is also justification for build­
ing up a royalty rate based upon the measure of 
IP protection obtained. For example, a licensee 
might pay a royalty of 3% on the basic patent 
and 1% for the use of the two other patents in 
the package, or 1% for the use of the unpublished 
technical information and an additional 3% for 
the patents, and so forth. Of course, this should 
only be considered if it relates to an economic 
benefit (lower k, higher margins, and so on). 
Many licensees ask for a declining royalty rate 
with increasing sales, a so-called staircase or wed-
ding-cake royalty structure. One example would 
be a royalty of 5% on the first $1 million in sales, 
3% for the next $9 million, and 1% for all sales 
above $10 million, based on annual sales. The un­
derlying theory of this approach appears to be an 
economy-of-scale argument similar to bulk pur­
chasing. If a company buys one box of paper clips, 
it might conclude that $5 is reasonable; if it buys 
1,000 boxes it may expect to pay only $3 each; 
and if it commits to buying trainloads per year, it 
may expect to pay only $1 each. Companies com­
monly leverage volume purchases when they buy, 
and apply this same kind of thinking when they 
sell. However, there is no economy-of-scale prin­
ciple for IP rights. The licensor’s costs of provid­
ing the grant to the licensee are not relevant, nor 
do they decline based on sales volume, as would 
the costs of a paper-clip supplier. In fact, based 
upon an economic-return model, it can be argued 
that the profitability to the licensee increases with 
increasing sales, and so, the royalty rate should 
actually go up with increasing sales. For practical 
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reasons, the parties may elect to simply compro­
mise and keep the royalty rate fixed regardless of 
sales volume. 
Developing a staircase royalty structure based 
on cumulative sales or on years from first com­
mercial use may have a rational economic basis. 
Ordinarily, after the initial introduction, the prof­
itability of a product climbs to a peak and then, 
as the product matures, pricing pressures tend to 
squeeze margins. A royalty structure that attempts 
to model this profile makes sense, providing the 
rate during the high-profit years has been set to 
correspond with economic benefits. For practical 
reasons, parties frequently elect a single rate over 
the life of the patents that balances all these fac­
tors. Regardless of the approach, the rate agreed 
to tends to act as a cap for the reasons discussed 
in the introduction to this chapter. The licensor 
does not have a vehicle for increasing the rate, 
and the licensee can come back to the licensor 
and threaten to drop the license because of less­
than-anticipated margins unless it gets a reduc­
tion in the rate. 
Licensees sometimes propose capping the to­
tal economic return to the licensor. This may be 
expressed as some multiple of the licensor’s costs 
(You shouldn’t expect to get more than ten times 
what you’ve invested in this!) or simply as some 
statement of moral principle ($10 million should 
be more than enough, after all you are a public, 
not-for-profit institution!). This is nonsense. A 
licensor who is the rightful owner of a portfolio 
of technologies has a stewardship responsibility 
to return value to the institution for the transfer 
of such rights. Furthermore, all portfolios exhibit 
many losers, a few moderate successes, and only 
a few agreements that perform really well. If the 
licensor agrees to caps on the total return of all 
agreements in the portfolio, then the portfolio 
will produce only losers and moderate returns. 
Without the occasional big win (at a fair royalty 
rate), the portfolio will not produce a fair overall 
return. 
What about the approach of a one-time, paid-
up license—that is, setting a higher licensing fee 
with a zero running royalty? Some licensees push 
hard for this approach—and not always from a 
pure heart. There are several common arguments 
in favor of the approach: (1) it eliminates the ad­
ministrative burdens (quarterly or annual reports 
and checks) for both the licensor and licensee and 
(2) basing royalties on sales may divulge highly 
sensitive licensee business information, which is 
against company policy or wishes. Recall the ear­
lier discussion about setting the values of future 
income streams in well-defined situations such as 
office rent. When a stream of cash payments is 
well defined and the risk is low or at least well 
understood, then two parties can readily agree 
on the conversion value of the future stream into 
one present payment (which is really just the 
NPV of the future stream). However, for early-
stage technologies, estimates of the range of pos­
sible dollar returns from royalties can vary over 
several orders of magnitude. This is precisely why 
a royalty rate so effectively deals with such un­
certainties. When either the licensee or licensor 
seeks to reduce such uncertainties to a one-time 
lump sum, there is greater risk involved in mak­
ing the conversion. One possible motivation for a 
prospective licensee is simply to see if the license 
can be acquired cheaply. Every agreement has as­
sociated with it a range of expected outcomes. If 
a licensee can acquire the license by the one-time 
payment of the NPV associated with the most 
conservative outcome, then it is in the licensee’s 
interest to do so. 
Rest assured, a licensee is unlikely to agree 
to an NPV associated with the most optimistic 
outcome. It should be recognized, however, that 
sustaining ongoing agreements is both a business 
cost and a risk. An ongoing payment arrangement 
could possibly lead to a dispute or even litigation. 
And there may be situations where the licensor’s 
cash needs are such that the institution is willing 
to forgo the returns associated with more opti­
mistic possible projections. If this becomes the 
licensor’s practice, however, the overall returns on 
the licensor’s portfolio of technologies will be re­
duced because the licensor will not experience the 
rare but important higher-than-projected returns 
from an exceptional license. 
Having said all this, sometimes such an ar­
rangement can be in the interests of both parties 
(beyond the simple example given above). The 
licensor may wish to take advantage of the high 
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CHAPTER . 
opportunity value associated with a paid license 
so that the funds can be used to move further and 
faster other technology opportunities that will 
lead to even more substantial returns. Or perhaps 
the licensees are cash-rich from a current high-
outcome year and are simply willing to make a 
fair and substantial payment to own and control 
an opportunity because of its perceived strategic 
importance. Overall, in those cases where the fu­
ture use and value of an opportunity appears to 
be reasonably well-bounded, then an NPV calcu­
lation can be made that is fair to both parties. 
Upfront payments. Upfront payments take 
many possible forms. As discussed earlier, the 
extreme case is a one-time payment in lieu of 
running royalties.50 A series of payments can also 
be made, either by calendar (such as annual pay­
ments) or by progress (such as upon filing an IND 
[Investigational New Drug application, a filing 
with the U.S. Food and Drug Administration], 
upon first commercial sale or other milestones) in 
conjunction with or instead of royalties. Or the 
licensee can commit to R&D to fund certain ac­
tivities at the licensor’s laboratories. 
All of these are basically down payments on 
the NPV opportunity as calculated earlier, and 
the purpose of any down payment is the same. It 
combines a form of diligence and commitment, 
and provides an early return for the original in­
vestor, the licensor. In university-industry licens­
ing, the upfront payment will commonly at least 
exceed the licensee’s payment of all the licensor’s 
costs in filing and obtaining a patent or patents 
incurred to date. If the license corresponded to 
an NPV of $1.6 million as in the previous ex­
ample, and the patent costs were $5,000, such an 
upfront commitment covering only the licensor’s 
costs would be cheap—too cheap. 
For well-established transactions such as 
buying a house or a car, a down payment of 10%, 
more or less, is common, although for highly 
motivated sales of, say, certain out-of-popularity 
automobiles, might be happy with “no money 
down” deals. For highly speculative opportuni­
ties, such as a license to new technology, 10% 
may be on the high side. Consider in the pre­
vious example, that the $1.6 million NPV was 
computed on the basis of a single, time zero, cash 
payment of $100,000 and then royalties on sales. 
Such a figure would then correspond to a down 
payment of a little more than 6%. This might be 
quite reasonable. Some negotiators use, as a rule 
of thumb, one year of projected mature-earned 
royalties as an appropriate down payment; this is 
approximately 5%–10% of the NPV. 
Minimums. Another form of diligence is 
the minimum cash payment. Also, agreeing 
upon such payments increases the likelihood 
that both parties are looking at the opportunity 
from similar perspectives. Generally, exclusive li­
censes contain minimums. Nonexclusive licenses 
may or may not include minimums. The rule of 
thumb appears to be an annual payment in the 
amount of one-fourth to one-half the annual 
projected reasonable royalty based on sales esti­
mates. Again, the higher the risk and uncertainty 
of such sales estimates, the lower the minimum 
royalty, and vice versa. 
It is important to realize that the licensee 
still has significant negotiating leverage on the 
minimums. If they end up being too high, and 
it is now five years into the agreement, the li­
censee can exert a lot of influence on the licensor 
by threatening to drop the license if the mini­
mums are not reduced in line with the actual 
sales (assuming the licensee has been diligent in 
developing the technology and the market). In 
addition, getting back a five-year-old technology 
may make it difficult for a licensor to find an­
other party interested in licensing the product. 
As discussed earlier, the wish, or threat, for bet­
ter terms, of a licensee in a licensee-initiated ne­
gotiation, puts in jeopardy the licensee’s invest­
ment in the technology (any upfront payments, 
milestones, annual royalties, and of course its 
own R&D and market development). So a li­
censee would have to take a dramatic step to ful­
fill such a threat and drop its license should the 
licensor not agree. 
Equity consideration. A full treatment of 
this subject is beyond the scope of this chapter. 
However, much of what has been discussed above 
regarding NPV calculations using discounted 
cash-flow analysis and hurdle rates applies. The 
reader is referred to the author’s Wiley-published 
books for more information. 
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Summary observations and valuation principles 
based on Method IV are given in Box 2 and Box 3. 
. Advanced tools 
Once a DCF model has been established, it is 
possible to extend such analysis by application of 
quite complex mathematical modeling tools and 
gain a better understanding of their economic 
impact. 
The basic tool is sometimes called probabilis­
tic modeling and, most commonly, Monte Carlo
analysis. The complexity of such models used to 
require mainframe or minicomputers, but at least 
two such products now run on personal comput­
ers. 51 
This tool works by replacing certain cells in a 
spreadsheet with a probabilistic value rather than 
a single number as was done in Method IV. Then 
the model is run over and over again, hundreds 
of times, to develop a distribution of outcomes. 
It is much like running the company 1,000 times 
(or more) and comparing the outcomes. Under 
the DCF approach, each outcome is the same. 
However, under a Monte Carlo method, each of 
the 1,000 runs would produce somewhat differ­
ent values for those cells that were selected for 
treatment in this manner. It may sound more 
complicated, but in many ways it is simpler. In 
fact, Monte Carlo methods are particularly useful 
when modeling a start up situation. 
Below is an example taken from one of the 
companies that offers a PC product.52 This con­
siders a fictitious drug, ClearView, which may be 
a cure for nearsightedness. The key assumptions 
are shown in Figure 9. 
In this illustration, the impact on profitabil­
ity will be examined through the probabilistic in­
vestigation of five assumptions. These are shown 
in Figure 10. 
First, consider the testing costs. The origi­
nal model assumed the testing costs would be 
$4 million. Assume there is an equal probability 
that the costs will range between $3 million and 
$5 million but will never be less than $3 million 
and never more than $5 million. This is shown as 
the uniform distribution at the top left of Figure 
10A. 
Next, reconsider the estimate for the num­
ber of patients cured: 25 out of 100. Now assume 
a binomial distribution, a commonly occurring 
natural distribution, with a mean of 25 as shown 
in Figure 10B. 
Now, adjust the assumption for the market­
ing costs from simply $16 million to the triangu­
lar distribution shown in Figure 10C. The most 
probable outcome is shown as $16 million, and 
the minimum and maximum are $12 million and 
$18 million. 
Similarly, the growth rate of the market and 
the market penetration single values are replaced 
by the distributions shown in Figure 10D and 
Figure 10E. 
Every simple-value cell in a spreadsheet can 
be replaced by any of the available probability 
distributions. As a technology transfer manager 
gains experience using this tool, it becomes in­
creasingly clear which cells to treat in this man­
ner and which probability distribution makes the 
most sense. There never is a right answer. In fact, 
one of the great powers of this methodology is 
that the model can be run over and over again 
with changing assumptions to better understand 
the key assumptions that should be investigated 
in more detail to reduce overall uncertainty. The 
result of the Monte Carlo simulation is shown in 
Figure 11. 
This outcome shows what happened when 
this business venture was run 998 times. The 
financial outcome ranged from the worst case, 
when all things broke the wrong way (the high­
est marketing cost, the fewest number of cured 
patients, and so on), with a loss of $14.9 million, 
to the most-favorable outcome (when everything 
went right) of a net gain of $51.9 million. Half 
the time, the net gain was less than $9.8 million, 
and half the time it was more. The big spike to the 
left on the graph of Figure 11 reflects the severe 
loss that occurs because the cure rate was so low 
that U.S. Food and Drug Administration (FDA) 
approval was never obtained. 
Another advanced method of increasing im­
portance is the use of real options (as opposed to 
financial options). Indeed, an increasing number 
of books explore the use of real options in busi­
ness decision making. Their potential application 
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CHAPTER . 
Box 2: Summary Observations 
1. Value is dependent on risk—the risk-adjusted hurdle rate (for the same magnitude and timing 
of future net cash flows). 
2. There is no one right risk model. 
3. Price is determined by what a buyer will give for the rights to such cash flows. 
4. As a licensor’s price aspirations correspond to low (optimistic) values of RAHR, the likelihood of 
finding such a buyer is reduced (which translates to increased time and resources required to 
find such a buyer). 
5. There is no one right price (providing No. 2 is true). 
6. The longer the period of such future cash flows, the wider the risk limits and the greater the 
uncertainty in price aspiration. 
7. For cash streams that meet certain standard categories, such as home mortgages, there are well-
established markets that significantly reduce the scatter on risk and price. No such market exists 
for early-stage technologies. 
8. Net-cash-flow models require more work and are subject to significant assumptions about
operations and the future (but the licensee is using them to analyze the opportunity and so 
should the licensor). 
Box 3: DCF Valuation Principles 
1. Value calculations may have wide limits because of the range of estimates of the magnitude,
timing, and risk of future net cash flows. 
2. Value is given by a down payment (option/license fee) and a future royalty, which may, in the 
end, be used to determine the one-time,  upfront payment for a fully paid-up license. 
3. The down payment for a running royalty license should (normally) be a small fraction of the 
total estimated value based on one or the other of the following: 
- approximating the higher risk bound (but, nonzero) 
- 5%–10% of the total NPV (best estimate basis) 
4. A fair royalty can only be negotiated when reasonable estimates can be made of future net
cash flows. 
5. The royalty should be uncapped. 
6. Royalty scales dependent on total sales, if used, should be based on value not on a quantity 
discount model. 
7. Royalties based on figures below the top line (sales) put the licensor at risk for inefficiency/
ineffectiveness of the licensee, which has the effect of double accounting for risk.
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RAZGAITIS 
to early, high-risk technologies can be useful 
because real options do not punish substantial 
but distant future outcomes by high and com­
pounded risk-adjusted hurdle rates. The DCF 
approach in particular can calculate an almost 
negligible value to a $1 billion opportunity that 
occurs, say, 10 years in the future with substan­
tial average risk. Real options can be used to take 
such risk apart by valuing an opportunity stage 
by stage, risk by risk, as decisions are reached 
and investments made. An introduction to such 
methods is given in the author’s Wiley-pub­
lished books and, in particular, another 2003 
Wiley book by the author: Dealmaking: Business 
Negotiations Using Monte Carlo and Real Options 
Analysis. These resources give a more comprehen­
sive treatment of Monte Carlo and real option 
methods and negotiation planning and strategy. 
The 2003 Valuation and Pricing of Technology-
Based IP also gives a more extensive discussion 
of various forms of deal structures and financial 
payments. 
. Auctions 
This analysis of methods and tools began by con­
sidering the use of industry standards. In a sense, 
by considering options it ends there as well. An 
auction is simply a formalized way of obtain­
ing bids from competitive potential buyers. As a 
method, it dates from antiquity and is the preva­
lent form of commodity transactions, ranging 
from the New York Stock Exchange to commod­
ity markets to estate and sheriff sales caused by 
owner bankruptcies. 
Figure 9: Sample Monte Carlo Method—Basic Assumptions
 
Fictitious new drug, ClearView, for correcting nearsightedness 
Costs (in millions):

Development cost of ClearView to date....................................$10,000
 






Drug test (sample of 100 patients)

Patients cured ........................................................................................... .0.25
 
FDA approved if 20 or more patients cured

(1 approved, 0= rejected)
 
Market study
Persons in U.S. with nearsightedness today..............................40,000 
Growth rate of nearsightedness ..................................................... 1.00% 
Persons with nearsightedness after one year........................... 40,400 
Gross profit on dosages sold
Market penetration..............................................................................8.00% 
Profit per customer in dollars ......................................................... $12.00 
Gross profit, if approved ..................................................................$38,784 
Net profit ...........................................................................................($14,000)
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Figure 10: Specific Monte Carlo Assumptions for ClearView Example 
Testing costs 




























C. TRIAnGuLAR 	dISTRIBuTIon 
(Continued on Next Page) 
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Its use in technology licensing contexts, 
however, has been comparatively rare because of 
various structural difficulties. One of the most 
significant barriers is the need for any prospec­
tive buyer to perform extensive due diligence 
and analysis. Imagine the contrast between be­
ing on the floor of an exchange and being of­
fered 100 shares of IBM at $100 share or 100 
bushels of corn at $3 per bushel. No investiga­
tion is needed to determine exactly what is being 
sold or whether there is a market for it. Contrast 
this with a vice president of an electronics firm 
receiving a letter from a university or institute 
offering to license or sell a portfolio of patents 
relating to a new approach for making a blue-
green laser. For the VP to have any rational idea 
as to his or her potential interest, he or she will 
have to substantially invest in learning how this 
offered technology differs from its own or other 
published literature, the stage of development, 
the key benefits, the scope of the intellectual 
property, and so on. 
Another barrier to the use of auctions is that 
the mosaic of the licensing deal is typically much 
more complicated than a simple cash payment, as 
in the case of IBM shares or bushels of corn. An 
upfront payment or payments is to be expected, 
but so might royalties, additional R&D invest­
ments at the discovery institution, and many 
other deal features. These aspects are not as eas­
ily communicated by bidders or compared by 
sellers. 
Growth rates of nearsightedness 



















d. CuSToM 	dISTRIBuTIon 
E. 	noRMAL 	dISTRIBuTIon 
5% to – 
SD = 2% 
16% 
Figure 10 (continued) 
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Nonetheless, auctions for intellectual prop­
erty do occur. Perhaps the most common occur­
rence is in the context of a shutdown or bankrupt­
cy proceeding, where the investors are seeking to 
recoup some of the investment and the alterna­
tive of continuing as a standalone company no 
longer exists. All the parties understand that the 
court has ordered a process, and there will be a 
sale to the highest bidder. 
A famous university example of opportunity 
licensing is associated with a fat gene discovered 
at Rockefeller University. According to a Business 
Week article.53 Rockefeller University and a then 
recently started biotechnology company initiated 
discussions; the invention, which has the promise 
to “cure” obesity by a gene, attracted significant 
interest by other companies, which led to other, 
parallel discussions. However, when a large num­
ber of companies expressed interest (reportedly 
more than a dozen), all of them were invited to 
bid on the opportunity. On 28 February 1995, 
Rockefeller announced that Amgen had won by 
agreeing to pay a US$20 million signing fee plus 
unspecified royalties. According to Rockefeller’s 
vice president for academic affairs, “Amgen pur­
chased a scientific concept”: a pretty valuable sci­
entific concept. 
The very high-perceived potential value of 
the Rockefeller gene gave the institution enor­
mous bargaining power (some might argue that 
Figure 11: Simulation Output (Forecast) for ClearView 
Forecast: Net Profit (mm)
Frequency distribution 998 Trials 
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RAZGAITIS 
it created a feeding frenzy). In most licensing 
circumstances, the seller/licensor is simply not 
going to be able to attract a sufficient number of 
simultaneous bidders. This is because the cost of 
the due diligence, coupled with the reduced like­
lihood of being the successful acquirer, will en­
courage already busy companies to do something 
else with their precious time and energy. Some 
additional examples of successful and unsuc­
cessful auctions are included in the earlier-cited 
author’s Wiley books. 
.	 ConCLuSIonS 
This chapter started with a letter requesting mon­
ey for an investment. It will close with another 
one (again, one actually received by a venture 
capitalist):54 
“Hello, How are you doing? My work is nec­
essary for the survival of life of the planet. I need 
money. Minimum investment $100,000. Profit 
25%. Thank you.” 
This letter has all the basic elements of a good 
marketing instrument: friendly beginning, state­
ment of mission, expression of need, identifica­
tion of benefit, friendly close. Now you have the 
tools to decide whether this is a good deal. 
Finally, for those of you whose mind has 
wandered reading all these pages and looking at 
all these figures and perhaps now find yourself 
completely lost, I understand that, you the reader, 
were hoping that by this time I would lead you 
to the number. OK, here it is: 3.14156. It is the 
best this author can do. Use it with great caution. 
That is it. That is all you need to know. Happy 
pricing. n 
RichaRd RaZgaiTis, Senior Advisor, CRA International, 
Inc., P.O. Box 65, Milford, NJ, 08848, U.S.A. richard@ 
razgaitis.com 
1 The initial version of this chapter was created during 
the author’s tenure with Battelle Memorial Institute,
a relationship the author gratefully acknowledges.
For more on this topic see Razgaitis R. 1999. Early Stage 
Technologies: Valuation and Pricing, John Wiley & Sons;
Razgaitis R. 2002. Technology Valuation. In The LESI 
Guide to Licensing Best Practices: Strategic Issues and 
Contemporary Realities, chap. 2. John Wiley & Sons,
2002; Razgaitis R. 2003. Valuation and Pricing of Tech-
nology-Based Intellectual Property. John Wiley & Sons;
Razgaitis R. 2003. Dealmaking: Using Monte Carlo and 
Real Options Methods. John Wiley & Sons. For further in-
formation about the author, visit www.razgaitis.com. 
2	 Malone MS. Upside. September 1992. 
3	 See, also in this Handbook, chapter 11.11 by D 
Bobrowicz. 
4	 The American Heritage Dictionary, New Collegiate 
Edition. 1980. 
5	 If the licensor has multiple licenses (that is, two for 
two different applications within the same territory),
it is not uncommon to have each licensee pay half the 
patent costs. When developing the initial agreement
with the first licensee, the language can provide that,
in the event that there is a second licensee, the cost
would be shared. 
6	 Even for conventional manufacture, this approach to 
pricing is rapidly being supplanted by value pricing.
This is because it has been determined that, in many 
cases, such pricing shielded manufacturing and 
overhead inefficiencies that are not being tolerated 
by a market that can turn to more efficient sellers.
In other cases, such a cost-based approach did not
capture, for the seller, the high value present in its 
products. 
7	 Notice that even in this example there are some 
important risks and timing issues. The technology, in 
this example, is in hand, ready, and works. Launching 
an R&D project always involves risk, no matter how 
confident anyone may claim to be about the outcome.
For example, it may be that no alternative work-
around is possible, or that it will take $20 million, or 
that it will only work 80% as well, or that it will take 
much longer than anticipated, and so on. Having 
something in hand today is less risky than attempting 
an independent solution. On the other hand, there are 
many examples where a highly sophisticated buyer 
can invent around an institution’s invention cheaply 
and quickly, even though the institution may have 
made an enormous investment in developing the 
invention in the first place.
8	 Science & Technology Agency, Japan. Class A 
Technological Assistance Agreements (1975). 
9	 Actually, in reviewing the bottom of the table, under 
electrical, it appears that two agreements had no 
payments at all. So more than half of the agreements 
had no upfront fee! 
10 McGavock DM, et al. 1992. Factors Affecting Royalty 
Rates. les Nouvelles June 1992. p. 107.The data presented 
was obtained from the voluntary response to a mailed 
survey. The authors caution that the number of replies 
may not be statistically significant. Also, given the 
nature of voluntary replies, there is no assurance that
the survey is not biased. 
11	 Nelsen L. 1989. University Patents. Presented at the 
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1989 AUTM Annual Meeting. These rates were not
determined by a scientific study; rather, they are typical 
ranges estimated by Lita Nelsen, Director, Technology 
Licensing Office, M.I.T, based on extensive experience 
in this area. 
12	 Adapted from article published by Corey G and E 
Kahn. 1991. How to Negotiate Reasonable Royalty 
Rates for Licensing Novel Biomedical Products. Genetic 
Engineering News July–August 1991. p.4. A related 
article by the same authors was published in 1990 as 
Biomedical Royalty Rates: Some Approaches. Licensing 
Economics Review December 1990. p. 13. 
13	 Adapted from Corey and Kahn (supra note 2). 
14	 Kiley T. 1990. IPH Newsbrief April 1990. 
15	 Ibid. 
16 Source: Communication from the seller. 
17	 Private communication, Emmett Murtha, November 
1993. 
18	 Mike Carpenter presented at workshop given at the 
1979 LES Annual Meeting. 
19 Ibid.; See also the list of reasonable royalty 
determinations in Einhorn: Royalty Patent Licensing 
Transactions vol. I, sec 303, pp. 3–11ff; or search DIALOG. 
20 There is a widely held perception that royalties 
determined or negotiated before the mid-1980s,
when the Court of Appeals for the Federal Circuit was 
established, are lower than rates established since. 
21	 See Einhorn, supra note 19.
22 Stevens A. 2000. Finding Comparable Licensing Terms.
AUTM Technology Transfer Practice Manual. Part VII,
Chapter 5. AUTM: Northbrook. 
23 Edwards, M. Workshop presented at the AUTM 1993 
Annual Meeting. Since these data were published by 
Mark Edwards there has been an enormous increase in 
the number of such transactions, especially in the “life 
sciences/health” area. Examples of such additional 
data are available at www.recap.com. 
24 For more discussion on obtaining copies of comparable 
agreements see Stevens AJ. 2002. Finding Comparable 
Licensing Terms. AUTM Technology Transfer Practice 
Manual, Second Edition. part X, chap. 3.
25 Feinber RA. 1982. APA Proceedings. Division of Consumer 
Psychology. p. 28. 
26 Ibid. 
27 Arnold T and T Headley. 1997. 100 Factors. les Nouvelles,
March 1987. p. 31. 
28 Degnan SA and C Horton. 1997. A Survey of Licensed 
Royalties. les Nouvelles, June 1997. pp. 91–96. Reprinted 
with permission from les Nouvelles. 
29 When using a savings approach, the technology 
transfer manager should build in some inflation factor 
to avoid collecting 25 cents a unit over a 15-year period 
when inflation eats into the real value of the royalty.
Remember,the $1 savings is $1 in the currency of the year 
that the royalty is calculated (in this example).Ten years 
later, with inflation or increasing costs of electricity or 
a particular raw material, the savings could be $8 in 
the currency of that tenth year. The agreement should 
normally have some provision for the calculation of 
royalty to similarly inflate in dollars so that, as in this 
example, it would yield $2 in the tenth year. 
30 This particular form of the definition is adapted from 
an article by Sommer EM. 1993. Patent and Technology 
License Agreements Explained. The Licensing Journal,
August 1993. p. 3ff. This article and other similar 
sources also deal with an important but complicated 
issue of transfer pricing: that is, when a licensee sells 
or transfers the product made by the practice of the 
technology to another division or a subsidiary of the 
licensee. 
31	 All the materials, labor, electricity, and all other variable 
costs attributable to the manufacture of the product
sold. 
32 Because this is a gain in a part of the statement
where reductions are applied, it is shown as a negative 
number; minus a minus means a plus, and so forth.
33 Ibbotson and Associates, Chicago, Ill. www.ibbotson. 
com.
34 Robert Morris Associates, Philadelphia, Penn. 
35 Data from RMA Annual Statement Studies, 1991.
published by Robert Morris Assoc.; Philadelphia, Penn. 
36	 W.L. Gore and Associates v. International Medical 
Prosthetics, 16 USPQ Second. p. 1257. 
37 Lee Jr. W. 1992. Determining Reasonable Royalty. les 
Nouvelles, September 1992. p. 24. 
38 Duke Leahey has included this point in various 
talks. The version here was the subject of a private 
communication in 1993. 
39 This is part of a long, impassioned argument between 
business and science. Science argues that it is unwise 
to develop and apply technology that is not completely 
understood. Business says: If we took that view, we 
would still be sitting on a rock and arguing about the 
Pythagorean Theorem—so, let’s get on with it. 
40 Smith and Parr. 1989. Valuation of IP & Intangible 
Assets. Wiley. p. 125. See also, Razgaitis, Valuation 
and Pricing of Technology-Based Intellectual Property 
(supra note 1); see also, numerous papers and books by 
Gordon Smith and Russ Parr on DCF methods and ways 
of separating intangible and tangible values. 
41	 Some people prefer to use a mid-year convention: that
is, the costs and revenues occur on average on one day,
halfway through the year. For this convention, it should 
be 1/2, 3/2, 5/2, and so on, which can be generalized by 
using a discount factor of (1+k)(2n-1)/2. 
42 Smith G and R Parr. 1990. Royalty Rate Analysis 
Techniques. Licensing Economics Review November 
1990. p. 9ff; also published in the 1991 Supplement to 
the Razgaitis’ Valuation of Intellectual Property and 
Intangible Assets (supra note 1). Smith G and R Parr have 
written extensively on this subject. Their organization 
publishes the journal Licensing Economics Review,
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which frequently includes articles on the application 
of this method, as well as other news and information 
on valuation, pricing, and other IP matters. 
43 This model assumes that the licensor received up-
front and minimum payments as part of the $10 
million investment by the licensee and a reasonable 
royalty throughout all the period that the product
was in commerce, so that the $126 million cash flow 
to the licensee was net of all the licensee’s expenses,
including royalty. 
44 Also assumed in this model is that there is no net
residual value or cost after the product is withdrawn 
from the market and the business is exited. 
45 A quote heard during a talk by Ray Rogers, finance 
professor at the University of Michigan Business 
School. 
46 The summary incorporates some of the terms and 
values by Timmons. (See Timmons JA. 1990. New 
Venture Creation). 
47 Paul Purcell of Battelle, and others, have provided 
valuable initial insights to negotiating and valuation 
contexts. 
48 Earlier in this chapter, Kiley (see supra note 15) proposed 
nonexclusive royalties as being approximately one-
half the royalties paid under an exclusive license. The 
economic rationale for such a differentiation would 
need to derive from comparing the NPVs of two DCF 
scenarios—one as an exclusive license and one as a 
nonexclusive license. Although it seems obvious that
the nonexclusive licensee royalty should be less, it is 
difficult to generalize what a fair difference should be. 
49 Razgaitis R. 1999. Early-Stage Technologies: Valuation 
and Pricing. John Wiley and Sons. Razgaitis R. 2003.
Valuation and Pricing of Technology-Based Intellectual 
Property. John Wiley and Sons. 
50 However, this author generally recommends that a 
licensor of early-stage technology not sell out for a 
one-time, upfront payment. Exceptions to this rule, as 
to most rules, can be warranted, as discussed in the 
text. 
51	 The two products currently available for personal 
computers are Crystal Ball®, sold by Decisioneering 
of Denver, Colo., (800/289-2550) and @ Risk®, sold by 
Palisades, New York (607/277-8000). Both require 
the use of a spreadsheet program such as Microsoft
Excel®. 
52 Crystal Ball, sold by Decisioneering of Denver, Colo. 
53	 Business Week, 20 March, 1995. 
54 See supra note 2. 
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Valuation of Bioprospecting Samples: Approaches,

Calculations, and Implications for Policy-Makers
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anaTole KRaTTigeR, Research Professor, the Biodesign Institute at Arizona State University;
Chair, bioDevelopments-International Institute; and Adjunct Professor, Cornell University, U.S.A. 
ABSTRACT 
In this chapter, the revenue consequences of varying col­
lection fees and royalties with regard to germplasm pros­
pecting contracts are demonstrated. Principal factors are 
the uncertainty of finding marketable products and the 
value of these products. Negotiation factors are finding 
a good balance between collection (initial) fees as op­
posed to royalty (delayed) payments. Emphasizing col­
lection fees reduces total payments except when national 
interest rates are very high. Reducing the risk of failure 
through in-country screening, including the use of indig­
enous knowledge, is a potentially valuable activity. Issues 
for contract negotiators are outlined and the implications 
for biodiversity conservation discussed. Conceptually, the 
highest valuation approach, royalties, will most encour­
age conservation, but as the future is typically heavily dis­
counted, collection payments may get more attention and 
be most effective. Policy considerations for national gov­
ernments, nongovernmental organization (NGOs), and 
development agencies are reviewed and it is concluded 
that grants/loans and training/equipment for in-country 
screening should be given a high priority as a potentially 
viable activity in the long term. 
It should be noted that the figures and calculations 
in this chapter are merely for illustration. The valuation 
of samples, and by extension a country’s biodiversity, is 
a negotiation and will depend on many factors, includ­
ing alternative investment options by a company, alterna­
tive technologies that could be used for lead compounds, 
interest rates, and a range of risk factors, such as the polit­
ical situation in a given country surrounding the national 
debate on bioprospecting. The latter point is a key factor: 
valuation is always a calculation that has important politi­
cal consequences. Another complicating factor is the need 
for confidentiality with which a country and company 
will hold its overall business estimates. Neither a com­
pany nor a country will be likely to share their valuation 
basis purely for negotiation purposes and because neither 
want to tip off other entities about the opportunity. It is 
therefore concluded that, from a practical perspective, the 
proper valuation is the one that (1) provides the country 
with compensation and other benefits such that it does 
not feel taken advantage of and can withstand criticism 
from its constituents and (2) provides the licensee (typi­
cally a company) with a reasonable cost of obtaining the 
crucial raw or semifinished goods it requires as an input 
to its business. 
1. InTRoduCTIon 
Since the adoption of the Convention on 
Biological Diversity (CBD) in 1992, the le­
gal status of traditional knowledge is in the fo­
cus of international debate. Concurrent with 
CBD, Merck & Co. and INBio, the National 
Biodiversity Institute of Costa Rica, made a deal, 
Note: While we have been careful in pointing out throughout this chapter that the monetary figures used in 
the examples are illustrative, it is important to urge that these figures not be used in actual negotiations. In the 
authors’ opinion, one of the main reasons for the overall low level of interest in bioprospecting deals is that ex­
pectations based on the market potential for a blockbuster drug may scuttle a deal on samples to be used for an 
industrial application with a much lower market potential. 
Lesser WH and A Krattiger. 2007. Valuation of Bioprospecting Samples: Approaches, Calculations, and Implications for 
Policy-Makers. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Prac-
tices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at
www.ipHandbook.org. 
© 2007. WH Lesser and A Krattiger. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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lESSER & KRATTIGER 
which was widely publicized, for the payment of 
fees and royalties for germplasm collected inside 
Costa Rican conservation areas. Importantly, the 
agreement was renewed in 1994, 1996, and 1998 
in similar terms and by 2004 has led to the filing 
of more than 27 patents based on the collabora­
tion. Studies to determine the potential use of a 
limited number of extracts of plants, insects, and 
environmental samples have been completed, and 
the agreement has given INBio access to technol­
ogy, teams, and training. It marked the first of a 
series of deals made by INBio (Table 1). 
Such collection activities, so-called bio­
prospecting, have received considerable attention 
in the literature and have precipitated discussions 
on payments for collected samples and chemical 
extracts from samples. But the subject is gener­
ally treated in generalities, focusing on research 
needs, basic rights, and moral obligations. CBD 
itself is famous for broad language with multiple 
interpretations possible. On the subject of pay­
ments, CBD proposes “sharing in a fair and eq­
uitable way the results of research and development 
and the benefits arising from commercial and other 
utilization of genetic resources … upon mutually 
agreed terms” (Article 15(7)). There is no attempt 
to identify appropriate payment approaches or a 
system for valuing germplasm for specific uses. 
Even a full decade after the entering into force 
of CBD, the topic still receives attention, and 
15 years since its passing has not been resolved. 
Evidently, there cannot be resolution on actual 
terms and payments, since these will be a func­
tion of market conditions, alternative technolo­
gies (such as recombinatorial chemistry, to name 
one), and other factors. We hope to shed light 
on the approaches that could be used to calculate 
royalty rates and collection fees. 
The purpose of this chapter is also the pro­
vision of information on the revenue conse­
quences of alternative payment arrangements 
for collected germplasm. We do not attempt 
to present actual market values for the mate­
rial, although approximate figures are used for 
illustrative purposes. Commonly, germplasm­
rich countries charge for samples in the form 
of a fixed initial payment (collection fee), a de­
layed payment based on sales of the resultant 
commercial product (a percent royalty, that is, a 
form of sharing of benefits), or combination of 
the two. Here it is demonstrated that when the 
likelihood of finding a commercializable prod­
uct is small (the risk of failure great), empha­
sizing initial payments can be done only at the 
expense of a significant reduction in the royalty 
rate and, hence, in the expected overall rev­
enues. The importance of the failure risk is such 
that reducing it through preliminary in-coun­
try screening can improve the revenue prospects 
greatly. Whether that is a viable approach de­
pends on in-country skills, facilities and costs, 
which are not evaluated here. Use of indigenous 
knowledge of plants is another means of reduc­
ing the failure rate and can add value to the 
samples that might be used in determining an 
appropriate payment to indigenous groups for 
sharing their knowledge. 
The examples used herein apply to pharmaceu­
tical prospecting for medicinal products, the basis 
of the Merck/INBio agreement. Pharmaceuticals 
are typically high-value products so the revenue 
is potentially greatest. The approach developed 
here, however, is general and can be used as well 
for other products, such as crop varieties and cos­
metics. The variable likelihood of finding useful 
germplasm and values with respect to the resul­
tant products could lead to somewhat different 
conclusions. For example, the long standing (but 
possibly evolving) practice of placing plant vari­
eties in publicly accessible germplasm collections 
limits the market value of that material. 
This chapter does not attempt to identify a 
specific market value for germplasm. Most efforts 
to do so, thus far, date back well over a decade and 
have been conceptually general or relevant only 
to specific examples from developed countries. It 
is, nevertheless, well established that biodiversity 
provides two types of values. These are: 
1. direct value 
-	 consumptive-use value (that which 
derives from such activities 
as sport fishing, subsistence hunting, 
gathering) 
-	 productive-use value (that which derives 
from such activities as logging) 
2. indirect values 
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Table 1: Main Collaborative Research Agreements












Cornell University INBio’s capacity Chemical prospecting 1990-1992 
building 
Merck & Co. Plants, insects, Human health and 1991-1999 
micro-organisms veterinary 
British Technology Group DMDP, compound Agriculture 1992-present 
with nematocidal 
activity* 
ECOS Lonchocarpus felipei, Agriculture 1993-present 
source of DMDP* 
Cornell University and NIH Insects Human health 1993-1999 
Bristol Myers & Squibb Insects Human health 1994-1998 
Givaudan Roure Plants Fragrances and 1995-1998 
essences 
University of Massachusetts Plants and insects Insecticidal 1995-1998 
components 
Diversa DNA from bacteria Enzymes of industrial 1995-present 
applications 
INDENA SPA Plants* Human health 1996-present 
Phytera Inc. Plants Human health 1998-2000 
Strathclyde University Plants Human health 1997-2000 
Eli Lilly Plants Human health and 1999-2000 
agriculture 
Akkadix Corporation Bacteria Nematocidal proteins 1999-2001 
Follajes Ticos Plants Ornamental 2000-present 
applications 
La Gavilana S.A. Trichoderma spp* Ecological control of 2000-present 
pathogens of Vanilla 
Laboratorios Lisan S.A. None* Production of 2000-present 
standardized 
phytopharmaceuticals 
Bouganvillea S.A. None* Production of 2000-present 
standardized 
biopesticide 
Agrobiot S.A. Plants* Ornamental 2000-present 
applications 
(Continued on Next Page) 
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Guelph University Plants* Agriculture and 
conservation purposes 
2000-present 
Florida Ice & Farm None* Technical and scientific 
support 
2001-present 
ChagasSpace Program Plants, fungi* Chagas disease 2001-present 
SACRO Plants* Ornamental 
applications 
2002-
* These agreements include a significant component of technical and scientific support from INBio.
Source: Cabrera Medaglia 2004. 1 
Table 1 (continued) 
- nonconsumptive-use value (that which 
derives from such activities as tourism) 
- option value (that which derives from 
the delaying of destructive use
until the use and value are better 
understood) 
- existence value (bequest value; that 
which derives from leaving 
a resource for consumption by future 
generations) 
Valuation is complicated because, with the 
exception of productive-use value, none of these 
forms of use involves a marketed product from 
which value can be ascertained directly. Rather, 
indirect measures, such as travel expenditures, 
are used or, in cases of option and existence val­
ues, quite esoteric measures, the interpretation 
of which is not fully clear. Yet valuation is im­
portant because it indicates a potential economic 
justification for preservation or, more precisely, 
in the case of germplasm prospecting, for sub­
stituting sustainable use for destructive uses like 
logging. 
Further complicating valuation is the discus­
sion of appropriateness of adding opportunity 
cost, the value option foregone when another 
mutually exclusive use is selected (an opportunity 
cost of clear cutting is germplasm prospecting, 
for example). Opportunity costs are sometimes 
calculated (companies making mutually exclusive 
investment choices do this routinely) but, tradi­
tionally, never are subtracted from the value of 
the selected use as it is sometimes argued they 
should be. Conceptually, there is no reason to 
limit opportunity cost to a single alternative use 
where many likely exist, nor is there a reason in­
direct benefits (for instance, those derived from 
logging open land for farming or grazing) should 
not be added to the use value. There is the further 
issue of discount rate for future income—the re­
duction akin to an interest rate—in the value of 
delayed consumption compared to present con­
sumption. Typically, private (personal and corpo­
rate) discount rates are greater than social rates, 
although the determination of the social rate is 
open to different interpretations. Yet, as anyone 
who has paid off a loan over a ten- or 20-year pe­
riod recognizes, small changes in the interest rate 
have major implications on the outcome. Indeed, 
the use of opportunity cost is a complex matter 
yet to be resolved. 
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CHAPTER . 
2.  pRICInG	 CHoICES 
The Merck/INBio agreement of the early 1990s 
utilized a combination of the two principal pay­
ment alternatives: collection fees and royalties.
Merck paid to INBio a fee of US$1.1 million and 
an undisclosed royalty rate for resulting product 
sales. A collection payment can be (and in the 
Merck/INBio case was) paid in total, or in part, 
in services, such as providing training to national 
scientists in screening procedures, or as equip­
ment. The purpose here is to demonstrate how 
total revenues are affected by an emphasis on ini­
tial, as opposed to delayed, payments.
Delayed (royalty) payments are preferred by 
the contracting company, which, for the pur­
poses of this article, we shall assume is a mul­
tinational pharmaceutical company. Delaying 
payments means the company has no interest 
costs, which are required if payments are made 
before the product is marketed and revenues flow.
Pharmaceutical products can take up to 12 years 
to bring to the market in the United States, so the 
Table 2: Estimates of Variables for the Base Agreement

       Per-sample basis 
Item 
Value used in 
calculations Range Comments/Reference 
Collection fee US$50 50–200 Figures are intended to cover actual 
costs (packaging, transport and 
related costs) but not return a profit 
Royalty payment 5% 1%–5% Royalty of gross sales
Developing-country 
interesta 
15% 10%–25% Discount rate used by developing 
countries with hard currency 
shortages (a likely minimum figure) 
Corporate interest rate 7% 5%–9% Corporate interest rate charged to 
and by major corporations; lower 
than developing country rate 
because of better credit rating and 
more efficient credit markets in 
developed countries 
Product value US $500
million 
100 million–
1 billion + 
Total worldwide sales once 
developed and over the life span 
of the product. Below an expected 
market of US$100 million, returns 
generally do not cover development
and regulatory costs 
Development  delay 10 years 10–12 years – 
Hit rate 1:12,000 1:6,000– 
1:30,000 
Frequency with which collected 
material will result in a marketable 
product
a 	 This figure represents interest on a hard currency loan such as one denominated in dollars.
It does not reflect the occasionally very high rates - up to and exceeding 100% - for local currency
 loans during inflationary periods. 
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Full contract 
12,000 samples Item 
Collection fee _ _ 50 0.6 million 
Royalty fee paid
in year 10 
5% x $500 million x [1] 2000 25.0 million 
Present value of 
royalty fee
a [2] 500 6.0 million 
Total present
expected value 50 + 500 550 6.6 million 
a Where i=15% (developing-country interest level) and n=10 years (development delay). 




(1 + i)n 
Table 3: Computing Expected Return for the Base Agreement 
lESSER & KRATTIGER 
Per-sample basis 
Calculations Equation b Return 
interest cost could be considerable. As important, 
making initial payments shifts the risk of failure to 
the company, which will have expended the col­
lection and screening costs as well as development 
charges. With a successful product found in only 
one of some 12,000 tries and average product de­
velopment costs of US$230 million including the 
costs of failures, the risks are indeed large. Because 
of these risk and interest factors, along with tight 
budgets and scarce foreign exchange, contracting 
countries prefer initial payments to subsequent and 
uncertain royalties. However, the contracting com­
panies will seek compensation in the form of lower 
overall payments for accepting additional risk. Here 
we explore how much that compensation is likely 
to be. 
For the purposes of this article a base agree­
ment is computed on a per-sample basis (in U.S. 
dollars). This agreement is intended to represent 
the outcome of careful negotiations, with both 
sides reaching a minimal acceptable position from 
which they are unwilling to move without conces­
sions from the other party. 
Table 2 shows the estimates of the variables 
required for a bioprospecting agreement. As we 
are developing different variations, we call this the 
“base” agreement. 
From Table 2, the expected return per sample 
collected can be computed as shown in Table 3 
(figures are rounded for convenience). Total value 
for a 12,000-sample contract is also included. 
Of course, most samples would pay $50 with, 
on average, the 1/12,000 paying off $25 million. 
In other words: 
5% royalty of $500 million  = $25 million 
This is a general average with the likelihood of 
a hit2 having a wide latitude. Thus, countries select­
ing this approach would be operating in a “boom 
or bust” mode. The collection fee covers costs so 
that no real revenue comes in until and unless a hit 
is scored. No attempt was made here to determine 
the range (frequency distribution) with regard to 
the estimated 1/12,000 hit figure. The present value 
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Figure 1: Present and Future Value of Contract as a Function






























Product value (uS$ Million) 
Note: Collection fees of $50 per sample are included in the calculations. Other variables are 15% developing 





of the $25 million figure is only $6 million because 
of the high interest rate used (15%) and the ten-
year delay involved. Figure 1 gives an indication of 
how these values are affected by royalty rates and 
product value. 
.  EMpHASIzInG	 CoLLECTIon fEES 
ovER	 RoyALTIES 
What would be the ramifications of shifting fees 
forward, emphasizing current collection payments 
at the expense of longer term royalties? Suppose 
for our example the collection fee was increased by 
$150, to $200 per sample. What would change?
We shall assume that the basic revenue situation 
remains unchanged and that only the schedule is 
altered. Since there are just two payment param­
eters (collection fee and royalty rate), increasing 
one necessitates reducing the other. 
The point about raising collection fees neces­
sitating a reduction in the royalty rate has sev­
eral components. First, there is a direct transfer 
of dollars. Second, the company, which, in this 
example, is making payments today instead of 
ten years in the future, will add an implicit in­
terest charge (technically, a discount) to those 
payments. The third component, and the most 
complex to calculate, is the change in the risk 
undertaken by the company. Under the base 
agreement, the selling country accepts most of 
the risk; if no marketable product is forthcom­
ing no royalty payments are made. The 1/12,000 
hit-rate figure used here is an average and an ap­
proximation. It is possible that 12,000 samples 
will yield no marketable products or ones with 
low values. Shifting royalty payments to collec­
tion fees means, in effect, that some of the royalty 
has been “prepaid” so that the failure of a product 
to materialize is a loss for the company. That is, 
the company is taking on an additional risk of a 
loss. In this regard, the contracting company will 
act like a banker, and indeed like any private cor­
poration, which is a risk/reward managing entity, 
by demanding to be compensated financially for 
accepting additional risk. That required compen­
sation can be estimated. 
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lESSER & KRATTIGER 
Raising the collection fee by $150 would increase the expected costs for the company by $1.8 
million. In other words: 
$150 for 12,000=$1.8 million 
Moreover, the payments would be made today as opposed to 10 years hence so that the company 
would have total (including interest) costs of $3.5 million, that is: 
From Table 3, Equation [2]: $1.8 million x (1+ 7%)10  = $3.5 million 
The company is then willing to pay only $21.5 million (25 - 3.5) in royalties (from Table 3) so that 
the effective royalty rate becomes: 
Equation [3]: 5% x % 107.5= x = = 4.3% 
$25 million $21.5 million 25
But the company accepts additional risk ($1.8 million worth) and will want to be compensated.
The amount can be computed using the following the equation: 
Equation [4]: 
change in payment $3.5 3.5 = 30%= =size of  risk change = payment $21.5 / (1.07)10 + $0.6 11.5 
Thus the company is willing to offer a royalty rate 30% lower, that is: 
Equation [5]: 4.3% x 0.3 = 1.3% 
The new royalty rate is now 3.0%, that is: 
Equation [6], from [3]: 4.3% - 1.3% = 3.0% 
This is a reduction of 40% of the original value. The new present value of the expected payment 
per sample can now be computed as: 
Equation [7] (from Table 3, Equations [1] and [2]): 




, or $200 + = $500 
Hence, the country is giving up $50 ($550 - $500) or 9% per sample to ensure timeliness of the 
payment.
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CHAPTER . 
Interest Rate 10% 15% 20% 25% 
Collection fee 50 50 50 50 
Present value of royalty fee
a 
775 495 325 215 
Total expected present value/sample 825 545 375 265 
Collection fee 200 200 200 200 
Present value royalty fee
b 
465 300 195 130 
Total expected present value/sample 665 500 395 330 
Country loss/gain
c 
-160 -45 +20 +65 
a $2,000/(1+i)10 from Table 3, equation [2] (results rounded) 
b $1,250/(1+i)10 from Table 3, equation [2] (results rounded) 
c Total expected value/sample for $200 collection fee - total expected value/sample for $50 collection fee. 
Table 4: Impact of Country Interest Rate on Total Expected 
Present Values under Different Interest Rates 
An important insight can be derived from 
this example. The penalty for the germplasm­
providing country declines as its interest rate 
increases, or more correctly, as the gap between 
its interest rate and the corporate rate of the 
contracting company (7% in this example) in­
creases. This penalty is shown in Table 4 where, 
using the figures described above, the penalty 
declines to zero at a country rate near 20 per­
cent; at higher rates the country is actually bet­
ter off. The company is borrowing money at a 
preferential rate and lending it to the country at 
the same rate, plus risk premium. This approach 
might be an efficient way for the selling country 
to finance itself, but several additional factors 
must be considered. 
First, the contracting company must be 
agreeable to such an arrangement (not all will 
be). Second, a 15% figure is quite a high discount 
rate and involves a significant discounting of the 
future. Note that the country is paying the com­
pany 7%, along with discounting the future by 
15% for a total discounting of 22%, which re­
duces any future royalty payment by a factor of 7 
that is (from Table 4, Equation [2]): 
$25 million / (1 + 0.22) 10 or 25/7.3 
Third and finally, the country is effectively 
borrowing against the future; should a hit come, 
less additional revenue will be collected. While 
that may be undesirable for future generations, 
this approach does increase the awareness of the 
value of germplasm resources. Referring again 
to the Merck/INBio agreement, the more than 
US$1 million collection fee (a rather insignificant 
amount) received all the public attention while 
the level of the royalty figure has never been made 
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lESSER & KRATTIGER 
public and potentially could represent a much 
greater figure. 
It should be noted that it is very difficult to 
come up with an appropriate discount rate with­
out knowing specific country circumstances. It 
may also not be an objective figure. The concept 
of personal discount rate, that is, what the per­
son on the other side of the table has internalized 
about risk, as well as political and economic in­
stability and immediate need for money could all 
play major roles in the choice between collection 
payments and royalties. 
. pAyMEnT	 foR	 SCREEnInG 
One of the emphases on germplasm prospecting 
in the CBD, and elsewhere, is the performance 
of the maximum number of services in country 
(value added) as opposed to the export of raw 
germplasm materials. That emphasis not only 
increases payments but also enhances national 
scientific expertise while moving away from de­
pendency on commodity-type exports. Here we 
examine the revenue ramifications of such an 
approach. No attempt is made to determine the 
practicality of such a step that depends on the 
country of origin having adequately trained staff 
and adequate facilities to be able to complete 
screenings in an accurate, timely, and cost-effi­
cient manner. Screening near the source of ori­
gin has some advantages due to the cost of pack­
aging and transport and the volatility of some 
compounds. On the other hand, some screening 
procedures are technically complex or, for infec­
tious diseases, involve high standards for isola­
tion facilities. Those screenings would not be fea­
sible away from a major company’s laboratories, 
at least for the present.
The development of a marketable pharma­
ceutical product passes through several stages 
beginning with a primary screening and, if suc­
cessful, progressing through secondary screening 
(including isolation and preliminary toxicologi­
cal evaluations) and proceeding to the several 
stages of drug development. For purposes here, 
assume in-country collection with primary 
screening costs of $200 per sample. Prescreened 
samples in this example have a 1/3,000 chance 
of being a hit (four times the unscreened rate) 
because the least promising samples have been 
eliminated. The rate depends on several factors, 
including the stringency of the screens. This rate 
presumes relatively nonstringent tests that would 
be most appropriate for a range of developing 
countries.
Of course, screening does not change the 
underlying probability of finding a commer­
cializable product. Screening merely increases 
the value of the retained samples, because they 
have a higher probability of viability than the 
collected samples. There is a cost for this: every 
retained sample represents four screened sam­
ples, so the per-sample-retained cost is $800.
It is assumed the country will collect the out-
of-pocket costs, or $200 per sample, but be­
cause these represent actual costs, the country 
does not make a profit as in the earlier second 
example. Payments can be computed follow­
ing the royalty-rate calculation method shown 
earlier, using the hit rate of 1/3,000 and a col­
lection and screening fee of $800 (figures are 
rounded): 
Equation [8] (from Table 3, Equations [1] and [2]): 
Present value of royalty: 
1/3,000 $167,0005.0% x $500 million x = 5.0% x = $2,100 
(1 + i)n 4.04 
Total expected value per sample: $800 + $2,100 = $2,900 
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The total expected value per sample is now 
more than five times the base payment. 
It should be noted that both the royalty rate 
and the risk factor remain unchanged. The ad­
ditional “collection” fees are merely a transfer of 
expenses from the company’s in-house screening 
cost to the developing country, and this does 
not change the basic value of the contract. The 
calculations assume, however, that the quality 
of cost screening in the developing country is 
identical to that of the company. If the qual­
ity in the developing country is inferior, the 
value of the screenings is questionable, and the 
pharmaceutical company is likely to reject this 
option. Especially in the case of false negative 
results (improperly rejecting a potentially viable 
compound), inaccurate or inconsistent results 
must be repeated. If the total cost of screening 
in developing countries is less than that of the 
pharmaceutical company (a plausible situation 
due to lower wages and shipping costs), then 
the selling country can take the difference as 
profit. For the example just mentioned, imagine 
further that a screening by the pharmaceutical 
company costs $150, while in the country of 
origin it is $100. Total costs including the $50 
collection fee are then $200 versus $150. The 
company should, in theory, be willing to pay the 
full $200 cost to the developing country, which 
would yield it a “profit” of $50 per sample ($200 
payment - $150 costs). As discussed in the pre­
ceding example neither the royalty rate nor the 
risk factor would change. 
Now, however, imagine the costs are re­
versed, $100 for the pharmaceutical company 
and $150 for the selling country. This could hap­
pen for a number of reasons, such as a high cost 
of maintaining specialized equipment or simple 
inexperience and/or inefficiency. If the country 
still covered costs by negotiating a $200 collec­
tion plus screening fee, the company would treat 
$50 of it ($200 payment - $150 costs) as a higher 
fee, along the lines of the second example. Rather 
than repeating those calculations, note that the 
fee increase here is one-third ($50/$150) of the 
amount shown in the second example. The roy­
alty-rate reduction would likewise be one-third of 
that amount, or: 
From Equation [6]:   0.33x(5%-3.0%)=0.66 
This gives a final rate of: 
Equation [9]:   5%-0.66=4.34% 
While the amount is not huge, it represents 
a penalty and would likely not represent a viable 
option in the long term. 
These calculations, of course, are only illus­
trations and say nothing about the practicality of 
screening in-country. Actual cost and result fig­
ures will be required for such computations. The 
exercise does suggest that economical in-country 
screening is a potentially valuable value-added 
activity. Screenings in countries, following this 
strategy must, as noted, be less costly than con­
tracting-company screenings, and less accurate.
Indeed, to the extent screening in-country is less 
expensive due to lower salary levels, savings on 
shipping costs, and other factors, all parties may 
benefit. However, countries must invest in train­
ing and equipment/infrastructure before offering 
this service. Several sources of funds are possible, 
including the use of collection fees (as is provided 
to a small degree in the Merck/INBio agreement) 
or through a grant or loan from a bilateral or 
multilateral agency. 
. IndIGEnouS	knoWLEdGE 
Indigenous knowledge of plants can be an alter­
native to preliminary screening. Plants that can 
be identified as free from insect damage, for ex­
ample, likely contain potent alkaloids, called the 
most important group of medical chemicals. If 
plants identified by indigenous peoples as having 
particular attributes are collected, the probability 
of a hit is increased. Here, for simplicity, we will 
assume the increase is to 1/6,000. Some argue 
that the success of screening could double or tri­
ple if information based on traditional knowledge 
was utilized. Further, it is assumed that the cost 
of a single specimen collection is $100 because of 
the additional difficulty of finding selected plants.
Payments are then (again rounded): 
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Collection fee: $100 
Equation [10] (from Table 3, Equations [1] and [2]): 
Present value of royalties  = 5% x $500 million x 1/6,000 
4.04 
= 5% x $8,330 
4.04 
= $1000 
The royalty level in this example is the same as the base situation because: 
$50 x 12,000 = $100 x 6,000 
So there is no change in the timing of payments. Similarly, the risk factor is unchanged: 
Total expected value per sample:  $100 + $1,000 = $1,100 (double the base level of $550) 
Again, while only hypothetical, this example does indicate the potential value of indigenous 
knowledge, at least for plants (it is less indicative for microbes and insects with which indigenous 
cultures are typically less familiar). The additional amount of $500 per sample (Equation [11]), can be 
paid to indigenous groups for the value of their knowledge, but a suitable transfer mechanism must 
be developed. 
Equation [11] (from Table 3, Equation [2]): 
$1,100 - $100 collection fee - $500 present value of royalty = $500 
. ConCLuSIonS 
The negotiating of terms for germplasm collec­
tion is a complex matter, made more so by the 
absence of a generally accepted value of the ma­
terial in its raw form. This article is directed to 
a related issue: how any payments should be di­
vided between current (collection) fees and future 
royalties. The two are different because of the 
ramifications of who accepts the risk of finding a 
usable product and the capital cost/value of sales 
to be made ten or more years into the future. The 
examples shown here suggest, but do not guar­
antee, that increasing collection rates is costly in 
terms of overall expected payments. However, for 
countries short on foreign exchange and, hence, 
with high interest rates, raising collection fees is 
an economical means of “borrowing” from the 
contracting company. Seemingly more favorable 
is in-country screening, but costs, feasibility, and 
acceptability of results must be considered care­
fully before choosing this option. Utilizing in­
digenous knowledge is, according to the example 
used here, also remunerative along with the pros­
pect of providing equity payments to numerous 
groups otherwise far removed from market sys­
tems. However, to be utilized by companies, in­
digenous knowledge must be less costly than mass 
screening.
Overall, the aggregate payments for collected 
germplasm, given the current state of knowledge, 
appear limited. Similarly, the payments to indige­
nous groups will likely be fairly modest compared 
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CHAPTER . 
to the needs of those groups. These issues make 
careful valuation and contractual negotiation all 
the more critical. 
Negotiators need to consider, at least, two 
additional factors, which have not been discussed 
here. First is the granting of exclusivity for the 
samples. Companies, of course, will be hesitant 
to invest in a product when the possibility exists 
of a competitor bringing the technology to mar­
ket first or obtaining the patent. Therefore, com­
panies will seek exclusivity. Countries, however, 
will wish to find additional markets; certainly, the 
possibility of multiple products from the samples 
is there. Thus, countries will opt against exclu­
sivity. As a compromise, countries should (1) 
charge more for granting exclusivity and (2) set 
a time limit (it is four years in the Merck/INBio 
agreement). 
Second, negotiators must evaluate their level 
of trust in the opposite party. One way to consid­
er contracts is as a means of reducing the need for 
trust by specifying obligations in a way that can 
be adjudicated. However, it is not feasible to spec­
ify all aspects, so some level of trust is required.
With germplasm prospecting perhaps the most 
critical issue is identifying whether the material 
used in developing a product was derived directly 
or indirectly from a sample provided under the 
agreement. Unscreened samples, with the myriad 
compounds they could provide, and the numer­
ous analogs to them, will be virtually impossible 
to track thoroughly. Preliminarily screened sam­
ples are described in more detail and hence easier 
to track, but documenting a claim in court could 
still be difficult and expensive. Thus, considerable 
trust in the integrity of the contracting compa­
ny would seem to be critical, but perhaps some 
checks should be included in the agreement. 
In a broader context, this analysis suggests 
several policy considerations for national govern­
ments, nongovernmental organizations (NGOs), 
and international donors, such as foundations 
and bilateral and multilateral agencies. These 
considerations involve both the allocation of pay­
ments between collection fees and royalties and 
in-country screening. If the examples used herein 
are substantiated at all by actual cost figures, in-
country screening is attractive financially as well 
as for its effects on development and skills im­
provement. However, considerable investment 
will be required before such efforts are possible.
With adequate in-country funds lacking, inter­
national donors should seriously consider loans 
or grants for training and equipment purchases 
since in-country screening will be economically 
rewarding in the long term. Unlike numerous 
potential projects, there appears to be a ready 
market for the product, a preliminary-screening 
service. More, broader conclusions from INBio 
on their experiences are given in Box 1. 
The allocation of funds between collection 
fees and royalties can affect conservation incen­
tives. While a thorough treatment of that issue is 
outside of the scope of this article, it does warrant 
mentioning. Conceptually, the highest valuation 
approach—payment of royalties—will encourage 
conservation the most in the long term. However, 
people typically discount the future heavily so that 
up-front (collection fee) payments may get more 
attention and, in the long run, do most to encour­
age conservation. This is a matter of perception 
and not of business or economics, which needs 
exploration through other methodologies. n 
williaM h. lesseR, Susan Eckert Lynch Professor of Science 
and Business; Chair of the Department of Applied Economics 
and Management, Cornell University, 155 Warren Hall, 
Ithaca, NY, 14853, U.S.A. whl1@cornell.edu 
anaTole KRaTTigeR, Research Professor, the Biodesign 
Institute at Arizona State University; Chair, bioDevel­
opments-International Institute; and Adjunct Professor, 
Cornell University, PO Box 26, Interlaken, NY, 14847, 
U.S.A. afk3@cornell.edu
 1	 Cabrera Medaglia J. 2004. Bioprospecting Partner-
ships in Practice: A Decade of Experiences at INBio 
in Costa Rica. IP Strategy Today No. 11-2004. Pp. 27-40.
www.bioDevelopments.org/ip. 
2 	 A hit rate is the number of expected lead compounds 
divided by the number of samples to be screened to 
obtain the given lead compounds. 
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lESSER & KRATTIGER 
Box 1: lessons learned from a Decade of Bioprospecting Partnerships
at INBio in Costa Rica 
A. There must be a clear institutional policy for the criteria demanded in prospecting contract
negotiations. For INBio, these include the transfer of technology, royalties, limited quantity 
and time access, limited exclusiveness, no negative impacts on biodiversity, and direct
payment for conservation. This policy has led to the stipulation of minimum requirements 
for initiating negotiations, and these requirements have meant rejecting some requests (e.g.,
very low royalties, unwillingness to grant training, etc.). This institutional policy also provides 
greater transparency and certainty for future negotiations. These same policies must also be 
taken into consideration when local communities and indigenous peoples, such as the Kuna’s 
in Panama, adopt legal outlines in the contractual arrangements entered into by them. They 
should include other relevant ideas, such as those related to the impossibility of patenting 
certain elements, licensing instead of a complete transfer, etc. 
B.	 The existence of national scientific capabilities, and consequently the possibilities of adding 
value to biodiversity elements, increases the negotiating strengths and benefit sharing 
stipulated in contract agreements. As we previously mentioned, the need to grant an 
aggregated value to material, extracts, etc., is crucial if one wishes to be more that just a simple 
genetic resource provider. In this regard, the development of important human, technical, and 
infrastructure capacities through laboratories, equipment, etc., together with the institution’s 
prestige, have permitted better negotiation conditions. 
The existence of relevant traditional knowledge for operations, which INBio has not yet
experienced, implies greater scientific capacity and, consequently, should lead to better 
compensation conditions. 
C. knowledge of operational norms and of the changes and transformations taking place in the 
business sector, as well as the scientific and technological innovations that underlie these 
transformations, helps to define access and benefit-sharing mechanisms. It is essential to 
know how different markets operate and what access and benefit-sharing practices already 
exist in these markets.These vary from sector to sector: the market dynamics for nutraceuticals,
ornamental plants, crop protection, cosmetics, and pharmaceuticals are complex and different.
This knowledge is needed to correctly negotiate royalties and other payment terms. How can 
we otherwise know if a percentage is low or high? It is also crucial to be informed about the 
operational aspects of these markets. When INBio began negotiating new compensation 
forms, such as advance payments or payments on reaching predefined milestones, with Eli 
Lilly and Akkaddix, it was vitally important to know the approximate amounts the industry 
was likely to pay in order to negotiate appropriately. Otherwise, one will likely request terms 
that are completely off the market or accept terms that are inadequate. 
d. Internal capacity for negotiations, which includes adequate legal and counseling skills about
the main aspects of commercial and environmental law. The Institute now recognizes that
negotiations involve a scientific aspect (of crucial importance to define key areas of interest
such as a product, etc.), a commercial aspect, a negotiation aspect, and the respective legal 
aspects. These latter are composed not only of national trade law but also international 
environment law, conflict resolution, and intellectual property. For these reasons, creating 
interdisciplinary teams is crucial. At the same time, the need for such a team is one of the 
most important criticisms of the contractual mechanisms. Solutions such as facilitators or 
others that pretend to “level the negotiation power” have been proposed by several authors.
Unfortunately, until appropriate multilateral mechanisms exist, benefit sharing and 
contractual systems must go hand in hand. The absence of an interdisciplinary team keeps 
one of the parties at a disadvantage, particularly given the enormous legal and negotiation 
capabilities of pharmaceutical companies. 
(Continued on Next Page) 
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CHAPTER . 
Box 1 (continued) 
E. Innovative and creative ideas for obtaining compensation. An ample spectrum of potential 
benefits exists. In the past, interesting benefit-sharing formulas were developed through 
appropriate negotiations. Such formulas included, for example, fees for visiting gene banks,
collecting material, etc. The contractual path fortunately permits parties to adapt themselves 
to the unique situation of each concrete case and to proceed from there to stipulate new 
clauses and dispositions. 
f.	 understanding in such key subjects as: intellectual property rights; the importance of 
warranties for legality; clauses on ways to estimate benefits (net, gross, etc.); requirements 
and restrictions on third-party transference of material (including subsidiaries, etc.) and the 
obligations of such parties; precise definitions of key terms that condition and outline other 
important obligations (products,extracts,material,chemical entity,etc.);precise determination 
of property and ownership (IPR and others) of the research results, joint relationships, etc.;
confidentiality clauses in the agreements and how to balance them in relation to the need for 
transparency in the agreement; termination of obligations and the definition of the survivor 
of some obligations and rights (e.g., royalty, confidentiality, etc.); conflict resolutions. 
As sub-clause D makes very clear, negotiated agreements are complex. For example, the 
outcomes that give rise to benefit sharing, such as royalties, will depend on the nature of the 
definitions for “product,” “extract,” “entity,” etc. A more comprehensive definition will lead to 
a better position. Further examples of aspects that must be specified include delimiting the 
areas or sectors where samples can be used, the net sales, and what is possible to exclude 
from them. In addition, the procedures and rights in the case of joint and individual inventions 
are of interest (preference and acquisition rights, etc.), as are the conditions for the transfer of 
material to third parties (under the same terms as the main agreement? need for consent or 
information? transference to third parties so that certain services can be performed? etc.). 
G. proactive focus according to institutional policies. There is no need to remain inactive while 
waiting for companies to knock on the door to negotiate. An active approach to negotiations 
based on the institution’s own policy for understanding national and local requirements has 
produced important benefits. INBio’s Business Development Office and its highly qualified 
expert staff, the attendance of seminars and activities with industry, the distribution or 
sharing of information and material, and direct contacts, all of these empower an institution 
to deal with challenges. The current policy is based on the idea that it is not enough to wait to 
be contacted or to be available at the behest of a company; instead, one should possess and 
maintain one’s own approach. 
H. understanding national and local needs in terms of technology, training, and joint research.
International strategic alliances must be struck. Even when an institution or community 
possesses adequate resources to face a concrete demand, knowing the national situation and 
the strategic needs will permit it to reach better agreements and fulfill a mission that goes 
beyond merely satisfying the institution’s interests. It will permit the prospecting to benefit
society as a whole and demonstrate that it is possible to improve quality of life. 
I.	 Macro policies and legal, institutional, and political support. For prospecting to succeed,
so-called macro policies have to exist; that is to say, there must be clear rules about the 
“bioprospecting framework,” which requires biodiversity inventories, information systems,
business development, and technology access. One reason for Costa Rica’s success is that
institutions not only have experience in negotiation but also in setting policies and actions in 
this area overall.This includes,for example,a current biodiversity inventory rated as “successful”
(Continued on Next Page) 
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lESSER & KRATTIGER 
Box 1 (continued) 
that enables us to know what we possess. It is the first step in the quest to use this resource 
intelligently. Our relevant experience also includes a National Conservation Area System 
that assures the availability of resources, the possibility of future supplies and provisions,
mechanisms that contribute to the conservation of biodiversity as part of the contractual 
systems, etc. At the same time, the possibility of possessing adequate instruments to manage 
information, systems of land and property ownership, etc., contribute jointly with the existing 
scientific capacity to create a favorable environment for bioprospecting and to make possible 
the negotiation and attraction of joint enterprises. To this should be added other elements,
such as the existence of trustworthy partners, which is one of the most relevant aspects in 
joint undertakings. 
Lastly, one crucial topic is the constant denouncement of the business community because 
of the uncertainty caused by the new access rules (mainly in terms of who is the competent
authority, the steps to be taken, how to secure prior informed consent, etc.). The emergence 
of these new regimes, together with the fact that the intention is to essentially control 
genetic information, its flow, supply, and reception—a topic where little national, regional,
and international experience exists—has caused concern because of the possibility of 
contravening legal provisions. This has led to the establishment, as a policy, of the inclusion of 
clauses related to the need to fulfill local regulations, to demonstrate the contracting parties’
right to fulfill their obligations pursuant to national laws, to present the appropriate permits 
and licenses, etc. In some cases, this topic has generated important discussions and analyses in 
negotiations. At an international level, various bio-prospecting agreements around the world 
are the target of complaints, claims, and lawsuits precisely due to the lack of legal certainty.
This has created problems and discrepancies that hinder activities and joint ventures. A few 
examples would be complaints about the Agreement between Diversa and the Autonomous 
University of Mexico (which is still being litigated); or the deal between this company and 
Yellowstone National Park; or criticisms of the agreement between the Venezuelan Ministry 
of the Environment and the Federal University of Zurich. 
Source: Reproduced with permission from Cabrera Medaglia J. 2004. Bioprospecting Partnerships 
in Practice: A Decade of Experiences at INBio in Costa Rica. IP Strategy Today No. 11 (2004): pp. 27–40.
www.bioDevelopments.org/ip. 
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CHAPTER 10.1 
Defensive Publishing and the Public Domain
 
saRa boeTTigeR, Senior Advisor, PIPRA and Chief Economist, M-Cam, Inc., U.S.A.
cecilia chi-haM, Director, Biotechnology Resources, PIPRA, U.S.A. 
ABSTRACT 
IP (intellectual property) rights can reward innovators and 
encourage investment in developing new products and 
services. However, the exclusionary power of IP rights can 
sometimes have negative effects, making technologies less 
accessible and, thereby, potentially impeding innovation. 
To make informed decisions about how to balance ac­
cess and protection requires an understanding of both the 
traditional IP rights system (patents, copyrights, trade­
marks, and trade secrets) and alternative mechanisms for 
preserving access to technologies. This chapter provides 
a brief introduction to the public domain and defensive 
publishing and examines issues concerning the choice be­
hind the choice of whether to publicly disclose or to pat­
ent an innovation. Discussing the strategic use of defen­
sive publishing in IP management, the chapter considers 
both the utility of defensive publishing and its limitations 
for supporting broad innovation. After an examination of 
the public domain and how it relates to other open-ac­
cess concepts, such as open source and the commons, the 
chapter focuses on the practical considerations involved 
when using public-domain technologies and defensive 
publishing to manage intellectual property. 
1. InTRoduCTIon 
A well-functioning innovation system strikes a 
balance between protecting technologies and pre­
serving access to them. IP (intellectual property) 
rights can provide incentives that reward innova­
tors and encourage investment in the develop­
ment of new products and services. However, 
the exclusionary power of IP rights can also have 
negative effects. For instance, when research tools 
or enabling technologies are patented and not 
available for licensing, the creative and collabora­
tive process of innovation can potentially be im­
peded. To ensure the balance between access and 
protection requires an understanding of both the 
traditional IP rights system (patents, copyrights, 
trademarks, and trade secrets) and alternative 
concepts, such as defensive publishing, public 
domain, and open source. 
Debates about IP policy and the need to seek 
a socially optimal balance between IP rights and 
the public domain are important for the pursuit 
of vibrant national and international innovation 
systems. This chapter’s focus, however, is narrow­
er. Rather than examining how policies regard­
ing the public domain might support innovation, 
we look instead at how, given current IP laws, IP 
management practitioners can best use the public 
domain to support particular goals. 
The term public domain describes a body of 
work that is freely available, legally unprotected, 
and not subject to individual ownership. Public 
domain implies the absence of individual IP rights.
This definition exemplifies the language associat­
ed with the public domain and what remains after 
all the boundaries of IP rights have been staked. 
Likewise, we commonly refer to a technology 
falling into the public domain, as if there were 
never a conscious decision to place something in 
Boettiger S and C Chi-Ham. 2007. Defensive Publishing and the Public Domain. In Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Ox-
ford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. S Boettiger and C Chi-Ham. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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the public domain; instead, the public domain 
encompasses the residuals of the processes of the 
IP rights system. This chapter, however, does not 
view the public domain as simply a default for 
technologies that are not claimed via IP rights. 
Instead, the chapter aims to promote a broader 
appreciation of the public domain as a valu­
able resource. The authors seek to facilitate the 
discerning use of the public domain as a tool 
(among a set of tools that include traditional IP 
rights and related licensing mechanisms) of pru­
dent IP management. 
Section 2 provides background that illus­
trates the importance of the public domain and 
how it has changed in recent decades. Section 
3 briefly introduces two other open-access con­
cepts—the commons and open source—in order 
to distinguish three alternatives from one other 
and defines their relation to the IP rights system. 
Section 4 uses a narrower, legalistic definition of 
the public domain to discuss the practical impli­
cations surrounding public domain technologies. 
That section reviews the patent-law concepts nec­
essary for understanding both the construction 
of a successful defensive publication, how to as­
certain whether a technology is, in a legal sense, 
part of the public domain. Section 5 introduces 
the practice of defensive publishing, examining 
how best to place innovations into the public do­
main. Section 6 considers potential strategies for 
the IP manager choosing between patenting and 
defensive publishing. Section 7 outlines practi­
cal issues confronted by users of public domain 
technologies. 
2. InnovATIon 	And THE	 puBLIC	 doMAIn 
“There is no area in which public concern about in­
tellectual property and the public domain has been 
greater than in scientific and technical research. 
Whether it is the controversy over the patenting of, 
and access to, the humane genome or pluripotent 
stem cell lines, the appropriate role of intellectual 
property in university research, or the use of ethno­
botany and traditional herbal knowledge in phar­
maceutical patenting, the coexistence of science and 
property rights has been a fairly constant concern 
over the last 15 years.”  –James Boyle1 
In recent decades, many authors have exam­
ined how innovation systems have been changing 
in response to the expanding system of IP rights. 
As IP rights have become stronger, broader, and 
more far-reaching, many technologies that might 
previously have been freely accessible in the pub­
lic domain are now proprietarily owned. This 
phenomenon has been particularly noticeable in 
the fields of health and agriculture. 
In 1980, a landmark U.S. Supreme Court 
decision (Diamond v. Chakrabarty)2 set the stage 
for a burgeoning biotechnology industry and an 
exponential rise in the number of life-science pat­
ents. Allowing for the patenting of human-made 
microorganisms, the decision clarified the Court’s 
position that patentability did not depend on the 
distinction between living and inanimate things, 
but instead between inventions made by “man” 
and those that exist naturally. Among other influ­
ences to increased patenting during this period, 
the Bayh-Dole Act of 1980 has played a role. It 
set up new rules for the interface between aca­
demia, in which publications are the currency of 
the trade, and the commercialization of universi­
ty research through patenting and licensing.3 The 
rise in the patenting of life-science technologies 
and the corresponding reduction in the number 
of technologies remaining in the public domain 
has been most remarkable in developed countries. 
Still, in many developing countries, patenting re­
mains sparse.4 Indeed, despite the strengthening 
of IP rights policies worldwide through TRIPS 
(the Agreement on Trade-Related Aspects of 
Intellectual Property Rights) and TRIPS-plus, in­
ternational disparities in patenting behavior are 
likely to persist. Understanding these differences 
can be important for understanding how best to 
use the public domain. 
Substantial differences in patenting behavior 
can also be found between the public and private 
sectors within a country. Public sector patenting 
behavior and the use of the public domain may 
be influenced by culture (for example, the land- 
grant universities in the United States, the cen­
ters of the Consultative Group on International 
Agricultural Research, (CGIAR), and many other 
public sector agricultural research institutions 
worldwide have a strong history of contributions 
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CHAPTER 10.1 
to the public domain), a lack of resources relative 
to the private sector, and institutional structures 
that often are designed to accommodate differ­
ent goals. Although there clearly are exceptions, 
public sector institutions and individual research­
ers are generally at a disadvantage when it comes 
to strategically employing the patent system to 
achieve their research and development goals. In 
these instances, the public domain can be a cru­
cial resource. 
This chapter does not consider whether the 
shift in the relative strength of the public domain 
in the life sciences is disadvantageous, and, if so,
to whom. Such complex issues have been consid­
ered widely in the literature on IP policy. Instead, 
the chapter focuses on how to use the public do­
main to achieve individual IP management goals. 
Whether research and development goals in­
volve decisions about how to access technologies, 
how to preserve widespread access to newly de­
veloped technologies, or how to ensure that inno­
vations continue along the research and develop­
ment path toward commercialization unimpeded 
by IP issues, a solid understanding of the public 
domain is paramount. It is essential to know how 
the public domain interfaces with the IP rights 
system in order to know when and how to use it. 
. dEfInInG	 opEn-ACCESS	ConCEpTS 
In this section we compare the concept of pub­
lic domain with two other concepts: open source 
and the commons. These three terms all relate to 
open-access alternatives to the traditional IP 
rights system, but they are very different from one 
another. 
.1 Public domain 
In its usage to date, the term public domain is elas­
tic and inexact. A definition can be but one of many 
definitions, each surely a function of perspective and 
agenda ... 5 
Defining the term public domain as the ab­
sence of individual property rights creates two 
mutually exclusive sets of technology: one that is 
protected by some form (any form) of IP rights 
and another that has no IP rights. Thus, in patent 
law, a technology is considered to be in the public 
domain if one can make, use, offer for sale, sell, or 
import the invention without infringing an active 
patent and if there are no other types of IP rights 
that lay claim to the invention. Technologies in 
the public domain can be used with impunity be­
cause, by definition, there is an absence of owner­
ship and therefore free access. This description of 
the public domain as a distinct set of technologies 
with a defined boundary, though, is misleading. 
In fact, the boundary between the two sets can 
be difficult to discern, can vary from country to 
country, and is continually shifting. It is no sim­
ple task to ascertain whether or not a technology 
is in the public domain. 
.2 Open source 
Like the public domain, open source is character­
ized by free accessibility. However, with regard to 
open-source technology, free access derives from 
a different source. Free access in the public do­
main is defined by an absence of ownership, but 
free access in open source is dependent upon the 
presence of IP rights that enable the use of open-
source licenses. 
The concept of open source has its origins 
in computer software. Once computer code has 
been fixed in a tangible means of expression, it is 
automatically the subject of copyright protec­
tion. This copyright protection allows the owner 
to license the code. A typical (non-open source) 
license might, for example, contain terms that 
restrict the use of the licensed product or stipu­
late fees to be paid. But the terms of an open 
source license are seen as an unusual reversal of 
typical licensing terms (so unusual the license is 
sometimes called copyleft). By signing an open-
source license, the licensee agrees to ensure that 
the software will remain available for public use, 
modification, and redistribution; the licensee 
is then in breach if he or she privately appro­
priates the technology and restricts its public 
availability. 
Such legal protection from private appropri­
ation has been used to generate a self-defending 
commons of software code that is collaboratively 
added to and improved upon. A technology li­
censed under an open-source license, therefore, 
cannot be in the public domain; otherwise there 
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BOETTIGER & CHI-HAM 
would be no license and no way of enforcing the 
commons. 
Several versions of open-source licenses are 
commonly used, and they vary in the restrictive­
ness of their terms. For instance, there may be a 
provision that any code that is combined with 
the licensed code will fall under the ambit of the 
open-source license. Therefore the entire body of 
code can only be licensed under the same open-
source license terms—it cannot be privately ap­
propriated. This viral quality limits the utility of 
the open-source license in certain commercial 
contexts but increases the potential for growth 
of the protected commons of code. Other ver­
sions of open-source licenses are less viral and 
have been tailored to different business needs. 
In the fields of health and agriculture, open 
source has been most easily adopted in areas with 
similar technology characteristics (for example, 
genomics). Attempts to apply the open-source 
model to nondigital technology sectors6 encoun­
ter a range of difficulties. Patent law, not copy­
right law, protects technologies in these sectors of 
the life sciences. Applying open-source licensing 
mechanisms in patent law has its own set of le­
gal challenges. Also, there are differences related 
to the innovation processes of non-digital tech­
nologies. The amounts of time, capital, and risk 
involved in, for instance, the production process 
of pharmaceuticals, are vastly different from the 
production process in software production. In 
addition, some technologies simply lend them­
selves less easily to the type of collaborative in­
novation structures that successful open-source 
models are based upon. Still, the tenets of open 
source resonate among communities of innova­
tors in a wide range of technology sectors. The 
search for new applications of the open-source 
model is surely a worthwhile pursuit. 
.  The Commons 
The term commons has been used widely in vari­
ety of contexts; its meaning, as applied to IP, is 
less clear cut than those of either public domain 
or open source. Outside the field of intellectual 
property, the commons frequently refers to a com­
monly managed resource (for example, an ejido 
in Mexico describing commonly managed lands). 
The collective-management concept translates, 
albeit loosely, into the term’s use in reference to 
intellectual property. 
In addition to describing the management of 
a body of intellectual property, the term commons
has also been used in reference to characteristics 
of ownership and access.7 Whether a commons is 
defined by lack of private ownership, open access, 
or collective management seems to vary according 
to the context in which it appears and to the au­
thor’s own interpretation of the word. Depending 
on the choice of definition, commons can apply 
to the public domain and to open source. 
. REvIEW	 of 	RELATEd 	LEGAL	ConCEpTS	 
Before discussing the use of the public domain 
in greater detail, this section briefly reviews the 
relevant sections of patent law. The legal back­
ground presented here is important for defen­
sive publishing, that is, intentionally placing a 
technology in the public domain through pub­
lication and thereby preventing future patenting. 
In addition, understanding these legal concepts 
will make clearer the discussion in Section 7 on 
how to ascertain whether technologies are truly 
in the public domain. Much of this material will 
be familiar to the reader who has read in this 
Handbook the chapters on freedom to operate 
(FTO)8 and on various aspects of patenting and 
patenting strategies.9 
.1  Patentability requirements and their 
importance in defensive publishing 
Defensive publishing seeks to preclude future 
patenting in a technology area by making it
impossible for a potential patentee to satisfy one 
or more of the statutory patentability require­
ments.10 A solid understanding of patentability
requirements allows for greater success in de­
fensive publishing. In particular, the patent-law 
concepts of novelty, nonobviousness, and enable­
ment are key. 
.1.1  Prior art and the patent 
application process 
In order to meet patentability standards, the 
claimed invention must satisfy the statutory 
2 | HANDBOOK OF BEST PRACTICES 













      
       
        
       
      
        
        
        
         
       
        
       
         
       
      
        
         
       
        
         
CHAPTER 10.1 
requirements of utility,11 novelty,12 and nonobvi­
ousness,13 the latter two of which involve an eval­
uation of prior art. In addition, the patent must 
be sufficiently described and enabled in the patent 
application.14 If the patent examiner assesses the 
prior art and deems that the claimed invention is 
either not new, or is obvious, the patent may be 
denied, or the claims may need to be narrowed in 
order to account for the documented prior art. It 
should be noted that the term prior art encom­
passes both nonpatented and patented prior art. 
(This chapter does not consider the latter.) 
Citations of prior art can be added by either 
the applicant or the examiner.15 U.S. patent law 
does not require the patent applicant to search for 
prior art (that duty falls to the patent examiner).
However, if the applicant or inventor is aware of 
prior art, it must be included. The duty to dis­
close exists under the requirement that appli­
cants act in “candor and good faith” when deal­
ing with the U.S. Patent and Trademark Office 
(PTO) during the patent-prosecution process. 
A breach of this duty can be considered inequi­
table conduct and may result in the patent be­
ing unenforceable, but there is nothing to pre­
vent intentional ignorance of prior art on behalf
of the applicant. In fact, since 2001, when the 
PTO began to record which citations were added 
by the examiner, 40% of U.S. patents have re-­
sulted from applications in which the applicant 
has listed no prior art at all.16 
It is unclear how thoroughly examiners 
search for prior art. Patents, both domestic and 
international, are a kind of prior art that allows 
for relatively easy and expeditious searching. 
Defensive publishing, however, depends on the 
ability of patent examiners to find publications 
in nonpatent prior art searches. Sampat17 discusses 
the difficulties patent examiners face in searching 
for nonpatent prior art and notes the growing con­
cern that these various constraints on effective prior 
art searching are increasingly binding, and that the 
PTO is issuing more and more “low quality” pat­
ents, [that is,] patents that would not have been is­
sued had the examiner considered the entire universe 
of relevant prior art. 
So for those seeking to practice defensive 
publishing, the skills of crafting a good defensive 
publication must be matched with attention to its 
prominence in search engines that patent exam­
iners may be more likely to use. Perhaps more im­
portantly, diligent attention should also be paid 
to newly published patent applications in the 
field of interest. As these applications are issued, 
evidence suggests that the author of a defensive 
publication may need to make the publication 
known to the patent examiner in order to be con­
sidered as prior art and, therefore, limit the claims 
of the proposed patent. If defensive publications 
are brought to light after a patent issues, recourse 
through patent invalidation is possible but may 
be prohibitively expensive. There are provisions 
within U.S. patent law for the submission of pri­
or art during a patent’s application process, and 
this window of opportunity should be strategi­
cally utilized.18 
.1.2 Novelty and nonobviousness 
An invention is ineligible for patent protection 
if it is either not new or obvious in light of ex­
isting prior art. The novelty and nonobviousness 
requirements for patentability define the param­
eters within which defensive publishing can be 
implemented. The parameters define how public­
ly disclosed inventions, as prior art, can be used 
to support future patentability rejections. 
Disclosure of an invention, and the accom­
panying bar from future patentability due to lack 
of novelty, is not limited to publications in print­
ed form. An invention can become ineligible for 
patenting through any public knowledge of the 
invention, or though its being used or offered for 
sale. However, it is important to note that U.S. 
law limits the use of nonprinted evidence in sup­
port of a lack of novelty rejection to that which 
originates within the United States. If the inten­
tion is to use evidence from other countries to 
support a rejection on lack of novelty grounds, 
the evidence must be either a patent or a printed 
publication.19 The section of U.S. patent law rel­
evant to novelty and defensive publishing says 
that a patent application can be rejected on the 
basis of lack of novelty if “the invention was … 
patented or described in a printed publication in 
this or a foreign country, before the invention thereof 
by the applicant for patent, or … more than one 
HANDBOOK OF BEST PRACTICES | 
  
     
         
       
       
      
   
     
     
       
       
      
       
      
        
      
     
 
     
    
       
      
        
      
      
       
      
       
        
       
       
       
      
        




	 	 	 	 	
       
       
      
       
BOETTIGER & CHI-HAM 
year prior to the date of the application for patent 
in the United States.”20 In most other countries, 
the one-year grace period does not exist; public 
disclosure of an invention immediately bars pat­
entability in those countries. 
In addition to understanding the timing 
of disclosures, a successful defensive publishing 
strategy should consider the meaning of the words 
printed and publication. For example, is a docu­
ment posted on the Internet considered printed, 
such that the document constitutes prior art and 
works to reduce future patenting? Sections 5.1– 
5.4 discuss best practices in regard to the content 
of defensively published documents, as well as 
their date and mode of publication. 
The nonobvious requirement in U.S. law 
states that if the existing prior art is such that a 
person who is skilled in the art would not have 
difficulty coming up with the invention, the in­
vention is not patentable: “… if the differences 
between the subject matter sought to be patented 
and the prior art are such that the subject matter 
as a whole would have been obvious at the time the 
invention was made to a person having ordinary 
skill in the art to which said subject matter pertains. 
Patentability shall not be negatived by the manner 
in which the invention was made.”21 
In comparison to the novelty requirement, 
the patentability requirement of nonobviousness 
gives a broader range of possibilities for defensive 
publishing to prevent future patenting. The key 
difference is that in order to support a rejection 
under the novelty requirement, the printed pub­
lication must include each and every limitation 
of the claimed invention, either explicitly or im­
plicitly. A rejection under the nonobvious require­
ment, however, only requires that the content of 
the prior art publication can be modified in an 
obvious way to arrive at the claimed invention. 
In addition, the patent examiner can use combi­
nations of prior art to support a nonobviousness 
rejection, so even disclosures in defensive publish­
ing that are partially complete may still create dif­
ficulties for those wishing to patent in the field.
.1. Enablement 
Careful defensive publishing anticipates how best 
to support a patent examiner’s rejections under 
the two patentability requirements described 
above (novelty and nonobviousness). In order to 
support rejections under the novelty requirement, 
the publication, or nonpatent prior art, must be 
enabled. If the reference is supporting a rejection 
on grounds of nonobviousness, enablement may 
not be as critical a factor; a nonenabling publica­
tion can still be used to support a rejection on 
grounds of nonobviousness.22 This section con­
siders enablement for an author constructing a 
defensive publication. 
Although the legal definitions vary somewhat 
depending on the country in question, in general 
the enablement requirement is meant to ensure 
that the document contains enough detail for a 
person skilled in the art to be able to make and 
use the invention after reading the document. A 
key question is whether it is clear that the public 
possessed the invention prior to the date the pat­
ent applicant claims to have invented it. While 
the burden of proof of enablement for prior art 
falls to the patent applicant, who must provide 
facts supporting a purported lack of enablement 
(this presumption of enablement in prior art is no 
different for a nonpatent publication than for a 
patent), it is still worthwhile considering enable­
ment in a defensive publication. 
When plants are the claimed inventions that 
a defensive publication is seeking to protect from 
patentability, enablement may require that some­
one of ordinary skill be able to reproduce the 
plant. Descriptions of the plant variety, however 
detailed, may be insufficient. In one case, a ref­
erence describing a rose was found not enabled, 
despite explicit detail and evidence that the au­
thor was in possession of the rose.23 In this case 
the court ruled that, without information on the 
grafting process, reproduction of the rose was im­
possible. In other cases, supporting documenta­
tion may be necessary to indicate that seeds were 
publicly available within the time frame necessary 
to bar patenting. 
.2 Overlapping claims and dominant patents 
What are the legal concepts used to ascertain 
whether a technology is in the public domain 
and therefore freely available? This question is 
relevant to both scientists and IP managers who 
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CHAPTER 10.1 
are considering what technologies to choose for 
a project. These pesrons must proceed with cau­
tion, because the use of a technology in a publi­
cation, or the decision to in-license a technology 
under an active patent, may go only part way to 
providing the right to practice the technology or 
pursue a certain research project. 
A common misunderstanding in this area 
stems from a belief that patent claims define 
mutually exclusive areas of technology. In reality, 
the patent claims overlap each other: the use of 
one technology can infringe claims in more than 
one patent. While the issuance of a patent gives 
the patentee the right to exclude others from 
practicing the invention, it does not imply that 
the patentee can practice the invention without, 
perhaps, infringing existing patents. When the 
rights to existing patents are needed to practice 
a technology, those patents are considered domi­
nant patents. 
The existance of broad, pioneering patents 
illustrate how dominant patents can affect the 
rights to use downstream innovations. For ex­
ample, Monsanto’s claim to the plant transforma­
tion method using Agrobacterium means that all 
patents in which the claims specifically depend 
on this transformation method are blocked by a 
previous patent. U.S. Patent No. 6,369,298 is a 
patent assigned to Pioneer Hi-Bred International, 
Inc. (now a subsidiary of DuPont) for transfor­
mation of sorghum. In this case, the claimed 
technology depends on the Agrobacterium trans­
formation method. A third party intending to 
practice this technology would likely not only 
need a license for U.S. 6,369,298 but also for 
Monsanto’s Agrobacterium transformation domi­
nant patent(s).24 
Pioneering patents like the one described 
above are relatively uncommon, but overlapping 
claims and dominant patents exist in all areas of 
patented technology. Understanding the overlap­
ping nature of patent claims is crucial for those 
who intend to utilize the public domain, because 
using a technology that appears to be in the pub­
lic domain may involve infringing one or more 
patents.
The case study of the E8 fruit promoter pro­
vides another example (see the timeline in Figure 1 
of the chapter by Fenton et al. 25) An initial search 
delivers the documents detailed in this figure: sev­
eral scientific papers and a group of patents. Once 
the documents are arranged chronologically, we 
can see that the E8 promoter’s DNA sequence 
was disclosed early in our chronology in two 
scientific publications. But ascertaining whether 
the E8 promoter is still in the public domain and 
therefore available freely involves further investi­
gation. Years after the initial publications, several 
patents were issued that claimed variations on the 
sequence and the right to use of the original E8 
promoter sequence when combined with partic­
ular genes. Therefore, while the original sequence 
itself remains in the public domain, when using 
the sequence care must be taken to avoid infring­
ing subsequent patent claims. 
Published scientific literature, trade journals, 
conference proceedings, abandoned patents,26 
and expired patents are all good sources for find­
ing public domain technologies. In the case of 
expired and abandoned patents, the boundaries 
of the forfeited IP rights have been clearly de­
fined by the claims of the patent: the previous 
owner of the patent no longer has the legal right 
to exclude someone from using what is set out 
in the claims of the patent. But these two areas 
are especially prone to overlapping claims from 
other patents that may still be active and affect 
the freedom to use the technology. Companies 
often file multiple patents in a technology space, 
or there may be multiple patents in one family 
that arose from an initial application. Just be­
cause a patent has expired and entered the public 
domain does not mean the technology is avail­
able for use. 
When seeking to identify whether a technol­
ogy is in the public domain, one must be cau­
tious because of overlapping claims. Armed with 
this knowledge, research into a potential public 
domain technology begins with publicly available 
patent databases.27 These databases provide a great 
deal of information about the boundaries of the 
public domain. Nonetheless, it can be difficult to 
understand the interplay between the published 
scientific literature and patents, as illustrated in 
the E8 case study. PIPRA offers technical assis­
tance in this regard, analyzing technologies used 
HANDBOOK OF BEST PRACTICES | 
  
     
      
       
 




	 	 	 	 	
    
        
     
    
       
      
       
      
      
        
      
      
        
       
  
	 	 	 	 	 	 	
	 	 	 	 	
 
 	 	 	 	 	 	 		
	 	 	
BOETTIGER & CHI-HAM 
in public sector agricultural research to ascertain 
with greater accuracy the boundaries of the pub­
lic domain.28 
. WHEn To uSE	 dEfEnSIvE	 puBLISHInG:
THE	CHoICE	BETWEEn pATEnTInG	
And puBLISHInG 
Deciding whether to patent or publish is a stra­
tegic decision that must take into account a 
host of variables: the mission of the institution 
(and/or the funding agency) involved, the goals 
of the individual project, the financial resources 
available to spend on IP protection, the nature 
of the technology, the functionality of the court 
system in the countries where the technology will 
be used, and the strategies being employed by 
other institutions producing similar technologies. 
Moreover, defensive publishing and patenting 
inventions each has its limitations and benefits. 
Other strategies, such as trade secrecy, trademark 
protection, and bailment29 need to be considered 
as options when formulating an IP management 
strategy. 
Defensive publishing is often associated with 
promoting access, but there are instances where, 
perhaps counter-intuitively, defensive publish­
ing may not be the most appropriate choice for 
getting widespread access to either an end-prod­
uct or a newly developed technology. There are 
instances, however, where patenting has limita­
tions and defensive publishing may be the better 
choice. 
.1 Can defensive publishing promote access? 
Many institutions and/or sponsors, particularly 
in the fields of health and agriculture, place a 
high priority on promoting widespread access 
to developed technologies. Indeed, publishing 
continues to play a critical role in universities 
and at other public sector research institutions. 
Recent changes in the worldwide use of patent­
ing discussed above, however, are forcing these 
institutions to reassess whether this IP manage­
ment strategy is the best way to support their 
goals. This section focuses on promoting access 
and highlights some instances where the choice 
to patent a technology may be key to achieving 
the goals of promoting access, primarily by pro­
viding important leverage. 
.1.1  Will the technology need private-sector 
resources for further development and 
distribution? 
IP rights provide private economic incentives that 
can sometimes be critical to research, develop­
ment, and distribution processes. As an example, 
consider the investment needed to bring a drug 
from discovery through to delivery. Although 
an accurate estimate of the true cost of drug de­
velopment is the subject of a lively debate, it is 
inarguably hundreds of millions of dollars.30 In 
most cases it is unreasonable to expect the public 
sector to take on the levels of investment and risk 
involved in drug development. A parallel example 
can be seen in agriculture, where regulatory clear­
ance may be needed for a new product, or seed 
distribution networks may need to be engaged. 
It is important, therefore, to assess early whether 
private capital is likely to be necessary, at some 
point, for research, development, regulatory clear­
ance, manufacturing, and distribution. IP rights 
can facilitate the private sector’s engagement by 
providing critical assets for bargaining (for exam­
ple, in product development partnerships). 
.1.2	 Are there benefits to be gained 
from segmenting the market? 
One benefit of choosing to patent, rather than 
publish, is that patenting provides an opportu­
nity to segment the market of technology users 
or licensees. An IP manager may require differ­
ent licensing terms, for instance, depending on 
whether the technology will be used commer­
cially or for humanitarian purposes. Alternatively, 
the license might contain terms to segment the 
market geographically or by fields of use. An 
exclusive license may be implemented, for ex­
ample, to limit the technology’s use to one major 
crop, reserving all other uses of the technology 
for widely accessible and nonexclusive licens­
ing. Using such an approach, income generation 
and access may be complementary goals for the 
IP provider. Or the rights to a technology in, for 
instance, developed country markets may be ex­
changed for contractual obligations to deliver the 
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CHAPTER 10.1 
product to developing countries for a reasonable 
price. Choosing to protect the technology with 
IP rights instead of defensive publishing may pro­
vide bargaining leverage that ultimately achieves 
the institution’s goals. 
.1. Is the technology a research tool 
(enabling technology)? 
A body of evidence indicates that the patenting 
and access restrictions (through exclusive licens­
ing, for example) of enabling technologies can 
limit the progress of innovation in health and 
agriculture.31 Indeed, the existence and effects of 
patent thicket– or anticommons-dynamics are 
now fairly well accepted. The task of this section, 
however, is not to consider the policy question of 
whether research tools should be patentable, but 
to examine the choice between patenting (nota­
bly in the examples given here with widespread 
nonexclusive licensing) and defensive publishing 
for the IP manager whose goal is to promote ac­
cess in a context where research tools, and im­
provements to them, are widely patented. In 
other words, how can IP management preserve 
the right to use an enabling technology? 
As a first example, consider plant transfor­
mation that confers a new trait. Access to several 
complementary enabling technologies is required 
to produce a product. A vector that includes a 
promoter, selectable marker, a backbone, and a 
gene of interest must be used, as well as a trans­
formation method and germplasm. Lack of access 
to any one technology may delay research and de­
velopment or, in some cases, altogether prevent 
the progress of the project. 
In such a case, the complementary nature 
of the technologies implies that the decision to 
patent may confer bargaining leverage. If an IP 
manager chooses not to patent an enabling tech­
nology, for example, a novel selection system with 
wide applicability in plant transformation, the 
ability to control the technology’s applications is 
lost. Research projects where the selection system 
would otherwise have been the limiting factor 
(where all other technologies are owned or acces­
sible) could progress, without impediment, if the 
technology were to be published. Alternatively, if 
the IP manager chooses to patent, the essential 
nature of the technology may place the owner in 
a position to demand a wide range of contractual 
obligations in exchange for the use of the selec­
tion system. BiOS, for example, operates on this 
principle by providing patented enabling tech­
nologies under licensing terms that support the 
organizations open-access goals.32 
A second scenario concerns improvement 
patents. Here, as in the previous example, suppose 
the IP manager chooses not to patent the novel se­
lection system. Improvements to the technology 
are subsequently invented and patented, restrict­
ing the uses of the original technology. Had the 
IP manager patented the technology, the value of 
the subsequent improvement patents would de­
pend on access to the underlying dominant pat­
ent (see Section 4.2 on dominant patents). The 
E8 case study provides a concrete example where, 
had the original sequence been patented instead 
of published, the use of some of the downstream 
patents would depend on Agritope, Inc. or 
Epitope, Inc. licensing the original patent. For 
technologies that do not lend themselves to sub­
sequent restrictions from improvement patents, 
this is not a concern. Mouse models are an ex­
ample of this type of technology. The majority of 
mouse models used in research, for instance, are 
licensed and not patented. 
.2  Using defensive publishing as a tool 
in an IP management strategy 
Clearly, the common perception that publishing 
inherently promotes access may require recon­
sideration. Still, what are the merits of defen­
sive publishing for supporting a wide variety of 
IP management goals? And how does it high­
light the limitations of using patents to protect 
innovations? 
.2.1  	 The costs of maintaining 
a patent portfolio 
Patent portfolios are costly to develop and main­
tain. Moreover, they sometimes require a lengthy 
maturation period before reaching a point 
where they return income. Unless a licensee is 
found who will underwrite the cost before the 
prosecution process starts, the initial investment 
in the cost of prosecuting patents can be large, 
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BOETTIGER & CHI-HAM 
particularly where protection is sought in mul­
tiple countries. Even where licensees are already in 
place, it can be many years before a license gener­
ates a positive cash flow. In examining U.S. uni­
versity technology transfer offices (TTOs), Heher 
notes that 40%–50% operate at a net loss and 
that profitability often depends on income aris­
ing from one or more blockbuster patents.33 In a 
cross-country comparison of TTOs, he finds that 
“the first and foremost requirement for success from 
technology transfer is a well-funded high quality re­
search system as the benefits from commercialisation 
of research are directly proportional to the magnitude 
of the investment in research.”34 While direct and 
indirect economic impacts provide broad benefits 
from building an institutional patent portfolio 
and TTO, the investment is long term and high 
risk. If resources are particularly constrained, the 
decision to expend money on patenting deserves 
careful consideration. Less expensive alternatives 
to patenting may support IP management goals 
and allow more resources to be directed toward 
research. 
.2.2 Transaction costs of licensing 
The transaction costs of negotiating licenses are 
substantial and may need to be accounted for 
in the decision to patent. For instance, if the 
IP management goal is to promote access to a 
technology, and the choice is either defensive 
publishing or nonexclusive licensing, the costs of 
negotiating multiple nonexclusive licenses, or de­
vising licensing language to segment the market 
of technology users suitably, may outweigh the 
benefits. Transaction costs can be somewhat re­
duced in take-it-or-leave-it nonexclusive licenses, 
but these tend to be rare. 
.2. 	 Enforcement considerations: 
costs and legal Infrastructure 
The costs (and feasibility) of enforcing the patent 
may also need to be considered. Because a pat­
ent confers exclusionary rights, it may be worth­
less without the ability to enforce those rights. 
Enforcement may require litigation against infring­
ers or using the patent to invalidate subsequent 
blocking patents. In either case, patent litigation 
is a game for players with deep pockets. Average 
costs for patent litigation in the United States 
exceed $2 million dollars per case. Any decision 
to patent must include an assessment of whether 
the patentee can afford to enforce the patent. In 
addition to the expense, the maturity or efficacy 
of the patent law system in the countries likely to 
be involved should be considered. If the technol­
ogy lends itself to bailment, for example, more
control over the use of technologies may be
found through contract law, particularly in 
countries where the patent system is not well 
developed. 
.2.  Defensive publishing as an 
active strategy 
Defensive publishing is most effective as an active 
strategy. This is a different use of publishing than 
that found in many research institutions today. 
The use of defensive publishing requires carefully 
constructed disclosures with the greatest possible 
public exposure and diligent worldwide monitor­
ing of new patent applications as they arise in a 
particular technology field. When a patent appli­
cation appears for which the defensive publication 
has the potential to force a narrowing of the claims 
or a total rejection, the appropriate channels must 
be used to alert the patent office of the published 
prior art. 
.2.  Using defensive publishing in 
combination with patenting 
One of the strongest roles defensive publishing 
can play is when it is used, not as a substitute for 
patenting, but in conjunction with it. As an ex­
ample, consider a strategy where an IP manager 
patents a core technology and then defensively 
publishes the surrounding, related innovations, 
thereby reducing the likelihood that others will 
be able to obtain dominant patents. Obtaining 
patents on improvements to a core technology as 
they are discovered may be a poor use of limited 
resources. In addition to improvements, new uses 
of the core technology may be discovered as re­
search and development progress. But defensive­
ly publishing these improvements and alternative 
uses will inexpensively and effectively contribute 
to preserving the right to a wide field of applica­
tions for the core technology. 
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.  Preserving access: ten questions to consider 
For the IP manager deciding on a strategy for pre­
serving public access, considering the following 
questions should be helpful: 
•	 What are the IP management goals of the 
institution or inventor? 
•	 Will the technology need the engagement 
of private-sector resources for further devel­
opment and distribution? 
•	 Are there benefits to be gained from seg­
menting the market? 
•	 Is the technology a research tool (enabling 
technology)? 
•	 Do the benefits of patenting and licensing 
outweigh the costs? 
•	 How and where might the patent be 
enforced? 
•	 Are there other viable options for protec­
tion—trade secrecy, bailment, trademarks, 
and so forth? 
•	 In which territories/countries is the tech­
nology likely to be used? 
•	 Can the technology be licensed without 
patenting? 
•	 Can defensive publishing be used in con­
junction with traditional forms of IP 
protection? 
. uSInG	 puBLIC	 doMAIn TECHnoLoGIES 
Public domain technologies are valuable inputs 
to research. Indeed, they are a crucial but com­
monly underutilized resource for researchers. 
Using research tools or enabling technologies in 
the public domain reduces transaction costs and 
mitigates future potential IP impediments in the 
research and development process. 
In developed countries, many of the standard 
inputs of science in the fields of health and agri­
culture have been patented. Scientists, however, 
continue to use these tools because they have a 
well-known history, including known levels of 
efficiency and documented use in specific crops. 
The use of patented research tools, on the other 
hand, can open the institution to infringement 
liability and/or create problems in later stages 
of commercialization. While the maximum use 
of public domain technologies may be desirable 
at the outset of a research project, using better-
known tools (which are often proprietary) may be 
important in the initial proof of concept stages of 
research. In this case, it is worthwhile to identify 
whether public domain technologies are available 
for substitution at a later stage. 
The identification and promotion of substi­
tute technologies from the public domain is one 
of PIPRA’s important contributions to the field 
of agriculture. PIPRA’s mandate is to assist pub­
lic sector researchers worldwide in overcoming IP 
impediments to the research, development, and 
distribution of staple crops for developing coun­
tries and minor crops in developed countries. 
Because the commercial market for these crops 
is too small to attract private-sector investment, 
the public sector primarily pursues research and 
development with respect to such crops—often 
without the resources to successfully address IP 
issues. Public domain technologies are therefore 
a critical resource for developing these orphan
crops. 
As PIPRA’s library of technical and legal in­
formation on public domain and patented, but 
accessible-enabling technologies (including free-
dom-to-operate opinions from attorneys) in agri­
culture grows, so does the demand for knowledge 
of what technologies are in the public domain and 
how they might be employed in place of currently 
used patented technologies. Some practical con­
siderations for researchers and IP managers with 
regard to identifying public-domain technologies 
are laid out below. 
.1  Patent databases provide 
only part of the picture 
As the E8 case study illustrates, an investigation 
must begin with a search through both the pub­
lished scientific literature and patent databases. It 
is both the comparison of the content and the 
timing of the publication of each contributing 
document that will determine whether the tech­
nology in question is in the public domain and 
its limitations for use. A simple patent search 
may mislead by returning a bewildering number 
of related patents. But a comparison of these pat­
ents with the published literature can reveal that, 
for instance, the core technology is in the public 
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BOETTIGER & CHI-HAM 
domain and that the patent thicket is made up 
of improvements, and other patents, limiting 
the utility of the original technology. If this is 
the case, knowledge of these limitations may be 
critical in designing a research plan that invents 
around existing patents and maximizes the use of 
the public domain technology. 
Sequence comparisons may provide another 
critical piece of information for the researcher 
seeking to use a public domain technology. As an 
example, PIPRA’s analysis of the Soybean Heat 
Shock Promoter found that changing the se­
quence by one nucleotide allowed researchers to 
avoid infringing the issued patents.35 It should be 
noted, however, that this case is somewhat anom­
alous. The determination by PIPRA’s attorneys 
that altering a single nucleotide avoided existing 
patents was reached by carefully considering both 
prior art and patents. Generalizations cannot 
be made, because it is only through examining 
how both sets of specific documents interact that 
FTO can be evaluated. However, the example il­
lustrates how critical the use of sequence analy­
sis tools such as BLAST can be when analyzing 
patents. In general, careful attention to the prior 
art and the use of homology measures in patent 
claims may be necessary to identify the specific 
public domain sequence. 
.2 The landscape is continually changing 
The boundary of the public domain changes 
as new patents are issued. Periodic updates of
the analysis are necessary to check for recent­
ly issued patents that may restrict the use of
the original technology. Searches can be hindered
because patent applications remain unpub­
lished—and therefore invisible in patent search 
engines—for many months after their initial fil­
ing dates. 
. Geographical considerations 
Finding out what is in the public domain is 
made even more complex by the territorial 
nature of patents. The analysis for the E8 case 
study considered only the situation in the 
United States; any other country would re­
quire collecting a different set of documents. 
Nonetheless, because the boundaries of the 
public domain are more expansive in some 
countries than in others, opportunities may ex­
ist to design research strategies that take advan­
tage of these differences. 
For example, the territorial limits of patents 
have led to suggestions that developing-country 
research institutions should use technologies that 
are not patented domestically but are patented in 
more-developed countries. Legally, a researcher 
using a technology in a country where no pat­
ent has been filed is not infringing. However, an 
obvious constraint surfaces when the product of 
the research is destined for export into a country 
where there is patent protection. In this case, de­
spite the lack of patent protection domestically, it 
may be necessary to investigate the patent land­
scapes of export markets. 
There are still further considerations. In or­
der to use a technology that resides in the public 
domain domestically, but is patented elsewhere, 
a researcher may require the transfer of materials 
or know-how from the patentee. These often in­
volve material transfer agreements (MTAs) with 
restrictive terms and reach-through obligations 
that may hinder research and interfere with broad 
access for researchers in developed and develop­
ing countries alike. Even where no patent rights 
are found, this situation may involve negotiating 
agreements (such as nonasserts) with the technol­
ogy owner. In addition, even when large compa­
nies as patentees are not concerned with infringe­
ment issues or losing market share, the companies 
may be concerned about liability and stewardship 
issues. Finally, developing country research insti­
tutions, or the organizations that sponsor their 
research, may attach considerable value to the 
building of relationships with the company that 
has patented the technology. Therefore, despite 
the lack of patent protection and the legal free­
dom to use a technology, there may still be im­
portant reasons to negotiate a license. 
.  THE	MECHAnICS	 of 
dEfEnSIvE	 puBLISHInG 
This last section focuses on the mechanics of de­
fensive publishing: how to best ensure that a dis­
closure precludes downstream patenting by others. 
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CHAPTER 10.1 
Elements to consider in drafting a successful de­
fensive publication include: content, language of 
choice, publication venue, and publication date. 
The following sections elaborate on best practices 
in defensive publishing. 
.1 Content 
The goal of defensive publishing is to prevent pat­
enting in a particular technology area. Therefore, 
constructing a disclosure specifically designed to 
create evidence to prevent patentability will in­
crease the likelihood that fewer patents will issue 
in this technology space. The disclosure should 
be as complete and detailed as possible. Where 
relevant, a publication should include descrip­
tions of all parts of the experiment, experimental 
conditions, diagrams, formulas, procedures, se­
quences, materials, and methodologies. We indi­
cated earlier that enablement of the publication 
may be important; a defensive publication should 
include evidence illustrating possession of the in­
vention and enable a person skilled in the art to 
make and/or use the invention. 
.1.1  Consider disclosing the potential 
for combining technologies 
In addition to a thorough description, defensive 
publishing should include potential combinations 
of the target technology with other technologies. 
This is true even for combinations for which the 
author may not have detailed documentation. 
As the case study of E8 revealed, the inclusion 
of additional combinations can expand the use 
of the document to support future nonobvious­
ness rejections. Publishing the sequence of the E8 
plant promoter did not prevent the issuance of 
future patents claiming the use of the promoter 
combined with particular genes. If the authors of 
the original publication had ended their paper 
by articulating the likely success of the sequence 
for promoting the expression of broad classes 
of genes, there may have been stronger grounds 
for rejecting subsequent patents. To extend this 
point, a defensive publication may be even stron­
ger if it anticipates not only the promoter-gene 
combination, but also its potential use in entire 
systems, such as the transformation method, se­
lectable marker systems, and other elements of a 
plant transformation vector, as well as its use in 
particular crops. 
Whether the inclusion of certain language 
in a publication will prevent future patenting in 
this case is uncertain, and it should be noted that 
the combination of prior art references in support 
of a rejection on nonobviousness grounds comes 
with several caveats. A successful rejection of a 
claimed invention due to obviousness must show, 
not only that someone skilled in the art would 
have been able to combine the prior art refer­
ences, but that they would have been motivated to 
do so. Second, there must be a reasonable expec­
tation of success for the purported combination. 
Third, the references taken together must teach or 
suggest all the elements of the claimed invention. 
When drafting the content of a defensive publica­
tion, it is impossible to anticipate all the possible 
combinations of the author’s technology with 
that belonging to others, but by using language 
that acknowledges the caveats above, the author 
can broaden the subject matter of the disclosure 
as much as possible. 
.1.2  Consider disclosing potential 
alternative applications 
As with potential combinations, it may be worth­
while to include alternative applications of the 
technology, even if they are not documented in 
detail. If the technology is a product, the author 
may want to consider including the current prod­
uct, potential uses of the product, and derivative 
products. While defensive publication can place 
a product technology in the public domain, pro­
cesses developed later using that product can still 
be patented. By anticipating potential applica­
tions, the author of the defensive publication 
may contribute to an obviousness-type rejection 
in the future. If the technology disclosed is a pro­
cess, the author might consider including details 
of products derived from the process. These con­
siderations anticipate the patentability of product 
and process patents. As an example of product 
and process patents, consider the famous Cohen-
Boyer technology. This was not one patent, but 
three: (1) a process patent for the construction of 
molecular chimeras, (2) a product patent for pro­
teins made using recombinant eukaryote DNA, 
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BOETTIGER & CHI-HAM 
and (3) a product patent for proteins made using 
recombinant prokaryote DNA.36 
.1. Consider disclosing related alternatives 
One way to design around a defensive publica­
tion (or a patent) is to alter, even minimally, the 
structure of the technology. TGo anticipate this,
defensive publication can indicate how the tech­
nology may be altered while still maintaining 
the original disclosed functions and characteris­
tics. This follows common practice in drafting 
patent claims. For instance, a sequence may be 
published that includes a percentage homology 
within which the function of the technology re­
mains the same. In addition, it may be useful to 
include homologies across different species. 
.1. Consider depositing biological materials 
For some inventions involving biological mate­
rial, we have established that a written description 
is insufficient to convey the technology in such a 
way that a person skilled in the art can practice it. 
For such inventions, the patent system has come 
to depend on the deposit of biological materials in 
recognized, publicly accessible culture collections 
worldwide. As a rule of thumb, if the biological 
material can be made, or isolated, without undue 
experimentation, or if the material is otherwise 
known and readily available, it is not necessary 
to deposit material. In many cases, however, a 
defensive publication will be stronger if biologi­
cal materials are deposited (the deposit accession 
number should be referenced, where relevant, in 
the publication and sequence information given). 
Patent deposits worldwide have been regu­
lated since 1980 when the Budapest Treaty on 
the International Recognition of the Deposit 
of Microorganisms for the Purposes of Patent 
Procedure came into force.37 The World 
Intellectual Property Organization38 provides 
an updated list of the countries that have rati­
fied the Treaty and the collections that are rec­
ognized as international depositary authorities
(IDAs).39 
.2 Choice of language 
The choice of language (that is, English, or other) 
in a defensive publication can also be important. 
The publication language may need to be, for 
example, one spoken in the countries in which 
the patent will be barred. It may be important, 
however, to write at least the abstract and title in 
English to maximize the chances that this partic­
ular disclosure will be brought to the attention of 
the patent offices in the United States and Europe 
during prior art searches. Still, given the limita­
tions of nonpatent prior art searching in patent 
offices, the best post-publication strategy is to 
monitor the published application in the technol­
ogy field and alert the relevant patent office to the 
defense publication. 
. Where to publish 
As noted previously, U.S. law uses the words 
“printed publication” in its novelty require­
ment. U.S. courts have adopted a broad defini­
tion of the word printed, to include documents 
stored on electronic media, and on microfilm.40 
Documents posted on the Internet may therefore 
be used to satisfy the printed aspect of the novelty 
requirement. 
The word publication has also been fairly 
broadly interpreted to mean any printed docu­
ment that is freely available to the public. Peer-
reviewed publications are only one option for 
defensive publication, and their constraints on 
content may leave the author with a less than 
complete defense. Printed materials presented at 
trade shows, conferences, seminars, or on Web 
sites are all considered to satisfy the definition of 
publication. Indeed, major corporations have used 
this kind of defensive publishing as part of their 
IP management strategy for many decades. IBM 
provides perhaps the best-known example of the 
use of a technical journal for defensive publish­
ing. The success of that strategy is illustrated by 
a 2002 search of the U.S. patent database by Bill 
Barrett that found almost 10,000 patent citings 
of IBM’s Technical Disclosure Bulletin.41 By pub­
lishing technical disclosures without the content 
restrictions of peer-reviewed publications, IBM 
wields an inexpensive, flexible tool that comple­
ments its overall patenting strategy. 
A number of companies specialize in pub­
lishing nonpatent prior art. The Web site IP.com, 
for example, provides expertise in defensive 
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publishing and offers a search engine to make it 
easy for a patent examiner to navigate through 
the site’s library of disclosures.42 Disclosing an 
invention through such a company will increase 
the likelihood that a patent examiner will see it. 
The companies, however, may charge hundreds 
of dollars for such a disclosure. Another method 
of disclosure is the use of the statutory invention 
registration procedure, whereby the PTO allows 
for the registration of an invention that is unex­
amined. This method, too, can be expensive. The 
most cost-effective way to defensively publish is to 
publish for free on the Internet (but dating mate­
rial published on the Internet can be problematic; 
see next section). If the Internet is used to publish 
defensively, there may be a greater need to moni­
tor recently published patent applications in the 
field of interest. 
. Timing and date stamping 
The date of a defensive publication is a critical 
piece of information that must be documented 
and discernible by the patent office. It helps the 
patent examiner to determine whether the publi­
cation brings into doubt the patentability of the 
subject matter. The dating of material published 
on a Web site can be a difficult matter: many 
documents on the Web are date stamped on the 
date of access, not the date of posting. Obviously, 
this practice can cause problems for a party those 
attempting to preclude future patenting in a 
technology area by using the Internet for defen­
sive publishing. Fortunately, there are solutions. 
Many companies now offer digital time stamping 
(DTS) or digital notary services. This technology 
has become accepted legal proof that the con­
tents of a publication existed at a particular point 
in time and has not changed since that time.43 
Another readily accessible method of establishing 
the date of an Internet publication is to scan a 
document that includes a date and a signature, 
and post the pdf on the Web. 
.  ConCLuSIon 
This chapter has examined how IP managers and 
researchers can use the public domain and defen­
sive publishing to their advantage. A strategic IP 
management plan begins by identifying the in­
puts and enabling technologies used in research. 
A strategic IP plan also clearly articulates the in­
tended use of the technologies that are produced. 
Once this framework is established, IP manage­
ment tools can be used effectively to support the 
project’s goals. 
The public domain is a valuable resource 
for early-stage thinking about a project’s re­
search tools. The above practical considerations 
will hopefully assist in effectively incorporating 
public-domain technologies into an IP manage­
ment plan, thus reducing the need to in-license 
technologies and freeing up resources for more 
research. Moreover, when managing the prod­
ucts of a research project, one tool to consider 
alongside more traditional IP rights is defensive 
publishing, or placing a technology in the public 
domain. When considering defensive publishing, 
however, IP managers should keep in mind both 
its utility and its limitations. n 
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ABSTRACT 
In the United States, provisional patent applications can 
provide an additional year of patent protection, for a to­
tal of 21 years from the initial filing date. With such an 
extension, a provisional application provides parity with 
foreign applicants who, pursuant to the Paris Convention, 
may file for a U.S. patent within 12 months of the foreign 
filing. Provisional applications have both advantages and 
disadvantages, so proper management is essential. The ad­
vantages include the preservation of a priority date imme­
diately after an invention is conceived, a one-year delay 
for further developing the invention, an extra year of pat­
ent protection, and constructive reduction to practice of 
the invention. In addition, provisional applications pro­
vide an inexpensive way to avoid possible statutory bars 
and preserve absolute novelty for foreign filing purposes. 
They also enable the use of the phrase “Patent Pending” to 
mark products embodying the invention. The disadvan­
tages include a possible increased overall cost of obtaining 
a patent, potential loss of trade secrets, and a false sense 
of security. An inventor must also file a nonprovisional 
application within one year, and the subject matter of a 
nonprovisional application is limited to subject matter in 
the provisional application. 
1. INTRODuCTION 
Beginning in 1995, inventors were able to file 
provisional patent applications in the United 
States. This informal type of patent application 
establishes a priority filing date and provides in­
ventors one additional year to prepare and file a 
formal utility patent application. 
Provisional patent applications were estab­
lished in the United States to place domestic in­
ventors on an equal footing with foreign inventors. 
Before the advent of U.S. provisional applications, 
foreign (Paris Convention signatory) applicants 
could claim the benefit of a foreign priority date, 
yet have their U.S. patent term measured from a 
later U.S. filing date. Foreign inventors were thus 
granted a term of patent protection that could 
last for 21 years. U.S. applicants, on the other 
hand, were disadvantaged: their patent term was 
measured from their initial U.S. filing date and 
limited to 20 years. Effective June 8, 1995, do­
mestic applicants were given the opportunity to 
file provisional applications, thereby establishing 
U.S. priority dates that would not count against 
any resulting U.S. patent term. Allowing for U.S. 
patent protection that lasts 21 years from an ini­
tial filing date, this change in policy established 
parity between U.S. and foreign inventors. 
As an informal application, a provisional pat­
ent application does not require all the formal 
elements of a utility patent application. For ex­
ample, provisional applications are not required 
to include formal claims, a declaration of inven­
torship, or drawings, all of which are required for 
utility applications. Instead, all that is required is 
a written description of an invention and a cov­
ersheet that, among other things, identifies the 
document as a provisional patent application. 
Cruz RL. 2007. Provisional Patent Applications: Advantages and Limitations. In Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K.,
and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. RL Cruz. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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CRuZ 
Unlike utility patent applications, provi­
sional patent applications are not substantively 
examined by a U.S. Patent and Trademark Office 
(PTO) examiner. Instead, they are reviewed by 
the application division of the PTO to ensure 
that the minimum filing requirements have been 
met. As a result, the legal cost of preparing provi­
sional applications is relatively low compared to 
utility applications. Similarly, since the PTO does 
not have to perform a prior art search or analyze 
provisional patent applications, the cost of filing
these applications is also quite inexpensive when 
compared to utility applications. 
Aside from costs, several other factors should 
be considered when determining whether or not 
to file a provisional patent application. A few of
their advantages and limitations associated with 
provisional applications are outlined below. 
2. ADVANTAGES OF A PROVISIONAl 
APPlICATION 
2.1  Preserve a priority date 
Because they have fewer formal requirements, 
provisional applications are simpler and generally 
less expensive to prepare and file. A provisional 
application may therefore be used to quickly and 
inexpensively obtain an official filing date for an 
invention immediately after the invention has 
been conceived. An official filing date provides 
unequivocal proof that an invention was con­
ceived at least as early as its filing date. 
2.2  A useful one year delay 
Once a provisional application is filed, an inventor 
has up to one full year to file a formal utility ap­
plication. This one-year delay enables an inventor 
to further develop his or her invention, assess the 
invention’s commercial potential, and seek finan­
cial support for further developing and/or patent­
ing the invention. In addition, the one-year delay 
enables an inventor defer the bulk of the costs 
associated with preparing and filing a utility pat­
ent application until he or she is confident that 
the invention is commercially viable, and/or until 
he or she is able to secure financial support for the 
invention. If the inventor determines during this 
period that the invention is not commercially fea­
sible, he or she can avoid the substantially higher 
costs of pursuing a utility application. 
2.  An extra year of patent protection 
An issued patent gives an inventor the right to 
exclude others from using, selling, and/or of­
fering to sell the patented invention for twenty 
years. This twenty-year patent term is calculated 
from the filing date of the inventor’s utility pat­
ent application. The one-year delay between the 
filing of a provisional application and the filing 
of a utility application does not count against the 
twenty-year patent term. As such, filing a provi­
sional application provides up to an extra year of 
patent protection, effectively extending the pat­
ent term to 21 years. 
2.  Constructively reduce an invention 
to practice 
An invention is said to be reduced to practice 
when an inventor converts the inventive idea into 
something that is operable and capable of being 
reproduced by others. Filing a provisional ap­
plication has the effect of constructively reducing 
an invention to practice, insofaras the invention 
is adequately described so as to enable a person 
skilled in the art to reproduce it. By filing a provi­
sional application, a legal presumption is created 
that the invention was reduced to practice, albeit 
constructively, at least as early as the filing date 
of the provisional application. This presumption 
may be very advantageous to an inventor, partic­
ularly if another inventor claims to have invented 
the same invention first. 
In the United States, an inventor is entitled to 
a patent if he or she is the first to invent a particu­
lar invention. If a dispute arises over who actually 
invented the invention first, establishing a reduc­
tion to practice date may be paramount to deter­
mining which inventor is entitled to the patent. 
In such disputes, the inventor who establishes the 
earlier reduction to practice date (for example, by 
filing the earlier provisional application) will be 
presumed to be the first to invent. The challeng­
ing inventor, i.e., the inventor not deemed the 
first to invent, may only overcome this presump­
tion by forwarding evidence that establishes that 
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he or she (the challenging inventor) is entitled to 
an earlier reduction to practice date. Thus, filing 
a provisional application not only establishes an 
early reduction to practice date, but it also shifts 
the burden to any challenging inventor to prove 
that she or he invented the invention first. 
2. Preserve a non-U.S. priority date 
Most countries outside of the U.S. award patents 
on a first to file basis. That is, an inventor will be 
entitled to a patent if he or she is the first to file an 
application for a particular invention, regardless 
of whether another inventor was the first to actu­
ally reduce the invention to practice. As a result, 
many foreign inventors (and U.S. inventors seek­
ing international patent protection) seek to file 
patent applications in non-U.S. countries as soon 
as possible in order to preserve their foreign prior­
ity date. It should be noted that under U.S. law, 
establishing a foreign priority date does not neces­
sarily guarantee a specified period of time for filing 
in the United States. Still, as members of the Paris 
Convention, patent applicants in Convention 
member-nations have up to 12 months to apply 
for patent protection in the United States in order 
to preserve an international priority date. 
2. Avoid statutory bars 
Pursuant to 35 U.S.C. § 102(b), if an invention is 
published anywhere in the world more than one 
year before a U.S. patent application for that in­
vention is filed, the publication will act as a statu­
tory bar to obtaining a U.S. patent. This statutory 
bar is not limited to publications provided by an 
invention’s first inventor. If, for example, a second 
inventor independently conceives and publishes 
the invention more than one year before the first 
inventor files in the United States, the second in­
ventor’s publication will bar the first inventor from 
ever obtaining a U.S. patent on that invention. 
To illustrate, suppose inventor X, a German 
inventor, invents a novel widget on January 1, 
2005, and accordingly files a German patent ap­
plication describing the widget in April 2005. 
Independently, a French inventor, inventor Y, 
conceives of the same widget and publishes it on 
March 1, 2005 in a French publication. Under 
U.S. law, the German inventor may rely on his or 
her earlier invention date to predate the French 
publication date. However, if the German inven­
tor waits until after March 1, 2006 to file a U.S. 
application, the French publication will be deemed 
prior art under 35 U.S.C. § 102(b) and will bar the 
German inventor from obtaining a U.S. patent. 
To avoid this 102(b) U.S. statutory bar, the 
German inventor could file a U.S. utility pat­
ent application concurrently with, or even after, 
filing his or her German application. Pursuant 
to the Paris Convention, the German inventor 
would still have a period of one year after filing 
the German patent application to file a U.S. pat­
ent application. However, the utility patent appli­
cation option could be quite costly, particularly 
since the German application would have to be 
translated into English and include U.S.-style 
claims, drawings, and other formalities. 
As an alternative, if the German inventor was 
not prepared to incur such an expense, or if he or 
she preferred to further develop the widget be­
fore committing to the high costs of filing in the 
United States, he or she could simply file a U.S. 
provisional application. Since provisional applica­
tions are not required to be written in English or 
to include claims, drawings, or other formalities, 
the German inventor could simply file a copy of 
his or her German application in German as a 
U.S. provisional application. In this manner, the 
German inventor could preserve a U.S. filing date 
and avoid a § 102(b) statutory bar, all at a very 
reasonable cost. 
2. Preserve absolute novelty for foreign filings 
Most countries outside of the U.S. require abso­
lute novelty, which means that, as a prerequisite to 
receiving patent protection, a patent application 
must be filed before any public disclosure of that 
invention. In these absolute novelty countries, any
public disclosure of an invention prior to filing an 
application for patent acts as a bar to patentabil­
ity. As such, it is imperative for inventors seek­
ing foreign patent protection to preserve absolute 
novelty worldwide. Provisional applications may 
provide an easy, cost effective way to preserve ab­
solute novelty; however, this must be approached 
with caution, as adequate disclosure is required. 
There is still a general lack of consensus about 
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CRuZ 
how courts in various foreign jurisdictions will 
regard a U.S. provisional application as a basis for 
priority. Even so, if an inventor wished to pub­
licly disclose an invention as part of a presenta­
tion, the inventor could preserve absolute novelty 
by filing a copy of all of the presentation and 
handout materials as a provisional application. In 
this manner, the inventor could both preserve a 
U.S. filing date and preserve absolute novelty in 
Paris Convention nations, or in nations that have 
acceded to the WTO (as the TRIPS Agreement 
[Trade-Related Aspects of Intellectual Property 
Rights]) incorporates the Paris Convention). This 
includes the majority of the world’s nations. 
2. Patent pending 
Once a provisional application is filed, an inventor 
is permitted to apply the phrase “Patent Pending” 
to products embodying the invention. Use of this 
phrase indicates to the public that the marked 
product or products is or are believed to be inven­
tive and that any and all available patent rights 
in the invention are being pursued. Application 
of the phrase also enables the immediate com­
mercial promotion of an invention with less risk 
of having the invention copied and/or stolen. In 
addition, a “Patent Pending” notice gives official 
notice to competitors and potential infringers, 
which may be particularly useful in establishing 
a patent infringement claim once the invention 
is formally patented. It should be noted that the 
phrase “Patent Pending” does not give rise to en­
forceable patent rights. It is only after a patent is 
issued that enforceable patent rights attach. 
3. lIMITATIONS OF A PROVISIONAl 
APPlICATION 
Aside from the many advantages described above, 
there are several limitations and disadvantages as­
sociated with filing provisional applications. 
.1 Increased overall cost 
Although provisional applications are typically 
less expensive to prepare and file than utility pat­
ent applications, there are costs associated with 
the same. Filing a provisional application first, 
and then filing a corresponding utility application 
will always increase the overall cost of obtaining 
a patent. This is especially true when multiple 
provisional applications are filed to cover various 
aspects of an invention. 
.2 Disclosure of invention 
Although provisional applications do not have all 
of the formal requirements of utility patent appli­
cations, provisional applications must nonetheless 
meet the disclosure and enablement requirements 
of utility patent applications. That is, provisional 
applications must include a complete, adequate 
disclosure of an invention, a disclosure of the best 
mode of the invention, and any drawings nec­
essary for understanding and/or recreating the 
described invention. If a provisional application 
cannot adequately support the entirety of a cor­
responding utility application, then only those 
aspects that are adequately supported in the pro­
visional application will be entitled to the provi­
sional application’s priority date. All other aspects 
of the utility application will have a priority date 
corresponding to the filing date of the utility ap­
plication. In this regard, preparing a provisional 
application to fully support a later filed utility ap­
plication may be as time consuming and as costly 
as preparing a utility application. 
. Potential loss of trade secrets 
Another concern relating to provisional applica­
tions is the potential lose of trade secrets. As ex­
plained above, although provisional applications 
do not have all of the formal requirements of 
utility patent applications, they must nonetheless 
adequately disclose and enable inventions. In at­
tempting to satisfy these requirements, inventors 
may disclose too much information, including in­
formation they might later wish to retain as a trade 
secret. Once a provisional application is filed, all
information disclosed will be incorporated into a 
later filed corresponding utility application. When 
the utility application becomes a patent, the entire 
provisional application will become public, and 
any potential trade secrets it contains may be lost. 
. One-year filing deadline 
Once a provisional application is filed, an in­
ventor must file a utility application claiming 
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priority to the provisional application within one 
year. Failure to file a utility application within the 
one-year period will result in the provisional ap­
plication automatically being abandoned, which 
may prevent the inventor from ever patenting the 
invention. 
. False sense of security 
Filing a provisional application may give an in­
ventor a false sense of security. Although filing a 
patent application does provide some protections, 
it does not provide any enforceable patent rights. 
Furthermore, provisional applications never ma­
ture into patents. If an inventor falsely believes he 
or she is adequately protected by a provisional ap­
plication, he or she may delay filing a utility ap­
plication. And if an inventor fails to file a utility 
application during the one-year period, the pro­
visional application will automatically be aban­
doned thereby preventing the inventor from ever 
patenting the invention. 
. Other potential limitations 
There are other limitations to filing provisional 
patent applications. For example, since filing a 
provisional application delays the filing of a util­
ity patent application, any patent that may ulti­
mately issue may also be delayed. Depending on 
the inventor’s (or patent owner’s) patent strategy, 
such a delay may not be desirable. 
It is important to note that both provisional 
and utility patent applications trigger the time line 
forfilingapplicationsunder thePatentCooperation 
Treaty (PCT) and the Paris Convention. Since in­
ternational patent applications must be filed within 
one year of a U.S. filing, the high costs of inter­
national filing will be incurred within one year of 
filing a provisional application. 
Provisional applications may not be amend­
ed. If certain aspects of an invention are devel­
oped or changed after a provisional application 
has been filed, an inventor will be required to file 
another application to reflect these developments 
or changes. 
Similarly, if an inventor accidentally discloses 
secret information in a provisional application, 
the inventor will be precluded from going back 
and amending the provisional application to re­
move the secret information. In this scenario, the 
inventor would have the option of abandoning 
the provisional application and possibly hav­
ing the option of filing another provisional ap­
plication that excludes the secret materials. This 
would, however, reset the priority date. 
4. CONCluSION 
Provisional applications provide numerous ad­
vantages for both domestic and foreign inventors, 
which is why they are widely used and are often 
integral to successful patent strategies. There are 
also, however, certain risks and limitations associ­
ated with provisional applications, so filing provi­
sional applications may not always be desirable or 
appropriate. Accordingly, before deciding wheth­
er to file a provisional application, care must be 
taken to properly assess: 
• 	 the nature of the invention(s) 








RICHARd L. CRUZ, Intellectual Property Attorney, DLA Piper 
US LLP, 1650 Market St., Suite 4900, Philadelphia, PA, 
19103, U.S.A. richard.cruz@dlapiper.com 
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Designing Patent Applications 

for Possible Field-of-Use Licensing
 
aRne M. olson, Director, Olson & Hierl, Ltd., U.S.A 
ABSTRACT 
Patent applications should be organized and drafted with 
a long-term objective that carefully considers the multiple 
possibilities, and opportunities, of field-of-use licensing. 
This is particularly the case in the agricultural, pharmaceu­
tical, biochemical, and chemical disciplines, as inventions 
can have multiple applications that are sometimes impos­
sible to foresee. Technology managers must, therefore, fo­
cus strategically, not only on the basic idea of an invention 
but broadly, in order to consider the various ways such an 
invention might be put into more widespread and more 
profitable use. Therefore, the more details, examples and 
alternatives that are thought through and then disclosed in 
the patent application, the greater the opportunity for fu­
ture divisional or continuation applications, as well as fu­
ture claims that can be exclusively (field-of-use) licensed. 
By making all of the institution’s licenses, in effect, field­
of-use licenses, the technology manager retains the ability 
to take a possible future use and license it to someone else, 
maximizing the benefits of the inventions and generating 
higher royalties for the institution. 
1. InTRoduCTIon 
The life of a technology transfer administrator is 
not an easy one. With tight budgets, the more that 
a university can make from its licensing program, 
the better. One of the great benefits of field-of-use 
licensing is that it allows a licensor to license the 
same patent or related patents to different parties 
in different fields, thereby maximizing the in­
come stream from patent royalties. For example, 
part of a biotechnology invention could be used 
to make diagnostic tests for a disease, while an­
other part of the same invention could be used to 
prepare pharmaceuticals to treat the disease. One 
company may have expertise in the sale and dis­
tribution of diagnostics while another company 
has all the resources to get U.S. Food and Drug 
Administration (FDA) approval for human phar­
maceuticals. Either of these companies could be 
licensed to cover both areas, but maximum sales 
and royalties would be obtained by having each 
company sell in its area of expertise. This chapter 
focuses on specific examples of field-of-use licens­
ing and discusses how a manager can aid in the 
development of well-written patent applications 
that support this licensing approach. 
It might be useful to consider making ev­
ery license a field-of-use license. Even though a 
particular invention suggests a single use that ap­
pears to perfectly fit a potential licensee, there is 
simply no way of knowing what other uses may 
develop over the life of a patent. A piece of con­
trol technology developed solely for automobile 
manufacturing may turn out to be useful for op­
erating a rocket system developed several years 
Olson AM. 2007. Designing Patent Applications for Possible Field-of-Use Licensing. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (First Edition, Part III: Chapter 3). 
© 2007. AM Olson. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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thereafter. Rather than simply licensing such a 
patent exclusively to a particular automaker, an 
inventor should consider licensing the patent to 
a particular automaker in the field of automobile 
manufacturing. When a particular field of use is 
properly licensed, other fields of use developed in 
the future would remain the property of the uni­
versity for later exploitation. 
2. THE	 vALuE	 of 	A	 quALITy 	AppLICATIon 
There are some basic concepts that can apply to 
all patent applications, not just those that are ap­
propriate for a potential field-of-use license. First, 
it is important to have a well-written patent ap­
plication. Far too many technology managers 
look at the cost of preparing and filing a patent 
application as opposed to the total cost of obtain­
ing a patent. It is not the cost of filing the applica­
tion that counts, but the total cost of getting the 
patent. Although cost alone is not a determining 
factor of a well-written application, a frugally pre­
pared patent application may contain mistakes or 
omissions and/or may not be sufficiently thought 
out to provide broad coverage or ideas for pos­
sible future expansion into other opportunities. 
These initial oversights could lead to expensive 
amendments, the necessity of filing continua­
tion applications, and even continuation-in-part 
applications to rewrite the application and thus, 
raising the overall cost of the application. 
2.1 The patent application as a sales document 
One benefit of a properly written patent applica­
tion is that it provides a far more useful sales doc­
ument than one that is poorly prepared. Often, a 
particularly new and valuable development does 
not yet have a licensee. Thus, a well-written pat­
ent application is important for convincing a po­
tential licensee that the invention is worth licens­
ing. Both the potential licensee and the patent 
examiner need to be confident of the value of the 
invention, but for different reasons. The patent 
examiner will look for “statutory” value—wheth­
er the invention sought to be patented is novel, 
useful, and non-obvious to one skilled in that 
art. The potential licensee, in addition to statu­
tory value, may seek value based on the potential 
commercial or humanitarian value of an inven­
tion. An application that is poorly constructed 
and includes typographical errors or scientific in­
consistencies will make a negative impression on 
a potential licensee and on a patent examiner. 
2.2 Allow for future coverage 
A well-written application will reflect consider­
ations of possible areas of future coverage, de­
scribing not only the basic idea developed in the 
lab, but also peripheral ideas and extrapolations. 
Including such information supports broad and 
valuable coverage in a patent. It suggests areas for 
future development that can be covered in more 
detail in continuation applications. Specifically, if 
these future ideas are at least sketched out in an 
application’s specification (that is, are adequately 
disclosed in the original application), there can 
be a basis upon which to reach back to the earli­
est filing (priority) date for subsequent claims and 
related amendments disclosed in the original par­
ent application. Thus, the institution would have 
the benefit of a filing date that will avoid what 
otherwise would be prior art. 
Coming up with alternative uses of an inven­
tion, or other ideas for development, should be a 
collaborative effort between the patent attorneys, 
the technology managers, and the inventors. 
Recognizing that managers often prefer to mini­
mize direct contact between inventors and the at­
torneys in order to keep costs down, this is one 
instance where direct communication can prove 
to be particularly useful and valuable, as even the 
best patent attorney cannot think of all of the al­
ternative uses of an invention or all the modifica­
tions or possible future uses of an invention. 
Such contact between the inventor and the 
attorney is critical for developing examples of ad­
aptations or permutations needed to provide for 
future field-of-use licensing. Prior to this com­
munication, the technology manager may wish 
to encourage the inventor to describe addition­
al alternatives or other possible future uses and 
simply forward these descriptions to the patent 
attorney. This exercise could begin the creative 
thought process—the “what if ” thinking—need­
ed to come up with other possible future uses. 
The more the inventor engages in this type of 
0 | HANDBOOK OF BEST PRACTICES 
         
	 	 	 	 	
 	
        
      
       
      
      
     
        
        
      
        
    
          
        
        
        
          
      
        
       
        
      
        
     
      
     
      
        
         
      
        
       
CHAPTER 10. 
thinking, the less time it will take for the patent 
attorney to consider and describe the potential of 
the invention. A monetary savings can sometimes 
be realized as well since it will take less time for 
the patent attorney to prepare the application. 
2. Retain control over the patent application 
All too often, a university will turn over the writ­
ing of the patent application and the control of 
the patent prosecution to the licensee. This creates 
an inherent conflict of interest and a potential for 
future litigation. (The conflict arises because a li­
censee may prefer relatively narrow patent protec­
tion to minimize the amount of royalties it might 
have to pay in the future.) In patent prosecution, 
decisions need to be made as to what level of pro­
tection to seek. Relatively narrow patent claims 
can often be obtained without too much diffi­
culty and expense. Broad coverage, however, may 
be far more important for a university because it 
would allow for future licensing and would cover 
more products to be sold by the licensee. While 
broad coverage may have been originally sought 
to cover a licensee’s future developments, if, dur­
ing patent prosecution, the claims are narrowed 
so that the licensee’s future developments are out­
side of those patent claims, the university could 
lose significant royalties. 
Specific to a potential field-of-use licensing 
situation, the patent application will have disclo­
sures and possibly claims to uses of the invention 
that are outside a particular licensee’s interest. 
That licensee would, of course, have no incentive 
to spend any time or money expanding on the 
concepts outside of its own interests. 
Where the university controls the patent 
prosecution, it has the ability to determine the 
breadth of the patent protection it wishes to seek 
and whether to dedicate resources to expand the 
patent coverage into other fields of use. When 
preparing the patent application, one should 
think of all possible uses of the invention, not 
just those of a present licensee. These do not have 
to be worked into all of the claims, but the dis­
closures should appear in the patent application. 
At some future time, should another potential li­
censee show interest in that area, a continuation 
(or possibly, a continuation-in-part) application 
can be filed, expanding on that particular aspect 
of the basic concept. Thus, the institution has the 
benefit of the earlier filing date, and a new ap­
plication can expand on and claim the particular 
new development. 
While the university should retain control 
over the patent application, it is still possible for 
the license agreement to have the licensee pay for 
the prosecution of the patent application. In the 
case of two licensees for the same patent, the pat­
ent expenses can be divided equally between the 
two licensees. This also is discussed in greater de­
tail in the preceding chapter. 
.	 STRuCTuRInG	 THE	 
pATEnT	AppLICATIon 
In structuring the patent application, it is best to 
incorporate as many alternatives as possible for 
future expansion. Doing so can have two direct 
effects: (1) the application will support broader 
claims than might otherwise be possible—this can 
be particularly important in the biotechnology 
and chemical areas, where it is often necessary to 
give more than a simple example to support broad 
claims in the patent application—and, (2) having 
ideas for future uses in the application allows for 
continuation applications to these developments. 
This is a version of the “throw in the kitchen sink” 
approach. It is difficult to predict what will have 
future value, and it may not be worth having 
claims for ideas for potential uses in the applica­
tion, but it is worth having at least a sentence or 
paragraph about a possible alternative. Two or 
three pages of a patent application can include a 
great many of these “sleeper” inventions that can 
remain dormant and be brought to life when they 
are found to have a particular value. 
This is not a new idea. The 1876 Alexander 
Graham Bell patent titled Telegraphy describes 
Bell’s invention as a multiple telegraph using 
different frequencies of sound to simultaneous­
ly transmit several telegraph messages over the 
same wire. A reference is made toward the end 
of the patent that the invention can be used to 
transmit sounds and, if certain modifications are 
made, even the human voice. The value of this 
last extrapolation can be seen by the number 
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of infringement lawsuits referred to as “The 
Telephone Cases.” 
The claims of the patent application can also 
be structured for field-of-use licensing. There can 
be broad claims to the general overall concept 
that are licensed to more than one party on a 
field-of-use basis; there can also be narrow claims 
directed to specific fields of use that are licensed 
only to a particular licensee. The narrow claims 
can be written to define the field of use, for ex­
ample, the use of the invention as a diagnostic 
for a particular disease in farm animals; another 
narrow claim could define the use as a similar di­
agnostic for humans. Future continuation or di­
visional applications could have claims directed 
to other specific fields of use. 
The approach described here has the benefit 
of providing specific claims or specific patents that 
can be exclusively licensed to a particular licensee. 
Generally, licensees prefer to have an exclusive li­
cense, even if it is only for a specific claim or a spe­
cific patent. In addition, defining specific narrow 
claims for different licensees can provide a mecha­
nism for allocating the reimbursement cost of 
prosecuting the patent applications as well as for 
determining which licensee will be responsible for 
or involved with suing a potential infringer. For 
example, the license agreements can be structured 
such that if a patent claim exclusively licensed to a 
particular licensee is infringed, then that licensee 
is required to take part in the infringement liti­
gation. If different claims exclusively licensed to 
separate licensees are infringed, then both licens­
ees would be involved in the litigation. The idea is 
that if each licensee’s exclusive “turf” is invaded, 
they would want to be involved. Separate patents 
for exclusive licensing to different licensees can 
arise as a result of restriction requirements. This 
issue is discussed in more detail below. 
.1 Biotechnology example 
One of the wonders of biotechnology is the discov­
ery that genetic information can be used to code 
for proteins or parts of proteins. For example, it 
has been found that relatively short lengths of 
polypeptides can be used to form vaccines. Prior 
to this discovery, vaccines had been made from 
proteins obtained from dead or weakened viruses. 
By way of a fictional example, a scientist has 
discovered the gene coding for one of the envelope 
proteins of “RBS” virus. Suppose the RBS virus 
has only recently begun to infect the human pop­
ulation and some of its potential effects include 
a revival of a previously conquered illness. The 
scientist has also discovered that a 20-amino acid 
residue polypeptide which is named “Merkin” and 
which can serve as a vaccine against the dreaded 
RBS. In addition, the scientist has found that 
when the Merkin polypeptide is injected into 
animals, the animals exhibit an immune response 
and begin producing harvestable antibodies that 
react with RBS virus in a sample. The scientist has 
also recently successfully created a monoclonal cell 
line that produces antibodies to RBS. 
These anti-Merkin antibodies are particularly 
valuable because they have a high affinity for the 
RBS virus and, at least in the lab, protect precious 
bodily fluids from infection. Therefore, a possible 
use of the antibodies would be to create a direct 
treatment for an RBS virus infection: the anti­
body would be collected and then injected into 
the patient as a form of treatment. 
Another use for the Merkin polypeptide is 
in an assay to detect the presence of anti-RBS 
antibodies in human blood serum. It was found 
that using the antibody as a means to detect RBS 
was not successful because the RBS virus does 
not generally appear in a high concentration 
in blood. However, when the Merkin polypep­
tide was used, it reacted with antibodies in the 
patient’s blood and other precious bodily fluids 
to indicate whether there had been antibodies 
produced to fight the RBS virus, now present in 
the blood. One type of HIV assay system works 
similarly. It does not detect the presence of HIV 
itself, but rather it detects the presence of HIV 
antibodies in the patient’s blood. The success of 
the test depends on the assumption that if HIV 
antibodies are in the patient’s blood, the patient 
has been exposed to or infected by HIV. 
Thus, it appears as though the Merkin poly­
peptide has at least two immediate uses. The first 
is as part of an assay system to check for an RBS 
virus infection, and the second is for future de­
velopment as a vaccine. The antibodies that have 
been developed appear to have possible uses for a 
0 | HANDBOOK OF BEST PRACTICES 
         












       
       
       
       
       
       
        
      
        
    
       
        
       
      
     
      









future assay as well as possible future therapeutic 
value. 
A potential licensee, Assay Specialists, Inc. 
(ASI) has shown particular interest in the use of 
the Merkin polypeptide for conducting diagnos­
tic assays. ASI is a large company that has a great 
deal of experience in assays of this type, although 
it has little to no experience in therapeutic treat­
ments and vaccines. Another company, Vaccinia, 
has indicated an interest in possibly developing a 
vaccine and therapeutic treatment. At this point, 
Vaccinia’s interest is lukewarm, because prelimi­
nary studies of using a vaccine on animals are still 
being conducted. 
Based on this, therefore, a properly prepared 
patent application could cover the following 
inventions: 
1.	 The gene used to make the envelope 
protein. 
2.	 The purified envelope protein. 
3.	 The part of the gene that codes for the 
Merkin polypeptide. 
4.	 The Merkin polypeptide. 
5.	 A vaccine based on the Merkin 
polypeptide. 
6.	 Antibodies to the Merkin polypeptide. 
7.	 The monoclonal cell line. 
8.	 Diagnostic products based on the Merkin 
polypeptide or its antibodies. 
9.	 A therapeutic treatment based on the 
antibodies. 
10. A cure for the recurring illness. 
A field-of-use license can be granted now to 
ASI directed to diagnostic products. This would 
be a non-exclusive but field-of-use license to the 
claims directed to the Merkin polypeptide gen­
erally (4) and an exclusive license (meaning that 
ASI will be the only licensee) for those claims that 
are specifically directed to the use of the Merkin 
polypeptide for diagnostics (8). There can also be 
a non-exclusive license for the use of the part of 
the gene that codes for the Merkin polypeptide 
(3) so that ASI can also make the polypeptide, 
using DNA cloning techniques. This results in a 
licensee signed up in the initial stages and pro­
vides a source of revenue to support the patent 
application(s) and further research. 
As matters progress and Vaccinia becomes 
more interested, a non-exclusive but field-of-use 
license can be granted to Vaccinia on (3) and (4). 
Vaccinia would be the only licensee for the vac­
cine based on Merkin (5). At some future date, 
if there is a revival of the previously conquered 
illness in epidemic proportions, there may be an­
other potential licensee and, therefore, justifica­
tion for a divisional patent application directed to 
a cure for the recurring illness (10). 
.2	 Chemical example 
Dr. Lovejoy has discovered a highly toxic com­
pound that he has named oxymoronic acid. This 
compound is very useful in treating certain men­
tal disorders. The only known source of oxymo­
ronic acid is certain mutant desert bushes that 
grow only in the area surrounding nuclear test 
sites. The elimination of open air testing of nu­
clear weapons, however, has put great restrictions 
on the number of mutant plants available. All at­
tempts to cultivate oxymoronic-producing plants 
have thus far been unsuccessful, but Dr. Lovejoy 
has recently found a way of synthesizing a pre­
cursor of oxymoronic acid that he has named 
protomoronic acid that can be manipulated to 
form oxymoronic acid. Through this synthesis 
scheme, it is possible to produce oxymoronic 
acid in the quantities needed for medical treat­
ment purposes. 
Through encouragement by the technology 
manager and the patent attorney, Dr. Lovejoy 
has worked out alternative synthesis schemes for 
other possible precursors of oxymoronic acid, one 
of which is called “AP.” While these schemes have 
not been fully tested, they appear to provide oth­
er ways of making oxymoronic acid synthetically 
and thus may prove to have value in the future. 
A patent application is prepared having claims in 
the following areas: 
1. Oxymoronic acid in a purified form as a 
pharmaceutical. 
2. The precursor, protomoronic acid. 
3. Various alternative 	 precursors, including 
AP. 
4. The methods of making oxymoronic acid 
using the various precursors. 
5. A rat poison based on oxymoronic acid. 
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The last category listed above was a gratu­
itous discovery when one of Dr. Lovejoy’s gradu­
ate students, who had a laboratory in a less than 
desirable location, dropped some oxymoronic 
acid on the floor and it was sampled by one of the 
visiting rodents. It was discovered that it made an 
extremely effective rat poison. 
Because this discovery was fortuitously made 
and was not considered to have any immediate 
commercial value, the idea of using oxymoronic 
acid as a rat poison was put in as a sentence or 
two in the patent application. This did not cost 
anything, but it left open the possibility of future 
options. Some years later, while one of the patent 
applications was still pending, a major pesticide 
company came to the university asking for a li­
cense to further develop this rat poison. Because 
a divisional application was still pending, it was 
possible to file a continuation (or a continua-
tion-in-part) application having claims directed 
to the use of oxymoronic acid as a rat poison and 
thereby grant the pesticide company an exclusive 
license in the field of using oxymoronic acid as a 
rat poison. In such a case, the graduate student 
could likely be a co-inventor (as opposed to the 
rat who actually made the discovery but did not 
live to tell about it). 
An exclusive field-of-use license in the medi­
cal area was granted for (1), the pharmaceutical, 
above. Later it was found that AP had particular 
usefulness as an adhesive and was licensed to a 
bumper sticker company because no exclusive li­
cense had been granted for (3) above. 
.	 RESTRICTIon 	REquIREMEnTS	
AS	 oppoRTunITIES 
It is quite likely that a patent examiner review­
ing a patent application directed to the above ex­
amples would take the position that there is more 
than one invention present in a given application 
(in some jurisdictions referred to a lack of unity 
of invention). For example, the examiner may 
say that the gene is one invention, the polypep­
tide is a second invention, the diagnostics are a 
third invention, the vaccine is a fourth invention, 
etc. When this is the case, the patent application 
is “restricted” to only one invention, and then 
one, or possibly more, divisional patent applica­
tions are carved out of the original parent patent 
application. 
The typical reaction to this is annoyance. 
After all, what has been filed as one patent appli­
cation will now be split up into four and perhaps 
as many as ten parts. However, one should not 
necessarily complain, as there might be a silver 
lining in this gray cloud. This situation, albeit 
initially annoying, can often be done relatively 
simply, and present new opportunities. 
Since the U.S. Patent and Trademark Office 
has taken the position that there are separate in­
ventions in the patent application, these inven­
tions can be prosecuted as separate applications. 
Thus, one can continue to prosecute the claims 
directed to the diagnostics until those are allowed. 
The diagnostic patent issues, and that patent can 
be exclusively licensed to ASI. Meanwhile, a se­
ries of other patents may be obtained from the 
same core invention (the parent application) via a 
series of divisional patent applications arising out 
of the restriction requirement. Each patent can 
be directed to a different field of use and licensed 
separately. Furthermore, depending on the cir­
cumstances of each application, there might be 
opportunities for patent term extensions due to 
delays in the patent office, certain administrative 
proceedings (for example, successful appeals), or 
for regulated medical products to compensate for 
regulatory delays. Thus, a restriction requirement, 
when strategically managed, can become an un­
expected series of opportunities. 
.	 ConCLuSIon 
The main point presented in this chapter is to 
encourage creative thinking when preparing pat­
ent applications. The technology manager should 
focus not only on the basic idea, but should also 
encourage inventors to think broadly regarding 
all the various ways their invention might be put 
into use. When the patent application is filed, 
there is no way of knowing every possible use of 
the invention. Thus, the more invention ideas 
that can be put into the patent application, the 
more support there is for future divisional or con­
tinuation applications, or future claims that can 
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be exclusively licensed. By making all of the in­
stitution’s licenses, in effect, field-of-use licenses, 
the technology manager has retained the ability 
to take one of these possible future uses and li­
cense it to someone else, maximizing the benefits 
of the inventions and generating higher royalties 
for the institution. n 
aRne M. olson, Director, Olson & Hierl Ltd., 20 North 
Wacker Drive, 36th Floor, Chicago, IL, 60606, U.S.A.
aolson@olsonhierl.com
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CHAPTER 10.4 
Patenting Strategies: Building an IP Fortress
 
JOHN dOddS, Founder, Dodds & Associates, U.S.A. 
ABSTRACT 
A comprehensive intellectual property (IP) portfolio can 
be of substantial value to both private and public sector 
entities. Patents are a key element of IP portfolios and 
must be managed according to the mission, objectives, 
and motivations of the organization that owns them. 
Large companies can afford an offensive patent strategy, 
but small companies may not have the resources for this. 
Therefore, it is extremely important for private sector 
entities, especially small- and middle-sized companies, 
to design and implement an effective and cost-efficient 
strategy for patent management. For public sector enti­
ties, patent strategies will focus on advancing social wel­
fare, and the mission of the institution will therefore drive 
objectives. A key factor to consider is the method of IP 
protection: patent, trademark, copyright, or trade secret. 
The costs of maintaining each of these IP categories are 
different. Although research institutes and companies 
will likely wish to reduce costs as much as possible, key 
technologies still need to be protected properly. A com­
pany can reduce costs by focusing the patent protection 
on those geographic areas where it has business. A uni­
versity can reduce costs by selectively prosecuting patent 
applications with broad claim structures, strategically li­
censing technologies, and enforcing patent rights if and 
when necessary. To build a strong basis of protection, 
several forms of IP may be used for the same invention 
or improvement. 
1. INTRODuCTION 
Historically, a patent was a grant made by a sover­
eign that would allow for the monopoly of a par­
ticular industry, service, or product. Over time, 
the concept has been refined and now stipulates 
a contract or compact between the government 
and the inventor/creator. In return for the right 
to exclude others from the practice of the inven­
tion, the government requests that the inventor 
fully disclose the enablement of the invention. 
Additionally, the monopoly is now limited by 
time and is only applicable in the territory under 
the jurisdiction of the government that granted 
the patent. 
In the United States, a patent is a fundamen­
tal right provided in Article I, Section 8 of the 
Constitution. Congress is empowered to “promote 
the progress of science and useful arts by securing for 
limited times to authors and inventors the exclusive 
right to their respective writings and discoveries.” 
In exchange for a right to exclude others from 
making, using, or selling the potential invention, 
the inventor must provide a complete and accu­
rate public description of the invention and the 
best mode of practicing it. This disclosure of in­
formation by the inventor allows others to invent 
further, thus pushing technology forward for the 
benefit of society. 
Congress has given the U.S. Patent and 
Trademark Office (PTO) the authority to grant 
an inventor the right to exclude all others from 
exploiting the invention in the United States for 
a period of 20 years, or for design patents, up to 
14 years, from the date of filing a patent applica­
tion with the PTO. This right to exclude makes a 
Dodds J. 2007. Patenting Strategies: Building an IP Fortress. In Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis,
U.S.A. Available online at www.ipHandbook.org. 
© 2007. J Dodds. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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patent a negative right, since a patent holder may 
only exclude others from using, manufacturing, 
copying, or selling his or her invention. 
Patents are territorial. For example, a U.S. 
patent generally has no force in other countries, 
just as a patent granted outside the United States 
has no force in the United States. However, prod­
ucts sold in the United States, even if they are 
made outside the patent domain, may infringe a 
U.S. patent. Procedures for filing, regulations for 
patentability, and patent terms vary considerably 
from country to country. 
The United States is the only country in the 
world that awards its patents using a first-to-in­
vent approach; all other countries have a first-to­
file approach. The first-to-invent approach has led 
to the development of patent interference prac­
tice, a quasi-litigation conducted within the PTO 
to determine the issue of priority, or who made 
the invention first. 
Another important difference between the 
U.S. system and the system adopted in many oth­
er countries, for example European countries, is 
the one-year grace period awarded in the United 
States. This means that an invention is patentable 
if it has not been published or otherwise brought 
into public awareness earlier than one year from 
filing the patent application. 
Patents are relatively complex documents to 
prepare and submit, and the time and expense 
in obtaining such protection can be substantial. 
Given the legal complexity and the costs in­
volved, it is important for the inventor to develop 
a coherent strategy with which to approach the 
patenting process. 
2. DEFINITIONS 
•	 design patent. A drawing or depiction of 
an original plan or conception for a novel 
pattern, model, shape, or configuration to 
be used in the manufacturing, textile, or 
fine arts, and chiefly of a decorative or or­
namental character. Design patents are is­
sued for a period of 14 years. 
•	 monopoly. A privilege or peculiar advan­
tage vested in one or more persons or com­
panies, consisting of the exclusive right or 
power to carry on a particular business or 
trade, to manufacture a particular article, 
or to control the sale of the whole supply 
of a particular commodity. Monopoly is a 
form of market structure in which one or 
only a few firms dominate the total sales of 
a product or service. 
•	 nonprovisional patent application. A 
patent that is filed with the PTO includes a 
written document that comprises a specifi­
cation (including a description and at least 
one claim), an oath or declaration, and, 
when necessary, one or more drawings. 
•	 patent. A grant or right to exclude others 
from making, using, selling, or offering to 
sell one’s invention and a right to license 
others to sell, make, use, or offer to sell that 
invention. 
•	 plant patent. A patent granted to an in­
ventor who has invented or discovered and 
asexually reproduced a distinct and new va­
riety of plant. (Plant patents are not issued 
for tuber-propagated plants or for plants 
found in an uncultivated state.) Plant pat­
ents are issued for 20 years. 
•	 plant variety protection. Protection for 
sexually reproduced (by seeds) or tuber-
propagated plants. Registration of Plant 
Varieties is administered by the U.S. 
Department of Agriculture. 
•	 provisional patent application. An inex­
pensive first patent application that allows 
filing without a formal patent claim. It 
provides means to establish an early filing 
date. Provisional patent applications expire 
12 months after filing. Before this, the in­
ventor has to file a nonprovisional patent 
application in order to protect his or her 
invention. 
3. TyPES OF PATENTS 
There are three types of patents: 
1. A 	design patent protects a new, original, 
and ornamental design for an article of 
manufacture. 
2. A plant patent protects a new and distinct, 
asexually reproduced variety of plant.
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Tuber propagated plants are excluded from 
plant patents. 
3. A utility patent is granted for any new and 
useful process, machine, manufacture, or 
composition of matter or for any new or 
useful improvement thereof. Most impor­
tantly, the invention has to be useful. A 
utility patent is the type of patent most 
people are familiar with. An application for 
a utility patent can be of either the provi­
sional or nonprovisional type. 
.1 Design patents 
A design patent protects the look of an article. 
In order to be patentable, the design or the look 
has to be original. One cannot, for example, get 
a design patent for a vase that is in the shape 
of Mickey Mouse, as this image is already pat­
ented and not original. A design patent might 
be granted, however, to a vase having a different 
mouse-shape. 
A design patent application should include 
the following elements: 
•	 title of the design 
•	 brief description of the nature and intend­
ed use of the article in which the design is 
embodied 
•	 drawings or photographs 
•	 description of the drawings or photographs 
•	 a single claim 
•	 an oath or declaration 
A design patent may have only one claim that 
covers the whole design. The following shows an 
example of a typical claim: “The ornamental de­
sign for a vase as shown (and described).” 
It is possible to file a utility patent for a new 
and original way an article is functioning and also 
file a design patent for the original design of the 
same article. 
.2 Plant patents 
A plant patent may be granted on an entire plant 
if it is a new and distinct variety and it is asexu­
ally propagated. Asexually propagated plants are 
those that are reproduced by means other than 
from seeds, such as by the rooting of cuttings, 
by layering, budding, grafting, or inarching. 
However, tuber-propagated plants are excluded 
from plant patents. 
An application for a plant patent consists of 
the following elements: 
•	 title, which must include the name of the 
claimed plant. The following shows an ex­
ample of the form of a typical title: Birch 
tree named “Renci.” 
•	 specification, which includes a description 
and one claim 
•	 one or more drawings or photographs 
•	 an oath or declaration 
The specification should include a complete 
detailed description of the plant. Characteristics 
that distinguish the claimed plant from related, 
known varieties should be described comprehen­
sively. The specification should also include the 
origin or parentage of the plant variety and must 
point out where and how the variety has been 
asexually reproduced. If the plant variety origi­
nated as a newly found seedling, the specification 
must fully describe the conditions under which 
the seedling was found growing. 
A plant patent is granted on the entire plant. 
Therefore, only one claim is permitted. The fol­
lowing is an example of a typical plant patent 
claim: “A new and distinct cultivar of a birch tree 
named ‘Renci,’ as illustrated and described.” 
The drawing must disclose all the distinctive 
characteristics of the plant capable of visual rep­
resentation. When color is a distinguishing char­
acteristic of the new variety, the drawing must be 
in color. As an alternative, a photograph may ac­
company the application. 
If the plant is a newly found plant, the oath 
or declaration must also state that the plant was 
found in a cultivated area. 
. Utility patents 
A utility patent can be issued for any new and 
useful process, machine, manufacture, or compo­
sition of matter. In order to be patentable, the 
invention has to be new, useful, and nonobvious. 
A patent cannot be obtained for pure ideas or 
theories, no matter how useful the theory might 
be. In addition to plant patents, utility patents 
can be issued for some types of plants, for exam-
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ple, transgenic plants. This is because a transgenic 
plant, if new and useful, may be regarded as a 
composition of matter or manufacture. 
An application for a utility patent requires 
the same elements as are required for a design 
patent application. 
..1 Nonprovisional application 
A nonprovisional (utility) patent application has 
to include the following parts: 
• title 
• specification, which includes a description 
and at least one claim
 
• one or more drawings
 
• an oath or declaration 
The description should be written in such a 
way that any person skilled in the field to which 
the invention pertains can make and use the 
invention. 
In a nonprovisional patent application, there 
must be at least one claim. The scope of the 
protection of the patent is defined based on the 
claims. Whether a patent will be granted is also 
largely decided by the choice of the claim. The 
optimal claim is one that is wide enough to cover 
as much as possible without overlapping anything 
that was already known. 
..2 Provisional application 
A provisional patent application is a lower cost, 
initial patent application that does not have to 
include any claims, oaths, or declarations. A pro­
visional patent application has a pendency of 12 
months from the date of its filing. A provisional 
patent application cannot mature to an issued 
patent, but it gives the inventor an early filing 
date and use of the term patent pending. In order 
to benefit from the early filing date of the pro­
visional application, a nonprovisional patent ap­
plication has to be filed before the end of the 12 
months pendency of the provisional application. 
4. PATENT HARMONIzATION 
A patent is valid and effective only in the country 
in which it is issued. Trade, however, is global, and 
thus it is important to have patent protection in 
more than one country. But because every coun­
try has its own laws and regulations for patenting, 
obtaining protection in multiple locations is rare­
ly simple or cheap. To ameliorate this situation, a 
great deal of effort has been spent, for more than 
100 years, to try to harmonize patentability stan­
dards across countries. 
The Patent Cooperation Treaty (PCT) is an 
international treaty harmonizing patent appli­
cation procedures across 117 countries. PCT is 
administered by the World Intellectual Property 
Organization (WIPO). With one PCT patent 
application, an inventor can get a filing date in 
all member countries. Eighteen months after the 
filing, the applicant has to decide in which of the 
member countries he or she actually wants and 
needs to have a patent. The benefit of a PCT ap­
plication is that there is no need to file separately 
in all countries, as the whole procedure can be 
accomplished in one application. Moreover, the 
PCT system gives the inventor 18 months time to 
shop around before deciding in which countries a 
patent would be most useful. 
All PCT applications will be published 18 
months from the filing, if not abandoned be­
fore that. This practice is generally in line with, 
although not precisely analogous to, that of the 
U.S. PTO. In the United States, the inventor may 
require a U.S. patent application not to be pub­
lished before issuance if the application is filed 
only in the United States. Nevertheless, the in­
vention may still be the subject of a PCT applica­
tion, with similar delay in publication, providing 
certain provisions are met. Specifically, pursuant 
to Article 64(3)(b) of the PCT, which articulates 
the U.S. Reservation, publication can be simi­
larly delayed. According to this article, if only 
the United States is designated, the international 
publication is postponed until after the issuance 
of the U.S. patent. Article 64(3)(b) of the PCT is 
therefore not inconsistent with the U.S. rule. 
5. REGIONAl PATENTS 
The creation of regional patent offices has 
helped to harmonize patent applications in dif­
ferent parts of the world. The European Patent 
Office (EPO) is the regional patent office serving 
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countries that are members of European Patent 
Convention (EPC). By filing a single application 
in one of the three official languages of the EPC
(English, French, German), it is possible to ob­
tain a patent in any or all of the 24 contracting 
countries. European patent applications can also 
be extended to some eastern European countries 
that are not parties to the contract. If a patent is 
granted by the EPO, then that patent must still 
be taken to each individual country and validated
there. 
Currently, there is major movement toward 
developing a community patent for the European 
Union. Once issued, a community patent would 
be enforced in all E.U.-counties without any vali­
dation requirement. Community patents would, 
however, require a centralized patent court sys­
tem, with specialized courts and a centralized ap­
peal court. 
Another effort at harmonizing patent ap­
plications involves participation by counties of 
the former Soviet Union in the Eurasian Patent 
Convention. By filing one application in Russian, 
a Eurasian patent may be granted in one or all 
of the contracting countries. Likewise, African 
countries in which English is spoken have estab­
lished the African Regional Intellectual Property 
Organization (ARIPO); African countries in 
which French is spoken have established the 
Organisation Africaine de la Propriete Intellectualle, 
or OAPI. 
6. FEES 
The fees charged by the U.S. PTO include filing 
fees, publication fees, issuing fees, and mainte­
nance fees. Updated information of the fees is 
available at the PTO’s Web site.1 
Maintenance fees on utility patents must be 
paid at 3½, 7½, and 11½ years after the date of 
issue of the patent, or it will expire. Once a patent 
expires, the invention is in the public domain and 
anyone may use it without authorization from the 
patent holder. 
The PTO gives a 50% reduction in most of 
the fees for organizations designated as “small 
entities.” Independent inventors, not-for-profit 
organizations, universities, and some small busi­
nesses will qualify as small entities. 
7.	 APPEAlS, INTERFERENCE, AND
OTHER PROCEDuRES 
The applicant can appeal the decision by a pat­
ent examiner to reject a patent application. In the 
United States, the Board of Appeals within the 
PTO hears the cases. If the applicant is dissatis­
fied with the decision of the Board of Appeals, he 
or she may appeal to the Court of Appeals for the 
Federal Court. 
A unique form of patent dispute is a prior­
ity dispute between two or more inventors claim­
ing to be the first to have developed an inven­
tion. These disputes are known as interference 
proceedings. 
Two types of post-issuance procedures are 
available in the United States. If someone believes 
there is a priority dispute that was not considered 
when the patent application was examined, that 
individual can ask for a reexamination of the pat­
ent. Anyone, including the patentee, can ask for 
reexamination. Often times, individuals accused 
of infringement use the reexamination procedure 
to question the validity of the patent. If the PTO 
finds the patent invalid in the reexamination 
process, there can be no grounds for claiming 
infringement. Reexamination procedures can be 
either ex parte or inter partes. In the ex parte reex­
amination process, the third party, even if it was 
the requester, does not have a right to participate 
in the proceeding after filing the request, nor does 
the third party have a right to appeal the deci­
sion. The inter partes reexamination procedure 
was created in 1999 and can be applied only to 
patents issued on or after November 1999. Inter 
partes reexamination gives the third party a right 
to provide comments and present arguments 
during the procedure and a right to appeal to the 
Patent Office’s Board of Appeals. 
The second type of post-issuance procedure is 
a reissue. Only the patentee can seek a reissue and 
only in the case of an error being made without 
deceptive intent, in the claims or in disclosure of 
the original application. If the patentee seeks to 
broaden the original claims, the reissue has to be 
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filed no later than two years from the issuance of 
the patent. However, if the patentee seeks to nar­
row the claims, a reissue can be filed at any time. 
The PTO charges fees for each of these pro­
cedures, with reexamination fees being the high­
est. In addition to these fees, attorney fees will 
have be paid by the applicant. Attorney fees will 
probably be significantly higher than PTO fees. 
8. OTHER NONPATENT INTEllECTuAl 
PROPERTy ElEMENTS 
Intellectual property (IP), sometimes also called 
“intangible property,” is any product of the hu­
man mind or intellect. Thus, IP can be almost 
anything, including a technical invention or an 
improvement of an earlier invention. It can also be 
a unique name or logo, design, method, software, 
database, domain name, or piece of writing. 
The broad area of IP is subdivided into dif­
ferent legal classes that are protected by different 
means. Patents are not the only way to protect 
IP. Trademarks, copyrights, and trade secrets are 
used as well, and very often they form an impor­
tant part of an overall IP strategy. 
.1 Trademarks 
A trademark is a word, phrase, symbol, design, 
or combination of these that distinguishes the 
source of one’s goods or services from those of 
another. A trademark can be valid only when it is 
used on or in connection with goods or services 
in commerce. A trademark provides protection to 
the owner of the mark by ensuring the exclusive 
right to use it to identify goods or services or to 
authorize another to use it in return for payment. 
Trademark protection keeps others from applying 
similar marks to inferior or different products or 
services. 
Rights to a federally registered trademark can 
last indefinitely if the owner continues to use the 
mark on, or in connection with, the goods and/or 
services stipulated in the registration, as long as 
the owner renews the mark with the PTO every 
ten years. 
There are various types of marks that can be 
registered with the PTO. In addition to laying out 
the provisions for trademarks and service marks, 
the Trademark Act provides for registration of 
collective marks, membership marks, and certi­
fication marks. A domain name, such as yahoo. 
com, can qualify as a trademark or service mark if 
it is used in connection with a Web site that offers 
goods or services to the public. 
The basis for filing a trademark can be either 
actual use or intent to use. If the applicant files a 
trademark based on intent to use, she or he has 
to swear to a bona fide intent to use the mark 
in connection with the proposed products or ser­
vices. If the mark is not actually used within 30 
months of registering the mark, the registration, 
as related to that specific class,2 would be consid­
ered abandoned. 
.2 Geographical indications 
A geographical indication is a sign used on goods 
that have a specific geographical origin and pos­
sess qualities or a reputation that rely on that place 
of origin. Geographical indications are defined in 
the TRIPS Agreement (Trade-Related Aspects of 
Intellectual Property Rights) as a type of IP. The 
World Trade Organization (WTO) provides legal 
means for interested parties to prevent the use of 
a geographical indication that indicates or sug­
gests that a good originates in a geographical area 
other than its true place of origin. Geographical 
indications cannot mislead the public as to the 
true geographical origin of the good, nor can they 
constitute an act of unfair competition. 
Most commonly, a geographical indication 
includes the name of the place of origin of the 
good. Agricultural products typically have quali­
ties that derive from their place of production 
and are influenced by specific local factors, such 
as climate and soil. Examples of geographical in­
dications are Idaho for potatoes or Roquefort for a 
type of French cheese. 
Whether a sign functions as a geographical 
indication is a matter of national law and con­
sumer perception. The TRIPS Agreement does 
not require that a WTO member extend protec­
tion to a geographical indication if that geograph­
ical indication is the generic name of the good in 
that member country. Therefore, the word “cham­
pagne” is not registrable as a geographical indica­
tion in the United States because champagne is 
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CHAPTER 10. 
a generic term in the United States meaning any 
light-colored wine with bubbles. 
The United States offers robust protection 
for geographical indications, generally by regis­
tering the good with a certification mark, which 
is a type of trademark. 
. Trade secrets 
Trade secrets are an important and widely used 
business asset in the United States. Both large and 
small businesses rely on trade secret protection, 
often without even realizing it. It has been esti­
mated that 90% of inventions are protected by 
trade secrets. 
There are various kinds of trade secrets. The 
most famous example of a trade secret is the 
formula of Coca Cola, which has been kept se­
cret for over 100 years. In addition to chemical 
formulas or processing methods, trade secrets 
can consist of software, accounting records, cus­
tomer lists, and plant designs, among others. 
Although trade secrets may overlap with patent­
able subject matter, they go well beyond that. 
Even failed experiments can qualify as trade se­
crets; knowledge that a method does not work, 
in some cases, can give an individual or business 
a huge competitive edge. 
The generally accepted definition of a trade 
secret appears in the 1939 Restatement of Torts. 
The subject matter of a trade secret must be secret; 
as such, matters of public or general knowledge in 
an industry cannot be appropriated by anyone as 
a secret. Information that is completely disclosed 
by the goods that one markets cannot be consid­
ered a trade secret. By definition, a trade secret is 
known only to those in the particular business in 
which it is used. 
. Copyrights 
A copyright is a type of IP protection for authors 
of original works. A copyright protects an original 
work and allows the author an exclusive right to: 
•	 reproduce the work exclusively 
•	 prepare derivative works 
•	 distribute copies or records by sale, lease, or 
other type of ownership transfer 
•	 perform the work publicly 
•	 display the work 
In the Copyright Act there is, however, a 
fair-use exception that states that the use of an 
author’s original creation is authorized for the 
purposes of criticism, comment, news reporting, 
teaching, scholarship, or research. Fair use takes 
into consideration the purpose and character of 
the use, the nature of the copyrighted work, the 
amount and substance of the portion used in re­
lation to copyrighted work as a whole, and the 
effect of the use upon the potential market. 
Generally the categories of works that are 
protected are: 
•	 literary works 
•	 musical works, including words accompa­
nying music 
•	 dramatic works 
•	 pantomimes and choreographic works 
•	 pictorial graphic and sculptural works 
•	 motion pictures and other audiovisual 
works 
•	 sound recordings 
•	 architectural works 
The work has to be original and in a fixed 
medium. This means that the work has to be an 
independent creation of the author and it must 
exhibit some creativity. Being in a fixed medium 
means that the creation is in a tangible form: A 
short story is written down, a song is recorded, 
and so on. A pure idea or concept cannot be 
copyrighted without description or illustration. 
9. ASSEMBlING A STRATEGy 
The development of a coherent IP strategy in­
volves an analysis of three types of IP: self-de­
veloped, incoming, and outgoing. In order to 
develop a strategy to manage IP, an organization 
generally conducts a freedom-to-operate study 
or IP audit. Such an analysis inspects all patents, 
trademarks, copyrights, contracts, material trans­
fer agreements, know-how, and anything else 
that could be part of the intellectual capital of an 
organization. 
The first step in developing an IP strategy 
is to document the technologies that already 
exist in the organization, plus the technologies 
in development. The existing technology could 
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consist of trade secrets, know-how, patents, or 
combinations thereof. The most critical elements 
of the technologies are placed in a database. The 
database could, for example, contain the follow­
ing elements: issued patents, filing and expira­
tion dates of the patents, abstracts of technolo­
gies, first claims of patents, current and future 
potential of IP, existence of licenses, and so on. 
Each project of the company can be similarly 
documented. Data of issued and applied patents 
in each project should be documented; valuable 
trade secret and contracts should likewise be 
documented. 
When all the IP is documented in a database, 
consideration should be given to the merits of the 
documented technologies. Questions to be asked 
are, for example: 
•	 What stage is the technology in? 
•	 What is the novelty of the technology? 
•	 Is the technology in use? 
•	 Are outside licenses needed to develop the 
technology further? 
•	 Does a competitive technology exist? 
•	 Is the technology commercially launched? 
•	 Are capital requirements needed to launch 
the technology? 
•	 Are there environmental or regulatory is­
sues related to the technology? 
Depending on the organization, the answers 
to the above questions will have varying impor­
tance. For example, a university technology trans­
fer office might not care too much if the stage of 
the technology is at a pilot level or whether the 
patent has been issued. For an organization bas­
ing its business on in-house developed technol­
ogy, however, these issues are crucial. 
Patenting is expensive. Therefore, it is impor­
tant, especially for a small organization, to criti­
cally assess which technologies it needs to patent 
and where. Even if an invention is patentable, it 
might not always be the best solution to patent it. 
If, for example, an invention is difficult to reverse 
engineer, or if it would be easy to invent around a 
patented technology, then keeping the invention 
as a trade secret might be more beneficial. Also, 
patenting might not be an effective tool if it would 
be difficult to ensure that no one is infringing on 
the patent. If an organization developed a patent­
able method for transforming a plant species, for 
example, it would be very difficult to ensure that 
no one was infringing on that method, and thus 
patenting would be largely ineffective. 
The organization should also analyze where 
it will need the protection. There might not be a 
need to keep a patent valid all over the world if 
the technology is used only in the United States, 
or if the only prospective market is in Germany. 
In these cases, it would be advisable to apply for 
patents only in the relevant countries. 
It is also important to get accurate knowl­
edge of the IP rights of competitors in your field. 
Knowing the IP rights of other organizations in 
your field will help you identify where your or­
ganization has a distinct competitive advantage, 
and will enable you to identify and eliminate 
costs of any out-of-date IP. By knowing your 
own IP, you can identify under-utilized IP that 
could potentially be sold or licensed out; know­
ing other people’s IP could help you to avoid 
costly infringements suits. Finally, knowing your 
IP gives you a road map to create a successful 
R&D strategy. 
Finally, an organization can choose an offen­
sive or a defensive patent strategy. This depends 
a great deal on the size of the company, but also 
on the demands of the particular industry within 
which the company operates. 
.1 Offensive patent strategy 
An offensive patent strategy is designed to build 
barriers to block competitors from gaining entry 
to your proprietary technologies. Using an offen­
sive patent strategy means filing patents as soon 
as is practicably possible. Filing a large number 
of patent applications and later maintaining the 
issued patents is expensive; on the other hand, an 
offensive patent strategy may derive large licens­
ing incomes. 
Given the expense, an offensive patent strat­
egy is often available only to large organizations, 
since small companies generally cannot afford the 
costs of filing and maintaining patents. Beyond 
size, an offensive patent strategy is more impor­
tant for companies operating in very competitive 
fields. 
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CHAPTER 10. 
.2	 Defensive patent strategy 
Using a defensive patent strategy, a company files 
patents primarily to ensure that innovations can 
be practically used. With a defensive strategy, fil­
ing and maintenance fees will be small, but the 
company will not gain royalties from licensing 
patents out. 
In addition to these two strategies (offensive 
and defensive) an organization can adopt some­
thing in between, depending on the field and the 
type of the technology it uses. A defensive patent 
strategy can be combined with a strong trade-
secret portfolio, or a large number of in-licensed 
technologies. An offensive patent strategy can be 
used to demonstrate innovations to industries 
and markets. 
. 	 Public and private sector strategies 
compared 
The public and private sectors by and large have 
different missions, objectives, and motivations. 
These, in turn, drive the overall patent strategies 
that each employs. 
Private sector organizations, primarily cor­
porations, are profit oriented and must aggres­
sively respond to the pressures imposed by the 
marketplace and shareholders who expect returns 
on their investments. Therefore, the private sector 
will use defensive and offensive patenting strate­
gies, often obtaining numerous patents contain­
ing narrowly drafted claims. In this way, a series of 
painstakingly prosecuted patent portfolios is stra­
tegically used to build proprietary fortifications. 
The private sector organization can thereby stake 
out its territory, protect its interests, and secure 
its profits. In the expanding world marketplace, 
this strategy is becoming more and more com­
mon; the use of foreign filing and patent families 
confirms the global strategic perspective of multi­
national companies. 
The public sector, on the other hand, has 
the very different mission of serving the greater 
public good. Additionally, for much of the pub­
lic sector, the perspective is primarily local: either 
national, or possibly regional. Patenting strategies 
will focus on more broadly drafted claims that 
will encompass a technology, or, more often, a 
key process, method, or technique (for example, a 
technique of genetic transformation). These types 
of patents, when strategically licensed, will en­
able effective development, broad dissemination, 
and maximum social usefulness of a technological 
advance. This is precisely in line with the public 
sector mission of providing for humanitarian in­
terests and the welfare of the general public, in 
contrast to the much more limited mission of the 
private sector. 
10. THE IP FORTRESS 
Building a strong base for IP protection will make 
it difficult for other people and companies to in­
fringe upon protected rights. One way to secure 
IP protection is to cover IP with various types of 
IP rights. 
Imagine that the IP of a particular U.S. 
company is a novel paintbrush. The company 
can obtain a utility patent in the United States 
covering the novel paintbrush. If the company 
has business in Europe, it might be wise to file 
a PCT as well. It might be beneficial to write a 
claim, also, for painting with the paintbrush. By 
doing so, the company would ensure that both 
people manufacturing the brush, and each small 
or large painting using the brush, would be guilty 
of infringement if they were not first granted a li­
cense to use the brush in any manner they saw fit. 
When the company holding the patent improves 
the tool, it can always file a new patent covering 
the improvement (continuation-in-part applica­
tion). Additionally, the design of the paintbrush 
might be protected by a design patent. Finally, 
the company might have a unique name for the 
tool that could be trademarked. 
Building such a fortress around the invention 
makes it difficult for others to use the invention 
without getting a license. Depending on the pol­
icy of the organization and the type of the inven­
tion, the organization can then grant either exclu­
sive or nonexclusive licenses to use the product. 
There are several ways to protect IP, but one 
should always remember that protecting IP is ex­
pensive. Therefore, an organization needs to think 
carefully about its competitors, likely infringers, 
and the geographical area where the invention is to 
be marketed. Sometimes keeping an invention as a 
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DODDS 
trade secret might be the cheapest way to protect 
it. Sometimes patenting, even if more expensive, 
might give better protection. Finding the best way 
to build and protect an IP portfolio requires imagi­
nation, in addition to a thorough knowledge of the 
company and its product lines. 
11. SuMMARy AND CONCluSIONS 
A comprehensive IP portfolio can be of substan­
tial value to both private and public sector enti­
ties. For both sectors, patents are a key element of 
an IP portfolio. Large companies can afford an of­
fensive patent strategy, but small companies may 
not have recourses for this. Therefore, especially 
for small- and middle-sized companies, planning 
and lateral thinking about how to put in place 
an effective and cost efficient strategy is extremely 
important. IP can be protected through patents, 
trademarks, copyrights, and trade secrets. The 
costs of maintaining each of these IP categories 
are different. A company can reduce costs by lim­
iting patent protection to those geographic areas 
where it has business. But even when a company 
wishes to reduce costs as much as possible, im­
portant technologies need to be protected prop­
erly. A strong protection may be built by using 
several forms of IP for the same invention or im­
provement.3 n 
JOHN dOddS, Founder, Dodds & Associates,1707 N Street 
NW, Washington, DC, 20036, U.S.A. j.dodds@doddsas­
sociates.com 
1	 www.uspto.gov/main/howtofees.htm. 
2	 See also in this Handbook, chapter 11.6 by WT Tucker 
and GS Ross. 
3	 Recommended reading for further information on this 
topic: 
Field TG, Jr. Avoiding Intellectual Property Problems.
www.piercelaw.edu/tfield/avoid.htm. 
Field TG, Jr. 1994. Intellectual Property: Some Practical 
and Legal Fundamentals. IDEA The Journal of Law and 
Technology 4: 79–129. 
Goldschreider R. 1998. Licensing In: A Key to Continued 
Corporate Health. IDEA The Journal of Law and 
Technology 2: 361–382. 
Patel R. A Patent Portfolio Development Strategy for 
Start-Up Companies. Fenwick & West LLP:Washington,
DC. www.fenwick.com/docstore/Publications/IP/IP_ 
bulletins/IP_Bulletin_Fall_2002.pdf. 
Rivette KG and D Klive. 1999. Rembrandts in the 
Attic: Unlocking the Hidden Value of Patents. Harvard 
Business School Press: Cambridge, Mass. 
U.S. Department of Commerce. 2000. Patents and How 
to Get One: A Practical Handbook. Dover Publications.
Unites States Patent and Trademark Office. Types of 
Patent Applications/Proceedings. www.uspto.gov/ 
web/patents/types.htm. 
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CHAPTER 10.5 
Cost-Conscious Strategies for Patent Application Filings 

oRen livne, Associate Director, Licensing, Office of Technology & Industry Alliances,
University of California, Santa Barbara, U.S.A. 
ABSTRACT 
Timing and cost are two key factors involved in patent-
filing decisions. This chapter explores mechanisms for de­
laying the high costs of filing a patent application as long 
as possible, so that additional information on an inven­
tion and evidence of its worthiness can be gathered. The 
efforts to minimize up-front costs are balanced against the 
potential need to secure viable patent rights at some point 
in the future. This chapter begins by walking through the 
stages of the publication process—from prior to submis­
sion, to after publication—and suggests cost-conscious 
patent-filing strategies that are possible at each stage. The 
focus is on delaying significant costs until the value of 
the invention is more certain. The chapter concludes with 
additional points to consider when making patent-filing 
decisions. 
1. InTRoduCTIon 
With university inventions, research is often early 
stage and an invention’s worthiness can be uncer­
tain from both a scientific and market perspec­
tive. At the same time there is a drive to publish 
that forces early patenting decisions. Companies 
have some extra leeway with respect to delaying 
publication, but are pushed by competitors and 
a need to demonstrate technical capabilities and, 
as a result, often face patenting decisions well in 
advance of a clearly defined product line. Both 
universities and companies must therefore make 
decisions on inventions that represent only pos­
sibilities—an invention that might end up in a 
product, an invention for which additional re­
search may demonstrate some significant result, or 
an invention that may be licensed in the future.1 
The cost-minimizing approach recommended in 
this chapter is intended for such inventions with 
questionable or uncertain value. The approach is 
not recommend for a blockbuster drug or an in­
vention that represents the core of a company’s 
products. 
2. dECISIonS, 	dECISIonS 
2.1 No publications planned 
When the inventors plan no publications and 
there are no other reasons (such as concerns over 
competing groups) to secure a priority date, a 
company or university can enjoy the luxury of 
time. There is no need to do anything on the pat­
ent side so long as the invention will not be sup­
pressed, concealed, or abandoned. Technical re­
search and market evaluation may continue until 
the invention’s value is determined. Then a patent 
application may be filed, if appropriate. 
2.2 Publication planned for a future date 
If there is significant time before publication sub­
mission, technical research and market evalua­
tion may continue in the hopes that additional 
information will be gathered that can support 
Livne O. 2007. Cost-Conscious Strategies for Patent Application Filings. In Intellectual Property Management in Health and 
Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. O Livne. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged. 
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lIVNE 
the patent filing decision. Often publication sub­
missions are delayed, providing additional time 
for evaluation. When submission becomes more 
definite, the steps in the following section may be 
followed. 
2. Publication submission 
Submission of a publication is not necessarily a 
dire situation. Not all submissions are considered 
publications. Usually submissions will be main­
tained in confidence until the publication date (it 
is advisable to note “CONFIDENTIAL” on the 
manuscript). If that is the case, several additional 
months are gained for technical research and mar­
ket evaluation (again, assuming there are no other 
reasons to secure an earlier priority date). If the 
submission will not be maintained in confidence 
and is considered a publication, then a patent ap­
plication may need to be filed prior to submission 
(see section 2.4). 
2. Publication imminent 
When publication is imminent, an application 
needs to be filed only if foreign (non-U.S.) patent 
rights are desired. If foreign patent rights are not 
desired, the U.S. patent-application filing does 
not need to occur until a year after publication. 
In this case, the steps in section 2.5 “Publication” 
can be followed (assuming there are no other rea­
sons to secure an earlier priority date). 
If foreign patent rights are desired, an ap­
plication must be filed prior to publication (only 
a few countries in addition to the United States 
have grace periods).2 Figure 1 details the steps 
that may be taken (see the left-hand “YES” side 
of the Figure). 
There are two main options to choose from. 
A U.S. provisional application can be filed. 
Alternatively, if the invention’s value is more cer­
tain or it has the potential to generate significant 
revenues, a nonprovisional U.S. application can 
be filed. By avoiding the provisional stage for 
more certain inventions, the total patenting cost 
can be reduced. 
2..1 Nonprovisional U.S. application 
If the nonprovisional application filing route is tak­
en,3 attorney costs can be reduced by providing a 
single cohesive document containing all data and 
information relating to the invention. If possible, 
this document can be drafted by the inventors 
and then reviewed by the invention manager. The 
invention manager can discuss the description 
with the inventors and work to add any missing 
information, alternative methods, compositions 
or devices, and additional breadth to the descrip­
tion. The attorney will then have a more-solid 
starting point from which to draft the applica­
tion. Depending on the nature of the invention, 
costs may be kept below US$10,000.4 
Once the nonprovisional U.S. application is 
filed, there is one year during which foreign rights 
can still be pursued (assuming no prior publica­
tion has taken place). If foreign patent rights are 
no longer desired, no action needs to be taken. If 
foreign rights are still desired, one of the two fol­
lowing filing approaches can be employed prior 
to one year from the initial filing: 
1. File a Patent Cooperation Treaty (PCT) 
application claiming all or specific na­
tions. Filing a PCT application provides 
30 months from the earliest priority date 
(filing date of the nonprovisional applica­
tion) before which national-stage patent fil­
ings need to occur. Most countries are now 
members of the PCT (with the Republic of 
China [Chinese Taipei] one notable excep­
tion), so the PCT application is a valuable 
interim step for maintaining worldwide 
patent protection. 
The PCT route will reduce initial costs 
significantly, but total costs will be higher 
(by the amount of the PCT filing). If the 
specific countries or regions of interest 
are not yet known, this is a good route 
to take (the PCT filing may designate all 
member nations). Since the U.S. applica­
tion was already drafted, PCT costs will 
be limited to governmental fees, and a 
small amount for attorney time (currently 
a total of less than US$4,000 for all na­
tions). The U.S. Patent and Trademark 
Office (PTO) and the World Intellectual 
Property Organization (WIPO) have ex­
tensive Web sites with helpful information 
on PCT filings.5 
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lIVNE 
2. File national-phase applications in spe­
cific countries or regions of interest. If the 
desired countries or regions of interest are 
already known, patent applications may be 
filed directly in those countries. The cost 
per country is significant, including transla­
tion costs, governmental fees, and attorney 
time. This route is typically reserved for in­
ventions whose potential has already been 
demonstrated or whose value, if proven, 
will be very significant. 
2..2 Provisional patent applications 
If the provisional-application filing route is taken, 
attorney costs can be reduced also by providing a 
single cohesive document containing all data and 
information relating to the invention. Like the 
nonprovisional application discussed above, this 
can be drafted by the inventors and then reviewed 
by the invention manager. The invention man­
ager can discuss the description with the inven­
tors and work to add any missing information, 
alternative approaches, and additional breadth to 
the description. 
This description can then be filed “as is,” with­
out claims, at minimal cost (roughly US$300, 
including attorney time) or, with some sample 
claims, for a little more. This is a somewhat risky 
approach, as the attorney will not have reviewed 
the description to ensure that it provides the in­
formation necessary to support desired claims. If 
it is very uncertain whether or not foreign rights 
are desired and the added provisional year is likely 
to provide that information, this may be an ap­
propriate approach. If foreign rights are very like­
ly of interest or the invention has strong potential 
in foreign markets, it may be preferable to pro­
vide the attorney with the single reviewed docu­
ment and ask that an additional review be con­
ducted and claims added (a total cost of roughly 
US$1,500–US$2,500, depending on the nature 
of the invention). 
2..2.1 Foreign rights desired 
Once the provisional U.S. application is filed, 
there is one year during which foreign rights 
can still be pursued. If foreign rights are de­
sired, one of the three following approaches can 
be employed up until one year after the initial 
filing: 
1. File a PCT application claiming all or 
specific nations. Filing a PCT application 
provides 30 months from the priority date 
(filing date of the provisional application) 
before which national-stage patent filings 
need to occur. Most countries are now 
members of the PCT (with the Republic 
of China one notable exception) so the 
PCT application is a valuable interim 
step for maintaining worldwide patent 
protection.
The PCT route provides the lowest up­
front costs, but total costs will be higher 
than the combined costs of filings directly 
in a few specific countries or regions of in­
terest. If the specific countries or regions of 
interest are not yet known, a PCT filing is 
a good route to take (it may designate all 
member nations). The cost of converting 
a previously filed provisional application 
into a full PCT filing can vary significantly 
depending on how strong the provisional 
filing was and whether any new informa­
tion needs to be incorporated (depending 
on the nature of the invention, costs may 
be kept below US$10,000) 
2. File a PCT application claiming all or spe­
cific nations and file a separate nonprovi­
sional U.S. application. Filing a U.S. patent 
application in addition to the PCT at this 
stage has certain benefits. The U.S. patent 
application will likely issue sooner. Also, it 
is possible that the PTO will issue an of­
fice action in time to help with the decision 
on whether or not to go national-phase in 
other countries. There will be added costs 
for filing the additional U.S. application, 
primarily in the form of government fees 
(roughly US$1,500 to US$2,500 for the 
filing fee, plus minimal attorney time). If 
an office action is issued on the U.S. ap­
plication, there will be additional costs for 
drafting and filing the response (roughly 
US$3,000, depending on the nature of the 
office action). 
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3. File applications in specific countries. If 
the desired countries or regions of interest 
are already known, patent applications may 
be filed directly in those countries. The cost 
per country is significant, including trans­
lation costs, government fees, and attorney 
time. This route is typically reserved for in­
ventions whose potential has already been 
demonstrated or whose value, if proven, 
will be very significant. 
2..2.2 Foreign rights not desired 
If foreign rights are not desired but U.S. rights 
still are, a full U.S. application must be filed with­
in one year of the provisional U.S. filing if the 
priority date of the provisional is needed. 
If priority to the provisional is not needed 
(for example, if there are no concerns about com­
peting groups), then a full U.S. application does 
not need to be filed. The provisional application 
can be refiled within one year of the earliest pub­
lication—the cost would be minimal since all the 
paper work would already be in place (roughly 
US$300 if an attorney is used). Using this strat­
egy, a company or university would have a year 
to decide if foreign patent rights were worthwhile 
(the first provisional) and an additional year to 
see if a full U.S. patent is desired (the second pro­
visional). If a full U.S. patent is desired, the ap­
plication must be filed within one year from the 
filing of the second provisional application. 
2. Publication 
If enabling details of the invention have already 
been published, then non-U.S. rights are gener­
ally not attainable.6 The right hand, “NO,” side 
of Figure 1 outlines the steps that may be taken 
in such cases. A U.S. patent application does not 
need to be filed until one year from the publi­
cation. During this time additional research and 
market analysis can occur. 
If, toward the end of the one-year time pe­
riod, the invention’s value becomes more certain, 
a nonprovisional U.S. patent application may be 
filed. 
If the value of the invention is still uncertain 
but it continues to have potential, a provisional 
U.S. application may be filed, providing an ad­
ditional year for evaluation. Filing a provisional 
application would raise the total costs somewhat, 
but can dramatically reduce the initial costs. If 
the evaluation proved positive and a U.S. patent 
is desired, a nonprovisional application must be 
filed by one year from the provisional filing date. 
. ConCLuSIonS 
This chapter offers ideas for delaying the upfront 
cost of patent filings in a manner that allows pat­
ent rights to be secured in the future. Below are 
some important points to consider when employ­
ing these strategies: 
•	 Before applying the strategies described in 
this paper, please consult with an attorney 
to confirm they are appropriate for your 
specific circumstances. 
•	 There are risks associated with delaying 
a patent filing. There may be prior art of 
which you were unaware. Sometimes a 
paper will be published online prior to 
print, or a journal will be mailed before 
its cover date, or conference proceedings 
sent to attendees prior to the conference. 
Other groups may publish before you have 
a chance to file. Foreign countries (and pos­
sibly soon, the United States) have a first­
to-file system, so delay may result in other 
groups securing patent rights before you 
have an opportunity to do so. 
•	 Consider what information will be gained 
before the next patenting-decision point. 
If, for example, it will take three years of 
research to confirm whether an invention 
is viable, filing a provisional application is 
not likely to be worthwhile: going straight 
to a nonprovisional filing will reduce the 
total costs. On the other hand, if only six 
months are needed to confirm the value 
of an invention, a provisional application 
might be preferable. 
•	 Delaying filings through provisional appli­
cations and the other approaches discussed 
in this paper makes sense only if some ap­
plications are abandoned at future decision 
points. The main benefit of the delay is that 
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lIVNE 
it allows additional time for research and 
market evaluation so the strong inventions 
1 Livne O. 2002. Investigation of At-Risk Patent Filings.
Journal of the Association of University Technology 
Managers 14:19-29. 
can be separated from the weak. If a patent 
filing is definitely going to occur, adding 
the provisional application will increase the 
total costs. 
• Evaluate whether or not foreign (non-U.S.) 
patent rights are truly desired. Significant 
flexibility is gained if foreign patent rights 
are not needed. 
• Remember, attorney costs can be reduced 
2 See Strauss J. 2000. Expert Opinion on the Introduction 
of Grace Period in the European Patent Law. Max-Planck 
Institute: Munich. www.european-patent-office.
org/news/pressrel/pdf/straus.pdf. Page 44 provides 
a summary of countries with various types of grace 
periods ranging from six to 12 months. If detailed 
information on specific countries is needed, see the 
WIPO Guide to Intellectual Property Worldwide at
www.wipo.int/about-ip/en/ipworldwide/country.htm.
WIPO provides a good starting point for information 
on the patent laws of specific countries.
by providing a single cohesive document 
containing all data and information relating 
to the invention, enhanced by the inven­
tion manager who could add any missing 
information, alternative methods, compo­
sitions or devices, and additional breadth to 
the description. n 
acKnowledgeMenT 





It is also possible to file a Patent Cooperation Treaty 
(PCT) filing in lieu of, or in conjunction with, the non-
provisional U.S. application if the desirability of foreign 
rights is more certain. 
All cost estimates in this paper are based on small-
entity filing fees. U.S. patent filing fees (effective 1 
February 2007) can be viewed at www.uspto.gov/web/
offices/ac/qs/ope/. 
See, also in this Handbook, chapter 10.7 by AM 
Schneiderman. 
See supra note 2 for information on exceptions. 
appeared under the title A Cost Conscious Approach to 
Patent Application Filings, Les Nouvelles, Vol. XLI, No. 
2, June 2006, pp. 115–19. 
oRen livne, Associate Director, Licensing, Office of 
Technology & Industry Alliances, University of California, 
Santa Barbara, 552 University Avenue, Santa Barbara, CA, 
93106-2055, U.S.A. livne@research.ucsb.edu 
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CHAPTER 10.6 
A Guide to International Patent Protection
 
ann s. viKsnins, Patent Attorney and Partner, Viksnins Harris & Padys PLLP, U.S.A. 
ann M. MccRacKin, Shareholder, Schwegman, Lundberg, Woessner & Kluth P.A., U.S.A. 
ABSTRACT 
When approaching the international production, mar­
keting, distribution, and sales of a patented product or 
process, several key factors must be carefully identified 
and evaluated. These factors include business and legal is­
sues. Business issues include market location, market size, 
presence (or absence) of competitors, emerging markets 
as opportunities, life cycle of the product, and taxes. Legal 
issues include the presence (or absence) of trade secrets in 
the patent application, the status of patent applications 
in foreign countries, the level of patent protection (both 
law and enforcement) in foreign countries, and statutes, 
such as novelty requirements, in prospective foreign mar­
kets. Having considered a full range of business and legal 
factors, options for international patent protection can 
then be evaluated and appropriately selected, according 
to the business goals and financial resources of the orga­
nization. Options include national, regional, and interna­
tional patent applications, each having its own advantages 
and disadvantages. This overall strategy can be effectively 
employed to maximize either business or humanitarian 
objectives. 
1.  BASICS 	of	InTERnATIonAL 
fILInG	STRATEGIES 
You have a researcher who has developed an excit­
ing invention, and you have already decided to 
file a patent application in the United States. Now 
you need to decide if you should also file patent 
applications abroad, and if so, where. The cost of 
filing patent applications in every country in the 
world can add up quickly, as there are about 200 
countries where some degree of patent rights are 
available. Therefore, you will need to be selective 
as to where you will file patent applications. 
Many factors need to be considered when de­
ciding where to file foreign patent applications. 
Some factors relate to the business development 
or marketing of the invention, and other factors 
relate to the legal status of the invention. For ex­
ample, will the invention be considered “novel” 
in the countries where you want to file? Do the 
countries permit patenting the type of technol­
ogy your inventor has developed? Some countries 
do not offer patent protection for computer soft­
ware, for instance. Another factor to consider is 
whether you will be able to enforce your patent 
once you receive it. The degree of judicial respect 
that patents are given in different countries varies 
considerably. Some countries have laws that al­
low a party to obtain a patent but have almost no 
enforcement mechanisms. International treaties 
such as the North American Free Trade Agreement 
(NAFTA) and the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) 
should help to make enforcement easier and rem­
edies for infringement more adequate. 
Viksnins AS and AM McCrackin. 2007. A Guide to International Patent Protection. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual Second Edition (Part IV: Chapter 2.2).
© 2007. AS Viksnins and AM McCrackin. Sharing the Art of IP Management: Photocopying and distribution through the 
Internet for noncommercial purposes is permitted and encouraged. 
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VIKSNINS & McCRACKIN 
Specifically, here are some of the business and for the short-term difficulties. As another 
legal questions to consider when planning a for- example, Vietnam’s recent accession to the 
eign patent filing strategy: World Trade Organization (WTO) will ne­
• How big is the market for your inven­ cessitate tangible progress towards TRIPS 
tion in a particular country? If the market provisions implementation.1 An important 
for the invention is a relatively small one, aspect of this will be strengthening patent 
it may not be worth the expense of filing laws and their enforcement. 
an application in that particular country. • Would a defensive patent be valuable? It 
A benchmark that some companies use is can be worthwhile filing in a particular 
US$5 million in revenue per year for the country, even if a market is small, if you 
invention. know that a major competitor is doing 
• How big is the market for your invention business or has a manufacturing plant in 
in a particular region? Many inventions are that country. You can possibly get the com­
region-specific. For example, if your inven­ petitor to license the new technology from 
tion is a transgenic blueberry plant, you you or at least prevent the competitor from 
likely do not need to consider filing in the commercializing your invention in that 
region of Equatorial Africa, since blueberry country. 
plants do not grow there. Also, it may be • Do you have limited time? Some technolo­
that a patented product has a major market gies only have a life span of a few years, and 
in a handful of countries and only a mi- you can expect to get income from licens­
nor amount of interest elsewhere. Further, ing fees only in the early years of a patent. 
covering the major markets may provide an Other technologies are in development for 
advantage in economies of scale. If most a long period of time and are only economi­
of your potential customers are in coun­ cally valuable in the last years of the patent. 
tries where you have patent protection, It can take ten years to get a Japanese patent 
you may have such strong manufacturing application issued. Even though you might 
and cost advantages that you do not need be able to successfully sue an infringer and 
to have patent coverage in less-important get retroactive royalties back to your filing 
countries. date, by then the competitor will already be 
• Where are the major manufacturing cen­ in the market. Also, you often cannot get 
ters for you and for your competitors? a restraining order to make the competitor 
Certain regions of the world are centers stop infringing until after the patent has ac-
of manufacturing for different industries. tually issued. 
For example, the Far East economies of • Do you have limited funds to spend on 
Singapore, Hong Kong, Korea, Indonesia, foreign patent protection? It may be more 
Thailand, the Republic of China, China worthwhile to carefully pick just a few 
(People’s Republic of China), and Japan are countries and spend all your money on 
important manufacturing countries for the getting well-prosecuted, broad patents in 
computer and semiconductor industries. those countries rather than getting nar­
• Where are the emerging markets? row patents in a lot of countries. Another 
Developing countries may be strengthening strategy would be to concentrate all your 
their patent laws and therefore make patents efforts on the key features of your technol­
more valuable in the near future. For ex­ ogy that competitors will need in order to 
ample, China has recently revised its patent be competitive. 
laws and should be considered for certain • What is the status of a patent application 
inventions. There are still many problems in in the foreign country of interest? In some 
enforcing patents in China, but in the long countries, such as Japan, published applica­
run, the size of the market could make up tions are respected almost as though they 
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were already-issued patents and can provide 
licensing opportunities. This local custom 
can make an unissued patent application 
valuable even if the national patent office 
has a reputation for letting patent applica­
tions pend for a long time. 
•	 Would your invention be considered novel 
in your country of interest? Most countries 
require that an invention be undisclosed, or 
novel, as of the effective filing date of the ap­
plication. Novelty requirements vary con­
siderably from country to country. Some 
countries require absolute novelty (which, in 
practical terms, means that a patent appli­
cation must be filed before any public dis­
closure), while other countries give inven­
tors or applicants grace periods, following 
disclosure, for filing patent applications. 
•	 Where are your competitors filing their 
patent applications? Place of filing can 
be indicative of future business plans. You 
may want to file in the same countries your 
competitors are filing in, even if you do not 
initially plan to manufacture or sell your 
invention in those countries. 
•	 Are there trade secrets in your applica­
tion? Most foreign applications (and most 
U.S. patent applications filed on or after 29 
November 2000) are published about 18 
months after their priority date. The inven­
tion may be of more value when kept as a 
trade secret for a potentially unlimited time 
than when disclosed in a patent, which has 
a limited life span. 
•	 Can holders of patent rights realize tax ad­
vantages in foreign countries? Patents can be 
bundled with a technology transfer license to 
transfer the situs of taxation, allowing expa­
triation of funds with less tax impact. 
2.  opTIonS	 foR	 fILInG	InTERnATIonAL	
pATEnT	AppLICATIonS 
2.1 Overview 
Once a decision has been made to file a patent ap­
plication, there are three choices for filing in a for­
eign country: (1) file directly in the patent office
of the country of interest, (2) file in a regional 
patent office, or (3) file using the procedures set 
forth in the Patent Cooperation Treaty (PCT).2 
These filing options are discussed below. Unlike 
in the United States, applications in most other 
countries are filed in the name of the assignee(s), 
not the inventor(s). 
2.1.1 National applications 
Prior to 1 June 1978, directly filing a patent ap­
plication in a foreign country’s patent office was 
the primary way to obtain foreign patent protec­
tion. Applicants often would rely on the rights 
granted under the Paris Union Convention (that 
is, for member nations of the Paris Convention) 
for a right of priority.3 This right of priority al­
lows a resident of a country that is a member of 
the Paris Convention to first file a patent applica­
tion in any member country, and then, within 12 
months of the original filing date, to file patent 
applications for the same invention in any of the 
other member countries. By treaty, the later ap­
plications receive effective filing dates that are the 
same as the original filing date. In other words, 
they would be treated as though they had been 
filed on the same day as the first application, 
so long as they were filed within the 12-month 
period. 
Applicants who file a subsequent applica­
tion in a country that is a member of the Paris 
Convention will not be given the priority of 
their original application. If possible, applicants 
should consider filing any applications in non­
member countries on the same day as their first 
Paris Convention application. 
It should be noted that even though the 
Republic of China is not a member of the Paris 
Convention, patent applications filed in the 
United States may have priority over applica­
tions filed in the Republic of China because of 
a bilateral agreement between the two countries 
(effective 10 April 1996). The priority period is 
12 months for inventions and new utility model 
applications; the period is six months for new de­
sign applications. Various requirements must be 
met in order for priority to be granted. For ex­
ample, priority must be claimed on the filing date 
of the application filed in the Republic of China, 
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VIKSNINS & McCRACKIN 
the applicant of that country’s application must 
be the same as the applicant on the U.S. applica­
tion, and the invention disclosed in the Republic 
of China application must be the same as that of 
the corresponding U.S. application. 
A major disadvantage of filing directly in 
individual countries is that such a strategy can 
be very expensive, as applicants must pay the 
individual national government filing fees, pat­
ent attorney fees, foreign associate fees, and 
potential translation costs early in the patent 
program. 
2.1.2 Regional applications 
A potential alternative to filing directly in each 
country of interest is to file in a regional patent 
office. These patent offices have come into exis­
tence through international treaties. Examples of 
regional patent offices are the European Patent 
Office (EPO),4 the African Regional Industrial 
Property Organization (ARIPO),5 the African 
Intellectual Property Organization (OAPI),6 and 
the Eurasian Patent Convention (EA).7 
Often, the EPO is the most commercially im­
portant of the regional patent offices, so its proce­
dures will be discussed in more detail. Use of the 
EPO allows for a uniform procedural system for 
filing a patent application in member European 
countries. The cost of filing a patent application 
in the EPO is about US$10,000. This figure 
includes the EPO filing fees, the U.S. attorney 
fees, and the fees charged by the EPO associate. 
The EPO does not allow U.S. patent attorneys 
to communicate directly with it, so a European 
patent attorney, or agent qualified to practice in 
the EPO, must be hired for certain aspects of the 
filing and prosecution process. 
The application is reviewed by an EPO exam­
iner based on the investigation of the prior art in 
light of the claims. The examiner must consider 
a PCT Chapter II examination report, if appli­
cable. (The PCT procedure is discussed in further 
detail below). The EPO issues an official action 
statement. The U.S. patent attorneys respond to 
the official action through their European asso­
ciates. After successful examination, the applica­
tion is granted as a European patent. It should 
be noted that interim protection can be available 
during pendency by filing a translation of claims 
in each designated country. 
An applicant, however, does not gain any en­
forceable patent rights until the European patent 
is registered, or “validated,” in each of the coun­
tries in which protection is sought. Registration 
can be expensive because in addition to govern­
ment issue fees and translation fees, further fees 
for the European associate and local agents in 
each country will be incurred. Once the European 
patent is validated, annual maintenance fees, or 
annuities, will be due periodically in each of the 
countries. Maintenance fees vary considerably 
from country to country. For example, annui­
ties in the United Kingdom and France can total 
about US$7,000, whereas in Germany they can 
total about US$18,000, over the life of the pat­
ent. Of course, these are estimates and are subject 
to change. 
2.1. PCT applications 
The Patent Cooperation Treaty (PCT) is an in­
ternational agreement that provides a unified and 
simplified procedure for filing multiple foreign 
patent applications via a single initial applica­
tion. Most industrialized countries are members 
of the PCT, including many countries that are 
also members of different regional patent offices. 
Please note that this list is constantly changing 
as new countries join the PCT. All PCT mem­
ber countries are bound by the Paris Convention; 
however, not all Paris Convention member states 
are PCT member countries.8 If you have ques­
tions as to whether certain countries are PCT 
member countries, you may check the most re­
cent PCT newsletter, on the Web, or contact the 
PCT Help Desk.9 
PCT Rule 4.10 enables applicants to claim 
priority of an earlier-filed application in, or for, a 
member country of the WTO10 that is not party 
to the Paris Convention. 
The procedures set forth in the PCT allow 
applicants to obtain and/or preserve the prior­
ity date of the first-filed application in any of the 
PCT member countries, including the United 
States. An applicant files a copy of the applica­
tion in a PCT office and pays the PCT filing fee. 
This filing of the patent application may be the 
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first time it has been filed anywhere, or it can be 
an application that claims priority over an earlier-
filed application, so long as it is filed within 12 
months of the initial filing date. 
Along with a copy of the application, the 
applicant files a PCT request. When the request 
is filed, the presumption is that the applicant 
would like to designate all available countries or 
regional offices, thereby reserving the right to, at a 
later time, file national (or regional) applications 
claiming priority to the first-filed application. In 
Box No. V of the PCT request form, it is stated 
that “The filing of this request constitutes, under 
Rule 4.9(a), the designation of all Contracting 
States [emphasis added] bound by the PCT on the 
international filing date, for the grant of every kind 
of protection available, and, where applicable, for 
the grant of both regional and national patents.” In 
other words, priority to the first-filed application 
is automatic and all-inclusive, with all possible 
designations. The PCT request form, however, 
provides for the “de-designation” of Germany, 
Korea, Russia, and Japan (for example, if applica­
tions have already been filed in these countries). 
It is critical to keep in mind that if patent protec­
tion is desired in a non-PCT country, an appli­
cant must file directly in that country. 
When filing an international application that 
relies on the Paris Convention one-year grace pe­
riod for a priority date, the time period for filing 
the foreign application is calculated from the date 
of the first-filed national application. For most 
U.S. applicants, the first-filed national applica­
tion is a regular nonprovisional U.S. application. 
It is important to note, however, that if a U.S. 
provisional application is filed as the first-filed ap­
plication, the one-year grace period begins with 
the filing of this provisional application and not 
with the filing of the “conversion” regular non-
provisional U.S. application that claims priority 
over the provisional application. Thus, if a provi­
sional application is filed, the conversion date for 
the nonprovisional U.S. application and the Paris 
Convention bar date for the filing of internation­
al applications fall on the same day. Therefore, the 
international application and the U.S. regular ap­
plication need to be filed on the same date. The 
applicant does not get an additional year beyond 
the regular U.S. application in which to file its 
international applications. 
Prosecution of a PCT application has two 
parts. Chapter I involves the initial processing 
of the application, a search of the prior art, and 
publication of the application and search results. 
Chapter II involves an optional international pre­
liminary examination. (Figures 1 and 2) 
Once an applicant decides to file a PCT ap­
plication, the applicant enters Chapter I by filing 
a PCT office request, a copy of the application, and 
the PCT filing fee. Application in most countries 
is made in the name of the owner of the invention, 
not of the inventor, as in the United States. The 
PCT filing of the patent application may be the 
first filing, or a PCT application that claims pri­
ority to an earlier-filed application can be filed, so 
long as it is filed within 12 months of the priority 
date. Either the U.S. Patent and Trademark Office 
(PTO) or the International Bureau of the World 
Intellectual Property Organization (WIPO) can 
act as PCT receiving offices for applications on 
inventions by applicants who are either nationals 
or residents of the United States. Either the PTO 
or the European Patent Office can be designated 
as the searching authority. 
The application is then reviewed by an au­
thorized examiner, and a prior art search is per­
formed. The examiner reviews patents and pub­
lications from around the world and lists those 
that are determined to be relevant prior art, with 
respect to the claims of the application. Within 
16 months of the priority date, a preliminary 
search report is issued. The applicant then has an 
opportunity to amend the claims in the applica­
tion. After 18 months from the priority date, the 
application is published. 
Under previous PCT procedure, within 19 
months of the priority date, applicants were re­
quired to choose to enter PCT Chapter II, enter 
the national stage (that is, file the application in 
at least some of the countries or regional offices 
designated), or abandon the application. If the 
applicant decided to enter PCT Chapter II, the 
filing of a demand for a preliminary examination 
was required and a Chapter II filing fee would 
be assessed. However, the Article 22(1) time limit
for filing national-stage applications without the 
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need to file a demand has been changed from 20 
or 21 months to 30 or 31 months. This change 
went into force on 1 April 2002. Applicants 
should recognize, however, that some PCT mem­
ber countries maintain reservations regarding this 
new timing rule and should remain cautious.11 
Applicants may file a preliminary amendment 
with the demand. When that has been done, the 
PCT examiner prepares a written opinion that 
should be received by the applicant within 22 
months of the priority date. The applicant has an 
opportunity to amend the claims and respond to 
the examiner’s opinion during the period between 
22 and 28 months following the priority date. A 
final PCT international preliminary examination 
report is published approximately 28 months 
from the priority date. PCT Chapter II is closed 
at 30 or 31 months from the priority date. 
Normally, just before the 30- or 31-month 
mark, the applicant again must decide whether to 
file applications in at least some of the designated 
countries, or regional offices, or to abandon the 
application. The applicant can choose to file the 
application in some or all of the countries origi­
nally designated. The applicant, however, cannot 
add to the list of countries originally designated. 
Because the PCT application does not, in itself, 
result in the granting of any national patent 
rights, the applicant must initiate the national 
stage in each of the national offices where patent 
protection is desired. At this point, the applicant, 
via a local attorney or agent, files a copy of the 
international application, a translation of the ap­
plication (if necessary), the national fee, and any 
other documentation required by the national of­
fice. The remainder of the prosecution is similar 
to that discussed above, when an application is 
filed directly in a national office. The national 
offices, however, do give deference to the PCT 
international preliminary examination report and 
may not conduct a further search. 
It should be noted that it is possible at any 
time during the PCT process to file one or more 
national-stage applications. It is not necessary to 
wait until the end of Chapter I or Chapter II to 
file a national or a regional application. 
For U.S. applicants using the PCT procedure 
and wanting to select the EPO to perform the 
prior art search, the EPO has limited the categories 
it will search and/or examine. The EPO will not 
search or examine applications in the areas of busi­
ness methods and related inventions. “[T]he EPO 
is no longer a competent [International Preliminary 
Examining Authority], within the meaning of PCT 
Article 32(3), for international applications filed by 
U.S. residents or nationals in the [U.S. Patent and 
Trademark Office] or [International Bureau] as a 
Receiving Office where the corresponding demand is 
filed with the EPO on or after 01 March 2002, and 
where the application contains one or more claims 
directed to the fields of business methods.”12 
In the 1990s, the EPO had indicated that 
it would search inventions in the area of tele­
communications, but would not examine these 
applications. This meant that U.S. applicants 
needed to have all telecommunications inven­
tions examined by the U.S. Patent Office, even 
if the EPO had performed the search. The EPO, 
however, resumed its competence as an interna­
tional preliminary examining authority, effective 
1 July 2004, for demands filed by U.S. residents 
or nationals on or after 1 July 2004, for interna­
tional applications filed by nationals or residents 
of the United States, where the application con­
tains one or more claims relating to the field of 
telecommunications.13 
Similarly, in the field of biotechnology, al­
though the EPO had earlier announced that it 
would neither search nor examine applications 
in that area, and that such applications were re­
quired to designate the U.S. Patent Office as the 
searching and examining authority, the EPO re­
sumed its competence as an international search­
ing authority and international preliminary ex­
amining authority, effective 1 January 2004, for 
international applications filed by nationals or 
residents of the United States, where the applica­
tion contains one or more claims relating to the 
field of biotechnology.14 
2.2  Advantages and disadvantages 
of different application strategies 
2.2.1 Direct national filings 
If an applicant has only a small number of coun­
tries where she or he wants to file and chooses to 
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CHAPTER 10. 
actively pursue prosecution in only those coun­
tries, the applicant can avoid the costs associ­
ated with the intermediate steps of filing in the 
PCT or regional patent office prior to filing na­
tionally. Some countries conduct no, or limited, 
examination. 
Disadvantages to direct national filing are 
that (1) each application will be independently 
examined (no deference given to a prior favorable 
review in a different country), and (2) govern­
ment filing fees and translation costs will be due 
early in the patenting process. 
2.2.2 Direct regional filings 
With direct regional filings, applicants may be 
able to avoid some translation costs (for example, 
the Eurasian Patent Convention requires applica­
tions to be filed in Russian, but no translations 
into different languages will be required by the 
various countries after grant of a Eurasian pat­
ent). Another advantage to direct filings is that 
substantive examination of the regional patent in 
each of the designated countries is no longer nec­
essary. This makes direct regional filing especially 
cost-effective if protection is desired in a number 
of member countries, since the single regional 
examination replaces national examinations per­
formed by each member country. 
If obtaining protection in only a few member 
countries is desired, it may be less expensive to file 
applications in each country individually, thus 
avoiding costs associated with the intermediate 
steps of first filing in the regional patent office. 
2.2. PCT filings 
PCT filings preserve future foreign patent rights 
and permit an applicant to delay national entry 
into PCT member countries for up to 30 or 31 
months from the priority date. This delay period 
may provide opportunities for further market 
analysis, obtaining a licensee or business partner 
for the invention, and obtaining a preliminary ex­
amination report regarding the issues of novelty, 
inventive step, and industrial applicability of the 
claimed invention. 
Ultimately, the same costs for national fil­
ing or registration (and possible further national 
prosecution), patent attorney fees, local associate 
fees, and translation costs, if appropriate, will be 
incurred just as they would if the national stage 
was entered directly. Also, the additional inter­
mediate costs associated with the filing and pros­
ecution of the PCT application will be incurred. 
Further, the countries of interest must be mem­
bers of the PCT. 
.  poSSIBLE	InTERnATIonAL
fILInG	 pLAnS 
The selected international filing strategy will de­
pend on the potential importance of the inven­
tion and other business and legal considerations. 
The following are examples of filing strategies in a 
variety of circumstances. 
.1  Invention has immediate international 
market potential 
1. File application in the United States; expe­
dite obtaining a foreign filing license from 
the U.S. Patent Office. 
2. After receipt of a foreign filing license, file 
in countries of interest that are not mem­
bers of the Paris Convention. 
3. File a PCT application designating all PCT 
countries within three months after the 
U.S. filing. 
4. Within 12 months after the U.S. filing date, 
pay designation fees for desired countries, 
and proceed with the PCT prosecution. 
5. Within 12 months after the U.S. filing date, 
file national applications in non-PCT coun­
tries that are Paris Convention countries. 
.2  Invention has international, but not global, 
market potential 
1. If it is known ahead of time which coun­
tries have market potential, one could: 
a. File a PCT application designating coun­
tries of interest, including the United 
States. If filing in any Paris Convention 
nonmember countries is desired, obtain a 
foreign filing license, and file applications 
upon receipt of the foreign filing license. 
b. Within 12 months after the PCT filing 
date, pay designation fees, and proceed 
with the PCT prosecution. 
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VIKSNINS & McCRACKIN 
c. Within 12 months after the PCT filing 
date, file national applications in non-
PCT countries that are Paris Convention 
countries. 
2. If it is not known which countries may 
be of interest at the initial filing date, one 
could: 
a. 	File a U.S. application (and obtain a 
foreign filing license if interested in any 
countries that are not members of the 
Paris Convention). 
b. Within 12 months after the U.S. filing 
date, file a PCT application designat­
ing EPO, Japan, Canada, and any other 
PCT countries of possible interest. 
c. Within 12 months after the U.S. filing 
date, file national applications in non-
PCT countries that are Paris Convention 
countries. 
.  Applicant is interested only 
in NAFTA countries 
1. File a U.S. application. 
2. Within a one-year grace period, file an ap­
plication in Canada and Mexico. (File in 
Canada within one year from any disclo­
sure by the inventor.) 
. 	 Bars to patentability in foreign countries 
Most countries require that an invention be “new 
or novel” in order for the inventor or applicant 
to obtain a patent for the invention. The defi­
nition of novelty varies considerably among the 
different countries of the world. Some countries 
have a requirement of absolute novelty, that is, 
the invention cannot have been described orally 
or in writing, anywhere in the world, or have 
been sold, used, and so forth, prior to the filing 
or priority date. Other countries have a require­
ment of relative novelty. For example, relative 
novelty can mean that the invention must not be 
known in the particular country or described in 
a written document anywhere in the world (but 
foreign oral disclosures may not destroy novelty). 
Also, a country might give inventors or appli­
cants a grace period in which to file their patent 
application after they, or a third party, disclose 
the invention. 
Under Chapter II of the PCT, a claim not 
disclosed by prior art is considered to be novel. 
The relevant prior art is anything made available 
to the public, anywhere in the world, by means of 
a written disclosure, drawings, or other illustra­
tions, prior to the relevant date (filing date of the 
first-filed patent application or the filing date of 
the PCT application). 
The European Patent Convention (EPC) has 
a more-restrictive view of what is new. Under the 
EPC, an invention is considered to be new if it 
does not form a part of the state of the art. The 
state of the art includes everything made avail­
able to the public by means of written or oral 
description, by use, or in any other way, before 
the effective date of filing of the European pat­
ent application or a patent application from 
which the European application claims priority. 
Additionally, the content of European patent 
applications that were filed prior to the priority 
application, but published after the priority date, 
are also part of the prior art for novelty purposes. 
There are many variations as to what consti­
tutes novelty in a particular country, and these 
national definitions can change. Therefore, it is 
highly advisable to inquire of a local patent at­
torney or agent as to the current novelty require­
ments for a given country. 
.  ConCLuSIonS 
When properly managed, international patent 
protection can afford many strategic and eco­
nomic advantages for an organization, as it seeks 
to optimize value in its inventions. However, 
implementation of such a patent-portfolio-man­
agement strategy requires careful planning, co­
herent organization, and a thorough knowledge 
of an invention’s potential. For example, critical 
considerations include market potential (both 
in terms of monetary and geographical factors), 
the presence or absence of competitors, and the 
overall patent protection regime (in terms of laws 
and enforcement) in the various nations or re­
gions where the invention might be used, sold, 
produced, or marketed. Having carefully weighed 
these considerations, options for patent protec­
tion can then be evaluated. For example, patent 
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applications can be filed within national (for ex­
ample the U.S. Patent Office), regional (for ex­
ample, the EPO), or international systems (for 
example the PCT), each with advantages and 
disadvantages, depending on the objectives and 
resources of the organization. Whatever course 
is taken, coherent planning is essential, and a 
thorough knowledge of all relevant parameters is 
fundamental. Finally, it is important to remem­
ber that such an overall strategy can be effectively 
employed to maximize either business or human­
itarian objectives. n 
ann s. viKsnins, Patent Attorney and Partner, Viksnins 
Harris & Padys PLLP, 7900 International Drive, Suite 
870, Bloomington, MN, 55425, U.S.A. aviksnins@vhpglo­
balip.com 
ann M. MccRacKin, Shareholder, Schwegman, Lundberg, 
Woessner & Kluth, P.A., 1600 TCF Tower, 121 South Eighth 
Street, Minneapolis, MN 55402, U.S.A. AMcCrackin@ 
slwk.com 
1	 Vietnam became the WTO’s 150th member following a 
decision by the General Council, on 7 November 2006,
to approve the southeast Asian country’s membership 
agreement. More information is available at www.wto. 
org/english/thewto_e/acc_e/a1_vietnam_e.htm. 
2	 www.uspto.gov/web/offices/pac/dapp/pctstate. 
html. See, also in this Handbook, chapter 10.7 by AM 
Schneiderman. 
3	 Listings of states party to the PCT and the Paris 
Convention and Members of the World Trade 
Organization can be found at www.wipo.int/pct/en/
texts/pdf/pct_paris_wto.pdf. 
4	 A listing of European Patent Organisation (EPO) 
member states can be found at www.european-
patent-office.org/epo/members.htm. 
5	 A listing of members of the African Regional Intellectual 
Property Organization (ARIPO) can be found at
www.aripo.org/articles.php?lng=en&pg=14. 
6	 A listing of members of the African organization of the 
Intellectual Property (OAPI) can be found at www.oapi. 
wipo.net/en/OAPI/historique.htm. 
7	 Web site of the Eurasian Patent Organization Office 
(EAPO): www.eapo.org/index_eng.htm. 
8	 See supra note 3. 
9	 The newsletter is available at www.wipo.int/
patentscope; to reach the help desk, call +1-703-305 3257 
(United States) or +41-22-338 8338 (Switzerland).
10 See supra note 3. 
11	 Time Limits for Entering National/Regional Phase 
under PCT Chapters I and II can be found at www.wipo.
int/pct/en/texts/pdf/time_limits.pdf. 
12	 Patent Cooperation Treaty (PCT) Information. European 
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Filing International Patent Applications 

under the Patent Cooperation Treaty (PCT):

Strategies for Delaying Costs and Maximizing 

the Value of Your Intellectual Property Worldwide 

anne M. schneideRMan, Registered Patent Attorney, Law Offices of Anne M. Schneiderman, Ph.D., U.S.A. 
ABSTRACT 
Obtaining international patent protection for an inven­
tion can present a significant financial commitment for an 
early-stage company, entrepreneurial venture or not-for­
profit organization with a limited budget for intellectual 
property management. This chapter examines the use of 
patent application filings under the Patent Cooperation 
Treaty (PCT) to delay, consolidate, or minimize the costs 
of patenting overseas. Using the PCT to file internation­
ally enables a patent applicant to delay, generally for up 
to 30 months after the first (priority) filing date, strategic 
decisions about the countries in which to pursue patent 
protection. The delay offers a significant advantage, since 
it allows the applicant more time in which to evaluate 
commercial demand for the invention, the likelihood of 
its success in overseas marketplaces, and the likelihood of 
obtaining a patent grant in a particular country, prior to 
filing national-phase patent applications in the countries 
in which patent protection is sought. 
1. InTRoduCTIon 
Obtaining international patent protection for an 
invention can present a significant financial com­
mitment, especially for small or early-stage com­
panies, entrepreneurial ventures, not-for-profit 
organizations (such as universities and charitable 
organizations), and independent inventors. Such 
entities usually have to conserve their financial re­
sources while striving to build, maintain, protect, 
and expand their intellectual property (IP). The cost 
of procuring a national or regional patent, from the 
initial drafting of the application through prosecu­
tion of the patent application, allowance, issuance, 
and post-issuance maintenance of the patent, can 
easily run from US$30,000 to US$50,000 in legal 
and patent-office fees. Should patent protection 
for an invention be sought in more than one coun­
try, the costs of international patent procurement 
can multiply accordingly. Since the costs associated 
with obtaining patent protection are so significant, 
IP protection strategies that delay, consolidate, or 
minimize costs are advantageous. 
The Patent Cooperation Treaty (PCT) is an 
important IP protection tool that can be used to 
confront the financial challenges associated with 
international patent protection. By facilitating 
the filing in any number of PCT member coun­
tries of parallel patent applications, a PCT patent 
application offers a valuable means of managing, 
delaying, or consolidating the costs of interna­
tional patent protection for a given invention. 
The PCT can buy time to strategically evaluate 
the overall potential value of an invention, that is, 
provide time within which to make an informed 
decision as to how to best proceed.1 
The challenge of managing the costs of pro­
tecting IP so that the IP becomes a commercial 
asset—and not a financial liability—is one that is 
faced universally by technology managers. An en­
terprise that has developed (or acquired) IP must 
Schneiderman AM. 2007. Filing International Patent Applications under the Patent Cooperation Treaty (PCT): Strategies for 
Delaying Costs and Maximizing the Value of Your Intellectual Property Worldwide. In Intellectual Property Management
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR:
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. AM Schneiderman. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged. 
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decide at the outset whether that IP is worth 
protecting with a patent. The costs and benefits 
of patent protection must be carefully analyzed. 
Although a discussion of such a cost-benefit 
analysis is beyond the scope of this chapter, it is 
worth noting here that a granted patent generally 
“protects” the subject IP only to the extent that it 
confers to the patent owner the right to enforce 
the patent, that is, to exclude others from making 
the invention, using it, importing it, and so forth. 
In conducting a cost-benefit analysis, an enter­
prise may decide that the total expected value of 
a particular piece of IP simply does not merit the 
expense of obtaining a patent and enforcing the 
rights the patent confers. 
The patent applicant (or IP owner) must de­
termine the merits of the invention, the commer­
cial demand for the product or process provided 
by the invention, the likelihood of its success in 
the marketplace, and whether protection should 
be sought in a particular country.2 The applicant 
must also determine, preferably with the advice 
of a patent attorney, patent agent, or other profes­
sional with expertise in patent law, the likelihood 
that the patent application would succeed in the 
patent office of a particular country or region and 
whether that national patent office would decide 
that the invention meets its requirements for pat­
entability and, thereby, grant a patent. 
Ideally, these analyses are conducted prior to 
selecting specific countries in which to file pat­
ent applications. Thus, any strategy that extends 
the time limit for filing a patent application in a 
country, while preserving the priority (first filing) 
date for the application, potentially gives the pat­
ent owner more time for analysis and decision-
making before making the financial commitment 
to seek patent protection abroad. 
For patent owners and other entities with 
a proprietary interest in the subject matter to be 
patented, but without large budgets for patent 
portfolio development (for example, not-for-profit 
organizations, universities, regional technology in­
cubators, and agricultural cooperatives), extending 
the time limit for filing a patent application can 
provide a much-needed opportunity to stimulate 
investment and technology transfer. The extended 
time period afforded by filing an international 
PCT application, as described below, is increas­
ingly recognized by developing countries as an 
opportunity to publicly promulgate an invention 
with “patent pending” status, to identify and nego­
tiate with potential corporate sponsors, investors, 
licensees, and others involved in technology devel­
opment and commercialization and to stimulate 
further domestic inventive and related technologi­
cal activities. 
2.	 AppRoACHES	 To InTERnATIonAL	
pATEnT	pRoTECTIon 
There are three basic approaches to procuring in­
ternational patent protection on an invention.3 
The first approach, and the most expensive, is 
to file (usually on the same day) separate patent 
applications in the national patent office of each 
country or region4 in which protection is sought.5 
The drawback of this approach is that legal and 
filing fees for each country begin to accrue as 
soon as the application is filed. 
The second approach for filing internation­
ally is to file a patent application in accordance 
with the Paris Convention for the Protection of 
Industrial Property.6 Taking this route, the ap­
plicant files a patent application in a single Paris 
Convention member country7 (usually required 
to be the country of residence of at least one of 
the inventors), which establishes a first or priority
filing date for the application. The applicant can 
then delay filing in other Paris Convention coun­
tries for up to 12 months after the priority filing 
date. Member countries of the Paris Convention 
agree to recognize the priority date of a patent 
application filed in one member country and 
to give the benefit of that priority date to cor­
responding applications in all member countries. 
This approach delays the costs associated with 
international patent procurement for one year. 
Procurement costs initially accrue in the coun­
try of first filing, and then, up to one year later, 
the costs associated with filing applications in the 
other Paris Convention countries begin to accrue 
(Figure 1). 
The third and least-expensive approach, 
which is the primary focus of this chapter, is to 
file a single “international” application under the 
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auspices of the PCT. Of the three approaches, fil­
ing a PCT patent application is, financially and 
strategically, the most advantageous for manag­
ing, delaying, or consolidating the costs of inter­
national patent procurement. Filing a PCT pat­
ent application allows the applicant to delay, for 
up to 18 months after the filing the application 
or in most cases, for up to 30 months after the 
filing of the first (priority) application, strategic 
decisions about which countries to pursue patent 
protection in. The delay provides a significant ad­
vantage, since it allows the applicant more time 
to evaluate the commercial strength and viabil­
ity of the invention prior to filing national-phase 
patent applications in the countries in which pat­
ent protection is sought. 
.	 THE	pATEnT	 CoopERATIon
TREATy (pCT) 
The Patent Cooperation Treaty (PCT) is a coop­
erative agreement entered into by more than 130 
countries (called PCT contracting states) with 
the purpose of bringing international conformity 
to the filing and preliminary evaluation of patent 
applications,8 both simplifying and making more 
economical the process of seeking patent protec­
tion in other countries. An applicant does not ap­
ply for an “international” patent by filing an ap­
plication under the PCT. The World Intellectual 
Property Organization (WIPO), which adminis­
ters the processing of PCT applications, does not 
grant international patents. Instead, the PCT fil­
ing process produces a single patent application 
that has been vetted for compliance with filing 
formalities and that has undergone a preliminary 
search and evaluation. This single application can 
then be transmitted to the national patent offices 
of as many PCT member countries as the appli­
cant chooses, for filing as a national-phase appli­
cation in that country. The PCT thus streamlines 
and consolidates the process of seeking patent 
protection in more than one country into a single 
series of steps and a single set of preliminary re­
quirements (see Section 4). 
Filing international applications with the 
PCT is becoming increasingly popular. In January 
2005, the one millionth PCT application was 









Local first-filed patent application followed within 12 months by multiple foreign
applications claiming priority under the Paris Convention: 






•	 multiple examinations and prosecutions of applications
 
• translations and fees required at 12 months
 
Some rationalization because of regional arrangements: ARIPO, EAPO, EPO, and OAPI†
 
†	 African Regional Intellectual Property Organization, European Patent Office, Eurasian Patent
Organization, Organisation Africaine de la Propriété Intellectuelle. 
Source: Courtesy TDR Patents: T. David Reed LLC. 
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SCHNEIDERMAN 
filed, with the doubling time for numbers of ap­
plications filed having gone from 22 years (for the 
first half million applications) to just 4 years (for 
the next half million applications).9 
.1	 Non-PCT member countries 
More than one hundred countries, however, are 
not members of the PCT, including a number 
of countries in Asia (for example, Cambodia, 
Nepal, Pakistan, Thailand), South America (for 
example, Bolivia, Chile, Guyana, Paraguay, Peru, 
Suriname, Uruguay, Venezuela), Central America 
(for example, Panama), the Middle East (for 
example, Iran, Iraq, Jordan, Kuwait, Lebanon, 
Saudi Arabia, Yemen), and Africa (for example, 
Ethiopia, Rwanda, Somalia). To obtain patent 
protection in nonmember countries, a patent 
application must generally be filed directly with 
the national (or regional) patent office.10 Since 
patent protection involves complex questions of 
law, the applicant is well-advised to consult with 
patent counsel familiar with local patent law, in­
ternational Paris Convention patent practice, and 
international PCT patent practice before filing a 
patent application, especially if applicants are ei­
ther residents of non-PCT contracting states or 
inventions were made in non-PCT contracting 
states. For example, if all of the applicants on a 
patent application are residents or nationals of 
non-PCT countries, then an application filed 
with the PCT is generally denied an international 
PCT filing date. 
In general, if the application is first filed in 
a country that is not a member of the PCT but 
is a member of the Paris Convention,11 then the 
applicant will be ineligible to file a PCT appli­
cation but may choose to file additional applica­
tions in the national patent offices of other Paris 
Convention member countries within 12 months 
of the filing (priority) date of the first application 
(Section 2, second approach, above). 
If the application is first filed in a country 
that is not a member of the PCT or the Paris 
Convention, then the applicant will be ineligible
to file a PCT application, or an application under 
the Paris Convention in Paris Convention mem­
ber countries, within 12 months of the filing (pri­
ority) date of the first application. The applicant 
will be obliged to file a separate patent application 
(usually on the same day) in the national patent 
office of each country or region in which protec­
tion is sought (Section 2, first approach, above).
.2	 Costs associated with filing 
a PCT patent application 
Filing a PCT patent application entails paying a 
single set of filing fees, as opposed to multiple filing 
fees for each country in which patent protection 
is sought. Currently, PCT filing fees are approxi­
mately US$1100 for filing an application (with a 
fee reduction for filing electronically online or via 
other electronic media), from US$200 to US$2100 
for a search of prior art publications (depending on 
which international searching authority performs 
the search), and a nominal transmittal fee (around 
US$300) charged by the PCT receiving office. The 
applicant can also elect to file a demand (request) 
for international preliminary examination of the 
application, which entails an additional fee of ap­
proximately US$600 to US$750. 
. 	 PCT filing consolidates and 
delays patent prosecution costs 
Filing a patent application under the PCT con­
solidates or eliminates the duplication of costs 
associated with multiple filings in multiple coun­
tries and enables the applicant to submit a single 
patent application in a single language and in a 
format that conforms to the requirements of all 
the national patent (or regional) offices of PCT 
contracting states. The added burden and expense 
of translating the application and of filing it in a 
particular format for a particular national patent 
office is thus avoided. 
During the international phase of its pendency, 
a PCT application undergoes a preliminary evalua­
tion that comprises an international search for prior 
art publications, a written opinion and a prelimi­
nary report on patentability, and optionally, a pre­
liminary examination and a second, more detailed, 
report on patentability. The applicant can then 
choose to transmit the uniform application and ac­
companying evaluation documents to the national 
patent offices of as many PCT contracting states as 
desired, in which the application enters the national 
phase of the patent procurement process. 
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By far, the most expensive aspect of interna­
tional patent procurement is the national-phase 
cost, which includes the fees paid to each national 
patent office for entrance into the national phase 
and during the patent prosecution process, the 
legal fees of local attorneys or agents to obtain a 
national patent, and the fees to the national pat­
ent office to maintain the granted patent in force. 
Filing under the PCT enables costs associated 
with the national phase to be deferred, in most 
cases for up to 30 months from the priority (first 
filing) date, while an international patent-protec­
tion strategy is formulated and decisions are made 
about which countries to seek protection in. 
. 	 The role of WIPO in the 
Patent Cooperation Treaty 
WIPO, an international organization based in 
Geneva, Switzerland, is the administrative body 
that oversees the filing of international applica­
tions under the PCT. The International Bureau 
of WIPO administers the international phase of 
the PCT application process, prior to entrance 
into the national phase of countries in which 
patent protection is sought. WIPO receives and 
stores PCT applications, along with their associ­
ated files of patent search and examination doc­
uments and correspondence. WIPO examines 
each application for its adherence to filing for­
malities (such as the required format for the pat­
ent application, accompanying administrative 
filing papers, and fees paid). Based on this initial 
examination, the applicant may be required to 
correct any formal defects to bring the applica­
tion into conformity with the PCT format ac­
cepted by patent offices in the member states. 
The carrying out of these procedures reduces the 
costs of patent procurement at an early stage. 
Formalities defects in the PCT application that 
are identified during the international phase can 
be rectified before the application reaches the 
national patent offices and enters the national 
phase of the patent examination and procure­
ment process. Thus, separate formalities rejec­
tions by national patent offices in which patent 
protection is sought can be avoided. 
WIPO is responsible for publishing PCT 
applications12 and accompanying information 
about them, which can be accessed worldwide 
via the Internet at the WIPO Web site. WIPO 
oversees translation of portions of the PCT ap­
plication and associated documents into English 
or French, also available on the Internet, and can 
provide the national patent offices of contracting 
states with application documents. 
.	 opTIonS	And 	STEpS	 foR	
fILInG	 undER	 THE	pCT 
.1	 Alternative 1: File an international 
PCT application that complies 
with PCT formality requirements 
and pay one set of fees. 
An international patent application can be filed 
under the PCT if at least one of the inventors of 
the invention is a resident of a PCT contract­
ing state. Applicants can generally file an in­
ternational PCT application with the national 
patent office of their country of residence, with 
the national office acting as a receiving office for 
the PCT. Under some circumstances, the PCT 
application can be filed directly with WIPO in 
Geneva. 
The WIPO Web site provides detailed guides 
to PCT filing requirements,13 as well as a guide to 
PCT time limits14 and a PCT time-limit calcu­
lator15 to assist applicants in computation of es­
sential time limits for filing applications and for 
submissions of other required documents. Time 
limits under the PCT are measured from the 
priority date of the application (Figure 2). The 
priority date is defined in PCT Article 2(xi) as 
follows: 
(xi) “priority date,” for the purposes of computing 
time limits, means: 
(a) where the international application con­
tains a priority claim under Article 8 [of 
the PCT], the filing date of the application 
whose priority is so claimed; 
(b) where the international application con­
tains several priority claims under Article 
8, the filing date of the earliest application 
whose priority is so claimed; 
(c) where the international application does 
not contain any priority claim under 
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Time limits for international PCT applications filed on or after 1 January 2004.
•	 “Month 0” corresponds to the priority date, the date of earliest filing of a local, regional or 
national application. An international PCT application claiming priority to the priority date 
must be filed prior to the expiration of 12 months from the priority date.
•	 Approximately 16 months after the priority date, the international search report and the 
written opinion are issued by the international searching authority (ISA).
•	 Approximately 18 months after the priority date, the application is published.
•	 In countries that have not withdrawn their notifications of the incompatibility of the time limit
under PCT Article 22(1) with applicable national law, a demand for international preliminary 
examination should be filed prior to the expiration of 19 months from the priority date, if the 
applicant wishes to postpone entry into the national phase. Otherwise, a demand may be filed 
for up to three months from the date of transmittal of the international search report and 
written opinion of the ISA, or 22 months from the priority date, whichever expires later.
•	 The international preliminary report on patentability (Chapter II) is issued by the international 
preliminary examining authority (IPEA), approximately 28 months from the priority date.
Unless an international preliminary examination report is established under Chapter II, the 
International Bureau of WIPO issues a report on behalf of the ISA that has the same contents 
as the written opinion. This report, the international preliminary report on patentability 
(Chapter I), is communicated to each designated national-phase office not before the 
expiration of 30 months from the priority date.
•	 The national phase usually must be entered prior to the expiration of 30 months from the 
priority date. Some countries make provisions for entering the national phase later than the 
PCT 30-month time limit (see endnote 15). As with all deadlines mentioned in this chapter, the 
PCT articles, rules, applicant’s guides, and the PCT time-limit calculator should be consulted,
and deadlines should be confirmed by a qualified patent attorney or agent. 
•	 For all designated states to which new Article 22(1) of the PCT does not yet apply, the applicant
must decide whether to file demand by 19 months or to enter national phase by 20 months.
As of 26 June 2006, these countries maintain reservations to the new Article 22(1) timing:
Switzerland, Lithuania, Sweden, Tanzania, and Uganda.
Source: Modified after the U.S. Patent and Trademark Office.17 
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CHAPTER 10. 
Article 8, the international filing date of 
such application[.]16 
The time limits are based on the earliest pri­
ority date of the PCT application and include: 
•	 time limit for submission of the priority 
document on which the priority date of the 
PCT application is based 
•	 earliest potential date for international 
publication of the PCT application, which 
is usually 18 months after the priority date 
•	 time limit for a demand for international 
preliminary examination 
•	 time limit for entry of the application into 
the national/regional phase 
.2	 Alternative 2: File a national 
application first and then a PCT application 
within 12 months 
Once a PCT application is filed, the applicant 
has up to 18 months to delay before deciding 
to enter the national phase and file national 
applications in one or more PCT contracting 
states (Figure 2). To delay even further the time 
between the first filing (priority) date of an ap­
plication and entry into the national phase, the 
applicant has the option of filing a national ap­
plication first, and then, up to 12 months lat­
er, filing a PCT application claiming priority 
to the national application. Laws of individual 
PCT contracting states generally require that if 
an applicant desires to file a patent application 
and the invention was made in a particular state, 
then either a national patent application must be 
filed in that state (and generally, a foreign filing 
license obtained) before the application is filed as 
a national application in other states, or an inter­
national PCT application must be filed directly 
with a PCT receiving office. 
During the 12-month period following the 
filing of the priority application, the applicant 
can choose to file one or more additional national 
applications, as new refinements or embodiments 
of the invention are developed. A PCT applica­
tion must be filed no later than 12 months after 
the filing date of the first application, however, to 
claim benefit of that earliest application’s priority 
date. 
The PCT application, however, can incor­
porate the disclosures of, and claim priority to, 
all the national applications directed to that 
invention that were filed during the previous 
12-month period. The disclosure and claims of 
the PCT application may therefore differ from 
those of the priority application(s) preceding it 
in the patent family.18 The PCT application can 
also include new disclosure pertaining to the in­
vention (for example, a description of new em­
bodiments of the invention) or new claims that 
were not set forth in any of the priority applica­
tions. However, to obtain benefit of an earlier 
priority date, a new claim included in the PCT 
application must be supported by the disclosure 
of the priority application filed on that date. 
After filing the PCT application, the appli­
cant has, as described above, up to 18 months 
to delay before deciding to enter the national 
phase and to file national-phase applications in 
separate PCT member countries. Hence, the ap­
plicant can delay for 12 months plus 18 months, 
or in most cases up to 30 months, after the filing 
of the initial priority application before entering 
the national phase in a desired PCT contracting 
state.19 In the meantime, the applicant can use 
this delay to advantage, and take the time to eval­
uate the merits of seeking protection in specific 
countries and to delay the assessment and accrual 
of patent prosecution fees in multiple countries. 
Hence, with this approach: 
•	 A national patent application is filed in the 
patent office of a PCT contracting state 
(member country), establishing the priority 
(first filing) date. This national application is 
sometimes referred to the priority application. 
•	 Within 12 months after the priority date, 
a PCT application is filed and enters the 
international phase. 
•	 Within 18 months of PCT filing, or within 
30 months of the priority date, the PCT 
application enters the national phase of se­
lected PCT member countries.20 
. 	 Designating countries in which 
to file a national-phase application 
When a PCT application is filed, all contract­
ing states that are bound by the PCT to the 
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international filing date are designated, by de­
fault, as potential venues for filing subsequent 
national-phase applications.21 Before the expira­
tion of the 30-month time limit after the priority 
date, the applicant can select a specific subset of 
the designated states for actual filing of national-
phase applications with national patent offices. 
The transmittal to, and filing of, the international 
PCT application with the national patent office 
of a contracting state is known as entering the na­
tional phase of international patent prosecution 
(Figure 2). By filing under the PCT just before 
the expiration of the 30-month time limit, the 
applicant delays examination of the application 
for patentability by a national patent office signif­
icantly past the point at which national examina­
tion would normally occur had application been 
filed directly with the national patent office. 
The prosecution phase of a national-phase 
patent application can become very expensive. 
It can take several years of interaction between 
the patent attorney and the patent examiner dur­
ing the examination proceedings and cost tens of 
thousands of dollars (US$) in attorney costs and 
national-patent-office prosecution fees, before 
patent claims are possibly allowed and the appli­
cation issues as a patent. If patent prosecution is 
undertaken in more than one country, then the 
costs of obtaining patent protection multiply ac­
cordingly. Thus, one of the chief advantages of 
filing under the PCT is the permitted delay of up 
to 30 months after the priority date to enter the 
national phase. 
. 	 PCT international search 
report and written opinion 
Prior to publication of the PCT application 18 
months after the priority date, and during the 
international phase, a PCT international search­
ing authority (ISA) conducts a search of the in­
ternational technical literature to identify patent 
publications, technical publications, and other 
prior art references that are material to patent-
ability of the claimed invention. Current ISA’s 
are the European Patent Office and the nation­
al patent offices of Australia, Austria, Canada, 
China, Finland, Japan, the Republic of Korea, 
the Russian Federation, Spain, Sweden and the 
United States. The ISA conducts the search ac­
cording to search standards set by the PCT and 
compiles an international search report contain­
ing a list of references that are deemed material 
to patentability. For each reference, the search re­
port states the patentability criteria (for example, 
novelty, nonobviousness or inventive step, and 
industrial applicability) for which the reference 
is considered material. The ISA issues a written 
opinion that accompanies the search report and 
that states whether the invention appears to be 
patentable based on the results of the search. 
The international search report and the writ­
ten opinion provide the applicant with an early 
indication of the likelihood of success in obtain­
ing a patent based on the claims as filed. This 
early indication is another significant advantage 
of filing under the PCT. In view of the search re­
port and the written opinion, the patent claims 
can be amended by the applicant to better dis­
tinguish the invention from the prior art before 
the application enters the national phase. Thus, 
the possibility of having the same claims rejected 
by multiple national patent offices for the same 
(or similar) reasons can be minimized or avoided. 
The added legal and administrative expense of fil­
ing separate claim amendments in each national 
patent office can also be avoided. 
Another distinct advantage is that the ap­
plicant may submit to WIPO informal written 
comments addressing, and possibly rebutting, the 
reasoning and conclusions set forth in the writ­
ten opinion. This enables the applicant to begin 
creation of a prosecution record for the applica­
tion that sets forth reasons for patentability of the 
claims, and that accompanies the application as it 
enters the national phase in each country and is 
examined by each national patent office. 
The applicant (as explained in Section 4.5) 
also has the option to file a demand and to pay 
for an international preliminary examination 
(a Chapter II examination), which is a more de­
tailed evaluation of the patentability of the claims 
that results in the issuance of an international 
preliminary report on patentability (IPRP 
Chapter II). The time limit for filing a demand 
is three months from the date of transmittal of 
the international search report and the written 
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opinion, or 22 months from the priority date, 
whichever comes last.22 
If the applicant does not file a demand for 
international preliminary examination, the ISA’s 
written opinion will be subsequently converted 
into an international preliminary report on pat­
entability (IPRP Chapter I), which is sent, along 
with the applicant’s informal comments respond­
ing to the written opinion, to each of the patent 
offices selected for national-phase entry, not be­
fore the expiration of 30 months from the prior­
ity date. 
Thus, when the national phase is entered in 
each country, each national-phase patent applica­
tion is accompanied by the same search and in­
ternational preliminary report(s) on patentability 
(a Chapter I report, and optionally, a Chapter II 
report, depending on whether international pre­
liminary examination has been elected or not). 
This significantly reduces the search and exami­
nation effort required for each separate national 
patent office. 
. International preliminary examination 
If an applicant requests and pays the additional 
fee for international preliminary examination, 
then a second, more-detailed evaluation of the 
patentability of the claims is conducted by a PCT 
examiner associated with one of the internation­
al preliminary examining authorities (IPEAs), 
which are the same as the international search­
ing authorities (ISAs) described above. A demand 
(request) for international preliminary examina­
tion may be made at any time prior to (a) three 
months from the date of transmittal to the ap­
plicant of the international search report and the 
written opinion or (b) 22 months from the earli­
est priority date (whichever is later). 
The international preliminary examination 
provides a formal opportunity for the applicant to 
respond to the reasoning and conclusions of the 
PCT examiner, as set forth in the written report 
or the international preliminary report on patent-
ability (Chapter I), regarding patentability of the 
claims, and to set forth on the record amended 
claims and arguments for patentability. The inter­
national preliminary examination concludes with 
the issuance, by the PCT examiner, of a second or 
international preliminary report on patentability 
(Chapter II), which is transmitted to the national 
patent offices. The international preliminary re­
port on patentability (Chapter II) will be issued 
by the IPEA, in general, at around 28 months 
from the priority date (see Figure 2). 
This creation of a formal-patent prosecution 
record prior to national-phase entry further re­
duces the duplication of efforts of each separate 
national office in performing a separate prelimi­
nary examination and the expense incurred by 
the applicant in responding to the results of each 
such national examination. The international pre­
liminary report on patentability (Chapter II) ac­
companies the patent application as it enters the 
national phase, which can further reduce the du­
plication of examination efforts in each national 
patent office. It also can serve to consolidate and 
focus the prosecution strategy for the application 
and avoid the duplication of efforts by patent at­
torneys or agents prosecuting the application in 
each country. 
Although national patent offices have no le­
gal obligation to consider the reasoning and con­
clusions of the international preliminary reports 
on patentability (Chapters I and II), they will 
frequently do so. Thus, international preliminary 
examination is a means to reduce the effort ex­
pended on separate examination of the same ap­
plication in various national patent offices, and 
hence to reduce the applicant’s legal fees associ­
ated with separate examinations. For example, 
examiners in several national patent offices may 
have the same basis for objection to (or rejection 
of ) the same group of claims in the application, 
and the applicant may choose to submit similar 
arguments to each examiner to overcome the ob­
jection. The examiner in each country, however, 
may respond very differently to these arguments, 
taking into account the differences in national or 
regional patent law. Thus, although a national- 
phase application may elicit similar objections in 
the initial office actions issued by examiners in 
different national or regional patent offices, there 
may be much less conformity in the subsequent 
prosecution history of the application as the ap­
plication progresses through the various patent 
offices. In patent offices of countries that have less 
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capacity or resources for patent examination, how­
ever, patent examiners may rely on IPRPs more 
extensively. Thus, the IPRPs can have a greater 
influence on the patent claims that eventually are 
granted in those countries, thus promoting some 
similarity or uniformity in the claims granted in 
various countries. 
Furthermore, the PCT examiner who is­
sues the written report or the international pre­
liminary report on patentability (Chapter I), 
and who performs the optional international 
preliminary examination and issues the more-
detailed international preliminary report on 
patentability (Chapter II), may be the same per­
son and be assigned to examine the application 
during the national phase. For example, the ex­
aminer who examines a PCT application sub­
mitted to the U.S. receiving office may be the 
same person who examines the corresponding 
application filed with the United States Patent 
and Trademark Office (PTO). This also avoids 
duplication of efforts and can result in a more 
thorough and informed evaluation by the pat­
ent examiner, who has previous experience with 
the application during the international phase. 
. National-phase entry 
National-phase entry of a PCT application re­
quires, by the end of the 30th month after the 
first priority date of the application, that the 
applicant selects the PCT contracting states in 
which to file a national phase application, files an 
application with each national-patent office, pays 
the associated national filing fees, and, under cer­
tain circumstances, furnishes a translation of the 
application.23 
An advantage of filing a national-phase ap­
plication, as opposed to filing a national appli­
cation directly with a patent office, is that the 
applicant can use information acquired during 
the PCT international phase to strengthen the 
application upon entry into the national phase. 
The applicant can use information derived from 
the written opinion and the international pre­
liminary report(s) on patentability to plan which 
claims to amend or eliminate prior to entry into 
the national phase. In countries that charge fil­
ing surcharges for claims in excess of a prescribed 
number, such surcharges can be reduced or 
avoided.24 For example, the United States charg­
es significant surcharges for independent claims 
in excess of three or total claims in excess of 20 
in an application. Under the PCT, there is no 
claim limit or charge for excess claims. Hence, an 
applicant planning a subsequent U.S. national-
phase entry can choose to include a large number 
of contemplated claims in the PCT application 
and then consider the results of the PCT evalua­
tion from the international phase and amend or 
eliminate claims accordingly. 
.	 SuMMARy 	And ConCLuSIonS 
Filing a patent application under the PCT en­
ables the applicant to delay strategic decisions 
about where to pursue patent protection by: 
•	 consolidating patent prosecution costs: sin-
gle-application format, language, and set of 
fees 
•	 providing the applicant with preliminary 
feedback regarding patentability of the 
invention 
•	 providing the applicant with the opportu­
nity to present arguments for patentability, 
to amend claims, and to strengthen the ap­
plication prior to filing with national pat­
ent offices 
•	 enabling the applicant to delay filing the 
application in individual national patent 
offices for up to 30 months after the first 
(priority) filing date 
•	 delaying prosecution costs of filing applica­
tions in multiple countries 
•	 streamlining the process of filing applica­
tions in multiple countries 
Delaying international patent prosecution 
provides more time to determine: 
•	 the value of IP to applicant or owner 
•	 the strength of commercial demand abroad 
•	 which claims in a patent application are 
likely to be patentable 
•	 which countries are most attractive for pur­
suing patent protection 
•	 the likelihood of obtaining a patent grant 
in target countries. n 
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CHAPTER 10. 
anne M. schneideRMan, Registered Patent Attorney, Law Brochure on Intellectual Property Rights For Universities 
Offices of Anne M. Schneiderman, Ph.D., 102 East State and R&D Institutions in African Countries. WIPO:
Street, Suite 7, Ithaca, NY, 14850, U.S.A. anne@schneider- Geneva, Switzerland. ISBN 92-805-1097-7. www.wipo.
manlaw.com	 int/freepublications/en/intproperty/849/wipo_pub_ 
849.pdf. 
11 See supra note 7.
1	 This chapter reflects the present considerations and 12 Languages of international publication: Arabic,
views of the author and provides information for edu- Chinese, English, French, German, Japanese, Russian,
cational purposes only. It is not intended to constitute and Spanish. 
legal advice or to substitute for obtaining legal advice 13	 WIPO provides detailed guides online to filing under 
from a lawyer about a particular legal issue. Legal ad- the PCT: World Intellectual Property Organization 
vice needs to be tailored to specific circumstances, and (WIPO). PCT Applicant’s Guide (Volumes 1 and II).
readers are therefore urged to consult directly with a WIPO: Geneva, Switzerland. Volume I is available at
lawyer for assistance regarding their particular legal www.wipo.int/pct/guide/en/gdvol1/pdf/gdvol1.pdf
issues. and Volume II at www.wipo.int/pct/guide/en/gdvol2/
2 See also Radack DV. 1992. Patents Outside of the U.S.: A pdf/gdvol2.pdf. 
Cost-Effective Approach. JOM 44(4): 62. www.tms.org/ 14	 World Intellectual Property Organization (WIPO). PCT 
pubs/journals/JOM/matters/matters-9204.html. Timelines and Time Limits. WIPO: Geneva, Switzerland.
3 World Intellectual Property Organization (WIPO). www.wipo.int/pct/en/seminar/basic_1/timeline.pdf. 
2006. WIPO Publication, No. 433(E): Protecting Your 15	 PCT time limit calculator. www.wipo.int/pct/en/ 
Inventions Abroad: Frequently Asked Questions about calculator/pct-calculator.html.

the Patent Cooperation Treaty (PCT). WIPO: Geneva,






4 Examples of regional patent offices include African 17	 www.uspto.gov/web/offices/pac/mpep/documents 
/1800_1842.htm.Regional Industrial Property Organization www.aripo.

wipo.net/index.html; Eurasian Patent Organization 18 The term patent family is used to designate a 

www.eapo.org/index_eng.html; and the Gulf relationship between a patent application and 

Cooperation Council www.gulf-patent-office.org.sa. its priority application(s) or other patent priority

document(s). At least three descriptions are commonly 5 Since patentability is based, in part, on novelty and 
used in patent practice to characterize a patentnonobviousness of an invention, patent applications 

family:
 on the same invention should be filed on the same 

day and should not be spaced out (filed in different (1) The applications or documents are directly or in-

countries at different times). directly linked to a specific priority application or 

document.6	 Articles of the Paris Convention for the Protection of 
(2) All applications or documents have at least one pri-Industrial Property can be viewed online at www.wipo.

ority application or document in common.
 int/treaties/en/ip/paris/pdf/trtdocs_wo020.pdf. 
(3) All documents have exactly the same priority or pri-
7	 Many, but not all, members of the Paris Convention orities in combination. 
are also members of the PCT (and vice versa). List of See also European Patent Office (EPO). About: Patent
Paris Convention contracting parties (currently 170) Families at gb.espacenet.com/espacenet/gb/en/help 
can be viewed online at www.wipo.int/treaties/en/ /161.htm.
ShowResults.jsp?lang=en&treaty_id=2.
 
19 There are a few instances in which the national law 

8	 Articles of the Patent Cooperation Treaty (PCT) can be of a contracting state is incompatible with the PCT 
viewed online at www.wipo.int/pct/en/texts/pdf/pct. 30-month time limit-rule and in which the national 
pdf. PCT Regulations, including rules and requirements patent offices of these countries still adhere to the old 
for filing applications, time limits, and so on, can be 20-month time limit for entering the national phase 
viewed online at www.wipo.int/pct/en/texts/pdf/pct_ (This older rule was replaced on 1 April 2002 with the 
regs.pdf. A list of PCT contracting states (currently 134 new time limit). In countries with a 20-month time 
contracting states) can be viewed online at www.wipo. limit for entry into the national phase, the limit can be 
int/treaties/en/ShowResults.jsp?lang=en&treaty_ extended to 30 months if a demand for international 
id=6. preliminary examination is made. Some countries 
9	 World Intellectual Property Organization (WIPO). 14 make provisions for entering the national phase later 
January 2005. Press Release 401: WIPO Marks Filing than the PCT 30-month time limit. In these cases, if the 
of One Millionth PCT Application. WIPO: Geneva, applicant fails to meet the time limit to nationalize 
Switzerland. www.wipo.int/edocs/prdocs/en/2005/ their PCT application within 30 months, the time 
wipo_pr_2005_401.html. limit can be extended upon petition and payment of 
extension fees. As with all deadlines mentioned in 10 See also World Intellectual Property Organization 
this chapter, the PCT Articles, Rules, Applicant’s Guides,(WIPO). No stated date. WIPO Publication No. 849(E): A 
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and the PCT Time Limit Calculator (available online at
www.wipo.int) should be consulted in determining 
time limits and the deadlines confirmed by a qualified 
patent attorney or agent. 
20 If the country in which the national (priority) 
application was filed is also selected as a country into 
which the PCT application enters the national phase,
this essentially creates a continuation application in 
that country. 
21	 The PCT request form,which is one of the administrative 
forms filed with a PCT application, sets forth this 
default designation. Certain exclusion provisions 
can be selected, using the request form, to exclude a 
country from designation. 
22 A demand should be filed prior to the expiration of 
19 months from the priority date if the applicant
wishes to postpone entry into the national phase in 
countries that have not withdrawn their notifications 
of the incompatibility of the time limit under PCT 
Article 22(1) with applicable national law (see Figure 
1 and World Intellectual Property Organization). PCT 
Practical Advice 2003. www.wipo.int/pct/en/newslett/
practical_advice/pa_122003.htm. 
23 The general national-phase entry requirements and 
the specific requirements for each PCT contracting 
state are described in detail in: World Intellectual 
Property Organization (WIPO). PCT Applicant’s Guide 
Volume II. WIPO: Geneva, Switzerland. www.wipo.int/ 
pct/guide/en/gdvol2/pdf/gdvol2.pdf. 
24 See also Austin CB. 2005. Leveraging PCT Patent
Applications to Gain Advantages in Patent Prosecution.
www.michaelbest.com/articles.cfm?action=view&pu 
blication_id=1648. 
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CHAPTER 10.8 
Filing and Defending Patents in Different Jurisdictions
 
Ronald yin, Partner, DLA Piper US LLP, U.S.A.
 
sean cunninghaM, Partner, DLA Piper US LLP, U.S.A.
 
ABSTRACT 
In order to build an effective patent portfolio, an organi­
zation must (1) understand the dynamics of the interna­
tional patent landscape: how to establish foreign prior­
ity, where to file patent applications, and the advantages 
and disadvantages of pursuing various filing options; (2) 
determine in which countries and/or jurisdictions the 
organization should seek patent protection based on its 
objectives (whether commercial or humanitarian access); 
and (3) anticipate the possibility of litigation and know 
what its options for litigation are. 
1. InTRoduCTIon 
In February 2006, the U.S. Patent and Trademark 
Office (PTO) issued its seven millionth patent. It 
took 75 years for the PTO to issue its one-mil­
lionth patent (in the year 1911), but in less than 
a tenth of that time the office issued its last mil­
lion.1 Inventors in the United States and abroad 
are seeking to obtain patents at a pace unparal­
leled in history, and revenue from patent licens­
ing is at an all-time high. 
A company must ask itself several key ques­
tions before assembling a patent portfolio (or 
portfolios). What do we plan to do with our pat­
ents once we have them? Do we intend to assert 
our patents offensively (that is, with the aim of pro­
tecting market share), either as part of a licensing 
strategy or in litigation if companies are unwill­
ing to license? Or do we plan to use our patents 
defensively, as leverage in licensing negotiations 
or in order to ward off litigation by others? If a 
portfolio is to be used offensively, where are our 
potential targets located and/or doing the most 
business? If a portfolio is to be primarily defensive, 
in what location is our company most at risk from 
licensing approaches or litigation offensives? 
2. ovERvIEW	 of pATEnTInG	 pRoCEduRES 
To obtain a patent for an invention, the inven­
tor (often called the applicant) must file an ap­
plication for a patent at one or more national or 
regional patent offices. Once the necessary docu­
ments are filed and any fees paid, the patent office 
will examine the patent and decide whether or 
not to grant the applicant patent rights for the 
claimed invention. A patent’s first application 
date is commonly called its “priority date.” 
In most instances, an applicant will file a pat­
ent application in a national patent office in the 
country where he or she is located (such as the U.S. 
Patent Office [PTO], the Japanese Patent Office 
[JPO] or the European Patent Office [EPO]), in 
order to protect the invention for domestic mar­
kets; later, he or she can file patent applications 
in other countries or file an international applica­
tion under the Patent Cooperation Treaty (PCT) 
procedure (see Section 3) in order to protect the 
invention in foreign markets. Importantly, patent 
Yin R and S Cunningham. 2007. Filing and Defending Patents in Different Jurisdictions. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.).
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. R Yin and S Cunningham. Sharing the Art of IP Management: Photocopying and distribution through the Internet
for noncommercial purposes is permitted and encouraged. 
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YIN & CuNNINGHAM 
rights awarded by a patent office protect the inven­
tion only within the jurisdiction of that particular 
patent office, and not in other parts of the world. 
.  ovERvIEW	 of THE	pARIS
ConvEnTIon TREATy 
The Paris Convention, formally known as the 
Paris Convention for the Protection of Industrial 
Property, established the system of priority rights 
that is now internationally accepted. The United 
States and 171 other countries are signatories to 
the Paris Convention Treaty, and the signatories 
are sometimes collectively referred to as the “Paris 
Union.”2 
Under the Paris Convention Treaty, if an in­
ventor files a patent or trademark application in 
another Paris Convention member nation with­
in 12 months of the priority date, he or she is 
granted the right of priority: in other words, his 
or her patent or trademark application will take 
precedence over that of any identical patent or 
trademark application filed in the second country. 
Therefore, an inventor will not lose patent rights 
even if it takes him or her a long time to transfer 
the application to another country and have it 
translated into that country’s language. Since the 
Paris Convention Treaty is reciprocal (in other 
words, country A must accord to the inventors of 
country B the same right of priority as country B 
accords to the inventors of country A), no mem­
ber has an advantage over any other. 
Not every country is a member of the Paris 
Union. However, some countries that are not sig­
natories of the Paris Convention Treaty, such as 
Thailand, have entered into bilateral treaties with 
the United States that grant inventors rights simi­
lar to the right of priority. 
.  fILInG	A	 pATEnT	AppLICATIon 	In 
dIffEREnT	 TERRIToRIES 
Significant differences exist between patent offic­
es. Table 1 provides the main differences between 
the three major patent offices, and the following 
text describes them in more detail. 
Table 1: Significant Differences between the Three Main Patent Offices3 
Issue EPO JPO u.S. PTO 
Status of successful First to file First to file First to invent 
patent applicant
Patent duration 20 years	 20 years 20 years 
Application language English, French, or Japanese English
German 
Area in which the Designated EPCa Japan United States 
patent is valid member and extension 
countries 
Request for Yes, within 6 months Yes, within 3 years No provision 
re-examination 
of the patent
Time of publication of 18 months 18 months from 18 months from 
application from priority date priority date priority date4 
a European patent convention 
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.1  Filing with the U.S. Patent and Trademark 
Office 
When an application is filed at the U.S. Patent 
Office [PTO], it is assigned to a patent examiner. 
On the date 18 months from the priority date, 
the application is published (that is, information 
about the application is made available to the 
general public). It is possible for an applicant to 
request that the application not be published, but 
this request will be considered only if a patent for 
the invention has not been, and will not be, filed 
in a foreign country. The patent examiner search­
es through U.S. and foreign patent documents 
and published patent applications dated prior to 
the priority date in order to determine whether 
or not the claimed invention fulfills the require­
ments of being new, useful, and nonobvious. 
If a patent application is rejected, the ap­
plicant is notified in writing and given the op­
portunity to challenge the rejection. At any time 
during the lifetime of a patent, any person may 
file a request for the PTO to conduct a second 
examination of any claim of the patent on the 
basis of prior art patents or printed publications. 
In order to keep the patent in force (that is, to 
keep the invention protected by the patent), the 
applicant must pay maintenance fees within cer­
tain time periods. 
In the calendar year 2005, the PTO granted 
a total of 157,740 patents: 143,806 utility pat­
ents, 12,950 design patents, 716 plant patents, 
245 reissue patents, and 23 statutory invention 
registrations.5 The total number of patents issued 
in 2005 was 13% less than the number issued in 
2004 and 8.7% less than the number issued in 
2000; the number of utility patent grants issued 
in 2005 was 12.5% less than the number issued 
in 2004 and 10.4% less than the number issued 
in 2000.6 
In 2005, U.S.-resident inventors were grant­
ed 52.4% of all U.S. patents—a half-percent in­
crease over 2004—and foreign-resident inventors 
were granted the remaining 47.6%.7 
.2  Filing with the JPO 
The patent application process of the JPO is simi­
lar to that of U.S. PTO, although there are some 
important differences. Patent applications filed 
with the JPO are not automatically examined by 
patent examiners. Instead, the applicant has to 
file a request for examination within three years 
(reduced from seven years in 2001) of the appli­
cation date. If the applicant fails to file a request 
for examination within the time limit, the appli­
cation is withdrawn. All applications pending ex­
amination are published in an official Patent and 
Utility Model Gazette 18 months after the prior­
ity date. If the patent examination process does 
not turn up any reasons for refusal, the patent is 
granted and published in the gazette. After the 
patent is granted, anyone can request an appeal 
examination of the patent on the basis of lacking 
novelty or an inventive step (obviousness).8 
.  Filing with the EPO 
By filing a single patent application with the EPO 
in one of the three official languages (English, 
French, or German), an applicant can obtain the 
patent rights to an invention in one or more coun­
tries that are signatories of the European Patent 
Convention Treaty (EPC Treaty). Currently, 31 
countries have signed the treaty, and five addi­
tional countries are covered by an extension agree­
ment. At the time of filing, the applicant has to 
specify the EPC countries and “extension” coun­
tries in which he or she wishes to seek protection. 
If the applicant pays designation fees for seven 
countries, then the patent will automatically be 
granted in all EPC member states. Consequently, 
each patent application to the EPO is usually a 
bundle of patents, one for each country in which 
the applicant is seeking protection. 
There are three different ways to file EPO 
patent applications: 
1. Direct filing with the EPO; filing date be­
comes the priority date 
2. National patent application extended 	 to 
the EPO application within 12 months of 
the priority date, that is, the EPO applica­
tion is filed after first application 
3. International application filed under EPC 
Treaty 
Once an application is filed with the EPO, 
it is subjected to a two-phase examination proce­
dure. First, the patent examiner will search for pri-
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or art relevant to the invention; this search report, 
along with the patent application, is published 18 
months after the priority date. The applicant then 
has six months to file a request for a further ex­
amination. If he or she files such a request, the 
EPO will conduct a substantive examination to 
decide whether or not to grant the patent. If the 
applicant does not file a request within that time 
period, the application is deemed to have with­
drawn. Within nine months of a successful EPO 
patent grant, anyone can file an opposition to the 
patent.9 
In 2002, more than 110,000 patent appli­
cations were filed at the EPO. This represented 
an 84% increase from 1991. In 2002, residents 
of the European Union were granted the largest 
share of EPO patent applications (44.7%), a share 
that far exceeded that of U.S. residents (27.3%) 
and Japanese residents (17.4%). The share of bio­
technology patents filed with the EPO grew by 
8.3% a year between 1991 and 2002, while total 
EPO patent applications grew by 5.7%. In 2002, 
more than 5,800 biotechnology patents were 
filed at the EPO, with 39.9% coming from the 
United States, 34.5% from the European Union, 
and 14% from Japan. The proportion of residents 
of European Union being granted EPO patents is 
consistent with the proportion of U.S. residents 
being granted U.S. patents, suggesting that, over­
all, U.S. residents and E.U. residents must “share” 
their home market with residents from other ju­
risdictions. However, the growth of biotech pat­
ents has exceeded the growth of nonbiotech pat­
ents, and U.S. residents have filed proportionally 
more patents in this area than E.U. residents, sug­
gesting the lead U.S. residents have in this area of 
technology. 
.  Filing international applications 
under the PCT 
On January 24, 1978, the United States became 
a signatory to a multijurisdiction treaty, the PCT. 
The PCT allows an applicant to seek patent rights 
in a large number of countries by filing a single 
international application with a single patent of­
fice. The PCT is not a single patent filing effec­
tive in many jurisdictions. Instead, an applicant 
who files a PCT application is allowed to prolong 
his or her right to file patent applications in the 
national or regional jurisdictions designated in 
the PCT application for up to 30 months from 
the priority date. 
During the 1990s, the average annual growth 
rate for PCT filings was 17%. More recently, 
the growth rate has slowed, but there were still 
135,602 PCT applications filed in 2005, a 10.6% 
increase over the previous year and a more than 
45% increase over the number of applications
filed in 2000 (93,237). These figures demonstrate 
the increasing importance of PCT filings. 
.  A 	GLoBAL	 pATEnT-fILInG	 pRoGRAM	 
For several reasons, a global patent-filing program 
can quickly become prohibitively expensive if it is 
not managed properly. Patents are only enforce­
able within certain geographical regions. Patent 
prosecution (that is, the process of obtaining the 
patent) can be costly and time consuming. In 
many countries, the applicant must pay regular 
post-issuance fees (“maintenance fees” or “annui­
ties”) in order to keep the patent in force. Finally, 
patent applications must be filed before the in­
vention is disclosed—in other words, when its 
commercial merits are uncertain. Global patent 
filing is a high-stakes gamble. 
Nevertheless, the risk can be reduced some­
what by considering the following questions: 
•	 Does the invention have global market po­
tential? If the invention has only regional 
application, then it does not merit global 
patents. 
•	 Will the invention still be useful 15 or 
20 years from the date of filing? In many 
countries, the typical lifespan of a patent is 
15 to 20 years from the date of filing. If 
the invention will quickly become obso­
lete, then a global filing program may not 
be economical. Furthermore, it often takes 
two to three years from the date of filing for 
a patent to issue. Until a patent is issued, 
the invention will not have any enforceable 
legal protection. In that case, it may not be 
worth applying for patent protection at all: 
it may be more cost-effective to cash in on 
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the advantages of being the first to bring 
the invention to market. 
•	 Are the rights accorded to the patent owner 
separable? That is, has the owner the right 
to exclude another from selling the inven­
tion or the right to exclude another from 
manufacturing the invention? Countries 
can be divided into two categories: those 
where the invention can be manufactured 
and those where the invention can be sold. 
Of course, some of these countries may 
overlap. Nevertheless, it is not necessary to 
file patent applications in both countries 
where the invention can be made and in 
countries where the invention can be sold. 
Protection in only the countries where the 
invention can be sold effectively controls 
the world. Even though a would-be in­
fringer/competitor can make the product 
in a country not protected by any patent, 
the product cannot be sold in other coun­
tries. Furthermore, during the time a pat­
ent offers protection, capital markets and 
labor markets change—thus changing the 
situs of manufacturing over the life of an 
issued patent. In general, therefore, filing 
patent applications in the countries where 
the invention can be sold offers sufficient 
protection. 
•	 Is it necessary to file for patent protection 
in every country in which the invention 
might be marketed? This may not be neces­
sary. If patents are filed in 80%–90% of the 
countries where the invention can be mar­
keted, no competitor could capture more 
than 10%–20% of the worldwide market. 
If the cost of producing the product can 
be brought low enough, there may be no 
would-be competitors at all. 
.  LITIGATIon 	ConSIdERATIonS 
Patents often lead to litigation, both at home and 
abroad. This is not, however, all bad. Patents can 
be used prospectively—by threatening or initiat­
ing litigation to help preserve market share. Patent 
rights can, of course, be used by a company to 
protect itself from other companies that would 
accuse it of patent infringement. Parties seeking 
to initiate patent litigation in the United States 
can do so in various federal district courts or be­
fore the U.S. International Trade Commission 
(ITC). 
.1 Filing in a federal district court 
When filing a patent lawsuit in a federal district 
court in the United States, a litigant must first 
identify which courts would be proper venues. 
Then it must consider which of the permissible 
district courts would best suit its litigation goals. 
.1.1 Finding the proper venue for litigation10 
For a court to be a proper venue for patent litiga­
tion, the court must have jurisdiction with regard 
to the subject matter of the dispute and the per­
sons or entities involved. Jurisdiction is the power 
of a court to adjudicate a dispute. 
A corporation is considered to “reside” in any 
judicial district in which it is subject to personal 
jurisdiction at the time an action is commenced.11 
According to the U.S. Court of Appeals for the 
Federal Circuit, personal jurisdiction exists in a 
patent infringement case in which a defendant de­
liberately places infringing products in the stream 
of commerce with the expectation of exploiting 
business in the forum state. Accordingly, an action 
for patent infringement may be brought against a 
corporation in any district where the corporation 
is subject to personal jurisdiction at the time the 
suit is commenced. An action for patent infringe­
ment may be brought in any judicial district 
where the defendant resides.12 
U.S. district courts that hear patent litigation 
cases are located in various states. Each district 
court in a state (the forum state), may properly 
exercise personal jurisdiction over a party outside 
the forum state if: (1) the party is amenable to 
service of process under the long-arm statute of 
the forum state; and (2) the party’s activities in 
the forum state satisfy the minimum contacts re­
quirement of the Due Process Clause.13 With re­
gard to the first requirement of long-arm statute, 
various states have enacted legislation permitting 
its courts (including the federal district courts in 
that state) to exercise personal jurisdiction over 
nonresidents of the forum state, under certain 
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YIN & CuNNINGHAM 
conditions. As for the second requirement of due 
process, the Supreme Court of the United States 
has decided that the Constitution permits a non­
resident of a forum state to be subject to the ju­
risdiction of the courts in the forum state, if the 
nonresident had certain minimum activities with 
the forum state, thereby satisfying due process. 
Because several state long-arm statutes, includ­
ing those of Texas and California, are coextensive 
with the Due Process Clause, the questions of 
personal jurisdiction often collapse into a consti­
tutional due process inquiry. 
Even if a court is chosen for litigation pro­
ceedings, the case will not necessarily be held in 
that court. Patentee plaintiffs are often subject 
to venue challenges in the form of (1) a motion 
to dismiss for lack of personal jurisdiction,14 (2) 
a motion to dismiss for forum non conveniens, 
which is to say, the forum is inconvenient for wit­
nesses, experts, documents, and so forth, or (3) a 
motion to transfer to an alternate venue. When 
the original venue is improper, and not merely 
inconvenient, the defendant can file a motion to 
dismiss for improper venue. If a plaintiff files a 
lawsuit in a district of proper venue that is incon­
venient for the defendant or the witnesses, and 
if there is a more convenient federal court where 
the lawsuit could have been brought, the defen­
dant may file a motion to transfer venue under 28 
U.S.C. § 1404(a). When the more convenient fo­
rum is abroad, the defendant can file a motion to 
dismiss for forum non conveniens.15 A defendant 
should request a transfer of venue in a separate 
motion filed either at or near the time the defen­
dant files its answer. 
.1.2 Evaluating the proper venues 
Next, the patent applicant must decide which 
federal district courts and divisions are most fa­
vorable. This decision will likely depend on the 
average time to resolution, the cost of litigation, 
and the likelihood of litigation success. Other fac­
tors, such as potential for a retaliatory suit, may 
also need to be taken into account, but they are 
not within the scope of this article. 
Time to resolution is a critically important 
consideration. Some district courts are known 
for prompt resolution; others are not. Some are 
known for being especially fast and are familiarly 
known as “rocket dockets”: the Eastern District 
of Texas, the Eastern District of Virginia, and 
others who have adopted specific local patent 
rules that require expedited disclosures and trial 
time lines. 
Federal Court Management Statistics for 
200516 reveal that the median time from filing to 
trial in civil cases during the twelve-month period 
ending September 30, 2005, was approximately 
22.5 months. During this period, an estimated 
253,273 civil cases came before federal courts, 
of which approximately 12,184 were classified as 
intellectual property cases involving copyrights, 
patents, and/or trademarks (Table 2). 
Rocket dockets may become more com­
mon. In September 2006, the U.S. House of 
Representatives passed a bill to create a pilot 
program designed to encourage and develop 
the expertise of district judges in patent cases. 
Should the bill become law, it would establish 
a ten-year pilot program in at least five federal 
district courts and grant US$5 million each year 
to educate judges and hire additional staff with 
expertise in patent matters. The five courts will be 
chosen from the 15 district courts with the larg­
est number of patent cases in the previous year 
and only those that (1) are authorized to have at 
least ten district judges and (2) have at least three 
judges who have requested to hear patent cases. 
According to a study recently performed by the 
law firm of Fulbright & Jaworski LLP, if the pilot 
program were to become law this year, the five 
participating district courts would likely be cho­
sen from among the following fourteen candidate 
districts:17 
• Central District of California 
• Southern District of New York 
• Northern District of California 
• District of New Jersey 
• Southern District of California 
• District of Massachusetts 
• Middle District of Florida 
• Eastern District of Michigan 
• Southern District of Florida 
• Eastern District of Pennsylvania 
• Northern District of Georgia 
• Northern District of Texas 
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• Northern District of Illinois 
• Southern District of Texas 
The cost of litigation (see Table 3) should also 
be considered by plaintiffs when choosing where 
to initiate patent litigation. According to a 2005 
study of the American Intellectual Property Trial 
Lawyers Association, the location of patent litiga­
tion can greatly influence litigation costs.18 
Finally, although the likelihood of success 
is difficult to predict, George Mason University 
School of Law Professor Kimberly A. Moore 
says that “choice of forum plays a critical role in 
the outcome of patent litigation.”19 Ms. Moore 
conducted an empirical analysis of the ten most 
frequently selected district courts for patent litiga­
tion between 1983 and 1999. She concludes that, 
overall, patentees won 58% of all patent suits but 
that the win rate varies by region (Table 4). 
.2 Filing in the U.S. ITC 
Although federal district courts are the custom­
ary venues for patent litigation, plaintiffs can also 
file a complaint in the U.S. ITC under certain 
circumstances. Under the Tariff Act of 1930 (19 
Table 2: Median Time from Filing to Trial 
for Civil Cases in 2005 in 20 Districts20 
District court Months from filing to trial Number of IP cases 
Eastern District of Virginia 9.4 182 
Western District of Wisconsin 11.3 51 
District of Maine21 13.0 17 
Southern District of Texas 15.3 366 
Eastern District of Texas 15.9 193 
Southern District of Florida 16.7 332 
Middle District of Florida 20.0 280 
Eastern District of Wisconsin 20.3 76 
Central District of California 20.5 1427 
Northern District of Texas 20.7 279 
Eastern District of Pennsylvania 20.8 1005 
Southern District of New York 22.0 876 
Eastern District of Michigan 22.0 208 
District of Minnesota 23.0 201 
District of Delaware 23.5 149 
Southern District of California 25.4 162 
Northern District of Georgia 27.0 273 
Northern District of Illinois 27.0 462 
Northern District of California 28.0 467 
District of Massachusetts 31.0 221 
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U.S.C. § 1337), the ITC conducts investiga­
tions into allegations of certain unfair practices 
in import trade, including patent infringement, 
via the importation of infringing products. In 
2003, the ITC initiated 18 patent investigations; 
in 2004, it initiated 28; and in the first half of 
2005, it initiated 21. 
Plaintiffs are required to provide more evi­
dence to the ITC than they are to federal courts. 
In patent cases, for example, the Commission re­
quires the following documents in order to initi­
ate a “Section 1337 investigation”: claim charts 
that purport to show infringement, copies of li­
cense agreements pertaining to each asserted pat­
ent, copies of certified prosecution histories for 
each asserted patent, and copies of the technical 
references cited in the prosecution histories for 
each asserted patent.22 
After a complaint is filed with the Commission, 
the Office of Unfair Import Investigations (OUII) 
examines the complaint and determines whether 
or not to initiate a Section 1337 investigation, 
usually within 30 calendar days of the filing of the 
complaint. In the event the Commission opts to 
institute such an investigation, the Commission 
serves all respondents named in the investiga­
tion, as well as the U.S. embassy for the coun­
try in which they are located, with a copy of the 
complaint and a notice of investigation. A notice 
of investigation is also published in the Federal 
Register. The OUII only rarely decides not to ini­
tiate an investigation.23 
Table 3: All-Inclusive Cost of Patent litigation in 2005
 
Geographic region 
Average cost of patent 
litigation for cases valued 
from uS$1 to uS$25 million 
(in uS$) 
Average cost of patent 
litigation for cases valued 
above uS$25 million 
(in uS$) 
Boston 2,638,889 4,107,143 
New York City 3,667,308 6,190,000 
Philadelphia 3,287,500 4,712,500 
Washington, DC 3,167,742 6,947,917 
Other East 2,468,750 3,076,923 
Metro Southeast 3,285,294 9,440,909 
Other Southeast 1,662,500 3,342,857 
Chicago 2,133,000 4,404,412 
Minneapolis-St. Paul 1,567,500 3,688,889 
Other Central 1,686,098 3,258,571 
Texas 2,847,826 4,993,750 
Los Angeles 3,015,000 4,866,667 
San Francisco 2,823,529 7,985,714 
Other West 2,279,630 5,283,333 
0 | HANDBOOK OF BEST PRACTICES 
        
     
     
        
      
 
      
      
       
      
       
         
        
       
     
        
      
          
     
        
          
       
     
    
      
    
 
CHAPTER 10. 
Once an investigation is instituted, the 
Commission assigns an investigative attorney from 
the OUII to function as an independent litigant rep­
resenting the public interest in the investigation. 
A Section 1337 investigation is conducted in 
accordance with procedural rules unique to the 
ITC, although these rules have some similarities 
with the Federal Rules of Civil Procedure. The 
Federal Rules of Civil Procedure are the rules 
by which litigation is conducted before all U.S. 
District Courts. However, for example, during a 
Section 1337 Investigation, it is the administra­
tive law judge who issues subpoenas24 with nation­
wide jurisdiction. Another important distinction 
is timing. Typically, a Section 1337 investigation 
moves quickly, with quick deadlines for discovery 
responses and briefing (usually ten days, rather 
than 30 days) and statutory target dates that re­
quire completion of the Commission’s proceed­
ings “at the earliest practical time.” This often 
occurs within 15 months, depending on the com­
plexity of the case. As a result, parties initiating 
ITC investigations can reasonably expect a trial 
within nine or ten months from filing. 
A Section 1337 investigation often leads to 
a formal evidentiary hearing before the presiding 
administrative law judge. At the conclusion of this 
hearing, the administrative law judge issues an 
initial determination that serves as an initial deci­
sion of the merits of the case. The initial determi­
nation may then be subject to a review by the full 
Commission of the ITC (if the parties so choose) 
before it becomes the final determination of the 
ITC Commission. The initial determination often 
issues at least three months prior to the 15-month 
target date for the investigation’s completion. At 
the request of one of the parties for a review of 
the initial determination, the Commission may 
review and adopt, modify, or reverse the initial de­
termination or it may decide not to review it at all. 
If the Commission declines to review the initial 
determination, it becomes the final determination 
of the Commission by default.25 
Table 4: Win Rate Distribution Among 

Some Prolific District Courts (1983-1999)
 
District court Patentee wins 
(percent of total cases) 
Infringer wins
(percent of total cases) 
Northern District of California 68 32 
District of Minnesota 67 33 
Central District of California 63 37 
Southern District of New York 63 37 
Southern District of Florida 63 37 
District of New Jersey 61 39 
Eastern District of Virginia 58 42 
Northern District of Illinois 48 52 
District of Delaware 46 54 
District of Massachusetts 30 70 
Source: The Federal Judiciary26 
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YIN & CuNNINGHAM 
In the event that the Commission determines 
that Section 1337 has been violated, the commis­
sion may issue a cease-and-desist order, directing 
the violating parties to cease their illegal activities, 
as well as one of two types of exclusion orders: gen­
eral (applying to all infringing articles, regardless 
of source) or limited (applying to those infringing 
articles imported by a respondent to the investiga­
tion) barring certain products from entry into the 
United States.27 The Commission cannot assess 
monetary damages. The Commission’s exclusion 
orders are enforced by the U.S. Customs Service, 
although the Commission enforces its own cease­
and-desist orders. 
The president has 60 days to review 
Commission orders before they become effec­
tive. During this period, infringing articles may 
enter the United States if the importer posts a 
bond with the Customs Service for an amount 
determined by the Commission. Similarly, activi­
ties prohibited by a Commission cease-and-desist 
order may also continue during the Presidential 
review period if the respondent posts a bond with 
the Customs Service. Appeals of Commission 
orders pursuant to Section 1337 investigations 
are heard by the U.S. Court of Appeals for the 
Federal Circuit. 
There are advantages and disadvantages to 
using the International Trade Commission as a 
forum for patent litigation (see Table 5). Perhaps 
the greatest advantage is that the win rate of 
plaintiffs in ITC investigations is approximate­
ly 70%, as opposed to 58% in federal district 
courts. 
.  ConCLuSIonS 
A global patent filing program is an essential 
component of an integrated system of IP man­
agement. It maximizes value and protects the 
integrity of an organization’s patent portfolio. 
Such a program requires knowledge, organiza­
tion, and planning. The dynamics of the interna­
tional patent landscape must be understood (for 
example, issues relating to establishing foreign 
priority, where to file patent applications, and 
the advantages and disadvantages of the various 
filing options). Organizational efforts will focus 
on arranging the patent portfolio to achieve stra­
tegic global objectives (for example, determining 
in which countries and/or jurisdictions to seek 
patent protection according to (in the case of pri­
vate sector) commercial objectives, or, (in the case 
of the public sector) humanitarian access objec­
tives. Planning requires foresight. For example, 
one must anticipate the possibility of litigation 
and know what the venue options are based on 
the cost, speed, and likelihood of success in liti­
gation. With such a comprehensive program in 
place, both public and private sector organiza­
tions will be positioned to anticipate, manage, 
and overcome the uncertainties and challenges 
that characterize the international technology 
marketplace in agricultural and health innova­
tions. n 
Ronald yin, DLA Piper US LLP, 2000 University 
Avenue, East Palo Alto, CA, 94303, U.S.A.. Ronald. 
Yin@dlapiper.com 
sean cunninghaM, DLA Piper US LLP, 401 B Street, 
Suite 1700, San Diego, CA, 92101, U.S.A. sean.cun­
ningham@dlapiper.com 
1 	 PTO Press Release (February 14, 2006) titled United 
States Patent and Trademark Office Issues 7 Millionth 
Patent. 
2	 For a current listing of members of the Paris Union:
www.wipo.int/treaties/en/ShowResults.jsp?lang= 
en&treaty_id=2. 
3	 A patent application filed with the EPO may be 
submitted in the official language of any EPC member 
state (including the extension states), but a translation 
must be submitted in one of the three official EPO 
languages (English, French, or German) within three 
months of filing the application and no more than 
13 months after the earliest requested priority date.
The date of application is the actual filing date. If a 
request for priority is also filed, that is, the application 
was initially filed in a foreign jurisdiction, then the 
“requested priority date” is the priority date that the 
applicant requests the EPC application be accorded. A 
patent application filed with the JPO must be written 
in Japanese, but the specification, claims, drawings,
and abstract can be written in English, as long as a 
Japanese translation of the English documents is 
filed within two months of the initial filing date. It
is possible to file a patent with the U.S. Patent Office 
in any language, as long as an English translation is 
submitted within two months. 
4	 The application for an invention that has not and 
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will not be patented in foreign countries will not be 
published if the applicant so requests. 
7 U.S. Patent and Trademark Office. 8 February 2006.
Patent Trends Calendar Year 2005.
5
6
A Statutory Invention Registration is authorized by law:35 
U.S.C. § 157. It permits a party to publish an invention, but
without all theattributesofapatent,that is,thepublished 
invention can be used defensively, as a publication, but
not offensively to assert infringement against others. 
U.S. Patent and Trademark Office. 2006. Calendar Years 
1790 to the Present. Table of Annual U.S. Patent Activity 
Since 1790. www.uspto.gov/web/offices/ac/ido/oeip/taf/
h_counts.pdf. 
8 OECD. 2005. Compendium of Patent Statistics.
Organisation for Economic Co-Operation and 
Development: Paris. p. 55. 
9 OECD. 2005. Compendium of Patent Statistics.
Organisation for Economic Co-Operation and 
Development: Paris. pp. 55–56. 
10 Subject matter jurisdiction (that is, the power of 
the district court to hear the subject matter of the 
controversy) is not an issue for patent cases because 
Table 5: Advantages and Disadvantages to Initiating ITC Investigations
 
Advantages Disadvantages 
Broad injunctive remedies exclude Section 1337 refers only to imported goods;
importations or order infringing parties to ITC does not award monetary damages.
cease and desist from particular activities. (However, filing a case with the ITC does not
prohibit one from filing a parallel case in 
federal court.) 
Investigations are usually completed in 15 The discovery and motion practice is fast,
months or less, faster than most district permitting little time to search for prior 
courts. art that might invalidate a patent or other 
evidence to render a patent unenforceable.
Responses are often due within 10 calendar 
days. Furthermore, because in an ITC 
investigation the OUII is another party,
discovery and response briefing are served/
filed not only by the opposing party, but also 
by the OUII. 
Broad (in rem) jurisdiction means jurisdiction The domestic industry requirement mandates 
is derived from the imported articles, as that the complainant demonstrate that:
opposed to the presence of particular parties • there exists a domestic industry protected 
or acts in and around Washington, DC. Thus, by the patent right that the plaintiff seeks 
goods of a downstream importer who is not to enforce 
named in the ITC, and who normally might • the defendant has performed an unfair act 
not be subject to the jurisdiction of the 
• the defendant’s act has a detrimental effectcourts (such as a foreign resident), may be 
or tendency (above and beyond mere legal excluded. 
infringement). 
No counter-claims are permitted.	 The plaintiff must provide detailed factual 
allegations for each element of each claim. 
The trier of fact is an administrative law There is no possible recourse to trial by jury. 
judge with experience in patent lawsuits. 
The administrative law judges are rotated on In recent months, the rotation of judges has 
a regular basis. Thus, assignment of a case to become less predictable 
an administrative judge might be predicted. 
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federal courts have exclusive jurisdiction over patent
issues. See 28 U.S.C. § 1338. However, if the litigation 
involves other claims, those other claims might be 
permissible in federal court.
11	 28 U.S.C. § 1391(c).
12	 See 28 U.S.C. § 1400(b).
13	 See Hildebrand v. Steck Mfg. Co., Inc., 279 F.3d 1351, 1354 
(Fed. Cir. 2002). 
14	 Unlike challenges to subject matter jurisdiction, the 
defense of lack of personal jurisdiction must be raised 
at the outset of litigation or else the defense is deemed 
waived. See Fed. R. Civ. P. 12. 
15	 Quackenbush v. Allstate Ins. Co. (517 U.S. 706, 722 
[1996]). 
16	 www.uscourts.gov/fcmstat/index.html. 
17	 Anonymous. 2006. Patent Rocket Dockets? House 
Approves Bill for Pilot Program to Enhance Patent
Expertise in Certain Federal District Courts.
Fulbright & Jaworski LLP Client Alert (October 
2006). www.fulbright.com/images/publications/
FulbrightClientAlertPatentRocketDockets1.pdf. 
18	 American Intellectual Property Lawyers Association.
2005. AIPLA Report of the Economic Survey 2005. pp.
109–10.
 19 Moore KA. 2001. Forum Shopping in Patent Cases: Does 
Geographic Choice Affect Innovation? N.C. L. Rev. 79:
889.
20 The median time was calculated using the date a case 
was filed and the date the trial began. In the case of 
reopened cases that resulted in a second completed 
trial, the median time was calculated using the 
original filing date and the date the second trial was 
completed.
21	 Statistics for the District of Maine were not available 
for 2005. These statistics are for 2004. 
22 See Rule 210.12(c–g), 19 C.F.R. § 210.12(c–g). 
23 See U.S. International Trade Commission. 2004. Section 
1337 Investigation: Answers to Frequently Asked 
Questions. Publication No. 3708. p. 21.
24 See Rule 210.32, 19 C.F.R. § 1337. Investigation: Answers 
to Frequently Asked Questions 210.32.The Federal Rules 
of Civil Procedure limit the scope of any subpoena to 
command a person within 100 miles where the court
sits if the rules of state statute permit issuance of state 
-wide subpoena. 
25 Ibid. 
26 See supra note 21 at page 916. 
27 The remedy of an exclusion order has become a more 
powerful tool (and threat) after eBay v. MercExchange 
(126 S.Ct. 1837 [U.S. 2006]). In the wake of the eBay 
decision, patent owners can no longer assume that
injunctions will issue if infringement is found in a case 
brought in federal district court. 
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ABSTRACT 
All biotechnology and pharmaceutical products must be 
approved by both the U.S. Patent and Trademark Office 
(PTO) and the U.S. Food and Drug Administration 
(FDA). To maximize the impact of a product’s market 
exclusivity, the time spent on getting approval should 
be minimized. This chapter discusses how the interplay 
between PTO and FDA applications affect the patent 
approval process, and by extension the patent term, and 
how these impact the commercial life of a product. 
1. InTRoduCTIon 
The goals of the public and private sectors of 
the drug industry are often different. The public 
sector’s main goal is to provide drugs to the public 
for the lowest possible price, while the private 
sector is most interested in achieving the greatest 
possible profit. Many private company tactics are 
employed for maximizing revenue are important 
to understand as they can also help the public 
sector to achieve its goals. For example, price 
discrimination—the practice of selling health 
products at different prices to different customers 
in various markets—is commonly used by private 
corporations to increase their profit margins. This 
practice, however, can also be used by nonprofit 
organizations: if they were to sell their products to 
developed countries at higher prices—or to license 
them to manufacturers in developed countries— 
the organizations would be better able to subsidize 
drug prices in poorer countries. 
There are other ways that companies can 
maximize their revenue. For instance, companies 
in the biotechnology and pharmaceutical area 
must apply for approval from the U.S. Patent and 
Trademark Office (PTO) and Food and Drug 
Administration (FDA). Both of these applications 
are necessary: the PTO approves patents that pro­
tect a company’s inventions, and FDA approval 
of a product is necessary before a new product 
can be marketed. These approval processes are 
lengthy, and companies should minimize the time 
spent on the process as part of a profit-maximiz­
ing strategy. This chapter outlines various ways to 
extend a patent’s effective life through the strate­
gic management of these approval processes. 
2. pTo	 And	fdA AppRovAL 	pRoCESSES 
2.1 Patent applications 
ThePTOgrantspatents to inventions thatarenovel, 
useful, and nonobvious.1 The novelty requirement 
Fernandez DS, J Huie and J Hsu. 2007.The Interface of Patents with the Regulatory Drug Approval Process and How Result-
ing Interplay Can Affect Market Entry. In Intellectual Property Management in Health and Agricultural Innovation: A Hand-
book of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available 
online at www.ipHandbook.org. 
Editors Note: This chapter is included in this Handbook to show the important interface of patents and the regulatory 
drug approval process and how this interplay affects market entry. It is not intended as an endorsement of effective pat-
ent life extensions to delay the market entry of generic drugs. 
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FERNANDEZ, HuIE, & HSu 
prevents anyone from patenting an invention 
that is already available to the public. The useful­
ness, or utility, requirement states that one skilled 
in the art must be able to utilize the invention 
in a manner that provides immediate benefit to 
the public. The obviousness requirement prevents 
applicants from patenting products or processes 
that are insignificant modifications of already ex­
isting products or processes. 
The inventor of a patented invention has 
the right to exclude others from making, using, 
offering for sale, or selling the invention in the 
United States or in U.S. territories or possessions. 
A limited 20-year monopoly2 is granted to the 
inventor in exchange for public disclosure of the 
invention.3 In the United States, the average time 
between filing of the application and approval of 
the patent is 3 ½ years, while the average time for 
a biotechnology patent is nearly 4 ½ years. 
2.2 Discovery phase and preclinical studies 
Simply put, in the discovery phase of research, sci­
entists identify specific chemical or biochemical 
entities that are worth testing further. Next, pre­
clinical studies are undertaken comprising in vi­
tro studies and animal testing, pharmacodynamic 
responses, metabolic profiling, cellular receptor 
interaction, and/or physiology that is generally 
analogous to humans. Preclinical studies take 
an average of five years, but the precise length of 
time depends on the complexity of the study and 
the success achieved by initial research. 
2. FDA approval process 
The FDA approval process usually requires ten to 
12 years and US$100 to US$500 million. The 
process is accomplished in two phases: clinical tri­
als and new drug application (NDA) approval. 
The FDA approval process begins when a 
manufacturer requests permission, by submitting 
an investigational new drug (IND) application, 
to begin human testing. The IND application 
must provide preclinical data of high quality to 
justify the testing of the drug in humans. Once 
the IND application is filed, the manufacturer 
must allow the FDA 30 days to review the pro­
spective study before clinical trials can begin. 
IND applications must be re-filed annually until 
clinical testing is completed. Approximately 
85% of all drugs for which IND applications 
are filed are subjected to clinical trials. 
The next stage is Phase I clinical trials, which 
use human subjects. Phase I trials focus on es­
tablishing a drug’s safety profile and examining 
how the drug is absorbed, distributed in the body, 
metabolized, and finally excreted. Phase I trials 
usually do not use more than 100 healthy volun­
teers, and the trials last, on average, from one to 
three years. 
If the drug successfully passes Phase I, it is 
submitted to Phase II trials, which evaluate dos­
age, broad efficacy and additional safety. In this 
phase, volunteers who suffer from the targeted 
disease are given the drug. Phase II lasts two 
years, on average. 
Phase III trials attempt to verify the effec­
tiveness of the drug with double-blind studies 
that involve at least 1,000 patients. (A double-
blind study is a stringent way of conducting clin­
ical trials whereby subjective bias is eliminated 
by neither doctors/nurses nor patients knowing 
whether they administer/receive a placebo or ex­
perimental drug.) This phase continues to build 
the drug’s safety profile by monitoring any side 
effects that result from long-term use of the drug. 
This phase lasts, on average, between three and 
four years. 
If the drug successfully passes the first three 
phases of clinical trials, researchers can then file 
a new drug application (NDA) that includes the 
drug’s proposed labeling. A team of physicians, 
statisticians, chemists, pharmacologists, and oth­
er scientists at the Center for Drug Evaluation 
and Research review the company’s NDA by ex­
amining the preclinical and clinical reports and 
using risk-benefit analysis to determine whether 
or not the product’s beneficial effects outweigh 
its possible harmful effects. Approval of an NDA 
can take from two months to several years, but, 
on average, approval is granted within two years. 
Once the NDA is approved, the innovating 
company is allowed to distribute and market the 
drug. 
Once the drug is distributed in the public 
market, it is considered to be in Phase IV trials. 
The manufacturer must continue to monitor and 
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Figure 1: Timeline for Patent/Product Approval 
and Profit-Maximizing Options 
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FERNANDEZ, HuIE, & HSu 
evaluate the drug’s safety during routine use (see 
Figure 1 for a timeline of the above process). 
2. Filing PTO and FDA applications 
The “effective life” of a patent is defined as the pe­
riod of time between a product’s introduction to 
the market and the patent’s expiration date. The 
manufacturer of a product with a long effective 
life will enjoy extended market exclusivity and 
thereby recover research and development costs. 
When the patent expires, the manufacturer will 
be at a real disadvantage: on average, generic drug 
companies capture 57.6% of the market for drugs 
with expired patents. Obviously, the faster the 
drug is approved and thus comes to market, the 
longer the marketing period and thus the genera­
tion of revenues and profits. 
Preclinical studies are the rate-limiting step 
in the FDA approval process because clinical tri­
als cannot begin until there is sufficient data to 
justify human testing. Therefore, as many pre­
clinical studies should be performed as early as 
possible and preferably before a patent applica­
tion is filed, as the results of such studies also help 
support claims for the utility of an invention. 
There are several reasons why innovating 
companies should file patents for their products 
before seeking FDA approval for them. In the 
first place, the PTO has lower safety standards 
than the FDA;4 although a patent application 
must demonstrate that a drug has a “sufficient 
probability” of safety in humans, the applicant 
is not required to provide any clinical evidence 
of its safety.5 
Next, patents are important IP (intellectual 
property) safeguards. If an innovating company 
were to begin the FDA process before filing a 
PTO application, another company could patent 
the invention before them. The innovating com­
pany would either have to license the biophar­
maceutical from the other company (losing royal­
ties, market exclusivity, and company value in the 
process) or abandon the FDA process altogether 
and forfeit millions spent in research and devel­
opment.6 Even if another company does not pat­
ent the product, the innovating company must 
be careful not to disclose the invention, otherwise 
the innovating company would have one year to 
file the patent before the patent enters the public 
domain (internationally, the patent application 
must be filed before disclosure). 
There are two other reasons to file patents 
before beginning an FDA application: (1) FDA 
approval is accelerated for patented compounds, 
and (2) patents attract the notice of potential in­
vestors who can provide the capital to fund FDA 
clinical trials. Ideally, preclinical studies should 
end before, or concurrently with, patent issuance, 
and FDA clinical trials should begin immediately 
thereafter. But before clinical trials can begin, the 
manufacturer must turn over several documents 
justifying the conduct of the trial, verifying the 
quality of the data produced, and demonstrating 
the compliance of the investigator with all regula­
tory requirements. These documents include: sci­
entific journal publications, in vitro and animal 
data, trial subject information, financial analysis, 
and laboratory protocol. The FDA must review 
and approve these documents before clinical trials 
can begin. As mentioned above, the filing of the 
patent should be done first, or the drug manufac­
turer runs the risk of missing the one-year dead­
line for establishing priority of invention. 
Once the FDA has approved the drug for 
U.S. consumers, the innovating company will 
enjoy market exclusivity for the patent’s effective 
life. A strategically written patent will effectively 
and efficiently protect against product infringe­
ment by other companies. The innovating com­
pany should take pains to develop brand recogni­
tion and build consumer reliance on its products 
in order to retain the largest possible market share 
once the patent term ends. 
. ExTEndInG A 	pATEnT TERM 
Once the patent term ends, the innovating com­
pany need not lose its market exclusivity imme­
diately. Various tactics can be used to extend a 
patent term and delay generic market entry. 
Assuming a patent satisfies certain basic 
criteria,7 the PTO will grant patent extensions 
when its approval process takes longer than 
three years. If, for example, a patent took four 
years to issue, the patent term may be extended 
by an additional year.8 
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CHAPTER 10. 
Two laws also allow for patent terms to be 
extended: the Drug Price Competition and 
Patent Term Restoration Act of 1984 (also known 
as the Hatch-Waxman Act) and the Generic 
Animal Drug and Patent Term Restoration Act 
of 1988. Title II of the Hatch-Waxman Act (the 
“patent term restoration” or “extension” clause) 
gives certain patent holders the opportunity to 
extend patent terms for human drug products, 
including antibiotics and biologics, medical 
devices, food additives, and color additives. 
The Generic Animal Drug and Patent Term 
Restoration Act provides a similar opportunity 
to holders of patents for animal drug products 
(excluding those derived from recombinant 
DNA technology). These laws were designed 
to stimulate innovation by domestic drug 
companies. Both acts allow a patent term to be 
extended by up to five years. However, the total 
effective patent life cannot exceed 14 years from 
the date of FDA approval.9 
In order for an innovating company to
obtain a patent term extension, certain criteria 
must be met: 
1. The patent has not expired. 
2. The 	 patent has not previously been 
extended. 
3. The patent owner or its agent submits the 
application. 
4. The product has been subjected to a regu­
latory review period with the FDA or the 
U.S. Department of Agriculture (USDA) 
before its commercial marketing or use. 
5. The permission for commercial marketing 
or use represents the first permitted com­
mercial marketing or use of the product 
for which the regulatory review occurred 
(see below). For products produced using 
recombinant DNA technology, excluding 
animal drug products, the product must be 
the first produced using that technology. 
6. The patent restoration application must be 
submitted within 60 days of the product’s 
initial FDA approval.10 
The regulatory review period is composed of 
a testing phase and an approval phase. The testing 
phase is the period between the effective date of 
an investigational product exemption (for exam­
ple, an IND application) and the initial submis­
sion of a marketing application (for example, an 
NDA). The approval phase is the period between 
the submission and the approval of the marketing 
application.11 The PTO calculates the length of 
the extension by considering both the lengths of 
the aforementioned testing and approval phases. 
It is important to note that the PTO does not 
consider times the applicant did not exercise due 
diligence12 during the regulatory review period. 
After the innovating company’s patent term 
expires, generic companies may enter the mar­
ket with generic drug equivalents. Whereas the 
initial FDA approval process may have taken 
ten to 12 years, the Hatch-Waxman Act allows 
generic companies to use the abbreviated new 
drug approval (ANDA) process to gain approval 
for generic equivalents within six months. There 
are three requirements for filing an ANDA 
application: 
1. The company must show that the proposed 
generic drug is the same as, or bioequiva­
lent to, an FDA-approved drug. 
2. The company must certify that a patent 
protected the approved drug. 
3. The company must not use a production 
method that has been patented by the in­
novating company (a so-called production 
method patent). 
Because of the third stipulation, it is wise 
to file the drug production method patent a few 
years after filing the original patent (generally 
focusing on the composition of the drug). This 
will ensure that even when the drug composition 
enters the public domain, the production meth­
od will continue to be protected. This strategy is 
even more effective for biopharmaceuticals than 
for traditional chemical pharmaceuticals because 
it is so difficult to create production methods us­
ing complex microbiological systems. 
Another strategy is known as the metabolite13 
defense involves filing patents for useful drug me­
tabolites in years subsequent to the filing date of 
the main patent. Once the generic version of the 
drug is marketed, the innovating company can 
bring a patent infringement claim against the 
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FERNANDEZ, HuIE, & HSu 
generic company, since the company will inevi­
tably be manufacturing infringing products via 
its customers’ metabolic processes.14 While the 
effectiveness in court of the metabolite defense 
may be debatable,15 litigation can delay market 
entry of generics. 
Finally, an innovating company can file a 
citizenpetitionwith theFDA,citing safetyconcerns 
regarding a generic biopharmaceutical. Although 
the majority of citizen petitions are eventually 
rejected by the FDA or withdrawn by innovating 
companies, filing such a petition can delay generic 
market entry for six months or more. 
.  ACCELERATInG MARkET EnTRy 
There are essentially five ways in which compa­
nies may accelerate the introduction to market of 
a new drug: 
•	 PTO special status: The PTO awards spe­
cial status to certain biotechnology inven­
tions, processing them ahead of all others. 
To qualify for a special status the company 
must be a small entity (a company with 
fewer than 50 employees) or a nonprofit 
organization. The petition must state that 
the patent applicant’s technology will be 
significantly impaired if a patent examina­
tion is delayed. 
•	 FDA well-characterized status: The FDA 
can designate a biopharmaceutical as a well 
characterized biotechnology product if its 
identity, purity, potency, and quality can be 
substantially determined and controlled. 
As long as the manufacturer is able to pro­
duce the same product, the manufacturing 
technologies of a well-characterized phar­
maceutical can be altered without having to 
repeat clinical trials. If a company develops 
a well-characterized biotechnology product, 
it can begin FDA clinical trials immediately 
and improve the manufacturing process at 
a later date. 
•	 FDA expanded access exception: This excep­
tion allows manufacturers to market the 
product before completing clinical trials 
(before completing the approval process). 
Expanded access is available for a very 
limited number of new drugs that are pend­
ing final FDA approval. This program al­
lows drugs to be used and marketed before 
the FDA approval process is completed. The 
manufacturer must apply for a drug to be 
made available through an expanded access 
program. To acquire such status, the com­
pany must provide sufficient evidence that 
the drug will be effective against a given dis­
ease and that the drug has not been linked 
to unreasonable health risks. The provision 
is somewhat uncommon because the FDA 
generally allows expanded access only if 
there are no other satisfactory treatments 
available for the given disease. 
•	 FDA accelerated approval process: The FDA 
may accelerate approval of a biopharma­
ceutical if adequate and well-controlled 
clinical trials indicate that it will provide 
considerable therapeutic benefit over exist­
ing therapies, particularly in cases of serious 
or life-threatening diseases. 
.  ConCLuSIon 
The PTO and FDA approval processes are expen­
sive and time-consuming. By the time a drug can 
be marketed to the public, part of its patent term 
will have already expired. In order to maximize 
profits, FDA processing time should be mini­
mized as far as possible. In addition, patent terms 
can sometimes be extended, and various strategies 
can be used to prevent generic companies from 
taking too much of market share. Nonprofit orga­
nizations in particular may benefit from the strate­
gies outlined in this chapter, especially if they are 
used in conjunction with price discrimination. n 
dennis s. feRnandeZ, Managing Partner, Fernandez & 
Associates L.L.P., 1047 El Camino Real, Suite 201, Menlo 
Park, CA, 94025, U.S.A. dennis@iploft.com 
JaMes huie, Associate, Fernandez & Associates L.L.P., 
(Currently: Associate, Wilson, Sonsini, Goodrich & Rosati, 
P.C., U.S.A.,) 1047 El Camino Real, Suite 201, Menlo 
Park, CA, 94025, U.S.A. james_huie@yahoo.com 
JusTin hsu, Summer Associate, Fernandez & Associates 
L.L.P., 1047 El Camino Real, Suite 201, Menlo Park, CA, 
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94025, U.S.A. currently: Wilson, Sonsini, Goodrich & 
Rosati, P.C., 650 Page Mill Road, Palo Alto, CA, 94304, 
U.S.A. justinhsu@berkeley.edu 
1	 35 U.S.C. § 102; 35 U.S.C. § 103. 
2	 On December 8, 1994, President Clinton signed the 
Uruguay Round Agreements Act into U.S. law. The 
Uruguay Round Agreements Act gives all patents that
were in force or filed as of 8 June, 1995 an effective term 
of 17 years from the date the patent was granted or 
20 years from the date of the first filing of the patent
application. All patents filed after 8 June, 1995 have a 
patent expiration date of 20 years from the date of the 
first filing of the patent application. 
3	 Nelson v. Bowler 626 F.2d 853 Cust. & Pat. App., 1980 
(C.C.P.A. 1980), “Knowledge of the pharmacological 
activity of any compound is obviously beneficial to 
the public. It is inherently faster and easier to combat
illnesses and alleviate symptoms when the medical 
profession is armed with an arsenal of chemicals having 
known pharmacological activities. Since it is crucial 
to provide researchers with an incentive to disclose 
pharmacological activities in as many compounds as 
possible, we conclude that adequate proof of any such 
activity constitutes a showing of practical utility.” 
4	 35 § U.S.C. 102; 35 U.S.C. 103. 
5	 See In re Hartop, 311 F.2d 249 (C.C.P.A. 1962). 
6	 The Federal Circuit recognized such concerns of 
pharmaceutical companies in In re Brana, 51 F.3d 
1560 (Fed. Cir. 1995): “FDA approval, however, is not a 
prerequisite for finding a compound useful within the 
meaning of the patent laws. . . . Usefulness in patent
law, and in particular in the context of pharmaceutical 
inventions, necessarily includes the expectation of 
further research and development.The stage at which an 
invention in this field becomes useful is well before it is 
ready to be administered to humans.Were we to require 
Phase II testing in order to prove utility, the associated 
costs would prevent many companies from obtaining 
patent protection on promising new inventions, thereby 
eliminating an incentive to pursue, through research 
and development, potential cures in many crucial areas 
such as the treatment of cancer.” 
7	 21 C.F.R. Part 60. 
8	 35 U.S.C. § 155; 35 U.S.C. § 156. 
9	 If the patent was issued before 24 September, 1984 
and the product’s regulatory review period began 
before that date, then the limit is two years. For animal 
drug products whose regulatory review periods began 
before 16 November, 1988 the limit is three years. In 
all cases, the total patent life for the product cannot
exceed 14 years from the product’s approval date. 
10 The FDA defines product approval as the date the FDA 
sends a letter notifying the marketing applicant that
(1) the FDA approved the marketing application, (2) the 
product development protocol was completed, or (3) 
the listing of used food or color additives. The 60-day 
term begins on the day after approval; the PTO must
receive the application for patent extension on the 
60th day (or the next business day after the 60th day 
if this day falls on a weekday or holiday). 
11	 The FDA has 30 days by law to determine the regulatory 
review period for a product. After this period, there 
is a 60-day comment period during which parties 
can request revisions to the regulatory review period 
determination.The end of the 60-day comment period 
marks the end of the regulatory-review period stage. 
12	 Due diligence is defined as “that degree of attention,
continuous directed effort, and timeliness as may 
reasonably be expected from,and are ordinarily exercised 
by, a person during a regulatory review period.” 35 U.S.C.
§ 156(d)(3). 
13	 Metabolites are the metabolized derivatives of a drug. 
14	 In Hoechst-Roussel Pharms., Inc. v. Lehman, 109 F.3d 759 
(Fed. Cir. 1997), the court “recognized that a person may 
infringe a claim to a metabolite if the person ingests a 
compound that metabolizes to form the metabolite.”
See also Zenith Labs., Inc. v. Bristol-Meyers Squibb Co., 19 
F.3d 1418 (Fed. Cir. 1994) (stating that a compound claim 
could cover a compound formed upon ingestion).
15	 In Schering Corporation v. Geneva Pharmaceuticals,
Inc., 339 F.3d 1373 (Fed. Cir. 2003), a Federal Circuit
panel recognized that patent protection is available 
for metabolites of known drugs: “[A] patentee may 
obtain patent protection for an inherently anticipated 
compound through proper claiming.”
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CHAPTER 10.10 
Deposit of Biological Materials in 

Support of a U.S. Patent Application
 
dENNIS J. HARNEy, Attorney, Sonnenschein Nath & Rosenthal LLP, U.S.A. 
TIMOTHy B. MCBRIdE, Attorney, Senniger Powers, U.S.A. 
ABSTRACT 
The deposit of biological material in support of a U.S. 
patent application is a mechanism by which an applicant 
can cure what might otherwise be potentially fatal defects 
in a patent application and even an issued patent. A bio­
logical deposit can, in some cases, satisfy the requirements 
of enablement, written description, and best mode, and 
potentially broaden the scope of claims in the event of 
litigation. This chapter briefly explores the relationship 
between biological deposits and patentability require­
ments, what can be deposited, where and when a deposit 
can be made, and who has access to the deposit. 
1. WHAT DOES A DEPOSIT ACCOMPlISH? 
Referencing deposited biological material in the 
specification of a U.S. patent application provides 
the advantage of the deposited material being in­
corporated into that patent’s disclosure.3 As part 
of the disclosure, the deposited material may be 
employed to augment or correct deficiencies in 
the specification of the application, specifically, 
as to enablement, written description, and best 
mode requirements. 
1.1	 Deposit and the enablement requirement 
While not always required, a deposit of biologi­
cal material is one way to satisfy the enablement 
requirement of 35 U.S.C. § 112. The specifica­
tion of a patent must enable a person skilled in 
the art to make and use the invention claimed, 
aided only by his or her ordinary skill and the 
state of the art.4 The enablement requirement is 
typically accomplished through a written descrip­
tion of the invention within the specification. But 
inventions not easily or reasonably described by 
the written word alone may be “described in sur­
rogate form by a deposit that is incorporated by refer­
ence into the specification.”5 By providing access to 
biological material that is difficult to describe, an 
applicant enables the public to make and use the 
claimed invention. 
A deposit of biological material also can re­
duce the amount of disclosure required in the 
application to enable the claimed invention. For 
example, in In Ex parte C, by describing the pa­
rental varieties and the selection process in con­
junction with a seed deposit, applicants success­
fully enabled a novel variety of soybean plant, 
seeds from the plant, and a method of producing 
seeds by self-pollination.6 Notably, the Board of 
Patent Appeals and Interferences (BPAI) did not 
require an exacting description of breeding, selec­
tion, and testing since the invention, a disease-re­
sistant soybean plant, was placed in deposit. 
A deposit of biological material may enable 
more than just the species so deposited. For exam­
ple, in Ajinomoto v. Archer-Daniels-Midland, the 
Federal Circuit held that a method for producing 
an amino acid from a genetically engineered bac­
terium was enabled, despite the fact that only one 
altered strain of bacteria that produced threonine 
Harney DJ and TB McBride. 2007. Deposit of Biological Materials in Support of a U.S. Patent Application. In Intellectual 
Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. DJ Harney1 and TB McBride2. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged. 
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HAREY & MCBRIDE 
was disclosed and deposited.7 However, the BPAI 
was not quite so generous in several previous 
cases. For example, in Ex parte Hata, the BPAI 
affirmed the rejection of claims directed to treat­
ment of infectious disease by administering spe­
cific strains of Lactobacillus on the grounds that 
the select strains deposited were narrower than 
the broader class of all strains and that undue ex­
perimentation would be required to locate new 
microorganisms covered by the claim.8 
1.2  Deposit and the written description 
requirement 
While not always required, a deposit of biologi­
cal material is one way of satisfying the written 
description requirement of 35 U.S.C. § 112. 
This requirement is met if the specification de­
scribes the claimed invention in sufficient detail, 
such that one skilled in the art would reasonably 
conclude that the applicant was in possession of 
the claimed invention at the time of filing. This 
can be achieved by describing the invention with 
all its limitations using such descriptive means 
as words, structures, figures, diagrams, and for­
mulas that fully set forth the claimed invention.9 
Put simply, the specification must describe the 
invention such that it is distinguishable. 
Until 2002, it was somewhat uncertain 
whether a deposit of a biological sample could 
satisfy the written description requirement. But 
in that year, the Federal Circuit, in Enzo v. Gen-
Probe, held that deposit of a biological sample 
in a public repository could fulfill the require­
ment.10 The specification of the Enzo patent 
provided a functional description (hybridization 
characteristics) and referenced a biological de­
posit, but disclosed no sequences or structural 
descriptions of any of the claimed nucleic ac­
ids. Thus, under Enzo, a reference to a deposit 
coupled with a functional description meets the 
written description requirement so long as a 
known correlation exists between the described 
function and a deposited or described structure. 
The generic scope of claims supported would 
be that which a person of skill would deem the 
patentee to possess based upon the disclosure, 
which includes information obtainable from the 
deposits.11 
The information obtainable from deposits in 
support of a patent can potentially broaden inter­
pretation of the claims. For example, in Schering 
v. Amgen, the patent owner could have used de­
posited biological material to show that the claims 
to leukocyte interferon encompassed the subtype 
IFN-alpha14, despite that the specification dis­
closed only two other subtypes.12 In Schering, the 
patent owner provided evidence that the deposit 
coded for IFN-alpha14, but only to the appellate 
court and not to the trial court. The court held 
that, although a deposit could satisfy the enable­
ment requirement, the deposit must be part of 
the record before it is used to provide support 
for a particular claim construction. Because the 
patent owners in Schering presented the evidence 
too late, the deposit could not influence claim 
construction. However, the lesson remains that 
deposited biological material incorporated into 
the disclosure may be used to support a claim 
interpretation more broadly than that explicitly 
disclosed in the specification. 
1.  Deposit and the best mode requirement 
A deposit of biological material may also satisfy 
the best mode requirement under 35 U.S.C. § 112, 
¶ 1,13 but a deposit is not strictly necessary.14 The 
best mode of carrying out an invention must be 
disclosed in sufficient detail at the time of filing 
the application to allow one of ordinary skill to 
practice it. To satisfy the best mode requirement, 
there must be no concealment of a mode of prac­
tice known by the inventor at the time of filing to 
be better than that disclosed.15 
In Amgen v. Chugai Pharmaceutical, the de­
fendants argued that, in the field of living materi­
als, a biological deposit should be required so that 
the public has access to exactly what the patent 
applicant contemplates as the best mode.16 The 
Federal Circuit held that a deposit was not neces­
sary where the best mode of preparing a cell line 
necessary to practice the invention was disclosed 
and enabled in the specification.17 
Similarly, in Scripps v. Genetech, where a 
patent specification described the process for 
producing, screening, and evaluating mono­
clonal antibodies, the Federal Circuit held that 
applicants had not concealed the best mode for
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practicing the invention of protein purification 
using antibodies, despite not having deposited 
successfully isolated antibodies.18 In Scripps, the 
court specifically rejected the argument that the 
“laborious nature of the process of screening the 
monoclonal antibodies” required deposit of the an­
tibodies representing the best mode. 
2. WHAT CAN BE DEPOSITED? 
Biological material eligible for deposit are those 
materials capable of direct or indirect self-replica­
tion.19 Representative examples include bacteria, 
fungi, yeast, algae, protozoa, eukaryotic cells, cell 
lines, hybridomas, plasmids, viruses, plant tissue 
cells, lichens, and seeds. Furthermore, the deposit 
rules provide that viruses, vectors, cell organelles, 
and other nonliving material existing in, and re­
producible from, a living cell may be deposited 
by means of a deposit of the host cell capable of 
reproducing the nonliving material. 
Generally, for each deposit, the specification 
of the patent must contain the accession number 
for the deposit, the date of the deposit, a descrip­
tion of the deposited biological material sufficient 
to specifically identify it and to permit examina­
tion, and the name and address of the deposi­
tory.20 
3. IS A DEPOSIT REQuIRED? 
The biological deposit “requirement” is not a re­
quirement per se. Rather, the deposit rules pro­
vide a mechanism by which an applicant can 
overcome what would otherwise be a deficiency 
in the patent application. It is important to note 
that a biological deposit may be referenced in a 
specification even when not required. Moreover, 
referencing a biological deposit in the specifica­
tion does not give rise to a presumption that the 
deposit was necessary under 35 U.S.C. § 112. 
A biological deposit may be necessary where 
biological material is required to practice an 
invention and “words alone cannot sufficiently 
describe how to make and use the invention in a 
reproducible manner.”21 For example, a deposit 
could be required where an invention cannot 
be practiced without access to an organism only 
obtainable from nature.22 In the words of the 
Federal Circuit: 
When an invention relates to new biological 
material, the material may not be reproducible even 
when detailed procedures and complete taxonomic 
description are included in the specification. It is 
then a condition of the patent grant that physical 
samples of such materials be deposited and made 
available to the public, under procedures established 
by the [U.S. Patent and Trademark Office] and in­
ternational treaty.23 
Even so, if “words alone cannot sufficiently de­
scribe” the invention such that a biological deposit 
would normally be required, such a deposit would 
still not be necessary if the biological material nec­
essary to the invention is (1) known and readily 
available to the public or (2) derived from readily 
available starting materials through routine screen­
ing that does not require undue experimentation.24 
.1 Known and readily available 
Biological material need not be deposited unless 
access to the material is required under 35 U.S.C. 
§ 112 and the material is not otherwise known 
and not readily available to the public. Indica­
tions that biological material is known and avail­
able include: 
• 	 commercial availability 
• 	 references to biological material in printed 
publications 
• 	 declarations of accessibility by those work­
ing in the field 
• 	 evidence of predictable isolation techniques 
• 	 an existing deposit 
Thus a patentee may forgo a deposit in favor 
of assuming an obligation to make the necessary 
biological material publicly available. 
While the U.S. Patent and Trademark Office 
(PTO) will accept a showing of current availabil­
ity, the patentee takes the risk that the biologi­
cal material will cease to be known and readily 
available.25 The rules do not provide for post-is­
suance original deposits. But the PTO will accept 
a replacement deposit when a patent owner has 
diligently provided the replacement deposit after 
receiving notification that the depository can no 
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HAREY & MCBRIDE 
longer furnish samples of the original deposit, or 
that the deposit has become contaminated or lost 
its capability to function.26 Failure to diligently 
make a replacement deposit will preclude grant of 
a certificate of correction.27 A replacement depos­
it subsequently made will not be recognized by 
the PTO, and a request for a certificate of correc­
tion, even if made promptly thereafter, will not 
be granted.28 Furthermore, the failure to make a 
replacement deposit where a deposit is considered 
to be necessary to satisfy the requirements of 35 
U.S.C. § 112, will cause a patent involved in a 
reissue or reexamination proceeding to be treated 
by the PTO as if no deposit had been made.29 
As such, unavailability of biological material 
necessary to practice the invention is a defect that 
cannot be cured after the grant of a patent and 
can result in unenforceability. This risk is reflect­
ed in advice from the PTO: 
[Where] an applicant for patent has any doubt 
as to whether access to a biological material specifi­
cally identified in the specification is necessary to 
satisfy 35 U.S.C. § 112 or whether such a mate­
rial, while currently freely available, may become 
unavailable in the future, the applicant would be 
well-advised to make a deposit thereof before any 
patent issues.30 
.2 Derived without undue experimentation 
If only starting materials are readily available, 
the specification must provide sufficient guid­
ance on making or isolating the biological ma­
terial necessary to the invention without undue 
experimentation, or else a deposit of the material 
will be required.31 Undue experimentation is de­
cided under a standard of reasonableness; it is not 
merely a quantitative determination. Generally, 
there is no undue experimentation where time- 
consuming experiments are merely routine, such 
as a reliable screening test performed on a large 
number of samples.32 
4. WHEN CAN BIOlOGICAl MATERIAl 
BE DEPOSITED? 
Under current U.S. patent laws and practice, bio­
logical material may be deposited at any time pri­
or to the issue of the patent the deposit supports. 
This includes deposits made during the pendency 
of the application. But deposit after application 
can seriously compromise international rights. 
In the United States, biological material spe­
cifically identified in the patent application may 
be deposited during the pendency of the applica­
tion (i.e., before issuance of the application as a 
patent).33 A reference to a deposit in the specifica­
tion provides a basis for making a deposit after 
the filing date of the application. The applicant 
must merely provide a corroborating statement 
that the deposited biological material is that spe­
cifically identified in the application as filed. If 
the requirements are met, the post-filing addition 
to the application of a deposit date and accession 
number at an independent depository will not be 
considered new matter prohibited by 35 U.S.C. 
§ 132.34 
As such, a U.S. patent applicant could pri­
vately deposit a biological sample on or before the 
patent application date, identify the deposited 
material in the disclosure, and then later trans­
fer the sample to a recognized public depository 
and add the depository data at any time prior to 
the issuance of the patent. Such a private deposit 
may be in the inventor’s own laboratory or in the 
laboratory of a colleague, so long as the PTO has 
access to the samples during pendency and the 
samples are transferred to a public depository be­
fore the patent issues. 
For example, in In re Lundak, the inventor 
deposited a biological sample necessary to his in­
vention in the laboratory of a colleague.35 After 
filing a patent application that identified the pri­
vately held sample, the inventor transferred the 
sample to the American Type Culture Collection 
(ATCC) and amended his application with the 
accession number and deposit date. The Federal 
Circuit held that for the purposes of 35 U.S.C. 
§ 112, it was “not material whether a [biologi­
cal] sample … resided in the [inventor’s] hands or 
the hands of an independent depository as of filing 
date.” 36 
As another example, in In re Argoudelis, Ar­
goudelis deposited biological material with a 
depository prior to filing the patent application 
but restricted access to the deposit during the 
pendency to persons authorized by the patent 
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applicant.37 The court found the deposit met the 
requirements of 35 U.S.C. § 112 despite the re­
striction on public access, because access would 
be unrestricted after patent issuance.38 Similarly, 
in Feldman v. Aunstrup, Aunstrup deposited bio­
logical samples at a recognized depository in the 
Netherlands before his filing date, but restricted 
deposit availability to his designees.39 These re­
strictions were removed before the patent issued. 
The court found the deposit sufficient because the 
PTO could access the deposit through Aunstrup 
during application pendency, and the public was 
assured access upon issuance.40 
To the contrary, many foreign jurisdictions 
require a deposit to be made before the filing date 
of the priority application to obtain foreign prior­
ity rights. For example, an applicant who deposits 
biological material after filing a U.S. provisional 
application but before filing a PCT application 
will be unable to benefit from the U.S. provision­
al application priority date to the extent it is de­
pendent on the deposit. As such, to fully preserve 
foreign rights, an applicant should make any de­
posit of biological samples before the priority ap­
plication is filed.41 
Examples of jurisdictions that require de­
posits to be made before the filing date of the 
priority application include Australia, Canada, 
China, and the European countries that are 
members of the European Patent Organization 
(as established by the European Patent Conven­
tion). While certain of these jurisdictions pro­
vide means of correcting for a late deposit, such 
remedies often require that (1) the failure to de­
posit be the result of an error in judgment or an 
omission that led to the failure to deposit (such 
error not being the failure to deposit itself and 
not including intentional delay, for example, for 
strategic or financial reasons) or (2) the applicant 
be able to declare that, although a deposit was 
not made, the biological sample was nevertheless 
available to the public on the filing date of the 
application. Because the successful use of such 
remedies is not a foregone conclusion, it is high­
ly encouraged that any deposit be made prior to 
the filing of an application that may be called to 
serve as a priority document for an international 
application. 
Again, while a post-filing, pre-issuance de­
posit is sufficient for the purposes of a U.S. patent 
application, this approach may not fully preserve 
foreign patent rights. 
5.	 WHERE IS BIOlOGICAl
MATERIAl DEPOSITED? 
A U.S. applicant may deposit biological mate­
rials in any of the 35 International Depositary 
Authorities (IDA) recognized by the World In­
tellectual Property Organization (WIPO) un­
der the Budapest Treaty.42 Signatory countries 
(64, as of 2006),43 including the United States, 
are required to recognize a biological deposit 
made in any depository institution approved by 
WIPO, no matter the location. Under the Buda­
pest Treaty, storage time is required to be at least 
30 years, and after the applicant has made the 
deposit, it cannot be reclaimed. Furthermore, 
the depository has a duty of secrecy concerning 
the fact of a deposit and the nature of the depos­
ited material. 
Only two of the 37 IDAs recognized by 
WIPO are in the United States—the American 
Type Culture Collection (ATCC) in Manassas, 
Virginia, and the Agricultural Research Service 
Culture Collection (NRRL, acronym based on 
former name) in Peoria, Illinois. But as of 1999, 
these two U.S. depositories held 51.6% (or 20,461 
deposits) of the world‘s total patent-related bio­
logical deposits.44 As an example of applicable 
fees, the ATCC charges US$2,500 for a patent-
related deposit. This fee includes viability testing, 
a deposit certificate, 30 years of storage, release 
of samples according to deposit rules, quarterly 
informing report of distribution of released mate­
rials, and regulatory compliance reviews.45 
A recent report from the U.S. Government 
Accounting Office (GAO) compiled empirical 
data regarding the deposit practice in the United 
States.46 The GAO reported that about 0.6% of 
U.S. patents (308 out of 52,841) granted during 
the final three months of 1999 were supported by 
biological deposits in the two IDAs in the United 
States. Of these, only 53 patents (about 0.1%) 
were supported by biological deposits of seeds. 
The ATCC, one of only four IDAs accepting seed 
HANDBOOK OF BEST PRACTICES | 
  
     





       
        
       
      
       
       
       
      
      
        
         
      
      
       
         
     
 
      
      
        
      
       
     
     
       
       
       
       
        
       
      
     
     
 
      
        
       
      
       
      
      
       
        
        
       
       
         
       
        
       
         
        
        
       
       
    
  
HAREY & MCBRIDE 
deposits, estimated that less than 8% of its total 
deposits were for seeds. 
An applicant should also maintain his or her 
own samples of the biological material during the 
term of deposit. As discussed above, unavailability 
of biological material necessary to practicing the 
invention is a defect that cannot be cured after 
the grant of a patent and can result in unenforce­
ability. The applicant’s practice of maintaining his 
or her own samples for the duration of the pat­
ent protects against any circumstances wherein 
samples would no longer be available from the 
depository. 
6. WHO IS ENTITlED TO SAMPlES OF
DEPOSITED BIOlOGICAl MATERIAl? 
During pendency of an application, a deposit in­
corporated into a patent application specification 
need not be available to the public, but must be 
available to the PTO.47 
After issuance of a patent, deposited biologi­
cal material that is incorporated into the specifi­
cation by accession number must be freely avail­
able to the public.48 That is to say, all restrictions 
on availability of the deposit to the public must 
be irrevocably removed upon granting of the pat­
ent, unless the request is not made according to 
proper procedures. As a small measure of protec­
tion, a depositor can contract with the depository 
to require that samples of a deposited biological 
material will only be furnished if the request is in 
a dated writing that contains the name and ad­
dress of the requesting party and the accession 
number of the deposit, and the depositor is noti­
fied in writing of such a request.49 
The deposit of biological material in a rec­
ognized depository is not a grant of a license, 
either express or implied, to infringe the pat­
ent. Furthermore, the release of deposited ma­
terial from the depository to others does not 
grant them a license, either express or implied, 
to infringe the patent. The ATCC, for example, 
provides a standard disclaimer in its catalogs, 
reference guides, and to recipients of cultures: 
“This material is cited in a United States and/or 
other Patent and may not be used to infringe the 
patent claims.” 50 Regardless, a depositor should 
supplement this disclaimer with a letter tailored 
to each notification of request for samples, mak­
ing it clear there is no implied or express license 
covering the biological materials received from 
the depository. 
The number of samples estimated to have 
been released worldwide to legally entitled par­
ties in 1999 was estimated at 7,400. In that 
year, the ATCC released about 7,000 samples, 
or 95% of the worldwide total. In comparison, 
NRRL (the other recognized U.S. depository) 
released 123 samples, European IDAs released 
190 samples, and a Japanese IDA released 63 
samples. 
In its recent report to Congress, the GAO 
was unable to identify a single documented case 
in which a person or organization had gained 
access to a biological deposit and then used it 
to infringe the underlying patent.51 This lack of 
findings was based on court cases, representatives 
from the biotechnology industry, and officials 
from PTO, ATCC, NRRL, and WIPO. 
7. CONCluSION 
The rules governing biological deposits in sup­
port of a patent application provide a means of 
curing potentially fatal patent defects, as well as 
flexibility in the preparation of the application. 
As discussed above, a biological deposit can in 
some cases satisfy the requirements of enable­
ment, written description, and best mode, and 
potentially broaden the scope of claims in the 
event of litigation. A deposit will usually be nec­
essary only when words fail to explain how to 
make and use the invention, but an applicant 
may reference a deposit even when not required. 
While a deposit can be made at any time dur­
ing pendency of a U.S. application, those seeking 
foreign rights are advised to deposit before the fil­
ing of any priority application. A U.S. applicant 
can deposit in any of the 35 IDAs recognized by 
WIPO, with two of these in the United States 
The public will have free access to biological ma­
terials deposited in support of an issued patent, 
but the patent owner is somewhat protected by 
receiving information regarding who receives 
such deposits. n 
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Protecting New Plant Varieties through PVP: Practical 

Suggestions from a Plant Breeder for Plant Breeders
 
williaM d. paRdee, Professor Emeritus, Department of Plant Breeding and Genetics, Cornell University, U.S.A. 
ABSTRACT 
A plant variety protection (PVP) certificate preserves a 
plant variety owner’s exclusive rights to sell, reproduce, 
import, and export a plant variety and its seed. In ad­
dition, a PVP certificate prevents others from claiming 
PVP or utility patent rights. This chapter walks the reader 
through the process of applying for a PVP certificate and 
describes other ways to prevent the unauthorized use or 
sale of protected plant varieties. 
1.  InTRoduCTIon 
A plant variety protection (PVP) certificate pre­
serves a plant variety owner’s exclusive rights to 
sell, reproduce, import, and export the plant vari­
ety and its seed; In addition, a PVP certificate can 
also prevent others from claiming PVP or utility 
patent rights. The duration of a PVP certificate 
is 20 years (25 years for a tree or vine). A PVP 
certificate can, when combined with licensing, 
develop future funds for a breeding program. It 
also can preserve the financial and other interests 
of participants in a program, who may have pro­
vided upfront funds. 
To be eligible for PVP, a variety must be: 
•	 new and distinct from other varieties 
(novel) 
•	 genetically uniform 
•	 stable through successive generations 
This chapter discusses the rules governing the 
U.S. PVP application procedure, which is admin­
istered by the U.S. Department of Agriculture 
(USDA).1 The U.S. PVP Act is very similar to the 
provisions developed by the Convention of the 
International Union for the Protection of New 
Plant Varieties (UPOV), which have been, or are 
being, adopted in many nations around the world. 
Of course, anyone considering applying for a PVP 
certificate must thoroughly familiarize him- or 
herself with local laws and application procedures. 
The U.S. PVP Office (PVPO) considers a 
variety to be new, and therefore eligible for PVP 
certification, only if propagating or harvested ma­
terial of the variety has not been sold, or other­
wise disposed of to other persons, for the purpose 
of exploiting the variety for more than one year, 
in the United States, or four years outside of the 
United States. 
2. THE	CounTdoWn To 
pvp	CERTIfICATIon 
The breeder should be the person to complete the 
PVP certificate application because only he or she 
will possess the required information and be able 
to answer follow-up questions from the examin­
ers. It is important to maintain good breeding 
records, because they are invaluable in case of an 
infringement challenge. 
Pardee WD. 2007. Protecting New Plant Varieties through PVP: Practical Suggestions from a Plant Breeder for Plant Breed-
ers. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krat-
tiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org. 
© 2007. WD Pardee. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged. 
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2.1  Two years in advance 
Obtain from the U.S. PVPO the instructions for 
application as well as the proper (species-specific) 
Exhibit C form (see Section 3.4 below for more 
details). Start conducting any tests that will be 
required to fill out Exhibit C (such as those for 
disease and pest resistance); such tests may take 
one or two years to complete. 
2.2  One year in advance 
Verify that the crop variety is worth protecting 
and that the potential returns on the sale of the 
crop justify the expense of the PVP certificate. 
The plant breeder should consult with his or her 
seed project leader (if he or she works for a na­
tional research center or a university) or his or her 
supervisor or sales manager (if he or she works 
in the private sector). The decision of whether or 
not to apply for a PVP certificate and subsequent 
commercialization must be driven by objective 
analysis, not emotion. It is easy to form an emo­
tional attachment to a project that has required 
a great deal of time, effort, or money. Seek ad­
vice and suggestions from seed growers, advisory 
committees, company sales representatives, and, 
most critically, the farmers who will ultimately be 
growing the crops. 
The following questions are important to 
consider: 
•	 Is it likely that royalties or other returns on 
the variety will repay the cost of PVP cer­
tificate application? 
•	 Does the variety have sufficient advantages 
over standard varieties? Is it likely to attract 
the interest of seed companies, seed grow­
ers, and (most importantly) farmers? 
•	 How large are the new variety’s seed vol­
umes likely to become? 
•	 How broad will the variety’s geographical 
area of adaptation be? 
•  How large will the variety’s potential market be? 
•	 Do any seed companies or seed growers 
have a particular interest in the variety? 
Depending on the answers to these questions, 
you will want to consider whether the variety is 
appropriate for general release (that is, release to 
all interested companies or growers) or exclusive/ 
limited release (that is, to one or a limited group 
of companies and/or growers). PVP is most use­
ful when the release is exclusive. 
If there were several contributors to the breed­
ing project, you would need to decide whether 
or not to pursue an application for a joint PVP 
certificate with them. Consider the following 
questions: 
•	 What entities (companies, associations, 
and so on) contributed to the development 
of the new variety? 
•	 Do these entities wish to seek a license for 
the new variety? 
•	 Will these entities help to cover the ap­
plication costs for a PVP certificate and 
certification? 
•	 Do these entities have first refusal rights for 
licensing? 
.  pREpARInG	 THE	pvp
CERTIfICATE	AppLICATIon 
The U.S. PVPO provides detailed instructions for 
how to fill out and submit application forms for PVP 
certification. All documents can be accessed online.2 
.1  General application requirements 
and procedure 
A PVP application consists of: 
1) A completed and signed Form S&T-470 
(Application for Plant Variety Protection 
Certificate). The applicant must provide 
his or her name, address, and representa­
tive, and the variety’s genus, species, and 
variety name (a temporary variety name 
will suffice until the PVP certificate is is­
sued). The proposed variety name or ex­
perimental number must be cleared with 
the Seed Regulatory and Testing Branch of 
the USDA.3 
2) the following “exhibits,” all of which will 
be discussed in detail in the following 
sections: 
•	 Exhibit A: Breeding History, consisting of 
the variety’s genealogy, the methods used to 
develop the variety, a statement of the level 
of variability in any variety characteristics, a 
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statement of genetic stability, and the type 
and frequency of variants 
•	 Exhibit B: Statement of Distinctness 
Guidelines, stating how the variety may be 
distinguished from all other varieties in the 
same crop 
•	 Exhibit C: Objective Description of Variety, 
a crop-specific form 
•  Exhibit D: Optional Supporting Information 
•	 Exhibit E: Statement of the Basis of 
Ownership, stating who owns the variety 
and verifying that the applicant is eligible 
to file for PVP in the United States 
•	 Exhibit F: Declaration Regarding Deposit, 
stating that the applicant will submit a cer­
tain amount of propagation material to a 
seed depository 
Included with the forms must be a check 
drawn on a U.S. bank (as of 6 October 2006, the 
fee for filing and examination was US$4,382), 
payable to “Treasury of the United States.” Since 
fees are subject to change periodically, always 
check current schedules at the U.S. PVPO Web 
site.4 Issue fees will also be charged when the cer­
tificate is issued. 
The U.S. PVPO office maintains databases 
of known varieties of most U.S. crops (includ­
ing those originating in the United States and in 
some foreign countries). The PVP examiner will 
compare the information given in the application 
with the database for that crop. The examiner 
may request additional data if he or she finds one 
or more varieties in the database with essentially 
similar descriptions (which often happens). Please 
note that if all other traits seem similar to another 
variety, then DNA profiling may be useful, at the 
discretion of the PVP examiner. 
Remember, that the U.S. PVPO does not 
conduct actual field/greenhouse evaluation (so-
called growing out) or other tests on varieties that 
are described in PVP applications. The applicant 
must provide all data. Diligence in this regard will 
be well worth the effort. 
.2 Exhibit A: Breeding History 
.2.1 Parentage and breeding methods 
Exhibit A describes a number of different aspects 
of the variety’s breeding history. First, it describes 
the pedigree of the new variety, including both 
the parents used in each cross and the source and 
pedigree of each parent. The PVP office specifies 
that: 
Obtaining intellectual property rights requires 
disclosure. As part of this disclosure the applicant is 
to provide the public with information about his/her 
invention in exchange for protection of the variety. 
For Plant Variety Protection, this includes a full dis­
closure of the parentage and breeding methodology 
in the Exhibit A, Origin and Breeding History. This 
information would specify the plant material the ap­
plicant started from, i.e., the parentage. All material 
in the parentage must be traceable back to varieties, 
lines, or clones, etc. that are publicly known or a 
matter of common knowledge.5 
Exhibit A also describes the breeding meth­
ods used in creating the new variety, including 
any specific selection criteria that were used. Keep 
it simple to avoid confusing the examiner. There 
is no need to say why certain selections were car­
ried out, merely what was accomplished and when
it took place. 
.2.2 Uniformity and stability 
This statement declares that the variety has been 
observed to be uniform and stable for all char­
acteristics over a certain number of generations. 
The words “uniform” and “stable” must be used 
in the statement. 
The statement specifies the number of cycles 
of seed reproduction through which the variety 
has remained unchanged for all distinguishing 
characteristics. It is likely that stability dates from 
when you initiated increase of the line that be­
came this variety. Remember that variation is ac­
ceptable, as long as it is predictable and the vari­
ants are describable and commercially acceptable. 
Many modern varieties include a low level of one 
or more variants. 
A variant is a predictable phenotype that dif­
fers in one or more ways from the main pheno­
type of the variety. The applicant must identify 
the variant as typical of the variety and provide 
data on the percentage and frequency distribu-
HANDBOOK OF BEST PRACTICES | 
     
 
 





     
      
     
      
     
    
       
 
     
       
         
       
      
     
       
      
       
         
       
       
         
         
        
     
	 	 	 	 	
 	 	 	
PARDEE 
tion of variant plants. It is permissible to have 
more than one variant, so long as each one is 
accounted for. However, the total frequency of all 
variants in the population cannot exceed 5%; a 
variety that is composed of more than 5% vari­
ants will be deemed a mixture (and thus not eli­
gible for PVP). 
An off-type is a phenotype that is not speci­
fied as an expected variant. If you find that you 
cannot remove a certain phenotype from your 
variety, consider describing it as a variant. If you 
do not describe it as a variant, the variant will be 
considered an off-type by certification inspectors 
or seed analysts. 
. Exhibit B: Statement of Distinctness 
In order to demonstrate distinctiveness, the vari­
ety must be shown to be distinct in one or more 
traits from either: 
(1) the variety that is most similar to it 
(2) several similar varieties 
(3) all other varieties of the species 
When measuring quantitative traits, describe 
your statistical design and provide statistical ref­
erences such as F values, least significant differ­
ences (LSD’s), standard deviations (SD’s), range, 
or other references, that may indicate the degree 
of variability in the tests; this provides an indica­
tion of just how distinct the variety really is, that 
is, if it can be distinguished from similar variet­
ies. Include data taken from at least two locations 
(preferably from two different states) or over two 
years, but do not pool data across years or loca­
tions. The more data, the better. Sources of data 
may include trials at state agricultural colleges, 
cooperative tests performed by breeders in several 
states, or industry tests. However, be aware that 
the PVP office also has access to results from most 
of these tests and will likely use these to evalu­
ate the distinctiveness of your variety. For many 
crops, the PVP office requests that several stan­
dard varieties be included in comparative tests 
against the variety submitted in the PVP applica­
tion in order to provide a point of reference to 
evaluate distinctness. 
The U.S. PVP application instructions indi­
cate that: 
•	 Differences in quantitative characters such 
as plant size, seed size, and maturity, that 
are not obvious and detectable without a 
direct comparison, must be supported by 
evidence provided by the applicant. The 
evidence must be given as numerical data 
obtained from at least two trials. 
•	 Distinction based on differences in color 
needs to be referenced with a standard 
such as the Royal Horticultural Society 
Colour Chart or the Munsell Book of 
Color, unless dramatic (i.e., red versus 
green). Color chart measurements must 
be conducted in two or more localities or 
growing seasons.6 
It is sometimes helpful to submit photos to 
demonstrate color differences. 
Distinctions in disease reaction between the 
new variety and other varieties must be support­
ed with data or results from at least two trials 
conducted in two or more localities or growing 
seasons, unless the distinction is dramatic (for 
example, other varieties are highly susceptible 
to disease, while the new variety is disease-resis­
tant). Remember to include the following: the 
disease reaction to the causal agent or organ­
ism; the causal agent or source of the disease (if 
it has been demonstrated or identified); and the 
race, strain, or pathotype of the disease, where 
appropriate. 
It is important to note that yield is not ac­
cepted by the PVP office as a basis for distinct­
ness because it is not a sufficiently stable trait. 
Yields depend largely on environmental factors. 
. Exhibit C: Objective Description of Variety 
As in Exhibit B, numerical data must be provided 
to support certain elements of the variety descrip­
tion: performance characteristics, pest resistance, 
quality, or other traits. Data should be gathered in 
at least two locations or over two years. Describe 
the statistical methods used, plus coefficient of 
variance (CV), SD, LSD, range, or other esti­
mates of test variability. 
..1 Essentially derived varieties 
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CHAPTER 10.11 
An essentially derived variety is usually developed 
when one or a few genes or traits are added to 
a preexisting variety, resulting in a phenotypic 
change or changes. The change may be cosmetic 
(for example, a change in flower color) or eco­
nomic (for example, the addition of a value-add­
ed, genetically engineered trait, such as an insect-
resistance gene, into an existing variety). 
The U.S. PVPO will approve an essentially 
derived variety if it shows one or more distinguish­
ing characteristics and if the original variety has a 
PVP certificate issued after 1994. The U.S. PVPO 
will not protect an essentially derived variety if the 
original variety was not protected, or was protected 
only with pre-1994 criteria. PVP protection may 
not protect the owner of the variety from infringe­
ment liability if the original variety’s germplasm 
comprises the majority of the essentially derived va­
riety. For that reason, it is sensible to make arrange­
ments to compensate the owner of the original va­
riety for the use of the germplasm. At the time of 
this writing, there was no absolute rule regarding 
which varieties are essentially derived and which 
are not, though seed committees and organizations 
are working to develop criteria. Disagreements 
must be worked out between variety owners, or if 
this is not successful, by the courts. 
.  Exhibit D: Optional Supporting 
Information 
Exhibit D is required for wheat (milling and bak­
ing quality must be described), but it is optional 
for other crops. This exhibit describes quality fac­
tors of the crop and/or offers other information 
pertaining to variety uniqueness that is not in­
cluded in the other exhibits. 
. 	 Exhibit E: Statement of Ownership 
Exhibit E is a statement of who developed the 
variety, who owns it, and who or what entity, 
if any, has rights to it. A single paragraph will 
suffice. 
.  Exhibit F: Declaration Regarding Deposit 
In Exhibit F, the applicant declares that he or 
she has included with the application a “voucher 
sample” of at least 3,000 untreated, viable seeds 
capable of propagating the application variety 
(minimum germination rate 85%). In the case of 
vegetative and clonal crops, the applicant declares 
that he or she will deposit a viable cell culture in a 
public depository, where it will be maintained for 
the duration of the certificate. 
The U.S. PVPO may use a small subsample 
of the submitted seed (no more than 25 seeds) 
in the process of examining the application. The 
rest of the seed sample will be deposited by the 
U.S. PVPO in the National Seed Depository 
Laboratory (NSDL) at Fort Collins, Colorado. 
The NSDL keeps PVP seeds separate from their 
normal collections and only the applicant and the 
U.S. PVPO will have access to the seed for the 
duration of the certificate. These deposited seeds 
will be used in case of an identity challenge. The 
NSDL will return any remaining seed to the ap­
plicant after the PVP certificate has expired or is 
no longer in force. 
. oTHER	ConSIdERATIonS 
.1	 Critical dates to keep in mind 
1. Date of first sale. You must apply for a PVP 
certificate within one year after the date of 
the first commercial sale of seed or planting 
stock of your variety. (Sales of experimental 
seed for further testing only are exempt.) 
You have four years from the date of the 
first commercial sale (six years for a tree 
or vine) to apply for a PVP certificate for 
foreign varieties. Keep evidence of the date 
of first sale in the form of an invoice or 
receipt. 
2. Date application is received in the U.S. 
PVPO. The date the original application 
was received is considered to be the date 
of application, though requests for addi­
tional information may take months or 
years to satisfy. The variety can be sold 
while a PVP certificate is being sought 
for it. 
.2  When to apply 
Apply for PVP certificate as soon as you decide to 
protect the variety and can assemble the necessary 
information (which should be before the date of 
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first sale). The amount of time it takes to get a 
PVP certificate application approved is highly 
variable. It depends on the current workload at 
the U.S. PVPO and can be lengthened by re­
quests for additional information. Figure on at 
least a year or possibly two years. 
. After filing 
Be prepared to respond to questions and re­
quests from the PVP examiner; few applications 
are accepted as originally submitted. Some of 
these questions may be answerable with exist­
ing data; for others, more data may need to be 
collected. 
.  fuRTHER	 pRoTECTIon
foR	 pLAnT	 vARIETIES 
Although a PVP certificate gives you or your 
agent the sole right to sell the plant variety in 
question and protects the variety name from 
infringement, it is sensible to take additional 
precautions: 
•	 Control all breeder seed that you or your 
organization grow, harvest, and maintain. 
•	 Control all foundation seed production by 
producing it only within your organization 
or granting tight licenses or contracts to 
trusted seed producers. 
•	 Control who gets foundation seed, through 
licenses or sales, with tight contracts. 
.1 Enforce protection 
Stay alert for unauthorized sales of your PVP 
seed: such things as advertisements in local news­
papers are giveaways of illegal activity. Tell any in­
dividuals, companies, or other organizations that 
sell or distribute your variety to be alert to illegal 
sales and to notify you immediately if they detect 
them. 
It is important to realize that the unauthor­
ized seller may very well not realize that the va­
riety is protected. Notify the offender that he or 
she is selling a PVP-protected variety. A warning 
is often sufficient to stop the problem. If the of­
fender persists in making illegal sales, threaten 
to cut him or her off from future releases. Sue 
only as a last resort, and consider whether a court 
battle is worth the cost in money and public 
relations. 
.2 Bag-tag warning 
Before the PVP certificate is awarded, label all 
seed containers of the variety as follows: 
Unauthorized Propagation Prohibited 




After the PVP certificate is awarded, label 
seed containers as follows: 
U.S. Protected Variety PVPA 1994
 




. Brown-bag sales 
Under the farmer exemption, farmers are permit­
ted to grow and save enough seed of a PVP va­
riety to plant their own acreage.7 If they decide 
not to plant the seed, they are allowed to sell it. 
However, some farmers produce and sell large 
volumes of seed, far more than they would be 
able to plant on their own farms. In the United 
States, this practice is unfortunately common in 
the Midwest and South, particularly with soy­
beans, cotton, and peanuts. Because the illegal 
seed is often sold in unmarked brown bags, this 
practice is popularly called “brown bagging.” A 
recent Supreme Court decision that upholds the 
rights of PVP certificate owners may discourage, 
but will not stop, brown-bag sales. 
Title V of the U.S. Federal Seed Act makes it 
unlawful to sell uncertified seed of a PVP variety 
by the variety name. Many state seed laws include 
similar provisos. On page one of the PVP appli­
cation, you can state your intention to also apply 
for Title V protection. Of course, brown bagging 
can still occur even if Title V is in force. In such 
cases, you will need to seek help from the appro­
priate state, federal, or state seed-law enforcement 
agency. Seed-law enforcers can issue orders that 
prohibit offenders from further action, and may 
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CHAPTER 10.11 
issue a stop-sales order or fines to a persistent 
offender. 
6. ConCLuSIon 
Assembling and submitting a PVP application for 
your variety can be either a nearly unbearable ag­
gravation or a very easy task. It all depends on 
how organized, diligent, and proactive you are. 
The key elements are to plan well ahead, keep 
careful records, know what you need to do, know 
when you need to do it, and know what the PVP 
offices needs (not less and not more) to process 
your application. From a practical standpoint, 
this means keeping good breeding records, being 
familiar with the PVP Web site, knowing what 
the forms and exhibit schedules are, and keeping 
track of time. If you are organized, the application 
process will likely go smoothly. And remember, 
after your PVP certificate is issued, be diligent 
and watch for infringers. PVP can provide your 
variety, and your breeding program or business, 
with a foundation for realizing returns on your 
investments, which can then be used to develop 
the next round of improved varieties from your 
breeding program, for which you will then seek 
PVP. n 
williaM d paRdee, Professor Emeritus, Department of Plant 
Breeding and Genetics, Emerson Hall, Cornell University, 
Ithaca, NY, 14853, U.S.A. wdp5@cornell.edu 
1	 Pursuant to the PVP Act of 1970, 7 U.S.C. § 2321–2583. 
2	 www.ams.usda.gov/science/pvpo/apply.htm. 
3	 They may be contacted at: U.S. Department of 
Agriculture, Agricultural Marketing Service, Livestock 
and Seed Programs, Seed Regulatory and Testing 
Branch, 801 Summit Crossing, Place, Suite C, Gastonia,
North Carolina, 28054-2193 (Phone: 704-810-8870).
www.ams.usda.gov/lsg/seed.htm. 





7	 McCarthy JT, RE Schechter and DJ Franklyn. 2004.
McCarthy’s Desk Encyclopedia of Intellectual Property,
Third Edition. The Bureau of National Affairs, Inc.:
Washington, DC. 
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